<SEC-DOCUMENT>0001628280-26-052635.txt : 20260804
<SEC-HEADER>0001628280-26-052635.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804163021
ACCESSION NUMBER:		0001628280-26-052635
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pacira BioSciences, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				510619477
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35060
		FILM NUMBER:		261239260

	BUSINESS ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 900
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		650-242-8052

	MAIL ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 900
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pacira Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20101029

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pcrx-20260630.htm
<DESCRIPTION>10-Q - PCRX - 06.30.2026
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e4244-8139-7e27-b3f4-c33a61dfef92,g:c636850a-8e11-4f67-b4ef-051f1780002d,d:c3d6b4f5cd834aefb39683a79b5e86d0-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:pcrx="http://www.pacira.com/20260630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pcrx-20260630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001396814</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-89" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" id="f-481">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-95" name="pcrx:AccountsReceivablePaymentTerms" id="f-493">P0D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="f-762">0.0252752</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="pcrx:DebtInstrumentMarketPrice" id="f-763">0.999000</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pcrx-20260630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>pcrx:product</xbrli:measure></xbrli:unit><xbrli:unit id="customer"><xbrli:measure>pcrx:customer</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>pcrx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="trading_day"><xbrli:measure>pcrx:trading_day</xbrli:measure></xbrli:unit><xbrli:unit id="wholesaler"><xbrli:measure>pcrx:wholesaler</xbrli:measure></xbrli:unit><xbrli:unit id="offering_period"><xbrli:measure>pcrx:offering_period</xbrli:measure></xbrli:unit><xbrli:unit id="period"><xbrli:measure>pcrx:period</xbrli:measure></xbrli:unit><xbrli:unit id="certificate"><xbrli:measure>pcrx:certificate</xbrli:measure></xbrli:unit><xbrli:unit id="manufacturer"><xbrli:measure>pcrx:manufacturer</xbrli:measure></xbrli:unit><xbrli:unit id="notice"><xbrli:measure>pcrx:notice</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>pcrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-06-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:RevenueMilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:RevenueMilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:RevenueMilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-07-31</xbrli:startDate><xbrli:endDate>2026-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-07-01</xbrli:startDate><xbrli:endDate>2026-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pcrx:WorkInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pcrx:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:IoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pcrx:CappedCallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-31</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2028-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pcrx:GQBioAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:EquityInvestmentAndConvertibleNoteReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">pcrx:ConvertibleNoteReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-06-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:MyoScienceMilestoneLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:MyoScienceMilestoneLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:LGChemPartnershipAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:JohnsonJohnsonMedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:JohnsonJohnsonMedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:InitiationOfAPhase2ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:BaylorCollegeOfMedicineBaylorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:BaylorCollegeOfMedicineBaylorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-27</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.946%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.946%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2026</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160; to</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-35060</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.946%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="pcrx-20260630_g1.jpg" alt="PaciraLogo.jpg" style="height:112px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-1"/></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">PACIRA BIOSCIENCES,&#160;INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.946%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.435%"><tr><td style="width:1.0%"/><td style="width:48.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">51-0619477</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>&#160;Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">2000 Sierra Point Parkway, Suite 900</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94005</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Address and Zip Code of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">242-8052</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:108%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.758%"><tr><td style="width:1.0%"/><td style="width:37.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">PCRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>   &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files.)&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Yes   &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of August&#160;3, 2026, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">39,861,886</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value per share, were outstanding.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED JUNE 30, 2026</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Page #</span></td></tr><tr><td colspan="6" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_10">PART&#160;I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_10">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_13">Item&#160;1.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_22">Condensed Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_34">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_112">Item&#160;2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_112">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_112">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_136">Item&#160;3.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_136">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_136">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_139">Item&#160;4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_139">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_139">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_142">PART&#160;II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_142">52</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"/><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"/><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_145">Item&#160;1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_145">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_145">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_148">Item&#160;1A.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_148">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_148">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_151">Item&#160;2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_151">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_154">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_157">Item&#160;3.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_157">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_157">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_160">Item&#160;4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_160">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_160">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_166">Item&#160;5.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_166">Other Information</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_163">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_172">Item&#160;6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_172">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_172">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_178">Signatures</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#f9f9f9;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_178">55</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  1</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_10"></div><hr style="page-break-after:always"/><div style="min-height:28.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:3pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_13"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FINANCIAL STATEMENTS (Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:3pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_16"></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.865%"><tr><td style="width:1.0%"/><td style="width:74.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">205,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">158,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Short-term available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-32">45,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-33">79,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">132,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">124,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-36">134,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">152,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">67,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">29,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">32,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">615,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">547,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">130,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">140,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">44,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">41,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">19,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-49">20,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">285,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-51">368,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-52">124,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-53">123,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pcrx:EquityMethodInvestmentsAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-54">23,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pcrx:EquityMethodInvestmentsAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-55">22,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">1,243,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-57">1,264,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">17,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">15,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">93,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">95,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">10,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">9,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="f-64">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">122,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">120,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">363,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">372,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">38,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">36,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pcrx:ContingentConsiderationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">17,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pcrx:ContingentConsiderationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">18,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-74">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-75">4,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">26,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">20,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-78">572,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-79">571,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 17)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-80"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-81"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-82"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-83">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-85">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-89">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at June&#160;30, 2026 and December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-92"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-93">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-95">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-96">48,840,889</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-97">39,822,298</ix:nonFraction> shares outstanding at June&#160;30, 2026 and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-98">47,890,777</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-99">41,116,739</ix:nonFraction> shares outstanding at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-100">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-101">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, inclusive of excise tax and broker fees, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-102">9,018,591</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-103">6,774,038</ix:nonFraction> shares at June&#160;30, 2026 and December&#160;31, 2025, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-104">227,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-105">176,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-106">1,087,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-107">1,064,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-108">191,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-109">199,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-110">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-111">4,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">671,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">693,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">1,243,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">1,264,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  2</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-116">190,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-117">180,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-118">367,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">347,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-120">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-121">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-122">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-123">2,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-124">192,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-125">181,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-126">369,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-127">350,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold (exclusive of amortization of acquired intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-128">44,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-129">40,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-130">80,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-131">75,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">30,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">28,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">58,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">53,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">91,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">88,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-138">185,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-139">175,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-140">14,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-141">14,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-142">28,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-143">28,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-144">7,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-145">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-146">5,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-147">6,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-148">188,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-149">172,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-150">358,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-151">339,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">4,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">8,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">11,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">10,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-156">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-157">5,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">3,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">11,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-160">3,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-161">4,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-162">7,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-163">9,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-164">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-165">10,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-166">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-167">6,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-168">1,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-169">10,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-170">3,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-171">3,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-172">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-173">1,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-174">7,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-175">6,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-176">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-177">2,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-178">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-179">6,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-181">4,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-183">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-184"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-185">0.12</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-186"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-187">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-188"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-189">0.19</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-190"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-191">0.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-192">39,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-193">45,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-194">39,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-195">45,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-196">40,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-197">45,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-198">40,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-199">45,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  3</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-201">4,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-203">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-204">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-205">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-206">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-207">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-208">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-209">2,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-210">1,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-211">3,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-212">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-213">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-214">1,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-215">3,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-216">4,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-217">2,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-218">6,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-219">3,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  4</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.413%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-220">48,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-221">9,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-222">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">227,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">1,073,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">196,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">653,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-228">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-229">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-230">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-231">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-232">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-233">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-235">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-236">3,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-237">3,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-238">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-239">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-240">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-241">14,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-242">14,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss (Note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-243">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-244">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-245">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-246">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-247">48,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-248">9,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-249">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">227,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">1,087,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">191,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">671,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.413%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-255">47,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="f-256">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-257">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">25,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">1,023,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">201,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">798,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-263">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-264">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-265">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-266">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-267">5,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-268">5,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-269">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-270">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-271">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-272">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-273">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock, inclusive of excise tax and broker fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-274">1,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-275">50,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-276">50,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (Note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-277">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-278">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-279">4,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">4,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-281">47,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-282">2,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-283">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">75,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-285">1,035,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-286">206,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">4,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-288">757,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.413%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-289">47,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-290">6,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-291">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">176,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">1,064,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">199,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-295">4,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">693,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-297">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-298">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-299">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-300">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-301">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-302">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-304">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-305">7,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-306">7,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock<br/>purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-307">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-308">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-309">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-310">28,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-311">28,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock, inclusive of excise tax and broker fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-312">2,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-313">50,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-314">50,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-315">1,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-316">1,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-317">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-318">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-319">48,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-320">9,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-321">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-322">227,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-323">1,087,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-324">191,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-325">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-326">671,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.413%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-327">47,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="f-328">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-329">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-330">25,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-331">1,009,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-332">206,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-333">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-334">778,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-335">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-336">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-337">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-338">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-339">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-340">5,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-341">5,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-342">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-343">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-344">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-345">30,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-346">30,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock, inclusive of excise tax and broker fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-347">1,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-348">50,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-349">50,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (Note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-350">3,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-351">3,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-352">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-353">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-354">47,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-355">2,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-356">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-357">75,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-358">1,035,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-359">206,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-360">4,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-361">757,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  6</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-362">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-363">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Release of valuation allowance on deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-364">6,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-367">11,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-368">5,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-369">2,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of fixed assets and amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-370">42,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-371">48,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs and debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-372">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-373">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of cloud computing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherAmortizationOfDeferredCharges" scale="3" id="f-374">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherAmortizationOfDeferredCharges" scale="3" id="f-375">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-376">28,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-377">30,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-378">614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-379">3,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net accretion of discount on available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-380">927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-381">3,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other net gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForOtherLosses" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProvisionForOtherLosses" format="ixt:num-dot-decimal" scale="3" id="f-383">5,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-384">12,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-385">1,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-386">8,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-387">22,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-388">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-389">15,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-390">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-391">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-392">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-393">14,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-394">4,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-395">10,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-396">83,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-397">47,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="f-398">335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-399">16,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-400">4,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-401">11,245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-402">3,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-403">74,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales of available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-404">39,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-405">140,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of convertible notes receivable investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-407">1,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-408">31,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-409">36,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-410">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="f-412">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="f-413">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payment of employee withholding taxes on restricted stock unit vests</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-414">7,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-415">5,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury stock, inclusive of broker fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-416">50,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-417">50,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Excise taxes paid on treasury stock repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pcrx:ShareRepurchaseProgramExciseTaxPaid" format="ixt:num-dot-decimal" scale="3" id="f-418">1,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pcrx:ShareRepurchaseProgramExciseTaxPaid" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Term loan A facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-421">6,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-422">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-424">67,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-425">60,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-426">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-427">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-428">47,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-429">23,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-430">158,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-431">276,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-432">205,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-433">300,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="12" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">See accompanying notes to condensed consolidated financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.678%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-434">6,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-435">7,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-436">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-437">8,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-438">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-439">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Excise tax on treasury stock repurchases included in accrued liabilities</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareRepurchaseProgramExciseTaxPayable" scale="3" id="f-440">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ShareRepurchaseProgramExciseTaxPayable" scale="3" id="f-441">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  8</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_37"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-442" continuedAt="f-442-1" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-442-1"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Pacira&#8221;) deliver innovative, non-opioid pain therapies to transform the lives of patients. The Company&#8217;s long-acting, local analgesic, EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company&#8217;s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia in adults via (i) an interscalene brachial plexus block in adults; (ii) a sciatic nerve block in the popliteal fossa; or (iii) an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks other than an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, and an adductor canal block). In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the &#8220;Flexion Acquisition&#8221;), and added ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. The Company is also advancing two Phase 2 clinical programs&#8212;PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy for OA of the knee, and PCRX-2002, a complementary, long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. PCRX-201 is the lead program from the Company&#8217;s proprietary high-capacity adenovirus, or HCAd, vector platform, which enables local administration of genetic medicines and has the potential to unlock gene therapy for large prevalent diseases affecting millions of people. In February 2025, the Company acquired the remaining <ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-443">81</ix:nonFraction> percent equity interest that it did not already own in GQ Bio Therapeutics GmbH, or GQ Bio (the &#8220;GQ Bio Acquisition&#8221;), a privately-held biopharmaceutical company, which included the novel HCAd platform, a preclinical portfolio of HCAd-based assets and research and development talent. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies and potential generic entrants, reliance on revenue from <ix:nonFraction unitRef="product" contextRef="c-70" decimals="INF" name="pcrx:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-444">two</ix:nonFraction> commercialized products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, tariffs, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company divested iovera</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#176;, a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to Zimmer, Inc., or Zimmer, a subsidiary of Zimmer Biomet Holdings, Inc. on July 31, 2026. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-445" continuedAt="f-445-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-447" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-446" escape="true"><ix:continuation id="f-445-1" continuedAt="f-445-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#8220;2025 Annual Report&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#8217;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.</span></div></ix:continuation></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-445-2" continuedAt="f-445-3"><ix:nonNumeric contextRef="c-1" name="pcrx:AssetsAndLiabilitiesHeldForSalePolicyTextBlock" id="f-448" continuedAt="f-448-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities available for sale and expected to be sold within one year are classified as either assets or liabilities held for sale on the condensed consolidated balance sheets at the lower of their carrying value or fair value less any costs to sell. Any loss, or gain up until any previously recorded loss, is recognized in the period in which the held for sale criteria are met. The Company will recognize contingent consideration related to the sale of a business as a gain contingency. Under this policy, contingent consideration is excluded from the initial measurement of gain or loss upon the divestiture of a business and is recognized in earnings when the contingency is resolved and the consideration becomes realizable. </span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><ix:continuation id="f-448-1" continuedAt="f-448-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company agreed to divest its cryoanalgesia business&#8212;including iovera&#176;&#8212;to Zimmer and reclassified certain of its assets and liabilities to assets and liabilities held for sale. For more information, refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-448-2">.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-449" continuedAt="f-449-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-449-1">The Company grants performance share units, or PSUs, under its Amended and Restated 2011 Stock Incentive Plan to certain of its employees, including its executive officers. The expense associated with these awards is recognized in the Company&#8217;s consolidated statements of operations based on their grant date fair values at the closing price of the Company&#8217;s common stock on the date of grant. The expense is recognized over a <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-450">four-year</ix:nonNumeric> service period using graded vesting based on the Company&#8217;s interim estimates of achievement of a stated performance objective during the <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-451">one year</ix:nonNumeric> period subsequent to the grant date. Changes in estimates are recorded on a cumulative catch-up basis. After the one year performance period, the number of shares the employee is entitled to is fixed.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Major Customers</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-452" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s <ix:nonFraction unitRef="customer" contextRef="c-71" decimals="INF" name="pcrx:ConcentrationRiskNumberOfCustomers" format="ixt-sec:numwordsen" scale="0" id="f-453">three</ix:nonFraction> largest wholesalers in each period presented: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Largest wholesaler</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-454">30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-455">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-456">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-457">32</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Second largest wholesaler</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-458">25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-459">26</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-460">25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-461">26</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Third largest wholesaler</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-462">21</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-463">21</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-464">22</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-465">21</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-466">76</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-467">78</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-468">78</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-469">79</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-470" continuedAt="f-470-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of June&#160;30, 2026</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment improves financial reporting by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU&#8217;s amendments are effective for annual reporting periods beginning after December 31, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. This ASU amendment can be applied on a prospective basis or retrospectively. The Company is currently evaluating the impact of adopting ASU 2024-03 on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40), Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment removed all references to prescriptive and sequential software development stages (referred to as project stages) throughout Subtopic 350-40. This had been replaced by the requirement to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding a software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition threshold&#8221;). The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The ASU&#8217;s amendments may be adopted on a prospective, modified transition approach that is based on the status of a current project and whether software costs were capitalized before the date of adoption or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-06 on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-470-1"><ix:continuation id="f-445-3"><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Grants (Topic 832), Accounting for Government Grants Received by Business Entities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU provides the recognition requirements for a government grant received, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. This ASU provides for adoption either on a modified prospective, modified retrospective, or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-11,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interim Reporting (Topic 270): Narrow-Scope Improvements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU is intended to update the guidance in Topic 270 by improving navigability of the required interim disclosures and establishing a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted at any time prior to the effective date and should be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2025-11 on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_1452"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-471" continuedAt="f-471-1" escape="true">ASSETS AND LIABILITIES HELD FOR SALE</ix:nonNumeric></span></div><ix:continuation id="f-471-1" continuedAt="f-471-2"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company and Pacira CryoTech, Inc.&#8212;its wholly-owned subsidiary (the &#8220;Subsidiary&#8221;)&#8212;entered into a Stock and Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Zimmer, a subsidiary of Zimmer Biomet Holdings, Inc. Pursuant to the Purchase Agreement, the Company agreed to divest to Zimmer (i) all of the issued and outstanding capital stock of the Subsidiary and (ii) certain assets and liabilities of the Company and certain of its subsidiaries relating to the Company&#8217;s handheld cryoanalgesia devices and related products&#8212;including iovera&#176; (the &#8220;Transaction&#8221;)&#8212;for up to $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="f-472">140.0</ix:nonFraction>&#160;million, including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" scale="6" id="f-473">70.0</ix:nonFraction>&#160;million, subject to customary adjustments for cash, accounts receivable, indebtedness, transaction expenses and inventory.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the iovera&#176; assets and liabilities included in the Purchase Agreement were reclassified to assets and liabilities held for sale due to meeting the required held for sale criteria. As of June&#160;30, 2026, assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="f-474">67.3</ix:nonFraction> million consisted of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="6" id="f-475">53.3</ix:nonFraction> million of intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="f-476">9.8</ix:nonFraction> million of inventory, $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="f-477">3.7</ix:nonFraction> million of accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="f-478">0.5</ix:nonFraction> million of fixed assets, net of depreciation. As of June&#160;30, 2026, liabilities held for sale of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="f-479">0.7</ix:nonFraction> million consisted of accrued expenses. The Company determined that the held for sale disposal group was not impaired because its fair value less the cost to sell exceeded its carrying value.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement provides for potential contingent consideration of up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" scale="6" id="f-480">70.0</ix:nonFraction>&#160;million in the aggregate, payable upon the achievement of the following revenue-based milestones (in each case, excluding any net revenue previously applied towards the achievement of any other milestone threshold) up to and through the period ending December 31, 2031:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the current version of iovera&#176; available for sale to end users as of the closing date of the Transaction (the &#8220;Business Products&#8221;) during any of the <span style="-sec-ix-hidden:f-481">five</span> (5) calendar year periods commencing on January 1, 2027 through December 31, 2031 (each an &#8220;Applicable Milestone Period&#8221;) equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" scale="6" id="f-482">50.0</ix:nonFraction>&#160;million, the Company will receive $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" scale="6" id="f-483">18.5</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" scale="6" id="f-484">60.0</ix:nonFraction>&#160;million, the Company will receive $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" scale="6" id="f-485">23.5</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" scale="6" id="f-486">70.0</ix:nonFraction>&#160;million, the Company will receive $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" scale="6" id="f-487">28.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any single year equals or exceeds the sum of any two or more milestones, then the highest applicable milestone payment shall be paid with respect to such year.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that execution of the Purchase Agreement did not qualify as discontinued operations since it did not have a major effect on the Company&#8217;s operations and financial results.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Transaction closed on July 31, 2026 in which the Company received cash of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="f-488">73.6</ix:nonFraction>&#160;million, after customary purchase price adjustments. The $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" scale="6" id="f-489">70.0</ix:nonFraction>&#160;million of additional contingent milestones will be recognized in the period if and when they are each earned. As part of the Transaction, there are $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationTransactionBonus" scale="6" id="f-490">2.2</ix:nonFraction>&#160;million of transaction bonuses payable to certain employees of the Company that were hired by Zimmer at close that the Company will record as an expense in the third quarter of 2026. The $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationTransactionBonus" scale="6" id="f-491">2.2</ix:nonFraction>&#160;million of transaction bonuses will be paid by Zimmer. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-471-2">Upon the close of the Transaction on July 31, 2026, the Company entered into a transitional services arrangement, pursuant to which the Company will provide recordkeeping and other services; a development and commercialization agreement, pursuant to which both parties intend to continue the label expansion of iovera&#176; in the field of spasticity through United States Food and Drug Administration, or FDA, approval; and a sublease agreement, all of which are expected to operate through 2028.</ix:continuation> </span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-492" continuedAt="f-492-1" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="f-492-1" continuedAt="f-492-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales are primarily within the U.S. and consist of EXPAREL, ZILRETTA, and sales of bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of the Company&#8217;s bupivacaine liposome injectable suspension for veterinary use. In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, and as such, the Company will no longer recognize revenue associated with iovera&#176; after this date. For additional information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, customer rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to Department of Veterans Affairs hospitals, participating GPO members, 340B qualified entities and other contracted customers at prices lower than the list price. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers claim the difference between the amount invoiced and the discounted selling price through a chargeback issued by a wholesaler. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are determined at the time of sale and the Company generally issues credits for such amounts within weeks of receiving notification from a wholesaler. Reserves for chargebacks consist of anticipated credits the Company expects to issue based on expected units sold and chargebacks that customers have claimed for which credits have not yet been issued.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-492-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from&#160;<span style="-sec-ix-hidden:f-493">zero</span> to <ix:nonNumeric contextRef="c-96" name="pcrx:AccountsReceivablePaymentTerms" format="ixt-sec:durwordsen" id="f-494">four months</ix:nonNumeric> from the date of the transaction, and accordingly, there is no significant financing component.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company&#8217;s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company&#8217;s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-495" escape="true"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;EXPAREL</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-496">147,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-497">142,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-498">291,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-499">279,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-500">32,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-501">31,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-502">59,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-503">54,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;iovera&#176; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-504">6,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-505">5,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-506">12,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-507">10,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-508">3,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-509">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-510">4,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-511">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total net product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-512">190,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-513">180,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-514">367,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-515">347,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, after which the Company will no longer recognize revenue associated with iovera&#176;. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-516" continuedAt="f-516-1" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="f-516-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-517" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-518">28,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-519">43,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-520">38,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-521">28,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-522">68,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-523">81,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-524">134,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-525">152,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="f-526">9.8</ix:nonFraction> million of inventories related to iovera&#176;, comprised of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="f-527">5.6</ix:nonFraction> million of raw materials, $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="f-528">1.2</ix:nonFraction> million of work-in-process and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="f-529">3.0</ix:nonFraction> million of finished goods, were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  13</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-530" continuedAt="f-530-1" escape="true">FIXED ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-530-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-531" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-532">162,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-533">163,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-534">77,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-535">77,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-536">26,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-537">26,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-538">2,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-539">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-540">11,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-541">9,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-542">281,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-543">278,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-544">150,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-545">137,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-546">130,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-547">140,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="f-548">0.5</ix:nonFraction> million of fixed assets related to iovera&#176;, comprised of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="f-549">0.5</ix:nonFraction> million of machinery and equipment, net, along with nominal amounts of computer equipment and software, net, and office furniture and equipment, net, were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Depreciation on these fixed assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2026, depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-550">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-551">14.0</ix:nonFraction> million, respectively. For the three and six months ended June&#160;30, 2025, depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-552">13.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-553">19.8</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="f-554"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="f-555">5.5</ix:nonFraction></ix:nonFraction>&#160;million of accelerated depreciation expense during the three and six months ended June&#160;30, 2025 as a result of decommissioning its 45-liter EXPAREL batch manufacturing suite located at its Science Center Campus in San Diego, California. The Company continues to operate its 200-liter EXPAREL batch manufacturing suite at the same facility.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located outside of the U.S. in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-556">38.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-557">41.9</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, the Company had asset retirement obligations of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AssetRetirementObligation" scale="6" id="f-558">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetRetirementObligation" scale="6" id="f-559">3.9</ix:nonFraction>&#160;million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.</span></div></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-560" continuedAt="f-560-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-560-1" continuedAt="f-560-2"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases all of its facilities, including its EXPAREL and iovera&#176; handpiece manufacturing and research facilities at its Science Center Campus in San Diego, California. In April 2025, the Company moved its principal executive offices and corporate headquarters to Brisbane, California and in June 2026, the Company entered into a new lease in Brisbane, California to retain this office through 2036. The Company also has <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="pcrx:NumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="f-561">two</ix:nonFraction> embedded leases with Thermo Fisher Scientific Pharma Services, or Thermo Fisher, for the use of their manufacturing facility in Swindon, U.K. for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees have been allocated to the lease components based on a relative fair value basis. As part of the GQ Bio Acquisition in February 2025, the Company assumed GQ Bio&#8217;s European offices that include a research and development lab and offices in Luckenwalde, Germany.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Between February 2023 and April 2025, the Company had been recognizing sublease income for a portion of office space leased in Burlington, Massachusetts that was assumed as part of the Flexion Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, upon which the Company also entered into a sublease agreement through 2028. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-560-2"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. <ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-562" continuedAt="f-562-1" escape="true">Total operating lease expense, net is as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-562-1" continuedAt="f-562-2"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-563">3,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-564">3,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-565">6,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-566">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-567">620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-568">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-569">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-570">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="3" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-572">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-574">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-575">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-576">3,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-577">7,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-578">7,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-579">6,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-580">6,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recorded in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-581">7,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-582">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to net the reduction of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. <ix:continuation id="f-562-2" continuedAt="f-562-3">The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:</ix:continuation></span><ix:continuation id="f-562-3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-583">4.94</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-47" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-584">4.79</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-585">6.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-47" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-586">6.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-587" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Minimum<br/>Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-588">6,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-589">13,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-590">12,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-591">12,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-592">6,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-593">8,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-594">58,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-595">9,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-596">48,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  15</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-597" continuedAt="f-597-1" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-597-1" continuedAt="f-597-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill arose from the GQ Bio Acquisition in February 2025. As of June&#160;30, 2026 and December 31, 2025, the goodwill balance was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-598">19.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-599">20.2</ix:nonFraction>&#160;million, respectively. The change in the goodwill balance from December 31, 2025 was due to $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-600">0.6</ix:nonFraction>&#160;million in foreign currency translation adjustments. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had goodwill resulting from the acquisition of Pacira Pharmaceuticals, Inc. (the Company&#8217;s California operating subsidiary) from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc, a subsidiary of Molex Asia Holdings Ltd.) in 2007, the acquisition of MyoScience, Inc. (the &#8220;MyoScience Acquisition&#8221;) in 2019 and the Flexion Acquisition in 2021. Accumulated goodwill impairment charges through June&#160;30, 2026 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-601">163.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="f-602" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consists of in-process research and development, or IPR&amp;D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition. In June 2026, $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="6" id="f-603">53.2</ix:nonFraction>&#160;million, net, of developed technologies and a <ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-604">nominal</ix:nonFraction> amount of customer relationships related to iovera&#176; from the MyoScience Acquisition were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Amortization on these intangible assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, as of June&#160;30, 2026 are summarized as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-605">480,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-606">228,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-607">251,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-132" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="f-608">9 years, 9 months</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-609">33,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-610">33,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-611">513,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-612">228,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-613">285,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(1) The change in the gross carrying value compared to December&#160;31, 2025 reflects the impact of foreign currency translation adjustments related to the IPR&amp;D acquired from the GQ Bio Acquisition.</span></div></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-614">590,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-615">256,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-616">333,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-135" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="f-617">10 years, 5 months</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-618">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-619">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-620">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-137" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-621">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-622">590,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-623">256,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-624">333,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-625">34,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-626">34,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-627">624,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-628">256,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-629">368,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-630"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-631">14.3</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended June&#160;30, 2026 and 2025. Amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-632"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-633">28.6</ix:nonFraction></ix:nonFraction>&#160;million for both the six months ended June&#160;30, 2026 and 2025.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-597-2">Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="f-634">24.7</ix:nonFraction>&#160;million for the remaining six months of 2026, $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-635"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-636"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-637"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-638">49.4</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million each year from 2027 to 2030, and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-639">29.5</ix:nonFraction>&#160;million in 2031</ix:continuation>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  16</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-640" continuedAt="f-640-1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="f-640-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-641" escape="true"><div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pcrx:AccruedSellingGeneralAndAdministrativeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-642">26,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pcrx:AccruedSellingGeneralAndAdministrativeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-643">17,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pcrx:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-644">8,243</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pcrx:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-645">6,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued production costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pcrx:AccruedProductionCost" format="ixt:num-dot-decimal" scale="3" id="f-646">10,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pcrx:AccruedProductionCost" format="ixt:num-dot-decimal" scale="3" id="f-647">9,002</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-648">8,235</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-649">12,864</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-650">26,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-651">37,841</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-652">778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-653">782</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and wholesaler service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-654">12,682</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-655">11,554</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-656">93,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-657">95,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="f-658">0.7</ix:nonFraction>&#160;million of accrued expenses related to iovera&#176;, comprised of $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="6" id="f-659">0.5</ix:nonFraction>&#160;million of other accrued operating expenses and $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" scale="6" id="f-660">0.2</ix:nonFraction>&#160;million of product returns and wholesaler services, were reclassified to liabilities held for sale in conjunction with entering into the Purchase Agreement with Zimmer. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE&#160;10&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-661" continuedAt="f-661-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="f-661-1" continuedAt="f-661-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-662" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s outstanding debt is summarized as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-663">2.125</ix:nonFraction>% Convertible senior notes due May 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-664">282,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-665">281,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-666">81,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-667">91,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-668">363,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-669">372,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2029</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-670">287.5</ix:nonFraction>&#160;million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-671">2.125</ix:nonFraction>% convertible senior notes due 2029, or 2029 Notes, and entered into an indenture with Computershare Corporate Trust, N.A., or 2029 Indenture, with respect to the 2029 Notes. The 2029 Notes accrue interest at a fixed rate of <ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-672">2.125</ix:nonFraction>% per year, payable semiannually in arrears on May 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and November 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The 2029 Notes mature on May 15, 2029.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-673" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2029 Notes was as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-674">2.125</ix:nonFraction>% convertible senior notes due May 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-675">287,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-676">287,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-677">5,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-678">6,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt, net of deferred financing costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-679">282,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-680">281,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, the 2029 Notes had a market price of $999 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2029 Notes will be paid pursuant to the terms of the 2029 Indenture. In the event that all of the 2029 Notes are converted, the Company would be required to repay the $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="pcrx:DebtInstrumentRepurchasedInConversionFaceAmount" scale="6" id="f-681">287.5</ix:nonFraction>&#160;million in principal value in cash, whereas any conversion premium would be required to be repaid in any combination of cash and shares of its common stock (at the Company&#8217;s option).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding November 15, 2028, the 2029 Notes are convertible only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on June 30, 2024 (and only during such calendar quarter), if the last reported sale price of the Common Stock for at least <ix:nonFraction unitRef="trading_day" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-682">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="trading_day" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-683">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is equal to or greater than <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-684">130</ix:nonFraction>% of the conversion price on each applicable trading </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-661-2" continuedAt="f-661-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">day; (ii) during the <ix:nonFraction unitRef="trading_day" contextRef="c-147" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-685">five</ix:nonFraction> business-day period after any <ix:nonFraction unitRef="trading_day" contextRef="c-147" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-686">five</ix:nonFraction> consecutive trading-day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of the 2029 Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="pcrx:DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" scale="-2" id="f-687">98</ix:nonFraction>% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; (iii) upon the occurrence of specified corporate events; or (iv) upon a Company redemption. On or after November 15, 2028, until the close of business on the second scheduled trading day immediately preceding May 15, 2029, holders of the 2029 Notes may convert all or a portion of their 2029 Notes, at any time. No sinking fund is provided for the 2029 Notes. As of&#160;June&#160;30, 2026, the conditions for conversion were not met. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2029 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the <ix:nonNumeric contextRef="c-148" name="pcrx:SettlementPeriodConvertibleDebtConversionRequest" format="ixt-sec:durday" id="f-688">50</ix:nonNumeric> consecutive trading days during the observation period (as more fully described in the 2029 Indenture). For the principal, the Company will settle in cash per the terms of the 2029 Notes. For any excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2029 Notes is 25.2752 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-144" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-689">39.56</ix:nonFraction> per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2029 Notes represents a premium of approximately <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock" scale="-2" id="f-690">32.5</ix:nonFraction>% to the closing sale price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-691">29.86</ix:nonFraction> per share of the Company&#8217;s common stock on the Nasdaq Global Select Market on May 9, 2024, the date that the Company priced the private offering of the 2029 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On or after May 17, 2027 and on or before the <ix:nonFraction unitRef="trading_day" contextRef="c-150" decimals="INF" name="pcrx:DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" scale="0" id="f-692">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> scheduled trading day immediately before the maturity date, the Company may redeem for cash all or part of the 2029 Notes if (i) the 2029 Notes are &#8220;freely tradable&#8221; (as defined in the 2029 Indenture) and any accrued and unpaid additional interest has been paid as of the date the Company sends the related notice of the redemption and (ii) the last reported sales price of the Company&#8217;s common stock exceeds <ix:nonFraction unitRef="number" contextRef="c-151" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-693">130</ix:nonFraction>% of the conversion price then in effect for (1) each of at least <ix:nonFraction unitRef="trading_day" contextRef="c-151" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-694">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="trading_day" contextRef="c-151" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-695">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of the redemption; and (2) the trading day immediately before the date the Company sends such notice. The redemption price of each 2029 Note to be redeemed will be the principal amount of such 2029 Note, plus accrued and unpaid interest, if any. In addition, calling any 2029 Notes for redemption will constitute a make-whole fundamental change, in which case the conversion rate applicable to those 2029 Notes, if converted in connection with the redemption, will be increased in certain circumstances. Upon the occurrence of a &#8220;make-whole fundamental change&#8221; (as defined in the 2029 Indenture), subject to a limited exception for certain cash mergers, holders may require the Company to repurchase all or a portion of their 2029 Notes for cash at a price equal to <ix:nonFraction unitRef="number" contextRef="c-151" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-696">100</ix:nonFraction>% of the principal amount of the 2029 Notes to be repurchased plus any accrued and unpaid interest.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While the 2029 Notes are currently classified on the Company&#8217;s condensed consolidated balance sheet at June&#160;30, 2026 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company&#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2029 Notes have the election to convert the 2029 Notes at any time during the prescribed measurement period, the 2029 Notes would then be considered a current obligation and classified as such.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2024, in connection with the pricing of the 2029 Notes, and on May 10, 2024, in connection with the exercise in full by the initial purchasers of the 2029 Notes (the &#8220;Initial Purchasers&#8221;) of their option to purchase additional 2029 Notes, the Company entered into privately negotiated capped call transactions (the &#8220;Capped Call Transactions&#8221;) with certain of the Initial Purchasers of the 2029 Notes and/or their respective affiliates and/or other financial institutions (the &#8220;Option Counterparties&#8221;). The Capped Call Transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2029 Notes, the number of shares of the Company&#8217;s common stock underlying the 2029 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Capped Call Transactions are expected to reduce the potential dilution to the Company&#8217;s common stock upon any conversion of the 2029 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2029 Notes, as the case may be, upon any conversion of the 2029 Notes, with such reduction and/or offset subject to a cap. The cap price of the Capped Call Transactions will initially be approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="pcrx:DerivativeCappedCallPrice" scale="0" id="f-697">53.75</ix:nonFraction> per share, representing a premium of approximately <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="pcrx:DerivativePremiumPercentage" scale="-2" id="f-698">80</ix:nonFraction>% over the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-699">29.86</ix:nonFraction> per share of the Company&#8217;s common stock on May 9, 2024, and is subject to certain adjustments under the terms of the Capped Call Transactions. During the year ended December 31, 2024, the capped call was recorded as a reduction to additional paid-in capital at its cost of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" scale="6" id="f-700">26.7</ix:nonFraction>&#160;million, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" scale="6" id="f-701">6.5</ix:nonFraction>&#160;million deferred tax asset.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Capped Call Transactions are separate transactions entered into by the Company with the Option Counterparties, are not part of the terms of the 2029 Notes and will not affect any holder&#8217;s rights under the 2029 Notes. Holders of the 2029 Notes will not have any rights with respect to the Capped Call Transactions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-661-3" continuedAt="f-661-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2025, the Company entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Wells Fargo Bank, N.A., as administrative agent, swingline lender and an issuing bank, and certain lenders, to, among other things, retire the indebtedness outstanding under the Company&#8217;s then-existing TLA Credit Agreement and provide ongoing working capital. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a senior secured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) in an aggregate commitment amount of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-702">300.0</ix:nonFraction>&#160;million, with a letter of credit sublimit of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-703">10.0</ix:nonFraction>&#160;million and swingline loan sublimit of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-704">15.0</ix:nonFraction>&#160;million. The credit facility is secured by substantially all of the Company&#8217;s and each subsidiary guarantor&#8217;s assets and is scheduled to mature on July 3, 2030, subject to certain exceptions set forth in the Credit Agreement. Subject to certain conditions, the Company may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of any existing class of term loans by requesting one or more incremental term facilities in an aggregate principal amount not to exceed the greater of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="INF" name="pcrx:DebtInstrumentCovenantIncrementalDebtMaximum" scale="6" id="f-705">225.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="pcrx:DebtInstrumentCovenantIncrementalDebtMaximumPercent" scale="-2" id="f-706">100</ix:nonFraction>% of Consolidated Earnings Before Interest Taxes Depreciation and Amortization (EBITDA) (as defined in the Credit Agreement).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each revolving loan borrowing which is an alternate base rate borrowing will bear interest at a rate per annum equal to (i) a base rate, plus (ii) a spread based on the Company&#8217;s Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) ranging from <ix:nonFraction unitRef="number" contextRef="c-158" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-707">1.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-159" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-708">2.25</ix:nonFraction>%. Each revolving loan borrowing which is a term benchmark borrowing or daily simple SOFR (as defined in the Credit Agreement) borrowing will bear interest at a rate per annum equal to (i) a forward-looking term rate based on SOFR or a rate determined by reference to the daily simple SOFR, plus (ii) a spread based on the Company&#8217;s Senior Secured Net Leverage Ratio ranging from <ix:nonFraction unitRef="number" contextRef="c-160" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-709">2.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-161" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-710">3.25</ix:nonFraction>%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of June&#160;30, 2026, the Company was in compliance with all covenants under the Credit Agreement. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company incurred financing fees of approximately $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="f-711">2.1</ix:nonFraction>&#160;million which were recorded as a noncurrent other asset on the Company&#8217;s condensed consolidated balance sheet. The financing fees are amortized over the term of the Credit Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into the Credit Agreement, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="f-712">101.0</ix:nonFraction>&#160;million under the Revolving Credit Facility, of which $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:LineOfCredit" scale="6" id="f-713">81.0</ix:nonFraction>&#160;million is outstanding as of June&#160;30, 2026 after the Company made repayments of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="f-714">10.0</ix:nonFraction>&#160;million during the six months ended June&#160;30, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="f-715">10.0</ix:nonFraction>&#160;million during the year ended December&#160;31, 2025. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, borrowings under the Revolving Credit Facility consisted entirely of term SOFR borrowings at an approximate all-in rate of <ix:nonFraction unitRef="number" contextRef="c-164" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="f-716">6.72</ix:nonFraction>%.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Term Loan A Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the Company entered into a credit agreement (as amended and/or restated to date, the &#8220;TLA Credit Agreement&#8221;) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders. The term loan issued under the TLA Credit Agreement (the &#8220;TLA Term Loan&#8221;) was issued at a <ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="pcrx:DebtInstrumentDiscountRate" scale="-2" id="f-717">0.30</ix:nonFraction>% discount and provided for a single-advance term loan A facility in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-718">150.0</ix:nonFraction>&#160;million, which was secured by substantially all of the Company&#8217;s and any subsidiary guarantor&#8217;s assets. The net proceeds of the TLA Term Loan were approximately $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="f-719">149.6</ix:nonFraction>&#160;million after deducting an original issue discount of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="f-720">0.4</ix:nonFraction>&#160;million. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The TLA Term Loan was scheduled to mature on March 31, 2028 and the TLA Credit Agreement required quarterly repayments of principal in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="f-721">2.8</ix:nonFraction>&#160;million which commenced on June 30, 2023 and increased to $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="f-722">3.8</ix:nonFraction>&#160;million on March 31, 2025, with an originally stated balloon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="f-723">85.3</ix:nonFraction>&#160;million due at maturity.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2025, the Company used a portion of the $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-724">300.0</ix:nonFraction>&#160;million of Revolving Credit Facility to repay the remaining indebtedness outstanding under the TLA Credit Agreement, which consisted of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:DebtInstrumentRepaidPrincipal" scale="6" id="f-725">98.8</ix:nonFraction>&#160;million and its final interest payment of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:InterestPaid" scale="6" id="f-726">0.1</ix:nonFraction>&#160;million, and terminated the TLA Credit Agreement. The Company did not incur any prepayment penalties or fees in connection with the termination of the TLA Credit Agreement. The prepayment resulted in a loss on early extinguishment of debt of approximately $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-727">1.0</ix:nonFraction>&#160;million which was recognized during the three months ended September 30, 2025. Prior to the TLA Credit Agreement extinguishment, the Company made voluntary principal prepayments of $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RepaymentsOfDebt" scale="6" id="f-728">6.6</ix:nonFraction>&#160;million during the year ended December 31, 2025.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-661-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2025</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-729">402.5</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-174" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-730">0.750</ix:nonFraction>% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), with respect to the 2025 Notes. The 2025 Notes accrued interest at a fixed rate of <ix:nonFraction unitRef="number" contextRef="c-174" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-731">0.750</ix:nonFraction>% per year, which was payable semiannually in arrears on February 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and August 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company used part of the net proceeds from the issuance of the 2029 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="f-732">200.0</ix:nonFraction>&#160;million aggregate principal amount of the 2025 Notes in privately negotiated transactions at a discount for $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="f-733">191.4</ix:nonFraction>&#160;million in cash (including accrued interest). The partial repurchase of the 2025 Notes resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-734">7.5</ix:nonFraction>&#160;million gain on early extinguishment of debt during the year ended December 31, 2024. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2025, the 2025 Notes matured and the Company settled the remaining outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:DebtInstrumentRepaidPrincipal" scale="6" id="f-735">202.5</ix:nonFraction>&#160;million in cash. Upon the maturity of the 2025 Notes, a <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="f-736">nominal</ix:nonFraction> gain on extinguishment of debt was recognized due to certain holders having converted their 2025 Notes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="c-1" name="pcrx:ScheduleOfInterestExpenseTableTextBlock" id="f-737" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-738">3,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-739">3,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-740">6,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-741">7,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-742">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-743">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-744">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-745">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-746">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-747">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-748">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-749">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" format="ixt:fixed-zero" scale="3" id="f-750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" format="ixt:fixed-zero" scale="3" id="f-751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" format="ixt:fixed-zero" scale="3" id="f-752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" scale="3" id="f-753">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-754">3,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-755">4,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-756">7,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-757">9,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-758">3.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-759">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-760">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-761">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-764" continuedAt="f-764-1" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="f-764-1" continuedAt="f-764-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The Revolving Credit Facility reprices within a maximum of three months due to its variable interest rate terms. The fair value of the Company&#8217;s Revolving Credit Facility approximates carrying value (Level 2) due to its repricing feature. The fair value of the Company&#8217;s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company&#8217;s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amount of equity investments and convertible notes receivable without readily determinable fair values included in investments and other assets on the consolidated balance sheet are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-764-2" continuedAt="f-764-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="f-765" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2026, the carrying values and fair values of the Company&#8217;s financial assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-766">7,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-769">7,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-770">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-773">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-774">17,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-777">17,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;<ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-778">2.125</ix:nonFraction>% convertible senior notes due 2029 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-779">282,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="f-780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-781">287,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-783">81,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="f-784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-785">81,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="f-786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The closing price of the Company&#8217;s common stock as reported on the Nasdaq Global Select Market was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-787">25.37</ix:nonFraction> per share on June&#160;30, 2026, compared to a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-788">39.56</ix:nonFraction> per share. At June&#160;30, 2026, as the conversion price was above the stock price, the requirements for conversion have not been met.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis, including assets and liabilities acquired in a business combination and long-lived assets, which would be recognized at fair value if deemed impaired. The fair value in these instances would be determined using Level 3 inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity and Convertible Note Investments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. For the equity investments as of June&#160;30, 2026, there have not been any impairments or upward adjustments. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-789" continuedAt="f-789-1" escape="true">The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-789-1" continuedAt="f-789-2"><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Equity Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes Receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-790">15,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-791">11,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-792">27,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="3" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="f-794">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="f-795">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" format="ixt:num-dot-decimal" scale="3" id="f-796">4,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" format="ixt:num-dot-decimal" scale="3" id="f-797">7,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" format="ixt:num-dot-decimal" scale="3" id="f-798">11,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain of prior investments </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="f-799">4,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="f-800">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="f-801">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settled investments </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="f-802">8,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="f-803">5,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="f-804">13,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-805">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-807">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-808">7,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-809">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-810">10,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212; No activity for the six months ended June&#160;30, 2026 &#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-814">7,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-815">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-816">10,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:2pt"><ix:continuation id="f-789-2" continuedAt="f-789-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company&#8217;s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining <ix:nonFraction unitRef="number" contextRef="c-202" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-817">81</ix:nonFraction>% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-818">4.2</ix:nonFraction>&#160;million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-819">1.7</ix:nonFraction>&#160;million in interest income. These gains were included in the condensed consolidated statement of cash flows for the six months ended June&#160;30, 2025 within other net gains</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-789-3">.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, an impairment of an equity investment and convertible note receivable totaling $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-820">11.0</ix:nonFraction>&#160;million was recorded in other, net in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the Company invested $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="6" id="f-821">1.3</ix:nonFraction>&#160;million in a convertible note receivable related to one of its existing early-stage strategic investments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-764-3" continuedAt="f-764-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized a contingent consideration liability related to the Flexion Acquisition in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-822">17.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-823">18.1</ix:nonFraction>&#160;million as of June&#160;30, 2026 and December&#160;31, 2025, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a Monte Carlo simulation. These inputs include, as applicable, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-824">372.3</ix:nonFraction>&#160;million if certain regulatory and commercial milestones are met. The aggregate amount was initially $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-825">425.5</ix:nonFraction>&#160;million prior to the Company&#8217;s September 2022 decision to formally discontinue further development of Flexion&#8217;s investigational product candidate, PCRX-301. The Company&#8217;s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within <ix:nonNumeric contextRef="c-209" name="pcrx:ContingentConsiderationPaymentTerm" format="ixt-sec:durday" id="f-826">60</ix:nonNumeric> days of the end of the fiscal quarter of achievement. During the three months ended June&#160;30, 2026, the Company recognized contingent consideration charges of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-827">1.7</ix:nonFraction>&#160;million due to revisions to the latest discount rates. During the six months ended June&#160;30, 2026, the Company recognized contingent consideration gains of $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-828">0.6</ix:nonFraction>&#160;million due to a reduction in its sales forecast through the milestone expiration date of December 31, 2030, partially offset by revisions to the latest discount rates. During the three and six months ended June&#160;30, 2025, the Company recognized contingent consideration gains of $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-829">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-830">3.0</ix:nonFraction>&#160;million, respectively, due to revisions to the latest discount rates. These adjustments were recorded within other operating expenses, net in the condensed consolidated statements of operations. At June&#160;30, 2026, the weighted average discount rate was <ix:nonFraction unitRef="number" contextRef="c-214" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-831">7.8</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-832" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company&#8217;s contingent consideration:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Ranges Utilized as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June&#160;30, 2026</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-215" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-833">7.6</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-216" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-834">8.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for remaining regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-217" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-835">0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-836" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company&#8217;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-837">20,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-838">2,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-839">18,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-840">614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-841">17,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale <span id="i82c77417cd18446ea0aa2ecbfbc45bff_9868"></span>Investments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency, government and Yankee bonds with maturities greater than three months, but less than one year. Net unrealized gains and losses (excluding credit losses, if any) from the Company&#8217;s short-term investments are reported in other comprehensive income (loss). At June&#160;30, 2026 and December&#160;31, 2025, all of the Company&#8217;s short-term investments are classified as available-for-sale investments and are determined to be Level 2 instruments which are measured at fair value using standard industry models with observable inputs, with the exception of U.S. government bonds. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an &#8220;A&#8221; or better rating by Standard&#160;&amp; Poor&#8217;s.&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-764-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-842" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s available-for-sale investments at June&#160;30, 2026 and December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30, 2026 Investments</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-843">27,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-845">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-846">27,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-847">18,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-849">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-850">18,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-851">45,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-853">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-854">45,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2025 Investments</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-855">54,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-856">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-857">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-858">54,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-859">24,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-860">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-862">24,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-863">79,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-864">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-865">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-866">79,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2026, there were no investments available for sale that were materially less than their amortized cost.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects to recognize its interest receivable separate from its available-for-sale investments. At June&#160;30, 2026 and December&#160;31, 2025, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InterestReceivable" scale="6" id="f-867">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InterestReceivable" scale="6" id="f-868">0.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As of June&#160;30, 2026, <ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="pcrx:NumberOfMajorCustomers" format="ixt-sec:numwordsen" scale="0" id="f-869">three</ix:nonFraction> wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable, at <ix:nonFraction unitRef="number" contextRef="c-233" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-870">32</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-234" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-871">27</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-235" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-872">17</ix:nonFraction>%, which excludes the amounts that were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer (for more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). At December&#160;31, 2025, <ix:nonFraction unitRef="wholesaler" contextRef="c-195" decimals="INF" name="pcrx:NumberOfMajorCustomers" format="ixt-sec:numwordsen" scale="0" id="f-873">three</ix:nonFraction> wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable, at <ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-874">32</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-237" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-875">23</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-238" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-876">17</ix:nonFraction>%. For additional information regarding the Company&#8217;s wholesalers, see Note 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company&#8217;s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of June&#160;30, 2026, the allowance for credit losses on the Company&#8217;s accounts receivable was <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-877">not</ix:nonFraction> material. As of December&#160;31, 2025, there were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-878">0.7</ix:nonFraction>&#160;million of allowances for credit losses on the Company&#8217;s accounts receivable.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  23</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-879" continuedAt="f-879-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-879-1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-880" continuedAt="f-880-1" escape="true"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the changes in the balances of the Company&#8217;s accumulated other comprehensive income for the periods presented (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-881">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-882">4,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-883">4,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net unrealized loss on investments, net of tax </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-884">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-886">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-888">1,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-889">1,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-890">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-891">3,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-892">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-893">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-894">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-895">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net unrealized loss on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-896">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-898">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-900">3,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-901">3,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-902">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-903">4,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-904">4,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-880-1">(1) Net of a <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:fixed-zero" scale="6" id="f-905"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:fixed-zero" scale="6" id="f-906">nominal</ix:nonFraction></ix:nonFraction> tax benefit for both the six months ended June&#160;30, 2026 and 2025, respectively.</ix:continuation> </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2025, the Company announced that its board of directors approved a share repurchase program which authorizes the Company to repurchase up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-907">300.0</ix:nonFraction>&#160;million of its outstanding common stock. Repurchases under this program may be made at management&#8217;s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026. During the six months ended June&#160;30, 2026, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-908">2,244,553</ix:nonFraction> shares of its common stock through open market transactions for $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-909">50.4</ix:nonFraction>&#160;million which included less than $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="pcrx:ShareRepurchaseProgramBrokerFees" scale="6" id="f-910">0.1</ix:nonFraction>&#160;million of broker fees and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTax" scale="6" id="f-911">0.4</ix:nonFraction>&#160;million of accrued excise tax. As of June&#160;30, 2026, $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="f-912">100.0</ix:nonFraction> million remains available for future repurchases under this authorization.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of the Company&#8217;s common stock are accounted for at cost and recorded as treasury stock. The broker fees incurred and excise tax on repurchases of the Company&#8217;s common stock are recorded as a cost of acquiring treasury stock. Any reissued treasury stock will be accounted for at average cost. Gains or losses on reissued treasury stock arising from the difference between the average cost and the fair value of the award will be recorded in additional paid-in capital.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company&#8217;s share repurchase plan, during the six months ended June&#160;30, 2026, the Company withheld <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-913">366,650</ix:nonFraction> shares of common stock to cover employee tax withholding obligations of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-914">7.8</ix:nonFraction>&#160;million for vested restricted stock units. All shares of common stock withheld to cover employee tax withholding obligations are retired and are done so pursuant to the terms of the Company&#8217;s stock incentive plans and related equity grant agreements rather than the Company&#8217;s share repurchase program. Retired shares of common stock are not available for future issuance under the Company&#8217;s stock incentive plans.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  24</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE&#160;13&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="f-915" continuedAt="f-915-1" escape="true">STOCK PLANS</ix:nonNumeric></span></div><ix:continuation id="f-915-1" continuedAt="f-915-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plans</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pacira BioSciences, Inc. Amended and Restated 2011 Stock Incentive Plan, or 2011 Plan, was originally adopted by the Company&#8217;s board of directors and approved by its stockholders in June 2011 and was amended and restated in June 2014, June 2016, June 2019, June 2021, June 2023 and June 2025. The 2011 Plan allows for the granting of incentive stock options, non-statutory stock options, restricted stock units, and other stock-based awards&#8212;including PSUs.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan, or as amended and restated to date, the A&amp;R Inducement Plan, was originally approved and adopted by the Company&#8217;s board of directors in April 2014, pursuant to which awards could be made to new employees as a material inducement to such persons entering into employment with the Company. The A&amp;R Inducement Plan was amended and restated in December 2023, September 2024, January 2025 and January 2026. The January 2026 amendment and restatement added an additional <ix:nonFraction unitRef="shares" contextRef="c-252" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-916">750,000</ix:nonFraction> shares of the Company&#8217;s common stock to bring the total amount of shares reserved for issuance under the A&amp;R Inducement Plan to <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-917">3,060,000</ix:nonFraction>, of which <ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-918">703,390</ix:nonFraction> shares remained available for issuance as of June&#160;30, 2026, and extended the term of the A&amp;R Inducement Plan such that it will now expire on January 1, 2036. The A&amp;R Inducement Plan allows for the granting of nonstatutory stock options, restricted stock awards and other stock-based awards.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R Inducement Plan was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with this rule, awards under the A&amp;R Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors or the board of directors or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if they are granted such award in connection with their commencement of employment with the Company or a subsidiary and such grant is an inducement material to their entering into employment with the Company or such subsidiary.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Awards</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the board of directors, upon recommendation of the People and Compensation Committee of the board of directors, has approved individually negotiated grants of options and restricted stock units for certain of the Company&#8217;s officers in connection with their respective appointments, in each case, pursuant to the inducement plan in effect at such time.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-919" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-920">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-921">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-922">3,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-923">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-924">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-925">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-926">4,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-927">4,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-928">10,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-929">11,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-930">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-931">21,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-932">14,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-933">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-934">28,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-935">30,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-936">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">4,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-938">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-939">8,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-940">11,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">10,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">21,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">20,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-944">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-946">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-948">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-949">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-950">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-951">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-952">14,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-953">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-954">28,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-955">30,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-915-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-956" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company&#8217;s stock option, RSU and PSU activity for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Number of Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Weighted Average Exercise Price (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Outstanding at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-957">6,374,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-958">40.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-959">300,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-960">22.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-961">27,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-962">16.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-963">90,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-964">26.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-965">432,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-966">44.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Outstanding at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-967">6,123,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-968">39.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Weighted Average Grant Date Fair Value (Per Share)</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-969">4,160,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-971">27.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-972">2,245,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-973">202,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-974">21.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-975">1,205,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-977">30.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-978">355,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-980">26.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-981">4,845,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-982">202,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-289" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-983">24.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted during the six months ended June&#160;30, 2026 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-984">12.58</ix:nonFraction> per share. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-985" continuedAt="f-985-1" escape="true">The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-985-1"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumptions</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-986">None</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-987">4.10</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-988">56.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-989">5.74</ix:nonNumeric> years</span></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP. The ESPP was amended to increase the number of shares of common stock that may be sold under the ESPP by an additional <ix:nonFraction unitRef="shares" contextRef="c-290" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-990">800,000</ix:nonFraction> shares, bringing the total amount of shares reserved for issuance under the ESPP to <ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-991">1,800,000</ix:nonFraction>, of which <ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-992">869,062</ix:nonFraction> shares remained available for issuance as of June&#160;30, 2026, and extended the term of the ESPP such that it will now expire on June 9, 2036.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP features <ix:nonFraction unitRef="offering_period" contextRef="c-281" decimals="INF" name="pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" format="ixt-sec:numwordsen" scale="0" id="f-993">two</ix:nonFraction> <ix:nonNumeric contextRef="c-281" name="pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="f-994">six-month</ix:nonNumeric> offering periods per year, running from January 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to June 30</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and July 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to December 31</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-995">85</ix:nonFraction>% of the closing fair market value of the Company&#8217;s common stock on either the offering date or the purchase date, whichever is lesser. During the six months ended June&#160;30, 2026, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-996">82,837</ix:nonFraction> shares were purchased and issued through the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  26</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE&#160;14&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-997" continuedAt="f-997-1" escape="true">NET INCOME (LOSS) PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="f-997-1"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and PSUs and the purchase of shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible senior notes are treated under the if-converted method. Adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible senior notes on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible senior notes on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-998" escape="true"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per common share for the three and six mon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ths ended June&#160;30, 2026 and 2025 (in thousands, except per common share amounts):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net income (loss)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-999">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1000">4,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1001">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1002">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Weighted average common shares outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1003">39,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1004">45,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1005">39,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1006">45,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1007">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1009">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Dilutive effect of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1011">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1013">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Weighted average common shares outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1015">40,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1016">45,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1017">40,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1018">45,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1019"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1020">0.12</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1021"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1022">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1023"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1024">0.19</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1025"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1026">0.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1027" escape="true"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1028">5,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1029">6,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1030">6,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1031">6,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2025 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-296" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1033">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="f-1034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1035">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1036">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-301" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1037">4,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-302" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1038">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1039">4,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-304" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1040">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1041">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-306" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1042">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1043">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1044">8,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1045">14,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1046">8,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1047">14,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">The table above does not include contingent shares associated with the 2029 Notes being convertible at a premium, nor does it include PSUs as their performance targets have not yet been achieved.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  27</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1048" continuedAt="f-1048-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-1048-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1049" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Domestic</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1050">5,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1051">4,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1052">10,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1053">6,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1054">3,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1055">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1056">2,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-1057">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1058">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1059">1,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1060">7,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1061">6,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1062">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1063">2,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1064">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1065">6,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1066">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1067">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1069">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax expense represents the estimated annual effective tax rate applied to the year-to-date operating re</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sults, adjusted for certain discrete tax items.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate for the three and six months ended June&#160;30, 2026 was primarily impacted by the reversal of its U.K. operating subsidiary&#8217;s valuation allowance, partially offset by costs related to non-deductible stock-based compensation and non-deductible executive compensation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate for the three and six months ended June&#160;30, 2025 was primarily impacted by costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2026, the Company recorded a discrete benefit of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlementsForeign" scale="6" id="f-1070">6.4</ix:nonFraction>&#160;million resulting from a change in judgment regarding future-year realizability of deferred tax assets in its U.K. operations, primarily related to fixed asset temporary differences. The reduction reflects management&#8217;s conclusion, based on all available positive and negative evidence, that realization of the U.K. deferred tax assets is more likely than not. As a result, the discrete benefit significantly reduced the Company&#8217;s effective tax rate for the three and six months ending June 30, 2026.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest the Company&#8217;s iovera&#176; business. The Transaction closed on July 31, 2026. The parties agreed to treat the transaction as a deemed asset sale for U.S. federal income tax purposes through an election under Section 338(h)(10) of the Internal Revenue Code. As the Transaction closed subsequent to June 30, 2026, the income tax effects of the transaction, including changes in the valuation allowance for capital-loss carryforwards, were not recognized in the income tax provisions for the three and six months ending June 30, 2026. For more information on the divestiture of iovera&#176;, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of both June&#160;30, 2026 and December&#160;31, 2025, the Company had an income taxes payable balance of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccruedIncomeTaxes" scale="6" id="f-1071"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedIncomeTaxes" scale="6" id="f-1072">6.1</ix:nonFraction></ix:nonFraction>&#160;million that was included in other liabilities within the condensed consolidated balance sheet, related to unrecognized tax benefits. As of both June&#160;30, 2026 and December&#160;31, 2025, the Company had less than $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-1073"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-1074">0.1</ix:nonFraction></ix:nonFraction>&#160;million of current income taxes payable that was included in accrued expenses within the condensed consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, the Company had income taxes receivable and prepaid income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-1075">8.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-1076">8.2</ix:nonFraction>&#160;million, respectively, which were included in prepaid expenses and other current assets within the condensed consolidated balance sheet. The balances include a $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-1077">4.6</ix:nonFraction>&#160;million tax refund claim for estimated federal taxes made prior to the July 2025 enactment of federal legislation known as the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Reform</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA resulted in changes to U.S. federal income tax law. Significant provisions of the OBBBA include the permanent extension of certain provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. In accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company was required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring its estimated U.S. deferred tax assets and liabilities. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-1078">124.6</ix:nonFraction>&#160;million of a gross deferred tax asset attributed to unamortized U.S. capitalized research and development costs as of December&#160;31, 2024, of which $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="pcrx:DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" scale="6" id="f-1079"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="pcrx:DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" scale="6" id="f-1080">62.3</ix:nonFraction></ix:nonFraction>&#160;million will be deductible on both its 2025 and 2026 income tax returns. There are no other material impacts to the Company related to the enactment of the OBBBA.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  28</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE&#160;16&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" id="f-1081" continuedAt="f-1081-1" escape="true">OTHER OPERATING EXPENSES, NET</ix:nonNumeric></span></div><ix:continuation id="f-1081-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" id="f-1082" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses, net for the six months ended June&#160;30, 2026 and 2025 are summarized below (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1083">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" format="ixt:fixed-zero" scale="3" id="f-1084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1085">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" format="ixt:fixed-zero" scale="3" id="f-1086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration charges (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-1087">1,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-1088">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-1089">614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-1090">3,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="3" id="f-1092">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1094">2,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:fixed-zero" scale="3" id="f-1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:fixed-zero" scale="3" id="f-1096">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:fixed-zero" scale="3" id="f-1097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:num-dot-decimal" scale="3" id="f-1098">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-1099">7,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-1100">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-1101">5,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-1102">6,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture-Related Expenses</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized divestiture-related expenses of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" scale="6" id="f-1103"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" scale="6" id="f-1104">5.9</ix:nonFraction></ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2026, primarily related to third-party services and legal fees associated with divesting iovera&#176; to Zimmer. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flexion Acquisition Contingent Consideration</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized contingent consideration charges of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1105">1.7</ix:nonFraction>&#160;million and gains of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1106">0.6</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2026, respectively. The Company recognized contingent consideration gains of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1107">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1108">3.0</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2025, respectively. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Expenses</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related expenses of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-1109">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-1110">2.5</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2025, respectively, primarily related to third-party services and legal fees associated with the GQ Bio Acquisition. </span></div><div style="margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Settlement</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:LitigationSettlementLoss" scale="6" id="f-1111">7.0</ix:nonFraction>&#160;million</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of costs during the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related to the patent infringement suits against the eVenus ANDA Filers (as defined below). For more information, see Note 17, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies.</span></div></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE&#160;17&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1112" continuedAt="f-1112-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-1112-1" continuedAt="f-1112-2"><div style="margin-bottom:7pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to its patents and intellectual property, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows. The Company is not in a position to assess the likelihood of any potential losses or adverse effect on its financial condition or to estimate the amount or range of potential losses, if any, from the following actions at this time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Milestone Litigation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (&#8220;Pacira CryoTech&#8221;), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (&#8220;Fortis&#8221;), solely in its capacity as representative for the former securityholders of MyoScience and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the &#8220;MyoScience Merger Agreement&#8221;), specifically related to the achievement of certain milestone payments under the MyoScience Merger Agreement. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the MyoScience Merger Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-1112-2" continuedAt="f-1112-3"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A trial was conducted in September 2023. In January 2025, the Court issued its decision, finding that the disputed milestones were not met and therefore granted judgment to the Company in full. In March 2025, the Company filed a motion to recover attorney fees, and the parties subsequently agreed to settle the amount of expenses owed to the Company, whereby Fortis agreed to pay the Company $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="f-1113">5.2</ix:nonFraction>&#160;million and waived its rights to appeal the decision. A final judgment and order was entered in April 2025. The $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="f-1114">5.2</ix:nonFraction>&#160;million payment received was accounted for as a recovery of losses and recorded against selling, general and administrative expense in the six months ended June&#160;30, 2025 within the condensed consolidated statement of operations, consistent with where the previous expenses were recorded.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eVenus Pharmaceutical Laboratories Litigations</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, December 2021, April 2023 and May 2024, the Company received Notice Letters advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application, or ANDA, with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic bupivacaine liposome injectable suspension in the U.S. prior to the expiration of certain of the Company&#8217;s U.S. patents.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in November 2021, the Company filed various patent infringement suits against eVenus, its parent company (Jiangsu Hengrui Pharmaceuticals, Co. Ltd., or Jiangsu Hengrui) and Fresenius Kabi USA, LLC, or Fresenius, (together, the &#8220;eVenus ANDA Filers&#8221;) in the U.S. District Court for the District of New Jersey asserting infringement of U.S. Patent No. 11,033,495 (the &#8216;495 patent) (21-cv-19829), U.S. Patent No. 11,179,336 (the &#8216;336 patent) (22-cv-00718), U.S. Patent No. 11,426,348 (the &#8216;348 patent) (23-cv-02367), U.S. Patent Nos. 11,819,574 (the &#8216;574 patent) and 11,819,575 (the &#8216;575 patent) (24-cv-06294), and U.S. Patent No. 11,925,706 (the &#8216;706 patent) (24-cv-07680). In December 2024, the Company filed a patent infringement suit against Fresenius and Jiangsu Hengrui in the Northern District of Illinois (24-cv-12416) asserting that the ANDA products will infringe U.S. Patent No. 12,156,940 (the &#8216;940 patent). Also in December 2024, the eVenus ANDA Filers filed an action for declaratory judgment of non-infringement and invalidity with respect to the &#8216;940 patent in the District Court of New Jersey (24-cv-11014).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2025, the Company, along with its operating subsidiary, Pacira Pharmaceuticals, Inc., entered into a settlement agreement with the eVenus ANDA Filers with respect to the litigations noted above. Pursuant to the settlement agreement, the eVenus ANDA Filers will be enjoined from marketing a generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit, except as provided for in the settlement agreement, as described below. In settlement of all outstanding claims in the litigations, the Company agreed to provide the eVenus ANDA Filers with a license to the Company&#8217;s patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date that is sometime in early 2030. While the agreed-upon volume-limited percentages are confidential, they begin at a high single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each <ix:nonNumeric contextRef="c-311" name="pcrx:LitigationSettlementVolumeLimitedIncreasePeriod" format="ixt-sec:durwordsen" id="f-1115">12-month</ix:nonNumeric> period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next <ix:nonFraction unitRef="period" contextRef="c-311" decimals="INF" name="pcrx:LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" format="ixt-sec:numwordsen" id="f-1116">two</ix:nonFraction> <ix:nonNumeric contextRef="c-311" name="pcrx:LitigationSettlementVolumeLimitedIncreasePeriod" format="ixt-sec:durwordsen" id="f-1117">12-month</ix:nonNumeric> periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final <ix:nonNumeric contextRef="c-311" name="pcrx:LitigationSettlementVolumeLimitedMaximumPercentagePeriod" format="ixt-sec:durwordsen" id="f-1118">three years</ix:nonNumeric> of the agreement. In addition, the Company has agreed to provide the eVenus ANDA Filers with a license to its patents required to manufacture and sell an unlimited quantity of a generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date in 2039. In addition, in recognition of the Company&#8217;s expected savings with respect to, among other things, the avoidance of fees, costs, time and resources associated with continuing the litigations, the Company paid the eVenus ANDA Filers $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:LitigationSettlementLoss" scale="6" id="f-1119">7.0</ix:nonFraction>&#160;million. This legal settlement cost was recorded within other operating expenses, net in the six months ended June&#160;30, 2025 in the Company&#8217;s condensed consolidated statement of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The WhiteOak Group and Qilu Pharmaceutical Litigations</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, the Company received <ix:nonFraction unitRef="certificate" contextRef="c-312" decimals="INF" name="pcrx:NumberOfParagraphIVCertifications" format="ixt-sec:numwordsen" id="f-1120">two</ix:nonFraction> separate Paragraph IV Certifications from <ix:nonFraction unitRef="manufacturer" contextRef="c-312" decimals="INF" name="pcrx:NumberOfGenericDrugManufacturers" format="ixt-sec:numwordsen" id="f-1121">two</ix:nonFraction> Chinese generic drug manufacturers (The WhiteOak Group, Inc., or WhiteOak, of Rockville, Maryland (a subsidiary of Zhejiang Haichang Biotechnology Co., Ltd.) and Qilu Pharmaceutical (Hainan) Co., Ltd., or Qilu), each advising that they had submitted an ANDA to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of EXPAREL in the U.S. Each letter alleged that EXPAREL patents listed in the FDA&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Orange Book&#8221;) are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed products described in these ANDA submissions.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November, 26, 2025, the Company filed a patent infringement suit against WhiteOak and Qilu in the U.S. District Court of the District of Delaware (25-cv-1445) asserting infringement of U.S. Patent No. 11,033,495 (the &#8216;495 patent), U.S. Patent Nos. 11,819,574 (the &#8216;574 patent) U.S. Patent No. 12,144,890 (the &#8216;890 patent), U.S. Patent No. 12,151,024 (the &#8216;024 Patent), U.S. Patent No. 12,156,940 (the &#8216;940 patent), U.S. Patent No. 12,251,468 (the &#8216;468 Patent), U.S. Patent No. 12,296,047 (the &#8217;047 Patent), U.S. Patent No. 12,318,483 (the &#8216;483 Patent), and U.S. Patent No. 12,370,142 (the &#8216;142 Patent). On January 23, 2026 and February 5, 2026, Qilu and WhiteOak, respectively, each answered the complaint and asserted affirmative </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-1112-3" continuedAt="f-1112-4"><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">defenses and counterclaims asserting, inter alia, invalidity, unenforceability and non-infringement. On June 24, 2026, WhiteOak amended their answer to assert counterclaims for inequitable conduct. The Company intends to vigorously defend its intellectual property rights relating to EXPAREL. The Company is unable to predict the outcome of this litigation at this time.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, Leandro Alvarez filed a putative class action on behalf of Company shareholders between August 2, 2023 and August 8, 2024 against the Company and certain of its officers, in the District Court of New Jersey (25-cv-322). The complaint alleged that the Company made materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The Company filed a motion to dismiss the complaint, and in February 2026, the suit was dismissed with prejudice. An appeal was filed in March 2026 which was voluntarily dismissed with prejudice in May 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Action</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2025, a Shareholder Derivative suit, Young v. Lee, et al, was filed in the District of New Jersey (25-cv-11841). The complaint alleges that certain of the Company&#8217;s officers and members of the Company&#8217;s board of directors breached their fiduciary duties by making materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The suit was voluntarily dismissed without prejudice in May 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Development Foundation</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company&#8217;s &#8216;495 patent was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company&#8217;s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit sought a declaration from the court that the Company owed no royalties to RDF with respect to its EXPAREL product after December 24, 2021.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the U.S. District Court, District of Nevada granted the Company&#8217;s motion for partial summary judgment in respect to the Company&#8217;s claim for a declaration that it no longer owes royalties for EXPAREL made under its 45-liter batch manufacturing process as of December 24, 2021. A trial as to whether royalties were owed on EXPAREL made under the Company&#8217;s enhanced, larger-scale manufacturing process was conducted in September 2024. In April 2025, the Court issued judgment in favor of the Company. As a result, the low single-digit royalty that the Company had been paying RDF is eliminated, and the Company sought repayment of up to $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="pcrx:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" scale="6" id="f-1122">23.1</ix:nonFraction>&#160;million, plus interest, from RDF, representing the royalties that the Company paid to RDF under protest on the collection of revenues of EXPAREL that occurred after December 24, 2021. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the U.S. District Court for the District of Nevada issued judgment in favor of the Company declaring that RDF is required to repay Pacira $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="f-1123">23.1</ix:nonFraction>&#160;million in royalties on EXPAREL sales that were previously paid under protest. The Nevada Court also awarded Pacira an additional interest payment of $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:LitigationSettlementInterest" scale="6" id="f-1124">5.2</ix:nonFraction>&#160;million in statutory interest on the royalties paid under protest. In July 2025, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:ProceedsFromLegalSettlements" scale="6" id="f-1125">28.3</ix:nonFraction>&#160;million cash payment for which $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="f-1126">23.1</ix:nonFraction>&#160;million was recorded within other operating expenses, net and $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:LitigationSettlementInterest" scale="6" id="f-1127">5.2</ix:nonFraction>&#160;million was recorded within interest income in the three months ended September 30, 2025 in the Company&#8217;s condensed consolidated statements of operations. In May and September 2025, RDF filed <ix:nonFraction unitRef="notice" contextRef="c-316" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-1128">two</ix:nonFraction> notices of appeal. A consolidated appeal is pending.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments, Contingencies and Commercial Partners</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LG Chem</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, the Company and LG Chem, Ltd., or LG Chem, entered into a partnership agreement to expand access to EXPAREL in select Asia&#8211;Pacific markets. Under the terms of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. The Company received a $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1129">2.0</ix:nonFraction>&#160;million upfront payment that it will recognize over the license term upon commercialization and will receive a contractually stated price and tiered royalties on future commercial sales by LG Chem in its licensed territories. The Company will manufacture EXPAREL and LG Chem will be responsible for securing regulatory approvals in the licensed territories. LG Chem has filed for marketing authorization in South Korea and plans to do so in Thailand in the second half of 2026.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-1112-4" continuedAt="f-1112-5"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Johnson &amp; Johnson MedTech</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, the Company entered into a co-promotion agreement, with Johnson &amp; Johnson MedTech, or J&amp;J MedTech, (the &#8220;J&amp;J Agreement&#8221;), to market and promote the use of ZILRETTA for OA knee pain in the U.S. J&amp;J MedTech&#8217;s specialized early intervention sales force will extend the reach of ZILRETTA beyond orthopedic practices, into multiple new physician specialties, including sports medicine, osteopathy, pain management and rheumatology. </span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the J&amp;J Agreement, J&amp;J MedTech is the exclusive third-party co-promoter for ZILRETTA in the U.S. The initial term of the J&amp;J Agreement extends through 2031 with an option to extend under mutual agreement.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to recognize all revenue from sales of ZILRETTA. As compensation for its promotional efforts, for the first <ix:nonNumeric contextRef="c-318" name="pcrx:ContractualObligationMinimumMonthlyCommissionDuration" format="ixt-sec:durmonth" id="f-1130">12</ix:nonNumeric> months of the J&amp;J Agreement the Company will pay J&amp;J MedTech a minimum monthly commission. For the remaining term of the agreement, Pacira will pay a tier-based commission with higher commission percentages earned at higher annual ZILRETTA sales levels. J&amp;J MedTech will receive a tiered commission ranging from low single digits to double digits.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and J&amp;J MedTech have mutual termination rights under the J&amp;J Agreement, subject to certain terms, conditions and advance notice requirements, provided that the Company or J&amp;J MedTech generally may not terminate the J&amp;J Agreement, without cause, within <ix:nonNumeric contextRef="c-319" name="pcrx:ContractualObligationMutualTerminationRightsTerm" format="ixt-sec:durwordsen" id="f-1131">one year</ix:nonNumeric> of the effective date of the J&amp;J Agreement. The Company also has additional unilateral termination rights under certain circumstances. The J&amp;J Agreement contains customary representations, warranties, covenants and confidentiality provisions, as well as mutual indemnification obligations. J&amp;J MedTech is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and the Company&#8217;s policies, in connection with fulfilling their obligations under the J&amp;J Agreement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Trial Commitments</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL for infiltration and as a brachial plexus block in pediatric patients. The Company was granted deferrals for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the European Union, or E.U. Despite the U.K.&#8217;s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notification from both the FDA and EMA that its pediatric studies requirement had been waived for the indications of brachial plexus interscalene nerve block, lower extremity nerve block, sciatic nerve block in the popliteal fossa and adductor canal block indications to produce postsurgical regional analgesia in pediatric patients. The Company is still working with the FDA, EMA and Medicines and Healthcare products Regulatory Agency (MHRA) to finalize the regulatory pathways for its remaining pediatric commitments.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has successfully completed Part 1 of a Phase 1 pharmacokinetic pediatric study in children aged two to less than six years of age and has completed enrollment for Part 2 of the study in children aged six months to less than two years of age using the same dosage that was utilized in Part 1. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 11,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for information on potential contingent milestone payments related to the Flexion Acquisition.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-201</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 (enekinragene inzadenovec) is a novel, locally administered gene therapy product candidate that boosts cellular production of the anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) for treating OA pain in the knee. PCRX-201 was added to the Company&#8217;s portfolio as part of the Flexion Acquisition in November 2021. In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy designation to PCRX-201.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in 2017, Flexion entered into an agreement with GQ Bio to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" scale="6" id="f-1132">56.0</ix:nonFraction>&#160;million of payments could have become due upon the achievement of certain development and regulatory milestones, including up to $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" scale="6" id="f-1133">4.5</ix:nonFraction>&#160;million through initiation of a Phase 2 clinical trial and up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" scale="6" id="f-1134">51.5</ix:nonFraction>&#160;million in development and global regulatory approval milestone payments. In February 2025, Pacira Therapeutics, Inc., a wholly-owned subsidiary of the Company, completed the GQ Bio Acquisition and acquired the remaining <ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-1135">81</ix:nonFraction>% of GQ Bio that was not already owned by the Company. As of the date hereof, GQ Bio is a wholly-owned subsidiary of the Company.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2017, in an agreement between The Baylor College of Medicine, or BCM, and GQ Bio, the Company (through the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><ix:continuation id="f-1112-5"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Flexion Acquisition) became the direct licensee of certain underlying BCM patents and other proprietary rights related to PCRX-201. The license agreement grants the Company an exclusive, royalty-bearing, world-wide right and license under its patent and other proprietary rights directly related to PCRX-201. The license agreement with BCM includes a low single-digit royalty on net product sales of PCRX-201. Milestone payments range from $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="pcrx:RevenueFromContractWithCustomerMilestonePaymentsMaximum" scale="6" id="f-1136">0.1</ix:nonFraction>&#160;million up to $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="pcrx:RevenueFromContractWithCustomerMilestonePaymentsMaximum" scale="6" id="f-1137">0.6</ix:nonFraction>&#160;million based on the completion of a Phase 1 FDA trial up to a Phase 3 clinical trial.</span></div></ix:continuation><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1138" continuedAt="f-1138-1" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="f-1138-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain therapies. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer&#8212;who is the Company&#8217;s chief operating decision maker, or CODM&#8212;manages and allocates resources at a consolidated level. Accordingly, the Company views its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1139">one</ix:nonFraction> operating segment and <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1140">one</ix:nonFraction> reportable segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The key measure of the Company is GAAP net income. The CODM uses this measure to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are significant expense categories and amounts that are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company&#8217;s financial results. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1141" continuedAt="f-1141-1" escape="true">The table below reconciles the significant expense categories provided to the CODM to the Company&#8217;s expenses as disclosed under GAAP (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-1141-1"><div style="margin-bottom:2pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1142">192,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1143">181,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1144">369,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1145">350,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="pcrx:CostOfGoodsSoldAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1146">42,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="pcrx:CostOfGoodsSoldAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1147">32,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="pcrx:CostOfGoodsSoldAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1148">77,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="pcrx:CostOfGoodsSoldAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1149">65,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="pcrx:ResearchAndDevelopmentAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1150">27,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="pcrx:ResearchAndDevelopmentAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1151">24,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="pcrx:ResearchAndDevelopmentAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1152">52,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="pcrx:ResearchAndDevelopmentAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1153">47,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="pcrx:SellingAndMarketingAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1154">52,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="pcrx:SellingAndMarketingAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1155">50,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="pcrx:SellingAndMarketingAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1156">110,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="pcrx:SellingAndMarketingAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1157">106,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted general and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="pcrx:SellingGeneralAndAdministrativeAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1158">29,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="pcrx:SellingGeneralAndAdministrativeAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1159">26,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="pcrx:SellingGeneralAndAdministrativeAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1160">54,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="pcrx:SellingGeneralAndAdministrativeAdjusted" format="ixt:num-dot-decimal" scale="3" id="f-1161">46,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1162">14,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1163">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1164">28,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1165">30,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1166">14,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1167">14,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1168">28,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1169">28,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture and acquisition-related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1170">6,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1171">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1172">7,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1173">3,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-1174">1,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-1175">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-1176">614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-1177">3,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:fixed-zero" scale="3" id="f-1178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:fixed-zero" scale="3" id="f-1179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:fixed-zero" scale="3" id="f-1180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:LitigationSettlementLoss" format="ixt:num-dot-decimal" scale="3" id="f-1181">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decommissioning of manufacturing suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="f-1182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-1183">6,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="f-1184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-1185">6,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1186">188,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1187">172,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1188">358,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1189">339,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1190">1,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1191">10,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1192">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1193">3,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1194">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1195">1,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1196">7,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1197">6,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1198">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1199">2,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1200">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1201">6,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1202">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1203">4,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1204">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1205">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The adjustments are primarily related to stock-based compensation being noted separately as a line item.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(2) During the three and six months ended June&#160;30, 2026, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" scale="6" id="f-1206"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" scale="6" id="f-1207">5.9</ix:nonFraction></ix:nonFraction>&#160;million of divestiture-related expenses, primarily related to third-party services and legal fees, which were recorded to other operating expenses, net in the condensed consolidated statement of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2025, the Company acquired the remaining <ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-1208">81</ix:nonFraction>% of GQ Bio that it did not already own. During the three and six months ended June&#160;30, 2025, the Company incurred acquisition-related expenses of $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-1209">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-1210">2.5</ix:nonFraction>&#160;million, respectively, mainly related to third-party services and legal fees associated with the acquisition of GQ Bio, which were recorded to other operating expenses, net in the condensed consolidated statement of operations. As part of the purchase agreement, $<ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" scale="6" id="f-1211">7.8</ix:nonFraction>&#160;million of expense will be recognized and paid over <ix:nonNumeric contextRef="c-333" name="pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" format="ixt-sec:durwordsen" id="f-1212">three years</ix:nonNumeric> pursuant to a key employee holdback agreement in increments of <ix:nonFraction unitRef="number" contextRef="c-332" decimals="INF" name="pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" scale="-2" id="f-1213">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-332" decimals="INF" name="pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" scale="-2" id="f-1214">30</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-332" decimals="INF" name="pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" scale="-2" id="f-1215">20</ix:nonFraction>%, respectively. This resulted in $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="f-1216">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="f-1217">1.5</ix:nonFraction>&#160;million recognized within research and development in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2026, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="f-1218">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="f-1219">1.5</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2025, respectively.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The measure of segment assets is reported on the Company&#8217;s consolidated balance sheet as total assets. Substantially all of the Company&#8217;s assets are used to support its mission in delivering innovative, non-opioid pain therapies to transform the lives of patients. As of June&#160;30, 2026 and December 31, 2025, the Company&#8217;s long-lived assets were primarily located in the U.S. (<ix:nonFraction unitRef="number" contextRef="c-336" decimals="2" name="pcrx:PercentOfLongLivedAssets" scale="-2" id="f-1220">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-337" decimals="2" name="pcrx:PercentOfLongLivedAssets" scale="-2" id="f-1221">83</ix:nonFraction>%, respectively), and, to a lesser extent, Germany (<ix:nonFraction unitRef="number" contextRef="c-338" decimals="2" name="pcrx:PercentOfLongLivedAssets" scale="-2" id="f-1222">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-339" decimals="2" name="pcrx:PercentOfLongLivedAssets" scale="-2" id="f-1223">9</ix:nonFraction>%) and the U.K. (<ix:nonFraction unitRef="number" contextRef="c-340" decimals="2" name="pcrx:PercentOfLongLivedAssets" scale="-2" id="f-1224">9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-341" decimals="2" name="pcrx:PercentOfLongLivedAssets" scale="-2" id="f-1225">8</ix:nonFraction>%). For information on the Company&#8217;s fixed assets, refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  33</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MANAGEMENT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q and certain other communications made by us contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the ability to realize the anticipated benefits of the divestiture of iovera</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#176;; the ability of Zimmer, Inc., or Zimmer (a subsidiary of Zimmer Biomet Holdings, Inc.), to unlock the full potential of iovera&#176;; '5x30', our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (&#8220;NOPAIN&#8221;) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We often use the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions to help identify forward-looking statements. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks associated with divestitures; our manufacturing and supply chain, global and United States, or U.S., economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> (bupivacaine liposome injectable suspension) and ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> (triamcinolone acetonide extended-release injectable suspension); the rate and degree of market acceptance of EXPAREL and ZILRETTA; the size and growth of the potential markets for EXPAREL and ZILRETTA and our ability to serve those markets; our plans to expand the use of EXPAREL and ZILRETTA to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, and any of our other product candidates, including, but not limited to, PCRX-201 (enekinragene inzadenovec) and PCRX-2002; the commercial success of EXPAREL and ZILRETTA; the related timing and success of U.S. Food and Drug Administration, or FDA, supplemental New Drug Applications, or sNDAs, and premarket notification 510(k)s; the related timing and success of European Medicines Agency, or EMA, Marketing Authorization Applications, or MAAs; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary high-capacity adenovirus (&#8220;HCAd&#8221;) vector platform; the approval of the commercialization of our products in other jurisdictions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(by either us or our partners); clinical trials in support of an existing or potential HCAd-based product candidate; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; and the anticipated funding or benefits of our share repurchase program.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included in this Quarterly Report on Form 10-Q represent our views as of the filing date of this Quarterly Report on Form 10-Q. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on the forward-looking statements as representing our views as of any date subsequent to the date of the filing of this Quarterly Report on Form&#160;10-Q.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include items mentioned herein and the matters discussed and referenced in Part&#160;I-Item&#160;1A. &#8220;Risk Factors&#8221; included in our </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1396814/000162828026012297/pcrx-20251231.htm">Annual Report on Form 10-K for the year ended December 31, 2025</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> (the &#8220;2025 Annual Report&#8221;); in Part II. Item 1A in this Quarterly Report on Form 10-Q; and in other reports filed with the SEC.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references to &#8220;Pacira,&#8221; the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;we&#8221; in this Quarterly Report on Form&#160;10-Q refer to Pacira BioSciences,&#160;Inc. and its subsidiaries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  34</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pacira&#8217;s mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. We are focused in two therapeutic areas as defined by the indications within our approved commercial portfolio and the indications we are pursuing within our clinical development pipeline. One area is postsurgical pain control and the second is early intervention osteoarthritis, or OA, pain management. EXPAREL is our long-acting, non-opioid analgesic for postsurgical pain control. EXPAREL utilizes our unique pMVL drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In the U.S., EXPAREL is the only product indicated for local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and adductor canal block in adults. In Europe, EXPAREL is approved as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults and children aged six years and older. We drop-ship EXPAREL directly to end-users based on orders placed to wholesalers or directly to us. ZILRETTA is our extended-release corticosteroid approved to manage OA knee pain. With a single injection, ZILRETTA can significantly reduce knee pain for three months of relief. ZILRETTA is a potential alternative to hyaluronic acid, or HA, platelet rich plasma injections or other early intervention treatments.</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL and ZILRETTA are highly complementary products as long-acting, non-opioid therapies that alleviate pain. We are also advancing two Phase 2 clinical programs&#8212;PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy for the treatment of OA of the knee, and PCRX-2002, a complementary, long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. PCRX-201 is the lead program from our proprietary high-capacity adenovirus, or HCAd, vector platform, which enables local administration of genetic medicines and has the potential to unlock gene therapy for large prevalent diseases affecting millions of people.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to invest in commercial resources to expand the utilization of EXPAREL and ZILRETTA; advance regulatory activities for EXPAREL and ZILRETTA, and progress our clinical-stage product candidates&#8212;including PCRX-201 and PCRX-2002; expand and enhance our commercial manufacturing efficiencies; invest in new products, businesses and technologies through business development; and support legal matters.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2026, we completed the divestiture of iovera&#176;, a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve, to Zimmer, Inc., a subsidiary of Zimmer Biomet Holdings, Inc. (&#8220;Zimmer&#8221;). For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Conditions, Inflation and Tariffs </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct and indirect effects of global economic conditions have in the past, and may continue to, negatively impact our business, financial condition and results of operations. Such impacts may include the effect of prolonged periods of inflation, the imposition of tariffs or increases in the prices of commodities, such as fuel, which could, among other things, result in higher costs for raw materials, equipment and other goods and services; cause patients to defer or cancel medical procedures, thereby adversely impacting our revenues; and negatively impact our suppliers, which could result in negative impacts on gross margins, longer lead-times or the inability to procure a sufficient supply of materials.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced a material impact from tariffs to date, the current macroeconomic environment remains dynamic and subject to rapid and potentially material change. Our business may be adversely impacted by ongoing risks associated with global macroeconomic conditions, including international relations and trade disputes. In particular, EXPAREL and ZILRETTA are manufactured into finished dosage by a contract development and manufacturing organization in the United Kingdom, or U.K., and the active pharmaceutical ingredients, or API, for both products are sourced primarily from the European Union, or E.U., or Switzerland. On April 2, 2026, the President of the U.S. issued a proclamation under Section 232 of the Trade Expansion Act of 1962, imposing tariffs on certain pharmaceutical products imported to the U.S. This order (the &#8220;Presidential Order&#8221;) applies to patented pharmaceutical products, associated APIs and other products classified under Harmonized Tariff Schedule (HTS) U.S. codes listed in Annex I. The Presidential Order imposes country-specific tariffs, including 15% tariffs on certain products imported from the E.U., Japan, South Korea, Switzerland and Liechtenstein; and a 10% tariff on products imported from the U.K. with a potential reduction to 0%, subject to a future U.S. and U.K. pharmaceutical pricing agreement. Patented pharmaceutical products imported from certain other countries may be subject to tariffs of up to 100%. As a result, we expect tariffs will impact our products and/or their ingredients imported into the U.S. However, tariff rates can change quickly and unexpectedly. We will continue to monitor developments and assess any potential impacts and related trade measures on our business and supply chain.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such tariffs imposed by the U.S. and/or other countries that are currently in effect, or may take effect in the future, could increase our manufacturing and operating expenses in future periods, including the cost to deliver our products to commercial markets, the cost to source raw materials for the manufacturing of our products and the cost of materials used in our research </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development activities. The previous imposition of tariffs and future tariffs impacting our industry, the magnitude of response by other countries to such tariffs and the length of time such tariffs are in effect may also increase uncertainty and adversely impact our business.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that tariffs will have a negative impact on gross margins. We are currently evaluating the magnitude of this impact but are unable to quantify the expected impact with specificity at this time due to the rapidly changing political policy environment. There has been significant volatility in U.S. tariff and customs policy recently, with frequent changes in rates, sudden elimination or reinstatement of exemptions, shifts in implementation dates and reversals of prior actions. This volatility makes it more difficult to forecast costs, plan our global supply chain and provide reliable financial guidance. Policy changes often require rapid operational adjustments that can increase costs and reduce efficiency. We expect such volatility and uncertainty related to tariffs and customs to continue, potentially posing ongoing challenges to our operations, financial planning and investor communications.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Highlights</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In June 2026, we entered into a Stock and Asset Purchase Agreement with Zimmer to divest iovera&#176; for up to $140.0 million, including an upfront payment of $70.0 million and potential contingent consideration of up to an additional $70.0 million in the aggregate, payable upon the achievement of revenue-based milestones up to and through the period ending December 31, 2031 (the &#8220;Transaction&#8221;). The Transaction closed on July 31, 2026, in which we received cash of $73.6&#160;million, after customary purchase price adjustments. Going forward, we will collaborate with Zimmer on advancing the iovera&#176; spasticity program with an opportunity for us to receive incremental compensation assuming successful completion of a registrational study and subsequent regulatory approval. We also entered into a customary transition services agreement with Zimmer in connection with the closing. </span></div><div style="margin-bottom:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe this transaction advances our transition into an innovative biopharmaceutical company and aligns with our 5x30 strategy and that Zimmer&#8217;s global scale, established expertise commercializing medical devices and commitment to significantly expanding access can unlock the full potential of iovera&#176; to benefit more patients and providers globally.</span></div><div style="margin-bottom:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In June 2026, Thomas Wiggans was elected by stockholders to our board of directors. Mr. Wiggans brings with him more than 40 years of leadership experience across commercial operations, corporate strategy and executive management within the global life sciences industry, as well as significant experience leading biopharmaceutical companies through successful acquisitions. Mr. Wiggans has served as chief executive officer of four biopharmaceutical companies with successful exits through acquisition or strategic transactions, and most notably co-founded Dermira, Inc. in 2010 and was its chief executive officer and chairman until its acquisition by Eli Lilly in 2020. Mr. Wiggans was concurrently appointed to the People and Compensation Committee and Nominating, Governance and Sustainability Committee of our board of directors.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In July 2026, we announced that UnitedHealthcare&#8212;the largest health insurer in the U.S. with approximately 40 million covered lives&#8212;now provides separate reimbursement for EXPAREL across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members, representing an additional step in expanding access to non-opioid postsurgical pain management options. With this addition, UnitedHealthcare joins a growing list of national payers, including Aetna, Cigna, TRICARE and Humana, as well as numerous regional plans that provide separate reimbursement for EXPAREL. In total, approximately 150 million covered lives in the U.S. now have access to separate reimbursement for EXPAREL, representing roughly half of all medically insured lives nationwide. This ensures patients have greater access to safe, effective pain management options during and after surgery without the burden of financial barriers.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In July 2026, we announced that we have successfully transitioned PCRX-201 (enekinragene inzadenovec), our investigational locally administered gene therapy for OA of the knee, to a U.S.-based scalable commercial manufacturing process intended to support future registrational development and commercialization. With drug product from the new manufacturing process now available, we are currently screening subjects for Part B of our Phase 2 ASCEND study. Enrollment in Part A of ASCEND concluded in June 2026, with topline data expected by the end of this year.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  36</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXPAREL</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., EXPAREL is currently indicated for local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block in adults. Safety and efficacy have not been established in other nerve blocks. In Europe, EXPAREL is approved as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults and children aged six years and older. We are currently advancing a registration program for EXPAREL in pediatric patients under six years of age.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EXPAREL Clinical Benefits</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe EXPAREL can replace the use of bupivacaine delivered via elastomeric pumps as the foundation of a multimodal regimen for long-acting postsurgical pain management. Based on our clinical data, EXPAREL:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provides long-lasting local or regional analgesia;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">is a ready-to-use formulation;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expands easily with saline or lactated Ringer&#8217;s solution to reach a desired volume;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">can be administered for local analgesia via infiltration and for regional analgesia via field block, as well as brachial plexus nerve block, sciatic nerve block in the popliteal fossa and adductor canal block; and</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilitates treatment across a variety of surgical sites.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe EXPAREL is a key component of long-acting postsurgical pain management regimens that reduce the need for opioids. Based on the clinical data from our Phase&#160;3 and Phase 4 clinical studies as well as data from retrospective health outcomes studies, EXPAREL significantly reduces opioid usage while improving postsurgical pain management.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have successfully completed Part 1 of a pediatric study in children aged two to less than six years of age. We have completed enrollment for Part 2 of the pediatric study in children aged six months to less than two years of age using the same dosage that was utilized in Part 1.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ZILRETTA</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA is the first and only extended-release, single-shot corticosteroid IA injection therapy for OA knee pain. ZILRETTA employs a proprietary, extended-release microsphere technology combining triamcinolone acetonide, or TA, a commonly administered, immediate-release corticosteroid, with a poly lactic-co-glycolic acid, or PLGA, matrix to provide extended pain relief. PLGA is a proven extended-release delivery vehicle that is metabolized to carbon dioxide and water as it releases drug in the IA space and is used in other approved drug products and surgical devices. The ZILRETTA microspheres slowly and continuously release TA into the knee to provide significant pain relief for 12 weeks, with some people experiencing pain relief through 16 weeks. ZILRETTA was approved by the FDA in October 2017 and launched in the U.S. shortly thereafter.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing a Phase 3 registration study to evaluate the safety and efficacy of ZILRETTA for the management of OA pain of the shoulder and concluded patient enrollment in April 2026. If the study is successful, we plan to seek approval to expand the ZILRETTA label to include OA pain of the shoulder, which could make ZILRETTA the first product with such an on-label indication.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZILRETTA Clinical Benefits</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA combines TA with a proprietary, extended-release microsphere technology to administer extended therapeutic concentrations in the joint and persistent analgesic effect. Based on the strength of both its pivotal and other clinical trials, we believe that ZILRETTA represents an important treatment option for the millions of patients in the U.S. in need of safe and effective extended relief from OA knee pain. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The pivotal Phase 3 trial showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through 16 weeks. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that ZILRETTA has the potential to become the corticosteroid of choice given its safety and efficacy profile, and the fact that it is the first and only extended-release corticosteroid on the market. In August 2021, the American Association of Orthopaedic Surgeons, or AAOS, updated its evidence-based clinical practice guidelines, finding ZILRETTA can improve patient outcomes over traditional immediate-release corticosteroids.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Innovations in Genicular Outcomes Registry (IGOR)</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently sponsoring a prospective, real-world registry called the Innovations in Genicular Outcomes Registry, or IGOR, which is a patient-focused registry governed in collaboration with a steering committee of scientific experts that evaluates clinical, economic- and health-related patient-reported outcomes in patients who have received any treatment for knee OA pain, including total knee arthroplasty, or TKA, for a minimum of 18 months. A unique feature of IGOR is that if patients receive additional treatments for OA, data capture resets so that outcomes of their treatment journey can be followed over multiple years. Unlike in clinical studies, treatment decisions in IGOR are decided by physicians and patients in a shared decision-making manner rather than being driven by treatment assignment, so that outcomes are truly those from real-world applications. The IGOR registry is tracking outcomes of ZILRETTA and EXPAREL, along with iovera&#176; and comparator treatments. In addition, the IGOR registry is tracking outcomes for OA and TKA related to our product candidates PCRX-201 and PCRX-2002.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The Osteoarthritis Market</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OA is the most common form of arthritis. It is also called degenerative joint disease and occurs most frequently in the knees, hips, hands and spine. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and worsen over time. OA can cause pain, stiffness and swelling. In some cases, it also causes reduced function and disability&#8212;some people are no longer able to do daily tasks or work. According to the Centers for Disease Control and Prevention (CDC), OA affects over 32.5 million adults in the U.S.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The lifetime risk of developing symptomatic knee OA is 45 percent according to the Arthritis Foundation. The prevalence of symptomatic knee OA increases with each decade of life, with the annual incidence of knee OA being highest between age 55 and 64 years old. There are 15 million individuals in the U.S. who have symptomatic knee OA, and nearly two million are under the age of 45. Surgical intervention is typically a last resort for patients suffering from OA of the knee.</span></div><div style="margin-bottom:5pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinicians have the flexibility to individualize OA knee pain treatment with ZILRETTA based on patient factors and preference, physician training, site of care and reimbursement considerations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Unmet Need in Osteoarthritis of the Knee</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OA knee pain has a significant impact on patients&#8217; health and quality of life. Patients report being unable to engage in basic everyday tasks, such as climbing stairs, getting in and out of a car or participating in social activities. The pain associated with OA of the knee can impact individuals&#8217; ability to sleep, work and exercise, resulting in serious impacts on overall patient health and quality of life.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The patient journey for OA knee pain often spans decades, and requires ongoing management across multiple stages of disease progression. Current treatments target symptoms through lifestyle modifications, physical therapy and pharmacological treatments, such as over-the-counter or prescription nonsteroidal anti-inflammatory drugs (NSAIDS) and intraarticular corticosteroids or HA. Ultimately, late-stage disease often leads to surgical intervention, such as TKA.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The lack of available safe and novel disease modifying treatments for OA of the knee highlights the high unmet need. As the U.S. population ages, the number of OA patients is increasing, and trends in recent years towards younger onset of disease mean that in the absence of a disease modifying therapy for OA, more patients will likely progress to disability and TKA. This would become an increasing burden not only for these patients, but for the healthcare system as well.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the high prevalence of OA, its associated morbidity and excess mortality and the lack of therapies that can reverse, slow or stop the degenerative processes of OA, in 2018 the FDA recognized OA as a serious disease with significant unmet medical need. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA has demonstrated significant, durable relief of OA knee pain out to three months and, as such, is addressing an important unmet need among patients, physicians and healthcare payers. In addition, we are advancing a Phase 2 clinical study of our lead clinical asset, PCRX-201 (enekinragene inzadenovec), in moderate to severe knee OA as discussed below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The HCAd Vector Platform</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary HCAd vector platform solves many of the challenges in the field of genetic medicine that have prevented its utilization in treating common diseases like OA. Key features include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The HCAd vector is much more efficient at delivering genes into cells compared to many other gene therapies that rely on adenovirus associated virus, or AAV, vectors. As a result, the desired effect can be achieved with much smaller doses;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The vector used in the HCAd platform can carry up to 30,000 base pairs of DNA, which enables gene therapy with multiple or larger genes compared to AAV vectors;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Genetic medicines based on the HCAd platform can be administered locally and have the potential for redosing at therapeutically appropriate intervals; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Lower dose levels mean that thousands of doses can be produced in a single batch. As a result, we expect that any therapies built on the HCAd platform will have a commercially attractive and viable cost of goods profile.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_121"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Development Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PCRX-201</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 is the lead program from our HCAd platform, and we believe it underscores its promise for treating common diseases given its encouraging data in OA. PCRX-201 is targeting the IL-1 pathway, which triggers inflammation in response to pathogens and cellular stress. IL-1Ra is a core regulator of this pathway and helps to keep inflammation in balance by turning off the IL-1 pathway when it&#8217;s not needed. As people get older, their bodies have a more challenging time maintaining that balance resulting in chronic IL-1-driven inflammation that eventually causes joint damage and pain.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After injection of PCRX-201, the HCAd vector enters joint cells and turns them into factories to boost cellular IL-1Ra production, which blocks IL-1 pathway activation to reduce inflammation and pain in the knee. PCRX-201 uses an inflammation-responsive promoter to only produce IL-1Ra when needed, mimicking how the body naturally responds to inflammation. In a Phase 1 proof-of-concept study of patients with moderate to severe OA of the knee, PCRX-201 was well tolerated with improvements in knee pain observed across all doses. The study enrolled 72 patients who were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pre-treatment with an IA corticosteroid (methylprednisolone 40 mg), a technique common in gene therapy dosing to improve tolerability and gene transfer. PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts. The highest level of efficacy was achieved in the co-administered steroid group, which showed a greater percentage of patients with at least a 50% improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and stiffness scores, as well as a meaningful improvement in Knee Injury and Osteoarthritis Outcome Score (KOOS) functional assessment. In all 3 doses, over 70% of patients saw a 50% or greater improvement in pain compared to baseline at week 16 and 78. PCRX-201 was well-tolerated with no serious treatment-emergent adverse events related to the treatment or procedure reported regardless of steroid pretreatment or dose level administered. While other therapies typically provide relief for three to six months, PCRX-201 has shown the potential to set a new standard with pain relief lasting at least 2 years from a single injection.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Given these highly encouraging Phase 1 data, we are advancing a Phase 2 clinical study in knee OA. The two-part, multicenter study&#8212;known as ASCEND&#8212;will involve approximately 135 patients, 45 to 80 years old with painful OA of the knee at a Kellgren-Lawrence (K-L) Grade of 2, 3 or 4. Subjects are randomly assigned to a treatment dose group and stratified by K-L Grade, a semiquantitative method for evaluating the severity of OA on a scale of 0-4.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASCEND will evaluate two doses of PCRX-201, Dose A is 1.4 x 10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> genome copies and Dose B is 1.4 x 10</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">11</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> genome copies. Patients are being randomized 1:1:1 to Dose A, Dose B or saline. All cohorts will receive concurrent pretreatment with an IA corticosteroid (methylprednisolone 40 mg).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have completed patient enrollment in Part A of the study with a total of 49 patients randomized. We are currently screening subjects for Part B of the Phase 2 ASCEND study.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Part B will randomize approximately 90 patients. The drug product used in Part B of the study will be manufactured using our newly developed, suspension-based batch manufacturing process intended for commercial scale-up. We expect to report topline twelve-month data results from Part A of the ASCEND study before the end of 2026.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For both Parts A and B of the study, the primary endpoint is the number and percent of treatment-emergent adverse events, adverse events of special interest, and serious adverse events for PCRX-201 plus steroid pretreatment versus saline plus steroid pretreatment from Week 1 through Week 52. The study&#8217;s secondary and exploratory endpoints include efficacy assessments such as changes in pain and physical function from baseline at Weeks 38 and 52. Efficacy will be measured using the Numerical Rating Scale (NRS), WOMAC and KOOS. Biomarkers, including structural endpoints, as well as immunogenicity and biodistribution will also be evaluated and all subjects will be followed for 5 years.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 has received Regenerative Medicine Advanced Therapy, or RMAT, designation from the FDA and Advanced Therapy Medicinal Products, or ATMP, designation from the EMA. RMAT and ATMP are regulatory programs designed to expedite the development and review processes for promising therapies targeting a significant unmet need with preliminary clinical evidence indicating that the therapy has the potential to offer a major advantage over existing treatments.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also recently received an important validation of our PCRX-201 program with the acceptance of a Phase 1 manuscript for publication. The publication will appear in the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annals of the Rheumatic Diseases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, a world-leading peer-reviewed rheumatology journal. The paper highlights the encouraging results from the 72-patient Phase 1 study supporting further development of PCRX-201.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other HCAd Product Candidates</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to PCRX-201, we currently have prioritized three other preclinical HCAd-based gene therapy programs that we believe have disease modifying potential in other painful conditions. These include Investigational New Drug (IND) enabling studies of PCRX-1002 for Dry Eye Disease and PCRX-1003 for Degenerative Disc Disease. We are also advancing a preclinical program for PCRX-1001 in canine OA, recently completed a pilot safety study and our pilot efficacy study is now initiating.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe this indication offers significant out-licensing potential.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PCRX-2002</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we announced an exclusive worldwide license agreement with AmacaThera, Inc., or AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, for the development and commercialization of PCRX-2002 (previously known by AmacaThera as AMT-143).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-2002 is a long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain. It is a slow-release, non-opioid local analgesic providing long-acting post-operative pain relief. PCRX-2002 is administered via instillation at the time of the surgery and utilizes AmacaThera&#8217;s innovative hydrogel platform, a fast-gelling physical hydrogel composed of two well-established polymers enabling slow-release while minimizing systemic side effects. It is delivered via a conventional syringe and rapidly forms a depot as it warms to body temperature. In a Phase 1 study, PCRX-2002 demonstrated sustained release of ropivacaine through 14 days. We expect to initiate a Phase 2 program in bunionectomy later this year in Canada.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Portfolio and Internal Pipeline</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current product portfolio and internal product candidate pipeline, along with anticipated milestones over the next 12 to 18 months, are summarized in the table below</span></div><div><span><br/></span></div><div><img src="pcrx-20260630_g2.gif" alt="Product Pipeline Table 2026 Q2.gif" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:725px" id="i-2"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Expansion</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, we and LG Chem, Ltd., or LG Chem, entered into a partnership agreement to expand access to EXPAREL in select Asian&#8211;Pacific markets. Under the terms of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. We will receive a contractually stated price and tiered royalties on future commercial sales by LG Chem in its licensed territories. We will manufacture EXPAREL and LG Chem will be responsible for securing regulatory approvals in the licensed territories. LG Chem has filed for marketing authorization in South Korea and plans to do so in Thailand in the second half of 2026. We currently expect that revenue under this partnership will begin in 2027 and extend into the mid-2040s.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  41</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_124"></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three and Six Months Ended June&#160;30, 2026 and 2025 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our net product sales are primarily within the U.S. and consist of EXPAREL, ZILRETTA and sales of bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to the sale of bupivacaine liposome injectable suspension for veterinary use. In June 2026, we entered into a Stock and Asset Purchase Agreement with Zimmer to divest iovera&#176;. Net product sales of iovera&#176; will be recognized through the completion of the Transaction on July 31, 2026, after which we will no longer recognize revenue associated with iovera&#176;.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">EXPAREL</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147,823&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142,917&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291,097&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">279,446&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,648&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,334&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59,415&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,672&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">iovera&#176;</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,588&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,982&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,216&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100+%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">190,493&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">367,869&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">347,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100+%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,081&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">192,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">369,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350,022&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL revenue increased 3% and 4% in the three and six months ended June&#160;30, 2026 versus 2025, respectively. Components of the increase included a 4% and 6% increase in gross vial volume in the three and six months ended June&#160;30, 2026 versus 2025, respectively, partially offset by a shift in product mix, and a less than 1% lower net selling price in both periods, as group purchasing organization contracting discounts more than offset a price increase.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA revenue increased 4% and 9% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, due to respective 2% and 6% increases in kit volume and 2% and 3% increases in net selling price primarily due to price increases, partially offset by higher customer discounting.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of iovera&#176; increased 22% and 21% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, driven by increases in Smart Tip volume of 19% and 23%, partially offset by decreases in Smart Tip net selling price of 2% and 3%. In June 2026, we entered into a Stock and Asset Purchase Agreement with Zimmer to divest iovera&#176; for up to $140.0 million, including an upfront payment of $70.0 million. In July 2026, we received an upfront payment of $73.6&#160;million from the closing of the Transaction that divested iovera&#176; to Zimmer, consisting of an upfront payment of $70.0 million and $3.6 million of adjustments for cash, accounts receivable, indebtedness, transaction expenses and inventory. The Transaction closed on July 31, 2026, after which we will no longer recognize revenue associated with iovera&#176;. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Bupivacaine liposome injectable suspension revenue increased by more than 100% and 41% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, due to supply price increases and the timing of orders placed by our commercial partner for veterinary use. The related royalties also increased by more than 100% and decreased 8% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, primarily due to both the timing of orders and the sales mix of vial sizes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a summary of activity with respect to our sales-related allowances and accruals related to EXPAREL and ZILRETTA for the six months ended June&#160;30, 2026 and 2025 (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Returns Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Prompt Payment Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Service Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Customer Rebates and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,607&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,225&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99,027&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">124,113&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,524)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,075)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(97,778)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,329)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121,147)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Returns Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Prompt Payment Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Service Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Customer Rebates and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,918&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,189&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">76,044&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">96,666&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,838)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,320)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(76,113)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,815)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(96,353)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total reductions of gross product sales from sales-related allowances and accruals were $124.1 million and $96.7 million, or 25.2% and 21.7% of gross product sales, for the six months ended June 30, 2026 and 2025, respectively. The overall 3.5% increase in sales-related allowances and accruals as a percentage of gross product sales was primarily related to accruals as a result of higher chargeback-related allowances from expanded contracting efforts and increased product returns due to weather-related disruptions in the first quarter of 2026.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, quality control and engineering. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cost of goods sold and gross margin during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,164</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,866</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,172</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin was flat and decreased one percentage point in the three and six months ended June 30, 2026 versus 2025, respectively, due to higher EXPAREL product costs resulting from lower production volumes. Production volumes were higher in the prior year in order to achieve higher inventory levels to meet increased demand. This was substantially offset by fewer inventory reserves and less downtime in the current year.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, or R&amp;D, expenses primarily consist of costs related to clinical trials and related outside services, product development and other R&amp;D costs, including trials that we are conducting to generate new data for EXPAREL, ZILRETTA and iovera&#176;, clinical trials for PCRX-201 and PCRX-2002 and stock-based compensation expense. Clinical and preclinical development expenses include costs for clinical personnel, clinical trials performed by third-parties, materials and supplies, database management and other third-party fees. Product development expenses include development costs for our products, which include personnel, research equipment, materials and contractor costs for process development and product candidates, and facility costs for our research space. Regulatory and other expenses include regulatory activities related to unapproved products and indications, medical information and scientific communication expenses, expenses related </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to our IGOR registry study and related personnel. Stock-based compensation expense relates to the costs of stock option grants, awards of restricted stock units, or RSUs, and performance share units, or PSUs, and our employee stock purchase plan, or ESPP. Additionally, as part of the acquisition of GQ Bio Therapeutics GmbH, or GQ Bio, in February 2025 (the &#8220;GQ Bio Acquisition&#8221;), expenses related to a key employee holdback are also included in product development.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakout of our R&amp;D expenses during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and preclinical development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,794</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(24)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,726</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product development</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,390</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,715</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,457</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,501</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,062</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,605</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,407</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,435</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,648</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,243</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58,315</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53,893</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total R&amp;D expense increased 7% and 8% in the three and six months ended June&#160;30, 2026 versus 2025, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical and preclinical development expense decreased 24% and 11% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, primarily due to the completion of patient enrollment in Part A of our PCRX-201 Phase 2 ASCEND trial for knee OA, the ZILRETTA Shoulder OA trial, the iovera&#176; Spasticity trial, as well as completion of an EXPAREL Phase 1 trial for intrathecal administration. Additional reductions were driven by fewer Investigator Initiated Trial (IIT) milestones achieved. In the three months ended June 30, 2026 versus 2025, these decreases were partially offset by start-up expenses related to the PCRX-2002 Phase 2 bunionectomy trial. For the six months ended June 30, 2026 versus 2025, these decreases were also partially offset by ongoing enrollment in cohort 2 of our EXPAREL pediatric trial. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product development expense increased 48% and 36% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, due to continued investment in our HCAd platform, primarily for the PCRX-201 program. In addition, we recorded $0.6 million and $1.5 million in the three and six months ended June&#160;30, 2026, respectively, related to a key employee holdback from the GQ Bio Acquisition.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory and other expense increased 31% and 28% in the three and six months ended June 30, 2026 versus 2025, respectively, due to increased headcount within the function, as well as additional subjects enrolled in the IGOR registry study.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense increased 8% in the three months ended June&#160;30, 2026 versus 2025 primarily due to the acceleration of stock-based compensation awards related to a terminated employee. Stock-based compensation decreased 5% in the six months ended June&#160;30, 2026 versus 2025 primarily due to the forfeiture of equity awards in the current periods.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses primarily consist of compensation and benefits for our sales force and personnel that support our commercial, sales, marketing, medical and scientific affairs operations, and insights and analytics. They also include expenses related to the commercialization of our products&#8212;including marketing, health outcome communications, provider-level market access, patient reimbursement support and customer educational programs. General and administrative expenses consist of compensation and benefits for legal, finance, regulatory activities related to approved products and indications, compliance, information technology, human resources, business development, executive management and other supporting personnel. It also includes professional fees for legal, audit, tax and consulting services. Stock-based compensation expense relates to the costs of stock option grants, awards of RSUs, PSUs and our ESPP.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our selling, general and administrative expenses during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,117</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50,964</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">110,283</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,231</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,860</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46,840</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,544</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,383</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,610</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 7pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,979</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91,809</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88,578</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">185,753</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">175,354</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total selling, general and administrative expense increased 4% and 6% in the three and six months ended June&#160;30, 2026 versus 2025, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense increased 2% and 4% in the three and six months ended June&#160;30, 2026 versus 2025, respectively. The increase in the six months ended June&#160;30, 2026 was driven by expanding our market access and reimbursement teams to strengthen our key commercial capabilities and execute on commercial payer separate reimbursement for EXPAREL. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased 11% and 17% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, primarily driven by a 2025 recovery of $5.2 million in legal expenses related to litigation pertaining to the acquisition of MyoScience, Inc., third party investor relations advisory services, as well as increased headcount in our business development, procurement and legal departments. The three months ended June 30, 2026 included additional costs related to the solicitation of proxies in connection with a contested election of directors at our 2026 annual meeting of stockholders that we would not typically have incurred in the absence of a contested election.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense decreased 7% and 6% for the three and six months ended June&#160;30, 2026 versus 2025, respectively, primarily due to the prior year equity compensation related to our former Chief Executive Officer whose post-employment consulting services ceased in August 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, we received two separate Paragraph IV Certifications from two Chinese generic drug manufacturers&#8212;The WhiteOak Group, Inc., or WhiteOak, of Rockville, Maryland (a subsidiary of Zhejiang Haichang Biotechnology Co., Ltd.) and Qilu Pharmaceutical (Hainan) Co., Ltd., or Qilu&#8212;each advising that they had submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of EXPAREL in the U.S. In November 2025, we filed a patent infringement suit against WhiteOak and Qilu. As a result, we have incurred and expect to continue to incur additional legal costs to defend our intellectual property, although we cannot predict the extent of costs or the outcome of this matter at this time. For more information, see Note 17, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-bottom:10pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of Acquired Intangible Assets</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the amortization of acquired intangible assets during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisitions of Flexion Therapeutics, Inc., or Flexion, (in 2021) and MyoScience, Inc. (in 2019), we acquired intangible assets consisting of developed technology intangible assets and customer relationships. In June 2026, $53.2&#160;million, net, of developed technologies and a nominal amount of customer relationships related to iovera&#176; from the acquisition of MyoScience, Inc. were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Amortization on these intangible assets ceased being recorded at the time the assets were classified as held for sale. As such, the amount of amortization of acquired intangible assets will decrease during the second half of 2026, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">assuming no changes in the gross carrying value of our remaining intangible assets. For more information, see Note 8, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Expenses (Gains), Net</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the costs related to the other operating expenses, net during the periods indicated, including percent changes (dollar amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration charges (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(80)%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100+%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(18)%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other operating expenses, net significantly increased in the three months ended June&#160;30, 2026 versus 2025. Total other operating expenses, net decreased 18% in the six months ended June&#160;30, 2026 versus 2025.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2026, we recognized divestiture-related expenses of $5.9&#160;million, primarily related to third-party services and legal fees associated with divesting iovera&#176;. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included herein.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2026, we recognized contingent consideration charges of $1.7&#160;million due to revisions to the latest discount rates. During the six months ended June&#160;30, 2026, we recognized contingent consideration gains of $0.6&#160;million due to a reduction in our sales forecast through the milestone expiration date of December 31, 2030, partially offset by revisions to the latest discount rates. During the three and six months ended June 30, 2025, we recognized contingent consideration gains of $0.4 million and $3.0 million, respectively, primarily due to revisions to the latest discount rates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2025, we recognized acquisition-related expenses of $1.0 million and $2.5 million, respectively, primarily related to third-party services and legal fees associated with the GQ Bio Acquisition.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2025, we recognized legal settlement costs of $7.0 million related to the settlement of patent infringement suits against eVenus Pharmaceutical Laboratories, Inc., its parent company&#8212;Jiangsu Hengrui Pharmaceuticals, Co. Ltd., and Fresenius Kabi USA, LLC.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For more information on these events, see Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Note 16, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Expenses (Gains), Net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and Note 17, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included herein. </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding other expense, net during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(61)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(67)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,622)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,695)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,321)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,275)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(21)%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,739)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,338)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(97)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,712)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,426)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(84)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,710)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2026, total other expense, net was $1.7 million and $3.6 million, respectively. During the three and six months ended June&#160;30, 2025, total other expense, net was $10.4 million and $3.7 million, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased 61% and 67% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, due to interest realized in the prior year on a GQ Bio note receivable investment we had made prior to the GQ Bio Acquisition as well as lower overall investment balances and interest rates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased 23% and 21% in the three and six months ended June&#160;30, 2026 versus 2025, respectively, primarily due to lower outstanding debt principal driven by the repayment of the 2025 Notes (as defined herein) in the third quarter of 2025. For more information, see Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The $10.7 million and $6.3 million other net loss during the three and six months ended June 30, 2025, respectively, was primarily driven by an impairment of an equity investment and convertible note receivable totaling $11.0&#160;million. For the six months ended June 30, 2025, the other net loss was partially offset by a realized gain associated with a previously acquired equity investment in GQ Bio that increased in fair value resulting from the GQ Bio Acquisition. For more information, see Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.75pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit (Expense)</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our income tax expense during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.997%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,555</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,927)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,553</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,779</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,920)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 7pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Effective tax rate </span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax benefits of $2.1 million and less than $0.1 million for the three and six months ended June&#160;30, 2026, respectively. We recorded income tax expense of $2.9 million and $6.8 million for the three and six months ended June 30, 2025, respectively. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates of (82)% and 0% for the three and six months ended June&#160;30, 2026, respectively, differed from the U.S. statutory rate of 21% primarily due to the reversal of our U.K. operating subsidiary&#8217;s valuation allowance, partially offset by costs related to non-deductible executive compensation and non-deductible stock-based compensation.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates of (152)% and 101% for the three and six months ended June 30, 2025, respectively, differed from the U.S. statutory rate of 21% primarily due to costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2026, a discrete benefit of $6.4&#160;million was recorded resulting from a change in judgment regarding future-year realizability of deferred tax assets in our U.K. operations, primarily related to fixed asset temporary differences. The reduction reflects our conclusion, based on all available positive and negative evidence, that realization of the U.K. deferred tax assets is more likely than not. The discrete benefit significantly reduced our effective tax rate for the three and six months ended June&#160;30, 2026.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, we entered into a Stock and Asset Purchase Agreement with Zimmer to divest our iovera&#176; business. The Transaction closed on July 31, 2026. Both parties agreed to treat the transaction as a deemed asset sale for U.S. federal income tax purposes through an election under Section 338(h)(10) of the Internal Revenue Code. As the Transaction closed subsequent to June 30, 2026, the income tax effects of the transaction, including changes in the valuation allowance for capital-loss carryforwards, were not recognized in the income tax provisions for the three and six months ended June 30, 2026. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  47</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_127"></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2006, we have devoted most of our cash resources to manufacturing, R&amp;D and selling, general and administrative activities related to the development and commercialization of EXPAREL. In addition, we acquired ZILRETTA as part of the acquisition of Flexion Therapeutics, Inc. in November 2021 and GQ Bio in February 2025 to further develop PCRX-201 and establish our HCAd platform, as well as completing other strategic acquisitions of companies, products and product candidates. We are primarily dependent on the commercial success of EXPAREL and ZILRETTA. We have financed our operations primarily with the proceeds from the sale of convertible senior notes and other debt, common stock and product sales. As of June&#160;30, 2026, we had an accumulated deficit of $191.8 million, cash and cash equivalents and available-for-sale investments of $251.0 million and working capital of $493.2 million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2026, we received an upfront payment of $73.6&#160;million from the closing of the Transaction that divested iovera&#176; to Zimmer, consisting of an upfront payment of $70.0 million and $3.6 million of adjustments for cash, accounts receivable, indebtedness, transaction expenses and inventory. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our cash and cash equivalents and available-for-sale investments on hand will be adequate to cover our short-term liquidity needs, and that we would be able to access other sources of financing should the need arise.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83,140&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,471&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,200&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,534&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(67,048)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(60,499)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,330&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2026, net cash provided by operating activities was $83.1 million, compared to $47.5 million during the six months ended June&#160;30, 2025. The increase&#160;of $35.7 million was primarily attributable to an initiative to increase inventory days on hand in 2025 and was partially offset by fewer receipts on our accounts receivable due to the extension of payment terms in 2026 and the recovery of $5.2 million in legal expenses received in 2025. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2026, net cash provided by investing activities was $31.2 million, which reflected $35.6 million of inflows from available-for-sale investment sales (net of purchases), partially offset by $4.1 million of capital expenditures.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2025, net cash provided by investing activities was $36.5 million, which reflected $65.7 million of inflows from available-for-sale investment sales (net of purchases), partially offset by $16.7 million related to the cash consideration for the GQ Bio Acquisition (net of cash acquired), as well as $11.2 million of capital expenditures for manufacturing product fill lines and the build-out of our new corporate headquarters in Brisbane, California.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2026, net cash used in financing activities was $67.0 million, which primarily consisted of $50.0&#160;million in repurchases of common stock under a $300.0 million share repurchase program; $10.0 million in repayments of the Revolving Credit Facility (as defined herein); $7.8&#160;million to withhold shares of common stock to cover employee tax withholding obligations on restricted stock unit vests, as well as $1.3&#160;million of excise taxes paid on repurchases of our common stock. Partially offsetting these uses were proceeds of $1.7 million from the issuance of common stock through our ESPP and $0.5 million from the exercise of stock options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2025, net cash used in financing activities was $60.5 million, which primarily consisted of $50.0 million in purchases of treasury stock under the then-new $300.0 million share repurchase program authorized by our board of directors in April 2025, $6.6 million of voluntary prepayments associated with the TLA Term Loan, as well as $5.5 million to withhold shares of common stock to cover employee tax withholding obligations on restricted stock unit vests. There were also $1.6 million of proceeds from the issuance of common stock through our ESPP.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein for further discussion of the TLA Term Loan and the Revolving Credit Facility. For more information on our share repurchase program, see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Note 12, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2029 Convertible Senior Notes</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we completed a private placement of $287.5&#160;million in aggregate principal amount of our 2.125% convertible senior notes due 2029, or 2029 Notes, and entered into an indenture with respect to the 2029 Notes. The 2029 Notes accrue interest at a fixed rate of 2.125% per year, payable semiannually in arrears on May 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and November 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The 2029 Notes mature on May 15, 2029. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2026, all $287.5&#160;million of principal was outstanding on the 2029 Notes. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein for further discussion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2025, we entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank, and certain lenders, to, among other things, refinance the indebtedness outstanding under our TLA Credit Agreement (as defined below) and provide ongoing working capital. The Credit Agreement provides for a senior secured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) in an aggregate commitment amount of $300.0&#160;million, with a letter of credit sublimit of $10.0&#160;million and swingline loan sublimit of $15.0&#160;million. The credit facility is secured by substantially all of our and each subsidiary guarantor&#8217;s assets and matures on July 3, 2030, subject to certain exceptions set forth in the Credit Agreement. Subject to certain conditions, we may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of any existing class of term loans by requesting one or more incremental term facilities in an aggregate principal amount not to exceed the greater of $225.0&#160;million and 100% of Consolidated EBITDA (as defined in the Credit Agreement).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each revolving loan borrowing which is an alternate base rate borrowing will bear interest at a rate per annum equal to (i) a base rate, plus (ii) a spread based on our Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) ranging from 1.50% to 2.25%. Each revolving loan borrowing which is a term benchmark borrowing or daily simple SOFR (as defined in the Credit Agreement) borrowing will bear interest at a rate per annum equal to (i) a forward-looking term rate based on SOFR or a rate determined by reference to the daily simple SOFR, plus (ii) a spread based on our Senior Secured Net Leverage Ratio ranging from 2.50% to 3.25%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of June&#160;30, 2026, we were in compliance with all covenants under the Credit Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into the Credit Agreement, we borrowed $101.0&#160;million under the Revolving Credit Facility, of which $81.0&#160;million is outstanding as of June&#160;30, 2026. We made repayments of $10.0&#160;million during the six months ended June&#160;30, 2026. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents, available-for-sale investments and cash received from product sales will be sufficient to enable us to fund our operating expenses, capital expenditure requirements and payment of the interest and principal on our Revolving Credit Facility and 2029 Notes through the next 12 months from the date of this filing. Our future use of operating cash and capital requirements will depend on many forward-looking factors, including, but not limited to:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of the potential milestone payments to former Flexion Therapeutics, Inc. stockholders, which could be up to an aggregate of $372.3&#160;million if certain regulatory and commercial milestones are met. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein for more information;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global economic conditions&#8212;including the impact of inflation and tariffs&#8212;on our products, material and labor costs, supply chain, longer lead-times, an inability to procure a sufficient supply of materials, our operating expenses and our business strategy;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and extent to which the holders of our 2029 Notes elect to convert their 2029 Notes, and the amount of borrowings and interest payments on our Revolving Credit Facility. Per the terms of the 2029 Notes, we will settle the principal in cash. For any excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and our ability to successfully continue to expand the commercialization of EXPAREL and ZILRETTA;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of expanding and maintaining our manufacturing facilities and capabilities;</span></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of additional strategic investments, including additional investments under existing agreements;</span></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs related to legal and regulatory matters, including those to develop and defend our intellectual property;</span></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of performing additional clinical trials for our products and product candidates, including the additional pediatric trials required by the FDA and EMA as a condition of the approval of EXPAREL and clinical trials for PCRX-201, PCRX-2002 and other clinical-stage product candidates;</span></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs for the development and commercialization of other product candidates;</span></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future payments under our employee benefit plans, including but not limited to our cash long-term incentive plan and non-qualified deferred compensation plan;</span></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in products, businesses and technologies; and</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and the number of shares of our common stock either repurchased through our $300.0 million share repurchase program announced in April 2025, which has an expiration date of December 31, 2026 or withheld to cover employee tax withholding obligations on restricted stock unit vests.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional debt or equity financing to meet our future operating and capital requirements. We have no committed external sources of funds, and additional equity or debt financing may not be available on acceptable terms, if at all. In particular, capital market disruptions or negative economic conditions may hinder our access to capital.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_130"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to our </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001396814/000162828026012297/pcrx-20251231.htm">2025 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. There have been no significant changes to our critical accounting policies nor any recently issued accounting pronouncements that are expected to have a material impact on our financial results since December&#160;31, 2025.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_133"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, we entered into a new lease obligation in Brisbane, California of approximately $8.0&#160;million to retain our principal executive offices and corporate headquarters through 2036. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth above, there have been no material changes in our contractual obligations relating to our indebtedness, lease obligations and purchase obligations from those reported in our 2025 Annual Report. For more information on our contractual obligations and commercial commitments, see Part II, Item 7 in our </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001396814/000162828026012297/pcrx-20251231.htm">2025 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_136"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our cash equivalents and investment activities is to preserve principal while at the same time maximizing the income that we receive from our investments without significantly increasing risk. We invest in corporate bonds, commercial paper, asset-backed securities and U.S. Treasury and other government agency notes for purposes other than trading which are reported at fair value. These securities are subject to interest rate risk and credit risk. This means that a change in prevailing interest rates may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, we expect that the fair value of our investment will decline. A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at June&#160;30, 2026 by approximately $0.1&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our 2029 Notes is impacted by both the fair value of our common stock and interest rate fluctuations. As of June&#160;30, 2026, the estimated fair value of the 2029 Notes was $999 per $1,000 principal amount. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein for further discussion of our 2029 Notes, which bear interest at a fixed rate. At June&#160;30, 2026, $287.5 million of principal remains outstanding on the 2029 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility provides for a senior secured revolving credit facility in an aggregate commitment amount of $300.0&#160;million, with a letter of credit sublimit of $10.0&#160;million and swingline loan sublimit of $15.0&#160;million. Each revolving loan borrowing which is an alternate base rate borrowing will bear interest at a rate per annum equal to (i) a base rate, plus (ii) a spread based on our Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) ranging from 1.50% to 2.25%. Each revolving loan borrowing which is a term benchmark borrowing or daily simple SOFR (as defined in the Credit Agreement) borrowing will bear interest at a rate per annum equal to (i) a forward-looking term rate based on SOFR or a rate determined by reference to the daily simple SOFR, plus (ii) a spread based on our Senior Secured Net Leverage Ratio ranging from 2.50% to 3.25%. Upon entering into the Credit Agreement, we borrowed $101.0&#160;million under the Revolving Credit Facility, of which $81.0&#160;million is outstanding as of June&#160;30, 2026. As of June&#160;30, 2026, borrowings under the Revolving Credit Facility consisted entirely of term SOFR borrowings at an approximate all-in rate of 6.72%. A hypothetical 100 basis point increase in interest rates would increase interest expense over the next 12 months by approximately $0.8&#160;million based on the balance outstanding for these borrowings as of June&#160;30, 2026.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with certain vendors and partners that operate in foreign jurisdictions. The more significant transactions are primarily denominated in the U.S. Dollar, subject to an annual adjustment based on changes in currency exchange rates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our accounts receivable are primarily concentrated with three large wholesalers of pharmaceutical products. In the event of non-performance or non-payment, there may be a material adverse impact on our financial condition, results of operations or net cash flow.</span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_139"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) under the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. As defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, disclosure controls and procedures are controls and other procedures which are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June&#160;30, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_142"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_145"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For information related to Item 1. Legal Proceedings, refer to Note 17, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated financial statements included herein.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_148"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RISK FACTORS</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the factors discussed in Part I, Item 1A. &#8220;Risk Factors&#8221; in our </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1396814/000162828026012297/pcrx-20251231.htm">2025 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which could materially affect our business, financial condition, cash flows or future results. Except as described below, there have been no material changes in our risk factors included in our 2025 Annual Report. The risks described in our 2025 Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the anticipated benefits of the divestiture of iovera&#176;.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may continue to incur costs or liabilities related to the divestiture of iovera&#176;, including, among other things, obligations under a transition services agreement, indemnification provisions or other contractual commitments. The divestiture of iovera&#176; also may divert management attention, result in higher-than-anticipated costs or disrupt our ongoing operations. Further, the divestiture may not achieve our anticipated strategic, operational or financial objectives, including allowing us to focus resources on our core business, improving our operating results and financial condition.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to realize the expected benefits of the divestiture of iovera&#176;, do not receive any or all of the $70.0 million of potential revenue-based milestone payments or incur greater-than-expected costs or liabilities in connection with the divestiture, our business, financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not receive some or all of the potential revenue-based milestone payments associated with the divestiture of iovera&#176;.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that any or all of the $70.0 million of potential revenue-based milestone payments (as outlined below) will ever be achieved or become payable to us. The achievement of the applicable milestones depends on numerous factors outside of our control, including, among other things, Zimmer&#8217;s commitment of financial and operational resources, clinical and regulatory outcomes, manufacturing capabilities, commercialization efforts, market acceptance, competitive dynamics, strategic decisions and other business priorities, among other things.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The potential revenue-based milestone payments associated with the divestiture of iovera&#176; to Zimmer consist of:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the current version of iovera&#176; available for sale to end users as of the closing date of the iovera&#176; divestiture transaction (the &#8220;Business Products&#8221;) during any of the five (5) calendar year periods commencing on January 1, 2027 through December 31, 2031 (each an &#8220;Applicable Milestone Period&#8221;) equals or exceeds $50.0&#160;million, we will receive $18.5&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $60.0&#160;million, we will receive $23.5&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $70.0&#160;million, we will receive $28.0&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any single year equals or exceeds the sum of any two or more milestones, then the highest applicable milestone payment shall be paid with respect to such year.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result, actions taken or not taken by Zimmer may delay, reduce or eliminate our ability to receive some or all of the potential revenue-based milestone payments, which expire on December 31, 2031 if not met.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For more information on the divestiture of iovera&#176; to Zimmer, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_154"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_157"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_160"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_163"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended June&#160;30, 2026, no director or executive officer of the Company <ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1226"><ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1227">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1228"><ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1229">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div><span><br/></span></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_172"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this report.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-06302026xex21.htm">2.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock and Asset Purchase Agreement by and between Pacira BioSciences, Inc., Pacira CryoTech, Inc. and Zimmer, Inc.*  #</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101teehanexecutiveagreem.htm">10.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Employment Agreement, dated January 21, 2025, by and between Pacira Pharmaceuticals, Inc. and Brendan Teehan.* &#8224;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pacira2014amendedandrestat.htm">10.2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2014 Employee Stock Purchase Plan.(1)&#8224;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-06302026xex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;and 15d-14(a), as amended.*</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-06302026xex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;and 15d-14(a), as amended.*</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-06302026xex321.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.**</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended June&#160;30, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss); (iv) the Condensed Consolidated Statements of Stockholders&#8217; Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.*</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denotes management contract or compensatory plan or arrangement.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certain schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K under the Securities Exchange Act of 1934, as amended. The Registrant hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission upon request.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed on June 11, 2026.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  54</span></div></div></div><div id="ic3d6b4f5cd834aefb39683a79b5e86d0_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic3d6b4f5cd834aefb39683a79b5e86d0_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:509.50pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.317%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.066%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">PACIRA BIOSCIENCES,&#160;INC.<br/>(REGISTRANT)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ FRANK D. LEE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Frank D. Lee</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SHAWN M. CROSS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shawn M. Cross</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  Q2 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> Quarterly Report on Form 10-Q  |  55</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>pcrx-06302026xex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i107d82aceeb64a04aa1708299fef6524_1"></div><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-right:17.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 2.1</font></div><div style="margin-top:3.9pt;padding-right:17.85pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.982%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3.9pt;padding-right:17.85pt;text-align:right"><font><br></font></div><div style="margin-top:3.9pt;padding-right:17.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTION VERSION</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:2.1pt"><font><br></font></div><div style="padding-left:114.27pt;padding-right:114.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">STOCK AND ASSET PURCHASE AGREEMENT DATED AS OF JUNE 28, 2026</font></div><div style="padding-left:114.27pt;padding-right:114.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">AMONG ZIMMER, INC.,</font></div><div style="padding-left:166.12pt;padding-right:166.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">PACIRA BIOSCIENCES, INC.,</font></div><div style="padding-left:166.12pt;padding-right:166.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">AND</font></div><div style="padding-left:166.12pt;padding-right:166.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">PACIRA CRYOTECH, INC.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:114.3pt;padding-right:114.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-top:23.5pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE I DEFINITIONS AND RULES OF CONSTRUCTION</a><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">1</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 1.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Defined Terms</a><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">1</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 1.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Rules of Construction</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">19</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE II PURCHASE AND SALE OF SHARES&#59; CLOSING</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">19</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Agreement to Purchase and Sell</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">19</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Purchase Price</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">19</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Closing and Closing Payments</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">20</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Purchase Price Adjustment</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">21</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Preparation of the Closing Statement</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">21</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Disputes Regarding Closing Statement</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">22</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Additional Consideration.</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">24</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Closing Deliveries</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">27</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 2.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Withholding Rights</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">28</a></font></div><div style="margin-top:5.85pt;padding-left:107.95pt;padding-right:21.5pt;text-indent:-90pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:118%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER REGARDING THE</a> <a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">COMPANY AND THE PURCHASED ASSETS</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">29</a></font></div><div style="margin-top:5.6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Organization, Existence and Good Standing</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">29</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Power and Authority, Authorization and Execution</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">29</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Enforceability</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">30</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Consents&#59; Non-Contravention</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">30</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Capitalization</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">31</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Financial Statements&#59; Undisclosed Liabilities</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">31</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Title to Assets and Related Matters</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">31</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Insurance</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">32</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Taxes</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">32</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.10</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Conduct of Business</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">34</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.11</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Contracts</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">36</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.12</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Permits</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.13</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Compliance with Laws</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.14</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Proceedings and Orders</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">38</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.15</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Real Property</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">38</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.16</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Environmental Matters</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">39</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.17</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Benefit Plans</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">40</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.18</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Employee Relations</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">41</a></font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.19</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Intellectual Property</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">43</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.20</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Privacy and Data Security</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">45</a></font></div><div style="margin-top:11.8pt;padding-left:114.42pt;padding-right:114.42pt;text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.21</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Anti-Bribery and Anti-Corruption</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">46</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.22</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">International Trade Compliance</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">46</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.23</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Related Parties Transactions</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">47</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.24</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">FDA and Related Matters</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">47</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.25</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Healthcare Regulatory Compliance</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">48</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.26</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Sufficiency of Purchased Assets</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">48</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 3.27</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Brokers</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">48</a></font></div><div style="margin-top:6.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF SELLER</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Organization, Existence and Good Standing</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Power and Authority</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Enforceability</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Consents&#59; Non-Contravention</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Title to</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Brokers</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 4.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Litigation</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE V REPRESENTATIONS AND WARRANTIES OF PURCHASER</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Organization, Existence and Good Standing</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Power and Authority</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Enforceability</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Consents&#59; Non-Contravention</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Brokers</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">51</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Investment Representation</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">51</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Sufficient Funds</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">51</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Litigation</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">51</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 5.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Non-Reliance</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">51</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE VI COVENANTS OF THE COMPANY AND SELLER</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 6.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Reasonable Access</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 6.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Operation of the Business</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 6.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Actions Outside the Ordinary Course</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 6.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Exclusivity</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">53</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 6.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Restrictive Covenants.</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">53</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 6.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Release</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">56</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE VII COVENANTS OF PURCHASER</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.1&#160;&#160;&#160;&#160;Contact with Business Relations&#160;&#160;&#160;&#160;57</font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.2&#160;&#160;&#160;&#160;       Transfer of Permits&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        57</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Liability Insurance and Indemnification</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Reserved</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">58</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Labor Matters</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">58</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Confidentiality.</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">60</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Other Applications</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">60</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Spasticity License</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">61</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 7.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Seller Marks</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">61</a></font></div><div style="margin-top:6.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE VIII JOINT COVENANTS</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">62</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 8.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Governmental Consents</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">62</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 8.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Efforts to Consummate</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">62</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 8.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Inspection of Records</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">62</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 8.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Publicity</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">63</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 8.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Further Assurances&#59; Shared Contracts</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">63</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 8.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Termination of Intercompany Arrangements</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:6.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE IX CONDITIONS TO CLOSING</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 9.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Conditions to Seller&#8217;s Obligations</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 9.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Conditions to Purchaser&#8217;s Obligations</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 9.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Joint Conditions to the Parties&#8217; Obligations</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 9.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Frustration of Closing Conditions</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:6.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE X TAX MATTERS</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Preparation and Filing of Tax Returns</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Straddle Periods</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">68</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Refunds</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">69</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Control of Audit or Tax Litigation</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">69</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Transfer Taxes</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Cooperation</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Tax Sharing Agreements</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Intercompany Debt</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Post-Closing Actions</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 10.10</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 338(h)(10) Election</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">71</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE XI TERMINATION</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">71</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 11.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Right to Terminate</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">71</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 11.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Remedies Upon Termination</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">72</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE XII INDEMNIFICATION&#59; SURVIVAL</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">72</a></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Indemnification by Seller</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">72</a></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Indemnification by Purchaser</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">73</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Indemnification Notice&#59; Litigation Notice</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">73</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Disagreement Notice</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">73</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Defense of Third-Party Claims</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">73</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Survival</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">74</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Limitation on Indemnified Costs</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">75</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Special Rule for Fraud</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">75</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Exclusive Remedy</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.10</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Payment of Losses</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 12.11</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Tax Treatment of Indemnity Payments</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:5.95pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE XIII MISCELLANEOUS</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.1</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Disclosure Schedule</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.2</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Transaction Expenses</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">77</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.3</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Notices</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">77</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.4</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Entire Agreement&#59; Amendments</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">78</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.5</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Non-Waiver</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">78</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.6</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Counterparts</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">78</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.7</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Delivery by Electronic Transmission</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">78</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.8</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Severability</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">78</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.9</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Arm&#8217;s Length Negotiations&#59; Drafting</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.10</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Applicable Law</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.11</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Third-Party Beneficiaries</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.12</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Binding Effect&#59; Benefit</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.13</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Assignment</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:6.05pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.14</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Waiver of Trial by Jury</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.15</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Consent to Jurisdiction</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:6.1pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.16</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Specific Performance</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">80</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.17</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Headings</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">80</a></font></div><div style="margin-top:5.95pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Section 13.18</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Legal Representation</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">80</a></font></div><div style="margin-top:5.85pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Form of Escrow Agreement</font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:124.6pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit B&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Form of Assignment and Assumption Agreement Exhibit C&#160;&#160;&#160;&#160; &#8212;&#160;&#160;&#160;&#160;Form of Sublease Agreement</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.55pt">Exhibit D&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Form of Transition Services Agreement</font></div><div><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Schedule A&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Purchased Assets</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Schedule B&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Excluded Assets</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.60pt">Schedule 1.1&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Accounting Principles</font></div><div style="padding-left:18pt;padding-right:233.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 2.8&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Allocation Methodology Schedule 7.5(b)(iv)&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Transaction Bonuses</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 7.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;Spasticity Collaboration Terms</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:66.12pt;padding-right:66.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">STOCK AND ASSET PURCHASE AGREEMENT</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">This STOCK AND ASSET PURCHASE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) is made as of June 28, 2026 among (i) Zimmer, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), (ii) Pacira BioSciences, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), and (iii) Pacira CryoTech, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Purchaser, Seller, and the Company are referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.&#8221; Capitalized terms used but not otherwise defined in this Agreement have the meanings ascribed to those terms in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article I</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_4" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.15pt;padding-left:66.15pt;padding-right:66.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">RECITALS</font></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">WHEREAS, Seller owns all of the issued and outstanding capital stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59;</font></div><div style="margin-top:10.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">WHEREAS, Purchaser desires to purchase from Seller, and Seller desires to sell to Purchaser, all of the Shares&#59;</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">WHEREAS, Pacira Pharmaceuticals, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">PPI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and Pacira Ireland Limited (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Pacira Ireland</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; and, collectively with PPI and Seller, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Asset Sellers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) collectively own all of the Purchased Assets and hold all of the Assumed Liabilities (each as defined herein)&#59;</font></div><div style="margin-top:10.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">WHEREAS, Purchaser desires to purchase and assume from the Asset Sellers and Seller desires to sell and transfer to Purchaser (or cause the other Asset Sellers to sell and transfer to Purchaser), the Purchased Assets and the Assumed Liabilities&#59; and</font></div><div style="margin-top:10.65pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">WHEREAS, simultaneously herewith Purchaser, the Company and each Seller Group Entity party thereto are entering into the Assignment and Assumption Agreement whereby all of the Purchased Assets will be purchased by and assigned to Purchaser.</font></div><div style="margin-top:11pt;padding-left:66.12pt;padding-right:66.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">AGREEMENT</font></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">In consideration of the terms set forth in this Agreement, and for other good and valid consideration, the receipt and sufficiency of which are acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:10.9pt;padding-left:66.12pt;padding-right:66.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE I</font></div><div style="margin-top:0.1pt;padding-left:66.12pt;padding-right:66.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">DEFINITIONS AND RULES OF CONSTRUCTION</font></div><div style="margin-top:11.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The following terms, as used herein, have the following meanings&#58;</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Accounting Expert</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the accounting principles, policies, methodologies, procedures set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule 1.1</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Accounts Receivable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all gross amount of accounts receivable related exclusively to the Business as of the Measurement Time, in accordance with the Accounting Principles but without regard to any reserves or allowances. For the avoidance of doubt, any pre-closing sales Taxes of the Business Products will not be part of the Purchased Assets.</font></div><div style="margin-top:12.15pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Accounts Receivable Target</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $4,300,000.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Acquired Entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Acquisition Proposal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any written, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">offer, proposal or indication of interest from a third party with respect to (a) the acquisition of (i) a majority of the Shares, (ii) a majority of the Purchased Assets, or (iii) a majority of the assets of the Business, taken as a whole, or (b) any merger, consolidation, recapitalization, reorganization or business combination involving the Company.</font></div><div style="margin-top:12.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Additional Consideration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Additional Consideration Cap</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, with respect to any Person, any other Person who directly or indirectly Controls, is Controlled by, or is under common Control with such Person.</font></div><div style="margin-top:11.65pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preamble</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Antitrust Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the United States Sherman Antitrust Act of 1890, the United States Clayton Act of 1914, the HSR Act, the United States Federal Trade Commission Act of 1914, and all other Laws, including foreign Laws designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition.</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act of 2010, and other applicable Laws concerning or relating to bribery or corruption, as applicable.</font></div><div style="margin-top:11.65pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Asset Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $34,850,000.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Asset Seller</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preamble</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Assignment and Assumption Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means an Assignment and Assumption Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> to be entered into on the Closing Date by and among Purchaser and each Asset Seller party thereto.</font></div><div style="margin-top:11.7pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Associated Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Assumed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the following Liabilities of the Asset Sellers, in each case, to the extent arising out of or relating to the Business&#58; (a) all Liabilities with respect to Transferred Employees related to their service relationship with Purchaser (or one of its Affiliates) from and after the Closing,</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) all product warranty obligations and product return Liabilities related to the Business (in each case, whether arising before, on, or after the Closing Date, and including all accrued warranty and reserve obligations as of the Measurement Time), (c) all Liabilities to the extent arising out of or relating to the monitoring, investigation, reporting, management, or remediation of adverse events, product complaints, or other safety issues with respect to the Business, initially arising as of and following the Closing, (d) all Liabilities related to future payment or performance under the Transferred Contracts which&#58; (i) initially accrue or arise on or after the Closing Date, (ii) are not the result of or caused by any breach or default of any Asset Seller thereunder prior to the Closing Date or any event, circumstance or condition occurring or existing prior to the Closing Date that, with notice or lapse of time, would constitute or result in a breach or default thereof, and (iii) do not arise from actions taken (or omitted from being taken) by any Asset Seller prior to the Closing Date, including the provision of any products or services prior to the Closing Date, and (e) all other Liabilities to the extent arising from or related to the conduct or operation of the Business or the ownership of the Purchased Assets or Assumed Liabilities, in each case, from and after the Closing.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any employee benefit plan, program or arrangement (including but not limited to any &#8220;employee benefit plan&#8221; as defined in Section 3(3) of ERISA) sponsored or contributed to or required to be contributed to by the Company for the benefit of any current or former employee, officer or director of the Company or any current or former Business Employee or with respect to which the Company has any liability&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the term &#8220;Benefit Plan&#8221; does not include any employee benefit plan, program or arrangement that is mandated, maintained or administered by any Governmental Authority or required to be contributed to by the Company pursuant to applicable Law and is not sponsored, maintained, or administered by the Company or an Affiliate of the Company.</font></div><div style="margin-top:11pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the Bill of Sale by and between the Asset Sellers and Purchaser (or it's appliable Affiliate), in a form and substance reasonably acceptable to Seller and Purchaser.</font></div><div style="margin-top:11.5pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the business of developing, commercializing and selling handheld cryoanalgesia devices and related products under the &#8220;iovera&#8221; name, including employees primarily involved in the foregoing.</font></div><div style="margin-top:11.75pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a day on which banks are open for business in New York City, New York, but does not include any day that is a Saturday, Sunday or a statutory holiday in the State of New York.</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means each individual (or sole proprietor acting through an entity) independent contractor engaged by the Company and each independent contractor engaged by a Seller Group Entity to provide services relating to the Business, each as of the date hereof.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Product</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the current version of the handheld cryoanalgesia devices and related products that are available for sale to end users under the &#8220;iovera&#8221; name as of the Closing Date.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Transfer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(g)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Cash</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means an aggregate amount, determined on a consolidated basis, as of the Measurement Time equal to, without duplication, (a) all cash and cash equivalents on hand in the bank and lock box accounts of the Company (including (i) in any money market accounts and (ii) cash resulting from the clearance of any checks, wire transfers, drafts or other deposits in transit deposited by the Company before, whether or not such clearance occurs before, the Measurement Time), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) all marketable securities owned by the Company including accrued interest thereto, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c) all cash and similar deposits, escrows and sureties held by third parties for the benefit of or as security for any obligation of the Company as of such time, including all lease and tenant improvement deposits and escrows.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing Consideration Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means an aggregate amount equal to (i) the Purchase Price, determined without regard to any Additional Consideration or Assumed Liabilities, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (ii) the Adjustment Escrow Amount.</font></div><div style="margin-top:11.7pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the United States Internal Revenue Code of 1986, as amended.</font></div><div style="padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preamble</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Company&#8217;s Knowledge</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; and words of similar import mean the actual knowledge of Brendan Teehan, &#91;Omitted&#58; Non-Executive Employee&#93;, Krys Corbett, &#91;Omitted&#58; Non-Executive Employee&#93;, &#91;Omitted&#58; Non-Executive Employee&#93; and &#91;Omitted&#58; Non-Executive Employee&#93;, after reasonable due inquiry.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the Intellectual Property Assets and other information regarding the Company, the Business and the other business operations of the Company that is treated as confidential or proprietary by the Company, including the Company&#8217;s Trade Secrets, customer and supplier lists and pricing information.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means that certain Confidentiality Agreement, dated as of February 23, 2026, by and between Seller and Zimmer Biomet Holdings, Inc.</font></div><div style="margin-top:11.5pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Consolidated Tax Return</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all Tax Returns of a Tax Group that actually include the Company on the one hand and a Seller Group Entity on the other hand.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any agreement, contract, lease, sublease, license, sublicense, note, mortgage, debenture, indenture, letter of credit or instrument, in each case, that creates a legally binding obligation, and, in each case, whether written or oral (to the extent legally binding).</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through ownership of Equity Securities, by contract or otherwise.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Controlled Affiliates&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> means, with respect to Seller, any Person directly or indirectly controlled by Seller (within the meaning of &#8220;Affiliate&#8221; as defined herein, but excluding any Person that controls, or is under common control with, Seller).</font></div><div style="margin-top:12.1pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Covered Person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means each Person who is as of the date of this Agreement, has been at any time prior to the date of this Agreement or who becomes prior to the Closing Date a director, manager, officer, employee and agent of the Company.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Data Breach</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means&#58; (i) &#8220;personal data breach,&#8221; &#8220;security incident,&#8221; and similar terms as defined by Privacy Laws&#59; or (ii) any loss, damage or unauthorized or illegal use, disclosure, modification, possession, interception, or other processing of or access to, or other misuse of, any of the Personal Information or other data or information in any of the Company databases.</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Data Security Requirements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, collectively, all of the following to the extent relating to the access, collection, use, import, export, processing, storage, sharing, distribution, transfer, disclosure, security, destruction, or disposal of any Personal Information or sensitive or confidential information or data (whether in electronic or any other form or medium) or otherwise relating to personal information data protection, privacy, security, or security breach notification requirements and applicable to the Company, to the conduct of the Business, or to any of the Information Systems or any Company Data&#58; (a) the Company&#8217;s own rules, policies, and procedures&#59; (b) all Laws, including HIPAA Part 2, and state medical privacy laws&#59; (c) industry standards applicable to the industry in which the Business operates&#59; (d) </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Contracts into which the Company has entered or by which the Company is otherwise bound&#59; and (e) any public commitments or statements.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disagreement Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="padding-left:18pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">.</a></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Dispute Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disputed Elements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Election Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Enforceability Exceptions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all Laws and Orders that, in each case, pertain to protection of the environment (including ambient air, surface water, groundwater and surface or subsurface strata), natural resources, or worker health and safety including but not limited to&#58; the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. &#167; 9601 et seq., the Resource Conservation and Recovery Act, 42 U.S.C. &#167; 6901 et seq., the Clean Air Act, 42 U.S.C. &#167; 7401 et seq., the Federal Water Pollution Control Act, 33 U.S.C. &#167; 1251 et seq., the Oil Pollution Act of 1990, 33 U.S.C. &#167; 2701 et seq., the Toxic Substances and Control Act, 15 U.S.C. &#167; 2601 et seq., the Safe Drinking Water Act, 42 U.S.C. &#167; 300(f) et seq., the Hazardous Materials Transportation Act, 49 U.S.C. &#167; 5101 et seq., the Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167; 301 et seq., and the Occupational Safety and Health Act, 29 U.S.C. &#167; 651 et seq., as well as their applicable State and local counterparts, and all amendments and regulations adopted thereto.</font></div><div style="margin-top:1.3pt;padding-left:54pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Permits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Permits related to or issued under Environmental Laws. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) equity securities, (b) securities convertible into or exchangeable for</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">equity securities, (c) options, warrants, call rights or other equity-based awards exercisable or exchangeable for or convertible into or other rights to acquire any equity securities or securities convertible into or exchangeable for equity securities, (d) equity appreciation rights, phantom stock units, performance units, profit participation or similar equity based-rights and (e) bonds, indentures, notes or other indebtedness, providing for the right to vote (or convertible into securities that have the right to vote) on any matters on which equity holders may vote.</font></div><div style="margin-top:12.2pt;padding-left:54pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the United States Employee Retirement Income Security Act of 1974, as amended.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Escrow Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means U.S. Bank National Association, a national banking association.</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means an Escrow Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_1" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit A</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> to be entered into at the Closing by and among Purchaser, Seller and the Escrow Agent.</font></div><div style="margin-top:10.7pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Estimated Closing Consideration Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Estimated Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exception Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.5(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">.</a></font></div><div style="padding-left:54pt;padding-right:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excess Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is defined on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule B</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Excluded Liabilities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all Liabilities of the Asset Sellers that are not Assumed Liabilities, and without limitation to the generality of the foregoing, Excluded Liabilities shall include the following&#58;</font></div><div style="margin-top:0.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) all Indebtedness&#59; (b) any Liability of the Asset Sellers for products liability claims to the extent arising out of or related to products or services manufactured, produced, provided or sold by the Asset Sellers prior to the Closing Date (provided, for the avoidance of doubt, that this clause (b) shall not apply to any product warranty obligations or product return Liabilities that constitute Assumed Liabilities pursuant to clause (ii) of the definition of Assumed Liabilities, regardless of whether such obligations or Liabilities could also be characterized as products liability claims)&#59; (c) any Liability under any Transferred Contract to the extent arising out of or relating to any breach by the relevant Asset Seller that occurred prior to the Closing Date&#59; (d) any Liability for Taxes of Seller or the Asset Sellers, including&#58; (i) any Taxes measured by or with respect to income, net worth, or capital of Seller or the Asset Sellers, (ii) any Taxes arising as a result of the operation of the Business or ownership of the Purchased Assets prior to the Closing Date, (iii) any Taxes that will arise as a result of the sale of the Purchased Assets pursuant to this Agreement (other than Transfer Taxes which shall be governed by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">), and (iv) any deferred Taxes of any nature of the Seller or the Asset Sellers&#59; (e) any Liability to the extent resulting from, arising out of relating to, in the nature of, or caused by any breach of Contract, breach of warranty, tort, or infringement of an Asset Seller prior to the Closing&#59; (f) any Liability resulting from a violation by any Asset Seller of any Environmental Laws relating to the operation of the Business or any Seller Group Entity's ownership, leasing or operation of any real property prior to the Closing Date&#59; (g) any Liability of any Seller Group Entity under or with respect to any Benefit Plan or relating to payroll, incentive pay, vacation, sick leave, retirement benefits, employee equity-based or profit-sharing plans, health or welfare plans or benefits or any other Benefit Plan or benefits of any kind relating to periods of employment or service with any Seller Group Entity&#59; (h) any and all liabilities in existence prior to or as of the Closing, or that arise at or after the Closing and are based on events, acts, omissions, conditions or any other state of facts first occurring prior to or otherwise existing as of the Closing associated with the Business Employees or Business Independent Contractors, which shall include all liabilities with respect to such employees or contractors for all wages, salary, bonuses (whether accrued or otherwise but excluding the Transaction Bonus Amounts), other compensation, accrued vacation and sick days, employee benefits, supplemental employee benefits, payroll Taxes, worker&#8217;s compensation and other claims, and all other liabilities attributable to or related to such employees&#8217; employment or contractors&#8217; services with Seller Group Entities through and including the Closing Date&#59; (i) any Liability to any Personnel, equity holder or Affiliate of Seller, provided that any Liabilities with respect to Transferred Employees related to their service relationship with Purchaser (or one of its Affiliates) from and after the Closing shall be the responsibility of Purchaser&#59; (j) any Liability to indemnify, reimburse or advance amounts to any Personnel, equity holder or Representative (other than such Liabilities arising as of or following Closing with respect to Transferred Employees in connection with such Transferred Employees' employment with Purchaser or an Affiliate of Purchaser)&#59; (k) any Liability of an Asset Seller arising out of any Proceeding pending as of the Closing Date or any Proceeding commenced after the Closing Date and arising out of, or relating to, any occurrence or event happening prior to the Closing Date, in each case whether or not set forth in the Disclosure Schedules&#59; (l) any Liability arising out of or resulting from any Asset Seller&#8217;s non-compliance with any Law&#59; (m) any Liability of any Asset Seller under this Agreement or the </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Purchase Agreement&#59; (n) any Liability arising from or relating to any COBRA obligation of an Asset Seller arising from any qualifying event as defined under Code Section 4980B(f)(3) and ERISA Section 603 occurring before the Closing Date with respect to any Person that does not become an employee of Purchaser following the Closing&#59; (o) any Liability of Seller based upon the acts or omissions of Seller occurring following the Closing Date&#59; (p) any Liability of any Asset Seller resulting from, arising out of, relating to, in the nature of, or caused by any infringement, misappropriation, unauthorized use of, or any other claim related to the intellectual property of any other Person, or any noncompliance or breach of any licensed third party intellectual property, that occurs or relates to any period prior to the Closing Date, whether or not set forth in the Disclosure Schedules&#59; (q) all accounts payable outstanding as of the Closing Date&#59; and (r) any other Liabilities of Seller of any kind or character whatsoever incurred, whether existing as of the Closing or incurred thereafter. Notwithstanding the foregoing, no Liability of any Asset Seller shall be deemed to be an Excluded Liability to the extent such Liability is expressly required to be assumed or performed by Purchaser pursuant to the terms of the Transition Services Agreement.</font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the Arms Export Control Act, International Traffic in Arms Regulations, Export Administration Regulations and Laws administered and implemented by the</font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">U.S. Department of Treasury&#8217;s Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), Foreign Trade Regulations, and any other U.S. or foreign Law related to the exportation or importation of supplies or services, including any export or import declaration filing and payment of customs duties.</font></div><div style="margin-top:11.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Extra-Contractual Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 5.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the United States Food and Drug Administration.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Files and Records</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> attached hereto.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.6(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">First Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $18,500,000.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">First Milestone Threshold</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $50,000,000.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">FLSA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.18(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Fraud</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means actual and intentional fraud of a Party with respect to the making of any representation or warranty by such Party set forth in this Agreement, which constitutes common law fraud under the laws of the State of Delaware.</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Fundamental Representations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means (a) those representations and warranties of the Company set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Organization&#59; Existence), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Power and Authority), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Enforceability), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Consents&#59; Non-Contravention), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Capitalization), the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.7</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Title to Assets) and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.27</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (<a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Brokers</a>) and (b) those representations and warranties of Seller set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Organization, Existence and Good Standing), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (<a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Power and Authority</a>), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Enforceability), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (Consents&#59; Non-Contravention), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (<a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Title to Shares</a>) and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (<a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Brokers</a>).</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means generally accepted accounting principles as in effect in the United States of America from time to time.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Governing Documents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the articles of incorporation, certificate of incorporation, charter, bylaws, articles of formation, certificate of formation, operating agreement, limited liability company agreement, certificate of limited partnership, partnership agreement and all other similar documents, instruments or certificates executed, adopted or filed in connection with the creation, formation or organization of a Person.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any nation, any state, any province or any municipal or other political subdivision thereof, and any agency, commission, department, board, bureau, official, minister, tribunal or court, whether national, state, provincial, local, foreign or multinational, exercising executive, legislative, judicial, taxing, regulatory or administrative functions of a nation, state, province or any municipal or other political subdivision of any of the foregoing, or any Notified Body.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any substance, material, waste, chemical, pollutant, contaminant or toxic substance that is regulated, defined or designated under any Environmental Law as hazardous, toxic, radioactive, dangerous or a pollutant or contaminant, or for which liability or standards of care are imposed pursuant to any Environmental Law, including petroleum and petroleum products, asbestos and asbestos-containing materials, polychlorinated biphenyls, per- and polyfluoroalkyl substances (PFAS), mold, urea formaldehyde foam insulation, lead and lead-based paint, silica dust, radon, radioactive materials, hazardous wastes, solid wastes, toxic substances and ozone-depleting substances.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Inactive Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a Business Employee who is on a leave of absence, short-term or long-term disability leave, medical leave, military leave or any similar leave.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Incidental License</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any (a) nondisclosure agreement or Contract permitting the use of confidential information&#59; (b) Contract pursuant to which current or former employees or contractors of the Company assign or license Intellectual Property rights to (or waive such rights for the benefit of) the Company&#59; (c) Contract under which Intellectual Property is licensed to a contractor or vendor of the Company for the benefit of the Company or that permits the contractor or vendor to identify the Company as a customer of such contractor or vendor&#59; (d) Contract by which the Company grants an Intellectual Property license in the ordinary course of business or to a customer&#59; (e) Contract containing a non-exclusive license of Intellectual Property that is merely incidental to the transaction contemplated in such Contract, the commercial purpose of which is primarily for something other than such license, such as (i) a sales or marketing agreement that includes a license to use trademarks or other rights for the purposes of advertising or providing products or services during the term of and in accordance with such agreement, or (ii) a Contract for the purchase or lease of a photocopier, computer, network equipment, mobile phone or other equipment that also contains a license of Intellectual Property&#59; (f) non-exclusive shrink wrap, click-wrap, or browse-wrap Contract&#59; (g) non-exclusive license or terms of use that permits the use of generally available software, data or content&#59; or (h) non-exclusive licenses implied by law to end-user customers for use of products or services.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, without duplication, all obligations of the Company as of immediately prior to the Closing for (a) the principal amount of, and accrued interest with respect to, all indebtedness for borrowed money and other indebtedness evidenced by notes, bonds, debentures or other debt securities (including any prepayment and breakage premiums and penalties, expenses, costs and fees payable as a result of the consummation of the transactions contemplated by this Agreement), (b) in respect of letters of credit or banker&#8217;s acceptances, in each case, to the extent drawn, (c) indebtedness for the deferred purchase price of property or services with respect to which the Company is liable, other than ordinary course trade payables, (d) any earn out obligations, (e) any severance payments or benefits due or that may become due to any former Personnel of the Company or any current Personnel of the </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Company with an effective date of termination that is prior to the Closing, including the amount of the employer portion of any payroll, social security, unemployment or similar Taxes related thereto, (f) any payroll Taxes with respect to the Pre-Closing Tax Period deferred to a period that is not a Pre-Closing Tax Period under Section 2302 of the CARES Act, or any similar election under state or local Law, (g) any and all other Unpaid Taxes (whether or not such Taxes are due and payable as of the Closing Date) and (h) obligations of the Company in respect of leases which are, or otherwise should be, characterized as finance leases (formerly capital leases) in accordance with GAAP. Notwithstanding the foregoing, &#8220;Indebtedness&#8221; will not include any amounts included as Transaction Expenses.</font></div><div style="margin-top:12.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Basket</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.7(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Cap</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.7(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="padding-left:18pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any of the following Taxes, in each case, regardless of whether any such Taxes are reflected or shown as due or payable on any Tax Return, and regardless of whether any such Taxes are assessed, payable, or due prior to, on, or after the Closing Date&#58; (a) any and all Taxes imposed on or payable by Seller or any of its Affiliates (excluding the Company but including the Asset Sellers), regardless of the Tax period to which such Taxes relate&#59; (b) any and all Taxes imposed on or payable by the Company, or for which the Company (or any assets or properties thereof) may be liable or subject, to the extent such Taxes are payable with respect to any Pre-Closing Tax Period (including the pre-closing portion of any Straddle Period)&#59; (c) any and all Taxes attributable to a Post-Inclusion Item, (d) any employer Taxes required with respect to any payments under or contemplated by this Agreement (other than any payments for services performed after the Closing Date)&#59; (e) any and all Taxes of any member of an affiliated, consolidated, combined, or unitary group of which the Company (or any member or predecessor thereof) is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulation Section 1.1502-6 or any analogous or similar state, local, or foreign Law&#59; (f) any and all Taxes of any Person imposed on or payable by the Company (or for which the Company has an obligation to pay, fund or reimburse), as a transferee or successor, by Contract or pursuant to any Law, which Taxes relate to an event or transaction occurring on or prior to the Closing Date&#59; and (g) fifty percent (50%) of any Transfer Taxes.</font></div><div style="margin-top:12.1pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnity Loss</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any damages, losses, Liabilities, Liens, penalties, costs, expenses, deficiencies, demands, Proceedings, assessments and Taxes (including costs of investigation and defense and reasonable attorneys&#8217; fees and expenses)&#59; provided, however, that &#8220;Indemnity Loss&#8221; shall not include</font></div><div style="margin-top:0.1pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) incidental or special damages, (b) punitive damages, in each case of clauses (a) and (b), except to the extent actually awarded and paid to a third party in connection with a Third-Party Claim, or</font></div><div style="margin-top:0.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c) consequential damages, except to the extent reasonably foreseeable.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Information Systems</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all computer systems, networks, hardware, Software, databases (including all data and information owned or licensed or subscribed by Company), websites (and all content and materials thereon), and equipment used to process, store, maintain and operate data, information and functions used in connection with the business of the Company as presently conducted, in each case whether owned, used, operated, leased or licensed by the Company or by a third party on behalf of Company.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all&#58; (a) patents, utility models and industrial design registrations and applications (including any continuations, divisionals, continuations-in-part, provisionals, renewals, reissues, re-examinations and applications for any of the foregoing)&#59; (b) trademarks, or service marks, in each case, together with all goodwill, registrations and applications for registration related to any of the foregoing&#59; (c) copyrights and works of authorship (including any registration and applications for any of the foregoing)&#59; (d) trade secrets&#59; and (e) all claims, causes of action and rights to sue for past, present and future infringement or misappropriation of the foregoing, and all proceeds, rights of recovery and revenues arising from or pertaining to the foregoing.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Intellectual Property Assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all intellectual property owned, in whole or in part, by the Company, whether arising or protected under the laws of the United States or any other jurisdiction or treaty, including but not limited to&#58; (a) the Company&#8217;s name, all assumed fictional business names, trade names, registered and unregistered trademarks and service marks, trade dress and similar rights and applications for registration of any of the foregoing, together with the goodwill of the business associated therewith or symbolized thereby, and any and all common law rights and other applications and registrations therefor owned by the Company together with the goodwill of the business associated therewith or symbolized thereby&#59; (b) all patents (including certificates of invention, industrial rights and other patent equivalents), provisional, non-provisional, divisional, continuation, continuation in-part and reissue applications and patents issuing therefrom, and any revivals, renewals, extensions thereof&#59; (c) all registered and unregistered copyrights in both published works and unpublished works and applications for registration, all transferrable moral rights and all rights to register and obtain renewals and extensions of registrations&#59; (d) all know-how, trade secrets, concepts, processes, customer lists, technical information and other confidential or proprietary information (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Trade Secrets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; (e) all user guides, manuals, instructions, forms, data, software, architecture designs, layouts, programmer notes or logs, source code annotations, designs, plans, drawings, process technology, plans, blue prints, documentation or materials that relate solely to the Intellectual Property Assets identified in clauses (a)-(d) and (f)-(h) herein, in tangible or electronic or other intangible form&#59; (f) all rights in internet web sites and FTP sites, internet domain names and social media accounts of the Company&#59; (g) all Software (including software programs, applications, objects, modules, routines, interfaces, algorithms and code, in source code, object code and executable form)&#59; and (h) all rights in mask works and similar rights protecting circuits and chip topographies and layouts.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Intellectual Property License</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any agreement between the Company, on the one hand, and any other Person, on the other hand, granting any right to use or practice any rights under any of the Intellectual Property owned either by the Company or by any other Person, including licenses and leases of Software, other than any Incidental License.</font></div><div style="margin-top:11.7pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Interim Operating Carveouts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">International Trade Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all applicable Laws concerning importation, exportation, or economic sanctions.</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Inventory</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all inventory used or intended for use exclusively in the Business, including finished goods, work in progress, raw materials and samples, in each case, calculated net of reserves and warranty provisions as of the Measurement Time and in accordance with the Accounting Principles&#59; provided that the calculation of Inventory shall include the quality reserve relating to a tip issues reversed by Seller prior to the date of this Agreement, which shall be deemed to be reinstated for purposes of such calculation.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.1pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Inventory Target</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $5,684,000.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Invoice Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, the actual invoice price set forth on the applicable invoice related to the specific sale of such Business Product.</font></div><div style="margin-top:11.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">IRS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the United States Internal Revenue Service.</font></div><div style="margin-top:10.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">IT System(s)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all computer systems (including those for electronic data processing, telecommunications, or record keeping), networks, hardware, software (including proprietary software), databases, websites, interfaces, peripherals, platforms, servers and other equipment used to Process, store, maintain and operate data, information and functions, including any outsourced systems or equipment, that are owned, held by, or used in connection with or for the benefit of the Business.</font></div><div style="margin-top:11pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any law, statute, ordinance, regulation, rule, code, treaty or administrative interpretation or principle of common law or other requirement having the force of law of any Governmental Authority, applicable, as the context requires, to the business or operations of the Company or to any Party.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Leased Real Property</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.15</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Leases</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.15</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:3.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Liability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; with respect to any Person, means any liability or obligation of such Person of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint or several, due to become due, vested or unvested, executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financial statements of such Person.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all legally binding options, proxies, voting trusts, voting agreements, judgments, pledges, charges, escrows, rights of first refusal, first offer or negotiation, liens, claims, hypothecations, attachments, rights of way, encroachments, easements, servitudes, conditional sale agreements or other title retention agreements, restrictions on transfer, charges, mortgages, deeds of trust, security interests, indentures and other similar encumbrances.</font></div><div style="margin-top:11.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Litigation Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any and all judgments, losses, liabilities, amounts paid in settlement, damages, fines, Taxes, penalties, interest, awards, charges, deficiencies and expenses, including reasonable costs of investigation and defense (including reasonable fees of attorneys).</font></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any event, effect, circumstance, change, occurrence, fact or development that, individually or in the aggregate with other events, effects, circumstances, changes, occurrences, facts or developments, has had or would reasonably be expected to have a material adverse effect on the business, operations or financial condition of the Company, taken as a whole, or the consummation of the transactions contemplated by this Agreement, in each case taken as a whole&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that any such event, effect, circumstance, change, occurrence, fact or development resulting from or relating to any of the following will not be considered when determining whether a Material Adverse Effect has occurred&#58; (a) general business or economic conditions or changes generally affecting the industries, markets or geographical areas in which the Company conducts its business, (b) national or international political or social conditions, including (i) the engagement by the United States in hostilities, whether or not pursuant to the declaration of a national emergency or war, (ii) the occurrence of any military or terrorist attack upon the United States or any of its territories, possessions or diplomatic or consular offices or upon any military installation, equipment or personnel of the United States, or (iii) the </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">escalation or worsening of any of the foregoing, (c) any epidemic or pandemic and any rules, regulations or other restrictions issued by any Governmental Authority arising from or relating thereto, (d) natural disasters, weather conditions, or force majeure events or acts of God, (e) financial, banking or securities markets (including any disruption thereof and any decline in the price of any security or any market index), (f) changes in interest rates or inflation, (g) disruptions or changes in international trade conditions, including the imposition or modification of tariffs, duties, quotas, embargoes, sanctions, or other trade restrictions&#59; (h) supply chain disruptions, (i) changes in GAAP or interpretations thereof, (j) changes in Law or interpretations thereof, (k) the negotiation or execution of this Agreement or any of the other Transaction Documents, the identity or business plans of Purchaser or any of its Affiliates, or the announcement, pendency or consummation of any of the transactions contemplated hereby or thereby, including any impact thereof on relationships, contractual or otherwise, with patients, customers, payors, suppliers, distributors, partners, physicians or employees, (it being understood and agreed that this clause (k) will not apply with respect to the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">), (l) the taking of, or the failure to take, any action contemplated by this Agreement or any of the other Transaction Documents, (m) any failure by the Company to meet any internal or published projections or forecasts or revenue or earnings predictions for any period (provided that the underlying causes of such failures, subject to the other provisions of this definition, will not be excluded), or (n) any adverse event, effect, circumstance, change, occurrence, fact or development regarding the business, operations or financial condition of the Company that was, in all material respects, cured or otherwise mitigated before the earlier to occur of (i) the Closing or (ii) the date on which this Agreement is terminated under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XI</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.11</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Measurement Time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means 11&#58;59&#58;59 p.m. (Eastern Time) on the date immediately preceding the Closing Date.</font></div><div style="margin-top:11.65pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any or all of the First Milestone Payment, the Second Milestone Payment or the Third Milestone Payment, as context requires.</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the period commencing on January 1, 2027 and ending on December 31, 2031.</font></div><div style="margin-top:11.65pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Threshold</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any or all of the First Milestone Threshold, the Second Milestone Threshold or the Third Milestone Threshold, as context requires.</font></div><div style="margin-top:12pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Year</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any of the first five (5) calendar years beginning on January 1, 2027.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Most Recent Balance Sheet</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.6(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Most Recent Balance Sheet Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means December 31, 2025.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Net Revenue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means (a) the cumulative gross Invoice Price at which the Business Products are sold to end users during any measurement period by the Company, Purchaser or any of their respective Affiliates, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">less</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> the following deductions directly, consistently, and proportionately applied to the Business Products (i) trade, cash, and quantity discounts, (ii) returns, rebates, chargebacks, refunds and credits granted to managed health care organizations, (iii) taxes or fees levied on, determined or imposed by Governmental </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Authorities, including import taxes, export taxes, excise taxes, sales taxes, value-added taxes, consumption taxes, tariffs and duties (for the avoidance of doubt, tariffs and duties deducted pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall include only tariffs and duties imposed directly on the sale or export of Business Products to end users to the extent included on the invoice, and shall not include any tariffs or duties on imported raw materials, components, or manufacturing inputs or income taxes), in each case on account of such sales of Business Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (b) the amount of any royalties or license fees received by the Company, Purchaser or any of their respective Affiliates from a license to a third party for use outside the Business&#59; provided that, to the extent any of the Business Products are sold in combination or as part of a bundle or kit with any products that are not Business Products, the Net Revenue attributable to the Business Product from any such combination, bundle or kit will be determined by multiplying the actual Net Revenue of such combination, bundle or kit by the fraction A &#47; (A+B), where A is the cumulative gross Invoice Price of the Business Products sold as part of such combination, bundle or kit, if sold separately, and B is the Invoice Price of all other products included, or sold as part of, the combination, bundle or kit, if sold separately. With respect to a combination where a component product is not sold separately (i.e., one of the products within the combination does not have its own separate SKU), then the Net Revenue attributable to the Business Product from any such combination will be determined by multiplying the actual Net Revenue of such combination by the fraction C &#47; (C+D), where C is the standard cost of manufacturing of the single Business Product and D is the standard cost of manufacturing of all other products included or sold as part of the combination. If, on a country-by-country basis, the other products in the combination, bundle or kit are not sold separately in that country, Net Revenue shall be calculated by multiplying actual Net Revenue of such combination, bundle or kit by the fraction A &#47; E, where A is the cumulative gross Invoice Price of the Business Product if sold separately, and E is the cumulative gross Invoice Price for the combination, bundle or kit. If, on a country-by-country basis, neither the Business Product nor the other product(s) contained in the combination, bundle or kit is&#47;are sold separately in any such country, Net Revenue shall be determined by the Parties in good faith. All components of Net Revenue shall be determined from the books and records of Purchaser and its Affiliates (including the Company) in accordance with GAAP using its then-current standard procedures and methodology for applying GAAP and for converting foreign currencies to United States dollars. If Purchaser or its Affiliates change accounting policies that would materially affect the calculation of Net Revenue, Purchaser shall provide Seller written notice within thirty (30) days of the implementation of such change, together with a quantification of the estimated impact on Net Revenue.</font></div><div style="margin-top:11.05pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Nonassignable Assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.5(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Non-Solicit Business Relations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(c)(i)</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Notified Body</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means an organization accredited, designated, licensed, authorized or approved by a member state of the European Union or the United Kingdom to carry out certain tasks in connection with conformity assessment procedures relating to medical devices that are required in the European Union or in the United Kingdom.</font></div><div style="margin-top:10.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Order</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any applicable order, judgment, ruling, award, writ, injunction or decree of any Governmental Authority.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Owned Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any Intellectual Property and Intellectual Property Assets owned or purported to be owned by the Company.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preamble</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Payoff Letters</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the payoff letters, each in form and substance reasonably satisfactory to Purchaser, from each holder of Indebtedness for borrowed money indicating the amount required to discharge in full such Indebtedness at the Closing and, if such Indebtedness is secured, an undertaking by such holder to discharge in connection with the Closing any Liens securing such Indebtedness.</font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">PC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Permits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all licenses, permits, registrations, authorizations, consents, orders, certifications, clearance and approvals issued or granted by any Governmental Authority.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, collectively&#58; (a) Liens set forth in the Disclosure Schedule or referenced in the Financial Statements, each of which will be released at or before the Closing&#59; (b) Liens for Taxes, assessments, and other governmental charges that are not yet due and payable, that may thereafter be paid without penalty, or the validity of which is being contested in good faith&#59; (c) Liens arising under original purchase price conditional sales contracts and equipment leases with third parties&#59; (d) easements, covenants, conditions, and restrictions of record&#59; (e) easements, covenants, conditions, and restrictions not of record as to which no material violation or encroachment exists or, if such violation or encroachment exists, as to which the cure of such violation or encroachment would not materially interfere with the conduct of the business of the Company&#59; (f) zoning or other governmentally established restrictions or encumbrances&#59; (g) pledges or deposits to secure obligations under workers or unemployment compensation Laws or similar Laws or to secure public or statutory obligations&#59; (h) mechanic&#8217;s, materialman&#8217;s, supplier&#8217;s, vendor&#8217;s or similar Liens arising or incurred in the ordinary course of business securing amounts that are not overdue for a period of more than ninety (90) days or the validity of which is being contested in good faith&#59; (i) other imperfections of title, licenses, or encumbrances, if any, that do not materially impair the continued use and operation of the assets to which they relate&#59; (j) in respect of the Shares, any restrictions (whether on the transferability thereof or otherwise) imposed under securities Laws&#59; (k) performance bonds, letters of credit or similar arrangements securing the Company&#8217;s performance of contractual obligations&#59; and (l) any right, restriction or covenant associated with any license of Intellectual Property.</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any natural individual, corporation, partnership, limited liability company, joint venture, association, bank, trust company, trust or other entity, whether or not a legal entity, or any Governmental Authority.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Personal Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;individually identifiable health information,&#8221; &#8220;protected health information,&#8221; &#8220;personal information&#8221; or &#8220;sensitive personal information&#8221; and similar terms as defined by Privacy Laws.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Personnel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any director, manager, officer, employee, consultant, agent or other personnel of such Person.</font></div><div style="margin-top:12.05pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Post-Closing Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Post-Closing Tax Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means (a) any Tax period that begins after the Closing Date, and</font></div><div style="margin-top:0.05pt;padding-left:54pt;padding-right:18pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) with respect to a Straddle Period, the portion of such Straddle Period after the Closing Date. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PPACA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.17(i)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">.</a></font></div><div style="padding-left:54pt;padding-right:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PPI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is defined in the recitals.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Pre-Closing Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Pre-Closing Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:10.85pt;padding-left:54pt;padding-right:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pre-Closing Tax Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any Tax period that ends on or before the Closing Date, and</font></div><div style="padding-left:18pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) with respect to a Straddle Period, the portion of such Straddle Period that ends on and includes the Closing Date.</font></div><div style="margin-top:10.55pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means&#58; (i) Laws applicable to the Company governing the collection, use, disclosure or protection of Personal Information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 and the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020&#59; the Utah Consumer Privacy Act, the Colorado Privacy Act, and the Virginia Consumer Data Protection Act (in each case, once effective)&#59; and any other applicable standard, rule, requirement, code, principle or policy of any self-regulatory organization&#59; (ii) all applicable industry standards relating to privacy, data protection, or data security applicable to the Business or the personal data Processed by the Company&#59; (iii) all obligations relating to privacy, data protection, or data security under any Contracts to which the Company is a party or by which it is bound&#59; and (iv) all representations, obligations, and commitments set forth in any Company Privacy Policy.</font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any audit, litigation (in law or in equity), arbitration, mediation, action, lawsuit, proceeding, charge, claim, demand, hearing, inquiry, investigation or similar matter before or by any Governmental Authority, whether administrative, judicial or arbitral in nature.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Process</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the access, creation, collection, use, storage, maintenance, processing, recording, sharing, distribution, transfer, transmission, receipt, import, export, protection, safeguarding, access, disposal or disclosure or other activity regarding data (whether electronically or in any other form or medium).</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Protected Communication</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Protected Data</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means Personal Information, confidential, proprietary information of the Company, and all data and information for which the Company is required by law, rules, regulation, agreement, or privacy policy to safeguard and&#47;or keep confidential or private.</font></div><div style="margin-top:12.25pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> attached hereto.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preamble</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Designee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means one or more Affiliates of Purchaser identified to Seller in writing prior to the Closing Date.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Group</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5(b)(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Registered IP</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.19(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Related Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any of the current officers, directors or managers of the Company.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, migrating, dumping, disposing, depositing, emanating or other release or threatened release of any Hazardous Materials into or upon the indoor or outdoor environment, including the ambient air, surface water, groundwater, land surface or subsurface strata, sewer systems, publicly owned treatment works, septic systems or any building or structure, in each case as defined under or regulated by Environmental Laws.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Replacement Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.5(f)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a Person&#8217;s directors, managers, general partner, officers, trustees, fiduciaries, employees, attorneys, accountants and advisors.</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Restricted Area</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the area (i) within one hundred (100) miles of Seller&#8217;s offices in Brisbane, California, (ii) in the State of California, (iii) in any state with a mutual border with the State of California, (iv) in the United States of America, and (v) in any county or parish in which the Business Products were sold or services related to Business Products were provided (through the internet or otherwise and, in the case of the internet, in any county or parish where the purchaser or user of the Business Products or such services were located or provided or where the Business was conducted) during the twelve (12) month period ending on the Closing Date.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Restricted Business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the business of developing, manufacturing, commercializing and selling cryoanalgesia devices or radiofrequency ablation devices&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that &#8220;Restricted Business&#8221; shall not include (a) any pharmaceutical products, services or business lines (other than the Business), including any pharmaceutical products or services that utilizes or incorporates, or is delivered through, a device, (b) any pharmaceutical non-cryoneurolysis pain management therapies, (c) any of the activities contemplated by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Sections 7.7</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">7.8</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> hereof or (d) for avoidance of doubt, any business lines or activities of an acquirer, co-promoter, successor or other counterparty to any acquisition, merger, consolidation, sale of equity or assets, change of control or other business combination involving Seller or any of its controlled Affiliates (so long as such business lines and activities are not conducted by Seller or its controlled Affiliates).</font></div><div style="margin-top:12.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Restricted Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means Seller and each of its Controlled Affiliates.</font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Review Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Second Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $23,500,000.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Second Milestone Threshold</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $60,000,000.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preamble</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Account</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, with respect to Seller, one or more bank accounts from time to time designated by Seller by written notice to Purchaser.</font></div><div style="margin-top:12.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Group</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Group Entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Marks</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.9</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Share Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the Purchase Price, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> the Asset Purchase Price.</font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Shared Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means each Contract that is not a Transferred Contract whereby the goods or services thereunder are provided for the benefit of both the Business and the business of the Seller or its Subsidiaries other than the Business.</font></div><div style="margin-top:11.75pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Recitals</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Shortfall Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.4(c)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Software</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means all computer programs (including any and all software implementation of algorithms, models and methodologies whether in source code or object code), databases and computations (including any data and collections of data), documentation (including user manuals and training materials) relating to any of the foregoing and the content and information contained in any web sites.</font></div><div style="margin-top:1.15pt;padding-left:54pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Spasticity Collaborative Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means an amount in cash equal to $1,000,000. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any Tax period that begins before the Closing Date and ends after (and</font></div><div style="margin-top:0.25pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">includes) the Closing Date.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Sublease Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means a Sublease Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> to be entered into at the Closing by and among Seller (or its applicable Subsidiary) as the sublessor, and Purchaser, as the sublessee.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, with respect to any Person (other than a natural Person), (a) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees thereof is at the time owned or Controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (b) if a limited liability company, partnership, association, or other business entity (other than a corporation), a majority of the membership, partnership or other similar equity interests thereof is at the time held or Controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof. For purposes of clause (b) above, a Person or Persons will be deemed to hold a majority equity interest in a business entity (other than a corporation) if such Person or Persons (i) is allocated a majority of such business entity&#8217;s gains or losses or (ii) is the managing director or general partner of such business entity. The term &#8220;Subsidiary&#8221; includes all Subsidiaries of such Subsidiary.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Supporting Detail</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Group</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any &#8220;affiliated group&#8221; of corporations within the meaning of Section 1504 of the Code (or any similar affiliated, combined, consolidated, or unitary group or arrangement for group relief for state, local, or foreign Tax purposes).</font></div><div style="margin-top:11.7pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.9(n)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, collectively, all returns, declarations, reports, statements, elections, estimates, claims for refund, information returns and other documents (including any related or </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">supporting schedules, statements or information, any amendment to the foregoing, and any sales and use and resale certificates), in each case, that are maintained or required to be maintained, or filed or required to be filed with a Governmental Authority, by the Company in respect of any Taxes, including any amendments thereto.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, collectively, all federal, state, local, and non-U.S. income, corporation, capital gains, excise, gross receipts, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">ad valorem</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, sales, goods and services, harmonized sales, use, employment, franchise, profits, gains, property, transfer, payroll, social security contributions, intangibles and other tax or governmental charge in the nature of a tax (whether payable directly or by withholding), whether disputed or not, together with any interest, penalties, fees, charges, levies, assessments, duties, tariffs, imposts or additions to tax or additional amounts imposed by any Governmental Authority with respect thereto and any liability in respect of such amounts arising as a result of being a member of any Tax Group, as a successor to or transferee of another person or by Contract.</font></div><div style="margin-top:11.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Third Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $28,000,000.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Third Milestone Threshold</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means $70,000,000.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Third-Party Claim</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transaction Bonus Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5(b)(iv)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:10.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means this Agreement, the Escrow Agreement, the Assignment and Assumption Agreement, the Sublease Agreement, the Transition Services Agreement and all the other agreements, certificates, instruments and other documents to be executed or delivered by one or more of the Parties in connection with the transactions contemplated by this Agreement.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means, without duplication, all of the Company&#8217;s expenses, fees and charges incurred as of immediately prior to the Closing to the extent not paid as of the Closing, in connection with the preparation, negotiation, execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, including (a) all attorneys&#8217;, accountants&#8217;, consultants&#8217;, professionals&#8217;, investment bankers&#8217; and other advisors&#8217; fees and expenses payable by the Company in connection with the transactions contemplated by this Agreement (in each case, that have not been paid in full as of the Closing), and (b) all fees, expenses or payments that have not been paid in full as of the Closing related to any &#8220;sale&#8221; and &#8220;transaction&#8221; bonuses and similar incentive compensation payments (including the employer portion of payroll Taxes) payable to current or former Business Employees other than any such arrangements implemented by Purchaser (including any &#8220;retention&#8221; or &#8220;stay&#8221; bonus payable after the Closing). Notwithstanding the foregoing, &#8220;Transaction Expenses&#8221; shall not include the Transaction Bonus Amount or any amounts included as Indebtedness.</font></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transaction Tax Deductions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means any Tax deductions arising from the Transaction Expenses or the payment of any Indebtedness, or from any other payment made in connection with the transactions contemplated in this Agreement that are economically borne by the Seller, in each case which are deductible at a &#8220;more likely than not&#8221; or greater level of comfort for applicable income Tax purposes. For purposes of this Agreement, with respect to any applicable success-based fees (as defined in Treasury Regulation Section 1.263(a)-5(f)), 70% of such fees will be treated as deductible in accordance with IRS Revenue Procedure 2011-29, 2011-1 C.B. 746.</font></div><div style="margin-top:11.1pt;padding-left:54pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transferred Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> attached hereto. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transferred Domains</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> attached hereto. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transferred Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transition Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Transition Services Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> to be entered into at the Closing by and among Purchaser and each Seller Group Entity party thereto.</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Treasury Regulations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the U.S. Department of Treasury Regulations promulgated under the Code.</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Unpaid Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the amount (which shall not be less than zero in the aggregate, with respect to any Tax paying entity or in any jurisdiction) equal to the sum of all unpaid Taxes of the Company attributable or payable with respect to any Pre-Closing Tax Period (including the pre-Closing portion of any Straddle Period, ignoring for this purpose any Tax payments on the Closing Date prior to the Closing, to the extent such payments were taken into account as Cash) and for which the applicable Tax Return for such period has not been filed as of the Closing Date and is not required to have been filed as of the Closing Date, taking into account extensions validly obtained, which shall (a) exclude any deferred Tax liabilities or assets, (b) be determined by including in taxable income any adjustment pursuant to Section 481 of the Code (or any corresponding or similar provision of other Law) and prepaid amounts and deferred revenue that, in each case, would not otherwise be included in taxable income on or prior to the Closing Date, (c) be calculated on an entity-by-entity basis (such that deductions and losses of one entity may not be used to offset income and gain of another entity unless such offset actually reduces the Taxes of such other entity), (d) in the case of any Straddle Period, be determined applying the conventions set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.2,</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (e) by excluding any effects or reductions with respect to Tax Refunds or overpayments, (f) be calculated in accordance with the past practices of the Company, to the extent such practices are permitted under applicable Law, (g) be calculated by taking into account any Transaction Tax Deductions, to the extent deductible in such period at a &#8220;more likely than not&#8221; or greater comfort level, and (h) by excluding any Taxes imposed with respect to a period covered by a Consolidated Tax Return.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means the Worker Adjustment and Retraining Notification Act and any similar state or local Law.</font></div><div style="margin-top:12.15pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Withholding Agents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 1.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Rules of Construction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Any reference in this Agreement to a Law refers to such Law as amended and as in effect on the date of this Agreement or, if the context so requires, the applicable date or time period in question. Any reference to a contract, instrument or other document as of a given date means the contract, instrument or other document as amended, supplemented and modified from time to time through such date. All preamble, recital, article, section, exhibit and schedule references are to the preamble, recitals, articles, sections, exhibits and schedules of this Agreement unless otherwise specified. The provision of a Table of Contents and the division of this Agreement into Articles, Sections and other subdivisions are for convenience of reference only and will not affect or be utilized in construing or interpreting this Agreement. All references herein to &#8220;dollars&#8221; or &#8220;$&#8221; are to United States dollars. The specification of any dollar amount or the inclusion of any item in the representations and warranties contained in this Agreement or the Disclosure Schedule or any other Schedules or Exhibits attached to this Agreement will not be deemed to establish a threshold for materiality or to establish the standard for whether a particular act or agreement is within or outside the ordinary course of business for purposes of this Agreement. All references herein to any period of days will mean the number of calendar days unless </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">otherwise specified. When calculating the period of time before which, within which or following which, any act is to be done or step taken under this Agreement, the date that is the reference date in calculating such period will be excluded. If the last day of any such period is a non-Business Day, the period in question will end on the next succeeding Business Day. Words in the singular will include the plural and vice versa. Words of one gender will be held to include the other genders as the context requires. References herein to any Person will include such Person&#8217;s heirs, executors, personal representatives, administrators, successors and assigns&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that nothing contained in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 1.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. is intended to authorize any assignment or transfer not otherwise permitted by this Agreement. The terms &#8220;hereof,&#8221; &#8220;hereby,&#8221; &#8220;herein,&#8221; &#8220;hereunder,&#8221; &#8220;hereto&#8221; and &#8220;herewith&#8221; and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. The phrase &#8220;ordinary course of business&#8221; will mean the ordinary course of business of the Business taking into account any changes, modifications or adaptions required or reasonably believed to be required as a result of any pandemic or similar force majeure event or the escalation or worsening of the foregoing. The word &#8220;including&#8221; and words of similar import when used in this Agreement will mean &#8220;including, without limitation,&#8221; unless otherwise specified. The word &#8220;or&#8221; will not be exclusive. All references to &#8220;will&#8221; or &#8220;shall&#8221; will be construed as creating a mandatory obligation. The phrase &#8220;to the extent&#8221; will mean the degree to which a subject or other matter extends, and such phrase will not simply mean &#8220;if&#8221;. Any accounting term used in this Agreement will have, unless otherwise specifically provided herein, the meaning customarily given such term in accordance with GAAP&#59; provided that if there is any conflict between GAAP and the Accounting Principles, if applicable, the Accounting Principles will control.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18.02pt;padding-right:18.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE II</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">PURCHASE AND SALE OF SHARES&#59; CLOSING</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Agreement to Purchase and Sell</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. At the Closing, (a) Seller will sell, transfer, convey and assign to Purchaser, and Purchaser will purchase, acquire and accept from Seller, the Shares and, (b) Seller will (or will cause the relevant Asset Sellers to) sell, transfer, convey, and assign to Purchaser, and Purchaser will purchase, acquire, accept and assume from the Asset Sellers, subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> with respect to any Nonassignable Assets, the Purchased Assets and the Assumed Liabilities.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The aggregate purchase price for the Shares and the Purchased Assets (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) is equal to the following amount, plus the assumption of the Assumed Liabilities&#58;</font></div><div style="margin-top:11.95pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.8pt">$70,000,000&#59;</font></div><div style="margin-top:12pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:23.18pt">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the Spasticity Collaborative Adjustment Amount&#59;</font></div><div style="margin-top:12.05pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:23.8pt">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">an amount equal to all Cash (if any)&#59;</font></div><div style="margin-top:11.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">(i) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the amount, if any, by which the Inventory exceeds the Inventory Target or (ii) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">minus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the amount, if any, by which the Inventory Target exceeds the Inventory&#59;</font></div><div style="margin-top:11.5pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">(i) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the amount, if any, by which the amount of Accounts Receivable exceeds the Accounts Receivable Target or (ii) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">minus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the amount, if any, by which the Accounts Receivable Target exceeds the amount of Accounts Receivable&#59;</font></div><div style="margin-top:11.7pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:25.02pt">minus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">an amount equal to all Indebtedness&#59;</font></div><div style="margin-top:12.05pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:23.18pt">minus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">an amount equal to all Transaction Expenses&#59; and</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:23.18pt">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the Additional Consideration, if any.</font></div><div style="margin-top:11.85pt;padding-left:18pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">The portion of the Purchase Price to be paid for the Purchased Assets shall be equal to the Asset Purchase Price. The portion of the Purchase Price to be paid for the Shares shall be equal to the Share Purchase Price.</font></div><div style="margin-top:11.65pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing and Closing Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt;text-decoration:underline">Date and Time of Closing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The transactions contemplated by this Agreement will be consummated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) remotely by electronic exchange of documents and signatures as soon as reasonably practicable, but in no event later than five (5) Business Days following the satisfaction or waiver of the conditions to the Closing set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IX</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (other than those conditions that pursuant to their terms or by their nature are to be satisfied at the Closing but subject to the satisfaction or waiver of those conditions at such time), or on any other date, or at any other time or place, that may be mutually agreed upon by Seller and Purchaser. The date on which the Closing occurs in accordance with the preceding sentence is referred to in this Agreement as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.&#8221; Regardless of when the Closing actually occurs, the Closing will be deemed effective as of 12&#58;00&#58;00 a.m. (Eastern Time) (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, the beginning of the day) on the Closing Date. All Proceedings to be taken and all documents to be executed and delivered by all Parties at the Closing will be deemed to have been taken and executed simultaneously, and no proceedings will be deemed to have been taken nor documents executed or delivered until all have been taken, executed and delivered.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt;text-decoration:underline">Estimated Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. At least five (5) Business Days prior to the Closing Date, Seller will prepare and deliver, or cause the Company to prepare and deliver, to Purchaser a statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Estimated Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), containing its good faith estimate of the Closing Consideration Amount (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Estimated Closing Consideration Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), including its good faith estimate of Cash, Accounts Receivable, Inventory, Indebtedness, and Transaction Expenses, prepared in accordance with the Accounting Principles.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt;text-decoration:underline">Closing Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. At the Closing, Purchaser will pay, or will cause the following payments to be paid or deposited, as applicable, by wire transfer of immediately available funds&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">to Seller, the Estimated Closing Consideration Amount to the Seller Account&#59;</font></div><div style="margin-top:3.9pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">to the recipients of the Transaction Expenses, the Transaction Expenses in accordance with the wire transfer instructions designated by such recipients&#59;</font></div><div style="margin-top:10.95pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.58pt">to the holders of outstanding Indebtedness (if any), the amount due and owing to such holders as set forth in the Payoff Letters in accordance with the wire transfer instructions designated by such holders&#59; and</font></div><div style="margin-top:11pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:1.53pt">to the Escrow Agent, $1,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Adjustment Escrow Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; and together with any interest or earnings thereon, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Adjustment Escrow Fund</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), to be held pursuant to and in accordance with the Escrow Agreement.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt;text-decoration:underline">Assumption of Assumed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. At the Closing, Purchaser shall assume and agree to discharge in accordance with their respective terms the Assumed Liabilities pursuant to the Assignment and Assumption Agreement.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchase Price Adjustment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Following the Closing, the Closing Consideration Amount will be finally determined in accordance with the adjustments and procedures set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.55pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">If the Closing Consideration Amount, as finally determined, is greater than the Estimated Closing Consideration Amount (such excess, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Excess Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), then within five (5) Business Days following the final determination of the Closing Consideration Amount, (i) Purchaser will pay to Seller, the Excess Amount by wire transfer of immediately available funds to the Seller Account and (ii) Purchaser and Seller will jointly instruct the Escrow Agent to release the Adjustment Escrow Fund to Seller pursuant to the Escrow Agreement.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">If the Closing Consideration Amount, as finally determined, is less than the Estimated Closing Consideration Amount (such shortfall, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Shortfall Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), then within five (5) Business Days following the final determination of the Closing Consideration Amount, Purchaser and Seller will jointly instruct the Escrow Agent to disburse an amount equal to the Shortfall Amount from the Adjustment Escrow Fund to Purchaser, and if the Shortfall Amount is less than the Adjustment Escrow Fund, the remaining balance of the Adjustment Escrow Fund, if any, to Seller. Recovery from the Adjustment Escrow Fund will be the sole and exclusive remedy available to Purchaser for any Shortfall Amount and Seller will have no liability or obligation for any portion of the Shortfall Amount in excess of the amount of the Adjustment Escrow Amount.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">If the Closing Consideration Amount, as finally determined, is equal to the Estimated Closing Consideration Amount, then within five (5) Business Days following the final determination of the Closing Consideration Amount, Purchaser and Seller will jointly instruct the Escrow Agent to release the Adjustment Escrow Fund to Seller pursuant to the Escrow Agreement.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The Parties agree that any payment made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will be treated as an adjustment to the Purchase Price for Tax purposes, except to the extent otherwise required by applicable Law.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preparation of the Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. As soon as practicable, but no later than ninety (90) days after the Closing Date, Purchaser will prepare and deliver to Seller a statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) setting forth (a) Purchaser&#8217;s calculation of the amount of Cash, Accounts Receivable, Inventory, Indebtedness, the Spasticity Collaborative Adjustment Amount and Transaction Expenses, (b) the calculation of the Closing Consideration Amount therefrom, (c) a balance sheet of the Company as of the Closing and (d) reasonable supporting detail with respect to the calculation of each of the components of the Closing Consideration Amount. The Closing Statement will be prepared by Purchaser in accordance with the Accounting Principles. The Parties agree that the purpose of preparing the Closing Statement and determining Cash, Accounts Receivable, Inventory, Indebtedness, the Spasticity Collaborative Adjustment Amount, Transaction Expenses, and the final Closing Consideration Amount under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> is to adjust for inaccuracies in the estimates in the amounts of Cash, Accounts Receivable, Inventory, Indebtedness, and Transaction Expenses and to determine the final Closing Consideration Amount, and such processes are not intended to permit the introduction of different judgments, accounting methods, policies, principles, practices, procedures, classifications or estimation methodologies for the purpose of preparing the Closing Statement or determining the amounts of Cash, Accounts Receivable, Inventory, Indebtedness, Transaction Expenses or the final Closing Consideration Amount. Notwithstanding any adjustment to the foregoing items under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> the Closing Statement will be deemed issued as of the Closing Date for purposes of the Accounting Principles and for purposes of determining the impact of any subsequent events on the Closing Statement. In </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">preparing the Closing Statement, no effect will be given to (i) the financing of the transactions contemplated by this Agreement or other changes arising from or resulting as a consequence of the financing of transactions contemplated hereby or (ii) any purchase accounting or other similar adjustments resulting from the consummation of such transactions. For the avoidance of doubt, the Spasticity Collaborative Adjustment Amount shall not be adjusted in connection with the foregoing adjustments to the Purchase Price.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disputes Regarding Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) During the sixty (60) day period following receipt of the Closing Statement (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Dispute Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), Purchaser will provide to Seller such documents, books, records and work papers as Seller may reasonably request to review the Closing Statement. On or prior to the last day of the Dispute Period, Seller may provide written notice to Purchaser disputing the calculation of all or a part of the Closing Consideration Amount set forth in the Closing Statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), setting forth in reasonable detail the elements and amounts set forth in the Closing Statement with which Seller disagrees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). If Seller does not deliver to Purchaser the Dispute Notice within the Dispute Period, then the Closing Statement will be deemed to have been accepted and agreed to by Seller in the form in which it was delivered and will be final and binding on the Parties. If Seller delivers the Dispute Notice to Purchaser within the Dispute Period, then Purchaser and Seller will use commercially reasonable efforts to resolve the Dispute within thirty (30) days following receipt of the Dispute Notice, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that all such discussions will be governed by Rule 408 of the Federal Rules of Evidence and the corresponding provisions of state, local or foreign Law. If Purchaser agrees with Seller&#8217;s calculation of the Closing Consideration Amount set forth in the Closing Statement, then Seller&#8217;s calculation of the Closing Consideration Amount set forth in the Dispute Notice will be final and binding upon the Parties.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">If Purchaser and Seller cannot reach agreement to resolve every element of the Dispute within such thirty (30) day period, then Purchaser and Seller will jointly engage an accounting expert to resolve the Dispute (the Person appointed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Accounting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Expert</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Accounting Expert will be (i) one or more independent members (having no conflict of interest) of the dispute resolution group of KPMG LLP, or (ii) if such Person refuses or is unable to accept such appointment, another nationally recognized certified public accounting firm mutually agreed between Seller and Purchaser, or (iii) if following such Person&#8217;s refusal or unacceptance, Purchaser and Seller are unable to agree on such accounting firm, then either Purchaser or Seller may request that the CPR International Institute for Conflict Prevention and Resolution appoint a certified public accountant (having no conflict of interest) who at the time is, or for at least five (5) years formerly was, a partner (or in a position of equivalent stature) in an independent accounting firm of recognized national or regional standing, to serve as the Accounting Expert. Each of Seller and Purchaser will cooperate with the other Party and the Accounting Expert and use its reasonable efforts to complete the engagement of the Accounting Expert as promptly as possible.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">The Accounting Expert&#8217;s sole function will be to resolve each element of the Dispute as set forth in the Dispute Notice not resolved by Purchaser and Seller (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disputed Elements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) as an accounting expert and not as an arbitrator, by determining in accordance with this Agreement and with the Accounting Principles, whether and to what extent, if any, the calculation of the Closing Consideration Amount set forth in the Closing Statement delivered by Purchaser pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> requires adjustment with respect to such Disputed Elements and, if so, the amount of any such adjustment or adjustments.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">In resolving the Dispute, the Accounting Expert will limit its consideration to</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i) reviewing the Closing Statement and the Dispute Notice, as supplemented by written submissions of Seller and Purchaser, which may explain their respective positions, and (ii) conducting a conference at which each of Seller and Purchaser may present additional documents, materials, testimony and other information, and have present their respective advisors, counsel and accountants at the conference&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that Purchaser and Seller will be limited by their positions set forth in the Closing Statement and Dispute Notice, respectively, and the written submissions or other materials submitted by Purchaser and Seller or presented at the conference may not raise any element that is not a Disputed Element. Any such conference may be held, in the discretion of the Accounting Expert, by telephone conference, videoconference or in person. The Accounting Expert may not conduct any independent investigation or review concerning the Disputed Elements or any other matter. Each of Seller and Purchaser will provide to the other Party and the Accounting Expert any documents, books, records and work papers as such Party or the Accounting Expert may reasonably request to review the Closing Statement and to resolve the Dispute.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e) Purchaser and Seller will direct the Accounting Expert to as promptly as possible, and in any event within thirty (30) days after the date of its engagement, render its decision on each Disputed Element in a writing to Purchaser and Seller setting forth a written statement of findings and conclusions, including a written explanation of its reasoning, a revised Closing Statement reflecting its decision and a revised calculation of the Closing Consideration Amount based on the information in the revised Closing Statement.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f) The Accounting Expert will be bound by this Agreement and may not revise any element of the Closing Statement that is not disputed by the Parties or assign a value to any Disputed Element of the Closing Statement greater than the greatest value for such item claimed by either Party or less than the smallest value for such item claimed by either Party. The process set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will be the exclusive remedy of the Parties for any Dispute. Each of the Accounting Expert&#8217;s decisions, the revised Closing Statement, and the revised calculation of the Closing Consideration Amount, absent fraud or manifest error, will be final and binding upon the Parties, and judgment may be entered on the award. The Accounting Expert may not and will not have authority or jurisdiction to resolve or decide any matter or dispute other than, as provided in and in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, resolving the Dispute by determining whether and to what extent, if any, the Closing Statement and resulting calculation of the Closing Consideration Amount should be revised with respect to any elements or amounts of the Closing Statement subject to the Dispute. Any other dispute or matter arising under or with respect to this Agreement (including any dispute over whether any claim, issue, element or amount is within the authority of the Accounting Expert to determine) will be reserved for and determined by a court specified in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.15</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g) Seller and Purchaser will share the fees and expenses of the Accounting Expert in inverse proportion to the relative amounts subject to the Dispute determined in favor of such Party, in accordance with the following formulas&#58; (i) Purchaser will pay a portion of such fees and expenses equal to the total fees, costs and expenses multiplied by a fraction, the numerator of which is the dollar amount subject to the Dispute resolved in favor of Seller and the denominator of which is the total dollar amount subject to the Dispute, and (ii) Seller will pay a portion of such fees, costs and expenses equal to the total fees and expenses multiplied by a fraction, the numerator of which is the dollar amount subject to the Dispute resolved in favor of Purchaser and the denominator of which is the total dollar amount subject to the Dispute. Notwithstanding the foregoing, each of Purchaser and Seller will pay the fees, costs and expenses of their respective attorneys, accountants and other representatives in connection with the Dispute.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Additional Consideration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> Seller may be entitled to additional consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Additional Consideration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) for the Shares, not to exceed $70,000,000 in the aggregate (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Additional Consideration Cap</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) upon the achievement of one or more of the Milestone Thresholds during the Milestone Period. For the avoidance of doubt, the Additional Consideration Cap shall only apply to the Additional Consideration, if any, payable in accordance this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> and shall not limit the amount of any other payments that may become due or payable to Seller or its Affiliates pursuant to this Agreement (including, without limitation, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">) or any other Transaction Document. The Additional Consideration, if any, will be calculated as follows&#58;</font></div><div style="margin-top:11.95pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">If Net Revenue from the sale of Business Products during any Milestone Year equals or exceeds the First Milestone Threshold (but does not equal or exceed any higher Milestone Threshold), then, subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, Seller shall be entitled to receive the First Milestone Payment with respect to such Milestone Year.</font></div><div style="margin-top:10.95pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.63pt">If Net Revenue from the sale of Business Products during any Milestone Year equals or exceeds the Second Milestone Threshold (but does not equal or exceed any higher Milestone Threshold), then, subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, Seller shall be entitled to receive an amount equal to the Second Milestone Payment with respect to such Milestone Year.</font></div><div style="margin-top:10.6pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:1.53pt">If Net Revenue from the sale of Business Products during any Milestone Year equals or exceeds the Third Milestone Threshold, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, Seller shall be entitled to receive an amount equal to the Third Milestone Payment with respect to such Milestone Year.</font></div><div style="margin-top:10.95pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.13pt">If Net Revenue from the sale of Business Products during any single Milestone Year equals or exceeds the sum of any two or more Milestone Thresholds (to the extent a corresponding Milestone Payment has not already been earned), then the highest applicable Milestone Payment shall be paid with respect to such Milestone Year in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#59; provided that (x) each Milestone Payment may be earned only once (whether or not multiple Milestone Payments are earned in any single Milestone Year), and (y) in no event will the Milestone Payments, in the aggregate, exceed</font></div><div style="margin-top:0.15pt;padding-left:90pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">$70,000,000.</font></div><div style="margin-top:10.85pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">By way of example only, if Net Revenue from the sale of Business Products during the 2027 calendar year is equal to $75,000,000 and Net Revenue from the sale of Business Products during the 2028 calendar year is equal to $49,000,000, then Purchaser would pay Seller the Third Milestone Payment with respect to calendar year 2027 and no Milestone Payment would be payable with respect to calendar year 2028.</font></div><div style="margin-top:12pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.13pt">By way of another example, if Net Revenue from the sale of Business Products during the 2027 calendar year is equal to $65,000,000, Net Revenue from the sale of Business Products during the 2028 calendar year is equal to $55,000,000, and Net Revenue from the sale of Business Products during the 2029 calendar year is equal to $70,000,000, then Purchaser would pay Seller&#58; the Second Milestone Payment with </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:90pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">respect to calendar year 2027&#59; the First Milestone Payment with respect to calendar year 2028&#59; and the Third Milestone Payment with respect to calendar year 2029.</font></div><div style="margin-top:10.65pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:35.08pt">By way of another example, if Net Revenue from the sale of Business Products during the 2027 calendar year is equal to $65,000,000, Net Revenue from the sale of Business Products during the 2028 calendar year is equal to $75,000,000, Net Revenue from the sale of Business Products during the 2029 calendar year is equal to $45,000,000 and Net Revenue from the sale of Business Products during the 2030 calendar year is equal to $55,000,000, then Purchaser would pay Seller&#58; the Second Milestone Payment with respect to calendar year 2027&#59; the Third Milestone Payment with respect to calendar year 2028&#59; and the First Milestone Payment with respect to calendar year 2030. No Milestone Payment would be payable with respect to calendar year 2029.</font></div><div style="margin-top:10.95pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:32.03pt">In no event may more than one Milestone Payment be earned in any single Milestone Year.</font></div><div style="margin-top:10.55pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Within forty five (45) days after the end of each Milestone Year during the Milestone Period, Purchaser shall deliver to Seller a written statement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) prepared in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> setting forth Purchaser&#8217;s calculation of the Net Revenue for such period and the resulting Milestone Payment due, if any, under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> together with a reconciliation of any Milestone Payments previously paid to Seller during such Milestone Year, and delivered with reasonable supporting detail with respect to the calculation of each of the components of Net Revenue (including, without limitation, Net Revenue by quarter, sales by SKU, a gross-to-Net Revenue reconciliation of total revenues, Net Revenue by region, and volumes by SKU and region but excluding country-level sales data and customer-level information (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Supporting Detail</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)). Net Revenue shall be determined from Purchaser&#8217;s and its Affiliate&#8217;s (including the Company&#8217;s) books and records in accordance with Purchaser's revenue recognition policies. In addition, within fifteen (15) days after the end of each of (i) the third quarter of each Milestone Year and (ii) the fourth quarter of each Milestone Year, Purchaser shall deliver a written statement setting forth the aggregate amount of year-to-date Net Revenue for such Milestone Year, delivered with reasonable supporting detail (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Flash Report</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Parties acknowledge and agree that the Flash Reports will be delivered for informational purposes only and that the information in the Flash Report delivered for any fourth quarter of a Milestone Year will be superseded by the Milestone Statement, when issued&#59; provided, for clarity, that nothing in this sentence shall limit, modify or impair Seller&#8217;s rights with respect to the review, dispute or final determination of any Milestone Statement.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">As promptly as practicable, but in no event later than sixty (60) calendar days following delivery by Purchaser of a Milestone Statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Review Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), Seller shall notify Purchaser in writing whether Seller accepts or disputes the accuracy of the items contained in such Milestone Statement. In the event Seller disputes the accuracy of any items contained in the Milestone Statement, Seller shall, no later than the end of the Review Period, deliver written notice to Purchaser of any such good faith disagreement that Seller has with respect to the contents of the Milestone Statement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Milestone Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Milestone Dispute Notice shall explain, in reasonable detail, the basis for such disagreement. During the Review Period, (i) Purchaser shall provide Seller with reasonable access, during normal business hours and upon reasonable prior notice, to the relevant books and records of the Business for the purpose of Seller&#8217;s review of the Milestone Statement and (ii) upon Seller&#8217;s reasonable request, Purchaser shall make available personnel responsible for preparing, or qualified and knowledgeable regarding, the calculations set forth in any Milestone Statement or Flash Report to meet with Seller or its representatives and discuss such calculations and the supporting detail </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">delivered in connection therewith. If Seller does not deliver a Milestone Dispute Notice within the Review Period, such Milestone Statement shall be deemed final, conclusive, and binding on the Parties.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">If Seller delivers a Milestone Dispute Notice within the Review Period, then Purchaser and Seller shall negotiate in good faith to resolve any disagreement. If Purchaser and Seller, notwithstanding such good faith effort, fail to resolve a disagreement within thirty (30) days after Seller&#8217;s delivery of a Milestone Dispute Notice, then the dispute shall be submitted for resolution to the Accounting Expert in accordance with the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Milestone Statement (as modified by the Accounting Expert) shall be final, binding, and conclusive upon the Parties hereto.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The Milestone Payments subject to a Milestone Dispute Notice will be made in cash by wire transfer of immediately available funds to the Seller within five (5) Business Days after the determination of such Milestone Payment becomes final and binding upon the Parties as provided in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.02pt">During the Milestone Period, Purchaser will, and will cause each of its Affiliates to, (i) not act or fail to act with the primary purpose of undermining the achievement of the Milestone Payments contemplated hereby, including by reducing the Net Revenue or Milestone Payments, and (ii) use commercially reasonable efforts to continue the Medical Device Regulation (MDR) process in Europe for the Business Products, including pursuing CE marking certification for such products&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that, other than with respect to the obligations of the Purchaser set forth in this Agreement or any Transaction Document, Purchaser shall have sole and full discretion with regard to all matters relating to the operation of the Business following the Closing.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">In the event Purchaser or any of its Affiliates sells, transfers, or otherwise disposes of all or substantially all of the Business or the assets of the Business (whether by merger, sale of stock, sale of assets, or otherwise) to any third party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Transfer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) prior to the payment in full of all Milestone Payments that have been earned or may be earned hereunder, then (i) Purchaser shall require, as a condition to the consummation of such Business Transfer, that the acquiror or transferee expressly assume in writing all of Purchaser&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> with respect to any unpaid Milestone Payments (whether or not yet earned), on terms no less favorable to Seller than those set forth herein, and (ii) in the event such acquiror or transferee does not assume such obligations in full, all Milestone Payments that have not yet been earned shall be deemed earned and shall become immediately due and payable to Seller upon the closing of such Business Transfer.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Once per Milestone Year, the Seller (or its designated representative) shall have the right, upon reasonable prior written notice, to inspect Purchaser&#8217;s (or an applicable Affiliate&#8217;s) books and records relating to the calculation of Net Revenue and each component thereof (including, without limitation, the Supporting Detail), with such inspection to be conducted during normal business hours and at the Seller&#8217;s expense. Any inspection permitted under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.7(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> is strictly limited to reviewing only the documents necessary to verify the accuracy of the calculation of Net Revenue and each component thereof. Such inspection rights do not include, and shall not be construed to include, any right to evaluate, assess, opine upon, or determine Purchaser&#8217;s business judgment, commercial decisions, pricing strategy, sales practices, customer relationships, operation or management of the business, or any matter other than the calculation of Net Revenue and the resulting Milestone Payment, if any.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.68pt">Purchaser has neither furnished nor provided, whether written or oral, any assurances or commitments regarding the achievability of the Milestone Payments or the likelihood thereof and </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Seller acknowledges that there is no assurance that Seller will earn any portion of the Milestone Payments and the Parties solely intend the express provisions of this Agreement to govern their contractual relationship. Purchaser shall not be liable to Seller for any incidental, consequential or punitive damages arising out of the failure to satisfy conditions to the payment of any part of the Milestone Payments, whether liability is asserted in tort or contract, or otherwise. Seller acknowledges that Purchaser and its Affiliates shall have the right to operate the Business in accordance with their own commercially reasonable discretion and Purchaser is under no obligation to provide any specific level of investment or financial assistance to the Business. Seller further acknowledges that the payment of any Milestone Payments is speculative and subject to, among other things, the future performance of the Business, which cannot be predicted with accuracy. Accordingly, Purchaser makes no representations, warranties, covenants or guaranties as to the future performance of the Company or the likelihood of any Milestone Payments.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">Seller understands and agrees that&#58; (i) the contingent right to receive any portion of the Milestone Payments shall not be represented or memorialized by any form, certificate or other instrument and does not constitute an equity or ownership interest in the Company, Purchaser, or any of their respective Affiliates, is not transferrable, except by operation of Law or pursuant to a merger, consolidation, reorganization, liquidation, dissolution, or similar transaction, and any other attempted transfer shall be null and void&#59; and (ii) Seller shall have no rights as a security holder in the Company, Purchaser or any of their respective Affiliates solely as a result of Seller&#8217;s contingent right to receive any Milestone Payment hereunder.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(k)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Any Additional Consideration paid hereunder shall be treated for all purposes as part of the Share Purchase Price.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Closing Deliveries</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. At or before the Closing, the Parties will deliver the documents and instruments that are set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.8</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Subject to the delivery of the items set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.8(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> at or before the Closing, Purchaser will execute or deliver (or cause to be executed and delivered) to the Company the following&#58;</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.68pt">evidence that, concurrently with the consummation of the transactions contemplated by this Agreement, Purchaser has initiated the payments required under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3(c)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#59;</font></div><div style="margin-top:10.65pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.63pt">a counterpart to the Escrow Agreement, duly executed by Purchaser and the Escrow Agent&#59;</font></div><div style="margin-top:10.9pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:1.58pt">a counterpart to the Assignment and Assumption Agreement, duly executed by Purchaser&#59;</font></div><div style="margin-top:10.7pt;padding-left:161.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:20.13pt">a counterpart to the Bill of Sale, duly executed by Purchaser&#59;</font></div><div style="margin-top:10.85pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">a counterpart to the Transition Services Agreement, duly executed by Purchaser&#59;</font></div><div style="margin-top:11.05pt;padding-left:161.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:20.13pt">a counterpart to the Sublease Agreement, duly executed by the Company&#59;</font></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:17.08pt">a properly completed original IRS Form 8023 for the Section 338(h)(10)</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt;padding-left:89.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Election, duly executed by Purchaser&#59;</font></div><div style="padding-left:161.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.03pt"> and a certificate executed by an officer of Purchaser to the effect that the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> have been satisfied.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) Subject to the delivery of the payments set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3(c)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and the items set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.8(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> at the Closing, Seller or the Company, as applicable, will execute or deliver to Purchaser (or any other Person that is indicated below) all of the following&#58;</font></div><div style="margin-top:11.75pt;padding-left:161.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:25.63pt">a counterpart to the Escrow Agreement, duly executed by Seller&#59;</font></div><div style="margin-top:10.85pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.63pt">a counterpart to the Assignment and Assumption Agreement, duly executed by each Asset Seller to be party thereto&#59;</font></div><div style="margin-top:10.55pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:1.58pt">a counterpart to the Bill of Sale, duly executed by each Asset Seller to be party thereto&#59;</font></div><div style="margin-top:10.95pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.18pt">a counterpart to the Transition Services Agreement, duly executed by each Seller Group Entity to be a party thereto&#59;</font></div><div style="margin-top:10.55pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">a counterpart to the Sublease Agreement, duly executed by Seller (or its applicable Subsidiary)&#59;</font></div><div style="margin-top:10.9pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.18pt">evidence satisfactory to Purchaser that TPSC VI LLC, as landlord, has provided its consent to the Sublease Agreement&#59;</font></div><div style="margin-top:10.55pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:35.13pt">evidence satisfactory to Purchaser that the lien on the Shares and the Purchased Assets in favor of Wells Fargo Bank has been released&#59;</font></div><div style="margin-top:10.95pt;padding-left:90pt;padding-right:18pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:32.08pt">the consents of third parties identified on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.4(a) of the Disclosure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#59;</font></div><div style="margin-top:10.6pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.18pt">a properly completed IRS Form W-9, duly executed by each of Seller and the Asset Sellers&#59;</font></div><div style="margin-top:10.95pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(x)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">a counterpart IRS Form 8023 for the Section 338(h)(10) Election, duly executed by Seller&#59; and</font></div><div style="margin-top:10.55pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.18pt">a certificate executed by an officer of the Company to the effect that the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.2(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.2(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> have been satisfied with respect to the Company.</font></div><div style="margin-top:12pt;padding-left:53.95pt;padding-right:18pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.9 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Withholding Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Company, Seller, Purchaser and the Escrow Agent (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Withholding Agents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) may deduct and withhold from any consideration payable pursuant to this Agreement to any Person such amounts as such Withholding Agent is required to deduct and withhold with respect to the making of such payment under the Code or any other Tax Law&#59; provided that, with respect to any consideration payable pursuant to this Agreement after the Closing Date that is not treated as compensation for U.S. federal income Tax purposes, each applicable Withholding Agent will use commercially reasonable efforts to notify Seller of any amounts subject to deduction or withholding at least five (5) Business Days prior to the payment thereof&#59; provided further, however, that no failure of a </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Withholding Agent in providing such notice to Seller shall reduce or otherwise affect the obligations or liabilities of Seller pursuant to this Agreement, except to the extent Seller is actually and materially prejudiced thereby. And Purchaser and the applicable Withholding Agent will reasonably cooperate with Seller and the affected payee to minimize or eliminate any such deduction or withholding to the extent permissible pursuant to applicable Law. To the extent that such amounts are so deducted or withheld by a Withholding Agent and properly and timely paid over to the appropriate Governmental Authority, such deducted or withheld amounts will be treated for the purposes of this Agreement as having been paid to such Person in respect of whom such deduction or withholding was made. Purchaser will promptly furnish to Seller and the applicable payee evidence of the payment to the applicable Governmental Authority of any amount deducted or withheld pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 2.10  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Allocation of Asset Purchase Price and Share Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Seller and Purchaser agree to allocate the Asset Purchase Price and, in the event the Section 338(h)(10) Election is made, the Share Purchase Price (and, in each case, other relevant items of consideration paid to Seller) among the Purchased Assets and, if applicable, the assets of the Company, for all tax purposes in accordance with the methodology for allocation provided on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule <a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">2.10</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Allocation Methodology</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Within ninety (90) days after determination of the Closing Consideration Amount pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> Purchaser shall deliver to Sellers a statement allocating the Purchase Price (including those Assumed Liabilities that are Liabilities for Tax purposes) among the Purchased Assets and, if applicable, the assets of the Company, in accordance with the Allocation Methodology (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Allocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Parties agree that the Allocation shall be modified to reflect any adjustments made pursuant to this Agreement or the payment of any indemnification claims pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> as mutually agreed upon by Purchaser and Sellers in good faith (and, if applicable, consistent with the prior allocation of similar items). If Seller disagrees with any items reflected in the Allocation, Seller shall notify Purchaser within thirty (30) days of receiving the Allocation of such disagreement and its reasons for so disagreeing, in which case the Parties shall negotiate in good faith and use their commercially reasonable best efforts to resolve any disputed items prior to the finalization of the Allocation. In the event the Seller and the Purchaser cannot agree on the Allocation, Seller and Purchaser shall each determine their own allocation of the Asset Purchase Price (and other relevant items) for applicable Tax purposes and shall not be bound by the Allocation. To the extent that the Parties agree on the Allocation, (a) the Parties shall file all Tax Returns (including IRS Forms 8594 and 8883, if acceptable, amended returns and claims for refunds) in a manner consistent with the Allocation, including any adjustments to such Allocation made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.10</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> and shall use their commercially reasonable efforts to sustain such Allocation in any subsequent Tax audit or dispute, and (b) no party (and none of their respective Affiliates) will take any Tax position inconsistent with the Allocation on any Tax Return or otherwise, except as otherwise required by a &#8220;determination&#8221; within the meaning of Section 1313(a)(1) of the Code or any similar provision of any state, local or non-U.S. Law.</font></div><div style="margin-top:12pt;padding-right:18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE III</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF SELLER REGARDING THE COMPANY AND THE PURCHASED ASSETS</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Seller makes the representations and warranties regarding the Company and the Purchased Assets set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article III</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> on the date hereof and on the Closing Date.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Organization, Existence and Good Standing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Company is a corporation, duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company has full corporate power and authority to own all of its properties and assets and to carry on its business as </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">presently conducted and is qualified as a foreign corporation and is in good standing (where applicable) in all jurisdictions where the nature of its business or the nature and location of its assets or Personnel requires such qualification and where the failure to so qualify would have a Material Adverse Effect.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Power and Authority, Authorization and Execution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Company has all requisite corporate power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents to which it is, or at the Closing will be, a party. The execution and delivery of, and the performance of its obligations under, this Agreement and the other Transaction Documents to which it is, or at the Closing will be, a party by the Company and the consummation by the Company of the transactions contemplated by this Agreement and the other Transaction Documents have been, or prior to the Closing will have been, duly and validly approved by the board of directors of the Company. No other approvals or actions are necessary on the part of the Company to authorize the execution, delivery and performance of this Agreement and the other Transaction Documents to which it is, or at the Closing will be, a party or the consummation of the transactions contemplated herein or therein. This Agreement has been duly executed and delivered by a duly authorized officer of the Company.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.3 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (assuming that this Agreement has been duly and validly authorized, executed and delivered by the other Persons party thereto), except to the extent enforcement may be affected by Laws relating to bankruptcy, reorganization, insolvency and creditors&#8217; rights and by the availability of injunctive relief, specific performance and other equitable remedies (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Enforceability Exceptions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). At the Closing, the Transaction Documents to be executed and delivered by the Company at the Closing will constitute valid and binding obligations of the Company, enforceable in accordance with their terms (assuming that the Transaction Documents to which the Company is a party will be duly and validly authorized, executed and delivered by the other Persons party thereto), except to the extent enforcement may be affected by Enforceability Exceptions.</font></div><div style="margin-top:12.1pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Consents&#59; Non-Contravention</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.4(a) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, neither Seller, nor the Company is required to give any notice to, make any filing with, or obtain any authorization, consent, Order or approval of any Governmental Authority in connection with the execution and delivery by the Company of this Agreement and the other Transaction Documents to which the Company is, or at the Closing will be, a party or the consummation of the transactions contemplated herein or therein, except for any such notice, filing, authorization, consent, Order or approval as would not have a Material Adverse Effect.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Assuming that all notices, filings, authorizations, consents, Orders and approvals contemplated by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.4(a)</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> have been duly made or obtained, neither the execution, delivery and performance of this Agreement and the other Transaction Documents to which the Company or Seller is, or at the Closing will be, a party, nor the consummation of the transactions contemplated herein and therein&#58; (a) will violate any provision of the Governing Documents of the Company&#59; (b) will conflict with, result in a breach of, or constitute a default or an event creating rights of acceleration, termination, modification, or cancellation, or a loss of rights under, any Material Contract&#59;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c) will violate any material Law or material Order to which the Company, Seller or any of the Company&#8217;s or Seller&#8217;s assets are subject or otherwise bound&#59; or (d) will result in the creation or imposition of any Lien (other than a Permitted Lien) upon the Company or Seller, or any of the Company&#8217;s or Seller&#8217;s assets, except, in the case of clauses (b), (c) and (d) above, for any such conflict, breach, default, event, loss, violation, creation or imposition as would not have a Material Adverse Effect. </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">For the avoidance of doubt, given that the certificates allowing the CE marking of the Business Products are Excluded Assets, in order to operate the Business, Purchaser will need to independently obtain its own certificates (declarations of conformity and certificates issued by a competent Notified Body, all as applicable) relating to the CE marking of products aimed at the European Union market or other markets that recognize the authority of the CE marking.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, Seller makes no representation or warranty with respect to any notices, filings, authorizations, consents, Orders, approvals, Permits, registrations, certifications, designations or appointments that may be required in connection with Purchaser&#8217;s or its Affiliates&#8217; operation of the Business following the Closing, including any such requirements relating to European regulatory matters (including the Medical Device Regulation (MDR) process or CE marking certification for the Business Products), all of which are expressly disclaimed.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.8pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The ownership of the Company is represented by the Shares and all of the Shares are held by Seller. Other than the Shares, there are no Equity Securities of the Company authorized, issued, or outstanding. All of the Shares have been validly issued and there are no unsatisfied capital commitments in respect thereof. Except for its Governing Documents, the Company is not a party to any agreements with respect to the voting, ownership or transfer of any Shares. Upon the Closing, the Shares will be delivered to Purchaser, free and clear of all Liens (other than any Liens which may result from any actions taken by Purchaser or arising under any applicable securities Laws or the Governing Documents of the Company).</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Company does not directly or indirectly hold or beneficially own any Equity Securities in any Person.</font></div><div style="margin-top:11.55pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The Company has furnished to Purchaser complete, current and accurate copies of all Governing Documents of the Company as in effect as of the date of this Agreement. The Governing Documents of the Company are in full force and effect, and no other Governing Documents are applicable to or binding upon the Company. The Company is not in violation of its Governing Documents in any material respect.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Financial Statements&#59; Undisclosed Liabilities</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt;text-decoration:underline">Section 3.6(a) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> sets forth (i) the unaudited statements of selected assets and liabilities and selected revenue and costs of the Business for the year ending December 31, 2024 and (ii) the unaudited statements of selected assets and liabilities and selected revenue and costs of the Business for the year ending December 31, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Most Recent Balance Sheet</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Financial Statements have been derived from the consolidated financial statements and accounting records of Seller and its applicable Subsidiaries and present fairly, in all material respects, the selected assets, liabilities, revenues and expenses of the Business&#59; provided, however, that (i) the Company has not operated as a separate or standalone entity, but rather has historically been reported within the consolidated financial statements of the Seller and (ii) standalone financial statements have not historically been prepared for the Company.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.6(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule, there are no liabilities or obligations of the Company or, to the extent relating to the Business, a Seller Group Entity, </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">of any nature, whether absolute, accrued, contingent or otherwise and whether due or to become due, which would be required to be presented on the face of a balance sheet of the Business prepared in accordance with GAAP except (i) as disclosed in the Most Recent Balance Sheet, (ii) incurred in the ordinary course of business since the Most Recent Balance Sheet Date, (iii) incurred in accordance with obligations of a Seller Group Entity or the Company under this Agreement, (iv) arising under any Contract to which the Company or a Seller Group Entity is a party, (other than any liabilities or obligations arising from any breach of such Contract by the Company or such Seller Group Entity, as the case may be) or (v) any liabilities or obligations that would not reasonably be expected, individually or in the aggregate, to be materially adverse to the Business, taken as a whole.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.7&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Title to Assets and Related Matters</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule, and except for the goods and services to be provided pursuant to Transition Services Agreement and any assets that constitute Excluded Assets, as of immediately prior to the Closing, (a) the Company has good and valid title to, or a valid leasehold or licensed interest in, all of the tangible assets and properties used by the Company in the conduct of the Business, in each case free and clear of all Liens other than Permitted Liens, and (b) the Seller Group Entities have good and valid title to, or a valid leasehold or licensed interest in, all of the tangible Purchased Assets, in each case free and clear of all Liens other than Permitted Liens. The material tangible assets of the Company, as well as the material tangible assets included in the Purchased Assets, are in suitable operating condition and repair in all material respects, normal wear and tear excepted and are in conformity in all material respects with all applicable Laws and other applicable requirements.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.8  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. <a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Section</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"> 3.8</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule lists each current insurance policy maintained by the Company. All such insurance policies are in full force and effect, the Company and&#47;or the Business are not in default with respect to its payment obligations under any such insurance policies and as of the date of this Agreement, no written notice of cancellation or termination has been received by the Company or any Seller Group Entity with respect to any such insurance policy. There are no claims pending under any such insurance policy with respect to the Business or the Purchased Assets.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">In the past five (5) years all income and other material Tax Returns for the Business that were required to be filed have been duly and timely filed, and all material Taxes (whether or not shown on any Tax Return) for the Business have been timely paid in full. All such Tax Returns are true, correct and complete in all material respects.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.9(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule, the Company has not been the subject of any audits, examinations, claims, litigations, investigations or other Proceedings by any Governmental Authority with respect to Taxes or Tax Returns for which the statute of limitations has not expired and which has not been fully settled or resolved. No audits, examinations, claims, litigation, investigations or other proceedings are currently being conducted, pending or have been threatened in writing with respect to Tax Returns or Taxes of the Company. The Company has not received from any Governmental Authority (including jurisdictions where the Company has not filed Tax Returns) (i) any written notice indicating an intent to open an action, audit, examination, claim litigation or other proceeding related to Taxes or Tax Returns, (ii) any request for information related to Tax matters or (iii) any notice of deficiency or proposed adjustment for any amount of Tax by any Governmental Authority against the Company. No waivers of statutes of limitation with respect to the Taxes or Tax Returns of the Company that are currently in effect have been given by or requested in writing from the Company (except, for the avoidance of doubt, for automatic extensions of time to file </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Tax Returns). No written claim has been received in the past five (5) years by the Company from any Governmental Authority in a jurisdiction where the Company does not file a particular type of Tax Return, or pay a particular type of Tax, that it is or may be subject to taxation by that jurisdiction or required to file Tax returns in that jurisdiction.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.9pt">There are no Liens for Taxes upon the Shares, the Purchased Assets or any of the Company&#8217;s assets, other than Permitted Liens. All Taxes required to be withheld by Seller or the Company in connection with amounts paid or owing to any employee, independent contractor, creditor or other Person with respect to the Business have been withheld, and have been timely paid to the proper Governmental Authorities or, in circumstances where such Taxes have not yet become due and payable, have been set aside in segregated accounts to be paid to the proper Governmental Authority. Each of Seller and the Company has timely and accurately complied in all respects with all reporting and record keeping requirements related thereto with respect to the Business, including filing of Forms W-2 and 1099 (or other applicable forms). All Persons who have provided services to Seller or the Company with respect to the Business that have been classified by Seller or the Company as independent contractors for purposes of Tax withholding laws were properly classified, and Seller or the Company has fully and accurately reported their compensation on Forms 1099 when required to do so.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">The Company is not party to or bound by any Tax indemnity agreement, Tax sharing agreement, Tax allocation agreement or any similar Contract for the sharing of Tax liabilities or benefits (excluding Contracts not primarily related to Taxes, such as commercial agreements with lenders, vendors, customers and landlords and similar commercial agreements, and any Contracts solely among the Company, on the one hand, and one or more of its Affiliates, on the other hand, or among the Company&#8217;s Affiliates).</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">The Company (i) has not been a member of a Tax Group (other than a Tax Group the common parent of which is or was Seller or one of its Affiliates or a group including Purchaser or any of its Affiliates or a Tax Group that the Company will join upon or after the Closing) or (ii) has not had any liability for the Taxes of any Person (other than with respect to a Tax Group the common parent of which is or was the Company, Seller or one of its Affiliates) under Treasury Regulation Section 1.1502-6 (or any similar provision of applicable Law), as a transferee or successor, or by Contract (other than any Contracts not primarily related to Taxes, such as commercial agreements with lenders, vendors, customers and landlords and similar commercial agreements, or any Contracts solely among the Company, on the one hand, and one or more of its Affiliates, on the other hand, or among the Company&#8217;s Affiliates).</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.02pt">The Company has not participated in any &#8220;listed transaction&#8221; as defined in Treasury Regulation Section 1.6011-4(b)(2). The Company has not participated or engaged in any transaction that has required the filing of an IRS Schedule UTP and has not participated or engaged in any other transaction that is subject to disclosure requirements pursuant to a corresponding or similar provision of state, local or foreign Tax Law.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section 355 or Section 361 of the Code in the two (2) years before the date of this Agreement.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Company has not entered into any agreement with any Governmental Authority relating to any Tax (including a &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or foreign Tax Law) or any &#8220;gain recognition </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">agreement&#8221; under Section 367 of the Code (or any corresponding or similar provision of state, local or foreign Tax Law)).</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">The Company will not (nor will Purchaser as a result of the transactions contemplated by this Agreement) be required to include any item of income in, or exclude any item of deduction from, taxable income for any Post-Closing Tax Period as a result of&#58; (i) any change in method of accounting (including, for the avoidance of doubt, any adjustment under Section 481(a) of the Code (or any corresponding or similar provision of state, local or foreign Tax Law)) by the Company&#59; (ii) any use of an improper method of accounting, completed contract method of accounting, or the percentage of completion method of accounting by the Company for a Pre-Closing Tax Period&#59; (iii) entering into an agreement with any Governmental Authority relating to any Tax of the Company on or prior to the Closing Date (including a &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or foreign Tax Law) and a &#8220;gain recognition agreement&#8221; under Section 367 of the Code (or any corresponding or similar provision of state, local or foreign Tax Law))&#59; (iv) an installment sale or open transaction disposition made on or prior to the Closing Date by the Company&#59; (v) any prepaid amount received or deferred revenue accrued on or prior to the Closing Date by the Company&#59; (vi) Section 965 or Section 59A of the Code (or any corresponding or similar provision of state, local or foreign Tax Law)&#59;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vii) any election by the Company under Section 108(i) of the Code&#59; or (viii) any interest held by the Company in a &#8220;controlled foreign corporation&#8221; (as that term is defined in Section 957 of the Code) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">CFC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) on or before the Closing Date pursuant to Section 951, 951A, or 965 of the Code (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Post-Inclusion Item</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;).</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.9(k) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, the Company and the Asset Sellers (i) have timely and properly collected and remitted all sales, use, value added, and similar Taxes required to be collected by the Company or the Asset Sellers with respect to sales made to its customers, and (ii) has properly received and retained any appropriate tax exemption certificates and other documentation for all sales made without charging or remitting sales, use, value-added and similar Taxes that qualify such sales as exempt from sales and similar Taxes.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(k)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Company has not (i) deferred any amount of the employer&#8217;s share of any &#8220;applicable employment taxes&#8221; under Section 2302 of the CARES Act (as modified by the Consolidated Appropriations Act, 2021), (ii) claimed or received any Tax credits (including, but not limited to, the Employee Retention Credit) under Sections 7001 through 7005 of the Families First Act, Section 2301 of the CARES Act (as modified by the Consolidated Appropriations Act, 2021) or Section 3134 of the American Rescue Plan Act of 2021), (iii) sought a covered loan under paragraph (36) of Section 7(a) of the Small Business Act (15 U.S.C. 636(a)), as added by Section 1102 of the CARES Act, (iv) incurred any liability with respect to any claimed or received Tax credits (including, but not limited to, the Employee Retention Credit) under Sections 7001 through 7005 of the Families First Act, Section 2301 of the CARES Act (as modified by the Consolidated Appropriations Act, 2021), or Section 3134 of the American Rescue Plan Act of 2021, or (v) deferred any payroll tax obligations (including those imposed by Section 3101(a) and 3201 of the Code) pursuant to or in connection with the Payroll Tax Executive Order.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(l)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.68pt">Within the past five (5) years, the Company (i) is and has always been in compliance in all respects with all escheat, abandoned and unclaimed property applicable Laws, (ii) submitted to the appropriate Governmental Authority all amounts required to be paid thereunder, and (iii) filed all </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">statements, returns, and reports required to be filed thereunder. There is no escheat, abandoned, or unclaimed property obligation with respect to property or other assets held or owned by the Company.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(m)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.18pt">Neither the Company nor any of its assets, nor any of the Purchased Assets is subject to a Tax holiday, Tax incentive, Tax grant or similar Tax exemption in any jurisdiction (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) that will terminate (or be subject to clawback or recapture) as a result of the transactions contemplated by this Agreement. There is no potential for any Tax Incentive of the Company that was realized on or prior to the Closing Date to be subject to recapture as a result of any actions or activities following the Closing Date.</font></div><div style="margin-top:12.15pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(n)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">As a result of the election under Section 338(g) of the Code made in connection with Seller&#8217;s acquisition of the Company, the Company recognized gain inherent in the Company&#8217;s assets in accordance with the provisions of Section 338 of the Code and the Treasury Regulations thereunder.</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.10  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Conduct of Business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Since the Most Recent Balance Sheet Date, (a) there has not occurred any Material Adverse Effect and (b) other than in connection with this Agreement and the other Transaction Documents and other than as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.10</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i) the Company has not amended its Governing Documents in any material respect&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii) the Company has not (A) made any change in its authorized Equity Securities, (B) issued any Equity Securities or (C) purchased or redeemed any of its Equity Securities&#59;</font></div><div style="padding-left:17.9pt;padding-right:18pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii) no Seller Group Entity has sold or transferred any material portion of the Business assets or property, except for sales of inventory, dispositions of obsolete equipment and transfers of cash in payment of accrued expenses and accounts payable due and owing, all in the ordinary course of business&#59;</font></div><div style="padding-left:17.9pt;padding-right:18pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iv) the Company has not incurred, assumed or guaranteed any material indebtedness for borrowed money, other than in the ordinary course of business under existing revolving lines of credit and no Seller Group Entity has incurred or assumed any indebtedness for borrowed money creating or resulting in a Lien (other than a Permitted Lien) on any of the Business assets&#59;</font></div><div style="padding-left:17.9pt;padding-right:18pt;text-indent:54pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(v) no Seller Group Entity has made any capital expenditure relating to the Business that causes the aggregate amount of all capital expenditures by the Company since the Most Recent Balance Sheet Date to exceed $500,000&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vi) no Seller Group Entity has, except as required by applicable Law, instituted or made any material amendment to any Benefit Plan&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(vii) no Seller Group Entity has settled or compromised any claim relating to the Business, other than settlements or compromises involving solely money damages not in excess of $500,000 in the aggregate&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(viii) no Seller Group Entity has experienced any damage or destruction affecting a material portion of the assets or properties of the Business, taken as a whole&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ix) no Seller Group Entity has acquired (including without limitation, by merger, consolidation, or acquisition of stock or assets) any material interests in any Person or any </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:53.9pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">material assets of any Person, in each case, other than acquisitions of Inventory in the ordinary course of business&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(x) no Seller Group Entity has, with respect to the Business, entered into, amended, accelerated, terminated or modified any Material Contract&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(xi) other than in the ordinary course of business and consistent with past practice, no Seller Group Entity has increased or decreased the compensation (including bonus or incentive compensation) or benefits of any Business Employee or independent contractor of the Business&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(xii) no Seller Group Entity has, with respect to the Business, granted rights to severance, retention or termination pay to, or entered into any employment, consulting or severance agreement with any current or former Personnel or independent contractor of the Business&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(xiii) neither the Company nor any Seller Group Entity has&#58; (x) hired, terminated, promoted, demoted, or removed any Business Employee at the manager level or above or (y) materially changed the terms and conditions of employment of any Business Employee at the manager level or above&#59;</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(xiv) no Seller Group Entity has, in connection with the Business, (i) accelerated sales into a current period or deferred any sales into a future period, (ii) delayed or postponed any capital expenditures or the repair or maintenance of any of the Business&#8217;s properties or assets, or (iii) varied any of its inventory purchasing practices in any material respect&#59; and</font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font><br></font></div><div style="padding-left:53.9pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(xv) no Seller Group Entity has agreed to do any of the foregoing in connection with the Business.</font></div><div><font><br></font></div><div id="i107d82aceeb64a04aa1708299fef6524_13"></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:17.75pt;text-indent:72pt"><font><br></font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.11  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.11</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> contains a list of the following Contracts to which the Company or, to the extent related to the Business, any Seller Group Entity, is a party or otherwise bound as of the date of this Agreement and which has not been fully performed by the parties thereto as of the date of this Agreement (each Contract listed on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.11</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, and each Intellectual Property License that is not an Incidental License, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-top:12.1pt;padding-left:125.9pt;padding-right:18pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.60pt">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:12.60pt;padding-left:23.7pt">Contracts with any Business Employee whose annual salary was in excess of</font></div><div style="padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">$200,000 as of March 31, 2026 other than any at-will agreement (terminable at any time for any reason without any notice, severance, penalty, or the payment of any amount other than accrued wages) or any Independent Business Contractor whose aggregate fees exceeded $200,000 during the twelve (12) month period ended March 31, 2026&#59;</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.23pt">Contracts that provide for the payment to any employee, officer, director, independent contractor, or consultant of any change of control payment or retention payment as a result of the consummation of the transactions contemplated by this Agreement or the other Transaction Documents&#59;</font></div><div style="margin-top:12.05pt;padding-left:125.85pt;padding-right:18pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.7pt">Collective bargaining agreements or any Contracts with any labor union&#59;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.23pt">Contracts relating to indebtedness (i) pursuant to which the Company has incurred, assumed or guaranteed any indebtedness for borrowed money or (ii) which grants or evidences a Lien (other than a Permitted Lien) on the Shares, or the Purchased Assets&#59;</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.85pt">Contracts pursuant to which the Company or, to the extent related to the Business, any Seller Group Entity, acquired or disposed of any material assets of the Business or material amount of securities during the past three (3) years outside the ordinary course of business&#59;</font></div><div style="margin-top:12.1pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.07pt">Contracts with the twenty-five (25) largest customers of the Business, as measured by revenue for the twelve (12) month period ended December 31, 2025&#59;</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:117%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:5.23pt">Contracts with component suppliers, contract manufacturers, or similar providers for the manufacture or supply of products pursuant to which the Company or any Seller Group Entity made payments in respect of the Business in excess of $300,000 during the twelve (12) month period ended March 31, 2026&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.23pt">Contracts with the ten (10) largest distributors of the Business whereby any third-party is distributing any Business Product&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.68pt">Contracts with sales representatives, sales agencies, or other Persons engaged to solicit or generate product sales pursuant to which the Company or any Seller Group Entity made payments in respect of the Business in excess of $300,000 during the twelve (12) month period ended March 31, 2026&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.68pt">any Contract that (A) materially limits the freedom of the Company or the Business to compete in any line of business with any Person or in any area, (B) contains any exclusivity obligation that restricts the Company or the Business or (C) contains any provision that requires the Company or the Business to offer most favored nation pricing or volume discounts&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.23pt">any Contract for the settlement or compromise of any Proceeding pursuant to which, after the date of this Agreement, the Business will be required to satisfy any obligation&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.68pt">(i) any finance or capital lease or (ii) any lease or other Contract relating to equipment or machinery, in each case, that is material to the operation of the Business&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.18pt">any Contract, other than leases relating to equipment and machinery of the Business, relating to the lease or license of any assets of the Company, including any Intellectual Property Asset or Leased Real Property&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.23pt">any Contract relating to the Intellectual Property Assets, including, without limitation, Contracts relating to the development of the Intellectual Property Assets&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.23pt">any Contract relating to any joint venture, partnership, limited liability company, strategic alliance or sharing of profits or losses with any Person to which the Company is a party or by which the Business or any of its assets are bound&#59; and</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.23pt">any Contract between the Company and any Governmental Authority.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">All of the Material Contracts are in full force and effect and are valid and enforceable against the Company and any Seller Group Entity party thereto in accordance with their terms, except to the extent enforcement may be affected by Enforceability Exceptions, and except as would not reasonably be expected to individually or in the aggregate, be materially adverse to the Company or the Business. Neither the Company nor any Seller Group Entity party thereto is in material default under such Material Contract and, to the Company&#8217;s Knowledge, no other Person that is party to such Material Contract is in material default under such Material Contract. True, correct and complete copies of each Material Contract have been made available to Purchaser.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.12  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. The Seller Group Entities collectively hold all Permits that are required to be held by the Seller Group Entities in order to conduct the Business as presently conducted and that, if not possessed, would not reasonably be expected, individually or in the aggregate, to be materially adverse to the Business, taken as a whole (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Permits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). To the Company&#8217;s Knowledge, the Business is in compliance in all material respects with the terms and requirements of all Material Permits. All such Material Permits are set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.12 of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12.2pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.13 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws.</font></div><div style="margin-top:11.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.85pt">Except as set forth on Section 3.13 of the Disclosure Schedule, during the past three (3) years, (i) the Company has been, and with respect to the operation of the Business, Seller Group Entities have been, in compliance in all material respects with all applicable Laws and (ii) neither the Seller Group Entities nor the Company has received any written notice from any Governmental Authority or other Person claiming or alleging that the Company was not in compliance with all Laws applicable to the Company or the operation of the Business or that any Seller Group Entity was not in compliance with all Laws applicable to the operation of the Business.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.23pt">None of the Company or any Personnel of the Business or other Person acting on behalf of or associated with the Business, has at any time&#58; (i) received, directly or indirectly, any rebates, payments, commissions, promotional allowances or any other economic benefits, regardless of their nature or type, from any customer or supplier, or any employee or agent of any customer or supplier, or (ii) directly or indirectly given or agreed to give any money, gift or similar benefit to any official or employee of any Governmental Authority, or other Person who was, is or could reasonably be expected to be in a position to help or hinder the Business (or assist the Company in connection with any actual or proposed business transaction), including, without limitation, any customer or supplier of the Company or any Personnel or Representative of such customer or supplier, in each case which (x) could reasonably be expected to subject the Company to any damage or penalty in any civil, criminal or governmental Proceeding, (y) if not given in the past, could reasonably be expected to have had an adverse effect on the operations, cash flows or prospects of the Company or (z) if not continued in the future, could reasonably be expected to adversely affect the operations, cash flows or prospects of the Company or (iii) violated or is in violation of any provision of any Anti-Corruption Law.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.85pt">The Company and each Seller Group Entity have maintained systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with applicable Anti-Corruption Laws. Neither the Company nor any Personnel of the Company is the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to any Anti-Corruption Law.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.18pt">None of the Company, any Seller Group Entity nor any Personnel of the Business have violated or are in violation of any Export Control Law with respect to the operation of the Business. Neither of the Company, nor any Seller Group Entity has received notice alleging that it is not in compliance with applicable Export Control Laws with respect to the operation of the Business, and neither the Company nor any Seller Group Entity has filed any voluntary disclosures of possible violations of applicable Export Control Laws or any other export violations with respect to the operation of the Business. None of the Company, any Seller Group Entity nor any Personnel of the Company (i) is named or described in any screening list maintained by any Governmental Authority, including any list issued by OFAC or any other lists included in the U.S. government&#8217;s consolidated screening list or on any similar list, (ii) is otherwise a party with whom, or has its principal place of business or the majority of its business operations (measured by revenue) located in a country in which transactions are prohibited by Law, or (iii) have been convicted of a felony relating to money laundering or is under investigation by any Governmental Authority for money laundering.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.14 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Proceedings and Orders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.14</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> of the Disclosure Schedule, there are no Proceedings of any kind or nature pending or, to the Company&#8217;s Knowledge, threatened in writing against any Seller Group Entity relating to the operation of the Business. Neither the Company, nor any Seller Group Entity is bound by any material Order entered into in connection with any material Proceeding during the three (3) year period ended the date of this Agreement, in each case relating to the Business.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.15  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Real Property</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> The Company does not own and has never owned fee simple interest in any real property. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.15</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (a) identifies by street address all real property leased by the Company and any Seller Group Entity in connection with the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Leased Real</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Property</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; and the lease agreements related thereto, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Real Property Leases</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) as of the date of this Agreement and (b) lists the written leases under which the Leased Real Property is leased as of the date of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Leases</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Leases are in full force and effect and are valid and enforceable in accordance with their terms, except to the extent enforcement may be affected by Enforceability Exceptions. The Company is not and no Seller Group Entity is, as applicable, in material default under any Lease to which it is a party, and, to the Company&#8217;s Knowledge, no other Person that is party to any Lease is in material default under any Lease, except, in either case, for breaches or defaults as to which requisite waivers or consents have been obtained. The Company has not subleased any Leased Real Property to any Person. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.15 of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">as of the Closing, the Company will have a valid leasehold interest in the Leased Real Property, and the Company will not have collaterally assigned, mortgaged, deeded in trust or granted any other Liens in the Leased Real Property other than Permitted Liens&#59;</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">the Company&#8217;s leasehold interest in the Leased Real Property will not as of the Closing be subject to any Liens (other than the Lien, if any, of current property Taxes and assessments not in default and other than as provided for in the Real Property Leases)&#59;</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">except as set forth in the Real Property Leases, the Leased Real Property is not subject to any use restrictions, exceptions, reservations or limitations which interfere with or impair the present and continued use thereof as currently used by the Company in the conduct of the Business&#59;</font></div><div style="margin-top:12.1pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">there are no pending or, to the Company&#8217;s Knowledge, threatened, condemnation or other similar Proceedings or claims relating to any of the Leased Real Property&#59;</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">the Leased Real Property abuts on and has direct vehicular access to a public road, or has access to a public road via a permanent, irrevocable, appurtenant easement benefiting the Leased Real Property, and access to the Leased Real Property is provided by paved public right-of-way&#59;</font></div><div style="margin-top:12.1pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.02pt">all necessary utilities are currently available to the Leased Real Property in sufficient size and capacity to adequately serve the continued use thereof as currently used by the Company in the conduct of the Business&#59;</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">the Leased Real Property is properly zoned to permit the continued use of the Leased Real Property for the conduct of the Business, and, to the Company&#8217;s Knowledge, there are no pending amendments to any applicable zoning ordinance which are likely to curtail or to interfere with such continued use&#59;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">the conduct of the Business on the Leased Real Property is in compliance in all material respects with applicable Laws and the Real Property Leases, and no portion of the Leased Real Property is operated as a nonconforming use&#59;</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">all Permits necessary for the occupancy and use of the Leased Real Property for the conduct of the Business have been obtained and are in full force and effect&#59; and</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">no portion of the Leased Real Property is located in either a &#8220;Special Flood Hazard Area&#8221; pursuant to the Federal Insurance Rate Maps created by the Federal Emergency Management Agency or an area which is inundated by a &#8220;100 year&#8221; flood as provided by any Governmental Authority.</font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) The Company is and for the past three (3) years has been in compliance in all material respects with all applicable Environmental Laws. The Company possesses and is and for the past three (3) years has been in material compliance with all Environmental Permits that are required for the Company to operate its business as presently conducted. All such Environmental Permits held by the Company are valid and in good standing and there is no pending, or to the Company&#8217;s Knowledge, threatened, action to modify, revoke or rescind any such Environmental Permit. There are no pending actions or claims against the Company related to Environmental Laws. Within the past three (3) years, the Company has not received any written or, to the Company&#8217;s Knowledge, oral, notice, request for information, complaint, claim, citation, summons or other communication from any Governmental Authority regarding (i) any actual or alleged violation of any Environmental Laws or Environmental Permits or (ii) any investigatory, remedial, or corrective obligations relating to the Company arising under Environmental Laws. The Company has not entered into or assumed by contract or, operation of Law or otherwise, any obligation, liability or Order relating to or arising under Environmental Laws. No facts, conditions or circumstances exist with respect to the Company or the Business that would reasonably be expected to result in any claim, liability, investigatory obligation or remedial obligation under Environmental Laws. The Company has provided Purchaser with copies of all existing material reports, reviews, studies, audits, and other material documents that relate to the environmental condition of the real properties or assets currently or formerly used in connection with the operation of the Company&#8217;s business, or the Company&#8217;s compliance with Environmental Laws or Environmental Permits, and that are in the Company&#8217;s possession or under the Company&#8217;s reasonable control.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) There has been no Release of Hazardous Materials by the Company at, on, under or migrating from any real property or, to the Company&#8217;s Knowledge, by any Person, at, on, under or migrating from any real property currently or formerly operated or leased by the Company, that has resulted in or would reasonably be expected to result in liability to the Company under Environmental Laws. The Company has not transported, treated, stored, disposed of, arranged for disposal of, or released any Hazardous Materials except in compliance with Environmental Laws.</font></div><div style="margin-top:12.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.17</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> lists each Benefit Plan. The Company has made available to Purchaser with respect to each Benefit Plan (to the extent applicable thereto) copies of</font></div><div style="margin-top:0.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i) the current plan document and trust agreement or other funding documentation (including all amendments thereto) or, if such Benefit Plan is not in writing, a written description of the material terms of such Benefit Plan&#59; (ii) the three most recent Forms 5500 filed with respect to such Benefit Plan&#59; (iii) the </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">most recent summary plan description, and all summaries of material modifications related thereto, distributed to participants in such Benefit Plan&#59; (iv) the most recent annual compliance testing report&#59; and</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(v) the most recent determination, opinion or advisory letter issued by the IRS with respect to such Benefit Plan.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Each Benefit Plan has been documented in all material respects in compliance with all applicable Laws and maintained and administered in all material respects in accordance with its terms and in compliance with all applicable Laws. Except as would not reasonably be expected to result in liability to the Company&#58; (i) all contributions, premiums and other payments due or required to have been paid by the Company or an Affiliate (as applicable) to (or with respect to) any Benefit Plan prior to the date of this Agreement have been timely paid&#59; (ii) all contributions, premiums and other payments that have accrued but are not yet due to or with respect to any Benefit Plan prior to the date of this Agreement have been properly reflected in the Company&#8217;s or Affiliate&#8217;s (as applicable) financial statements&#59; and (iii) the Company has not and, to the Company&#8217;s Knowledge, no other Person has (A) engaged in a nonexempt prohibited transaction within the meaning of Section 406 of ERISA or Section 4975 of the Code with respect to any Benefit Plan that is subject to such sections, or (B) breached any fiduciary duty imposed upon it by ERISA with respect to any Benefit Plan that is subject to ERISA. With respect to employees, contractors, and other service providers of or to the Business, each Benefit Plan covers only current employees who are employed by the Company and their dependents (or former employees or their dependents with respect to former employee service with the Company).</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Each Benefit Plan intended to be qualified under Section 401(a) of the Code (i) is the subject of a favorable determination letter from the IRS, or (ii) utilizes a preapproved plan document that is the subject of a favorable opinion or advisory letter issued by the IRS to the sponsor of such preapproved plan. Nothing has occurred and, to the Company&#8217;s Knowledge, no circumstances exist that would reasonably be expected to cause the loss of qualification of any such Benefit Plan.</font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Each Benefit Plan that provides deferred compensation subject to Section 409A of the Code is and at all times has been documented in accordance with Section 409A of the Code and complies and has complied in all material respects with the requirements of Section 409A of the Code and the guidance issued thereunder, to the extent such requirements are applicable thereto. The Company does not have any obligation to indemnify or reimburse any individual for any additional Taxes or interest imposed on such individual pursuant to Section 409A of the Code.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">None of the Benefit Plans is or ever has been, and the Company does not have and never has had any liability (including contingent liability) with respect to, any (i) &#8220;employee pension benefit plan,&#8221; as defined in Section 3(2) of ERISA, that is or was subject to Section 302 of ERISA, Title IV of ERISA or Section 412 of the Code&#59; (ii) &#8220;multiemployer plan,&#8221; as defined in Section 3(37) of ERISA&#59; (iii) multiple employer plan, within the meaning of Section 210(a) of ERISA or Section 413(c) of the Code&#59; or (iv) &#8220;multiple employer welfare arrangement,&#8221; as defined in Section 3(40) of ERISA. The Company does not have any liability with respect to any &#8220;employee benefit plan,&#8221; as defined in Section 3(3) of ERISA, solely by reason of being treated as a single employer under Section 414 of the Code or Section 4001(a)(14) of ERISA with any other trade or business.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.17(f) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, no Benefit Plan provides life insurance, medical benefits or any other welfare benefits to any current or former employee or other service provider (or a dependent of such individual) of the Company after the employee&#8217;s or other service provider&#8217;s termination of employment or service, other than (i) as required by Law, including Section 4980B(f) of the Code and similar state Law, at the expense of the former employee or </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">service provider and&#47;or such employee&#8217;s or service provider&#8217;s dependent, (ii) coverage through the end of the month of termination of employment or service, and (iii) conversion rights at the sole expense of the converting individual.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">There are no claims or Proceedings (other than routine claims for benefits, appeals of such claims, and domestic relations order Proceedings in accordance with Benefit Plan terms and procedures) pending or, to the Company&#8217;s Knowledge, threatened with respect to (or against the assets of) any Benefit Plan.</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.17(h) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, except as required by Law or the terms of this Agreement, neither the execution of this Agreement by the Company nor the consummation of the transactions contemplated by this Agreement (either alone or in conjunction with another event) will&#58; (i) accelerate the time of payment or vesting of, or trigger any funding of benefits under, any Benefit Plan&#59; or (ii) entitle any current or former employee, officer, director or individual independent contractor of the Company or any Business Employee to any payment or increase in compensation or benefits or to any severance pay under any Benefit Plan or otherwise. The Company does not have any obligation to indemnify or reimburse any Business Employee or other individual for any Taxes imposed on such individual pursuant to Section 4999 of the Code or any other Tax law.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">The Company is and has at all times been in compliance in all material respects with all applicable requirements of the Patient Protection and Affordable Care Act, as amended (&#8220;PPACA&#8221;). The Company is not currently subject to, nor, to the Company&#8217;s Knowledge, are there any facts that could form a basis for, any assessment of taxes or penalties under PPACA.</font></div><div style="margin-top:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Employee Relations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.18(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule is a true, correct and complete list by name of all Business Employees, and for each such employee, such employee&#8217;s (i) name,</font></div><div style="padding-left:18pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii) job title, (iii) primary location of employment, (iv) employing entity, (v) exempt or non-exempt status under the Fair Labor Standards Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">FLSA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and any applicable state or local Law, (vi) current annual base salary or wages (listing hourly rate if paid hourly, listing annual salary if paid salary, or if neither, specifying the manner and amount of payment), (vii) full time or part time status&#59; (viii) whether they are an active employee or Inactive Employee&#59; and (ix) incentive compensation targets and outstanding long-term incentive award values, including scheduled vesting and payment values as of May 2026.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">No Business Employees are or heretofore in the past three (3) years have been covered by or subject to a collective bargaining agreement or other Contract with any labor organization, union, works council or association. For the past three (3) years there has not been any actual or threatened, and there is not presently any pending or, to the Company&#8217;s Knowledge, threatened in writing&#58; (i) any Proceeding against or affecting the Company or the Business relating to any alleged violation of any Law pertaining to labor relations or employment matters, including without limitation any charge or complaint filed by any Person with the National Labor Relations Board, the Equal Employment Opportunity Commission, U.S. Department of Labor, Officer of Federal Contract Compliance Programs, the Occupational Safety and Health Administration, or any other Governmental Authority&#59; (ii) any union organizational activity, labor strike, labor dispute, labor union grievance, labor strike, walkout, work stoppage, slow-down, lockout, or other labor or material employment dispute against or affecting the Company or the operation of the Business&#59; (iii) any charge, demand, petition, representation or certification proceedings or petitions seeking a representation proceeding to be brought or filed with the National Labor Relations Board or any other labor relations tribunal or authority, or otherwise efforts to </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">compel, require or demand any Seller Group Entity to bargain with any labor union or labor organization&#59; or (iv) any application for certification of a collective bargaining agent with respect to the Business Employees.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Within the past three (3) years, the Company and, to the extent relating to the operation of the Business, each Seller Group Entity has been in compliance in all material respects with all applicable Laws pertaining to employment and employment practices, including without limitation all Laws relating to labor relations, terms and conditions of employment, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages (including classification under the FLSA and other applicable state and local Laws), hours, overtime compensation, wage deductions, wage assignments, wage garnishments, workday&#47;workweek&#47;work hours, prevailing wages, pay transparency, pay equity, child labor, hiring, promotion and termination of employees, employee privacy, surveillance and monitoring, biometric data, data protection, pay statements, recordkeeping, postings, plant closings&#47;mass layoffs, background checks, testing (including drug and alcohol testing), paid and unpaid leaves of absence (including paid sick leave), vacation and paid time off, working conditions, meal and break periods, immigration, employment verification&#47;authorization, affirmative action, health and safety, workers&#8217; compensation, leaves of absence and unemployment insurance. Any person currently or formerly performing services for the Business as a consultant or independent contractor has been properly classified as an employee or non-employe under all applicable Laws except as would not result in a material liability to the Company. All current and former employees providing services for the Business have been properly classified as exempt or non-exempt under the FLSA and other applicable state and local Laws. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.18(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule, all Business Employees are employed or engaged on an at-will basis. Neither the Company, nor, as it relates to the operation of the Business, any Seller Group Entity is delinquent in any payments to any current or former employees or independent contractors for any wages, salaries, commissions, bonuses or other compensation or remuneration for any services performed as of the date hereof or any reimbursable amount.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Company and all Seller Group Entities have maintained workers&#8217; compensation coverage as required by applicable Law through the purchase of insurance and not by self-insurance or otherwise. No Business Employee has provided written notice to a Seller Group Entity to terminate their employment, and neither the Company nor any Seller Group Entity has any intention to terminate the employment of any Business Employee before the Closing Date. To the Knowledge of the Company, no Business Employee or Business Independent Contractor is in violation of any term of any employment contract, non-disclosure agreement, noncompetition agreement, or any restrictive covenant to a former employer relating to the right of such employee or independent contractor to be employed by or provide services to the Company or the Business.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Neither the Company, nor, as it relates to the operation of the Business, any Seller Group Entity has implemented any plant closing or layoff of employees that would implicate the WARN Act or any similar Law. Neither the Company, nor, as it relates to the operation of the Business, any Seller Group Entity has been affected by any transaction, engaged in any plant closing or relocations of operations, or engaged in layoffs or employment terminations or reduction of hours sufficient in number to trigger application of the WARN Act or of any similar Law.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.02pt">No Business Employee is an undocumented alien and each Business employee is authorized to work in the jurisdiction or location in which they are employed. Within the past three (3) years, no Seller Group Entity has received written notice or, to the Company&#8217;s Knowledge, other communication, from any Governmental Authority regarding any violation or alleged violation involving </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the Business of any Law relating to hiring, recruiting, employing of (or continuing to employ) any Person not authorized to work in the United States. The Company and, as it relates to the Business, each Seller Group Entity, is employing only individuals who are lawfully permitted to work in the United States, has in its files a current Form I-9 for all Business Employees that is validly and properly completed in accordance with applicable Laws, and has complied with required processes and all Laws with respect to obtaining such Forms I-9. The Company and each Seller Group Entity operating in the United States uses E-Verify in compliance with all Laws and any agreement with any Governmental Authority. None of the Seller Group Entities, within the past three (3) years, have been subject to or notified in writing of any pending or threatened investigation by U.S. Immigration and Customs Enforcement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ICE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) or any branch or department of ICE, or other federal agency charged with administration and enforcement of federal immigration laws in the United States concerning the Company, Business Employees, or the Business. As it relates to Business Employees and the Business, no Seller Group Entity is sponsoring any employee to work in the United States or any other country under a visa or work authorization, and no petition for admission of any alien under a non-immigrant or other visa, or for transfer of sponsorship of any such employee, is currently pending.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.19  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Intellectual Property. <a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.19</a> of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> sets forth, with the title, registration or serial number, filing date, issue date, jurisdiction, as applicable, a true, correct and complete list of all Intellectual Property Assets and other Intellectual Property owned by the Company that is currently registered or pending registration anywhere in the world, including all&#58; (i) trademark registrations and applications therefor&#59; (ii) copyright registrations and applications therefor&#59; (iii) patents and applications (such applications and registrations &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Registered IP</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; and (iv) domain names and social media accounts. The Registered IP that is issued is subsisting and enforceable and, to the Company&#8217;s Knowledge, valid.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) The Company owns, or is validly licensed or otherwise has the right to use, all Intellectual Property as used in the Business as presently conducted, except that the foregoing representation does not pertain to any infringement, misappropriation or violation of any Intellectual Property by the Company. The Company solely owns all Owned Intellectual Property as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.19</a> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">of the Disclosure Schedule free and clear of all Liens other than Permitted Liens, except that the foregoing representation does not pertain to any infringement, misappropriation or violation of any Intellectual Property by the Company.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c) The execution, delivery and performance of this Agreement and the other Transaction Documents by Seller or the Company and the consummation by Seller or the Company of the transactions contemplated in this Agreement and the other Transaction Documents will not result in the loss or impairment of any Licensed Intellectual Property or Owned Intellectual Property.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d) The Company has executed valid and enforceable written agreements with all Persons (including all of its past and present employees, consultants and independent contractors) who are or, to the Company&#8217;s Knowledge, would reasonably be expected to be privy to any trade secrets of the Company or who have contributed or are contributing to the creation or development of any Intellectual Property Assets owned or purported to be owned by the Company under which such Persons have, respectively, (i) agreed to hold all Trade Secrets and other Confidential Information of the Company in confidence both during and after their employment or retention, as applicable, and (ii) presently assigned to the Company all of such Person&#8217;s rights, title and interest in and to all such Intellectual Property Assets. To the Company&#8217;s Knowledge, no party thereto is in default or breach of such agreement. Each such agreement following the consummation of the transactions contemplated by this Agreement shall remain, as of immediately following the Closing, the legal, valid, binding and enforceable obligations of </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">such employees, consultants and independent contractors, and neither the execution, delivery or performance of this Agreement, nor the consummation of the transactions contemplated by this Agreement, will result in any right for any Person to terminate, restrict, limit or invalidate or otherwise result in the material loss of or materially adversely affect any right, title or interest in or to any licensed Intellectual Property or Intellectual Property Assets or other Intellectual Property held or used by the Company. No compensation, including, without limitation, royalties, is due or may become payable to any current or past employee, contractor or other Person for creation or use of any Intellectual Property Assets other than pursuant to a written Contract listed on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.19(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.19(e) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">of the Disclosure Schedule contains a correct, current and complete list of all Intellectual Property Licenses&#58; (i) under which Company is a licensor or otherwise grants to any Person any right or interest relating to any Intellectual Property Assets&#59; (ii) under which Company is a licensee or is otherwise granted any right or interest relating to Intellectual Property of any Person&#59; and (iii) which otherwise relates to the ownership or use by Company of any Intellectual Property in the conduct of the Business as currently conducted. All amounts payable under any Intellectual Property License that were owed as of the Closing Date have been paid, including, without limitation, any amounts payable in connection with the transfer of any Intellectual Property License in connection with the Closing. The Company and, to the Company&#8217;s Knowledge, each other Person that is a party to an Intellectual Property License, is in compliance in all material respects with all terms of any such Intellectual Property License.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f) The Owned Intellectual Property and the conduct of the business of the Company as presently conducted does not infringe upon, misappropriate or otherwise violate the Intellectual Property rights of any Person. There are no Proceedings pending or, to the Company&#8217;s Knowledge, threatened in writing against the Company that allege that the Company has infringed or is infringing, misappropriating or otherwise violating the rights of any Person with regard to any Intellectual Property. Without limiting the foregoing, other than office actions and other communications received from any Governmental Authority in the normal course of prosecuting Registered IP for issuance or registration of any Intellectual Property or any renewals, extensions or recordations thereof, the Company has not received in the past five (5) years any notice or claim from any Person challenging any Owned Intellectual Property or the right of the Company to own or use any Owned Intellectual Property.</font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">To the Company&#8217;s Knowledge, no Person is currently misappropriating, infringing, diluting or otherwise violating any of the material Intellectual Property owned by the Company.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">The Company has taken adequate steps, consistent with customary industry practices, to maintain the confidentiality and trade secret status of the trade secrets used in connection with the business of the Company as currently conducted.</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">The Company does not have any obligation to compensate any employee or any other Person (other than salaries or other payments payable to employees, consultants and independent contractors that are not contingent on or related to use of their work product) for the development, use, manufacture, sale or exploitation of any Owned Intellectual Property. No funding, facilities or personnel of any Governmental Authority, university, college, other educational institution or research center was used in the development of any Owned Intellectual Property in such a manner as to give any of the foregoing any claim or right, current or contingent, in or to any such Owned Intellectual Property.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">All Owned Intellectual Property was either&#58; (i) developed by employees of the Company or its Affiliates working within the scope of their employment at the time of such development&#59;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii) developed by officers, independent contractors, or other third parties who have executed written instruments of assignment in favor of the Company&#59; or (iii) acquired in connection with acquisitions in which the Company obtained any required present assignment of Intellectual Property from the transferring party.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(k)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">All Information Systems used by the Company in the Business as presently conducted are commercially available. The Information Systems used by the Company in the Business are in good operating condition and repair, free of material errors or other non-conformities, fit for the particular purpose for which they are intended, and are all of the Information Systems necessary or desirable for the operation of the Business as presently conducted. The Company&#8217;s use of Information Systems in the Business as presently conducted complies with the Contracts to which the Company is a party related to the license thereof. The Company, or the applicable Asset Seller, has in place written agreements with all vendors for all Information Systems, and for the support, maintenance, and services relating thereto, and cloud services and related infrastructure. The Information Systems have been subject to reasonable measures consistent with accepted industry practices for the size and type of company as the Company to prevent the introduction of, and does not contain, nor has contained at any time, any &#8220;back door,&#8221; &#8220;drop dead device,&#8221; &#8220;time bomb,&#8221; &#8220;Trojan horse,&#8221; &#8220;virus,&#8221; or &#8220;worm&#8221; (as such terms are commonly understood in the software industry) or any other code designed or intended to have, or capable of performing, any of the following functions&#58; (i) disrupting, disabling, harming or otherwise impeding in any manner the operation of, or providing unauthorized access to, a computer system or network or other device on which such code is stored or installed&#59; or (ii) damaging or destroying any data or file without the user&#8217;s consent.</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(l)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt;text-decoration:underline">Section 3.19(l) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> contains a complete and accurate list of all social media accounts of the Company. The Company has complied in all material respects with all terms of use, terms of service and other Contracts and all associated policies and guidelines relating to its use of any such social media platforms, sites or services.</font></div><div style="margin-top:12.25pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Privacy and Data Security</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) The Company&#8217;s collection, use, disclosure, and storage of Personal Information complies in all material respects with all Privacy Laws, the Company&#8217;s applicable privacy policies, and applicable contractual obligations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Privacy Commitments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Neither the execution, delivery, and performance of this Agreement nor the transfer of the Company&#8217;s Personal Information will cause a material breach of the Privacy Commitments. The Company employs commercially reasonable efforts to maintain appropriate technical and organizational measures designed to protect the Personal Information against Data Breaches. The Company has not experienced a Data Breach or received any written notice of an investigation by any Governmental Authority or a complaint from any other third party alleging a violation of any Privacy Laws during the past three (3) years.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) The Company maintains commercially reasonable administrative, technical, and physical safeguards designed to protect the confidentiality, integrity, and availability of IT Systems and Protected Data. The Company owns, licenses, or otherwise has valid rights to use all IT Systems used in the Business. Such systems are reasonably adequate for, and operate and perform in all material respects as required in connection with, the operation of the Business and do not contain any viruses or other malicious code designed to disrupt, disable, or permit unauthorized access to such systems or any Protected Data. During the past three (3) years, there has been no material breach of the confidentiality, integrity, or availability of IT Systems.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c) All third parties Processing Protected Data on behalf of the Company are bound by written agreements requiring compliance with applicable Data Security Requirements and implementation of appropriate safeguards. All products of the Business that include software or connectivity (including software as a medical device and embedded systems) have been developed, tested, maintained, and monitored in all material respects in accordance with applicable Law and industry standards. The Company has all rights necessary to Process Protected Data in connection with the Business, and the consummation of the transactions contemplated by this Agreement will not materially violate any Data Security Requirement or materially impair the Company&#8217;s rights to use or Process such Protected Data. The Company is in compliance with all agreements governing third-party software (including open source Software) and has obtained sufficient licenses for all software used in the Business.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.21  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Anti-Bribery and Anti-Corruption</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Company has not, nor has any representative acting for or on behalf of the Company (in the case of any representative other than an employee, to the Company&#8217;s Knowledge), in the past three (3) years, taken any action directly or indirectly in furtherance of an offer, payment, promise to pay, or authorization or approval of any contribution, gift, bribe, influence payment, kickback, or other payment to any government entity or official, public international organization, political party or candidate for public office in violation of the U.S. Foreign Corrupt Practices Act of 1977. No governmental official (a) holds any ownership or other economic interest, direct or indirect, of the Company, (b) serves as a representative of the Company or (c) will receive any economic benefit from the Company as a result of this Agreement.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.22  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">International Trade Compliance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. During the past five (5) years&#58; (i) the Company and, to the extent related to the Business, each Seller Group Entity, has been in compliance in all material respects with the International Trade Laws&#59; (ii) the Company has not and no Seller Group Entity has received written notice to the effect that any Governmental Authority has claimed or alleged that the Company or the Business is not in compliance in any material respect with any International Trade Law&#59; (iii) to the Company&#8217;s Knowledge, the Company and, to the extent related to the Business, each Seller Group Entity, has paid all duties, tariffs, fees or other payments required to be paid with respect to the import and export of any products in connection with the Business&#59; (iv) to the Company&#8217;s Knowledge, the Company has not and, to the extent related to the Business, no Seller Group Entity has, imported any article in connection with the Business that is the product of forced labor, or whose import is otherwise prohibited under the International Trade Laws&#59; (v) to the Company&#8217;s Knowledge, the Company has not and, to the extent related to the Business, no Seller Group Entity has, exported, re-exported, or transferred outside the United States any item in connection with the Business whose export, re-export or transfer was not authorized under the International Trade Laws&#59; and (vi) to the Company&#8217;s Knowledge, the Company has not, no Seller Group Entity has, and no director, manager, officer or employee of the Company or any Seller Group Entity has engaged in any transaction in connection with the Business, either directly or indirectly, with or for the benefit of any person with whom such transaction was prohibited pursuant to the International Trade Laws.</font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.23  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Related Parties Transactions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.23</a> of the Disclosure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#58; (a) the Company is not party to any Contract with any Related Party (other than any Benefit Plan, employment Contract or other employment arrangement or any Governing Document of the Company)&#59; (b) the Company is not owed or does not owe any amount from or to any Related Party (other than any employee compensation, Benefit Plans and other ordinary incidents of employment)&#59; and (c) no material asset that is necessary in the present operation of the business of the Company, is owned by or leased from any Related Party, other than the assets being transferred to the Company at or prior to </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Closing in accordance with the terms set forth in this Agreement, the Assignment and Assumption Agreement or any other Transaction Document.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">FDA and Related Matters</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The Seller Group Entities, collectively, hold all registrations, approvals, clearances, licenses, and authorizations required by the FDA and other regulatory authorities for the conduct of the Business, all of which are valid, in full force and effect, and no proceedings are pending or have been threatened in writing to revoke, suspend, or limit them. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.24 of the Disclosure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, and except for the goods and services to be provided pursuant to Transition Services Agreement and any assets that constitute Excluded Assets, all such registrations, approvals, clearances, licenses, and authorizations are either owned by the Company or included in the Purchased Assets.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Business Products have been developed, tested, manufactured, labeled, marketed, distributed, imported, and exported in material compliance with applicable FDA laws and related regulatory requirements. The Seller Group Entities have complied with all reporting obligations with respect to the Business, including adverse event reporting. In the past three (3) years, no Seller Group Entity has (i) made an untrue statement of a material fact or fraudulent statement to the FDA or any Governmental Authority, (ii) failed to disclose a material fact required to be disclosed to the FDA or (iii) committed any other act, made any statement or failed to make any statement, that (in any such case) establishes a reasonable basis for the FDA to invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy, in each case related to the Business Products.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">In the past three (3) years, no Seller Group Entity has received any Form FDA-483s, warning letters or similar notices with respect to the Business that remains unaddressed to the satisfaction of the issuing Governmental Authority. In the past three (3) years, no Seller Group Entity has been the subject of any FDA enforcement actions with respect to the Business. There are no pending or, to the Company&#8217;s Knowledge, threatened FDA enforcement actions, warning letters, or similar notices indicating non-compliance with respect to the Business. No Business Products have been seized, withdrawn, recalled, or subject to similar corrective actions at the request of any Governmental Authority or voluntarily, and no facts exist that would reasonably be expected to result in such actions.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">All clinical and preclinical studies related to the Business have been conducted in accordance with applicable laws, good clinical practices, and FDA regulations in all material respects. In the past three (3) years, no trials related to the Business have been terminated or placed on clinical hold by any Governmental Authority. No Seller Group Entity or any entity or individual associated with the Company has engaged in conduct with respect to the Business that would result in debarment or exclusion of the Company under FDA laws, and no such actions are pending or, to the Company&#8217;s Knowledge, threatened.</font></div><div style="margin-top:12pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The Company is in compliance with all applicable laws that govern, regulate, restrict or relate to medical device manufacturers and the regulation thereof, including the Federal Food, Drug and Cosmetic Act (21 U.S.C. 301 et seq.), the regulations promulgated thereunder.</font></div><div style="margin-top:11.7pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Healthcare Regulatory Compliance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">The Company is in compliance with all applicable healthcare laws, including but not limited to, laws that relate to the provision of medical device products and services and the regulation </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">thereof&#59; certification, qualification or authority to transact business relating to the provision of, or payment for, health care services&#59; and other health care regulatory matters (including, without limitation, (i) the Social Security Act, as amended, Sections 1128, 1128A and 1128B, 42 U.S.C. Sections 1320a-7, 7(a) and 7(b), including Criminal Penalties Involving Medicare or State Health Care Programs, commonly referred to as the federal Anti-Kickback Statute and similar state laws and regulations), (ii) the Social Security Act, as amended, Section 1877, 42 U.S.C. Section 1395nn (Prohibition Against Certain Referrals), commonly referred to as the Stark Law and similar state laws and regulations, (iii) the statute commonly referred to as the federal False Claims Act, (iv) HIPAA, and (v) the regulations promulgated under all of the foregoing statutes. Over the past six (6) years, neither the Company nor its personnel have engaged in conduct that would violate such laws.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Company has not, and to the Company&#8217;s Knowledge, no entity or individual associated with the Company has, been excluded, debarred, or is otherwise ineligible to participate in any federal healthcare program, nor are they subject to any investigations, audits, or proceedings relating to such programs.</font></div><div style="margin-top:12pt;padding-left:18.05pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">There are no pending or, to the Company&#8217;s Knowledge threatened governmental proceedings alleging violations of healthcare laws, and no whistleblower actions have been filed or threatened under the False Claims Act.</font></div><div style="margin-top:11.6pt;padding-left:18.05pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.13pt">The Company maintains appropriate compliance programs, policies, and procedures to ensure adherence to regulatory requirements.</font></div><div style="margin-top:12pt;padding-left:18.05pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.75pt">All reimbursement advice, billing practices, and coding for products are accurate and compliant with applicable healthcare regulations. Any arrangements with healthcare professionals are documented, are for bona fide services, and reflect fair market value compensation.</font></div><div style="margin-top:11.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 3.26 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Sufficiency of Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.26 of the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, for the goods and services to be provided pursuant to Transition Services Agreement and any assets that constitute Excluded Assets, the Purchased Assets and the assets owned by the Company constitute all tangible and intangible property, assets, personnel and rights of Seller and its Affiliates that are related to or used in the operation or conduct of the Business and such assets are sufficient for the continued conduct of the Business as of the Closing in substantially the same manner as conducted as of the date hereof and consistent with past practice.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.27  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The Company has not engaged any Person who is entitled to a broker&#8217;s commission, finder&#8217;s fee, investment banker&#8217;s fee or similar payment for which Purchaser or the Company is liable or responsible in connection with the transactions contemplated by this Agreement.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:69.1pt;padding-right:69.1pt;text-align:center;text-indent:103.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE IV</font></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF SELLER</font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Seller makes the representations and warranties set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IV</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> on the date hereof and on the Closing Date&#58;</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Organization, Existence and Good Standing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Seller is duly organized, validly existing and in good standing under the Laws of the State of Delaware.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Power and Authority</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Seller has full corporate power and authority to enter into and perform this Agreement and all the other Transaction Documents to be executed or delivered by Seller in </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">connection with the transactions contemplated by this Agreement. The execution, delivery and performance of this Agreement and the other Transaction Documents by Seller and the consummation by Seller of the transactions contemplated in this Agreement and the other Transaction Documents to which Seller is or will be a party have been, or at the Closing will be, duly and validly approved by the board of directors of Seller. No other Proceedings are necessary on the part of Seller to authorize the execution, delivery and performance of this Agreement and the other Transaction Documents by Seller and the consummation by Seller of the transactions contemplated herein and therein.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.3  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement has been duly authorized, executed and delivered by duly authorized officers or other signatories of Seller and constitutes a valid and binding obligation of Seller (assuming that this Agreement has been, and the Transaction Documents to which Seller is or will be a party will be, duly and validly authorized, executed and delivered by the other Persons party thereto), enforceable against Seller in accordance with its terms, except to the extent enforcement may be affected by Enforceability Exceptions. At the Closing, the Transaction Documents to be executed and delivered by Seller will be duly executed and delivered by Seller and will constitute valid and binding obligations of Seller, enforceable in accordance with their terms, except to the extent enforcement may be affected by Enforceability Exceptions.</font></div><div style="margin-top:12.15pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Consents&#59; Non-Contravention</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Seller is not required to give any notice to, make any filing with, or obtain any authorization, consent, Order or approval of any Governmental Authority in connection with the execution and delivery by Seller of this Agreement and the other Transaction Documents to which Seller is, or at the Closing will be, a party or the consummation of the transactions contemplated herein or therein, except for any such notice, filing, authorization, consent, Order or approval as would not prevent Seller from the consummation of the transactions contemplated by this Agreement.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Assuming that all notices, filings, authorizations, consents, Orders and approvals contemplated by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.4(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> have been duly made or obtained, neither the execution, delivery and performance of this Agreement and the other Transaction Documents to which Seller is, or at the Closing will be, a party, nor the consummation of the transactions contemplated herein and therein&#58; (a) will violate any provision of the Governing Documents of Seller&#59; (b) will conflict with, result in a breach of, or constitute a default or an event creating rights of acceleration, termination, modification, or cancellation, or a loss of rights under, any material Contract to which Seller is a party or by which any of its assets is bound&#59; (c) will violate any material Law or material Order to which Seller or any of its assets is subject or otherwise bound&#59; or (d) will result in the creation or imposition of any Lien (other than a Permitted Lien) upon Seller or any of its assets, except, in the case of clauses (b), (c) and (d) above, for any such conflict, breach, default, event, loss, violation, creation or imposition as would not prevent Seller from the consummation of the transactions contemplated by this Agreement.</font></div><div style="margin-top:12pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.5  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Title to Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> of the Disclosure Schedule, Seller holds beneficially and of record all of the Shares, free and clear of all Liens other than (a) Permitted Liens and (b) Liens arising under the Governing Documents of the Company.</font></div><div style="margin-top:11.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.6  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Seller has not engaged any Person who is entitled to a broker&#8217;s commission, finder&#8217;s fee, investment banker&#8217;s fee or similar payment for which Purchaser or the Company is liable or responsible in connection with the transactions contemplated by this Agreement.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 4.7  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. There are no Proceedings pending against, or, to the knowledge of the Company or Seller, threatened against or affecting, Seller before any court or arbitrator or any Governmental Authority which in any manner challenge or seek to prevent, enjoin, alter or materially delay the transactions contemplated by this Agreement.</font></div><div style="margin-top:10.55pt;padding-left:114.3pt;padding-right:114.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE V</font></div><div style="margin-top:0.1pt;padding-left:0.05pt;padding-right:0.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF PURCHASER</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Purchaser makes the representations and warranties set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article V</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> on the date hereof and on the Closing Date&#58;</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Organization, Existence and Good Standing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser is a corporation duly organized, validly existing and in good standing under the Laws of the state of its incorporation.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Power and Authority</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser has full corporate power and authority to enter into and perform this Agreement and all the other Transaction Documents to be executed or delivered by Purchaser in connection with the transactions contemplated by this Agreement. The execution, delivery and performance of this Agreement and the other Transaction Documents by Purchaser and the consummation by Purchaser of the transactions contemplated in this Agreement and the other Transaction Documents have been, or at the Closing will be, duly and validly approved by the board of directors of Purchaser. The approval of Purchaser&#8217;s shareholders for Purchaser to execute this Agreement and the other Transaction Documents to which Purchaser is a party or consummate the transactions contemplated by this Agreement is either not required or has been duly given. No other approvals or actions are necessary on the part of Purchaser to authorize the execution, delivery and performance of this Agreement and the other Transaction Documents by Purchaser and the consummation by Purchaser of the transactions contemplated herein and therein.</font></div><div style="margin-top:11.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.3   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement and each of the other Transaction Documents to be executed and delivered by Purchaser has been duly authorized, executed and delivered by duly authorized officers or other signatories of Purchaser and constitutes a valid and binding obligation of Purchaser (assuming that this Agreement has been, and the Transaction Documents to which Purchaser is a party have been or will be at the Closing, duly and validly authorized, executed and delivered by the other Persons party thereto), enforceable against Purchaser in accordance with its terms, except to the extent enforcement may be affected by Enforceability Exceptions. At the Closing, the Transaction Documents to be executed and delivered by duly authorized officers of Purchaser will be duly executed and delivered by Purchaser and will constitute valid and binding obligations of Purchaser, enforceable in accordance with their terms, except to the extent enforcement may be affected by Enforceability Exceptions.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.4  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Consents&#59; Non-Contravention</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser is not required to give any notice to, make any filing with or obtain any authorization, consent, Order or approval of any Governmental Authority in connection with its execution and delivery of this Agreement and the other Transaction Documents or the consummation by it of the transactions contemplated herein and therein. Neither the execution, delivery and performance of this Agreement and the other Transaction Documents by Purchaser, nor the consummation by it of the transactions contemplated herein and therein&#58; (a) will violate any provision of the Governing Documents of Purchaser&#59; (b) will conflict with, result in a breach of, or constitute a default or an event creating rights of acceleration, termination, modification or cancellation or a loss of rights under, any Permit or unsatisfied Contract to which Purchaser is a party, subject or otherwise bound&#59; (c) will violate any Law or Order to which Purchaser or any of Purchaser&#8217;s assets or businesses is subject or </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">otherwise bound&#59; or (d) will result in the creation or imposition of any Lien upon any of the assets or businesses of Purchaser.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.5   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Neither Purchaser nor any of its Affiliates has engaged any Person who is entitled to a broker&#8217;s commission, finder&#8217;s fee, investment banker&#8217;s fee or similar payment in connection with the transactions contemplated by this Agreement.</font></div><div style="margin-top:11.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.6  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Investment Representation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser is acquiring the Shares for its own account with the present intention of holding such securities for investment purposes and not with a view to, or for sale in connection with, any distribution of such securities in violation of federal or state securities Laws. Purchaser is an &#8220;accredited investor&#8221; within the meaning of Rule 501(a) of Regulation D under the United States Securities Act of 1933 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Purchaser understands that the Shares have not been registered under the Securities Act or any state securities Laws and are being transferred to Purchaser, in part, in reliance on the foregoing representations and warranties.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.7  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Sufficient Funds</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. As of the date of this Agreement, Purchaser has and, as of the Closing Date and as of immediately prior to the time any post-Closing payment obligation becomes due and payable hereunder (including any Milestone Payments and any payments under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> hereof), Purchaser will have sufficient cash or existing available borrowing capacity under committed borrowing facilities in immediately available funds to enable Purchaser to timely perform its obligations hereunder, including all such post-Closing payment obligations. In no event will the receipt of any funds or financing by, or availability of any funds or financing to, Purchaser or any of its Affiliates be a condition to any of Purchaser&#8217;s obligations hereunder.</font></div><div style="margin-top:11pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.8  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. There are no Proceedings pending against, or, to the knowledge of Purchaser, threatened against or affecting, Purchaser before any court or arbitrator or any Governmental Authority which in any manner challenge or seek to prevent, enjoin, alter or materially delay the transactions contemplated by this Agreement.</font></div><div style="margin-top:12.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Non-Reliance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Purchaser represents and acknowledges and agrees that it has conducted its own independent review, investigation and analysis into and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of the Company.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Purchaser represents and acknowledges that (i) Purchaser has relied solely upon its own review, investigation and analysis and the representations and warranties expressly set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article III</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IV</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> (ii) except for the representations and warranties expressly set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article III</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IV</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> none of Seller, the Company, any of their Affiliates, or any of the respective officers, partners, directors, managers, employees, agents, representatives, Affiliates, direct or indirect shareholders of any of the foregoing or any other Person makes or has made any representation or warranty to Purchaser or any other Person, written or oral, express or implied, at law or in equity, as to any matter whatsoever relating to Seller, the Company or any other matter relating to the transactions contemplated hereby including (A) as to the operation of the Business after the Closing, (B) as to the accuracy or completeness of any of the information provided or made available to Purchaser or any of its directors, officers, employees, partners, members, managers, shareholders, agents, representatives, lenders or Affiliates,</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">with respect to any due diligence materials or any presentation by management or others in connection with the transactions contemplated hereby, or (D) with respect to any projections, forecasts, estimates, plans or budgets of future revenues, expenses or expenditures, future results of operations (or any component thereof), future cash flows (or any component thereof) or future financial condition (or any component thereof) of the Company (collectively, the &#8220;Extra-Contractual Statements&#8221;), and (iii) Purchaser has not been induced by and has not relied on any Extra-Contractual Statement.</font></div><div style="margin-top:11.95pt;padding-left:66.12pt;padding-right:66.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE VI</font></div><div style="margin-top:0.2pt;padding-left:66.15pt;padding-right:66.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">COVENANTS OF THE COMPANY AND SELLER</font></div><div style="margin-top:10.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 6.1   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Reasonable Access</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> during the period between the date of this Agreement and the earlier to occur of the termination of this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XI</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or the Closing (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Pre-Closing Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), the Company will (a) give reasonable access to Purchaser&#8217;s duly authorized managers, directors, officers, employees, agents, attorneys, consultants, accountants and lenders during normal business hours of the Company, upon advance written notice, to the properties, books, contracts, documents, insurance policies, records and senior management reasonably requested by or on behalf of Purchaser, and (b) furnish to Purchaser and such representatives of Purchaser as Purchaser may from time to time designate in writing to the Company such information as Purchaser or such Persons may at any time and from time to time reasonably request&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that such access may not unreasonably disrupt the business or operations of the Company or its Affiliates. Notwithstanding anything to the contrary in this Agreement, the Company will not be required to (i) provide any information or access that the Company believes on the advice of counsel would (A) violate any Law, including any Antitrust Law, (B) violate the terms of any confidentiality obligation, or (C) forfeit any attorney&#47;client or other legal privilege (it being understood and agreed that, in each case, the Company will use commercially reasonable efforts to provide alternative means of disclosing such information to the extent reasonably practicable), or (ii) conduct, or permit Purchaser or any of its representatives to conduct, any environmental soil or groundwater investigation relating to any real property owned by or leased to the Company without the prior consent of the Company.</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 6.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Operation of the Business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. During the Pre-Closing Period, the Company and Seller will, except (a) as otherwise required by this Agreement or any other Transaction Document, (b) as otherwise required by Law, (c) as disclosed on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.2 of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, or (d) for actions consented to by Purchaser (which consent will not be unreasonably withheld, conditioned, or delayed) (subclauses (a) through (d), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Interim Operating Carveouts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), use its commercially reasonable efforts to (i) carry on the Business in the ordinary course of business and (ii) preserve substantially intact its present business organization, in all material respects. Notwithstanding the foregoing, nothing contained in this Agreement will prohibit the Company, whether or not in the ordinary course of business, to pay or prepay any obligation or to pay, transfer, dividend, or distribute to Seller any cash that may be lawfully paid, transferred, dividend or distributed to Seller.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 6.3  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Actions Outside the Ordinary Course</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. During the Pre-Closing Period, the Company and&#47;or the Business, as applicable, will not take or agree to take any of the following actions, in each case, except for the Interim Operating Carveouts&#58;</font></div><div style="margin-top:12.2pt;padding-left:125.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.75pt">amend its Governing Documents&#59;</font></div><div style="margin-top:11.85pt;padding-left:125.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.13pt">(i) make any change in its authorized Equity Securities or (ii) issue any Equity</font></div><div style="padding-left:18pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Securities&#59;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">sell or transfer any material portion of its assets or property, except for sales of inventory, dispositions of obsolete equipment and transfers of cash in payment of accrued expenses and accounts payable due and owing, all in the ordinary course of business&#59;</font></div><div style="margin-top:11.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">incur, assume or guarantee any material amount of indebtedness for borrowed money, other than draws under existing credit facilities&#59;</font></div><div style="margin-top:11.5pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">make any capital expenditure that causes the aggregate amount of all capital expenditures by the Company during the Pre-Closing Period to exceed $500,000&#59;</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.07pt">make any increase in the bonus, salary or other compensation of or enter into or amend any agreement with any of its officers or employees outside the ordinary course of business&#59;</font></div><div style="margin-top:12pt;padding-left:125.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.13pt">except as required by applicable Law, institute or make any amendment to any</font></div><div style="margin-top:0.05pt;padding-left:17.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Benefit Plan&#59;</font></div><div style="margin-top:11.95pt;padding-left:125.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.18pt">amend, terminate or otherwise modify any Material Contract&#59;</font></div><div style="margin-top:12.1pt;padding-left:125.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:25.63pt">cancel, terminate or fail to renew any Permit&#59; or</font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">settle or compromise any claim, other than settlements or compromises involving solely money damages not in excess of $500,000.</font></div><div style="margin-top:11.5pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 6.4  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. During the Pre-Closing Period, neither Seller nor the Company will solicit, initiate or engage in discussions with, or enter into any legally binding written agreement with, any Person (other than Purchaser, its Affiliates, and their respective agents or representatives) concerning any Acquisition Proposal&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that any representative of Seller or the Company may respond to unsolicited inquiries or offers for the purpose of communicating that Seller or the Company is not able to entertain such unsolicited inquiry or offer&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that Purchaser acknowledges that, before the date of this Agreement, Seller, the Company and their respective Affiliates, and their respective agents have provided information relating to the Company and have afforded access to, and engaged in discussions with, other Persons in connection with Acquisition Proposals and that such information, access, and discussions could reasonably enable another Person to form a basis for an Acquisition Proposal without any breach by Seller or the Company of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.25pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:125.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.75pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:25.58pt">Seller acknowledges and agrees that (A) the success of the Company and the Business after the Closing depends upon the continued preservation of the confidentiality of the Confidential Information by Seller, (B) the preservation of the confidentiality of the Confidential Information by Seller is an essential premise of the bargain between such Seller and Purchaser, and (C) Purchaser would be unwilling to enter into this Agreement in the absence of the obligations and restrictions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article VI</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> Accordingly, Seller hereby agrees with Purchaser that Seller, and its Controlled Affiliates and Representatives, will not, and that Seller will cause its Controlled Affiliates and Representatives not to, at any time on or after the Closing Date, directly or indirectly, without </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the prior written consent of Purchaser, use, disclose, communicate or otherwise divulge, any Confidential Information. Notwithstanding the foregoing, (x) the information subject to the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will not include any information generally available to, or known by, the public (other than as a result of disclosure in violation hereof) and (y) the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will not prohibit any disclosures (A) required by any applicable Law so long as reasonable prior notice is given to Purchaser of such disclosure and a reasonable opportunity is afforded to Purchaser or the Company to contest the same (to the extent permitted by Law), (B) made in connection with the enforcement of any right or remedy relating to this Agreement, any Transaction Document, or the transactions contemplated herein or therein, (C) made in connection with the performance by Seller or its Controlled Affiliates of any obligations arising under this Agreement, any Transaction Document, or the transactions contemplated herein or therein (including, without limiting the foregoing, disclosures made to investigators, research partners, key opinion leaders, or other third parties participating in collaborative research arrangements or investigator-initiated trials, in each case, to the extent necessary for the conduct of such research, collaboration, or trial) or (D) made to Representatives of Seller or its Controlled Affiliates on a need-to-know basis in connection with (1) the preparation of financial statements, Tax Returns, and other regulatory or compliance filings of Seller or its Controlled Affiliates, (2) post-Closing recordkeeping and accounting obligations of Seller or its Controlled Affiliates, or (3) any other post-Closing obligations of Seller arising under applicable Law&#59; provided that Seller shall be responsible for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> by any such Representative with respect to such disclosed Confidential Information.</font></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:22.53pt">The obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> and Purchaser&#8217;s rights and remedies with respect thereto, shall remain in full force and effect for a period of ten (10) years following the Closing Date&#59; provided that, if the Confidential Information loses its confidential nature through any act or omission of Seller (including any breach of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">), the obligations with respect to such Confidential Information shall continue until the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">) anniversary of the Closing Date regardless of such loss of confidentiality. To the extent this Agreement is being enforced in a jurisdiction that requires a time restriction for non-disclosure restrictions applicable to information that does not rise to the level of a statutory trade secret, the time restriction for the obligations in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> with respect to such information that does not qualify as a statutory trade secret shall be ten (10) years following the Closing Date.</font></div><div style="margin-top:11.1pt;padding-left:125.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.13pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:25.58pt">From the Closing Date until the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">) anniversary of the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), no Restricted Party shall, directly or indirectly, engage in, own, manage, operate or control, a Restricted Business in the Restricted Area. Notwithstanding the foregoing, nothing </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">in this Agreement or in the definition of Restricted Business shall prohibit or in any way restrict a Restricted Party from (A) making or maintaining passive investments of less than five percent (5%) of the outstanding equity securities in any entity engaged in the Restricted Business listed for trading on any recognized securities exchange or in the over-the-counter markets, (B) owning, managing, operating or otherwise engaging in any pharmaceutical business that is ancillary or complementary to a Restricted Business but does not constitute a Restricted Business, (C) fulfilling any contractual obligations of any Restricted Party or any of its Affiliates existing as of the Closing Date or arising under this Agreement or any Transaction Document, or (D) acquiring the equity securities or assets of any Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Acquired Entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) that engages in a Restricted Business, so long as (x) at the time of such acquisition, less than five percent (5%) of the consolidated revenues of the Acquired Entity and its subsidiaries for the most recently completed fiscal year prior to such acquisition are derived from activities that would be prohibited by this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, (y) at the time of such acquisition the Acquired Entity is in the development stage and has not yet achieved any revenue and (z) from and after the closing of such acquisition and for the remainder of the Restricted Period, none of the Restricted Parties shall, and the Restricted Parties shall cause their Affiliates and the Acquired Entity not to, (i) make any additional investment of capital (including capital expenditures, marketing spend, or R&#38;D expenditures) in, (ii) expand, develop or otherwise grow, or (iii) actively promote or solicit new business for, any portion of the Acquired Entity&#8217;s business that constitutes a Restricted Business (collectively, such Restricted Business of an Acquired Entity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">De Minimis Business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; provided that the foregoing shall not prohibit maintenance of existing operations of the De Minimis Business in the ordinary course as conducted as of the acquisition date.</font></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:22.53pt">Each Restricted Party hereby acknowledges and agrees that the restrictive period of time, geographic scope and scope of restricted activity specified herein are reasonable and necessary in view of the transactions contemplated by this Agreement and the nature of the business in which the Company was engaged or is engaged as of the Closing. Each Restricted Party further acknowledges and agrees that the restrictions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> are reasonable and necessary to protect Purchaser&#8217;s investment under this Agreement and to safeguard the value and goodwill associated with the Shares. Each Restricted Party acknowledges and agrees that Purchaser would not have entered into this Agreement but for each Restricted Party&#8217;s agreements and obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> to protect such value and goodwill. If the scope of any stated restriction is too broad to permit enforcement of such restriction(s) to its full extent, then the Parties agree that such restriction shall be enforced and&#47;or modified to the maximum extent permitted by Law. The Parties agree that in the event of a breach of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:161.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">6.5(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, the Restricted Period shall be extended with respect to the breaching party by the period of the breach.</font></div><div style="margin-top:11pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. During the Restricted Period, no Restricted Party shall, whether for its own account or for the account of any Person, directly or indirectly&#58;</font></div><div style="margin-top:12.05pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.68pt">intentionally cause or induce any customer, supplier, licensee, licensor, franchisee, distributor, or other Person who is a business relation of the Company as of immediately prior to the Closing or who was a customer, supplier, licensee, licensor, franchisee, distributor, or business relation of the Company within the twelve (12) month period immediately preceding the Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Non-Solicit Business Relations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), to reduce or cease doing business with the Company, or otherwise intentionally interfere in any fashion with the operations of the Business or the Company&#59; provided, however, that no Restricted Party shall be deemed to have violated this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> by reason of marketing, selling or otherwise commercializing any products or services to Non-Solicit Business Relations that do not constitute a Restricted Business and that do not violate </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (provided, further, that for the avoidance of doubt, the De Minimis Business shall be expressly excluded from the scope of this proviso, and any activities undertaken in connection therewith shall be restricted or prohibited by this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(c)(i))</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#59; or</font></div><div style="margin-top:12pt;padding-left:53.95pt;padding-right:18pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.63pt">solicit for employment, hire or retain any Person who is an employee, independent contractor or other Personnel of the Company as of the Closing, or who was an employee, independent contractor or other Personnel of the Company at any time within the six (6) month period immediately preceding the Closing&#59; provided that, it shall not be a breach of this clause (iii) for such Restricted Party to post general solicitations or advertisements for employees or contractors so long as such general solicitations or advertisements are not specially directed to Personnel of the Company and no hiring or retaining results therefrom.</font></div><div style="margin-top:10.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Seller hereby acknowledges and agrees that the restrictive period of time, geographic scope and scope of restricted activity specified herein are reasonable and necessary in view of the transactions contemplated by this Agreement and the nature of the business in which the Company was engaged or is engaged as of the Closing. Seller further acknowledges and agrees that the restrictions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5(c)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> are reasonable and necessary to protect Purchaser&#8217;s investment under this Agreement and to safeguard the value and goodwill associated with the Shares. Each Seller Party acknowledges and agrees that Purchaser would not have entered into this Agreement but for Seller&#8217;s agreement and obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> to protect such value and goodwill. If the scope of any stated restriction is too broad to permit enforcement of such restriction(s) to its full extent, then the parties agree that such restriction shall be enforced and&#47;or modified to the maximum extent permitted by Law.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. For a period of ten (10) years following the Closing, each of Seller and Purchaser shall not, and shall cause their respective Controlled Affiliates not to, directly or indirectly, make any disparaging statement, or release any information that has the effect of disparaging</font></div><div style="padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i) in the case of Seller, the Company, Purchaser or any of their respective Affiliates, the Business, the products offered or provided in the Business, or (ii) in the case of Purchaser, Seller or any of its Controlled Affiliates, or any business or products of Seller or its Controlled Affiliates (for avoidance of doubt, other than the Business), in each case including any statements made to the press or other media in </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the United States of America or in any other country. Notwithstanding the foregoing, nothing herein shall limit any truthful statements made in connection with a Proceeding or otherwise required pursuant to applicable Law.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Upon any breach or alleged breach of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> by Seller, Purchaser and&#47;or the Company shall be entitled to each of the following remedies, which shall be deemed cumulative&#58;</font></div><div style="margin-top:11.6pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.63pt">Seller hereby acknowledges that any breach or threatened breach of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall cause irreparable injury to the goodwill and proprietary rights of the Company and Purchaser, for which the Company and Purchaser shall not have an adequate remedy at law. Accordingly, Seller agrees that the Company and&#47;or Purchaser shall be able to seek and obtain immediate injunctive relief in the form of a temporary restraining order, preliminary injunction, and&#47;or permanent injunction against Seller to restrain or enjoin any actual or threatened violation of any provision of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> without any requirement of posting a bond or other surety or proving damages.</font></div><div style="margin-top:11.05pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.58pt">To the extent calculable, the Company and&#47;or Purchaser shall also be entitled to recover from Seller monetary damages for any violation of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.05pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:1.58pt">The Company and&#47;or Purchaser shall be entitled to recover from Seller all costs, expenses and reasonable attorneys&#8217; fees incurred by them in seeking either enforcement of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 6.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or damages for a breach of such Sections or in defending any action brought by Seller to challenge or construe the terms of any of such Sections.</font></div><div style="margin-top:10.95pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.18pt">The Company and&#47;or Purchaser shall be entitled to pursue any other legal or equitable remedies that may be available to them.</font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:18pt;text-align:justify;text-indent:53.95pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 6.6  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Effective upon the Closing, each of Seller, on behalf of itself and its past, present or future successors, assigns, employees, agents, Controlled Affiliates and representatives (including their past, present or future officers and directors) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Releasors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) irrevocably and unconditionally releases, waives, acquits and forever discharges Purchaser, the Company, their Affiliates, and their respective successors, assigns, directors, managers, officers, employees and agents of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Releasees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), at or before the Closing, of and from any and all actions, suits, claims, causes of action, damages, accounts, liabilities and obligations (including attorneys&#8217; fees) held by any Seller Releasor, whether known or unknown, matured or unmatured, suspected or unsuspected, liquidated or unliquidated, absolute or contingent, direct or derivative, solely to the extent arising out of or relating to Seller&#8217;s capacity as a current or former owner of the Shares, the operation of the Business, or such Seller Releasee&#8217;s service, as applicable, as a director, manager or officer of the Company or the Seller Group, except for any of the foregoing set forth in, under or arising out of (i) any Transaction Document or the transactions contemplated by any Transaction Document, (ii) any claim that cannot be waived or released by applicable Law, (iii) any claim for Fraud by any Releasee, (iv) any rights or claims arising under any commercial agreement, arrangement or relationship with any Releasee entered into in the ordinary course of business, (v) in the case of a Covered Person, any claims with respect to indemnification, advancement of expenses and exculpation by the Company of the Covered Persons and (vi) any claims arising out of the fact that a Seller Releasor is or was a director, manager, or officer with respect to any directors&#8217; and officers&#8217; liability insurance maintained by the Company or its Affiliates immediately prior to the Closing Date (all collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Released Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The foregoing release </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">of Seller Released Claims are intended to be effective as a general release of, and bar to, all such claims, whether presently known or unknown. Accordingly, each party waives any and all rights and benefits under, or equivalent to, Section 1542 of the Civil Code of the State of California, which states as follows&#58;</font></div><div style="margin-top:10.95pt;padding-left:53.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#8221;</font></div><div style="margin-top:11.55pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Seller for itself and the other Seller Releasors, expressly acknowledges that it, he or she may later discover claims or facts in addition to or different from those which it or the respective Seller Releasor now knows or believes to exist with respect to the subject matter of this Agreement and which, if known or suspected at the time of executing this Agreement, might have materially affected its terms, but nevertheless hereby waives any claim that might arise as a result of such different or additional claims or facts.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">COVENANTS OF PURCHASER</font></div><div style="margin-top:10.85pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Contact with Business Relations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser acknowledges that it is not authorized to, and agrees that it will not, and it will not permit any member of the Purchaser Group to, contact any officer, director, manager, employee, client, patient, payor, supplier, vendor, referral source, lessee, lessor, shareholder, lender, noteholder or other material business relation of the Company or its Affiliates before the Closing with respect to the Company, the Business or the transactions contemplated by this Agreement, in each case, without receiving the prior written consent of the Company before each such contact.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transfer of Permits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. If any Permit (excluding any &#8220;CE&#8221; marking certifications) of any Seller Group Entity must be reissued to any Person to operate its business following the Closing because of the transactions contemplated by this Agreement, then Purchaser will use commercially reasonable efforts (and the Company will reasonably cooperate with Purchaser) to obtain such Permit&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the Seller Group Entities will not be required to make any payment to any third party with respect to Purchaser&#8217;s efforts to obtain any Permit unless Purchaser pays or reimburses the relevant Seller Group Entity for any such payment.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 5.3   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Liability Insurance and Indemnification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.8pt">&#91;Reserved&#93;</font></div><div style="margin-top:11.8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">For a period of six (6) years after the Closing Date, Purchaser will cause the Company to maintain on terms no less favorable than the current terms, and to honor in accordance with such terms, the provisions of the Governing Documents of the Company as in effect on the date of this Agreement and the provisions of any other agreements in effect on the date of this Agreement set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.3 of the Disclosure Schedules</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> with respect to indemnification, advancement of expenses and exculpation by the Company of the Covered Persons, it being the intent of the Parties that the Covered Persons will continue to be entitled to such exculpation, indemnification, and advancement of expense to the fullest extent of the Law.</font></div><div style="margin-top:12.1pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Effective upon the Closing, Purchaser and the Company each irrevocably and unconditionally releases, waives, acquits and forever discharges, on behalf of itself and the Company, any </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.1pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">claims that the Company currently has or, in the future, may have against Seller or Seller&#8217;s direct or indirect shareholders, partners, directors, managers, officers, trustees, employees or the representatives for any of such Person&#8217;s actions or omissions in his, her or its capacities as officers, directors or managers of the Company with respect to claims arising out of or relating to events which occurred on or prior to the Closing Date.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> are (a) intended to be for the benefit of, and will be enforceable by, each Person entitled to indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, and each such Person&#8217;s heirs, legatees, representatives, successors, and assigns (and the Parties expressly agree that such Persons will be third party beneficiaries of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">), (b) in addition to, and not in substitution for, any other rights to indemnification that any such Person may have by contract or otherwise and (c) will survive the consummation of a transaction involving the merger, consolidation or other reorganization of the Company and continue in full force and effect and binding against the survivor of any such transaction or successor to the Company. In the event Purchaser, the Company or any of its respective successors or assigns (i) consolidates with or merges into any other Person and will not be the continuing or surviving corporation or entity in such consolidation or merger or (ii) transfers all or at least a majority of its properties and assets to any Person, then Purchaser will cause proper provision to be made so that the successors and assigns of Purchaser or the Company, as the case may be, will assume all of the obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">7.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.1pt;padding-left:54pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.5   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Labor Matters</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:4.05pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.8pt;text-decoration:underline">Business Employees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> For purposes hereof, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Business Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; means each individual listed on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5 of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Between the date of this Agreement and the Closing Date, Purchaser or one of its Affiliates shall offer employment, effective as of the Closing and on terms and conditions consistent with this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> to each Business Employee who is not an Inactive Employee. With respect to each Business Employee who is an Inactive Employee as of the Closing Date and who returns to work within one hundred eighty (180) days after the Closing Date, or such longer period as may be required by applicable Law, Purchaser or one of its Affiliates will make an offer of employment to such Inactive Employee, with such offer to be on terms and conditions consistent with this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> Each Business Employee who accepts Purchaser&#8217;s or its Affiliate&#8217;s offer of employment and commences work for Purchaser or such Affiliate shall be referred to hereafter as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transferred Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;. Seller shall cooperate with Purchaser and support Purchaser&#8217;s offers to hire the Business Employees as reasonably requested by Purchaser. Seller shall terminate the employment of all Transferred Employees who are not Inactive Employees effective as of the Closing.</font></div><div style="margin-top:12pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.18pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.8pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.68pt">As of the Closing Date, and for a period of at least twelve (12) months thereafter, Purchaser and its Subsidiaries and Affiliates (including the Company following the Closing) will provide each Transferred Employee with (A) an annual base salary or an hourly wage rate, as applicable, that is not less than that provided to such Transferred Employee by the Company or its Affiliates immediately prior to the Closing, (B) incentive compensation opportunities that are no less favorable, in the aggregate, to </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.8pt;padding-left:89.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">those provided to such Transferred Employee by the Company or its Affiliates immediately prior to the Closing, and (C) employee benefits that are not less favorable in the aggregate than those provided to similarly situated employees of Purchaser or its Subsidiary or Affiliate that employs the Transferred Employee&#59; provided, however, that Purchaser or any Affiliate of Purchaser may, in its sole discretion, change other terms or conditions of employment of Business Employees at any time after Closing, and Purchaser or any Affiliate of Purchaser may terminate the employment of any Business Employee, at any time after Closing.</font></div><div style="margin-top:11pt;padding-left:89.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.63pt">Purchaser and its Subsidiaries and Affiliates (including the Company following the Closing) will use commercially reasonably efforts to treat and cause each benefit plan, program, practice, policy and arrangement maintained by Purchaser or its applicable Subsidiary or Affiliate (including the Company following the Closing) following the Closing in which any Transferred Employee (or the spouse, domestic partner or any dependent of any Transferred Employee) participates or is eligible to participate (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) to treat, for all purposes (including determining eligibility to participate, vesting, and level of benefits), all service with the Company and its Affiliates (or predecessor employers to the extent that the Company, any of its Affiliates or any Benefit Plan provides past service credit) as service with Purchaser and its Subsidiaries and Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that such service need not be taken into account to the extent it would result in duplication of benefits or was not taken into account for such purposes under the corresponding Benefit Plan, and further provided that Seller and the Company have provided or made available to Purchaser the data necessary and in the format required to allow Purchaser to satisfy such requirements.</font></div><div style="margin-top:11.05pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:1.53pt">Purchaser and its Subsidiaries and Affiliates (including the Company following the Closing) will use commercially reasonably efforts to cause each Purchaser Plan that is a welfare plan, within the meaning of Section 3(1) of ERISA, (A) to waive any and all eligibility waiting periods, actively-at-work requirements, evidence of insurability requirements, pre-existing condition limitations and other exclusions and limitations with respect to the Transferred Employees and their spouses, domestic partners and dependents to the extent waived, satisfied or not applicable under the corresponding Benefit Plan, and (B) to recognize for each Transferred Employee for purposes of applying annual deductible, co-payment and out-of-pocket maximums under such Purchaser Plan any deductible, co-payment and out-of-pocket expenses paid by such Transferred Employee and his or her spouse, domestic partner and dependents under the corresponding Benefit Plan during the plan year of such Benefit Plan in which occurs the later of the Closing Date and the date on which such Transferred Employee first becomes eligible to participate in such Purchaser Plan, provided that Seller and the Company have provided or made available to Purchaser the data necessary and in the format required to allow Purchaser to satisfy such requirements.</font></div><div style="margin-top:12pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:2.13pt">At Closing, each of the Transferred Employees set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule 7.5(b)(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall be granted the right to receive cash transaction bonuses in the amounts and on the dates set forth opposite their names on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule 7.5(b)(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The aggregate amount of the foregoing cash transaction bonuses shall not exceed $2,200,000. The aggregate amount of the foregoing bonuses </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">plus </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">the employer portion of any payroll, employment or similar Taxes payable in respect of such bonuses is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transaction Bonus Amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> is intended to, or will be construed to, (A) confer upon any Transferred Employee or any other Person other than the Parties to this Agreement any rights or remedies hereunder, including the right to continued employment or (B) establish, amend or be deemed to establish or amend any Benefit Plan or any benefit plan, program, policy or arrangement of Purchaser or any of its Subsidiaries or Affiliates or limit the rights of the Company, Purchaser or any of their respective Subsidiaries or Affiliates to establish, amend or terminate any Benefit Plan or any other benefit plan, program, policy or arrangement, whether before or after Closing, except, in the case of this clause (B), to the extent required to satisfy Purchaser&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.6  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser will be bound by and comply with the Confidentiality Agreement as if Purchaser was an original party to such agreement. The Confidentiality Agreement is incorporated into this Agreement by reference and made a part of this Agreement and will survive the execution of this Agreement notwithstanding any terms to the contrary set forth therein. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will terminate upon the Closing or, if this Agreement is terminated under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XI</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> then in accordance with the terms of the Confidentiality Agreement.</font></div><div style="margin-top:11.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Other Applications</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Following Closing, Purchaser shall use its commercially reasonable efforts, during the Milestone Period, to engage and license to a third party the spine application of the Intellectual Property of the Business solely for use in the spinal field (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Spine License</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Purchaser shall pay Seller twenty-five percent (25%) of any upfront and milestone consideration paid to Purchaser or its Affiliates (including the Company), plus an additional payment equal to 7.5% of net sales of Purchaser (or its Affiliates) to the licensee of the Spine License (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Additional Spine Consideration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), until the ten (10) year anniversary of Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Spine Consideration and Royalty Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Purchaser shall provide reasonable supporting detail with respect to the calculation of each of the components of net sales (including, without limitation, the Supporting Detail, to the extent applicable) with respect to the Spine License, to the extent any such net sales exist.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Once per calendar year during the Spine Consideration and Royalty Period, Seller (or its designated representative) shall have the right, upon reasonable prior written notice, to inspect Purchaser&#8217;s books and records to the extent necessary to verify the payments due to Seller pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.7</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, and Purchaser shall make available personnel responsible for preparing, or qualified and knowledgeable regarding, the calculations of net sales, and to meet with Seller or its representatives and discuss such calculations and the supporting detail delivered in connection therewith. Such inspection shall be conducted during normal business hours and at Seller&#8217;s expense. Any inspection permitted under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.7(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> is strictly limited to reviewing only the documents necessary to verify the accuracy of the calculation of net sales and each component thereof (including, without limitation, the Supporting Detail, to the extent applicable). </font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">If following such inspection, Seller does not agree with Purchaser&#8217;s calculation of net sales, then Purchaser and Seller shall negotiate in good faith to resolve any disagreement. If Purchaser and Seller, notwithstanding such good faith effort, fail to resolve the disagreement within thirty (30) days following the inspection, the dispute shall be resolved in accordance with the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The net sales calculation (as modified by the Accounting Expert) shall be final, binding, and conclusive upon the Parties hereto.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">The Additional Spine Consideration shall be calculated on a quarterly basis and Purchaser shall make such payment to Seller within forty-five (45) days of the end of the quarter in which the payment was received by Purchaser.</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Purchaser shall provide Seller written notice within ten (10) Business Days following the execution of any sublicense agreement with respect to a Spine License, together with a summary of the material economic terms thereof.</font></div><div style="margin-top:11.6pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.8  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Spasticity License</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Promptly following the date of this Agreement the Parties shall collaborate on the spasticity application of the Business Products on the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Schedule 7.8</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Spasticity Application</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The Parties shall use commercially reasonable efforts to</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i) finalize such terms prior to Closing on terms mutually agreeable to the Parties and (ii) enter into a definitive agreement reflecting such terms prior to Closing, including, with respect to clause (i), in the case of Seller, incurring expenses in an amount of up to the Spasticity Collaborative Adjustment Amount to support, and in furtherance of the Spasticity Application.</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 7.9  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Marks</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser shall, and shall cause the Company to (a) as soon as practicable after the Closing Date, cease all use of any and all trademarks, service marks, business names or domain names (other than the Transferred Domains) owned by Seller or any of its Affiliates (other than the Company), including, for the avoidance of doubt, any and all trademarks that include the word &#8220;Pacira&#8221; or any words or acronyms confusingly similar thereto (whether independently or in combination with any other sign, word, or name) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Marks</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), including by removing the Seller Marks from any and all assets, advertisements, communications, website content, other internet or electronic communications and other documents and materials of the business of the Company (provided that the foregoing shall not require the destruction or modification of materials that cannot be reasonably accessed or modified or that are retained solely for archival, legal, or compliance purposes) and (b) within sixty (60) days after the Closing Date pass all necessary resolutions and take all other necessary actions to cancel any corporate name or business name registrations, and change the Company&#8217;s corporate name, business name and any other trade or services marks to a name that does not include any Seller Mark. Notwithstanding anything herein to the contrary, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.9</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall prohibit Purchaser or any of its Affiliates from (A) making truthful statements required by applicable Law, regulation, or legal process, (B) using the Seller Marks in a descriptive or historical manner that does not suggest affiliation with Seller, (C) defending itself in any Proceeding initiated by Seller or any of its Affiliates relating to the Seller Marks, (D) using the Seller Marks to the extent required pursuant to the terms of the Transition Services Agreement, including using the Seller Marks solely to the extent required by the applicable European Governmental Authority or as part of the Medical Device Regulation (MDR) framework to maintain existing CE marking certifications for the Business Products during the relevant term of the Service, (E) selling or otherwise disposing of Inventory acquired from Seller or manufactured by Purchaser as contemplated by the Transition Services Agreement and having a label bearing one or more of the Seller Marks until such Inventory is sold or otherwise disposed of or the label is changed to a Purchaser label following the transfer of manufacturer of record status to Purchaser, and for no other commercial, marketing, or promotional purpose or (F) continuing to use schematics, plans, manuals, drawings, machinery, datasheets, tooling (including hand tools), and the like of the Business solely to the extent that such instrumentalities are used internally in the ordinary operation or conduct of the Business and are not used or disseminated in any external, customer-facing or public-facing manner (whether as advertisements to the public for use as means to effectuate or enhance sales or otherwise), and with respect to the Business Products, tangible parts and tangible components of such Business Products, only to the extent any Seller Mark is not visible to end consumers in the ordinary course of use and is not used for commercial or promotional purposes.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">JOINT COVENANTS</font></div><div style="margin-top:10.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 8.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Governmental Consents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Parties will use commercially reasonable efforts, and will cooperate, to obtain the consents, deliver the notices and making all necessary applications and filings with any Governmental Authority required to consummate the transactions contemplated hereby that are set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.1 of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that neither Seller nor the Company will be obligated to pay any consideration to any such Governmental Authority from whom consent or approval is requested (other than </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">de minimis </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">amounts). In furtherance of the foregoing, Purchaser agrees to use commercially reasonable efforts to provide reasonable assurances as to financial capability, resources, creditworthiness or other qualifications as may be reasonably requested by any Person whose consent or approval is sought hereunder.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 8.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Efforts to Consummate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Without limitation of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> during the Pre-Closing Period, each of the Parties will use commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to expeditiously satisfy the closing conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IX</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and consummate the transactions contemplated by this Agreement and the other Transaction Documents as soon as practicable. During the Pre-Closing Period, none of the Parties will intentionally perform any act that, if performed, or intentionally omit to perform any act that, if omitted to be performed, would prevent or excuse the performance of this Agreement by any Party or that would allow a Party to terminate this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.1(c)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.1(d).</a>Inspection of Records</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">For a period of six (6) years following the Closing Date (or such longer period as may be required by applicable Law), each of Purchaser, on the one hand, and Seller, on the other hand (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Requesting Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), shall, and shall cause its Controlled Affiliates to, provide the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Responding Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and its Representatives with reasonable access, during normal business hours and upon reasonable advance notice, to the books, records and personnel of the Requesting Party and its Controlled Affiliates to the extent relating to the Business or the Company for periods prior to or concurrent with the Closing Date, in each case as reasonably necessary in connection with (i) the preparation of Tax Returns or financial statements, (ii) the conduct of any audit, examination or Proceeding, (iii) the enforcement of rights under this Agreement or any other Transaction Document, or (iv) any other reasonable business purpose relating to the Business or the Company.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">The Requesting Party shall bear all of its out-of-pocket costs and expenses incurred in connection with any such access and shall, and shall cause its Representatives to, comply with the Responding Party&#8217;s reasonable security measures and policies. Such access shall not unreasonably interfere with the business or operations of the Responding Party or its Affiliates.</font></div><div style="margin-top:11.65pt;padding-left:125.95pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.8pt">Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font></div><div style="margin-top:11.95pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.68pt">the Responding Party shall not be required to provide access to any information to the extent such access would reasonably be expected to (A) waive any attorney-client privilege, work product doctrine or other applicable privilege, (B) violate applicable Law or any binding agreement with a third party, or (C) breach any confidentiality obligation&#59; provided that the Responding Party shall use commercially reasonable efforts to permit access in a manner that does not result in such waiver, violation or breach&#59; </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:90pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:4.63pt">and nothing in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall require the disclosure of information relating to the negotiation of this Agreement or any other Transaction Document, except to the extent necessary for enforcement thereof.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Each Party agrees to maintain, and cause its controlled Affiliates and Representatives to maintain, the confidentiality of any information obtained pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and to use such information only to the extent and for the purpose expressly permitted under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Seller shall retain, and shall cause its Controlled Affiliates to retain, all books and records relating to the Business or the Company for periods prior to the Closing Date for at least six (6) years following the Closing Date (or such longer period as required by applicable Law). Purchaser shall retain, and shall cause the Company to retain, such books and records for periods after the Closing Date in accordance with its standard record retention policies&#59; provided that Purchaser shall not destroy any such records within such six (6)-year period without first providing Seller reasonable prior written notice and an opportunity to obtain copies at Seller&#8217;s expense.</font></div><div style="margin-top:12pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">From and after the Closing, each Party will, and will cause their respective Controlled Affiliates and representatives to, maintain the confidentiality of this Agreement and the terms thereof. The Parties will not, and will cause each of their Affiliates not to, issue or cause the publication of any press release or other public announcement with respect to this Agreement or the transactions contemplated hereby except with the prior agreement of Seller and Purchaser (and the Parties will use commercially reasonable efforts to consult and agree with each other regarding the content of any press release or other public announcements), and no such disclosure will contain any financial terms related to the transactions contemplated hereby.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> (i) any Party may, without the prior consent of the other Parties, issue or cause the publication of any press release, public announcement or disclosure to the extent that such Party reasonably determines such action to be required by Law, in which event such Party will use its commercially reasonable efforts to allow the other Parties hereto reasonable time to comment on (or block or otherwise seek a protective order or other appropriate remedy regarding) such press release, public announcement or disclosure in advance of its issuance and such press release, public announcement or disclosure will only contain such information that the disclosing party was required by Law to disclose&#59; (ii) the Parties may make disclosures to their respective directors, managers, officers, employees, consultants, advisors, counsel, accountants, auditors and other representatives as necessary in connection with the ordinary conduct of their respective businesses or as necessary to assist such Party in exercising its rights or satisfying and performing its covenants and obligations under this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the provisions of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.4(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will apply to such directors, managers, officers, employees, consultants, advisors, counsel, accountants, auditors and other representatives and the Party disclosing such information will be responsible for any breach of the provisions hereof by them&#59; (iii) Seller or any of its Affiliates may disclose to its current, former or prospective partners, members, investors or other direct or indirect shareholders who are affiliated with investment funds of Seller&#8217;s Affiliates and their respective representatives, as applicable, the terms of the transactions contemplated hereby, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the recipient of such information is subject to confidentiality obligations&#59; and (iv) the Company may make any announcement to its employees, members, shareholders, customers, investigators, key opinion leaders, or other business relations, in each case, that the Company reasonably believes is required or desirable.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.2pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Further Assurances&#59; Shared Contracts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) From time to time following the Closing, Seller and Purchaser shall, and shall cause their respective Controlled Affiliates to, execute, acknowledge and deliver all such further conveyances, notices, assumptions, releases, acquittances and other instruments, and shall take such further actions, as may be necessary or appropriate to transfer fully to, and vest in, Purchaser and the Purchaser Designees and each of their respective successors or assigns, all of the properties, rights, titles, interests, estates, remedies, powers and privileges intended to be conveyed to Purchaser or a Purchaser Designee under this Agreement and the Assignment and Assumption Agreement and to assure fully to Seller and its Subsidiaries and each of their respective successors and assigns, the assumption of the liabilities and obligations intended to be assumed by Purchaser or a Purchaser Designee under this Agreement and the Assignment and Assumption Agreement, and to otherwise make effective the transactions contemplated hereby and thereby (including (i) transferring back to Seller or a Subsidiary any asset or liability that is not a Purchased Asset or an Assumed Liability, respectively, if and to the extent that any such asset or liability was erroneously or inadvertently transferred to Purchaser or a Purchaser Designee at or after the Closing and (ii) transferring to Purchaser or a Purchaser Designee any asset or liability contemplated by this Agreement to be a Purchased Asset or an Assumed Liability, respectively, which was erroneously or inadvertently not transferred to Purchaser or a Purchaser Designee at or after the Closing). If, at any time from and after the Closing, either Purchaser or Seller discovers that it or any of its Affiliates is the owner of, receives or otherwise comes to possess any Purchased Asset or Excluded Asset or is liable for any Assumed Liability or Excluded Liability that is properly attributable to the other Party (or its respective designees or Affiliates) pursuant to this Agreement or the Assignment and Assumption Agreement, such Party will promptly give notice in writing to the other Party and promptly take the actions contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> Each Party will cooperate with the other Party and use its commercially reasonable efforts to set up procedures and notifications as are reasonably necessary or advisable to effectuate the sale, assignment, transfer, conveyance and delivery contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.5(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) Nothing in this Agreement, the Assignment and Assumption Agreement nor the consummation of the transactions contemplated hereby or thereby shall be construed as an attempt or agreement to transfer or assign any Purchased Asset, including any Transferred Contract, Permit, certificate, approval, license, authorization or other right, which by its terms or by Law is nonassignable or cannot be entered into without the consent of a third party or a Governmental Authority or is cancelable by a third party in the event of an assignment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Nonassignable Assets</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) unless and until (i) such consents shall have been obtained or (ii) to the extent permitted by applicable Law or Contract, Purchaser or a Purchaser Designee notifies Seller that any such Purchased Asset should be transferred or assigned notwithstanding the absence of a requisite third party consent or Governmental Authority consent or the right of a third party to cancel such Nonassignable Asset in the event of a transfer or assignment hereunder, in which event such Purchased Asset shall not be a Nonassignable Asset for purposes of this Agreement and shall instead be transferred and assigned hereunder notwithstanding the absence of such third party consent or Governmental Authority consent or any right of a third party to cancel such Purchased Asset. Seller shall use commercially reasonable efforts to obtain such consents and deliver any required notices under all Nonassignable Assets, and Purchaser shall, and shall cause its Controlled Affiliates to, use commercially reasonable efforts to cooperate with Seller to obtain such consents promptly. To the extent permitted by applicable Law, in the event any requisite consent cannot be or is not for any reason obtained prior to the Closing, from and after the Closing, Seller and Purchaser shall, and shall cause their respective Controlled Affiliates to, use commercially reasonable efforts to develop a mutually agreeable arrangement (including by way of amendment or addition of services to the Transition Services Agreement) under which Purchaser or a Purchaser Designee would obtain the benefits </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">and assume the obligations under such Nonassignable Assets in accordance with this Agreement, including by sub-contracting, sub-licensing, or sub-leasing to Purchaser or a Purchaser Designee, and Seller or its applicable Controlled Affiliate shall hold such Nonassignable Assets in trust for the benefit or burden, as applicable, of Purchaser or the applicable Purchaser Designee until the consummation of the applicable assignment. From and after the Closing, Seller shall, and shall cause its Controlled Affiliates to, also take or cause to be taken at Seller&#8217;s or its designee&#8217;s expense such actions in its name or otherwise as Purchaser may reasonably request so as to provide Purchaser or the applicable Purchaser Designee with the benefits of the Nonassignable Assets and to effect collection of money or other consideration that becomes due and payable under the Nonassignable Assets, and Seller or the applicable Subsidiary shall promptly pay over to Purchaser or the applicable Purchaser Designee all money or other consideration received by it in respect to all Nonassignable Assets. If after the Closing Date any Nonassignable Asset becomes assignable (either because consent for the assignment or execution thereof is obtained or otherwise), Seller shall promptly notify Purchaser and cooperate to assign or transfer such previously Nonassignable Asset to Purchaser or the applicable Purchaser Designee.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Purchaser and Seller shall, and shall cause their respective Affiliates to, use their respective commercially reasonable efforts to obtain, or to cause to be obtained, any consent, substitution, approval, or amendment required to transfer all rights and obligations under any and all Transferred Contracts, Permits, certificates, approvals, licenses, authorizations or other rights or obligations or liabilities that constitute Purchased Assets or Assumed Liabilities or that are required to perform the obligations under the Assignment and Assumption Agreement.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">From and after the Closing Date, Seller on behalf of itself and its Affiliates authorizes Purchaser, to the extent permitted by applicable Law and the terms of the Nonassignable Assets, at Purchaser&#8217;s expense, to perform all the obligations and receive all the benefits of Seller or its Affiliates under the Nonassignable Assets.</font></div><div style="margin-top:11.5pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Notwithstanding anything in this Agreement to the contrary, unless and until any consent or approval with respect to any Nonassignable Asset is obtained, such Nonassignable Asset shall not constitute a Purchased Asset and any associated liability shall not constitute an Assumed Liability for any purpose under this Agreement.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.07pt">Set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.5(f) of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> is a list of the Shared Contracts to which Seller or any of its Subsidiaries is a party. If requested by Purchaser or a Purchaser Designee, and to the extent legally permissible, Seller and its Affiliates, as applicable, shall cooperate and use commercially reasonable efforts after the date hereof to facilitate and assist Purchaser or such Purchaser Designee, at the sole cost and expense of Purchaser, in negotiating new contracts with the counterparty to each of the Shared Contracts that will be effective on or after the Closing Date on terms that are substantially similar to the terms contained in the Shared Contracts solely to the extent exclusively related to the Business (each such new Contract, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Replacement Contract</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). If requested by Seller, and to the extent legally permissible, Purchaser and its Affiliates, as applicable, shall cooperate and use commercially reasonable efforts after the date hereof to facilitate and assist Seller in negotiating a Replacement Contract. The Parties will use commercially reasonable efforts to negotiate and enter into Replacement Contracts as promptly as practicable following the Closing Date (and to the extent legally permissible, prior to Closing).</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Except as otherwise agreed to between the Parties pursuant to the Transition Services Agreement, if Purchaser or its applicable Purchaser Designee is not able to obtain a Replacement Contract prior to the Closing, then, following the Closing Date, to the extent permissible under applicable Law and </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">under the terms of the applicable Shared Contract, (i) at the sole cost and expense of Purchaser, Seller and its Controlled Affiliates, as applicable, shall continue to perform the obligations under such Shared Contract primarily relating to the Business, (ii) Purchaser or such Purchaser Designee shall take all such actions necessary, or reasonably requested by Seller or its Controlled Affiliates, as applicable, to facilitate performance of the obligations under such Shared Contract primarily relating to the Business, (iii) Seller or its Controlled Affiliates, as applicable, shall hold in trust for the benefit of Purchaser or such Purchaser Designee, and shall promptly forward to Purchaser or such Purchaser Designee, any monies or other benefits received pursuant to such Shared Contract primarily relating to the Business, and (iv) the Parties shall use commercially reasonable efforts to institute alternative arrangements intended to put the Parties in a substantially similar economic position as if such Shared Contract had been replaced by a Replacement Contract. Seller shall not amend, modify, or voluntarily terminate any Shared Contract if such action would have a materially disproportionate effect on the Business in relation to Seller&#8217;s and its Affiliate&#8217;s other businesses without the advance written consent of Purchaser.</font></div><div style="margin-top:12.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Termination of Intercompany Arrangements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Except as otherwise expressly set forth in this Agreement or in any other Transaction Document, including the Transition Services Agreement, effective as of the Closing, all Contracts, arrangements, understandings and agreements of any nature (whether written or oral) solely between or among (i) the Company, on the one hand, and (ii) Seller or any of its Controlled Affiliates (other than the Company), on the other hand (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Intercompany Arrangements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), shall be terminated in their entirety, without any further force or effect.</font></div><div style="margin-top:11.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">As of the Closing, neither Seller nor any of its Controlled Affiliates (other than, following the Closing, the Company) shall have any further rights, obligations or liabilities under any Intercompany Arrangements, and each Party hereby waives any and all claims it may have against any other Party arising under or relating to any Intercompany Arrangements&#59; provided, however, that nothing herein shall (i) affect any rights or obligations under this Agreement or any other Transaction Document, (ii) limit or impair any rights to indemnification under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> or (iii) release or waive any rights or claims arising out of Fraud.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">All intercompany accounts between the Company, on the one hand, and Seller or any of its Affiliates (other than the Company), on the other hand, shall be satisfied, settled, canceled or otherwise extinguished as of the Closing, without any further liability to Purchaser or the Company, except to the extent specifically included in the calculation of the Closing Consideration Amount (including, if applicable, as Cash, Indebtedness or Transaction Expenses) or otherwise expressly provided for in this Agreement.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Each of Seller and Purchaser shall, and shall cause their respective Controlled Affiliates to, at the sole cost of the requesting Party, execute and deliver such further documents or instruments as may be reasonably requested by the other Party to evidence the termination of the Intercompany Arrangements in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Notwithstanding the foregoing, any Intercompany Arrangements identified on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 8.6 of the Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall survive the Closing to the extent and on the terms set forth therein.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CONDITIONS TO CLOSING</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 9.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Conditions to Seller&#8217;s Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The obligation of Seller to consummate the transactions contemplated by this Agreement is subject to the fulfillment of all of the following conditions on or before the Closing Date&#58;</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">The representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article V</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will be accurate as of the date of this Agreement and as of the Closing Date with the same force and effect as though made and on and as of the Closing Date (other than any representation or warranty that is limited by its terms to a specific date, in which case, on and as of such date).</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">All covenants and agreements of Purchaser to be performed hereunder through and including the Closing Date (including all covenants and agreements Purchaser would be required to perform at the Closing if the transactions contemplated by this Agreement were consummated) have been performed or complied with in all material respects, other than the covenants and agreements set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> which must have been performed or complied with in all respects.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Purchaser shall have delivered to Seller duly executed counterparts to the Transaction Documents and such other documents and deliveries set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.8(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 9.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Conditions to Purchaser&#8217;s Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The obligation of Purchaser to consummate the transactions contemplated by this Agreement is subject to the fulfillment of all of the following conditions on or before the Closing Date&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">(i) The representations and warranties of the Company set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article III</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and the representations and warranties of Seller set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IV</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> other than the Fundamental Representations, will each be accurate on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date (other than any representation or warranty that is limited by its terms to a specific date, in which case on and as of such date), without giving effect to any limitations as to &#8220;materiality&#8221;, &#8220;material adverse effect&#8221; or &#8220;Material Adverse Effect&#8221; set forth therein, except where the failure of such representation or warranty to be accurate would not have a Material Adverse Effect&#59; and</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(ii) the Fundamental Representations will each be accurate in all respects (other than de minimis inaccuracies) on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date (other than any representation or warranty that is limited by its terms to a specific date, in which case on and as of such date).</font></div><div style="margin-top:11.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">All covenants and agreements of the Company and Seller to be performed hereunder through and including the Closing Date (including all covenants and agreements of the Company and Seller would be required to perform at the Closing if the transactions contemplated by this Agreement were consummated) have been performed or complied with in all material respects.</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Seller shall have delivered to Purchaser duly executed counterparts to the Transaction Documents and such other documents and deliveries set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.8(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 9.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Joint Conditions to the Parties&#8217; Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The obligation of each Party to consummate the transactions contemplated by this Agreement is subject to the fulfillment of all of the following conditions on or before the Closing Date&#58;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">No preliminary or permanent injunction or other Order issued by a Governmental Authority nor any Law promulgated or enacted by any Governmental Authority will be in effect that would have the effect of (A) making the consummation of the transactions contemplated by this Agreement illegal or (B) otherwise prohibiting the consummation of the transactions contemplated hereby.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 9.4  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Frustration of Closing Conditions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. No Party may rely on the failure of any condition set forth in <a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Section</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"> 9.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> <a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">Section</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"> 9.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> as the case may be, if such failure was caused by such Party&#8217;s failure to perform any of its obligations under this Agreement.</font></div><div style="margin-top:11.05pt;padding-left:115.8pt;padding-right:115.8pt;text-align:center;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TAX MATTERS</font></div><div style="margin-top:11.05pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Preparation and Filing of Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) Seller will have the sole and exclusive right to prepare and file (i) all Consolidated Tax Returns for any taxable period, and (ii) all income Tax Returns of the Company for any Pre-Closing Tax Period or Straddle Period that are due for filing after the Closing. The Parties hereto and each of their Affiliates acknowledge and agree that any Transaction Tax Deductions shall be claimed on any Consolidated Tax Return or any income Tax Return of the Company for a Pre-Closing Tax Period to the maximum extent permissible by applicable Law and shall be reflected on such applicable Tax Returns. Each such income Tax Return described in the foregoing clause (ii) shall be prepared in a manner consistent with the past practices, procedures and accounting methods of the Company, except as otherwise required by this Agreement. Seller shall provide (or cause to be provided) each such income Tax Return of the Company described in the foregoing clause (ii) for any Pre-Closing Tax Period or Straddle Period to Purchaser for its review at least thirty (30) days prior to the due date of such income Tax Return (after applicable extensions) and shall incorporate all reasonable comments made by Purchaser. The party required to do so under Law shall file, or cause to be filed, each of such income Tax Returns consistent with the terms set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> Notwithstanding anything to the contrary in this Agreement, neither the Company nor Seller will be required to provide to Purchaser (or any of its Affiliates) any Consolidated Tax Return, provided, that, when a position, election or transaction on any Consolidated Tax Return has a material impact on the Tax attributes of the Company or when otherwise reasonably relevant to any Tax matter that is the subject of this Agreement, Seller shall provide relevant information to Purchaser in the form of appropriate redacted materials, excerpts, schedules or workpapers, or reproductions of portions of any such Consolidated Tax Return.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) Purchaser, at its cost and expense, will prepare or cause to be prepared, and timely file or cause to be timely filed, in a manner consistent with the past practices of the Company, all Tax Returns of the Company for Pre-Closing Tax Periods and Straddle Periods that are due for filing after the Closing Date (after giving effect to any valid extensions of the applicable filing deadline) that are not described in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> To the extent any items reported on any such Tax Returns could reasonably be expected to result in a Tax liability to or otherwise adversely impact Seller (including through any reduction in the amount of the Purchase Price payable pursuant to this Agreement) or could reduce the amount or value of any Tax Refund payable to Seller hereunder, Purchaser will cause such Tax Returns to be prepared in a manner consistent with the past practice of the Company unless otherwise required by Law, permit Seller to review and comment on each such Tax Return described in the preceding sentence at least thirty (30) days prior to filing, incorporate any reasonable comments of Seller with respect to each such Tax Return, and not file, or cause or permit to be filed, any such Tax Return without the prior written consent of Seller, which consent will not be unreasonably withheld, conditioned or delayed. Purchaser will elect to </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">file (and cause the Company to join in filing) a consolidated U.S. federal income Tax Return with the Company for the taxable period beginning on the day following the Closing Date.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.2 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Straddle Periods</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. For purposes of this Agreement, the Taxes of the Company attributable to any Straddle Period will be apportioned between the portion of the Straddle Period that begins on the first day of the Straddle Period and ends on the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Pre-Closing Straddle</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), and the portion of the Straddle Period that begins on the day immediately after the Closing Date and ends on the last day of the Straddle Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Post-Closing Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The amount of such Tax allocated to the Pre-Closing Straddle Period will&#58; (a) in the case of any property or similar ad valorem Taxes, be deemed to be the amount of such Tax for the entire Straddle Period multiplied by a fraction the numerator of which is the number of days in the Pre-Closing Straddle Period and the denominator of which is the number of days in the entire Straddle Period&#59; (b) in the case of any other Taxes, be deemed equal to the amount that would be payable if the relevant Tax period ended on the Closing Date (provided that exemptions, allowances or deductions that are calculated on an annual basis, such as the deduction for depreciation, will be apportioned on a daily basis&#59; and further provided that any Transaction Tax Deductions claimed on an income Tax Return of the Company for a Straddle Period shall be allocated to the Pre-Closing Straddle Period)&#59; and (c) in the case of any Tax imposed with respect to an interest in an entity treated as a CFC, partnership, or disregarded entity for purposes of the Code, be determined as if the taxable year of such CFC, partnership, or disregarded entity ended on the end of the Closing Date. The amount of such Tax allocated to the Post-Closing Straddle Period will equal the balance of such Tax attributable to the Straddle Period. To the extent permitted under applicable Law, the Parties will use commercially reasonable efforts to terminate the taxable year of the Company on the Closing Date.</font></div><div style="margin-top:10.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.3  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Refunds</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Seller will be entitled to any Tax Refunds or overpayments (or, in each case, credits in lieu thereof) that are received by Purchaser or the Company, which relate to any Pre-Closing Tax Period or any Pre-Closing Straddle Period of the Company, but excluding (a) any adjustment to a loss or other Tax attribute of the Company (as opposed to the receipt of cash), (b) refunds resulting from a carryback of a loss or other Tax attribute of Purchaser, any Affiliate thereof, or the Company from a Post-Closing Tax Period (or portion of a Straddle Period beginning after the Closing Date), (c) any refund that the Company is otherwise obligated to pay over to any third party due to contractual arrangements in existence at or prior to the Closing or (d) any refunds or overpayments (or, in each case, credits in lieu thereof) that were taken into account in calculating the Purchase Price (as finally determined) (each such refund, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Refund</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> in the event that any actual cash tax liability of the Company for Taxes with respect to any Pre-Closing Tax Period or any Pre-Closing Straddle Period is less than the amount of such liability for Taxes taken into account in calculating the Purchase Price (as finally determined), then such difference will be treated as a Tax Refund payable to Seller under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> Purchaser will cause the Company to make all filings and take all actions necessary to secure such Tax Refunds as promptly as possible (and in any event, within thirty (30) days after receiving notice from Seller regarding the availability thereof), and Purchaser will pay to Seller the amount of any such Tax Refund within 5 days after the actual receipt of such Tax Refund (or entitlement thereto, with respect to an amount credited in lieu of a refund). The Parties agree that any payment made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will be treated as an adjustment to the Purchase Price for applicable Tax purposes, except to the extent otherwise required by applicable Law.</font></div><div style="margin-top:11.15pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Control of Audit or Tax Litigation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">After the Closing, each of Purchaser, on one hand, and Seller, on the other hand, will promptly notify the other in writing within seven days following receipt of notice of any pending or </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10.85pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">threatened Proceeding regarding any Taxes or Tax Returns of the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Proceeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) for which such other party (or such other party&#8217;s Affiliates) may be liable.</font></div><div style="margin-top:11.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">After the Closing, Seller will (i) control the defense of any Tax Proceedings related to a Consolidated Tax Return for any taxable period and (ii) have the right, but not the obligation, to control the defense of any Tax Proceeding related solely to an income Tax Return of the Company for a Pre-Closing Tax Period at Seller&#8217;s sole cost and expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that (notwithstanding any contrary provision of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section10.4(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">), Seller shall not have the right to control any such Tax Proceeding described in the foregoing clause (ii) if (A) the outcome of such Tax Proceeding may materially adversely affect the Tax liability of the Company, Purchaser or any Affiliate of any of them, for any period ending after the Closing Date, or (B) Seller has failed or ceased diligently to defend against the adjustment in Tax proposed in such Tax Contest. With respect to any Tax Proceeding governed by the foregoing subsection (ii), Seller will (C) provide Purchaser with copies of all significant correspondence, notices or other written materials received from any Governmental Authority and otherwise keep Purchaser advised of any significant developments, and of any significant communications involving representatives of the Governmental Authorities, (D) permit Purchaser to participate in such Tax Proceeding at Purchaser&#8217;s cost and expense, (E) permit Purchaser to review and comment on any documents in connection with such Tax Proceeding and take any reasonable comments of Purchaser into consideration prior to filing any document and (F) shall not settle, adjust or compromise such Tax Proceeding in a manner that may materially adversely affect the Tax liability of the Company, Purchaser or any Affiliate of any of them, for any period ending after the Closing Date, without with Purchaser&#8217;s written consent, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">After the Closing, Purchaser will control the defense of any Tax Proceeding that is not described in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.4(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or the defense of which Seller, in its sole discretion, elects not to control or does not timely assume control. To the extent any such Tax Proceeding could reasonably be expected to result in a liability to or otherwise impact Seller or any of its beneficial owners (including through any reduction in the amount of the Purchase Price payable pursuant to this Agreement) or reduce the amount or value of any Tax Refund payable to Seller hereunder, Purchaser will (i) provide Seller with copies of all significant correspondence, notices or other written materials received from any Governmental Authority and otherwise keep Seller advised of any significant developments, and of any significant communications involving representatives of the Governmental Authorities, (ii) permit Seller to participate in such Tax Proceeding at Seller&#8217;s sole cost and expense, (iii) permit Seller to review and comment on any documents in connection with such Tax Proceeding and take any reasonable comments of Seller into consideration prior to filing any document, and (iv) not settle, adjust or compromise (or cause the Company to settle, adjust or compromise) any such Tax Proceeding without the prior written consent of Seller, which consent will not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.5  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser and Seller shall each pay fifty percent (50%) of all sales, use, transfer, real property transfer, value-added, stamp, documentary, recording, equity transfer, and similar Taxes and fees, and any deficiency, interest, or penalty asserted with respect thereto, arising out of or in connection with the transactions effected pursuant to this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). The party responsible under applicable Law will timely file or cause to be filed all necessary documentation and Tax Returns with respect to such Transfer Taxes and the other party shall promptly reimburse such filing party for its share of such Transfer Taxes. In the event that any Transfer Taxes may be reclaimed, recovered or refunded from any Person in accordance with customary practice, the Parties shall use commercially reasonable efforts to reclaim, recover or obtain a refund of such Transfer Taxes and shall cooperate with respect thereto in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.6</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The amount of </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">such reclaimed, recovered or refunded Transfer Taxes shall be shared 50% by Purchaser and 50% by Seller.</font></div><div style="margin-top:11.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.6  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser, the Company and Seller will use commercially reasonable efforts to cooperate as and to the extent reasonably requested by the other Party, in connection with the filing of any Tax Return or claim for refund and any Tax Proceeding with respect to any Pre-Closing Tax Period or Straddle Period. Such cooperation will include the retention and (upon the other Party&#8217;s request) the provision of records and information that are reasonably relevant to any such Tax Return or audit, examination, assessment or other Proceeding, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.</font></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.7  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Sharing Agreements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Tax sharing agreements or similar agreements and powers of attorney with respect to or involving the Company shall be terminated as of the Closing Date and, after the Closing Date, the Company shall not be bound thereby or have any liability thereunder.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.8  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Intercompany Debt</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Any accounts, loans, indebtedness, payables and receivables between the Company, on the one hand, and another member of the Tax Group, on the other hand, shall be settled, satisfied, canceled and terminated prior to the Closing Date. For the avoidance of doubt, any Taxes imposed on the Company or for which the Company is liable as a result of any such transaction shall constitute Unpaid Taxes and Indemnified Taxes.</font></div><div style="margin-top:11pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.9 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Post-Closing Actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except (a) to the extent expressly contemplated by this Agreement, or (b) to the extent any of the following actions is not reasonably expected to result in any incremental Tax to Seller (including through any reduction in the amount of the Purchase Price payable pursuant to this Agreement), Purchaser will not (and will cause the Company to not), without the prior written consent of Seller (which consent shall not be unreasonably withheld, conditioned or delayed)&#58; change or rescind any Tax election made prior to the Closing Date, (b) amend, refile or otherwise modify any Tax Return for any Pre-Closing Tax Period, (c) file any Tax Return for a Pre-Closing Tax Period in a jurisdiction in which the Company did not previously file any Tax Returns, (d) initiate, adjust, compromise or settle any Tax claim with a Governmental Authority for a Pre-Closing Tax Period, (e) engage in any voluntary disclosure or similar process with a Governmental Authority with respect to the Taxes of the Company for a Pre-Closing Tax Period, (f) surrender any right to a Tax Refund payable to Seller hereunder, or (g) extend the statute of limitations with respect to any Tax or Tax Return for a Pre-Closing Tax Period or reduce the amount or value of any Tax Refund otherwise payable to Seller hereunder.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.10  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 338(h)(10) Election</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Purchaser and Seller shall join in making an election under Section 338(h)(10) of the Code and Treasury Regulations promulgated thereunder and any comparable provisions of applicable Law in respect of the purchase of the Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 338(h)(10)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Purchaser and Seller shall report the sale and purchase of the Shares in a manner consistent with such Section 338(h)(10) Election on all Tax Returns, agree not to take any action that could cause such election to be invalid, and will take no position contrary thereto unless required to do so pursuant to a &#8220;determination&#8221; (as defined in Section 1313(a) of the Code or any comparable provisions of applicable Law).</font></div><div style="margin-top:10.9pt;padding-left:107.4pt;padding-right:107.4pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE XI</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TERMINATION</font></div><div style="margin-top:10.55pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 11.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Right to Terminate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement and the transactions contemplated by this Agreement may be terminated at any time before the Closing by prompt notice given in accordance with </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font></div><div style="margin-top:11.75pt;padding-left:125.95pt;padding-right:18pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:23.75pt">by the mutual written consent of Purchaser and Seller&#59;</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">in writing by either Purchaser or Seller if the Closing has not occurred at or before 11&#58;59&#58;59 p.m. Eastern Time on the date that is ninety (90) days after the date of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will not be available to any Party whose failure to fulfill any of its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such date&#59;</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">by Purchaser, if any of the representations or warranties of the Company or of Seller set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article III</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article IV</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> as applicable, are not accurate, or if the Company or Seller has failed to perform any covenant or agreement on the part of the Company or Seller, as applicable, set forth in this Agreement (including an obligation to consummate the Closing), such that the conditions to the Closing set forth in either </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.2(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.2(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> are not capable of being satisfied as of the Closing and the breach or breaches causing such representations or warranties not to be accurate, or the failures to perform any covenant or agreement, as applicable, are not cured within twenty (20) Business Days after written notice thereof is delivered to the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that Purchaser is not then in breach of this Agreement such as would cause the condition to the Closing set forth in either </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> to not be satisfied as of the Closing&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">by Seller, if any of the representations or warranties of Purchaser set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article V</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> is not accurate, or if Purchaser has failed to perform any covenant or agreement on the part of Purchaser set forth in this Agreement (including an obligation to consummate the Closing), such that the conditions to the Closing set forth in either </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> are not capable of being satisfied as of the Closing and the breach or breaches causing such representations or warranties not to be accurate, or the failures to perform any covenant or agreement, as applicable, are not cured within twenty (20) Business Days after written notice thereof is delivered to Purchaser&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that none of the Company or Seller is then in breach of this Agreement such as would cause the condition to the Closing set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.2(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.2(b)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> from being satisfied as of the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that neither a breach by Purchaser of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 5.7</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> nor the failure to deliver the Purchase Price or the payments contemplated by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> at the Closing (or the date on which the Closing would have occurred but for the breach of this Agreement by Purchaser) as required hereunder will be subject to cure hereunder unless otherwise agreed to in writing by the Company&#59; or</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">by Purchaser or Seller if there is in effect a final, non-appealable Order of a court of competent jurisdiction in effect precluding consummation of the transactions contemplated by this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.1(e)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will not be available to any Party whose failure to fulfill any of its obligations under this Agreement has been the cause of or resulted in the Order.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 11.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Remedies Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. If this Agreement is validly terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> then it will forthwith become null and void, and each of the Parties will be relieved of its duties, liabilities and obligations to any other Party under this Agreement and no Party will have any claim against any other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that (a) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XIII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will survive any termination of this </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Agreement and no Party will be relieved of its duties, liabilities and obligations to any other Party under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XIII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and (b) nothing contained in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> will relieve any Party from liabilities, losses or damages arising out of any willful and intentional breach prior to the termination of this Agreement by such Party of any covenants or other obligations to be performed by such Party contained in this Agreement (which, for the avoidance of doubt, will be deemed to include any failure by Purchaser to consummate the transactions contemplated hereby if obligated to do so under this Agreement).</font></div><div style="margin-top:12pt;padding-left:171.77pt;padding-right:171.77pt;text-align:center;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE XII</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">INDEMNIFICATION&#59; SURVIVAL</font></div><div style="margin-top:10.55pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification by Seller</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Subject to the applicable provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> as of and following the Closing, Seller shall indemnify and hold harmless Purchaser, the Company and their respective successors, equity holders, Personnel, Representatives and Affiliates (other than the Seller Indemnified Parties) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) from and against any and all Indemnity Losses incurred or suffered by the Purchaser Indemnified Parties or any of them as a result of or arising out of&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">any breach of, or inaccuracy in, any of the representations or warranties of or related to the Company or Seller contained in Articles III and IV&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">any breach or failure to perform by the Company (solely with respect to those covenants, obligations or agreements to be performed by the Company prior to Closing) or Seller of any of their respective covenants, obligations or agreements contained in this Agreement&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">any Indemnified Taxes&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">any Indebtedness not paid pursuant to Section 2.2(f) or taken into account in the determination of the Closing Consideration Amount pursuant to Section 2.4&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">any Transaction Expenses not paid pursuant to Section 2.2(g) or taken into account in the determination of the Closing Consideration Amount pursuant to Section 2.4&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:7.02pt">any Excluded Asset or any Excluded Liability&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">any Proceedings identified on, or which should have been identified on, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.14</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 4.5 of the Disclosure Schedules</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification by Purchaser</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Subject to the applicable provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> as of and following the Closing, Purchaser shall indemnify and hold harmless Seller and its respective successors, equity holders, Personnel, Representatives and Affiliates (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) from and against any and all Indemnity Losses incurred or suffered by the Seller Indemnified Parties or any of them as a result of, arising out of, or directly or indirectly relating to&#58;</font></div><div style="margin-top:11pt;padding-left:17.95pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">any breach of, or inaccuracy in, any of the representations or warranties of Purchaser contained in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article V</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#59; and</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">any breach or failure to perform by Purchaser of any of its covenants, obligations or agreements contained in this Agreement.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.5pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.3  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Notice&#59; Litigation Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. If a party believes that it has suffered or incurred any Indemnity Loss to which it is entitled to indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Sections <a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">12.1</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">12.2</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (such party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), the Claimant shall so notify, as the case may be, (a) Purchaser, in the event the Claimant is a Seller Indemnified Party, or (b) Seller, in the event the Claimant is a Purchaser Indemnified Party, promptly in writing (x) identifying the party or parties which the Claimant believes has an obligation to indemnify (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and (y) describing such Indemnity Loss, including the amount thereof, if known, in such detail as is reasonably practicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). If any Proceeding is instituted by a third party with respect to which the Claimant intends to claim any Liability or expense as an Indemnity Loss under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Third-Party Claim</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), it shall promptly notify the applicable party (as set forth above) of such Third-Party Claim describing such Indemnity Loss and the amount thereof, if known, all with reasonable detail (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Litigation Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) in lieu of an Indemnification Notice.</font></div><div style="margin-top:11.05pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disagreement Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. If the Indemnifying Party does not agree that the Claimant is entitled to full reimbursement for the amount specified in the Indemnification Notice or the Litigation Notice, as the case may be, the Indemnifying Party shall notify the Claimant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disagreement Notice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) within thirty (30) calendar days of its receipt of the Indemnification Notice or the Litigation Notice, as the case may be. Failure to deliver a Disagreement Notice in a timely manner shall be considered an express acknowledgment by the Indemnifying Party of its obligation to indemnify and hold harmless the Claimant with respect to the Indemnity Loss set forth in the Indemnification Notice or the Litigation Notice, as the case may be, and the Indemnifying Party shall pay to the Claimant the amount specified in the Indemnification Notice or the Litigation Notice within five (5) Business Days after the expiration of such thirty (30) day period. Any dispute regarding indemnification shall be resolved as provided for in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:11.1pt;padding-left:54pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Defense of Third-Party Claims</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) The Indemnifying Party shall have thirty (30) calendar days after receipt of the Litigation Notice to (i) notify the Claimant, in writing, that it elects to conduct and control the Third-Party Claim (the &#8220;Election Notice&#8221;) and (ii) appoint counsel reasonably acceptable to the Claimant to be lead counsel in connection with the defense of such Third-Party Claim. If the Indemnifying Party does not give the foregoing Election Notice during such thirty (30) day period, the Claimant shall have the right (but not the obligation) to defend, contest, settle or compromise such Third-Party Claim in the exercise of its reasonable discretion. Notwithstanding the foregoing, the Indemnifying Party shall not have the right to assume control of the defense of such Third-Party Claim, and shall pay the reasonable fees and expenses of one counsel to all Claimants arising out of the same or similar set of circumstances in connection with such defense, to the extent such Third-Party Claim (i) seeks non-monetary relief, (ii) involves a criminal allegation by a Governmental Authority, (iii) involves a claim by a current customer or supplier of the Claimant (or the Company in the event the Claimant is another Purchaser Indemnified Party) or involves a claim which, if adversely determined, would be reasonably expected to establish a precedent, custom or practice adverse to the continuing business interests or prospects of the Claimant (or the Company in the event the Claimant is another Purchaser Indemnified Party), (iv) would reasonably be expected to result in an Indemnity Loss (including the cost of defense) which exceeds the amount, if any, then remaining under the Indemnification Cap, (v) involves, in the opinion of counsel of the Claimant, a conflict of interest between the Indemnifying Party and the Claimant, or (vi) involves a claim that the Indemnifying Party failed or is failing to vigorously prosecute or defend (clauses (i) through (vi), the &#8220;Exception Claims&#8221;).</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) If the Indemnifying Party timely gives the foregoing Election Notice and such Third-Party Claim is not an Exception Claim, the Indemnifying Party shall have the right to undertake, conduct and control, at the Indemnifying Party&#8217;s sole expense, the conduct and settlement of such Third-Party Claim, and the Claimant shall provide its reasonable cooperation, at the Indemnifying Party&#8217;s expense, including providing reasonable access during regular business hours to records and Personnel of the Claimant to the Indemnifying Party in connection therewith&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that (i) the Indemnifying Party shall not thereby consent to the imposition of any injunction against the Claimant (or the Company in the event the Claimant is another Purchaser Indemnified Party) without the prior written consent of the Claimant, (ii) the Indemnifying Party shall permit the Claimant to participate in such conduct or settlement through legal counsel chosen by the Claimant, but the fees and expenses of such legal counsel shall be borne solely by the Claimant, (iii) upon a final determination of such Third-Party Claim, the Indemnifying Party shall promptly reimburse the Claimant for the full amount of any Indemnity Loss incurred by the Claimant, except fees and expenses of legal counsel that the Claimant incurred pursuant to clause (ii) following the receipt by the Claimant of the Election Notice, (iv) the Indemnifying Party shall have the right to pay or settle such Third-Party Claim </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (A) the claim is solely for monetary damages, all of which are being paid, satisfied or otherwise resolved by the Indemnifying Party, (B) the Claimant has no Liability with respect to such settlement and (C) the terms of such settlement provide for a full release of the Claimant, and (v) the Claimant shall have the right to pay or settle any such Third-Party Claim with the consent of the Indemnifying Party.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c) If (i) the Claimant does not receive an Election Notice within thirty (30) days after the Indemnifying Party&#8217;s receipt of the Litigation Notice with respect to a Third-Party Claim or (ii) such Third-Party Claim is an Exception Claim, in each case, the Claimant may defend against such matter as it deems appropriate at the expense of the Indemnifying Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> that the Indemnifying Party shall be entitled to participate in the defense of such claim and to employ counsel of its choice for such purpose&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that the fees and expenses of such separate counsel shall be borne by the Indemnifying Party and shall not be recoverable from such Claimant under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> XII in the event that the Claimant assumes the defense of any such matter, it shall not settle or consent to an entry of judgment without the prior written consent of the Seller, which shall not be unreasonably withheld or delayed&#59; provided, further, that no such settlement or consent to entry of judgment entered into without the prior written consent of the Indemnifying Party (or which the Indemnifying Party is required to provide in order to comply with this Section 12.5(c)) shall be determinative of the existence of a claim covered by this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or the amount of any Indemnity Loss for which the Indemnifying Party is liable hereunder.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">To the extent of any conflict between this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 10.4</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall govern.</font></div><div style="margin-top:12pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 10.6  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Claims for indemnification under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.2(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall only be valid to the extent that such claims are made on or prior to the eighteen (18) month anniversary of the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that notwithstanding the foregoing, claims arising from any breach of any of the Fundamental Representations or representations under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Taxes</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">) shall survive for the greater of (a) the six (6) year anniversary of this Agreement and (b) the applicable statute of limitation, plus sixty (60) days.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10.75pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Limitation on Indemnified Costs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.8pt">Seller shall not be required to indemnify the Purchaser Indemnified Parties for Indemnity Losses arising under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> unless and until the aggregate amount of such Indemnity Losses for which the Purchaser Indemnified Parties are otherwise entitled to indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> exceeds $1,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Basket</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that the Indemnification Basket shall not apply to Indemnity Losses arising from any breach of any Fundamental Representation or any representations under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Taxes</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">). After the Indemnification Basket is exceeded, the Purchaser Indemnified Parties shall be entitled to be paid the amount of all Indemnity Losses from the first dollar, subject to the limitations on recovery and recourse set forth herein.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Seller in the aggregate shall not be liable to indemnify the Purchaser Indemnified Parties for Indemnity Losses arising under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 12.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> in excess of ten percent (10%) of the total consideration actually paid to Seller from time to time pursuant to the terms of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification Cap</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that the Indemnification Cap shall not apply to Indemnity Losses arising from any breach of any Fundamental Representation or any representations under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 3.9</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Taxes</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">). Notwithstanding anything to the contrary contained herein, Seller in the aggregate shall not be liable to indemnify the Purchaser Indemnified Parties for any Indemnity Losses in excess of the total consideration actually owed to and received by Seller (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Aggregate Cap</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;)&#59; provided, however, that the Aggregate Cap shall not apply to Indemnity Losses arising from any Excluded Liabilities.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">For the purpose of calculating Indemnity Losses hereunder (but not for purposes of determining the existence of any breach of or inaccuracy in any representation or warranty in this Agreement), except for the Specified Instances, each qualification to a representation or warranty by use of the word &#8220;material&#8221; or &#8220;materially&#8221; or the words &#8220;in all material respects&#8221; or &#8220;Material Adverse Effect&#8221; shall be disregarded. For purposes hereof, &#8220;Specified Instances&#8221; means (a) the use of the word &#8220;Material Adverse Effect&#8221; in Section 3.10 and (b) the use of the word &#8220;Material&#8221; when used as the first word of the defined terms &#8220;Material Contracts&#8221; and &#8220;Material Permits&#8221;.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.18pt">Notwithstanding anything to the contrary contained in this Agreement&#58; (i) in calculating the amount of any Indemnity Loss, the amount of such Indemnity Loss shall be reduced by</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(A) the amount of any insurance proceeds actually received by the Claimant in respect of such Indemnity Loss, net of related costs reasonably incurred in obtaining such recovery, and (B) any amount actually recovered by the Claimant from any third party with respect thereto, net of related costs reasonably incurred in obtaining such recovery&#59; (ii) each Claimant shall use commercially reasonable efforts to mitigate any Indemnity Loss for which indemnification may be sought hereunder&#59; and (iii) no Claimant shall be entitled to recover the same Indemnity Loss more than once.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.8  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Special Rule for Fraud</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Notwithstanding anything to the contrary contained in this Article XII, in the event of any breach of or inaccuracy in any representation or warranty by any party hereto that constitutes Fraud by or on behalf of Seller or the Company (including any Fraudulent act committed by and Personnel or Representative of Seller, the Company or a Seller Group Entity, in each case who is entitled to act under applicable Law on behalf of Seller, the Company or a Seller Group Entity) (as of or prior to Closing) on the one hand, or Purchaser or the Company (following Closing), on the other hand, then (a) claims of Fraud with respect to such representation or warranty shall survive indefinitely and the limitations set forth in Section 12.7, as applicable, shall not apply to any Indemnity Loss that the Purchaser Indemnified Parties or the Seller Indemnified Parties, as the case may be, may suffer, sustain or become subject to, as a result of, arising out of, relating to or in connection with any such breach.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.9  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Exclusive Remedy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 11.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.16</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, for specific performance or injunctive relief with respect to claims under any Transaction Document, and for legal or equitable relief for any claim for Fraud, the right to indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall constitute the sole and exclusive right and remedy available to any party hereto for any claims or losses under this Agreement or the transactions contemplated hereby, and no party hereto shall initiate or maintain any Proceeding against any other party hereto which is directly or indirectly related to any such claims.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.10 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Payment of Losses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Any Indemnity Losses to which a Purchaser Indemnified Party becomes entitled by reason of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> shall be paid as follows, for the avoidance of doubt, subject to the limitations and qualifications set forth in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font></div><div style="margin-top:10.65pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">First, Purchaser shall set off all or any portion of such amount against any earned, but unpaid Milestone Payments or any amounts owed to any Seller Group Entity pursuant to the TSA, in either case existing as of the date such payment is due, at its sole option&#59;</font></div><div style="margin-top:11.6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">and thereafter, only after any earned but unpaid Milestone Payments have been exhausted, from Seller.</font></div><div style="margin-top:11.5pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 12.11  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Tax Treatment of Indemnity Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. To the maximum extent permitted by Law, it is the intention of the Parties to treat any indemnity payment made under this Agreement as an adjustment to the Purchase Price for all Tax purposes, and the Parties agree to file their Tax Returns accordingly.</font></div><div style="margin-top:10.65pt;padding-left:112.07pt;padding-right:112.07pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">ARTICLE XI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MISCELLANEOUS</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.1  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. All representations and warranties of the Company and Seller in this Agreement are made subject to and modified by the exceptions noted in the schedules delivered by the Company to Purchaser concurrently herewith and identified as the &#8220;Disclosure Schedule&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Any item disclosed in the Disclosure Schedule referenced by a particular section or sub-section in this Agreement will be deemed to have been disclosed with respect to every other section or sub-section in this Agreement or any other Transaction Document if the relevance of such disclosure to such other section or sub-section is reasonably apparent, notwithstanding any cross-references (which are included solely as a matter of convenience) or lack of a Schedule reference or cross-reference in any representation or warranty or section of the Disclosure Schedule. Information reflected in the Disclosure Schedule is not necessarily limited to matters required by this Agreement to be reflected in the Disclosure Schedule. Such additional information is set forth for informational purposes and does not necessarily include other matters of a similar nature. Disclosure of such additional information will not be deemed to constitute an acknowledgment that such information is required to be disclosed, and disclosure of such information will not be deemed to enlarge or enhance any of the representations or warranties in this Agreement or otherwise alter in any way the terms of this Agreement. Inclusion of information in the Disclosure Schedule will not be construed as an admission that such information is material to the business, assets, liabilities, financial position, operations or results of operations of the Company. No description of any information in the Disclosure Schedule purports to be comprehensive. In disclosing any information in the Disclosure Schedule, the Company does not waive any attorney-client privilege associated with, or any protection afforded by the work-product doctrine with respect to, any such information. Nothing in the Disclosure Schedule constitutes (a) an admission of any breach or violation of any Contract, Law or Order or of any liability or obligation of Seller or the Company to any third party, </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b) an admission against the interest of Seller or the Company or (c) represents the legal position or legal rights of Seller or the Company on the matter so disclosed. The information contained in the Disclosure Schedule is confidential, proprietary information of the Company and is subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 7.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a> From time to time prior to the Closing, Seller will have the right (but not the obligation) to supplement or amend the Disclosure Schedule hereto with respect to any matter hereafter arising or of which it becomes aware after the date of this Agreement.</font></div><div style="margin-top:11.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.2  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as otherwise provided herein, each Party will bear all fees and expenses incurred by such Party in connection with, relating to, or arising out of the negotiation, preparation, execution, delivery or performance of this Agreement or any other Transaction Document or the consummation of the transactions contemplated by this Agreement or any other Transaction Document, including financial advisors&#8217;, attorneys&#8217;, accountants&#8217; and other professional fees and expenses in connection with the transactions contemplated by this Agreement or any other Transaction Document.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.3  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. All notices required or permitted to be given hereunder will be delivered in writing by email and will be deemed conclusively to have been given (a) if sent by email at or before 5&#58;00 p.m. Eastern Time on a Business Day, then on such Business Day and (b) if sent by email after 5&#58;00 p.m. Eastern Time on a Business Day or at any time on a day that is not a Business Day, then on the immediately following Business Day&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">, that any such notice delivered by email that has not been confirmed or acknowledged in writing via email by the applicable recipient will only be effective if such notice is also (i) delivered by hand, (ii) deposited in the United States mail, postage prepaid, registered or certified mail, or (iii) delivered by nationally recognized private courier, in each case, on or before the third Business Days after such notice was delivered by email.</font></div><div style="margin-top:12.15pt;padding-left:18pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">All notices will be addressed as follows&#58;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:1.1pt;padding-left:126pt;padding-right:18pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">If to Seller or the Company (before the Closing), then to&#58; Pacira BioSciences, Inc.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:0.1pt;padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">1 Sylvan Way, Suite 300 Parsippany, New Jersey 07054 Attention&#58; Anthony Molloy</font></div><div style="margin-top:0.05pt;padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Email&#58; Anthony.Molloy&#64;pacira.com</font></div><div style="margin-top:11.15pt;padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">with copies (which will not constitute notice) to&#58; Perkins Coie LLP</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:0.35pt;padding-left:126pt;padding-right:18pt"><font><br></font></div><div style="padding-left:90pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1301 Second Avenue, Suite 4200</font></div><div style="padding-left:126pt;padding-right:18pt"><font><br></font></div><div style="padding-left:90pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Seattle, WA 98101</font></div><div style="padding-left:126pt;padding-right:18pt"><font><br></font></div><div style="padding-left:90pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Arian Galavis and Jackie Wilcox</font></div><div style="margin-top:0.2pt;padding-left:89.95pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Email&#58; Agalavis&#64;perkinscoie.com&#59; jwilcox&#64;perkinscoie.com</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">If to Purchaser or the Company (following the Closing), then to&#58;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:125.95pt;padding-right:18pt"><font><br></font></div><div style="padding-left:90pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Zimmer, Inc.</font></div><div style="padding-left:125.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">345 East Main Street Warsaw, Indiana 46580 Attn&#58; General Counsel</font></div><div style="padding-left:90pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">E-mail&#58; legal.americas&#64;zimmerbiomet.com</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">with a copy (which will not constitute notice) to&#58;</font></div><div style="margin-top:10.85pt;padding-left:126pt;padding-right:18pt"><font><br></font></div><div style="padding-left:90pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Ice Miller LLP</font></div><div style="padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">One American Square, Suite 2900 Indianapolis, Indiana 46282</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Attn&#58; Stephen Hackman &#38; Pierce H. Han</font></div><div style="margin-top:0.05pt;padding-left:126pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">E-mail&#58; stephen.hackman&#64;icemiller.com&#59; pierce.han&#64;icemiller.com</font></div><div style="margin-top:0.15pt;padding-right:18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">or to any other address that may be designated by notice given under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">.</a></font></div><div style="margin-top:10.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement and the other Transaction Documents constitute the entire agreement of the Parties with respect to the transactions contemplated hereby and thereby, and supersede all prior or contemporaneous written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the Parties with respect to the transactions contemplated hereby or thereby. The Parties agree that no Party will have any remedies or cause of action (whether in contract or in tort) for any statements, communications, disclosures, failures to disclose, representations or warranties not set forth in this Agreement or the other Transaction Documents. Each exhibit and schedule to this Agreement will be considered incorporated into this Agreement. Any amendments, or alternative or supplementary provisions, to this Agreement must be made in writing and duly executed by each Party.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The failure in any one or more instances of a Party to insist upon performance of any of the terms, covenants or conditions of this Agreement or to exercise any right or privilege in this Agreement conferred, or the waiver by such Party of any breach of any of the terms, covenants or conditions of this Agreement, will not be construed as a subsequent waiver of any such terms, covenants, conditions, rights or privileges, but the same will continue and remain in full force and effect as if no such forbearance or waiver had occurred. No waiver will be effective unless it is in writing and signed by the waiving Party.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.6 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement may be executed and delivered by each Party in separate counterparts, each of which when so executed and delivered will be deemed an original and all of which taken together will constitute one and the same agreement.</font></div><div style="margin-top:11.95pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Delivery by Electronic Transmission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement and any other Transaction Document, and any amendments hereto or thereto, to the extent signed and delivered by means of .PDF or other electronic transmission will be treated in all manner and respects as an original contract and will be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person. No Party or any party to any such contract will raise the use of .PDF or other electronic transmission to deliver a signature or the fact that any signature or contract was transmitted or communicated through the use of .PDF or other electronic transmission as a defense to the formation of a contract and each such Party forever waives any such defense.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.8 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, and, for purposes of such jurisdiction, such provision or portion thereof will be struck from the remainder of this Agreement, which will remain in full force and effect. This Agreement will be reformed, construed and enforced in such jurisdiction to best give effect to the intent of the Parties under this Agreement.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Arm&#8217;s Length Negotiations&#59; Drafting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Each Party represents and warrants to the other Parties that such Party has fully informed itself of the terms, contents, conditions and effects of this </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Agreement and such Party has obtained the advice of counsel before executing this Agreement, which is the result of arm&#8217;s length negotiations conducted by and among the Parties and their respective counsel. This Agreement will be deemed drafted jointly by the Parties and nothing will be construed against one Party or another as the drafting Party.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 2.6</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"><a href="#i107d82aceeb64a04aa1708299fef6524_7" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:none">,</a> this Agreement and any controversy related to or arising, directly or indirectly, out of, caused by, resulting from or relating to this Agreement will be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement is solely for the benefit of the Parties and those Persons (or categories of Persons) specifically described herein, and, except as set forth above, no provision of this Agreement will be deemed to confer any remedy, claim or right upon any third party. Without limiting the generality of the foregoing, the Parties expressly confirm their agreement that, in addition to Purchaser, the Company and Seller, the Covered Persons and non-Party Affiliates also will enjoy the benefits of covenants made herein which are expressly stated to be in their favor. Such Persons will have the right to enforce those provisions directly against the applicable Party making such covenants.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.12 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Binding Effect&#59; Benefit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement will inure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. This Agreement may not be assigned by the Company or Seller without the prior written consent of Purchaser. This Agreement may not be assigned by Purchaser without the prior written consent of Seller&#59; provided, however, that Purchaser may assign the right to purchase any of the Purchased Assets from the Asset Sellers to any of its Affiliates without Seller's prior written consent, so long as Purchaser remains primarily liable for all of its obligations under this Agreement.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Waiver of Trial by Jury.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> EACH OF THE PARTIES WAIVES THE RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR SEEKING ENFORCEMENT OF SUCH PARTY&#8217;S RIGHTS UNDER THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. ANY PARTY MAY FILE A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.15  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Consent to Jurisdiction. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">EACH OF THE PARTIES IRREVOCABLY AGREES AND WILL SUBMIT TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE DELAWARE CHANCERY COURT OR, IN THE EVENT THAT COURT LACKS OR DECLINES TO EXERCISE JURISDICTION, ANY OTHER STATE OR FEDERAL COURT LOCATED IN DELAWARE (AND ANY APPLICABLE APPELLATE COURT IN THE EVENT OF ANY APPEAL), WITH RESPECT TO ANY CLAIM OR CAUSE OF ACTION ARISING UNDER OR RELATING TO THIS AGREEMENT, AND WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS UPON IT, AND CONSENTS THAT ALL SERVICES OF PROCESS BE MADE BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, DIRECTED TO IT AT ITS ADDRESS AS SET FORTH IN SECTION 13.3, AND SERVICE SO MADE WILL BE DEEMED TO BE COMPLETED WHEN RECEIVED. EACH OF THE PARTIES WAIVES ANY OBJECTION BASED ON FORUM NON </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">CONVENIENS AND WAIVES ANY OBJECTION TO VENUE OF ANY ACTION INSTITUTED HEREUNDER. NOTHING IN THIS SECTION 13.15  WILL AFFECT THE RIGHTS OF THE PARTIES TO SERVE LEGAL PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.16 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, including each Party&#8217;s right to consummate the transactions contemplated by this Agreement. The Parties further agree that each of the Parties will be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement (including for specific performance of any transaction contemplated by this Agreement), this being in addition to any other remedy to which such Party is entitled at law or in equity or pursuant to this Agreement. Each of the Parties waives</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any Law to post security, such as a bond or undertaking, as a prerequisite to obtaining equitable relief.</font></div><div style="margin-top:11.5pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section 13.17 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">. The headings contained in this Agreement are for convenience of reference only and will not affect the meaning or interpretation of this Agreement.</font></div><div style="margin-top:11.7pt;padding-left:53.95pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Section  13.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Legal Representation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:11.95pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Each of the Parties acknowledges that Perkins Coie LLP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">PC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) currently serves as counsel to each of Seller and its Subsidiaries and its Affiliates, including in connection with the negotiation, preparation, execution and delivery of this Agreement, the other Transaction Documents and the consummation of the transactions contemplated by this Agreement. There may come a time, including after consummation of the transactions contemplated by this Agreement, when the interests of Seller and the Company may no longer be aligned or when, for any reason Seller, PC or the Company believes that PC can or should no longer represent Seller and the Company. The Parties understand and specifically agree that PC may withdraw from representing the Company and continue to represent Seller and its Affiliates, even if their respective interests, and the interests of the Company, are or may be adverse, including in connection with any dispute arising out of or relating to this Agreement or the transactions contemplated by this Agreement, and even though PC may have represented the Company in a matter substantially related to such dispute or may be handling ongoing matters for the Company or any of its Affiliates, and each of Purchaser and the Company, on behalf of itself and its Affiliates, hereby consents thereto and waives any conflict of interest arising therefrom.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.23pt">Notwithstanding anything to the contrary contained herein, the Parties intend that all communications at or before the Closing between the Company, Seller and Seller&#8217;s Affiliates (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Group</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; and each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Seller Group Entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) or any of them, on the one hand, and any of their attorneys, on the other hand, including all communications relating to the negotiation of the transactions contemplated by this Agreement and any alternative transactions (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Protected</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Communication</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), and all associated rights to assert, waive and otherwise administer the attorney-client privilege and right of confidentiality of any Seller Group Entity (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Associated Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), will, from and after the Closing, rest exclusively with Seller and its Affiliates (excluding the Company) and will not be transferred, assigned, conveyed or delivered, by operation of law or otherwise, to Purchaser or any of its Affiliates or any successor or assign of any of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Purchaser Group</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Accordingly, as of immediately before the Closing, for the consideration set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged&#58; (i) all </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">Protected Communication and Associated Rights are, and will be deemed for all purposes, transferred, assigned, conveyed and delivered in full to Seller and its Affiliates (excluding the Company) and (ii) no member of the Purchaser Group will have any right, title, interest or benefit in or to any of the Protected Communication or any Associated Rights.</font></div><div style="margin-top:12pt;padding-right:18pt;text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:17.95pt;padding-right:18pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:5.85pt">Purchaser agrees, on its own behalf and on behalf of the other members of the Purchaser Group, from and after the Closing, that Seller and its Affiliates (excluding the Company) (i) will have the right to take possession and control of all Protected Communication effectively as of the Closing and (ii) if and to the extent Seller and its Affiliates (excluding the Company) fail to take such possession and control (which failure will not, alone or in association with any other act or omission, be deemed a waiver of any of their rights under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="#i107d82aceeb64a04aa1708299fef6524_13" style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 13.18</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">), each of Seller and its Affiliates (excluding the Company) will have the right to access and copy, from time to time, any Protected Communication in the possession or control of any member of the Purchaser Group from and after the Closing, during normal business hours and on not less than twenty-four (24) hours prior written notice, as Seller or any of its Affiliates (excluding the Company) (as applicable) determines, in its sole discretion, may be necessary or desirable in connection with any post-Closing matter, whether or not such matter is known to any member of the Purchaser Group. If and to the extent that, at any time from and after the Closing, any member of the Purchaser Group will have any right or opportunity to assert or waive an attorney-client privilege or right of confidentiality with respect to any Protected Communication, each member of the Purchaser Group will not, and will cause the other members of the Purchaser Group not to, waive such privilege or right of confidentiality without the prior written consent of Seller (which consent may be withheld, conditioned or delayed in its sole discretion).</font></div><div style="margin-top:12.1pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">The remainder of this page is intentionally left blank</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">.&#93;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_16"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Parties have executed this Agreement as of the date indicated in the first sentence of this Agreement.</font></div><div style="margin-top:11.05pt;padding-left:233.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">PURCHASER&#58;</font></div><div style="margin-top:11.15pt;padding-left:233.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ZIMMER, INC.</font></div><div style="margin-top:9.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:234pt;padding-right:17.95pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; CHAD PHIPPS                                                      </font></div><div style="padding-left:198pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Chad Phipps</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.184%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:234pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SELLER&#58;</font></div><div style="margin-top:10.95pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</font></div><div style="margin-top:9.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:234pt;padding-right:17.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; ANTHONY MOLLOY                                   </font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Anthony Molloy</font></div><div style="margin-top:0.15pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Chief Legal &#38; Compliance Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.3pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">COMPANY&#58;</font></div><div style="margin-top:11pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">PACIRA CRYOTECH, INC.</font></div><div style="margin-top:11pt;padding-left:234pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:234pt;padding-right:17.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; ANTHONY MOLLOY                                   </font></div><div style="padding-left:198pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Anthony Molloy</font></div><div style="padding-left:198pt;padding-right:28.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Chief Legal Officer, Vice President &#38; General Counsel</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.184%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_19"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:10.95pt;padding-left:114.27pt;padding-right:114.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Form of Escrow Agreement</font></div><div style="margin-top:11pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:8.184%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_22"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:114.37pt;padding-right:114.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-top:10.95pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Assignment and Assumption Agreement</font></div><div style="margin-top:11pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:8.184%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit B</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_25"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:114.3pt;padding-right:114.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT C</font></div><div style="margin-top:10.95pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Form of Sublease Agreement</font></div><div style="margin-top:11pt;padding-left:66.15pt;padding-right:66.15pt;text-align:center"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:8.184%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit C</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_28"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div style="margin-top:10.95pt;padding-left:114.3pt;padding-right:114.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Form of Transition Services Agreement</font></div><div style="margin-top:11pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font><br></font></div><div id="i107d82aceeb64a04aa1708299fef6524_31"></div><div style="margin-top:4.05pt;padding-left:114.27pt;padding-right:114.27pt;text-align:center"><font><br></font></div><div style="margin-top:4.05pt;padding-left:117pt;padding-right:117pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE A</font></div><div style="margin-top:10.95pt;padding-left:114.35pt;padding-right:114.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Purchased Assets</font></div><div style="margin-top:10.9pt;padding-left:18pt;padding-right:17.7pt;text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:8.184%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit D</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_34"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:114.3pt;padding-right:114.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SCHEDULE B</font></div><div style="margin-top:10.95pt;padding-left:114.32pt;padding-right:114.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Excluded Assets</font></div><div style="margin-top:10.9pt;padding-left:18pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:9.523%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Schedule B</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_37"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:196.75pt;padding-right:196.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">Schedule 1.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%;text-decoration:underline">Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%"> </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.714%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 1.1</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_40"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:195.45pt;padding-right:195.45pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">Schedule 2.10 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%;text-decoration:underline">Allocation Methodology</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%"> </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.755%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 2.1</font></div></td></tr></table></div></div></div><div id="i107d82aceeb64a04aa1708299fef6524_43"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:202.8pt;padding-right:202.8pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">Schedule 7.5(b)(iv) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%;text-decoration:underline">Transaction Bonuses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%"> </font></div><div id="i107d82aceeb64a04aa1708299fef6524_46"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:28.650%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.7pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-top:4.05pt;padding-left:17.95pt;padding-right:178.1pt;text-indent:44.25pt"><font><br></font></div></div><div style="display:inline-block;max-width:3.154%;min-width:2.154%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.196%"><div style="padding-left:17.95pt;padding-right:178.1pt;text-indent:44.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%">Schedule 7.8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:217%;text-decoration:underline">Spasticity Collaboration Terms</font></div><div style="padding-left:61.3pt"><font><br></font></div></div></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.922%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Schedule 7.5(b)(iv)</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex101teehanexecutiveagreem.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i4db274e3ed2e445c980d59027a190f1c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This Executive Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is entered into as of January 21, 2025, by and between Pacira Pharmaceuticals, Inc., a California corporation, any of its past, present, or future parents, subsidiaries, predecessors, affiliates, successors, officers, directors, assigns, investors, agents, owners, managing agents and insurers (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Brendan Teehan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Company is a wholly-owned subsidiary of Pacira BioSciences, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Company wishes to employ the Executive, and the Executive desires to be employed by the Company, for such purpose and upon the terms and conditions hereinafter provided, effective as of January 21, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties wish to establish the terms of the Executive&#8217;s future employment with the Company and set out fully their respective rights, obligations and duties.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In consideration of the promises and the terms and conditions set forth in this Agreement, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Title and Capacity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby agrees to employ the Executive, and the Executive hereby accepts employment with the Company, under the terms set forth in this Agreement. The Executive will serve as the Chief Commercial Officer and shall perform such duties as are ordinary, customary and necessary in such role. The Executive will report directly to Chief Executive Officer. The Executive shall devote the Executive&#8217;s full business time, skill and attention to the performance of the Executive&#8217;s duties on behalf of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees to pay the Executive an annual base salary of Five Hundred and Thirty Thousand Dollars ($530,000) payable in accordance with Company&#8217;s customary payroll practice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Executive&#8217;s Base Salary shall be reviewed periodically by the Board of Directors of Parent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that any such review will not necessarily result in an adjustment to the Executive&#8217;s Base Salary. Any change in the Executive&#8217;s Base Salary must be approved by the Board. References in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement to the Board will be interpreted to include the Compensation Committee or such other committee of the Board (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as applicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive is eligible to receive, in addition to the Base&#160;Salary and subject to the terms hereof and at the full discretion of the Board, a targeted incentive bonus of Fifty Percent (50%) of Base Salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Targeted Incentive Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Targeted Incentive Bonus shall be based on the Executive&#8217;s and the Company&#8217;s performance during the applicable fiscal year, as determined by the Board. The Targeted Incentive Bonus criteria or &#8220;goals&#8221; will be determined by agreement between the Board and the Executive at the beginning of each fiscal year. The award of the Targeted&#160;Incentive Bonus may be in an amount either above or below the amount specified by the Board at the beginning of each fiscal year based on the ultimate performance assessed by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Targeted Incentive Bonuses shall be determined and approved by the Board in its sole discretion and, if awarded, shall be payable no later than March 15 of the calendar year immediately following the last day of the fiscal year to which the applicable Targeted&#160;Incentive Bonus relates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All salary and bonuses shall be subject to all applicable withholdings and deductions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Long-Term Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Effective as of January 21, 2025, subject to approval by the Board, the Executive will be eligible to participate in Parent&#8217;s cash-based Long-Term Incentive Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">LTIP</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as established by Parent from time to time on substantially the same terms as are made available to other similarly-situated officers of the Company. Awards, if any, under the LTIP shall be subject to the approval of, and determined by, the Board in its sole discretion and, if granted, will be subject to the terms and conditions of the applicable plan document and any applicable award letter or agreement evidencing the awards. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options and Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to approval by the Board, Parent will grant to the Executive a non-qualified stock option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to purchase an aggregate of Ninety Nine Thousand Five Hundred (99,500) shares of Parent&#8217;s common stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">New Hire Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and a restricted stock unit (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RSU</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) award for Fifty Four Thousand (54,000) shares of Parent&#8217;s common stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">New&#160;Hire RSUs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the New Hire Option, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">New&#160;Hire Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to Parent&#8217;s Amended and Restated 2014 Inducement Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) The exercise price, vesting schedule and other terms and conditions for the New Hire Awards and any future equity incentive awards will be set forth in the applicable award agreement for each such award and all Options and time-based RSUs granted to the Executive are subject to accelerated vesting as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> hereof. The New Hire Awards and any future equity incentive awards, if any, shall be subject to the approval of, and determined by, the Board in its sole discretion. All share figures set forth herein shall be subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations and similar events. Any grant of an equity incentive award must be accepted within ninety (90) calendar days of the date of grant, otherwise the Executive will forfeit the award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive (and, where applicable, the Executive&#8217;s qualified dependents) will be eligible to participate in health insurance and other employee benefit plans and policies established by the Company for its executive team from time to time on substantially the same terms as are made available to other such employees of the Company generally. The Executive&#8217;s participation (and the participation of the Executive&#8217;s qualified dependents) in the Company&#8217;s benefit plans and policies will be subject to the terms of the applicable plan documents and the Company&#8217;s generally applied policies, and the Company in its sole discretion may from time to time adopt, modify, interpret or discontinue such plans or policies. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Company will reimburse the Executive for all reasonable and necessary expenses incurred by the Executive in connection with the Company&#8217;s business, in accordance with the applicable Company policy as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vacation and Holidays</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive shall be eligible for thirty (30) days&#8217; paid vacation&#47;flexible time off per calendar year subject to the applicable terms and conditions of the Company&#8217;s vacation policy and applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> (h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> or as otherwise specified herein or in any other agreement between the Executive and the Company, if the Executive&#8217;s employment is terminated by the Company for any reason, with or without Cause (as defined below), or if the Executive resigns the Executive&#8217;s employment voluntarily, with or without Good Reason (as defined below), no compensation or other payments will be paid or provided to the Executive for periods following the date when such a termination of employment is effective, provided that any rights the Executive may have under the Company&#8217;s benefit plans shall be determined under the provisions of such plans. If the Executive&#8217;s employment terminates as a result of the Executive&#8217;s death or disability, no compensation or payments will be made to the Executive other than those to which the Executive may otherwise be entitled under the benefit plans of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">(i) Relocation Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Company will provide the Executive with relocation assistance, according to the terms of the Company&#8217;s Relocation Policy. The relocation assistance outlined in the policy will be available to the Executive for a period of up to one year from the Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Executive&#8217;s employment is terminated for Cause or the Executive resigns other than for Good Reason prior to the first anniversary of the Effective Date, the Executive will repay one hundred percent (100%) of the gross amount of the Relocation Benefits costs (including any tax assistance provided) to the Company within thirty days following the Executive&#8217;s last day of employment. If the Executive&#8217;s employment is terminated for Cause or the Executive resigns other than for Good Reason prior to the second anniversary of the Effective Date, the Executive will repay fifty percent (50%) of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">gross amount of the Relocation Benefits costs (including any tax assistance provided) to the Company within thirty days following the Executive&#8217;s last day of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation and Benefits Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. Upon termination of the Executive&#8217;s employment (such date of termination being referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), the Company will pay the Executive the compensation and benefits as described in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Benefits Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Company will pay the Executive on or about the Termination Date all salary and vacation&#47;personal time off pay, if any, that has been earned or accrued through the Termination Date and that has not been previously paid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination without &#8220;Cause&#8221; or for &#8220;Good Reason&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that the Company terminates the Executive&#8217;s employment without Cause (as defined below) after the first anniversary of the Effective Date or, in the event the Executive terminates the Executive&#8217;s employment for Good Reason (as defined below), in each case, (i) the Executive shall be entitled to receive (A) continuing payments of the then effective Base Salary for a period of twelve (12) months beginning on the Payment&#160;Commencement Date (as defined below) and payable in accordance with the Company&#8217;s payroll policies as in effect on the date the Executive&#8217;s employment terminates and (B) the benefits set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> for period of twelve (12) months beginning on the Payment Commencement Date, and (ii) the Executive shall be entitled to acceleration of vesting of such portion of the then unvested Options and time-based RSUs then held by Executive as would have vested in the nine (9) month period following the Termination Date had the Executive continued to be employed by the Company for such period, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that in each case the receipt of such payments and benefits is expressly contingent upon the Executive&#8217;s execution and delivery of a severance and general release of claims agreement drafted by and satisfactory to counsel for the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) which Release must be executed and become effective within sixty (60) days following the Termination Date. The payments and benefits shall be paid or commence on the first payroll period following the date the Release becomes effective (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the foregoing, if the 60th day following the Termination Date occurs in the calendar year following the termination, then the Payment Commencement Date shall be no earlier than January 1 of such subsequent calendar year. For the avoidance of doubt, any time-based RSUs that accelerate and vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> will be settled by no later than March 15 of the calendar year immediately following the calendar year that includes the Termination&#160;Date. The provision of payments and benefits pursuant to this Section shall be subject to the terms and conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination without &#8220;Cause&#8221; or for &#8220;Good Reason&#8221; Prior to or Following a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. In the event that the Company terminates the Executive&#8217;s employment without Cause (as defined below) or, in the event the Executive terminates the Executive&#8217;s employment for Good Reason (as defined below), in each case, within thirty (30) days prior to, or twelve (12) months following, the consummation of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">Change&#160;of Control, then </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> shall not apply and instead (i) the Executive shall be entitled to receive (A) continuing payments of the then effective Base Salary for a period of eighteen (18) months beginning on the Payment Commencement Date and payable in accordance with the Company&#8217;s payroll policies as in effect on the date the Executive&#8217;s employment terminates, (B) in lieu of the Targeted Incentive Bonus, a bonus payment equal to one hundred and fifty percent (150%) of the Executive&#8217;s then current annual Targeted Incentive Bonus, payable in one lump sum on the Payment Commencement Date and (C)&#160;the benefits set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> for a period of eighteen (18) months beginning on the Payment Commencement Date, and (ii)&#160;acceleration of vesting of one hundred percent (100%) of the then unvested Options and time-based RSUs then held by Executive, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, that in each case the receipt of such payments and benefits is expressly contingent upon the Executive&#8217;s execution and delivery of a Release as described above drafted by and satisfactory to counsel for the Company, which Release must be executed and become effective within sixty (60) days following the Termination Date. For the avoidance of doubt, any time-based RSUs that accelerate and vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;3(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> will be settled by no later than March 15 of the calendar year immediately following the calendar year that includes the Termination Date. The provision of payments and benefits pursuant to this Section shall be subject to the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means (A) a merger or consolidation of either the Company or Parent, into another entity in which the stockholders of the Company or Parent (as applicable) do not control fifty percent (50%) or more of the total voting power of the surviving entity (other than a reincorporation merger)&#59; (B) the sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets in liquidation or dissolution of the Company&#59; or (C) the sale or transfer of more than fifty percent (50%) of the outstanding voting stock of the Company. In the case of each of the foregoing clauses (A), (B) and (C), a Change of Control as a result of a financing transaction of the Company or Parent shall not constitute a Change of Control for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means (A) the Executive&#8217;s failure to substantially perform the Executive&#8217;s duties to the Company pursuant to this Agreement after there has been delivered to the Executive written notice setting forth in detail the specific respects in which the Board believes that the Executive has not substantially performed the Executive&#8217;s duties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">and, if the Company reasonably considers the situation to be correctable, a demand for substantial performance and opportunity to cure, giving the Executive thirty (30) calendar days after the Executive receives such notice to correct the situation&#59; (B) the Executive&#8217;s having engaged in fraud, misconduct involving sexual harassment and&#47;or sexual assault, dishonesty, gross negligence or having otherwise acted in a manner causing material injury to the Company, including reputational harm, or in intentional disregard for the Company&#8217;s best interests&#59; (C) the Executive&#8217;s failure to follow reasonable and lawful instructions from the Board and the Executive&#8217;s failure to cure such failure after receiving twenty (20) days advance written notice&#59; (D) the Executive&#8217;s material breach of the terms of this Agreement or the Employee Confidential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">Information and Inventions Assignment Agreement or any other similar written agreement between the Parties that may be in effect from time to time&#59; or (E) the Executive&#8217;s conviction of, or pleading guilty or nolo contendere to, any misdemeanor involving dishonesty or moral turpitude or related to the Company&#8217;s business, or any felony. The determination as to whether Cause exists for termination of Executive&#8217;s employment will be made by the Board in its reasonable judgment.</font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the occurrence of any one or more of the following events without the prior written consent of the Executive&#58; (A) any material reduction of the then effective Base Salary other than in accordance with this Agreement or which reduction is not related to a cross-executive team salary reduction&#59; (B) any material breach by the Company of this Agreement&#59; or (C) a material reduction in the Executive&#8217;s responsibilities or duties, provided that in the case of clause (C), a mere reassignment following a Change of Control to a position that is substantially similar to the position held prior to the Change of Control transaction shall not constitute a material reduction in job responsibilities or duties&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, that no such event or condition shall constitute Good Reason unless (x)&#160;the Executive gives the Company a written notice of termination for Good Reason not more than ninety (90)&#160;days after the initial existence of the condition constituting Good Reason (which notice specifies in reasonable detail the condition giving rise to Good Reason), (y)&#160;the condition giving rise to Good Reason (if susceptible to correction) is not corrected by the Company within thirty (30)&#160;days of its receipt of such notice and (z) the Termination Date occurs after the expiration of such correction period and within one (1) year following the Company&#8217;s receipt of such notice. </font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Benefits Continuation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. If the Executive&#8217;s employment is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> and provided that the Executive is eligible for and elects to continue receiving group health and dental insurance pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167;&#160;1161 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">seq.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, the Company will, for the period set forth in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> following the Payment Commencement Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Benefits Continuation Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), continue to pay the share of the premium for such coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage.&#160;The remaining balance of any premium costs shall be paid by the Executive on a monthly basis for as long as, and to the extent that, the Executive remains eligible for COBRA continuation. Notwithstanding the above, in the event the Executive becomes eligible for health insurance benefits from a new employer during the Benefits Continuation Period, the Company&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> shall immediately cease and the Executive shall not be entitled to any additional monthly premium payments for health insurance coverage.&#160;Similarly, in the event the Executive becomes eligible for dental insurance benefits from a new employer during the Benefits Continuation Period, the Company&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> shall immediately cease and the Executive shall not be entitled to any additional monthly premium payments for dental insurance. The Executive hereby represents that the Executive will notify the Company in writing within three (3) days of becoming eligible for health or dental insurance benefits from a new employer during the Benefits Continuation Period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement shall automatically terminate upon the death of the Executive and all monetary obligations of Company under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> of this Agreement shall be prorated to the date of death and paid to the Executive&#8217;s estate. </font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. The Company may terminate the Executive&#8217;s employment if the Executive is unable to perform any of the duties required under this Agreement for a period of three (3) consecutive months due to a &#8220;Total and Permanent Disability&#8221;. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Total and Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; shall mean the existence of a permanent physical or mental illness or injury, which renders the Executive incapable of performing any material obligations or terms of this Agreement. Any dispute regarding the existence of a Total and Permanent Disability shall be resolved by a panel of three (3) physicians, one selected by Company, one selected by the Executive, and the third selected by the other two physicians. A termination of employment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> shall constitute a termination for Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. The Executive will be an &#8220;at-will&#8221; employee of the Company, which means the employment relationship can be terminated by either the Executive or the Company for any reason, at any time, with or without prior notice and with or without Cause. The Company makes no promise that the Executive&#8217;s employment will continue for any particular period of time, nor is there any promise that it will be terminated only under particular circumstances. No raise or bonus, if any, shall alter the Executive&#8217;s status as an &#8220;at-will&#8221; employee or create any implied contract of employment. Discussion of possible or potential benefits in future years is not an express or implied promise of continued employment. No manager, supervisor or officer of the Company has the authority to change the Executive&#8217;s status as an &#8220;at-will&#8221; employee. The &#8220;at-will&#8221; nature of the employment relationship with the Executive can only be altered by a written resolution approved by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Solicit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive agrees that during the term of the Executive&#8217;s employment with the Company, and for a period of twelve (12) months immediately following the termination of the Executive&#8217;s employment with the Company for any reason, whether with or without Cause or Good Reason, the Executive shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company&#8217;s or its affiliates&#8217; employees or consultants to terminate such employee&#8217;s or consultant&#8217;s relationship with the Company or its affiliates, or attempt to solicit, induce, recruit, encourage or take away employees or consultants of the Company or any of its affiliates, either for the Executive or for any other person or entity. Further, during the Executive&#8217;s employment with the Company or any of its affiliates and at any time following termination of the Executive&#8217;s employment with the Company or any of its affiliates for any reason, with or without Cause or Good Reason, the Executive shall not use any Confidential&#160;Information of the Company or any of its affiliates (as defined in the Employee Confidential Information and Inventions Assignment Agreement or other similar agreement(s) that the Executive may execute) to attempt to negatively influence any of the Company&#8217;s or any of its affiliates&#8217; clients or customers from purchasing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct such person&#8217;s or entity&#8217;s purchase of products and&#47;or services to any person, firm, corporation, institution or other entity in competition with the business of the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. Executive agrees that the remedies at law of the Company for any actual or threatened breach by Executive of the covenants in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> would be inadequate and that the Company will be entitled to specific performance of the covenants in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, including entry of an ex parte, temporary restraining order in state or federal court, preliminary and permanent injunctive relief against activities in violation of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, or both, or other appropriate judicial remedy, writ or order, in addition to any damages and legal expenses that the Company may be legally entitled to recover. Executive acknowledges and agrees that the covenants in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> will be construed as agreements independent of any other provision of this or any other agreement between Executive and the Company, and that the existence of any claim or cause of action by Executive against the Company, whether predicated upon this Agreement or any other agreement, will not constitute a defense to the enforcement by the Company of such covenants. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Director and Officer Liability Insurance&#59; Indemnification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. During the term of the Executive&#8217;s employment hereunder, the Executive shall be entitled to the same indemnification and director and officer liability insurance as the Company and its affiliates maintain for other corporate officers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">7. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidential Information and Inventions Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. As a condition to Executive&#8217;s employment hereunder, the Executive has, contemporaneously with the Executive&#8217;s execution and delivery of this Agreement, executed and delivered the Company&#8217;s standard Employee Confidential Information and Inventions Assignment Agreement or similar agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Attention to Duties&#59; Conflict of Interest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. While employed by the Company, the Executive shall devote the Executive&#8217;s full business time, energy and abilities exclusively to the business and interests of the Company, and shall perform all duties and services in a faithful and diligent manner and to the best of the Executive&#8217;s abilities. The Executive shall not, without the prior written consent of the Board (or, if applicable, a Committee), render to others services of any kind for compensation, or engage in any other business activity that would materially interfere with the performance of the Executive&#8217;s duties under this Agreement. The Executive represents that the Executive has no other outstanding commitments inconsistent with any of the terms of this Agreement or the services to be rendered to the Company. While employed by the Company, the Executive shall not, directly or indirectly, whether as a partner, employee, creditor, shareholder, or otherwise, promote, participate or engage in any activity or other business competitive with the Company&#8217;s business. The Executive shall not invest in any company or business which competes in any manner with the Company, except those companies whose securities are listed on reputable securities exchanges in the United States or European Union. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties agree that, subject to the exclusions set forth in this Section </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, any dispute, controversy or claim arising out of or relating to (i) this Agreement, (ii) any alleged breach of this Agreement, (iii) executive&#8217;s employment with the Company, (iv) any claim as to arbitrability, enforceability, validity or the scope of this agreement to arbitrate, (v) any claims for alleged discrimination, harassment, or retaliation, (vi) any claims related to wages or compensation or (vii) any claims related to any alleged violation of any federal, state or local law, must be submitted to binding arbitration in accordance with the terms of this agreement to arbitrate. The Parties agree that this agreement to arbitrate does not include&#58; (i) claims for emergency or temporary injunctive relief, (ii) claims for sexual harassment and sexual assault, and (iii) claims that, as a matter of federal, state or local law, the Parties cannot agree to arbitrate, on a pre-dispute basis or otherwise (unless such claims are preempted by federal law). In the event of a dispute regarding sexual assault or sexual harassment claims, the Parties can, at that time, agree to arbitrate such sexual harassment and sexual assault claims. The arbitration will take place in Parsippany, New Jersey, or such other location as the Parties may agree, or where otherwise required by applicable law. The arbitration will take place in accordance with the rules of the American Arbitration Association then applicable to employment-related disputes (available at https&#58;&#47;&#47;www.adr.org&#47;sites&#47;default&#47;files&#47;Employment_Rules_Web.pdf ), and any judgment upon any award may be entered in the state or federal court having jurisdiction over such award. Unless applicable law requires otherwise, the arbitrator will apply the substantive law of New Jersey, except for any claim to which federal substantive law would apply. The Parties expressly acknowledge and agree that this Agreement involves interstate commerce and the interpretation and enforcement of the arbitration provision will be governed by the provisions of the Federal Arbitration Act, 9 U.S.C. 1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">et seq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The arbitration fees and costs relating to the arbitrator and the arbitration proceeding itself will be paid for by the Company&#59; each party shall be responsible for its respective attorneys&#8217; fees and costs. However, if any party prevails on a statutory claim that affords the prevailing party the right to recover attorneys' fees and costs, or if there is a written agreement providing for attorneys' fees and costs to be awarded to the prevailing party, the Arbitrator may award reasonable attorneys' fees in accordance with the applicable statute or written agreement. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The Parties each expressly waive the right to a jury trial and any other civil court proceeding and are giving up the right to file a lawsuit in court with respect to disputes subject to this agreement to arbitrate.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Should any provision of this agreement to arbitrate be deemed unenforceable or invalid, such provision will be severed and the remainder of this agreement to arbitrate will be enforceable to the fullest extent of the law.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Excluding the arbitration agreement in Section 9(a) (which contains its own severability provision), should any other provision of this Agreement be held by a decisionmaker of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, that holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding on the Parties with any modification to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">become a part of and treated as though originally set forth in this Agreement. The Parties further agree that, with the exception of the arbitration agreement in Section 9(a), any such decisionmaker is expressly authorized to modify any unenforceable provision of this Agreement instead of severing the unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement, or by making any other modifications it deems warranted to carry out the intent and agreement of the Parties as embodied in this Agreement to the maximum extent permitted by law. The Parties expressly agree that this Agreement as so modified by the decisionmaker shall be binding upon and enforceable against each of them. Should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, that invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and if such provision(s) are not modified as provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The failure by either party at any time to require performance or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either party of a breach of any provision hereof shall not be taken or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding, unless it is in writing and is signed by the party against whom such waiver is sought to be enforced.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and all rights hereunder are personal to the Executive and may not be transferred or assigned by the Executive at any time. The Company may assign its rights, together with its obligations hereunder, to any parent, subsidiary, affiliate or successor, or in connection with any sale, transfer or other disposition of all or substantially all of its business and assets&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that any such assignee assumes the Company&#8217;s obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding&#59; Section 280G</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. All sums payable to the Executive hereunder shall be reduced by all federal, state, local and other withholding and similar taxes and payments required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of the Agreement to the contrary, if any payments or benefits provided for under the Agreement, together with any payments or benefits otherwise payable or provided to the Executive by the Company or Parent (or any of their respective subsidiaries or affiliates) or otherwise (A) constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Internal&#160;Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (B) would be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the Executive&#8217;s payments and benefits will be either (1) delivered in full or (2) delivered to such lesser extent which would result in no portion of such payments and benefits being </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by the Executive on an after-tax basis, of the greatest amount of payments and benefits, even if the payments and benefits may still be taxable under Section 4999 of the Code. If clause (2) applies, the payments and benefits will be reduced by the Company in its reasonable discretion in the following order&#58; (x) reduction of cash payments, which will occur in reverse chronological order with the cash payment owed on the latest date following the event triggering the Excise Tax being the first cash payment to be reduced&#59; (y) cancellation of accelerated vesting of equity awards, which will occur in the reverse order of the date of grant for the equity awards (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">i.e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the vesting of the most recently granted equity awards will be reduced first)&#59; and (z) reduction of other employee benefits, which will occur in reverse chronological order with the benefit owed on the latest date following the event triggering the excise tax being the first benefit to be reduced. With respect to each of clauses (x)-(z) of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9(e)(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, if any payments or benefits constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A of the Code, the reduction will occur first as to amounts that are not &#8220;nonqualified deferred compensation.&#8221; If two or more of the same type of awards are granted on the same date, the &#8220;parachute payments&#8221; associated with each award will be reduced on a pro-rata basis. In no event will the Executive have any discretion with respect to the ordering of payment reductions. Any determination required under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9(e)(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> will be made in writing by an independent nationally recognized tax or accounting firm appointed by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Counsel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whose determination will be conclusive and binding on the Executive and the Company for all purposes. The Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Section 280G and Section 4999 of the Code. The Company and the Executive will furnish to the Tax Counsel information as the Tax Counsel may reasonably request to make a determination under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9(e)(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, including the agreements referred to herein (which are deemed incorporated by reference herein) constitute the entire and only agreement and understanding between the Parties governing the terms and conditions of employment of the Executive with the Company. In the event of any conflict between the terms of any other agreement between the Executive and the Company entered into prior to the Effective Date, the terms of this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be amended, modified, superseded, cancelled, renewed or extended only by an agreement in writing executed by both Parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The headings contained in this Agreement are for reference purposes only and shall in no way affect the meaning or interpretation of this Agreement. In this Agreement, the singular includes the plural, the plural included the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">singular, the masculine gender includes both male and female referents, and the word &#8220;or&#8221; is used in the inclusive sense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including, personal delivery by facsimile transmission or the third day after mailing by first class mail) to the Company at its primary office location and to the Executive at the Executive&#8217;s address as listed on the Company payroll (which address may be changed by written notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which, taken together, constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law&#59; Jury Waiver&#59; Choice of Venue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the rights and obligations of the parties hereto shall be construed in accordance with the laws of the State of New Jersey without giving effect to the principles of conflict of laws. For claims arising out of or relating to this Agreement that are not subject to the Parties&#8217; agreement to arbitrate, such actions shall be commenced only in a state or federal court of competent jurisdiction in Morris County, New Jersey and the Company and the Executive each consents to the jurisdiction of such a court. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Both the Company and the Executive expressly and irrevocably waive, to the fullest extent permitted by applicable law, any right that any party either has or may have to a jury trial of any dispute, legal action, proceeding, or cause of action arising out of or in any way related to the Executive&#8217;s employment with or termination from the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This jury waiver includes both claims that are subject to the Parties&#8217; agreement to arbitrate and claims that are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> subject to the Parties&#8217; agreement to arbitrate. Each party certifies and acknowledges that (a) no representative of the other party has represented, expressly or otherwise, that the other party would not seek to enforce the foregoing jury waiver in the event of a legal action, (b) it has considered the implications of this jury waiver, (c) it makes this jury waiver knowingly and voluntarily, and (d) it has decided to enter into this agreement in consideration of, among other things, the mutual waivers and certifications in this section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(l) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts&#59; Electronic Signature</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in counterparts and each counterpart, when executed, shall have the legal effect of a second original. Photographic or facsimile copies of any such signed counterparts may be used in lieu of the original for any purpose. The Parties mutually agree that either Party may use electronic signature technology to expedite the execution of this Agreement, pursuant to the Electronic Signatures in Global National Commerce Act, the Uniform Electronic Transaction Act, and&#47;or any other applicable state or local law, and such electronic signatures will be enforceable as if original&#47;handwritten.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</font></div></div></div><div id="i4db274e3ed2e445c980d59027a190f1c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">, the Company and the Executive have executed this Executive Employment Agreement as of the date first above written.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PACIRA PHARMACEUTICALS, INC.&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#47;s&#47; LOREN LAFFERTY</font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Loren Lafferty </font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Sr. Vice President, Human Resources</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#47;s&#47; BRENDAN TEEHAN</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Brendan Teehan</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT&#93;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PAYMENTS SUBJECT TO SECTION 409A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;Subject to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, any severance payments and benefits that may be due under the Agreement shall begin only upon the date of the Executive&#8217;s &#8220;separation from service&#8221; (determined as set forth below) which occurs on or after the termination of the Executive&#8217;s employment. The following rules shall apply with respect to distribution of the severance payments and benefits, if any, to be provided to the Executive under the Agreement, as applicable&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;It is intended that each installment of the severance payments and benefits under the Agreement provided under shall be treated as a separate and distinct &#8220;payment&#8221; for purposes of Section 409A. Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</font></div><div style="padding-left:35pt;text-align:justify"><font><br></font></div><div style="padding-left:35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If, as of the date of the Executive&#8217;s &#8220;separation from service&#8221; from the Company, the Executive is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments or benefits shall be made on the dates and terms set forth in the Agreement.</font></div><div style="padding-left:35pt;text-align:justify"><font><br></font></div><div style="padding-left:35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If, as of the date of the Executive&#8217;s &#8220;separation from service&#8221; from the Company, the Executive is a &#8220;specified employee&#8221; (within the meaning of Section&#160;409A), then&#58;</font></div><div style="padding-left:35pt;text-align:justify"><font><br></font></div><div style="padding-left:70pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Each installment of the severance payments and benefits due under the Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Executive&#8217;s separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and shall be paid at the time set forth in the Agreement&#59; and</font></div><div style="padding-left:70pt;text-align:justify"><font><br></font></div><div style="padding-left:70pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Each installment of the severance payments and benefits due under the Agreement that is not described in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, Section 1(c)(i) and that would, absent this subsection, be paid within the six-month period following the Executive&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive&#8217;s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div></div><div style="padding-left:70pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">and terms set forth herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that the preceding provisions of this sentence shall not apply to any installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation&#160;1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section&#160;1.409A-1(b)(9)(iii) must be paid no later than the last day of the Executive&#8217;s second taxable year following the taxable year in which the separation from service occurs.</font></div><div style="padding-left:70pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The determination of whether and when the Executive&#8217;s separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Exhibit A, Section 2, &#8220;Company&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;With regard to any provision in the Agreement that provides for reimbursement of expenses or in-kind benefits (except for any expense, reimbursement or in-kind benefit provided pursuant to the Agreement that does not constitute a &#8220;deferral of compensation,&#8221; within the meaning of Treasury Regulation Section 1.409A-1(b)), each reimbursement or in-kind benefit provided under the Agreement shall be provided in accordance with the following&#58; (a) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any calendar year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year&#59; (b) any reimbursement of an eligible expense shall be paid to the Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred&#59; and (c) any right to reimbursement or in-kind benefits under the Agreement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company makes no representation or warranty and shall have no liability to the Executive or to any other person if any of the provisions of the Agreement (including this Exhibit) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.</font></div><div><font><br></font></div><div style="padding-left:27pt"><font><br></font></div><div style="padding-left:27pt"><font><br></font></div><div style="padding-left:27pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>pcrx-06302026xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i73d1f42156524dcdb267b04692db4af3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Frank D. Lee, certify that&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this quarterly report on Form&#160;10-Q of Pacira BioSciences,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.57pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.57pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.57pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; FRANK D. LEE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Frank D. Lee</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>pcrx-06302026xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic2e3216276134c4295134859bcc096a6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Shawn M. Cross certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this quarterly report on Form&#160;10-Q of Pacira BioSciences,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.57pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.57pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.57pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SHAWN M. CROSS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shawn M. Cross</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>pcrx-06302026xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i6aacd42ec1f64234b067868fce146781_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C.&#160;&#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this Quarterly Report on Form&#160;10-Q of Pacira BioSciences,&#160;Inc. for the quarter ended June&#160;30, 2026, fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira BioSciences,&#160;Inc. at the dates and for the periods indicated.</font></div><div><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; FRANK D. LEE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Frank D. Lee</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SHAWN M. CROSS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shawn M. Cross</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>pcrx-20260630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e4244-8139-7e27-b3f4-c33a61dfef92,g:c636850a-8e11-4f67-b4ef-051f1780002d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pcrx="http://www.pacira.com/20260630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacira.com/20260630">
  <xs:import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20260630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20260630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20260630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20260630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pacira.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>9952157 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSANDLIABILITIESHELDFORSALE" roleURI="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE">
        <link:definition>9952159 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://www.pacira.com/role/REVENUE">
        <link:definition>9952160 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.pacira.com/role/INVENTORIES">
        <link:definition>9952161 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETS" roleURI="http://www.pacira.com/role/FIXEDASSETS">
        <link:definition>9952162 - Disclosure - FIXED ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.pacira.com/role/LEASES">
        <link:definition>9952163 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>9952164 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSES">
        <link:definition>9952165 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.pacira.com/role/DEBT">
        <link:definition>9952166 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTS">
        <link:definition>9952167 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952168 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANS" roleURI="http://www.pacira.com/role/STOCKPLANS">
        <link:definition>9952169 - Disclosure - STOCK PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERCOMMONSHARE" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE">
        <link:definition>9952170 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.pacira.com/role/INCOMETAXES">
        <link:definition>9952171 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEROPERATINGEXPENSESNET" roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET">
        <link:definition>9952172 - Disclosure - OTHER OPERATING EXPENSES, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952173 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.pacira.com/role/SEGMENTINFORMATION">
        <link:definition>9952174 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://www.pacira.com/role/REVENUETables">
        <link:definition>9955513 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.pacira.com/role/INVENTORIESTables">
        <link:definition>9955514 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETSTables" roleURI="http://www.pacira.com/role/FIXEDASSETSTables">
        <link:definition>9955515 - Disclosure - FIXED ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.pacira.com/role/LEASESTables">
        <link:definition>9955516 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>9955517 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9955518 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.pacira.com/role/DEBTTables">
        <link:definition>9955519 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9955520 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955521 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSTables" roleURI="http://www.pacira.com/role/STOCKPLANSTables">
        <link:definition>9955522 - Disclosure - STOCK PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERCOMMONSHARETables" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables">
        <link:definition>9955523 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.pacira.com/role/INCOMETAXESTables">
        <link:definition>9955524 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEROPERATINGEXPENSESNETTables" roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETTables">
        <link:definition>9955525 - Disclosure - OTHER OPERATING EXPENSES, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONTables">
        <link:definition>9955526 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>9955527 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails">
        <link:definition>9955529 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Revenue Comprised of Three Largest Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSANDLIABILITIESHELDFORSALEDetails" roleURI="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails">
        <link:definition>9955530 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUENarrativeDetails" roleURI="http://www.pacira.com/role/REVENUENarrativeDetails">
        <link:definition>9955531 - Disclosure - REVENUE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEScheduleofDisaggregatedRevenueDetails" roleURI="http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails">
        <link:definition>9955532 - Disclosure - REVENUE - Schedule of Disaggregated Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESScheduleofComponentsofInventoriesDetails" roleURI="http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails">
        <link:definition>9955533 - Disclosure - INVENTORIES - Schedule of Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESNarrativeDetails" roleURI="http://www.pacira.com/role/INVENTORIESNarrativeDetails">
        <link:definition>9955534 - Disclosure - INVENTORIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails">
        <link:definition>9955535 - Disclosure - FIXED ASSETS - Schedule of Fixed Assets Summarized by Major Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETSNarrativeDetails" roleURI="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails">
        <link:definition>9955536 - Disclosure - FIXED ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.pacira.com/role/LEASESNarrativeDetails">
        <link:definition>9955537 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" roleURI="http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails">
        <link:definition>9955538 - Disclosure - LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>9955539 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9955539 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSNarrativeDetails" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails">
        <link:definition>9955540 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails">
        <link:definition>9955541 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESScheduleofAccruedExpensesDetails" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails">
        <link:definition>9955542 - Disclosure - ACCRUED EXPENSES - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESNarrativeDetails" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails">
        <link:definition>9955543 - Disclosure - ACCRUED EXPENSES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofLongTermDebtInstrumentsDetails" roleURI="http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails">
        <link:definition>9955544 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.pacira.com/role/DEBTNarrativeDetails">
        <link:definition>9955545 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofDebtDetails" roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails">
        <link:definition>9955546 - Disclosure - DEBT - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofInterestExpenseDetails" roleURI="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails">
        <link:definition>9955547 - Disclosure - DEBT - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails">
        <link:definition>9955548 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails">
        <link:definition>9955549 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>9955550 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails">
        <link:definition>9955551 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails">
        <link:definition>9955552 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails">
        <link:definition>9955553 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Short-Term and Noncurrent Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>9955554 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955555 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSNarrativeDetails" roleURI="http://www.pacira.com/role/STOCKPLANSNarrativeDetails">
        <link:definition>9955556 - Disclosure - STOCK PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>9955557 - Disclosure - STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails_1" roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails_1">
        <link:definition>9955557 - Disclosure - STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails" roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails">
        <link:definition>9955558 - Disclosure - STOCK PLANS - Schedule of Stock Option Activity and RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSScheduleofValuationAssumptionsDetails" roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails">
        <link:definition>9955559 - Disclosure - STOCK PLANS - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails">
        <link:definition>9955560 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Computation of EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>9955561 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails" roleURI="http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails">
        <link:definition>9955562 - Disclosure - INCOME TAXES - Schedule of Income Before Income Taxes and Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.pacira.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9955563 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails" roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails">
        <link:definition>9955564 - Disclosure - OTHER OPERATING EXPENSES, NET - Schedule of Other Operating Expenses, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEROPERATINGEXPENSESNETNarrativeDetails" roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails">
        <link:definition>9955565 - Disclosure - OTHER OPERATING EXPENSES, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955566 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>9955567 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails">
        <link:definition>9955568 - Disclosure - SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails_1" roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails_1">
        <link:definition>9955568 - Disclosure - SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pcrx_EquityMethodInvestmentsAndOtherAssets" abstract="false" name="EquityMethodInvestmentsAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ContingentConsiderationNoncurrent" abstract="false" name="ContingentConsiderationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" abstract="false" name="DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" abstract="false" name="ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ShareRepurchaseProgramExciseTaxPaid" abstract="false" name="ShareRepurchaseProgramExciseTaxPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" abstract="false" name="AssetsAndLiabilitiesHeldForSalePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_GQBioTherapeuticsGmbHMember" abstract="true" name="GQBioTherapeuticsGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_LargestCustomerMember" abstract="true" name="LargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_SecondLargestCustomerMember" abstract="true" name="SecondLargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ThirdLargestCustomerMember" abstract="true" name="ThirdLargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ThreeLargestCustomersMember" abstract="true" name="ThreeLargestCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ConcentrationRiskNumberOfCustomers" abstract="false" name="ConcentrationRiskNumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_PaciraCryoTechIncAndIoveraMember" abstract="true" name="PaciraCryoTechIncAndIoveraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_RevenueMilestoneOneMember" abstract="true" name="RevenueMilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_RevenueMilestoneTwoMember" abstract="true" name="RevenueMilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_RevenueMilestoneThreeMember" abstract="true" name="RevenueMilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransactionBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_EXPARELMember" abstract="true" name="EXPARELMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ZILRETTAMember" abstract="true" name="ZILRETTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_IoveraMember" abstract="true" name="IoveraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_BupivacaineLiposomeInjectableSuspensionMember" abstract="true" name="BupivacaineLiposomeInjectableSuspensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_WorkInProcessMember" abstract="true" name="WorkInProcessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_FinishedGoodsMember" abstract="true" name="FinishedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_NumberOfLeases" abstract="false" name="NumberOfLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccruedSellingGeneralAndAdministrativeExpenses" abstract="false" name="AccruedSellingGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccruedProductionCost" abstract="false" name="AccruedProductionCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccruedExpensesTable" abstract="true" name="AccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_AccruedExpensesLineItems" abstract="true" name="AccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotesDue2029Member" abstract="true" name="ConvertibleSeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" abstract="true" name="WellsFargoBankNationalAssociationCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_TermLoanAFacilityDueMarch2028Member" abstract="true" name="TermLoanAFacilityDueMarch2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtConversionTermsThreeMember" abstract="true" name="DebtConversionTermsThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_CappedCallMember" abstract="true" name="CappedCallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentMarketPrice" abstract="false" name="DebtInstrumentMarketPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" abstract="false" name="DebtInstrumentRepurchasedInConversionFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" abstract="false" name="DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_SettlementPeriodConvertibleDebtConversionRequest" abstract="false" name="SettlementPeriodConvertibleDebtConversionRequest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" abstract="false" name="DebtInstrumentConversionObligationPremiumOnCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" abstract="false" name="DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_DerivativeCappedCallPrice" abstract="false" name="DerivativeCappedCallPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pcrx_DerivativePremiumPercentage" abstract="false" name="DerivativePremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" abstract="false" name="DebtInstrumentCovenantIncrementalDebtMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" abstract="false" name="DebtInstrumentCovenantIncrementalDebtMaximumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_DebtInstrumentDiscountRate" abstract="false" name="DebtInstrumentDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_ConvertibleNotesReceivableMember" abstract="true" name="ConvertibleNotesReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_GQBioAcquisitionMember" abstract="true" name="GQBioAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" abstract="true" name="EquityInvestmentAndConvertibleNoteReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ConvertibleNoteReceivableMember" abstract="true" name="ConvertibleNoteReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_FlexionAcquisitionMember" abstract="true" name="FlexionAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MajorCustomerOneMember" abstract="true" name="MajorCustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MajorCustomerTwoMember" abstract="true" name="MajorCustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MajorCustomerThreeMember" abstract="true" name="MajorCustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ContingentConsiderationPaymentTerm" abstract="false" name="ContingentConsiderationPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_NumberOfMajorCustomers" abstract="false" name="NumberOfMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_MeasurementInputExpectedMilestonePaymentMember" abstract="true" name="MeasurementInputExpectedMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" abstract="true" name="ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_InvestmentCategorizationAxis" abstract="true" name="InvestmentCategorizationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_InvestmentCategorizationDomain" abstract="true" name="InvestmentCategorizationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ShareRepurchaseProgramBrokerFees" abstract="false" name="ShareRepurchaseProgramBrokerFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_InducementPlan2014Member" abstract="true" name="InducementPlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" abstract="true" name="RestrictedStockUnitsAndPerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_MyoScienceMilestoneLitigationMember" abstract="true" name="MyoScienceMilestoneLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ResearchDevelopmentFoundationMember" abstract="true" name="ResearchDevelopmentFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_LGChemPartnershipAgreementMember" abstract="true" name="LGChemPartnershipAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_JohnsonJohnsonMedTechMember" abstract="true" name="JohnsonJohnsonMedTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_GeneQuineMember" abstract="true" name="GeneQuineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_BaylorCollegeOfMedicineBaylorMember" abstract="true" name="BaylorCollegeOfMedicineBaylorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfMilestoneAxis" abstract="true" name="AchievementOfMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_AchievementOfMilestoneDomain" abstract="true" name="AchievementOfMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_InitiationOfAPhase2ClinicalTrialMember" abstract="true" name="InitiationOfAPhase2ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" abstract="true" name="DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_FlexionTherapeuticsIncMember" abstract="true" name="FlexionTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" abstract="false" name="LitigationSettlementVolumeLimitedIncreasePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" abstract="false" name="LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" abstract="false" name="LitigationSettlementVolumeLimitedMaximumPercentagePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_NumberOfParagraphIVCertifications" abstract="false" name="NumberOfParagraphIVCertifications" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_NumberOfGenericDrugManufacturers" abstract="false" name="NumberOfGenericDrugManufacturers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" abstract="false" name="LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ContractualObligationMinimumMonthlyCommissionDuration" abstract="false" name="ContractualObligationMinimumMonthlyCommissionDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_ContractualObligationMutualTerminationRightsTerm" abstract="false" name="ContractualObligationMutualTerminationRightsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" abstract="false" name="CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" abstract="false" name="RevenueFromContractWithCustomerMilestonePaymentsMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_PercentOfLongLivedAssets" abstract="false" name="PercentOfLongLivedAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_CostOfGoodsSoldAdjusted" abstract="false" name="CostOfGoodsSoldAdjusted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ResearchAndDevelopmentAdjusted" abstract="false" name="ResearchAndDevelopmentAdjusted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_SellingAndMarketingAdjusted" abstract="false" name="SellingAndMarketingAdjusted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_SellingGeneralAndAdministrativeAdjusted" abstract="false" name="SellingGeneralAndAdministrativeAdjusted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" abstract="false" name="AcquisitionRelatedCostAndDivestitureRelatedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" abstract="false" name="BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" abstract="false" name="BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" abstract="false" name="BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" abstract="false" name="BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>pcrx-20260630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e4244-8139-7e27-b3f4-c33a61dfef92,g:c636850a-8e11-4f67-b4ef-051f1780002d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e4244-838c-7e57-a34c-2c877f08f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_us-gaap_AssetsCurrent_019e4244-838c-7e57-a34c-2c877f08f4ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-722b-8e4e-8285ec1efcee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-722b-8e4e-8285ec1efcee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019e4244-838c-7186-8e28-09d1d805c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019e4244-838c-7186-8e28-09d1d805c71a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019e4244-838c-72d1-afb5-71363e9cb909" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_us-gaap_Goodwill_019e4244-838c-72d1-afb5-71363e9cb909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-781f-9d11-e203a4a9d508" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-781f-9d11-e203a4a9d508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_019e4244-838c-7048-9bfd-2ebd5f73f44e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_019e4244-838c-7048-9bfd-2ebd5f73f44e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EquityMethodInvestmentsAndOtherAssets_019e4244-838c-7b8a-8d0b-e703c11aad11" xlink:href="pcrx-20260630.xsd#pcrx_EquityMethodInvestmentsAndOtherAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e4244-838c-76a0-b790-ed8bf7f5f413" xlink:to="loc_pcrx_EquityMethodInvestmentsAndOtherAssets_019e4244-838c-7b8a-8d0b-e703c11aad11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019e4244-838c-7ba6-9d03-9227f21603ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:to="loc_us-gaap_PreferredStockValue_019e4244-838c-7ba6-9d03-9227f21603ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e4244-838c-70ba-907e-684cedc13f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:to="loc_us-gaap_CommonStockValue_019e4244-838c-70ba-907e-684cedc13f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019e4244-838c-7a1f-93d9-795ac034642a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019e4244-838c-7a1f-93d9-795ac034642a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e4244-838c-7463-95aa-ff9a0d2c54b3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e4244-838c-7463-95aa-ff9a0d2c54b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019e4244-838c-7614-b076-869761c63d76" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019e4244-838c-7614-b076-869761c63d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e4244-838c-7707-b6ff-aee1d8bbf1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e4244-838c-7d05-8121-85ed5d31a2f0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e4244-838c-7707-b6ff-aee1d8bbf1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-838c-7ad3-8fe6-e9bfb2989f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e4244-838c-7fa7-a483-8a2126231876" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-838c-7ad3-8fe6-e9bfb2989f8d" xlink:to="loc_us-gaap_Liabilities_019e4244-838c-7fa7-a483-8a2126231876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e4244-838c-73f2-b448-7eacbcec977b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-838c-7ad3-8fe6-e9bfb2989f8d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e4244-838c-73f2-b448-7eacbcec977b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-73f6-9e6d-5d589c1c73cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-838c-7ad3-8fe6-e9bfb2989f8d" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-838c-73f6-9e6d-5d589c1c73cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-754d-8383-be977202302a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019e4244-838c-7da6-98f6-85bb03d98b28" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-754d-8383-be977202302a" xlink:to="loc_us-gaap_AccountsPayableCurrent_019e4244-838c-7da6-98f6-85bb03d98b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838c-78d0-bd69-dcde5804b54f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-754d-8383-be977202302a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838c-78d0-bd69-dcde5804b54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019e4244-838c-7ac2-91b9-5caa50400064" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-754d-8383-be977202302a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019e4244-838c-7ac2-91b9-5caa50400064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8b-d5eb-7df2-9fa1-82fc278eac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-754d-8383-be977202302a" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8b-d5eb-7df2-9fa1-82fc278eac4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e4244-838c-7bc9-9b9f-2302b6c7b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e4244-838c-7bc9-9b9f-2302b6c7b2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019e4244-838c-7cdd-8395-19471a4f9614" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:to="loc_us-gaap_ShortTermInvestments_019e4244-838c-7cdd-8395-19471a4f9614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019e4244-838c-777f-8657-07be50526922" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019e4244-838c-777f-8657-07be50526922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019e4244-838c-7377-8984-dfa6dc58a53e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:to="loc_us-gaap_InventoryNet_019e4244-838c-7377-8984-dfa6dc58a53e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e4244-838c-7667-a7a6-c9e0b1ad35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e4244-838c-7667-a7a6-c9e0b1ad35c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8a-7556-7693-b363-ef2a6c57d61c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e4244-838c-7ca9-9d97-371d4e81426e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8a-7556-7693-b363-ef2a6c57d61c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-7c8e-a83f-a3aeb5852dce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-7c8e-a83f-a3aeb5852dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019e4244-838c-7399-a4c3-4ecd9858be80" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019e4244-838c-7399-a4c3-4ecd9858be80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019e4244-838c-7cc4-898b-f27a5cafd2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019e4244-838c-7cc4-898b-f27a5cafd2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019e4244-838c-7a7c-b8d7-dfde7f3c2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019e4244-838c-7a7c-b8d7-dfde7f3c2d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationNoncurrent_019e4244-838c-7df7-8f17-ff2e653e44a5" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:to="loc_pcrx_ContingentConsiderationNoncurrent_019e4244-838c-7df7-8f17-ff2e653e44a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019e4244-838c-788a-b01c-55eaf0c288dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e4244-838c-7ba9-9ab7-bc42434cd35b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019e4244-838c-788a-b01c-55eaf0c288dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-79be-996f-a68b1eed0c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7fa2-b11d-e303bbf4891d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e4244-838c-79be-996f-a68b1eed0c1c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7fa2-b11d-e303bbf4891d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-838c-7d04-ba91-3a43306975f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e4244-838c-79be-996f-a68b1eed0c1c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-838c-7d04-ba91-3a43306975f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7a98-b77d-86ca9e6e775a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019e4244-838c-7b02-beb2-3b943c34c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7a98-b77d-86ca9e6e775a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019e4244-838c-7b02-beb2-3b943c34c0f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019e4244-838c-7f1f-bb2d-7a7c6b8a6ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7a98-b77d-86ca9e6e775a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019e4244-838c-7f1f-bb2d-7a7c6b8a6ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e4244-838c-75f9-b4aa-126d31481f59" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7a98-b77d-86ca9e6e775a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e4244-838c-75f9-b4aa-126d31481f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-78c1-95b1-6fe40dd79940" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7108-812e-35a4d66f3106" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-78c1-95b1-6fe40dd79940" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7108-812e-35a4d66f3106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-838c-793d-a215-6bcccb224b40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-78c1-95b1-6fe40dd79940" xlink:to="loc_us-gaap_CostsAndExpenses_019e4244-838c-793d-a215-6bcccb224b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7b3d-bbd1-b74009974229" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-764a-ab2f-93e1a8044728" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7b3d-bbd1-b74009974229" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-764a-ab2f-93e1a8044728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-781e-a49d-6a98dfb6419e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7b3d-bbd1-b74009974229" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-781e-a49d-6a98dfb6419e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-838c-7e27-9837-5140757b6191" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_019e4244-838c-7c6d-9308-d0616e91b096" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-838c-7e27-9837-5140757b6191" xlink:to="loc_us-gaap_CostOfRevenue_019e4244-838c-7c6d-9308-d0616e91b096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e4244-838c-7da1-a2f1-41f269112238" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-838c-7e27-9837-5140757b6191" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e4244-838c-7da1-a2f1-41f269112238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-838c-7ff0-9788-57321dfca677" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-838c-7e27-9837-5140757b6191" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-838c-7ff0-9788-57321dfca677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-72d8-a00d-c93acda51fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-838c-7e27-9837-5140757b6191" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-72d8-a00d-c93acda51fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-838c-7a13-99ad-7516c30befbc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-838c-7e27-9837-5140757b6191" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-838c-7a13-99ad-7516c30befbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7344-933c-4fa1c4f11671" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-838c-7083-a829-078c9b0827e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7344-933c-4fa1c4f11671" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-838c-7083-a829-078c9b0827e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019e4244-838c-78f8-a255-d2bb92ddd31b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7344-933c-4fa1c4f11671" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019e4244-838c-78f8-a255-d2bb92ddd31b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e4244-838c-7d13-b040-2d4752e17624" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-708f-b890-e503c7a76c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e4244-838c-7d13-b040-2d4752e17624" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-708f-b890-e503c7a76c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7fe8-85c4-97d0b8eed2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e4244-838c-7d13-b040-2d4752e17624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7fe8-85c4-97d0b8eed2e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_019e4244-838c-756f-af08-9ddb84211c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_019e4244-838c-756f-af08-9ddb84211c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019e4244-838c-7b5e-beb6-4f154ffff1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019e4244-838c-7b5e-beb6-4f154ffff1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e4244-838c-73c0-9ad8-69cb7edab537" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e4244-838c-73c0-9ad8-69cb7edab537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019e4244-838c-7e94-b5e7-b7103bc74512" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019e4244-838c-7e94-b5e7-b7103bc74512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-7e94-b64a-45174db54084" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-7e94-b64a-45174db54084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838c-7403-b8d5-9220b9d89dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838c-7403-b8d5-9220b9d89dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e4244-838c-78fc-b472-16c227ecf8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e4244-838c-78fc-b472-16c227ecf8f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019e4244-838c-7b5a-b0e7-1821d99bf58f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019e4244-838c-7b5a-b0e7-1821d99bf58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019e4244-838c-7153-951f-d137722483a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019e4244-838c-7153-951f-d137722483a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019e4244-838c-7319-bd41-a22a89f4d391" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019e4244-838c-7319-bd41-a22a89f4d391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherLosses_019e4244-838c-718d-8e4e-ba6c260020a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProvisionForOtherLosses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_ProvisionForOtherLosses_019e4244-838c-718d-8e4e-ba6c260020a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e4244-838c-7216-9307-05afc125ca09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_ShareBasedCompensation_019e4244-838c-7216-9307-05afc125ca09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019e4244-838c-79fa-9094-2aea1c78c8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019e4244-838c-79fa-9094-2aea1c78c8e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e4244-838c-76ee-9572-cc1cb5db3b63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e4244-838c-76ee-9572-cc1cb5db3b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_019e5eb2-ed71-7cb9-a54d-c6fdb017d449" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_019e5eb2-ed71-7cb9-a54d-c6fdb017d449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_019f94b1-8937-795c-a560-026eca39ad91" xlink:href="pcrx-20260630.xsd#pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_019f94b1-8937-795c-a560-026eca39ad91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAmortizationOfDeferredCharges_019fa727-3d4c-7a2b-96de-8bbde2d25ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAmortizationOfDeferredCharges"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7f8c-8f18-e762883cc1b2" xlink:to="loc_us-gaap_OtherAmortizationOfDeferredCharges_019fa727-3d4c-7a2b-96de-8bbde2d25ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7705-aaf1-3a9dcb72a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019e4244-838c-7e1f-9e83-78590c776eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7705-aaf1-3a9dcb72a16b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019e4244-838c-7e1f-9e83-78590c776eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_019e4244-838c-7743-9a47-ec2f1852e809" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7705-aaf1-3a9dcb72a16b" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_019e4244-838c-7743-9a47-ec2f1852e809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e4244-838c-7029-8b97-5a69e5ed7f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7705-aaf1-3a9dcb72a16b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e4244-838c-7029-8b97-5a69e5ed7f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_019e4244-838c-7ac7-b826-63fcc81ddda4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7705-aaf1-3a9dcb72a16b" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_019e4244-838c-7ac7-b826-63fcc81ddda4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019e5eb6-8f1f-745b-ad17-71a84d745657" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7705-aaf1-3a9dcb72a16b" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019e5eb6-8f1f-745b-ad17-71a84d745657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-72e4-a918-ef6b0e4af46b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7b92-8c23-6455a5600534" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-72e4-a918-ef6b0e4af46b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-7b92-8c23-6455a5600534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7c97-9cda-85ececcc6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-72e4-a918-ef6b0e4af46b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7c97-9cda-85ececcc6ef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7257-b1a9-e46c90939a34" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-72e4-a918-ef6b0e4af46b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7257-b1a9-e46c90939a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7d6d-bd30-7627006eb774" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-72e4-a918-ef6b0e4af46b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7d6d-bd30-7627006eb774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019e4244-838c-7594-8b4a-a074bb5b8337" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019e4244-838c-7594-8b4a-a074bb5b8337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-7602-a207-360fe39e9359" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-7602-a207-360fe39e9359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019e4244-838c-7d26-97c3-33a58685be44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019e4244-838c-7d26-97c3-33a58685be44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_019e4244-838c-79b6-83d2-3fe6bf3a0b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_019e4244-838c-79b6-83d2-3fe6bf3a0b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_019e4244-838c-7819-8afd-f7a0d47547fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_019e4244-838c-7819-8afd-f7a0d47547fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_019e5eb3-ac6e-7751-bc0b-0a1ee7a5a837" xlink:href="pcrx-20260630.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_019e5eb3-ac6e-7751-bc0b-0a1ee7a5a837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareRepurchaseProgramExciseTaxPaid_019fa728-ab38-77e3-94fc-9412a5a7df80" xlink:href="pcrx-20260630.xsd#pcrx_ShareRepurchaseProgramExciseTaxPaid"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7eaf-9181-6346b2cff6ce" xlink:to="loc_pcrx_ShareRepurchaseProgramExciseTaxPaid_019fa728-ab38-77e3-94fc-9412a5a7df80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INVENTORIESScheduleofComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019e4244-838c-725f-b696-40952ddcd967" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019e4244-838c-702f-9dcd-7c941523669f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019e4244-838c-725f-b696-40952ddcd967" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019e4244-838c-702f-9dcd-7c941523669f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019e4244-838c-72d8-a362-55f1db469e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019e4244-838c-725f-b696-40952ddcd967" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019e4244-838c-72d8-a362-55f1db469e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019e4244-838c-75b2-aa22-d8e41772e044" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019e4244-838c-725f-b696-40952ddcd967" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019e4244-838c-75b2-aa22-d8e41772e044" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-762b-97d0-99867c60af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019e4244-838c-7a39-a644-09c584d69de9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-762b-97d0-99867c60af3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019e4244-838c-7a39-a644-09c584d69de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-838c-7345-b514-1ac52719459f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-762b-97d0-99867c60af3b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-838c-7345-b514-1ac52719459f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_019e4244-838c-7144-a79e-250d7bd544e2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_019e4244-838c-706c-8dbe-df4217180185" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_019e4244-838c-7144-a79e-250d7bd544e2" xlink:to="loc_us-gaap_OperatingLeaseCost_019e4244-838c-706c-8dbe-df4217180185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_019e4244-838c-76b4-adf0-4070c8e0003e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_019e4244-838c-7144-a79e-250d7bd544e2" xlink:to="loc_us-gaap_VariableLeaseCost_019e4244-838c-76b4-adf0-4070c8e0003e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_019e4244-838c-7a9b-ad5d-cc76e9e58c14" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_019e4244-838c-7144-a79e-250d7bd544e2" xlink:to="loc_us-gaap_SubleaseIncome_019e4244-838c-7a9b-ad5d-cc76e9e58c14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_019e4244-838c-757c-bf0a-7355365c5de0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_019e4244-838c-757c-bf0a-7355365c5de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019e4244-838c-7494-b58c-f7e03d94d61e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019e4244-838c-7494-b58c-f7e03d94d61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019e4244-838c-77a8-b558-703ad2a2eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019e4244-838c-77a8-b558-703ad2a2eb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019e4244-838c-7076-97c3-4198cb4f6c66" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019e4244-838c-7076-97c3-4198cb4f6c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019e4244-838c-741d-b53d-0c73988af33b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019e4244-838c-741d-b53d-0c73988af33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_019e4244-838c-7138-ab60-fe1014a89f49" xlink:href="pcrx-20260630.xsd#pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-717b-8970-4861db9e86a2" xlink:to="loc_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_019e4244-838c-7138-ab60-fe1014a89f49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-7ac0-a690-b93b48eb3a08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019e4244-838c-7b54-9176-178edf4fbb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-7ac0-a690-b93b48eb3a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019e4244-838c-7b54-9176-178edf4fbb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_019e4244-838c-7d12-aec5-a11bc87be47c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-7ac0-a690-b93b48eb3a08" xlink:to="loc_us-gaap_OperatingLeaseLiability_019e4244-838c-7d12-aec5-a11bc87be47c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838d-708d-8936-6e23b63e1b21" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838d-7297-ba0a-8f666ced7059" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838d-708d-8936-6e23b63e1b21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838d-7297-ba0a-8f666ced7059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-838d-793f-a608-ea107d3806e7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838d-708d-8936-6e23b63e1b21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-838d-793f-a608-ea107d3806e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838d-7b29-a3c9-47d813070ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838d-7d7c-b70f-db13acd024e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838d-7b29-a3c9-47d813070ddf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838d-7d7c-b70f-db13acd024e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838d-7590-be22-7aa1e3f726f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838d-7b29-a3c9-47d813070ddf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838d-7590-be22-7aa1e3f726f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838d-77e1-bee7-185a104c3422" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838d-7a9e-92da-70354835a6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838d-77e1-bee7-185a104c3422" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838d-7a9e-92da-70354835a6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838d-788b-b1c3-6527c52915dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838d-77e1-bee7-185a104c3422" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838d-788b-b1c3-6527c52915dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_019e4244-838d-79c8-a296-d114f0545b92" xlink:href="pcrx-20260630.xsd#pcrx_AccruedSellingGeneralAndAdministrativeExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_019e4244-838d-79c8-a296-d114f0545b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedResearchAndDevelopmentExpenses_019e4244-838d-7235-886b-62e7c9fc4673" xlink:href="pcrx-20260630.xsd#pcrx_AccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_pcrx_AccruedResearchAndDevelopmentExpenses_019e4244-838d-7235-886b-62e7c9fc4673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e4244-838d-7a19-8bc1-1a66e4457055" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e4244-838d-7a19-8bc1-1a66e4457055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e4244-838d-7f43-a289-8ea7cd681a85" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e4244-838d-7f43-a289-8ea7cd681a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_019e4244-838d-7d48-98bf-e176be3929a1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_us-gaap_InterestPayableCurrent_019e4244-838d-7d48-98bf-e176be3929a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_019e4244-838d-75e7-ada3-cc780ae97ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_019e4244-838d-75e7-ada3-cc780ae97ff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedProductionCost_019e4244-838d-7760-8d2e-b17a704d14f2" xlink:href="pcrx-20260630.xsd#pcrx_AccruedProductionCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7524-8248-82eda49e94ac" xlink:to="loc_pcrx_AccruedProductionCost_019e4244-838d-7760-8d2e-b17a704d14f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019e4244-838d-7422-97c8-59d0846ba7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019e4244-838d-7afd-9ffb-62b2dcb3b820" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019e4244-838d-7422-97c8-59d0846ba7ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019e4244-838d-7afd-9ffb-62b2dcb3b820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_019e4244-838d-7097-ad5f-1cd90939146c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019e4244-838d-7422-97c8-59d0846ba7ff" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_019e4244-838d-7097-ad5f-1cd90939146c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019e4244-838d-7fb6-83d1-189e7a244e04" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_019e4244-838d-7cf9-a4d1-33869fab230a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_019e4244-838d-7fb6-83d1-189e7a244e04" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_019e4244-838d-7cf9-a4d1-33869fab230a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_019e4244-838d-7241-ada4-62a2fef72bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_019e4244-838d-7fb6-83d1-189e7a244e04" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_019e4244-838d-7241-ada4-62a2fef72bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_019e4244-838d-7c7d-a47a-100160b0c70a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_019e4244-838d-7fb6-83d1-189e7a244e04" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_019e4244-838d-7c7d-a47a-100160b0c70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment_019e4244-838d-7605-803a-a132a862a4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_019e4244-838d-7fb6-83d1-189e7a244e04" xlink:to="loc_us-gaap_InterestCostsCapitalizedAdjustment_019e4244-838d-7605-803a-a132a862a4c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7f00-9718-768db99f1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-838d-769d-a9d8-2468703451d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7f00-9718-768db99f1f86" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-838d-769d-a9d8-2468703451d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-838d-769b-acac-f4124f895eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7f00-9718-768db99f1f86" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-838d-769b-acac-f4124f895eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-8453-7efd-a72e-a230e40cd495" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7f00-9718-768db99f1f86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-8453-7efd-a72e-a230e40cd495" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8453-72f9-9bbb-6784e28a9925" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019e4244-8454-7345-b37e-4f8e4dc83b98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8453-72f9-9bbb-6784e28a9925" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019e4244-8454-7345-b37e-4f8e4dc83b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019e4244-8454-78f5-a98d-d88f575b5c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8453-72f9-9bbb-6784e28a9925" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019e4244-8454-78f5-a98d-d88f575b5c9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-707d-81de-06443798635d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019e4244-8454-7d58-b5a5-51bc7006fac8" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-707d-81de-06443798635d" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019e4244-8454-7d58-b5a5-51bc7006fac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7e58-804c-29af91a466a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-707d-81de-06443798635d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7e58-804c-29af91a466a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-8454-7f96-ba4e-c8e2ea51ed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-707d-81de-06443798635d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-8454-7f96-ba4e-c8e2ea51ed9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019f6ec3-f9f4-75bf-b389-6640092ffc61" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-707d-81de-06443798635d" xlink:to="loc_us-gaap_LitigationSettlementLoss_019f6ec3-f9f4-75bf-b389-6640092ffc61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-706a-829c-b4ab1d7da1de" xlink:href="pcrx-20260630.xsd#pcrx_CostOfGoodsSoldAdjusted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-706a-829c-b4ab1d7da1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-7196-81bb-59c54bc35619" xlink:href="pcrx-20260630.xsd#pcrx_ResearchAndDevelopmentAdjusted"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-7196-81bb-59c54bc35619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-784f-b970-01eb4af4282b" xlink:href="pcrx-20260630.xsd#pcrx_SellingAndMarketingAdjusted"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-784f-b970-01eb4af4282b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-769a-bd12-32a91a03865b" xlink:href="pcrx-20260630.xsd#pcrx_SellingGeneralAndAdministrativeAdjusted"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-769a-bd12-32a91a03865b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7d84-9c51-b4f39452e609" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7d84-9c51-b4f39452e609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-7e3c-83b4-37eef0f91311" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-7e3c-83b4-37eef0f91311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7bd0-be7e-5d38f5361afc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7bd0-be7e-5d38f5361afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-795a-aea6-78e8a199883e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-795a-aea6-78e8a199883e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019fa951-13c0-7d7e-8cdc-89722f9b2873" xlink:href="pcrx-20260630.xsd#pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019fa951-13c0-7d7e-8cdc-89722f9b2873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d9-7a85-794d-9469-470c98b4af35" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e4244-8454-7b39-923d-6bd1b0f3ef99" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d9-7a85-794d-9469-470c98b4af35" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>pcrx-20260630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e4244-8139-7e27-b3f4-c33a61dfef92,g:c636850a-8e11-4f67-b4ef-051f1780002d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:to="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-838c-7457-8013-1b7f48607fea_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-838c-7457-8013-1b7f48607fea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019e4244-838c-78d7-be85-63f506273d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:to="loc_us-gaap_ProductMember_019e4244-838c-78d7-be85-63f506273d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_019e4244-838c-7fb3-98ba-f9423fda569c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:to="loc_us-gaap_RoyaltyMember_019e4244-838c-7fb3-98ba-f9423fda569c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019e4244-838c-7958-98d4-8f5f3878fea1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_RevenuesAbstract_019e4244-838c-7958-98d4-8f5f3878fea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7b48-8ca8-17459ad3aa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019e4244-838c-7958-98d4-8f5f3878fea1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7b48-8ca8-17459ad3aa3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_019e4244-838c-7af2-979e-6f2adb9507f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_CostOfRevenue_019e4244-838c-7af2-979e-6f2adb9507f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e4244-838c-735e-b9cc-13248473176c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e4244-838c-735e-b9cc-13248473176c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-838c-7918-924b-bee390325e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-838c-7918-924b-bee390325e2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-75b1-beb7-4b9b9f5aef14" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-75b1-beb7-4b9b9f5aef14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-838c-7fe9-8d56-24e95e8429b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-838c-7fe9-8d56-24e95e8429b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-838c-7f82-b547-ccfbb2f49b12" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_CostsAndExpenses_019e4244-838c-7f82-b547-ccfbb2f49b12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-7ba1-978a-9e5147bb18fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-7ba1-978a-9e5147bb18fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019e4244-838c-7685-9a78-f48c8b1e4805" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019e4244-838c-7685-9a78-f48c8b1e4805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019e4244-838c-70a7-b643-28c5ebb648fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019e4244-838c-70a7-b643-28c5ebb648fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e4244-838c-78bd-a978-4c03f8624cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e4244-838c-78bd-a978-4c03f8624cb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7eae-8f65-cc108dd74ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7eae-8f65-cc108dd74ab0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7f99-8750-83d557213c37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7f99-8750-83d557213c37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-838c-7431-be38-6f7854960215" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-838c-7431-be38-6f7854960215" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-77e8-907e-4faa36c71c65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-77e8-907e-4faa36c71c65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e4244-838c-75d8-9ac0-a1cf436201fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e4244-838c-75d8-9ac0-a1cf436201fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e4244-838c-744f-b8b0-cf54b37f7ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e4244-838c-744f-b8b0-cf54b37f7ac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-838c-7a48-8e20-69286e11524f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-838c-7a48-8e20-69286e11524f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-838c-70f6-879d-835ef90cc0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-838c-70f6-879d-835ef90cc0e1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e4244-838c-763d-b593-9023eab9a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-763d-b593-9023eab9a9bb" xlink:to="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-838c-7ed0-a931-5bc942d290d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-838c-7ed0-a931-5bc942d290d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e4244-838c-7e7c-8c48-f91c7540882a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_CommonStockMember_019e4244-838c-7e7c-8c48-f91c7540882a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019e4244-838c-7e60-b3bd-2326c4f30348" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019e4244-838c-7e60-b3bd-2326c4f30348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838c-71a2-9674-f0b0090fde1f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838c-71a2-9674-f0b0090fde1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019e4244-838c-7ade-bfac-588f99dd8826" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_RetainedEarningsMember_019e4244-838c-7ade-bfac-588f99dd8826" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-838c-7842-836a-ab5d8a5aba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-838c-7842-836a-ab5d8a5aba3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-763d-b593-9023eab9a9bb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-760f-aad7-e5c4c7442dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-760f-aad7-e5c4c7442dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-7b47-a48c-2c698e5ef2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-7b47-a48c-2c698e5ef2d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-7588-bccf-0978af82c232" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-838c-7588-bccf-0978af82c232" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-838c-7cd8-b521-6aa9e8cb7cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-838c-7cd8-b521-6aa9e8cb7cb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019e4244-838c-7eea-85d9-15e7f7b29118" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019e4244-838c-7eea-85d9-15e7f7b29118" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019e4244-838c-7744-b1f4-3b32a60b232b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019e4244-838c-7744-b1f4-3b32a60b232b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_019e4244-838c-7857-a322-3d3e1bc3c0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_019e4244-838c-7857-a322-3d3e1bc3c0e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-838c-72cb-8879-686eaa729df8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-838c-72cb-8879-686eaa729df8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-78b8-9389-be699df50b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-78b8-9389-be699df50b8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e5fb1-bdef-7f4a-854a-6a8adb87ff7d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e5fb1-bdef-7f4a-854a-6a8adb87ff7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019e5fb2-30f6-7292-a2d1-fafd0b6bd584" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019e5fb2-30f6-7292-a2d1-fafd0b6bd584" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e4244-838c-7cc7-bfe7-ecf479c69ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e4244-838c-7cc7-bfe7-ecf479c69ae5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019e4244-838c-7090-9a29-5fc4e48de810" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019e4244-838c-7090-9a29-5fc4e48de810" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-838c-7e0a-bd7c-e802ffe48597" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-838c-7e0a-bd7c-e802ffe48597" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7b11-8c89-835b657d9e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7b11-8c89-835b657d9e0c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-7b96-b67c-37d3982da6da" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-7b96-b67c-37d3982da6da" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-7c16-8c27-7d8949054a17" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-74a5-812c-5a30a9de0c03" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-72df-b78c-f9ba105d3f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:to="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7d12-ae85-145085f0596e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7d12-ae85-145085f0596e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7146-9603-14a105b76db3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7146-9603-14a105b76db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-838c-7531-ab18-07d77a001568" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7146-9603-14a105b76db3" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-838c-7531-ab18-07d77a001568" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7bd0-a4bf-2ae92425b59e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7bd0-a4bf-2ae92425b59e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7238-961b-8971e8c96504" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7238-961b-8971e8c96504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-73d7-a4ea-b95710a13938" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7238-961b-8971e8c96504" xlink:to="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-73d7-a4ea-b95710a13938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-7eeb-9efe-a62ae85f592e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-7eeb-9efe-a62ae85f592e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-723b-9c7e-8bbb81a5ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-723b-9c7e-8bbb81a5ddd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_019e4244-838c-7a8c-b52b-1b23b65fa781" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-723b-9c7e-8bbb81a5ddd3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_019e4244-838c-7a8c-b52b-1b23b65fa781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838c-7e1a-bf5d-cf730e13ea4c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838c-7e1a-bf5d-cf730e13ea4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfProducts_019e4244-838c-7a64-8dce-5ed68c2f8ffb" xlink:href="pcrx-20260630.xsd#pcrx_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:to="loc_pcrx_ConcentrationRiskNumberOfProducts_019e4244-838c-7a64-8dce-5ed68c2f8ffb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:to="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-785f-83d5-bdefedc07097_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-785f-83d5-bdefedc07097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-79fa-ab72-961ee3544135" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-79fa-ab72-961ee3544135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838c-7eb6-87d1-034f2ddd38d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-79fa-ab72-961ee3544135" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838c-7eb6-87d1-034f2ddd38d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-76ac-a5e0-29edba099a01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-76ac-a5e0-29edba099a01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-761b-9b0c-29a5b86db5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-761b-9b0c-29a5b86db5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-7960-b282-6794f12b29e3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-761b-9b0c-29a5b86db5ea" xlink:to="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-7960-b282-6794f12b29e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-79f7-8127-6d4e9feb8584_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:to="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-79f7-8127-6d4e9feb8584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:to="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LargestCustomerMember_019e4244-838c-7705-ace5-5ee15b550683" xlink:href="pcrx-20260630.xsd#pcrx_LargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_LargestCustomerMember_019e4244-838c-7705-ace5-5ee15b550683" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondLargestCustomerMember_019e4244-838c-7469-8bc3-d1816e70d709" xlink:href="pcrx-20260630.xsd#pcrx_SecondLargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_SecondLargestCustomerMember_019e4244-838c-7469-8bc3-d1816e70d709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThirdLargestCustomerMember_019e4244-838c-7a7d-9769-f6793685f070" xlink:href="pcrx-20260630.xsd#pcrx_ThirdLargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_ThirdLargestCustomerMember_019e4244-838c-7a7d-9769-f6793685f070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThreeLargestCustomersMember_019e4244-838c-74d7-9d96-af5c9e582fad" xlink:href="pcrx-20260630.xsd#pcrx_ThreeLargestCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_ThreeLargestCustomersMember_019e4244-838c-74d7-9d96-af5c9e582fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfCustomers_019e4244-838c-7f14-9ed5-434266ccfd6b" xlink:href="pcrx-20260630.xsd#pcrx_ConcentrationRiskNumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:to="loc_pcrx_ConcentrationRiskNumberOfCustomers_019e4244-838c-7f14-9ed5-434266ccfd6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838c-74de-9a08-9e69a685b90f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838c-74de-9a08-9e69a685b90f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ASSETSANDLIABILITIESHELDFORSALEDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-706c-bfaa-e648f12469b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-706c-bfaa-e648f12469b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-7cd2-aff9-e93fdfd3bd58" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-7cd2-aff9-e93fdfd3bd58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019f9441-d09c-7f33-bc17-bbac6242456a" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-7cd2-aff9-e93fdfd3bd58" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019f9441-d09c-7f33-bc17-bbac6242456a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-7f1b-a9f2-1d3140b30fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-7f1b-a9f2-1d3140b30fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-7a39-78ee-b5a9-2597edddbf75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-7a39-78ee-b5a9-2597edddbf75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_019faeaa-5b11-7543-9abd-abf8df602289" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_019faeaa-5b11-7543-9abd-abf8df602289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7c09-9475-ff587ce51a63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7c09-9475-ff587ce51a63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneOneMember_019f6f30-8e22-7199-9dfb-91d16d1671d2" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:to="loc_pcrx_RevenueMilestoneOneMember_019f6f30-8e22-7199-9dfb-91d16d1671d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneTwoMember_019f6f30-8e22-7aa0-a8ae-c8347e2ca371" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:to="loc_pcrx_RevenueMilestoneTwoMember_019f6f30-8e22-7aa0-a8ae-c8347e2ca371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneThreeMember_019f6f30-8e22-752f-a234-c8b3e261833e" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:to="loc_pcrx_RevenueMilestoneThreeMember_019f6f30-8e22-752f-a234-c8b3e261833e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7536-8cab-38d51ad4dc83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7536-8cab-38d51ad4dc83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7cae-9fd5-8743c12efa85" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7cae-9fd5-8743c12efa85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019fad31-d790-749c-ac63-2db1d124d0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7cae-9fd5-8743c12efa85" xlink:to="loc_us-gaap_SubsequentEventMember_019fad31-d790-749c-ac63-2db1d124d0a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7803-97f7-ae326272a5f8_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7803-97f7-ae326272a5f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7ea4-871a-912729488378" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7ea4-871a-912729488378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019fae8c-a40f-7623-9ba4-3b275442aece" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7ea4-871a-912729488378" xlink:to="loc_srt_ScenarioForecastMember_019fae8c-a40f-7623-9ba4-3b275442aece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019f9441-d09c-7c14-af7f-24128b125a57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019f9441-d09c-7c14-af7f-24128b125a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_019f942a-2296-71b8-8923-0c6920c50161" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_019f942a-2296-71b8-8923-0c6920c50161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019fa6db-7030-7554-9b19-439651cc25eb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019fa6db-7030-7554-9b19-439651cc25eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa6db-b258-7622-b53f-326e43779df9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa6db-b258-7622-b53f-326e43779df9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa6db-f8f8-746d-9258-df8a9d6e5b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa6db-f8f8-746d-9258-df8a9d6e5b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019fa6dc-1ca6-71c7-b8e2-1fdbec22330a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019fa6dc-1ca6-71c7-b8e2-1fdbec22330a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa6dc-45de-70c2-b57e-25c39c3c2c33" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa6dc-45de-70c2-b57e-25c39c3c2c33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5ecb-7dc3-7011-9343-229fde460d17" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5ecb-7dc3-7011-9343-229fde460d17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019fa70c-403b-77e9-a10c-a7b8251ef9ee" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019fa70c-403b-77e9-a10c-a7b8251ef9ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_019f94d8-0f4c-7324-81f8-c722e269bef4" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_019f94d8-0f4c-7324-81f8-c722e269bef4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_019f6f30-8e22-70ed-8f87-0c3a5058350a" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_019f6f30-8e22-70ed-8f87-0c3a5058350a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_019fc818-a1e4-751c-b95c-0d874646eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_019fc818-a1e4-751c-b95c-0d874646eee8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_019fa71a-a6f5-7ada-b3ff-22c3b0eba5cd" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_019fa71a-a6f5-7ada-b3ff-22c3b0eba5cd" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#REVENUENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7c61-9c49-1d17e78ec784" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7c61-9c49-1d17e78ec784" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:to="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838c-7e8a-aa53-7828c5ac0523_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:to="loc_srt_RangeMember_019e4244-838c-7e8a-aa53-7828c5ac0523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:to="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-838c-74ae-92ad-86e9277b94cc" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:to="loc_srt_MinimumMember_019e4244-838c-74ae-92ad-86e9277b94cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-838c-7f2f-be75-e96b2be55702" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:to="loc_srt_MaximumMember_019e4244-838c-7f2f-be75-e96b2be55702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccountsReceivablePaymentTerms_019e4244-838c-76ce-9091-8263700edc48" xlink:href="pcrx-20260630.xsd#pcrx_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7c61-9c49-1d17e78ec784" xlink:to="loc_pcrx_AccountsReceivablePaymentTerms_019e4244-838c-76ce-9091-8263700edc48" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#REVENUEScheduleofDisaggregatedRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7e24-a9ef-3b56cfbf9ece" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7e24-a9ef-3b56cfbf9ece" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:to="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-838c-7ab1-875f-12e04d02aa87_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-838c-7ab1-875f-12e04d02aa87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-838c-7023-8741-05574701eea1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-838c-7023-8741-05574701eea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-838c-7023-8741-05574701eea1" xlink:to="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EXPARELMember_019e4244-838c-77d9-ad8b-df2724bcd3bc" xlink:href="pcrx-20260630.xsd#pcrx_EXPARELMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_EXPARELMember_019e4244-838c-77d9-ad8b-df2724bcd3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember_019e4244-838c-70bf-99ff-6e9cef988fb8" xlink:href="pcrx-20260630.xsd#pcrx_ZILRETTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_ZILRETTAMember_019e4244-838c-70bf-99ff-6e9cef988fb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember_019e4244-838c-7511-b2af-cf4f666bae64" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_IoveraMember_019e4244-838c-7511-b2af-cf4f666bae64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_019e4244-838c-7a47-847c-56c8023efd0e" xlink:href="pcrx-20260630.xsd#pcrx_BupivacaineLiposomeInjectableSuspensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_019e4244-838c-7a47-847c-56c8023efd0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7df7-8316-87b4c54e234e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7e24-a9ef-3b56cfbf9ece" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7df7-8316-87b4c54e234e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INVENTORIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/INVENTORIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7777-8443-919f995ffefc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7777-8443-919f995ffefc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7ec4-b017-7e7c64564aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7ec4-b017-7e7c64564aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-1a63-77e9-9d3b-50c0dfe7c506" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7ec4-b017-7e7c64564aa4" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-1a63-77e9-9d3b-50c0dfe7c506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7a19-a71f-221f325cdd08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7a19-a71f-221f325cdd08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7cbe-85e3-cef5c3efcc75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7cbe-85e3-cef5c3efcc75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa717-2701-7e5e-bda8-d7f5d3ac5b78" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7cbe-85e3-cef5c3efcc75" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa717-2701-7e5e-bda8-d7f5d3ac5b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-70df-8216-52697b345c21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-70df-8216-52697b345c21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_019fa709-6a45-7c08-900d-6fce61cdcf57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_019fa709-6a45-7c08-900d-6fce61cdcf57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WorkInProcessMember_019fa70a-42d8-764a-b1ff-61954a8ea484" xlink:href="pcrx-20260630.xsd#pcrx_WorkInProcessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:to="loc_pcrx_WorkInProcessMember_019fa70a-42d8-764a-b1ff-61954a8ea484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FinishedGoodsMember_019fa70a-83c4-7ed9-9513-89ab3d4a626b" xlink:href="pcrx-20260630.xsd#pcrx_FinishedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:to="loc_pcrx_FinishedGoodsMember_019fa70a-83c4-7ed9-9513-89ab3d4a626b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019f6f3b-e381-752b-8019-aa176a0d588e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryNet_019f6f3b-e381-752b-8019-aa176a0d588e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019f6f3b-e381-7ea9-842e-383eb9b73ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019f6f3b-e381-7ea9-842e-383eb9b73ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019f6f3b-e381-7f17-bdb7-7a5ac4022a37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019f6f3b-e381-7f17-bdb7-7a5ac4022a37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019f6f3b-e381-7333-834c-3e45b725d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019f6f3b-e381-7333-834c-3e45b725d67e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa709-6a45-7e41-9ecc-cd31e60e9778" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa709-6a45-7e41-9ecc-cd31e60e9778" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-7344-9a4c-44b2dd0dafba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-7344-9a4c-44b2dd0dafba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_019e4244-838c-7eee-98c5-a4467ffc0e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_019e4244-838c-7eee-98c5-a4467ffc0e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-758a-8578-6f0cfb11b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-758a-8578-6f0cfb11b2a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_019e4244-838c-7dfd-aaad-387c1beac570" xlink:href="pcrx-20260630.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_019e4244-838c-7dfd-aaad-387c1beac570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019e4244-838c-776f-9a84-f4b6d5b7cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019e4244-838c-776f-9a84-f4b6d5b7cba1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_019e4244-838c-77ab-ad7f-d63d8b450b45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_ConstructionInProgressMember_019e4244-838c-77ab-ad7f-d63d8b450b45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019e4244-838c-7cff-8665-837ef62a96bd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019e4244-838c-7cff-8665-837ef62a96bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-838c-7c9e-9524-cfef607ee681" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-838c-7c9e-9524-cfef607ee681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-73dc-81ee-73e59e1aec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-73dc-81ee-73e59e1aec8f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-7d2a-b7e5-82c331acd9cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-7d2a-b7e5-82c331acd9cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_019f6f45-8875-7b66-b410-27e45f955089" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_019f6f45-8875-7b66-b410-27e45f955089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-7224-bb61-a0490b2a3eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-7224-bb61-a0490b2a3eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019e4244-838c-7fb3-a343-40472da65f14_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:to="loc_srt_SegmentGeographicalDomain_019e4244-838c-7fb3-a343-40472da65f14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019e4244-838c-7341-ba1b-6aa9832c90b6" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:to="loc_srt_SegmentGeographicalDomain_019e4244-838c-7341-ba1b-6aa9832c90b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_019e4244-838c-70ff-a872-527242ee38e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-838c-7341-ba1b-6aa9832c90b6" xlink:to="loc_us-gaap_NonUsMember_019e4244-838c-70ff-a872-527242ee38e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-70ff-bcec-95d09fdc1451_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-70ff-bcec-95d09fdc1451_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-75e1-84e0-abd819fe54a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-75e1-84e0-abd819fe54a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-8b02-7501-89e6-2f88dab5a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-75e1-84e0-abd819fe54a3" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-8b02-7501-89e6-2f88dab5a4e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7ce6-9232-6e99f50c5afc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7ce6-9232-6e99f50c5afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember_019f9437-d845-7e7d-b09e-2f6074c93c10" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:to="loc_pcrx_IoveraMember_019f9437-d845-7e7d-b09e-2f6074c93c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa706-3b33-7156-a83e-98245ce0a14e" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa706-3b33-7156-a83e-98245ce0a14e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-7248-925b-df6a6d7d6929" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-7248-925b-df6a6d7d6929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019f6f45-8875-73be-9bfd-7107d7991911" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019f6f45-8875-73be-9bfd-7107d7991911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019e4244-838c-7415-b584-edf29a524803" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_Depreciation_019e4244-838c-7415-b584-edf29a524803" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_019e5efa-c50c-7a55-86fb-4bc346716014" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_019e5efa-c50c-7a55-86fb-4bc346716014" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_019e4244-838c-7331-b23d-d2e76a23e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetRetirementObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_AssetRetirementObligation_019e4244-838c-7331-b23d-d2e76a23e5f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa706-3b33-7a11-b741-7e3e52ad1c01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa706-3b33-7a11-b741-7e3e52ad1c01" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7054-a66d-c1b50de2808a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7054-a66d-c1b50de2808a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7952-8b47-91fa60471797" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7952-8b47-91fa60471797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-e74e-7050-84a7-d5516fcbcae1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7952-8b47-91fa60471797" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-e74e-7050-84a7-d5516fcbcae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7965-8e68-0778bff901f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7965-8e68-0778bff901f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7892-a2d7-2c1871aa6552" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7892-a2d7-2c1871aa6552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa703-6e12-7670-af3d-aa792fb2f792" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7892-a2d7-2c1871aa6552" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa703-6e12-7670-af3d-aa792fb2f792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7eb1-9493-0ecf1d58ed5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7eb1-9493-0ecf1d58ed5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019fa738-3f79-78a1-864d-d2cfcc49070a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019fa738-3f79-78a1-864d-d2cfcc49070a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_019fa93b-bc16-7ccd-a265-f375a4570c04" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:to="loc_us-gaap_CustomerRelationshipsMember_019fa93b-bc16-7ccd-a265-f375a4570c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019e4244-838c-7fa6-8dee-33936983ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_Goodwill_019e4244-838c-7fa6-8dee-33936983ecfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_019e4244-838c-7105-ab41-2028e70d4c84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_019e4244-838c-7105-ab41-2028e70d4c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019e4244-838c-760b-ba4f-368058c305d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019e4244-838c-760b-ba4f-368058c305d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa703-6e12-7ec6-a0b6-c9e2e6bc1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa703-6e12-7ec6-a0b6-c9e2e6bc1e58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-7d0d-ac32-3f83e456cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-7d0d-ac32-3f83e456cb99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_019e4244-838c-759a-b8ce-f87954fe7510" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_019e4244-838c-759a-b8ce-f87954fe7510" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019e4244-838c-72e4-9c9f-6aa8139a573a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019e4244-838c-72e4-9c9f-6aa8139a573a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019e4244-838c-7174-a5c8-65b6df54b2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019e4244-838c-7174-a5c8-65b6df54b2f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019e4244-838c-74af-83f9-f309523b8e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019e4244-838c-74af-83f9-f309523b8e3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019e4244-838c-72d6-8892-63cae330ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019e4244-838c-72d6-8892-63cae330ee5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019e4244-838c-7c18-8374-c17b252eabcd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019e4244-838c-7c18-8374-c17b252eabcd" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-78a8-94fd-904ba78c2174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-78a8-94fd-904ba78c2174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019e4244-838c-7dba-a05f-6e6e86a61a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019e4244-838c-7dba-a05f-6e6e86a61a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_019e4244-838c-7556-9a24-af3dd0060a66" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:to="loc_us-gaap_CustomerRelationshipsMember_019e4244-838c-7556-9a24-af3dd0060a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7f35-9dde-f27e58452ea9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7f35-9dde-f27e58452ea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7712-9f68-48f59eaf2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7712-9f68-48f59eaf2c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_019e4244-838c-7125-8065-6a1cff444965" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7712-9f68-48f59eaf2c07" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_019e4244-838c-7125-8065-6a1cff444965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838c-76d0-bc2b-e40a856df73d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838c-76d0-bc2b-e40a856df73d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-838c-7fe8-be5a-bc491c78dc98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-838c-7fe8-be5a-bc491c78dc98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838c-76b6-9875-22695f5a95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838c-76b6-9875-22695f5a95e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838c-7cc6-bc55-3ad4bb04b883" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838c-7cc6-bc55-3ad4bb04b883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838c-7109-a43f-2e9a364cb586" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838c-7109-a43f-2e9a364cb586" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-7b37-a0b7-58f32f2219a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-7b37-a0b7-58f32f2219a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_019e4244-838c-77e0-94cb-acf3ea71d594" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_019e4244-838c-77e0-94cb-acf3ea71d594" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ACCRUEDEXPENSESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:href="pcrx-20260630.xsd#pcrx_AccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:href="pcrx-20260630.xsd#pcrx_AccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-72bb-be46-31767e836afc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-72bb-be46-31767e836afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-7923-ac64-4329c434e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-7923-ac64-4329c434e24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-b672-7e57-b820-199b8605b744" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-7923-ac64-4329c434e24c" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-b672-7e57-b820-199b8605b744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7da3-ab25-bdeafcb6a5a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7da3-ab25-bdeafcb6a5a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7dc0-8d22-f24ac8dc4965" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7dc0-8d22-f24ac8dc4965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember_019f94db-2962-76ad-9bb3-0b00a86de7dc" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7dc0-8d22-f24ac8dc4965" xlink:to="loc_pcrx_IoveraMember_019f94db-2962-76ad-9bb3-0b00a86de7dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f94db-2962-7421-b931-e32bfc508019" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f94db-2962-7421-b931-e32bfc508019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019fa6ff-690f-7046-904b-a7b4a7ce1880" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019fa6ff-690f-7046-904b-a7b4a7ce1880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_019fa700-c3b5-746d-80e5-551aa7253c3b" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_019fa700-c3b5-746d-80e5-551aa7253c3b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:to="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7fd4-81fb-5c14c8d233f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7fd4-81fb-5c14c8d233f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7ec9-aaab-f989cb10fee2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7ec9-aaab-f989cb10fee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7627-8670-d697eeea4004" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7ec9-aaab-f989cb10fee2" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7627-8670-d697eeea4004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7782-93af-8af61b1e50ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7782-93af-8af61b1e50ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7cc2-9e39-171f64f7c601" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7cc2-9e39-171f64f7c601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019e4244-838d-7840-86d0-bed351e0afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:to="loc_us-gaap_LineOfCreditMember_019e4244-838d-7840-86d0-bed351e0afdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74ce-b4d3-30861b6a8c8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74ce-b4d3-30861b6a8c8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-77e1-b21c-634a5010f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-77e1-b21c-634a5010f89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7ccc-b4a5-53432c9dc567" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-77e1-b21c-634a5010f89f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7ccc-b4a5-53432c9dc567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-74f1-9c08-116bd5ae0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-74f1-9c08-116bd5ae0d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019e4244-838d-7bc3-8703-a66a525d59af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:to="loc_us-gaap_LongTermDebt_019e4244-838d-7bc3-8703-a66a525d59af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-71b2-b7d3-21bceed10c5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-71b2-b7d3-21bceed10c5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-744e-9319-7d04dfdc645f" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-744e-9319-7d04dfdc645f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_019e4244-838d-79c0-bc55-38908b75b8bc" xlink:href="pcrx-20260630.xsd#pcrx_WellsFargoBankNationalAssociationCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_019e4244-838d-79c0-bc55-38908b75b8bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanAFacilityDueMarch2028Member_019e4244-838d-7c99-92ae-5819b3162b9f" xlink:href="pcrx-20260630.xsd#pcrx_TermLoanAFacilityDueMarch2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_TermLoanAFacilityDueMarch2028Member_019e4244-838d-7c99-92ae-5819b3162b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_019e4244-838d-7abb-9ecc-823a5eee172f" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_019e4244-838d-7abb-9ecc-823a5eee172f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7ba0-b9eb-a4c7be58cfae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7ba0-b9eb-a4c7be58cfae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7c78-8d9e-66406049ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7c78-8d9e-66406049ef4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019e4244-838d-7c13-97dc-4d39afc2c321" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_ConvertibleDebtMember_019e4244-838d-7c13-97dc-4d39afc2c321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019e4244-838d-7755-851a-f815b57c951f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_LineOfCreditMember_019e4244-838d-7755-851a-f815b57c951f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019e4244-838d-7ebb-828f-85501a7b7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_SecuredDebtMember_019e4244-838d-7ebb-828f-85501a7b7ae9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-7e81-9509-709b4031c5bd_default" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:to="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-7e81-9509-709b4031c5bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:to="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsOneMember_019e4244-838d-7b5d-8e05-fd626dd27ed5" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:to="loc_pcrx_DebtConversionTermsOneMember_019e4244-838d-7b5d-8e05-fd626dd27ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsTwoMember_019e4244-838d-7be6-9338-63b9adb02745" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:to="loc_pcrx_DebtConversionTermsTwoMember_019e4244-838d-7be6-9338-63b9adb02745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsThreeMember_019e4244-838d-7d09-b781-6034cba7b40f" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:to="loc_pcrx_DebtConversionTermsThreeMember_019e4244-838d-7d09-b781-6034cba7b40f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7c82-885d-72b5bef7d86f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7c82-885d-72b5bef7d86f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7e94-82d5-fd8fbf8ad3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7e94-82d5-fd8fbf8ad3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CappedCallMember_019e4244-838d-7462-9f7f-e3304bdb63f1" xlink:href="pcrx-20260630.xsd#pcrx_CappedCallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7e94-82d5-fd8fbf8ad3bc" xlink:to="loc_pcrx_CappedCallMember_019e4244-838d-7462-9f7f-e3304bdb63f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-838d-7a75-be0b-86471a6adf15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-838d-7a75-be0b-86471a6adf15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-838d-7ff2-98b7-231344614643" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-838d-7ff2-98b7-231344614643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838d-7e80-82c4-75f741bae116" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838d-7ff2-98b7-231344614643" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838d-7e80-82c4-75f741bae116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-718a-a5ec-3789f7ed5c9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-718a-a5ec-3789f7ed5c9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7716-993b-3739cc19ed83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7716-993b-3739cc19ed83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_019e4244-838d-77b1-8e35-f930adf8cdee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:to="loc_us-gaap_LetterOfCreditMember_019e4244-838d-77b1-8e35-f930adf8cdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_019e4244-838d-7f4d-bc38-e1740c2b1a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:to="loc_us-gaap_BridgeLoanMember_019e4244-838d-7f4d-bc38-e1740c2b1a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-7b2c-9b72-57932049465f_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:to="loc_srt_RangeMember_019e4244-838d-7b2c-9b72-57932049465f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:to="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-838d-73d7-9343-6422853df789" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:to="loc_srt_MinimumMember_019e4244-838d-73d7-9343-6422853df789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-838d-7b7d-9c28-871187d47f43" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:to="loc_srt_MaximumMember_019e4244-838d-7b7d-9c28-871187d47f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_019e4244-838d-70f7-a4d5-ae666ef2de5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:to="loc_us-gaap_VariableRateDomain_019e4244-838d-70f7-a4d5-ae666ef2de5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:to="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_019e4244-838d-718c-89c5-76c3f48609e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:to="loc_us-gaap_BaseRateMember_019e4244-838d-718c-89c5-76c3f48609e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019e4244-838d-75c2-ab5a-0de63a4ffdad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019e4244-838d-75c2-ab5a-0de63a4ffdad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7a81-981c-25780ee30435_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7a81-981c-25780ee30435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7da5-9609-07ba8957088d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7da5-9609-07ba8957088d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019e4244-838d-75b8-9c17-464c39021419" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7da5-9609-07ba8957088d" xlink:to="loc_srt_ScenarioForecastMember_019e4244-838d-75b8-9c17-464c39021419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019e4244-838d-741e-8946-aa46c3f6d3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019e4244-838d-741e-8946-aa46c3f6d3b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7838-ad99-9b161a5e55d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7838-ad99-9b161a5e55d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_019e4244-838d-7c0b-bc57-8bfa5934f744" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentMarketPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentMarketPrice_019e4244-838d-7c0b-bc57-8bfa5934f744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_019e4244-838d-7482-a6ef-ea85c86aa0df" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentRepurchasedInConversionFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_019e4244-838d-7482-a6ef-ea85c86aa0df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_019e4244-838d-7c50-9cfd-e3ad0c90349f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_019e4244-838d-7c50-9cfd-e3ad0c90349f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_019e4244-838d-7d69-bdab-997f63d389c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_019e4244-838d-7d69-bdab-997f63d389c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_019e4244-838d-73ea-a60b-63c6d6d44472" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_019e4244-838d-73ea-a60b-63c6d6d44472" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_019e4244-838d-710b-856e-57e95d9fa31d" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_019e4244-838d-710b-856e-57e95d9fa31d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_019e4244-838d-7e5d-b660-67cde0b66d77" xlink:href="pcrx-20260630.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_019e4244-838d-7e5d-b660-67cde0b66d77" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_019e4244-838d-71b3-ad23-b219d98bb424" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_019e4244-838d-71b3-ad23-b219d98bb424" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-77cc-bfb6-51579dc026f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-77cc-bfb6-51579dc026f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_019e4244-838d-714f-b4ec-9ae57d364930" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_019e4244-838d-714f-b4ec-9ae57d364930" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_019e4244-838d-7936-8739-9e3e88b2b712" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_SharePrice_019e4244-838d-7936-8739-9e3e88b2b712" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_019e4244-838d-7fe3-8fc1-e0dd3a5ad37c" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_019e4244-838d-7fe3-8fc1-e0dd3a5ad37c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_019e4244-838d-72cb-9f5b-cc598e1239f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_019e4244-838d-72cb-9f5b-cc598e1239f4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DerivativeCappedCallPrice_019e4244-838d-76e0-90f0-355e32de80e0" xlink:href="pcrx-20260630.xsd#pcrx_DerivativeCappedCallPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DerivativeCappedCallPrice_019e4244-838d-76e0-90f0-355e32de80e0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DerivativePremiumPercentage_019e4244-838d-79a0-9d6e-831dfdda41cb" xlink:href="pcrx-20260630.xsd#pcrx_DerivativePremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DerivativePremiumPercentage_019e4244-838d-79a0-9d6e-831dfdda41cb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_019e4244-838d-753d-a234-9be0472efba5" xlink:href="pcrx-20260630.xsd#pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_019e4244-838d-753d-a234-9be0472efba5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_019e4244-838d-7fb4-9e7f-3ed1e0b254a6" xlink:href="pcrx-20260630.xsd#pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_019e4244-838d-7fb4-9e7f-3ed1e0b254a6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019e4244-838d-7552-ba66-2a6806a02d39" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019e4244-838d-7552-ba66-2a6806a02d39" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_019e4244-838d-76bb-8c4d-426802121a22" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentCovenantIncrementalDebtMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_019e4244-838d-76bb-8c4d-426802121a22" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_019e4244-838d-7b89-9dfa-1976c7514f6e" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_019e4244-838d-7b89-9dfa-1976c7514f6e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019e4244-838d-7a22-928c-b03ab67c5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019e4244-838d-7a22-928c-b03ab67c5aa5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_019e4244-838d-7994-8ec6-6643418505fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_019e4244-838d-7994-8ec6-6643418505fc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019e4244-838d-72a6-9443-ffd36cd9629b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019e4244-838d-72a6-9443-ffd36cd9629b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_019e4244-838d-7829-861b-c7ae99caab46" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_LineOfCredit_019e4244-838d-7829-861b-c7ae99caab46" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_019e4244-838d-79c3-b9c8-e368328f7ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_019e4244-838d-79c3-b9c8-e368328f7ab0" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_019e4244-838d-7fc0-b57f-ea03ded3eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_019e4244-838d-7fc0-b57f-ea03ded3eaf0" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentDiscountRate_019e4244-838d-749a-93b4-e8258870c473" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentDiscountRate_019e4244-838d-749a-93b4-e8258870c473" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_019e4244-838d-7ff9-a6a3-52744db93a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_019e4244-838d-7ff9-a6a3-52744db93a38" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019e4244-838d-7ca1-8577-b9b01bef38ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019e4244-838d-7ca1-8577-b9b01bef38ce" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_019e4244-838d-712b-abb3-465e09eaddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_019e4244-838d-712b-abb3-465e09eaddd0" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal_019e4244-838d-773e-8a82-edc5e08a4358" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepaidPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentRepaidPrincipal_019e4244-838d-773e-8a82-edc5e08a4358" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_019e4244-838d-70f8-a311-8dd372085290" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_InterestPaid_019e4244-838d-70f8-a311-8dd372085290" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019e4244-838d-7b4a-a75b-633cf3d91f99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019e4244-838d-7b4a-a75b-633cf3d91f99" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_019e4244-838d-77e4-8088-54c0b51b727f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_RepaymentsOfDebt_019e4244-838d-77e4-8088-54c0b51b727f" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_019e4244-838d-700f-a31e-b5bdf1d5b140" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_019e4244-838d-700f-a31e-b5bdf1d5b140" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_019e4244-838d-790b-9bab-7cd5cf7226a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_019e4244-838d-790b-9bab-7cd5cf7226a4" xlink:type="arc" order="37"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7e2f-80f3-5e35d10ab766_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7e2f-80f3-5e35d10ab766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7b4b-b2a6-b46fe9f79aac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7b4b-b2a6-b46fe9f79aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7bda-a52c-3d6c955c2a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7b4b-b2a6-b46fe9f79aac" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7bda-a52c-3d6c955c2a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7549-8773-ad822870b750_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7549-8773-ad822870b750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-722d-88fd-925b097913ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-722d-88fd-925b097913ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7c4e-9dd8-3f1787536402" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-722d-88fd-925b097913ef" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7c4e-9dd8-3f1787536402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7de6-8529-d2d314d000c0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7de6-8529-d2d314d000c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019e4244-838d-7f37-9814-a4dcef3c72f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019e4244-838d-7f37-9814-a4dcef3c72f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_019e4244-838d-7613-9203-fb39b63d0ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_019e4244-838d-7613-9203-fb39b63d0ba0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019e4244-838d-74ee-bb0c-640b41da4ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_LongTermDebt_019e4244-838d-74ee-bb0c-640b41da4ee5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-756a-abb3-eca80a52d2b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-756a-abb3-eca80a52d2b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-838d-7eca-b14c-cab18eb4f08c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-838d-7eca-b14c-cab18eb4f08c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-838d-7eca-b14c-cab18eb4f08c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019e4244-838d-7790-8847-ff81d657ffe5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019e4244-838d-7790-8847-ff81d657ffe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019e4244-838d-767e-9548-711197cfd0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019e4244-838d-767e-9548-711197cfd0ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7d68-92cb-40b4471ad284_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7d68-92cb-40b4471ad284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019e4244-838d-7db3-990a-7a41f40bc2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019e4244-838d-7db3-990a-7a41f40bc2c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7669-bc75-95ea567932a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7669-bc75-95ea567932a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7ba3-8c4b-7b4a36d6950c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7ba3-8c4b-7b4a36d6950c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7321-a5c2-b4676a5fd23d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7321-a5c2-b4676a5fd23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-741a-95f8-c2db9c14c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-741a-95f8-c2db9c14c46b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7b7d-bed7-08c4e2494978" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-741a-95f8-c2db9c14c46b" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7b7d-bed7-08c4e2494978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7908-a51c-929326fd1b5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7908-a51c-929326fd1b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7f31-98b8-6bc8fa624d74" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7f31-98b8-6bc8fa624d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019e4244-838d-7661-a77f-bb4b0370a0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:to="loc_us-gaap_LineOfCreditMember_019e4244-838d-7661-a77f-bb4b0370a0b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-7e0c-b938-bc5de3d44b7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-7e0c-b938-bc5de3d44b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-796a-988c-f975e6db025c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-796a-988c-f975e6db025c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7210-b45a-38caecdaf7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-796a-988c-f975e6db025c" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7210-b45a-38caecdaf7fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivablesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019e4244-838d-7577-81e5-a27e04f386f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019e4244-838d-7577-81e5-a27e04f386f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure_019e4244-838d-72e2-8758-1625d1a8d964" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:to="loc_us-gaap_NotesReceivableFairValueDisclosure_019e4244-838d-72e2-8758-1625d1a8d964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-838d-7cd7-a7cf-f81fb47531db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-838d-7cd7-a7cf-f81fb47531db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7104-9640-7f57f6d358fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-838d-7cd7-a7cf-f81fb47531db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7104-9640-7f57f6d358fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7642-92ef-d01fcb7a560d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7642-92ef-d01fcb7a560d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_019e4244-838d-793f-9922-40eddcfd3dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_DebtInstrumentFairValue_019e4244-838d-793f-9922-40eddcfd3dfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_019e4244-838d-7a39-b691-885608b1675a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_SharePrice_019e4244-838d-7a39-b691-885608b1675a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-7d34-9514-cf8cf1253826" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-7d34-9514-cf8cf1253826" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-79ef-a61b-31eaa8fd8a37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-79ef-a61b-31eaa8fd8a37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019e4244-838d-7606-be82-b28917cb93f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:to="loc_us-gaap_EquitySecuritiesMember_019e4244-838d-7606-be82-b28917cb93f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleNotesReceivableMember_019e4244-838d-76dc-b9c3-57b508eb4f0e" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleNotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:to="loc_pcrx_ConvertibleNotesReceivableMember_019e4244-838d-76dc-b9c3-57b508eb4f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e4244-838d-76bc-8d47-c10933be0dfc_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:to="loc_srt_OwnershipDomain_019e4244-838d-76bc-8d47-c10933be0dfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e4244-838d-7e53-85ef-36ef19907a52" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:to="loc_srt_OwnershipDomain_019e4244-838d-7e53-85ef-36ef19907a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7ab5-877d-ee666d97fdef" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019e4244-838d-7e53-85ef-36ef19907a52" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7ab5-877d-ee666d97fdef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7f9f-8b5f-4c18ca18e9e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7f9f-8b5f-4c18ca18e9e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7768-9c99-9d66371883ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7768-9c99-9d66371883ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7c1e-8e05-6419ffe1246a" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7768-9c99-9d66371883ff" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7c1e-8e05-6419ffe1246a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7cd2-b90f-8927b26fcf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7cd2-b90f-8927b26fcf7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019e4244-838d-73b2-943d-07890c8d6fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019e4244-838d-73b2-943d-07890c8d6fb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_019e4244-838d-7f63-8247-4469347e338a" xlink:href="pcrx-20260630.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_019e4244-838d-7f63-8247-4469347e338a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019e4244-838d-705e-aa64-c3db9c34e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019e4244-838d-705e-aa64-c3db9c34e1b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019e4244-838d-7aed-8708-d9863d5eac1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019e4244-838d-7aed-8708-d9863d5eac1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-7064-a847-aa6d320bd798" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-7064-a847-aa6d320bd798" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019e4244-838d-7047-a491-b2a31ba93e50" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019e4244-838d-7047-a491-b2a31ba93e50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7b8d-9492-d57de985a094" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838d-7d2a-bd2d-626861aa625b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838d-7d2a-bd2d-626861aa625b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7ad5-a367-17cba7bef49e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7ad5-a367-17cba7bef49e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_019e4244-838d-7360-89f0-68fd468b7ab9" xlink:href="pcrx-20260630.xsd#pcrx_EquityInvestmentAndConvertibleNoteReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:to="loc_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_019e4244-838d-7360-89f0-68fd468b7ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_019e4244-838d-73a5-a6a7-d3c8be7d22b4" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:to="loc_pcrx_ContingentConsiderationMember_019e4244-838d-73a5-a6a7-d3c8be7d22b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-7c31-9484-0fd0a461fdef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:to="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-7c31-9484-0fd0a461fdef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-714e-af51-7d2feabff1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:to="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-714e-af51-7d2feabff1fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleNoteReceivableMember_019e4244-838d-74c3-a83f-badab89a8b62" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleNoteReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-714e-af51-7d2feabff1fa" xlink:to="loc_pcrx_ConvertibleNoteReceivableMember_019e4244-838d-74c3-a83f-badab89a8b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-73fa-be8e-e610d9561338_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-73fa-be8e-e610d9561338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-78a3-b105-33904e8ac914" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-78a3-b105-33904e8ac914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7316-be17-16fb2d270ef4" xlink:href="pcrx-20260630.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-78a3-b105-33904e8ac914" xlink:to="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7316-be17-16fb2d270ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-72a5-b95d-d1c94bf2c0f8_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:to="loc_srt_RangeMember_019e4244-838d-72a5-b95d-d1c94bf2c0f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-713b-af47-8ec338f290a1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:to="loc_srt_RangeMember_019e4244-838d-713b-af47-8ec338f290a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_019e4244-838d-7b46-915a-d08301f00b72" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838d-713b-af47-8ec338f290a1" xlink:to="loc_srt_WeightedAverageMember_019e4244-838d-7b46-915a-d08301f00b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-769a-aa60-ee5c1acea43c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-769a-aa60-ee5c1acea43c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7bdc-aecd-c3053b7ec992" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7bdc-aecd-c3053b7ec992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-753b-b380-ea48a68bc226" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7bdc-aecd-c3053b7ec992" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-753b-b380-ea48a68bc226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7b5d-a9f3-53b17dda5fdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7b5d-a9f3-53b17dda5fdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-739e-9d42-156a05e3c51e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-739e-9d42-156a05e3c51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-7c92-b684-1f22375aafb4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-739e-9d42-156a05e3c51e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-7c92-b684-1f22375aafb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-703b-a93d-46515af6fe59_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:to="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-703b-a93d-46515af6fe59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:to="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerOneMember_019e4244-838d-720b-bb92-04e27592ce97" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:to="loc_pcrx_MajorCustomerOneMember_019e4244-838d-720b-bb92-04e27592ce97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerTwoMember_019e4244-838d-7350-8ee5-bca207840af1" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:to="loc_pcrx_MajorCustomerTwoMember_019e4244-838d-7350-8ee5-bca207840af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerThreeMember_019e4244-838d-7f05-af71-0b282c25b01a" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:to="loc_pcrx_MajorCustomerThreeMember_019e4244-838d-7f05-af71-0b282c25b01a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-76d9-a9cf-b58c9648b7dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-76d9-a9cf-b58c9648b7dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-78e1-a817-c310d7e19898" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-78e1-a817-c310d7e19898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_019e4244-838d-7b17-8db5-e738403d4723" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-78e1-a817-c310d7e19898" xlink:to="loc_us-gaap_AccountsReceivableMember_019e4244-838d-7b17-8db5-e738403d4723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-761a-9709-75bd2ee186b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-761a-9709-75bd2ee186b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-7c54-bab9-0d51e1ba37e6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-7c54-bab9-0d51e1ba37e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838d-7659-b213-e443b9e43780" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-7c54-bab9-0d51e1ba37e6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838d-7659-b213-e443b9e43780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_019e4244-838d-71ba-97be-86349a206914" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_AssetImpairmentCharges_019e4244-838d-71ba-97be-86349a206914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_019e4244-838d-73fc-bdb7-f47b53e0850a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_019e4244-838d-73fc-bdb7-f47b53e0850a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7f84-871d-2917ee4baefb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7f84-871d-2917ee4baefb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPaymentTerm_019e4244-838d-7203-9d38-cb509df780f4" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_pcrx_ContingentConsiderationPaymentTerm_019e4244-838d-7203-9d38-cb509df780f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838d-7582-9806-93c194405053" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838d-7582-9806-93c194405053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-7f52-915d-b0864a44a909" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-7f52-915d-b0864a44a909" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_019e4244-838d-7715-aaed-efcce538b880" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_InterestReceivable_019e4244-838d-7715-aaed-efcce538b880" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfMajorCustomers_019e4244-838d-7dfa-967d-0d2cd59d6c14" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_pcrx_NumberOfMajorCustomers_019e4244-838d-7dfa-967d-0d2cd59d6c14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838d-7423-8640-91003c23189c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838d-7423-8640-91003c23189c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019e4244-838d-7d92-91e4-4ac481bef6af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019e4244-838d-7d92-91e4-4ac481bef6af" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-838d-75b8-b248-d07427804b71" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-838d-75b8-b248-d07427804b71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-77ff-b82d-68b86b746f24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-77ff-b82d-68b86b746f24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7968-89d9-f71fa0ac854b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7968-89d9-f71fa0ac854b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7b4f-a806-e35e599086b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7968-89d9-f71fa0ac854b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7b4f-a806-e35e599086b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-7d7c-bb8a-e0fde352a849_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:to="loc_srt_RangeMember_019e4244-838d-7d7c-bb8a-e0fde352a849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:to="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-838d-7145-adc8-6e171b2ca3d1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:to="loc_srt_MinimumMember_019e4244-838d-7145-adc8-6e171b2ca3d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-838d-710c-a981-ba871e3ea486" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:to="loc_srt_MaximumMember_019e4244-838d-710c-a981-ba871e3ea486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7e94-9513-aaa6efe8dd4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7e94-9513-aaa6efe8dd4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7dbe-80bf-7767e262ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7dbe-80bf-7767e262ce09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7ff4-ab7a-f68828193e66" xlink:href="pcrx-20260630.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7dbe-80bf-7767e262ce09" xlink:to="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7ff4-ab7a-f68828193e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7b8c-ac1e-9e760195a45f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7b8c-ac1e-9e760195a45f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-771e-a86b-45a2ed27c867" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-771e-a86b-45a2ed27c867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7413-9862-636815898828" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-771e-a86b-45a2ed27c867" xlink:to="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7413-9862-636815898828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7f55-8927-0d377a020a99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7f55-8927-0d377a020a99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-78c4-bd31-bd2406055272" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-78c4-bd31-bd2406055272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_019e4244-838d-72db-97c1-1f65c26a8c54" xlink:href="pcrx-20260630.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:to="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_019e4244-838d-72db-97c1-1f65c26a8c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-76b0-bd66-12f3db7197ca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-838d-75b8-b248-d07427804b71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-76b0-bd66-12f3db7197ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-7d0a-8c1e-b5315e1c90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-7d0a-8c1e-b5315e1c90e7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-76dd-9413-5c9e3d03907f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-76dd-9413-5c9e3d03907f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-7d09-8c24-29c5264412b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-7d09-8c24-29c5264412b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7fbe-bfdd-2dbecc5d6d64" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-7d09-8c24-29c5264412b7" xlink:to="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7fbe-bfdd-2dbecc5d6d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-7d0a-8c1e-b5315e1c90e7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7d19-9e44-42da368254c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7d19-9e44-42da368254c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-79ce-bb14-ddb11b1c3a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-79ce-bb14-ddb11b1c3a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7973-aaf2-8f1dd072ad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:href="pcrx-20260630.xsd#pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-743d-a443-b7031fd9e1fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-743d-a443-b7031fd9e1fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e4244-838d-789f-be85-0126d8f6aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:to="loc_us-gaap_CommercialPaperMember_019e4244-838d-789f-be85-0126d8f6aff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e4244-838d-7680-973b-b0e7dc0b0f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e4244-838d-7680-973b-b0e7dc0b0f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7553-bdd1-c29e23f753c7_default" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:to="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7553-bdd1-c29e23f753c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7add-b765-aaa7875623c0" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:to="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7add-b765-aaa7875623c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_019e4244-838d-7000-b277-691daf772295" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7add-b765-aaa7875623c0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_019e4244-838d-7000-b277-691daf772295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7511-a0a0-5f4c11bfa500_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7511-a0a0-5f4c11bfa500_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-75e6-8763-6eddafbfafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-75e6-8763-6eddafbfafa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7f5f-9d79-c7b19d336964" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-75e6-8763-6eddafbfafa2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7f5f-9d79-c7b19d336964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7af3-a22e-dcede5922d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7af3-a22e-dcede5922d1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-838d-746d-be6a-a0a1b346bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-838d-746d-be6a-a0a1b346bab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-838d-7229-94f2-915ae57b14a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-838d-7229-94f2-915ae57b14a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-838d-73ce-8910-3f2c83182814" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-838d-73ce-8910-3f2c83182814" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-8453-7c26-83f2-269bc3c27051_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-8453-7c26-83f2-269bc3c27051_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-8453-770e-bca6-caa2a8ef744d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-8453-770e-bca6-caa2a8ef744d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-8453-770e-bca6-caa2a8ef744d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_019e4244-8453-7ab9-89dd-d7491214b4db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_019e4244-8453-7ab9-89dd-d7491214b4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019e4244-8453-7337-8e67-2d63234a5766" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019e4244-8453-7337-8e67-2d63234a5766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-8453-704c-96ee-acbf29ad9eef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-8453-704c-96ee-acbf29ad9eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-8453-75ba-b8f7-73c6c40c6391" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-8453-75ba-b8f7-73c6c40c6391" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019e4244-8453-735e-b8da-7a153da52406" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019e4244-8453-735e-b8da-7a153da52406" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-8453-7bba-b108-b1fed97d0ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_019e4244-8453-7792-aeac-2a16a5b74ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_019e4244-8453-7792-aeac-2a16a5b74ab8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:to="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e4244-8453-738a-aab8-80f689f25279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:to="loc_us-gaap_PlanNameDomain_019e4244-8453-738a-aab8-80f689f25279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e4244-8453-7e6b-b1b6-c682d47f57b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:to="loc_us-gaap_PlanNameDomain_019e4244-8453-7e6b-b1b6-c682d47f57b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InducementPlan2014Member_019e4244-8453-7441-894a-916c4aac7180" xlink:href="pcrx-20260630.xsd#pcrx_InducementPlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019e4244-8453-7e6b-b1b6-c682d47f57b9" xlink:to="loc_pcrx_InducementPlan2014Member_019e4244-8453-7441-894a-916c4aac7180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-73f4-9e79-28bc54008be3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-73f4-9e79-28bc54008be3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-77df-aec5-f3f3bd91b093" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-77df-aec5-f3f3bd91b093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-74c8-a7f5-2402753c8d79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-74c8-a7f5-2402753c8d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e4244-8453-7cba-b23e-6fb455700def" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e4244-8453-7cba-b23e-6fb455700def" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019e4244-8453-760f-9a3f-ab96e263cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019e4244-8453-760f-9a3f-ab96e263cc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019e4244-8453-71c6-84a7-f8d4e617bcef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019e4244-8453-71c6-84a7-f8d4e617bcef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c41-90ea-62164a32db31" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c41-90ea-62164a32db31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019f5f27-88d5-76fd-8d1b-6c106544faa5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_019e4244-8453-7cbd-90b5-ce05d6ea036a" xlink:href="pcrx-20260630.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_019e4244-8453-7cbd-90b5-ce05d6ea036a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_019e4244-8453-76f1-9fa1-74f5400fe804" xlink:href="pcrx-20260630.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_019e4244-8453-76f1-9fa1-74f5400fe804" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019e4244-8453-78f9-894a-987e4c2cf14c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019e4244-8453-78f9-894a-987e4c2cf14c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e4244-8453-7e66-932f-895fc34f25b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e4244-8453-7e66-932f-895fc34f25b4" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e4244-8453-719e-a6d0-6dd5afa23e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e4244-8453-719e-a6d0-6dd5afa23e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7289-9936-55b0a7b45410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7289-9936-55b0a7b45410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7ea4-a74e-5df5269310f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7ea4-a74e-5df5269310f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7a2c-a9f0-d7a776337197" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7a2c-a9f0-d7a776337197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019e4244-8453-75b2-878e-1c043a867a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_PerformanceSharesMember_019e4244-8453-75b2-878e-1c043a867a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-730f-bbed-28cd15d49131" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-730f-bbed-28cd15d49131" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-8453-775f-b067-d99b6731c419" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-8453-775f-b067-d99b6731c419" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails_1" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails_1"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7289-9936-55b0a7b45410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7289-9936-55b0a7b45410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7ea4-a74e-5df5269310f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7ea4-a74e-5df5269310f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7a2c-a9f0-d7a776337197" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7a2c-a9f0-d7a776337197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019e4244-8453-75b2-878e-1c043a867a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_PerformanceSharesMember_019e4244-8453-75b2-878e-1c043a867a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-730f-bbed-28cd15d49131" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-730f-bbed-28cd15d49131" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-8453-775f-b067-d99b6731c419" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-8453-775f-b067-d99b6731c419" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-702f-a32e-9a45d7022aa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-702f-a32e-9a45d7022aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-747a-8022-a1de8bb9295d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-747a-8022-a1de8bb9295d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:href="pcrx-20260630.xsd#pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-747a-8022-a1de8bb9295d" xlink:to="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7625-91bb-92791f0c1335" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7625-91bb-92791f0c1335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019e4244-8453-74e9-8cdd-0e1e3ad88aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:to="loc_us-gaap_PerformanceSharesMember_019e4244-8453-74e9-8cdd-0e1e3ad88aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-7153-9563-c5a3670a6bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-7153-9563-c5a3670a6bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e4244-8453-78de-a3c9-5ee59ec794f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e4244-8453-78de-a3c9-5ee59ec794f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-8453-77ce-b9ab-589a8ce550a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-8453-77ce-b9ab-589a8ce550a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019e4244-8453-7a82-bfe7-091f5b8e0015" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019e4244-8453-7a82-bfe7-091f5b8e0015" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_019e4244-8453-71ac-b69c-e7a1cf016512" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_019e4244-8453-71ac-b69c-e7a1cf016512" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-774c-80d8-3737a0bfea56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7969-b138-2225a14bdd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7969-b138-2225a14bdd3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e4244-8453-7d50-a0cb-c0674729dbff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e4244-8453-7d50-a0cb-c0674729dbff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019e4244-8453-7f77-94b3-e2a704963c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019e4244-8453-7f77-94b3-e2a704963c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019e4244-8453-7bc7-8f47-76bb5a193a30" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019e4244-8453-7bc7-8f47-76bb5a193a30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_019e4244-8453-765c-bafe-1f477baffee2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_019e4244-8453-765c-bafe-1f477baffee2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7395-b5aa-8f934b4a3c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-76cb-99da-ec12cf6466dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-76cb-99da-ec12cf6466dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e4244-8453-79b8-a4f8-62610a272c09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e4244-8453-79b8-a4f8-62610a272c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019e4244-8453-70f0-a0ba-67d183d27ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019e4244-8453-70f0-a0ba-67d183d27ac5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019e4244-8453-78eb-a94e-4a9946abba89" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019e4244-8453-78eb-a94e-4a9946abba89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-74b6-b79a-0ea2d4db3d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-75d2-b6ba-b338f68f808c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-75d2-b6ba-b338f68f808c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7f90-bb02-75bda671c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7f90-bb02-75bda671c2a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c12-81c6-1efada340a96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c12-81c6-1efada340a96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019e4244-8453-77e3-ac27-8b226cad13b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019e4244-8453-77e3-ac27-8b226cad13b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-7dd9-80dd-e463ea92a180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-75e0-8b35-39431497d1fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-75e0-8b35-39431497d1fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-765d-815c-b51675082e47" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-765d-815c-b51675082e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7aa7-bdc5-a1e9defe63fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-765d-815c-b51675082e47" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7aa7-bdc5-a1e9defe63fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e4244-8453-79f5-ab16-2e47d32529e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e4244-8453-79f5-ab16-2e47d32529e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e4244-8453-7e62-9882-98fcf1d72a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e4244-8453-7e62-9882-98fcf1d72a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e4244-8453-7db4-bf22-c01dbcfa31a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e4244-8453-7db4-bf22-c01dbcfa31a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e4244-8453-7878-9ed2-6c1555fa3044" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e4244-8453-7878-9ed2-6c1555fa3044" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d44-8a44-81454f49e330_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d44-8a44-81454f49e330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7a21-88dc-6c0ad55749a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7a21-88dc-6c0ad55749a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-711b-aaa4-5bd9d239e7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-711b-aaa4-5bd9d239e7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-8453-78b0-bf47-1a73f02966fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-8453-78b0-bf47-1a73f02966fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-8453-745d-bd07-22aa027452eb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-8453-78b0-bf47-1a73f02966fc" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-8453-745d-bd07-22aa027452eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-8453-7b0b-8551-f8b0a8f1e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-8453-7b0b-8551-f8b0a8f1e34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019e4244-8453-7269-b821-993cd3ce4828" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019e4244-8453-7269-b821-993cd3ce4828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-8453-7621-8b8b-213253a87d10" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-8453-7621-8b8b-213253a87d10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:href="pcrx-20260630.xsd#pcrx_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e4244-8453-794d-9409-af80c8a3c211" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e4244-8453-794d-9409-af80c8a3c211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e4244-8453-70e6-bb8a-e0e69536255d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e4244-8453-70e6-bb8a-e0e69536255d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-7b5b-85dc-a7ddfb777349" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-7b5b-85dc-a7ddfb777349" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-722d-bea2-a4c372b98279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-722d-bea2-a4c372b98279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7761-9e1e-ffa6f68500c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7761-9e1e-ffa6f68500c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_019e4244-8453-7545-8fc7-fedd541e686f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_SeniorNotesMember_019e4244-8453-7545-8fc7-fedd541e686f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7880-822c-b7d06cf453dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7880-822c-b7d06cf453dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-7ddd-99b8-5bca17547413" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-7ddd-99b8-5bca17547413" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e4244-8453-7734-a805-a8b33eccf492" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-7b5b-85dc-a7ddfb777349" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e4244-8453-7734-a805-a8b33eccf492" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7224-8427-3022759731f2_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:to="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7224-8427-3022759731f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:to="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoScienceMilestoneLitigationMember_019e4244-8454-72d9-a2d0-ffe1161bf600" xlink:href="pcrx-20260630.xsd#pcrx_MyoScienceMilestoneLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:to="loc_pcrx_MyoScienceMilestoneLitigationMember_019e4244-8454-72d9-a2d0-ffe1161bf600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchDevelopmentFoundationMember_019e4244-8454-7f2a-9625-804db08a9eda" xlink:href="pcrx-20260630.xsd#pcrx_ResearchDevelopmentFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:to="loc_pcrx_ResearchDevelopmentFoundationMember_019e4244-8454-7f2a-9625-804db08a9eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-71d2-b74c-1fab73309749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-71d2-b74c-1fab73309749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-7eba-8662-a5101ae7d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-7eba-8662-a5101ae7d14c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LGChemPartnershipAgreementMember_019e4244-8454-7b1a-a8fc-a380a0ab9994" xlink:href="pcrx-20260630.xsd#pcrx_LGChemPartnershipAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-7eba-8662-a5101ae7d14c" xlink:to="loc_pcrx_LGChemPartnershipAgreementMember_019e4244-8454-7b1a-a8fc-a380a0ab9994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-7498-94b4-63ee314d4756_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-7498-94b4-63ee314d4756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_JohnsonJohnsonMedTechMember_019e4244-8454-74a6-9880-11da5aa50db8" xlink:href="pcrx-20260630.xsd#pcrx_JohnsonJohnsonMedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:to="loc_pcrx_JohnsonJohnsonMedTechMember_019e4244-8454-74a6-9880-11da5aa50db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember_019e4244-8454-7759-b81f-8562b44303fb" xlink:href="pcrx-20260630.xsd#pcrx_GeneQuineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:to="loc_pcrx_GeneQuineMember_019e4244-8454-7759-b81f-8562b44303fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BaylorCollegeOfMedicineBaylorMember_019e4244-8454-7008-95cd-5bc8bd3368b5" xlink:href="pcrx-20260630.xsd#pcrx_BaylorCollegeOfMedicineBaylorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:to="loc_pcrx_BaylorCollegeOfMedicineBaylorMember_019e4244-8454-7008-95cd-5bc8bd3368b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-8454-752a-9c48-b80c1c5f4525_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-8454-752a-9c48-b80c1c5f4525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-8454-7569-aa78-8d427338d974" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-8454-7569-aa78-8d427338d974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember_019e4244-8454-730d-8922-38c72d4e302b" xlink:href="pcrx-20260630.xsd#pcrx_ZILRETTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-8454-7569-aa78-8d427338d974" xlink:to="loc_pcrx_ZILRETTAMember_019e4244-8454-730d-8922-38c72d4e302b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-72fa-81ab-ebe000c9b331_default" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-72fa-81ab-ebe000c9b331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_019e4244-8454-715b-8096-fbd6c2d95f11" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:to="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_019e4244-8454-715b-8096-fbd6c2d95f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InitiationOfAPhase2ClinicalTrialMember_019e4244-8454-799e-96bd-2a9726c861b9" xlink:href="pcrx-20260630.xsd#pcrx_InitiationOfAPhase2ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:to="loc_pcrx_InitiationOfAPhase2ClinicalTrialMember_019e4244-8454-799e-96bd-2a9726c861b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_019e4244-8454-7105-86fa-8642497c6c34" xlink:href="pcrx-20260630.xsd#pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:to="loc_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_019e4244-8454-7105-86fa-8642497c6c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e4244-8454-7425-a5c4-92a8230b40de_default" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:to="loc_dei_EntityDomain_019e4244-8454-7425-a5c4-92a8230b40de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e4244-8454-7964-bd5e-0afb60d6fa38" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:to="loc_dei_EntityDomain_019e4244-8454-7964-bd5e-0afb60d6fa38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_019e4244-8454-77c4-8c8f-5ad8bdadcbba" xlink:href="pcrx-20260630.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019e4244-8454-7964-bd5e-0afb60d6fa38" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_019e4244-8454-77c4-8c8f-5ad8bdadcbba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e4244-8454-729a-b4c8-83a6242fc4dc_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:to="loc_srt_OwnershipDomain_019e4244-8454-729a-b4c8-83a6242fc4dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e4244-8454-71e6-bb10-9b67b5380efe" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:to="loc_srt_OwnershipDomain_019e4244-8454-71e6-bb10-9b67b5380efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-789d-b974-6fb6f30a3366" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019e4244-8454-71e6-bb10-9b67b5380efe" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-789d-b974-6fb6f30a3366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-77f0-985c-85d46257f306_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-77f0-985c-85d46257f306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7f67-9a44-612f6775c66b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7f67-9a44-612f6775c66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-7729-af58-c748d0a82421" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7f67-9a44-612f6775c66b" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-7729-af58-c748d0a82421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-8454-7209-848b-04b8a2abf887_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:to="loc_srt_RangeMember_019e4244-8454-7209-848b-04b8a2abf887_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:to="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-8454-717b-9229-622993e33f8c" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:to="loc_srt_MinimumMember_019e4244-8454-717b-9229-622993e33f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-8454-708c-9c99-bc53cb129205" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:to="loc_srt_MaximumMember_019e4244-8454-708c-9c99-bc53cb129205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_019e4244-8454-7edf-a353-eb4a5b5b0c91" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_019e4244-8454-7edf-a353-eb4a5b5b0c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_019e4244-8454-78e1-8c2f-aa22d087241a" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedIncreasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_019e4244-8454-78e1-8c2f-aa22d087241a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_019e4244-8454-723d-80f0-62ceb393af1f" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_019e4244-8454-723d-80f0-62ceb393af1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_019e4244-8454-7962-be44-36e484a530fe" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_019e4244-8454-7962-be44-36e484a530fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-75f9-a797-b858c65cbca1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-75f9-a797-b858c65cbca1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfParagraphIVCertifications_019e4244-8454-7b75-b297-1542344d69b1" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfParagraphIVCertifications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_NumberOfParagraphIVCertifications_019e4244-8454-7b75-b297-1542344d69b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfGenericDrugManufacturers_019e4244-8454-7827-975b-d51667dcd534" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfGenericDrugManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_NumberOfGenericDrugManufacturers_019e4244-8454-7827-975b-d51667dcd534" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_019e4244-8454-7871-970f-cbfa190cfb17" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_019e4244-8454-7871-970f-cbfa190cfb17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_019e4244-8454-7018-8e5c-85950c47ffbb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LitigationSettlementInterest_019e4244-8454-7018-8e5c-85950c47ffbb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_019e4244-8454-714a-9f31-2dd6358a6d32" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_019e4244-8454-714a-9f31-2dd6358a6d32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_019e4244-8454-7f5e-943b-379284215b42" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_019e4244-8454-7f5e-943b-379284215b42" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019e4244-8454-79a5-9fb8-f5ca6a56f90e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019e4244-8454-79a5-9fb8-f5ca6a56f90e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_019e4244-8454-73ef-b44a-0fff44d330f1" xlink:href="pcrx-20260630.xsd#pcrx_ContractualObligationMinimumMonthlyCommissionDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_019e4244-8454-73ef-b44a-0fff44d330f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContractualObligationMutualTerminationRightsTerm_019e4244-8454-706f-9cee-65cce6f11061" xlink:href="pcrx-20260630.xsd#pcrx_ContractualObligationMutualTerminationRightsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_ContractualObligationMutualTerminationRightsTerm_019e4244-8454-706f-9cee-65cce6f11061" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_019e4244-8454-7307-855f-4e89649b04cd" xlink:href="pcrx-20260630.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_019e4244-8454-7307-855f-4e89649b04cd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-8454-7215-b50c-9da85b5c6287" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-8454-7215-b50c-9da85b5c6287" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_019e4244-8454-7485-9596-86dc49bcf4d5" xlink:href="pcrx-20260630.xsd#pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_019e4244-8454-7485-9596-86dc49bcf4d5" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-8454-708c-b131-d33d190168cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-8454-708c-b131-d33d190168cf" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:to="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019e4244-8454-71c8-9d65-92b437325f77_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:to="loc_srt_SegmentGeographicalDomain_019e4244-8454-71c8-9d65-92b437325f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:to="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019e4244-8454-72d4-87e3-cee749a4c08b" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:to="loc_country_US_019e4244-8454-72d4-87e3-cee749a4c08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_019e4244-8454-7e4a-acff-3da8616d2f85" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:to="loc_country_DE_019e4244-8454-7e4a-acff-3da8616d2f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019e4244-8454-7355-a173-368a5899cc9e" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:to="loc_country_GB_019e4244-8454-7355-a173-368a5899cc9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PercentOfLongLivedAssets_019e4244-8454-7360-b4db-f3333bac1d8a" xlink:href="pcrx-20260630.xsd#pcrx_PercentOfLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-8454-708c-b131-d33d190168cf" xlink:to="loc_pcrx_PercentOfLongLivedAssets_019e4244-8454-7360-b4db-f3333bac1d8a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e4244-8454-7c95-b687-5f1cb543b924_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:to="loc_us-gaap_SegmentDomain_019e4244-8454-7c95-b687-5f1cb543b924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:to="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReportableSegmentMember_019e4244-8454-7e73-b8f4-dd89b6c37b1d" xlink:href="pcrx-20260630.xsd#pcrx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:to="loc_pcrx_ReportableSegmentMember_019e4244-8454-7e73-b8f4-dd89b6c37b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-79c4-a482-69bfdf387fbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-79c4-a482-69bfdf387fbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-8454-7b95-99a8-9232add441ba" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-8454-7b95-99a8-9232add441ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c4-8a6d-7e0b-a5ca-ae395d9d5960" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c4-8a6d-7e0b-a5ca-ae395d9d5960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019fc9b4-12bd-7016-90aa-f64a28eb0ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019fc9b4-12bd-7016-90aa-f64a28eb0ed3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:to="loc_srt_OwnershipDomain_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:to="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c7-a4e0-7d0b-b302-82e59bc275f1" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c7-a4e0-7d0b-b302-82e59bc275f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-8454-78c4-b00e-73923a0134c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-8454-78c4-b00e-73923a0134c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-7a3f-8a06-81c5baf52182" xlink:href="pcrx-20260630.xsd#pcrx_CostOfGoodsSoldAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-7a3f-8a06-81c5baf52182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-74bc-a5f4-342df679e3d3" xlink:href="pcrx-20260630.xsd#pcrx_ResearchAndDevelopmentAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-74bc-a5f4-342df679e3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-7c5c-969b-3dc064ff3d22" xlink:href="pcrx-20260630.xsd#pcrx_SellingAndMarketingAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-7c5c-969b-3dc064ff3d22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-71be-aae0-f505e10b3bdf" xlink:href="pcrx-20260630.xsd#pcrx_SellingGeneralAndAdministrativeAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-71be-aae0-f505e10b3bdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7b3a-b903-bfc3eae3e960" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7b3a-b903-bfc3eae3e960" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-75f9-8582-a61b2fc8074f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-75f9-8582-a61b2fc8074f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019f7f76-16c6-7960-a40d-b945f82118d4" xlink:href="pcrx-20260630.xsd#pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019f7f76-16c6-7960-a40d-b945f82118d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-759f-b41a-263c5d782ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-759f-b41a-263c5d782ea5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7d57-a0d8-794be3e2bc55" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7d57-a0d8-794be3e2bc55" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d8-fa38-77b9-9d30-bac0f27a0ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d8-fa38-77b9-9d30-bac0f27a0ecd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-8454-7525-9ddd-4c164359ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_CostsAndExpenses_019e4244-8454-7525-9ddd-4c164359ac4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-8454-727c-9c43-1a015c2ecf00" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e4244-8454-727c-9c43-1a015c2ecf00" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8454-74b0-8f82-479d4fd56994" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8454-74b0-8f82-479d4fd56994" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8454-7d46-a4d9-525e6163c933" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8454-7d46-a4d9-525e6163c933" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-8454-72f2-8701-e8ce0861032c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-8454-72f2-8701-e8ce0861032c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019fca06-1e34-7c10-af5d-ffc7e310c282" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019fca06-1e34-7c10-af5d-ffc7e310c282" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019fc9c7-a4e0-749c-9d42-7b2219ee2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019fc9c7-a4e0-749c-9d42-7b2219ee2eb9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019fc9c7-a4e0-7b56-9150-de78ea0bd26c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019fc9c7-a4e0-7b56-9150-de78ea0bd26c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-8454-7edb-b056-30a00e98ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-8454-7edb-b056-30a00e98ee7c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-73f7-b88a-467d9572939d" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-73f7-b88a-467d9572939d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-8454-7dfe-812c-1e1b8ad7cec2" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-8454-7dfe-812c-1e1b8ad7cec2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-8454-7aba-bca8-db7dc6906774" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-8454-7aba-bca8-db7dc6906774" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-8454-7cc5-9e19-d89ba1732f05" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-8454-7cc5-9e19-d89ba1732f05" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019fc9cb-a4cf-779b-a08a-5a62a2bbd92b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019fc9cb-a4cf-779b-a08a-5a62a2bbd92b" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails_1" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails_1"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e4244-8454-7c95-b687-5f1cb543b924_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:to="loc_us-gaap_SegmentDomain_019e4244-8454-7c95-b687-5f1cb543b924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:to="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReportableSegmentMember_019e4244-8454-7e73-b8f4-dd89b6c37b1d" xlink:href="pcrx-20260630.xsd#pcrx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:to="loc_pcrx_ReportableSegmentMember_019e4244-8454-7e73-b8f4-dd89b6c37b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-79c4-a482-69bfdf387fbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-79c4-a482-69bfdf387fbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-8454-7b95-99a8-9232add441ba" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-8454-7b95-99a8-9232add441ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c4-8a6d-7e0b-a5ca-ae395d9d5960" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c4-8a6d-7e0b-a5ca-ae395d9d5960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:to="loc_srt_OwnershipDomain_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:to="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c7-a4e0-7d0b-b302-82e59bc275f1" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c7-a4e0-7d0b-b302-82e59bc275f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-8454-78c4-b00e-73923a0134c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-8454-78c4-b00e-73923a0134c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-7a3f-8a06-81c5baf52182" xlink:href="pcrx-20260630.xsd#pcrx_CostOfGoodsSoldAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-7a3f-8a06-81c5baf52182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-74bc-a5f4-342df679e3d3" xlink:href="pcrx-20260630.xsd#pcrx_ResearchAndDevelopmentAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-74bc-a5f4-342df679e3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-7c5c-969b-3dc064ff3d22" xlink:href="pcrx-20260630.xsd#pcrx_SellingAndMarketingAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-7c5c-969b-3dc064ff3d22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-71be-aae0-f505e10b3bdf" xlink:href="pcrx-20260630.xsd#pcrx_SellingGeneralAndAdministrativeAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-71be-aae0-f505e10b3bdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7b3a-b903-bfc3eae3e960" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7b3a-b903-bfc3eae3e960" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-75f9-8582-a61b2fc8074f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-75f9-8582-a61b2fc8074f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019f7f76-16c6-7960-a40d-b945f82118d4" xlink:href="pcrx-20260630.xsd#pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019f7f76-16c6-7960-a40d-b945f82118d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-759f-b41a-263c5d782ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-759f-b41a-263c5d782ea5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7d57-a0d8-794be3e2bc55" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7d57-a0d8-794be3e2bc55" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d8-fa38-77b9-9d30-bac0f27a0ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d8-fa38-77b9-9d30-bac0f27a0ecd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-8454-7525-9ddd-4c164359ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_CostsAndExpenses_019e4244-8454-7525-9ddd-4c164359ac4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-8454-727c-9c43-1a015c2ecf00" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e4244-8454-727c-9c43-1a015c2ecf00" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8454-74b0-8f82-479d4fd56994" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8454-74b0-8f82-479d4fd56994" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8454-7d46-a4d9-525e6163c933" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8454-7d46-a4d9-525e6163c933" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-8454-72f2-8701-e8ce0861032c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-8454-72f2-8701-e8ce0861032c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019fca06-1e34-7c10-af5d-ffc7e310c282" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019fca06-1e34-7c10-af5d-ffc7e310c282" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019fc9c7-a4e0-749c-9d42-7b2219ee2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019fc9c7-a4e0-749c-9d42-7b2219ee2eb9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019fc9c7-a4e0-7b56-9150-de78ea0bd26c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019fc9c7-a4e0-7b56-9150-de78ea0bd26c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-8454-7edb-b056-30a00e98ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-8454-7edb-b056-30a00e98ee7c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-73f7-b88a-467d9572939d" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-73f7-b88a-467d9572939d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-8454-7dfe-812c-1e1b8ad7cec2" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-8454-7dfe-812c-1e1b8ad7cec2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-8454-7aba-bca8-db7dc6906774" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-8454-7aba-bca8-db7dc6906774" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-8454-7cc5-9e19-d89ba1732f05" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-8454-7cc5-9e19-d89ba1732f05" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019fc9cb-a4cf-779b-a08a-5a62a2bbd92b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019fc9cb-a4cf-779b-a08a-5a62a2bbd92b" xlink:type="arc" order="24"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>pcrx-20260630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e4244-8139-7e27-b3f4-c33a61dfef92,g:c636850a-8e11-4f67-b4ef-051f1780002d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019e4244-851a-7a6a-b43d-23aead9bfa8f_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_019e4244-851a-7e55-b047-52e4d1fa8d54_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-85af-78be-821d-6d19ce8b6adc_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019e4244-851a-75d0-8d72-0038d669966a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019e4244-85af-72f1-b78f-d6be430805b1_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_019e4244-85b0-7052-ac2a-9785c815ce49_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019e4244-851a-73ff-9d6c-bbfa28eda9de_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-851a-7c07-a68e-f5bfa86bdcec_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Liabilities:</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e4244-85af-7333-9079-17182da46eb1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RevenueMilestoneThreeMember_019f6f30-8e22-761b-af49-f0f12cf5fb79_terseLabel_en-US" xlink:label="lab_pcrx_RevenueMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Milestone Tier 3</link:label>
    <link:label id="lab_pcrx_RevenueMilestoneThreeMember_label_en-US" xlink:label="lab_pcrx_RevenueMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Milestone Three [Member]</link:label>
    <link:label id="lab_pcrx_RevenueMilestoneThreeMember_documentation_en-US" xlink:label="lab_pcrx_RevenueMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneThreeMember" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RevenueMilestoneThreeMember" xlink:to="lab_pcrx_RevenueMilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_PaciraCryoTechIncAndIoveraMember_019f9441-d09c-72e9-b1c3-695ad844535a_terseLabel_en-US" xlink:label="lab_pcrx_PaciraCryoTechIncAndIoveraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pacira CryoTech, Inc, and iovera&#176;</link:label>
    <link:label id="lab_pcrx_PaciraCryoTechIncAndIoveraMember_label_en-US" xlink:label="lab_pcrx_PaciraCryoTechIncAndIoveraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pacira CryoTech, Inc, And iovera&#176; [Member]</link:label>
    <link:label id="lab_pcrx_PaciraCryoTechIncAndIoveraMember_documentation_en-US" xlink:label="lab_pcrx_PaciraCryoTechIncAndIoveraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pacira CryoTech, Inc, And iovera&#176;</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaciraCryoTechIncAndIoveraMember" xlink:to="lab_pcrx_PaciraCryoTechIncAndIoveraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_019e4244-851a-756a-a020-a2d762bf9a8c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019e4244-85af-7e1f-8924-381c9fbfb6a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_019fc818-a1e4-755d-a99e-04c6af07fbbc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-851a-7747-b418-447be56925cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price of notes into common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019e4244-851a-7a08-8312-d4e604252de8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_019e4244-851a-73f0-bdf2-1b410e29f2d9_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technologies</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NumberOfLeases_019e4244-851a-7a21-9dcf-bf5470f64a16_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of embedded leases</link:label>
    <link:label id="lab_pcrx_NumberOfLeases_label_en-US" xlink:label="lab_pcrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Leases</link:label>
    <link:label id="lab_pcrx_NumberOfLeases_documentation_en-US" xlink:label="lab_pcrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfLeases" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfLeases" xlink:to="lab_pcrx_NumberOfLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_019e4244-85af-7014-a107-2ae74bd7a5a8_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-851a-7ae8-b516-ed38bd86c7de_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Acquired [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Acquired [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e4244-851a-7665-a6d6-117590b742cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019e4244-851a-75c4-901d-5422a5814e71_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RevenueMilestoneOneMember_019f6f30-8e22-77a4-a19c-eebc87d52dfa_terseLabel_en-US" xlink:label="lab_pcrx_RevenueMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Milestone Tier 1</link:label>
    <link:label id="lab_pcrx_RevenueMilestoneOneMember_label_en-US" xlink:label="lab_pcrx_RevenueMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Milestone One [Member]</link:label>
    <link:label id="lab_pcrx_RevenueMilestoneOneMember_documentation_en-US" xlink:label="lab_pcrx_RevenueMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneOneMember" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RevenueMilestoneOneMember" xlink:to="lab_pcrx_RevenueMilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-851a-7d1a-8812-2d18349990c4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-851a-7a9b-867d-251761fe91e2_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Excluding Goodwill, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-851a-7486-bfc4-062694224f28_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-851a-7946-bc77-53ad0b2dff0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at end of period in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e4244-8454-7f77-bb03-5f3c17ab2418_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net accretion of discount on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligation_019e4244-85af-7740-bb20-a3ad9982e6b3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligation_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetRetirementObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligation" xlink:to="lab_us-gaap_AssetRetirementObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-85af-7880-84a0-09831e053976_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019e4244-85af-75e8-8e30-a146965222f7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019e4244-851a-7f28-904c-afd01417db30_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_019e4244-851a-704a-9b35-27a829e7f3dd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_019e4244-851a-75d8-b8fe-54a35b3ff253_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_019e4244-85af-71ea-923e-303da77b1d30_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentDiscountRate_019e4244-85af-749f-a990-491d4d3adaf6_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentDiscountRate_label_en-US" xlink:label="lab_pcrx_DebtInstrumentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Discount Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentDiscountRate_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentDiscountRate" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentDiscountRate" xlink:to="lab_pcrx_DebtInstrumentDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_019e4244-8454-79a9-abda-c1fd9e578923_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease expense, net</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019e4244-851a-7f90-bc29-7ced573e31fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e4244-851a-76ec-8733-b0441bcede58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-85af-7e30-868c-f10a349dd9d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019e4244-851a-73db-8f7c-6cfa2533841f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationMember_019e4244-85af-70a6-8da3-965120432b46_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationMember_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationMember" xlink:to="lab_pcrx_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_019e4244-851a-7d2f-80f4-fb7effff4cf3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_019e4244-851a-709c-aeb1-f82c44cabc25_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_019e4244-851a-7a2a-a7b8-cdda534ab4da_terseLabel_en-US" xlink:label="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of capped calls</link:label>
    <link:label id="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_label_en-US" xlink:label="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Before Tax</link:label>
    <link:label id="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_documentation_en-US" xlink:label="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" xlink:href="pcrx-20260630.xsd#pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" xlink:to="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-85af-7aa9-8fd4-5150cbd4b3c2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareRepurchaseProgramBrokerFees_019e4244-85af-7057-b0aa-5d2f08a5f844_terseLabel_en-US" xlink:label="lab_pcrx_ShareRepurchaseProgramBrokerFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Broker fees</link:label>
    <link:label id="lab_pcrx_ShareRepurchaseProgramBrokerFees_label_en-US" xlink:label="lab_pcrx_ShareRepurchaseProgramBrokerFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Broker Fees</link:label>
    <link:label id="lab_pcrx_ShareRepurchaseProgramBrokerFees_documentation_en-US" xlink:label="lab_pcrx_ShareRepurchaseProgramBrokerFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Broker Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareRepurchaseProgramBrokerFees" xlink:href="pcrx-20260630.xsd#pcrx_ShareRepurchaseProgramBrokerFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareRepurchaseProgramBrokerFees" xlink:to="lab_pcrx_ShareRepurchaseProgramBrokerFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_019e4244-85af-765f-a842-f06f269cd4bd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionTermsThreeMember_019e4244-85b0-7d14-a03b-779c3ada63ca_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term three</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsThreeMember_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Three [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsThreeMember_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsThreeMember" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsThreeMember" xlink:to="lab_pcrx_DebtConversionTermsThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019e4244-8454-778c-951f-26108691a40f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-85af-7f9c-a072-0b7a109012cb_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_019e4244-85af-777e-9bf8-55c2a8ded29c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-851a-73d1-bbf0-1137b2336858_terseLabel_en-US" xlink:label="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU and PSU</link:label>
    <link:label id="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_label_en-US" xlink:label="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance Stock Units [Member]</link:label>
    <link:label id="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_documentation_en-US" xlink:label="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:href="pcrx-20260630.xsd#pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:to="lab_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019e4244-851a-7e11-8153-961792852c76_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-851a-7992-a18b-00fc9d1ff56c_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key employee holdback recognition year three</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_label_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Percent, Year Three</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Percent, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" xlink:to="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_019e4244-851a-747f-b748-5e9152ba5468_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_019e4244-851a-7d00-b02c-311eadecb15d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019e4244-85af-7881-9205-5d08cfdc4fba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_019f94b1-3e26-76c1-b9f6-6e7e0a26648d_negatedTerseLabel_en-US" xlink:label="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Release of valuation allowance on deferred tax assets</link:label>
    <link:label id="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_label_en-US" xlink:label="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes, Valuation Allowance On Deferred Tax Assets</link:label>
    <link:label id="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_documentation_en-US" xlink:label="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes, Valuation Allowance On Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" xlink:href="pcrx-20260630.xsd#pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" xlink:to="lab_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019e4244-851a-7618-955e-7e57813185eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Significant Expense Categories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionTermsOneMember_019e4244-85af-7ae5-a8fc-5f51b551450f_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terms one</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsOneMember" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsOneMember" xlink:to="lab_pcrx_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_019e4244-85af-73d5-9a07-a3ddaa37570a_terseLabel_en-US" xlink:label="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wells Fargo Bank</link:label>
    <link:label id="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_label_en-US" xlink:label="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wells Fargo Bank, National Association, Credit Agreement [Member]</link:label>
    <link:label id="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_documentation_en-US" xlink:label="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wells Fargo Bank, National Association, Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" xlink:href="pcrx-20260630.xsd#pcrx_WellsFargoBankNationalAssociationCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" xlink:to="lab_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-85af-78d8-b759-c114e9465887_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-85af-783a-94fc-96a29405a0ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e4244-85af-741c-817c-a3cd2fb09739_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_019e4244-851b-7015-9483-475ca2111565_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019fc9ff-41d2-77d8-bcbd-0456b1d72ffc_terseLabel_en-US" xlink:label="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestiture and acquisition-related expenses</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_label_en-US" xlink:label="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-Related Cost and Divestiture-related Expense</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_documentation_en-US" xlink:label="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisition-Related Cost and Divestiture-related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" xlink:href="pcrx-20260630.xsd#pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" xlink:to="lab_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableFairValueDisclosure_019e4244-85af-7d05-9c55-748f53b3f083_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableFairValueDisclosure" xlink:to="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_019e4244-85af-7f36-8427-3406dee056bd_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP purchasing period</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="pcrx-20260630.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_019e4244-851a-7822-ae6a-a85e090c3c5e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019e4244-85af-71f3-821c-11916dfb062d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-7a39-7974-9737-e42e7ed3ca5d_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-for-Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Held-for-Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8a-ff4a-7591-8d40-1ec9a63c873a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f94db-ad19-72ff-ba37-153246941a1b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses related</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019e4244-851a-740a-b0ba-2998bead691c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_019e4244-851a-73b2-8c19-64d7bdc4d2fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019e4244-851a-7252-90db-c166a69be240_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_019e4244-85af-7fb4-9dc5-f138a023fb1a_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of last reported sale price of common stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:to="lab_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_019e4244-851a-71cb-888d-cdb26b5e5d97_terseLabel_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Shares Issued Under Employee Stock Purchase Plans</link:label>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from shares issued under Employee Stock Purchase Plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" xlink:href="pcrx-20260630.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" xlink:to="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_019e4244-85af-7032-b0df-4961c8208321_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at June&#160;30, 2026 and December&#160;31, 2025, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_019e4244-851a-79c0-9841-7990fd25d069_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e4244-851a-7506-96dc-34c9740c6cbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019e4244-85af-70c8-abba-27a89bf7c910_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-851a-7091-8737-51d6ad38d764_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency adjustments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-851a-70c3-8ea0-fbfad9c67cc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments and accretion</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019e4244-851a-7732-8c30-f90e4b270eeb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019e4244-85af-79dc-a826-bf25e7b9f10f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET INCOME (LOSS) PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_019e4244-851a-724c-8013-e7616d7ab9bd_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required principal repayment on conversion</link:label>
    <link:label id="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_label_en-US" xlink:label="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased In Conversion Face Amount</link:label>
    <link:label id="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased In Conversion Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentRepurchasedInConversionFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" xlink:to="lab_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_019e4244-85af-799b-8fd2-a2a980484a35_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019e4244-851a-7838-babb-14c75afedc75_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019e4244-85af-74e5-b4f1-17b514d8267f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019e4244-851a-7f3a-b612-353fab53ca62_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_019e4244-85b0-727e-a0e7-9a41ae98ad42_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rates</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e4244-85b0-76e1-a2f8-34caf53d995e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_019e4244-85af-7fe0-93cb-33108a7bc80d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_019e4244-851a-7ff0-8d4e-1b5f8aed2ad9_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of offering periods for ESPP</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:href="pcrx-20260630.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019f94c3-5c41-7037-998c-3a5937a1c4be_terseLabel_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestiture-related expenses</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_label_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Divestiture-related Expenses</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_documentation_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Divestiture-related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" xlink:to="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_019e4244-85af-7499-89d1-dfc1d4fc8754_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_019e4244-8454-7738-953e-393c9b264b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_019e4244-8454-700d-9837-d0fd741d0137_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Major Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_019e4244-85af-70e4-a99f-12965eb195b5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019e4244-85af-77ae-b945-0234503606ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e4244-85af-721a-a8d4-180817ced8ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_019e4244-851a-72af-8dec-9ae890eaec59_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_InducementPlan2014Member_019e4244-851a-798a-9556-6b3c579204ab_terseLabel_en-US" xlink:label="lab_pcrx_InducementPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Plan 2014</link:label>
    <link:label id="lab_pcrx_InducementPlan2014Member_label_en-US" xlink:label="lab_pcrx_InducementPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan 2014 [Member]</link:label>
    <link:label id="lab_pcrx_InducementPlan2014Member_documentation_en-US" xlink:label="lab_pcrx_InducementPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Plan 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InducementPlan2014Member" xlink:href="pcrx-20260630.xsd#pcrx_InducementPlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InducementPlan2014Member" xlink:to="lab_pcrx_InducementPlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_019e4244-85af-7f8a-9ad3-7df57150459c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-85af-765c-971d-dcfe7d22d80c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationPaymentTerm_019e4244-851a-7a8c-80a7-54573eb53fbc_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment term</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationPaymentTerm_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Payment Term</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationPaymentTerm_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPaymentTerm" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationPaymentTerm" xlink:to="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e4244-85af-736d-80b3-b451ebfe806b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments without Readily Determinable Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_019fa954-7322-7710-9bb3-e4dba5f1a5e9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Discrete benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_019e4244-851a-76e4-8d74-5e51e6249c3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating lease liabilities, net of lease incentives</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e4244-85af-7b51-8d8d-e7b215cc6f14_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019e4244-85af-78e1-9f88-873e3712de08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019e4244-85af-79bd-be7d-d7e7142fe6a5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Percentage of Revenue Comprised of Three Largest Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019e4244-85af-7d1d-b756-440d1849f127_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate (in percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_019e4244-85af-79bc-8271-c0f9c7a09474_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019e4244-85af-7e93-a20b-c3fc4c8ce92c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of share based compensation arrangements (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_019f6f3b-e381-72d3-80cb-2532caf70663_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019e4244-851a-7446-b3ea-cbaf1db6539a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019e4244-85af-7f79-93d9-b90918f726f5_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019e4244-8454-7b68-874d-1ec72119a573_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019fa6dc-1ca6-712f-ab1d-1c7f1f872479_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-851a-7501-a658-4f11bb9d426d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_019e4244-85af-7667-b8d8-7f06e1a5efdc_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-85af-7e68-8d42-8be43eca647a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-85af-74d3-b05c-1d952652e5ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfProducts_019e4244-85af-71b3-b2fd-9ce2f7030f1a_terseLabel_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of products (in products)</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfProducts" xlink:href="pcrx-20260630.xsd#pcrx_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConcentrationRiskNumberOfProducts" xlink:to="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_019e4244-851a-7ec4-b116-031745ce0937_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_019e4244-851a-73d1-a49b-cb16395bf517_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_019e4244-851a-7c21-9bb1-39c6489f67b3_terseLabel_en-US" xlink:label="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued selling, general and administrative expenses</link:label>
    <link:label id="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_label_en-US" xlink:label="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Selling, General, And Administrative Expenses</link:label>
    <link:label id="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_documentation_en-US" xlink:label="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of liabilities incurred and payable to vendors for goods and services related to selling, general, and administrative activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:href="pcrx-20260630.xsd#pcrx_AccruedSellingGeneralAndAdministrativeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:to="lab_pcrx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019e4244-85b0-7e3b-b552-1049c474069f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019e4244-85af-7222-aa18-9b130b5edc39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_019e4244-85af-7a18-bf24-e3326e257c63_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_019e4244-85af-782d-91c1-5c614cf80265_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_019e4244-851a-78a7-8975-8dd4bd111173_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EBITDA (in percent)</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_label_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Incremental Debt, Maximum Percent</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Incremental Debt, Maximum Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" xlink:to="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a43-8b2c-7325f3200ff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_019e4244-851a-706b-a2a4-a43159af421d_terseLabel_en-US" xlink:label="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Global Regulatory Approval Milestone Payments</link:label>
    <link:label id="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_label_en-US" xlink:label="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Global Regulatory Approval Milestone Payments [Member]</link:label>
    <link:label id="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_documentation_en-US" xlink:label="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development and Global Regulatory Approval Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" xlink:href="pcrx-20260630.xsd#pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" xlink:to="lab_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-851a-77aa-861d-c65534f25a86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7a19-af9a-bdd826bb934a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019e4244-851a-75aa-87c9-0c5063dc3f1a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_019e4244-851a-752a-a565-d89ed93e376e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_019e4244-851a-7523-9d65-f3146961138b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-7baa-898e-4a93f8e8f26d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_019e4244-851a-70eb-8fc3-fd99ce70de8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SellingAndMarketingAdjusted_019e4244-851a-7ab4-b840-b49a53eeb05d_terseLabel_en-US" xlink:label="lab_pcrx_SellingAndMarketingAdjusted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted selling and marketing</link:label>
    <link:label id="lab_pcrx_SellingAndMarketingAdjusted_label_en-US" xlink:label="lab_pcrx_SellingAndMarketingAdjusted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling And Marketing, Adjusted</link:label>
    <link:label id="lab_pcrx_SellingAndMarketingAdjusted_documentation_en-US" xlink:label="lab_pcrx_SellingAndMarketingAdjusted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling And Marketing, Adjusted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingAndMarketingAdjusted" xlink:href="pcrx-20260630.xsd#pcrx_SellingAndMarketingAdjusted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SellingAndMarketingAdjusted" xlink:to="lab_pcrx_SellingAndMarketingAdjusted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_019e4244-85af-7c5c-9add-f5e9575c1f72_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_019e4244-85af-7530-864d-eccf09db43d8_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-85b0-75ee-92b0-ec79ff892a7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019e4244-851a-71e5-99bb-4ab8e5de1188_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019e4244-851a-7c6b-abe1-55a39ffc72a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019e4244-851a-727f-b638-7565161b92e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at ending of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019e4244-851a-7284-b034-8b5dffbaf019_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-85af-719e-adb0-259bc192a5e0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019e4244-85af-72c5-bfe3-d91ac76ac685_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019e4244-8454-7c4e-8b09-cecfdee2a5c0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_019e4244-851a-7393-ad73-21f830efa777_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_019e4244-851a-7ae6-b201-0bf7651415de_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e4244-85af-73fa-a44c-9c1b15adfa4a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-851a-7ffb-9d30-67d54866ffc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-85af-798d-9d56-48477b913568_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019e4244-8454-7429-9048-6fcf78c68b4e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e4244-851a-716c-89e8-3f6eff9bc54e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive effects of including these potential shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_019e4244-85af-74db-b64e-4c043dcdadc3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019e4244-851b-7d15-a494-2388f502b63f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-851a-772b-9f33-f7801a6dd3a1_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_019e4244-85af-7255-ab8f-06f8faf094e8_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-85af-7427-8f10-6604087b083f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_019e4244-8454-738e-b4cb-23b11924819e_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_label_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_documentation_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by categories of milestones achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfMilestoneAxis" xlink:to="lab_pcrx_AchievementOfMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_019e4244-851a-7e15-90e5-0c0ed3f6840d_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of commercial milestones (up to)</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payments to be Received, Maximum</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:href="pcrx-20260630.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:to="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_019e4244-8454-7dbd-a379-f0edc0d2dc64_terseLabel_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volumes distributed in US market in duration period</link:label>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_label_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Volume-Limited, Increase Period</link:label>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_documentation_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Volume-Limited, Increase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedIncreasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" xlink:to="lab_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019e4244-85af-7e70-9aa9-8c167d5559e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8454-7824-8f18-4928b5cb7f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalizedAdjustment_019e4244-85af-7384-b77f-75b6d536ab68_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalizedAdjustment_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalizedAdjustment" xlink:to="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019e4244-85b0-79db-a9b5-49b17af67584_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net leverage ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_019e4244-85af-7bc2-92c8-4233c66c6314_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation expense</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_019e4244-85af-7452-b8e2-9130197a59c1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-85af-7b92-8140-144efad2e453_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CappedCallMember_019e4244-851a-7ee0-b76e-7340ef61f171_terseLabel_en-US" xlink:label="lab_pcrx_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capped Call</link:label>
    <link:label id="lab_pcrx_CappedCallMember_label_en-US" xlink:label="lab_pcrx_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capped Call [Member]</link:label>
    <link:label id="lab_pcrx_CappedCallMember_documentation_en-US" xlink:label="lab_pcrx_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capped Call</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CappedCallMember" xlink:href="pcrx-20260630.xsd#pcrx_CappedCallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CappedCallMember" xlink:to="lab_pcrx_CappedCallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-851a-7663-b1ba-90a6004c7c48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Without Readily Determinable Fair Value Roll Forward [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_019e4244-851a-79af-b596-0297fa014bd2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019e4244-851a-7791-b81c-037ac74286ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_019e4244-851a-77bb-a2b9-679396c03dee_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019e4244-851a-7075-b3ae-f2fcd325582d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_019e4244-85af-756f-940f-4b394c35fb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8454-7426-89b0-77b9177102eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019e4244-8454-73dd-a19a-ea3236cd1348_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019e4244-85af-76e6-b5ed-4a9d1d6bbc91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019e4244-85af-7f78-a27e-9119659f7c3c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-85af-76da-ae1d-690beccad967_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-851b-7e5d-ac3a-6354c5ef6316_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid_019fa729-9240-710d-a85a-892e350ab486_terseLabel_en-US" xlink:label="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excise taxes paid on treasury stock repurchases</link:label>
    <link:label id="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid_label_en-US" xlink:label="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax Paid</link:label>
    <link:label id="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid_documentation_en-US" xlink:label="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareRepurchaseProgramExciseTaxPaid" xlink:href="pcrx-20260630.xsd#pcrx_ShareRepurchaseProgramExciseTaxPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareRepurchaseProgramExciseTaxPaid" xlink:to="lab_pcrx_ShareRepurchaseProgramExciseTaxPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_019fa71a-a6f5-79aa-8a7b-a56a1ecf9cb7_terseLabel_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction bonus</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_label_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Bonus</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_documentation_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" xlink:to="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_019e4244-851a-7d2c-b06a-5c8a6ccda430_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_019e4244-851a-79e7-851e-a9d4c9452d63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_019e4244-851a-7af1-a4e4-b001441c0d10_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_019e4244-851a-7a1b-94af-d932a47f6403_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balloon payment to be paid</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_019faeaa-5b11-7d93-b442-89bf83856196_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sold</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019e4244-851a-7306-942c-4e326b7c221a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019e4244-85af-740a-99aa-814d20bc1668_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_019e4244-85af-7c5f-abfb-b5e996efa04e_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-85af-793c-a6b1-03370e2f8874_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e4244-85af-73ab-bed9-c86742cc5faa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e4244-85af-7fed-9946-0665cadbd19f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e4244-85af-76d2-913a-534c101d9a27_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_019e4244-851a-7d4f-912c-c8cf573d79ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019e4244-85af-77a6-805b-b440e848b2af_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-851a-7aca-8eb3-4f8e02cd7f83_terseLabel_en-US" xlink:label="lab_pcrx_SellingGeneralAndAdministrativeAdjusted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted general and administrative</link:label>
    <link:label id="lab_pcrx_SellingGeneralAndAdministrativeAdjusted_label_en-US" xlink:label="lab_pcrx_SellingGeneralAndAdministrativeAdjusted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General And Administrative Adjusted</link:label>
    <link:label id="lab_pcrx_SellingGeneralAndAdministrativeAdjusted_documentation_en-US" xlink:label="lab_pcrx_SellingGeneralAndAdministrativeAdjusted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling, General And Administrative Adjusted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingGeneralAndAdministrativeAdjusted" xlink:href="pcrx-20260630.xsd#pcrx_SellingGeneralAndAdministrativeAdjusted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SellingGeneralAndAdministrativeAdjusted" xlink:to="lab_pcrx_SellingGeneralAndAdministrativeAdjusted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e4244-851a-73ac-9c01-a6d0e64b1ffb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MyoScienceMilestoneLitigationMember_019e4244-85b0-7bdd-861e-727075107e59_terseLabel_en-US" xlink:label="lab_pcrx_MyoScienceMilestoneLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MyoScience Milestone Litigation</link:label>
    <link:label id="lab_pcrx_MyoScienceMilestoneLitigationMember_label_en-US" xlink:label="lab_pcrx_MyoScienceMilestoneLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MyoScience Milestone Litigation [Member]</link:label>
    <link:label id="lab_pcrx_MyoScienceMilestoneLitigationMember_documentation_en-US" xlink:label="lab_pcrx_MyoScienceMilestoneLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MyoScience Milestone Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoScienceMilestoneLitigationMember" xlink:href="pcrx-20260630.xsd#pcrx_MyoScienceMilestoneLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MyoScienceMilestoneLitigationMember" xlink:to="lab_pcrx_MyoScienceMilestoneLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_019e4244-8454-784c-8f8c-50181260bbf9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_019e4244-851a-7c2a-9ab0-52c014355c5c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_019e4244-851b-788d-b71b-9ffd55ab6474_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_019e4244-851a-74f1-9c67-4ce6888a516a_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_019e4244-85af-70a7-9d67-5e89ad3845ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-85af-7cf6-b379-4bb3143846f7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-85af-7319-94e2-2bee707936fb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa6db-f8f8-7ba6-9412-5deb30cb88c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-851b-76c5-9641-c0de653c0899_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f94e9-5938-759d-b12a-0da46aff9447_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_019e4244-85b0-7500-8264-58b7520113b7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-851a-700d-818b-764357c05b2e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Excluding Goodwill, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_JohnsonJohnsonMedTechMember_019e4244-851a-775d-8937-03126875e3aa_terseLabel_en-US" xlink:label="lab_pcrx_JohnsonJohnsonMedTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson MedTech</link:label>
    <link:label id="lab_pcrx_JohnsonJohnsonMedTechMember_label_en-US" xlink:label="lab_pcrx_JohnsonJohnsonMedTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson MedTech [Member]</link:label>
    <link:label id="lab_pcrx_JohnsonJohnsonMedTechMember_documentation_en-US" xlink:label="lab_pcrx_JohnsonJohnsonMedTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson MedTech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_JohnsonJohnsonMedTechMember" xlink:href="pcrx-20260630.xsd#pcrx_JohnsonJohnsonMedTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_JohnsonJohnsonMedTechMember" xlink:to="lab_pcrx_JohnsonJohnsonMedTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_019e4244-8454-7b9f-82a1-601097853fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedProductionCost_019e4244-851a-74cd-ba67-ad30c12fa0b3_terseLabel_en-US" xlink:label="lab_pcrx_AccruedProductionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued production costs</link:label>
    <link:label id="lab_pcrx_AccruedProductionCost_label_en-US" xlink:label="lab_pcrx_AccruedProductionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Production Cost</link:label>
    <link:label id="lab_pcrx_AccruedProductionCost_documentation_en-US" xlink:label="lab_pcrx_AccruedProductionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Production Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedProductionCost" xlink:href="pcrx-20260630.xsd#pcrx_AccruedProductionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedProductionCost" xlink:to="lab_pcrx_AccruedProductionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_019e4244-85b0-7185-814b-57281ec37bfd_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product returns and wholesaler service fees</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTax_019e4244-851a-75e5-bac5-4fff030b36d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued excise tax</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTax_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramExciseTax" xlink:to="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EquityMethodInvestmentsAndOtherAssets_019e4244-851a-7182-8e4b-0176f25c0d5e_terseLabel_en-US" xlink:label="lab_pcrx_EquityMethodInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_pcrx_EquityMethodInvestmentsAndOtherAssets_label_en-US" xlink:label="lab_pcrx_EquityMethodInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Other Assets</link:label>
    <link:label id="lab_pcrx_EquityMethodInvestmentsAndOtherAssets_documentation_en-US" xlink:label="lab_pcrx_EquityMethodInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EquityMethodInvestmentsAndOtherAssets" xlink:href="pcrx-20260630.xsd#pcrx_EquityMethodInvestmentsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EquityMethodInvestmentsAndOtherAssets" xlink:to="lab_pcrx_EquityMethodInvestmentsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019e4244-851a-718a-951c-264a7d4793b4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019e4244-85af-7c72-814f-734c8b6bb808_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-851a-7ce5-a110-59de46558a58_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_label_en-US" xlink:label="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term and Noncurrent Available-For-Sale Investments [Table]</link:label>
    <link:label id="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term and Noncurrent Available-For-Sale Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" xlink:href="pcrx-20260630.xsd#pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" xlink:to="lab_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContractualObligationMutualTerminationRightsTerm_019e4244-85af-7d20-8f11-52ae188726c8_terseLabel_en-US" xlink:label="lab_pcrx_ContractualObligationMutualTerminationRightsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual termination rights term</link:label>
    <link:label id="lab_pcrx_ContractualObligationMutualTerminationRightsTerm_label_en-US" xlink:label="lab_pcrx_ContractualObligationMutualTerminationRightsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Mutual Termination Rights Term</link:label>
    <link:label id="lab_pcrx_ContractualObligationMutualTerminationRightsTerm_documentation_en-US" xlink:label="lab_pcrx_ContractualObligationMutualTerminationRightsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Mutual Termination Rights Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContractualObligationMutualTerminationRightsTerm" xlink:href="pcrx-20260630.xsd#pcrx_ContractualObligationMutualTerminationRightsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContractualObligationMutualTerminationRightsTerm" xlink:to="lab_pcrx_ContractualObligationMutualTerminationRightsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CostOfGoodsSoldAdjusted_019e4244-851a-7bc4-a000-e0afa722ea84_terseLabel_en-US" xlink:label="lab_pcrx_CostOfGoodsSoldAdjusted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted cost of goods sold</link:label>
    <link:label id="lab_pcrx_CostOfGoodsSoldAdjusted_label_en-US" xlink:label="lab_pcrx_CostOfGoodsSoldAdjusted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Goods Sold, Adjusted</link:label>
    <link:label id="lab_pcrx_CostOfGoodsSoldAdjusted_documentation_en-US" xlink:label="lab_pcrx_CostOfGoodsSoldAdjusted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost Of Goods Sold, Adjusted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CostOfGoodsSoldAdjusted" xlink:href="pcrx-20260630.xsd#pcrx_CostOfGoodsSoldAdjusted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CostOfGoodsSoldAdjusted" xlink:to="lab_pcrx_CostOfGoodsSoldAdjusted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_019e4244-851b-7ea7-8a96-15e8a1845f1b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_019e4244-851a-739b-b708-1e2860712881_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-851a-7f3b-a28f-ba83b720fe47_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019e4244-851a-78cc-a53a-123cbcb27744_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-85af-7635-88a7-84e98ebb92d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-85af-7086-a709-d3cf40ed940a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_019e4244-85af-7318-89b1-3435b37bee74_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information related to operating leases</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepaidPrincipal_019e4244-85af-72f0-96f6-85cc8d86d17a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepaidPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding principal balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepaidPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepaidPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repaid, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepaidPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepaidPrincipal" xlink:to="lab_us-gaap_DebtInstrumentRepaidPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_019e4244-851a-7947-b9be-daaa7b8305e7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019e4244-85af-7d06-adea-657df138ede2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_019e4244-85af-723b-92be-9b344cbb8536_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_019e4244-851a-7d8b-8522-da6995386eb3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_019e4244-851a-7113-8c02-5447beb2a2cc_terseLabel_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third largest wholesaler</link:label>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_label_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_documentation_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the third largest customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThirdLargestCustomerMember" xlink:href="pcrx-20260630.xsd#pcrx_ThirdLargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ThirdLargestCustomerMember" xlink:to="lab_pcrx_ThirdLargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019e4244-85af-76d3-9c26-ff674edb8ff9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-851a-7240-9ed6-9ec8c0870014_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key employee holdback recognition year two</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_label_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Percent, Year Two</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Percent, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" xlink:to="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_019f5e94-ddb4-7319-93a5-5de31e2b2bde_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS AND LIABILITIES HELD FOR SALE</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019e4244-851a-78c8-9c14-87cbae4d2187_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019e4244-851a-776a-8961-f61ac7a882c3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_019e4244-85af-7234-adad-474843988b1c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_019e4244-85af-7465-b391-294f80776a72_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase price percent</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_019e4244-851a-74ff-a4bf-83ec59e3b905_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining available for future purchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019e4244-851a-7953-893a-bd0b935d4334_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019e4244-85af-7413-a296-0ecf84644008_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_019e4244-851a-77aa-af25-20906cdf9273_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-851a-74ee-a154-9073b1420fe4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e4244-85af-7de2-9843-6a620c9342b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_019e4244-851a-7232-881b-4abd74d9aed6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_019e4244-85af-7f27-ad78-f64243a5702a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-85af-713d-842b-9be672f2e906_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-851a-7bc4-904a-49eea074e918_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_019e4244-851a-7a01-8350-64c76b69dd07_terseLabel_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement period of volumes distributed in market</link:label>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_label_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Volume-Limited, Maximum Percentage, Period</link:label>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_documentation_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Volume-Limited, Maximum Percentage, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" xlink:to="lab_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_019e4244-851a-7246-88c5-0758b997c1d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019e4244-851a-76c3-899f-41585d1cb9aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_019e4244-85af-7923-ad57-c64ff099d975_terseLabel_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increasing modestly period</link:label>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_label_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods</link:label>
    <link:label id="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_documentation_en-US" xlink:label="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" xlink:to="lab_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e4244-85af-721e-852d-b2fdc58d9115_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019e4244-85af-7040-8a01-54457d9a3eca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense year one</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019e4244-851a-7a3d-847c-baa9c7979c07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock, inclusive of excise tax and broker fees (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019e4244-851a-7472-8e0c-9cee667c0b99_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock, inclusive of excise tax (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_019e4244-85af-7445-a09c-b7990d7505f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_019e4244-85af-7950-9375-e17a34dd056c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Closing sale price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_019e4244-851a-72b2-bf0d-3a452145a72b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne_019e4244-851a-7cd4-8d87-ca5c786510fe_terseLabel_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets, deduction year one</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne_label_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year One</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" xlink:href="pcrx-20260630.xsd#pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" xlink:to="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_019e4244-85af-7f23-a0a7-a3fc5459a4a1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_019e4244-851a-7051-9298-b95d3b25f2fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_019e4244-851a-712c-99db-dcfe1ca4c2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_019e4244-851a-7776-9c49-b1a19d883e25_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_019e4244-85af-789c-86d6-ef986c17ca9d_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_019e4244-8454-75b8-b8a9-bd1c2581d727_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ZILRETTAMember_019e4244-85b0-72a5-af39-ce7950a22cac_terseLabel_en-US" xlink:label="lab_pcrx_ZILRETTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZILRETTA</link:label>
    <link:label id="lab_pcrx_ZILRETTAMember_label_en-US" xlink:label="lab_pcrx_ZILRETTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZILRETTA [Member]</link:label>
    <link:label id="lab_pcrx_ZILRETTAMember_documentation_en-US" xlink:label="lab_pcrx_ZILRETTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZILRETTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember" xlink:href="pcrx-20260630.xsd#pcrx_ZILRETTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ZILRETTAMember" xlink:to="lab_pcrx_ZILRETTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-851a-7834-a907-b7346d99d5e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock, inclusive of excise tax and broker fees</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-851a-762b-9b6b-fd7685e9c4c4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock, inclusive of excise tax and broker fees</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-85af-7627-8e49-69a4f1a6aace_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-85af-703d-a895-0c5d6f633b12_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019e4244-85af-7cf5-8e46-70ff0680a4d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_019e4244-8454-7ce6-a7bf-dbb2ce7ba1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Composition of the Company's Debt and Financing Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_019e4244-85af-7a62-811f-f8be45f850ad_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019e4244-851a-71e7-9282-86960be979ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_019e4244-851a-725c-a08f-558038559ef1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_019e4244-851a-711f-85e4-1073c3837574_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019e4244-8454-7a26-a148-b16c3debf355_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock, inclusive of broker fees</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019e4244-85af-7d93-9b24-7dc55fcd5629_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_019e4244-851a-7063-b6b2-221af3983b9a_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market price of principal amount of notes</link:label>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_label_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Market Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt market price, per $1,000 principal amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentMarketPrice" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentMarketPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentMarketPrice" xlink:to="lab_pcrx_DebtInstrumentMarketPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_019e4244-851a-787d-97cf-b9e659e1086b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold (exclusive of amortization of acquired intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019e4244-851a-7f0f-bdc1-889c1a1e1156_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019e4244-85af-755a-8d63-dfab4ccd0ad4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019e4244-851a-7e20-bbce-700b3a506775_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_019e4244-851a-71a0-a01f-7707370149b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_019f94d8-0f4c-755c-899e-6df2f38ce0ac_terseLabel_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue threshold period</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_label_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold, Period</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_documentation_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" xlink:to="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-85af-7526-94c8-72bbbd07d49b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-85af-78cf-8057-0af83c7215db_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-85af-74d3-85da-9a4b23a1e233_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration charges (gains)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-85af-70ab-b950-e01d232cfff2_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Changes in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_019e4244-85af-7d0e-97a6-3824358a973f_terseLabel_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement period - convertible debt conversion request</link:label>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_label_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Period - Convertible Debt Conversion Request</link:label>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_documentation_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of trading days in a settlement period for convertible debt conversion requests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:href="pcrx-20260630.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:to="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019e4244-851a-7868-9f06-1d9c6dfa2eca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019e4244-851a-7cd9-a62f-54ff183825d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excise tax on treasury stock repurchases included in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:to="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-851a-722f-a42f-8b53d012f49b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_019e4244-851a-7f1f-a9f0-7c801b05b865_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e4244-851a-7025-958d-2d3923982cbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_019e4244-851a-7f0c-b80c-f6e46602b987_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside of the U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_019e4244-851a-7e6b-9f1a-026a7fc195b0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_019e4244-851a-7788-ac38-361be90f2425_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scheduled trading day</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Redemption, Trading Days From Maturity</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Redemption, Trading Days From Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" xlink:to="lab_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_019e4244-851a-7b78-b94d-f7c58606ae85_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-85af-7486-90b3-445a2d786824_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_019e4244-8454-7915-a670-4ba00b171734_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-85af-7055-952a-b48c08296dd2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_019e4244-85af-78c3-9457-90e29c91fab3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019e4244-85b0-77fd-a21f-90dfcd8c3a8f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019e4244-85b0-741f-915d-5fd9c533226a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019e4244-85af-7bf6-9a09-c0d4a66ebeb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-851a-733f-a915-b0cfc514152f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_019e4244-85af-709d-9df8-2549fe4f31c0_terseLabel_en-US" xlink:label="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of capped calls, tax</link:label>
    <link:label id="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_label_en-US" xlink:label="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Tax</link:label>
    <link:label id="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_documentation_en-US" xlink:label="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" xlink:href="pcrx-20260630.xsd#pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" xlink:to="lab_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019e4244-85af-7bb0-9eaf-fd9aee71a04c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_019e4244-85af-7c5c-8f1d-3299e9eab801_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019e4244-851a-7e30-b4ec-4445740f7380_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019e4244-85af-7eaf-a69a-61dafff73cad_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense year three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_019e4244-85af-7f4d-a271-ef3bd0efee85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_019e4244-851a-793a-83ad-ea982fe52e07_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense, remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-851a-78bc-b8be-0b5043de4592_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_019f6ec5-1fdd-727c-aa61-5ec1fed011c4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total other operating expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember_019e4244-85af-738f-9d38-10ac47053f3c_terseLabel_en-US" xlink:label="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initiation of a Phase 2 Clinical Trial</link:label>
    <link:label id="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember_label_en-US" xlink:label="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initiation of a Phase 2 Clinical Trial [Member]</link:label>
    <link:label id="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember_documentation_en-US" xlink:label="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initiation of a Phase 2 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InitiationOfAPhase2ClinicalTrialMember" xlink:href="pcrx-20260630.xsd#pcrx_InitiationOfAPhase2ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InitiationOfAPhase2ClinicalTrialMember" xlink:to="lab_pcrx_InitiationOfAPhase2ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-8454-7632-b32a-1a7dfcbf396c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Asset, Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-85af-7ad1-8aa0-d6e56ad98db3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-85af-7cc9-b82d-d1d11036116c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_019e4244-851a-713d-9941-3c0d7bfcccaf_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at June&#160;30, 2026 and December&#160;31, 2025</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_019e4244-851a-707b-8cad-13c233ed6d80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Intangible Asset, Acquired, Finite-Lived [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_019e4244-85af-748f-99fa-9e24e925f060_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_019f6f3b-e381-7683-b97e-0a009cbdaf79_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_019f942a-2296-7a15-951c-d5b66cb60434_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment to be received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses and Interests in Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_019e4244-851a-78e4-b501-155479cedefd_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-851a-7663-9a33-5bb90f4bbcb1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019e4244-851a-7352-b83f-864fa60f18d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019e4244-851a-7b0a-8e81-dcf009ca2b5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019e4244-8454-76e1-85fc-58307939d7a0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-851a-7dc3-8cf9-954f017f6812_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived, Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived, Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_019e4244-8454-7d1a-a266-8f96c488c138_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfCustomers_019e4244-85af-7ff1-93b1-8a8c7be74fbd_terseLabel_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of customers</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfCustomers_label_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfCustomers_documentation_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfCustomers" xlink:href="pcrx-20260630.xsd#pcrx_ConcentrationRiskNumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConcentrationRiskNumberOfCustomers" xlink:to="lab_pcrx_ConcentrationRiskNumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_019e4244-851a-7ad8-a698-9d9a53a5002c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e4244-85af-7a13-93cd-8028709f9efa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_019e4244-85af-744f-9da0-b5ee348f597b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedExpensesTable_019e4244-85af-79ed-9270-9ed5e5f028c0_terseLabel_en-US" xlink:label="lab_pcrx_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Table]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesTable_label_en-US" xlink:label="lab_pcrx_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Table]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesTable_documentation_en-US" xlink:label="lab_pcrx_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesTable" xlink:href="pcrx-20260630.xsd#pcrx_AccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedExpensesTable" xlink:to="lab_pcrx_AccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_019e4244-85af-71d3-9bfe-f7b98905a0de_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of fixed assets and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_019e4244-851a-75dd-a5f2-b8617e62cac0_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_019e4244-85af-7fb9-9b5c-addd38070b63_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_019e4244-851a-719d-a1b3-700fe27b6281_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_019e4244-851a-7890-a895-96332c630806_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerOneMember_019e4244-8454-7d31-bd5c-5b2face8f131_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customer One</link:label>
    <link:label id="lab_pcrx_MajorCustomerOneMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customer One [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerOneMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerOneMember" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerOneMember" xlink:to="lab_pcrx_MajorCustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-8454-767d-a30a-88237341bfee_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_019e4244-851a-75b9-a5a5-94fde07a02db_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e4244-851a-7792-99ab-a9adb5061aed_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e4244-851a-733f-b283-766f22ae6133_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e4244-851a-745c-8321-053479dd2362_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e4244-851a-7267-a3a7-06b09c4e1f78_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_019e4244-851a-7bb3-acab-a6585231733e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_019fa709-6a45-70d1-826a-8f6e85667f46_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw Materials</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:to="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_019e4244-85af-7bbc-959d-c854e31ac31e_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FlexionTherapeuticsIncMember_019e4244-851a-7ab0-acf2-5ce0d2a5f4b9_terseLabel_en-US" xlink:label="lab_pcrx_FlexionTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Flexion</link:label>
    <link:label id="lab_pcrx_FlexionTherapeuticsIncMember_label_en-US" xlink:label="lab_pcrx_FlexionTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Flexion Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_pcrx_FlexionTherapeuticsIncMember_documentation_en-US" xlink:label="lab_pcrx_FlexionTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Flexion Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember" xlink:href="pcrx-20260630.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FlexionTherapeuticsIncMember" xlink:to="lab_pcrx_FlexionTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_019e4244-851a-7f89-98ea-4c26dc8fda61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_019e4244-85af-7056-87cf-7a1894d7bac1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_019e4244-851a-7bc2-8e94-4279f62dbe1d_terseLabel_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember" xlink:href="pcrx-20260630.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_019e4244-85af-718b-843e-163b53cbe86e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-851a-7b2f-9b6f-d6c8cff5a3be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_019e4244-85af-7676-bcc9-4bebf71bf775_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-851a-7668-96d5-e4b24bf555ff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-851a-7cef-adac-4675ce61f20f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019e4244-851a-7792-b602-a70dc8603dd1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019e4244-8454-795d-97c7-79f1aa3c00c7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-85af-7dd5-a47f-d876e2599d86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition-Related Cost, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementLoss_019e4244-851a-735a-9591-318b49f0300c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementLoss_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementLoss" xlink:to="lab_us-gaap_LitigationSettlementLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_019e4244-851a-75ec-af01-ec5542e38c70_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customer Two</link:label>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customer Two [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerTwoMember" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerTwoMember" xlink:to="lab_pcrx_MajorCustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-85af-77a9-b496-ed4fd6c63731_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_019e4244-85af-78ff-8586-fb1e06f9ceff_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019e4244-851a-7fb2-92fa-e9e6eaef8b01_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.001; 250,000,000 shares authorized; 48,840,889 shares issued and 39,822,298 shares outstanding at June&#160;30, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December&#160;31, 2025</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019e4244-851a-7d4c-9267-c0dbb72eac57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-8454-7398-a49e-5c9fe1bd2e24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of employee withholding taxes on restricted stock unit vests</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_019e4244-851b-794d-9dcc-d218798a8885_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019e4244-85af-7be4-8e98-73625d196423_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_019e4244-85b0-75c8-ae19-a6dc16dc9db4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_019e4244-8454-7dcf-9183-147ccf3569f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Expenses, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember_019e4244-851a-7332-ac63-e44d3fa2d3aa_terseLabel_en-US" xlink:label="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of payment for remaining regulatory milestones</link:label>
    <link:label id="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember_label_en-US" xlink:label="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Milestone Payment [Member]</link:label>
    <link:label id="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember_documentation_en-US" xlink:label="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Milestone Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:href="pcrx-20260630.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:to="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019e4244-85b0-73ca-89f4-87cf6aedcb76_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019e4244-851a-7ace-a2a1-5e3c247f4603_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-7f43-af99-a5ce7fa956d9_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-734b-aa5f-a1a760b52ce5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_019e4244-851a-72ea-977e-ebd871030cc9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payment</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-851a-7a54-8fca-3177f8dad4f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_019e4244-8454-7f2a-bc03-f69aebeb9e5e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_PercentOfLongLivedAssets_019e4244-851a-75c1-baf6-1b887897df34_terseLabel_en-US" xlink:label="lab_pcrx_PercentOfLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of long lived assets</link:label>
    <link:label id="lab_pcrx_PercentOfLongLivedAssets_label_en-US" xlink:label="lab_pcrx_PercentOfLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent Of Long Lived Assets</link:label>
    <link:label id="lab_pcrx_PercentOfLongLivedAssets_documentation_en-US" xlink:label="lab_pcrx_PercentOfLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent Of Long Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PercentOfLongLivedAssets" xlink:href="pcrx-20260630.xsd#pcrx_PercentOfLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PercentOfLongLivedAssets" xlink:to="lab_pcrx_PercentOfLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa6dc-45de-7b44-b727-1bac4f51ea2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-851a-72f9-bdee-b18f31412c03_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019e4244-851a-7b0d-b88e-07d6c81592d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019e4244-851a-764e-b58b-e6aecb2fdba4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019e4244-851a-7fd1-921f-ec491efaefb2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-85af-7c27-85b8-0033fa0d62ef_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-85af-7c25-a4fd-982054e77bab_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-85af-7afa-8844-7248b61d844e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_019e4244-8454-764f-b24e-51c9380ba9b6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019e4244-85af-7ace-b089-6f6f866ede3d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LGChemPartnershipAgreementMember_019e4244-851a-768b-b6e4-a84a5c30df30_terseLabel_en-US" xlink:label="lab_pcrx_LGChemPartnershipAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LG Chem, Partnership Agreement</link:label>
    <link:label id="lab_pcrx_LGChemPartnershipAgreementMember_label_en-US" xlink:label="lab_pcrx_LGChemPartnershipAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LG Chem, Partnership Agreement [Member]</link:label>
    <link:label id="lab_pcrx_LGChemPartnershipAgreementMember_documentation_en-US" xlink:label="lab_pcrx_LGChemPartnershipAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LG Chem, Partnership Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LGChemPartnershipAgreementMember" xlink:href="pcrx-20260630.xsd#pcrx_LGChemPartnershipAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LGChemPartnershipAgreementMember" xlink:to="lab_pcrx_LGChemPartnershipAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019fa6db-7030-7bc0-8ff7-e8d2af4755e8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019e4244-851a-7cee-9fc4-c41f9755f3c2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019fc8d8-0eb2-77ae-86af-7531c15716a6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_019e4244-85b0-7b7b-9f84-90c71bd0bd9a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-851a-7bd8-9d5a-78d48e4c2257_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_019e4244-85af-798a-a69a-cd7235aad104_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019e4244-851a-7c70-b24e-86c86a408d8c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e4244-85af-7fb0-b86f-1775baffba7f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_019e4244-85af-7edc-8494-9647a261a4b7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019e4244-85af-74b0-9096-fad700064b50_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019e4244-851a-716c-8e1b-8058bf68eeaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_019e4244-85af-79f0-8292-8c97bf28e94a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_019e4244-85af-7144-8ca2-fa62b0197412_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019e4244-8454-791c-8576-053deac20159_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_019e4244-85af-73f5-b101-eb70745e6fcf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_019e4244-85af-7c62-b0c7-e0d7c56b3e19_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt, net of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019e4244-851a-77a4-b2b3-bb09a01a5a47_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FIXED ASSETS</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-8454-7977-aa60-d532a1818be9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-851a-756a-83b8-4c1b9b65b5db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019e4244-8454-7461-aa8d-01bc517d301e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019e4244-851a-7f7a-85d8-bd1807442278_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_019e4244-851a-7398-8dd3-08ab2484737a_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of major customers</link:label>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_label_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_documentation_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers of the reporting entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfMajorCustomers" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfMajorCustomers" xlink:to="lab_pcrx_NumberOfMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e4244-85af-77d9-9aa7-fd45cdc29342_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_019e4244-851a-7db0-8df5-ac7387338b33_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_label_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Incremental Debt, Maximum</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Incremental Debt, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentCovenantIncrementalDebtMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" xlink:to="lab_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_019e4244-85af-7f1a-9cf1-d5e77f65eed4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019e4244-85af-78e1-bc79-df6450171075_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock incentive plan, awards reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_019e4244-851a-7a20-b479-2b0b7660562b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_019e4244-851a-7803-b31a-597cdf9099e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fixed Assets Summarized by Major Category</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e4244-851a-7be5-bef1-487f942141b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_019e4244-851a-7592-95a0-f944412fc5ef_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-851a-71a0-9a5b-0006307877c2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Excluding Goodwill, Indefinite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_WorkInProcessMember_019fa70a-42d8-7f0b-94ef-e07f3b5769ee_terseLabel_en-US" xlink:label="lab_pcrx_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_pcrx_WorkInProcessMember_label_en-US" xlink:label="lab_pcrx_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_pcrx_WorkInProcessMember_documentation_en-US" xlink:label="lab_pcrx_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WorkInProcessMember" xlink:href="pcrx-20260630.xsd#pcrx_WorkInProcessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_WorkInProcessMember" xlink:to="lab_pcrx_WorkInProcessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_InvestmentCategorizationAxis_019e4244-851a-7edc-b073-e10425765678_terseLabel_en-US" xlink:label="lab_pcrx_InvestmentCategorizationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Categorization [Axis]</link:label>
    <link:label id="lab_pcrx_InvestmentCategorizationAxis_label_en-US" xlink:label="lab_pcrx_InvestmentCategorizationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Categorization [Axis]</link:label>
    <link:label id="lab_pcrx_InvestmentCategorizationAxis_documentation_en-US" xlink:label="lab_pcrx_InvestmentCategorizationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Categorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationAxis" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InvestmentCategorizationAxis" xlink:to="lab_pcrx_InvestmentCategorizationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_019e4244-85b0-7fc3-999b-cec557a008d3_terseLabel_en-US" xlink:label="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="pcrx-20260630.xsd#pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019e4244-851a-7e9f-8053-6748a0c8fb72_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_019f6f30-8e22-728f-9886-ff21609860b5_terseLabel_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue threshold</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_label_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_documentation_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" xlink:to="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e4244-8454-7d2f-893a-3f5ec36e1a5f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_019e4244-8454-75bd-ba0a-35eb21f55819_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.125% convertible senior notes due May 2029</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-85af-7c74-b7e6-313c35508cb8_terseLabel_en-US" xlink:label="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share:</link:label>
    <link:label id="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="pcrx-20260630.xsd#pcrx_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DerivativePremiumPercentage_019e4244-851a-7edc-8147-6ee1e5ea4cde_terseLabel_en-US" xlink:label="lab_pcrx_DerivativePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium</link:label>
    <link:label id="lab_pcrx_DerivativePremiumPercentage_label_en-US" xlink:label="lab_pcrx_DerivativePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Premium Percentage</link:label>
    <link:label id="lab_pcrx_DerivativePremiumPercentage_documentation_en-US" xlink:label="lab_pcrx_DerivativePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative, Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DerivativePremiumPercentage" xlink:href="pcrx-20260630.xsd#pcrx_DerivativePremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DerivativePremiumPercentage" xlink:to="lab_pcrx_DerivativePremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-85af-7784-a49f-e8dfa8859479_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Voting Equity Interest Acquired, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-851a-7b77-8ee6-bb05fd709658_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-851a-71c5-aad8-a29add0a1040_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_019e4244-851a-733a-946f-7c21941f5fb5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_019e4244-851a-7925-98cd-aa3bdb8d38d9_terseLabel_en-US" xlink:label="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option extended term</link:label>
    <link:label id="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_label_en-US" xlink:label="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Minimum Monthly Commission, Duration</link:label>
    <link:label id="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_documentation_en-US" xlink:label="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Minimum Monthly Commission, Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContractualObligationMinimumMonthlyCommissionDuration" xlink:href="pcrx-20260630.xsd#pcrx_ContractualObligationMinimumMonthlyCommissionDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContractualObligationMinimumMonthlyCommissionDuration" xlink:to="lab_pcrx_ContractualObligationMinimumMonthlyCommissionDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019e4244-851a-72e6-beaa-03bfd9ec0e1f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_019e4244-85af-77e7-b730-c68cddfd7877_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_019e4244-851a-7c7a-b30c-04ae975745dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-7be8-9e87-26882ee1f8d4_terseLabel_en-US" xlink:label="lab_pcrx_ResearchAndDevelopmentAdjusted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted research and development</link:label>
    <link:label id="lab_pcrx_ResearchAndDevelopmentAdjusted_label_en-US" xlink:label="lab_pcrx_ResearchAndDevelopmentAdjusted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Adjusted</link:label>
    <link:label id="lab_pcrx_ResearchAndDevelopmentAdjusted_documentation_en-US" xlink:label="lab_pcrx_ResearchAndDevelopmentAdjusted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development, Adjusted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchAndDevelopmentAdjusted" xlink:href="pcrx-20260630.xsd#pcrx_ResearchAndDevelopmentAdjusted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ResearchAndDevelopmentAdjusted" xlink:to="lab_pcrx_ResearchAndDevelopmentAdjusted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019e4244-851a-7d82-b8eb-828de3c40d31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-85af-7d3f-b7f0-7a7be59cf890_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_019e4244-851a-7852-ab95-74d2f7388467_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-851a-7ca0-92b1-ea1bbd8d4661_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Goodwill and Other [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Goodwill and Other [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-85af-727a-a56c-d3cedeb34bc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-851a-71b7-b430-eae05f8e0240_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-851a-75cf-a758-de10fc4a0b91_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived, Class [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived, Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-851a-714b-ac77-d84f704e2346_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForOtherLosses_019e4244-851a-7bc8-a8f1-4d7875d9a199_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForOtherLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other net gains</link:label>
    <link:label id="lab_us-gaap_ProvisionForOtherLosses_label_en-US" xlink:label="lab_us-gaap_ProvisionForOtherLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for Other Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProvisionForOtherLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForOtherLosses" xlink:to="lab_us-gaap_ProvisionForOtherLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-851a-753e-8941-c6164d4b8833_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-851a-72cd-804c-6f9d9cd8839a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LargestCustomerMember_019e4244-851a-7b0c-8fae-2217c6dc51d7_terseLabel_en-US" xlink:label="lab_pcrx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Largest wholesaler</link:label>
    <link:label id="lab_pcrx_LargestCustomerMember_label_en-US" xlink:label="lab_pcrx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_LargestCustomerMember_documentation_en-US" xlink:label="lab_pcrx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the largest customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LargestCustomerMember" xlink:href="pcrx-20260630.xsd#pcrx_LargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LargestCustomerMember" xlink:to="lab_pcrx_LargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e4244-8454-7de7-ba02-191df578f78f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa6db-b258-741d-81f3-f90dee7a2ec5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019e4244-851a-76bf-8c7c-382ac7ea8947_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settled investments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_019e4244-85af-7d7b-97aa-00162049a267_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.750% Convertible senior notes due August 2025</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019e4244-851a-7b37-9d6b-1c2bc354f526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_019e4244-85af-7f9f-9809-eca02265c426_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NumberOfParagraphIVCertifications_019e4244-85af-7430-a3f5-0b8d1d036b19_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfParagraphIVCertifications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of paragraph certification</link:label>
    <link:label id="lab_pcrx_NumberOfParagraphIVCertifications_label_en-US" xlink:label="lab_pcrx_NumberOfParagraphIVCertifications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Paragraph IV Certifications</link:label>
    <link:label id="lab_pcrx_NumberOfParagraphIVCertifications_documentation_en-US" xlink:label="lab_pcrx_NumberOfParagraphIVCertifications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Paragraph IV Certifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfParagraphIVCertifications" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfParagraphIVCertifications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfParagraphIVCertifications" xlink:to="lab_pcrx_NumberOfParagraphIVCertifications" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019e4244-851a-70b3-acb9-b1bb93919f52_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019e4244-85af-7230-9c73-789d9efc200d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleNotesReceivableMember_019e4244-851a-796f-aea2-0dd089b024b4_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Receivable</link:label>
    <link:label id="lab_pcrx_ConvertibleNotesReceivableMember_label_en-US" xlink:label="lab_pcrx_ConvertibleNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Receivable [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleNotesReceivableMember_documentation_en-US" xlink:label="lab_pcrx_ConvertibleNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleNotesReceivableMember" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleNotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleNotesReceivableMember" xlink:to="lab_pcrx_ConvertibleNotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-851a-70a6-aa99-0b71a69339dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_019e4244-8454-7036-b09a-37523685994b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-85af-7914-a462-7f117190c9fd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeLocationBalanceAxis_019e4244-851a-7b01-8728-dbdbf7d9cc18_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeLocationBalanceAxis_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:to="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_019e4244-851a-7d39-a2d0-54690941a567_terseLabel_en-US" xlink:label="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expect to receive partial summary judgment</link:label>
    <link:label id="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_label_en-US" xlink:label="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Expected To Be Awarded from Other Party</link:label>
    <link:label id="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_documentation_en-US" xlink:label="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Expected To Be Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:to="lab_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-85af-72cc-88a0-0701757ed6c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedExpensesLineItems_019e4244-851a-7ce1-a63f-632e3ac5c10c_terseLabel_en-US" xlink:label="lab_pcrx_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesLineItems_label_en-US" xlink:label="lab_pcrx_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesLineItems_documentation_en-US" xlink:label="lab_pcrx_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesLineItems" xlink:href="pcrx-20260630.xsd#pcrx_AccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedExpensesLineItems" xlink:to="lab_pcrx_AccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019e4244-851a-73ef-81db-3cd5d6cb4523_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-851a-7aa8-9118-2946d585b83c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_019e4244-85af-74e0-99bd-700b2a025fb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_019e4244-85af-7113-9f2d-b9a4556e3281_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019e4244-851a-7185-a1e6-abe0ef4f5163_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_019e4244-85b0-7025-9762-d602bea126cb_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019e4244-85af-709f-8901-517716f7a6ad_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-851a-78c4-afae-552f8af75b16_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation from:</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019e4244-851a-7cec-a70c-e9f68ce1f64b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_019e4244-8454-7447-9d07-2c113980b8df_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019e4244-85b0-756e-8f62-441c0468d2e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain of prior investments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_019fa700-c3b5-70ab-9dc4-637058931c10_terseLabel_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product returns and wholesaler services</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_label_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Product Liabilities, Current</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_documentation_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Product Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" xlink:to="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019f9441-d09c-72af-9a58-7d3b5baea14b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration (up to)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-85af-75c7-b2fc-4823c5cbfe3f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019e4244-851a-7c86-9975-324d63b66632_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019e4244-851a-7301-bde0-8bba86913b54_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019e4244-85af-7cbe-aa24-b0530db45af2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e4244-85af-7dbf-a8bb-7772123372c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_GQBioTherapeuticsGmbHMember_019e4244-85af-7665-9336-c4286ab17fbf_terseLabel_en-US" xlink:label="lab_pcrx_GQBioTherapeuticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GQ Bio Therapeutics GmbH</link:label>
    <link:label id="lab_pcrx_GQBioTherapeuticsGmbHMember_label_en-US" xlink:label="lab_pcrx_GQBioTherapeuticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GQ Bio Therapeutics GmbH [Member]</link:label>
    <link:label id="lab_pcrx_GQBioTherapeuticsGmbHMember_documentation_en-US" xlink:label="lab_pcrx_GQBioTherapeuticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GQ Bio Therapeutics GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GQBioTherapeuticsGmbHMember" xlink:to="lab_pcrx_GQBioTherapeuticsGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_019e4244-85af-7c36-8ed2-e8c7607618ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-85af-7aa9-953e-b8c2c10cac71_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-85af-7dab-badb-22ea179521b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-85af-7545-8e4a-f27ecc4517a6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_019e4244-851a-7b5d-8882-79383cf0dcb2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ReportableSegmentMember_019e4244-85af-7f3a-bb14-b0eca021da77_terseLabel_en-US" xlink:label="lab_pcrx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_pcrx_ReportableSegmentMember_label_en-US" xlink:label="lab_pcrx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_pcrx_ReportableSegmentMember_documentation_en-US" xlink:label="lab_pcrx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReportableSegmentMember" xlink:href="pcrx-20260630.xsd#pcrx_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ReportableSegmentMember" xlink:to="lab_pcrx_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-85af-7a9b-a422-2248a0e9f556_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_019e4244-85af-7b58-b4ef-923cda3dcb0c_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019e4244-85af-7690-9847-4acd6b0b9e52_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019e4244-85af-7947-b918-6c218cebb2d7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019e4244-85af-761f-88f3-c62d32bc1ac4_netLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019e4244-85af-7438-a334-e8d6e4cf05b6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e4244-851a-7d8c-b9f2-47bb5753ae9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_019e4244-851a-7212-80ee-9b00036495fc_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_019e4244-85af-7d81-a344-59e751873206_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-85af-7e8b-9e51-c8eaf596aa34_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_019e4244-851a-7c8b-a293-e127b0149cf7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_019e4244-851a-7265-9438-669d9807a507_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019e4244-85af-7744-b144-69001aef0353_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019e4244-85af-7059-851c-1876b7571f02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e4244-851a-761e-83b8-b070cc918a3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019e4244-8454-7a7e-a23d-66087fa8f5d3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019e4244-851a-7e7e-858b-bb40c73e49eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_019e4244-851a-767e-b0d2-f184058fd12d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FinishedGoodsMember_019fa70a-83c4-761b-808a-8436280f854a_terseLabel_en-US" xlink:label="lab_pcrx_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:label id="lab_pcrx_FinishedGoodsMember_label_en-US" xlink:label="lab_pcrx_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_pcrx_FinishedGoodsMember_documentation_en-US" xlink:label="lab_pcrx_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FinishedGoodsMember" xlink:href="pcrx-20260630.xsd#pcrx_FinishedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FinishedGoodsMember" xlink:to="lab_pcrx_FinishedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-851a-766c-92f8-586350028eea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Acquired [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Acquired [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019e4244-85b0-7409-b475-d24d2953c613_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_019e4244-851a-709a-ba5b-23bb2337ded9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-851a-7461-a065-f4866e48da9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value (Per Share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_019e4244-851a-767f-8917-74c9fbbc9afb_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_019e4244-85b0-77cd-a8ff-d38821e06bcb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019e4244-851a-7759-b085-a30d9edfd273_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019e4244-8454-71fe-95c8-1891ad6b2c1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-85af-7ef2-88e5-77384b643002_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_019e4244-85af-7467-a617-3b42f33452e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e4244-85af-7dcd-8552-a795c4b5ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-851a-793f-aa2e-56ec5c02e027_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-851a-7150-9361-3662a24621b5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-851a-70be-80f2-d136664fee4b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-851a-7087-8eb2-9d370003f72b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_019e4244-85af-7f4d-b757-d6b328fc80d8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019e4244-85af-7e01-90f8-712ddd174fe9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_019e4244-851a-718b-b3f0-ab517e54eadc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Unrealized Gain (Loss) From Available-For-Sale Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019e4244-8454-73d3-bb90-b323c9e23fd7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019e4244-85af-7ffc-9412-0ae5017ae6be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Key Assumptions used in the Valuation of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-85af-74ee-a3d0-b018a83c45a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-851a-7259-b222-2431c7d60dfb_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-851a-743c-a53f-e5b9451c0d1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019e4244-851a-7b8b-a457-3750a4a717a7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-8454-78b5-9d5f-ec2e55e54841_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019fa6ff-690f-78c3-a789-582c6b870fb3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-851a-7e14-a28b-75567aad4dce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-851a-757d-9ae9-3ae99d604b0a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock withheld for employee tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-851a-7b10-9554-31c66ffb52c2_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets:</link:label>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivablesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_019e4244-851a-764c-aa06-b7ad82d7d334_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Amount and Fair Value of the Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-851a-7ecc-a57b-1d7c3ad713ee_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.125% Convertible senior notes due May 2029</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2029Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2029 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDue2029Member" xlink:to="lab_pcrx_ConvertibleSeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-7c80-9f8b-78dc50a76d27_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019e4244-85af-72ed-b9a4-bcac9a4eed37_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-85af-74d1-8100-2f37da64ffd5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationNoncurrent_019e4244-851a-7422-83d8-d3111ae5c425_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationNoncurrent_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Noncurrent</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationNoncurrent_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationNoncurrent" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationNoncurrent" xlink:to="lab_pcrx_ContingentConsiderationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019e4244-851a-7ee6-affa-6b68888dc7a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019e4244-851a-7bac-8b6b-2af719fc5262_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-85af-7262-a4a2-cf154cf40656_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember_019e4244-8454-7ab6-8ac8-452bef2bd191_terseLabel_en-US" xlink:label="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bupivacaine liposome injectable suspension</link:label>
    <link:label id="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember_label_en-US" xlink:label="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bupivacaine Liposome Injectable Suspension [Member]</link:label>
    <link:label id="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember_documentation_en-US" xlink:label="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bupivacaine Liposome Injectable Suspension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:href="pcrx-20260630.xsd#pcrx_BupivacaineLiposomeInjectableSuspensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:to="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019fa70c-403b-763e-b3c1-d37466274352_terseLabel_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential contingent consideration</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_label_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:label id="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_documentation_en-US" xlink:label="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:to="lab_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-85af-7e56-b4d2-63b0773a4735_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_019e4244-851a-7b29-ab71-683f17b3c823_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-851a-72f1-afda-68daa49e51ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019e4244-851a-7936-9163-5e2e5ff586fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_019e4244-851a-754e-8f8a-4862d45d8ed4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset and Goodwill [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019e4244-851a-784b-a3e7-6d2f8d61281e_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements Using</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_019e4244-851a-789a-a5c7-111dcab77fb8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleNoteReceivableMember_019e4244-85af-77d1-8ddd-cf897e3c3fbf_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Note Receivable</link:label>
    <link:label id="lab_pcrx_ConvertibleNoteReceivableMember_label_en-US" xlink:label="lab_pcrx_ConvertibleNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note Receivable [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleNoteReceivableMember_documentation_en-US" xlink:label="lab_pcrx_ConvertibleNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleNoteReceivableMember" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleNoteReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleNoteReceivableMember" xlink:to="lab_pcrx_ConvertibleNoteReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019e4244-85b0-7e09-b9da-736081a548fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Before Income Taxes and Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019e4244-85af-7d40-a3ce-9586f6aaaea2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EXPARELMember_019e4244-851a-754e-b21f-3a60f899b3ae_terseLabel_en-US" xlink:label="lab_pcrx_EXPARELMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EXPAREL</link:label>
    <link:label id="lab_pcrx_EXPARELMember_label_en-US" xlink:label="lab_pcrx_EXPARELMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EXPAREL [Member]</link:label>
    <link:label id="lab_pcrx_EXPARELMember_documentation_en-US" xlink:label="lab_pcrx_EXPARELMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EXPAREL/bupivacaine liposome injectable suspension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EXPARELMember" xlink:href="pcrx-20260630.xsd#pcrx_EXPARELMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EXPARELMember" xlink:to="lab_pcrx_EXPARELMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_019e4244-85af-749f-b2f4-62778844e8e5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_019e4244-85b0-7419-a878-8d6df55fe6e8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_019e4244-851a-705b-b0e2-a9496d6d24b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment, principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_019e4244-8454-77b4-9ef3-21788bdf9357_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-851a-7c44-bd46-92970b717a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019e4244-851a-7c62-8609-6b6c18bdcb14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares remaining available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-851a-7632-b550-89e2548c23c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_019e4244-85af-78f2-9c04-469fb607e3c9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Expense and Other Operating Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_019e4244-851a-7c6d-90e7-2fcdc783f25f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term and Noncurrent Available-for-Sale Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e4244-8454-7d92-801e-1e310157246f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-851a-7ee0-bf73-c1d5f588304d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-851a-7e91-9bc5-8a51a6b05c9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_InvestmentCategorizationDomain_019e4244-851a-7d3e-9b94-d1b29da49b51_terseLabel_en-US" xlink:label="lab_pcrx_InvestmentCategorizationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Categorization [Domain]</link:label>
    <link:label id="lab_pcrx_InvestmentCategorizationDomain_label_en-US" xlink:label="lab_pcrx_InvestmentCategorizationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Categorization [Domain]</link:label>
    <link:label id="lab_pcrx_InvestmentCategorizationDomain_documentation_en-US" xlink:label="lab_pcrx_InvestmentCategorizationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Categorization [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationDomain" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InvestmentCategorizationDomain" xlink:to="lab_pcrx_InvestmentCategorizationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019e4244-85af-7609-b36f-782c666105b2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_GeneQuineMember_019e4244-851a-79f9-9c9d-1e9d8407d1fc_terseLabel_en-US" xlink:label="lab_pcrx_GeneQuineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GeneQuine</link:label>
    <link:label id="lab_pcrx_GeneQuineMember_label_en-US" xlink:label="lab_pcrx_GeneQuineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GeneQuine [Member]</link:label>
    <link:label id="lab_pcrx_GeneQuineMember_documentation_en-US" xlink:label="lab_pcrx_GeneQuineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GeneQuine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember" xlink:href="pcrx-20260630.xsd#pcrx_GeneQuineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GeneQuineMember" xlink:to="lab_pcrx_GeneQuineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_019e4244-851a-7c1a-b770-de6c5b44c8eb_negatedTerseLabel_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairments</link:label>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_label_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Impairments</link:label>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_documentation_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Impairments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" xlink:href="pcrx-20260630.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" xlink:to="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NumberOfGenericDrugManufacturers_019e4244-85af-7dd8-9ac2-aa582353362a_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfGenericDrugManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of generic drug manufacturers</link:label>
    <link:label id="lab_pcrx_NumberOfGenericDrugManufacturers_label_en-US" xlink:label="lab_pcrx_NumberOfGenericDrugManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Generic Drug Manufacturers</link:label>
    <link:label id="lab_pcrx_NumberOfGenericDrugManufacturers_documentation_en-US" xlink:label="lab_pcrx_NumberOfGenericDrugManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Generic Drug Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfGenericDrugManufacturers" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfGenericDrugManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfGenericDrugManufacturers" xlink:to="lab_pcrx_NumberOfGenericDrugManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RevenueMilestoneTwoMember_019f6f30-8e22-767b-b7db-86dd21f07c34_terseLabel_en-US" xlink:label="lab_pcrx_RevenueMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Milestone Tier 2</link:label>
    <link:label id="lab_pcrx_RevenueMilestoneTwoMember_label_en-US" xlink:label="lab_pcrx_RevenueMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Milestone Two [Member]</link:label>
    <link:label id="lab_pcrx_RevenueMilestoneTwoMember_documentation_en-US" xlink:label="lab_pcrx_RevenueMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneTwoMember" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RevenueMilestoneTwoMember" xlink:to="lab_pcrx_RevenueMilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019e4244-851a-734d-b8eb-57c098246994_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_019e4244-851a-776b-a005-6a226a7e1162_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019e4244-85af-7275-be33-e0fcbe388f4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity and RSU and PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-851a-77d0-bc38-210195e320fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (Per Share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock_019fa395-6bdc-7c10-875d-ef4a2862ff2e_terseLabel_en-US" xlink:label="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held for Sale</link:label>
    <link:label id="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock_label_en-US" xlink:label="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock_documentation_en-US" xlink:label="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" xlink:href="pcrx-20260630.xsd#pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" xlink:to="lab_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_TermLoanAFacilityDueMarch2028Member_019e4244-851a-70eb-abb4-47262936f66a_terseLabel_en-US" xlink:label="lab_pcrx_TermLoanAFacilityDueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan A facility maturing March 2028</link:label>
    <link:label id="lab_pcrx_TermLoanAFacilityDueMarch2028Member_label_en-US" xlink:label="lab_pcrx_TermLoanAFacilityDueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A Facility Due March 2028 [Member]</link:label>
    <link:label id="lab_pcrx_TermLoanAFacilityDueMarch2028Member_documentation_en-US" xlink:label="lab_pcrx_TermLoanAFacilityDueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan A Facility Due March 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanAFacilityDueMarch2028Member" xlink:href="pcrx-20260630.xsd#pcrx_TermLoanAFacilityDueMarch2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TermLoanAFacilityDueMarch2028Member" xlink:to="lab_pcrx_TermLoanAFacilityDueMarch2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_019e4244-851a-7523-b613-5361f1dc4a64_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019e4244-85b0-78c0-9c4a-526f40cf0ca5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019e4244-85b0-7070-bb49-ed0bc6d8928c_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019e4244-85af-7ed3-bf94-0c6bccbd9fc4_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019e4244-851a-78df-a12b-ad04bfff5e99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_019e4244-85af-7280-ae3c-51cf7cb3aee0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_019e4244-8454-71ca-b67b-d1ddc4e383dd_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional interest payment</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest" xlink:to="lab_us-gaap_LitigationSettlementInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019e4244-85af-75dc-ab9c-99122ddf42b8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_019e4244-851a-7547-af7a-cffd3ba500d4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_019e4244-851a-7d17-91dd-7c27061228db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019e4244-851a-7bb0-885a-f05a08e10ba6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019e4244-851a-7dd9-9cd8-ba6e4e7f22b2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_019e4244-8454-73c4-9b61-da3ebb049551_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-851a-7628-a13b-445646fb1378_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-851a-7dd8-ba4f-209664f2060d_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Withheld shares in common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_019e4244-851a-77d2-9306-8456956c3b96_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Useful Lives</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Acquired, Weighted-Average Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-851a-7234-8ae4-85025d7cdb8b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FIXED ASSETS</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ThreeLargestCustomersMember_019e4244-8454-7117-8de1-5ecc1f83c925_terseLabel_en-US" xlink:label="lab_pcrx_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_pcrx_ThreeLargestCustomersMember_label_en-US" xlink:label="lab_pcrx_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Largest Customers [Member]</link:label>
    <link:label id="lab_pcrx_ThreeLargestCustomersMember_documentation_en-US" xlink:label="lab_pcrx_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThreeLargestCustomersMember" xlink:href="pcrx-20260630.xsd#pcrx_ThreeLargestCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ThreeLargestCustomersMember" xlink:to="lab_pcrx_ThreeLargestCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_019e4244-851a-7e33-82ba-9396f7ce8c36_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_019e4244-851a-703f-8c5f-607d41898df9_terseLabel_en-US" xlink:label="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of milestone payment</link:label>
    <link:label id="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_label_en-US" xlink:label="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Milestone Payments, Maximum</link:label>
    <link:label id="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" xlink:href="pcrx-20260630.xsd#pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" xlink:to="lab_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-85af-746f-a76b-d1d02cdf1099_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019e4244-851a-766b-9268-b2c2148fe7ca_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_019e4244-85af-7de7-b227-69e19caf5904_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased aggregate principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019e4244-85af-7d09-ae64-f70c4e3d4fe4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_019e4244-85af-736c-8d04-a5ea620d1cef_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019e4244-851a-73de-a9b5-ecfff094340e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-851a-7c81-bbae-7590aa3bfc3d_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key employee holdback recognition year one</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_label_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Percent, Year One</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Percent, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" xlink:to="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_019e4244-85af-7ec4-a99f-b3bca207ac86_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments for royalties</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019e4244-85af-7325-a031-293208a1c672_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019e4244-85af-7c8a-bbbf-51dcc963589a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019e4244-851a-7c7a-ad19-87ce1d241fa3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for achievement of regulatory milestone</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAmortizationOfDeferredCharges_019fa739-a915-7d9b-92a4-10ac9ffd3154_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of cloud computing arrangements</link:label>
    <link:label id="lab_us-gaap_OtherAmortizationOfDeferredCharges_label_en-US" xlink:label="lab_us-gaap_OtherAmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Other Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAmortizationOfDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAmortizationOfDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="lab_us-gaap_OtherAmortizationOfDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-85af-7b5d-99f7-3dd643cacc03_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-85af-766f-9db0-7f47563f5052_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019e4244-851b-739e-a1ba-5e743d6ff564_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-851a-7b91-8e8e-d1d0b170e0eb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_019e4244-851a-74be-943d-39e8e7d833c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_019f6f46-c3e2-70fd-a004-f993865d0454_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019e4244-851a-7903-aa13-176519c0dad4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense year four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_019e4244-851a-72a3-8f4f-832880514b12_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-851a-7aa4-b7ed-65ed75f526f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019e4244-851a-75cf-8712-cf6c1d0ca852_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-851a-796c-9b7d-447de7a1953e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo_019e4244-851a-74ab-a69b-234f25ad5731_terseLabel_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets, deduction year two</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo_label_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year Two</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" xlink:href="pcrx-20260630.xsd#pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" xlink:to="lab_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedResearchAndDevelopmentExpenses_019e4244-85af-7aac-b9a3-cf64affa006b_terseLabel_en-US" xlink:label="lab_pcrx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_pcrx_AccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_pcrx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expenses</link:label>
    <link:label id="lab_pcrx_AccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_pcrx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of liabilities incurred and payable to vendors for goods and services related to research and development activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedResearchAndDevelopmentExpenses" xlink:href="pcrx-20260630.xsd#pcrx_AccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_pcrx_AccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_019e4244-851a-7ac6-9a1b-2f0c6e44f526_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_019e4244-851a-752c-abce-afcde08f032c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_019e4244-85b0-765c-a04f-df1f16a75032_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of convertible notes receivable investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_019e4244-8454-730e-a932-9a68997f64d9_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_label_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_documentation_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Different categories of achievement of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfMilestoneDomain" xlink:to="lab_pcrx_AchievementOfMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_019e4244-851a-7c86-8ca2-182d7250cbd4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_019e4244-85b0-7d5a-869f-3e47d26c5430_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FlexionAcquisitionMember_019e4244-8454-716b-b6b0-5ad5cd7ff0fa_terseLabel_en-US" xlink:label="lab_pcrx_FlexionAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Flexion Acquisition</link:label>
    <link:label id="lab_pcrx_FlexionAcquisitionMember_label_en-US" xlink:label="lab_pcrx_FlexionAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Flexion Acquisition [Member]</link:label>
    <link:label id="lab_pcrx_FlexionAcquisitionMember_documentation_en-US" xlink:label="lab_pcrx_FlexionAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Flexion Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember" xlink:href="pcrx-20260630.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FlexionAcquisitionMember" xlink:to="lab_pcrx_FlexionAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-85b0-7b24-9de6-02681fcbe343_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Asset, Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_019e4244-851a-7123-afb2-b619eb6e369e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of Term loan A facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019e4244-85af-79e4-a5cc-3e24cc93e5be_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-85af-7d27-8384-7e3e90a8683b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key assumptions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_019e4244-85b0-7649-ae7c-bd5c033984db_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019e4244-8454-78a7-9457-d498a7a332f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019e4244-85af-720b-85a5-e60bd680c9e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019e4244-851a-7481-8a79-3870d2be1889_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019e4244-851a-71aa-9351-0d15e7e7bf8f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_019e4244-85af-7dfd-9885-6c7ae6f4d1a3_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019e4244-85b0-7ca1-8ba7-e1e62eb8cd86_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019e4244-85af-7838-ad96-a6506af86c15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019e4244-851a-798c-b11a-2254ef83a643_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_019e4244-851a-7334-af25-65886034379d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019e4244-85af-7ed3-8d67-fa323c594236_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, ESPP (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e4244-85af-73b0-b4f4-be62b5b4e2fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_019e4244-851a-7dc9-919b-4da27558e912_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_019e4244-851a-7efc-a161-7c8fad46fb51_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan share options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_019e4244-851a-71f4-afa3-0c695286b82c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average ESPP share options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019e4244-85af-792e-9d61-c6a76e9ae99d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net income (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_019e4244-851a-7ed8-904b-643488f06732_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019e4244-851a-7f68-bdaa-91204acfcdfd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BaylorCollegeOfMedicineBaylorMember_019e4244-85af-79a9-9e60-45c9123d0ffe_terseLabel_en-US" xlink:label="lab_pcrx_BaylorCollegeOfMedicineBaylorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baylor College of Medicine (Baylor)</link:label>
    <link:label id="lab_pcrx_BaylorCollegeOfMedicineBaylorMember_label_en-US" xlink:label="lab_pcrx_BaylorCollegeOfMedicineBaylorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baylor College of Medicine (Baylor) [Member]</link:label>
    <link:label id="lab_pcrx_BaylorCollegeOfMedicineBaylorMember_documentation_en-US" xlink:label="lab_pcrx_BaylorCollegeOfMedicineBaylorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baylor College of Medicine (Baylor)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BaylorCollegeOfMedicineBaylorMember" xlink:href="pcrx-20260630.xsd#pcrx_BaylorCollegeOfMedicineBaylorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BaylorCollegeOfMedicineBaylorMember" xlink:to="lab_pcrx_BaylorCollegeOfMedicineBaylorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_019e4244-85af-72e4-9cff-ad03a196602a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_019e4244-851a-7bc6-a1cf-56b30daeaf25_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Development and Regulatory Milestones</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement of Development and Regulatory Milestones [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of Development and Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_019e4244-85af-7d5e-9809-dbaea1185a81_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccountsReceivablePaymentTerms_019e4244-851a-7451-ba94-044d31bdc999_terseLabel_en-US" xlink:label="lab_pcrx_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_pcrx_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_pcrx_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_pcrx_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_pcrx_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccountsReceivablePaymentTerms" xlink:href="pcrx-20260630.xsd#pcrx_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccountsReceivablePaymentTerms" xlink:to="lab_pcrx_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fca02-e004-7897-9a36-d9e8f7eb7854_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decommissioning of manufacturing suite</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e4244-851a-7f95-a11c-3739328e604d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-85af-7f02-993a-d55f14c3b339_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-851a-7ff9-80be-ccccb75ebc17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019e4244-851a-7e17-83a5-0957f62c27f6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IoveraMember_019e4244-85af-720a-b229-4de0971b12d9_terseLabel_en-US" xlink:label="lab_pcrx_IoveraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">iovera&#176;</link:label>
    <link:label id="lab_pcrx_IoveraMember_label_en-US" xlink:label="lab_pcrx_IoveraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">iovera&#176; [Member]</link:label>
    <link:label id="lab_pcrx_IoveraMember_documentation_en-US" xlink:label="lab_pcrx_IoveraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">iovera&#176; [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IoveraMember" xlink:to="lab_pcrx_IoveraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_019e4244-851a-75f5-8ddd-3f893e439ffe_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.K</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-85af-75ff-b421-1ed11a4e27bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_019e4244-851a-7694-9626-90bc1d1baa31_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenue from customers to total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_019e4244-851a-7a19-9662-c3b409529d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-85af-72da-9f23-99b0c0e3f534_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e4244-851a-7150-94d2-757fa4ebec00_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019e4244-851a-7cbc-ace4-4f84da16b145_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_019e4244-851a-77a9-9c2c-e987ce2300c7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_GQBioAcquisitionMember_019e4244-85af-724b-8a2e-f40a35789bec_terseLabel_en-US" xlink:label="lab_pcrx_GQBioAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GQ Bio Acquisition</link:label>
    <link:label id="lab_pcrx_GQBioAcquisitionMember_label_en-US" xlink:label="lab_pcrx_GQBioAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GQ Bio Acquisition [Member]</link:label>
    <link:label id="lab_pcrx_GQBioAcquisitionMember_documentation_en-US" xlink:label="lab_pcrx_GQBioAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GQ Bio Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GQBioAcquisitionMember" xlink:to="lab_pcrx_GQBioAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019e4244-85af-76bd-91b4-d5aabe3898bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019e4244-851a-76e2-97f1-4bfc4c52c007_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense year five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_019e4244-851a-7734-9cd7-610cd207bbac_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_019e4244-85af-7b8c-8144-4a680992e630_terseLabel_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second largest wholesaler</link:label>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_label_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_documentation_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the second largest customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondLargestCustomerMember" xlink:href="pcrx-20260630.xsd#pcrx_SecondLargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SecondLargestCustomerMember" xlink:to="lab_pcrx_SecondLargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019e4244-85af-7602-a4d2-96c09a27ec09_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019e4244-8454-745e-a85f-a9bfe740587e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_019e4244-851a-7bf4-8ae9-f3315b59e81b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of notices are filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ResearchDevelopmentFoundationMember_019e4244-85af-7b83-b3ae-882749b7070a_terseLabel_en-US" xlink:label="lab_pcrx_ResearchDevelopmentFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Development Foundation</link:label>
    <link:label id="lab_pcrx_ResearchDevelopmentFoundationMember_label_en-US" xlink:label="lab_pcrx_ResearchDevelopmentFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Development Foundation [Member]</link:label>
    <link:label id="lab_pcrx_ResearchDevelopmentFoundationMember_documentation_en-US" xlink:label="lab_pcrx_ResearchDevelopmentFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Development Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchDevelopmentFoundationMember" xlink:href="pcrx-20260630.xsd#pcrx_ResearchDevelopmentFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ResearchDevelopmentFoundationMember" xlink:to="lab_pcrx_ResearchDevelopmentFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019e4244-85af-78a6-a1b3-2a3c20d1a550_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_019e4244-851a-70a8-a3df-d07801c13f2e_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customer Three</link:label>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customer Three [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerThreeMember" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerThreeMember" xlink:to="lab_pcrx_MajorCustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_019e4244-85af-7320-ac17-b0a3bcb00886_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_019e4244-85af-7ec1-9f8a-9b8b3cce5ee3_terseLabel_en-US" xlink:label="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investment And Convertible Note Receivable</link:label>
    <link:label id="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_label_en-US" xlink:label="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investment And Convertible Note Receivable [Member]</link:label>
    <link:label id="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_documentation_en-US" xlink:label="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investment And Convertible Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" xlink:href="pcrx-20260630.xsd#pcrx_EquityInvestmentAndConvertibleNoteReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" xlink:to="lab_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019e4244-851a-7e49-82e1-b0377af5cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019e4244-8454-7fde-87b7-dec80eacb866_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019e4244-85af-7489-a2da-81f0838254f9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_019e4244-85af-7fd4-9814-c445fe8b9f37_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-851a-7112-bb84-23b1c16493a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key employee holdback agreement</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingency Recognized at Acquisition Date, Liability Assumed, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_019e4244-851a-7203-812c-a97942ab6aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate on total debt (in percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-85af-7aad-af75-00b376ac819b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_019e4244-85af-7d30-b952-ffeafbf32ca0_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Interest Expense Recognized Related to the Notes</link:label>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the amount of interest rate expenses related to convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pcrx-20260630.xsd#pcrx_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_019e4244-8454-7b49-816f-0427bf6044a2_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt, premium on common stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Premium on Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:to="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019e4244-851a-74f6-ac21-5c9dc29ae4e3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_019e4244-851a-74d8-bed4-908a754c1060_verboseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019e4244-851a-73bc-92cc-980b50e5f06e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_019e4244-851a-7f6f-8e60-ba44fbe06c00_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets recorded in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019e4244-851a-7d53-84c2-a92aa07a88dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019e4244-851a-7eab-b300-6ac2bb160f10_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019e4244-851a-7476-98b6-363df410e814_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_019e4244-85af-701a-8d4e-729689e47369_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER OPERATING EXPENSES, NET</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_019fc8d8-6e12-7051-aeda-42144d2ff34d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_019e4244-85af-7ce0-8fd4-dabbf83eb8e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-85af-7dc3-b0fa-3a7ee3055d2a_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019e4244-85af-770d-a1be-7d32098c7316_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_019e4244-851a-727e-99b1-5f35a68fd80d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-851a-71aa-a4fb-fda6ce813c29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019e4244-851a-748d-81c2-c3b88ec72457_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-76f0-be1a-b6913372d1fa_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key employee holdback agreement payment period</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_label_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Period Of Recognized</link:label>
    <link:label id="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Period Of Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" xlink:to="lab_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DerivativeCappedCallPrice_019e4244-85af-78c6-b6d8-79013b9a5daa_terseLabel_en-US" xlink:label="lab_pcrx_DerivativeCappedCallPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cap price (in USD per share)</link:label>
    <link:label id="lab_pcrx_DerivativeCappedCallPrice_label_en-US" xlink:label="lab_pcrx_DerivativeCappedCallPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Capped Call Price</link:label>
    <link:label id="lab_pcrx_DerivativeCappedCallPrice_documentation_en-US" xlink:label="lab_pcrx_DerivativeCappedCallPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative, Capped Call Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DerivativeCappedCallPrice" xlink:href="pcrx-20260630.xsd#pcrx_DerivativeCappedCallPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DerivativeCappedCallPrice" xlink:to="lab_pcrx_DerivativeCappedCallPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionTermsTwoMember_019e4244-8454-752c-b0fc-15d02d664671_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term two</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsTwoMember" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsTwoMember" xlink:to="lab_pcrx_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>pcrx-20260630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e4244-8139-7e27-b3f4-c33a61dfef92,g:c636850a-8e11-4f67-b4ef-051f1780002d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacira.com/role/Cover" xlink:type="simple" xlink:href="pcrx-20260630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e4244-838c-7e88-8b78-a5042b66f909" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_DocumentType_019e4244-838c-7e88-8b78-a5042b66f909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019e4244-838c-7617-8972-929c485a87d7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_DocumentQuarterlyReport_019e4244-838c-7617-8972-929c485a87d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e4244-838c-7dab-8ec9-b2a30ee786b7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_DocumentPeriodEndDate_019e4244-838c-7dab-8ec9-b2a30ee786b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019e4244-838c-73f8-b19a-d50023094b08" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_DocumentTransitionReport_019e4244-838c-73f8-b19a-d50023094b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e4244-838c-7386-9493-d1bd64386c88" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityFileNumber_019e4244-838c-7386-9493-d1bd64386c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e4244-838c-7455-b10d-81d430763b72" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityRegistrantName_019e4244-838c-7455-b10d-81d430763b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e4244-838c-7b6c-b8a9-c62ba9196396" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e4244-838c-7b6c-b8a9-c62ba9196396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e4244-838c-7239-87b2-3612f4df8095" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e4244-838c-7239-87b2-3612f4df8095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e4244-838c-735b-bb85-ae8e07be2053" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityAddressAddressLine1_019e4244-838c-735b-bb85-ae8e07be2053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e4244-838c-796d-813a-8e0964012750" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityAddressCityOrTown_019e4244-838c-796d-813a-8e0964012750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019e4244-838c-7763-bc8d-c1a1264a8324" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityAddressStateOrProvince_019e4244-838c-7763-bc8d-c1a1264a8324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e4244-838c-78d1-a0eb-8586482b0666" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityAddressPostalZipCode_019e4244-838c-78d1-a0eb-8586482b0666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e4244-838c-7b0c-b0c7-fc2abfed74eb" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_CityAreaCode_019e4244-838c-7b0c-b0c7-fc2abfed74eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e4244-838c-76b0-b36d-29ade30c3b8b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_LocalPhoneNumber_019e4244-838c-76b0-b36d-29ade30c3b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e4244-838c-7442-9aeb-01dd987d44b6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_Security12bTitle_019e4244-838c-7442-9aeb-01dd987d44b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e4244-838c-78c1-9db3-a309467bf072" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_TradingSymbol_019e4244-838c-78c1-9db3-a309467bf072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e4244-838c-7ba5-a27a-f462bbb4bbe4" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_SecurityExchangeName_019e4244-838c-7ba5-a27a-f462bbb4bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019e4244-838c-716b-a426-a032c3c02338" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityCurrentReportingStatus_019e4244-838c-716b-a426-a032c3c02338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019e4244-838c-747d-a113-82ca0cc09d7b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityInteractiveDataCurrent_019e4244-838c-747d-a113-82ca0cc09d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019e4244-838c-7739-906c-630b6d9a8ef9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityFilerCategory_019e4244-838c-7739-906c-630b6d9a8ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019e4244-838c-7578-a12a-6c2915ee6b8c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntitySmallBusiness_019e4244-838c-7578-a12a-6c2915ee6b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e4244-838c-7ac5-beb7-182db9c97ecd" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e4244-838c-7ac5-beb7-182db9c97ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019e4244-838c-7459-ad93-39f1dbed1d38" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityShellCompany_019e4244-838c-7459-ad93-39f1dbed1d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019e4244-838c-7993-9515-4bcb8a8b7e46" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019e4244-838c-7993-9515-4bcb8a8b7e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e4244-838c-7baf-a80a-52f61f8eab30" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_EntityCentralIndexKey_019e4244-838c-7baf-a80a-52f61f8eab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019e4244-838c-7e0a-babe-dea33f8217a1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_CurrentFiscalYearEndDate_019e4244-838c-7e0a-babe-dea33f8217a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019e4244-838c-77d2-9d27-dc147c8d86fe" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_DocumentFiscalYearFocus_019e4244-838c-77d2-9d27-dc147c8d86fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019e4244-838c-7ea6-a6e5-16d79033a35e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019e4244-838c-7ea6-a6e5-16d79033a35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e4244-838c-71aa-8b6f-21040a27477e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e4244-838c-72c8-9123-52d974f04cd3" xlink:to="loc_dei_AmendmentFlag_019e4244-838c-71aa-8b6f-21040a27477e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-770b-bc33-bd16d4dda66a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-770b-bc33-bd16d4dda66a" xlink:to="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e4244-838c-76df-ab43-6a949c7b8a14" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e4244-838c-76df-ab43-6a949c7b8a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_019e4244-838c-771a-a708-56d3bb49ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_ShortTermInvestments_019e4244-838c-771a-a708-56d3bb49ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019e4244-838c-71ff-9da7-c951f04e9def" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019e4244-838c-71ff-9da7-c951f04e9def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019e4244-838c-7d62-941d-ec4204fb26a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_InventoryNet_019e4244-838c-7d62-941d-ec4204fb26a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e87-96c2-76c3-9e70-3d49971dea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e87-96c2-76c3-9e70-3d49971dea1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e4244-838c-785d-ac3a-9d63e2fb0cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e4244-838c-785d-ac3a-9d63e2fb0cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e4244-838c-799f-84cd-b5debf930001" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e4244-838c-7405-8ecf-c7c605630270" xlink:to="loc_us-gaap_AssetsCurrent_019e4244-838c-799f-84cd-b5debf930001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-7204-be67-40cc3f119320" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-7204-be67-40cc3f119320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019e4244-838c-7cea-88ca-a512414a8205" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019e4244-838c-7cea-88ca-a512414a8205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019e4244-838c-7aa9-a881-97f41f1fb299" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_Goodwill_019e4244-838c-7aa9-a881-97f41f1fb299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-7876-84cb-5b01870e5ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-7876-84cb-5b01870e5ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_019e4244-838c-77d7-887f-1f1d1d9660e2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_019e4244-838c-77d7-887f-1f1d1d9660e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EquityMethodInvestmentsAndOtherAssets_019e4244-838c-784e-8f25-934b452d70bd" xlink:href="pcrx-20260630.xsd#pcrx_EquityMethodInvestmentsAndOtherAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_pcrx_EquityMethodInvestmentsAndOtherAssets_019e4244-838c-784e-8f25-934b452d70bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e4244-838c-7a42-ab81-99a2e896df52" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e4244-838c-7e37-8b53-cf495bac3837" xlink:to="loc_us-gaap_Assets_019e4244-838c-7a42-ab81-99a2e896df52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-770b-bc33-bd16d4dda66a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019e4244-838c-761b-8e27-e23b00778da2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:to="loc_us-gaap_AccountsPayableCurrent_019e4244-838c-761b-8e27-e23b00778da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838c-7113-bbfa-16411e8627a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838c-7113-bbfa-16411e8627a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019e4244-838c-7959-9015-d56c7cf3e841" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019e4244-838c-7959-9015-d56c7cf3e841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8a-ff4a-743c-82b1-084c2da3b115" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5e8a-ff4a-743c-82b1-084c2da3b115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-7be2-95a2-4d7c4b15d07c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e4244-838c-78e9-aeca-0945bd2ffaeb" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e4244-838c-7be2-95a2-4d7c4b15d07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019e4244-838c-7f93-a13d-33531d24c12d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019e4244-838c-7f93-a13d-33531d24c12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019e4244-838c-70a4-9cd8-c81aae36e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019e4244-838c-70a4-9cd8-c81aae36e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationNoncurrent_019e4244-838c-7ee5-9a8a-1f7ddfb02b9d" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_pcrx_ContingentConsiderationNoncurrent_019e4244-838c-7ee5-9a8a-1f7ddfb02b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019e4244-838c-7817-8c0a-a74b8bc1c50e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019e4244-838c-7817-8c0a-a74b8bc1c50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019e4244-838c-7c83-9bb3-14449ee53776" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019e4244-838c-7c83-9bb3-14449ee53776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e4244-838c-7b35-a67a-fce3c7927233" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_Liabilities_019e4244-838c-7b35-a67a-fce3c7927233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e4244-838c-7ed7-8e41-c8f74845c4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e4244-838c-7ed7-8e41-c8f74845c4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019e4244-838c-705a-9088-8c97cb88f765" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_PreferredStockValue_019e4244-838c-705a-9088-8c97cb88f765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e4244-838c-7700-8790-aa4f0d1aad99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_CommonStockValue_019e4244-838c-7700-8790-aa4f0d1aad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019e4244-838c-7f0d-86f1-d11bc58ff52b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019e4244-838c-7f0d-86f1-d11bc58ff52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019e4244-838c-7bb6-8e75-ee5b19a3c978" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019e4244-838c-7bb6-8e75-ee5b19a3c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e4244-838c-7b86-9051-16071c4819f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e4244-838c-7b86-9051-16071c4819f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e4244-838c-72a7-a364-aa3d5fb130ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e4244-838c-72a7-a364-aa3d5fb130ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-70bd-bb39-7836c1d1148a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e4244-838c-752b-8120-b85cbcdd991d" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-838c-70bd-bb39-7836c1d1148a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-838c-7c4d-b90e-7c29966a365f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e4244-838c-726f-a9e7-5f918701b5b4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e4244-838c-7c4d-b90e-7c29966a365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019e4244-838c-7468-8c99-86ba671403e7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019e4244-838c-7468-8c99-86ba671403e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019e4244-838c-721b-a24b-cc6813b4337c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019e4244-838c-721b-a24b-cc6813b4337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019e4244-838c-7a2f-942b-a730e8e86812" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019e4244-838c-7a2f-942b-a730e8e86812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e4244-838c-7124-a406-e4418a75a313" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e4244-838c-7124-a406-e4418a75a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e4244-838c-7fd5-b127-d415dee4a575" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e4244-838c-7fd5-b127-d415dee4a575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019e4244-838c-7daa-9708-c055ea5346a5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019e4244-838c-7daa-9708-c055ea5346a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019e4244-838c-7340-8cb1-e3b16cb3bc27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_CommonStockSharesIssued_019e4244-838c-7340-8cb1-e3b16cb3bc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-7484-819d-a233b033d988" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-7484-819d-a233b033d988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-7caa-a51e-f4e67ffb1659" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e4244-838c-745c-af16-0b77b10f22be" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-7caa-a51e-f4e67ffb1659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019e4244-838c-7f22-a556-3fb79ad81c02" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019e4244-838c-7f22-a556-3fb79ad81c02" xlink:to="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:to="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-838c-7457-8013-1b7f48607fea" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019e4244-838c-78d7-be85-63f506273d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:to="loc_us-gaap_ProductMember_019e4244-838c-78d7-be85-63f506273d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_019e4244-838c-7fb3-98ba-f9423fda569c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-838c-743d-816b-6ecd94e4df78" xlink:to="loc_us-gaap_RoyaltyMember_019e4244-838c-7fb3-98ba-f9423fda569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e4244-838c-7606-99e9-212adcfb88a7" xlink:to="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019e4244-838c-7958-98d4-8f5f3878fea1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_RevenuesAbstract_019e4244-838c-7958-98d4-8f5f3878fea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7b48-8ca8-17459ad3aa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019e4244-838c-7958-98d4-8f5f3878fea1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7b48-8ca8-17459ad3aa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_019e4244-838c-7af2-979e-6f2adb9507f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_CostOfRevenue_019e4244-838c-7af2-979e-6f2adb9507f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e4244-838c-735e-b9cc-13248473176c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e4244-838c-735e-b9cc-13248473176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-838c-7918-924b-bee390325e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019e4244-838c-7918-924b-bee390325e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-75b1-beb7-4b9b9f5aef14" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-75b1-beb7-4b9b9f5aef14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-838c-7fe9-8d56-24e95e8429b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-838c-7fe9-8d56-24e95e8429b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-838c-7f82-b547-ccfbb2f49b12" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e4244-838c-77a1-85a1-368c6e0db5e9" xlink:to="loc_us-gaap_CostsAndExpenses_019e4244-838c-7f82-b547-ccfbb2f49b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-7ba1-978a-9e5147bb18fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e4244-838c-7ba1-978a-9e5147bb18fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019e4244-838c-7685-9a78-f48c8b1e4805" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019e4244-838c-7685-9a78-f48c8b1e4805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019e4244-838c-70a7-b643-28c5ebb648fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019e4244-838c-70a7-b643-28c5ebb648fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e4244-838c-78bd-a978-4c03f8624cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e4244-838c-78bd-a978-4c03f8624cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7eae-8f65-cc108dd74ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e4244-838c-7b08-8031-581ee8ac7540" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e4244-838c-7eae-8f65-cc108dd74ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7f99-8750-83d557213c37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-838c-7f99-8750-83d557213c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-838c-7431-be38-6f7854960215" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-838c-7431-be38-6f7854960215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-77e8-907e-4faa36c71c65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-77e8-907e-4faa36c71c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e4244-838c-75d8-9ac0-a1cf436201fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e4244-838c-75d8-9ac0-a1cf436201fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e4244-838c-744f-b8b0-cf54b37f7ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-838c-7c4e-ba20-2ececcbdb410" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e4244-838c-744f-b8b0-cf54b37f7ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-79ed-88ca-924fc5934458" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-838c-7a48-8e20-69286e11524f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-838c-7a48-8e20-69286e11524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-838c-70f6-879d-835ef90cc0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-838c-7fba-a524-6d9739eed7c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-838c-70f6-879d-835ef90cc0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e4244-838c-7ff7-bdc3-e1b159da5992" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-7fc8-bb5f-2ac0c567d559" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e4244-838c-7ff7-bdc3-e1b159da5992" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-7fc8-bb5f-2ac0c567d559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e4244-838c-7454-9d10-57132326a9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e4244-838c-7ff7-bdc3-e1b159da5992" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e4244-838c-7454-9d10-57132326a9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-838c-72ea-8315-34d356e4bf84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e4244-838c-7454-9d10-57132326a9cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-838c-72ea-8315-34d356e4bf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019e4244-838c-7de3-b361-c28361809482" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e4244-838c-7454-9d10-57132326a9cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019e4244-838c-7de3-b361-c28361809482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7182-b048-b74394604889" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e4244-838c-7454-9d10-57132326a9cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7182-b048-b74394604889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e4244-838c-7bdf-80e1-f6cef96efdde" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e4244-838c-7ff7-bdc3-e1b159da5992" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e4244-838c-7bdf-80e1-f6cef96efdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019e4244-838c-7b8b-abc3-e426a6953c86" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019e4244-838c-7b8b-abc3-e426a6953c86" xlink:to="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838c-7ed0-a931-5bc942d290d6" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e4244-838c-7e7c-8c48-f91c7540882a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_CommonStockMember_019e4244-838c-7e7c-8c48-f91c7540882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019e4244-838c-7e60-b3bd-2326c4f30348" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019e4244-838c-7e60-b3bd-2326c4f30348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838c-71a2-9674-f0b0090fde1f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838c-71a2-9674-f0b0090fde1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019e4244-838c-7ade-bfac-588f99dd8826" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_RetainedEarningsMember_019e4244-838c-7ade-bfac-588f99dd8826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-838c-7842-836a-ab5d8a5aba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838c-70a7-aa0e-1ef9ceec931f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-838c-7842-836a-ab5d8a5aba3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e4244-838c-763d-b593-9023eab9a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e4244-838c-799b-b953-3a229827ffd5" xlink:to="loc_us-gaap_StatementLineItems_019e4244-838c-763d-b593-9023eab9a9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e4244-838c-763d-b593-9023eab9a9bb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-760f-aad7-e5c4c7442dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-760f-aad7-e5c4c7442dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-7b47-a48c-2c698e5ef2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-7b47-a48c-2c698e5ef2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-7588-bccf-0978af82c232" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-838c-7588-bccf-0978af82c232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-838c-7cd8-b521-6aa9e8cb7cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-838c-7cd8-b521-6aa9e8cb7cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019e4244-838c-7eea-85d9-15e7f7b29118" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019e4244-838c-7eea-85d9-15e7f7b29118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019e4244-838c-7744-b1f4-3b32a60b232b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019e4244-838c-7744-b1f4-3b32a60b232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_019e4244-838c-7857-a322-3d3e1bc3c0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_019e4244-838c-7857-a322-3d3e1bc3c0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-838c-72cb-8879-686eaa729df8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-838c-72cb-8879-686eaa729df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-78b8-9389-be699df50b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-78b8-9389-be699df50b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e5fb1-bdef-7f4a-854a-6a8adb87ff7d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e5fb1-bdef-7f4a-854a-6a8adb87ff7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019e5fb2-30f6-7292-a2d1-fafd0b6bd584" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019e5fb2-30f6-7292-a2d1-fafd0b6bd584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e4244-838c-7cc7-bfe7-ecf479c69ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019e4244-838c-7cc7-bfe7-ecf479c69ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019e4244-838c-7090-9a29-5fc4e48de810" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019e4244-838c-7090-9a29-5fc4e48de810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-838c-7e0a-bd7c-e802ffe48597" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-838c-7e0a-bd7c-e802ffe48597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7b11-8c89-835b657d9e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019e4244-838c-7b11-8c89-835b657d9e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-7b96-b67c-37d3982da6da" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-7b96-b67c-37d3982da6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-7c16-8c27-7d8949054a17" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e4244-838c-7c16-8c27-7d8949054a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-74a5-812c-5a30a9de0c03" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019e4244-838c-74a5-812c-5a30a9de0c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-838c-72df-b78c-f9ba105d3f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e4244-838c-7099-9c93-f4f128f9e114" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-838c-72df-b78c-f9ba105d3f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019e4244-838c-7eb2-bdd8-c1677197d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019e4244-838c-7eb2-bdd8-c1677197d2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-838c-7080-a02c-6df15d2d3af6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019e4244-838c-7eb2-bdd8-c1677197d2e8" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-838c-7080-a02c-6df15d2d3af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019e4244-838c-7eb2-bdd8-c1677197d2e8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_019fa738-9c7f-7601-9d67-76a8cd8933f0" xlink:href="pcrx-20260630.xsd#pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets_019fa738-9c7f-7601-9d67-76a8cd8933f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_019e5eb2-7089-7873-90e5-0fa2ec296b61" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_019e5eb2-7089-7873-90e5-0fa2ec296b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_019e4244-838c-72a5-955a-ccf354bda82b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_019e4244-838c-72a5-955a-ccf354bda82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019e4244-838c-7181-acbe-6c5c3e528c37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019e4244-838c-7181-acbe-6c5c3e528c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019e4244-838c-758e-881e-12fea6a219c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019e4244-838c-758e-881e-12fea6a219c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAmortizationOfDeferredCharges_019fad1f-dde3-74e5-9fb8-4f58e5e135f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAmortizationOfDeferredCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_OtherAmortizationOfDeferredCharges_019fad1f-dde3-74e5-9fb8-4f58e5e135f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e4244-838c-7a74-8c55-903b94b77faa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_ShareBasedCompensation_019e4244-838c-7a74-8c55-903b94b77faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838c-7fc6-8c3c-91aa5b9cf36d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838c-7fc6-8c3c-91aa5b9cf36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e4244-838c-7150-9012-7c5645f43c98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e4244-838c-7150-9012-7c5645f43c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherLosses_019e4244-838c-7cf3-8a39-5a7e59474952" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProvisionForOtherLosses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_ProvisionForOtherLosses_019e4244-838c-7cf3-8a39-5a7e59474952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e4244-838c-71f5-b434-87f982abe4df" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019e4244-838c-7146-a4d6-dd7e1a5d1c40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019e4244-838c-7146-a4d6-dd7e1a5d1c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019e4244-838c-7043-8cbb-1bf96fc2484d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019e4244-838c-7043-8cbb-1bf96fc2484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e4244-838c-766c-a985-64312ff35723" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e4244-838c-766c-a985-64312ff35723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019e4244-838c-7bd6-955d-7e30be4c424b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019e4244-838c-7bd6-955d-7e30be4c424b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019e4244-838c-7cb9-9ef8-d572b083cce3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019e4244-838c-7cb9-9ef8-d572b083cce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e4244-838c-71ea-9176-4a26cd647a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e4244-838c-7279-9a57-cf70bc8ae58e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_019e4244-838c-71ea-9176-4a26cd647a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-74cc-8cc3-81d5a2928c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_019e4244-838c-7eb2-bdd8-c1677197d2e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e4244-838c-74cc-8cc3-81d5a2928c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019e4244-838c-7cab-bdfd-662f0766ba97" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019e4244-838c-7cab-bdfd-662f0766ba97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e4244-838c-713b-be01-fab31aa398d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e4244-838c-713b-be01-fab31aa398d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_019e4244-838c-7b17-ba03-be70d71632cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_019e4244-838c-7b17-ba03-be70d71632cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_019e4244-838c-7233-b5cb-616202c5c7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_019e4244-838c-7233-b5cb-616202c5c7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019e5eb6-5f84-7ed2-b563-7c30dd27f30d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019e5eb6-5f84-7ed2-b563-7c30dd27f30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7c27-b3ec-da964e58601f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_019e4244-838c-75fc-964b-e4a3240494ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e4244-838c-7c27-b3ec-da964e58601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019e4244-838c-73cf-8949-4a85c7d09b96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019e4244-838c-73cf-8949-4a85c7d09b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_019e5eb3-5e96-7337-8445-ac2503373d37" xlink:href="pcrx-20260630.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans_019e5eb3-5e96-7337-8445-ac2503373d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-77c8-9da7-e30d1b94f413" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-838c-77c8-9da7-e30d1b94f413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019e4244-838c-71e5-854d-20d8dd939c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019e4244-838c-71e5-854d-20d8dd939c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareRepurchaseProgramExciseTaxPaid_019fad21-6a53-7bf7-857b-691a5cb6a605" xlink:href="pcrx-20260630.xsd#pcrx_ShareRepurchaseProgramExciseTaxPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_pcrx_ShareRepurchaseProgramExciseTaxPaid_019fad21-6a53-7bf7-857b-691a5cb6a605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_019e4244-838c-7868-9d2b-0d178c84d0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_019e4244-838c-7868-9d2b-0d178c84d0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_019e4244-838c-79e1-b2f3-8044cf03e6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_019e4244-838c-79e1-b2f3-8044cf03e6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7087-b6da-3d6aa4746242" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_019e4244-838c-7811-9e75-c4f7514939a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e4244-838c-7087-b6da-3d6aa4746242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7e26-93fc-a1c0726b4465" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7e26-93fc-a1c0726b4465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-7a34-9b54-497ebf3a9237" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e4244-838c-7a34-9b54-497ebf3a9237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7a1e-a769-d7e5d86f98c2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7a1e-a769-d7e5d86f98c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7150-9965-0e1ce338d3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e4244-838c-7150-9965-0e1ce338d3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019e4244-838c-7b47-a929-692f9e856c68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019e4244-838c-7b47-a929-692f9e856c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_019e4244-838c-7ab1-9768-a28caaa42a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019e4244-838c-7b47-a929-692f9e856c68" xlink:to="loc_us-gaap_InterestPaidNet_019e4244-838c-7ab1-9768-a28caaa42a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019e4244-838c-7f2c-8913-4091302d7d98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019e4244-838c-7b47-a929-692f9e856c68" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019e4244-838c-7f2c-8913-4091302d7d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e4244-838c-7109-b5da-97425405a234" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e4244-838c-7906-b3ad-4e7b19ea80f6" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e4244-838c-7109-b5da-97425405a234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019e4244-838c-77bf-bbf7-98a036a0a868" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e4244-838c-7109-b5da-97425405a234" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019e4244-838c-77bf-bbf7-98a036a0a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019e4244-838c-7623-8f0f-33f1d6baf589" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e4244-838c-7109-b5da-97425405a234" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019e4244-838c-7623-8f0f-33f1d6baf589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-838c-70bd-9fe4-1a10e8e1f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019e4244-838c-7d5d-9f77-342690dc972f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-838c-70bd-9fe4-1a10e8e1f72f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019e4244-838c-7d5d-9f77-342690dc972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7db4-9831-a82eb42d1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019e4244-838c-7931-8d82-1b90505097d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7db4-9831-a82eb42d1ddf" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019e4244-838c-7931-8d82-1b90505097d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ASSETSANDLIABILITIESHELDFORSALE"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019f5e93-414e-75ee-b11b-a60cdc1f956a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_019f5e94-ddb4-7cbe-970c-3143c4fd3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019f5e93-414e-75ee-b11b-a60cdc1f956a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_019f5e94-ddb4-7cbe-970c-3143c4fd3c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUE" xlink:type="simple" xlink:href="pcrx-20260630.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-7eca-9bf0-7914c665eb22" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_019e4244-838c-7dce-a022-da69304ca20c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-7eca-9bf0-7914c665eb22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_019e4244-838c-7dce-a022-da69304ca20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIES" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-78f9-8baf-e9b493146da0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_019e4244-838c-7cde-bba5-bb514389074d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-78f9-8baf-e9b493146da0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_019e4244-838c-7cde-bba5-bb514389074d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7cb0-94a0-4303d9708c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019e4244-838c-7d0d-86b9-eea8a3f75062" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7cb0-94a0-4303d9708c6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019e4244-838c-7d0d-86b9-eea8a3f75062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASES" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019e4244-838c-7327-a990-1888dc0edaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_019e4244-838c-7cd7-b622-4fe14b272ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7327-a990-1888dc0edaf7" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_019e4244-838c-7cd7-b622-4fe14b272ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-7e94-ba7f-2ce5e87eaa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_019e4244-838c-78b8-9224-ebb1473dc9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-7e94-ba7f-2ce5e87eaa0d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_019e4244-838c-78b8-9224-ebb1473dc9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7c59-8632-8a8901457412" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019e4244-838d-7481-affe-676ab3a3d388" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7c59-8632-8a8901457412" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019e4244-838d-7481-affe-676ab3a3d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBT" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-711f-b28f-aac309c10815" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_019e4244-838d-7aa6-8b36-69842239f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-711f-b28f-aac309c10815" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_019e4244-838d-7aa6-8b36-69842239f06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-79fd-bbd1-9b5dbd0a95bf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_019e4244-838d-772c-966f-8350bbf33863" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-79fd-bbd1-9b5dbd0a95bf" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_019e4244-838d-772c-966f-8350bbf33863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7468-9b7c-a9be3d94760a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019e4244-8453-7dce-bd37-5f1fff922c48" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7468-9b7c-a9be3d94760a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019e4244-8453-7dce-bd37-5f1fff922c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANS" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7d09-afae-dd0db13c6bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_019e4244-8453-756b-a2fb-7400e6e668d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7d09-afae-dd0db13c6bcc" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_019e4244-8453-756b-a2fb-7400e6e668d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="pcrx-20260630.xsd#NETINCOMELOSSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-765f-b095-fd67f5b40c95" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019e4244-8453-728b-8c23-8af1da826608" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-765f-b095-fd67f5b40c95" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019e4244-8453-728b-8c23-8af1da826608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXES" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7c00-b0e2-e544cc5c1d56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019e4244-8453-778b-8bca-60a1664d2e06" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7c00-b0e2-e544cc5c1d56" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019e4244-8453-778b-8bca-60a1664d2e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET" xlink:type="simple" xlink:href="pcrx-20260630.xsd#OTHEROPERATINGEXPENSESNET"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7486-8667-b85874978931" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_019e4244-8454-7402-af62-5a5e9442771d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7486-8667-b85874978931" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_019e4244-8454-7402-af62-5a5e9442771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pcrx-20260630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e4244-8454-7bd4-bab5-b4f4bcdb7984" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019e4244-8454-758b-9147-e7a0ea9aedba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e4244-8454-7bd4-bab5-b4f4bcdb7984" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019e4244-8454-758b-9147-e7a0ea9aedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-795a-9f0e-6d9151595cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019e4244-8454-7f6f-a6ac-64a998aaf79e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-795a-9f0e-6d9151595cc8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019e4244-8454-7f6f-a6ac-64a998aaf79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7195-98b6-3d00962b042a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019fc8d8-0eb2-71b1-8245-3b56ddd80482" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7195-98b6-3d00962b042a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019fc8d8-0eb2-71b1-8245-3b56ddd80482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_019fc8d8-6e12-7e04-b81e-f22bbcbd9545" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7195-98b6-3d00962b042a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_019fc8d8-6e12-7e04-b81e-f22bbcbd9545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock_019fa395-6bdc-7c68-96be-88811e10387b" xlink:href="pcrx-20260630.xsd#pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7195-98b6-3d00962b042a" xlink:to="loc_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock_019fa395-6bdc-7c68-96be-88811e10387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019e4244-838c-7b83-941f-b9e9c12b77f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7195-98b6-3d00962b042a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019e4244-838c-7b83-941f-b9e9c12b77f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e4244-838c-72b6-a5f1-314bd880160c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7195-98b6-3d00962b042a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e4244-838c-72b6-a5f1-314bd880160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7696-9bf6-1d629f9dcd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019e4244-838c-76bb-9bed-e6f1dc12c4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7696-9bf6-1d629f9dcd3e" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019e4244-838c-76bb-9bed-e6f1dc12c4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUETables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-7213-8eb6-0edb82a8b3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_019e4244-838c-70af-bbce-ea21003a7815" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-7213-8eb6-0edb82a8b3c9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_019e4244-838c-70af-bbce-ea21003a7815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7a5d-9790-f3c728c6055f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019e4244-838c-7a00-925f-fde82eaceccb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7a5d-9790-f3c728c6055f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019e4244-838c-7a00-925f-fde82eaceccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7b8e-9fe4-1435a7ef960e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019e4244-838c-7340-ac46-c27ce5cf8d44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7b8e-9fe4-1435a7ef960e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019e4244-838c-7340-ac46-c27ce5cf8d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019e4244-838c-7366-9255-5a2d170006cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_019e4244-838c-748a-90e3-0b13d3ad57ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7366-9255-5a2d170006cd" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_019e4244-838c-748a-90e3-0b13d3ad57ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_019e4244-838c-762f-bd10-03c80b7aeb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7366-9255-5a2d170006cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_019e4244-838c-762f-bd10-03c80b7aeb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-7205-85bc-0a3c0e79fca9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_019e4244-838c-7d3c-9930-6a9c7e6e713d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-7205-85bc-0a3c0e79fca9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_019e4244-838c-7d3c-9930-6a9c7e6e713d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7647-8b0a-9c245b073f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019e4244-838d-7ab5-9ef0-7b9577976393" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7647-8b0a-9c245b073f7c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019e4244-838d-7ab5-9ef0-7b9577976393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7992-af2b-cbca0e835e81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_019e4244-838d-74d4-a1a8-f451b0f14617" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7992-af2b-cbca0e835e81" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_019e4244-838d-74d4-a1a8-f451b0f14617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_019e4244-838d-7569-a801-a47f3a51715e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7992-af2b-cbca0e835e81" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_019e4244-838d-7569-a801-a47f3a51715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_019e4244-838d-77fd-a686-28582f8df046" xlink:href="pcrx-20260630.xsd#pcrx_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7992-af2b-cbca0e835e81" xlink:to="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_019e4244-838d-77fd-a686-28582f8df046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7ff0-98fd-a851d2f0cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_019e4244-838d-7a9f-b24f-882ec2d32b99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7ff0-98fd-a851d2f0cb85" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_019e4244-838d-7a9f-b24f-882ec2d32b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e4244-838d-7297-a805-08a7fbac3317" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7ff0-98fd-a851d2f0cb85" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e4244-838d-7297-a805-08a7fbac3317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019e4244-838d-7610-af3d-bf8e0cf57e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7ff0-98fd-a851d2f0cb85" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019e4244-838d-7610-af3d-bf8e0cf57e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e4244-838d-7371-9605-950037292eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7ff0-98fd-a851d2f0cb85" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e4244-838d-7371-9605-950037292eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_019e4244-838d-71c1-a40c-fce3702bbe36" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7ff0-98fd-a851d2f0cb85" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_019e4244-838d-71c1-a40c-fce3702bbe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7edf-b87b-110eeba301cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_019e4244-8453-74cf-b4ae-2cbc2992cb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7edf-b87b-110eeba301cf" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_019e4244-8453-74cf-b4ae-2cbc2992cb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-709d-906a-c5a4c88ebbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019e4244-8453-7101-a3c2-069d1cc29a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-709d-906a-c5a4c88ebbb9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019e4244-8453-7101-a3c2-069d1cc29a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019e4244-8453-7a4c-bdf6-85b06b2a3ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-709d-906a-c5a4c88ebbb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019e4244-8453-7a4c-bdf6-85b06b2a3ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019e4244-8453-721b-b099-9d30aca5ea95" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-709d-906a-c5a4c88ebbb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019e4244-8453-721b-b099-9d30aca5ea95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#NETINCOMELOSSPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-7d17-8b2a-d5c7edc80d81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019e4244-8453-746f-afcb-15ec4d3714bb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-7d17-8b2a-d5c7edc80d81" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019e4244-8453-746f-afcb-15ec4d3714bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e4244-8453-70e2-ab09-06e1b365e31a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-7d17-8b2a-d5c7edc80d81" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e4244-8453-70e2-ab09-06e1b365e31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7c34-9eb3-f87f0a6769ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019e4244-8453-7b11-8671-f15be353fba8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7c34-9eb3-f87f0a6769ee" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019e4244-8453-7b11-8671-f15be353fba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#OTHEROPERATINGEXPENSESNETTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7190-98bf-16d1d925f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_019e4244-8454-741a-ab3d-62d512f316f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7190-98bf-16d1d925f4f5" xlink:to="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_019e4244-8454-741a-ab3d-62d512f316f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-7d01-9270-d3eae38d2aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019e4244-8454-74b2-ba60-7866fb111571" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-7d01-9270-d3eae38d2aa1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019e4244-8454-74b2-ba60-7866fb111571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-838c-7cb1-a899-1ec7ed3e3947" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-838c-7cb1-a899-1ec7ed3e3947" xlink:to="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7146-9603-14a105b76db3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838c-7d12-ae85-145085f0596e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7146-9603-14a105b76db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-838c-7531-ab18-07d77a001568" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838c-7146-9603-14a105b76db3" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-838c-7531-ab18-07d77a001568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7238-961b-8971e8c96504" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-7bd0-a4bf-2ae92425b59e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7238-961b-8971e8c96504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-73d7-a4ea-b95710a13938" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-7238-961b-8971e8c96504" xlink:to="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-73d7-a4ea-b95710a13938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-723b-9c7e-8bbb81a5ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-7eeb-9efe-a62ae85f592e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-723b-9c7e-8bbb81a5ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_019e4244-838c-7a8c-b52b-1b23b65fa781" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-723b-9c7e-8bbb81a5ddd3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_019e4244-838c-7a8c-b52b-1b23b65fa781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7a1e-95de-5700c3d143f4" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838c-7e1a-bf5d-cf730e13ea4c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838c-7e1a-bf5d-cf730e13ea4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfProducts_019e4244-838c-7a64-8dce-5ed68c2f8ffb" xlink:href="pcrx-20260630.xsd#pcrx_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-729c-899a-f7cd54d9ae83" xlink:to="loc_pcrx_ConcentrationRiskNumberOfProducts_019e4244-838c-7a64-8dce-5ed68c2f8ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7a9d-8892-39e0754f293b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019e4244-838c-791d-8830-fcbd77950999" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7a9d-8892-39e0754f293b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019e4244-838c-791d-8830-fcbd77950999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e4244-838c-75b7-836e-eca9673898f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-7a9d-8892-39e0754f293b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e4244-838c-75b7-836e-eca9673898f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-72d9-892a-2c1821aa8fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e4244-838c-72d9-892a-2c1821aa8fc9" xlink:to="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-79fa-ab72-961ee3544135" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838c-785f-83d5-bdefedc07097" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-79fa-ab72-961ee3544135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838c-7eb6-87d1-034f2ddd38d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838c-79fa-ab72-961ee3544135" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838c-7eb6-87d1-034f2ddd38d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-761b-9b0c-29a5b86db5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838c-76ac-a5e0-29edba099a01" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-761b-9b0c-29a5b86db5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-7960-b282-6794f12b29e3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838c-761b-9b0c-29a5b86db5ea" xlink:to="loc_us-gaap_SalesRevenueNetMember_019e4244-838c-7960-b282-6794f12b29e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019e4244-838c-79f7-8127-6d4e9feb8584" xlink:to="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LargestCustomerMember_019e4244-838c-7705-ace5-5ee15b550683" xlink:href="pcrx-20260630.xsd#pcrx_LargestCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_LargestCustomerMember_019e4244-838c-7705-ace5-5ee15b550683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondLargestCustomerMember_019e4244-838c-7469-8bc3-d1816e70d709" xlink:href="pcrx-20260630.xsd#pcrx_SecondLargestCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_SecondLargestCustomerMember_019e4244-838c-7469-8bc3-d1816e70d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThirdLargestCustomerMember_019e4244-838c-7a7d-9769-f6793685f070" xlink:href="pcrx-20260630.xsd#pcrx_ThirdLargestCustomerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_ThirdLargestCustomerMember_019e4244-838c-7a7d-9769-f6793685f070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThreeLargestCustomersMember_019e4244-838c-74d7-9d96-af5c9e582fad" xlink:href="pcrx-20260630.xsd#pcrx_ThreeLargestCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838c-7bd1-9a5d-537eec87479d" xlink:to="loc_pcrx_ThreeLargestCustomersMember_019e4244-838c-74d7-9d96-af5c9e582fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838c-7efd-bddf-000170fb4083" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfCustomers_019e4244-838c-7f14-9ed5-434266ccfd6b" xlink:href="pcrx-20260630.xsd#pcrx_ConcentrationRiskNumberOfCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:to="loc_pcrx_ConcentrationRiskNumberOfCustomers_019e4244-838c-7f14-9ed5-434266ccfd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838c-74de-9a08-9e69a685b90f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838c-7b37-846b-1f78b6a039ee" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838c-74de-9a08-9e69a685b90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ASSETSANDLIABILITIESHELDFORSALEDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019f5e93-414e-7323-9704-e619f8bf0da9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019f5e93-414e-7323-9704-e619f8bf0da9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-7cd2-aff9-e93fdfd3bd58" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f5ed5-e916-706c-bfaa-e648f12469b4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-7cd2-aff9-e93fdfd3bd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019f9441-d09c-7f33-bc17-bbac6242456a" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f5ed5-e916-7cd2-aff9-e93fdfd3bd58" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019f9441-d09c-7f33-bc17-bbac6242456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9430-a723-7f1b-a9f2-1d3140b30fd3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-7a39-78ee-b5a9-2597edddbf75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-7a39-78ee-b5a9-2597edddbf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_019faeaa-5b11-7543-9abd-abf8df602289" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9430-a723-75ea-a5db-132857810bd8" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_019faeaa-5b11-7543-9abd-abf8df602289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019f6f30-8e22-7c09-9475-ff587ce51a63" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneOneMember_019f6f30-8e22-7199-9dfb-91d16d1671d2" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:to="loc_pcrx_RevenueMilestoneOneMember_019f6f30-8e22-7199-9dfb-91d16d1671d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneTwoMember_019f6f30-8e22-7aa0-a8ae-c8347e2ca371" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:to="loc_pcrx_RevenueMilestoneTwoMember_019f6f30-8e22-7aa0-a8ae-c8347e2ca371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueMilestoneThreeMember_019f6f30-8e22-752f-a234-c8b3e261833e" xlink:href="pcrx-20260630.xsd#pcrx_RevenueMilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019f6f30-8e22-7641-b51a-a7ff4d7ed10c" xlink:to="loc_pcrx_RevenueMilestoneThreeMember_019f6f30-8e22-752f-a234-c8b3e261833e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7cae-9fd5-8743c12efa85" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019fad31-576b-7536-8cab-38d51ad4dc83" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7cae-9fd5-8743c12efa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019fad31-d790-749c-ac63-2db1d124d0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019fad31-576b-7cae-9fd5-8743c12efa85" xlink:to="loc_us-gaap_SubsequentEventMember_019fad31-d790-749c-ac63-2db1d124d0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7ea4-871a-912729488378" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_019fae8c-5b42-7803-97f7-ae326272a5f8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7ea4-871a-912729488378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019fae8c-a40f-7623-9ba4-3b275442aece" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019fae8c-5b42-7ea4-871a-912729488378" xlink:to="loc_srt_ScenarioForecastMember_019fae8c-a40f-7623-9ba4-3b275442aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019f5ed5-e916-7da0-9a15-97f327c58da9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019f9441-d09c-7c14-af7f-24128b125a57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019f9441-d09c-7c14-af7f-24128b125a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_019f942a-2296-71b8-8923-0c6920c50161" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_019f942a-2296-71b8-8923-0c6920c50161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019fa6db-7030-7554-9b19-439651cc25eb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019fa6db-7030-7554-9b19-439651cc25eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa6db-b258-7622-b53f-326e43779df9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa6db-b258-7622-b53f-326e43779df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa6db-f8f8-746d-9258-df8a9d6e5b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa6db-f8f8-746d-9258-df8a9d6e5b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019fa6dc-1ca6-71c7-b8e2-1fdbec22330a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019fa6dc-1ca6-71c7-b8e2-1fdbec22330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa6dc-45de-70c2-b57e-25c39c3c2c33" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa6dc-45de-70c2-b57e-25c39c3c2c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5ecb-7dc3-7011-9343-229fde460d17" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f5ecb-7dc3-7011-9343-229fde460d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019fa70c-403b-77e9-a10c-a7b8251ef9ee" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019fa70c-403b-77e9-a10c-a7b8251ef9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_019f94d8-0f4c-7324-81f8-c722e269bef4" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod_019f94d8-0f4c-7324-81f8-c722e269bef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_019f6f30-8e22-70ed-8f87-0c3a5058350a" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold_019f6f30-8e22-70ed-8f87-0c3a5058350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_019fc818-a1e4-751c-b95c-0d874646eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_019fc818-a1e4-751c-b95c-0d874646eee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_019fa71a-a6f5-7ada-b3ff-22c3b0eba5cd" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019f5ed5-e916-7a8f-99b7-b92817f87c73" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus_019fa71a-a6f5-7ada-b3ff-22c3b0eba5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#REVENUENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-7708-919b-66f77fd8afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-7708-919b-66f77fd8afaa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:to="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e4244-838c-7e8a-aa53-7828c5ac0523" xlink:to="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-838c-74ae-92ad-86e9277b94cc" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:to="loc_srt_MinimumMember_019e4244-838c-74ae-92ad-86e9277b94cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-838c-7f2f-be75-e96b2be55702" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838c-7352-91c7-d616fa43c1d1" xlink:to="loc_srt_MaximumMember_019e4244-838c-7f2f-be75-e96b2be55702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7c61-9c49-1d17e78ec784" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7fcd-8d93-956269ea5faa" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7c61-9c49-1d17e78ec784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccountsReceivablePaymentTerms_019e4244-838c-76ce-9091-8263700edc48" xlink:href="pcrx-20260630.xsd#pcrx_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7c61-9c49-1d17e78ec784" xlink:to="loc_pcrx_AccountsReceivablePaymentTerms_019e4244-838c-76ce-9091-8263700edc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#REVENUEScheduleofDisaggregatedRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-72d1-873a-c712e741323c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019e4244-838c-72d1-873a-c712e741323c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:to="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-838c-7023-8741-05574701eea1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-838c-7ab1-875f-12e04d02aa87" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-838c-7023-8741-05574701eea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-838c-7023-8741-05574701eea1" xlink:to="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EXPARELMember_019e4244-838c-77d9-ad8b-df2724bcd3bc" xlink:href="pcrx-20260630.xsd#pcrx_EXPARELMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_EXPARELMember_019e4244-838c-77d9-ad8b-df2724bcd3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember_019e4244-838c-70bf-99ff-6e9cef988fb8" xlink:href="pcrx-20260630.xsd#pcrx_ZILRETTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_ZILRETTAMember_019e4244-838c-70bf-99ff-6e9cef988fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember_019e4244-838c-7511-b2af-cf4f666bae64" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_IoveraMember_019e4244-838c-7511-b2af-cf4f666bae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_019e4244-838c-7a47-847c-56c8023efd0e" xlink:href="pcrx-20260630.xsd#pcrx_BupivacaineLiposomeInjectableSuspensionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019e4244-838c-7628-969c-b4817bb8c37c" xlink:to="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_019e4244-838c-7a47-847c-56c8023efd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7e24-a9ef-3b56cfbf9ece" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019e4244-838c-7720-8755-50a288a99f3c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7e24-a9ef-3b56cfbf9ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7df7-8316-87b4c54e234e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019e4244-838c-7e24-a9ef-3b56cfbf9ece" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-838c-7df7-8316-87b4c54e234e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INVENTORIESScheduleofComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7c23-9e45-f4a33ef9b930" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019e4244-838c-7bdb-ba86-7139bf01d78a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7c23-9e45-f4a33ef9b930" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019e4244-838c-7bdb-ba86-7139bf01d78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019e4244-838c-70f4-b342-90262b67f082" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7c23-9e45-f4a33ef9b930" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019e4244-838c-70f4-b342-90262b67f082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019e4244-838c-7106-946a-184e6c04824d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7c23-9e45-f4a33ef9b930" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019e4244-838c-7106-946a-184e6c04824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019e4244-838c-7629-99ac-83d9b9d38404" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7c23-9e45-f4a33ef9b930" xlink:to="loc_us-gaap_InventoryNet_019e4244-838c-7629-99ac-83d9b9d38404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa707-5558-7bc1-a084-b7606813916b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7c23-9e45-f4a33ef9b930" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa707-5558-7bc1-a084-b7606813916b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INVENTORIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7da4-8bfc-dd5bacdcf274" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019e4244-838c-7da4-8bfc-dd5bacdcf274" xlink:to="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7ec4-b017-7e7c64564aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9443-4fcd-7777-8443-919f995ffefc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7ec4-b017-7e7c64564aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-1a63-77e9-9d3b-50c0dfe7c506" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9443-4fcd-7ec4-b017-7e7c64564aa4" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-1a63-77e9-9d3b-50c0dfe7c506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7cbe-85e3-cef5c3efcc75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa717-2701-7a19-a71f-221f325cdd08" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7cbe-85e3-cef5c3efcc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa717-2701-7e5e-bda8-d7f5d3ac5b78" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa717-2701-7cbe-85e3-cef5c3efcc75" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa717-2701-7e5e-bda8-d7f5d3ac5b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_019fa709-6a45-70df-8216-52697b345c21" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_019fa709-6a45-7c08-900d-6fce61cdcf57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_019fa709-6a45-7c08-900d-6fce61cdcf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WorkInProcessMember_019fa70a-42d8-764a-b1ff-61954a8ea484" xlink:href="pcrx-20260630.xsd#pcrx_WorkInProcessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:to="loc_pcrx_WorkInProcessMember_019fa70a-42d8-764a-b1ff-61954a8ea484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FinishedGoodsMember_019fa70a-83c4-7ed9-9513-89ab3d4a626b" xlink:href="pcrx-20260630.xsd#pcrx_FinishedGoodsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_019fa709-6a45-72be-86e8-8c31914902c4" xlink:to="loc_pcrx_FinishedGoodsMember_019fa70a-83c4-7ed9-9513-89ab3d4a626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_019f6f3b-e381-765b-8fc7-422c9860fc2d" xlink:to="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019f6f3b-e381-752b-8019-aa176a0d588e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryNet_019f6f3b-e381-752b-8019-aa176a0d588e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019f6f3b-e381-7ea9-842e-383eb9b73ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019f6f3b-e381-7ea9-842e-383eb9b73ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019f6f3b-e381-7f17-bdb7-7a5ac4022a37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019f6f3b-e381-7f17-bdb7-7a5ac4022a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019f6f3b-e381-7333-834c-3e45b725d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019f6f3b-e381-7333-834c-3e45b725d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa709-6a45-7e41-9ecc-cd31e60e9778" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_019f6f3b-e381-71a0-9488-169f56b3303a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_019fa709-6a45-7e41-9ecc-cd31e60e9778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7bec-b2b8-40d7b1705fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7bec-b2b8-40d7b1705fa0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7344-9a4c-44b2dd0dafba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_019e4244-838c-7eee-98c5-a4467ffc0e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_019e4244-838c-7eee-98c5-a4467ffc0e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-758a-8578-6f0cfb11b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-758a-8578-6f0cfb11b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_019e4244-838c-7dfd-aaad-387c1beac570" xlink:href="pcrx-20260630.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_019e4244-838c-7dfd-aaad-387c1beac570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019e4244-838c-776f-9a84-f4b6d5b7cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019e4244-838c-776f-9a84-f4b6d5b7cba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_019e4244-838c-77ab-ad7f-d63d8b450b45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-795b-9791-69cb421efdec" xlink:to="loc_us-gaap_ConstructionInProgressMember_019e4244-838c-77ab-ad7f-d63d8b450b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-7562-9302-3a59af33fbbc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019e4244-838c-7cff-8665-837ef62a96bd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019e4244-838c-7cff-8665-837ef62a96bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-838c-7c9e-9524-cfef607ee681" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e4244-838c-7c9e-9524-cfef607ee681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-73dc-81ee-73e59e1aec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-77fe-b0bd-90bfb2445998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-73dc-81ee-73e59e1aec8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FIXEDASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7cff-be85-aa094c56979e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019e4244-838c-7cff-be85-aa094c56979e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019e4244-838c-7d2a-b7e5-82c331acd9cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_019f6f45-8875-7b66-b410-27e45f955089" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_019f6f45-8875-7b66-b410-27e45f955089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-7224-bb61-a0490b2a3eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e4244-838c-72c8-a80d-b2593beb898a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019e4244-838c-7224-bb61-a0490b2a3eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019e4244-838c-7341-ba1b-6aa9832c90b6" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019e4244-838c-7fb3-a343-40472da65f14" xlink:to="loc_srt_SegmentGeographicalDomain_019e4244-838c-7341-ba1b-6aa9832c90b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_019e4244-838c-70ff-a872-527242ee38e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-838c-7341-ba1b-6aa9832c90b6" xlink:to="loc_us-gaap_NonUsMember_019e4244-838c-70ff-a872-527242ee38e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-75e1-84e0-abd819fe54a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f9437-3b03-70ff-bcec-95d09fdc1451" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-75e1-84e0-abd819fe54a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-8b02-7501-89e6-2f88dab5a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f9437-3b03-75e1-84e0-abd819fe54a3" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae88-8b02-7501-89e6-2f88dab5a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f9437-3b03-7ce6-9232-6e99f50c5afc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember_019f9437-d845-7e7d-b09e-2f6074c93c10" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:to="loc_pcrx_IoveraMember_019f9437-d845-7e7d-b09e-2f6074c93c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa706-3b33-7156-a83e-98245ce0a14e" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f9437-3b03-7fe7-9907-08556bb353a4" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa706-3b33-7156-a83e-98245ce0a14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019e4244-838c-761b-8350-ed86e3308fca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-7248-925b-df6a6d7d6929" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e4244-838c-7248-925b-df6a6d7d6929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019f6f45-8875-73be-9bfd-7107d7991911" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019f6f45-8875-73be-9bfd-7107d7991911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019e4244-838c-7415-b584-edf29a524803" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_Depreciation_019e4244-838c-7415-b584-edf29a524803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_019e5efa-c50c-7a55-86fb-4bc346716014" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_019e5efa-c50c-7a55-86fb-4bc346716014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_019e4244-838c-7331-b23d-d2e76a23e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetRetirementObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_AssetRetirementObligation_019e4244-838c-7331-b23d-d2e76a23e5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa706-3b33-7a11-b741-7e3e52ad1c01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019e4244-838c-7ccf-8ad8-f263540f6df4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_019fa706-3b33-7a11-b741-7e3e52ad1c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019e4244-838c-7813-9c56-189153ec20f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfLeases_019e4244-838c-7d3b-ae59-38dc2f57e0e5" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7813-9c56-189153ec20f5" xlink:to="loc_pcrx_NumberOfLeases_019e4244-838c-7d3b-ae59-38dc2f57e0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019e4244-838c-7931-94f5-c308a5846b73" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_019e4244-838c-7881-9461-fdef0d66f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7931-94f5-c308a5846b73" xlink:to="loc_us-gaap_LeaseCostAbstract_019e4244-838c-7881-9461-fdef0d66f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_019e4244-838c-745c-a636-73e8bc2fabdd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_019e4244-838c-7881-9461-fdef0d66f69f" xlink:to="loc_us-gaap_OperatingLeaseCost_019e4244-838c-745c-a636-73e8bc2fabdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_019e4244-838c-7f5a-ac0d-15cec450eed9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_019e4244-838c-7881-9461-fdef0d66f69f" xlink:to="loc_us-gaap_VariableLeaseCost_019e4244-838c-7f5a-ac0d-15cec450eed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_019e4244-838c-7142-8f3a-79281104fb90" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_019e4244-838c-7881-9461-fdef0d66f69f" xlink:to="loc_us-gaap_SubleaseIncome_019e4244-838c-7142-8f3a-79281104fb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_019e4244-838c-7b3f-b5f4-05f3366db872" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_019e4244-838c-7881-9461-fdef0d66f69f" xlink:to="loc_us-gaap_LeaseCost_019e4244-838c-7b3f-b5f4-05f3366db872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_019e4244-838c-7450-9187-bb755b593c94" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7931-94f5-c308a5846b73" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_019e4244-838c-7450-9187-bb755b593c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_019e4244-838c-7423-b011-f276c92f5e08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_019e4244-838c-7450-9187-bb755b593c94" xlink:to="loc_us-gaap_OperatingLeasePayments_019e4244-838c-7423-b011-f276c92f5e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_019e4244-838c-77c2-bb66-1e7de7d4b01c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_019e4244-838c-7450-9187-bb755b593c94" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_019e4244-838c-77c2-bb66-1e7de7d4b01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_019e4244-838c-7f22-a6c6-4e13fd73af2f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7931-94f5-c308a5846b73" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_019e4244-838c-7f22-a6c6-4e13fd73af2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_019e4244-838c-7dff-9234-33999ae11d11" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7931-94f5-c308a5846b73" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_019e4244-838c-7dff-9234-33999ae11d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_019e4244-838c-7b9c-b2ad-39c11fafff26" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_019e4244-838c-7b9c-b2ad-39c11fafff26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019e4244-838c-78ff-b81f-0cc04a93802a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019e4244-838c-78ff-b81f-0cc04a93802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019e4244-838c-793f-8ce9-b41f43608701" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019e4244-838c-793f-8ce9-b41f43608701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019e4244-838c-7922-8670-d89ac1303444" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019e4244-838c-7922-8670-d89ac1303444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019e4244-838c-70fc-b93b-65ced224a275" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019e4244-838c-70fc-b93b-65ced224a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_019e4244-838c-7cdd-8744-c2c85c2ec6bf" xlink:href="pcrx-20260630.xsd#pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_019e4244-838c-7cdd-8744-c2c85c2ec6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-719a-a12a-4292c332a3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019e4244-838c-719a-a12a-4292c332a3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019e4244-838c-7b94-b1f3-7419b2ce9b37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019e4244-838c-7b94-b1f3-7419b2ce9b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_019e4244-838c-7f2c-afc4-71a86598fde0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019e4244-838c-7649-8712-31d952ae32bc" xlink:to="loc_us-gaap_OperatingLeaseLiability_019e4244-838c-7f2c-afc4-71a86598fde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-732f-83c3-36bdc0568da5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-732f-83c3-36bdc0568da5" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7952-8b47-91fa60471797" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019fa703-6e12-7054-a66d-c1b50de2808a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7952-8b47-91fa60471797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-e74e-7050-84a7-d5516fcbcae1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019fa703-6e12-7952-8b47-91fa60471797" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-e74e-7050-84a7-d5516fcbcae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7892-a2d7-2c1871aa6552" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019fa703-6e12-7965-8e68-0778bff901f5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7892-a2d7-2c1871aa6552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa703-6e12-7670-af3d-aa792fb2f792" xlink:href="pcrx-20260630.xsd#pcrx_PaciraCryoTechIncAndIoveraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019fa703-6e12-7892-a2d7-2c1871aa6552" xlink:to="loc_pcrx_PaciraCryoTechIncAndIoveraMember_019fa703-6e12-7670-af3d-aa792fb2f792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019fa738-3f79-7eb1-9493-0ecf1d58ed5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019fa738-3f79-78a1-864d-d2cfcc49070a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019fa738-3f79-78a1-864d-d2cfcc49070a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_019fa93b-bc16-7ccd-a265-f375a4570c04" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019fa738-3f79-7dfc-9e34-1f84171774c0" xlink:to="loc_us-gaap_CustomerRelationshipsMember_019fa93b-bc16-7ccd-a265-f375a4570c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019fa703-6e12-7700-a41f-3256700a39f8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019e4244-838c-7fa6-8dee-33936983ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_Goodwill_019e4244-838c-7fa6-8dee-33936983ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_019e4244-838c-7105-ab41-2028e70d4c84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_019e4244-838c-7105-ab41-2028e70d4c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019e4244-838c-760b-ba4f-368058c305d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019e4244-838c-760b-ba4f-368058c305d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa703-6e12-7ec6-a0b6-c9e2e6bc1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_019fa703-6e12-7ec6-a0b6-c9e2e6bc1e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-7d0d-ac32-3f83e456cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-838c-7d0d-ac32-3f83e456cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_019e4244-838c-759a-b8ce-f87954fe7510" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_019e4244-838c-759a-b8ce-f87954fe7510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019e4244-838c-72e4-9c9f-6aa8139a573a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019e4244-838c-72e4-9c9f-6aa8139a573a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019e4244-838c-7174-a5c8-65b6df54b2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019e4244-838c-7174-a5c8-65b6df54b2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019e4244-838c-74af-83f9-f309523b8e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019e4244-838c-74af-83f9-f309523b8e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019e4244-838c-72d6-8892-63cae330ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019e4244-838c-72d6-8892-63cae330ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019e4244-838c-7c18-8374-c17b252eabcd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019fa703-6e12-7fbc-9965-6e1367723b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019e4244-838c-7c18-8374-c17b252eabcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-7949-b782-a85b3664e4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019e4244-838c-7949-b782-a85b3664e4ba" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-78a8-94fd-904ba78c2174" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019e4244-838c-7dba-a05f-6e6e86a61a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019e4244-838c-7dba-a05f-6e6e86a61a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_019e4244-838c-7556-9a24-af3dd0060a66" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-781f-9e9c-5ad784543fca" xlink:to="loc_us-gaap_CustomerRelationshipsMember_019e4244-838c-7556-9a24-af3dd0060a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7712-9f68-48f59eaf2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_019e4244-838c-7f35-9dde-f27e58452ea9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7712-9f68-48f59eaf2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_019e4244-838c-7125-8065-6a1cff444965" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_019e4244-838c-7712-9f68-48f59eaf2c07" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_019e4244-838c-7125-8065-6a1cff444965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_019e4244-838c-738f-8650-86c46cf2b174" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838c-76d0-bc2b-e40a856df73d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019e4244-838c-76d0-bc2b-e40a856df73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-838c-7fe8-be5a-bc491c78dc98" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019e4244-838c-7fe8-be5a-bc491c78dc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838c-76b6-9875-22695f5a95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_019e4244-838c-76b6-9875-22695f5a95e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838c-7cc6-bc55-3ad4bb04b883" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_019e4244-838c-7cc6-bc55-3ad4bb04b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838c-7109-a43f-2e9a364cb586" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_019e4244-838c-7109-a43f-2e9a364cb586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-7b37-a0b7-58f32f2219a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e4244-838c-7b37-a0b7-58f32f2219a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_019e4244-838c-77e0-94cb-acf3ea71d594" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_019e4244-838c-7ee1-8549-be87a9ff1305" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_019e4244-838c-77e0-94cb-acf3ea71d594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_019e4244-838d-71a7-971b-8a626fffc10b" xlink:href="pcrx-20260630.xsd#pcrx_AccruedSellingGeneralAndAdministrativeExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_pcrx_AccruedSellingGeneralAndAdministrativeExpenses_019e4244-838d-71a7-971b-8a626fffc10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedResearchAndDevelopmentExpenses_019e4244-838d-7e17-a2a7-ad1b52f17fe3" xlink:href="pcrx-20260630.xsd#pcrx_AccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_pcrx_AccruedResearchAndDevelopmentExpenses_019e4244-838d-7e17-a2a7-ad1b52f17fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedProductionCost_019e4244-838d-7560-812e-c0775f815f82" xlink:href="pcrx-20260630.xsd#pcrx_AccruedProductionCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_pcrx_AccruedProductionCost_019e4244-838d-7560-812e-c0775f815f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e4244-838d-77d0-a115-093b27266160" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e4244-838d-77d0-a115-093b27266160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e4244-838d-7c43-a498-07b4cab1c785" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e4244-838d-7c43-a498-07b4cab1c785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_019e4244-838d-7c86-aae4-cdead5abe0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_us-gaap_InterestPayableCurrent_019e4244-838d-7c86-aae4-cdead5abe0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_019e4244-838d-78e4-9ff5-56f7f1a6f4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_019e4244-838d-78e4-9ff5-56f7f1a6f4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7011-a027-37c12ae7ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7ff3-9a65-811826b01a44" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019e4244-838d-7011-a027-37c12ae7ef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#ACCRUEDEXPENSESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7a03-b091-7c97ad3c5b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:href="pcrx-20260630.xsd#pcrx_AccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e4244-838d-7a03-b091-7c97ad3c5b9b" xlink:to="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-7923-ac64-4329c434e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019f94db-2962-72bb-be46-31767e836afc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-7923-ac64-4329c434e24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-b672-7e57-b820-199b8605b744" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019f94db-2962-7923-ac64-4329c434e24c" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_019fae87-b672-7e57-b820-199b8605b744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7dc0-8d22-f24ac8dc4965" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019f94db-2962-7da3-ab25-bdeafcb6a5a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7dc0-8d22-f24ac8dc4965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMember_019f94db-2962-76ad-9bb3-0b00a86de7dc" xlink:href="pcrx-20260630.xsd#pcrx_IoveraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019f94db-2962-7dc0-8d22-f24ac8dc4965" xlink:to="loc_pcrx_IoveraMember_019f94db-2962-76ad-9bb3-0b00a86de7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:href="pcrx-20260630.xsd#pcrx_AccruedExpensesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesTable_019e4244-838d-7dca-b39f-e63369bc9208" xlink:to="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f94db-2962-7421-b931-e32bfc508019" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019f94db-2962-7421-b931-e32bfc508019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019fa6ff-690f-7046-904b-a7b4a7ce1880" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019fa6ff-690f-7046-904b-a7b4a7ce1880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_019fa700-c3b5-746d-80e5-551aa7253c3b" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_019e4244-838d-7be4-8c23-312d05798b62" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent_019fa700-c3b5-746d-80e5-551aa7253c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7d5b-bba7-ed13bf08fdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7d5b-bba7-ed13bf08fdf5" xlink:to="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7ec9-aaab-f989cb10fee2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7fd4-81fb-5c14c8d233f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7ec9-aaab-f989cb10fee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7627-8670-d697eeea4004" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7ec9-aaab-f989cb10fee2" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7627-8670-d697eeea4004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7782-93af-8af61b1e50ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7cc2-9e39-171f64f7c601" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7cc2-9e39-171f64f7c601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019e4244-838d-7840-86d0-bed351e0afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7c08-9a02-99e3e1eef9a0" xlink:to="loc_us-gaap_LineOfCreditMember_019e4244-838d-7840-86d0-bed351e0afdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-77e1-b21c-634a5010f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-74ce-b4d3-30861b6a8c8f" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-77e1-b21c-634a5010f89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7ccc-b4a5-53432c9dc567" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-77e1-b21c-634a5010f89f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7ccc-b4a5-53432c9dc567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7a6a-922d-667ef582fd40" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-74f1-9c08-116bd5ae0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-74f1-9c08-116bd5ae0d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019e4244-838d-7bc3-8703-a66a525d59af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-739f-bf36-73f1fab2960f" xlink:to="loc_us-gaap_LongTermDebt_019e4244-838d-7bc3-8703-a66a525d59af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7514-b68c-91426fb2c39c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7514-b68c-91426fb2c39c" xlink:to="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-71b2-b7d3-21bceed10c5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-744e-9319-7d04dfdc645f" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-744e-9319-7d04dfdc645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_019e4244-838d-79c0-bc55-38908b75b8bc" xlink:href="pcrx-20260630.xsd#pcrx_WellsFargoBankNationalAssociationCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_WellsFargoBankNationalAssociationCreditAgreementMember_019e4244-838d-79c0-bc55-38908b75b8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanAFacilityDueMarch2028Member_019e4244-838d-7c99-92ae-5819b3162b9f" xlink:href="pcrx-20260630.xsd#pcrx_TermLoanAFacilityDueMarch2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_TermLoanAFacilityDueMarch2028Member_019e4244-838d-7c99-92ae-5819b3162b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_019e4244-838d-7abb-9ecc-823a5eee172f" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-7f2e-9ec4-d916794bd8e0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_019e4244-838d-7abb-9ecc-823a5eee172f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7ba0-b9eb-a4c7be58cfae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7c78-8d9e-66406049ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7c78-8d9e-66406049ef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_019e4244-838d-7c13-97dc-4d39afc2c321" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_ConvertibleDebtMember_019e4244-838d-7c13-97dc-4d39afc2c321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019e4244-838d-7755-851a-f815b57c951f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_LineOfCreditMember_019e4244-838d-7755-851a-f815b57c951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019e4244-838d-7ebb-828f-85501a7b7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-78af-83c9-0c1207870a75" xlink:to="loc_us-gaap_SecuredDebtMember_019e4244-838d-7ebb-828f-85501a7b7ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis_019e4244-838d-7e81-9509-709b4031c5bd" xlink:to="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsOneMember_019e4244-838d-7b5d-8e05-fd626dd27ed5" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:to="loc_pcrx_DebtConversionTermsOneMember_019e4244-838d-7b5d-8e05-fd626dd27ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsTwoMember_019e4244-838d-7be6-9338-63b9adb02745" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:to="loc_pcrx_DebtConversionTermsTwoMember_019e4244-838d-7be6-9338-63b9adb02745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsThreeMember_019e4244-838d-7d09-b781-6034cba7b40f" xlink:href="pcrx-20260630.xsd#pcrx_DebtConversionTermsThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtInstrumentConvertibleTermsOfConversionDomain_019e4244-838d-715d-b834-657cf231728b" xlink:to="loc_pcrx_DebtConversionTermsThreeMember_019e4244-838d-7d09-b781-6034cba7b40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7e94-82d5-fd8fbf8ad3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e4244-838d-7c82-885d-72b5bef7d86f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7e94-82d5-fd8fbf8ad3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CappedCallMember_019e4244-838d-7462-9f7f-e3304bdb63f1" xlink:href="pcrx-20260630.xsd#pcrx_CappedCallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019e4244-838d-7e94-82d5-fd8fbf8ad3bc" xlink:to="loc_pcrx_CappedCallMember_019e4244-838d-7462-9f7f-e3304bdb63f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-838d-7ff2-98b7-231344614643" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-838d-7a75-be0b-86471a6adf15" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-838d-7ff2-98b7-231344614643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838d-7e80-82c4-75f741bae116" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-838d-7ff2-98b7-231344614643" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e4244-838d-7e80-82c4-75f741bae116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-718a-a5ec-3789f7ed5c9d" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7716-993b-3739cc19ed83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7716-993b-3739cc19ed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_019e4244-838d-77b1-8e35-f930adf8cdee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:to="loc_us-gaap_LetterOfCreditMember_019e4244-838d-77b1-8e35-f930adf8cdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_019e4244-838d-7f4d-bc38-e1740c2b1a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-74f2-a4ba-e60e2de7e34e" xlink:to="loc_us-gaap_BridgeLoanMember_019e4244-838d-7f4d-bc38-e1740c2b1a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e4244-838d-7b2c-9b72-57932049465f" xlink:to="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-838d-73d7-9343-6422853df789" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:to="loc_srt_MinimumMember_019e4244-838d-73d7-9343-6422853df789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-838d-7b7d-9c28-871187d47f43" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838d-74ed-b661-b17e69fcda51" xlink:to="loc_srt_MaximumMember_019e4244-838d-7b7d-9c28-871187d47f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_019e4244-838d-70f7-a4d5-ae666ef2de5a" xlink:to="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_019e4244-838d-718c-89c5-76c3f48609e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:to="loc_us-gaap_BaseRateMember_019e4244-838d-718c-89c5-76c3f48609e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019e4244-838d-75c2-ab5a-0de63a4ffdad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_019e4244-838d-72d5-a915-9ee6096a4aa3" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019e4244-838d-75c2-ab5a-0de63a4ffdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7da5-9609-07ba8957088d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_019e4244-838d-7a81-981c-25780ee30435" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7da5-9609-07ba8957088d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019e4244-838d-75b8-9c17-464c39021419" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019e4244-838d-7da5-9609-07ba8957088d" xlink:to="loc_srt_ScenarioForecastMember_019e4244-838d-75b8-9c17-464c39021419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-7184-a3f7-72a0d7f653b6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019e4244-838d-741e-8946-aa46c3f6d3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019e4244-838d-741e-8946-aa46c3f6d3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7838-ad99-9b161a5e55d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7838-ad99-9b161a5e55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_019e4244-838d-7c0b-bc57-8bfa5934f744" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentMarketPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentMarketPrice_019e4244-838d-7c0b-bc57-8bfa5934f744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_019e4244-838d-7482-a6ef-ea85c86aa0df" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentRepurchasedInConversionFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount_019e4244-838d-7482-a6ef-ea85c86aa0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_019e4244-838d-7c50-9cfd-e3ad0c90349f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_019e4244-838d-7c50-9cfd-e3ad0c90349f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_019e4244-838d-7d69-bdab-997f63d389c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_019e4244-838d-7d69-bdab-997f63d389c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_019e4244-838d-73ea-a60b-63c6d6d44472" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_019e4244-838d-73ea-a60b-63c6d6d44472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_019e4244-838d-710b-856e-57e95d9fa31d" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_019e4244-838d-710b-856e-57e95d9fa31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_019e4244-838d-7e5d-b660-67cde0b66d77" xlink:href="pcrx-20260630.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_019e4244-838d-7e5d-b660-67cde0b66d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_019e4244-838d-71b3-ad23-b219d98bb424" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_019e4244-838d-71b3-ad23-b219d98bb424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-77cc-bfb6-51579dc026f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-77cc-bfb6-51579dc026f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_019e4244-838d-714f-b4ec-9ae57d364930" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_019e4244-838d-714f-b4ec-9ae57d364930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_019e4244-838d-7936-8739-9e3e88b2b712" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_SharePrice_019e4244-838d-7936-8739-9e3e88b2b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_019e4244-838d-7fe3-8fc1-e0dd3a5ad37c" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity_019e4244-838d-7fe3-8fc1-e0dd3a5ad37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_019e4244-838d-72cb-9f5b-cc598e1239f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_019e4244-838d-72cb-9f5b-cc598e1239f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DerivativeCappedCallPrice_019e4244-838d-76e0-90f0-355e32de80e0" xlink:href="pcrx-20260630.xsd#pcrx_DerivativeCappedCallPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DerivativeCappedCallPrice_019e4244-838d-76e0-90f0-355e32de80e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DerivativePremiumPercentage_019e4244-838d-79a0-9d6e-831dfdda41cb" xlink:href="pcrx-20260630.xsd#pcrx_DerivativePremiumPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DerivativePremiumPercentage_019e4244-838d-79a0-9d6e-831dfdda41cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_019e4244-838d-753d-a234-9be0472efba5" xlink:href="pcrx-20260630.xsd#pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax_019e4244-838d-753d-a234-9be0472efba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_019e4244-838d-7fb4-9e7f-3ed1e0b254a6" xlink:href="pcrx-20260630.xsd#pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax_019e4244-838d-7fb4-9e7f-3ed1e0b254a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019e4244-838d-7552-ba66-2a6806a02d39" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019e4244-838d-7552-ba66-2a6806a02d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_019e4244-838d-76bb-8c4d-426802121a22" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentCovenantIncrementalDebtMaximum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum_019e4244-838d-76bb-8c4d-426802121a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_019e4244-838d-7b89-9dfa-1976c7514f6e" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent_019e4244-838d-7b89-9dfa-1976c7514f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019e4244-838d-7a22-928c-b03ab67c5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019e4244-838d-7a22-928c-b03ab67c5aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_019e4244-838d-7994-8ec6-6643418505fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_019e4244-838d-7994-8ec6-6643418505fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019e4244-838d-72a6-9443-ffd36cd9629b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_019e4244-838d-72a6-9443-ffd36cd9629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_019e4244-838d-7829-861b-c7ae99caab46" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_LineOfCredit_019e4244-838d-7829-861b-c7ae99caab46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_019e4244-838d-79c3-b9c8-e368328f7ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_019e4244-838d-79c3-b9c8-e368328f7ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_019e4244-838d-7fc0-b57f-ea03ded3eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_019e4244-838d-7fc0-b57f-ea03ded3eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentDiscountRate_019e4244-838d-749a-93b4-e8258870c473" xlink:href="pcrx-20260630.xsd#pcrx_DebtInstrumentDiscountRate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_pcrx_DebtInstrumentDiscountRate_019e4244-838d-749a-93b4-e8258870c473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_019e4244-838d-7ff9-a6a3-52744db93a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_019e4244-838d-7ff9-a6a3-52744db93a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019e4244-838d-7ca1-8577-b9b01bef38ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019e4244-838d-7ca1-8577-b9b01bef38ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_019e4244-838d-712b-abb3-465e09eaddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_019e4244-838d-712b-abb3-465e09eaddd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal_019e4244-838d-773e-8a82-edc5e08a4358" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepaidPrincipal"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentRepaidPrincipal_019e4244-838d-773e-8a82-edc5e08a4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_019e4244-838d-70f8-a311-8dd372085290" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_InterestPaid_019e4244-838d-70f8-a311-8dd372085290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019e4244-838d-7b4a-a75b-633cf3d91f99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_019e4244-838d-7b4a-a75b-633cf3d91f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_019e4244-838d-77e4-8088-54c0b51b727f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_RepaymentsOfDebt_019e4244-838d-77e4-8088-54c0b51b727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_019e4244-838d-700f-a31e-b5bdf1d5b140" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_019e4244-838d-700f-a31e-b5bdf1d5b140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_019e4244-838d-790b-9bab-7cd5cf7226a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7112-812c-a1549d88a49d" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_019e4244-838d-790b-9bab-7cd5cf7226a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7934-9aa6-d60c953a486e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-7934-9aa6-d60c953a486e" xlink:to="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7b4b-b2a6-b46fe9f79aac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7e2f-80f3-5e35d10ab766" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7b4b-b2a6-b46fe9f79aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7bda-a52c-3d6c955c2a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-7b4b-b2a6-b46fe9f79aac" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7bda-a52c-3d6c955c2a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-722d-88fd-925b097913ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7549-8773-ad822870b750" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-722d-88fd-925b097913ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7c4e-9dd8-3f1787536402" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-722d-88fd-925b097913ef" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7c4e-9dd8-3f1787536402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019e4244-838d-76e2-ba0a-0d0ccac0b335" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7de6-8529-d2d314d000c0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7de6-8529-d2d314d000c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019e4244-838d-7f37-9814-a4dcef3c72f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019e4244-838d-7f37-9814-a4dcef3c72f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_019e4244-838d-7613-9203-fb39b63d0ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_019e4244-838d-7613-9203-fb39b63d0ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019e4244-838d-74ee-bb0c-640b41da4ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019e4244-838d-7702-bead-9788133895a3" xlink:to="loc_us-gaap_LongTermDebt_019e4244-838d-74ee-bb0c-640b41da4ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#DEBTScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_019e4244-838d-7cc6-9b19-f950a9fd6f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_019e4244-838d-7cc6-9b19-f950a9fd6f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_019e4244-838d-74a3-8ab0-7b62b1a0631c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_019e4244-838d-74a3-8ab0-7b62b1a0631c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_019e4244-838d-7be2-a09c-1f07303e7d37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_019e4244-838d-7be2-a09c-1f07303e7d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment_019e4244-838d-764e-a4ee-3d4ba0e9ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:to="loc_us-gaap_InterestCostsCapitalizedAdjustment_019e4244-838d-764e-a4ee-3d4ba0e9ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019e4244-838d-701a-a2bc-5cd2f0ad575a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:to="loc_us-gaap_InterestExpenseDebt_019e4244-838d-701a-a2bc-5cd2f0ad575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_019e4244-838d-7a1f-9ab9-31a51520176b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019e4244-838d-791b-b460-216cd13325c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_019e4244-838d-7a1f-9ab9-31a51520176b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7dfc-b1b1-5fd96441e853" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7dfc-b1b1-5fd96441e853" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-838d-7eca-b14c-cab18eb4f08c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019e4244-838d-756a-abb3-eca80a52d2b5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-838d-7eca-b14c-cab18eb4f08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019e4244-838d-7eca-b14c-cab18eb4f08c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019e4244-838d-7790-8847-ff81d657ffe5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_019e4244-838d-7790-8847-ff81d657ffe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019e4244-838d-767e-9548-711197cfd0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019e4244-838d-7221-917d-c8796db311b5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019e4244-838d-767e-9548-711197cfd0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7d68-92cb-40b4471ad284" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019e4244-838d-7db3-990a-7a41f40bc2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019e4244-838d-7db3-990a-7a41f40bc2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7669-bc75-95ea567932a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7669-bc75-95ea567932a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7ba3-8c4b-7b4a36d6950c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7a6d-9895-3e3bd80aa2ff" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7ba3-8c4b-7b4a36d6950c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-741a-95f8-c2db9c14c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019e4244-838d-7321-a5c2-b4676a5fd23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-741a-95f8-c2db9c14c46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7b7d-bed7-08c4e2494978" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleSeniorNotesDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019e4244-838d-741a-95f8-c2db9c14c46b" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2029Member_019e4244-838d-7b7d-bed7-08c4e2494978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019e4244-838d-7908-a51c-929326fd1b5b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7f31-98b8-6bc8fa624d74" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:to="loc_us-gaap_UnsecuredDebtMember_019e4244-838d-7f31-98b8-6bc8fa624d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019e4244-838d-7661-a77f-bb4b0370a0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019e4244-838d-777f-929d-61ca089b841d" xlink:to="loc_us-gaap_LineOfCreditMember_019e4244-838d-7661-a77f-bb4b0370a0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019e4244-838d-796a-988c-f975e6db025c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019e4244-838d-7e0c-b938-bc5de3d44b7d" xlink:to="loc_us-gaap_CreditFacilityDomain_019e4244-838d-796a-988c-f975e6db025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7210-b45a-38caecdaf7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019e4244-838d-796a-988c-f975e6db025c" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_019e4244-838d-7210-b45a-38caecdaf7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_019e4244-838d-75ee-be34-5ff34d71629d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivablesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019e4244-838d-7577-81e5-a27e04f386f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019e4244-838d-7577-81e5-a27e04f386f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure_019e4244-838d-72e2-8758-1625d1a8d964" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_019e4244-838d-7cdf-9621-e150350e9e84" xlink:to="loc_us-gaap_NotesReceivableFairValueDisclosure_019e4244-838d-72e2-8758-1625d1a8d964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-838d-7cd7-a7cf-f81fb47531db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-838d-7cd7-a7cf-f81fb47531db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7104-9640-7f57f6d358fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_019e4244-838d-7cd7-a7cf-f81fb47531db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7104-9640-7f57f6d358fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7642-92ef-d01fcb7a560d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019e4244-838d-7642-92ef-d01fcb7a560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_019e4244-838d-793f-9922-40eddcfd3dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_DebtInstrumentFairValue_019e4244-838d-793f-9922-40eddcfd3dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_019e4244-838d-7a39-b691-885608b1675a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_SharePrice_019e4244-838d-7a39-b691-885608b1675a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-7d34-9514-cf8cf1253826" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_019e4244-838d-70da-9e8c-cd99ea8fd569" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_019e4244-838d-7d34-9514-cf8cf1253826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-74d8-a93e-800f932fc7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-74d8-a93e-800f932fc7f3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-79ef-a61b-31eaa8fd8a37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019e4244-838d-7606-be82-b28917cb93f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:to="loc_us-gaap_EquitySecuritiesMember_019e4244-838d-7606-be82-b28917cb93f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleNotesReceivableMember_019e4244-838d-76dc-b9c3-57b508eb4f0e" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleNotesReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-75fa-9431-9c3ecfce75ee" xlink:to="loc_pcrx_ConvertibleNotesReceivableMember_019e4244-838d-76dc-b9c3-57b508eb4f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e4244-838d-7e53-85ef-36ef19907a52" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_019e4244-838d-76bc-8d47-c10933be0dfc" xlink:to="loc_srt_OwnershipDomain_019e4244-838d-7e53-85ef-36ef19907a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7ab5-877d-ee666d97fdef" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019e4244-838d-7e53-85ef-36ef19907a52" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7ab5-877d-ee666d97fdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7768-9c99-9d66371883ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7f9f-8b5f-4c18ca18e9e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7768-9c99-9d66371883ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7c1e-8e05-6419ffe1246a" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7768-9c99-9d66371883ff" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-838d-7c1e-8e05-6419ffe1246a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7153-b469-63a2330b9b06" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7cd2-b90f-8927b26fcf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7cd2-b90f-8927b26fcf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019e4244-838d-73b2-943d-07890c8d6fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_019e4244-838d-73b2-943d-07890c8d6fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_019e4244-838d-7f63-8247-4469347e338a" xlink:href="pcrx-20260630.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments_019e4244-838d-7f63-8247-4469347e338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019e4244-838d-705e-aa64-c3db9c34e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019e4244-838d-705e-aa64-c3db9c34e1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019e4244-838d-7aed-8708-d9863d5eac1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_019e4244-838d-7aed-8708-d9863d5eac1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-7064-a847-aa6d320bd798" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-7064-a847-aa6d320bd798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019e4244-838d-7047-a491-b2a31ba93e50" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_019e4244-838d-7047-a491-b2a31ba93e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7b8d-9492-d57de985a094" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7563-954c-7598721460d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_019e4244-838d-7b8d-9492-d57de985a094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838d-7d2a-bd2d-626861aa625b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-72c8-aae9-dd82f894ecdf" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-838d-7d2a-bd2d-626861aa625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-75bb-b166-1bb4ff2ef7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-75bb-b166-1bb4ff2ef7d8" xlink:to="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7ad5-a367-17cba7bef49e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_019e4244-838d-7360-89f0-68fd468b7ab9" xlink:href="pcrx-20260630.xsd#pcrx_EquityInvestmentAndConvertibleNoteReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:to="loc_pcrx_EquityInvestmentAndConvertibleNoteReceivableMember_019e4244-838d-7360-89f0-68fd468b7ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_019e4244-838d-73a5-a6a7-d3c8be7d22b4" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-716f-b302-c3d816b2e3c9" xlink:to="loc_pcrx_ContingentConsiderationMember_019e4244-838d-73a5-a6a7-d3c8be7d22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-714e-af51-7d2feabff1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_019e4244-838d-7c31-9484-0fd0a461fdef" xlink:to="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-714e-af51-7d2feabff1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleNoteReceivableMember_019e4244-838d-74c3-a83f-badab89a8b62" xlink:href="pcrx-20260630.xsd#pcrx_ConvertibleNoteReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_019e4244-838d-714e-af51-7d2feabff1fa" xlink:to="loc_pcrx_ConvertibleNoteReceivableMember_019e4244-838d-74c3-a83f-badab89a8b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-78a3-b105-33904e8ac914" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-73fa-be8e-e610d9561338" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-78a3-b105-33904e8ac914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7316-be17-16fb2d270ef4" xlink:href="pcrx-20260630.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-78a3-b105-33904e8ac914" xlink:to="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7316-be17-16fb2d270ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-713b-af47-8ec338f290a1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e4244-838d-72a5-b95d-d1c94bf2c0f8" xlink:to="loc_srt_RangeMember_019e4244-838d-713b-af47-8ec338f290a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_019e4244-838d-7b46-915a-d08301f00b72" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838d-713b-af47-8ec338f290a1" xlink:to="loc_srt_WeightedAverageMember_019e4244-838d-7b46-915a-d08301f00b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7bdc-aecd-c3053b7ec992" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-769a-aa60-ee5c1acea43c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7bdc-aecd-c3053b7ec992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-753b-b380-ea48a68bc226" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7bdc-aecd-c3053b7ec992" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-753b-b380-ea48a68bc226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-739e-9d42-156a05e3c51e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7b5d-a9f3-53b17dda5fdb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-739e-9d42-156a05e3c51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-7c92-b684-1f22375aafb4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-739e-9d42-156a05e3c51e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-7c92-b684-1f22375aafb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019e4244-838d-703b-a93d-46515af6fe59" xlink:to="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerOneMember_019e4244-838d-720b-bb92-04e27592ce97" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:to="loc_pcrx_MajorCustomerOneMember_019e4244-838d-720b-bb92-04e27592ce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerTwoMember_019e4244-838d-7350-8ee5-bca207840af1" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:to="loc_pcrx_MajorCustomerTwoMember_019e4244-838d-7350-8ee5-bca207840af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerThreeMember_019e4244-838d-7f05-af71-0b282c25b01a" xlink:href="pcrx-20260630.xsd#pcrx_MajorCustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019e4244-838d-7d2e-a2a0-884d2151df16" xlink:to="loc_pcrx_MajorCustomerThreeMember_019e4244-838d-7f05-af71-0b282c25b01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-78e1-a817-c310d7e19898" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019e4244-838d-76d9-a9cf-b58c9648b7dd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-78e1-a817-c310d7e19898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_019e4244-838d-7b17-8db5-e738403d4723" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019e4244-838d-78e1-a817-c310d7e19898" xlink:to="loc_us-gaap_AccountsReceivableMember_019e4244-838d-7b17-8db5-e738403d4723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-7c54-bab9-0d51e1ba37e6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019e4244-838d-761a-9709-75bd2ee186b0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-7c54-bab9-0d51e1ba37e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838d-7659-b213-e443b9e43780" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019e4244-838d-7c54-bab9-0d51e1ba37e6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019e4244-838d-7659-b213-e443b9e43780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019e4244-838d-7b80-9194-997dc0fad62d" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_019e4244-838d-71ba-97be-86349a206914" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_AssetImpairmentCharges_019e4244-838d-71ba-97be-86349a206914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_019e4244-838d-73fc-bdb7-f47b53e0850a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_019e4244-838d-73fc-bdb7-f47b53e0850a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7f84-871d-2917ee4baefb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019e4244-838d-7f84-871d-2917ee4baefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPaymentTerm_019e4244-838d-7203-9d38-cb509df780f4" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationPaymentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_pcrx_ContingentConsiderationPaymentTerm_019e4244-838d-7203-9d38-cb509df780f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838d-7582-9806-93c194405053" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-838d-7582-9806-93c194405053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-7f52-915d-b0864a44a909" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-7f52-915d-b0864a44a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_019e4244-838d-7715-aaed-efcce538b880" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_InterestReceivable_019e4244-838d-7715-aaed-efcce538b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfMajorCustomers_019e4244-838d-7dfa-967d-0d2cd59d6c14" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfMajorCustomers"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_pcrx_NumberOfMajorCustomers_019e4244-838d-7dfa-967d-0d2cd59d6c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838d-7423-8640-91003c23189c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019e4244-838d-7423-8640-91003c23189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019e4244-838d-7d92-91e4-4ac481bef6af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019e4244-838d-78f6-9c61-cbea75640fdd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019e4244-838d-7d92-91e4-4ac481bef6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7e99-82ea-4b2fb7573457" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-7e99-82ea-4b2fb7573457" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7968-89d9-f71fa0ac854b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-77ff-b82d-68b86b746f24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7968-89d9-f71fa0ac854b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7b4f-a806-e35e599086b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-7968-89d9-f71fa0ac854b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e4244-838d-7b4f-a806-e35e599086b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e4244-838d-7d7c-bb8a-e0fde352a849" xlink:to="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-838d-7145-adc8-6e171b2ca3d1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:to="loc_srt_MinimumMember_019e4244-838d-7145-adc8-6e171b2ca3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-838d-710c-a981-ba871e3ea486" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-838d-7d1b-8814-44cb72d798d7" xlink:to="loc_srt_MaximumMember_019e4244-838d-710c-a981-ba871e3ea486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7dbe-80bf-7767e262ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-838d-7e94-9513-aaa6efe8dd4f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7dbe-80bf-7767e262ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7ff4-ab7a-f68828193e66" xlink:href="pcrx-20260630.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-838d-7dbe-80bf-7767e262ce09" xlink:to="loc_pcrx_FlexionAcquisitionMember_019e4244-838d-7ff4-ab7a-f68828193e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-771e-a86b-45a2ed27c867" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-7b8c-ac1e-9e760195a45f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-771e-a86b-45a2ed27c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7413-9862-636815898828" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-771e-a86b-45a2ed27c867" xlink:to="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7413-9862-636815898828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e4244-838d-7f55-8927-0d377a020a99" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-78c4-bd31-bd2406055272" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019e4244-838d-78c4-bd31-bd2406055272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_019e4244-838d-72db-97c1-1f65c26a8c54" xlink:href="pcrx-20260630.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e4244-838d-7585-85b1-384713ee82b4" xlink:to="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_019e4244-838d-72db-97c1-1f65c26a8c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-838d-75b8-b248-d07427804b71" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_019e4244-838d-729e-bf88-3f22a6e5db70" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-838d-75b8-b248-d07427804b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-76b0-bd66-12f3db7197ca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_019e4244-838d-75b8-b248-d07427804b71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_019e4244-838d-76b0-bd66-12f3db7197ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-75ee-a87a-68b95345631c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-75ee-a87a-68b95345631c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-7d09-8c24-29c5264412b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019e4244-838d-76dd-9413-5c9e3d03907f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-7d09-8c24-29c5264412b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7fbe-bfdd-2dbecc5d6d64" xlink:href="pcrx-20260630.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e4244-838d-7d09-8c24-29c5264412b7" xlink:to="loc_pcrx_ContingentConsiderationMember_019e4244-838d-7fbe-bfdd-2dbecc5d6d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-7d0a-8c1e-b5315e1c90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e4244-838d-7fbc-9476-a5962421b7cd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-7d0a-8c1e-b5315e1c90e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e4244-838d-7d0a-8c1e-b5315e1c90e7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7d19-9e44-42da368254c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7d19-9e44-42da368254c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-79ce-bb14-ddb11b1c3a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e4244-838d-79ce-bb14-ddb11b1c3a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7973-aaf2-8f1dd072ad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e4244-838d-7147-8212-c2d7e98a7e8f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e4244-838d-7973-aaf2-8f1dd072ad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-70bf-b62e-85643b6e8085" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:href="pcrx-20260630.xsd#pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e4244-838d-70bf-b62e-85643b6e8085" xlink:to="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e4244-838d-743d-a443-b7031fd9e1fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e4244-838d-789f-be85-0126d8f6aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:to="loc_us-gaap_CommercialPaperMember_019e4244-838d-789f-be85-0126d8f6aff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e4244-838d-7680-973b-b0e7dc0b0f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e4244-838d-7fee-b7e0-0f23bed156e4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e4244-838d-7680-973b-b0e7dc0b0f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7add-b765-aaa7875623c0" xlink:href="pcrx-20260630.xsd#pcrx_InvestmentCategorizationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_InvestmentCategorizationAxis_019e4244-838d-7553-bdd1-c29e23f753c7" xlink:to="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7add-b765-aaa7875623c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_019e4244-838d-7000-b277-691daf772295" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_InvestmentCategorizationDomain_019e4244-838d-7add-b765-aaa7875623c0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_019e4244-838d-7000-b277-691daf772295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-75e6-8763-6eddafbfafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e4244-838d-7511-a0a0-5f4c11bfa500" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-75e6-8763-6eddafbfafa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7f5f-9d79-c7b19d336964" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e4244-838d-75e6-8763-6eddafbfafa2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019e4244-838d-7f5f-9d79-c7b19d336964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable_019e4244-838d-77ae-bd98-c9509cc842b8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7af3-a22e-dcede5922d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e4244-838d-7af3-a22e-dcede5922d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-838d-746d-be6a-a0a1b346bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e4244-838d-746d-be6a-a0a1b346bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-838d-7229-94f2-915ae57b14a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e4244-838d-7229-94f2-915ae57b14a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-838d-73ce-8910-3f2c83182814" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e4244-838d-7d30-bfca-ad7a19a5ed10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e4244-838d-73ce-8910-3f2c83182814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7d42-a4e3-1d080ce2d674" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7d42-a4e3-1d080ce2d674" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e4244-8453-770e-bca6-caa2a8ef744d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e4244-8453-7c26-83f2-269bc3c27051" xlink:to="loc_us-gaap_EquityComponentDomain_019e4244-8453-770e-bca6-caa2a8ef744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e4244-8453-770e-bca6-caa2a8ef744d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_019e4244-8453-7ab9-89dd-d7491214b4db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_019e4244-8453-7ab9-89dd-d7491214b4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019e4244-8453-7337-8e67-2d63234a5766" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e4244-8453-7551-82d2-07c39579f0d9" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_019e4244-8453-7337-8e67-2d63234a5766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_019e4244-8453-7787-98e6-e3970e188ad3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-8453-704c-96ee-acbf29ad9eef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-8453-704c-96ee-acbf29ad9eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-8453-75ba-b8f7-73c6c40c6391" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e4244-8453-75ba-b8f7-73c6c40c6391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019e4244-8453-735e-b8da-7a153da52406" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019e4244-8453-735e-b8da-7a153da52406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e4244-8453-7bba-b108-b1fed97d0ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_019e4244-8453-7473-99d2-4849e74a958e" xlink:to="loc_us-gaap_StockholdersEquity_019e4244-8453-7bba-b108-b1fed97d0ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_019e4244-8453-7792-aeac-2a16a5b74ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_019e4244-8453-7114-a078-9ba9e7883a83" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_019e4244-8453-7792-aeac-2a16a5b74ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019e4244-8453-7a12-8846-d442a4431788" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019e4244-8453-7a12-8846-d442a4431788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019e4244-8453-7701-a579-5a027fedb829" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019e4244-8453-7701-a579-5a027fedb829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-8453-769d-9ed0-72527707cb46" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019e4244-8453-769d-9ed0-72527707cb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareRepurchaseProgramBrokerFees_019e4244-8453-7fb5-a340-2222c36715f2" xlink:href="pcrx-20260630.xsd#pcrx_ShareRepurchaseProgramBrokerFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_pcrx_ShareRepurchaseProgramBrokerFees_019e4244-8453-7fb5-a340-2222c36715f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax_019e4244-8453-71de-a007-bf41c2cc1fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTax_019e4244-8453-71de-a007-bf41c2cc1fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_019e4244-8453-7eff-b9a1-9b083cc2a5df" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_019e4244-8453-7eff-b9a1-9b083cc2a5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-8453-7172-9df7-e1caf09d8e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019e4244-8453-7172-9df7-e1caf09d8e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-8453-7294-aa5b-809e742eeb80" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-79ba-a00c-5012c0c25f41" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019e4244-8453-7294-aa5b-809e742eeb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7900-aac9-40465251c00e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7900-aac9-40465251c00e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:to="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e4244-8453-7e6b-b1b6-c682d47f57b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019e4244-8453-738a-aab8-80f689f25279" xlink:to="loc_us-gaap_PlanNameDomain_019e4244-8453-7e6b-b1b6-c682d47f57b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InducementPlan2014Member_019e4244-8453-7441-894a-916c4aac7180" xlink:href="pcrx-20260630.xsd#pcrx_InducementPlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019e4244-8453-7e6b-b1b6-c682d47f57b9" xlink:to="loc_pcrx_InducementPlan2014Member_019e4244-8453-7441-894a-916c4aac7180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-73f4-9e79-28bc54008be3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-77df-aec5-f3f3bd91b093" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-77df-aec5-f3f3bd91b093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-74c8-a7f5-2402753c8d79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7d64-bac9-c4c8805e8c3c" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-74c8-a7f5-2402753c8d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7e7a-8fc1-1b5e1df9e9fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e4244-8453-7cba-b23e-6fb455700def" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e4244-8453-7cba-b23e-6fb455700def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019e4244-8453-760f-9a3f-ab96e263cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019e4244-8453-760f-9a3f-ab96e263cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019e4244-8453-71c6-84a7-f8d4e617bcef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019e4244-8453-71c6-84a7-f8d4e617bcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c41-90ea-62164a32db31" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c41-90ea-62164a32db31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019f5f27-88d5-76fd-8d1b-6c106544faa5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_019e4244-8453-7cbd-90b5-ce05d6ea036a" xlink:href="pcrx-20260630.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_019e4244-8453-7cbd-90b5-ce05d6ea036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_019e4244-8453-76f1-9fa1-74f5400fe804" xlink:href="pcrx-20260630.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_019e4244-8453-76f1-9fa1-74f5400fe804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019e4244-8453-78f9-894a-987e4c2cf14c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019e4244-8453-78f9-894a-987e4c2cf14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e4244-8453-7e66-932f-895fc34f25b4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-78bd-91b2-96ad06f28183" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019e4244-8453-7e66-932f-895fc34f25b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7b51-a87d-94c3fad0f50a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7b51-a87d-94c3fad0f50a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e4244-8453-719e-a6d0-6dd5afa23e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e4244-8453-719e-a6d0-6dd5afa23e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7289-9936-55b0a7b45410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7ea4-a74e-5df5269310f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7ea4-a74e-5df5269310f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7a2c-a9f0-d7a776337197" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7a2c-a9f0-d7a776337197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019e4244-8453-75b2-878e-1c043a867a38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_PerformanceSharesMember_019e4244-8453-75b2-878e-1c043a867a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-730f-bbed-28cd15d49131" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7950-a334-15b8c1e1257d" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-730f-bbed-28cd15d49131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e4244-8453-7d33-aed0-201f1b4ba56d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-8453-775f-b067-d99b6731c419" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e4244-8453-756e-96cc-4ef15025cda8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e4244-8453-775f-b067-d99b6731c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7a99-8c43-b4b3b80bacba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-7a99-8c43-b4b3b80bacba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-747a-8022-a1de8bb9295d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-702f-a32e-9a45d7022aa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-747a-8022-a1de8bb9295d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:href="pcrx-20260630.xsd#pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-747a-8022-a1de8bb9295d" xlink:to="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7625-91bb-92791f0c1335" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7625-91bb-92791f0c1335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019e4244-8453-74e9-8cdd-0e1e3ad88aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember_019e4244-8453-7574-a07a-2115cf74f3c1" xlink:to="loc_us-gaap_PerformanceSharesMember_019e4244-8453-74e9-8cdd-0e1e3ad88aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-75c7-a6b0-193bfbd16f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-7153-9563-c5a3670a6bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-7153-9563-c5a3670a6bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e4244-8453-78de-a3c9-5ee59ec794f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e4244-8453-78de-a3c9-5ee59ec794f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-8453-77ce-b9ab-589a8ce550a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019e4244-8453-77ce-b9ab-589a8ce550a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019e4244-8453-7a82-bfe7-091f5b8e0015" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019e4244-8453-7a82-bfe7-091f5b8e0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_019e4244-8453-71ac-b69c-e7a1cf016512" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_019e4244-8453-71ac-b69c-e7a1cf016512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-774c-80d8-3737a0bfea56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019e4244-8453-7dad-bcc7-33273d54dae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e4244-8453-774c-80d8-3737a0bfea56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7969-b138-2225a14bdd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7969-b138-2225a14bdd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e4244-8453-7d50-a0cb-c0674729dbff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e4244-8453-7d50-a0cb-c0674729dbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019e4244-8453-7f77-94b3-e2a704963c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019e4244-8453-7f77-94b3-e2a704963c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019e4244-8453-7bc7-8f47-76bb5a193a30" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019e4244-8453-7bc7-8f47-76bb5a193a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_019e4244-8453-765c-bafe-1f477baffee2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_019e4244-8453-765c-bafe-1f477baffee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7395-b5aa-8f934b4a3c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019e4244-8453-7c6b-b61a-e2bce2f5fd86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019e4244-8453-7395-b5aa-8f934b4a3c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-76cb-99da-ec12cf6466dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-76cb-99da-ec12cf6466dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e4244-8453-79b8-a4f8-62610a272c09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e4244-8453-79b8-a4f8-62610a272c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019e4244-8453-70f0-a0ba-67d183d27ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019e4244-8453-70f0-a0ba-67d183d27ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019e4244-8453-78eb-a94e-4a9946abba89" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019e4244-8453-78eb-a94e-4a9946abba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-74b6-b79a-0ea2d4db3d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019e4244-8453-7f49-af6a-2f5e702215f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019e4244-8453-74b6-b79a-0ea2d4db3d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7092-b3e5-72da8ac8269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-75d2-b6ba-b338f68f808c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-75d2-b6ba-b338f68f808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7f90-bb02-75bda671c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7f90-bb02-75bda671c2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c12-81c6-1efada340a96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019e4244-8453-7c12-81c6-1efada340a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019e4244-8453-77e3-ac27-8b226cad13b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019e4244-8453-77e3-ac27-8b226cad13b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-7dd9-80dd-e463ea92a180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019e4244-8453-77a7-9ed8-0a076c4a7bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019e4244-8453-7dd9-80dd-e463ea92a180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#STOCKPLANSScheduleofValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-76cd-ac92-b8c433dbe894" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019e4244-8453-76cd-ac92-b8c433dbe894" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-765d-815c-b51675082e47" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-75e0-8b35-39431497d1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-765d-815c-b51675082e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7aa7-bdc5-a1e9defe63fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-765d-815c-b51675082e47" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7aa7-bdc5-a1e9defe63fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e4244-8453-7b2f-a97c-d474ff62dfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e4244-8453-79f5-ab16-2e47d32529e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e4244-8453-79f5-ab16-2e47d32529e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e4244-8453-7e62-9882-98fcf1d72a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e4244-8453-7e62-9882-98fcf1d72a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e4244-8453-7db4-bf22-c01dbcfa31a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e4244-8453-7db4-bf22-c01dbcfa31a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e4244-8453-7878-9ed2-6c1555fa3044" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e4244-8453-7811-9583-74c1c2d24094" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e4244-8453-7878-9ed2-6c1555fa3044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-761f-86db-80e8a6659565" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-761f-86db-80e8a6659565" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:to="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e4244-8453-7d44-8a44-81454f49e330" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7a21-88dc-6c0ad55749a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7a21-88dc-6c0ad55749a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-711b-aaa4-5bd9d239e7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e4244-8453-7e54-a0de-f5127b417e29" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-711b-aaa4-5bd9d239e7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7ab6-b095-b7eaae604533" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-8453-78b0-bf47-1a73f02966fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-8453-78b0-bf47-1a73f02966fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-8453-745d-bd07-22aa027452eb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e4244-8453-78b0-bf47-1a73f02966fc" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-8453-745d-bd07-22aa027452eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-8453-7b0b-8551-f8b0a8f1e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e4244-8453-7b0b-8551-f8b0a8f1e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019e4244-8453-7269-b821-993cd3ce4828" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019e4244-8453-7269-b821-993cd3ce4828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-8453-7621-8b8b-213253a87d10" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019e4244-8453-7c9d-8c95-acccd3806dc3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e4244-8453-7621-8b8b-213253a87d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:href="pcrx-20260630.xsd#pcrx_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-76c0-b1b4-c326c04d261c" xlink:to="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e4244-8453-794d-9409-af80c8a3c211" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e4244-8453-794d-9409-af80c8a3c211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e4244-8453-70e6-bb8a-e0e69536255d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract_019e4244-8453-78dc-ad06-de20c99e08f3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e4244-8453-70e6-bb8a-e0e69536255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-704d-9b6c-a6515376848b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e4244-8453-704d-9b6c-a6515376848b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e4244-8453-722d-bea2-a4c372b98279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7761-9e1e-ffa6f68500c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e4244-8453-7761-9e1e-ffa6f68500c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_019e4244-8453-7545-8fc7-fedd541e686f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_SeniorNotesMember_019e4244-8453-7545-8fc7-fedd541e686f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7880-822c-b7d06cf453dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e4244-8453-7880-822c-b7d06cf453dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e4244-8453-7ddd-99b8-5bca17547413" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e4244-8453-7ead-a93c-669ef7384bba" xlink:to="loc_us-gaap_EmployeeStockMember_019e4244-8453-7ddd-99b8-5bca17547413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-7b5b-85dc-a7ddfb777349" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e4244-8453-7974-a6c8-13251c98b3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-7b5b-85dc-a7ddfb777349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e4244-8453-7734-a805-a8b33eccf492" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e4244-8453-7b5b-85dc-a7ddfb777349" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e4244-8453-7734-a805-a8b33eccf492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7d8b-b2b9-2fb7d816c9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_019e4244-8453-7067-b7da-2989863caeff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7d8b-b2b9-2fb7d816c9b8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_019e4244-8453-7067-b7da-2989863caeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019e4244-8453-7737-bcad-e2f56c7c5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_019e4244-8453-7067-b7da-2989863caeff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019e4244-8453-7737-bcad-e2f56c7c5b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019e4244-8453-7460-a8f2-ca9113c42951" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_019e4244-8453-7067-b7da-2989863caeff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019e4244-8453-7460-a8f2-ca9113c42951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8453-74bd-afbf-d4fe73600996" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_019e4244-8453-7067-b7da-2989863caeff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8453-74bd-afbf-d4fe73600996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8453-7cd9-9a21-2bae3e0920ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7d8b-b2b9-2fb7d816c9b8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8453-7cd9-9a21-2bae3e0920ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019e4244-8453-7d58-aab6-c47efa6237bf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8453-7d8b-b2b9-2fb7d816c9b8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019e4244-8453-7d58-aab6-c47efa6237bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_019f946c-6e39-7e25-b1f7-915fc043d278" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign_019f946c-6e39-7e25-b1f7-915fc043d278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_019e4244-8454-705b-9d30-1e5742817f10" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_us-gaap_AccruedIncomeTaxes_019e4244-8454-705b-9d30-1e5742817f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_019e4244-8454-793f-ad05-f191e2b42720" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_019e4244-8454-793f-ad05-f191e2b42720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_019e4244-8454-79c7-b1ea-b8f4b478e180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_us-gaap_IncomeTaxesReceivable_019e4244-8454-79c7-b1ea-b8f4b478e180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019e4244-8454-73cb-976f-c99a20b63c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019e4244-8454-73cb-976f-c99a20b63c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne_019e4244-8454-757c-a830-7b2f61760762" xlink:href="pcrx-20260630.xsd#pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne_019e4244-8454-757c-a830-7b2f61760762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo_019e4244-8454-77ab-8aa4-99fed5271ecc" xlink:href="pcrx-20260630.xsd#pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019e4244-8454-7ec7-835a-7a7d29f9aef7" xlink:to="loc_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo_019e4244-8454-77ab-8aa4-99fed5271ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7111-ba0c-8314620b9002" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019f94d4-956f-7e6b-9c6f-3680a42c3e0d" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7111-ba0c-8314620b9002" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019f94d4-956f-7e6b-9c6f-3680a42c3e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7f96-91f8-7f785ec10f85" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7111-ba0c-8314620b9002" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7f96-91f8-7f785ec10f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-8454-760f-be8e-e3ef10bb38b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7111-ba0c-8314620b9002" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-8454-760f-be8e-e3ef10bb38b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-786d-a674-87419911587f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7111-ba0c-8314620b9002" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-786d-a674-87419911587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-7393-81ae-70bd71864161" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7111-ba0c-8314620b9002" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_019e4244-8454-7393-81ae-70bd71864161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#OTHEROPERATINGEXPENSESNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7f45-9c4f-d9abac50950f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019f94e2-0f0a-7b12-bffd-6b80dc8cc0ff" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7f45-9c4f-d9abac50950f" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019f94e2-0f0a-7b12-bffd-6b80dc8cc0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7ef0-9575-b1296b53ecf2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7f45-9c4f-d9abac50950f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-7ef0-9575-b1296b53ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-8454-7ada-b5e5-9afda6ea6023" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7f45-9c4f-d9abac50950f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019e4244-8454-7ada-b5e5-9afda6ea6023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7a6b-8e82-bdcf4f25793e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e4244-8454-7f45-9c4f-d9abac50950f" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7a6b-8e82-bdcf4f25793e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e4244-8454-77a3-aba9-47a69e739726" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019e4244-8454-77a3-aba9-47a69e739726" xlink:to="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_019e4244-8454-7224-8427-3022759731f2" xlink:to="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoScienceMilestoneLitigationMember_019e4244-8454-72d9-a2d0-ffe1161bf600" xlink:href="pcrx-20260630.xsd#pcrx_MyoScienceMilestoneLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:to="loc_pcrx_MyoScienceMilestoneLitigationMember_019e4244-8454-72d9-a2d0-ffe1161bf600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchDevelopmentFoundationMember_019e4244-8454-7f2a-9625-804db08a9eda" xlink:href="pcrx-20260630.xsd#pcrx_ResearchDevelopmentFoundationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019e4244-8454-7621-88aa-cc41625eef0e" xlink:to="loc_pcrx_ResearchDevelopmentFoundationMember_019e4244-8454-7f2a-9625-804db08a9eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-7eba-8662-a5101ae7d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019e4244-8454-71d2-b74c-1fab73309749" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-7eba-8662-a5101ae7d14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LGChemPartnershipAgreementMember_019e4244-8454-7b1a-a8fc-a380a0ab9994" xlink:href="pcrx-20260630.xsd#pcrx_LGChemPartnershipAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019e4244-8454-7eba-8662-a5101ae7d14c" xlink:to="loc_pcrx_LGChemPartnershipAgreementMember_019e4244-8454-7b1a-a8fc-a380a0ab9994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019e4244-8454-7498-94b4-63ee314d4756" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_JohnsonJohnsonMedTechMember_019e4244-8454-74a6-9880-11da5aa50db8" xlink:href="pcrx-20260630.xsd#pcrx_JohnsonJohnsonMedTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:to="loc_pcrx_JohnsonJohnsonMedTechMember_019e4244-8454-74a6-9880-11da5aa50db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember_019e4244-8454-7759-b81f-8562b44303fb" xlink:href="pcrx-20260630.xsd#pcrx_GeneQuineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:to="loc_pcrx_GeneQuineMember_019e4244-8454-7759-b81f-8562b44303fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BaylorCollegeOfMedicineBaylorMember_019e4244-8454-7008-95cd-5bc8bd3368b5" xlink:href="pcrx-20260630.xsd#pcrx_BaylorCollegeOfMedicineBaylorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019e4244-8454-723d-a60b-2ba6c3838c23" xlink:to="loc_pcrx_BaylorCollegeOfMedicineBaylorMember_019e4244-8454-7008-95cd-5bc8bd3368b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019e4244-8454-7569-aa78-8d427338d974" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019e4244-8454-752a-9c48-b80c1c5f4525" xlink:to="loc_srt_ProductsAndServicesDomain_019e4244-8454-7569-aa78-8d427338d974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember_019e4244-8454-730d-8922-38c72d4e302b" xlink:href="pcrx-20260630.xsd#pcrx_ZILRETTAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019e4244-8454-7569-aa78-8d427338d974" xlink:to="loc_pcrx_ZILRETTAMember_019e4244-8454-730d-8922-38c72d4e302b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_019e4244-8454-72fa-81ab-ebe000c9b331" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_019e4244-8454-715b-8096-fbd6c2d95f11" xlink:href="pcrx-20260630.xsd#pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:to="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_019e4244-8454-715b-8096-fbd6c2d95f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InitiationOfAPhase2ClinicalTrialMember_019e4244-8454-799e-96bd-2a9726c861b9" xlink:href="pcrx-20260630.xsd#pcrx_InitiationOfAPhase2ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:to="loc_pcrx_InitiationOfAPhase2ClinicalTrialMember_019e4244-8454-799e-96bd-2a9726c861b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_019e4244-8454-7105-86fa-8642497c6c34" xlink:href="pcrx-20260630.xsd#pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_019e4244-8454-7850-a920-75dc13df8dec" xlink:to="loc_pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember_019e4244-8454-7105-86fa-8642497c6c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019e4244-8454-7964-bd5e-0afb60d6fa38" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019e4244-8454-7425-a5c4-92a8230b40de" xlink:to="loc_dei_EntityDomain_019e4244-8454-7964-bd5e-0afb60d6fa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_019e4244-8454-77c4-8c8f-5ad8bdadcbba" xlink:href="pcrx-20260630.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019e4244-8454-7964-bd5e-0afb60d6fa38" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_019e4244-8454-77c4-8c8f-5ad8bdadcbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e4244-8454-71e6-bb10-9b67b5380efe" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_019e4244-8454-729a-b4c8-83a6242fc4dc" xlink:to="loc_srt_OwnershipDomain_019e4244-8454-71e6-bb10-9b67b5380efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-789d-b974-6fb6f30a3366" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019e4244-8454-71e6-bb10-9b67b5380efe" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-789d-b974-6fb6f30a3366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7f67-9a44-612f6775c66b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-77f0-985c-85d46257f306" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7f67-9a44-612f6775c66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-7729-af58-c748d0a82421" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7f67-9a44-612f6775c66b" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019e4244-8454-7729-af58-c748d0a82421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e4244-8454-7209-848b-04b8a2abf887" xlink:to="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e4244-8454-717b-9229-622993e33f8c" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:to="loc_srt_MinimumMember_019e4244-8454-717b-9229-622993e33f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e4244-8454-708c-9c99-bc53cb129205" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e4244-8454-7f68-84fd-57cebe131515" xlink:to="loc_srt_MaximumMember_019e4244-8454-708c-9c99-bc53cb129205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019e4244-8454-7f4a-9ab5-20f17ebb10dc" xlink:to="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_019e4244-8454-7edf-a353-eb4a5b5b0c91" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_019e4244-8454-7edf-a353-eb4a5b5b0c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_019e4244-8454-78e1-8c2f-aa22d087241a" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedIncreasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod_019e4244-8454-78e1-8c2f-aa22d087241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_019e4244-8454-723d-80f0-62ceb393af1f" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods_019e4244-8454-723d-80f0-62ceb393af1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_019e4244-8454-7962-be44-36e484a530fe" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod_019e4244-8454-7962-be44-36e484a530fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-75f9-a797-b858c65cbca1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-75f9-a797-b858c65cbca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfParagraphIVCertifications_019e4244-8454-7b75-b297-1542344d69b1" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfParagraphIVCertifications"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_NumberOfParagraphIVCertifications_019e4244-8454-7b75-b297-1542344d69b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfGenericDrugManufacturers_019e4244-8454-7827-975b-d51667dcd534" xlink:href="pcrx-20260630.xsd#pcrx_NumberOfGenericDrugManufacturers"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_NumberOfGenericDrugManufacturers_019e4244-8454-7827-975b-d51667dcd534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_019e4244-8454-7871-970f-cbfa190cfb17" xlink:href="pcrx-20260630.xsd#pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty_019e4244-8454-7871-970f-cbfa190cfb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_019e4244-8454-7018-8e5c-85950c47ffbb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LitigationSettlementInterest_019e4244-8454-7018-8e5c-85950c47ffbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_019e4244-8454-714a-9f31-2dd6358a6d32" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_019e4244-8454-714a-9f31-2dd6358a6d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_019e4244-8454-7f5e-943b-379284215b42" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_019e4244-8454-7f5e-943b-379284215b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019e4244-8454-79a5-9fb8-f5ca6a56f90e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019e4244-8454-79a5-9fb8-f5ca6a56f90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_019e4244-8454-73ef-b44a-0fff44d330f1" xlink:href="pcrx-20260630.xsd#pcrx_ContractualObligationMinimumMonthlyCommissionDuration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_ContractualObligationMinimumMonthlyCommissionDuration_019e4244-8454-73ef-b44a-0fff44d330f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContractualObligationMutualTerminationRightsTerm_019e4244-8454-706f-9cee-65cce6f11061" xlink:href="pcrx-20260630.xsd#pcrx_ContractualObligationMutualTerminationRightsTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_ContractualObligationMutualTerminationRightsTerm_019e4244-8454-706f-9cee-65cce6f11061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_019e4244-8454-7307-855f-4e89649b04cd" xlink:href="pcrx-20260630.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_019e4244-8454-7307-855f-4e89649b04cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-8454-7215-b50c-9da85b5c6287" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019e4244-8454-7215-b50c-9da85b5c6287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_019e4244-8454-7485-9596-86dc49bcf4d5" xlink:href="pcrx-20260630.xsd#pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019e4244-8454-7ced-8c4a-84a44ac23f75" xlink:to="loc_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum_019e4244-8454-7485-9596-86dc49bcf4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-7add-8363-f0554c879642" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019e4244-8454-776b-b7a2-c1929892c8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-7add-8363-f0554c879642" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019e4244-8454-776b-b7a2-c1929892c8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019e4244-8454-7260-b0fc-e8f737261cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-7add-8363-f0554c879642" xlink:to="loc_us-gaap_NumberOfReportableSegments_019e4244-8454-7260-b0fc-e8f737261cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-7add-8363-f0554c879642" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:to="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019e4244-8454-71c8-9d65-92b437325f77" xlink:to="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019e4244-8454-72d4-87e3-cee749a4c08b" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:to="loc_country_US_019e4244-8454-72d4-87e3-cee749a4c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_019e4244-8454-7e4a-acff-3da8616d2f85" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:to="loc_country_DE_019e4244-8454-7e4a-acff-3da8616d2f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019e4244-8454-7355-a173-368a5899cc9e" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_GB"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019e4244-8454-76f9-b389-ca9082dc8804" xlink:to="loc_country_GB_019e4244-8454-7355-a173-368a5899cc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-8454-708c-b131-d33d190168cf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019e4244-8454-7b25-906c-9204d84d2e97" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-8454-708c-b131-d33d190168cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PercentOfLongLivedAssets_019e4244-8454-7360-b4db-f3333bac1d8a" xlink:href="pcrx-20260630.xsd#pcrx_PercentOfLongLivedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019e4244-8454-708c-b131-d33d190168cf" xlink:to="loc_pcrx_PercentOfLongLivedAssets_019e4244-8454-7360-b4db-f3333bac1d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="pcrx-20260630.xsd#SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-75af-9ed7-4882fadc2440" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e4244-8454-75af-9ed7-4882fadc2440" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e4244-8454-7c95-b687-5f1cb543b924" xlink:to="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReportableSegmentMember_019e4244-8454-7e73-b8f4-dd89b6c37b1d" xlink:href="pcrx-20260630.xsd#pcrx_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019e4244-8454-74f8-8a98-04cb33c77b79" xlink:to="loc_pcrx_ReportableSegmentMember_019e4244-8454-7e73-b8f4-dd89b6c37b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019e4244-8454-79c4-a482-69bfdf387fbd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioAcquisitionMember_019e4244-8454-7b95-99a8-9232add441ba" xlink:href="pcrx-20260630.xsd#pcrx_GQBioAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:to="loc_pcrx_GQBioAcquisitionMember_019e4244-8454-7b95-99a8-9232add441ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c4-8a6d-7e0b-a5ca-ae395d9d5960" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019e4244-8454-7d5f-93a1-30db88ccda65" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c4-8a6d-7e0b-a5ca-ae395d9d5960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019fc9b4-12bd-7016-90aa-f64a28eb0ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019fc9b4-12bd-7016-90aa-f64a28eb0ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_019fc9c7-a4e0-79d3-b0a0-d1b2adadf283" xlink:to="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c7-a4e0-7d0b-b302-82e59bc275f1" xlink:href="pcrx-20260630.xsd#pcrx_GQBioTherapeuticsGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019fc9c7-a4e0-73e0-8829-af6f80fa6507" xlink:to="loc_pcrx_GQBioTherapeuticsGmbHMember_019fc9c7-a4e0-7d0b-b302-82e59bc275f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e4244-8454-7372-9b04-2d573fb95644" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-8454-78c4-b00e-73923a0134c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019e4244-8454-78c4-b00e-73923a0134c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-7a3f-8a06-81c5baf52182" xlink:href="pcrx-20260630.xsd#pcrx_CostOfGoodsSoldAdjusted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_CostOfGoodsSoldAdjusted_019e4244-8454-7a3f-8a06-81c5baf52182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-74bc-a5f4-342df679e3d3" xlink:href="pcrx-20260630.xsd#pcrx_ResearchAndDevelopmentAdjusted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_ResearchAndDevelopmentAdjusted_019e4244-8454-74bc-a5f4-342df679e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-7c5c-969b-3dc064ff3d22" xlink:href="pcrx-20260630.xsd#pcrx_SellingAndMarketingAdjusted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_SellingAndMarketingAdjusted_019e4244-8454-7c5c-969b-3dc064ff3d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-71be-aae0-f505e10b3bdf" xlink:href="pcrx-20260630.xsd#pcrx_SellingGeneralAndAdministrativeAdjusted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_SellingGeneralAndAdministrativeAdjusted_019e4244-8454-71be-aae0-f505e10b3bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7b3a-b903-bfc3eae3e960" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_ShareBasedCompensation_019e4244-8454-7b3a-b903-bfc3eae3e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-75f9-8582-a61b2fc8074f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019e4244-8454-75f9-8582-a61b2fc8074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019f7f76-16c6-7960-a40d-b945f82118d4" xlink:href="pcrx-20260630.xsd#pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense_019f7f76-16c6-7960-a40d-b945f82118d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-759f-b41a-263c5d782ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019e4244-8454-759f-b41a-263c5d782ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7d57-a0d8-794be3e2bc55" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_LitigationSettlementLoss_019e4244-8454-7d57-a0d8-794be3e2bc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d8-fa38-77b9-9d30-bac0f27a0ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019fc9d8-fa38-77b9-9d30-bac0f27a0ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e4244-8454-7525-9ddd-4c164359ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_CostsAndExpenses_019e4244-8454-7525-9ddd-4c164359ac4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e4244-8454-727c-9c43-1a015c2ecf00" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e4244-8454-727c-9c43-1a015c2ecf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8454-74b0-8f82-479d4fd56994" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e4244-8454-74b0-8f82-479d4fd56994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8454-7d46-a4d9-525e6163c933" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e4244-8454-7d46-a4d9-525e6163c933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e4244-8454-72f2-8701-e8ce0861032c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_NetIncomeLoss_019e4244-8454-72f2-8701-e8ce0861032c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019fca06-1e34-7c10-af5d-ffc7e310c282" xlink:href="pcrx-20260630.xsd#pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses_019fca06-1e34-7c10-af5d-ffc7e310c282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019fc9c7-a4e0-749c-9d42-7b2219ee2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_019fc9c7-a4e0-749c-9d42-7b2219ee2eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019fc9c7-a4e0-7b56-9150-de78ea0bd26c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019fc9c7-a4e0-7b56-9150-de78ea0bd26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-8454-7edb-b056-30a00e98ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_019e4244-8454-7edb-b056-30a00e98ee7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-73f7-b88a-467d9572939d" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized_019e4244-8454-73f7-b88a-467d9572939d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-8454-7dfe-812c-1e1b8ad7cec2" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne_019e4244-8454-7dfe-812c-1e1b8ad7cec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-8454-7aba-bca8-db7dc6906774" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo_019e4244-8454-7aba-bca8-db7dc6906774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-8454-7cc5-9e19-d89ba1732f05" xlink:href="pcrx-20260630.xsd#pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree_019e4244-8454-7cc5-9e19-d89ba1732f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019fc9cb-a4cf-779b-a08a-5a62a2bbd92b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e4244-8454-7c8d-843d-22c4dfec952b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_019fc9cb-a4cf-779b-a08a-5a62a2bbd92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pcrx-20260630_g1.jpg
<DESCRIPTION>PACIRA BIOSCIENCES LOGO
<TEXT>
begin 644 pcrx-20260630_g1.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
M]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &#
M 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"
M00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A
M RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$
M.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W
M!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&
M]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6
M"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*
M@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.
M#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.
M[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M
M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4
M211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!
M%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:
MGAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6
M'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA
M^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W
M)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J
M:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N
M+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S
M\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%
M.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^
MH#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'
M1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*
M?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[
M40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17
MDE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL
M7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)E
MYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@
M;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AU
MA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA
M?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z&
M<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\V
MCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8
MN)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(F
MHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL
M7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV ;9Y
MMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!
M9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPU
MS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7
MX-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZBWRG?K^ VX+WA1.',XE/BV^-C
MX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#O
MS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'
M_)C]*?VZ_DO^W/]M____X92[:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C$M8S P,B W.2YA-F$V,SDV
M+" R,#(T+S S+S$R+3 W.C0X.C(S(" @(" @(" B/@H@(" \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM
M9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R
M871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O
M<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CY086-I<F$M1F%M:6QY7TQO9V]S+4QI8G)A<GDM,C R-5]&24Y!3%]N871I
M=F4@9FEL92!C;&5A;G5P(#(\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(U+3 Q+3$T5# X.C(Y.C4T+3 X.C P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TP,2TQ-%0Q
M-CHR.3HU-%H\+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C R-2TP,2TQ-%0P.#HR.3HU-"TP.#HP,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T
M;W(@,C@N-R H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,3 X/"]X;7!'26UG
M.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,C4V
M/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O
M-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!
M045!)B-X03M!44))04%!04%104(O*TE-5T5L1%$Q.5%5:SE'4U5X1D%!14)!
M04%-4T5X<&)M.$-%04%!8E<U,&-L2DA1:4)95U9O9T(X-$%!9T%*)B-X03M!
M05E!35%!05E73GIC13%44FQ104%!04%3559$24A.4U(P24%!04%!04%!04%!
M04%!04%!05!B5T%!14%!04%!,'DQ255#06=!04%!)B-X03M!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!05)9,T)Y9$%!04%604%!04%Z)B-X03M:1U9Z67=!04%944%!04)S9#-2
M=V1!04%!9D%!04%!55EM='=D04%!06=104%!055C;&A:5V=!04%H9T%!04%5
M6C%H6E=G04%!:7=!)B-X03M!04%566QH6E=G04%!:T%!04%!55I',75:04%!
M06Q104%!0G=:1S%K6D%!04%S44%!04-)9&Y6;%I!04%!,'=!04%#1V1M;&QD
M=T%!)B-X03M!.5%!04%!:V)(5G1A44%!02]G04%!055B5U9H8W=!04)!=T%!
M04%K9$=6:F%!04%"1$%!04%!36-L4E-1=T%!0D1W04%!9TU:,5)3)B-X03M1
M=T%!0D1W04%!9TU9;%)347=!04)$=T%!06=-9$=6-&1!04%!04)$8C-"-6-M
M;&YA2%%G2T=-<$E$135/5&=G4T=6,V)'5C!D0S%1)B-X03M95TYR65A*:TE%
M3G9B6$)H8FYK04%'4FQC,DU!04%!04%!04%%;DY34C!)9U-55D1.:D4U3FI9
M=$UI-'A!04%!04%!04%!04%!04%3)B-X03MC,4I(46E"2E)533)-5&LR3FDP
M>4QJ14%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!)B-X03M!04%!04%!04%!04%!1FA:5VE!04%!04%!041Z
M55%!0D%!04%!4F)-5T9L84E!04%!04%!04%!04%!04%!04%!04%"65=6;V=!
M04%!)B-X03M!04%!8C9)04%$:C%!04%$:T9H6E=I04%!04%!04%":6U104%T
M-%5!04)J85=&;&%)04%!04%!04%#4V=!04%0:$%!071S.6M:6$YJ)B-X03M!
M04%!04%!04%"6DI254UG84A2,&-$;W9,,V0S9'DU<%I73759,F=!04%!04%!
M04%!04%!04):2E)536=A2%(P8T1O=DPS9#-D>35P)B-X03M:5TUU63)G04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!05I'5GI9=T%!)B-X03M!04%!04%!=5-55D1)1%EX3U19
M,DQ4275-4T)%6E=::&17>#!)1DI(46E":F(R>'9D6$EG8S-":%DR56=,4T)Z
M56MD0T%!04%!04%!)B-X03M!04%!04%!=5-55D1)1%EX3U19,DQ4275-4T)%
M6E=::&17>#!)1DI(46E":F(R>'9D6$EG8S-":%DR56=,4T)Z56MD0T%!04%!
M04%!)B-X03M!04%!04%!04%!04%!04%!04%!04%'4FQC,DU!04%!04%!04%,
M1DIL6FU6>5I7-6I:4T)785=6,V%7-6Y)14YV8FU2<&1';'9B:4)P)B-X03MB
M:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!04%#>%-:5UIL8VU6=5DR
M56=6;6QL9#)L=5IY0D1B,C5K85A2<&(R-&=A5S1G)B-X03M3559$3FI%-4YJ
M671-:31X04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04(R85=6
M,T%!04%!04%4<% T049&.'5!0D10)B-X03M&04%$-V-W04)"34Q!04YC;F=!
M04%!1EE75F]G04%!04%!0DU#5EE!54%!04%&8V8U,C%L65A-04%!04%!04%!
M05%!04%!04%!04%!)B-X03M!04%!04%!04%!04%!04M004%!04%N3G!:>4%!
M04%!05$Q2E5)1TXQ8VY904%!04%!04%%04%!04%!54%#9T%004)104=1065!
M0TU!)B-X03M+04%T041)04YW03=!14%!4E%"2T%%.$%604):048T05EW0F]!
M1S!!8V=",T%(=T%G44-'04ES06M!0U9!2F]!;G=#:T%+:T%R9T-Y)B-X03M!
M3&-!=D%$0D%-64%Y=T1104Y503)W1&=!3U5!-G=$=T%064$K=T5"05%C0D11
M151!4FM"2'=%;$%3<T)-9T4T050T0E)11DU!5DE")B-X03M7449G05=C0F)G
M1C%!6'="9W='3$%:24)M9T=H06%K0G-11S5!8T5">5%(4D%D:T(T44AP069)
M0BMG241!9W=#1D%)9$%I64-,=TDT)B-X03M!:T5#4W=*54%L,$-:=TIX06YO
M0VA!2T]!<&=#;V=+<T%R64-W44Q,07150S1!3')!=E5$04%-3$%X641)44UT
M07IG1%%W3E!!,6]$)B-X03M:9TYY03,T1&EG3U=!-DE$<F=/-D$X8T0P=U!G
M02MW1"M144="0DU%24%1=$)$<T5305)60D=-16-14BM"27=%;6=3;T),645X
M0514)B-X03M"3T5%.$%4*T)1,$9(055R0E1O1E-15EE"5V-&9'=71T):649P
M9U<Q0F-51C%16&Q"9EE'0F=95T)I8T=.=UI)0FQK1V%G6C=";W=')B-X03MN
M46%V0G-!1S!18FI"=E5(0G=C6D)Y<TA046100C)%2&1!94="-6M(<D%E+T(Y
M24@U468T0T%S24AW9WE#15E)5V=H=4-)24EL9VEQ)B-X03M#3#1),&=J;D-0
M<TI%06ML0U1O2E1W;&M#6&M*:G=M:T-B;TIZ=VYL0V9S2T51;VY#:C!+5D%P
M<4-O14MM07%U0W-52S-!<GI#=W-,)B-X03M)9W,U0S%%3&%1=4%#-6=,<T%V
M24,K14PK47=31$-O35%W>&-$2%5-:F=Y;D1-04TR47IZ1%$P3DIG,4%$5F].
M9$$R3T1A:TYW=S-E)B-X03M$9F=/17<T=41K:T]:034O1'!S3W1G-U-$=310
M0U$X;$0P15!89SDV1#594'-W+U!$*W=10U)!;45%35%94D(K14IS47521%A%
M4%52)B-X03M%>$5X154X4F)21TU%86]2>5)(;T5G8U-*:$I&16U14VA"2VI%
M<TU3-'A-1$5Y3511>$YJ131-5'!"4$9%*U550FA1;D9%:U5A:%-,)B-X03M&
M2S!5>FA4=T92259.0E971EAG5FUX5SE&94%707A9;49K:U=B0F%01G))5S%H
M8C9&>#!845)D;$8T:UAR:&931B]C64=X:$%'1U59)B-X03MI:&EV1TY562MH
M:V='555:87AM4D=B8UHS4F]%1VEO8552<#-'<#1A>%)R<T=X46)/>'1J1S1O
M8G-H=F%(04EC2VAX4TA(<V-O>'I-)B-X03M(4%5D2&@Q2$A8061M4C-$2&5W
M949H-4%(;6]E;$(V*TAU:V9%>#@K2#)K9FQ"*R](*V]G1E-"0DE'=V=M0T1%
M25!!:$A#1DE)6%5H)B-X03MO4TA/269S:4IY2E9);TEI<GE,9$EW;VI/0TYM
M2351:G=I4'=*0CAK5%-2.$I+<VLR:55*2E1G;&%#5UA*8V-L.7E9;DIL8VUH
M>6$S)B-X03M*=6=N1T-D2DHS;VYQ>69C2T$P;U!Y:'A+2TEO,4-K1TM49W!A
M>6UD2V1!<4%I;S%+;6=Q;7ER4$MW27).:71P2S4P<C!3=T9,1&MS)B-X03MB
M:7EI3$YC=$1#,4),6%ET<7DS:$QH67540S9#3')C=3=I.&M,,6]V:U,O2$PO
M-'=.5$)S34M1=S)Z15--56]X9VI'-DUF27E+:DIJ)B-X03M-<'-Y,41-3DTP
M67IF>D\T32]%,$MZ4FQ.2C0P,D155$Y5,#%H>EA#3F8P,DYZ6GE.<30R-E1C
M:TXR03-N1&983T)1-%5$:4U/36<U)B-X03M"5&Q#3U@X-79$;C5/:EDV9$1Q
M>4]U.#=,5'1R3S9O-S9$=VY01U4X<$1Z:E!323E95#)H4&5!*TE$-6=0<4$K
M-$0X:% R12]O:B]I)B-X03M10TY!6D5#;5%/9$)+549Q46%X0C=K27=1;DI#
M=%5,,U%Z<$1F55!!4D%.15(P4TM2335&16M65E):<$8S:UEI4FUD1W$P8G=2
M>E9()B-X03ME,&9!4T%625,P:5)33F1*2%5L:E-A;$HX16\S4VXQ2WA%<TU3
M,4Y,;6MV:51#<$UC:WDV5%%*3E-K,E149'A/2E4U=51R9%!!13E*)B-X03M4
M-4Y0,U9!;E5(1E%U,45'559"4FTQ2&U5:D939D9,2%5X3E18,4]Q52]:55%L
M4U!63G162T96,59C2E=$,5IC5G%L5SDQ9$56-4I8)B-X03LT1F=V5T@Q67DQ
M:V%75VQ:=49O2%=L6F%P;'(Q5S!68FQ6=FQ81%9C:&QZ5UA39&1E1C-*6&AP
M96)&-CE8=SEF658K>EE!5F=6,D-Q)B-X03M94'AH5#)':5EF5FE35TMC679"
M:E$R3UA9*W1K44=355I/;&Q05U=36F5D;5!785-:=6AN4%=E5%HK;&]0,FE7
M84]X<%$R;6%A9D9Q)B-X03M31W%F879D<E0R=6YA+SES5C)Y=F)1:'191S(U
M8FA*=6$R-T5B>#5V94<O4F-#='=H;D1G8U1P>&Q82'=C:W1Y<&Y-0F,Q,7IU
M2%%5)B-X03MD2$(P>DA5;V195C$T6%DK9'!T,BM(9%=D-TXT15AH=65->#5+
M;FU*965D-E)N<6QE=U(W63-V0V9#1CAG6'IH9E5&.6]8-$)F;4HK)B-X03MW
M;CAJ9C12+S590DAG2VE"0V]&<F=C,D--24M39W931%8T3S9H0C)%9TE4:FA5
M949Q-%E/:&Y+1S$T8S=H-2M)0DEH<&E--DI--&U:)B-X03MI9C9+6DER2VEZ
M0TQL;W8X:D=/37EO,'AJ6FE.+S0U;6IS-E!.;RME:T%A46)P1%=K5"M2<4I)
M4FMN<5,T-4Y.:S=A54E*4TML4%-6)B-X03M8-5A*;&I35VXU8TML,U=8-$IH
M36U,:5I*2FU1;69Y86%*<E9M,$MB<C5W8VY);6,Y-3%K;F1+95%*-G5N>#)F
M:34O-F]';6<R2T9()B-X03MO8F%I2G%+5V]W86ID<5!M<$9A:W@V531P86UM
M1W%A3'!V,FYB<69G<49+;WA+:S-Q86UQ2$MQ4'%W2W)D879P<D9Y<S!+,45R
M8FEU)B-X03M,839H<GAA=FDW04%S2%=W-G)&9W-D87E3-TQ#<WII>G)R46QT
M2GDQ13=72W1G1S)E8F)W=#)I,S1,:%IU3D<U4W)N0W5J=39T8G-U)B-X03MU
M-F4X26)Y8G925SEJ-S1+=F]3*R\W.39V+UA!8TU$<W=79D(T.$IF=W1V1%=-
M4%5X1DA%>G-63'AC:D=2<V)$>#!(2'8X9SEY3'I*)B-X03M/<VTU>6IJ2W0X
M<S)Y-V)-3F-Y,7I46$YT8S0R>G)B4$XX*S0P1&Y1=71%.#!B-U-0.4Q",#!4
M5'AT4DHQ37965'184C%L6%<R3F1C)B-X03LQ*T196DYJ;S)7>EHX9' R,G9V
M8F=.=T8S27)D14XR5S-H>F5O=#AP,S8O9TYU0SDT551H>D]*5#1T=FI9*U!R
M-4A0:R]/5T4U9S-M)B-X03ML=6-F-39N;TUU:3@V56)P,$]P8C9U6')C3W8W
M-TEB=$5E,F,W:6IU=$\Y03<X>G=74$1L.%A,>"\O2TTX>&YZ<"]1,#E-3#%5
M4%AE)B-X03LY;3,R*R]E2RM";C1Q4&LT*V-F-E8O<FXK,V8X0B]Y62]3;CEU
M=C5,+W1Z+V)F+R\O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!)B-X03M"
M9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TM$0D%-1$%W341!
M=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF)B-X03M(>#AF2'@X9DAW
M14A"=V-.1$$P645"05E':%521E)O9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X
M9B\X04%%46="04%"<T%W15)!04E205%-4D%F+T5!84E!04%!2$%114)!445!
M04%!04%!04%!05%&)B-X03M!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!
M04%!04%!04%!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!
M;DU")B-X03M!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$)5
M=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&15)B-X03M:
M2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4Q3U0P6EA71FQA
M5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58)B-X03MP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5IQ8FY*,F5N-4MJ<$M7;7 V:7!Q
M<75S<F$V=F]204%)0T%1241"455%)B-X03M"45E%0T%-1&)114%!:$5$0D-%
M4TU514954DYH26=:>&=:17EO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%3
M57E7:5DW3$-",U!3)B-X03M.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S
M.'%/>G=Y9W P*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P
M<F)')B-X03LQ=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K
M1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A)B-X03M!
M07=$05%!0T5135)!1#A!-V0U<S%4>6IF87)(1&9$4DQU5%1(0W-.5VM-36M-
M<&172WAU,%5I-VQ%63 V54)08DTS1F\U4VI:170K)B-X03M60R\P=30P+UI5
M-31X27=Y97)C8TU23&(U9W-:,69Z1#5+:VYT,74T+TQ5<S%P1TE);C583GEG
M:%%C56I$4C(O17%U*WA*1UI-97IR)B-X03LO:&XX9U P=7=X97HP<$,K1$Y8
M.5=%9G9M9U8Q:CAT94I:<DAY,3E956-96E%L,D%O2G$O=R]6<2]%04]J1&9F
M9D0O2G!V;% O62\X)B-X03M5>E!S,T\O;WDQ-V]F.%<Q2'$S-5HK:DQ(3G O
M;&=I44U/36-6,&EF141Y-7(Y5E!,:U15.4\O:EA%.6UN;THO-T@O:6QL-TYZ
M=F%')B-X03M8-5DO*TQ4;E-F>DLP8E-B3T-W<TQV47)85')F84LP9T8W17%Q
M5TQ&57!!471A*T=*-TXO;WHO,E V,&XR8FQ7,$TS+T%%<B]!3TMD)B-X03LO
M=T%R8G5V*W(Q;T@O27959BMA36PO2G<O;350.6DS9C9(22\V;FXK95 X05=Z
M4'E0-6]B>D):6$UZ,V1L9'9"245,5T-Z<6EG<4-!)B-X03LS<FA7-61E;5E/
M<C O:&M#:5!F6#9(4F1Q-D0X=$U!4FY'>"](=S,O04Q&5S%8>E!B=T@O045/
M-W-F,T5R43-I,VMZ44)7544X5F-*)B-X03M)3U9&3WA'1$9P>659;'5.<49T
M96XP17!F5D=E-'501$AI*WEX<VM.>C4O=EEP94@Q-U)!4C%#>C--=S9N.7!)
M<5IK>#!C939F>4$O)B-X03M3-TA(,E!%:2M(3B]P66HW-4XO.'))+S!B:CE9
M,'(V>E0K."MS6%AP,3AE2#%7=B]!03)$.&E,-51R,T0O:6PO:U0Q8W-V1"]!
M1EE8)B-X03LX*U Y0W<O;4Y-659!=DY(13E2>6-Y,UI1:F5T1CE!161V,G8Q
M-T@X:TPU5'(S4B]7;BM20F8P-6$Y,% K3"]1:'!F>D0Q9WEU6713)B-X03LP
M1DEI>$UA4#EE9&=T9&=70TM#860V1#5:26%+2&10+T%'3&1(<V)&5SA-.2]W
M1$I0.6$S+VQ93W4O.$%6,#!$+V=B-R]M;D@X;$0K)B-X03MB:R\R2V8U1W<O
M>DTO=T0P<F0O>7-(6&8K<G!O2"]!,S,O3D]0-4M(.#-*+W-6+VMB1"]->B\X
M05-T;#-M931T9$YT>')&-W%6-5HR)B-X03MD<S!34$1A;TI223!S<7AX<5DQ
M:6UL674W<79W+V@Q>D)W,TPP:4E*4&8X03)H-7I(;D5):T=-6E@Q3C)09%)#
M6%=V-7 K4F)U6C1,)B-X03M456AC5$DV4BMN1DA+>%!Q2U=2>%)A96UA1F5F
M,E$R>$YC;61&;$A-530O145B<'9N>GEV<5=S4C9083-B2%5*65=U26]:27!9
M:3AA)B-X03M-55EQ6D952&-61E!T1&-61U%N<'!X:GA%8DQA86%J67DS:U-P
M2&54,E)6=5)K=&I'1T\Q2T@Q16M&4&]Y=DA0:%!)2#-T*T1+24=Z)B-X03M'
M379F9C9#1E=Y=&YT<EI)2'5*3'!K<E=E8FE:1W%39FDT2VDW5G P=U1L6G5Q
M635::6-I44)(>4A,-V)85S@V>GAL,4)!1'9(42M-)B-X03MB;$0K2S1Y:E17
M<5I&56DX,5AL<'!6<4YA=G13=3=/>71N:&IE1S)62%=2-7 Q:6I5<5DU2%!.
M-49866HK3UI'04=8<$514V4O=T(S)B-X03MV8CAE8U%I45EX;&95,UDY,45*
M9&$O;70U1W5P,W0T3E$Y4V1(:6I-66IK<BLO1$=.+W,O6E!P<T-4.6MG:'%(
M2FY26E)Z1&HX45)/)B-X03MK+VU,-54Q5%9O9$IT<G!L,4,T:FML9V=L:F%-
M=7-4;4XK4$EF>DMA9GI!17)58C5(2G!*>&IX16)"45AM9CA!>FMP-7DX-F%"
M<4AK)B-X03LK>#AR6&HR='IR370S03!A='=%:V=A,E=%1G%Q0E%Y;G%A8C1-
M0D%U=T0W,F-.4C1:*VU--R]N6"MG:#5.8V$Y+W=!-4MC5W5"<3DP)B-X03MS
M2'%E:WI2>G=L1G)#6G<Q4U0X2FI5;74K-' Y<F)*4S13951J-4UK<%-*045F
M26-V='1">&5B=BMC:' Y36XQ1S,Q*S9N=#=A03--)B-X03MY>'I23DES661O
M,DI11&Q53D<O=SE305=&5D9C6E%I1%188VU5+SA!2WHO4"]W1#!,=CA!-&@O
M5&QZ*VUV.%%F5E!R.5(V;F]E:'DY)B-X03M/=$]L9#AH=VII<&QX2&AT.4PV
M,69E5UAK:C!J5C4W8W9D1T]33WEN659K-%-":U!!+V%(3DU'3$AK<FEI1'0Q
M8S9';GE4:5I20DE$)B-X03M7<6559DPR<4]*3'4P+V5"=5IE1U-3,UIM1D%#
M-6AA3752>$9/5F%D<T5-.#0X:3!5;V%F-4<X<U=';U%A:&)7<FDW=&Q:3&53
M4S1U)B-X03M*46ET5V]66EI(6#EO,#(R<FMP86UC:%)/>#AG=$IL<65S-E9P
M55-3-FQD>%=K8VIC23)L64M'86QA0W9E9WE'4$9+6G%)='5X64HU)B-X03M$
M54):5G)/.71,,C)3-G1*5FYT-4LX2E502E11:T=H2'5-:D]":6%/>%)L>%-X
M>4U:0W!"5WE,5S=&57 Q<E5F3%!Q4C98<D9X8C@U)B-X03MZ2$Y(851S2W59
M-4$X8D)4,7!*1TME-'DW1FIY16-5461M-TAP<VU16$=*24,W5E!,1V@V;S9V
M93(S3FM*87%02D96:4%+=C942GE))B-X03M#:6AA=$\R0T=A565284M1;6TK
M4E!+,FTS,%8Y85=J<F111FI$2DIC6$4S2&U#1%):6DA7;GA'9W!T6&)*5#%-
M-4-I9'9C1G U5B]Z)B-X03MK,S5::#%Q-#AQ5$YR.6YO53EG,3=*8G1D<D]X
M:UEM,DY9+U%J;"MW549E5D]O=S9F2$M6.$E*6E(P=51-86=,<#1B1#52=&1(
M=C5#)B-X03MV-6HV4$AD;S5:+U5I=G!G2D=O4SE(=%A8;#A)*TQR:S5!9S!1
M,%I-17-C:D=7,&=J2&A:;TI)4"M6;&%#<V,P3%<X;D-Y;E)J1S5Q)B-X03M2
M>5=X1$$K0D)Q3S)2*T1#=DYL=BM%3D0O=T-H9"\P6"]I>E1F<68K25!8+T%%
M=G=U+W$O4#!+96IX.4@Q969F-T909DDS-G543&@Y)B-X03M.4&]J>G)P3C Y
M;"ML3D5S3&5B>DY&2F%W,FPS3$=H9$EN=6]X3CA:5G%"66UD=6AP,7!J9VM,
M<5)00G8Y>F-1>#8W,4@X,V1.;D%V)B-X03M)3%<K=#5:23)6=$]J:V0P54E2
M3W U2E%+5TMM3V\U9F%"8F%P>4EX=U,U5U!E<3=Y='(S-6M84&U+>F@Q1WE0
M-DEM:6PK='908G9B)B-X03MT131K8WAL1S1N+V1A<4-'4'A%,4A(=35S9452
M3D@Q93E1>GDX,#=4-S!2:3AT66)K4DYZ:44P87EC1W!4:W9)1V@Y>&U&1UIJ
M>4Y*)B-X03M)4D=25E1G4U9526QF;3-.>4=P5#13-4MJ+UEQ44U*239+1E1!
M<D<O3T]M6$@Q56%T;S)N5S$Q-6MH:W1O8E<T;6I6;E-&-VQ&;6\R)B-X03MX
M2$-*,UEB,$(S>2]"25A5:65(9C=T:T5*1F5A=BMA,FXS4E<X<W)/-71*2D9-
M56QH2%!/-%)54'%Q,G=O0S-%<%56-FIE9TQ8>&AG)B-X03MK3FEB.#96<GEX
M-6TO364W.'@R,71Q96Q&3DIL4U9B;6%3,VMG94]26&-X;%-3-FME;49",RM*
M:G1X<%%U8D9I14-9;C%E.5$X-2\U)B-X03MY=VYI:3%F>4=T>$\Y=EI3>C-Q
M6&MS6D-U<TIE,$5H56M':$-K-5)H:U)D1G)Y4$9,2W<O2T\X2FE3-C%#0S17
M47-H=41$2$,P9G!5)B-X03MO>FMK+W=".75/:#16-S=M93=$6EAJ.'%F;#!U
M:EA:=3E94U!5;W)2-4QD-V4U:6U6<FE/4B]H.4UH5%%O27AX0DI9;&U"1D%P
M2FQV)B-X03MS=$)/=B]85W8O0FTO=T-X9DDO>$HO:&99=6]89'IA=7-Z4&)2
M86-L4')-.7A)67ET5W!T='@X2U906$M2=S%V9'5:05DK13-F1C W)B-X03ML
M4G15,'A59'ID=VA)-5!2:V(Q1F]S;$LX1'9S,W0Q>415-C Q5%1,>'EL<F1W
M>GE"43533C%:9W R<59"<4U654Y:8EAX1$@K:%5T)B-X03M(;35F=E)E3DEI
M.&%F<RMM<FUT8W1X8T8K=2]G-4]M1T=Z-'!L6#E'=C!K2RMN;E5486]D4E=&
M3'8O9&=T,EIO-BMX8TLS-%I'9D1F)B-X03MP=79.<GIE2'AF=3<T9E!N.6E*
M>415-T952F546'-->4]V,61B1F%'-&QM9&M:9#DK4'=L96YI8VU/1W0W='1G
M369#8G9I-F1Y<6(V)B-X03MY0W5X;FHT>'8V8V@U3#A,,')W3R]W0G%H-EI"
M<61"93)C-SA)6C0U6$-H>6E-1TE5-T$P0G)1-'$X4"]!3V-O9DU'9S91,VQG
M870U)B-X03MF='1D3G@Y945!=5=N57A&9G$O3&@V37-.969)5G)8<&QM3U%(
M3R]G,EDT-'HY9"]"-%!D96103%-Z+S90*UA';6E'4U)O;T)+,F\X)B-X03MY
M-C U2G1C54Q$:TMG67EN=G-D;4]314PY3C$U<DI03V5I4GAT2R\U8V%5<V%"
M4SAH8E5U241G1F%N-GI15G)T:V9%3$1G1#!B+T8R)B-X03MH9CA!479(-E0O
M=W!P=C%0.5 X06\O;VIN9"]6*V9O5CEB;#8S<3@K,S(V93)01V5A.$EF5$AM
M5%%,5%@Y2F)43'0S4S-E83)N8WAS)B-X03M58B]2<FE/-$%$2U%2>4U62V<U
M1DQ'<C<X;R],8C-+,T=M1CE.;'%H;6%.<$I/66A5<D-T2&5I<D=(64)A57!1
M9$950E8R9R]L8F$V)B-X03M6<G1J<D18>E145T-44E%O:4Y#=D-D,FM:9FAK
M3WAD=51!+V%)>%9N1TMU>%8R2W5X5DLO379L*S X=V%1*VPS8G5L=DI.8GI/
M,%IO)B-X03LQ8F$T:G5&04DV5F%)0W5+<UEV9GEI,$$S475T2FMB5'!M6D=M
M6G95=65F;W%6:4@W>51B:4=99DMG-DMO0W%Z>34K5D5E:C8Y6C9W)B-X03LR
M<'1.3%IR2VE2>'<K9T=76FYE44YX:UE%3DI*>6(T9'II<D)V*V-M=DPO;2]5
M9%8X:S9J-6(P:34Q5UA32C=U-&Q7,VEA54EW93%E)B-X03M-4'A"<'E-6BLW
M1EAL=6UJ."LT2DA7.3AQ,SDU6GE-2DI,6F))45994D=!2&UK5F8W<&EN=41V
M,$=+55<S+TLR0G!T>EEX95%.4D5D)B-X03MX6FUW<$MK<WE,1E9Y;S1.2%1J
M>6Q::6]P5G%(<6]O<6I0.$%L6&YN;B]O6% Y0B]O2SDO5$@K269R4#%$,%@Y
M8C!F430K<'=P6&I8)B-X03MA=4MV;RLY,$=+,RMP4E<Y;F%0<&1M5UET95A%
M+TM0,7!E8VQ!>7E+=SA/5&5W;TUY-%IR<VMN:5!C03=+1W1S4VQ/56A/6#@R
M36$R)B-X03M&1'%+*T$X*V%P96564$M6,V)E:DQ!:7A24%%T1$Y*07=D43-W
M=$I%-E X070W<50T94%Y3612;$(R4#)7,30K,4TX1'A#6'I!22M2)B-X03M"
M2%0X5U5&1BM8=FMA5FES4U1334%'25A53#!M:#9(869,1')C=S4Q+W!9+W%C
M:BM89%8O3VHO<$UF.$%X3'IV.#9R=GDQ*UAE;F%:)B-X03MD,BMK>EAV-E%N
M94%O,2]F,4)647=O0F-,,7EZ1')*>5!Q4'EJ2#E44$@R.6Q"+V53;V8P8V5-
M+V5!.&=L+U!A05-5:3AO;&M:9VE&)B-X03LY4C%.5TQ%03AA0V1T.2ML8VY,
M57IV63=F,5DO<6%C=G1&<4]).$)":C4T.%E0,E)+>'9Z,T-P-FIE5'=%;T<U
M2%5T54$T;F]A*W0P)B-X03M.8T(Q1U5D4B]P62]Q878Y165Q-S0O-E-(+T5V
M9B\X06Y(9GI80C5Q.&XS*W)2-F5.3EI.464Q849B:31U47=J9VEK1&-R:#5'
M2#DX)B-X03M246)::6%J2DM2.5@S069C-"MF6#5D5%)Y5EDW:$5F-VM";4=Q
M95@T>&1E<$AA5S!L;DQ,-CDU2F185G=J0U)I47A604A4-TQB0V]()B-X03LT
M6E!(;C(S2G9P441M661D55!62U%K0E%Q3658=C)+=F5E5U!+;#-B4U%Y,CAA
M>"MR5C)H:V%">$E.*U!Q4DUJ<B]Q,7 W6D-/;WE!)B-X03LR1"ML<7@Y<%HT
M2&E%=FY22'E.:C0X,'9I+TPS>4Y+>%=*2G!'041%3'%&-E11.41T4&QP,759
M8S8O,'-F,4]4+TQU<2]N4B\P;5 O)B-X03M!26PU;"MD,G-E5W9Y-&)21G0Y
M2&UV=C!T.5I"-5@Y+U948BMJ44%#-%@W6'):8F@Q8S58>$@U4FDR62LS.&]0
M-WE69C%C94TO94$X)B-X03MO;2]084I:2U(K54MO>D99>2MO-F]R16IQ2T-9
M-RLR4VQQ6C-S9'8V<V8Q3U!K.6]T4GA(:$DT9E!(:G8O8VQA,S4W:%EZ23-K
M.$--)B-X03M52F,V;'%L4&DV8BMT,W=(55I2,4@K;&HK<'(O04Y%97$W-"\V
M4T@O04),378K5F<V5"]Y<4@O2%@K2"]!4%,O,'0K:E!Q9C93,4@P)B-X03LK
M2'!E<'HU971Y<FM0>E=7-G-F-E=0-FUF*VE(5F-.,T@O4U$O=T-*9E)F;6IY
M-5HK671'9E-B>&U3,FMM='!N2U5Q9G%T>$AC0F0Y)B-X03MV:4U10GI%=S54
M:FQX1'HK,%4V=VAH.34K5&1G=7!F5SE(=3%S66DX36AG;E,T=6='='=Y<'A*
M=5EW2TLU07%#44M$;T9!>30V.#%5)B-X03MH9GE(-D5C2TPP1#AR;W1),2MX
M,6A,,41*85)34E!(1$1,1#9N<DTP:VXK-S-3:GE.>5E&0U118C=:1$QR3T]*
M:EA0.&1Y9TU,+S5Y)B-X03MG,&IZ2F9A9#58=4Y#,&TW,65F5#E23GI*0F%1
M4WIK0D9"2$U22WA516EL8W@X6D1$2T1S.&AS9%@O3W!7=GAQ4&MV5C=U2SEK
M5V)J)B-X03M&<'-S1'))<4-+<&Q.<DLU+V0Q6'%#2VUH1F-N564Y<G588W%P
M9F9M4$)A>G=7=C5E82M"3&%45U-,4$),4$=Q6$1T2DPX1%=)2'AT)B-X03M)
M4S%+12]$=CA+,$I)4$UR=C-0668K8U9.0C$S4E!Y.#%',#%N5')R5$QP.5AM
M;%-#.&AK=#5':DYT8G%(0WE+<$MK<5)8,GER2V),)B-X03M::49"-FHU;SAU
M5V9M3%)N,&TX6FMT<$IR85IY;$MN-G)C4C-!6&9B-&I%06-/2$MC8W5)968R
M:6UW:&@Q-2M49&=U<&TX,&4X5WAI)B-X03M:-$I$8GIP8UA11%=Y=7%C4V)M
M34-I>55(=VMG8E9O04)L>#$U<7!#+VM/9G=2=V]R45!Y<VHP:GI$639W;#9N
M2WII;&IA2T-'5T@Q)B-X03M$3WI34VLO=C5%;SAR.#)"46MK1&9)-61B>'=-
M834O:G554F5F9CA!3U57:BMB3'969DDK<&589$AV3E=M,&UE-W5*0EHR.'1W
M15I8)B-X03MT6&HY5#!L9FIY35IP6'=/63)-:F4R=DM$=%1Z1%-T5B]/5TI:
M;SE7.&QA,69X4U1,3VEW,D5T<WEL65=T-F-Z87I-9C-48U%A.'%D)B-X03MZ
M=%-:164Y9T1,=54P:R]->4A4<G94<F9Y1G(U<S=M,&%Z5T<T=#5P,5986C5$
M54=Z6%EY>6-Y<3AA;C-#;%-30V)*6&9U5%@O02]N)B-X03M4+V]7>CE%9F]$
M578P="]I3#9X*VHO<6LO=T)9.4@P2V5P-EA$;G=R='EP5$)X1&E4=VYH9E)F
M;G$R=#E/:V@X,5A&>G%%:V1I,71B)B-X03M$4W)344I&2S Y>7-+338O0V1M
M;4A).'9S:G!K.4Y+4G9'3TAE.7E02GI986EC26M$:V9)2#=W;U)F;7!9=F93
M,DUM:C9L8C-%8GA,)B-X03LK+V=-83A:54Q!;FMA9W)X25E5.$-+9V<T5&]Z
M5CA55VTP5&\S-6I7;7!A>F)A5RMM6&QQ,3-'.&M&>DEG84=Q3WE"5V1#47!K
M15ID)B-X03M0.&YR>$I!>4]44VU-5$MW85<S;C,O3U5&-W%D=%HK5EDY4&YA
M0V$W,4)R9EHR4D0V:7%">C1B:T$T-EA,=T5M9V9E>FIN;FI.>#8K)B-X03M1
M4#,R.$YL.')E9#=M5S=K+W=!65%34&%4<&)3<DAF4T)M6# Q;S!C861E;U-L
M0E4O5%%Y;EIS:'%Y-4I:2D=5<78T1#="<VAO4$LS)B-X03MN964R:VQJ.#!C
M6F\W85,V345T,U!'5#95:E)I34UX-&QP4%1*5&8K6&QX-7)63D)Q;W9F+W=$
M;D5U+W9R,SAU9%)L=DQI5S5L6%=*)B-X03ML5U-:,FM92TQ7,DY+<U-A5D]5
M6F5B8FHU33<X.5<Q=' P:U!M<35U=%%E3WAA,G1H<&1P249I:V%E-5=&1V12
M46UJ5$1L.%@R4C!Y)B-X03LO5%-K8GAJ:#-V8VIY8VE';VY#2D$U2'E"*SA+
M55@U<%=$,W-T;$IP1W!7.#A5:U-%5'='36-::UIG5'E)24LX0T=&4$%I;TE/
M139-)B-X03LQ9'AA8E9T2"]-:7DQ2%=R6%-P3DYV3%-3.&IK94-E4D$P3E5D
M;$-S-FMH5$E),EI08C=816M$235.2UEX37)"<&)E6B]W1$]51W!A)B-X03MN
M8C9T-4ES8D-C=U!Q53$U8FQJ23AC65HR=%52<$]'-4,X-C0V6$M96'-$-WAB
M3T]O;FI0<#8K45 S9W9'2F9,2&Y7-CE7-E1Z;$)C)B-X03M-2GI&34ER,E%.
M6#!F5G%Q3%1F.6IJ<V5F<V$T6E1S,E$P-4IY;DEY4% U9EE.:TAA*UAF3VPQ
M<%4Y-T(U;E!R43(O,6XV;DID>E)Y)B-X03M-3U1J9W!C:%-X5TEU2T=L0W13
M1UI15U9!=%E"6E0K;3EA+S9&:RMT+U@W;C8S+VE4,"]R2')397!W*W(Q-#@V
M.'%E,E%R,4UR.4PV)B-X03LT=DPK,FIU-$Q/5S)N;4UX5FQD24I*659)8C13
M.&=5;VA6:%AC-V1C<FI!:T4R4&TU<TU";$%Y=4\S9DE!+T%C>38Y,%12<C91
M4S-T)B-X03MH8EA5:3=+.#!-8VI#;F=70G=2>5-(26M.1&1V;S)J,C!Q5%<Y
M:F)W>7AJ:DA*2$5I<W$P<%)304-"5$4U2DAM4W)Y6"]N2F5W.')8)B-X03MM
M:C9'=FU$5F)N4UDT-W%2-V%A,FA367,T459".5-71&I4<4M(2C114V5N>$Y.
M;4Q42$MA0FE095%0=F909C%(.'%T3'5'*W$K8W1B)B-X03M74U)16DIB5WAI
M04E0>&-76F)S5F]E=5-N3&A.1W9N8D1,<&IJ;%))4'5)4#-,<$PS.'5P561*
M9D\O;58P:UAG-G1:2U%Y+WEK1SDS)B-X03M'43A8>6$O1#@S,%@O=T$T>#(O
M;&U$>49F<#5D=F)Q+W-J<7-X:VUV245T<$),.5AT-G%%4U-91F5013%R.4=1
M;$LP>&I4,4,X=C=A)B-X03M/-V=S-6)A95EZ1E=6,&=K;&A5:'9H3'E"4VE&
M5T9D>G0Q>55916=M>#@S2FAG36]'5G@R-S5!2#1$;5A8=6EA3F930U<Y<TQA
M-FQ&)B-X03M!2&UH:FM9539B<T0T-$DU2D1K4T=H,71O;6I7<WE45S%H8E%4
M4FII:W-C2TEY<G5+0FQ!24<K2GE33WA*5C1X+W=!-4\V6C51=E@X)B-X03MS
M3C5H,6DU,&PT9G)R5V)7<T5C>&-N-G9Z2DUK,$A(:E)A57(Q.7-S=V=M*UAX
M3DYU3%-N2V%":4LW>4(Y-W=L3%0X<DY)=5I9-TQZ)B-X03MN<FM416=03%HR
M35-Q.4]H-4IE3%AR:&Y/:E)R-S)R3'!J0U9%9RLT9R]A2%,S2#5B5$-14RMD
M9DUC9VQ8:$M(<U5B:W1#3TQ6=DYX)B-X03M1:U5Y2&DK5%@T9FUZ+S9H*UA0
M+T%%3'@V4#9:,4PY0F9P+VPY9"MO>&974')(;V99.40Q*U!$:BLQ>BMJ0C1M
M.7 T3G%F4W9M<3 Q)B-X03MY-S!34S,P3S5&<'%,>3(S1S1/-%=)6$5:;BLK
M14].="]$9DLR8D5B=E)V>E!T8BM61C%78E9,1V0T;G)$1F)18V%+>5-Q4%5L
M1&IN)B-X03LX2F]P;T-#4CEQ9U926&PS5&9Z1'0Y9'-P<BLY;&LP>C!P23=Y
M,VU%1$-P6FY29S!B.&=Y1&EI,%AC9F%*3RM+=E!0*V-T;7,P,'9Y)B-X03MM
M.39V3WI853).>6]R=D5%2$UB8B]:<FER=WEY.'=F;&1C4&5X,T=G<%IJ-G=*
M-T<T96%:=W%"5E0P>6MA4'E'>&9I*WA0,#%5<3AM)B-X03MQ+VQ964IK;7-O
M2FEB0G)D1VE.,4A*.5ER.$5Y<S!F2&MG0U5&0412=59E6'=Q=F1V*V-0=B]*
M86%N+S(R<"\K;U<Q>%$Y9#@P,G5U)B-X03M896EY5RMI6$ET3E%E83(T,T)P
M4EEH8U)M9G(T=VAX='8T8C1Q>$<U,&8X04Y',#%'6E8Q4UA63$=:-'!!66]R
M841J4E=35F%34VAG)B-X03M'*T4P0C0Q<5%.-D)61658=$XO36$S,2MY;78W
M>5-44VA%.&0U8GII0F=35V0P64Y'-5E&0G=155AC9F%*3S1695<O.#5D4U=%
M97)E)B-X03M16DY2:DTR;G!0971E4D%K1C11.6U:1G%..3%Q3G-5=DAT3C$W
M.')B<4]33S<P3DY0:VIM17-%.',P.&]+=$-59&5-35)Q0DE&:T-T)B-X03MS
M1'-0:$I'2W1Y87 K5THP*S=T<')/1U-:<DY9-$QM,RMS>'E#-%1M,W%$;D=2
M>4HY3E%0:%AI1%AD=5-Q<#,O04]U<R]W1&=Z+SA!)B-X03M9=FER-G8Q0UA8
M3&1,3WDO4TTU=E=::DQE46%C6F]85C-)45!X3$Q'55=G2C5E.4UY-$-"=59#
M=3=I;R]T9'!H:FAK6E0T23A(.# U)B-X03M+3W<S<G%B.3-K,TYO,VY9.&91
M.'E1<#$U8SE04C8K1DM3<%1!375(<D$O-F(Y:4EA;E-D8TI0+T%#54DO=T(V
M5DPY0V5F.$$O<6%,)B-X03MB+W5'3"\R55EF1G=F>D0O04MB.6I0.$%.84PO
M049#6"]+,R]!231W>CAZ3E%0;#9Z<W!F3U=V5TXQ8EA%:G)A0V)266)H439Q
M0S%0)B-X03M6=4M+84A,8UAG>DY#2'IN6#9',T9L,%5Z6&A6+U=Z8U S>&5B
M>2]M:BM68U5H4G(O5&E2,U1Y=F)S3GA867)/4FAK35%.8T@K>B]9)B-X03LQ
M6F18;UE3351H2G)U>3)0;4ER4"M6<2]L5B]Y,U=(+T%)4S!(+U9B22]U=C5H
M+S S-T=V*U5.1"]Q378K5FXO04)X-TXK4S)V84AR)B-X03MN;'4X=F1$=4E:
M<D),>&]324Y/5%1&5UI9;S)E<U-024A*5C K3#9->',O1&9P2$0X8F-455IS
M3U%G-&]'03@U8U@V06YU<%1A,4)C)B-X03MM,E<O;D0S36Y/,VMG,#5P;S1K
M6FE"2$DT3$QS3W!*2&HP,GDS1TE%6%$R+W!5-6U#3TM594QG:C92=F53:50S
M9V9J=6)M,&9Z;59!)B-X03MH.'AX23%D>3EG:FEN>45Q9G)W1$QH-G=0*VTO
M66E/<#!T-S14+WES4"]%;%(O46YN+SA!-FUI,B]W0S19=CA!,E599D9W9GI$
M+W!V)B-X03LR3FXU<E)F-FA,+VQB+WAX9W8U;F%R8BM85'!G.#9A-UE84G5V
M6"MO979O:T9X>#E0,"]6<#9T>#A.96%D3W8P6F)I.$MF2TAZ;E@V)B-X03M'
M,T1L,%5Z6&A6+U=Z0U S>&5F4V9M:BM68V)L1&8V8U-/<%AY=F)S4&]);7!H
M:TU13F-(*WHO63 U3EIO65--5&A*<G5Y,E!M27)0)B-X03LK5G$O;%8O>3-7
M2"]!25,P2"]68DDO=78U:"\P,S='2#AO84@O55IF.')0*T]-;R]X;#59+W=#
M5F0O-&<O4S%L+VA4.4EF5E!Q,RM()B-X03M9=5 Q=FAY-65H-B](-U W5T1I
M=S-8068Y3BMX4#4W43%F9U,O=T-6;B](2',S;38R,2LU,$M31%%,:C9R<6)Z
M5W9#9C1F:&E&>D=B)B-X03MJ-UE99C-(361+*T<K62M!=T5R;G5.+W4R*S$Q
M4EEF9F%B*V)D:F9U:T]P4'$Y:3=W>7$P159R07<T0FQL:F(Q<%9).50T5V]O
M;T-$)B-X03M1<E=I-6-*-$-/6$-F:68P26]Q+VPR,2]-,D1Z3F%.<4TP.'5J
M1T]:3#!8071#=DIM36MB2S!5=G%$9W1),6]M*R]+=7I:2$Y,0UE')B-X03MQ
M-'9J*W(X9$9&<T,O=T-C=#)S,3!Z>6DQ.$LR43%-;39'-7)%14A0<'8X05IR
M,'I&>&17=DPP94@R3W,O;$9D4S-A5#9,.5%P3W-T)B-X03MN4$Q.8U!%1459
M47 V8U-33W<U5F9I>F(W9D5U-$YT1G%U2W-J+VQ#;&Q02&-08GIU3%-71T9O
M4'(X8W!U1V1M:FPU4$%5+V1,=U56)B-X03MP>6\S3&QY0E5Y2DI8,'9D4"MC
M4% O2EHV;B\R,G O*V]3,7EN3'IB<U!*-C,U=G1V348Q;U5K1V=82#%853-M
M=%%L>#A0=WA#-6I.)B-X03MW9FI$1"LT-3EI9D1F1&=-0DLU:7AV.$%D=#ER
M65=)6#)M+VTS63,W3$1Q3#9V674X37%T0D9A44U/05I:63(Y85934%4K1G%+
M2T%G)B-X03LP2S%O=5A#94%J8V-**THO46EI<F57-V8X>C1F371K9%)K;6LP
M6F]P;'9X8R]61T%D;4UK8DLP37!F-$%6:E=I8C!*875Z6DA.3$-9)B-X03M'
M=G$V5F8V=FEO=#5L+WIL,4I94C9V-4%K,4905C Y3&DY83AJ*TEC;U$Y;5I&
M*T@T=#%R,#-Z1WAD5W9.,&5085IR2#54,W%33&5A)B-X03M1=6U3>'IH-'!:
M2F)L,&%-=VU-:FA#:W O=F%31E=/,U%.43!&;$9Q0D,R2V(X<G8P4F4R.7E,
M9#=K5W)*85A-2#$Q2FIC2WI/<C!A)B-X03M)>#=Q5FI&84$P4$E64$U'4DI+
M-THW+S8V=CA!*T10+T%.:3)2+VE4+T(X6#%H-6LQ3'I"<'5O=UAV,7%W<W9,
M16%X<F8S3C!7.5E3)B-X03M34SA!<6HT5BM,:W%R=EAK8T='34I!:6E:.4MD
M:$-C0D5I56)09F1F;TM0:C@S958U2%I).59T6&M2,&I:1FQ5='EK6&UN=V<Q
M4$YD)B-X03LQ4&9T:U!!;C-&<'1D<"]M;GDU<4XP='!9-FI"8UA,2S=P0VIG
M=59I8FA)4795.$@K1G9!-TA"3$1/27-H1G9,+W=$;DI(>D%D2# O)B-X03MY
M*U P6EIA;4QU-VMH14XY6G<S>$1L1C0K:VMY<T%X-F):8G!U0WIX,SA'8UIW
M:CEC94PT,2MG=D)R:GI4-7I-<VAI.&=A2D9(2$ES)B-X03M%:71O3G$O0U5X
M.#9/,W!#;DI15S-P=#AS;$QH=F$V.3=4;&Q%>4IH2&AJ,V,O=&]F8V\O-'0X
M-F96:F1$>4YO2G0Q:6MN36<P1S!))B-X03M%54QC2E@R5'!'>&\O=T1,,W='
M3F17=2]*.41F.#1X*UE:9&4X:%@Y-4Q9,D]N=$AQ<S!):# R,6ES-%-"8C(W
M8VUJ:4-Q6"M+:&)R)B-X03M11'=Y;DE+3&)$:WIN>DIQ4&U(5'13=#=W6%9H
M6F5727A'="]C6%)B,6A,2DQW0V]0:%@T=5-Q=3EE4GEZ0TE30D9%>C95-4U*
M=T53)B-X03M*4G,Y.3$K9V\V4'IB-5EL9&\T.59T6&M2,&I:1FQ5='EK6&UM
M=TYF:EAD5#!08DEE0E!U3%1A-U0O3E!L>E5B<&)3>#%'0S1U5U8S)B-X03M3
M1DA"8W)%,T-1:&5P-% X3&5",D]#5T=C4EI#3&53+S@U2F59;#!Q-SAQ,C,V
M2W-D56PQ0G)Y3T=+.7-)9%%K.5%',T-P07-Q='A,)B-X03ML-D=N6&)W>3=4
M8T<O2&9W6GAN:FHY8V5,-#$K9W9%3')Z5#4P5U)N5#AV.45H:$UH:597,$<Q
M8FEW:CE8:7IE;5 X061:-3<O<S<Y)B-X03M-375'.7(K8E1K351);4UA:C-C
M+W1O26,K8U!/4#%"=%$O=U)O0G-5:CE:<F=A1&%&0D=(.4UV54HY:T]/2E!9
M-TA!63%T8EAF:WIR)B-X03LO2'0Q+W="0SAF<'(Y0S9*-FXV9BMR+U5F,&)B
M9E4V96AY.50V='@Y4#%/,T]L85I$:#E42R]3*VTY8C!Z4W17<R\P8G%62&=K
M;&AM)B-X03LY171X3$YB>DI.2#<O8FI'47AY;$4X46)X16M84U-8;C5:959*
M-W<S9'1B:E1P;30X>EIX=WAG;$LX5%)O,W!4:V5M,C4W:S5B2%9Z)B-X03M!
M;VTO97AP9G S-6,V0EEA>&)A=$<P<VPS87%6:%HO4C)69S(Q5FI6<6-N6G5V
M56Y'97%L2TIJ,$MA648O=T$U2BM7.6,Q<E1V3'(V)B-X03M02F%2,U=N,WI8
M24XU8W=7>3%6459O6C-13G5.=TUR>&]-2E,U0S-J1G1O9C5V,D4Y>#E9,693
M-6MU,D4P,7)D87IA0TYI=TAX8U9U)B-X03M5,EI603A#36U41F=94TA.5FIS
M4'I+:%=55SAV;#)"<&]J07IX87AB<5)%>&1I9R\P>6Q/57)N8T@W5&5*<4]+
M2T]'5#)R+VY'4'DQ)B-X03MQ2&PW>49F,E8Y3&%Y>7EA<DY-<E=D>D1D>#A7
M=#=D84=30FY53E9$.$YA+V9L95-12EI11D(V8G)E;6%6<3%N*VID4V\X16MS
M33-O)B-X03ML=4I:<F5:2F\O9C=C67<T-5-I94E.9VE33'!*3'HX<W9+:SDT
M8G4R='AP,'IC95IS-#19=U-L94IO,&(P<'E05&)C.7EC=&IQ-6=5)B-X03M4
M9G99,'4P,SAU3D%S3EAT9%=J86%3-W,Q2W=M45$W0F=W<'E73EAP5C)A;DQQ
M5&I05E-L17@V1DY03F8K8VPO2W9M2%=R,WEH939*)B-X03M,85)81VQ3,V,S
M2SAU;TQ8-'DQ<S!:6#$S:C4P364O2' Y3U8T:GI9;DA+6$E7.&MS=$,O3G94
M4DYA>C9T<%9W:E!Z:W0W<E=R4VES)B-X03M%35I(1F)M36=C1S0X96Q-;5I2
M64=%:'I85RMK9FU28E<Y>F(R,7@U9F=J=6\R:&Q#87AA:C1'1$%#;C%U:#0K
M;S5(24@W4G)51VU!)B-X03MZ:79$2FM0+T%#<GI89CA!;UAN.4(O5V1.*W5F
M<"\V>C9V-E%T4'$O1#!/3E!R2'%E;'HO04UN;%A">&II=&5%,50V33@T>4Q9
M860K)B-X03ML-V)32716,5=#5S)H=$5:1DUG.64U:FE,2S5(265M2D,Y2VIP
M,4A8241*24-G5%1L47HU27A-4DEI2C5I.6EX>3<O351Z5%I8<S%P)B-X03MQ
M5V=*<"]X4FTS;6QU;S-":F132%!&0V58<'5V54AC16)!,4%G,4LS;#<X=W19
M,41Z0F%A6&1A6$=K1GI&27I854UY=5DS4FTT5E$P)B-X03M9:#1W1TIP.$YA
M5F)R:7)!9BMC<TDS;# W>6YB<F-.86DU,4IO2&Y5,$MR27%G;G%.:#$V-4M%
M-5(K:VM.=4Q04$=B:$EX4&MA949W)B-X03LK4G9+,G%83C)K2&UI4SAU-U<T
M5TY)+W$X<G9.0G=!2D1B.%0V:#1G-VEN6'-'6E1-:EI.<FMY>FUB:U1)*V4V
M<R\U5F%18F5:+S!P)B-X03M08G9&6DY-6&QT;4U1=6QR>&A9<6511&E-:VUN
M=V-L*S!!,4ET8C-8+VY$-R]W06QP<68O04<R<"]W1'%&=&-54%903T1R639C
M3EAT)B-X03MT26DQ5%992G)A1S%6:U5Y3#8Y>DA%5U9Y0W<Y35-&-D%J<#%(
M6$IJ2DE#9U148D10:VI%>$5I26YM3#),2&)N.'<O33EL9517=7 V)B-X03M!
M;6XO04)2;4-74S9J8FQ%-G0V:&]L95AP=7952&--3F=144E.4W(U9"]-4%8Y
M4C$K>C!Y-3!U3EE,<4M2;75O6C%C;S9L:6Q9>E)I)B-X03MR>'%'2G X2EE$
M-'1Z:7)Z2"]N3%)';3%B>49A9E<R<V]R=64Y:&UU5DHK0DAE,%5U44-T94E.
M8VY$2DM0,&MH=7<U.&U0945J2#-')B-X03MN:E9V-44X<F%U2G!R4'I/.2]C
M>%1"6DEX8E1/-WAT0UA8-&U#,$EK6# V-V<O84A1:DEY:UI'>6),2$IL;$TS
M26MN>C-C9GDQ,%(Y)B-X03M.=35L,5=7,W4W93!79%DU-$=%4FY!6FYI3')Y
M;T]#03AI0G5W,DE$34%W5'HO,3%N+W=:+W=$<UAX5CED>F$U95%25S1M<VM3
M.&XU)B-X03LX<E$S54E:845I3&1U4$QN=# V92]F26IH0DIO-T1R4F,R3VMJ
M26UP2&A&8CA**U!U<C=60U16+TYW8VE0>3AJ2C):<C9.5#EW:F)$)B-X03LT
M5TPK9B]S5WE/;3 Q8C54+W!$*W1B*VU03U@O049,<V8O4V5N+U9,1#173"MF
M.$$W2#EQ9GDR;"]W0E=0+TMS+W=$1DU%+TYJ43=4)B-X03MZ6%E71G(U=S V
M3%1R93-L95<P8CE-5S%Q6&-Q1EE6;&A02V<X36Q(0FIL>6M4+VUN.6)/1VDP
M.'9P>7E0+TI-+W)E5U,O;&(K5$5-)B-X03MH:FQV<F%/4F9T22]M9E1L27%+
M-V=W-&Y4-'AZ:V8X05-L:E!485=*;S5I1"]W04Q0+T9,4"M66F9K;"\Q8V)4
M+W=!2VI49BMQ3T1W)B-X03M-9CA!3U X07!F,G-F0C!N*W)F-T$O.$%&4&)F
M>4\P5'EZ;S-L93AS+TQC:V,R;DYE=DTX,%=O46%M4%AA2TY857DR-DEQ,%)%
M4$4W)B-X03LW,3<U5&QH1THR3B]#;D8Q14U54U!$;GAJ,U8K:W-U=4YB=7)E
M8W=Y,FMA<UI1:TMM-6E6-4EY865O<756+S1'=E@W.&Q(0T-,0BMW)B-X03MT
M<TY,1U%S4U!,9C!M9V4W8C<Q0UA6+TYO86M8;#E(5VTU83EJ6&8U0D=Y6&A9
M=C4O=T1S5WE/;3 S6$PO<T0K=%HK;5!/6"]!1DQS)B-X03MF+U-E;B]63$0T
M5TPK9CA!-T@Y<DPX='!F.5=0+TMS+SA5.#@O3G9Y,7!N;3,Y1F8T>7-).4XK
M<&974'%(*S5M,G1E9G$K;#9V.3=#)B-X03ME6$@P,#9D2RLK4VIP.&-U56EF
M.#!S-&%,5'DK;DQ)+SAK>BMT-7!,*U9V-4QX4T=/5RMT;S5&*S!J95HY3U5J
M=G5$1&ED4&I(.%(O)B-X03LP<%E3,"ML:6%/66<O=T1#>B]X4WHO;%=8-4IF
M.5A',"]W1$-O,#,O04MO-%!!>"]Z:B]P9C)O.$A39C9T+W-$+W=!57DS+T-8
M:U0O)B-X03M!2E9J*V=Q,C,K168P;#E:+U-8*TE,3&HY8SE0:C98,6HP=E-R
M>#,T9&-F0G@O>FHO<&8R<C1':R]W0E=0*VM0+T906B]/56QX6C93)B-X03LR
M;V%F<&-E<6%R2$YB43(P5%)P23E*<FU/2FU8:S!8.3)S:&9D,4<R-T%B-414
M-WDT5$QH:G8X06,T16,P-&EO:V=(>E-#9GIB*UED)B-X03MN2DTR<"M863=A
M=T4P2U%88TUY,TQL6E9)9%1#:F-V9VM8*S@W9VHY,S%Y-D]$0V%Q5FXU9F(K
M:C=7<7DQ-60X.2MA3"]W07@R;6XS)B-X03M7:TM.4'59-696=6M*4C1*635'
M0T)H25)Z-5)Q1U!%0VA/,TMH;S5T3D--0U%D,4)91"]Z;'!'2F1..'!13D]B
M84]F56UI;&Y"-#A%)B-X03MD1D1.6&)P,3-Y:D))9VUL;&QL1&5*369D<SA#
M4&QZ.'0U-VTT:"]X3DTY,FPP<V1U<&AL6DQI3&EQ:V5S66@V6CE1+V)+;C1F
M,D11)B-X03MC<D1+4C-,4D]816)K4U-I52],;GDR,6I02E!Q+W="5W5)-TM3
M6DI&6F)I2#9Y<G8V54)%64UH1'AX+T5W*WE81D$Q0TU:4S,R63A,)B-X03LS
M>B]N1'HO>5=E<"\Y='%F+W%%=&-P>3@R-T1Y97)E8UI,:3 P:S9H66%82'%E
M<7AZ5W-.=$4P85-/0DYC>'A-=S5.2"]D<DE8,V12)B-X03MT=5(Q>5=N,VQW
M;5A$2&8W;DEJ;6Y%5D5K02MA47IE8F9Z0G,S;695+TQS9'19:65"26)Q1UIB
M:'EK<7-(6#!58FPX1'%0,VTQ47<O)B-X03MD-TA,>&=X1W%L6BM8-#DS,G16
M;%HU8S@K96%.43AY5W5N6%=K2TQ#-&IM.5<U46U.-$I),V)G2%=5<GI$4G%#
M94E&0V1U5D11-71.)B-X03M#34-19#%"95DO.$%/6$5A5&%T-4-T6F)L<E,S
M=5HW,DLT=4902&A'-S)A<S4O,5%A-5)G:U)D26QL;D%J:$IJ-VI4>$I03%@U
M8UAK)B-X03MG:F@X>E-Y6'HS2$));FAL-%12=$9Y2#<U-&LY4&I+3TA*;$Y1
M95A%9$UM6E-/-6%*2&E.:S)685 X=G9,4C!I-VQU=%@K<#9H1F%T)B-X03M.
M0V53>G='94YN3%%K4D(U1"LV4E1Y2#=48DMW56Y'570Y:V-+9CA!+W)Q+R]G
M>B]!4%ET:V8T:R]W04AX9EAM;V596C=86&)84VLP)B-X03LK961B;$$U=D9$
M0T9#5TDT;&=R0W4Q9756>'AX35-383AN3VE)5G531#=V,G!Y4T%#4V%!8FMN
M2VUT=TE)0D)Q1'5#359E3B\X-4IZ)B-X03ME56LP<E%O+TUM;'IA;F)Y6$UV
M;V5J9&EZ.4YW9W%767!*>4)">DHP,$]);F9H6&AG9G)*2'5&+W!$-79U=DU(
M-4YP359T=DID.4Y&)B-X03M24TI',6QO>5-60EEC9G%R9$=Q3W4K4TE.-T9P
M>5)G1%5D>#AL22M9=GEK1W@X:EAO4%AF5S(W-R]W1$Q(9W%897=Q4&,K;E K
M8UER)B-X03LS>3=E95%R*UA13DML,&5Z1W%Z3$IB5%A2=E=A55<Y=51)2D1(
M1%%&4V\T.&4S6&9+8VPR,UDV<EHV2'%0;4<T=$YC='1+:3 V86-8)B-X03M#
M8R]R9T1#1D-34GA:=W)#=3%E=5-H:FE9:VLQ-4XX0D-T>5%F9&8V539*0494
M<T(Q3U5T8F=144-$54AC15EQ.%$O-7E74&LS;C5B)B-X03M8>DQP32MP9VDK
M3G$P3C9,25)5*W(K<'EQ:VY0;#A.4$-N=FU4<&]C5C<X2SA-1#E:23EW=CE)
M9E!6,35G+TIU3S1K4S(X;#,P.$-M)B-X03MK8W)A>3!:665*6#9Q,5!V>5)"
M-S)I8UE!-V)H4U!M3#AP06%(>4YE9RM",71V.$%S:G=63'99,4AU96TO<&IY
M0B\P3'@Y82]W>&,O)B-X03MO6#E0.% P6"MK>C9N<BMH6#%F<E Q9G!48FAW
M*VY)565*;E$T6#!P-70X=FYZ0F]C=6Q#-6$P5V%A,FME9$92,C116$5C>G%&
M:T1O)B-X03ME87AL9FE5<G9U0TYS:FAY8T5U2W(U+V,S35EU9GEN:F=A4S0P
M:E8W>4\V;75)3&E23'E15#(U845-<E V6$5!>7E+=S53;7)M9RM+)B-X03MU
M*UI),70O54(X4'@Y;DI&3BM7+WDT,5139DUL=')$-FQY.4M/5TLU4TQK=C%H
M2E=E465T>35C>7)V=%4W1'!4=4UU<45O1TYF<U=M)B-X03M%+SA!3U9-1C8R
M;F568FDR<UIB.%=M<$=A5T-&1VMQ<4M$43A1,4$Q2V(U:C1U<D1).%-8>G(U
M,6%D,6XX<&\Y:DID3&,K;CE3=51,)B-X03M%5E)9=55-<E!Z4U0P,6]*0651
M-T5C5C0R54\Y:%I20V5:3&U05&)M>%1Y<'%"9VYT2F)0,$I92&QJ+V9/.&I4
M1W%Q>&PU371'<CA0)B-X03M&94Y+5G=N8W)B,C<O;D5U=W9R3#AU9%)I=DQE
M5S)L8E=*;5=/6D=J67%B5S)&84U!859'535E8EIJ-5!64$YE9TYR*VE385=,
M;')1)B-X03M3>E<P:GI)<7,S0T,U:FUD47)H,%!.67EN>$M2=G5#3G-/2$IW
M4S1Q=FXY>DYI.7HK53AC1%-4-E)Q.3=(8WI8149X26PU27,Y=5=H)B-X03M$
M2WHK;55&6EA6=FEL2C5K9TAL6$UK83(O<4$K2#0K>FMI;79,;C5B-G)P6&U3
M,3%I5%5W9E)35TLT5TAK<'5)-4=A44-934<U.%I()B-X03LR,S)!*T=N9'DV
M<4UO1TYF<U=N;F8O3U9K3V]$5G9);#EA-F9,<4M713DU4$Y"2$<P:6M).6\S
M0BM)86=F:5)V;4YI-G--;E(U1F(K)B-X03MD4$]J4WA*92M61F4P5S0K<T5X
M,FPP3&A#66I%-6AN9#-K4FY(>$UW4$IM05EM=5=53SEH6E99+TU.-T1O,3-P
M369L4RMK<S=Q,F$R)B-X03LK<C-%36MK665S:GAZ8DMH.5):2F$X<3$R6&I1
M0VU%-VTQ5&8Y0V$Q+W="0WEF5E!Q1GHY8B]X2C9N,68P6E!5-&96-F-U1D]6
M4&9))B-X03LS-FLQ-E@Q3C5U=CE-,%=Y+W=!439H3F1*0EI01$=9;THO4VI:
M<' Q:51M<G9&1%1N2T]29&=+6EA(2E%);V(K5&UW>FU-5$=O-SDT)B-X03M"
M4'=04DHW8C@S+TM6,4Q,8G=E=4QQ2C0T+U)M45$Q.5I'94TX<$=64GE#2#1+
M*W O:UI7,$EV4G9Z3#AU-FYQ.71P4$=A,79B>4HU)B-X03MB551Q;U-4,#-A
M3FQ6;%IT-F]X6&M">4%Q35991B]Z:W@U:#@P85!P+VQP4$QU;WIA9F0V:&9.
M87,X37)X0G5A<49$.$-.9S)4>#5/)B-X03M%.&=F94QB.$=9-'I9150W=T0Y
M-W@S54Q8."\W:6%A42MA8GA485-*8EA%9'9Q1C-#5DAO<DE*4%(K0C)*1$%C
M5E5Y37A&15!*86EC)B-X03LK23)X>35/33-12'5&24M3,R]01# S3G8U=S%/
M-&UJ<U1Q5%=I-FQF3% V2VMQ,4999V-U4T]&5W17-#=#=3)283-U;B]/2S)V
M835R)B-X03MF-64V:&1A>G%.,7%D,&UR5%)*4&544UA%9VI&=&)S14131FE&
M0EEM;G9I:#9,-75V.4TP5WDO>$1Q13$P:T9K.$U::6=N.4M.;6UN)B-X03M7
M2D]A=3A53D]C;S5&,D%P;&MC;$%I:'8U3CA--6I%>'%/+V5!5#A$,%-E,B].
M+WEL8WI3=U)F5T9U67!);R]3;5)982MU:E!',TM2)B-X03ML6#1G:"]D:RMP
M6#EJ2S)H1F%0*UIN;#-5=%ET9$DT>E=T-V5X4$QA:6160U-E:S=2<W%S<DUE
M5EDR2SAG3U%&4FER>F(O;DIV>DXU)B-X03MV,&Y59DIT:#5A,4]B5' Y5VQU
M-V0O4VQE2EAF;&%P1GI+16)+6D0X<35::GE'4%%(,VDR+T)N3TUK9U)0=D%0
M,W9*<C9$."]B:5(W)B-X03MX=DY&+T=J5"MH2VM.+V5X*VUX:4UY,'0Q<$PX
M4T0W2TE70C):461S:D]816)96DUN1V)O1#-#:T=)+WIV;7-*<GEZ.#1A;F1.
M0F%2)B-X03LS,&QO;7!8=C%J,%I!.6%)5S0X;#E*+V@U8VE"541)<T=29C0S
M.#9F.4,S9G!F.$%4*W!F<&(O15@Q9CE)9E<U+W)(;RMH6# O5C4X)B-X03LK
M1F0K3F%9<2MN<G989$AM<S=6-VDS;6QH=4IE55-.035):W1:9U9D9U(X4$=2
M47ES9'4T>3AA95)*1S(S;35G,$UZ26DT*VUU;S9I)B-X03LO=T%F2DQV35!M
M1'EP8WAR639X<#EX9E$X=E9735=C=#%'1VID:T)R17-I9V=Q86(Y3BMH1U-J
M<$I3-FHU9V9E,C1U>7-S>%E-4&I+)B-X03M-9E!R6#0R-6A+.5 Q6#AU=$]U
M;S=U=S!/-G1R;4QL-F-S5VU887-O8U590VMF8V1C;BM3;C-X+S!W+U<R+WE,
M;3<X9B]+>4@V,D@O)B-X03M!2C$R5G8U+W-.26<P>35V9$YU3DQU5W523DIP
M=#@R-55"95!#4%EG:75$.&Q0=FHO<&@K=&8U1GID*U O;%I$.6)Y0TPX:'13
M:'4P)B-X03MU-#ED;E<U4GA+:W<P<E5E46-(:T=R-F97=5 U2V9F2"]41#EA
M9C5&>F0K4"]L6D0Y86-Y9FQX-39L=#)T<'9/3CE,039L2&IK,#-5)B-X03M8
M0E4W14AL1V1T.&9Y52LK4"MM2#8P9GE,;3<X9B]+>4@V,W-N+T]02&Q)*U90
M2T8O<$Q83#-4=G%$,U)L93)N=%%"2D)&1T9#>G%R)B-X03M.+V-N8UI4;'=M
M2$]V9V)C3%9A4V5!9U--5&9D25,K-6Y';S8W;S5J9$QU,VYM:F=U14)8-G9)
M-#E71B]54C$R+UIE24U$.&HT6DM/)B-X03MN:V4W-7-O84=C<6]X,T8O545V
M.'@V-356=4EX639Z<#@Y.4-(5U%2<F%36%5F3D%'5G5526M88FPT*TDX8VQ$
M4WEK3$9F340W,C-$)B-X03LR6&MY0W=99D=1:B]!3'%K;S S52]W075D374P
M=3E0,$\V=&)M4&U5;&DP>3=5:C%"4BMK9C=89DHO:W Y.&8Y35 Q=#,X:35U
M+T@O)B-X03M!37))9G)93"MD*VI29FU&3F]%,FU89#=P:W5I=&-V>FPP,BM9
M;'!Z0U5+1DDY:7!G=V9K<#DX9CE-4#%R+TEU8G9X+SAR269R95=7)B-X03M8
M-45A;EI8558S86$Y4$)C=W-(:6U44W121$MW-V<K;FHK4VXS>"\P=R]7;BM2
M8S-F:B\U5U$O5VUT>"M79FYE-&EE1S0X-%@X<U5I)B-X03M01390<'5P34-K
M9V\V:T=0;W<V-"]K<#DX9CA!5$0Y85 U1GID*U O04I742]7;E@O2W5K+W=#
M5E)F-$8K=EA0,78X05,S-E0K=69O)B-X03MU+SA!5#1E;#9F1&HV9DMU4#5+
M9F9(+U1$.6$O>4QM-SAF.$%Y<V@K=#<W-3!V3DDP9E1J-6<Q15AJ>#)B=U)I
M2S!U-4QC33 Y=VM+)B-X03MC:TTY=&)K8S52>4UH<'@K-TDV8FEK94-.8C-Z
M05!4,T4O2C$K4%5Y>'A-44DP92M-4V9G4T-2.$-L3FXK8C-L,C=U2DQ72WIV
M-#=Q)B-X03M+5TM*-')I1F)E;G)O>F]X37)Q0G-N,E W>G=1-5ED1$UB:VEV
M;BM0=3@S1S1K6'!(-6PV2G%/=%<R:G9B6&1J9#-C8VMT<3%Y:4Q&)B-X03M+
M235':DE6:V1Z5FI'>%AK0E5E*S)2>6%355EM5F=G2D)E9F8X-5 V=C5H,"]4
M+TQ%5V@S>C).,68S-U=P9%A:5E!Q2V]8;GAR<T0W)B-X03M:1%1Z-%-4=#A1
M1#DW3T]P;&E.>#1D+S4P67DO,U%,>$\X.'8O;2]*3F-Y9C1T3$<S;E<S;E=(
M54QQ37%40W-G6EE/2U-B.&=O:E90)B-X03M56FHX2T=O2FY+66MB22MW1#=N
M2'I:2C5*1U)Q+TE#22M544(Y:4-I,'(X,4QI2C)S+TYT>&-4>#)J,WAS+W(Q
M-TA/66\U1VDR5U%+)B-X03MT6&%.=4$U5D\S47-O3$QH0F%G2E!F=BMC5'18
M,5A64'DV,4<T,4\Y;G9P,3%E84Y:<FU6-6Y#0S%T:49$3U=.2W-45$M-;S-B
M<U(R)B-X03ME:BMD3'I33D@P-"M93E)&-#AD;3A%66ET3'53,T1.4&-*0VY*
M1%!B5S5(3U5C:DEA8V9U>3-48U5J=U)R92M90C9E-&XU3UIJ,4US)B-X03MC
M5$5#3DAV:D5N-$5G:V9!<%1:+VTW-61U-VE3,FIS-RM+-6IL:6EE2S1H5S-)
M.6179$=*;&113FLK>"]E94-:661$36(R2RMF-"LW)B-X03MZ8V)I4E=K9FU8
M;VUO-C-B84TY<F0R3C-E4GE35VHS2U)R1DPV8VIX.%5:2&,Q8C!M6E%W1E%0
M2&))-4Y(2TU42W=116=V368K8V]T)B-X03MB.'I73W!E4W)$461187=M,5=A
M.'0R64]547-8=%5J3&M6,E5Y2'1K3E!0:',W9D5!+V5Y:G%:-&HV94AF*V1'
M378X061!=DAR;E)0)B-X03MZ9&MR9&YZ6DHV6FXK<GEE:F989TM.-E!Q<E<S
M4D),5FQ!2$)9*UE9,%I2:S530DXP-"M38W!Y36I7+V-+2'E&069!24<S<U!Z
M5'9.)B-X03M.;G9R2'I:9%A,,CES3'E3>%<K=E9U9E-,4TQ655E"5W(V3$5!
M3E5I;F1G35I#24Q73TIL6"M+=DTO.$$P3% K:V8P>&4O<$0O169O)B-X03LO
M6%!R379R96XY6')W.51L>30Q-U9Y1D1I6E=E1CE3-G0U;CAQ,BMS5W9L+U5:
M,&95-VXP-VDR<U1%.'A00U-S8VYW;S9R>&MJ<7!0)B-X03M1:75$2&=Y1TIN
M2#92-6=/9D1!6E)-<FI1-S520BM!2D)0=T-0,4Q1.48Q4F]7,4Q4-V$K83,U
M96<Q>D1(35DK64%B:'I$8V560E=M)B-X03M6=WE3:CE*26%A56)4>70U67,W
M,D\K=$Y)<W)E.6A1>'A8559V16MQ25%&2W$V<4=#.%)39T]'5V%:1D=2<C-O
M<#5B+T%--4HV2'!/)B-X03MS86(U9F=V=&0O454P5C-*3%IZ0T(U,V5254%O
M;D)K2W-T45)V;'5L=WIY16E)=C5$-S)C9$Y,3'-$158O3VQ'4#)Y26900RM6
M+TI')B-X03MK86E:669Z2FMT8CA#<'5,8E0W=FY35E$S.3=&269T2S(K+WIY
M56=184DK,$]0:W=M16I%:U=/-&=J-6=K26U4+T0P:4]K;C5T-F<V)B-X03M3
M;S!C:71:86E1>4UP5FQ91UAD4W!O4C1:2#1-2S@S,$PO>FI$<'5G-F8U0W8T
M9$8Q:CE.5W)A<DTW,U@Q85,P-'E',W1W62M%<$Q')B-X03MI9TAL-RLR5EI$
M=3(T>%%E:&%T-6XX<3(K<U=V;"]56C!F53=N,#=I,G-413AX4$-3<V-N=V\V
M<GAK:G%P4%%I=51X-$UH:5IX*VME)B-X03M91&Q1=T=55$LT,$\K55%F9T-1
M5#A!;4=O-DIO,G!M239L65<Q.%E#>&<K<WA*3'=,0VIC95EB:E5D85I81$I+
M4$EK3DM(=&9+=FQI)B-X03LP=EER-C P97ET-S9&1$A$9%)7,%-3;VA8:596
M,55-0GA&2T$Y36Q,3DUI:DDQ-S!5.&DO-7E8.',V5')D>#5783DQ+SE"6$9O
M8C$W)B-X03M2;'0S;F52:CE82DMM3C!+1U!G1#E0=&QU;7=Z;F9#3"M)2#-S
M-#9A5U4W1TER*V1+368Y,%$X16DX<V533D1V<&QT9GI+:W-R=%%9)B-X03M:
M6DQ45#=S17%A17(V:TUL1U4P2&5M1U9J66HW6$=N:#1$4DEV>3,K,&));5$K
M6#5)-VE/5#@R.5%E3SA5>#-A3EIA:59L4FPT;%I!)B-X03M:9FI"6&%H-UI(
M-$UA.#)B+W=#2&9*4"]!14QV.5(O>%@O=4DO5"]Q+W!F.4@S2#DY-D904BMR
M.'5F5&9L5VU2<SA82FQW:F@U=G!,)B-X03MZ9F)A.5!O:G(U9EE2875:<EE1
M>B]U9U5I3GI(.5E)86%/9$(K-#4O-W)9*T%*<&MC2F=*978V9"]U,BLQ=EER
M9#(S-7973C)%83A')B-X03MS,E4P<V)+.6I(85=S<V%O:$5Q>6975T%#4TU2
M4E4U4'-F,VDW1$UQ2G=%8W5%*V1N-W9X-4E895A:9GI7:CAZ5TUE<%%Y>39&
M2D1,)B-X03LY9F4U*V],-E5H9&UJ-$YB4U!+,T9/2T-Q,%!X5E!1-$UV9T="
M<C9U;E X05-O64XO=T$U6DYA3'!V;$DS<$ES=C!M9G)D3U@Y>GA8)B-X03LQ
M4'-F1CEM=E1F36)&,5E:2&AT=F9F:S-C,V1X0RMM>E=3*W9Z=$QQ5U,U3G0V
M87A"94UK56)4>CA42E8K06)K,G<Y5D%D<F0R1WEO)B-X03MS4#521S)M:G5R
M:4%U3$M54C-&;TY35U4S6EHR:C1P3$=9=4MO23!(2VY).'586&MP:U-39T%0
M9"]W1&Y$+SA!.&QP<68O8EIN+S9H)B-X03MB6$MC=DYS>#AN<DAN0S,Q*V)2
M2D8X=DU)=%E-,7-)6GHV44M21S5J*W-%3DY(3V<O8V,O.3%S9D%%,'AW1T%L
M-B]P,RLW8C=7>&ET)B-X03MZ82]N0EI80V@W>&19=%I:66UR65(R;'1):6]H
M17%V.5I)06ID:4M+;DHY:BLX6'!M5D=703E/12MD;C=V-U!*0R]Y-THK87-F
M;5=W)B-X03MJ,4M'85A1-4E:=G(W,U V4%%24T9M95!G8EHS;5EQ=D)"5F%(
M-'52-DA";#A!=TYF5C K<CE/>6@U<B]!335A>3)C97)E46IF;'8P)B-X03MD
M-CDW.6564WDQ9S4R;G%$-%!I*WI8<'9M4&DV<TUN4C1Z65AV-5(S<$UC*VYY
M85I-:W!D8FE:-VU3,F5)4F-/3%)1=DQ-0S!P.51G)B-X03M(1D%+96]A-5IU
M,3=+,$YV*U5Z851F45AL,V)I*VES>CE4=G)29%,Y4U,V0FMC0EEP63%H<%0P
M-'AZ2S%O4V%6-4%Y2DI504IZ+S8V)B-X03LQ+S1-,R]9=FMF-&LO=T%,-B\Q
M;3EM,"]H9C-'<#)7;F%01'A&-#DU1U(Y<'=O<&-'94M/4&M70VIK:F(O9&Q5
M5$-J64XK+SE&9G!C)B-X03LR17-80U))4TUU:$5G0CA2=VTO;4<S.'IE6%52
M,V)63%1I:VEW=%-A36XQ6%AK:V1!83@R6&16-FYT;&)3=3 W>D9O1W!30TQ4
M.5)T)B-X03MR<5EQ>BMJ1DMJ>4)58F<U2T$X:'A9.%=Q3FIS9#A6959F.$%/
M4W9M2TA2=$HP17EA3%HV-&)Q-VMI:71R>454:T]52$5X9S$S4%1P)B-X03MV
M;&U/55%F54-F8V$O45<W0V-6+W9)>6M02U%J.3A:4$)B+WIF<D,S9F\R=C5B
M859$>&1,9#1:.4ED<$)C;$]::BM(:#A26#1L5VQA)B-X03M9>FYV-F)!.3DO
M;T1$2TU:4&]"03AZ9C(P4'558FYZ6C5M=&]0<D4O-60V1VQV-E)N.6,V4$E9
M+U-(2&LO35!X;W9-0G0O:$]X;V-J)B-X03MX;'(T42MI4"MC679-2#9D.&A8
M.3,K:F)(4RM'<7I29E8Y3F<K<G=T4S-T,C5S;DIQ=6560V9!1$%486%P-E9R
M3C=.<"]#+W5.5'-T)B-X03M/,&5(:4QX-WE-:C=4:%)3-$TX56-F27-&2$I'
M,RLW2GA-2TYG,S<O04Y&9G!B;U-X8TI%:$EY-D5304AX2$-B*UEB8GI,-615
M351Q)B-X03ML<%)*1FAB.2]'85-Y1&MK9C)V='-.,5AQ8W)A5C)N95ET03%+
M45)A9G%.=&141E=F,%EP56512VIC2$I12&M/3$AI,5)S9&IV:7)X)B-X03LS
M+VY*;GI.0F\P+VQA0CE!<SEE;78R=D5T-')U05A$<39M,T%72E-#875806]/
M=$)L=4]54CE12CEX<CE"8G-*>%@K.&I+43AP0U S)B-X03MX:SA2=B].,G1R
M971&8B]L='!536)3;4='1V92-4=L-6A0531';D-R.%!I;T(P,W=3;G9T9&4O
M*WAH:T=-;C!G9V5:=CE!*S53=5!.)B-X03MV;5,R=%1D>F9L,V]A5VEX<DTQ
M,2MI2$U):EEH435K1#A+8VU#.65U,UA).%IA*T5--B]X,R\Q:G@K;68X4&%,
M+W=!9"]W0W(O;S<V)B-X03MN+V]F.7AY.50P968Y-3(U5C993TEP-%$K;4YB
M<V1*,6944EHS,#%,5U-71UE.2$PV6DQ7<S94<'AD4T-0:FI&94IR.'-E13EZ
M35DU)B-X03MC<4Q(3'(X=2]*3%AA,V5M>7)O,#1)37)70G0P.5)60D-O,W%X
M>F-56&LS=TIX53%024A$=TAU5#15*S0O2F1P=FM4>35983=:-GEU)B-X03MQ
M5%,S3FI%,$U333%N1VA6-FLX=E)H:6,O17I(-U9..39I9W@T1#-,-%4K-"]*
M:#,O3U)0;&IZ4#5N<U!,>F563&5(54QZ4S<T,U5I)B-X03M.8U<X455+;S1%
M*W1*14-/439!-#A"-VPX2V9C9FLX;',O2FXO3U)T=DI+2F1.:'4W2V1I.#)N
M4S,Y9W1S>$MH849)8G%).$M+3U-C)B-X03MU3&9T0G%N2&=08VYW<&1X*U-*
M:3AO+VYX04IV<79L6%0W8WI7<E=*2S9L1W=706@V2W%386DV8D=6:G5P-FM'
M<6MG=D%E-4AH4S=J)B-X03LX;G)V+T].6&LW>D8U4SAJ6"MM-B]A<F%8<W5P
M>3-+4DQ.1%!72C=E0D9B;$$X<6HT;S(R2G)G24DU<UI2235H-E!R;&AP3W)A
M93%J)B-X03MF>3!T+U=G;&)H3#9B0U,R;5-D0GI"1$PX8U$V8BM'4$-5:DA)
M.4-X,C4O3#-Y53$P3')4<%8P86-S<&QE=TYU=G%+9TE336E73UE+)B-X03MI
M.&TK1D])3E17=4AG4&-N=W Y>"M45VYE479,;&IR,6QR839R3DQD5T5B47=X
M<S%N1VA6*U)04#!)66Y0>$]Z5355<60Y<4%0064U)B-X03MF0VXS2#5-0R]W
M0V-J4$M0;2]Z3F8K56(W>6AB4E@Y>&]S=#%0351C,C!)4C)A,F%'=G)3>&-Q
M;49V<RM'4$%E-69#;C-(-5!-3D\X)B-X03MK9CA!3U)&;W)W>C980G%&:S5*
M3FIC,SEI24ML4D=0:&=U;V9H0U954C$T54HK2&9(9U!C;G=P9'@K4TEH.&UF
M;FYB,C$Y8C(O;%!4)B-X03M9-#<V,BMP<U P:DA)<V-15F=O4DID4F1$>#E2
M=G1Q=TY31%5B63A"-VME1E!U4'E45"]L52]N>B]L468K1E P9D@K;B]W0D\O
M6'9Q)B-X03MF,7EZ+W="-2]2-&,O53EB,'9T9'569F)(9U!C=FA4-VHX;C!"
M<FUL-F1P.7!&3$IC-F)P96<R<'!C0SEH64Q7961786LS,6E"13E3)B-X03M8
M:E1K<F9(43=N36Y&;$I*,FQ+6C=J,T1U;R\R3UIJ,3%82V9'6FYQ2D%C:%$R
M351Y1S--8F))139"*U591$@V<F\Y1FQ&=6%E9V8S)B-X03MX0DEI,E R>4)S
M=EA*:E!Q92MF,G-V-6(Q9CA!<7,O.4U6,6@U8R]+9E5*,G0W0WHP:39U1D1-
M.$50;U!);U9U1$9K56QH>&(T5%5B)B-X03M(8D)056%M4$UY2'I59'0V=B]6
M6B]W0VU,>C<X.3=N4E!)96XV3E!O,VQN5#=Q8E5R;#=9=W1B2S=%:%%50T%$
M<51T4VU4=S9Y6E!Q)B-X03ML22LV5F9O3%I$=#=54E W>65742]O>C1F=FI*
M-#-E+VUB-35I=6UJ6'E(<#!!.5IB6EEP=$MM36=N6D))26IU;GAS<#5"859P
M:S5A)B-X03MQ9#=3;%AV+T%,1VI.,B]Q>DDX1U1)23EX;%HK9%(K-5-M+TTW
M>C=$8FTU;#AK85-L<T9A47IN4W!F5$-O47)K=GHT+T-X;S(K>#)/)B-X03LK
M039J2U T-69.<2]L+UAF-G)0-6PY068X-# K6C5V33-K;E5.575,0WES2C Q
M2U,R2V%F1#9%8DI(0D,V;&Q,4%9Q>71V6$U455I*)B-X03M34'%*4'9A<VUT
M>F%J9DQ)>4DW,F)A+W!U;E=)9E5:-VY43DTP=FU(,4-A*VA)-4Y->&IB.2\X
M05=)150Q4%8T9D5P<5<W,7!L;4A+)B-X03M4=%5P4S959C!5951L-'1D=WAQ
M6$=33U9304$W=&I%.&E",4-#9E)F>6QL3'ET1&\X:DY-25AF;$%X33=G<TEY
M86MM4G%%.&5P>5EZ)B-X03MA;FQC=G133S)D5T)1>7IR,W0R2&QZ.' Y46YA
M,W-,4%-,<31537IW42MG.&EH5S1-5U)35TA&=FA.4G-D<T4Y4G%9.'I)9DY)
M-V(Q)B-X03MF*W%Z+W="35AM9C4Y87!O+VM+8GDW0F]V;&94-W5B5U=U:TU4
M5WEU-65%=T-.54%&4U=->#)Y>D)Q-6TK2U5J-W!6*V=T:T\S<SA4)B-X03LK
M.&YL;"]6;G<O9D=4>6$T+TTS>GHY84554&M05&LY4U%W=W=Y851-,&AL4F54
M>#=&87-O0DI!1E%-37143SEP>7(S=5!K-V8Q:&ME)B-X03M(2FM%96QY<R]0
M8C=G<%,O;6@U-VES:F9Y95-D2E=X54)M=7IP579O9T5L9#5/9D0W44DV.61S
M5'%-;TYC8W9M,2]Y+W)V.$%66B]-)B-X03MS=2]X,R]Y0D@O1W8K2'1%+U1(
M-F$O4C-(-FXK-3E(,&5F,D]D959E+TQ)9FUC=D982$PU<R\U9#%V1&9I>BM:
M9E1U=F%(6C8U<' P)B-X03LV.&%68F1P64HR341M2U1L8E1P8TE!-B]%=%AI
M1E-P0G P24\K66U,25E'>#4O84MC26A+<E@X='9*1FYC=F,R96Q*87I30TY8
M84(U)B-X03M9:'=I0D-*>%(Q05-J1W%5-&YU371/<GE%551A2U5R5#AT.4%T
M4$U.<G)K16LV5#)3>5(R,75R4G)%<5-L;4MK<6=L66-P1U!X3V5U)B-X03LY
M8TUT6$UW350Q5VU"9CA!3U,S;')Z4G)7;F57-69,,6MT-V1A8F9M-F%.<$DT
M,4A&459R-FIX,4)99&IL3TUG8S)V24-E5'A.=DQV)B-X03LO3U)*1GEI,C53
M0S99=$YB<DQP+W!%1E%P:C1&>5!42W)2:RMY,CE186UT='AA-FMU,'9Y>BME
M96Y14U)W-DA!-WDR>C)44W9.8D$O)B-X03M6-4=D>6YP<&-*1CEQ5GIU;%15
M9S%"27A-9V5Q,4HW;B]W031W*U9D93AS*U%B*W<Q=3$K<5AC=7%Z5'!(-FMC
M;%DR=')D03%9;61F)B-X03MT264K5EI$6F)C44E$,#=8=$1S.6,P,#9D94Y+
M='4P<T4W1T)Z1DIY=' P=45!9&9I5W)X0W!59S V14AF2$9K3419."]T1DYH
M0U4R)B-X03MV-6%E4C=3-64U<SE+4S%M:SE-33!$>7A$:D5#<4E!:G%!;$=.
M54$T;G5$;' Q955I:6)2454W5#AT+TPY<#5G=&1C9V5D3&EY5C!T)B-X03MO
M1EI&:59*0S5+2&EI>4UV2U)J.%1N,W=Y,6-Z07A05F%E868X-4YE5G9.*W-A
M:C5.=CA!>3%:0SAN,&EA-VYF;$I&1T9F;&)01E@Q)B-X03M(:DI"35(K>6-Q
M>&MB,C$U45164$A$-58O=T-C9WIA=%IM,3578D]R;3)-;6UM3#1)+U-69E1,
M8V5!:BM%2E1J5'1L;'AA<6MR85(U)B-X03M7+T\W4SE.=7)#2'DO8E-*9#)X
M<S5*2EIR8VM1;C%+05)I-%=(67I/9FE1,7%E5F-424AQ;7!-;"]W0U9:9650
M*VAD+SA0.$$V3B\S)B-X03M,+S1G*W0O5G98="\W;C!/4$QN-FY$<C(U5GE0
M14]*4$-E1VYV9FXO044W4C=*679.,&UM2%4Y6'-(=&)7>FA-<S9O9G).,&M)
M*T-*)B-X03M,:7!5>F-V:&E::C!Y>E1:2FTX66QW>$YK+T%F1#<S3VAQ8W-)
M;4U:4T54>D%*05!V0VQA*V4O3E4Y>$IB>2M53'EZ6DI)5DUS>G,X)B-X03MF
M0U9'66M.1$9*>61#;T)!*T1F95%D34HP.$%,-'=F>"M04'EA1DA24'I55S@X
M,E<S;&TK<T5T8C(V:FU:4%-U4E!):G=Y379#5T5))B-X03MR>&YI;DIQ+UIQ
M=&5T8T]44C%!>D)S1'E51FA(+T]5>'5J82M566)A63(X='IQ5%<O<6=C9T)+
M<6EP5V]$8C!.1&M.3&YN:DI-5%1:)B-X03M$535C4G9(2U5#9C5P22LU-$AQ
M4&MF44HW;3=M=69/,7),4&)Z<&)S<WE,-CAI3$-O2$-K>E)L9S%)>"LX.4U$
M9'!&;U%$3$I);7IU)B-X03M7:DQ/5U-2;$]2;$DY5'57=% X07ES=#E5,#9A
M.7-.5TI71S!L=6UE4S,O,&9L13=Q251C>'E327)S:V9.:%0T07DQ<4]42WEK
M05=S)B-X03M292\O05!/2"]W1#5,5%4O*S)Z4"]W0E%T<FQ/6&TR62M4,$1Z
M+W R:C)3>&5B<$Y-3W V=EE083)T;D-:6C%1+U=B<$E2.$536$93)B-X03MP
M;35F1$5Z2'!L,FUY5$XT>$QH:6)**T$K2#-U5D15-5E235EY:TEN;4%3069E
M1D\P.#EE87 W:#1*=DM&,UIL2DEL.5=7479(-F-Q)B-X03M->D5'1TM3<VE&
M44-O*T1F95%D34HP.$%,-'=F>"M04'EA1D124'I23C4U<G1F3&PY<'E7=#%D
M2DU684LU13=O.$QU=D-A14ER>#%3)B-X03M-<V%N-&%G9#8T8VUJ<4)M1%E(
M:V],>G8O;DME93@O5%!K4WET-V=7,S$K93AT,VU+.'=G:V4P5&U5<4]82&Q7
M;5$P=65E3WI%,#)1)B-X03LQ3UA%9C-C<%%V.$%M:VHW;FAD-S5/.'8S:G9F
M>65C-V4T;FMU1$A/:W%X<F-(.7IZ3$-S+W!..&1)-BMQ13=H>4)H37E4=30K
M4V-P)B-X03MN:6MB4&UU,'(X<2\P=C5F=DY7,#=56%HW3S!A.&5/4S-P8FM)
M6D]39E=X25DQ25-,:S-)9D1Y05!C:&Q)07-"2%IK4"]R<E@O9WIF)B-X03LY
M:2M2+VE4+T%!=G-E-'9B;4LX:&=J,"LT=4EP86,W=4YO0D9(53 K35-3<$IT
M,2M&1&Q564%G;7=03&8Y5F9A-7--551%>4TT9VIO)B-X03ME2WHW<6E2.'E%
M6&QB4S=&6&I(+T%$:S%$-4QM,%A213@Q5%AS1G-,;54R>C)0<%8U*VU+:"]5
M5BLS4V=Y-T16-VM2.3DO;T)B8U=#)B-X03M/43%+8UEE+VDO,W-:4&Y3.'0O
M>4QT-5)';'@U:7515E9V56@K<&-2>49E4'AQ:'%/*S)'95-J44E0>B]!13 Q
M-6101TIO4T5V35@K)B-X03MK02]9;U8O23<O=C5V*S5F:V9&3%@T4694;B]/
M368X06A8+T%6+SA!-%HK=F954#!R3C9V-E,Y2#%V5RMR,B],:C9(=SA/4$=N
M971C)B-X03MH2U9S:$=N<59X93--5C5$0DAP.7AC4E,P-3-C8E%#2T]P<#A9
M:VQ35&)R.$M(2E)G0T-B03AT+S%6.7)F1$9%>$UJ3TE)-DAI<RLV)B-X03MO
M:V9-:$8U5S!U>%8T5B]Z:R]B95$U=CA.9C1S=4PV,S0O6'9Q6#%$,'0V+U8O
M534K;W(O04]44VYV;#)'=7!%9F9F-D%7,T9G:FM0)B-X03MQ;D=(=C1V.3='
M5'='-V<O27DS=4AH4V9Z1F-+:&]*;V9Q6$)V9&5A;S,T65I:2T\Q2#4O<&%S
M;4--5%%K2F59=CE)0E5A+VMD+S,X)B-X03LS+V-V>5!I;&@T465N5B],3"]O
M6&HO<&1F-&8O044O+T%-=6XQ>C9X-D@O27(P*U P,7E0:4<W5'=B52ML4$YE
M:S9H<3)I4U=&:&5.)B-X03M96$5K,7,S,7!(;&I94GA816-K<6AO6&EK*T]*
M1U0T6$A8<4UG>5-/3'E$<DM45&5R-7$Q0S9T6DI);D9V3V1G23%:5T)A2F]I
M969,)B-X03MD9&\Y:%9#86MQ<4=I955V3U=L*V%,5V1.5$UM9U%X>E)4450S
M:SEW>F@S3&]Y=U!%15%J-%9&2F9G03)Q1%1&6&YN+T%$;'108C(K)B-X03ML
M*U4W:35J.6$R:#%.<$IO4T$S3D911FQO,GAQ0E1F1EAG8W8U:"M8;4YX>#AO
M86-7;'5&;6AN2V]R>'%)>$=115=-42M,0E1(-F1D)B-X03LR4GE.,4M)<R]0
M6&LV87=L5%=.16EL;2MO=EIW>'A7:TE94%$K;D]B;U-24V-G3T-J.3-206\T
M-V-L6E8W.2]Z:#DO-4Q452\K,C%0)B-X03LO=T)1=')I:#8U-7(P;E5.5S!3
M4W=S3'AR0S1K;71M*W1).'-B0T]+-&IK;%5.0SA5;GAX27EF0S0V.5)I<5)1
M*U%.86IN;6%8>EAQ)B-X03M.,6)34WA33&)Z='-"1W)+=TQ23D54>C5B<CEJ
M6591;7!+<6IO;FQ,>FQP;FUE,G5&,5%Y841#:W-5,7909'HS1%-+-TTV3W-$
M>$MK)B-X03MB1#16045L14$R<4141EAL9B]/6%8Q8E=M<F518G4V:$9Z8E<X
M.3=,4&)S07EY4F\Y;7I)5F)9:&=+54]+6&E,9FU$;U1P4B]+5VYE)B-X03MO
M2B]75V1%:E9W;F\K;'A+:4PP4V0K6G)(=S5525%D,5546BMD4$HP*V@S;'1R
M5VQ+.30Y:4Q7,6$S<W)F;7-S9%-K<'5Z26MG2BM%)B-X03M6.4TX44M56F%Q
M>7))4#A!,3%N+T%-1V8O<UAX5B\O6CPO>&UP1TEM9SII;6%G93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'AM<$U-.DEN<W1A
M;F-E240^>&UP+FEI9#HT,C<X.#$R-2TX,V0Y+30U.#8M8C(X,2TS,C1A-30Y
M-V$W,30\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z-#(W.#@Q,C4M.#-D.2TT-3@V+6(R.#$M,S(T834T
M.3=A-S$T/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP
M1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.E)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC
M94E$/G5U:60Z9C@P965F.#DM9C<R92UD830X+3@W,S@M-&4P96$W93=D,3=A
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.F(Q-# U-C(S+65E9F(M-&)D9BUB9C(R+34S9C4U,#,T
M.3(S9CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y
M,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\+W-T4F5F.G)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z,34T,S1A,S$M83 X82UB.#1F+6)F,F0M-&$S,6)F-#(R
M,F1D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(T+3$R+3 T5#$T.C,V.C(Q+3 X.C P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B R."XW("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-#(W.#@Q,C4M.#-D.2TT-3@V+6(R.#$M,S(T834T.3=A-S$T/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(U+3 Q+3$T5# X.C(Y.C4T+3 X.C P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R
M871O<B R."XW("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QI
M;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z
M4W1A<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R
M4W5B5&]O;#Y!25)O8FEN/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#X*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q-RXP
M,#PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_^  $$I&248  0(! E@"6   _^T +%!H
M;W1O<VAO<" S+C  .$))30/M       0 E@    !  $"6     $  ?_; (0
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M]O?X^?K_V@ , P   1$"$0 _ -_
M
M
M
M
M
M
M
M
M             '__T-_
M
M
M
M
M
M
M
M
M     '__T=_
M
M
M
M
M
M
M
M                                                         '__
MTM_
M
M
M
M
M
M
M
M                                                 '__T]_
M
M
M
M
M
M
M
M
M                                         '__U-_
M
M
M
M
M
M
M
M
M                                 '__U=_
M
M
M
M
M
M
M
M
M                         '__UM_
M
M
M
M
M
M
M
M
M                 '__U]_
M
M
M
M
M
M
M
M
M         '__T-_
M
M
M
M
M
M
M
M
M '__T=_
M
M
M
M
M
M
M
M                                                     '__TM_
M
M
M
M
M
M
M
M
M                                             '__T]_
M
M
M
M
M
M
M
M
M                                     '__U-_
M
M
M
M
M
M
M
M
M                             '__U=_
M
M
M
M
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MBNBY3UZ)BJF>V)UA_<_-_0
M
M
M                                             !__UM_
M
M
M
M
M
M     =4][<S-%Z!I)MV2Y)\OYBPFM*8-B-(]XR!IVM.Z47:OQ#%LQ]/WR55I
M-?9>4VKR;;<_!6P[O-QF\'>/U,3E6%]39)5_CO$ZV[,Q_2_%FN]VQK:HJIBJ
M-*JJ>;A&TV\'9K9?6UC+WA<?'ZS:TJKU_;<8IH^[JB=.,1+R:VEU3-W94Y)B
M:ULV.ZPM*E5I'F5CM9;E/M]O&ONS[S&I8&Z.4^^\46WS;K7M1Q7;O7[*V1Z(
M>P.3TTWMJK^*S;&1'C4ZSAL/KY*+57AITY:S?TGMHC72(;G6^O:/&S-O)[=K
M!6.R=(NW/PJXZGHMZQWSS=%\QWEN38*GOGIM'.\C9?5Y+@W+)[N[:D_3W\6+
M0F4BUQD=Z=_%ME">_P"L?0>1[O\ 8;9J*?D#E&786NF.%=%BW%SV[G5FY5/E
MJJF4TS#:3:#-9GY(XW%7J9[*KE75]JG7JQ[40XK.7O2 'WMARC)L6E?'8QD5
M]QR;2M*TF6&[S[1*I5/\K7XBWR([O=/ZWT_0>OS'*,JS>SZGS;"X?%6/8WK=
M%RG\&NFJ/<>5AL;C,%7X3!W;MFYWT554SZ:9B7;_ %GU">3NN76&I.:IV%:&
MZHHY:=AQ?EYQQ-*IHM5+^T["RBCU44[4JN:XW17TU0JO?O$]J^C5NGVHHJKM
M8"<LQL\KF"J\#$?Y#,56-->ZU$Z<(JCLY[D^]7;+**HIKQ'JNQ'UM^.O_9\+
MFOGKF/)+U/T5U+M-;+=AV+8C#FHLH?HEI,B\36Y^$S'^Z$4HSDU&HB[2IZM5
M+\9[#$=I-/'XAQ7;R^0MX714VYV4HKS#9FJ,ZRBGCU;5,T8JF.,\;&M7A-.$
M:V:ZZZIX^"IC72U[-;X=G\XJIPV;1. QL]M4]:S,^2YI'5UY^/3%,<NO,\_1
MUA]B4PS)C/-2(\AIM^/(8<0ZP^PZBCC3S+K=5-NM.MJHI*DUK15*]Z'R]<MW
M+5RJU=IFF[3,Q,3$Q,3$Z3$Q/&)B>$Q/&)5NFJFNF*Z)B:)C6)CC$Q/*8GN?
MU/X?T
M
M
M                         #__U]_
M
M
M
M
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M;S/++D7,)<C6)CG$]M-4<Z:J9X3$\8E^W/0/9
M
M
M                                                        !__0
MW\
M
M
M
M
M            /\.NMLMN//.(:9:0MUUUU:6VVFVTU4MQQ:JT2A"$TK6M:UI2
ME*']4457*HHHB:JZITB(XS,SRB([9E_DS%,355,13$<99S^=?,VX[OR&?K;7
M]S=C:>Q^?[3K\52F5; NT!ZM/EB:XE=:NXY&D-^5NCUI1+G:DEU-7*M(8[/.
MCWN+PNP&66]J=I+45[;XFWK$5<?4=NN/H=,:<+]5,Z7J^,QQM43%/7FY\F;R
M]X5W:3%U91E=<QD%JK36.'AZJ9]?/?;B?64]OKZN/5BGSE/I])
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M*J:HG6*J9C6)B>V)CC#[ \9^H
M
M
M                                           __]'?P
M
M
M
M
M                                                           \
MO.IER,>UU@$/3>+3E1\MV9"?=R&1'71+]IP!#CL.6S6M*T<:>RJ8VN*E5*5I
M6*Q*37QJI%3ZVZ*6["C:?:2O;C-[<59-E5<19BJ.%S&:153/=,8>F8N3'#YY
M79GC$50B^^+:VK*<KIV?P56F.QE,S<F.=-CE,>2;DZTQ^UBOMF)9]3LG?+
M           'N_TM-^.Y+B5]T3D4Y3]UPEMS(L*5(<JMU_$9LMMJZVIM2JU4
MI%@O,I#C=*UK7V9U$)I1#-*4Z\.EWNYHRK.</O#RRW%.#Q\Q9Q75CA&)IIF;
M=R?Z]:IF)_;6NM.M5?'Z:W*[43C,#=V9Q=6M_#1X2SKSFU,^-3]Q7,3'DKTC
MA3P];CXQ74
M
M
M                            ?__2W\
M
M
M
M
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M5D6U."S'72U3>BFO^MW/$K]%-4S'EB)[-8UFG36^Y@
M
M
M                                                           !
M_]/?P
M
M
M
M
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M:@
M
M
M                  '_U-_
M
M
M
M
M                                '4CG:M;?$O<ZFUJ0JMBLZ*J0JJ:U
M0[EE@;=16J>U:H<;75*J?@JFM:5^BI9^CS335OER**HB8]479X]\8>],3[4Q
MK'=+@N\R9C8;,9CA/@J?=NT,M)V[/BH               UF\4D.M\:=$I>0
MXA==686M*74J2JK3MCB.1UTHNE*U;<86E2*_@JBM*T^BM#IJWQ545;U=H9MS
M$T_)?%1P[XNU1,>>)B8GNG77B^YMB(JC8_+(JUB?45GT31&GN<O([ $W<I
M
M
M
M               /_]7?P
M
M
M
M
M                             !UOY?X^YDW&+=UK9:4^ZW@%YO*&D^7F
MM6-(;R2GA1+C2EKI\D]TII6OE6G;Q5W\:U'<GF5.4[V,@Q=<]6B<RM6IGLCP
M\S8X\)TCYYQGLYZQSCB.WN%G&;&YE9IC6J,+77_!_//\S_-/*<H1W&/AX
M          !_I"%NK0VVA3CCBDH;;0FJUK6NM$H0A":54I2E5I2E*4[UJ?Y5
M5313-54Q%,1K,SRB.^7^Q$S.D<9EL4UGC*L+UQK_  Y:4H7B>$8IC*TI55:4
MJL-A@6M24KK]*DTK%^BOZYTA;5YK&>[49EGE,ZTXS'XB_P#PUZNY_FGWYD^#
MG+LHPN7SSL8:U;_ HII^!^W/0/9
M
M
M                                            '__6W\
M
M
M
M
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MN1>N=W4M3%4Q/DJJBFCSU1RYQJJ.GY]M
M
M
M                                                  #_U]_
M
M
M
M
M
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MQ,1Z:'RBL8
M
M
M                            _]#?P
M
M
M
M
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M"'^S^7^@
M
M
M                         #__T=_
M
M
M
M
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MNFUA+5,4TTTQI$1'^&LS/&9UF9F9F7WQZYY0
M
M
M                                                       ?_]+?
MP
M
M
M
M
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M*4^BE*4/FJ9F9UGFJG+A')_T
M
M
M                                             /_3W\
M
M
M
M
M
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M\F(?L#TCV
M
M
M                                 !__U-_
M
M
M
M
M
M
M
M
M                         '__U=_
M
M
M
M
M
M
M
M
M                 '__UM_
M
M
M
M
M
M
M
M
M         '__U]_
M
M
M
M
M
M
M
M
M '__T-_
M
M
M
M
M
M
M
M                                                     '__T=_
M
M
M
M
M
M
M
M
M                                             '__TM_
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MTXFO=*DUJFM/P$ZKMUVJYMW(FFY3.DQ,:3$]TQ/&)>7$Q/&.3Y)_(
M                                              #\)EFTM98'7MG.
MQ<$PRM%,HK3+,NQ_':T5(2M<=/:\7"'7R?0TJJ*?Y%1-:T[]J]O8X+)\VS'Z
M7X7$7^?T.W77RY^MIGEVOXJN44>NF(\\NLF4]2?IWX4EWYU<[>'UD>:85)K!
MF<D=/TNKK"75,J7%M#>8.729V=0I/9IE=?)-:=OHKVY;@]U.\_,-/4>SN>7*
M9G36,#B>KKSXU>"ZL<.^8?C5C<'3ZZ[;C[J/C==<HZYW22Q!:T7;G5I:75N2
MW$57%Y&39PBKKK"Y"5(<PK'<@;=C4;16BGDUJRA?9"E476B:\HP?1YWU8Z-;
M.SN/IUC7YY%NUVZ?KM=''R<YCCIIQ?C5FF7T\[M/M<?>=>\A]2[T;+&I"(7*
M2]Y2Y54I#R<>T'R"HF.N-5NB$K?O^L;#&D)EJ6KVEL+>17PK52DTJBJN387H
MH;]<1&MS)[=F.&G7QF"XZ^2C$5S&G;$Q$\>&O'3\9SK+HY5S/W-7Q.";UZKO
MI46M4=,%SDCDE'DN5<79=/0&$Q*HJBB42*9#FUA6I3M%5JGVJ.TIXU\JI^CO
MR*QT-=\EZ)FY&56M/98F9U\W4M5\O+I\7Y3GV CEUY]K^=PG>?6!]/9AIFN/
M<?.9=T>4M5)#=YQ+2-B:::HG[U;+L+>N1J?757T52I#=*4^GRK^ Y!8Z#^\V
MJ9]4YGD-%.G#JW,77Z8G"4:>F7Y3M#A/K:+GHI_2EQ)>O6.<;6*3_F[PTWA=
M5-J<^2Z7K/L"L%)B:*[-5GU@QLDK;5+1]*J-TE^-?HI57X3W6'Z#&U=75]59
M[E]$3Z[J6;U>GFUFCK>WU?:?Q.T5GLMU>F'%]Y]9GBS#;-<?Z>N07-Y2U4D-
MWGD[;K$VTW1/WJV786ALB4^NJOHJE2&Z4I]/E7\![>QT$L95,^J=IK5%.G#J
MX"JOTQ.,HT],OSG:.GZVS/X7][+CV\>LRRQ]]I6/]/?';9&HUXO,WCDU<KZ^
MX_YJK[C4B%HK'6V6O;JFGA5I:O*E:^7:M*4]G8Z"6"IIF,3M-=KKUX33@*:(
MT\TXNO6?+K'F[_XG:.KZVS'X7][#\->/61;W??:5C_"34ELC4:[/,WC:^8WU
M]Q_S57W&I$+&<=;9:]NJ:>%6EJ\J5KY=JTI3V-CH+;.TTS&)V@QM=>O":</:
MHC3S3<KUGRZQYN_^9VBN]EJGTR_,W+UC'*AV$\W9^(7'Z!<5>W\/*N65[&NT
M)KL\W5[WK?%G65^1YL44E/C);\%UHJOE1-4*\NUT&=CXN1-_/,RJM=L4V[%,
MSPX:53%<1Q_:SPX<.<?S.T5_LMT:^>7Y3[L,YP_BR<4_ZGV[_"4>9\P[N^^V
M^<^G#?R#_/EBQ/L+?N_&?=AG.'\63BG_ %/MW^$H?,.[OOMOG/IPW\@?+%B?
M86_=^,^[#.</XLG%/^I]N_PE#YAW=]]M\Y].&_D#Y8L3["W[OQGW89SA_%DX
MI_U/MW^$H?,.[OOMOG/IPW\@?+%B?86_=^,^[#.</XLG%/\ J?;O\)0^8=W?
M?;?.?3AOY ^6+$^PM^[\;YUL]8AS.:FLN7CBQQAGVY/N?$1;9)VK:9KO=ERC
M/LW"5FUZ8C^#]4J5Y1G/-":IIXUK1:?SN]!S82;<Q8SC-Z;O9-48>J(X\=:8
MM43/#]M''CQY2C:+$]MNC3V_C?K/NQSDK^)MHW_#YGW_ )R>%\PQLI]O<P_@
M;/QOZ^6*]]CI],OUEO\ 64;;;AL(NO!/7,VX)2KXF5;]X9-;(;JO-54U8@R=
M=W=^.FC=:4K14AWNJE:]Z4KVIX=WH*Y+-R9L[18JFUV15A+=4QYYB_3$_@Q\
M?]1M'<[;5.O[J?B?L+/ZS6^,1G$7_IVVFYS*OJ4T_9^5,RQQD1JMM40RY$F\
M>,A=<?2[1=:N4>0FJ5)3X4JFJE>#?Z".'JKUPVU%=%O3E5E\5SKWZQC:.'+A
MI/GXZ1_4;1SVV8U_=?WLOWMJ]9CAKT2B[WT^\GM\[S714:U<E;5>(E&J5_4U
MTFR](6)Y2UT_ED_#THG]92OUO6WN@ECZ:],/M-9JMZ<ZL#53/HC%UQ_9/ZC:
M.GMLSK^Z_O7(5N]8]QV=C157;A?NF%,6E-9K%NV/@UTC1U55]_2++DVRT.RT
MI3]-*K98[U^CM3\)ZR[T&-J(KF+.?8"JWV358O4S/GB*JM/:F7]QM%9[;=7I
MARI:O6#\"'I=$7SCCR]MT#VUU5)M5CTS>9=':4_4T4A2]PV)E3:Z_P LKXBE
M4_K)4>GO=![>131KA\UR2JYW55XJF/3&%KG^Q?I&T.$[:+FGM?'#E?'O5K]+
MN]4C?*6)<M,1]^3[#M,AU1@4FL)KRHGXR3\U-P9/1<;M7R[,^\]VI_*=^U*^
MEQ70LWO8?7P5[);^D:^)B+T:^2/"8:WQ\^D>5^D9_@9YQ<CVH^"9<\8QZGGH
M]7]4=-UWSGN$4><D(<7D^AMORTQ$LM+<;=D4PS$LN6IN6I-$-^U1U5%*IYT0
MGNJG'<7T2-^.&B? Y;AL1I$?0\9AHUU[O"W+?+G.NGDUGA/ZTYWET\ZYCSTS
M\$2['8AUZ>D+G"HZ;+SDU;"K*^"]KYWV?8FO4I^/7[;'Q"L^PO&DP_;5_-O=
MJCX9/WSOA3Z3BN.Z..^W+]?#[/8RK37Z%59O<N>G@;MS7R::];ZW5^U.:Y?5
MRNT^WK'OQ#M7@_48Z?\ LJK#6!\W>)F52Y'A1NUVCD+JB1>DU<6\VTA^Q_.M
M-WBN/*CK\$NL(4M*>Z:5I])P[,-UV\K*M9S+9_.K-$?758+$13V<J_!]6=-8
MUTF='[TXS"5^LNVY^ZCXW:['<JQ?,+>W=\2R2PY1:G4M*:N>.WBWWNWN)?8;
MDL*;FVR1)C+2]&>0XBM%??(715/HK2M>&XK!XO W? 8VU<LWHU\6NFJBKA.D
M\*HB>$Q,3Y8>13535&M,Q,>1]\>,_P!
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M/*\VW>LW?H5=-7FF)]YS:>@?J
M
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M%&;YQ%>G"9]33&O9K'@8UCR:QYX/EBQ/V.W[OQOVOW8YR5_$VT;_ (?,^_\
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MC3E%IS?76/*;<4JO="54HIU/WR**32M:<8QG1JWXX'A?V?Q-6FGT.[AKW/\
MK5^OV^[E.DOVIS;+JN5V/;B8]^':G$.IMTYL]5[6)\[N(EWE^3B:6U/(?5,.
M[J2U5E*WDV>X95$NBHU%2$)H[1FK=5*[456O>E.'8[=+O1RV.MC=G<[HH]EZ
MBQ$T]O#K4VYIUX3PUU?O3C<'7ZV[;_"CXW;;$\^P7/8E9^#9KB69P4I\E3<3
MR.SY%$2GWGHWE639YDQFB?B(SC??R_EVU)_"FM*<*QN6YCEU?@\PP]ZQ<[KE
M%5$\HGE5$3RF)\TP\BFNBOC3,3'DE^M/"?T
M                                                '__3W\
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M*J:HF)B8YQ,3QB8[8E[")B8UCD^:?F_T
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M%LILMEGTNRW+\/PT^=X>S;YSK/K:(YS&OGXO'JO7J_75U3YYEPH>_?D
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M&5YGE&(G"9KAK^%Q4<Z+MNNW7'GIKBF?<>?3717'6HF)I\DZOV1X+^@
M
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M0M-:*2I*J=TJ2JG>BDJI7O2M/PDHF)B=)YO-?Z
M
M                                   #\WDF98AAL:DW+\JQO%8=6)DJ
MDO)+Y;+'&K&M[:'9\BC]SE16JL06G4J>7W\6DJI55:4K3OY6%P.-QU?@\%9N
MWJ]8C2BBJN=:N4:4Q/&>R.WL?S5533ZZ8CSNNF3\\^#6$*D(S/F=Q0Q%<1<=
MJ4C)^16H+ J,[+:0_%;D)NN81*LKDLN)6W17:JTJI6G>E:5.4X/=SO"S"(G
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M==<552E*K6JJU[U^DY)33313%%$1%$1I$1PB(CE$1W/RYOY'^O\
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M-RFF?<>PHNV[L=:W535'DF)]YR>>H?V
M                                     '__U-_          !FRZGGJ
M+L,Z:?*F[<7[WQ6R?;<ZU83AN9JS&U;8M6(1'FLOAR9;<"EFEX)D#R%P:1_%
M3GQ%:.=^]$I/JK='T7<?O7V.HVNP^<V<%;KQ%VUX*K#U79CP4Q&O6B]1''7E
MU>#TV.SBG!7_  $VYJG2)UUTY^T\\_NRS6WXA.<?V0%A_@H*=\PIFW[),/\
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MZ:8F?+,:O4W+MR[5UKM5557?,S/ON,3VS\P
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MV[7NQK[[#9G@\5I%NN(KGLGA/Q3[4R]7B-//
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MO 8BK"8ZU<LXJB=*J+E,T5TSW54U1$Q/DF'LJ:J:HZU,Q-/D?>GCO]
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MQ;=-,3/EGB]5<NW+L]:[5555WS,S[[C$]L_,
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MO-H=9>:6EQIUIQ-%MN-N(K5*VUIK2M*TK6E:5(7,33,TU1I5'.'L7]#_
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M1LAO3P^UF<TY/;P==BJJW55UIN15'BQKII%%//SO1$^957
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MIBKP\Z35U=-=)TUUTGD_2UM!1<N4V_!3'6JB/7=\Z=S82?#SD(
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M?2G"_O>W^12F=SZ)5YY?ASV#^
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M<X7$83'4\[=ZW7:N1V<:*Z::HXQIQA[.BNBY3UK<Q53WQ.L/W)ZY_8
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MZ*=;UR(^R7Z^M=N=_CUU<>6CC]_%8C$SK?KFKWH\T<H=2CFCQP
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M6'Q%%5N_15--5-433535$Z3%43I,3$\)B8UB7N8F)C6.,/L#\G^@
M                         =4^=_\ G1[F5_DJ?(?]J+,#F6[KZH.1?Z6<
M%_&;3\,5_B:Y_6ZO>E&).]]-P
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M-B,'?KPN+MUVL3;JTJHKIFFJF8YQ53,1,3'=,1+VL3%4:TS$Q+[8_%_H
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MKIGLKIF:9CC$S#WUJ]:OT]>S5%5/?$N9#T3]
M           &87J'_P"=P]O_ /# _:NPD[9NC-]1')/OS^/XI\:;U_\ 7?8_
M_(/XM9=+"[IV        >A'3'_SM/:?V%9C_ -<XY\U=+#ZD-[]_X;\JI5=S
M?^NUM_O>[[T-(IU;OKH                    !@U]99_G)? G]@V__ /L?
MU4=C/04^E.TG[XP?Y&(<5VC^B6O-5\#%.??#C0       !VKX)?YW?X;?Y-7
MQY_;=Q X=O%^I]GO^D;&_P 6NO(PO^*;?]<I]^%G<Z'U'
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M)V%^SC+/^QZ>: <H^E.%_>]O\BE,[GT2KSR_#GL'\
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M5Y=G&&OX3,+<Z56KUNNU<I_=45Q35'MQ#W%%=%RGK6YBJF>V)UA^R/!?T
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M;LT4T4Z]M4Q3$=:J=/&KJUJJGC5,SQ<=NW;EZOKW:IJKGMEQ0>Y?F
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M',MW7U0<B_TLX+^,VGX8K_$US^MU>]*,2=[Z;@
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MFOT.]1UK5SE,^)75PYO?V,5A\33UK%<51[L>>.<.UYPQY
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M !WBNK>Q&O?1,TQ19G^LT6]8G29EQK%9EB\7PN5:6_8T\(_G]O5Y.EF>O
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M_L*S'_KG'/FKI8?4AO?O_#?E5*KN;_UVMO\ >]WWH:13JW?70
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MQ.)G6_755'=V>B.'N.G)SEXP              !<B,]RG@
M$179W^<D["_9QEG_ &/3S0#E'TIPO[WM_D4IG<^B5>>7X<]@_@
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MPV.PN+CYQ7$U=W*?1/\ ]3OX39Y8
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MO7)UN7:^,^-755,1.D:4Z1'%;^)O8FOPE^J:JO<CS1RCVG68Y8_
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M.9;NOJ@Y%_I9P7\9M/PQ7^)KG];J]Z48D[WTW
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MHF>V.V//'^$.[Q/WE
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M6-(KFN8U<4Q>8XK&3I<JTM^QCA'\_MO*<L;P
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M?_.T]I_85F/_ %SCGS5TL/J0WOW_ (;\JI5=S?\ KM;?[WN^]#2*=6[ZZ
M                  8-?66?YR7P)_8-O_\ [']5'8ST%/I3M)^^,'^1B'%=
MH_HEKS5? Q3GWPXT        =J^"7^=W^&W^35\>?VW<0.';Q?J?9[_I&QO\
M6NO(PO\ BFW_ %RGWX6=SH?4<            #P[Y^^H'Z?/ UZ[X=)SIWD+
MNZV*D1'=1:,E6K)';'=&?-'PF?9VY,1A>%JCR4^W*BUDS+U'[^7R>NA]![MN
MC3O,WC4T8ZC#1EFS]>D^J<7%5$5TSVV;.GA;NL<::NK3:J^RP]9B\VPF%UIU
MZ]WNI^&>4>_Y&*GG1ZDSJ*\PZWG%<$S!CB3I^X./,LX5HFX7&W9S<+:I=5,,
M99NE[X?.)\M+2ULOTLGS=MLQE7B]"7V[U^]]WG14W7[#^#QF8V)SK/*8B9NX
MN*:K5-7;-O"QK:B.4QX7P]=,\:;D.-8K.<9B-::)\';[J>?MU<_1I'D> $R9
M,N,R5<+A*DSI\Z2_,G3IC[LJ9,F2G5/R94J2^I;TB3(>6I:UK552U5K6M:UK
M6I]*V[=%JBFU:IBFW3$1$1&D1$<(B(CA$1'"(CD]3SXSS?&/Z?X
M        %R(SW*>               1%=G?YR3L+]G&6?]CT\T Y1]*<+^][
M?Y%*9W/HE7GE^'/8/X
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MC6N(BJU5/91>HMU5<>K%41JY-A,PPN,CYU5X_L9X3_/[6KT\)(\X
M                                             '__T-_
M !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F
M    /<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
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M7JN/CTTU>#CAV.S7$8R9HCQ+'L8[?//;YN7OO"<^B'J@
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MJ+,#F6[KZH.1?Z6<%_&;3\,5_B:Y_6ZO>E&).]]-P
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M)K5ZU?H\)9JBJB>V'-9Z!^H
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MO>M55K7Z:_KGUE$1$:1R>E?Y#_
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MJ:IYVKFG.W<TGA,T373'6GF."S##XVG6W.ER.=,\X^./+'N/44D+S@
M                      #,+U#_ /.X>W_^&!^U=A)VS=&;ZB.2??G\?Q3X
MTWK_ .N^Q_\ D'\6LNEA=T[        /0CIC_P"=I[3^PK,?^N<<^:NEA]2&
M]^_\-^54JNYO_7:V_P![W?>AI%.K=]=                     ,&OK+/\
M.2^!/[!M_P#_ &/ZJ.QGH*?2G:3]\8/\C$.*[1_1+7FJ^!BG/OAQH
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M$J\\OPY[!_
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MIUHN4\8UZLZTZQ%<4U<(Y3A\58Q5'7L515';WQYX[';,X6\@
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M+DW+U4U5SW_X<(\C@LY"_(
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MJB*J:HGA,3$3$N64U4UTQ53,33,<)CD_0'C/Z
M    ZI\[_P#.CW,K_)4^0_[468',MW7U0<B_TLX+^,VGX8K_ !-<_K=7O2C$
MG>^FX
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M1:C37EN SFSBM+=[2B_[D^:?@GVM6D\^5'N@
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M=.-=<S.G"-(B(CB%_$7L3<\)>JFJKWO)$=D.MYRE^
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M\R\VAUEYI:7&G6G$T6VXVXBM4K;6FM*TK2M:5I4^&9B:9FFJ-*HYPY$_H?X
M                          9A>H?_ )W#V_\ \,#]J["3MFZ,WU$<D^_/
MX_BGQIO7_P!=]C_\@_BUETL+NG8       !Z$=,?_.T]I_85F/\ USCGS5TL
M/J0WOW_AORJE5W-_Z[6W^][OO0TBG5N^N@                    &#7UEG
M^<E\"?V#;_\ ^Q_51V,]!3Z4[2?OC!_D8AQ7:/Z):\U7P,4Y]\.-
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M13%---,13333$:1%-,:1$1'"(B-(AQ^9F9UGC+Z\_1_@
M     !<B,]RG@              $179W^<D["_9QEG_8]/- .4?2G"_O>W^1
M2F=SZ)5YY?ASV#^
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MB8[)CMAR'GQCD_N?R
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M7^2I\A_VHLP.9;NOJ@Y%_I9P7\9M/PQ7^)KG];J]Z48D[WTW
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MR7.<JQ=4\HLXNQ<GOY47)G7A/#36-)[GC5X;$6_HENNGSTS'P.M1RM^
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M-)IJC6FJF8JIF:9B9YC;N47:(N6YB:)CA,.1CU;^P
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MW1V1YH_PETB* \4                        +D1GN4\
M B*[._SDG87[.,L_['IYH!RCZ4X7][V_R*4SN?1*O/+\.>P?P
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MZ:6IN1:OSKR^<7O!WO[#GPYO5WL#B\/]&MU1'?IK'IC6'10HCQ
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M[_\ .CW,K_)4^0_[468',MW7U0<B_P!+."_C-I^&*_Q-<_K=7O2C$G>^FX
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M8INV:](BY:KTGJUQVQ--44UTU4QSC#XBUB;47;,ZT3[GDGNEV3.*OV
M                  #,+U#_ /.X>W_^&!^U=A)VS=&;ZB.2??G\?Q3XTWK_
M .N^Q_\ D'\6LNEA=T[        /0CIC_P"=I[3^PK,?^N<<^:NEA]2&]^_\
M-^54JNYO_7:V_P![W?>AI%.K=]=                     ,&OK+/\ .2^!
M/[!M_P#_ &/ZJ.QGH*?2G:3]\8/\C$.*[1_1+7FJ^!BG/OAQH        [5\
M$O\ .[_#;_)J^//[;N('#MXOU/L]_P!(V-_BUUY&%_Q3;_KE/OPL[G0^HX
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M$1#BE55554U53,U3VR^A/(?R                         "Y$9[E/
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MWHYT_#'?'^$^7UZ(B]@
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M:\=>/A*ZNWCY^/-YM%FS;^ATTT^:(CWG,AZ)^@
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M&QF!JY7+%RB[;GS5VZJJ9]J7JZ[==NKJW(FFKNF-)]U^$/8OX
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M3'7HF8ZT4<XR_,+6.MZT\+L<Z?ACOC_#S^N!%7L
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MWBS6C(;9-LE_M5MOEFN3"HMQM%X@Q;G;+A&7V\X\V!-:?BRF%]J=T.(4FO\
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M5F/_ %SCGS5TL/J0WOW_ (;\JI5=S?\ KM;?[WN^]#2*=6[ZZ
M          8-?66?YR7P)_8-O_\ [']5'8ST%/I3M)^^,'^1B'%=H_HEKS5?
M Q3GWPXT        =J^"7^=W^&W^35\>?VW<0.';Q?J?9[_I&QO\6NO(PO\
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M-7?YO)Y>WS<\>A]PN.@                           +D1GN4\
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M&-I\'<TIQ,=G95Y8^&/\(T+'S*]N
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MB=+UVF9TC6U;JZG7JN\+S7-)Q=7@;,Z8:/[*>^?)W1[<^3-6?5KTH
M    /0;@UTNN:W4/R:/:.-NGKO=,3;N%+?D&XLM1*Q336(J2I-)-;WG<N&]%
MFS82%46Y;;4U<KPI'TMQ%T)GO"WO; [L,)-_:K'448V:>M1AK>ES%7.[J68F
M)B)Y17<FW:UYUP\S"X'$XRK2S3XO?/"(]OXM9;=.!?I4N'W'^MIS?EYD<WES
MLEAIB37$78LW"]%6*X531QQM&-0YZ\FSU4)VM6TO7::S;Y;=/)RU(56B4]?^
M\?IC[<;2]?+]B;5.295,S'A(F+N+KI_KDT^#LZ\]+=$UTSPB],<9Y-A,BP]G
MQL1/A*^[E3Z.WV_0U!8=A>':[QFSX7K_ !/&<&P['H35NL&)X=8;7C.,V.WL
M)\6(%GL-EBPK7;(3*:=D-,M(0FGX*4/D7'8_'9GBZ\?F5Z[B,==JFJNY=KJN
M7*ZIYS577,U53/;,S,O=TTTT4Q31$13'9'"'Z8\1_0
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M*ZZHB([(B-(B-(X0_.W8L6OH5%-/FB(<]G&WZ@
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M,L+1CLNO6L1@KE.M%RW73717'?373,TU1Y8F8>HJIJHGJUQ,51V2_.'E/Y
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MB:J*.<Y=F%O'6M>$7X]='PQY)]SEY_84ASV(
M    !^ VGM/7>D==9EMO;6863 =;:^L,[)LQS#(I5(=HL=EMS?G(E2'*)6\\
MZXJJ6F([*')$J0M#+*''5H0KV63Y/FFT&:6,ER6Q<Q.:XFY%NU:HC6JNJKE$
M=D1VS,S%-,1-54Q3$S'\7+E%JB;ER8BB(UF4MWK5=9#8W5$W!3'\<^.PKB5J
MS(+DK3>NU54S/R:8BDBV5VSL/M1-9.7WVW+52'"KWCV& _6,SYON39<OM]W!
M[B\KW0Y'ZIQ75Q&VN,M4^JK_ #BW'"KU-9[K=%7KJ_77JXZ]6E,6Z*.#YEF-
M>.N:4\,/3/"._P L^7WO3KX?'T$]6              ^PM-INM^NEOLECMEP
MO5YN\V-;K5:+3"DW&Z7.X3'D1X<"WP(;3TN;-E/N)0VTVA2W%JI1-*UK2A^=
MZ]9PUFK$8BNFW8HIFJJJJ8IIIIB-9FJJ=(B(CC,S.D0_V(F9TCC+1UP/],+S
MXY7,6C--Y,0N&>J)ZFGOB=JV2?<MS72 XA2O?LNE8\FT7.TJ2XCVW$9+<,>D
M)HJCC3+Z.W?Y9WC=+C=OL;57@-GIJS[.:>&F'KBG"TSW58J8JIJ[XFQ1>I[)
MJIGE[G"Y)B\1XUWYW;\O/\'X]&R;A-Z?OIL<**6C(+7IYK?6U;:F,_7:G(>E
MLV'<XUS8720F=C.&NVV'KG$G8<SNJ')B6GY4CHHA*YKRT^Y7X6V_Z2N];;[K
MX:]CIRW)J]8]3X+K6:9IGAI<N]:;]R)CUU-5SP<SKI;IB=(Y%ALIP6&TF*>O
M<[ZN/HCE'HU\KVP2E*$I0A*4(0FB4(32B4I2FG9*4IIVHE*:4[4I3\! 9F9G
M6>;V;_0                              !^;R[#<0V!CEVP[/,5QO-L1
MOT1R!?<6RZQVS),<O4%VG9V%=K'>8LVV7&([3^6;>:6A7Z]#RL%CL;EF*HQV
M77KN'QMNK6BY;KJHKIGOIKIF*J9\L3$OYJIIKCJUQ$TSV2S=<X?2U\">25+U
MEO'9=YX=;0G>_+;;P5A63Z7N5P<0ZJE;CJJ\3XU<=86Y[2$(QRY6>%';2I7P
M;JU5K7ZIW?=+_>/LKX/!;4>#SW**=(^?3X/%4T\/6XBFF>O/.=;]%VJ9TCKQ
M$/38K(\)>UJLZVZ_)QCT?%,,77/WHB\_.GDJZY'L_5ZMC:8@*<=1OK37RCFF
MNHL*E>Z7\O12W0LHUTIM*D(<7?+?"@KD+]N-)D]O*OWENVZ0&[;>=%&%RC&>
MI<^J_P 9XKJVK\SW6O&FW?[9B+5=5<1&M=%/)QS%Y9B\'XU=/6M^RCC'M]L>
MV\BRV/7              /2_I>=4#>W2\WVQM'6+Z\GUQE2[9:MV:8N5P=B8
MSL[%83[RF>SM&Y";%FN/)F/NV6\MM..PGG7&W$/PY$N*_)][VZ+9W>]LW.49
MM$6<ULQ55A<53&MS#W)B->[KVJ](B[:F8BJ(B8FFNFBNGS<#CKN!N^$HXT3Z
MZ.^/C[I58.)'+'2?-K0F"<B] Y4QD^ YS;6GJLK7&;R#$<A:887?<%S6UQI,
MOY"S+%Y3]&)L6KBT=_%YAQZ,ZP^YTX;:[&9_L!M'B=E]I;,V<RP]>FO'J7*-
M9ZEZU5,1U[5R(UHJTB>=-44UTU4QSS#XBUB;47K4ZT3[GDGRP[)G%7[
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M6(X1\]UFCB.;9M-^9PV&GYQVS[+R1^U]_P W/)6?:3CX
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MP                                            /_6W\
M$Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
M   ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G:>7Z
MC'KC*Y(Y#D?!#B5EZE<>\1N]8&\=GXY/K\-O'+;/([KPS'+E!E5:GZCQ:XMT
MK(>^EN_71BCC?E C,/3>SCHN='N-E<+:WB[:6/\ 1FOT:X3#UT\<);JCZ+73
M,<,3<I];'.S;G2?GE55-OB.<9GX:9PN'GYS'KICZZ>[S1[L^3GD1/MEQX
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M\\>['FG77>?$KD
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M8INV]=:*^,35;JHKJY[@<;;QUF+M'"J/71W3\7=/\^GHX2UY@
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MJ>.L:T=:9NU1V5WJKE<?6S$<'*L)E^%P<?.J?']E/&?YO:T>G1)'G
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MB8F-)IJIF::J9BJF9IF)GG=NY1=HBY;G6BJ-8ER2>J?V
M     S"]0_\ SN'M_P#X8'[5V$G;-T9OJ(Y)]^?Q_%/C3>O_ *[['_Y!_%K+
MI87=.P       #T(Z8_^=I[3^PK,?^N<<^:NEA]2&]^_\-^54JNYO_7:V_WO
M=]Z&D4ZMWUT                     P:^LL_SDO@3^P;?_ /V/ZJ.QGH*?
M2G:3]\8/\C$.*[1_1+7FJ^!BG/OAQH        [5\$O\[O\ #;_)J^//[;N(
M'#MXOU/L]_TC8W^+77D87_%-O^N4^_"SN=#ZC@ # _ZC[KDR-AW7,NGGQ S-
MQK7=H?N&,<G]L8Q<*IIL&ZL+>@WO26-3V64N4PFSOMJ9R*9'?JF]2/.WT_C!
MJ32?V0=%CH]4Y99L;SMM[$3FE<1<P&'N4_0:9TFC%W(F?HM4<;%-4?.J=+OT
M2:/!\4SG-.O,X/#SXD<*ICM_:QY._OY<N>+T^\7&P             '-.E..
M'('DCD-<4X_Z3VING(6U-TDVK6."9+FLBWH<_E9-UK8+;.:M,)*:54M^2IIE
MM%*J4JB:5K3T.?[5;,[*X;U9M+F&#P&%[*L1>MVHJ\E/7JB:I[HIUF9X1#];
M5F[>GJV::JJO)$R]VN._I9.J-N9,*Y;'L.J.,U@D*0ZXO;.P(M[RA<%=$U]Z
M#BFJXF?.-S>ROHC7.5:G*>-?.J*]J*^==I^F#N@R&:K657,;FV)CA^IK,T6]
M>Z;F(FSP_;6Z;D=VO9[2SD6.N<:XIHCRSQ]$:^[H]RM!>CSXSXVB'.Y*\I]P
M;7N#?M2'[)J?',6T_CGO4JE3EOES,A3M6_W2!2G=%76';4^Y3LJGM?RI\];2
M=.+:S%S5;V4R? X*U/"*\17<Q->G?$4>IZ*9[=)BY$<N/-[2UL[8CC>N553Y
M-(^/X'LYI'H-])?0R6',9X8:RS.YMJ;<?N^Z5W_>#\N0U3LF0NU[4O&58U"5
MVI3NW#@1F*UIY>'E6M:PC:#I&;Z-HYF,7GV+L6IY4X7J82(CNZV'IMW)\]5=
M4^71[*UE6 M>MMTS/[;QO?UAZDX1KS -9V5G&]<8-A^O\=CI;1'L&$8S9<4L
MK"6D>VTEFU6&# @M);;^]31+=/&GT4^@D&89GF6;8B<5FN(OXG%3SKNW*[E<
MZ]]5<S/NO.IHHHCJT1$4^2-'[ \%_0
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M,<8[_+'D]Z?:U]P#Y]>S
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MM4Z46Z?)3$35/C5S55,S/+L/AK&%H\'8IBFGW9\\]KM6<.?N
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M7+P==4T5U?0Z^M53:CB.89-<PVM[#ZUV.[MI^./+Z>]EH/L!Z(
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M;AXNQPKY51W3\4\X>E1*7F@
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MA::U2I-:5I6M*G4]717;KFW<B:;E,S$Q,:3$QSB8[)CMAS7GQCD_N?R
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MQ/K]8ZERY\Z\:*+U,>ASG,O4]'J:S/S^J.,^QCXY[.Z./<G'':2X<
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M_0
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M+%4SU+M'/GI--=.L]2Y351K/5UGG^#Q=O&6(O6_;CNGN_P .QWJ)V\H
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M4(0FB4(32B4I2FG9*4IIVHE*:4[4I3\!\73,S.L\WOW^@
M                       !C\ZV7IN,5WO&R[E1T_L9LV$[QI\HY)L7CY;4
M1K+A6X'?;7+G7C7+*?8M>%[+DNH4IR!V9M-[=<\_*'+]QR;]O[@>E3C-G*[&
MQV\J[<Q&SWBV[&-JUJNX;LBF_/&J[8CLKXW+41IX]&D6^/9GDU-W6_A(B+O.
M:>R?-W3[D^_/WR#'[]B=]O.+Y39+OC638[=)UDR#'<@MLRS7VQ7JUR785SM%
MYM%Q9C7"V72W3&%M/QWVT.LNH4E::*I6E.RS#8G#8W#V\9@[E%W"7:(KHKHJ
MBJBNBJ-::J:J9FFJFJ)B8F)F)B=8G1Q*8FF9IJC2J'U!^S_           ]D
MNB!U-;ITT>8]@RW)KC.7QSV_\FZZY#6)FLN0S$QJ1.[V'9<&VQZN4D9!K"ZR
M53$^++TA^TOW"&RE+DNBT0OI!;IK.]C86Y@L)33\M&!ZU_!5SI$S<B/'L35/
M*C$4QU><1%R+5RKA1,3[++,;."Q$55?0:N%7F[_/'O:JP5KNELO=LMUZLMQ@
MW>SW>#$NEINUKEQ[A;+I;+A';EP+C;I\1QZ+-@S8KR'67FEJ;<;512:UI6E:
M],UZS=P]VJQ?IJHOT533535$Q535$Z335$Z3$Q,:3$\8GA+GD3$QK')\X_-_
MH
M                 #S/ZBG2<X@=2["7+/O/"&[-LNUVUZ'@F^,(8@VC:>&.
M]JKBQU7=49UC+,70_6M7+/=D2H54N.*8I&D*3(16-U^^?;?=/F$7]G<1X3*:
MZHF]@[LS5A[O?/5UUMW-.5VW--7"(JZU,31/A8S 8?&TZ78\?LJCG'QQY)3?
M.I_T:^5W2_RY;^PK3]DC05[NJK?@7(G#+=)IAUX<=\G(5BS*VJ=F3=<YLY'I
MW^3YSBXTI2'?D^7.0RZM':?NBWZ[&;W<%U<LK]2[26Z.M>P5VJ/"TZ<Z[57"
M+]K7Z^B(JIUCPM%N:J8GAN.RZ_@:O'\:U/*J.7M]T_X1J\D"U/7@
M   TH^G0ZN3_  2Y L\;]U9$IGB?R+R6VP)UPNDQ:+=IC;$^C5HQ[8K"GE_"
M6_%LB7\/;,EJJK3;49,:X*<HFWN-R/E/I1;E*=XNS4[59!:UVSRNU55$4QXV
M*PT>-78G3C5<H\:Y8YS-77M1&MR)I]UD^8>I;O@;L_.*Y]$]_FGE/I[.-,]*
MDK2E:%)6A::*0M-:*2I*J=TJ2JG>BDJI7O2M/PG4U,3$Z3S<U?Z
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M/9PUN+5FF*:/\.?>['G%G[
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M;M4Z7^ZY,79U\)<FGE629CUHC!7I\:/6SY/8^UV>3AV0VI'P2Y*
M          !F%ZA_^=P]O_\ # _:NPD[9NC-]1')/OS^/XI\:;U_]=]C_P#(
M/XM9=+"[IV        >A'3'_ ,[3VG]A68_]<XY\U=+#ZD-[]_X;\JI5=S?^
MNUM_O>[[T-(IU;OKH                    !@U]99_G)? G]@V_P#_ +']
M5'8ST%/I3M)^^,'^1B'%=H_HEKS5? Q3GWPXT        =J^"7^=W^&W^35\
M>?VW<0.';Q?J?9[_ *1L;_%KKR,+_BFW_7*??A9W.A]1WFOU6>HO@73-XD9C
MOC(:6V][%NONX9HO7LQ]27,[VC=(4ERTLRV&'69=,4QIAE=SO3Z%MU1!CU9;
M<I)D1D.5;<WNNS+>SMK8V<PO6MY71\]Q=Z(^@X>F8ZTQ,Q,>$N3,6[43KK75
MUICJ4US'A8_&48+#S=GC7RICOGXHYRDD[;VOL+>NS<[W'M?*+EF>Q]E9/=LP
MS+)[L[[DV[7R]2G)<M[Q31+,6(U5=&H\9E*(\6.A#+*$-(0A/=1DN399L[E&
M&R+)K-%C*L)9IM6K=/*FBF-(COF9YU53K555,U53,S,SP"Y<KNUS<N3K75.L
MRX[/9OX         '>GA;TV.:/4!R2MCXP:0R;-+/#F)A9%LBYH;Q?5.).=D
M..HR+8=]K#QUFX,QE^]2W1W9-UD-TK5B*[6G8GFWN];8+=IA/5&UV86K%^JG
M6BQ3\\Q%SNZEFC6N:9GAUZHIMQ/KJZ7E8;!8G%U:6*9F.V>41[?+VN;9?P9]
M)%Q^UTU9LSYW;2NN_P#+V_A)DG4FKY5WP#3UO?HGO*M=XRU-8>S,\CT=2E3<
MF(O%*4I52%QW:=E5^$MX?35VFS2;F W=8.C+<#.L1B<1%-[$U1V54V^-BS/?
M35&([XJCDY)A=G[-'C8JKKU=T<(]/.?<:JM)<?-&<;,,C:\T!J+7>G,*B^"J
M8YKG$K+BEOE2$)JFMPN:;1$C.7>ZO54I3TR6IZ4^M2EN.*4JM:_'6?[3;0[5
M8^<SVEQN*QV83]??N57*HCNIZTSU:8[*:=*8B(B(B(A[VU9M6:>I:IIII\D:
M.8#T;]
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M/&*J:HF)CLF'/*:J:Z8KIG6F8UB?(_1'BOZ
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M=-:8<QR+&^&L^I;D_/*(X>6G^;EYM&L4^,GO@
M                                                      #\CGV
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M75,U55553K5555.LU553,S,S,S,SK/%RN(B(TCA$/LC\G^@
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M'/FKI8?4AO?O_#?E5*KN;_UVMO\ >]WWH:13JW?70
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MZ0\5_0
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M-JK29JN51RG(L=K^HKL\>=/PT_#'M^1MW.OYR8
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M<+9PEJ+5F-([9[9GOEW&."O)
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M6<SPE^NU=HGG3715--7GC6-8F.%43$QPF%$MW*;M$7*)UHJC6'(AZM_8
M
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MY'Y7QXX\97;_ ._W^9S;)MC;%DFM_P!\7\I(L5BD(_C_ .\F3$?"^RS*Z_\
MI+])?U/ZHW=;NL1^J/&MXW&VZO6=E>'P]<?7\Z;UZF?$XV[<]?K54<FRG*==
M,5BHX<Z:9]^?@C_"=UQUW.4@
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M[3VG]A68_P#7..?-72P^I#>_?^&_*J57<W_KM;?[WN^]#2*=6[ZZ
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M(<JM6;5BB+=FF*:([(<S'HGZ
M
M  ,I?7@]/WCG,"V9ARZX=8Y!QOEG#8>OVP=<V^L:VXWR,CQ(]539<5E?LP;'
MN13#5%,S/)J+?7$U:F>,EVDQ/V3T=.DMBMA[MC8G;F[5=V+JF*+-^K6JO S,
M\(F>,UX77G3QJLQQM^)$VY]#FN4TXB)Q&'C3$=L=E7\_O]O>G1WFS7?';O=<
M?R"U7*Q7ZQ7*=9KW9+S!E6R[V:[VR4["N5JNMMFM,3;=<K?-86R^P\A#K3J%
M(6FBJ5I3M#L7[&*L48G#5T7,-<HBJBNF8JIJIJC6FJFJ-8JIJB8F)B9B8G6.
M#A\Q,3I/"8?6GZO\         '[O5^R\WTSL?!-MZTR"9BNP=:Y98,XPO([>
MI-)=FR7&;G&N]HGM)7133R6)L5%5M.)4TZCNA:5(56E?79OE.7Y]E6)R7-K5
M-[+,79KM7:*N55NY3--4>36)X3'&)XQI,0_NBNJW7%RB=*Z9UB?+"OWTVN<&
M%=0WAYJ7DWB/PD&YY+:OD+9>*QG%KK@VV,<;CP\ZQ1=':U?I$CW)=)=O6YV7
M)M,R*_6E/=I2G2'O5W?8_=CMSC=DL;UJK-JOKV+D_KV'KUFS<[M9I\6N(X4W
M*:Z?K5"P6*IQF'IOT\YCC'=/;'^'8[V$[>4
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MBB:/)X"./C0Y9D&*Z]NK"5>NIXQYIY^B??;(SX6<C
M
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MZNSQ:M;%54\9ZUBF.%+D^08SC.#KGASI^&/A]+=.=>#E
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MI3M2E/P'63,S,ZSS<N?Z
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M2^!/[!M__P#8_JH[&>@I]*=I/WQ@_P C$.*[1_1+7FJ^!BG/OAQH
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MU\\-8LTZ6J)TUBY53%R>9Y?E5G!1%=6E>([^R/W/Q\_-R>^1\WO:@
M
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MK6]YD>,\!B/4]<_.[GN5=GIY>CN4G3JI<S
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MJIXTS&L/NSQW^@
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M775,U55553K,U53,S,SQF9<ZIIBF(IIB(IB.$/O3QW^@
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M=OP5F-([9[9\LS_AIV.YYP-Y(
M
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M/0<F;RP                                      __5W\
M$Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
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MFJNJJJ>>X;#6L)9BS:CQ8],SWSY7:\X8\@
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MLDQ/A\'X.J?'MSI[79\7M-(!\L/<@
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MC1ZFQ,QR]46:=;557[:[8B:(\F']/+=G\3U[56%JGC3QCS3S]$^^V-'PRY$
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MIL6:=8M6:.7BT4\YB(Z]<UW*HZU=4S0L+AK>$L4V+?*.<]\]L_X>9W#.#O(
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MU>9YUB;^+S&Y.M=V]<JN7*I\M=<S5/I>XHHHMT]2W$4TQV1&D/W)Z]_8
M                                                         &#7
MUEG^<E\"?V#;_P#^Q_51V,]!3Z4[2?OC!_D8AQ7:/Z):\U7P,4Y]\.-
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M.+-FW8MQ:M1$41_AZ7-!Z%^H
M
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M5VOG,]6B)\'1;BGGN P5O V/!T\:YXU3WS\4=G_UO3<DKS0
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M?67(ZOM\X^+VU/8ZCW-P
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M*XX>2G^?WM.]K</BM[\
M
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MZ)^@
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MFBNF?+353,>TH]%5-=,5T\:9B)CS2_6GA/Z
M            '__7W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2
MCBORJ7"<]_Q?/[BEG%/J5Z8           ']6&'Y3[,6*R[)DR76V(\=AM;S
M[[[RZ-M,LM-T4XZZZXJB4I32M55KVI])_E55-%,UUS$41&LS/"(B.<S/<_WF
MIN>GMZ.D7I]Z53O[>F-1D\P]XX[$7>8MPCT<GZ0UO<?A;G!U;$JZCRAY3<W6
MF9>3N([=I;3,%-5(AU=D=2W2:WYU[R\_^5K9V[/RC9?=GJS3/#%WZ=:9Q$]]
MNG6:;$3];-5SA-S2GFN49=ZDM>%NQ^J*H_!CN\_?Z.SCI!/EA[D
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M<MUTSK3717$54U4SVQ53,3$]L2GE5,TU335PJB=)?1GD/Y        /UVO\
M.LFU?GF$[+PJY.6?,M=Y=C>=8E=VJ>3MJR;$KS"O]AN3::]J5<@W6WM.TI^O
M5!X69Y=A,WRW$93CZ8KP.*L5V;E/LK=RF:*Z?;IJF/;?W175;KBNGA53,3'G
MA:#XS;SQKDYQXTER&P_Q1CFZ-7X5LBW1:.I=<M=,LL$&[RK)+4FM:)N%AG27
M84E'?NB0PM-?II4Z&]K-GL7LEM/F&S&._P 58#&7;%4^R\'7-,5Q^UKB(JI[
MXF)4>S=IOV:;U/K:J8GTN<3C[]0
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M1=B-=9HJF-*[=4\NM:N15;JTX=:F=$YQ%FK#WJK-?KJ9T^*?;CBZ]')GX@
M      "P'TC.4RN9'3FXJ;SN-U3>,ON>LK;ANR)BEU5,>V5K-Z1KW-YUP:4E
M#D:3?;[C;MR2BM.U6)K:T54VI"U=(.^S8^-A=Z6<[.VJ.I@:,75=L1V18OQ%
MZU$3VQ117%&O?3,3I,3$4/+[_JG!V[L^NZND^>.$^]J]'R6/,
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MC2.$0^R/R?Z
M
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MVJ9F>K;MQ.E,:S,SK77-5=554\^PV'M86S%FU&E,>F9[9GRR[2'#W[@
M
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MIH2/F5[<                                     ?_0W\
M$Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
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MQXSS3(;_ (3!^"GUUNJ8]J>,>[KZ&G@^2'NP
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MX_<]GIY^W'<TT'R:]V
M
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MJ]C3%%OCU-9YYEN!IP-CJSQO5<:I^#S1_.]A"'O8@
M
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M^Q8JC76KR4W;%NF.Z;DZ<Y<AV>O=6_78GE53K[<?S3/H4)CK+<N
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MB/(_8'@OZ
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MQ==5S%7KE5==4\9JKKF:JJIGOF9F9\LJ+3$4Q%-/"F(?<GX/]
M
M                                                    !@U]99_G
M)? G]@V__P#L?U4=C/04^E.TG[XP?Y&(<5VC^B6O-5\#%.??#C0
M  -SOI6>E2PU#<ZF6\<<2[*E*O6*\4K!>8*%)BQFER+)FVZTM2&U*I)D/(D6
M*Q.?>50VBXR/%5'8;R>O/IB[XZIN1NFV>NZ41U+F8UTSSGA7:PNL=D1U;MZ.
M.LS:IUC2Y3/*,BP'^/;L>2GX:O@CV_(W"G7TY.
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M+IB:(CRU56HI[-==)G29>=EUWP..M5]G6TGS3P^%7N.D=00
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M$_1)I[+E^?GES7C&M-O6:;=.G/LNP5."P\6_UV>-4^7N\T<H]/:]7"-//
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M8'!X.U$::6+-NU&G=I;IIC1X5=V[<G6Y555/EF9]]Q>>W?F
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MQ&$OU8;%VZ[6(HG2JBNF::J9[IIF(F)\DP\Z)BJ-:9B8?:GXO]
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M=CE(
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MIB-(CR0_4GAOZ
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MPNW:9TGP46XXTW:H<ER' ]:KU;<CQ8X4^?MGVN4>77N;U3KC<J
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MF6(LT_N+=VNFB8\DT13,:\=)X\5'PUWPV'HN]M5$3Z8=F#B;]P
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M.7C7=)NU\.&M5<SIPY/4WL3B+_T:NJKSSP]')U;.7OP
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M>I\%;HGUTQK/GGC[G+VGJV1MYX
M                                                        ";5U
M]?K:>6'_ !!/Z-.FSN5Z*7U LA^_OSCBU&R'Z4VONORZGCP?0SVX       !
M[T^F^^LUQ;_=GMM_]A$ ^5^F/]16_P#Z4<+^74]%M']+9_=TJ&9U&)^
M                P:^LL_SDO@3^P;?_ /V/ZJ.QGH*?2G:3]\8/\C$.*[1_
M1+7FJ^!BG/OAQH          *>7IK.G2UPQX/6K=.>61N)OKEW$L>SLB5,@I
M9NV(ZI7$7(U-@E7'>\IAR39K@N_W!M26'$3;O2*\A2H+:Z]2'2LWHSMYO!KR
M'+KG6V<R2JO#T:3K3<Q&NF)O=TZ54Q9HGC$TV^O3.ER8<WR7!^IL+%RJ/GMS
MC/DCLCX?;\C1@?+KW
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M4.U;HLVZ;5N-**8TAR@>H?H
M                      &.CUB&C$Y#QGXG<BXD13DS5FY<KU3='X[%*K39
M-QXA3)(\FXNH3YUA6^\:@:99JNO@T]<:I3V4]7R^Y>@YM#.%VLSK9>NK2WC,
M!;Q%,3/U^%N]28ICOFG$S,Z<9BCCPIX<=VBM:V+=[MIJF/3&OP>ZGZ'98XD
M        *F_II=MJVGTA^/MOE252[KJ/(MKZDNCRWZO+2FR[!O>38[&K12UK
M83!PS+K8PA%:T[-MIJFE$U32G3YTKLEC)]]N9W*(ZMG&VL/B:8TT]?9HMUSY
M=;MNY,SWSWZN=9+<\)E]$3SIF8]WXIA[UGSB]J
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M:HM4SIRFKJ1'6J[ZJM:IF9F9F9F9]+<NW;U77NU355Y9U<1'NWY@
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M4WK=5$51$Z35;JF.K<IU^NHFJF>R7N[5^S?IZ]FJFJGR3[_=[;G@XX_4
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MTW1+;333::)2E-*)2FG:GT'1#55575-=<S-<SK,SQF9GG,SWJ._J?X
M
M                         )M77U^MIY8?\03^C3IL[E>BE]0+(?O[\XXM
M1LA^E-K[K\NIX\'T,]N        >]/IOOK-<6_W9[;?_ &$0#Y7Z8_U%;_\
MI1POY=3T6T?TMG]W2H9G48GX                    #!KZRS_.2^!/[!M_
M_P#8_JH[&>@I]*=I/WQ@_P C$.*[1_1+7FJ^!BG/OAQH         >MO1)X%
MTZA'4!U-JK)+2[<M-X&ZO<6]U584[!?UQ@TN"_\ -6:KLE-&MAY1*MU@<HE:
M'D1K@\^WWJQ7M%=_^\?^AENTQN<X6N*,]Q,>IL)QXQ?NQ,>$CRV;<5WHX3$U
M44TSZY[#+,+ZKQ=-NJ/G<<:O-'9[<\/;5L6FFF&FV66VV666T-,LM(2VTTTV
MFB&VVVT4HE#:$TI2E*4I2E*'2S,S5,U53K5/.7/W]#_
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M,_MJ+N(M3'/LIHHGLCCWZN9Y!7UL%-/L;D^]$M11\AO>
M                    '__5W\          $Q?U4?UM&7_[L;I7_L%N1VV=
M#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SW
MTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
M                                 /%WU"6HD;BZ0_+ZVM1F';M@N,8E
MMVS27VU.*MZ]7Y_B^69!)C^*5*0_)PN!=(E%?@HF2KO6E.Y>>C+G<Y'OMR.[
M,S%G$7KF&JB/KO5%FY;HB?)%VJW5]R];F]OPF7W([8B)]$Q/O:I/YW,.!
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MJJZMOV-/"/;[9]N='CJ7)ZX
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MX6[RTUTF[9UU^N^A::^3J_6\>:Y#5UL!IW5S'O3\+2L?*3W0
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M'PRIB'4ZYJ
M                                          3:NOK];3RP_P"()_1I
MTV=RO12^H%D/W]^<<6HV0_2FU]U^74\>#Z&>W        />GTWWUFN+?[L]M
MO_L(@'ROTQ_J*W_]*.%_+J>BVC^EL_NZ5#,ZC$_
M8-?66?YR7P)_8-O_ /[']5'8ST%/I3M)^^,'^1B'%=H_HEKS5? Q3GWPXT
M       *3_I6N$:./?!2Z<FLJM3<;9',+($9);W7VE4GVS2^"2;KC^O8"DO-
M45&^<5X?O%\\F5U;EP)\!2_OFDT3U4=,3>!.TV\2C9/!US.59':\'5$<JL5>
MBFN]5PY]2F+5KCQIKHN:<*IUYGD6%\#A?#U>ON3K[4<OAGVX:@SY%>\
M                                                   >*?4$Z]W
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MUK6M:UK6M3Z1B(IB*:8B*8CA#U3_  ?Z_P
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M:TB]:TC2:JIHFW&ND7*M-7(L+FV#Q6E,5=2YW5</1/*??\CVT("]F
M  /%'U$N#TSSHZ\QX3;*G)N/675^<074-*>7&KAFZ]<7^YO4:3(C)JERP0YC
M2U*JJC3;JG*(4I-$UOO1@S#Y';\LBN3.EN[<Q%J>S7PN%OT4QRGZ^:9CEK,:
M:Q$ZO69Q1U\NN1VQ$3Z)A*+.Y1P,         ;VO1L9@J;J#G3@'Q"5)QG9.
MDLPI%\I-5,JSG&,_LJI%4*K\&E,FFO*)I5NE':^S7W.Z:-]NN'IU8'P>>;.Y
MEIQO83%6M>''P-RS7IW\/#]O#CP[7*]G*M;=VCNJIGTQ/Q-I!\&.2
M                             '__UM_          !,7]5'];1E_^[&Z
M5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUTW#+\
MHG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
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MSPGBQ78GC'"[333,ZQ177I,N3X3,\+C.%N=+GL9X3[79/M>X];"+/8
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MUQWS=KMVK<S^Y\#=B/W4\^&G*MG+>E%V[WS$>C69]^&UX^!7)0
M
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MHBBCA3$1$>:'Z\\)_0
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M.DQ7<F[<B8ZU%5&O5CB>,SC%8K6BCYW9[HYSYY^+2/.SY'TP]0
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M/$8RCK:\O"48>K337M\%KKIPZO.->/)=G)\>[3WQ3[FOQMYAURN5
M                            '__7W\          $Q?U4?UM&7_[L;I7
M_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB
M?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
M                                          $6CF#@"-4<M>4>K6F?
MAF]:\B]VX W'[53\.C#=EY/CJ&?%4J>JGM)MU$]JOO5IV_EU_P M7OIV'S*<
MYV*R?.)G6<7E>$O:]_A;%NO7E'LNZ/-'*)MB*/!XBY1[&NJ/1,NNARA^(
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M +OE@?\ E@O'6KTY_P#769%_I.O?Y<Y;L[]!N?NH]YL?/AAR(
M "8KZJ'.:Y9U:<RL%7%+^QCH_2N#42KP[-4N%BG[*]M'C*D5HFM=A57]\ABO
M=5?O*T[..=MG0\R_U%N6L8G3_%>88J[Y]*Z;'='V'3M\_9'"<]JZV/F/8TTQ
M\/PLXY]2O3         "G7Z5_6M,$Z2N%Y11CVJ[GW?NO92G.R*?$UM5^@Z>
M]_NAAE2O%.IZ-=U*=5^I_P M2G9".I+IAYM\D=].(P>NOJ#+\+8\W6HG$Z<Y
M_P!Q&O9SY=L\WR*CJY?%7LJJI^#X&C<^6WN
M
M       ";5U]?K:>6'_$$_HTZ;.Y7HI?4"R'[^_..+4;(?I3:^Z_+J>/!]#/
M;@       'O3Z;[ZS7%O]V>VW_V$0#Y7Z8_U%;_^E'"_EU/1;1_2V?W=*AF=
M1B?@                    ,&OK+/\ .2^!/[!M_P#_ &/ZJ.QGH*?2G:3]
M\8/\C$.*[1_1+7FJ^!BG/OAQH        [5\$O\ .[_#;_)J^//[;N('#MXO
MU/L]_P!(V-_BUUY&%_Q3;_KE/OPL[G0^HX
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M:>K;M6J*:+=%/=313$4TQV\(YSJXS57575-=<S-4\YGC+\F>:_D
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MR3$QIX.C,[E,]^M=BJ8]K2B=?:]KD6SL_/[D=O4CWU!<ZT'+0
M                        #__0W\          $Q?U4?UM&7_[L;I7_L%N
M1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-
MZ'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
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M_P#J><14GA
M     <RZ$Y#[OXN;,L.XN/FSLLU-LK&G?<M>4XA<E092F%J363:[K#<2_:\@
ML%P2BB)=NN#$F!,:[MOLN(K5-?1;2;,;/[7Y3<R+:;"6<;E5V/&MW*=8U[*J
M9X545T\Z:Z)IKIGC35$\7ZVKUVQ7%RS5--<=L-[G2>]4!J?D.]C&B>?5,9T1
MNF8IBT6+>$5QNS:-V'-^\:C)RQ4V15&H\FG=Z>3DAU>/2'4K521 JMF'7K@W
MS=$;.MF*;VT6[?PN8Y!3K57A)\;%V([?!Z1^J;<=U,1>IC2.K<TJKCE6 SNW
M>TM8O2F[[+ZV?/W3[GFY-;C#[$IAF5%>:DQI+3;\>0PXAYA]AY%'&GF76ZJ;
M=:=;5125)K5*DU[T^@^*ZJ:J*IHKB8KB=)B>$Q,<XF.]R!_4_P   !XW^H'^
MIXYN_L'P3]N76Y=.C3]7'9_]\7OXK?>NS;Z77?-'OPDVG<ZX"         -Z
M7HUIDI>JN=]O7(=5!B[!T5,CQ:K55AF5.QS93$R0VW_*I=DLVYA*U4^E2644
MK_*T[=<G3KMT1G.SEV(CPDX7%Q,]LQ%=B8CS1-4Z>>7*]G/H=V.S6GWI;4#X
M)<D             DT^H!RI69=87F]=U+<<K#SW"L5HIQAJ.JB<%U!KO"$(H
MVU6J5-MHQZB4KK]\ZFE%J[*56E.Y_HU8.,#N.V?L1IXV&NW.>OT;$W[O;^[Y
M=G*.$. YM5ULQNSY8CT1$/',N3UP         KD]#K"DX#TEN"=C0VEJD[1]
MMS6J4UHJE5;)OE\V*MSO1B/3R>7E-5UIXU[55V\E_P NKI2Z0>/G,M].T6(F
M=>KF%5K^ HHL=\\O!Z?!'**!E=/4R^U'[77T\?A>K)&WG@
M
M                 $VKKZ_6T\L/^()_1ITV=RO12^H%D/W]^<<6HV0_2FU]
MU^74\>#Z&>W        />GTWWUFN+?[L]MO_ +"(!\K],?ZBM_\ THX7\NIZ
M+:/Z6S^[I4,SJ,3\                    !@U]99_G)? G]@V__P#L?U4=
MC/04^E.TG[XP?Y&(<5VC^B6O-5\#%.??#C0       !VKX)?YW?X;?Y-7QY_
M;=Q X=O%^I]GO^D;&_Q:Z\C"_P"*;?\ 7*??A9W.A]1P
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MR/?\7B\O6@
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M[;NM3XHZ<7U/LH_TLQ_%K[D.SO\ BFO^M_#"AZ=8KEP
M                  !__]'?P          3%_51_6T9?_NQNE?^P6Y';9T.
M_J+V/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2
MJ^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
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M,ZU5UU<ZZZYJKKGC55,\7"KMZY?N3=NS-5<]KAH]Z_(
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M=$6\C%^K]XF?XZ)B8O9UCKFL<IZ^)NU:QY./!1\)3U<+:I[K=,>Y#MJ<+>0
M
M                               3:NOK];3RP_X@G]&G39W*]%+Z@60_
M?WYQQ:C9#]*;7W7Y=3QX/H9[<        ]Z?3??6:XM_NSVV_P#L(@'ROTQ_
MJ*W_ /2CA?RZGHMH_I;/[NE0S.HQ/P                    &#7UEG^<E\
M"?V#;_\ ^Q_51V,]!3Z4[2?OC!_D8AQ7:/Z):\U7P,4Y]\.-        ':O@
ME_G=_AM_DU?'G]MW$#AV\7ZGV>_Z1L;_ !:Z\C"_XIM_URGWX6=SH?4<
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MV=_Q37_6_AA0].L5RX                                    __TM_
M         !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3
MZE>F        /<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14J
MM'3DYV
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M\/EF'MTV[5JW3%-%%%,:133$<HCW><\7"JZZKE4UUS,US.LS+\:><_@
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MP>-P>88>G%X"[:OX6N/%KMU4UT3YJJ9F)]J7@54U4SU:HF*O*_/GDOY
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M^<;<]OV<<?\ _L!VN=<W3K^FVS?[WQGY>'<JV<^AW?/3\+:R? [DH
M     $9CJ!W29>^>G-R]7%Q+UPN_+ODG=)SJ6T-)=F3]RYI+E.):;HEMM*WW
ME5HE-*)3W[4^@[V]VEFWA]W&S]BU&EJC),#3$>2,+:B/<A.,7,SBKLSSFY5[
M\NHAS9XX         MIZ2L\;'M,:CL$)Q]V'8]88#9XCLI3:Y+D:V8K:83#D
MA;33#2WUM,4JNJ4(357?LFE/HIT"Y_?KQ.?8W$W-(N7,7>JG3EK5<JF=.?#C
MPXRI=J-+5,=U,>\Y//4/T
M                                                     )M77U^M
MIY8?\03^C3IL[E>BE]0+(?O[\XXM1LA^E-K[K\NIX\'T,]N        >]/IO
MOK-<6_W9[;?_ &$0#Y7Z8_U%;_\ I1POY=3T6T?TMG]W2H9G48GX
M            #!KZRS_.2^!/[!M__P#8_JH[&>@I]*=I/WQ@_P C$.*[1_1+
M7FJ^!BG/OAQH        [5\$O\[O\-O\FKX\_MNX@<.WB_4^SW_2-C?XM=>1
MA?\ %-O^N4^_"SN=#ZC@
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MM3XHZ<7U/LH_TLQ_%K[D.SO^*:_ZW\,*'IUBN7
M              '_T]_          !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_
MTHXK\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUTW#+\HG]%#>A\]]*KZ@N?
M?>7YQPCVF3?3*W]U^14JM'3DYV
M                           !,7]5'];1E_\ NQNE?^P6Y';9T._J+V/]
M*.*_*I<)SW_%\_N*6<4^I7I@       #O)TPOK*NGG_D\G$S]OS ">[W/J4[
M3_\ #>S'^)WGE8'_ !;9_KM'Y4+'QT8**            !X^]9/JO:_Z6_'&
M3DK-;-E7(_9D2[6+C]K"<^M;4^]L,(9G; RR+%6B6C7^".3&7YB4K8<N<E;,
M!EUE3ZY$>X;BMS69[W]J8PE7A+.RN$JIKQF(B.5$SK%FW,\/#7M)BGA,6Z8J
MN54U13%%7KLQQ]&!L];A-ZKUL?#/DC^;S2I-N;;V/OG9N<;DV]EUWSS9>Q\B
MN&4YEEE]?H_<;Q>;D[YNN*HA+<>'#C-T2Q%BL(:BPXK3;##;;+:$)[C<DR7*
MMG,IP^19)8HPV4X6U3;M6Z(TIIIIY>69GG55,S555,U53-4S,\$N7*[M<W+D
MZUS.LRXZ/:/X             ]!^&G2PYX<]I<9WC=Q\R[),.<EIBS-K9(VQ
M@^IK=1+[D>8XK/LJ<MEDO+]L4RJLB%:EW"Y)HGLF,I2DI5,]N]\.[G=Q1,;5
M9G8M8Z*=8P]&MW$U<-8^<V^M73%6L=6JYU*/VT1$S'F8; XK%?0:)FGOGA'I
MGX-9:T>'/I ]:8^U:LGYS\A+SL*\H^%DR]5: ;<Q/"67VT]Y%ONNR\JMCV89
M/;9"E>-:P;3C<A'AW2]7R^]^+MN>F[FV)FO";O,LMX6QQB,1C/GEV8[*J;%N
MJ+5NJ/V]R_3.OK>''W^&V>HCQL57K/=3PCTSQGT0T\\7>G7P@X80X[/&?C-J
MO5]TCQDQ%9E"L";]LF;'2U5GV;GL_*W;[L*Z,U2M7WDBYN([K76E*54KO\C[
M7[T-X.WE<U;69MC,99F=?!37U+$3SUIP]OJ6:9\M-N)X1W1I[NQ@\+AOH%%-
M,]_;Z9XNZ)P-Y(                              XBV_Q_T5R"L*L6WM
MIG5NY,=JVMM-EVA@6+YU;V/.OE[D2-DMKN3<-]#E*+0XU1#C:Z44E5%4I6GN
M\DVEVBV9Q/JS9W'XS 8KV6'O7+-4^>;=5.L=DQ.L3'">#\[EJU>CJW:::J?+
M$2\,>2OI>^EMO>L^Z8#AFPN,64RTK>I<-*YM+>QEVX>*TM.S,$V*QG&/Q+?3
MNFBXMGI9DJHBE4J0M2UJ^AME.EWO?V<ZMG,K^%S?!T\.KBK41<T\EZQ-JN:N
MZJ[X7GRF(B(]7>R/ W>-$315^UGAZ)U]S1G=Y2^D8YF:W3<[WQ9W#J_DM8V'
M7UP<3R*BM*[.?8713D:+&9O]QO>MI[K%*>TX_(R&V4<5XK2RE*E(:^GMC^FO
ML)FLT8?;# XS*<1,1K<H_56'B>V9FBFB_$3SB*;-S3C$U3I$U>HO[/XFCC8J
MIKCN];/Q>[#.1R3X6<L>'U^ICO)KC]M#34QZ2[$M]PS#%YT?%[Z\S5='?FQF
ML-,S#LJ915M7ZI;9\IOZ/Y8^I-E-O=C-N,-ZJV2S/!X^B(UJIM7(FY1$_9+4
MZ7;<^2NBF7IKV&Q&'GJWZ*J9\L</:GE/M.L)RY^          [:<+.;7(3@'
MO.P<@...7JQK+[4R[;+W9[@V[<,.SW%9CC3ESPW.L?3(C-7W';BIA#GAYMR(
MLEIJ3%=8E,LO(X7M[L!LSO)V>N;-;4V/"X*N>M153I3=LW(];=LUZ3U*Z=9C
ME--5,S17351553/D8;$WL)=B[9G2KW)CNE52Z8W4KTAU...]IW%K"9"L6=V5
MJWVC=6GI%S3.R75&:OL.+5;Y=5QX+]VQ:]_#.OV6[H81'N,9"TUHW*CRXT?I
MTWM[J-H-TFU%>1YO35<RZY-56%Q,4Z6\1:B?71QF*;E&L1=M3,U453$\:*J*
MZN=X+&VL;9BY1PJCG';$_%W3_A'!?J!_J>.;O[!\$_;EUN<BZ-/U<=G_ -\7
MOXK??EFWTNN^:/?A)M.YUP$         ;R?1I_YQMSV_9QQ__P"P':YUS=.O
MZ;;-_O?&?EX=RK9SZ'=\]/PMK)\#N2@            1B.=O^=W^9/\ DU?(
M;]MW+SO@W=?4^R+_ $C8+^+6DXQ7^*;G]<J]^750YB\<         7 ,0L[^
M.XGB^/RG6GY-BQVR6>0\QY^P\_;+;%A.NL^XE#GM..,5JGR317C7Z:4K]!GX
MQU^G%8V]B:(F*+EVNJ(GG$553,:^7BIM,=6F*>Z'Z(\5_0
M
M                 !-JZ^OUM/+#_B"?T:=-G<KT4OJ!9#]_?G'%J-D/TIM?
M=?EU/'@^AGMP       #WI]-]]9KBW^[/;;_ .PB ?*_3'^HK?\ ]*.%_+J>
MBVC^EL_NZ5#,ZC$_                     8-?66?YR7P)_8-O_P#[']5'
M8ST%/I3M)^^,'^1B'%=H_HEKS5? Q3GWPXT        =J^"7^=W^&W^35\>?
MVW<0.';Q?J?9[_I&QO\ %KKR,+_BFW_7*??A9W.A]1P
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MKNW)]?=N5?77+D\9GE$:4TQ31333' <1B+N*O3>NSK5/N1W1Y(=83EK\
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M%%>D<(FN*JN>M4S,S/O+& P>&XVK=,5=\\9],\?0]%27O,
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MIXX>N*H[IX3Z>,>\S?\ *7IL<Z^%LB7]LIQBVEKFR0WZ1E9U6QTRG6,AY?\
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MI]E'^EF/XM?<AV=_Q37_ %OX84/3K%<N
M        /__4W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBOR
MJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'
M"/:9-],K?W7Y%2JT=.3G8
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MJJJ[U4S-554S,S,\YF9XS,]LR]Q$1$:1R?-/S?Z
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M,\3;MQ%-NF_<B(B-(B(KG2(CLB.R%-HXT1,\](?LCP7]
M
M                $VKKZ_6T\L/^()_1ITV=RO12^H%D/W]^<<6HV0_2FU]U
M^74\>#Z&>W        />GTWWUFN+?[L]MO\ ["(!\K],?ZBM_P#THX7\NIZ+
M:/Z6S^[I4,SJ,3\                    !@U]99_G)? G]@V__ /L?U4=C
M/04^E.TG[XP?Y&(<5VC^B6O-5\#%.??#C0       !VKX)?YW?X;?Y-7QY_;
M=Q X=O%^I]GO^D;&_P 6NO(PO^*;?]<I]^%G<Z'U'
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MKKF:JI\LS,O>TTTT4Q31$13'9'"'Z<\1_0
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M/XM?<AV=_P 4U_UOX84/3K%<N
M /_5W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?
M/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K
M?W7Y%2JT=.3G8
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MKJGC-5554S555,\9F9F9<CIIIICJTQ$4QV0^[/'?Z
M                       Z+\R>FOPHY[V%5IY.:'Q'-[TS$<BV78T!AS%M
MJ8UY,599K9-B8ZNWY,B)&5X.4@2'Y%L><:1[\9U*:)*'L+O6V^W;XGPVR68W
M\/8F=:K$SX3#W..L]>Q7UK>L\8Z],4W(B9ZM=.NKQ<3@L-BXTOT1,]_*8]OG
M\#%5U!/2?\C=-?+>P."N9?;+Z\C?$3?L4Y<[9\5WO8X*/)SX>V3OY&8+LWX:
M.VI:UL5L=P=75+4>W2%U[U^]]VG3,V6SWP>6;Q+'R)S.=(]46XJN82N>^J/&
MO6-9X1$^%HCC55=ICEQK%Y#>MZUX6>O1W3PJ^*?<\S*'FV#YIK7++]@>Q<1R
M7 \XQ:X.VG)L/S&QW/&LHQ^Z,435ZWWJPWF+#NELFMI72M6GFD+I2M*]NU:=
M_LS+\PP&;8*WF.5W[.)R^]3UK=VU73<MUTSRJHKIF::H\L3,/0U4U45317$Q
M5'.)X2_+'EOY      [5:3YA;?T9I+DWQVQFZ_&Z@Y6X58,6V1AUQ>>5;F;Q
MB.76/+\3SFRMIK5$+)[/(L[D-3G:J)-OFO-.4JI+#C/#MH-ALCVBS_*-J,71
MU<\R;$5W+%VF(ZTTW+==NY9K[[=4515ISIKIIF.$U15Y%K$7+5JNS3]#N1I,
M>:=8GSNJIS%XX         WD^C3_ ,XVY[?LXX__ /8#M<ZYNG7]-MF_WOC/
MR\.Y5LY]#N^>GX6UD^!W)0            (U74<L[&.]0SGCC\5UU^-8N9O*
M&SQWG_#WWF+9N_.833KWMI0W[KC;%*J\4T3Y5^BE*?0=ZVZR_5BMV.SF)KB(
MKN9#E]4Q'*)JPEJ9T\G%.<9'5Q=VGNN5?E2Z9'.WC         "UYQROCF4<
M>M#Y*](C2W<ATSJ^^.RH=6ZPY+EVPBQSUR(E6E+:K&>5(JI'C6J?&M.U:T.@
MO:G#QA-ILQPE,333:Q^(HTGG'5NUQI/EC3BI=F>M9HJ[Z8]YS,>B?H
M
M                          3:NOK];3RP_P"()_1ITV=RO12^H%D/W]^<
M<6HV0_2FU]U^74\>#Z&>W        />GTWWUFN+?[L]MO_L(@'ROTQ_J*W_]
M*.%_+J>BVC^EL_NZ5#,ZC$_                     8-?66?YR7P)_8-O_
M /[']5'8ST%/I3M)^^,'^1B'%=H_HEKS5? Q3GWPXT        =J^"7^=W^&
MW^35\>?VW<0.';Q?J?9[_I&QO\6NO(PO^*;?]<I]^%G<Z'U'
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MJJ*ICA5%-5/D8?$7,/5-5N>%5,TS'?$Q_A,>5U:.8/'         &N7T>?\
MG>'DW_DJ<C]MW6I\4=.+ZGV4?Z68_BU]R'9W_%-?];^&%#TZQ7+@
M                           #_];?P          3%_51_6T9?_NQNE?^
MP6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_
M10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
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MEJ4M:E+6M55+6JM5*4I5>ZE*57O6JJUK]-?USN,B(B-(Y."O\A_@
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M313,Q/-\#E]C T:4<;L\ZIYSYNZ/)Z7K*1AYX
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M_</>G2.M,\K5R**]9BFB;LZRXGCLGQ&$UN6_'L=\<X\\?#'#S,\!].O3@
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M[TMH\'QZM&>8[36=9ZLXFY-.LQVS3,3*BX*KKX.U5_2Z?>AWA)\\H
M
M                         FU=?7ZVGEA_Q!/Z-.FSN5Z*7U LA^_OSCBU
M&R'Z4VONORZGCP?0SVX       ![T^F^^LUQ;_=GMM_]A$ ^5^F/]16__I1P
MOY=3T6T?TMG]W2H9G48GX                    #!KZRS_ #DO@3^P;?\
M_P!C^JCL9Z"GTIVD_?&#_(Q#BNT?T2UYJO@8IS[X<:        .U?!+_ #N_
MPV_R:OCS^V[B!P[>+]3[/?\ 2-C?XM=>1A?\4V_ZY3[\+.YT/J.
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M-9HM6K=/"FBW;IBFBBF.ZFF(B/)">U555U377.M4SK,^67Y8\M_(
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MV56L%$7*]*L3W]D?N?CY^;D]^3YM>V
M                !U5Y9\).+/./7R]:\HM-8EM3'VDOJLD^Z1G8&78A,D)H
MERYX3FUH=@97B5P7X)]Q<&6RF0A/MO)<:JI"N8[%[P-L-WN9QFVR&/O8/$SI
MUXIG6W<B/K;MJJ)MW*>Z*Z9TGC3I.DQ^&(PUC%4=2_3%4>['FGG#!UU//2Z\
MA^,C%_VYPDG9)RETK"^,N5QURY BKY#8';$+=<0EBRV=F/!W%!C,I31;UDB1
M+NI:_HM*FFW)%.QC='TO=F-K:K62;P*;63Y_5I33?UGU%>J\M54S.%F9[+M5
M5K2/HT3,4.*X[([UC6YA=;EKN^NCX_:X^1E3E19,&3(A38[\29$?>BRXDIER
M/)BR8[BFGX\AAU*'67V7452M"J44E5*TK2E:'V-171<HBY;F*K=41,3$ZQ,3
MRF)[8GLEZ+EPGF_@?T_P               UR^CS_P [P\F_\E3D?MNZU/BC
MIQ?4^RC_ $LQ_%K[D.SO^*:_ZW\,*'IUBN7
M           '_]??P          3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.
M*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE
M^<<(]IDWTRM_=?D5*K1TY.=@
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MO"W:IF>$<(ZU7KKE4=:N9GESW"82S@[46K,>>>V9[Y_PX.[A/WD@
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M.L>$M4XJW5SX=3&8B*>?/6CJSPX<=.&FD<$SBGJYC<[ITG^QAXA'T"]6
M     *P_I\,];V'T?.%]THXVJ38<1SO IK*:I]R*YK[;>?X=$;?0EY^K;C]J
ML\>0FE:TJIIY"O%-%433IEZ3.6SE>_#/K.GBW+]F]$]_AL-9NSIPCE555'GB
M8UG36>>Y17U\NMSW1,>B9A[-D(>R
M
M)M77U^MIY8?\03^C3IL[E>BE]0+(?O[\XXM1LA^E-K[K\NIX\'T,]N
M  >]/IOOK-<6_P!V>VW_ -A$ ^5^F/\ 45O_ .E'"_EU/1;1_2V?W=*AF=1B
M?@                    ,&OK+/\Y+X$_L&W_\ ]C^JCL9Z"GTIVD_?&#_(
MQ#BNT?T2UYJO@8IS[X<:        .U?!+_.[_#;_ ":OCS^V[B!P[>+]3[/?
M](V-_BUUY&%_Q3;_ *Y3[\+.YT/J.
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M7SK+\OMX&WI'&]/KJO@CR>_[WKN1-[
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M,:^#O6]=:*XXZ<Z:XCK6ZJZ)BJ>&XG"W\)<\'?C2>SNGRQ/^'E=1CFKQP
M          &N7T>?^=X>3?\ DJ<C]MW6I\4=.+ZGV4?Z68_BU]R'9W_%-?\
M6_AA0].L5RX                                    __]#?P
M   3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@
M     #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
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M:HF>.E$3-%%&G/LOP-&!L1;CC<GC5/?/Q1V/4PC[S@
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MJH\LQ11:G7]M$=G'F>07.M@IH[::Y]$Q$_&U'GR"]X
M
M              3:NOK];3RP_P"()_1ITV=RO12^H%D/W]^<<6HV0_2FU]U^
M74\>#Z&>W        />GTWWUFN+?[L]MO_L(@'ROTQ_J*W_]*.%_+J>BVC^E
ML_NZ5#,ZC$_                     8-?66?YR7P)_8-O_ /[']5'8ST%/
MI3M)^^,'^1B'%=H_HEKS5? Q3GWPXT        =J^"7^=W^&W^35\>?VW<0.
M';Q?J?9[_I&QO\6NO(PO^*;?]<I]^%G<Z'U'
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M7S0T%'S0]L
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M.1^V[K4^*.G%]3[*/]+,?Q:^Y#L[_BFO^M_#"AZ=8KEP
M                   !_]'?P          3%_51_6T9?_NQNE?^P6Y';9T.
M_J+V/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2
MJ^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
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MGA3Y([9]OE'DU[VU ^"7)0
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M;]G''_\ [ =KG7-TZ_IMLW^]\9^7AW*MG/H=WST_"VLGP.Y*
M!A%]9/K1<;-N"VXX\=*V[WBV[-:7:4GV$J87B]VP#*<>CN5[)DNIEIS"YJ1V
MJM#?L+[^%5T\^Q3H*YM%> VBR*J>-N]A;],<>/A*;UNN>[AX.WKRF=8YZ<.+
M;1T>-:N=\51Z-)^&6)<^_7&0        !M9]&]N5$'9/-CCW,G*6O)\'U9N7
M'K8M5/&,C!+]D.$YE.831-*U5-KL6Q-NU4JO;X=OQI3NKO\  _3HR*;F59!M
M-13PLXC$86NKO\-11=M1/F\!>F///DTY+LY<TKNV9[8B?1PGWX;R3KF<J
M
M                             )M77U^MIY8?\03^C3IL[E>BE]0+(?O[
M\XXM1LA^E-K[K\NIX\'T,]N        >]/IOOK-<6_W9[;?_ &$0#Y7Z8_U%
M;_\ I1POY=3T6T?TMG]W2H9G48GX                    #!KZRS_.2^!/
M[!M__P#8_JH[&>@I]*=I/WQ@_P C$.*[1_1+7FJ^!BG/OAQH        [5\$
MO\[O\-O\FKX\_MNX@<.WB_4^SW_2-C?XM=>1A?\ %-O^N4^_"SN=#ZC@
M                                       #(!ZO7E2[@G%[0?$BPSW&
M;KOW8EPV-F[49]2:JU]IUB%\F6BY,4[)7$O^?95 G,5KW_5L>5_@=S[>Z$>Q
MT9CM?F6VN)IB;.6X6+%K6/U[%3/6JIGOHLVZZ)\EZ''MH;_5L48>.=<ZSYH_
MGGW$]P[,W$0        !KB]+#TQHV_=W7?GOMZPMSM5<<,@38M-VJY1FW8.7
M;]^ BW%62*8D,O-R;;J*RW)B:S7LBOR].@/,N55 ?;K\4],+>W7LWL_1NWR2
MY-.<YK:Z^*JIGC;P>LT^#UB8TJQ-=,TSS^<T7*:HTN4RY!D6!\+=]5W(^=T3
MP\M7?[7OZ=RB =8CEX
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M#R;_ ,E3D?MNZU/BCIQ?4^RC_2S'\6ON0[._XIK_ *W\,*'IUBN7
M                            '__2W\          $Q?U4?UM&7_[L;I7
M_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]K_3J9%8<7ZS'
M"NY9'>+;8K?)O.YL=CS;K,8@Q7[]E_''<.)XK9VGI"VVUW+(LGO<.WPV:5\Y
M$R2TTBE5K32L"Z4.%Q.,W$Y_:PMNNY=BWA:YBF)F8HM8[#7+E6D?6T6Z*JZI
MY4TTS,\(E[/)YBG,K4S.D<?=IF(]U5S.FMSP
M                                    &;+U56ZOL8]*V\X!'EMM3^0N
M[]5:R7&2YXRW;-CLVY[CN<EI"5)<^$:EZQAL/K[53_'26U?S2E*_570YR#Y+
M[XK>954ZV\LR_$7]>R*JXIPM,>?3$53$?M9F.3TV>W>I@.IVUU1'P_ F5';.
MX2         *4OI,-5_,CICY'GLAE-)FY^2FR<JBRJ+>JIS'\5L&$:X@Q%-J
M\6$IC7[$KHY12*54KWZT4JO9*4=4_30SCY(;V[66TSXF RJQ;F.'K[E=V_,]
M_&BY;CCW<(YS/-,@M]7!37VU5S/HTCX):?3Y&>[         $?/JV\BG>574
MCYA;F1/^4;)==T9-B.%RT.J<8?U_K!;6L\$E1TU6M#"+ABF)1)2T(KX^Z^NO
MTUK6M>\'<KLO&QVZO(\AFGJXBC 6[MV-.,7L1\_O1/?U;ERJF)GLB/-$\S"]
MX?&7+G9UIB/-'"/<AYTE0>&        =N^!G$O*><W+S1/%G%'I,"1M?-X5L
MR"^Q6/B7,5P2U,2,@V#EB6JMN,N.XWA=JG2V6W/%MZ0TVU52?/O3A.\?;3![
MO-B,QVPQL153@L/-5%$SIX2]5,46;??I7=JHIF8XQ3,SI.CR,+AZL5B*+%/U
MT^B.V?:A8QUKKO#=0Z\P75.N['$QG M;8ACN"X7CT&E:1+)B^*6F)8[%;&/*
MJEJ;A6V"VWY*K5:_'NJM:UK6O1GFN:8[.\TQ&<YI<JNYEB[]=Z[7/.NY<JFN
MNJ?/5,RHM%%-NB+=$:44Q$1YH?MCP']
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M\/?B/&HJ[Z9]=:KY5T3$Z4U1513P+&X.Y@K\VKG+G$]\?X<_\->@)27B
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MA1KRJUI]/+W=%5$Z=7.P
M                                                   ";5U]?K:>
M6'_$$_HTZ;.Y7HI?4"R'[^_..+4;(?I3:^Z_+J>/!]#/;@       'O3Z;[Z
MS7%O]V>VW_V$0#Y7Z8_U%;_^E'"_EU/1;1_2V?W=*AF=1B?@
M        ,&OK+/\ .2^!/[!M_P#_ &/ZJ.QGH*?2G:3]\8/\C$.*[1_1+7FJ
M^!BG/OAQH        [5\$O\ .[_#;_)J^//[;N('#MXOU/L]_P!(V-_BUUY&
M%_Q3;_KE/OPL[G0^HX
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MT6X[XIUGC,S-%PUBG#6*;%'*F/3/;/MSQ=HSB#]P
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M&%#TZQ7+@                                   #__3W\
M$Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
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MBY^N1PJCR_%//W.QZID=>>
M                     &!_UB^_/E;<?#_C';[AV:P77><;MRBWL+\FWYVR
M<ABX5B"YW92DIEVF%K6[*91V0M+5R4I7DEQNM.Q_H-;-^!R+/-K;M/'$8JUA
M+=4]D6*)NW=/)5-^WK/&-:(B-)B=>*;17=;ENQ'9$U3[?"/>GTL7I]Y.-@
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MGL/K->*GL\6/?GX&ZDZ[W*
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MC;GM^SCC_P#]@.USKFZ=?TVV;_>^,_+P[E6SGT.[YZ?A;63X'<E
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M)NV+D=U=JNJW7'M54RI-NNFY1%RGUM41,>:>+]Z>M?V
M
M              FU=?7ZVGEA_P 03^C3IL[E>BE]0+(?O[\XXM1LA^E-K[K\
MNIX\'T,]N        >]/IOOK-<6_W9[;?_81 /E?IC_45O\ ^E'"_EU/1;1_
M2V?W=*AF=1B?@                    ,&OK+/\Y+X$_L&W_P#]C^JCL9Z"
MGTIVD_?&#_(Q#BNT?T2UYJO@8IS[X<:        .U?!+_.[_  V_R:OCS^V[
MB!P[>+]3[/?](V-_BUUY&%_Q3;_KE/OPL[G0^HX
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M5+F8
M  ZI<U^'.G>>7'#87&G=UI3-Q3-K?5=IOD=B.Y?\#S&"T\K&,^Q.1(36D/(L
M:FO56W7O1N2PMZ*]1<=]YM?,M@=N<\W<[587:O9^OJXS#U>-1,SU+UJ=/"6;
MD1SHN1&D]M,Q373I533,>/B</;Q5F;-WUL^Y/9,>5(PYH\0]M<%>26S.,NZ+
M<F-E^O+O1F+>(C+Z+%FF+7%I,[%LXQA]]-*RK!DUG>;?;^FKD=VKD9ZB)##S
M:.Z_8+;?)=XFRF$VMR&K7 XJC6:9F.O:N4\+EJY$<J[=43$]E4:5TZTU4S/
M,3A[F%O56+GKH]V.R8\[JR<P>.         -<OH\_P#.\/)O_)4Y'[;NM3XH
MZ<7U/LH_TLQ_%K[D.SO^*:_ZW\,*'IUBN7
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MDTU1.DQ,3&DQ/&)X2YY$Q,:QR?./S?Z
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MM,6:NKY*KM-RONUKG3AHY]E5GP. MT]LQUI^ZX^]I#V"(>]B
M                                               &,SU572X9V#@,
M/J2:9QU-<YUG;[5BG)NV6R/WD95K1#D6T8;LY4=BE%R;OKJ4^BVW-WP==<L,
MB.ZXMJ-:*^7W;T.=[]669E5NJSV[_H.Q=55S 553PMW^-5VQK/*F_$37;C6(
MB]35$1-=_AQS/<#UZ/5MN/&IX5>6.R?:Y3Y/,P('9(XF         -Y/HT_\
MXVY[?LXX_P#_ & [7.N;IU_3;9O][XS\O#N5;.?0[OGI^%M9/@=R4
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MPO<
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MQGF]#9_*ZHUM7<XPO7C^ETWJ*[G?QZE-6G!XN-K\'@[M?;%NKTZ<$<,[SDZ
M        %*STH''UC5O33N.Y94-*+[R9W3G&6LW!3*&WWL+UP\WJK'[;5=*J
M<>C0<HQC()+:E>/94Y=*4[=E*ZI>F9M-5G&]>G(J*OU/E. M6YIUX1=OQZHK
MJ\DS;N6:9_<1YHYID-GP>"\)VUU3/M1P]^)]+3L?)#W8
M                                           9O?4B=+MKG!Q1D<@-
M68_\9R9XKV*\Y-9&+;"2]=ME:@8HY=\\URI,9E5PN=VLS33M[Q]E/O*K-:E0
MV&O<N:G$?5'17WO3N^VSC9K.+O5V3SBY3;KFJ=*;&)GQ;-_C.E--4S%J]/".
MK-%=4Z68B?39S@?56'\+;CY_;C7SQVQ\,?SICYVTN$@        #7+Z//_.\
M/)O_ "5.1^V[K4^*.G%]3[*/]+,?Q:^Y#L[_ (IK_K?PPH>G6*Y<
M                            ?__5W\          $Q?U4?UM&7_[L;I7
M_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8          * ?I9^JU]E7
M $].#>.2>[L;5%CF7CC->KH_WDY?J6TMKEWW5]9,A?N2[YJYNJI5K:HI:W,;
M4MIM#;%GJI?6KTP=S?R&S/\ HI[/6M,KQMR*<?33'"UB:N%&(TCE1B/6W)X1
M%_2J9FJ_I'+<BQ_A*/4=V?'ICQ?+'=[79Y/,V/GPPY$
M                                        =+NHIRAA\,.$')GDP](C
M1[IJ_5=_FX:F6II,>;LF_):Q36%L>]VBTU9NFPK[;(Z_O5U\'*UHA5:>->>;
MK]D*]O-X.4[)TQ,V<9C*(NZ<XL4?/,15&G;39HN51RXQSCG'C8R_ZFPM=[MI
MIX>?E'NZ(VLJ5)G29$V;(?ES);[TJ7+E/.2),J3(<4Z_(D/NJ6Z\^\ZNJEK5
M6JE*K6M:UK4[TZ**+=$6[<13;IB(B(C2(B.41'9$=D)USXSS?P/Z?X
M  >ZWIO^/OV?>K1Q\?F0?CL<T9!S+D%D:?;\_AOF#956_"IWE6BDM?";3R:P
M+\JT_6[4[*K2M/G?I3[3?*WN7S.FW5U<5F-5K!4>7PU76NQ[>'MWH_FU>UR:
MSX7'T:\J=:O1R]V853#IV<Z         &43U?.8.6GIYZ-PZ.Y[;N8\N<2F2
MZ?QLKW[3B^I=P/OQ_;=0N0GO=KI!=]QJJ:I]KP4KQ<\5?9?0BP,7]YV8XZJ-
M8L9)<B.?"JYB<-$3W>MIKC2>_6.6L>AVAJTP=-/?<CW(E.8.T9PX
M^^Q7&[IF63XWB%D:2]>LJOUGQNT,JH[5+MTOEPCVR TJC#3[]4N2Y2*5\$+7
M]/T)K7M2OCXS%6<!@[N.Q$Z8>S;JKJGAPIHIFJKGI'*)YS$/ZIIFJJ*8YS.B
MVW@V'V;7N$X?@..,JCX]@^+8_A]BCJ5Y*8LV,VF)9;6RI5?I4IJ%"0FM?U^Q
MT!9ACK^9X^_F6*G7$XB]7=KGOJN5355/IF5+HIBBF*(Y1&GH?J3PW]
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M[:E"=5#F8
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MM^ZX^:%WU?LCS'\*C] ^2^9?9JS^(^=,K\333W];KM^ZX^:%WU?LCS'\*C]
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MB!P[>+]3[/?](V-_BUUY&%_Q3;_KE/OPL[G0^HX
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MM^"P=JCMBB/3,:S[KOX39Y8
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M]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F
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M-P\7:>%?*J.Z?B[8>DY*GF@
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MU3V3<I]^%E(Z*E&
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MP=ECBC]@
M
M           8-?66?YR7P)_8-O\ _P"Q_51V,]!3Z4[2?OC!_D8AQ7:/Z):\
MU7P,4Y]\.-        ':O@E_G=_AM_DU?'G]MW$#AV\7ZGV>_P"D;&_Q:Z\C
M"_XIM_URGWX6=SH?4<
M S6^JUOB;3TI)T!3;JZY-R*TY8T*;71"&51VLNR2KCZ:_2ZU5&/511-/P+6F
MOZQ]6=#;#S>WRTW(F/G.5XJOSZ^#HX>7Q]?-$O39].F T[ZX^%,O.V5PD
M      6_,+QF+A6'8GAL&K2H6)8S8<9AJ8C4A,5BV&UQ;7'JS#2Z^F(U5F+3
MQ:HM=&Z?>^5>W>N?G'XNO'XZ]CKFOA+UVNY.LZSK75-4ZSPUG6>>D:J;33U:
M8I[(C1^F/$?T
M            "/SU?_K2>?O^36;E_P O*YG=_N0^I!LU_I&PO^54I[F/^+KO
M]<GWWG&5)X0       !KE]'G_G>'DW_DJ<C]MW6I\4=.+ZGV4?Z68_BU]R'9
MW_%-?];^&%#TZQ7+@                                   #__7W\
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M[8F-8JB8JIF8F)GGMNY1=HBY;G6BJ-8ER >M?V
M                               #X-TN=NLELN-YO$Z):[1:(,NYW2YS
MWVXL&W6Z!'<E3ITV4\I#,:)$C-*<<<76B4(36M:TI0_2S9NXB[38L4U5WZZH
MIIIB-9JJF=(B(CC,S,Z1$<Y?Y,Q$:SR1\>J9S,F<^.=W(#DFAZ;7#\FRQ6.Z
MK@3%NT5:]3X1':Q; 6DPW$HI;9-WLEL1=)L=%/%-RGR5=U*4I:N\'<_L)1NW
MW=99LI,4^KK5GKXB8T\;$W9\)>X_71375X.B?L=%'*(B(GN.Q/JO%5WOK9GA
MYHX1\?G>?)3'A@        "N%T0.+].)72_XHZYGVU5NS#*L!8W1L)$B.N-<
M_GCN9]S8+UNO+*D-U;NF)V.]0+$M/C3Q1:DTK52J56KI4Z0.U_RZ;W<YS2W7
MUL#9Q,X6SI.M/@L+'@8JIGV-RNBN]'EN3RCA% RRQZGP-NB?73&L^>>/N<O:
M>L!&7G@        #%-ZRS_.-N!/[..0'_8#J@^^.@I]-MI/WO@_R\0XUM']#
MM>>KX&#8[&7%0       #T<Z0'UI/ +_ ":S37^7E;"6[[_J0;2_Z1L5_E53
MS<N_Q=:_KD>^L#'2 H0
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MI-:5.]:S>M8FS1B+%45V+E,54U1QBJFJ-8F)[8F)UA.9B8G2>;Z\_1_@
M     VZ>D@Z@GR=>]F].;8E[[1<@^5]V<=?CY'?PO<&(S]ES7MN]U2W%?*-F
MB,9)"BM40RS\!>'U=UO_ $]?_35W:>%P^$WI97;\>UU<+C=(^LF9]37JOW-4
MS8JJG69Z]BF.%+DVS^+TFK!USS\:GX8^'VI;KCKN<I
M
M                                             !@U]99_G)? G]@V
M_P#_ +']5'8ST%/I3M)^^,'^1B'%=H_HEKS5? Q3GWPXT        =J^"7^=
MW^&W^35\>?VW<0.';Q?J?9[_ *1L;_%KKR,+_BFW_7*??A9W.A]1P
M                                   #,5ZM#ZK;'O\ )K-2_P"6;M8^
MMNA=]5^[_I&Q/^6X=Z3/_P#$,?UR/>E-2.UMPL        _<:Q_SDG7O[.,3
M_P"QZ >OS?Z4XK][W/R*G]V_HE/GA;J,_P I@
M                                      $?GJ__ %I//W_)K-R_Y>5S
M.[_<A]2#9K_2-A?\JI3W,?\ %UW^N3[[SC*D\(        UR^CS_ ,[P\F_\
ME3D?MNZU/BCIQ?4^RC_2S'\6ON0[._XIK_K?PPH>G6*Y<
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M53NE254[T4E5*]Z5I^$ZLYB8G2>;F+_0
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M'=6-=-:HPURJCC/#UT1SX/*P-75QEJKL\)3[\+'9T8J*
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MCVI=H3B+]P
M
M            P:^LL_SDO@3^P;?_ /V/ZJ.QGH*?2G:3]\8/\C$.*[1_1+7F
MJ^!BG/OAQH        [5\$O\[O\ #;_)J^//[;N('#MXOU/L]_TC8W^+77D8
M7_%-O^N4^_"SN=#ZC@
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MN:9TY:TSI.GDUA38G6(F.4OM#\7^@
M                             C\]7_ZTGG[_ )-9N7_+RN9W?[D/J0;-
M?Z1L+_E5*>YC_BZ[_7)]]YQE2>$        :Y?1Y_P"=X>3?^2IR/VW=:GQ1
MTXOJ?91_I9C^+7W(=G?\4U_UOX84/3K%<N
M          /_T=_          !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK
M\JEPG/?\7S^XI9Q3ZE>F              ;Z/3:=;Q.S;5B?3NY:YA6NRK'"
M9LO&':>37&BE[ L%OC53#TQDMQE437YZ8["CT1CTEYU:KQ"32!7QF1XU)_6[
MTJNC]\B;U[>?L78_T%7*IKQ^'MT_0:YGCBK=,?K5<S\^IB(\%7\\^AU5^#Y9
MDV9]>(P>(GQX];,]ODGR]W?RY\]G1\(.1@
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M&(MUS353/.*J9TJB?+$Q,*7$Q5$3'*7VA^+_ $
M                                     .LO,?E5K3A-QHVYR<VS,0SB
M6JL4F7I%KI+;AW#+LD>\8&(X-9'7&GTTON:9+*BVV*JJ%-M.R*.N=FD.*3RS
M8;8[-MO]K,%LEDM.N-QEZ*.MIK3;HCC<O5\O$M6XJKJXZS%.D<9B)_#$WZ,-
M9JOW/6TQZ9[(]N48_(KR[D607W('F6XSU]O%SO+L=I2EM,.W.:_-<9;4O[Y3
M;2GZII6OTUI0[WL+8C"X:WAJ9UIMVZ:8GOZL1&ON)S5/6F:N^7TY^[^0
M   #>3Z-/_.-N>W[../_ /V [7.N;IU_3;9O][XS\O#N5;.?0[OGI^%M9/@=
MR4               S-^J4X2*Y)\ FN0.*6=5PV7PWOTK8/>,W5R=,TWEE+;
M9-N0&D)12E6K+2#:<B?<6NB6(-BD^-*J<I2OUCT0-OXV4WDSLUC*^KE.>VXL
M\>48JWUJ\-/GKUN6(B(XUWJ->$</2YYAO#83PM/K[<Z^U//X)]I-!.V!PH
M        -3WIB>J4QQ0Y"R>&FY,C^ T#R@R2#3"KG<GUIM>N>0<IJ#9+!,=<
M6\EFWV+:<&+'LD]SVU^%R8M3JU,QT2G#X]Z6^Y^K;/9B-N\BM=;:3*+4^%II
MCQK^"B9KKCEK57AYFJ[1&L>)-Z(ZU4T0][DF.]3WO4UR?G5<\/)5_/R]'E4A
M#JP<R
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MCMB8B7F4U4U1UJ9B:9[8?=GCO]
M                            P:^LL_SDO@3^P;?_ /V/ZJ.QGH*?2G:3
M]\8/\C$.*[1_1+7FJ^!BG/OAQH        [5\$O\[O\ #;_)J^//[;N('#MX
MOU/L]_TC8W^+77D87_%-O^N4^_"SN=#ZC@
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M"6Z^^BGWN+NB<#>2
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M[*/]+,?Q:^Y#L[_BFO\ K?PPH>G6*Y<
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MMGYS7XW@ZKO,\IS.,73X"]/ZHB/PH[_/WQ[??IIL/DM[L
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M;Q41B:(I\E%-WJ>2:9B>,2H.6W?#8&W7V]72?/'#X'I\2-YP
M                                               39_4O=5]CF+OQ
MCB)I')%3N.'&C);DWDUYM$Y#]CV[O.(A^SW?((ST9UR-<\6UO&=E6BSO)_4Y
M$J1<I2%/1WH;B>U7HG[F:MAMFYVVV@M=7:K-K5/@Z:HTKPV$G2JFB8GC3<OS
MU;EV.=---JB8IJIN1/#<ZQ_JB[ZGM3\YHGCY:OBCE'M^1EU/KQZ(
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MC$^77N
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M[/?](V-_BUUY&%_Q3;_KE/OPL[G0^HX
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M[X3 11VT53'P_"T9'RX]P
M                    &%CU4/5=1<Y7\3/T1DZ'8%O?M.1\L,BLDZJT2;I'
M<CWC#](_$1UT:6W:G4,7K(&Z57VET@1:J0XQ.8KV']#S<U-JC^BQM'9TN515
M1EU%<<J9UINXO2?91K:LSP\7PE>DQ5;JCB^>X_7]16IX<ZY]ZGX9]KRL0AV!
M.,         #7+Z//_.\/)O_ "5.1^V[K4^*.G%]3[*/]+,?Q:^Y#L[_ (IK
M_K?PPH>G6*Y<                                    ?__3W\
M    $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
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MD8F(_"\L?#'P<M"Y\R/;@
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ME=44V,/FN&FY/]*F[33=_P"HZJ_Y^3QL;;\+A+EOMFB=//IP]U&S.]-.0
M     !O;]'SRMBWO57)CA;?+A_)O \KM_(/7T1]YQU^5B.:1+3A&P8D%NM*M
MQ;;B^3V*S2%)[T\Y&1+52E:^=:=</3@V-KP^<Y3M[AZ?U/B;,X*],1PBY:FJ
M[9F>^JY;KNT^2FQ$=SE>SU^)MUX:><3UH\T\)]$Z>EM'/@QR0
M                                               97O4>=9=CA[J^
M[<+^.>5);Y2[BQE4?/LHL-P0FY:#U;D,3Q?E(E17*R+1LW/K5(JU:*)]N5;+
M:\NYI4R\JVN.?8?19W$U;<9O1MYM19UV/P-W6S;KI\7&8BB>$:3PJL6:HUN<
MZ;E<19F*J8NQ'HLYS'U/;]369^?U1QGV,?'/9Y./<F_':<X:          &\
MGT:?^<;<]OV<<?\ _L!VN=<W3K^FVS?[WQGY>'<JV<^AW?/3\+:R? [DH
M             R,^K Z??V9..>&\ZM?V3XG87&CVL1VM\#'\YU\T3E5X_C&Z
M2/;0Y(D_8RSJYT?0A*4H9MU\N,AU5$1Z=OM?H9[R_D%M3?W=YG<TRS-M;F'U
MGA1B[=/&F.R/#V:=)GG-=JU33&M7'C^?83PEF,51'CT<)_<S\4^_*>&=G3B
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M17$QQIZM57/L%B[>-L1>M\^4QW3W?%_AIW\)L\L
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MA_NQNZO^P6VGRUTQ/J+W_P#2CA?RJGN<B_Q?'[BI3H.I-S8
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M&S]_J8BK#SRKIUCST_S:^A0Y.L9R\
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M[-NFW;HHB*::**(BFFBFF.$4TTQ$1$<(B-(<&JF:IFJJ=:IGB^D/W?R
M    -<OH\_\ .\/)O_)4Y'[;NM3XHZ<7U/LH_P!+,?Q:^Y#L[_BFO^M_#"AZ
M=8KEP                                   !__4W\          $Q?U
M4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
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MK1C*?!7M*<3'HJ\L>7OCVXX<M'Y\LO<@
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M-K6:+-'#2GK5S'A+ER:N!8_&UXZ_-RKA;CA3'='QSV_%$/,8K;P0
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MKVZXXTSI$Q.M-44UTU4T\\P^(M8JU%ZS.M$^YY)\KLT<3?N
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M9_G)? G]@V__ /L?U4=C/04^E.TG[XP?Y&(<5VC^B6O-5\#%.??#C0
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M=HXT51K#ED]*_0
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M\/)O_)4Y'[;NM3XHZ<7U/LH_TLQ_%K[D.SO^*:_ZW\,*'IUBN7
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M8B]RB>RKS]T^Y/OZWSXJ<@
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M8^.GO0
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M-N>W[../_P#V [7.N;IU_3;9O][XS\O#N5;.?0[OGI^%M9/@=R4
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MLUS$1<MU:<)C2:9B:*XIKIJIIYSAL39Q5J+MF=:9],3W3W2[5'#G[@
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MIBJFOK6ZIJJHJJGG&77\1B<-%[$4Q35/+3MCOT[-?YWJ81]YP
M       )4OJ2?KIN9OY.WZ*&BSN-Z*OU!<A^_?SCBW!,Y^F5S[G\BEX;GT(]
M6        :.O2N?6T8A_NQNZO^P6VGRUTQ/J+W_]*.%_*J>YR+_%\?N*E.@Z
MDW-@                    &#7UEG^<E\"?V#;_ /\ L?U4=C/04^E.TG[X
MP?Y&(<5VC^B6O-5\#%.??#C0       !VKX)?YW?X;?Y-7QY_;=Q X=O%^I]
MGO\ I&QO\6NO(PO^*;?]<I]^%G<Z'U'
M               &)'UAW%ERX8QQ5YGV.V^:\=N-^XY;&GM1U.O_ "9?47#8
M>K%R'F_IC6VV7.!E#2EN4JW61<V444E:Z)<^_N@YMA%K%YSL'B*^%VBC'6(F
M=(ZU'5LXC2.VJJFK#SI''JVZITF(UCC.T5C6FWB8[/%GWX^'TL)9V)N+
M     #<3Z3WJ91(E,DZ:>WLD]E4N7?ME<6)MWFU]IQ]Y"[OL[3UN]YWQ9<<4
MV_E-JCMHI1Q:KTI:_.L=M77STS=TU=?@MZ^26M8BFBQF$4QQTCQ</B:M.?9A
M[E4SPCP&D:=:8Y/D.-TUP5R?+3\,?#'MMS)UZ.4
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MLQ_%K[D.SO\ BFO^M_#"AZ=8KEP
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MA\?9KFBY;N4U47**Z9TJIKHJB*J:HGA,3$3#E=-5-=,543$TSRF.3](>*_H
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MOE/..Z>V)=Q3@SR
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M_P#8#M<ZYNG7]-MF_P![XS\O#N5;.?0[OGI^%M9/@=R4
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MXQ';X.[$<:[-4S53I,TS71I75S?!8^QCK?6MSI7'.F><?''E][D]-23/-
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M_557?KJFJJJJ9FJJJ9UFJJ9UF9F9UF9XS/&7.HB(C2.3YQ^;_0
M        2I?4D_73<S?R=OT4-%G<;T5?J"Y#]^_G'%N"9S],KGW/Y%+PW/H1
MZL        T=>E<^MHQ#_=C=U?\ 8+;3Y:Z8GU%[_P#I1POY53W.1?XOC]Q4
MIT'4FYL                     P:^LL_SDO@3^P;?_ /V/ZJ.QGH*?2G:3
M]\8/\C$.*[1_1+7FJ^!BG/OAQH        [5\$O\[O\ #;_)J^//[;N('#MX
MOU/L]_TC8W^+77D87_%-O^N4^_"SN=#ZC@
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M4=T]_FGL]'8]7B-//
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M]'G_ )WAY-_Y*G(_;=UJ?%'3B^I]E'^EF/XM?<AV=_Q37_6_AA0].L5RX
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MM3$T3'^'MN:#T+]0
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MV_9QQ_\ ^P':YUS=.OZ;;-_O?&?EX=RK9SZ'=\]/PMK)\#N2@
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M*J>YR+_%\?N*E.@ZDW-@                    &#7UEG^<E\"?V#;_ /\
ML?U4=C/04^E.TG[XP?Y&(<5VC^B6O-5\#%.??#C0       !VKX)?YW?X;?Y
M-7QY_;=Q X=O%^I]GO\ I&QO\6NO(PO^*;?]<I]^%G<Z'U'
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M7P6(M:Z4W;54\XGE53/C45:TU1$PYYA,7:QEJ+MJ>';';$]TNZQP%Y(
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MQ_%K[D.SO^*:_P"M_#"AZ=8KEP
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M35$\)B8B8ER&)BJ.M3,33+[<_!_H
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M]_6[T1$=;2-?!UQ1=B-)JMTQ,:\MPN-PV,IZUFK6>V)YQYX^'EY7?@F[RP
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MK,4UW*Z8YQE67Q@K77N?XHJCCY([OC\OFA[^GS8]L
M  E2^I)^NFYF_D[?HH:+.XWHJ_4%R'[]_..+<$SGZ97/N?R*7AN?0CU8
M   !HZ]*Y];1B'^[&[J_[!;:?+73$^HO?_THX7\JI[G(O\7Q^XJ4Z#J3<V
M                   8-?66?YR7P)_8-O\ _P"Q_51V,]!3Z4[2?OC!_D8A
MQ7:/Z):\U7P,4Y]\.-        ':O@E_G=_AM_DU?'G]MW$#AV\7ZGV>_P"D
M;&_Q:Z\C"_XIM_URGWX6=SH?4<
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MQ'K[-4]:GG$U43375SC!8ZQCK?6M3I7'.GMCXX\O_P!4>E!*7F@
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MB9U\)1GUJF.[2O"8R9]O6B-/;]KW^ST_JRN.SP<_E4J,1U=.8
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M8K"UTW,-=HBNBNF8JIJIJC6FJFJ-8FFJ)B8F.$Q.L.%3$TSU9X3#ZP_5_@
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MS=MTQ&M5=/*.5X/.,+BM*:Y\'=[IY>U/+TZ2T#'S2]L
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MC\\MVJM(GLB?!<8[=(GLX<DV<J^>7:>^F)]$S\;? =<#E8
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MV-W5_P!@MM/EKIB?47O_ .E'"_E5/<Y%_B^/W%2G0=2;FP
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M5?/6JJQ/5LW)T];-FJ9JJKJEPS.\#ZGO^J+<?.;D^BKM]/./;[F7\^N7HP
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M+K=5-NM.MJHI*DUJE2:]Z?0?&=5-5%4T5Q,5Q.DQ/"8F.<3'>]\_J?X
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M6KEG%VYTKHN4S173/=535$54SY)B)>YIJIJCK4S$TSVP^]/'?Z
M             /J;[?K'B]GN60Y->;3CM@L\1V?=[Y?;C#M%GM4%A/D_-N5S
MGO1X4&(RGZ5N.K0A-/PU/VP^&Q&,OT87"6Z[N)KJTIHHIFJJJ9Y133$3,S/=
M$3+_ "9BF-:IB(AG_P":/J7^FWQ4;NN/ZZS2X<N-G0U/1F,9T.Y#GX)'F-+=
M0E=\W+<5(PCY+<4PI/O6*N0R$JJBM8_MK\Z?2NP71/WJ[8S1B<TP].2935I,
MW,9K3>F/VF%I^>];CRO>!IY^-K&D^IQ.=8*QPHGPE?=3R]/+T:L>'.OU('42
MYE4O6)X?F+'%+3MS^*BTP31<^Y6S+;I:9"*-_!YAMYY3&:79:V5.-/HM7R%;
MI;+E4/0UT[5/N/=WT6-V&PO@\;CK$YSGE&D^&Q<4U6Z:H[;6&C6U3QTF)N>&
MKIF-::X<=Q6<XS$ZTTSX.WW4\_;GGZ-(> KKKC[CCSSBWGGEK====6IQQUQQ
M55N...+K52UK56M:UK6M:UJ?241%,133$13$<(>J?X/]?X            !^
MNP# <TVIF^)ZVUSC%YS3/<[R"U8KA^)8]"=N-[R+(KW,:@6JTVR$Q13C\N;+
M?2A-/HI3OWK6E*5K3PLRS+ 9/E][-<TO6\/EN&M57+MRN8IHHHHC6JJJ9Y1$
M1J_JBBJY5%%$3-<SI$*EO0_Z0&)=,#0U;QFL>T9)RWV_:+=+W1FL9$2:QB,"
MJF;A#T[A%S;2M?S6QR4AM=QDMN53>[LS\2K]09@LQ^G_ *06^_&[W=H_ 8":
M[6Q6!KJC"VIUB;D\:9Q-VG[)7&L44S'SJW/4]=5<JJYSEF7TX&UK5I.(JCC/
M=Y(\GOS[6GN.?/;V@                   'G#U3^G=K[J8<2<TT#E*H-CS
MJ%WS#26Q'XOOR=?;1M,9]-GN#BFTJ?=QN_L/.VN\QTT55ZW2W%MT3):C.M5/
M<]O/S/=/MKA]I<'UKF75?.L78B=(O8>J8ZU/=UZ)B+EJKLKIB)\2JN)\/'8.
MC&X>;57"KG3/=/Q=DI(^YM.['X^[5S[2FWL7N&%[*UGDMRQ/,<:N:/&3;;O;
M'?;75MQ/=F;;YK-42(DIE2X\N(ZV^TM;3B%5[J,ASS*MILFPV?Y)>IOY3B[-
M-RU<IY54U1Z8JB=::J9TFFJ)IJB)B8C@%RW79N3:N1I73.DPXS/;/S
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M44WJ;=4SRIF.,\HPN8X7&1\ZJ^>>QGA/H[?:U>GQ(WG
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M%5,Q,3$Q.DQ,3QB8GA,3QB7LHF)C6.3Y9_#_ $
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M7BM+]^*H^NMZTQ;LU>6Q;MS,<)F7'L5F>,Q?"Y5I;]C3PCV^V?;F7DD6IZ\
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MLL_SDO@3^P;?_P#V/ZJ.QGH*?2G:3]\8/\C$.*[1_1+7FJ^!BG/OAQH
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MPEVB*Z*Z*HJHKHJC6FJFJF9IJIJB8F)B9B8G6)T</F)IF::HTJA]0?L_P
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MTNW(BKJ46^9Y5E<82GP][CB)C\&.[S]\^UY],Q\FO=@
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ML7L/C;<Z56[M%5NNF>ZJBN(JB?),0]M35373UJ)B:9[8XP_3GB/Z
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MPM&!RZS:P^"MTZ46[=%-%%$=U-%,133'DB(AZJJJJN>M7,S5/;+\X>4_D
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MBYAKE$545TS%5-5-4:TU4U1K%5-43$Q,3,3$ZQP<1F)B=)X3#ZT_5_@
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M+ 4\K=BU1:HC[FBFF-?+IK+U%=RY=JZ]RJ:JN^9UGW7'![1_
M     VA= 'T^4G8\G$>;_//!'X>N8;\3(=$<=\OMCD>3L23'<3(MFR=JV&X-
M(=8U\PZA+MHLDENBK^JB9,M%+71IJZ?!O24Z3%&5T7]WV[G$Q5FE431C,;:J
MUBS$\*K&'KCG>GE<NTS\YXT43X;6JUR3*<HZ^F*Q4>)];3/;Y9\G=';YN>]Y
M*4H2E"$I0A":)0A-*)2E*:=DI2FG:B4II3M2E/P'7!,S,ZSS<K?Z
M                )4OJ2?KIN9OY.WZ*&BSN-Z*OU!<A^_?SCBW!,Y^F5S[G
M\BEX;GT(]6        :.O2N?6T8A_NQNZO\ L%MI\M=,3ZB]_P#THX7\JI[G
M(O\ %\?N*E.@ZDW-@                    &#7UEG^<E\"?V#;_P#^Q_51
MV,]!3Z4[2?OC!_D8AQ7:/Z):\U7P,4Y]\.-        ':O@E_G=_AM_DU?'G
M]MW$#AV\7ZGV>_Z1L;_%KKR,+_BFW_7*??A9W.A]1P
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M\O5KBF=.Z>4]CW-NY;NT]>W5%5/?$ZN23U3^P
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M0ZR\TM+C3K3B:+;<;<16J5MK36E:5I6M*TJ="TQ-,S35&E4<X4E_0_P
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MD'2J^H+GWWE^<<(\[)OIE;^Z_(J56CIR<[          #__4W\
M$Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
M   ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
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M#CHTQF"Q5VQ<X:>/9N56ZN'9QIE2K=<7;=-RGUM5,3'MQJY)/5/[
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MG=_AM_DU?'G]MW$#AV\7ZGV>_P"D;&_Q:Z\C"_XIM_URGWX6=SH?4<
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MFM*TK6E275T5VZYMW(FFY3,Q,3&DQ,<XF.R8[8>9SXQR?W/Y
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M'DAX$S,SK/&7UI^K_           ^SLEDO.2WBU8]CEHN=_R"^7"':;)8[)
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M8._5QKBC'68UX:QU;&(]N8]3::<=*:M>$<.,[16.%O$Q^YGWX^%A>.PUQ8
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MKG4O1P[)[)\WQ<W0LHSQ
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M9HHG2JJ:ZZ:9HYIEN56\%'A+FE6)F.?9'DCX_>[="A\RO;@
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MGP5OG$55SPF]>TG2;E<<-9BW313,TN:8'+[&!HTM\;LQQJGG/Q1Y'JN1QYX
M  >$/J,.%[W,'IH;0GXS:%W7:/&N6QR'P%F*RZ[/G0,-A3HNS+$PF,EV5)^4
M-9W*YRF(J$.5E7*!#1XT5XK3]%]%W;RG8?>Q@[>+KBC*,UIG!7IF8TB;LQ-B
MN=>$=6_3;IFJ9CJVZZY[XGU6<8;U1@JII]?1XT>US]S7V]$KL[AG!0
M  !3J]+URO9Y"=,W&]5W:XHDYUQ/S*^Z@NL=RJ_CWL&NC[N;:RN[U/I9I!19
M[Y)L<;Q\55I8%^2>_9;G4ETN]C*MF=[-W.+-.F79U8HQ-,]D7:8\%?I[]>M1
M3=J_KT:3V1S?(\1X;!1;GU]N=/:YQ\7M-'!\MO<
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M6W:)JMU\8BKK1533PK%X*_@KG4O1P[)CE/F^+F\_2EO$
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M_6/:6<OP&'K\)A[%FW<TYTT4TSZ8B)?Q-=4\)F9A^8/+?R
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MM=;LU3U:*.8Y;E%O":7KVE6(]RGS>7R^CRZ7SY/>Z
M        E2^I)^NFYF_D[?HH:+.XWHJ_4%R'[]_..+<$SGZ97/N?R*7AN?0C
MU8       !HZ]*Y];1B'^[&[J_[!;:?+73$^HO?_ -*.%_*J>YR+_%\?N*E.
M@ZDW-@                    &#7UEG^<E\"?V#;_\ ^Q_51V,]!3Z4[2?O
MC!_D8AQ7:/Z):\U7P,4Y]\.-        ':O@E_G=_AM_DU?'G]MW$#AV\7ZG
MV>_Z1L;_ !:Z\C"_XIM_URGWX6=SH?4<
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MW+5VW5%5%=%4:Q53,<XGW.4\7#:Z*K=4T5Q,5Q.DQ+\:><_@
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M]I/BUXJN/7SVQ:I^=43IPKKIBY/,LORJS@HZ]7C8CO[(\WQ\_-R>\I\YO:@
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M3;?73<,ORB?T4-Z'T)TJOJ"Y]]Y?G'"/5Y-],K?W7Y%2JT=.3G8
M ?_6W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?
M/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K
M?W7Y%2JT=.3G8     '"'(CC=HWECJG(M(\B=:XWM36.4-H^4\9R2.ZI+$QE
M#J(5ZL=TA/1+SC626SWUUB7.W2(L^(I5:M.HK6M:\@V8VJVAV,SFUM!LOB[N
M#S>SZVY1/.)YT5TS$TW**M(ZUNNFJBKZZF7Y7K-K$6YM7J8JHGLG_#A/E3S.
MK1Z:_?G#5[)=U\1V<IY'\9(ZI-UN5BCP47/=NH+8GNX]3);):([/V0<6MZ*>
M:KU:8C;\9GR5-A,,LJEN=G&Y?I6;-[=4VL@VVFSE6ULZ4TUS/5PF)J[/!UU3
M/@;D\O!7*IBJ=(MW*JJHHCB.89-=PVMW#ZUV/[*//WQY8]OO9?SZY>C
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M337'9+A\]V_(
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M)S:BGU/BXC3AB;,1375I'*+M,T7Z8[*;E,=B?9CA?4F+JM1ZSG3YI^+E[3S
M*X\$        T7>F2YO1N*/42LNK,OO+5JU;R_M$73%[<FR%,6Z!LQB8[=-+
M7EVB?H<FS,G?D8XQY?>(^<JUJ[43Y)^7NEIN_KVRW87,XP-N:\XR.N<51I&M
M4V)B*<53YHMQ3?GMGP$1'/2?<Y)B? 8R+=4_.[D:>W];[O#VU/0ZCW-@
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MMQIQM54.-N-KI12%H52M*TK2E:5H?9D3%4153,33,<)>A?X/]?X
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M0_W8W=7_ &"VT^6NF)]1>_\ Z4<+^54]SD7^+X_<5*=!U)N;
M         ,&OK+/\Y+X$_L&W_P#]C^JCL9Z"GTIVD_?&#_(Q#BNT?T2UYJO@
M8IS[X<:        .U?!+_.[_  V_R:OCS^V[B!P[>+]3[/?](V-_BUUY&%_Q
M3;_KE/OPL[G0^HX
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M1XU%55$Q5/"L3A;V$N>"OQI5[D^6)[74TYF\<
M                              '^DI4M24(2I:UJHE"$TJI2E*KV2E*:
M=ZU56M?HI^N)F(C6>3_6G;I6>FDY(<QG,=W!RR1DO&#C9+3%NL"US[<B%O/:
M=J?0U(C*Q7&;S%>:P/';C'<\D7F]1UNN(JA<2WRF7:2&_DC?%TK]E=AHNY'L
M7X+-]JJ=:9JBK7"8>J.$^$N4S'AJZ9_6K541$ZQ7=HJCJS[K Y+>Q.ES$:T6
M?[*?-'9YY]"@WQ:XC\=>%NJ[7IGC1JW&]78+;?;?DQ;-'6]><DNR([<9W(LR
MR6<N3?\ +LDE--)2Y-N$B0_X)2VE26T(0GK.VPVUVHV]SBO/MK,9=QF8U\(F
MJ=*:*==>I:MQI1;HC7A113$:ZSQF9F>76,/9PUOP=BF*:??\\]LNQYQ9^P
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M--,<*:*8BBB-*::8B(B.66K5NS1%NU$4T1V0Y:/2OT
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MU8>OQ8OT<Y\6*;E,1,UVZ:=*IX;CLLQ&"GK3XUGV4?#'9[WE>+Q>7K0
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MXFUWZV]9Z]$?9+4UV^,1-45:Q'$L7@,3@ZM+U/B=E4<8GV^SS3I+S=*H\(
M                                                  /V>O-<Y_MO
M-,>UQJW"LIV)G^6W!JU8SAF%V*Y9+DU^N+W>J(EJLMHC2Y\Q[P352J(17P0F
MJE=DTK6G@9GFF6Y)@+N:YQB+.%RVQ3UKEV[73;MT4QVU553$1'GGC/#F_NBB
MNY5%%N)FN>41S;7.EIZ5!=:XWNSJ8SDI314*\6;BEA5\JJJD>#4AMC=.?V1]
M-&U>=5)>LF/2%?11%7;I]+L2GP-O@Z8\?/<@W3T]]-68W:/:UPMFN/1=O4]^
MEGUM<\EP.1<KN-_!C_-3\$>GL;:,&P3"M8XAC^O]<8EC>!X-B=M8L^,8?B%E
MMV.XUC]JC=_9M]GLMICQ;=;XC=55KX--I352JUK]-:UK\!9CF./S?'7<RS2_
M=Q.8WJYJN7;M55=RNJ>=55=4S55/EF7)::::*8HHB(ICE$<GZL\-_0
M                      !*E]23]=-S-_)V_10T6=QO15^H+D/W[^<<6X)G
M/TRN?<_D4O#<^A'JP       #1UZ5SZVC$/]V-W5_P!@MM/EKIB?47O_ .E'
M"_E5/<Y%_B^/W%2G0=2;FP                    #!KZRS_.2^!/[!M_\
M_8_JH[&>@I]*=I/WQ@_R,0XKM']$M>:KX&*<^^'&@       #M7P2_SN_P -
MO\FKX\_MNX@<.WB_4^SW_2-C?XM=>1A?\4V_ZY3[\+.YT/J.
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MPQP\S.B?4+TX
M   ](N G2?YK=2#(D1./.KI+>OH=T;MF4[RSM4G%=.XHY1;5)C4G*G8<E_)+
MO;VWT+>M5BC76ZMMN(6J,EM7G25[R=\VP.ZS"S7M/C(G,ZJ.M;PEG2YB;G=I
M;B8BW35I,1<O56[<S$Q%<S&CS<)@,3C)^<T^)VU3PB/;^"-94!>F5Z>3AKT_
M:V#8^9PV.3O):VN,7%G:NQ+!#:Q;"+LRMMYAW5.MWG[M:\:EV]UE"F;M.?N5
MZ0^E3D>3$;<^'1UJ[VNDYMWO+\)E6 JG*-DZXFF</8KGPEVF>$^J+\135<B=
M9UMT1;M3&D545S'6GEF"RC#832NKQ[_?/*/-'9Y^,O?L^;'M@       #R:Z
MTG3UA]1W@OL34MEM[#^Z,$]S;''Z<IR+%>KL[%K7<41\4>GRO;:CVK85EFRK
M,_[KK<9E^5'EN=ZQ$=K/N%WFW-UF\/"YUB*IC(<3^I\9'&8]3W*J=;D1'.JS
M5%-V-(FJ8IJHCU\Z^!F6#]686;<?1(XT^>.SV^22=<;=<+/<)]INT"9:[K:Y
MDJW7.V7&*_!N%NN$%]R--@3X4EMJ3#F0Y+2FW6G$I6VM-4JI2M*TIW3VKMJ_
M:IOV*J:[-=,54U4S$TU4S&L3$QPF)CC$QPF' )B8G2>;X9_;_        "GO
MZ:_J),<S>#5GTUG%\5.WUQ#A6+6&5TGR$+N64ZP]B5'U%FR?-UR5,4UCUK58
MY[RZK>7.M%9+RJ5F-TKU']*S=?5L'O"N9[E]OJ[.9W57B+>D>+;Q&L3B;7='
MCU>%HB-(BBYU:?63IS?)L9ZIPL6ZI^>V^$^6.R?1P]KRM%9\O/<       )?
M?J)-$;PS/K%\P<EP_36U<KQVY?:_?)U_QK7F77VRS_@^+>DH$OX*ZVNSRH,K
MX6=%=9<\'%>#K:D*[*36E.W3HP;1[/8#<9D>$QV/P5G%4>K.M1<OVJ*XUS#%
MS&M-543&L3$QK'&)B>4N$9Q:NU9C<JIIJF/%Y1/L:7J#Z174VU-=<C.7DW8.
MM-@8+#N.E,'BV^7F6&Y'C$:?):SIUUV/"?O=M@M2GVVJ^2D(JI24_36G8D73
M8SK)\TV7R2WEF+PV)N48^]-46KM%R8B;,<9BBJ=(\LO.V?MW*+USKTS'BQSC
M3M;PSKH<I  $4_[6'DK^+SO+\TN??O?._#Y;MD_MIEWXS9_337P%[V%7HE4Y
MZ#..9#B720X88[E5BO.,Y!;,*SAJY6+(+7.LUXM[KNW]B26FYULN+$:;$6Y'
M>0XFCB$UJA:54^BM*UZ?.D;BL-C=]6?8K!W+=[#5XBUU:Z*HJIJ_4UF.%5,S
M$\8F.$\X<ZRJ)IR^W%4:3I/OR]=R)/8   !BG]81K#9>R/XG?]CO7F<Y[\C?
M;;?+'S+Q*_Y3\E?*/VLOR?\ *7R';YWP/QWP+_L^[X>[[*_'OX*[??'0>S?*
M<J^6?Y*8K#X;PGR-ZOA;E%OK=7U?UNKUZHUTUC73736-><.-;0T5U^!ZD3.G
M7Y1K[%XI^G;T1O##.L7P^R7,--;5Q3';;]L#\HW_ "37F76*RP/C.+>[8$3X
MVZW2SQ8,7XJ=*:9;\W$^;KB4)[J52E;YTG]H]GL?N,SS"8''X*]BJ_4?5HMW
M[5=<Z9AA)G2FFJ9G2(F9TCA$3/*'K<GM7:<QMU54U1'C<XGV-2H(=1;FX
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M+W\/>PU?@[],TU>7X)Y3[3KB<I?@
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M)B,+5U;],T^7LGS3R=.SG#Q@
M           /[Q8LF=)CPH4=^7,EOLQ8D2*RY(DRI,AQ+3$>.PTE;KS[SJZ)
M0A-*J4JM*4I6M3^:ZZ+=$W+DQ3;IB9F9G2(B.<S/9$=LO]Y\(YM)73F],QS2
MY?N638'(>/,X?Z)E*8F5E9W8Y#N[,NMRT>^BF):KEJ@2;!&EII1NL_(GK;[2
M74/QXD]%*HK\J[TNEGL%L1%S+-F)ISS:*-8TLUQ&%MU<OGF(C6*YCGU+$5ZZ
M3357;GB]S@\EQ.(TKO?.[7E]=/FCX]/;;T."'3$X;].;#ZX[QKU9!M63W*VL
MV[,-NY0IG(]N9VAIU+ZDY%F3\5AV/;7)*$NTMEM:@6AMQ-%MQ4K[JKUR;Q=[
M>W6]''>JMJ\957A**YJM8:WK1AK/9XEJ)F)JTX>$KFNY,<)KF.#E6%P.&P=.
MEFGQNV9YS[?P1I#T!)J\L                               )4OJ2?KI
MN9OY.WZ*&BSN-Z*OU!<A^_?SCBW!,Y^F5S[G\BEX;GT(]6        :.O2N?
M6T8A_NQNZO\ L%MI\M=,3ZB]_P#THX7\JI[G(O\ %\?N*E.@ZDW-@
M             &#7UEG^<E\"?V#;_P#^Q_51V,]!3Z4[2?OC!_D8AQ7:/Z):
M\U7P,4Y]\.-        ':O@E_G=_AM_DU?'G]MW$#AV\7ZGV>_Z1L;_%KKR,
M+_BFW_7*??A9W.A]1P
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MB-9ZL5QUK54^LKJCBXIB<'B,)5U;],Q'9/9/FG_"71\H+Q0
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MFFJ)[)TF.$Q,Q,<8F8F)F@45TW*(N43K15&L3Y'[L]<_L
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M1/!Z"Y:N6:NI=IFFONF-'%![E^8
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M5-5=RY5-===4\ZJJJIFJJ9[9F9F7OJ:::8ZM,1%,=D/O3QW^@
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M/7U+U,TU>7X)Y3[3KZ<E?B
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MQ%4Z7.RF_.NL^&B*>6Y)F'A*(P=Z?GE,>+/?'=YX[/)YN.Q4^&G(@
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M\YQ,3W1:KF/":=M5F;E$:QK5K.CCN)R_%X3C=HGJ=\<8]/9[>CS6*L\(
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MC=U?]@MM/EKIB?47O_Z4<+^54]SD7^+X_<5*=!U)N;
M   ,&OK+/\Y+X$_L&W__ -C^JCL9Z"GTIVD_?&#_ ",0XKM']$M>:KX&*<^^
M'&@       #M7P2_SN_PV_R:OCS^V[B!P[>+]3[/?](V-_BUUY&%_P 4V_ZY
M3[\+.YT/J.
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MA%4T]2J?6U51Q<;Q&$Q&%JZM^F:?+V3YIY.G!SEXP
M                      #U+X1]&;J%<^E6J[Z4T9=;%K*Z^TZC=VVE2=<Z
MEI!<6TW6Y6J_72"_=\VB-*=IYIQRWWE]-*5K5OLE7:/[P-^^[+=MU[&?YC1<
MS:C_ !IAM+^)U]C513,4VIX</#UVH\O&'GX;+<7B^-JG2CV4\(_G]K5LFX(>
ME*X@:&59<VY?Y5<N6NQH;D2X?,Y$>=@FB[/-;:2[6&[CT*X.Y5L!N'._ [<Y
M\6WSFD42_:DI4MNOPMO%Z9.V^T<7,OV(LT9+E=433X76+V+JCOZ\TQ;LZQV6
MZ*JZ)GQ;VL1,<BPN0X>UI5B)\)7W<J?CGV_0U$85@V$ZVQ>T81KK#\6P'"\?
MC?!6'$<*Q^TXKB]DAT6ISX2T6"Q1(%JML;W%U5[;+2$]ZUKV[U/D/'YAC\UQ
M=>89I?O8G'W9UKN7:ZKERN>^JNN9JJGRS,O>4T4T4Q31$13'9'"'ZD\-_0
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M$3K'@=*N1Y)F'@ZO4=Z?G<SXL]T]WFGL\OG4"#K4<L
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M^69F7NJ:::8ZM,1%,=D/T!XS_0
M        #B_<&DM/<@<(N6MMY:PP3;>!79*OCL3V%B]GRNR+>JRZPW.8A7B)
M*;A72*V^JK$MCVY,==?-IQ"J4K3V^1[09YLUF%&:[/8O$8+,J.5RS<JMUZ:Q
M.DS3,:TSIQIG6FJ.$Q,<'YW+5N]3U+M,54=TQJRR\UO22\7=I5NN6\+-H9)Q
MJRQ_WY+.N,V5<=GZ<EOJ75;4.W7&;+ILK"VW%.*]Q]R=D+2$)0AJ&CLJM?L'
M8'IJ;7Y/U,%M[@[6;8*-(F_:ZN'Q41WU4Q'@+ODB*+,S,S,USPT]'B<@L7/&
MPU4T5=T\8^./=\S)-S&Z)74CX0UNUUVIQXR+,-=VE+S[VWM*ID[5UNBW,)>6
M[=[M.Q^'7(L+M:*1U=W,AMEHK3NGZ/OT>7VIL-O_ -U>\#J6<GS2U8S2O2(P
MV*TP]_K3II33%<]2[5QY6;ESM[IT]!B<LQN&XW*)FCOIXQ\<>W$/* LKUX
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ME$N-.M.)JE254I5-:=J_2=K=-5-=,5T3$T3&L3'&)B>4Q/<X9R?R/]?X
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MKY*XIF9HJ_:U1$QVP]-=LWK%75O4U4U>6-'!YR!^0
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MYR7P)_8-O_\ [']5'8ST%/I3M)^^,'^1B'%=H_HEKS5? Q3GWPXT
M=J^"7^=W^&W^35\>?VW<0.';Q?J?9[_I&QO\6NO(PO\ BFW_ %RGWX6=SH?4
M<                                                          ?
MF,SPC#-CXQ>,*V%B.,9YAN0Q%P+_ (EF=@M648Q?(+G:KD*\6&]Q)UJN<1=:
M4[MO-+17M^ \O 9AC\KQ=&/RR_>PV/M5:T7+5=5NY1/?371,54SY8F)?S533
M73--<1-,]D\89H.;?I5^"O(/Y7RSC-><DX?[&E-O/LVO'&W,[TI<9Z_U2JIV
MO;]<8]\QWWUH2TCY$O4&!$0I2Z0'JTHFOUAN_P"F+O$V9ZF"VLMVL\RN-(FJ
MOYSBJ8\EZBF:*].<^%M5UU3$1X2GF]+B<BPM[QK$S;K\G&GT?%/M,D',?T]7
M4WX>UNE[DZ6<Y :VM_Q#U-C<<W9VQH[4%E;BOB+S@K=NM^SK'[$-*79+SEF7
M;F.]:4EN42I5/M787I-[I=N.IAZ<?&69K5I'@,=I8G6>RF]UJK%>L\*8B[%<
M^PC6(>@Q.48W#\>KUZ.^GC[G/W-'B3*BR8,F1"FQWXDR(^]%EQ)3+D>3%DQW
M%-/QY##J4.LOLNHJE:%4HI*J5I6E*T+_ $5T7*(N6YBJW5$3$Q.L3$\IB>V)
M[)>LY<)YOX']/\                                   <O:7X_[RY&Y
M:Q@>A-1;&W%F#ZF*5Q_7&(7S+KA%;D+6AN7<F[-"EHM5OI5M55R9*FH[:4*4
MM:4IK6GI,^VEV>V6P4YCM)C<+@<#&OCW[M%N)T[*>M,=:KNIIUJG6(B-9A^E
MJU=O5=2U3-57DC5I2X>>DVYN;C7:,CY4YQ@W%'"I/PLJ5CK;L7;&X7XCE&Y%
M8Z<>QFZ1L%L*Y4>OMU<E9 [*ANJ[NP5U15NORGMSTS]W^117A=CL/B,YQ\:Q
M%?'#8:)Y:]>Y3-ZO2>.E-F*:HY7(UB8]UA\@Q-SC?F+=/IGW.'N^TUB<+_3]
M]-'A:]:<CLFFD[SV?:U1Y+.S^1#UOV/=8EP8_5&YM@Q%RV6W6V-28DI57(TF
M)9DW%CLCO*6I"5GQCMYTE=[&WM->%Q&/^1V45ZQ.'P456*9IGLKN=:J_<B8X
M54U79HGCXD1,P]]ALIP6&TF*>O<[ZN/N<H]&KVL2E*$I0A*4(0FB4(32B4I2
MFG9*4IIVHE*:4[4I3\! YF9G6>;V;_0                !XM];+I-XKU0^
M-J[?C;5HQ_E!J.-=;]H3.)]6X<6=*DH9>O6K\NGT:6[3#\W3#;0AZO>MKN:&
M):?)I,EB1>=P.^?&;H=JO"XJ:[NR.-FFC&6HXS$1K%&(MQ]EM:S.GZY;FJCA
M,T54^MS/ 4XZSI'"_3ZV?@GR3[D^[*LSK!LPUEFF5ZZV#CEUQ#.<'R"[8KEV
M+7V*N#>,?R*Q37K==K3<HKGWS,N#-CK;73Z:=T]Z5K2M*U[C,NS' YO@+.:9
M9=HOY=B+5-RW<HG6FNBN(JIJIGMB8F)<$KIJHJFBN-*HG28?E#S'\@
M/ZL/OQ7V945YV-)C.MOQY##BV7V'V5T<:>9=;JEQIUIQ-%)4FM*IK3O3Z3_*
MJ::Z9HKB)HF-)B>,3$\XF.Y_O)2@]/#UJ8O.36\'B=R/RAI'+W5&.MIQ[(+L
M[1M_D+KBQQ/;^<C$EQU59VS<0A1TTR%A7B]<(]471GW?Y(TB=5'2=W"5[O<U
MJVSV5LS\I&-N^/13'#!7ZY^AS'98NS/SF>5%6MFKJ_.NOS/*,R]54>I[T_JB
MF/PH^..WT]^FGT^1GNP                               __T]_
M     !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F
M        /<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3D
MYV                 'E-RTZ)O31YF*GW7:G&7#\;SJ<E:E;-TZE>H\Z5,<
MJ[WN=UF872W63,+A1+U4T7?H%U3XT33Q^\;\;)L7O^WL;"139R?-K]W+J?UC
M$_JFSI[&F+O6KM4\.5FNWV]\Z^!B,LP6)XW*(BKOCA/N<_;U9JN4'H[LBB?&
M7CAIROMMY9I\2N+@/)&P/6><VVWY.1T4VAK:UW&%<9;Z:T;\5XK :2M/E5VB
M55HW]6[(].3"U]6QMWDU=NKAK>P-<51Y?U/?JIFF(Y\,17.G#36-9]+?V=JC
MCAKFODJ^./B9X^2'1&ZHW%I4Z5L3B%LW(L:A*<77--/0HVZL65!;JY3Y5FR=
M92,EN..6]7M5^^N\6W.([I\T)\D>7T[LKT@-T&V$4T97G>$M8NK]:Q,SA;FO
ML8B_%NFNK^M55Q/'29TG3U%[+,=8]?;JFGOCC'N:^[H\KI463!DR(4V._$F1
M'WHLN)*9<CR8LF.XII^/(8=2AUE]EU%4K0JE%)52M*TI6A8:*Z+E$7+<Q5;J
MB)B8G6)B>4Q/;$]DO!Y<)YOX']/\                      /G6RUW*]7"
M':;-;IUVNMP?1%@6RV1)$^X3I+M?%J/#AQ6W9$E]Q7T)0A*E5K^"A^=V]:P]
MJJ]?JIHLTQK-54Q%,1WS,Z1$>67^Q$S.D<WKGQHZ#?50Y1_ 3\2XJYEKG%)W
M9?STWTJ/I>S,QE>/M3VK1FRK?G%Y@/T52K;MLM$Y+B:^2>Z?OB*;6=(W<[LA
MUK>-SFQBL93^M8/7%53/=UK76M4S';%R[1IRY\'L+.58^_QIMS%/?5P]_CZ(
M:,>+'H\<:@.P+YS1Y4W#(5-JC.S-=<<;&FR6U3K79UYA[:6Q+;.N5PM\ES]2
M6AK%[=(HTFJD/H6NGM?+FV'3CQ=RFK#[!9/3:B=8B_CJ^O5Y)C#V*HIIJCGK
M.(KIUYTS$<?<6-G:8XXFYKY*?CGXH::^)/2OX!<'V[=*XZ\9M=XMEUM;\6MG
MW^WN9YMA3KB7:2GFMD9L]?LLM3<ZKRJNQH$F)"[=DI92A"$)^2]M=\6\G>#-
M5&U&;8J]@JY_Q/15X'#>2/ 6HHMU::<*JZ:JNV:IF9F?=X? 83"_0:*8J[^<
M^F>+T%)H\L
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M*2JE:5I2M"Q45T7*(N6YBJW5$3$Q.L3$\IB>V)[)>#RX3S?P/Z?X
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MJ8UC6=)TUXOZIMVZ)UHIIB?)$.2SU3^P
M     /R&=:^P+:&,7+"=F81B&Q,-O#=&KOB6=8U9LNQBZM)^E+=RL-_A7"U3
MFZ5K]%'6E4H>;EV9YEE&+HQ^4XB_A<?1ZVY9KJMW*?W-=$TU1[4P_FNBBY3U
M:XB:9[)C6'A3R?\ 3.=+'D56XW7%]7Y/QGR^?YN_+O'W*%V"R?$^='&O/765
M1,MU["@IK2J5LVRW6U2VU5I1Q"J(6GZ)V1Z6.^'9?J6<7C+.;8&GZS&V^O7I
MV_/[<V[TSVQ-RNO2>R8UB?5W\EP-[C33-%7[6?@G6/1$,]?)+T?W)_$/C[MQ
M:Y):IW3:V?.0SB^T+/>]/9HMJOC1JWVV=;:[!P^\SD*5]\[+EV1A2$U5V2KL
MW7Z:V5Z;^R.-ZMG;#*L9@+T\)N8>JC$VM>^J*O W:8\E--V=>^.,>HO;/7Z>
M-BNFJ.Z>$_#'O/!;D/TA>I9Q;7/<W!PXW/"LEM\US,PPG'*;7P6/&33S1+EY
MIJV1F.-6UAUOLJE)4EAQ/\JI*5T4FGT=LQONW4;813&1Y[@*L17RM7:_4]Z9
M[HM8B+5=4_N:9CMB9C29]5>R_&V/HENK3OB-8],:P\XG6G&''&7FULO,K6TZ
MTZA3;C3C:JH<;<;72BD+0JE:5I6E*TK0J43%4153,33,<)>&_P '^O\
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M,S,S.LS,\9F9GC,S/&9GF]C$:<(Y/DG\
M           <4Y+HC1^9WJ;DN8::U3E>17+X;Y1O^2Z\Q&^WJ?\ !Q&($3XV
MZW2SRITKX6#%:9;\W%>#3:4)[)32E/<X3:+:# 8>G"X''8RSA:->K1;O7**(
MUF9G2FFJ(C69F9TCC,S/.7YU6K54]:JFF9\L0^C^UAXU?B\Z-_-+@/[WSR/E
MNVK^V>8?C-[]-_G@+/L*?1!]K#QJ_%YT;^:7 ?WOCY;MJ_MGF'XS>_3/ 6?8
M4^B#[6'C5^+SHW\TN _O?'RW;5_;/,/QF]^F> L^PI]$'VL/&K\7G1OYI<!_
M>^/ENVK^V>8?C-[],\!9]A3Z(/M8>-7XO.C?S2X#^]\?+=M7]L\P_&;WZ9X"
MS["GT0?:P\:OQ>=&_FEP'][X^6[:O[9YA^,WOTSP%GV%/H@^UAXU?B\Z-_-+
M@/[WQ\MVU?VSS#\9O?IG@+/L*?1!]K#QJ_%YT;^:7 ?WOCY;MJ_MGF'XS>_3
M/ 6?84^B'Z/%=):8P6[(O^$:CUAAM];8?BMWK%<!Q7'KLW&DIHF3'1<K1:8<
MQ+$A*:46BB_%=*?32IXN,S_/<QL>ILPQN+OX>9B>I<O7*Z=8Y3U:JIC6.R='
M]4VK=,ZTTTQ/DB')YZA_8                    #\%F>J]8;&=@/;"UQ@6
M>/6IN0U:WLSP_'LH=MK4M32Y3<!R]VZ<J&W)5'15RC=4T75">_?M3M[' 9QF
M^5Q53EF*Q.&IKTZT6KM=OK:<M>I5&NFLZ:\M7\56Z*_7Q$^>-7XK[6'C5^+S
MHW\TN _O?/8?+=M7]L\P_&;WZ;^? 6?84^B#[6'C5^+SHW\TN _O?'RW;5_;
M/,/QF]^F> L^PI]$'VL/&K\7G1OYI<!_>^/ENVK^V>8?C-[],\!9]A3Z(/M8
M>-7XO.C?S2X#^]\?+=M7]L\P_&;WZ9X"S["GT0?:P\:OQ>=&_FEP'][X^6[:
MO[9YA^,WOTSP%GV%/H@^UAXU?B\Z-_-+@/[WQ\MVU?VSS#\9O?IG@+/L*?1!
M]K#QJ_%YT;^:7 ?WOCY;MJ_MGF'XS>_3/ 6?84^B#[6'C5^+SHW\TN _O?'R
MW;5_;/,/QF]^F> L^PI]$/E0.-_'BU3H5SMFA=+VZY6Z7'GV^X0-78/#G0)T
M-Y$B)-A2X]B;D19<60VE;;B%)6A::5I6E:4K3^+FU.T]ZW59O9CCZK55,Q53
M.(NS$Q,:3$Q->DQ,<)B>$P_V+-F)UBBG7S0YH/0OT
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MWOCY;MJ_MGF'XS>_3/ 6?84^B#[6'C5^+SHW\TN _O?'RW;5_;/,/QF]^F>
ML^PI]$'VL/&K\7G1OYI<!_>^/ENVK^V>8?C-[],\!9]A3Z(/M8>-7XO.C?S2
MX#^]\?+=M7]L\P_&;WZ9X"S["GT0^WL.@=$8K=X.0XOI34F-W^UNU?ME\L.M
M\.L]WMS]6UM5>@W*WV:/-B.U:<4FJFUI5XJK3\%:GX8G:3:+&6*L-B\?C;N&
MKC2JBN_=JIJCNFFJJ8F//#_8M6J9UIIIB?-#EL]*_0
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ME=*5I]"DTJ<ZMW+=ZB+EJJFJW,<)B8F)\TQPEX\Q,<)YOBG]O\
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M[#'&'[
M   '57D#P:X=<JV'6^17&;2VW9CC-6$9!F. 8_.S"$VI"6U4M6;-PF,OLZJM
MHI3RB3F5=DT^GZ*=N8[-;PMN=CJHG9?-L?@:(G7J6KU<6I_=6M9MU?=42_"[
MA<-?^C44U3Y8X^GF\.M^>E"Z9FTE3KAJ>;O#C;=WDNK@PL(SU.<X6Q)<KW\Y
MUBVM;LPR65&17OXLQK["I3OVHJB:4I3Z#V;Z9>]G)XIM9U3E^:V(YS=L^"NS
M'DKP]5JW$^6JS6]7=R'!7.-OK43Y)UCW=9]UXN;S]'ER?QQV=+XZ\J]+[5M[
M?D_#MFTL:R[3V0.-U5Y4@M.6"FVK'+ELIK1-'G9$%IZM/*J6>_A2];/=./9'
M%131M1DV/P=V>$U8>Y;Q-'G\?U-7$3W137,<M:N<^MN[.WX^@W*:H\NL?&\A
M=S>GZZN6DJS'[QP]S+/;1&<4EB\:9ON';=I<6TK]NC\/'<&R"[YNVVNM>]$R
M;5'=\?IJBE.]:6[(>DMN4S_JTV,\L8:_,<:<51=PW5\DUW:*;7X-R8\KU]S*
M<PM<[<S'DTGW(X^X\N]F:.W7I:?6U;CT_M+4USH_\+6W;,U_EF!SZ2?%U?P]
M8>4VBU2/?\&5U\/'R[(57M]%>U>RG:'(,_M^&R+'8/&V=->M8O6[T:=^MNJJ
M-.,<?*\&NU=MSI<IJIGRQ,>^XM/;OS                 #[6R6*^9+<XME
MQRS76_WF<Y[4&TV2W2[K<YCM?P-Q8$%F1*D.5_P$(K4_'$8C#X2S5B,5<HM6
M*8UFJNJ*:8\\S,1'MO\ 8B:ITIC67HCIOH\]4'?2H==<\'.02X=Q4W2!><YP
MJ1J+&YJ':THB1%RC;;V#XZ_#\J]JOIE5936E>ZJ>->TPSW?CNBV<BKY*;0Y9
MUZ>=-F[&)KCR3;PT7:XGR=77R/,MY=CKOK+5>GEC2/3.CUVT=Z23J*9^J%-W
M'L#C[H"SNI_CZ!.RJ][+SF&JM?O:,V3![&]ADQ*:4KYU^<C?:M4^-%=ZU3$M
MH>FINORV*K>18;,\ROQRF+=%BU/GKNUQ=CR?.)]KAK["UD&,KXW)HHCSZS[G
M#W7LYH;T@'#G#O@YW(7D9O+>%SC.(==MF$V[%M*8;/I]/N1KA;EM;+RY;%:5
M^A46^PW.]._>G?M2$;1]-[;K'=:WLSE>79?:F.%5VJYBKM/EIJ^<6]?W5FJ/
M?>RM;/8:GC>KJJGR:4Q\,^Z]Q>._1_Z:'%GX21I_ASIN'?(/M+C9?G-B>VUF
MT:2U]-9<#+]JR\RR"T/O+K52Z0GXS?X*431*4II\^;4;[][&V'6ISS/<=5AZ
MN=JU7&&M3'=-K#Q:HJB/VU-4^7769]G9R_!6/H=NG7OGC/IG5Z1I2E"4H0E*
M$(31*$)I1*4I33LE*4T[42E-*=J4I^ E4S,SK/-YK_0
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M8Y=5,<?#X:JN(GSX6K$3,=L3IRYQ$\'@W,BQ]'K8IK\T_'H\WMG]'?JCZ?\
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M3'=%,1$=D/96K%BSPLT4T^:(ASZ<;?J
M
M
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M(NU7K]55=ZJ=9JJF9JF>^9G69GRR\Z(B(TCD^<?F_P!
M                                                    _]7?P
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M<\HCG5,SRB(\T1W/(IHHHX4Q$1Y(?K3PG]
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M:/WYZU_8
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M$<(Y/EG\/]
M
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M-==<1?NWIUGC,ZW*JN,][S*+5JU]#IIICR1$>\Y=/2/T
M                                                          !_
M_];?P          3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.*_*I<)SW_%\_
MN*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_
M=?D5*K1TY.=@
M
M
M
M
M
M
M
M                                  ?_U]_          !,7]5'];1E_
M^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUT
MW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
M
M
M
M
M
M
M        !__0W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBOR
MJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'
M"/:9-],K?W7Y%2JT=.3G8
M
M
M
M
M
M
M
M                                           '_]'?P          3
M%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@
M #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
M
M
M
M
M
M
M                  ?_TM_          !,7]5'];1E_^[&Z5_[!;D=MG0[^
MHO8_THXK\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUTW#+\HG]%#>A\]]*K
MZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
M
M
M
M
M
M                                                    !__3W\
M        $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J
M5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT
M=.3G8
M
M
M
M
M
M
M
M                           '_]3?P          3%_51_6T9?_NQNE?^
MP6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_
M10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
M
M
M
M
M
M
M  ?_U=_          !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\
M7S^XI9Q3ZE>F        /<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3
M*W]U^14JM'3DYV
M
M
M
M
M
M
M
M                                    !__6W\          $Q?U4?UM
M&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]R/3;
M?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
M
M
M
M
M
M
M
M
M           '_]??P          3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.
M*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE
M^<<(]IDWTRM_=?D5*K1TY.=@
M
M
M
M
M
M
M
M                                              ?_T-_
M !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F
M    /<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
M
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MX['?;HM-:=TJK3O2M"?7;-W#W)LWZ:J+U/.FJ)B8\\3I,/)B8F-8Y/G'YO\
M0
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M]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F
M/<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
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M8G2*JJJ(]?:XS53'6M^-$TU>RR[.YNW/ XS2)GE5RCS3\?I\FTP^"W)
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M,P]J*IZU46[.(N6Z(JJ[9ZM,:SVSQ<OPURJ[AK=VOUU5%,SYYB)=G3B3]P
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MQTB[1,4UQ'.JW7&MN[3KPZUNJJG7AJ][9Q%G$4]>S5%5/D^'MCVW88XP_8
M      P\=;'KR]0/@OU#=L<;M!Y%JVWZRQ#&-5W6S1<GUG;<DO")>6ZYQW);
MQ61=Y,UEU]M=TN;M6TU33VT5HFGX#L%W!='+=IO$W8X+:K:2UC*LVOWL135-
MN_5;ITMWZ[=.E,1,1XM,:]\\7&,SS7%X7%U6;4T]2(CG&O.'D]]U1]6C^>_1
MOYE;+^Z19_F.]R_V#,?QJK]%X'R=Q_?1^"?=4?5H_GOT;^96R_ND/F.]R_V#
M,?QJK]$^3N/[Z/P3[JCZM'\]^C?S*V7]TA\QWN7^P9C^-5?HGR=Q_?1^"?=4
M?5H_GOT;^96R_ND/F.]R_P!@S'\:J_1/D[C^^C\$^ZH^K1_/?HW\RME_=(?,
M=[E_L&8_C57Z)\G<?WT?@GW5'U:/Y[]&_F5LO[I#YCO<O]@S'\:J_1/D[C^^
MC\$^ZH^K1_/?HW\RME_=(?,=[E_L&8_C57Z)\G<?WT?@GW5'U:/Y[]&_F5LO
M[I#YCO<O]@S'\:J_1/D[C^^C\$^ZH^K1_/?HW\RME_=(?,=[E_L&8_C57Z)\
MG<?WT?@GW5'U:/Y[]&_F5LO[I#YCO<O]@S'\:J_1/D[C^^C\$^ZH^K1_/?HW
M\RME_=(?,=[E_L&8_C57Z)\G<?WT?@GW5'U:/Y[]&_F5LO[I#YCO<O\ 8,Q_
M&JOT3Y.X_OH_!/NJ/JT?SWZ-_,K9?W2'S'>Y?[!F/XU5^B?)W']]'X)]U1]6
MC^>_1OYE;+^Z0^8[W+_8,Q_&JOT3Y.X_OH_!/NJ/JT?SWZ-_,K9?W2'S'>Y?
M[!F/XU5^B?)W']]'X)]U1]6C^>_1OYE;+^Z0^8[W+_8,Q_&JOT3Y.X_OH_!/
MNJ/JT?SWZ-_,K9?W2'S'>Y?[!F/XU5^B?)W']]'X)]U1]6C^>_1OYE;+^Z0^
M8[W+_8,Q_&JOT3Y.X_OH_!:=/3C=5'EIU,OMR/MH[Q@UU^PI]KU\QOF7A4+#
M_A_LD?9Q^<WRE\')D?*/N_,*W^SY=O9\5]N_G7M\D]*7<[L7NF^07RH48BCY
M(>K?#>%NS=U\!ZD\'U=8CJ_1J]>_AW/=Y/C\1C?">'T\7JZ:1ISZVOO-.A\D
MO=@      /&;FAU[^FEPF?N>.Y=NUK<&SK8EQ+NJ>/<:%L[)H\II:6G8-[R"
M-<[=K?%+A&<6FKL2ZWR'.2CNI#"^U:%VV#Z.&]?;^FC%8'+YP.45\L1C9G#V
MYCOHHFFJ_<IGLJMVJJ->=4/6XG-<%AO%JJZU?=3QGXH]N67;DWZOKE+FCLVT
M\4^/>K]'6-:G66,HV7/N>X,\6U3RHS/A1(J<*PJQR7/H4J/)@WMM'\K1Q7\M
M7Z]V2Z$6Q^ IIO;99GC,PQ'.;=B*<-9U[8F9\+=KCRTUVIGNCD]'?VAOU<+%
M%-,=\\9^"/?>#6].KOU,N1[TRNUN:F^)UOGJ567CF&Y@]JK#I"5>=/:?PS53
M6%XJ^TE*ZTHE<-7;_ESZ,V=W);IMEJ:?D-D&74W:>5=VU&(NQYKN(F[<CVJG
MJ[N88V]]$NUZ=T3I'HC2'G;,F2[A*D3I\J3.FRW5ORIDQ]V3*DON*\G'I$AY
M2W7G7%5[J4JM55K^$J%%NBU1%NW$4VZ8TB(C2(CNB(X1#PYF9XSS?&/Z?X
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MZJ:J*IHKB8KB=)B>$Q,<XF.][-_4_P
M       #_]+?P          3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.*_*I
M<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(
M]IDWTRM_=?D5*K1TY.=@
M
M
M                     .C?4]^K5ZAG^2-\L_V@\_*%NC^JMLQ_PX<N_CEE
MXN._Q%>_K5?Y,HX)WGIT                  #T-X/=4_G!T];_  )W'+=5
M^M^%,7!RX7;2N8R)N7:3R54EU+MPI<]?S9S4&V3;G5%*/7*T.6R\>-.R):"8
M[P=SV[[>;AJK>U. MU8^:>K3BK41;Q5O3UO5O1$S5%/91=BY:[Z)>9A<=BL)
M.MFJ>K[&>-,^U\6DJ%'27Z^?&OJ6)M^J\HC1- <L6H+KSNHK_>6Y>/;&3 96
M_<;IIO*I2(?SB<CQ&JR9%CDMLWJ(PEU;:)L6,_-3UE[Z.C=M7NHFK.,)-69;
M&35IZIHITKL:SI33BK<:]36?%INTS-JJ>K$S;KKIMSR[+\ULXWYW5XF([N_S
M3\'/S\WO:?.#VH      ##=ZSO\ TK<_+"_\2V=A/0/_ -G5_P AG_B@XQM)
M^L_=_P"98;CL(<7?N-8_YR3KW]G&)_\ 8] /7YO]*<5^][GY%3^[?T2GSPMU
M&?Y3         !X1=4?K\<1^G"F[ZXM+[7(?D^PTZRG2^#7V)'MN$S>W9IS;
MV;MQ[I"PM2:]U?);+$V]KIX57%88=1)I]%;H.C;MKO3FC-+T3E>R,S$^JKU$
MS5=CM]36M:9N_P!<F:+4<=*ZJJ9H>KQV;8?!^)'CW^Z.SSSV>;G[[ !SWZQ7
M.[J*7"XP=W[:F6'5#\RLFV:$UC\7AFHK<TV_[\)NYV.--D7+.ID!RGFS,R&9
M=93"ZJ]E;2*T13LIW;[C=W6Z^U3<V?P5-S.8ITJQF(TNXFJ=-)ZM<Q%-F)[:
M;--NF8]=%4\9XEB\QQ6,G2[5I;]C'"/Y_;U>7)7G@@            ?[:=<8
M<;>9<6R\RM#K3K2U-N-.-JHMMQMQ%:*0M"J4K2M*TK2M#_)B*HFFJ(FF8XP_
MUHIZ=7J3^<?#*38<'W/>IW+G04+X6 O%=FWQY>T,5M:'&FU.8/MN2Q<<@?\
M@HC=$,6^^_*L!#3:68](=*U<3\O[T.BIN]V[HN9AD-NG)-I*M9\)8HCU/<J_
MIN&B::(UGC-=GP=<S/6J\)RGV^#SG%8;2FY/A+7=/./-/QZ^TW_\"NI7Q)ZC
M^NEYYQJV$W<KM:6(Z\XU7E+<6P;8US(D5\&F<NQ%,V=6D%]S[QBYP'YUHE+H
MI#,I;C;B$=:V\?=1MKNLS3Y';5X7J6:YGP6(MZUX:_$=MNYI'&.<VZXHN4QI
M-5$1,3/+,)C</C*.O9GCVQ/.//'P\G?<G#RP        !YG=1_JP<2NF/@;-
M^WGE3M\V3D-ODRM=:*PE<.Y;,SAQOWFF9RH#LAJ+B>'IF,J;?O5S6Q$35MQN
M/25*2B*NL;K-S.VF]K,9PVSMF+>56JHB_B[NM-BURUCK:3-R[I.L6K<35QB:
MNI1K7'A8S'X?!4ZW9UKGE3'.?BCRRGF]1KKZ\Z>H-*OV(JS"3Q\X\W%4N''T
M;J.\7&UQ[Y9GZJ32+M'-V?@<CV0Z_'\4R(SOP=B6M"5MVUI?=2NSC=;T;MW>
M[.BWC8L1F>T].DSB\3335-%4=N'M3K18B)];5'6NQKI-V8X1Q'&9KBL7K3KU
M+/L8^&>WWO(\0#Z!>K              >G'!GJ_\]NGQ/MD71.ZKO<-:09-7
MI>B]EKF9UIRXLN+0Y*8C8K/G,RL0=F+;35V7C\NT3G/&E%/53W362[P]R&[?
M>9;KKVBP%%.;51I&+L:6<53/9,W(B8NZ=E-ZFY1&O"G728\["YAB\)/SJJ>I
M[&>,>CL]K1N+Z<?J;^''+^78M9\BF&.(.\;E\/ AJS*^LS](9E=ET]M+..[.
MD,6Y&)SIJT*6B%D3$%A*EMQV)\V0JE%=?&]+HE;=;#T7,VV7F<\V>HUF?!43
M&+M4]]>'B:O"1'+KV)KGA-55NW3'#D^#SO#8C2B]\[N^7UL^WV>WZ9:6VG6G
MVFWF7&WF7FT.LO-+2XTZTXFBVW&W$5JE;:TUI6E:5K2M*GRA,33,TU1I5'.'
MNG]#_          9Z>J9ZB+BET^I.1ZCULB-R5Y26I3UNG:^Q:[HC8%K>[)3
MX*;VIGD9N8Q%ND!RM?<L=L1+NE'&ZLRZV_S0Z?3>Y_HP[9;S*+6=YK,Y3L?7
MI5%ZY3K>OT_[U[,Z3-,]EVY--O2>M1X72:7J,=F]C":VZ/'O]T<H\\_!''S,
M!7.GJL\X.HA>Y+_(K<EWE8&FX?'V+2F%U>P_3>-U;>]Z#\-A=ND5:R"X6U5:
MT8N5[>NMV0E54_%>/9-.R7=WN;W?;L,/%.R^!HC,>KI7BKNEW%5\-)UNU1XE
M-7;;M1;MS[#7BXIBL?BL9/SZKQ/8QPB/:^&=9>=!47A             =Q^'
M7/\ Y<\"\V;S?B]NG*]=JD3HLW(\.3*^6-;9PF/5M%8N;:^NOQ6,9![D1%6$
M2G(Z;A$;6JL60PYV<IP7;G=KL3O'R^<OVOP%G%1%,Q1=TZM^UKVVKU.ERCCQ
MFF*NI5,1UZ:HX3Y.'Q>(PE76L53'?'9/GCDWP=*[U,''+F5)QO3'*R+C_%[D
M=<O@;5:KO)N3K6BMIWZ4XF,U$Q7([Q)?F:_R"XR%=F+1?)#C+JU-LQ;E+DNI
MCTZX-\71/VIV$HNY]L;-W-]EJ-:JJ8IUQ>'HCC,W**8B+U%,<[MJF)B(FJNU
M11$U.5X'.K.)TMW]*+W]C/F[O-/I:>SY'>[       1^>K_]:3S]_P FLW+_
M )>5S.[_ '(?4@V:_P!(V%_RJE/<Q_Q==_KD^^\XRI/":Y?1Y_YWAY-_Y*G(
M_;=UJ?%'3B^I]E'^EF/XM?<AV=_Q37_6_AA0].L5RX     "5+ZDGZZ;F;^3
MM^BAHL[C>BK]07(?OW\XXMP3.?IE<^Y_(I>&Y]"/5@
M ;R?1I_YQMSV_9QQ_P#^P':YUS=.OZ;;-_O?&?EX=RK9SZ'=\]/PMK)\#N2@
M  !G$]5']4OE_P#N^6E?^QJY'U+T//JTV/\ 2?BOR*7IL]_Q!/[JE,8.VQPD
M  ;G_3R]?:$Y"P+I_P#-W,/AIT;X/$^-V_<INKSC5R:<>]BQ:=V;>;G(<^&G
M1O<1#QJZNK2PZPEJVO\ @ZB,Y(Z\^DYT;KD7,3O*W?V-;<ZW,=@[=,:TSIK7
MB;%-,<8GC5?MQ&L3UKM.L37%/*,HS6-(PF)GCRIJGWI^"?:[M=P9U].3@
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M;%CC;LZ3QIJ\>['V67$L9FV+Q>M,3U+7='PSSGW(\CPP/H9ZL
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MVWUTW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
M                                                    Z-]3WZM7
MJ&?Y(WRS_:#S\H6Z/ZJVS'_#AR[^.67BX[_$5[^M5_DRC@G>>G0!IGZ;'IN,
MVZC'$C!.5UEY88MJJWYQ>\YLS6%734EVRR9;E83E]WQ-V0Y>XF>V)B2FX.6F
MKZ4TC(]M*_&M55IY5^3=ZW2IP&Z[;7$[&W\EO8R[A[=FKPM.)IMQ5X6U3<TZ
MDV:YCJ];3UTZZ:\.3W>"R:K&8>+\7(IB9GAIKRG3O=\?N-/9?X^N#?F O_\
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M/.W=HUTBY9N<KEN=.<<8F)IJBFNFJF.8X?$V<5;B[9G6GW8\DQV2[3'#W[@
M                               __]3?P          3%_51_6T9?_NQ
MNE?^P6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR
M_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
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MSIPUBJ)B=.Y1::HJIBJGC3,:OO3QW^@    PW>L[_P!*W/RPO_$MG83T#_\
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MJZ9[,1?CJUW?+33%NU,<[<S&L\NP>487":53'7O=\_!'9[L^5[Q'SF]J
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M[L;NK_L%MI\M=,3ZB]__ $HX7\JI[G(O\7Q^XJ4Z#J3<V
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MU:O3S_R1OB9^T'@!T8;W/JK;3_\ #AS'^.7E%P/^(K/]:H_)AWD)Z\H
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ML_:[O+Z.^-[)UQ.5                                 __5W\
M    $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8
M       ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G
M8
M
M
M  #HWU/?JU>H9_DC?+/]H//RA;H_JK;,?\.'+OXY9>+CO\17OZU7^3*."=YZ
M= %2#TQ/U/&@?V<[Z_;DS$Z@^EO]7',OWO@_XK:<YR3Z74>>KWY: CYJ>V
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M#0#Z8KZX?0'[!]]?M-9D?-?2W^H=F7[XP?\ &K3V^2?3&CS5>]*I"=03G
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M66FZ);:::;31*4II1*4T[4^@Z_*JJJZIKKF9KF=9F>,S,\YF>]R=_4_P
M                            !__6W\          $Q?U4?UM&7_[L;I7
M_L%N1VV=#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB
M?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
M
M
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MLSSC(]?D?3KRZU7OM#9\QO;@    PW>L[_TK<_+"_P#$MG83T#_]G5_R&?\
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M,M9+CJ[?[NG"W9I_LHAY&$B*L5:IJ];-RG7TPLV'1$HX
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M3CN_-QIM^8["C7!*:5<DX:PN#%QC6[:'%.);79(,2<J.OVI,J5V\Z_!>\KI
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MKVD5W)XZ>+;UFFW3+GV78&G V(HX>%GC5/?/=YH[/3VO5XC3SP
M    #\IG6#8?L["\KUUL''+3E^#9SC]VQ7+L6OL5$ZSY!CM]A/6Z[6FY17/O
M7HDZ%(6VNGT5I17>E:5I2M/,R[,<=E&/LYIEEVNQF.'NTW+=RB=*J*Z)BJFJ
MF>R8F(F'\UTTUTS17$33,:3"<EO7TN_-MWG;L32/''';6[Q=<F0\QP'D/LO(
MX]IQ#'\ R>1*<AXID"X:+GE&1Y]ADB+(MTJ-;;=(>DH8CSWDQ(\UJJ>TG9WI
M>; 1NZPNT&U-VN-KXIFU>P5BB:KE=ZW$:W*->K;HLW8FFNFJNNF*9FJW3-=5
MN=>'7<CQ/JJ;5F/G'.*IY:3V=^L?S]K2[T^_3-\$^('R)G&[('VX6ZX'P\SY
M:VA9(L;4N/W)OQ7YXKI[XFZ6>=[+E/O7\AD7MSS0EUA$57WM/D_>7TL=XFV_
MA,OR"KY!Y!5K'4P]<SB:Z?Z9B=*:HU[K--J-)ZM4UQQGW6$R7"X?2J[\\N^7
ME[4?'JT:18L:#&CPH4=B'#AL,Q8D2*RW'C18T=M+3$>.PTE#3###2*)0A-*)
M2FE*4I2E#Y<KKKN5S<N3-5RJ9F9F=9F9YS,]LSVR]SRX1R?W/Y    EO>IU^
MN'W_ /L'T+^TUAIV^]$CZAV6_OC&?QJZX/G?TQK\U/O0S_'TH]0T ^F*^N'T
M!^P??7[369'S7TM_J'9E^^,'_&K3V^2?3&CS5>]*I"=03G
M        !.4]7_.EN=1W1%M6^M4&)PEP&=&BUK3VF9=PWMR*8FOHIV[T7)9M
MD=*OI_ TG_?>TCH06Z(W6YC=B(\)5M!>B9[XIPF"F(]J:JO2X=M#/ZLHCL\%
M'Y53*0?9+T+N-T[;/8\AZ@?!:P9,W&=QN^<QN,EGR!J8IE$-RQW+=>$0KLW+
M7(I6.F,N ^Y1=7*511/?R^CN<&WH7\1AMVFT6)PFL8JWD6/JHTUUZ].%NS3I
MIQUUB--.+R<'$3B[45>MFY3^5"RX=$ZC
M                          __U]_          !,7]5'];1E_^[&Z5_[!
M;D=MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUTW#+\HG]%
M#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
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MUK5O&1AXTG6/U):MX:K3R=:U5/#A,S,]KG^5V_!9?:IGG-.OX4Z_"];B*O8
M    PW>L[_TK<_+"_P#$MG83T#_]G5_R&?\ B@XQM)^L_=_YEAN.PAQ=^XUC
M_G).O?V<8G_V/0#U^;_2G%?O>Y^14_NW]$I\\+=1G^4P    '@_ZCOEQ(XI=
M+S;L''[HJVY_R2N%LXW8@['?:1,8MV>1+G/V7.2QWI*K&^Q98;S!]]KQ^&F7
M",KRHJJ**^B^BSL33MEO>P5S%4=?+<JIJQUW6.$U69IBQ&O+7U17:KTGUU-%
M<:::S'JLYQ'@,#5IZ^OQ8]OG[FJ5Z=PS@H!O:]))T_86.:WV-U$\_LS3V1;$
MF7C3_']<QCR7:L%QNX?#;1S2WJ71;57<JS"$FQ,NH\'XR+%.;KW:EUI7KAZ:
MF\NYBLUPNZ_+;DQA<+33B<9I/KKURG7#VJNW2W:GPLQ.L53>MSSH<KR#"1%%
M6,KCC/"GS=L^W/#VI[VT@^#')                   2X/4>=/VW\(>?5ZR
MW +,JTZ1Y5PKMN?!(K###%JQ[,WKM[6W<%M:&*,M-0K)DUP8ND5AMIMF%;;[
M$BH\O8JJO;YT6=Y=W>!NVMX+,KG7V@R:JG"WIF9FJNU%/ZFO5:ZZS7;IFW5,
MS,U5V:ZYTZVC@^<X2,+BYJHCYU<XQY^V/3Q\TL_A]*O4.3-+[9S'0NWM7[MU
M[/5;,YU)GV);&Q.;2M?!F_8=?(-^MM)"/Y5^&])@I;?:52J'F5*0NE4JK2OJ
M<^R7 [1Y)C-G\SIZ^7XW#7+%R.^B[1-%6G=,1.L3SB8B8XP_2U<JM7*;M'KZ
M9B8]I9\T)N+%^0ND-0;XPI?EB6Y-:81L['D*>0^]&M6;XY;LBB09;B$-TI.M
M[=PHQ(35*%MOMK2I*54JFG0]M)D>,V8V@QVSF/\ \6X#%W</7PTB:K5=5$S'
MDJZNL<XF)B8F8XJ/:N4WK5-VGUM5,3Z7+1Z5^@  P3>L=TS<X.WN&G(5B*X]
M9LGUOL#3-SFMM=VK?<\%R>)F]CBRWO;IXN7B+L6X+CIJI7E2"_6E$]JU5V.]
M!C/;-S),^V9JF(OV<59Q5,>RIO6YM5S$?M9L415^[I]KBNT5N8N6[W9-,QZ)
MU^%BV/O1QI]SCF0WK$LAL65XW<'[1D6,WFUY#8;K%\/B;9>K+-8N5KN$?W$.
M-^_"G1FW$>25)\DT[TK3Z#\,5A</C<-<P>*IBO"WK=5%=,\JJ*HFFJF?),3,
M2_V)FF8JIYPL3=.CG%K;J&<2M6\E->3829F0VB/9MF8FP^AR;KK;-EAQ&LZP
MBY,U762RFWW-[XBWNNI;5.M$J),2FC<A%#HWWH[OLUW8[:8S93-*:NI:KFJQ
M<F.%_#53/@;M,\IZU,:5Q&O4N4UVYG6F5$P>*HQF'IO4<YCC'=/;'^'8[QD]
M>4                       ,XGJA>7$CCETUKWJ[&[JY;\YY9YE;=-1:1'
MO:GLZZAQW<LVI.1^J(\[;/LUKC6"8GLNJFL@\?'M6JD_4O1$V*IVIWK6\XQ5
M$59=DMBK%3K'";\S%O#Q^ZBJJJ]3RXV>?9/IL\Q'@<%-NGUUR=/:YS\7MIC!
MVV.$@%'7TJ? 2)H3B#>^9&;6+X?:_+"6ZUB$F8BM)EAT!BEQ5%QV,PRZTAZ"
MO/LMA3+P^I*U-3K:S:'*4I5ONKJTZ8V\FO:3;>WL+E]S7)LEI^>Q'*O&7*=:
MYF>4^!MS3:CMHKF_';PYED6$\%AYQ-4?/+G+]S'+TSQ\VC5:?'+WH
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MM7IY_P"2-\3/V@\ .C#>Y]5;:?\ X<.8_P <O*+@?\16?ZU1^3#O(3UY0
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M#[__ &#Z%_::PT[?>B1]0[+?WQC/XU=<'SOZ8U^:GWH9_CZ4>H: ?3%?7#Z
M_8/OK]IK,CYKZ6_U#LR_?&#_ (U:>WR3Z8T>:KWI5(3J"<X
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M1VQQCNGMC_#L=W"?O*
M          #_T-_          !,7]5'];1E_^[&Z5_[!;D=MG0[^HO8_THXK
M\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUTW#+\HG]%#>A\]]*KZ@N??>7Y
MQPCVF3?3*W]U^14JM'3DYV
M
M
M                        Z-]3WZM7J&?Y(WRS_:#S\H6Z/ZJVS'_#AR[^
M.67BX[_$5[^M5_DRC@G>>G0!4@],3]3QH']G.^OVY,Q.H/I;_5QS+][X/^*V
MG.<D^EU'GJ]^6@(^:GM@              "<IZGOJJX?RYVYA_#GC_EL3*]&
M\=<@N&1;"R^QRD2\;V%O=42;CU&K%-9=>C7G']66";,@1Y[-4M2[C=;C1'NQ
MV8LASM(Z(^YS';$Y)?VYVELU6=H<TM4T6;5<:5V<'K%>M<3I-->(KBFN:)XT
MT6[6O5JJKIIX=G>/IQ%R,/9G6U1/&>R:OYOAGR,I!]DO0NY_3VX@97SNYC:)
MXPXO'G4C[$S:W)SB]06JKKB.L+(OY:V1EKKJD_#LN63#X,M<5+JFT2I]8\9*
MJ./HI7@>\W;?![NMALQVNQDT];"X>KP5$_KF(K\2Q;[YZ]V:8JTUFFCK5Z:4
MSIY.$P]6*Q--BGMGCY([9]"Q[8;%9\7L=FQG'K;$L]@QVTVZQ6.T0&DL0;59
M[1#9@6RVPF$_>LQ(,*.AIM%/H2A%*?K'1AB<1?QF(N8O%5U5XF[75775/&:J
MJIF:JIGMF9F9GRRHL1%,13'"(A]L?B_T    &&[UG?\ I6Y^6%_XEL[">@?_
M +.K_D,_\4'&-I/UG[O_ #+#<=A#B[]QK'_.2=>_LXQ/_L>@'K\W^E.*_>]S
M\BI_=OZ)3YX6ZC/\I@    )_?K#=_NY#R,XJ<9H,WRM^K]2Y+MZ^QF*JHVK(
M-M9/7&;8S.KYU0Y+M5CU=5UE/C2K35S57O7W>R>RKH.;-1A=E\YVLN4_/<9C
M;>&HF?88:WX2J8\E5>(TGOFW'=QXGM%=UO6[$<J:9GTSI\'NL<)]SN./T6(8
MK?<[RS%\(Q: [=<FS+(K+BN.6N.FJG[E?<AN46T6B RE-%*4[,N$QMM-*4K6
MJE'C8[&8;+L%>S#&511A+%JNY75/*FBBF:JIGR13$R_JFF:ZHII]=,Z0L_\
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ML9I@[&*CNZVE6'N:>6:K$UU1QG6O7E5#F^1W?"8"*9YT533\,>_[C16?+SW
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MTM+C3K3B:+;<;<16J5MK36E:5I6M*TJ?.DQ-,S35&E4<X>U?T/\
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M '8W=7_8+;3Y:Z8GU%[_ /I1POY53W.1?XOC]Q4IT'4FYL
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MB:?)<JIKN\>VY/*-(B@998]3X*W1]=,=:?//'W.7M/5XC3SP
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M%2JT=.3G8
M
M
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MNU,Q>O86G#1ISGU5=HP]?HMW*Y\T>U/L<JM^%S"W3/*)U_!C7WX5I3I<<^
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M'G_G>'DW_DJ<C]MW6I\4=.+ZGV4?Z68_BU]R'9W_ !37_6_AA0].L5RX
M "5+ZDGZZ;F;^3M^BAHL[C>BK]07(?OW\XXMP3.?IE<^Y_(I>&Y]"/5M'7I7
M/K:,0_W8W=7_ &"VT^6NF)]1>_\ Z4<+^54]SD7^+X_<5*=!U)N;
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M] ?L'WU^TUF1\U]+?ZAV9?OC!_QJT]ODGTQH\U7O2J0G4$YP
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MWM;(ZFOC+G\@9+K#-YZ4T0EVE;OBU_F87&4[1-54JC'/O5JK7M5/9%/GG/\
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M%82J*,5:N6JYY173-,^B8A^T54U>MF)?=GCO]
M                    /__2W\          $Q?U4?UM&7_[L;I7_L%N1VV=
M#OZB]C_2CBORJ7"<]_Q?/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SW
MTJOJ"Y]]Y?G'"/:9-],K?W7Y%2JT=.3G8
M
M
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M$4]>->,6J8IMTSIK%RJF*W*<!E-C!?/*O'O]_9'FCX>?FY/?(^;WM@
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MK,HJ]0V\RR^9Y> Q,UQ''7_'-&(UCLXSKIVZ\7ET9[CZ/7315YX^+1Z8Z?\
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M(N?P6&OT\_\ )N7;[7'D&SM.N*KK[K>GIF/B4/3K%<O
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MNM7)GP5[6=>K%%?A)B-:K=/)Q7%95C,+K,T]:WWT\?3'./>\KQ=+R]:
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M]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
M                                                     .C?4]^K
M5ZAG^2-\L_V@\_*%NC^JMLQ_PX<N_CEEXN._Q%>_K5?Y,HX)WGIT
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M?!+_ #N_PV_R:OCS^V[B!P[>+]3[/?\ 2-C?XM=>1A?\4V_ZY3[\+.YT/J.
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MU8>QRGZ8VO//O2K)G3"Y\                          !+>]3K]</O_\
M8/H7]IK#3M]Z)'U#LM_?&,_C5UP?._IC7YJ?>AG^/I1Z@
M <Y<8?\ .RO'G_=\M2_Y?V/G'MKO]<GFG^D[$_Y36_6Q]&H_=1[ZU@=!ZE
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M*K1TY.=@
M
M
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M'6IO6-?^I]..L<>_28]UD-75Q^GLJ)CWI^!3$.IUS4
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MW</B-9U[NM11$QQUF8GL>_V>JTQ=='?;]Z846SJ\<P
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M]\9_%;KU.=_2ZOST^_"6^=OC@P!8^Z87U:O3S_R1OB9^T'@!T8;W/JK;3_\
M#AS'^.7E%P/^(K/]:H_)AWD)Z\H   )AWJF\4>QWJVYY=W:.T1GFEM)Y7&JX
MY'6A3,/&7\'55A+-:NLM?$88Y2J7NSE5T4JGZFI%:]MW0]QE.*W*X:Q&FN&Q
M^*MSSYS<B[QUYSI=CEPTTCG$N$Y[3IF$SWTTS[FGP,YQ]1O3/43HI9NWK_JO
M<#;\[)^$3/Y"8CA%'>T57FYLQ,S6[,;M+I5K^/7<K2SWI^JT]SNU^J>!(=_N
M7SF>YG:/#1'6FG++EWM_6-+\SPX\(MZ]W#CPU>=EM74Q]J?V\1Z>'PJ[QTF*
M"                          !+>]3K]</O_\ 8/H7]IK#3M]Z)'U#LM_?
M&,_C5UP?._IC7YJ?>AG^/I1ZAZ@=';A1JOJ#\]=7\6]SW_8&,Z_S7'-F7BZW
MC6%UQRRYC'DX9@%_RJUHM]PRK%,ULC3#]QM3:)%'+>ZI3*E40I"JT6F1;\MO
MLXW9[N,7M?D-K#7LSP]VQ333B*:ZK4Q=O46ZNM3;N6J]8IJF8TKCCIKK'"?.
MR[#6\7BJ;%R9BB8GEIKPC7MB6S7[D#Z:O]&_G)^<K0?^)G/A'YM[>M]K]GOX
M#&?W>Y'\KV"]E=]-/Z)]R!]-7^C?SD_.5H/_ !,X^;>WK?:_9[^ QG]WGRO8
M+V5WTT_HGW('TU?Z-_.3\Y6@_P#$SCYM[>M]K]GOX#&?W>?*]@O97?33^B?<
M@?35_HW\Y/SE:#_Q,X^;>WK?:_9[^ QG]WGRO8+V5WTT_HGW('TU?Z-_.3\Y
M6@_\3./FWMZWVOV>_@,9_=Y\KV"]E=]-/Z)]R!]-7^C?SD_.5H/_ !,X^;>W
MK?:_9[^ QG]WGRO8+V5WTT_HGW('TU?Z-_.3\Y6@_P#$SCYM[>M]K]GOX#&?
MW>?*]@O97?33^B?<@?35_HW\Y/SE:#_Q,X^;>WK?:_9[^ QG]WGRO8+V5WTT
M_HGW('TU?Z-_.3\Y6@_\3./FWMZWVOV>_@,9_=Y\KV"]E=]-/Z)]R!]-7^C?
MSD_.5H/_ !,X^;>WK?:_9[^ QG]WGRO8+V5WTT_HGW('TU?Z-_.3\Y6@_P#$
MSCYM[>M]K]GOX#&?W>?*]@O97?33^B?<@?35_HW\Y/SE:#_Q,X^;>WK?:_9[
M^ QG]WGRO8+V5WTT_HGW('TU?Z-_.3\Y6@_\3./FWMZWVOV>_@,9_=Y\KV"]
ME=]-/Z+]7@GI,NG/KW.,-SZR[HYK2KQ@^5X[F%IC738VBWK9(N>,W>'>H#%Q
M9B<<(4IV"[*A(2\EIYEQ3=:T2M->RJ>'F/30WHYGE]_+<1@,@BQB+-=JJ:;&
M+BJ*;E,TS-,SCIB)B)X:Q,:\XGD_JC(,'15%<57=8G7G3V?<M01\BO>
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MY7E6;S=F,-BI^><J:N_R3Y>Z>WS\]EQ\)N1@
M        _]7?P          3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.*_*I
M<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(
M]IDWTRM_=?D5*K1TY.=@
M
M
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MKWR/JO41'.:\+53BJ*8\M55F*8[]='G9;=\#CK5<\NMIZ>'PJ])TDJ"
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M5_V"VT^6NF)]1>__ *4<+^54]SD7^+X_<5*=!U)N;
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MQ]*]$CZN.6_O?&?Q6Z]3G?TNK\]/OPEOG;XX, 6/NF%]6KT\_P#)&^)G[0>
M'1AO<^JMM/\ \.',?XY>47 _XBL_UJC\F'>0GKR@   GX^L7U4]:.47$/=M(
MWA%V#H7+=7_%)]WL[+U'L"5E+C3E/<JQ1;<?=+=:5HE*U)KV4I5$IHCLMZ#6
M<TW]D,[V?U\?#9E;Q&G=&)LQ;\_/"SY/-K.O$MHK>E^W=[Z)CT3K_FF.L^Y'
M'7).FMD733>W]4[?L=%5O>JMDX-LBST3X>5;I@V3VO)[?1/GW1Y?%VM';O\
M1_@GJL]RJSGN1XS(\1_B?&82]8J_<WK=5NKW*I?I;KFW<IN1SIJB?1.JUSB6
M463.,5QG-<9FMW+&\OQ^S91C]Q:_F4^R9!;8UVM4UOZ:T]N5 EMN4^G\"CH,
MQN#Q&7XR[@,73U,58NU6ZZ>ZNBJ::H]J8F%*IJBJF*J?6S&K] >,_P!
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M>/):KF*J.ZU<MTZS,3,\YRC&SC,-X\_/J.$^7NGV_?B7NV?.SVH
M                      ?_UM_          !,7]5'];1E_^[&Z5_[!;D=M
MG0[^HO8_THXK\JEPG/?\7S^XI9Q3ZE>F        /<CTVWUTW#+\HG]%#>A\
M]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
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MU>7K6:J)GC.E6L:ZQ*BX._&)PM%Z.<T\?/V^Z[M' 'D@
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M<?M;E/5KIGMIJB>U2+%VF_9IO4>MJIB?\/,YX../U
M      !'YZO_ -:3S]_R:S<O^7E<SN_W(?4@V:_TC87_ "JE/<Q_Q==_KD^^
M\XRI/":Y?1Y_YWAY-_Y*G(_;=UJ?%'3B^I]E'^EF/XM?<AV=_P 4U_UOX84/
M3K%<N      E2^I)^NFYF_D[?HH:+.XWHJ_4%R'[]_..+<$SGZ97/N?R*7AN
M?0CU;1UZ5SZVC$/]V-W5_P!@MM/EKIB?47O_ .E'"_E5/<Y%_B^/W%2G0=2;
MFP                       SB>JC^J7R__ '?+2O\ V-7(^I>AY]6FQ_I/
MQ7Y%+TV>_P"()_=4IC!VV.$@%K#C#_G6KCS_ +L;J7_+!Q\Z#]KO]=7F?^E#
M$_Y=6I5CZ#1^YCWG.1QY^H       !TIY[\"- =1;0&0:"W[C_Q,&3[MTP?.
M+6U&;S75N:MQG6+;F>&7)]ISX:=&]SPDQE^42XQ%+C24+:76E.?;M]Y&TNZ[
M:6UM)LW=TN1XMVU5KX+$6M=:K5VF.<3SIJCQJ*M*J9B8>-B\):QEJ;5V.'9/
M;$]\)4O41Z=V_P#IK[_N^CMXVCXF#)^+NVL-GVF));PK;.%-R?9C9+C4E[W/
MAIT;W$-72UNK5+M4M7MN>;2V'W^XW=AO/V:WK;-4;0[/5Z7(TIQ&'JF/"X:[
MIK-NY$<XGC-NY$=6Y3QC28JIIX)C,'=P5WP5WEV3V3'D^&.SW^AI1GB/EP)\
MZUSH5SMDR7;KE;I<>?;[A D/0YT"=#>1(B3(4N.MM^++BOMI6VXA25H6FE:5
MI6E*T_BY;MWK=5F]337:KIF*J9B)B8F-)B8GA,3'"8GA,/\ 8F8G6.:C;T!N
MO/9.9&/8KP\Y99'$LO+/&+-'M& 9[>)GLP>25DLL*B$KD3);M?:W/ @1JN7&
M,I7\G$(7-C?JGQ+#75MTDNCEB-A<3>VXV+M57-B[UR:KUFF-9P-=<]D1_C69
MG2BK]:F8MU\.I55S'*<UC$Q&'Q$Z8B(X3[+^^[^_GYM51\=/>@&?WU.WU/&_
MOV<Z%_;DPX^E>B1]7'+?WOC/XK=>ISOZ75^>GWX2WSM\<& +'W3"^K5Z>?\
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M7[XP?\:M/;Y)],:/-5[TJD)U!.<
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MW#+\HG]%#>A\]]*KZ@N??>7YQPCVF3?3*W]U^14JM'3DYV
M
M
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M7CWFPL^'7(@   PW>L[_ -*W/RPO_$MG83T#_P#9U?\ (9_XH.,;2?K/W?\
MF6&X["'%W[C6/^<DZ]_9QB?_ &/0#U^;_2G%?O>Y^14_NW]$I\\+=1G^4P
M  'DKUPN'+_-WIK\A=7V"SJO6RL*LC.[=0Q6&EOW![8.JT2KZBSV=A-4I>N^
M:8BN[8]'HO[RB[OWK5/:BJ6GH^[<T[O]ZV69OB;G@\JQ%R<)B9GA3%G$:4=:
MJ>RFU<\'>G3CI;]J?7YGA_5."KHB-:XCK1YX^.-8]M)'.ZAP  V5^DWZB\/7
M.R\ZZ>>T,@3$QC<EPD[*X_2;G+::A6W:=NM2&,YP5AZ4]2J%9_C%JC3K>PCP
M:I/M#Z$)5(N%**^%.F?NNKS3*<-O.RBUUL7@:8L8R*8XU8>JK6S>F(C]9N55
M45S.L]2Y3,S%-KAR/(,9U*YP=<^+5QI\_;'MQ[WE;]SK9<L
M    #X5QN-OL]OGW>[SX5KM5KA2KC<[G<93$&WVZWP6'),V?/FR7&HT.%#C-
M*<==<4E#:$U4JM*4K6GZ6K5V_=IL6*:J[U=44TTTQ,U553.D1$1QF9GA$1QF
M7^3,1&L\DD[K4=0)?48YY;+W!C\I]>G<);:U%H:*ZM^B7-9X;/N56,I7'>;8
M4Q+V#D5PGWU3:VD/1F)[,5RJZQJ+KW3;A-VD;KMW.$R/$Q'R=Q'ZIQD\/H]V
MFG6WK&NL6:*:+.NLQ5-%5<:=?2. YEB_5F*JN1]#CA3YH[?;GB\FRSO7NRO#
MCC5E?,3E+HCC'A='T7O<VQ\>P]VX1V:R*X]CK\GXW,<N?92AU2X&&X?#G7:3
MV2NM(\-=:)57Z*\4VZVKP6PVQ^8[6X_3U/@,+7=ZLSIUZXC2U;B>^[=FBW3R
M\:J'[X:S5B;]%BGG55I[7;/M1Q69L(PW'-=89B.OL.MC%EQ'!,8L&&XM9HJ:
M(C6G',8M42R6.V1T4I2B6(%L@M-(I2E.R44.B3,,=BLTQ]_,\=7-S&XB]7=N
M53SJKN53775/EFJ9F?.HU---%,44\*8C2/-#].>(_H
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MB.V:(HHOT\YTM5TTQ-5>D^ZR3%QA\5X*N?G5SAYI[/B]OR*;!U,.:@
M          !_)+["GW(J7FE266F7WHZ7$5?:8DK?;CO.-4K[B&GW(KJ4*K2B
M5J;52G>J:]O]ZM44Q7,3U)F8B>S6--8U[XUC7SQWC^I_@     !+>]3K]</O
M_P#8/H7]IK#3M]Z)'U#LM_?&,_C5UP?._IC7YJ?>AG^/I1ZAH!],5]</H#]@
M^^OVFLR/FOI;_4.S+]\8/^-6GM\D^F-'FJ]Z52$Z@G.
M                           !*N]2-A%BPCK$<J$8]$9@1,KCZ?S>;"CM
M4:8;ON2:8P*1D,M/:JJK=O-[:?GOJK]*I$IS\%.QW%=%;,,3F&XW)YQ54U5V
M9Q-J)GGU*,5>BB/-31I1'[6F'!,YHBC,;FG*=)],0\+CZ'>K>PG0&E38G6!X
M/NP(:YSZ]B97%<8;E,Q%(A3=4Y_#N4RKKU4H6W;K=(=D*:I]^^EJK:.ZE4I6
M']).BW7N/V@BY5%-/J6W.NDSQC$69ICA[*J(IUY1KK/"'L<I^F%K3OGWI5GC
MI><^                               #_]#?P          3%_51_6T9
M?_NQNE?^P6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]
M=-PR_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
M                                                 .C?4]^K5ZAG
M^2-\L_V@\_*%NC^JMLQ_PX<N_CEEXN._Q%>_K5?Y,HX)WGIT 5(/3$_4\:!_
M9SOK]N3,3J#Z6_U<<R_>^#_BMISG)/I=1YZO?EH"/FI[8
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M3[55$^)<IHKBJF.68;%6<7;\+8G6GW8\DQV?X:.VQPIY
M  24^N_OFS<BNK!S#SC&ID2X8SCV>VO4=DF05M/PY2-+XCC^KKS-B3&:>W<(
MEQR?%9TEE]*EH<:>35M2F_"IW2]'39R_LON9R/+\73-.+NX:K$UQ/"8]57*\
M13$Q/K9IMW**9CA,3$ZQKJX#FMV+V/N54^MB=/1&GOP\B2V/7/>[TT&K9^R>
MK]QYNK#3KMKU+C6X=I9#5E*^[,"%K#)L+M#JW4?0RU3,<WM:5552J5T5[?X5
MTK3YPZ6&<6\JW(9G9JF(O8V[AL/1KVS.(MW:O//@K5SS<^Q[;);?7S"B>RF)
MGW-/?F%30Z?7.0 !_-UII]IQEYMMYEYM;3S+J$N-.M.)JAQMQM=*I6VM-:TK
M2M*TK2I_L3-,Q53.E4<I$D?K3=/FY=.GG9LS5EJL\F'I;/9+^UN/ESJE3D%_
M6>57"8XWBS4KNYY7#7%\:E6-]#JJ25LPV)2TT;ELJ7W4[A-YEK>CNZPF<7KD
M59_AHC#XVGMB_;ICYYI[&_1U;L3'BQ-55$3K15$< S+"3@\55;CZ'/&GS3V>
MUR>3)9WKW+FA-Y[+XS[FUMOS3N0OXMLO5.5VS+\2O+-7%-MS[<Y7WH%QCMNL
MTN-BO<%QZ%<8:U>U-@2'F'*5;<52OI=I-GLIVLR'%[-YY:B]E.,LU6KE,]U7
M*:9X]6NB=*Z*HXTUTTU1QB'Z6KM=FY3=MSI73.L*WG3+ZB.I.I;Q?Q/?>N9$
M*T96PU&Q[<NL*SDRKSJS9,:,E5VL,Q*O!^58+GVK-LMPJA*)]M=0I5&Y"),=
MCI5WL[L,ZW4;7WMF\TBJO!S,UX7$::4XBQ,^+7'9%=/K;M&OB5Q,<:9HJJH&
M"QEO&V(NT>N[8[I_PY>3W/0HF3RP              #RFZO_ %-L#Z8G%+(=
MFRY5KNV\,ZC77$>.^O9?\<.9/GRX::5R&ZP6W6GZX/@3<MNX7=WS:2XFC,-#
MB9$QCO9-R&Z7,=[>V5K*:(KHV?P\TW,;>CAX.SKZRF>,>%O:31;CCIXUR8FF
MBK3P,PQM."P\U_KL\*8[Y^*.<_SII7&/JO\ /SB-MO+=QZ>Y%9HQ?MCYI>=@
M;3QK*Y*<NUUM#*\EN3UUR2]YI@5XH]CTJ]WN5)=]RYQ&HEU82ZKX:4Q6M*T[
M7=K=S.[;;;);&19YE>'G#87#TV</<MQX._A[=NF*:*+5ZG2N**(B-+=4U6YT
MCKT5.%V,?B\/<FY;KG6J=9B>,3/;K'P\VT3I]^JVXO;T^1-?\V\5^U7V9*^'
M@_9'LM;KE.@+_/<\6_?DR/&=FFK_ (N2Y1*&KBB[6R,TE3LF[MI^BGP;O+Z&
MVU^SOA,RV O?)C*8UGP%75MXRB.Z(X6L1I'.:)MW*IX469<DPF?6+NE&*CP=
M??SI^./=CRM4V(9EB&PL8LN:X#E6-YQAN2P6KICF6XA?+9DN,7^V/]Z,W&RW
MZRRIMJNL%ZJ:^+S#KC:NWT5/CK'8'&Y9B[F S*S=P^/M5=6NW=HJMW**HYTU
MT51%5,QW3$2][35373%5$Q-,\ICC#](>*_H   (_/5_^M)Y^_P"36;E_R\KF
M=W^Y#ZD&S7^D;"_Y52GN8_XNN_UR??><94GA-<OH\_\ .\/)O_)4Y'[;NM3X
MHZ<7U/LH_P!+,?Q:^Y#L[_BFO^M_#"AZ=8KEP     $J7U)/UTW,W\G;]%#1
M9W&]%7Z@N0_?OYQQ;@F<_3*Y]S^12\-SZ$>K:.O2N?6T8A_NQNZO^P6VGRUT
MQ/J+W_\ 2CA?RJGN<B_Q?'[BI3H.I-S8                       9Q/51
M_5+Y?_N^6E?^QJY'U+T//JTV/])^*_(I>FSW_$$_NJ4Q@[;'"0"UAQA_SK5Q
MY_W8W4O^6#CYT'[7?ZZO,_\ 2AB?\NK4JQ]!H_<Q[SG(X\_4          .E
M//?@1H#J+: R#06_<?\ B8,GW;I@^<6MJ,WFNK<U;C.L6W,\,N3[3GPTZ-[G
MA)C+\HEQB*7&DH6TNM*<^W;[R-I=UVTMK:39N[I<CQ;MJK7P6(M:ZU6KM,<X
MGG35'C45:54S$P\;%X2UC+4VKL<.R>V)[X2I>HCT[M_]-??]WT=O&T?$P9/Q
M=VUAL^TQ)+>%;9PIN3[,;)<:DO>Y\-.C>XAJZ6MU:I=JEJ]MSS:6P^_W&[L-
MY^S6];9JC:'9ZO2Y&E.(P]4QX7#7=-9MW(CG$\9MW(CJW*>,:3%5-/!,9@[N
M"N^"N\NR>R8\GPQV>_T-*,\1]E9KS=\=N]JR#'[K<K%?K%<H-YLE[LTZ5;+O
M9KO;)34VVW6U7*$ZQ-MURM\UA#S#[*T.M.H2M"J*I2M/ROV+&*L5X;$T47,-
M<HFFNBJ(JIJIJC2JFJF=8JIJB9B8F)B8G2>#_8F8G6.$PHW=!#KWVCFG:,>X
MC\N,AMMBY<6*VI@X+G4Y46V6CDA:+9%K6M:4I1B%;]P6^$Q5R=!;HAJ\-(5,
MAIHNDB.SU;=)#HWW]@K]W;78JU7<V)N5ZWK,:U58&JJ?;FK#53.E%<ZS:F8H
MKG3J5U<QRK-8Q,1A\1.F(CE/LOY_?][M!ZG;ZGC?W[.="_MR8<<1Z)'U<<M_
M>^,_BMU^^=_2ZOST^_"6^=OC@P!8^Z87U:O3S_R1OB9^T'@!T8;W/JK;3_\
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MT7JHXZ\[5FY'DYQQB'MLDM]?,*9[*8F?<T]^85)CJ!<Y
M               #_]'?P          3%_51_6T9?_NQNE?^P6Y';9T._J+V
M/]*.*_*I<)SW_%\_N*6<4^I7I@       #W(]-M]=-PR_*)_10WH?/?2J^H+
MGWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
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M1>NT]7#T3W5469N5SSUIOT::<=>5[/8:::*\55'KO%CS1S]W2/:;0SX-<D
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MNFYF_D[?HH:+.XWHJ_4%R'[]_..+<$SGZ97/N?R*7AN?0CU;1UZ5SZVC$/\
M=C=U?]@MM/EKIB?47O\ ^E'"_E5/<Y%_B^/W%2G0=2;FP
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M:W5,3U:HUZ]^:=)B>I:FJ-+U#E60X*NB)QES6(F-*8[X[Y^#T]TMK1\#.2@
M !+>]3K]</O_ /8/H7]IK#3M]Z)'U#LM_?&,_C5UP?._IC7YJ?>AG^/I1ZAH
M!],5]</H#]@^^OVFLR/FOI;_ %#LR_?&#_C5I[?)/IC1YJO>E4A.H)S@
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M-GL---NO%5?7<(\T<_=X>TV8GPDY&
M'__2W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?
M/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K
M?W7Y%2JT=.3G8
M
M
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MPO\ Q+9V$] __9U?\AG_ (H.,;2?K/W?^98;CL(<7?N-8_YR3KW]G&)_]CT
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MIP1V[U%>4&!<<-30Y,9-[F-778N=JM[TZQZMUK;I+'SJSN_50MABJ;?%=HS
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MQ#_=C=U?]@MM/EKIB?47O_Z4<+^54]SD7^+X_<5*=!U)N;
M         #.)ZJ/ZI?+_ /=\M*_]C5R/J7H>?5IL?Z3\5^12]-GO^()_=4IC
M!VV.$@%K#C#_ )UJX\_[L;J7_+!Q\Z#]KO\ 75YG_I0Q/^75J58^@T?N8]YS
MD<>?J            !T,ZB/3NT!U*- 7?1V\;1\+/B_%W?6&S[1$C.9KJ;-7
M(WLQ\DQN0][?Q,"3[;;5TM;KB8EUB)]MSP=1'D,4;=AO/VEW4[2T;0[/5ZVY
MTIQ&'JF?!8FUKK-NY$<ICC-NY$=:W5QC6)JIJ\3&8.UC;7@KO/LGMB?)\,=O
MO2IN>_ C?_3JW_D&@M^X_P#"SXONW3!\XM;4ES"MHX4Y)=8MF9X9<WVF_B8$
MGVZHDQET3+MTM*XTE"'45I7N-W;[R-FMZ.S5K:39N[K;GQ;MJK3PN'NZ:U6K
MM,<ICG35'BUTZ54S,2X+B\)=P=V;5V./9/9,=\.E)SYXH   6/NF%]6KT\_\
MD;XF?M!X =&&]SZJVT__  X<Q_CEY1<#_B*S_6J/R8=Y">O*      \1.MIT
M?\+ZHVC&I^+5M6)<KM26JYR=*9[+HU#M^0QG5*FS-49_.1%?E.8;D$KR7#D4
M[N66YN?%-T4RY-CROH#<#OOQ^Z#:&;>,Z]_8S&UTQBK,:S51/*,19C6(\+1'
M"JGE=MQU)TJBW51ZS,\NIQUK6G2+],>+/P3Y/>GV]9;&U=5;&T=L;,M1[<PV
M^:_V5K^^3,;S'#LDAJA7BQWB$JGNQY#7=;3S#S2T/1Y#*W(TN,XV\RXXRXA:
MNW_)LYRO:'*[&=Y)?MXG*L3;BNU=HG6FNF>V.Z8Y54S$54U1--415$Q'!KEN
MNU7-NY$Q7$Z3$N/SV3^'VMBOM\Q>]6C)<9O-UQW(K!<H5YL5_L5QF6B]66[V
MV0W,MUUM%UM[T>=;;E ELH=8?9<0ZTXBBDJHJE*T_'$8?#XS#UX3%VZ+N%NT
M337173%5%=-4:54U4S$Q53,3,3$Q,3$Z2_V)FF>M3.E4-?O33]5KM34<''M2
M=0K&;WO3!X#4>UV[?V%,6Y&Z+-$;]F-$5GF/RY5HQ_9<:(PFGO7!MZWWM2$*
M=?K<Y*ZU5\0[U^AMD^=W+N=;LKMO+LPJF:JL'=FKU+5/&9\#7$55V)F>5$Q7
M:UF(I\#1'#D."SZY;B+>+B:J?91S]OO]_P [;'Q7YQ\2^;.)HS'B]O? =MP$
M0FIUTL]BNU(F;8RR]5I*4YAK^\MVW-L1=]Q]*:)N,"-Y*53Q\J5I6OP)MCN]
MVTV QOJ':_+L3@KG6F*:JZ=;5R8^Q7J>M:N1P^LKJ\NCDUC%8?$T]:Q7%4>[
M'GCG#M:<-?N        ?Y4I*$J6M24(0FJEK56B4I2FG=2E*KVHE*:4[UK7\
M B)F=(YCP-ZB/J)N!W!F%?L1PO*X/*CD! ;D1HVK=07Z'-QBQW9"%I0SL7;,
M6/=\2QAN/);4U*AP:7>]1G$^+L!NE?.GTCNPZ,&\;>'<MXW'V:LGV:JF)G$8
MFB8N5T]]C#3--RYK'&FJOP=JJ.,7)Y/4XS.,+A=::9\)=[HY>W/*/=GR)\'4
M(ZH/+;J5[";R_D1G/^,G8YTR3KW3>))E6;56NF97N-UK8L>7*E.W&^.15^T_
M>+D],NLAO]3J_1A+;*.S+=ENBV*W499.!V8P_P"K;E,1>Q5S2K$7YCV=>D=6
MC7C%JB*;<3QZO6F:IXEB\=B,;7UKT^+'*(Y1_AWSQ>>!3GA@&D'H,=$#).H=
ML&#R!W_9[KCG#'6^01ES694:Z6J?R'R.VR*N/8!B%Q;^#<:PJ"_']O([Q&>]
MUNE?@(:J2W'I%O\ ECI&](+"[L<LJV:V:N47=O,5:G28FFJ,%15'"]=IX_/9
MB=;%JJ-)^B5^)%-%SW.5995C*_#78TPU,_A>2/)WS[7FIGV:S6C';1:L?Q^U
M6VQ6"Q6V#9K)9+-!BVRT6:T6R*U"MMJM5MA-,0K=;;="80RPPRA#3+2$H0FB
M:4I3J:OW[^*OUXG$UUW,3<KFJNNJ9JJJJJG6JJJJ=9JJJF9F9F9F9G6>+FL1
M$1I'"(?9'Y/]   "6]ZG7ZX??_[!]"_M-8:=OO1(^H=EO[XQG\:NN#YW],:_
M-3[T,_Q]*/4- /IBOKA] ?L'WU^TUF1\U]+?ZAV9?OC!_P :M/;Y)],:/-5[
MTJD)U!.<                     /PVS-9:]W-@64ZMVOA>-[#UUFUJ>LF6
M89EUIB7O'K]:WU(<K%N%NFM.L.^T^TAUI?:CC#[:'6U)<0A5/893FV9Y%F5G
M.,FOW<+FF'KBNW=MU31715';35&D\M8F.4Q,Q.L3,3_%=%%RB;=R(FB><2GB
M=8KTVFU^)LK)^0?".TY+NGC/[MPO>1:UC)DW[;&C+=Y+E.T3'\GKKLG7MM;K
M5*+@PEZ\0(Z>\]IYMIVXK[.MQO2JR;;.BSLSO KLX#:S2FBB_.E&&Q=7+GPI
ML7JNVB=+5<_0YIF:;4<1S')KF'UO8;6JQW=M/QQ[O?WLJ)]CO0@ #VTZ?'7U
MY^=/V-:L)LN:QM\Z,MZHD=K3.[Y5YR2VX]:F%-H<A:WRYFX,97K]*(B5)CQ6
M7Y-C8=75U5M=76OE =YG1NW;;RZZ\POX><MVAJUGU5A(IHJKJGMOVIIFW>X^
MNJF*;LQ&D7:8Y>SPF:XO">+$]>UW5<?1/./>\C:5PH]31TY.5+-LQ_:64W#B
M!M&6F*R_C>[9$?['DN<]W]]./[GMC#>)_)T57C2KV0-8V\Y57ZFPJE%5I\%[
M?=$S>EL=57B<GLTYYE%.LQ7A(GPT1'+KX6J?"=:>ZS-^([:HX.28;.L'?X7)
M\'<[JN7X7+TZ-!..9+CF8V.V9/B.063*L:O49,RSY#CEU@7RQW:&I2D)EVR[
M6Q^5 GQE+16E%M.+36M*T[_0?-&*PF*P.(KPF-M7+.+MSI5173-%=,]U5-41
M,3Y)B'MZ:J:HZU,Q-,]S[L\=_H         _/Y5EN*X)CMVR_-\FQ_#<3L$1
M4^^Y1E5YMN/8[98*%(0N;=KW=Y,.VVV(E;B:5<>=0BE54IW^FAY.#P6,S'%4
M8'+[5V_C;E6E%NW35777/=313$U53Y(B9?Y5533'6JF(ICMEE#ZFGJG./NC[
M9D6J^ K-MY&;A<8F6M>XY[$QC1. SJ]V/E"R^ZB+<]O76)5*E,IA_"V&M5-O
M4GS$)<BK^R]TW0]VFVAO6LXWD37E>1Q,5>IHF)Q=Z.?5JYTX:F>WK=:]SI\'
M1,Q7'H,;GMFU$V\)X]SO^MCX_>\L\F S=>[]M<C=GY=N?>6?9%LS9^=71V[Y
M1F&3S*2KC/DN?>M1V&FD,0+3:+='2EB%;X;,>! BMH8C,M,MH;3V2Y!L_DNR
MV46,AV>PUK"91AZ(IMVK<:4Q'?,\9JJJGC775-5==4S57555,S/%+MVY>KFY
M=F:JYYS+BP]P_-WIZ=' S:_49Y2X'QRU?%DQ8ESDMWS9F<_#5?M6L]8VR7%3
ME&9W52JH94[&9D)CV^,I253[G(CQTUI[E5)GF]'>/DVZW8_$[4YO5$UT1U+%
MG72J_B*HGP=JGMTF8ZU=7UENFJKLTGR\'A;F,OQ9HY=L]T=L_P"':KQZ,TMK
MSCEIW6FB-3V1O'=<:FPVQX-B%J35#CS5HL,)J&U*N,E#3-;A>;FXA4J=+6GW
M9DQYUYSNMQ5:])6T.?YGM3GN+VCSJYX7-<;?KNW:NR:JYUTICCU::?6T4QPI
MIB*8X1"@6K5%FW3:MQI13&D.5CTS]
M __3W\          $Q?U4?UM&7_[L;I7_L%N1VV=#OZB]C_2CBORJ7"<]_Q?
M/[BEG%/J5Z8        ]R/3;?73<,ORB?T4-Z'SWTJOJ"Y]]Y?G'"/:9-],K
M?W7Y%2JT=.3G8
M
M
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M/.9GA-R[5I'7NU1K/*F**(IHCFN!P%G V^K;XUSSJ[9^*/(].B2/.
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MCP&R.5X3 ZQI-=%&MVJ.ZN_7UKUR/W==3U%_%8C$SK?KJJ][T<H]#J6<T>.
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MU<>?]V-U+_E@X^=!^UW^NKS/_2AB?\NK4JQ]!H_<Q[SG(X\_4
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M3WS\7='\[TN).\T                                '_]3?P
M   3%_51_6T9?_NQNE?^P6Y';9T._J+V/]*.*_*I<)SW_%\_N*6<4^I7I@
M     #W(]-M]=-PR_*)_10WH?/?2J^H+GWWE^<<(]IDWTRM_=?D5*K1TY.=@
M
M
M
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MM>GP&)U[HM7.K-S3MJM>$H[.LX]B<OQ>%XW:)ZG?'&/3'+V]'FV51X0
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M5N-*+5N)G7JT4Q$S,U3K5,S/*;&'LX:WX.Q3%-/O^>>V798XH_<
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MR>R8[X=*3GSQ0"Q]TPOJU>GG_DC?$S]H/ #HPWN?56VG_P"'#F/\<O*+@?\
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M,7[\13,4U1KK:M113I,TW*KL1$N58')L/A=+ESYY>[YY1YH^&?<:,#Y=>X
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M@
M
M
M  #@WD]IC[8_C5R&X\?.3YF_9ZT;MK3'SO\ D?YQ?-3[*. Y!@_SD^;_ ,J6
M/Y=^0OESXKX/XV'\5[7M^^UY>XGD.R.??*KM7EFT_@O#_(W,<-BO!=;J>$]3
MWJ+O@^OU:^IU^IU>MU*NKKKU:M-)_*_;\-9KLZZ=>F8U[M8TU8X/N,3^F1_V
MGO\ =2'W1\WA_4K_ &S_ ,[W'?E;_IW]A_?'W&)_3(_[3W^ZD'S>']2O]L_\
M[SY6_P"G?V']\?<8G],C_M/?[J0?-X?U*_VS_P [SY6_Z=_8?WQ]QB?TR/\
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M=7737[J'7'[C$_ID?]I[_=2'*OF\/ZE?[9_YWOQ^5O\ IW]A_?/7+H\]!/\
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MI\[W+ER]<JO7JJJ[M=4S55,S,S,SK,S,\9F9XS,\9E[2(B(TCD^6?P_T
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MUM_
M
M
M
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M[URN-)X3&E54QI,<)[W]Q:MT\:::8GS0Y0/4/T
M
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MZS,\9F9YS,][]7]3_
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MZ[ES336J9JG3NUG6='ZQ$1PB-(?:'XO]
M             __7W\
M
M
M
M
M
M
M
M
M    ?__0W\
M
M
M
M
M
M
M
M                                                        ?__1
MW\
M
M
M
M
M
M
M
M                                                ?__2W\
M
M
M
M
M
M
M
M
M                                        ?__3W\
M
M
M
M
M
M
M
M
M                                ?__4W\
M
M
M
M
M
M
M
M
M                        ?__5W\
M
M
M
M
M
M
M
M
M                ?__6W\
M
M
M
M
M
M
M
M
M        ?__7W\
M
M
M
M
M
M
M
M
M?__0W\
M
M
M
M
M
M
M
M                                                    ?__1W\
M
M
M
M
M
M
M
M
M                                            ?__2W\
M
M
M
M
M
M
M
M
M                                    ?__3W\
M
M
M
M
M
M
M
M
M                            ?__4W\
M
M
M
M
M
M
M
M
M                    ?__5W\
M
M
M
M
M
M
M
M
,            ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pcrx-20260630_g2.gif
<DESCRIPTION>PRODUCT PIPELINE
<TEXT>
begin 644 pcrx-20260630_g2.gif
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MSN;_0I24G A:[SKFWAD <SJ$G(REE(1[I5):8UKOQ8P Q8PI]QE[G(24K2$
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M#8WD[$ACCJOG2.^]1?88<,$'^TCP[;0/W'#"43K<\,-6;FGEQ.]T^:7%.@
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M4AX0F+NZ@YVYPX87/,);\PNH,O^-R,/"+-1"+&0K6U(Q>9$/ZR@W]!F";\.
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MO0,[.(("MAO(*"R$,S2 W[3(M.,Z4EG/&[ P=&C"0/53NZM(!ZPO4\%( ]
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M4 & K[4.<IR '*E=-M#!N8/'Y&A)$_S427;D=C1!P&MD=Q1;USW!;] P4 8
M&RR+N#4 %U#46/WELOB&[7S05,[(9(""4MY!6A["RG5'6BA(189/968#LX@
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M7P,0:;,V #9(ZP!-AO74YALX5,Z0;'(DZ_A]1W\PY((T587\9KU8.RH(_P,
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MK4ABE57@1 Q5_52UCM9"D.=DN %RT&5G5E4VB/\"LKC:X406.4);$Z0"-P0
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M)&S*#>%?)$P:0*5_&.PH011E\C7>EY.="604/%(4A0-U=E G(P[DN6>>>G;
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M&SE55D9R_XH:DIX&E59<)NH"O2QF U*P 65]"139 I2PZ%4N=%G6")6XK'M
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M?E@_A@,,. &,06[XPPL[U'"_;<CH*2:8%++II)F'+/-E+744Z:$E;9ZIRX>
MSFFGH6]N*"699&ZI2X-":GHBGYV.&J29@X99RZIQKFFGF'\6^FFI=1I))JE]
M'M3LL]%.6^VUV6X;*+/NNJNN2_W:BE.XUX([J[D'JTOOM10EZZNXN;);K4,9
M[;LPUU9SE=C*&(]LM'8F< SRTARC HQ=+3^LUETI&_:Q9/MX=MS=>&MN.=H
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M?>Z3G_WT9]L.%Y=0_>54<N&*J?)&T,/E+2\]-.C@Y@;1M% J+ PPE4 A:A
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MK[V L V[L!$[L ,;L;V L1O[L2$[LB5[LKV $U2@LB_;LCE!LU6 LSV[LU4
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M@,&%%1P37(UD%2"3DO]=<3)4*C(O:3(Z,#*:U#+0I4D[B5UXP9/7U05^,0*
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M0K875K:W*BK$*B*K*VFEH+[2LKZ"#+ZB0S-KH3N\0WM5+7]E6$7$H3Q+$+7
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M<:!!-D78@U\YEF.9-[7! .\_35'(&Z][EE#H[MKDW9P*85<H'N4$$!*&2/!
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M$2TMY,TJWTUS>48S@Q(DN<UU,9B&!2Z1"CL!* C7 )%="BZH4-FIC,( ;
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M!\( 'E9%6&]<#[*(6DZ)C&CE8DN(3K8B8<BU<$E;8@YE9VY*"08$3E1@B=$
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M\7K7J ; !$ D0*(W(I^7G?3U!E;ORH S&<AQ(%3O.W(3.N!! T1V/H&Y_20
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M(EQ;.XT"V6H-,!DP##"5%FR2H4(&#?ACPU1?!\ILOUL-P&"(S#3E58()7)
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M.-_82 L$%W03C<K2C$/R#)"T#F@#)4M"#TBJP.^(I$ER).U(#ZA,2._ZI/"
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M #U#XSRO<KVLF+WVU<8=04[D#,Y1^U<;64[F.PGD%*H;65]^99^(C5CHHPL
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M4-]-^ KWS=#^?14;)I7;X-^U'%5301L%-=4 31NWJ=\+<5WY-1L.%22ZD,M
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M)R0Q4$ _$D,2Y$#Y;2,YDC%Z0'4,2L$6S"J7<J+<!,=0A9Z>#D^*3H.0C$4
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M]G_?%X#K%W_?MX 75WX%.('O5WX9V'\_)](85U9C]54=>'(7%V7"2EC("?C
M%X03\V(\N##+I=1>A?9&J!"2-H4;QH5YMC1!]FV)-K3FLK-$$V6!CV37XC19
M1O5P+RUF]C)I-W4[JV9=A8>%&#1#=H:#&+(4<W2/MK$BRV9]_Q9DAK:0FC@U
M<1B+3[9XLS>,Q7B,R3A[!9A\&Q@D(Y1]N^D#LU;? G1T"/3>0N>,TS@RN'=
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MMLFV2ODV%!L9%NK3M_%8@#:JMRESCQ49;E+ZHVAAGIE2I0F+#;FIIU1@D@^
M"Q:A!90[ 8\KDOM*!4=! 0\P 28Y 5EZI?]I"IS8H &TP)R1"P:0H06C6P^C
MX*>N>Q1L8  8L+H&\ #<5:97*J<&0*=S"@"G>Z:IN[ICJ@6X6[DH>;IC&KG,
M>13+"Y(3$ \1<!2I6Z:TP :^B504F!DS1)Z9F(D1QXD5RT(GJ[%YUDR E9,5
MYXF-AR%V%;^[9$Q$J9Y1U3CD,C@QIU<V)Y4PLHJ:PZO>^7+\0L"J2L 3%QP.
M)H/S&6';(L PDG.T\W,=1F)GU!%)E"<<<WQO:2/((W22)4=,9XYXV2=B*U!)
M\G4GYK7C"GZ.F3T6E9I/)JZ)>U.*.%3?MJYT 794QZV1^14J%5%L)VU!]7<N
M)4 *F3_&0YI6!IK_UD:M,MQ]<_B'LQ4^HX*P*/F[1Z$!IVL _@  78J<5]JY
MD@L D7NZ(OFO5@J]9<R[   "<9S&IQL&DC''=^J<QCO&IQN\#/N< -#&N?G&
MR1G'SFG(:#S(<1RY?$K&5]H.1X$-B9R<5 "FJ1*QB,IX!3>*]A6^=D:^G@I?
MEE%$EO:=D5.!COJ,%+=5=<:4^^$N,PB_'7LPS]2Q)N2*Z1*J&]2??655TX$N
M:1)6QZ*A&",RGO-Q(")&$;:-5;LME!6%4/L8O9,QS!>7FU7-M$83#XI^JC8Q
MZQB.Z#>VG+5)Q8-])]9(AU%9>X*X);&1<"N1@<NCL%FV;)M)Q*6 ;U&D_X4D
MQ-I*?T9*7'?4Q#MC%X#[24_:?^A8%H>;PT'3I,A%D? 6B9RRQ?U*R!9-!2()
M!?!@ +?IG.T !4/PQ;J)L*"K!6 J ?\ZO'1<Q\(+ &":QT>1G,PITED*&3$=
MO%2  0#0Q1:=L,0;O"MML&K,DF"J!6SZTOP:O :+T[FI =REQK<YQRY-QMXK
M*G$3L9#G@1K[;XA3>5<9+8H6@AOX7^LUREP-+(JFLH"FJ&=)']<4. "<>J3J
ME24KJ\]D0X25LP!6@^PD&<#L3"0(33NW0JGH7^[4)1%VJ@]<P9V%6/=D.U6D
M('LS/&9$(31"P7+"EN2$PBFVPA3<0%N+)5;8)O]8M\*%6<-4IJX^%B<+^79W
M-T!:9F3U:*[&E9F;^5*=B:Y?UJY[-]J%F*0'1&2J"3:R13U7'%3(?8?%XU'(
M#8?;BJYWN!A%0BH(>Z43())J;,?%:P#= !D#6]*2C+M6*M0WG::0$;EC6M&5
MD=[-&<@^#:;KO;#N#<A,?=Y'(=*+O--+C=YQO-X D)S0V=Y'@:6R@KZVA-;,
M%'E;G>#B):J&NJE_H]6+5YX#%Y\KM#?CB8J0FH$2J+\X-+.V#$P MU;#K$(_
M*Y\?NWCI\:G^1=FQYE>/@ZO(Z&*!E6N<!H48XVH@D8T.2D<CJFO83*(_>UD=
M^LWB6(SN>!':]UES-!+_VN=])LH5#"DER-8S/K/-?MM(#*A)RYU(1[S/M"5=
M X&WB%3/Z"?=72Y!^.S0! F0;DNW^19)2TI(1EHT;!XS+TI;UP70?PML;S$J
MCXR<HW#)4WVZWJW4W"V2C^O%8%S>DFP KVO>ZHW&E5&F>NS2/KWH2@W4G<[2
MM@L9B\SI+!W3X>W>+(G3W$VG9Y/)H&&>$;[@4(5YF*+6'^1=EG;AE#'13+2_
MY7%Z#;*_ O94,'2!*[B4- =8YU&!YAOC+*YZEL-[\1%.W<3A$9R#,PYYD3US
M'Q=9O<9R^L1?%59K')R%:RE\6H@C;IF%7%CNYNAEY5Y0Y$/$P4-U]RK;2D;#
M__BS8XLHB(NIVSJ,PN5VFGB(VE,,/T/6VO1C9E[6SZ;)0("'KY39\.[Z\(YH
MVY%IKPU=/]^JD&"BQ8G>WWPJ&;FYZOP:WB1/W^YMWP9;QY2>L)2!T_.MZ3/_
MQRG/WT>1ZNL]ZD/MWXD>X"W_W08P"J22R9;8ZM=YX)K7X%JE&8VSJ30I8$NI
ME>9IUW+6BD!)7Y)SE9"FP(^*&_?K>K7G&WCMLK-:+,3!+LZ8B[:'37&U7XH-
ME8^-1EQ4:L@LM7>Q13-^8!4C:Y^JP!=L.=O,?.:':O,2,D=^M4JNV=W<C=QG
M;$?*8?N\Y'^^SC#SY%:^[_%'%&@[%:A4?F&!;="E=O_P1Y%&A8#L]_G!I6[,
MEG]%E?I@?E-@WJ/QG( O^HY^44D'N9'E=X"CM&RJZ790^O$O#[NY><>[R09@
MBKMLT*9[?,8&0. =O9O)N=)G"M,L+<=Q/ 1./01#, IQ.NFG?A2<2_.>7OTO
M#?2@FYM@JL8HZ9S6G_UCNOT&\-39;P W$/]!O^JFHEY'#Q!#  PD6-#@P8/)
M$!XL!*"A0X6%(@Y,]M#BP(8*"SY<2+'C1XX$-0Z4X!& QI$G,8(4&7+E1I(&
M'Y:LZ'"E1)L0"4IL>/&BSH0$2[Z\.'1H3H\X?R8M./$DQXA#"_6,Z?$H39LT
M>U:LV%,K4ZD*OU(]RI5B0PF:8M4^Q:E0+("2/ NEG5HRK4.L=L_F5:GU[5NM
M=ROR_0O7+5S#3__.3<QU[N*XR0#W-9N,)EW,3S.GO8M9[6/.ACT_MNQX-&?)
M=$>B]BP!->C2K ?'COW:LV38:6G;+IU;+>K9K7F+QBW[L43.PH.7[BV;-VKB
MO)M_/KV\.O+BNZ<O/^Z<Z_/OVG57E\W=NV_DYUM+GLUS^GK8'__ESZ=OD((!
M Q00LL'?/S\ +?PS@ H#, #@/@,&>D!  T 8*$#\'@  &P,D)(A""T<1$!N#
M,%2PP8$0U.) _ P$8$$'3P01P/XD!*%"@H8@4$ 3(8310P T%%"#@7 $ +\4
MZQ-R2"*+)'*DE*KB*"XCFX()(8N<6I(H*J%:*LF??&KI)9204@FQ+X\2"<R%
M<,I)*9T>FD@C- UBTLRW^OH2R3G/M$I)DBZJ*<TP[S3IK#Y5RH@J]VZJ2:F:
M4I*@4#FGVNK/B>1RM,O%5&)S,K<6=2LCQ [3%+'+<+)+U),^-14Y.?42J]!1
M,RT5.TUU0]6R62\K-3R)>OL.UE<MNS7_5EAA]0[8V"B*E39:BTWVV-"6=9:U
MN3A#;MK8>-TM6%^'30W68J$5+U?@6.M5W&JO_;9<;=,5#UU?V4TNM769Y3;6
MU]"==]GTGM576F2)-<XRUVHS=SSFQ&SR8(00U.^@>4"8 #\-%IZ00#:@ .,_
M# 8<:(B+#=! 0PX!X!@_#E_DD: 7+00 A'8&!$&@@DS^,&0$<2'1 )M5#'G!
MD$<VH&2/"X*"/RI 6'#A(1;\>>6@'^3/ #;"0+EI  CL!F&LBTQ2R*V=S-I.
ML+.D<FPCZ?P3JI?FP]+KI5@:\RFO(4)K)[*U/'2GB0Q>R*F@"#V+[R\[W7(K
MJO;4J"R;&'O[_\^KX"8\+,(=FOO2N2UUK_+(CDM,+S C&DRSPS95LR[!NR(,
M[L\W_2KUQG@2C#+74V?,5MD#^TZSS=<Z#?3.?J/N=]6ZR\ZWUX2:3OCUC#N/
M-MA(T_9>Z-1=+[KVGD^>..C?TS5Y\[1KGC?TX.->_-NG)Y_[[I7/KKQZP<,^
M>?C9^[Y[Y+^V_W[\\]=_?_[[ASEPA&S-;/+IFI!<,I0"E@UOB1-*VIZT%+VY
M)"F'HU)*J!(4,@'J2Q?D2.2>)*<&VD1*<!/AVPZ5* Q*A4M@BY.91$@H%#)I
M3XN#DUQB\JA./2HR@.*)3K!"*D[%Q89P8LNE/%*81<&%4V9*8A-1A?^550G.
M5L3JBZBHI<3):.6*K<J(75R5K=LE"XO'*E49G44M?EW&,>YJU['8J$9FY2E>
M<W1C&MTUKW'EBU_[0N.SYI4]?PUL66GL8QJ=\RL^"O)>3V1>O #I2#J6*UMV
M?"/! FE'3$9R/. "S2.=X\+^A5*4HR1E*4UYRC\U:8 R(<J:9D*W-DFP(TB2
MY=Y"TKCZO+(@1Y'@2.RVDIH8C(@9!"#?Q.8E9/K$+)SJTPE#^*1(">Z"@I);
MI'Y(-Q2225%C\DI5PG(3RZ$PF&P!DUP^]Z9-60IW?BF=3DP73L9XKHBD8^<X
M ;.IZH$.=/$TC.M@UT;#F$:?LLI6/SNS3R__'D=7V)G?_-H7&F-I#WEK;"CS
MV*<]]4CT>1I-G^_ LR[J@6][UB&I:L:'48NFM'WMJ5Y+P>-0@#&'?B+UHO?4
MEU+AY0XT7E3?=<2%2J &5:A#)>HLC?J1!!YU3L=$*GV2:K=:ND2937()!3'X
M-ED.*G!:-<B>VL9*-F%$GHAZH>,2M40'EI A@7M+#W&8N+'>,(1A!:+A-*C.
M)#(J=(@A7%=@V),E+K,K@PTGDT UN2JV98R@JB(6%=.J5I51+WE1;*P48T;'
MAJJ@FJW52;*5*^STLXW;(FVS-HDOU!*2786\%4G.*)Y2O2LYV/)6(&EKK8"]
M:WOSLB0D3RNOU-)V_U^UP<YPF66O1![7CX/<C?00>:P_EC:W,<UD;0NYW.-*
M#UR"S.Y(]594\(97O.,E+UN+%!)=AFVM#,Q)4M.J)AI24W"I'&8OW=:ET8'S
M)PALKUH]QT$^J9=N2.D@E[1JL'&2$"F1NELT>VB6RVYPF3#A94QFV$*\@+-2
MHHJ37RK70U5-)8?ZW&NAWHD5=<9PG7["E&+\V>+ Y% PW8&;;G3J8;\DM*6/
MZ91)?=?CF:ZQIR7MC4@RZCQ9)3DU0QZ?CS]ZFXG>YGRS0:GT^A5D)-,/I^IR
MWI:UHU(PAV]="EU/=I[KTCD2SZ8<55] PX5FSY17SG.F\U!7"<  +NY^6O\R
MB7NY]L"T"7/ 7W7J>E/)2@"V[2=GQ3.?_3:F"O-I3645J]Q0U[;_-N66J51A
M@_G*7G#*]5$0_N\VQ<2HRYG$G$[J\)T4:\^9,),LC'5L.D?%V-5)UCV?RF*/
M2W<J3U7Q+Y'5K&@UM:P\ZNXSR-84AYO]1H#M6C1Z3*VOQFA<1M:VM,F"WG8S
MB:[8<A>[X[XD&F\KGF%YN]N^Q>YU,=E':@G7R;O5I+!J=2[@!NS<^0Z/:JV+
M[=W46> #)SA0_U>?E/BYJ; L4Z6Y>LPKR0=Q"^'EUB"^I2?Q]TP6-V*!5\C5
M/?%WFH%2+YJ\"FAI;@W%%H;E:@R%MA]ZV*YN96__Y2R-DE33?(@J]&=_K>I@
MQ9JX+K-)<0X9PV-\JE-SP>9+7H*M.AG_3L:7[5T\>3R:SM9.V5?'59RC=[SN
M%:SKVC%R<$X*GK.#3UKDB_+8U:[)-(^YN417\B?5!U-N.32C:(_7F\D'E[N3
MQ^]L!G-,U3SXT:QYR%V.<\$=_WC([T_A>2:2G@Q=:#TC.DH=$5L!C8AGIL!D
M\L\,FU5KCDV$:#PDGX^TG@HWW[6"\M"9=F%;JS+@$9KI40^&_0X_#5AGYK4R
MJ38C.ILYQ;F-BHB$36+24=Q$)3H6UY5M"^=,Q=@O6G'8DO5UL3D+T&0I"XZI
M'=>O:H5&&Z=QC-F]8G1R-"5^>;>[8)Z$E_38C^_S5]N0;PPM'?L([=H:/[*[
M(_F[)/V[%P ,.'+C%O[SGH%Q-P"4-W?_BSP*K$ ++(B#D[RNZC,)^BH$NC@!
MJR7*0SBP83@R02_0DZ]($Z"'BYN0PSUD:B^/\Y*P"C# F2#$RB_X.KW\PKCA
M>\%HNB:CN"JU.BBYX92[\1M&:8F[63EQJI.H@*NI$!U5P9W", LHVIRI@Z(8
M8[H5@PP7$ZBM&ZV<.JCPT,*M(YBKVZ?IT PFHPWJF8EKV:BOLYZ4"K(I0ZG#
M@SO?H#+NB9;C03R6FBZN.[+X"2FXJ\,P(P_"B\.72CQ%) V8,L3N040[O$!,
MS,3R^I\,')([LY\.Q!\*FI(2_" 5RKP8I"$+2JN^81M@VD&Y\B6Z0IUR6J"J
M\"6',T&<2T4-_VH3_LJ<G.@T$V2F:MH@/7.,$AI"#CS":F(5MUJ5X*N3(<0<
MX.NQ*<2^Q(+&5.D^1-$^8:NUR"JH+^(UR*J^7L$B4FDC]_BL,30I<,&BT0*N
M:&N774.VY**(?4FVZC(W<=,W?'.6X8HN?O.7XO*W^#.N,>*M;;,C3V*H![3'
M?'/([DJW<1/(>B- UF#(X$I$C)Q 3?Q(D*RS)/$SDN0\+V$FB\M%L(FTRKN]
MKIFJVKN\!0L].LFJ0=.OM9+% =M M#HU2J,T-'D]5$,*,?&\MRHG$'.<V_NK
M"_.;KU@JR5%&+6(@W7,F9FP<)+PL+)2GLWHUTKG"KU0Z+_0B[+M&SO\1PWV2
MHJD[)Q>KNMYIG9H2+:XC,R"+CY>:N[U3*:%@*"N3CB,#N[<;LT<<Q$8ZNW-*
ML[?S.L&$ESUL*"DC*?I+NT4DLF'Y0_.I,BWC2+9+3,ILCY#\3- DJM'30&(B
M- QZ*B*4+YE,0433N+OBLYU$N31QI2/"DY44*Q2,P9E3R5KL$F3ZH6VR$F.$
MJQ BQD'!N;@BG" RQDR;K]#1H5>YH59S3A!:%+1P%*!HMF*<QG0*ILFYSNE;
M(T%QE7!\(EWS',$@Q_)#+6-[1WU!"]_92/&SQET1BV?3K/OL1Y0XI.3:-T#2
M-@#E1P"E2/[<O]]*+LVT2(B\R$_"2'U9K=?_^A<GB[]Y>S?]_#>"=-"50CSS
M"[C0_% 0)<W^&4VUL4E>G*'5%$$H:3B3'$%$VYN67#B$4]'5FX]'X\6.\$E4
MM)_14U$<)4%/W-$5;;BJ<E&&&#GZH@\1]%$;51NEBLW,>[W0BQL1)%'?])H!
MNE("TLT-I,4N/;0='4D8Q3@P_;.NJM$C246[BAO6#)P/O+U=(KV$&U(B%" "
MVD'?3#A8=!,ZQ3,2#5% #51!'51"+51#/51$351%751&;51'_4@MU1\?95)B
M@M(^O=0A8=(>RLD69<4;7"\2O5$S?5*31%)6^C"<O,D?E8E5))O4)$*T,<F5
M4\8Z(2&7^U(3*ARM_[*OM^J2:P**22LAK8(U\]JJEWA3Z,RTHCQ.4$LUR$'&
M7R4KW$1&&+(TP,H*_8(U6[.P#SLYIS2K#DHP;&6T-]TPFQ/",$S'V>PF,N$Y
M:!U/:<HA<8V<!HL<921&2*%.50LPPF"5E7C6;DW'R%%"!HJTT[F3L;*G<:74
M1VW8.?N?R9O3?%4E2WTT% 2PBKTJJ:HTH"A.%.K&0Z,YF& FO;F;EM.E!]-5
M.]D]1E/"MGK9U%M7%;LYOO(TWP3&$SI.$V,YOKB<E_79S (350&VPZ+6K).A
M^Q2A#*TQ=2H_ZZ256<DC 4U(=E0_8#%/RD(NR*+:H44_P ,\<^E/@#0DL/_-
MK=D2.]>@-MF:+9*@%^I*CK6EKK>56[C5I+HU6X$Q6]G*VWD\V^G"V[W]6WH1
MEKE-%P](6[JE6^=8W+>-V[_-6[@-W,(%W,K,%\6]7,1U7,V%W+XC7,#%7(<-
M7=#\TU$M$WFR)=:\V#+=0=DC,*KB6"<9)A;EILNK0=4\*]NUDVRB47&%TJA"
M74*[()ZC2B&EIAHE6+.)5+3:17Z:O91EPCX["_ADBZ=,L4&1BS>EBTN3$\+Z
M'"M<RUE9PWFR'8,"E>)@0Z[82IW:K-;:G3@KC8!2*( QJ"4#'N8@C8CR#N9P
M,WBYLOM]3+XCF"\KL]ZZJ)TJF+I#V_7IE_'X0[@GBZF6@LP*[=\N6X[.E*G
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MP=G%#[Z'20%= >I<T2W5$555SQ4([/B'72R=4:C;>A$E/AI(A@R>&38=Q$2
M5<!956R@GFV=6!%8V&%=5>R4V&$%U#$B66;%OG%%1+&5U?59V-4A +QA5?]@
MD5B6V=:AH8N$SR-1I6'4B&5EEB1Z >DM20PU5]*D$&+:S3,-$'1=5W0U4]G8
M4&*FRI_HS&(ZT[-14PXAIB^=5@<AT">)5]K(6F8^5V2&6PZ16Z^X$,QX9@!U
M5VSUS35*6PN=VF<*2G%YXV7^$FFFEF4*5REI)F[NIJJ8%Y'11;SX"X5YW$+@
M0[TEQ 6ZP 0DQ 0*1 5.Q 4&W$0XI 08@ M@!+*TF 1&8$%P"P#$&$X,U Z>
MYT(\P#=,1+RX0.IH)\@5A,*AIXQYIPP40@\&B!)!1$?9IT/*A%KN9T%\IQ52
M6;0@69/%#E#(1+@P1(1BE1Z9Q$-<J%+L"QQ)&5 #SJ!1_U!EB&K%&L)ELJ"9
M <#=3E6%6W)%6L%=51 8W &B5AP:5[!A1&$=BU[%FN&A59R+5@R2HM7(7J;%
M5#92)B%I8$):)H(:DY+,)EZ2QV3%#_")[C%)$6@0EC*F.%WF#TD-EVCI:=80
MEF8*Z@&*EF*7-&G3#O%6,2X;;)YF:"83FW(CK-76K:AIT""?9.JIXRWC-!4F
M;P9?XE ?-IECW;!IJR4. 7&I.E;FGW(-"_62E;)-G!8;TI#3<VV>*U5IJ_7B
MH*+-9TV)":B;[C@.SBF$(OH71XD8LNP@B-7D=,[;-T!+!?K3#J).) R$D '
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M,PYW*'<0)8$Y30%#GD![-T!8"^@:%VBCRJEXBF?C ;"8%K!!+;2 ST^;-AX
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MZ\RMT%E3)SZ]:%CEV).K5?Z]J_GSZ-.K7\^^O?OW\..OUV(: !3*737D[FH
MF\$';'1%WVD/P*4><*?E9Z!Y(.QG$!N=\:<!>@8\8,"%!FB!'F0: N 7+@ T
M"(5!]]E% 2T= F";?08L"( !$\JWWD<RSE@C0PS1>*.-Z$T$@(] _MB5CP9]
MP(L\ __PDJ0\2O)R9)-(.ODDDDPN.:644C+YY)0#6!GED0-4>2645W[II)9,
MIKFEEEZ"F269:(YIY9-)T@EFE45HR4M!YD&4DTM$_M@1CA^19-*A72GTD49"
M$N2C!!=Q=-Y))ETDD4&0=A0IIIS^J1"DG$**T583B8I0J7^"FJE*ISKJD$>
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M+C" "5\C >!T!LM;^8:W7D@0#+ A.1)030W&(]4;#ED@ ,L(D)M\(;#R!81
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MUBA#")"JU*0N=5%+)114WT>#I99A4>]KGZ3_'F6__'454R$@H*3"F@*K[H^
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MBIHWDDHI%4*.V2XM]5(FS$$VK<(U;4+O\E*BA-*X9#"D0\P_M::M$U2O&]1
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MY@=>@^]IR/_@? ]:N*!Z% *(H'H95NC>A/BA9R*+]G$XH8,$5OA?,O2UA^.
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MG@)53C^E*QWI4L<Z$V$H0Q3*T#^G?J("5:A%:U RB(1,H2*[Z.LI^OJ-K,
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M%4<9F7 <N5)8Z!9@H)&+(86/27:X<)+G^9*AUG<HF9*E!I-C2)-B2#_;,5^
M)VKQ>1+UA8F,1WP&YGO1=GS UI]]M8>&F(=--94'BFW,IJ!6.6)M&8==F5_W
M]8EWM9\^.6XX>55Y>$(CDWN[)*#)YD$/AI2E-WRWYTJH9EB'6*$1:J"B"&-K
M*6"]9FR6$VX2_Q,"2>,@0!8C6/:,P!-TT'B!R1 &Y.B,M@ATVBAQR:B.K]68
MK'DBYB2/TZ5R%>):V5=^W+>:^,1O;#!R^V81(O4 '.&+7@%>R7!P-Q 1P2@!
MQ.AQ^&B !C !W1&D17HBMEF/V) 3ML4S#Z*C^@:<7..0H[5O0P0U: 1;/=&*
M?[JH2_*/ BF03@-=T0D%*"5()_%'6*AQ&$ED<:%])4D7WUAG)Q$&%\F=*S4*
MZ&F2*]DEK+J>D'1XYB%J;(,N8AB&X6-XIF$%L8>*L=23M":4"Q:L%K-Y0;F6
M+49,HHBL&SICF1=66:E\&":L;A66*K24Q]:5JZ1-D^B@$YJMGZ=MUO_DHBI:
M36Z9>\\46)B7ECZ)K!RDE"YDB(C(>6<)53@4!-13&'F)+!+!?VHQ?5U!9!)
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M^I,D@P)!L"FR F1KUA1MULM-4BS-R1*Z8BK, V9XS('9HX]F4<?$:13@\X+
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M;5MZU5>]C5O%M5O!?=*]Q=NW15LG+0$]%4Q5*Q#%Q)NNXZ86HP\!D42N6[K
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M3N&R?=MW'6TRO>&YY5O"7F;"-H.9<0F"!+O!7(F++;:=:#4#+0FR Q<GMN(
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M  #\9(B$Q+^\$HK)"SU $N1N--; [19^#L' S"+16#59<LNB)0*C(6 #49^
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MNN1T(B5ZSB3O.2%R/@NPB5-0\AXY+2&7,J6W/"6ZS,O,;<NT::$U"AH\L:<
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MD[=YH_=XJ_=ZLW=[NS=[C\!VQ_=[6T!\VW=]WW=^U_=^Z_<(^/=_ WB "_B
M$WB!&[A_7\ ()/B"*__X@E^ @S]XA$OXA%/XA$=#A5OX@U]XA%]XAU^ AX/X
MAXMXAW= -)3XB9MXBI\XBG< BYMXB[?XB\-X-  !C-OXC>.XC==XC=_XCG>
MC_]XB_OXD-<X W1 %'2 D2,Y$# Y$#  $$1!DT<Y$)P#DT?YDT<!ECNYE#-
MEGMYEX/YEXMYF)/YF'NY!WQY!#" FD<!FDN E[_YFJ_YF[NYFD< G4<!GDO
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M^PB&,H2*/3KO$Q-\X.N>UL&O1>^&'RS)ZJ+8"PPE&8FQ %%>X%B9'<8#0V%
M9Q@[69E!YK*B[EEF.5-:R;QZ-+89[0;2H#0?#*40(R!MTFC_&M8&QS2O-4X&
MB'(!J25C*$"([="&3=O?NNUKLAWN;GU[[/#XH&SI,:XHCBO]NBW7/=2>3[:O
M2UWO_PT^_@'<@ [GM_Q\=T#H9Z:"TFO,];X?WLVDD+LM!,UYCXB]W+QFOE>G
M(OO*J'7R:[_V*^ "SG8,+L",I'=\Y.".A$@4C,"FY,#BJ9ZLI'F29WGXJ9\(
M"GHRK,+:I* *B@,U#*'_] 3D\$3$'"K$4%!\(BI]$D7E*HI1#"53"B52'D7F
M:&[%X@=^>@Y^!,CG_B<9:$Q5W"S*O S.GNP(IZS*Z(Q5H(SMDJ[+CDS*E Q7
MFLRJ)"@+)\@FCFR$JG )V:6'>.((C1"!RI"!NH[-ME#KP SXA@@H8@*$EHP.
MV0SNX"[/L@BN" _O#B_Q.@;Q'F\H_ SP^O"+_M /#:\0YV+Q$&8O$DO2#D,0
M < I@*#W6@83F>+M ( !6*9F/BW40"_4]*@S?@9J1M'T!$F1-F 2HZ V$BG6
MIJ;6@N,X)F\H.N UZ* H+HF38&-LBHV4O@88DRVX? L[H&_9DK&5CO&4K*\^
M_^"&/:J-EJ2+E_*C//K&/WI)N\POF+HK0-"O<6!@O,[+0<11W21DFCIG_N9-
M0]Y-F[(IFUB$_U3'=0+0WUP'G<Q)'_U+G02,=]J) =U)P:"$("F02AR.2O*)
M2R0N [M$PLH$XSJPXBZ,XS8LH4Q03_2D33*R?$X."$H.Q?"$Y4R,Y1X%HW0N
M4QC%Y4 *4CB%43@%QFJ.QD JI?3'?Y+!)J/PJY0N"M]E[(1.)T>B7HJ*ZK"*
M[)Q*K,I.S;Q.*6,%JN)%5XI%"HO0(9HJ*:-JZ8K.6:I.5:(NIHYR[8PR*S]B
MIYB.J.[PK :#K3+F]8YB"#I %$3F*1[FKBJ&8=@J8?\8@2@:;>[6PA#E\@ *
M:RVN(@FB8 CZ[@;B<F/L4HM^P2S4"-).I@.(0F88@"A&P+$P,08V40(H Q1%
M8PXN8Q1%T6=>K9!.SS-,H_5\HQ".HA"B@ Z()AJ(@@%D#;5N[VED\3A^2Q1L
M$0#@T@]$ ,\Z:;:N0_G AI/49FN(#9-$Z?B8[=E,*6Z@T9:<<3J/*]JBZY;L
MHY9ZZ3ZVK[H2!QNY37$ )-P,A-R,*3W5+]W:[;R<2;WBK7/>3;[F"W1*Q[Y:
M9![_CQ[OL9Q.H+\"M!_Y<9U^)'@BT'<.C $9L" 7+.*H! ^4!^+ ),(X$'D\
M<..L)WHR;$ZL9TY,T$TT,N3_[B1.S@?$2#10SJ>B,HI^U*?%5$S%&$5_',7F
M4*H'77)_<A* SJZ 5*K-W! ,H0P*:8B(AM0(Y0P)N>S)K-""C' -B0S.HI19
M0 )(58BH@E1*NXZ'PM )54(GG?#,DG2%Q.X-6XA)U47)B/1'#0(MT_**$FTV
ME4('&!'2((VN^"Q. 2"+JH(NU>)@"B8)B((,]*HLH,('#A,I,#.,$LTJ_.S2
M_"(PF&(2#T,X(V@&(HO3F"+S , #-FMF/#4&2',S;+$0Z( T0#.S@B9G4$,7
ME>(<5L,'-G$$D 9I<J.2= ]JT.8V?L,WA>\W-A$(BD.2GB,[A#$ZI&.WP",Y
M1\EM_YR/.9%1;>A&;.B&&9%KNF I&J-MNMP#_/ACV[[M/89I<;S1/+LQ0<9K
M<M -W39'_N@OO=KK_NK-0D@D'N_S_U8'7^]Q1@!40/?1 O@UG?H1 0&R 0G,
M'ZDD>*9$P1S4 A.R(1_V(0%JH"ZT>@1*0SWTX^I$(S-2(U4T?"0J4?S$Q%(,
M!E=N4#QEHV0NI%KL5 J%!V]0I$S%5'RNQV!**;E2"G6"*WERAG#%ZYQ278 J
MR[!2(WRLAG;VZ>Y%*9=6@\K.3,/22Q]HJ8"R)9(N6*H.AICR2]ONZXK.Z=;.
M*G<EJ-K4K)BH+N=.+_W%!Q8F,"6F;;<HL.!V$@/-C.JTB_\.X #R=&WK(BM>
MH#65 F_ODAD,(6(:\; :,64F]614IK$J8Q,9(#0S0]0J:V8F<RCHP%-_(0UV
MIM0D8S5)0P?^)1H2232(9K68!C5PU=:@PS=\LP.DH]:(CY.<H[:<+SF'35G%
M(VU**3J?S9:H<Y;F9I;H9ENUU?OTAKH(AV^LJ]L")#^R:_SZ !O3CT LYY@:
M!-W8+;W>51TQ9!VKR;WHBW3H*W52!W7Z,U_S55_[-4 #ED %SD"9).$8=)X,
M4@*9A!'HB7B6)WG$)$R<AP.;YWK29 0S-'LZ;GM8,.12D'Q<\%#ZQ% ^LJ(H
M*E,RJ@8A15)<%N8P6,;H1U0T17__/MA'<=3G!L(#B+"&'"@.I72%N?!8J I+
MT91+LU9(E])*I[2%:GB"N/1,T6S)AF5,A3(GR*QJL9 F,(@-X2Q,KW1H0P(.
MF]"'T\P-6]@,BRR#6(5LE0BQZL(0P$)OK>)0B2(**J:+P2@J"->*RGAA)G4J
MU+A0&Q6.I8@9 '$2Z8!CFJ*+IP)1 6 (Z, J1,%RVUB,Q$A@2,:Q F,2&3=4
M+P^."",*AD("[JCSW,B/+!< ,+=F1E%H2A<U4ZU5?U,S7N"1B0+U8-$V;6-7
M@P/WI":5>[4XIP,Y87?7B/.28'FX;KEMG)-MJ&^X.@E:6XEXY0:ZYD;:JNT:
MJRW\EG=P_[9-F(3);\A/7*DWF:;Y<JAYW:K9/>$-=.P/0]SQ<[X9_][QWLY7
M??VO'OLM8-M70 ]P8(6D=WYD 1NP?A7.01'2GA1R0K'D?R-,@">,8@.X RGL
M>@98P^K$3:)@H5#0Y!JJ1/]$9"4X)%',41*E!FG4?586?V(R4^Q'I#BZI$JE
M)@E"?SSBI9I86)X*B)646$3B[*#V*UOZ)YE6:U/(9_=%+(V2JZ"67[2J+,4%
MAK!2:)4VA66Z6ZA4I[RJIX4Z:9&ZZ<:2K.P%5K(XB0QC<.UT$OM@*D2A** B
M= '@ C;@' !@'J(!*^;  ?8X"BX@-*5H#ACA;\_!#^;V*KIZ'O\$>1[$6E%C
M@' +\ZX!( H8X0 "%2ET8"V;HJLCR#"@(@/\KBD6H 5&^1;WUK"'X@(.8 0V
M,1D4%;%^H0. CQ-GP)(/PS<KKS%FP#)O<0,V<8S=R (TA2@D  C\ #)\TRA&
M0#0 N:_]VE15M;,VP'5EPP\V$0!$P _:$@!&(&GZVC<LF0%BD_;  PB$VP,L
M(+9<]_>"#SH\VP\R0+JEM9-F(+IITP)(:92@LVZH+VZZXSQ4R;BFTY64R[FR
M\VX(1SNYS[Y_J3R[ZS\>!QRE&4'63T#"BW(P)YF@J9E 9_Z^][W&>7SEBYL>
M7'WO*YSX%1]IY+_\M4 '-B 15'[EN2#_]9=ACZ3!^!=B^?GB #J@UJ3"!!J!
M,S8%/^S#VN1$U>>A0Y+E%(5]<+#%] ?F "547!9^\,<D>;!3@K!4"$B$R!"*
M@S9(NRY)D5A(U7!5MHR*RS2HJ#P*=2AJE>R)>?C'G#2G2J*%C?1'SU"&5%@H
MI-BHC[2*K?#*T%"*?SJ)JU:XI5HI(#/2FF(2,P M#F"K8T 0.R "B,(?GN*P
MCV)M3:;.AP*RG2)/YZ+W C<&+/$H1B!/C2(:$.T A)O/I^@K*A4IDL I AVR
MB0((HB*XC^*T*9$PZKC39N!O7]NS)0"/*-TU+W42C:(#),.XC<(?2,\U NF3
M7Q4T-O62_4"P_T&Y-8CBDXN"NFV-#A8=DH'#E7_CM8FC]Y B Z3F!9J]*!@
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MZ.XKKA "\U,PP.VL2XX^YP#@L$,//P0Q1!$!V" &9F(P$4443XSA@!9?9/$
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M,H&QS,YLEAF@5:8TJ6' T%+S2$C:AC>2[ UM4I.;J7G -Y[T#=5<\[2^8>A
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M3Q'=4XPI^KXT<-10Z)N3I/QWOQS/SU#]X]_^]@=  8Z*@$<&U:=VFJI519"
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MV?VWY8"[.:PLA'[U[:&"MHYU[X01P.,)8'3JB!GOO-V.$OY?&-%3G:QKYXH
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MTI'2+$6Q5*-,-1-'0>I4V%+>+X/9FUJ12F+&NJ6K;B6P\$4/5:Y:YDY293$
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MII7"++LK6;\ZA!@:S26M*5E;K[A#"$G(P6AU25C!$Z]'WQ!"8W0)$EU#!?M
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MG$GJDS=QQKF('(U)C00 9=E%+!A\"TP^!M!A5'OLF&*<R\T)2]@)&!Q"V;>
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MN:*-JE9MU;99"V5]"R NW:AUZU*=>Y>O7;]YM:JM.X0JX:B&#U]%7#CJO,0
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M6F7]L27J3W.BQ62)HH9OXORF>:R2F#Z/6(C9.NU*YZTI   H +DG("J\V@!
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MFW\71[ !)TP6Y\.WX[ %9H(5B+KE=*%4PM0Z[($<]U0-Z^?ZY+$_BMC T];
M\\/>8K%8E<6"J2*8_7**2=B;W<9TO+XY)%!_S28U;,7S\L:*GMF-K9-.V^E4
M>]B/>2YA/'*<GMEPG%6 [69DW%5O#,A=$N.U;NNW_M&87*S&L6\'!UY+'L&P
MW#3*9J_3";=,D]L6_7S+IF\)_$B\[.2E[.P"^F^=G#55_EV?^SB9D^/^YXW9
MW<F+>W#\!R%)?8TY'!F N>1O'CG,I$.!R.S,-^BARPSG&LK,&>HEY[VDSVR!
M\W1/[24YN>N"[KV"%I8K^(WB;%HF-+JF99:(.8K.'OZ^48N[_MS@'9'0"&WQ
MY)S.7KKQ!NV^!J[QWK)F,!2DQ9OB(91F^21GD>C@YLO/-03/$R[.)\YA@5AF
M_[BN\SO/\Y%<W%HKMYL,39L<K#J-' _\-%5ST;N]- GZ(0=Z..^V;[PL[-J]
M.:73Y+^^<%:.(0-VY)W\(:)3KA &3V#.R?;5KD1.(F=^?Q+9:S[LKQS8Y6@^
MWD[LGVMNL.-]DD>,L-BD3B/BU227<3:)Q$2JUS-)I-XBQ6Z=)R['Q'C>L$M2
MV&,X54]R@Y/]3H0WM5FL^) >M7SWV57U^7.-F(/WV/M<+S4[F(89^A=>ZF;\
MZ?E<QQ NZ4]+ZH#'U["N)Z^NV&#2\[\/_!"]]$8OW+Y-XZQ-K^-.B4*_X[/E
MRC6^JQ#\:PFIVHKD'0UJN9#KN'$KP;:5]=BON,+:D/]=3X"M#*SA7CB^OI"=
MS'^ZW%Y7[J"A.^6?R\RGDR$H :_4U)'RI:\9!Q"%D@&00!! ,H$$!Q8<B%#"
MPH,""SV<&)&B0X,4&59D^/"@080.%R),6%!CQ&0=%182:/+@1H\I1[;,*%/B
M0XTB)WK$B;%GSI\B 5@4&12GA(DV>R8UJE1FSI1-E^9D*O-I5*=5%09-VG7J
MU:,VL3:M^E!D5+)-BX)=ZS796ZY4>VZ]ZE;N6K-NJ^X%BC<KUJ0AR=;->[?L
MV<,]!PYEW-CQ8\B1)4^F7-GR9<R9-6_FW-GS9] ?.2^&3/IR(<L% :!>/90U
MZM>;2;-N'-NT:,>P(<=N7;O_M6[&NG4/I$UZMN.""25^1+W8.6/5$1NK1NAZ
M-?&&!G\S_ZB:-?'@V'U#-+B\>4*(Y,]S;RY:_-#JWUMCEQB2-=+X#=%;AU@_
M8<22)$)O.:0&9 DBAKK;KT#Q%E(.P?(<A+"AY"9\"3[\6@I00H9F2NE"GFB"
MZR6!4M+01!1E(NA$DYYJ2;#ZEOKPIQ@_'.JGEP1+D2VC6'P1IQ]=A!%%":0:
M$K^+N.*Q)2.E*A%)LSHB$JP?2R2RR@]G?"I'+(U"<DHE>V0K2!J)' S():U"
M\Z<HS;R22C6;9-&O+Y$*[4X\\]1S3S[[]/.R(1B[[<_';HLNN-Y^&]2QY^ 3
M=#C>_WJ3+U%'K<OMNOD>HPVWZ2J]E%%+0]U.4$U]$Y522ZO3]+A35=V45.!8
M;>W0W6Y$-#+P&K./TN)FY2XZX'0[5+E1EX-UNP,S1<T[3-G;5326$F2I/=62
MDY:ZC_3[;S^2NLL6P(W.8PDD -.+UB*4NC.W/NU"0JDBDLQU-Z:2T,7(/BE1
MR@DW^[),2EUXR4V0I[=$1&^CZF;**TN! 49,*)CZU=?;]!K.[J)Y+Z207,$F
M5HEA%0F>&.*")1Y)78%/3E!EHN#U+V3]^OUW878O2M;?[. 5JE^7.JXP7805
M$IHGE&$B]&BDDU9Z:::;=OIIJ*.6>FJJJ[;Z:JRSUGIKKO^[]OIKL,,6>VRR
MRS;[;+335GMMMMMV^VVXXY9[;KJO;D^[5R,3#EE)3\7;NO6 8Y0VWEX[;F].
M<27UL6IM?1#5Q:+S+M?V'MP[\KZ+E2["=FN+SU;.F4L8OKLE!.F_G^T$SJ5Z
M)T4=4_PX]G;#%6N^[N6,#GP\PYKK-8E=W(.^., 5,S+^=YIB=^EC)%G,G4B0
M5&I>YC?7%'%Z['T44LPULX_J1AZK#W]-\>L<"T[SN2\??>S'1W]]\MDDT_TR
MZT>?22;!)+-+,,?O\L?T58],88'2^>)'/[ TR7\\JEL#'8B90$WF-HVBH*=T
MM3@+DJY3DUG=K3KSG\TT;H.<.D[_!1.UF.6XBF^J2IRE+$<IX_0&6*)RSJO$
M,Z!<+<HZ";)5# $7&]@ D5:(*IU\@N8H([IF<J"[S;CD<[>5P48_OL*4MES&
MG H-Z%O$69[QN'@\<XG,76-T6<7TLQ&@O0M?0,/7QG1R$AVMI"]#4]@;=:(4
M.0)&,45B"W3LR)2OW,2.?>$C7W1D%\(,TBEAF=E:SJ>7NS"238IT2R(A^<>O
M!%(M?-Q*7P+CR4!B<I%.T2.=2DD7K12F+89A91TOF9A#ZO"!LZ1E!O4D2\[8
MT);NR9NIUN,WRO%',T#T( <O8YI%@8>%D6JB!7.X-\/=JG#22>*WP@.J\%#K
M=N_B%\7*B"/,3Z&PFP-KEJHR-*]DV2D[,E34?TPT+HXMZV;%L]/O5I0=?'IS
MC-&3#H*2=T\O_HYA2.(G]DB4I19=3V/X0=$]3\1/L3"T3EAZT9;TAU#H82A-
M<$E@FN3TE !N;X%EHE]%%;C''(6II&XZZ4CG9SV.,M2C""3@^R8I49L^R:8N
MDDI+?1H^%/W_KY9#)>H%"Y4TT]Q-,I'R)71 ARW+]-)4)%R<4FL%*505+JDN
M[&&BHADX10&..]0$'5<KQ]5CZ6HX)QR5.'L%32KF#7._(6<[5V,L]]B5.L(I
MX79$QDUCG8PX\VQ</B\&KM58*[&([=GMEJ>MF*6L)-6)B<56<CJ$Z0Q>S+-7
MDA"#DSPR12$D V0;Z4+(4=YGE=^["\GB,A*5MK*5^6-3:(UB6U$:$I2'--*+
M]")*4W:%3D!!2B:SHDFK()*/!"L8D*"22>6.$KEVI*-N<QM)U!95N]M%&BY/
M]<NI?M"LKDDJYJ3JP5?91CLMK&$W1XBH13V.<$@$SZ:(>50T<F=T_R]<CS@3
ME9QR2E&;_!'P<VSGSLY=$,#$@I84O^FL;WX(=PJ^#^S.JKQTB@9Y\:)8O<C(
M+8]9LXL]:RR&)W3."C%/H2I&Z)-BE%*%PBQ']T030@_8O@!2YX TG6G\:/M2
MFD;I1#&U:(YY+*,;4_2B03%@1V^,E2D%2:3]>W+Z3%JEY=[/?;X5$I7ATE+^
M_;1-:^)NF1\80<\D$S/VC>_@T#J:4E7&.+UD8:/BS%3-%>JLB)KA?"K<-_IH
M,- Z#)98)>5?!T,56ID37'YG^+GT=G-9^B5KN-"(.O#DUUV@$Y!'DJA,<!UV
MBES$I^XX8B_&'L^+Z+H(RG:%(,'^:U[W,O\:T3S;2#IBMF,>(MAOK6NPN1#,
MN&[Q(W)WFTK8^J4J(/WC:C&6&.LB=R_'5?9K43MLU 9&UL*NME*,*UU'1I*4
MV3:+LQ-)[O==<K>]_8JY86EF>*\M@F@&C9IE$ZK[&AJ#YPT5LS U7U3Y>QZ.
ML8 /-A"# R1<X0E'^,(=_G"(1SSB,?B%#RR 9A5FZE->Y;A8K>KO2:G'F\?R
M+[:RF#A: =ABQF+6;%A(KG+>R,%=%3 5':3A"]%7GJA[HN-(DSIN+6B>AO56
MB9^7NX>ZZT3)\W 7TQ.BD'@(H$DZZ/5B--GD\6PA$]413,<,%O+FF,OJZZV6
MQT<^ (HTR2LU\MK_?1IF\96E[4#F>HNPEZ3YS<G*VR-?W'/JY3-U77MP+Z3:
MP33$>">^;3XT89KW+>>\%=J$.?S3$"X@"F;$0/,':/CF$?YYB3-<])P//><_
M#_K-OV $:MW<=R9MSDH9"X3UK?._1X7$C?MF]B>,U:;(\Q[=-XM9P!J=4V^G
M1:7>A+P#!G4_"937*"84L@,B9T7.Y3OCG7I@9T19P"BBZN_?RU[>9QEI>ZU*
M7!L[V:]\[FKS?NQBC[+)RSYV;+?T[;0TEZ/OQG;)K'W'+.L_1?J_LGLM0Z(_
M4PH3 N01F_$2_Y,N^V,W:KNILQN3)*D_L? NQ=O K]' ._' 7V*P]]*;_S=#
M%4:;*ZN"C!$X/<UC!M/+O!@P!!B<P1:LP1B@P1NT01R<0=/+0=*C@S?#,PL2
MG+\IM-@3)@33N-$YN>9+*P$AK]Z8J]M1NI=;I_[XKT=!%OMH#I4CCT,YN9-;
M*YF;HOT0$-^YF?.(K!G9(ME90R^BG8:*G8%:L8,9&1*KPQG!.H1:*)YQL2+C
MLJCX$1H[DO*Y,8WZDBA+Q+J["I:BLBZ!,9Y2NX,*O )"N_"Y'K5[*2#[GQZ+
MJ.V1,N\)$T[LNP!\D9?H'D9DD47T,2WSK%74NR/#'PZ<1>VRMSR9% W*G,SP
MP&(JO@O0/!\$1F$<1F TA&$T1F%$QF(\1F)DP?\:_(758Z+^NIN0*ZLL;+WM
M"*85NKW((R)(6Z_GRR#*\L;7NRM/,1=>&AK Z19NJI1]*KYJ\<*<B9;X$)!7
MZS"2Z*+V^"+O:T-R^D?2L36B.!V%834V4CXQ:D"-(3:@P*R%DJ.#$(MH,[>4
M<@KP^;4 U",#[(MN8\0%-*[\ZZ2B4*5)BJYV"TGUNS9*RC\+3$"\J*G_^R3>
M,I(W8K+=.BT$0K8YRK^*0B2PHT6@]!I>5)IIXL;30"LC+$I^"[@7R$'/TSP9
MM$'4:T9@[$%G;$89?,&I1+@7B )6 ;CQ\CW<P\)%ZR]IY+V\:AW_:A25>Y0@
M:K[66329LT:T!"'8N<O_1-.=;;J/9.FF^F*7,=2.>G*P;EF9;%D>=JD8Q#2C
MQFJH>,(G@;(8Z7FQ/0RJ%HNE2:205H2QZ8FH.>D2K_LYCQ*R_O%$J2 (O/M$
M^ DSO=L?(ANI5AQ%$* "MC   V"#NI@2P_NZCF#-9*   \  ^UE$G?+-^,$
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MUFU5V^3.V$5=S\6%W95LQZC6V_5</KYDJ[U45O5.;/A=6F"#VWU.W27;X-0
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M\PPB(SIB'$(B&AHB&@8B&0[B&+*8]BPBFM6>7^F01@R!!K2#0+#!M<7)M0$
M.A#%N P1%,3)9&G$KVG(8$$!1K !L6$ &TB# ;"!KT#?;!7$*4Y$+5X95Q7$
M\/'B25Q1H/\5A+U4!/J95O-)A!:PS@1@ _SM$ B0WP2 P;202QG!R[%DVZQA
MXW7U%6[)'U5H8,@MS'>QTG M!6]MW+[,0T'4XZW<HST"0#[>8SV.13ZV8RQ5
MDGW5$LJI#'SUEL_H#-OL1L918,F-$FI,4FG$4M#\"Q:B1GGT1G[]BRD9#<%(
MT\U)'2:Q$G(,7=V-Y&9,Q]#YTLPQ'4OVX-(I7<^!#=L<'1#F7#=)W6ULW3)Y
MW4^"75"F$S9YTQ*N1GIH$U'2(7D8".?1S%+"GA["'3N97G\HGE.*$U66TU X
MR*A(915&95@N'E9NGE7"75D^GE8F&I,Y2#^9'N>AY5HRGG" P0/_C-U<9J59
MIIWVQ&7KG:6!,)Y?ZN5?OIU+I5/:K5,G*N9B,F8+Y9"X-&9DYDNIP*)DGN-M
M_=9Y=: )YA\\GLQ[>>8&AF:^ .0^2J;3<!<E:69Y"9?.L"-"*E,(HAQVN:9)
M?AQ\8=(0;I*%@5* S5)YJ$;:#$T$ED=^\8P+JF3*N)B!;=?3863;(=C63!W:
M&"%V6-B&E<W5,&%U@MB).6'<!$\4BF=X\@>*>6>(\<U2XATFSB$A+EX6&H8C
MMB?@5*(F=I@>MJ?BS(T<TMUZ@B$FHAE^#F)^#.@C%N*!%JCA0"*/W$TD)BA\
M&BC>G6<C N@9DAXZ16)]SF> 7H^#)N)7_TYBUECFB)*H8K)?B:*H1LR9\2TF
M.L(1.F*F:H(7C++@:VJFK1!G_NE6BBY%/FZ70,970$I-?HE2"I)-?/T?>D4@
M9Y[7;KDF17J21"XI<-%?.YZ<1?K?5U3D1TZD87 <?RR=+?'&ZDG'';TD@ #8
M2JK2U=1'TED&>]3=3'K'T<$'?UE=SN5=?% 34)*388;AW1'FU^V2Z&F/X7T3
M83ZE8$HE7X)3&F+E8.)'5O*=6=8GV\$EI9Z=Z;4>I+(38?;EFWV3HRJ>>T8J
MJ:JEI>[E5X;EI^)E56ZBJ*KJ^X!>)JK=?_#HK>+JK1P$*N:J95;$8*$HC H<
M;>U?P6%@D]:6"O_BS ;RVWS1$AN5IC[RBW_Q6VV5H,%D$K8V!AU]X"8%*7#Q
M7&<<)'8=C=!LJU:$*WUADV2 I'2(JX6UEVKXQ@C::3N*!ML$9'"$)$;*5X/]
M'-HHF,L!;!*.9$72*0UBTX5Y6'408=\PD]L );S"JZM,H>'$FGYB+"..V.$4
M*">"YUY**(0*J'P&)N-<Z-]((NA9:LDJHH$NZI-U;,E:HLN6ZL@&7L:N)]W%
MVGTZXLY.Z(=F;,?>(<F";!G28<@*HH7R8<ZJ#1^V7:]";=1*[=2R4#G"*,/@
M5M,PA59P:SHR:_SIWXWJJ)+:*'QQ13U&Q6*E+50D13DR!/SE(\M)!I#_VM_<
MAMP[UA=X!=<=:6!)7N &/JFX^M;*H1?+V28J.4V1[JTGP>#-]!<J81YPPE)]
M'&>:2H?<#9-N7!W1[2383%,19EWFWE1QA*[9A-X1<ETWN0=3!B4YL1/HWI2?
MQIJ@1J5+W<DSN:IO(%Y?!LBASFJKTM.C<.IA4N7P_JY9]JFK7NJD_B6FKAWK
M(J:KJJSTGJKS2N_M!M[7#>;R6N\*'0ZK\FX:\F=44FWYFN_YHJ\*]FK?UJUZ
ML6"Q]I98C.VPTE;[1<558./]$I?*V6O4S)RZ0JENK==%'B0=P1'--&0KN:^4
M*C#7<N0)"FZ\SE)Q?$;2/)B6_M%QK@V]:J[@_[K<STDGER8PP&8'$VY-A$%8
MO<(<3J*P@2G8=QX=O$+L=6I8@#VA47ZOX*E8>KH>>L;AA#EMAP'*%[[LA3YH
MTD)B%2*>TH[O)8[L$S=QA+ZL^'8>'XHA$U_A@6KH#R^J$M\-TPJM$A.M\%+L
MXXCOSI*Q(,;AS^9G!*;O&\-Q'-^JL.(;4US2K8RF:B:,&Y>MDV*KO8)B)\H1
ME^J6=\6&.<[CM@X-1[;,4W+7D?ZM"5HDY!ZN;G9<QS7&L@8IQU4D 1>-?5&K
MT/ D"-[<UVBNFX;'_[HPSI!-TLDI3J[>V BL3C+LGC(G3<[>V'V8V?'7X5#=
MZ/FN4HJQ5@)*,"?:@$/LKC&+7:I2*O ^*NZB*JU(,X9N$Z.>ZN:]ZJ8R[Z&6
M4_<R,U16;S;?I>U.,>LJJC53;^]*Y5B>TU3Z*5Y>1U[&*O4*_X@<V_,]X[-E
MZIL$)NO6VO%[$1RRWBC*\7.4?I?"#+#'%70@OVVURF_ Z7%V[NA$&W+,?5)X
M.>M$9F?!"<U%3J"%Q1P%O^@($DS"<F!ZL<P13N!\29BXPJ#G3F#,!8\,:BYH
MF!=UGO(.QA()#^%.PS0-=BZ%2:R#(8W;7"%X5B=YUG 2FM@7EW&,E1C5_2<9
MYN<6]S RTRS,+JT>9O6'TFP;/\YY5B@:@RH8,W/.'FVMFK'@:3'.9BA\1J*C
M'O$B!F*E:BS)<K&!?G41XZ=[9K'01F(^"_9@#S;\Z1RNYG$_B]<>'7 ?RRC'
M):1#@ZVM<.T=R5\"7^ D=[1 0BFY"O^I(NO<;HS<0UKP+Z4F(#MR:732D@)I
M8A#I6$RI:Q-':G029Z/2X_(D3-?KUJUD*^=T3CHG8^0D,2DLF&+A?% N[/(&
MUJFNN.:=-06EGDH3=+MN->V-.W=O8H9J6MKJ<K.S[QJOGOKE,[_E[Y+SS2[O
M>:.J]@KO,[L4>U=S'99SV)537[YN,*,E&7,>F8;O>$>S6%IS6G*>/ ,XHD(3
M82-X@LLQ'5.V/RNV.L)ODW;@_':F1%(X<EK20CIX/#*KRH2FQG&F"%YRS/41
M;0>,!0YTB0.R 9,XO>Y1)M^?SE1V!8<2DIIXA767Z5IP>(;@2>,7SK4IA(6D
M=+874!]LV-C_C>6$H DWH8?Y(,&^J7<B-1(Z87I&1QAZYPXSM0^K&)F.<5;/
M88%B-6!S+()*,7VXM:F:^1%OE%UG855C+(>"-1)+<:UNJ/@&8N%P-3@#K5?/
M]Q*'\=O=-1H[91ZBK!-WZ%[?B8(S>J/G,]8*,B;G"X.O()5R>$3_;<'@UK^A
MUVQ"9/SYS/]Z^(N7#2C5IFF<W&*,8'9UEVR:JQ"6M$+WUY6JDREW=*J[DFOR
MK7G)W&P_KDM'*9""J9UZARG/7A ^W4S6)'$ C7?\LM P9^B6,'6PKFY.4S4-
M6#QSW;7WW#0=*O$VA^N%7E.2>[>'.UYB\W)'KX$WZC;K*163[_:J_W5X&W,X
M4_&C.B][^ZZ^*VKJ :]8^B6_H\TWFV7IG;-6JK=V__O!<^_*WJRC0WS$3RU?
MT3&E@^TAC[K8*G)(JV9 IZ 'OJ:*,_9DD-QB7/+^W9_8"F[)10W(N^A%I[A
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MZ!US^OC);U=8 ^#\Y\<F8K4-K GWY(O0P77[A;@>@5S@%VAW>[/YG_;^_Q\
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M#W4@1AGWR 63<:0 J0?[Y2S)1D"43.!FT&1LT 7SY6IF< :9BPA]([U$YN<
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M1N$;"E(> 6"&*2 97M@@%W)4D<(VEW53 0 ,;+5]7!<?1'-&]A.&1156:4%
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M:W*%104 4,SV\-%@)(W5TDW5]?)4^ND7XFY:0]A?5<D-=R'6]6$H<%471'=
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M$Y\"_Y@,EA@ 3\A"E4$R\J0 +O(AW!N-J&YRPF1TA22&,D"FY@2 ;VAKI \
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MAB1FUCW]-&=F!B]Z)F;Q)CY68F;<0Q3@$WOU5HO84XMZ%F^I16BR"'WSME8
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M#5S*A]Q@NBEAE7N2DMROM+4Y'MVF;GA-?R<X&T+)E0-DARMXR/EU<LC 4LC
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MK)%QG$YK E0"HS"  ;1@%"J,(EXG6M*.K@3/@)J]G')9=^0-PP9:8$/RT=-
MY=D$!EJ  *.&>@SUHH.!P$.!:>69M[Z[JQE_O,"X =]R# R1YMG[>^"V'Z[
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ML:0"TP,\K P\2IX'%%9;./1+?)0!:6 #TV/$6?Y1RS,]+<  % 5F?_9"QP4
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MRSH!:YL$\R0-JWQ;VK%GH@FKXY(?X4<*ILFJ>SIX[/S;Z; 7X9QVC?\7%]C
M($ZTU0;8A)2 (.8K_2!6"ID ?/AJ ^CK4Q_W,+A9!Y785 ?K!83A'1EM99V
M0A#8O 8 ?$"'@7!]H8#U)%; O%8*FZWWLR4*.8Z22FS),!Z(T+YLBI!L2<[M
M0J#9"F'M@JV0Y/X1-IC^?+WDIZQK_*0(,$#+X >(9  D)"LHP8",9 0-C *0
MS( 6A1(+29!A0"(^#0HGA%&(L- - Q@4AM0B892!E 8<4DR&S\"#B00)MFQ)
M<Z;,9"US#LQ)4"). $*'$BUJ]"C2I$8IJ#1 1<,-H5I28CB:$AL $%2'#ID
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M=B:#S00SO362!%,I-*F-$XSBT9[5&>!",M]@U:B<FMHY6J*0GOJ-!@7V21
M&=F(T* %3@""DPQ)!.@-9-I9B$6*&M!K,DQ5I<$W,UET0R&F"@3&!*ANJ2D
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M 85YX V2T:>>' 14(3$ FB RDPFX8""T6D@8)'"7IN3D+@5Q@0'@ :QA:=
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M8#:F8P8FH,1D4Q,NGL/\5^@%Y&,^C((\H5+9SH7PCAA^I)Y!B!^^#NGU39#
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MVANK#I]Y:>Y!*>L<6K<**]?JE.AHK3\W-+3J\T,/_\_^2J>E/3"$3V^[#E4
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M?,E[/,D# <F?/,:'O,@_O,MWO,P#P<)#@16H?,5'0!20_,[OO,[S_,K_O!6
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MJF2 2ED#[)^R)!! !0ZP5OT#(*@(R, '-K!6")1@!0\HP0P:4( 6M*#_(IC
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M;=3NBOQ(__Q"1?0_1SQ#5]R"3ZA"^[7XEB] 6_SX%O@_NT^K2+0@QDKY/CA
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M92YOQ=%=2%"7N\@5+W>]RUOP@I<>:["#/NZK7VN(%\%J0#!"*K)? S.8P-:
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MAXUK9QS3N::%A*G;/RH-IZPLU;A43D5*W#C,$8F8;6!F7(H8%&!# <UA6V&
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MBV,P.J9XT&LH2@^-AI+0=I\@.EE*"JQ[.J.0.FUT#4#&!>H336$@D%>Y4(D
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M!'73$240!,K6<0U@#6UQ$7W0="W7+0'R)Q^7(#F2=)%P<_V1*H&36>-V:@'
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C*>645%8;:>656&:IY99<=NGEEV"&*>:89)9IYIEH0AD0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Aug. 03, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PACIRA BIOSCIENCES,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0619477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Sierra Point Parkway, Suite 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">242-8052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,861,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001396814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 205,875<span></span>
</td>
<td class="nump">$ 158,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term available-for-sale investments</a></td>
<td class="nump">45,156<span></span>
</td>
<td class="nump">79,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">132,420<span></span>
</td>
<td class="nump">124,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">134,575<span></span>
</td>
<td class="nump">152,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">67,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">29,852<span></span>
</td>
<td class="nump">32,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">615,215<span></span>
</td>
<td class="nump">547,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">130,277<span></span>
</td>
<td class="nump">140,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">44,920<span></span>
</td>
<td class="nump">41,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">19,642<span></span>
</td>
<td class="nump">20,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">285,484<span></span>
</td>
<td class="nump">368,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">124,598<span></span>
</td>
<td class="nump">123,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_EquityMethodInvestmentsAndOtherAssets', window );">Investments and other assets</a></td>
<td class="nump">23,842<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,243,978<span></span>
</td>
<td class="nump">1,264,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,509<span></span>
</td>
<td class="nump">15,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">93,499<span></span>
</td>
<td class="nump">95,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">10,298<span></span>
</td>
<td class="nump">9,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">122,011<span></span>
</td>
<td class="nump">120,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">363,124<span></span>
</td>
<td class="nump">372,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">38,695<span></span>
</td>
<td class="nump">36,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ContingentConsiderationNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">17,452<span></span>
</td>
<td class="nump">18,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">4,070<span></span>
</td>
<td class="nump">4,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">26,650<span></span>
</td>
<td class="nump">20,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">572,002<span></span>
</td>
<td class="nump">571,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at June&#160;30, 2026 and December&#160;31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001; 250,000,000 shares authorized; 48,840,889 shares issued and 39,822,298 shares outstanding at June&#160;30, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December&#160;31, 2025</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at June&#160;30, 2026 and December&#160;31, 2025, respectively</a></td>
<td class="num">(227,013)<span></span>
</td>
<td class="num">(176,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,087,452<span></span>
</td>
<td class="nump">1,064,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(191,753)<span></span>
</td>
<td class="num">(199,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3,241<span></span>
</td>
<td class="nump">4,327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">671,976<span></span>
</td>
<td class="nump">693,111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,243,978<span></span>
</td>
<td class="nump">$ 1,264,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EquityMethodInvestmentsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments and Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EquityMethodInvestmentsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">48,840,889<span></span>
</td>
<td class="nump">47,890,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">39,822,298<span></span>
</td>
<td class="nump">41,116,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">9,018,591<span></span>
</td>
<td class="nump">6,774,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 192,399<span></span>
</td>
<td class="nump">$ 181,099<span></span>
</td>
<td class="nump">$ 369,775<span></span>
</td>
<td class="nump">$ 350,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold (exclusive of amortization of acquired intangible assets)</a></td>
<td class="nump">44,164<span></span>
</td>
<td class="nump">40,866<span></span>
</td>
<td class="nump">80,577<span></span>
</td>
<td class="nump">75,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,243<span></span>
</td>
<td class="nump">28,200<span></span>
</td>
<td class="nump">58,315<span></span>
</td>
<td class="nump">53,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">91,809<span></span>
</td>
<td class="nump">88,578<span></span>
</td>
<td class="nump">185,753<span></span>
</td>
<td class="nump">175,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expenses, net</a></td>
<td class="nump">7,594<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">5,317<span></span>
</td>
<td class="nump">6,470<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">188,132<span></span>
</td>
<td class="nump">172,600<span></span>
</td>
<td class="nump">358,606<span></span>
</td>
<td class="nump">339,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">4,267<span></span>
</td>
<td class="nump">8,499<span></span>
</td>
<td class="nump">11,169<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">5,008<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
<td class="nump">11,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3,622)<span></span>
</td>
<td class="num">(4,695)<span></span>
</td>
<td class="num">(7,321)<span></span>
</td>
<td class="num">(9,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(10,739)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(6,338)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(1,712)<span></span>
</td>
<td class="num">(10,426)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="num">(3,710)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">2,555<span></span>
</td>
<td class="num">(1,927)<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
<td class="nump">6,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(6,814)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,653<span></span>
</td>
<td class="num">$ (4,847)<span></span>
</td>
<td class="nump">$ 7,569<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">39,462<span></span>
</td>
<td class="nump">45,459<span></span>
</td>
<td class="nump">39,961<span></span>
</td>
<td class="nump">45,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">40,300<span></span>
</td>
<td class="nump">45,459<span></span>
</td>
<td class="nump">40,605<span></span>
</td>
<td class="nump">45,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 190,493<span></span>
</td>
<td class="nump">$ 180,347<span></span>
</td>
<td class="nump">$ 367,869<span></span>
</td>
<td class="nump">$ 347,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,906<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
<td class="nump">$ 1,906<span></span>
</td>
<td class="nump">$ 2,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,653<span></span>
</td>
<td class="num">$ (4,847)<span></span>
</td>
<td class="nump">$ 7,569<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">2,756<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 4,439<span></span>
</td>
<td class="num">$ (2,136)<span></span>
</td>
<td class="nump">$ 6,483<span></span>
</td>
<td class="nump">$ 3,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Beginning balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,793,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2024</a></td>
<td class="nump">$ 778,348<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="num">$ (25,121)<span></span>
</td>
<td class="nump">$ 1,009,435<span></span>
</td>
<td class="num">$ (206,356)<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(210,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</a></td>
<td class="num">(5,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock, inclusive of excise tax and broker fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,956,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock, inclusive of excise tax and broker fees</a></td>
<td class="num">(50,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period at Jun. 30, 2025</a></td>
<td class="nump">757,767<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="num">$ (75,515)<span></span>
</td>
<td class="nump">1,035,563<span></span>
</td>
<td class="num">(206,391)<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Beginning balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,793,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2025</a></td>
<td class="nump">798,541<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="num">$ (25,121)<span></span>
</td>
<td class="nump">1,023,808<span></span>
</td>
<td class="num">(201,544)<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</a></td>
<td class="num">(5,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock, inclusive of excise tax and broker fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,956,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock, inclusive of excise tax and broker fees</a></td>
<td class="num">(50,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(4,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period at Jun. 30, 2025</a></td>
<td class="nump">$ 757,767<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="num">$ (75,515)<span></span>
</td>
<td class="nump">1,035,563<span></span>
</td>
<td class="num">(206,391)<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">41,116,739<span></span>
</td>
<td class="nump">47,891,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Beginning balance (in shares) at Jun. 30, 2026</a></td>
<td class="num">(9,018,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,019,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2025</a></td>
<td class="nump">$ 693,111<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="num">$ (176,565)<span></span>
</td>
<td class="nump">1,064,623<span></span>
</td>
<td class="num">(199,322)<span></span>
</td>
<td class="nump">4,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">27,947<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares)</a></td>
<td class="num">(366,650)<span></span>
</td>
<td class="num">(367,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</a></td>
<td class="num">$ (7,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="nump">82,837<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">$ 1,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 28,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock, inclusive of excise tax and broker fees (in shares)</a></td>
<td class="num">(2,244,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,245,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock, inclusive of excise tax and broker fees</a></td>
<td class="num">$ (50,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 7,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2026</a></td>
<td class="nump">39,822,298<span></span>
</td>
<td class="nump">48,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="num">(6,774,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,774,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period at Jun. 30, 2026</a></td>
<td class="nump">$ 671,976<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (227,013)<span></span>
</td>
<td class="nump">1,087,452<span></span>
</td>
<td class="num">(191,753)<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Beginning balance (in shares) at Jun. 30, 2026</a></td>
<td class="num">(9,018,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,019,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2026</a></td>
<td class="nump">$ 653,893<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="num">$ (227,013)<span></span>
</td>
<td class="nump">1,073,809<span></span>
</td>
<td class="num">(196,406)<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee withholding tax liabilities on vested restricted stock units</a></td>
<td class="num">(3,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2026</a></td>
<td class="nump">39,822,298<span></span>
</td>
<td class="nump">48,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Shares, Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,019,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period at Jun. 30, 2026</a></td>
<td class="nump">$ 671,976<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (227,013)<span></span>
</td>
<td class="nump">$ 1,087,452<span></span>
</td>
<td class="num">$ (191,753)<span></span>
</td>
<td class="nump">$ 3,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 7,569<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets', window );">Release of valuation allowance on deferred tax assets</a></td>
<td class="num">(6,397)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Investment impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred taxes</a></td>
<td class="nump">5,644<span></span>
</td>
<td class="nump">2,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of fixed assets and amortization of intangible assets</a></td>
<td class="nump">42,626<span></span>
</td>
<td class="nump">48,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of cloud computing arrangements</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">28,497<span></span>
</td>
<td class="nump">30,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration</a></td>
<td class="num">(614)<span></span>
</td>
<td class="num">(3,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount on available-for-sale investments</a></td>
<td class="num">(927)<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherLosses', window );">Other net gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(12,074)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="nump">8,451<span></span>
</td>
<td class="num">(22,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">378<span></span>
</td>
<td class="num">(15,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,248<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,563<span></span>
</td>
<td class="num">(14,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">10,905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">83,140<span></span>
</td>
<td class="nump">47,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)</a></td>
<td class="num">(335)<span></span>
</td>
<td class="num">(16,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(4,060)<span></span>
</td>
<td class="num">(11,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of available-for-sale investments</a></td>
<td class="num">(3,905)<span></span>
</td>
<td class="num">(74,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Sales of available-for-sale investments</a></td>
<td class="nump">39,500<span></span>
</td>
<td class="nump">140,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of convertible notes receivable investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">31,200<span></span>
</td>
<td class="nump">36,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans', window );">Proceeds from shares issued under employee stock purchase plan</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding taxes on restricted stock unit vests</a></td>
<td class="num">(7,848)<span></span>
</td>
<td class="num">(5,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock, inclusive of broker fees</a></td>
<td class="num">(50,045)<span></span>
</td>
<td class="num">(50,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ShareRepurchaseProgramExciseTaxPaid', window );">Excise taxes paid on treasury stock repurchases</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of Term loan A facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of Revolving Credit Facility</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(67,048)<span></span>
</td>
<td class="num">(60,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">47,330<span></span>
</td>
<td class="nump">23,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">158,545<span></span>
</td>
<td class="nump">276,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">205,875<span></span>
</td>
<td class="nump">300,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,171<span></span>
</td>
<td class="nump">7,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Net cash paid for income taxes</a></td>
<td class="nump">910<span></span>
</td>
<td class="nump">8,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets included in accounts payable and accrued liabilities</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable', window );">Excise tax on treasury stock repurchases included in accrued liabilities</a></td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Taxes, Valuation Allowance On Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from shares issued under Employee Stock Purchase Plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareRepurchaseProgramExciseTaxPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Excise Tax Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareRepurchaseProgramExciseTaxPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to other loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Pacira&#8221;) deliver innovative, non-opioid pain therapies to transform the lives of patients. The Company&#8217;s long-acting, local analgesic, EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company&#8217;s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia in adults via (i) an interscalene brachial plexus block in adults; (ii) a sciatic nerve block in the popliteal fossa; or (iii) an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks other than an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, and an adductor canal block). In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the &#8220;Flexion Acquisition&#8221;), and added ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. The Company is also advancing two Phase 2 clinical programs&#8212;PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy for OA of the knee, and PCRX-2002, a complementary, long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. PCRX-201 is the lead program from the Company&#8217;s proprietary high-capacity adenovirus, or HCAd, vector platform, which enables local administration of genetic medicines and has the potential to unlock gene therapy for large prevalent diseases affecting millions of people. In February 2025, the Company acquired the remaining 81 percent equity interest that it did not already own in GQ Bio Therapeutics GmbH, or GQ Bio (the &#8220;GQ Bio Acquisition&#8221;), a privately-held biopharmaceutical company, which included the novel HCAd platform, a preclinical portfolio of HCAd-based assets and research and development talent. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies and potential generic entrants, reliance on revenue from two commercialized products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, tariffs, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company divested iovera</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#176;, a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to Zimmer, Inc., or Zimmer, a subsidiary of Zimmer Biomet Holdings, Inc. on July 31, 2026. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.4-03(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#8220;2025 Annual Report&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#8217;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities available for sale and expected to be sold within one year are classified as either assets or liabilities held for sale on the condensed consolidated balance sheets at the lower of their carrying value or fair value less any costs to sell. Any loss, or gain up until any previously recorded loss, is recognized in the period in which the held for sale criteria are met. The Company will recognize contingent consideration related to the sale of a business as a gain contingency. Under this policy, contingent consideration is excluded from the initial measurement of gain or loss upon the divestiture of a business and is recognized in earnings when the contingency is resolved and the consideration becomes realizable. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company agreed to divest its cryoanalgesia business&#8212;including iovera&#176;&#8212;to Zimmer and reclassified certain of its assets and liabilities to assets and liabilities held for sale. For more information, refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants performance share units, or PSUs, under its Amended and Restated 2011 Stock Incentive Plan to certain of its employees, including its executive officers. The expense associated with these awards is recognized in the Company&#8217;s consolidated statements of operations based on their grant date fair values at the closing price of the Company&#8217;s common stock on the date of grant. The expense is recognized over a four-year service period using graded vesting based on the Company&#8217;s interim estimates of achievement of a stated performance objective during the one year period subsequent to the grant date. Changes in estimates are recorded on a cumulative catch-up basis. After the one year performance period, the number of shares the employee is entitled to is fixed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Major Customers</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s three largest wholesalers in each period presented: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Largest wholesaler</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Second largest wholesaler</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Third largest wholesaler</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of June&#160;30, 2026</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment improves financial reporting by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU&#8217;s amendments are effective for annual reporting periods beginning after December 31, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. This ASU amendment can be applied on a prospective basis or retrospectively. The Company is currently evaluating the impact of adopting ASU 2024-03 on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40), Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment removed all references to prescriptive and sequential software development stages (referred to as project stages) throughout Subtopic 350-40. This had been replaced by the requirement to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding a software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition threshold&#8221;). The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The ASU&#8217;s amendments may be adopted on a prospective, modified transition approach that is based on the status of a current project and whether software costs were capitalized before the date of adoption or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-06 on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Grants (Topic 832), Accounting for Government Grants Received by Business Entities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU provides the recognition requirements for a government grant received, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. This ASU provides for adoption either on a modified prospective, modified retrospective, or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-11,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interim Reporting (Topic 270): Narrow-Scope Improvements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU is intended to update the guidance in Topic 270 by improving navigability of the required interim disclosures and establishing a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted at any time prior to the effective date and should be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2025-11 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES HELD FOR SALE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">ASSETS AND LIABILITIES HELD FOR SALE</a></td>
<td class="text">ASSETS AND LIABILITIES HELD FOR SALE<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company and Pacira CryoTech, Inc.&#8212;its wholly-owned subsidiary (the &#8220;Subsidiary&#8221;)&#8212;entered into a Stock and Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Zimmer, a subsidiary of Zimmer Biomet Holdings, Inc. Pursuant to the Purchase Agreement, the Company agreed to divest to Zimmer (i) all of the issued and outstanding capital stock of the Subsidiary and (ii) certain assets and liabilities of the Company and certain of its subsidiaries relating to the Company&#8217;s handheld cryoanalgesia devices and related products&#8212;including iovera&#176; (the &#8220;Transaction&#8221;)&#8212;for up to $140.0&#160;million, including an upfront payment of $70.0&#160;million, subject to customary adjustments for cash, accounts receivable, indebtedness, transaction expenses and inventory.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the iovera&#176; assets and liabilities included in the Purchase Agreement were reclassified to assets and liabilities held for sale due to meeting the required held for sale criteria. As of June&#160;30, 2026, assets held for sale of $67.3 million consisted of $53.3 million of intangible assets, $9.8 million of inventory, $3.7 million of accounts receivable and $0.5 million of fixed assets, net of depreciation. As of June&#160;30, 2026, liabilities held for sale of $0.7 million consisted of accrued expenses. The Company determined that the held for sale disposal group was not impaired because its fair value less the cost to sell exceeded its carrying value.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement provides for potential contingent consideration of up to an additional $70.0&#160;million in the aggregate, payable upon the achievement of the following revenue-based milestones (in each case, excluding any net revenue previously applied towards the achievement of any other milestone threshold) up to and through the period ending December 31, 2031:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the current version of iovera&#176; available for sale to end users as of the closing date of the Transaction (the &#8220;Business Products&#8221;) during any of the <span style="-sec-ix-hidden:f-481">five</span> (5) calendar year periods commencing on January 1, 2027 through December 31, 2031 (each an &#8220;Applicable Milestone Period&#8221;) equals or exceeds $50.0&#160;million, the Company will receive $18.5&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $60.0&#160;million, the Company will receive $23.5&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $70.0&#160;million, the Company will receive $28.0&#160;million.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If net revenue from the sale of the Business Products during any single year equals or exceeds the sum of any two or more milestones, then the highest applicable milestone payment shall be paid with respect to such year.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that execution of the Purchase Agreement did not qualify as discontinued operations since it did not have a major effect on the Company&#8217;s operations and financial results.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Transaction closed on July 31, 2026 in which the Company received cash of $73.6&#160;million, after customary purchase price adjustments. The $70.0&#160;million of additional contingent milestones will be recognized in the period if and when they are each earned. As part of the Transaction, there are $2.2&#160;million of transaction bonuses payable to certain employees of the Company that were hired by Zimmer at close that the Company will record as an expense in the third quarter of 2026. The $2.2&#160;million of transaction bonuses will be paid by Zimmer. </span></div>Upon the close of the Transaction on July 31, 2026, the Company entered into a transitional services arrangement, pursuant to which the Company will provide recordkeeping and other services; a development and commercialization agreement, pursuant to which both parties intend to continue the label expansion of iovera&#176; in the field of spasticity through United States Food and Drug Administration, or FDA, approval; and a sublease agreement, all of which are expected to operate through 2028.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text">REVENUE<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales are primarily within the U.S. and consist of EXPAREL, ZILRETTA, and sales of bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of the Company&#8217;s bupivacaine liposome injectable suspension for veterinary use. In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, and as such, the Company will no longer recognize revenue associated with iovera&#176; after this date. For additional information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, customer rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to Department of Veterans Affairs hospitals, participating GPO members, 340B qualified entities and other contracted customers at prices lower than the list price. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers claim the difference between the amount invoiced and the discounted selling price through a chargeback issued by a wholesaler. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are determined at the time of sale and the Company generally issues credits for such amounts within weeks of receiving notification from a wholesaler. Reserves for chargebacks consist of anticipated credits the Company expects to issue based on expected units sold and chargebacks that customers have claimed for which credits have not yet been issued.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from&#160;<span style="-sec-ix-hidden:f-493">zero</span> to four months from the date of the transaction, and accordingly, there is no significant financing component.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company&#8217;s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company&#8217;s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;EXPAREL</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147,823&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142,917&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291,097&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">279,446&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,648&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,334&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59,415&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,672&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;iovera&#176; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,588&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,982&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,216&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total net product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">190,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">367,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">347,941&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, after which the Company will no longer recognize revenue associated with iovera&#176;. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,096&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,201&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,319&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,327&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">134,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, $9.8 million of inventories related to iovera&#176;, comprised of $5.6 million of raw materials, $1.2 million of work-in-process and $3.0 million of finished goods, were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text">FIXED ASSETS<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">162,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">163,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,653&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,450&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,979&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,187&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,584&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,485&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">281,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">278,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(150,880)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(137,703)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">130,277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, $0.5 million of fixed assets related to iovera&#176;, comprised of $0.5 million of machinery and equipment, net, along with nominal amounts of computer equipment and software, net, and office furniture and equipment, net, were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Depreciation on these fixed assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2026, depreciation expense was $7.0 million and $14.0 million, respectively. For the three and six months ended June&#160;30, 2025, depreciation expense was $13.0 million and $19.8 million, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $5.5&#160;million of accelerated depreciation expense during the three and six months ended June&#160;30, 2025 as a result of decommissioning its 45-liter EXPAREL batch manufacturing suite located at its Science Center Campus in San Diego, California. The Company continues to operate its 200-liter EXPAREL batch manufacturing suite at the same facility.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located outside of the U.S. in the amount of $38.0 million and $41.9&#160;million, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, the Company had asset retirement obligations of $4.1&#160;million and $3.9&#160;million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases all of its facilities, including its EXPAREL and iovera&#176; handpiece manufacturing and research facilities at its Science Center Campus in San Diego, California. In April 2025, the Company moved its principal executive offices and corporate headquarters to Brisbane, California and in June 2026, the Company entered into a new lease in Brisbane, California to retain this office through 2036. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services, or Thermo Fisher, for the use of their manufacturing facility in Swindon, U.K. for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees have been allocated to the lease components based on a relative fair value basis. As part of the GQ Bio Acquisition in February 2025, the Company assumed GQ Bio&#8217;s European offices that include a research and development lab and offices in Luckenwalde, Germany.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Between February 2023 and April 2025, the Company had been recognizing sublease income for a portion of office space leased in Burlington, Massachusetts that was assumed as part of the Flexion Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, upon which the Company also entered into a sublease agreement through 2028. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recorded in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,962&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to net the reduction of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.94 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.79 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.98&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.91&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Minimum<br/>Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,268&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,239&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,159&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,972)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Asset, Goodwill and Other [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill arose from the GQ Bio Acquisition in February 2025. As of June&#160;30, 2026 and December 31, 2025, the goodwill balance was $19.6&#160;million and $20.2&#160;million, respectively. The change in the goodwill balance from December 31, 2025 was due to $0.6&#160;million in foreign currency translation adjustments. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had goodwill resulting from the acquisition of Pacira Pharmaceuticals, Inc. (the Company&#8217;s California operating subsidiary) from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc, a subsidiary of Molex Asia Holdings Ltd.) in 2007, the acquisition of MyoScience, Inc. (the &#8220;MyoScience Acquisition&#8221;) in 2019 and the Flexion Acquisition in 2021. Accumulated goodwill impairment charges through June&#160;30, 2026 were $163.2&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible Assets</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consists of in-process research and development, or IPR&amp;D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition. In June 2026, $53.2&#160;million, net, of developed technologies and a nominal amount of customer relationships related to iovera&#176; from the MyoScience Acquisition were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Amortization on these intangible assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, as of June&#160;30, 2026 are summarized as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">480,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(228,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">251,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9 years, 9 months</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,569&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,569&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">513,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(228,085)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">285,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(1) The change in the gross carrying value compared to December&#160;31, 2025 reflects the impact of foreign currency translation adjustments related to the IPR&amp;D acquired from the GQ Bio Acquisition.</span></div></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">590,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(256,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">590,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(256,274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,284&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,284&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">624,374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(256,274)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">368,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets was $14.3&#160;million for both the three months ended June&#160;30, 2026 and 2025. Amortization expense on intangible assets was $28.6&#160;million for both the six months ended June&#160;30, 2026 and 2025.</span></div>Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $24.7&#160;million for the remaining six months of 2026, $49.4&#160;million each year from 2027 to 2030, and $29.5&#160;million in 2031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible asset and goodwill. Includes, but is not limited to, finite- and indefinite-lived intangible assets, capitalized cost for internal-use software and software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,243</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,129</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued production costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,494</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,002</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,235</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,864</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,987</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,841</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">782</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and wholesaler service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,682</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,554</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">93,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">95,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, $0.7&#160;million of accrued expenses related to iovera&#176;, comprised of $0.5&#160;million of other accrued operating expenses and $0.2&#160;million of product returns and wholesaler services, were reclassified to liabilities held for sale in conjunction with entering into the Purchase Agreement with Zimmer. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s outstanding debt is summarized as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.125% Convertible senior notes due May 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">281,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">372,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2029</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company completed a private placement of $287.5&#160;million in aggregate principal amount of its 2.125% convertible senior notes due 2029, or 2029 Notes, and entered into an indenture with Computershare Corporate Trust, N.A., or 2029 Indenture, with respect to the 2029 Notes. The 2029 Notes accrue interest at a fixed rate of 2.125% per year, payable semiannually in arrears on May 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and November 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The 2029 Notes mature on May 15, 2029.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2029 Notes was as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.125% convertible senior notes due May 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">287,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">287,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,376)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,311)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt, net of deferred financing costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">281,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, the 2029 Notes had a market price of $999 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2029 Notes will be paid pursuant to the terms of the 2029 Indenture. In the event that all of the 2029 Notes are converted, the Company would be required to repay the $287.5&#160;million in principal value in cash, whereas any conversion premium would be required to be repaid in any combination of cash and shares of its common stock (at the Company&#8217;s option).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding November 15, 2028, the 2029 Notes are convertible only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on June 30, 2024 (and only during such calendar quarter), if the last reported sale price of the Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is equal to or greater than 130% of the conversion price on each applicable trading </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">day; (ii) during the five business-day period after any five consecutive trading-day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of the 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; (iii) upon the occurrence of specified corporate events; or (iv) upon a Company redemption. On or after November 15, 2028, until the close of business on the second scheduled trading day immediately preceding May 15, 2029, holders of the 2029 Notes may convert all or a portion of their 2029 Notes, at any time. No sinking fund is provided for the 2029 Notes. As of&#160;June&#160;30, 2026, the conditions for conversion were not met. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2029 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 50 consecutive trading days during the observation period (as more fully described in the 2029 Indenture). For the principal, the Company will settle in cash per the terms of the 2029 Notes. For any excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2029 Notes is 25.2752 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $39.56 per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2029 Notes represents a premium of approximately 32.5% to the closing sale price of $29.86 per share of the Company&#8217;s common stock on the Nasdaq Global Select Market on May 9, 2024, the date that the Company priced the private offering of the 2029 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On or after May 17, 2027 and on or before the 50</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> scheduled trading day immediately before the maturity date, the Company may redeem for cash all or part of the 2029 Notes if (i) the 2029 Notes are &#8220;freely tradable&#8221; (as defined in the 2029 Indenture) and any accrued and unpaid additional interest has been paid as of the date the Company sends the related notice of the redemption and (ii) the last reported sales price of the Company&#8217;s common stock exceeds 130% of the conversion price then in effect for (1) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of the redemption; and (2) the trading day immediately before the date the Company sends such notice. The redemption price of each 2029 Note to be redeemed will be the principal amount of such 2029 Note, plus accrued and unpaid interest, if any. In addition, calling any 2029 Notes for redemption will constitute a make-whole fundamental change, in which case the conversion rate applicable to those 2029 Notes, if converted in connection with the redemption, will be increased in certain circumstances. Upon the occurrence of a &#8220;make-whole fundamental change&#8221; (as defined in the 2029 Indenture), subject to a limited exception for certain cash mergers, holders may require the Company to repurchase all or a portion of their 2029 Notes for cash at a price equal to 100% of the principal amount of the 2029 Notes to be repurchased plus any accrued and unpaid interest.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While the 2029 Notes are currently classified on the Company&#8217;s condensed consolidated balance sheet at June&#160;30, 2026 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company&#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2029 Notes have the election to convert the 2029 Notes at any time during the prescribed measurement period, the 2029 Notes would then be considered a current obligation and classified as such.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2024, in connection with the pricing of the 2029 Notes, and on May 10, 2024, in connection with the exercise in full by the initial purchasers of the 2029 Notes (the &#8220;Initial Purchasers&#8221;) of their option to purchase additional 2029 Notes, the Company entered into privately negotiated capped call transactions (the &#8220;Capped Call Transactions&#8221;) with certain of the Initial Purchasers of the 2029 Notes and/or their respective affiliates and/or other financial institutions (the &#8220;Option Counterparties&#8221;). The Capped Call Transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2029 Notes, the number of shares of the Company&#8217;s common stock underlying the 2029 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Capped Call Transactions are expected to reduce the potential dilution to the Company&#8217;s common stock upon any conversion of the 2029 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2029 Notes, as the case may be, upon any conversion of the 2029 Notes, with such reduction and/or offset subject to a cap. The cap price of the Capped Call Transactions will initially be approximately $53.75 per share, representing a premium of approximately 80% over the closing price of $29.86 per share of the Company&#8217;s common stock on May 9, 2024, and is subject to certain adjustments under the terms of the Capped Call Transactions. During the year ended December 31, 2024, the capped call was recorded as a reduction to additional paid-in capital at its cost of $26.7&#160;million, partially offset by a $6.5&#160;million deferred tax asset.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Capped Call Transactions are separate transactions entered into by the Company with the Option Counterparties, are not part of the terms of the 2029 Notes and will not affect any holder&#8217;s rights under the 2029 Notes. Holders of the 2029 Notes will not have any rights with respect to the Capped Call Transactions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2025, the Company entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Wells Fargo Bank, N.A., as administrative agent, swingline lender and an issuing bank, and certain lenders, to, among other things, retire the indebtedness outstanding under the Company&#8217;s then-existing TLA Credit Agreement and provide ongoing working capital. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a senior secured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) in an aggregate commitment amount of $300.0&#160;million, with a letter of credit sublimit of $10.0&#160;million and swingline loan sublimit of $15.0&#160;million. The credit facility is secured by substantially all of the Company&#8217;s and each subsidiary guarantor&#8217;s assets and is scheduled to mature on July 3, 2030, subject to certain exceptions set forth in the Credit Agreement. Subject to certain conditions, the Company may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of any existing class of term loans by requesting one or more incremental term facilities in an aggregate principal amount not to exceed the greater of $225.0&#160;million and 100% of Consolidated Earnings Before Interest Taxes Depreciation and Amortization (EBITDA) (as defined in the Credit Agreement).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each revolving loan borrowing which is an alternate base rate borrowing will bear interest at a rate per annum equal to (i) a base rate, plus (ii) a spread based on the Company&#8217;s Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) ranging from 1.50% to 2.25%. Each revolving loan borrowing which is a term benchmark borrowing or daily simple SOFR (as defined in the Credit Agreement) borrowing will bear interest at a rate per annum equal to (i) a forward-looking term rate based on SOFR or a rate determined by reference to the daily simple SOFR, plus (ii) a spread based on the Company&#8217;s Senior Secured Net Leverage Ratio ranging from 2.50% to 3.25%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of June&#160;30, 2026, the Company was in compliance with all covenants under the Credit Agreement. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company incurred financing fees of approximately $2.1&#160;million which were recorded as a noncurrent other asset on the Company&#8217;s condensed consolidated balance sheet. The financing fees are amortized over the term of the Credit Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into the Credit Agreement, the Company borrowed $101.0&#160;million under the Revolving Credit Facility, of which $81.0&#160;million is outstanding as of June&#160;30, 2026 after the Company made repayments of $10.0&#160;million during the six months ended June&#160;30, 2026 and $10.0&#160;million during the year ended December&#160;31, 2025. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, borrowings under the Revolving Credit Facility consisted entirely of term SOFR borrowings at an approximate all-in rate of 6.72%.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Term Loan A Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the Company entered into a credit agreement (as amended and/or restated to date, the &#8220;TLA Credit Agreement&#8221;) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders. The term loan issued under the TLA Credit Agreement (the &#8220;TLA Term Loan&#8221;) was issued at a 0.30% discount and provided for a single-advance term loan A facility in the principal amount of $150.0&#160;million, which was secured by substantially all of the Company&#8217;s and any subsidiary guarantor&#8217;s assets. The net proceeds of the TLA Term Loan were approximately $149.6&#160;million after deducting an original issue discount of $0.4&#160;million. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The TLA Term Loan was scheduled to mature on March 31, 2028 and the TLA Credit Agreement required quarterly repayments of principal in the amount of $2.8&#160;million which commenced on June 30, 2023 and increased to $3.8&#160;million on March 31, 2025, with an originally stated balloon payment of approximately $85.3&#160;million due at maturity.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2025, the Company used a portion of the $300.0&#160;million of Revolving Credit Facility to repay the remaining indebtedness outstanding under the TLA Credit Agreement, which consisted of $98.8&#160;million and its final interest payment of $0.1&#160;million, and terminated the TLA Credit Agreement. The Company did not incur any prepayment penalties or fees in connection with the termination of the TLA Credit Agreement. The prepayment resulted in a loss on early extinguishment of debt of approximately $1.0&#160;million which was recognized during the three months ended September 30, 2025. Prior to the TLA Credit Agreement extinguishment, the Company made voluntary principal prepayments of $6.6&#160;million during the year ended December 31, 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2025</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company completed a private placement of $402.5&#160;million in aggregate principal amount of 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), with respect to the 2025 Notes. The 2025 Notes accrued interest at a fixed rate of 0.750% per year, which was payable semiannually in arrears on February 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and August 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company used part of the net proceeds from the issuance of the 2029 Notes to repurchase $200.0&#160;million aggregate principal amount of the 2025 Notes in privately negotiated transactions at a discount for $191.4&#160;million in cash (including accrued interest). The partial repurchase of the 2025 Notes resulted in a $7.5&#160;million gain on early extinguishment of debt during the year ended December 31, 2024. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2025, the 2025 Notes matured and the Company settled the remaining outstanding principal balance of $202.5&#160;million in cash. Upon the maturity of the 2025 Notes, a nominal gain on extinguishment of debt was recognized due to certain holders having converted their 2025 Notes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The Revolving Credit Facility reprices within a maximum of three months due to its variable interest rate terms. The fair value of the Company&#8217;s Revolving Credit Facility approximates carrying value (Level 2) due to its repricing feature. The fair value of the Company&#8217;s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company&#8217;s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amount of equity investments and convertible notes receivable without readily determinable fair values included in investments and other assets on the consolidated balance sheet are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2026, the carrying values and fair values of the Company&#8217;s financial assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2.125% convertible senior notes due 2029 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282,124&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">287,322&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The closing price of the Company&#8217;s common stock as reported on the Nasdaq Global Select Market was $25.37 per share on June&#160;30, 2026, compared to a conversion price of $39.56 per share. At June&#160;30, 2026, as the conversion price was above the stock price, the requirements for conversion have not been met.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis, including assets and liabilities acquired in a business combination and long-lived assets, which would be recognized at fair value if deemed impaired. The fair value in these instances would be determined using Level 3 inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity and Convertible Note Investments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. For the equity investments as of June&#160;30, 2026, there have not been any impairments or upward adjustments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Equity Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,000)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain of prior investments </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settled investments </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,277)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,322)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,599)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212; No activity for the six months ended June&#160;30, 2026 &#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company&#8217;s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2&#160;million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7&#160;million in interest income. These gains were included in the condensed consolidated statement of cash flows for the six months ended June&#160;30, 2025 within other net gains</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, an impairment of an equity investment and convertible note receivable totaling $11.0&#160;million was recorded in other, net in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the Company invested $1.3&#160;million in a convertible note receivable related to one of its existing early-stage strategic investments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized a contingent consideration liability related to the Flexion Acquisition in the amount of $17.5&#160;million and $18.1&#160;million as of June&#160;30, 2026 and December&#160;31, 2025, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a Monte Carlo simulation. These inputs include, as applicable, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3&#160;million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5&#160;million prior to the Company&#8217;s September 2022 decision to formally discontinue further development of Flexion&#8217;s investigational product candidate, PCRX-301. The Company&#8217;s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended June&#160;30, 2026, the Company recognized contingent consideration charges of $1.7&#160;million due to revisions to the latest discount rates. During the six months ended June&#160;30, 2026, the Company recognized contingent consideration gains of $0.6&#160;million due to a reduction in its sales forecast through the milestone expiration date of December 31, 2030, partially offset by revisions to the latest discount rates. During the three and six months ended June&#160;30, 2025, the Company recognized contingent consideration gains of $0.4&#160;million and $3.0&#160;million, respectively, due to revisions to the latest discount rates. These adjustments were recorded within other operating expenses, net in the condensed consolidated statements of operations. At June&#160;30, 2026, the weighted average discount rate was 7.8%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company&#8217;s contingent consideration:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Ranges Utilized as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June&#160;30, 2026</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6% to 8.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for remaining regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company&#8217;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,175)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale <span id="i82c77417cd18446ea0aa2ecbfbc45bff_9868"></span>Investments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency, government and Yankee bonds with maturities greater than three months, but less than one year. Net unrealized gains and losses (excluding credit losses, if any) from the Company&#8217;s short-term investments are reported in other comprehensive income (loss). At June&#160;30, 2026 and December&#160;31, 2025, all of the Company&#8217;s short-term investments are classified as available-for-sale investments and are determined to be Level 2 instruments which are measured at fair value using standard industry models with observable inputs, with the exception of U.S. government bonds. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an &#8220;A&#8221; or better rating by Standard&#160;&amp; Poor&#8217;s.&#160;</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s available-for-sale investments at June&#160;30, 2026 and December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30, 2026 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,027&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,022&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2025 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,971&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,976&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,881&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,903&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2026, there were no investments available for sale that were materially less than their amortized cost.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects to recognize its interest receivable separate from its available-for-sale investments. At June&#160;30, 2026 and December&#160;31, 2025, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.2&#160;million and $0.3&#160;million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As of June&#160;30, 2026, three wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable, at 32%, 27% and 17%, which excludes the amounts that were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer (for more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). At December&#160;31, 2025, three wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable, at 32%, 23% and 17%. For additional information regarding the Company&#8217;s wholesalers, see Note 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company&#8217;s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of June&#160;30, 2026, the allowance for credit losses on the Company&#8217;s accounts receivable was not material. As of December&#160;31, 2025, there were $0.7&#160;million of allowances for credit losses on the Company&#8217;s accounts receivable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/825/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the changes in the balances of the Company&#8217;s accumulated other comprehensive income for the periods presented (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net unrealized loss on investments, net of tax </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net unrealized loss on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) Net of a nominal tax benefit for both the six months ended June&#160;30, 2026 and 2025, respectively. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2025, the Company announced that its board of directors approved a share repurchase program which authorizes the Company to repurchase up to an aggregate of $300.0&#160;million of its outstanding common stock. Repurchases under this program may be made at management&#8217;s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026. During the six months ended June&#160;30, 2026, the Company repurchased 2,244,553 shares of its common stock through open market transactions for $50.4&#160;million which included less than $0.1&#160;million of broker fees and $0.4&#160;million of accrued excise tax. As of June&#160;30, 2026, $100.0 million remains available for future repurchases under this authorization.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of the Company&#8217;s common stock are accounted for at cost and recorded as treasury stock. The broker fees incurred and excise tax on repurchases of the Company&#8217;s common stock are recorded as a cost of acquiring treasury stock. Any reissued treasury stock will be accounted for at average cost. Gains or losses on reissued treasury stock arising from the difference between the average cost and the fair value of the award will be recorded in additional paid-in capital.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company&#8217;s share repurchase plan, during the six months ended June&#160;30, 2026, the Company withheld 366,650 shares of common stock to cover employee tax withholding obligations of $7.8&#160;million for vested restricted stock units. All shares of common stock withheld to cover employee tax withholding obligations are retired and are done so pursuant to the terms of the Company&#8217;s stock incentive plans and related equity grant agreements rather than the Company&#8217;s share repurchase program. Retired shares of common stock are not available for future issuance under the Company&#8217;s stock incentive plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.D.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.B.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">STOCK PLANS</a></td>
<td class="text">STOCK PLANS<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plans</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pacira BioSciences, Inc. Amended and Restated 2011 Stock Incentive Plan, or 2011 Plan, was originally adopted by the Company&#8217;s board of directors and approved by its stockholders in June 2011 and was amended and restated in June 2014, June 2016, June 2019, June 2021, June 2023 and June 2025. The 2011 Plan allows for the granting of incentive stock options, non-statutory stock options, restricted stock units, and other stock-based awards&#8212;including PSUs.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan, or as amended and restated to date, the A&amp;R Inducement Plan, was originally approved and adopted by the Company&#8217;s board of directors in April 2014, pursuant to which awards could be made to new employees as a material inducement to such persons entering into employment with the Company. The A&amp;R Inducement Plan was amended and restated in December 2023, September 2024, January 2025 and January 2026. The January 2026 amendment and restatement added an additional 750,000 shares of the Company&#8217;s common stock to bring the total amount of shares reserved for issuance under the A&amp;R Inducement Plan to 3,060,000, of which 703,390 shares remained available for issuance as of June&#160;30, 2026, and extended the term of the A&amp;R Inducement Plan such that it will now expire on January 1, 2036. The A&amp;R Inducement Plan allows for the granting of nonstatutory stock options, restricted stock awards and other stock-based awards.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R Inducement Plan was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with this rule, awards under the A&amp;R Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors or the board of directors or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if they are granted such award in connection with their commencement of employment with the Company or a subsidiary and such grant is an inducement material to their entering into employment with the Company or such subsidiary.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Awards</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the board of directors, upon recommendation of the People and Compensation Committee of the board of directors, has approved individually negotiated grants of options and restricted stock units for certain of the Company&#8217;s officers in connection with their respective appointments, in each case, pursuant to the inducement plan in effect at such time.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,435&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,544&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,383&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,979&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,749&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,681&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,303&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,287&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Awards</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company&#8217;s stock option, RSU and PSU activity for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Number of Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Weighted Average Exercise Price (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Outstanding at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,374,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">300,603&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22.56&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27,947)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16.44&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90,771)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(432,996)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44.61&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Outstanding at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,123,370&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.79&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Weighted Average Grant Date Fair Value (Per Share)</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,160,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,245,413&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">202,112&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.86&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,205,978)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.60&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(355,041)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26.00&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,845,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">202,112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24.43&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted during the six months ended June&#160;30, 2026 was $12.58 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumptions</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.10%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.74 years</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP. The ESPP was amended to increase the number of shares of common stock that may be sold under the ESPP by an additional 800,000 shares, bringing the total amount of shares reserved for issuance under the ESPP to 1,800,000, of which 869,062 shares remained available for issuance as of June&#160;30, 2026, and extended the term of the ESPP such that it will now expire on June 9, 2036.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP features two six-month offering periods per year, running from January 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to June 30</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and July 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to December 31</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company&#8217;s common stock on either the offering date or the purchase date, whichever is lesser. During the six months ended June&#160;30, 2026, 82,837 shares were purchased and issued through the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER COMMON SHARE</a></td>
<td class="text">NET INCOME (LOSS) PER COMMON SHARE<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and PSUs and the purchase of shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible senior notes are treated under the if-converted method. Adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible senior notes on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible senior notes on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per common share for the three and six mon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ths ended June&#160;30, 2026 and 2025 (in thousands, except per common share amounts):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net income (loss)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,847)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Weighted average common shares outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,462&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,961&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,867&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Dilutive effect of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Weighted average common shares outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,605&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.00)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2025 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,417&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">The table above does not include contingent shares associated with the 2029 Notes being convertible at a premium, nor does it include PSUs as their performance targets have not yet been achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Domestic</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,946&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,459&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,391)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,920)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax expense represents the estimated annual effective tax rate applied to the year-to-date operating re</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sults, adjusted for certain discrete tax items.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate for the three and six months ended June&#160;30, 2026 was primarily impacted by the reversal of its U.K. operating subsidiary&#8217;s valuation allowance, partially offset by costs related to non-deductible stock-based compensation and non-deductible executive compensation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate for the three and six months ended June&#160;30, 2025 was primarily impacted by costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2026, the Company recorded a discrete benefit of $6.4&#160;million resulting from a change in judgment regarding future-year realizability of deferred tax assets in its U.K. operations, primarily related to fixed asset temporary differences. The reduction reflects management&#8217;s conclusion, based on all available positive and negative evidence, that realization of the U.K. deferred tax assets is more likely than not. As a result, the discrete benefit significantly reduced the Company&#8217;s effective tax rate for the three and six months ending June 30, 2026.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest the Company&#8217;s iovera&#176; business. The Transaction closed on July 31, 2026. The parties agreed to treat the transaction as a deemed asset sale for U.S. federal income tax purposes through an election under Section 338(h)(10) of the Internal Revenue Code. As the Transaction closed subsequent to June 30, 2026, the income tax effects of the transaction, including changes in the valuation allowance for capital-loss carryforwards, were not recognized in the income tax provisions for the three and six months ending June 30, 2026. For more information on the divestiture of iovera&#176;, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of both June&#160;30, 2026 and December&#160;31, 2025, the Company had an income taxes payable balance of $6.1&#160;million that was included in other liabilities within the condensed consolidated balance sheet, related to unrecognized tax benefits. As of both June&#160;30, 2026 and December&#160;31, 2025, the Company had less than $0.1&#160;million of current income taxes payable that was included in accrued expenses within the condensed consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, the Company had income taxes receivable and prepaid income taxes of $8.4&#160;million and $8.2&#160;million, respectively, which were included in prepaid expenses and other current assets within the condensed consolidated balance sheet. The balances include a $4.6&#160;million tax refund claim for estimated federal taxes made prior to the July 2025 enactment of federal legislation known as the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Reform</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA resulted in changes to U.S. federal income tax law. Significant provisions of the OBBBA include the permanent extension of certain provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. In accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company was required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring its estimated U.S. deferred tax assets and liabilities. The Company had $124.6&#160;million of a gross deferred tax asset attributed to unamortized U.S. capitalized research and development costs as of December&#160;31, 2024, of which $62.3&#160;million will be deductible on both its 2025 and 2026 income tax returns. There are no other material impacts to the Company related to the enactment of the OBBBA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER OPERATING EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">OTHER OPERATING EXPENSES, NET</a></td>
<td class="text">OTHER OPERATING EXPENSES, NET<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses, net for the six months ended June&#160;30, 2026 and 2025 are summarized below (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration charges (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture-Related Expenses</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized divestiture-related expenses of $5.9&#160;million during the three and six months ended June&#160;30, 2026, primarily related to third-party services and legal fees associated with divesting iovera&#176; to Zimmer. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flexion Acquisition Contingent Consideration</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized contingent consideration charges of $1.7&#160;million and gains of $0.6&#160;million during the three and six months ended June&#160;30, 2026, respectively. The Company recognized contingent consideration gains of $0.4&#160;million and $3.0&#160;million during the three and six months ended June&#160;30, 2025, respectively. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Expenses</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related expenses of $1.0&#160;million and $2.5&#160;million during the three and six months ended June&#160;30, 2025, respectively, primarily related to third-party services and legal fees associated with the GQ Bio Acquisition. </span></div><div style="margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Settlement</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$7.0&#160;million</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of costs during the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related to the patent infringement suits against the eVenus ANDA Filers (as defined below). For more information, see Note 17, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:7pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to its patents and intellectual property, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows. The Company is not in a position to assess the likelihood of any potential losses or adverse effect on its financial condition or to estimate the amount or range of potential losses, if any, from the following actions at this time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Milestone Litigation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (&#8220;Pacira CryoTech&#8221;), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (&#8220;Fortis&#8221;), solely in its capacity as representative for the former securityholders of MyoScience and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the &#8220;MyoScience Merger Agreement&#8221;), specifically related to the achievement of certain milestone payments under the MyoScience Merger Agreement. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the MyoScience Merger Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A trial was conducted in September 2023. In January 2025, the Court issued its decision, finding that the disputed milestones were not met and therefore granted judgment to the Company in full. In March 2025, the Company filed a motion to recover attorney fees, and the parties subsequently agreed to settle the amount of expenses owed to the Company, whereby Fortis agreed to pay the Company $5.2&#160;million and waived its rights to appeal the decision. A final judgment and order was entered in April 2025. The $5.2&#160;million payment received was accounted for as a recovery of losses and recorded against selling, general and administrative expense in the six months ended June&#160;30, 2025 within the condensed consolidated statement of operations, consistent with where the previous expenses were recorded.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eVenus Pharmaceutical Laboratories Litigations</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, December 2021, April 2023 and May 2024, the Company received Notice Letters advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application, or ANDA, with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic bupivacaine liposome injectable suspension in the U.S. prior to the expiration of certain of the Company&#8217;s U.S. patents.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in November 2021, the Company filed various patent infringement suits against eVenus, its parent company (Jiangsu Hengrui Pharmaceuticals, Co. Ltd., or Jiangsu Hengrui) and Fresenius Kabi USA, LLC, or Fresenius, (together, the &#8220;eVenus ANDA Filers&#8221;) in the U.S. District Court for the District of New Jersey asserting infringement of U.S. Patent No. 11,033,495 (the &#8216;495 patent) (21-cv-19829), U.S. Patent No. 11,179,336 (the &#8216;336 patent) (22-cv-00718), U.S. Patent No. 11,426,348 (the &#8216;348 patent) (23-cv-02367), U.S. Patent Nos. 11,819,574 (the &#8216;574 patent) and 11,819,575 (the &#8216;575 patent) (24-cv-06294), and U.S. Patent No. 11,925,706 (the &#8216;706 patent) (24-cv-07680). In December 2024, the Company filed a patent infringement suit against Fresenius and Jiangsu Hengrui in the Northern District of Illinois (24-cv-12416) asserting that the ANDA products will infringe U.S. Patent No. 12,156,940 (the &#8216;940 patent). Also in December 2024, the eVenus ANDA Filers filed an action for declaratory judgment of non-infringement and invalidity with respect to the &#8216;940 patent in the District Court of New Jersey (24-cv-11014).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2025, the Company, along with its operating subsidiary, Pacira Pharmaceuticals, Inc., entered into a settlement agreement with the eVenus ANDA Filers with respect to the litigations noted above. Pursuant to the settlement agreement, the eVenus ANDA Filers will be enjoined from marketing a generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit, except as provided for in the settlement agreement, as described below. In settlement of all outstanding claims in the litigations, the Company agreed to provide the eVenus ANDA Filers with a license to the Company&#8217;s patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date that is sometime in early 2030. While the agreed-upon volume-limited percentages are confidential, they begin at a high single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement. In addition, the Company has agreed to provide the eVenus ANDA Filers with a license to its patents required to manufacture and sell an unlimited quantity of a generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date in 2039. In addition, in recognition of the Company&#8217;s expected savings with respect to, among other things, the avoidance of fees, costs, time and resources associated with continuing the litigations, the Company paid the eVenus ANDA Filers $7.0&#160;million. This legal settlement cost was recorded within other operating expenses, net in the six months ended June&#160;30, 2025 in the Company&#8217;s condensed consolidated statement of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The WhiteOak Group and Qilu Pharmaceutical Litigations</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, the Company received two separate Paragraph IV Certifications from two Chinese generic drug manufacturers (The WhiteOak Group, Inc., or WhiteOak, of Rockville, Maryland (a subsidiary of Zhejiang Haichang Biotechnology Co., Ltd.) and Qilu Pharmaceutical (Hainan) Co., Ltd., or Qilu), each advising that they had submitted an ANDA to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of EXPAREL in the U.S. Each letter alleged that EXPAREL patents listed in the FDA&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Orange Book&#8221;) are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed products described in these ANDA submissions.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November, 26, 2025, the Company filed a patent infringement suit against WhiteOak and Qilu in the U.S. District Court of the District of Delaware (25-cv-1445) asserting infringement of U.S. Patent No. 11,033,495 (the &#8216;495 patent), U.S. Patent Nos. 11,819,574 (the &#8216;574 patent) U.S. Patent No. 12,144,890 (the &#8216;890 patent), U.S. Patent No. 12,151,024 (the &#8216;024 Patent), U.S. Patent No. 12,156,940 (the &#8216;940 patent), U.S. Patent No. 12,251,468 (the &#8216;468 Patent), U.S. Patent No. 12,296,047 (the &#8217;047 Patent), U.S. Patent No. 12,318,483 (the &#8216;483 Patent), and U.S. Patent No. 12,370,142 (the &#8216;142 Patent). On January 23, 2026 and February 5, 2026, Qilu and WhiteOak, respectively, each answered the complaint and asserted affirmative </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">defenses and counterclaims asserting, inter alia, invalidity, unenforceability and non-infringement. On June 24, 2026, WhiteOak amended their answer to assert counterclaims for inequitable conduct. The Company intends to vigorously defend its intellectual property rights relating to EXPAREL. The Company is unable to predict the outcome of this litigation at this time.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, Leandro Alvarez filed a putative class action on behalf of Company shareholders between August 2, 2023 and August 8, 2024 against the Company and certain of its officers, in the District Court of New Jersey (25-cv-322). The complaint alleged that the Company made materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The Company filed a motion to dismiss the complaint, and in February 2026, the suit was dismissed with prejudice. An appeal was filed in March 2026 which was voluntarily dismissed with prejudice in May 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Action</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2025, a Shareholder Derivative suit, Young v. Lee, et al, was filed in the District of New Jersey (25-cv-11841). The complaint alleges that certain of the Company&#8217;s officers and members of the Company&#8217;s board of directors breached their fiduciary duties by making materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The suit was voluntarily dismissed without prejudice in May 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Development Foundation</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company&#8217;s &#8216;495 patent was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company&#8217;s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit sought a declaration from the court that the Company owed no royalties to RDF with respect to its EXPAREL product after December 24, 2021.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the U.S. District Court, District of Nevada granted the Company&#8217;s motion for partial summary judgment in respect to the Company&#8217;s claim for a declaration that it no longer owes royalties for EXPAREL made under its 45-liter batch manufacturing process as of December 24, 2021. A trial as to whether royalties were owed on EXPAREL made under the Company&#8217;s enhanced, larger-scale manufacturing process was conducted in September 2024. In April 2025, the Court issued judgment in favor of the Company. As a result, the low single-digit royalty that the Company had been paying RDF is eliminated, and the Company sought repayment of up to $23.1&#160;million, plus interest, from RDF, representing the royalties that the Company paid to RDF under protest on the collection of revenues of EXPAREL that occurred after December 24, 2021. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the U.S. District Court for the District of Nevada issued judgment in favor of the Company declaring that RDF is required to repay Pacira $23.1&#160;million in royalties on EXPAREL sales that were previously paid under protest. The Nevada Court also awarded Pacira an additional interest payment of $5.2&#160;million in statutory interest on the royalties paid under protest. In July 2025, the Company received a $28.3&#160;million cash payment for which $23.1&#160;million was recorded within other operating expenses, net and $5.2&#160;million was recorded within interest income in the three months ended September 30, 2025 in the Company&#8217;s condensed consolidated statements of operations. In May and September 2025, RDF filed two notices of appeal. A consolidated appeal is pending.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments, Contingencies and Commercial Partners</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LG Chem</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, the Company and LG Chem, Ltd., or LG Chem, entered into a partnership agreement to expand access to EXPAREL in select Asia&#8211;Pacific markets. Under the terms of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. The Company received a $2.0&#160;million upfront payment that it will recognize over the license term upon commercialization and will receive a contractually stated price and tiered royalties on future commercial sales by LG Chem in its licensed territories. The Company will manufacture EXPAREL and LG Chem will be responsible for securing regulatory approvals in the licensed territories. LG Chem has filed for marketing authorization in South Korea and plans to do so in Thailand in the second half of 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Johnson &amp; Johnson MedTech</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, the Company entered into a co-promotion agreement, with Johnson &amp; Johnson MedTech, or J&amp;J MedTech, (the &#8220;J&amp;J Agreement&#8221;), to market and promote the use of ZILRETTA for OA knee pain in the U.S. J&amp;J MedTech&#8217;s specialized early intervention sales force will extend the reach of ZILRETTA beyond orthopedic practices, into multiple new physician specialties, including sports medicine, osteopathy, pain management and rheumatology. </span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the J&amp;J Agreement, J&amp;J MedTech is the exclusive third-party co-promoter for ZILRETTA in the U.S. The initial term of the J&amp;J Agreement extends through 2031 with an option to extend under mutual agreement.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to recognize all revenue from sales of ZILRETTA. As compensation for its promotional efforts, for the first 12 months of the J&amp;J Agreement the Company will pay J&amp;J MedTech a minimum monthly commission. For the remaining term of the agreement, Pacira will pay a tier-based commission with higher commission percentages earned at higher annual ZILRETTA sales levels. J&amp;J MedTech will receive a tiered commission ranging from low single digits to double digits.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and J&amp;J MedTech have mutual termination rights under the J&amp;J Agreement, subject to certain terms, conditions and advance notice requirements, provided that the Company or J&amp;J MedTech generally may not terminate the J&amp;J Agreement, without cause, within one year of the effective date of the J&amp;J Agreement. The Company also has additional unilateral termination rights under certain circumstances. The J&amp;J Agreement contains customary representations, warranties, covenants and confidentiality provisions, as well as mutual indemnification obligations. J&amp;J MedTech is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and the Company&#8217;s policies, in connection with fulfilling their obligations under the J&amp;J Agreement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Trial Commitments</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL for infiltration and as a brachial plexus block in pediatric patients. The Company was granted deferrals for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the European Union, or E.U. Despite the U.K.&#8217;s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notification from both the FDA and EMA that its pediatric studies requirement had been waived for the indications of brachial plexus interscalene nerve block, lower extremity nerve block, sciatic nerve block in the popliteal fossa and adductor canal block indications to produce postsurgical regional analgesia in pediatric patients. The Company is still working with the FDA, EMA and Medicines and Healthcare products Regulatory Agency (MHRA) to finalize the regulatory pathways for its remaining pediatric commitments.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has successfully completed Part 1 of a Phase 1 pharmacokinetic pediatric study in children aged two to less than six years of age and has completed enrollment for Part 2 of the study in children aged six months to less than two years of age using the same dosage that was utilized in Part 1. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 11,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for information on potential contingent milestone payments related to the Flexion Acquisition.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-201</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 (enekinragene inzadenovec) is a novel, locally administered gene therapy product candidate that boosts cellular production of the anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) for treating OA pain in the knee. PCRX-201 was added to the Company&#8217;s portfolio as part of the Flexion Acquisition in November 2021. In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy designation to PCRX-201.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in 2017, Flexion entered into an agreement with GQ Bio to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0&#160;million of payments could have become due upon the achievement of certain development and regulatory milestones, including up to $4.5&#160;million through initiation of a Phase 2 clinical trial and up to an additional $51.5&#160;million in development and global regulatory approval milestone payments. In February 2025, Pacira Therapeutics, Inc., a wholly-owned subsidiary of the Company, completed the GQ Bio Acquisition and acquired the remaining 81% of GQ Bio that was not already owned by the Company. As of the date hereof, GQ Bio is a wholly-owned subsidiary of the Company.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2017, in an agreement between The Baylor College of Medicine, or BCM, and GQ Bio, the Company (through the </span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Flexion Acquisition) became the direct licensee of certain underlying BCM patents and other proprietary rights related to PCRX-201. The license agreement grants the Company an exclusive, royalty-bearing, world-wide right and license under its patent and other proprietary rights directly related to PCRX-201. The license agreement with BCM includes a low single-digit royalty on net product sales of PCRX-201. Milestone payments range from $0.1&#160;million up to $0.6&#160;million based on the completion of a Phase 1 FDA trial up to a Phase 3 clinical trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain therapies. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer&#8212;who is the Company&#8217;s chief operating decision maker, or CODM&#8212;manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one operating segment and one reportable segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The key measure of the Company is GAAP net income. The CODM uses this measure to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are significant expense categories and amounts that are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company&#8217;s financial results. The table below reconciles the significant expense categories provided to the CODM to the Company&#8217;s expenses as disclosed under GAAP (in thousands):</span></div><div style="margin-bottom:2pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">192,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">369,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,355&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,663&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,125&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65,253&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,053&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,686&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,415&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,787&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,117&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50,964&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">110,283&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106,535&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted general and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,148&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,231&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,860&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,497&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,025&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,322&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,322&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,644&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,644&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture and acquisition-related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decommissioning of manufacturing suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">172,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">358,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">339,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,712)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,426)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,927)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,920)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,847)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The adjustments are primarily related to stock-based compensation being noted separately as a line item.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(2) During the three and six months ended June&#160;30, 2026, the Company recognized $5.9&#160;million of divestiture-related expenses, primarily related to third-party services and legal fees, which were recorded to other operating expenses, net in the condensed consolidated statement of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2025, the Company acquired the remaining 81% of GQ Bio that it did not already own. During the three and six months ended June&#160;30, 2025, the Company incurred acquisition-related expenses of $1.0&#160;million and $2.5&#160;million, respectively, mainly related to third-party services and legal fees associated with the acquisition of GQ Bio, which were recorded to other operating expenses, net in the condensed consolidated statement of operations. As part of the purchase agreement, $7.8&#160;million of expense will be recognized and paid over three years pursuant to a key employee holdback agreement in increments of 50%, 30% and 20%, respectively. This resulted in $0.6&#160;million and $1.5&#160;million recognized within research and development in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2026, respectively, and $1.1&#160;million and $1.5&#160;million for the three and six months ended June&#160;30, 2025, respectively.</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The measure of segment assets is reported on the Company&#8217;s consolidated balance sheet as total assets. Substantially all of the Company&#8217;s assets are used to support its mission in delivering innovative, non-opioid pain therapies to transform the lives of patients. As of June&#160;30, 2026 and December 31, 2025, the Company&#8217;s long-lived assets were primarily located in the U.S. (81% and 83%, respectively), and, to a lesser extent, Germany (10% and 9%) and the U.K. (9% and 8%). For information on the Company&#8217;s fixed assets, refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#8220;2025 Annual Report&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#8217;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#8220;2025 Annual Report&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#8217;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock', window );">Assets and Liabilities Held for Sale</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities available for sale and expected to be sold within one year are classified as either assets or liabilities held for sale on the condensed consolidated balance sheets at the lower of their carrying value or fair value less any costs to sell. Any loss, or gain up until any previously recorded loss, is recognized in the period in which the held for sale criteria are met. The Company will recognize contingent consideration related to the sale of a business as a gain contingency. Under this policy, contingent consideration is excluded from the initial measurement of gain or loss upon the divestiture of a business and is recognized in earnings when the contingency is resolved and the consideration becomes realizable. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2026, the Company agreed to divest its cryoanalgesia business&#8212;including iovera&#176;&#8212;to Zimmer and reclassified certain of its assets and liabilities to assets and liabilities held for sale. For more information, refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span></div>The Company grants performance share units, or PSUs, under its Amended and Restated 2011 Stock Incentive Plan to certain of its employees, including its executive officers. The expense associated with these awards is recognized in the Company&#8217;s consolidated statements of operations based on their grant date fair values at the closing price of the Company&#8217;s common stock on the date of grant. The expense is recognized over a four-year service period using graded vesting based on the Company&#8217;s interim estimates of achievement of a stated performance objective during the one year period subsequent to the grant date. Changes in estimates are recorded on a cumulative catch-up basis. After the one year performance period, the number of shares the employee is entitled to is fixed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Adopted</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of June&#160;30, 2026</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment improves financial reporting by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU&#8217;s amendments are effective for annual reporting periods beginning after December 31, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. This ASU amendment can be applied on a prospective basis or retrospectively. The Company is currently evaluating the impact of adopting ASU 2024-03 on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40), Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment removed all references to prescriptive and sequential software development stages (referred to as project stages) throughout Subtopic 350-40. This had been replaced by the requirement to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding a software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition threshold&#8221;). The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The ASU&#8217;s amendments may be adopted on a prospective, modified transition approach that is based on the status of a current project and whether software costs were capitalized before the date of adoption or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-06 on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-10, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Grants (Topic 832), Accounting for Government Grants Received by Business Entities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU provides the recognition requirements for a government grant received, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. This ASU provides for adoption either on a modified prospective, modified retrospective, or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-11,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interim Reporting (Topic 270): Narrow-Scope Improvements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU is intended to update the guidance in Topic 270 by improving navigability of the required interim disclosures and establishing a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted at any time prior to the effective date and should be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2025-11 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Revenue Comprised of Three Largest Customers</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s three largest wholesalers in each period presented: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Largest wholesaler</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Second largest wholesaler</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Third largest wholesaler</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;EXPAREL</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147,823&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142,917&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291,097&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">279,446&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,648&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,334&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59,415&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,672&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;iovera&#176; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,588&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,982&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,216&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total net product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">190,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">367,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">347,941&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#176;. The Transaction closed on July 31, 2026, after which the Company will no longer recognize revenue associated with iovera&#176;. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,096&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,201&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,319&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,327&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">134,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets Summarized by Major Category</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">162,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">163,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,653&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,450&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,979&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,187&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,584&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,485&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">281,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">278,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(150,880)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(137,703)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">130,277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Expense and Other Operating Lease Information</a></td>
<td class="text">Total operating lease expense, net is as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recorded in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,962&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.94 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.79 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.98&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.91&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Minimum<br/>Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,268&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,239&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,159&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,972)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Asset, Goodwill and Other [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consists of in-process research and development, or IPR&amp;D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition. In June 2026, $53.2&#160;million, net, of developed technologies and a nominal amount of customer relationships related to iovera&#176; from the MyoScience Acquisition were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Amortization on these intangible assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, as of June&#160;30, 2026 are summarized as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">480,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(228,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">251,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9 years, 9 months</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,569&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,569&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">513,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(228,085)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">285,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(1) The change in the gross carrying value compared to December&#160;31, 2025 reflects the impact of foreign currency translation adjustments related to the IPR&amp;D acquired from the GQ Bio Acquisition.</span></div></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">590,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(256,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">590,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(256,274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,284&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,284&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">624,374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(256,274)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">368,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible asset acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,243</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,129</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued production costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,494</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,002</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,235</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,864</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,987</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,841</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">782</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and wholesaler service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,682</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,554</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">93,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">95,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s outstanding debt is summarized as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.125% Convertible senior notes due May 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">281,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">372,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Composition of the Company's Debt and Financing Obligations</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2029 Notes was as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.125% convertible senior notes due May 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">287,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">287,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,376)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,311)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt, net of deferred financing costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">281,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Total Interest Expense Recognized Related to the Notes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of interest rate expenses related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Carrying Amount and Fair Value of the Long-Term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2026, the carrying values and fair values of the Company&#8217;s financial assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2.125% convertible senior notes due 2029 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282,124&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">287,322&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The closing price of the Company&#8217;s common stock as reported on the Nasdaq Global Select Market was $25.37 per share on June&#160;30, 2026, compared to a conversion price of $39.56 per share. At June&#160;30, 2026, as the conversion price was above the stock price, the requirements for conversion have not been met.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Investments without Readily Determinable Fair Value</a></td>
<td class="text">The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):<div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Equity Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,000)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain of prior investments </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settled investments </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,277)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,322)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,599)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212; No activity for the six months ended June&#160;30, 2026 &#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company&#8217;s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2&#160;million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7&#160;million in interest income. These gains were included in the condensed consolidated statement of cash flows for the six months ended June&#160;30, 2025 within other net gains</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Key Assumptions used in the Valuation of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company&#8217;s contingent consideration:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Ranges Utilized as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June&#160;30, 2026</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6% to 8.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for remaining regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company&#8217;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,175)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Short-Term and Noncurrent Available-for-Sale Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s available-for-sale investments at June&#160;30, 2026 and December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30, 2026 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,027&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,022&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2025 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,971&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,976&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,881&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,903&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the changes in the balances of the Company&#8217;s accumulated other comprehensive income for the periods presented (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net unrealized loss on investments, net of tax </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net unrealized loss on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Net of a nominal tax benefit for both the six months ended June&#160;30, 2026 and 2025, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,435&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,544&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,383&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,979&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,749&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,681&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,303&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,287&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity and RSU and PSU Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company&#8217;s stock option, RSU and PSU activity for the six months ended June&#160;30, 2026:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Number of Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Weighted Average Exercise Price (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Outstanding at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,374,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">300,603&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22.56&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27,947)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16.44&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90,771)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(432,996)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44.61&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Outstanding at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,123,370&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.79&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Weighted Average Grant Date Fair Value (Per Share)</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,160,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,245,413&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">202,112&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.86&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,205,978)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.60&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(355,041)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26.00&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,845,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">202,112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24.43&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumptions</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.10%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.74 years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income Per Common Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per common share for the three and six mon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ths ended June&#160;30, 2026 and 2025 (in thousands, except per common share amounts):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net income (loss)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,847)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Weighted average common shares outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,462&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,961&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,867&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Dilutive effect of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Weighted average common shares outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,605&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.00)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Income Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2025 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,417&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Taxes and Income Tax Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Domestic</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,946&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,459&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,391)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,920)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER OPERATING EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Schedule of Other Operating Expenses, Net</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses, net for the six months ended June&#160;30, 2026 and 2025 are summarized below (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration charges (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reconciliation of Significant Expense Categories</a></td>
<td class="text">The table below reconciles the significant expense categories provided to the CODM to the Company&#8217;s expenses as disclosed under GAAP (in thousands):<div style="margin-bottom:2pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">192,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">369,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,355&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,663&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,125&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65,253&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,053&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,686&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,415&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,787&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,117&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50,964&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">110,283&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106,535&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted general and administrative</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,148&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,231&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,860&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,958&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,472&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,497&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,025&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,322&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,322&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,644&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,644&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture and acquisition-related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,032)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decommissioning of manufacturing suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">172,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">358,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">339,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,712)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,426)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,927)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,920)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,847)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The adjustments are primarily related to stock-based compensation being noted separately as a line item.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">(2) During the three and six months ended June&#160;30, 2026, the Company recognized $5.9&#160;million of divestiture-related expenses, primarily related to third-party services and legal fees, which were recorded to other operating expenses, net in the condensed consolidated statement of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2025, the Company acquired the remaining 81% of GQ Bio that it did not already own. During the three and six months ended June&#160;30, 2025, the Company incurred acquisition-related expenses of $1.0&#160;million and $2.5&#160;million, respectively, mainly related to third-party services and legal fees associated with the acquisition of GQ Bio, which were recorded to other operating expenses, net in the condensed consolidated statement of operations. As part of the purchase agreement, $7.8&#160;million of expense will be recognized and paid over three years pursuant to a key employee holdback agreement in increments of 50%, 30% and 20%, respectively. This resulted in $0.6&#160;million and $1.5&#160;million recognized within research and development in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2026, respectively, and $1.1&#160;million and $1.5&#160;million for the three and six months ended June&#160;30, 2025, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - product<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ConcentrationRiskNumberOfProducts', window );">Concentration of products (in products)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember', window );">GQ Bio Therapeutics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share based compensation service period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period when employee is required to provide service in exchange for share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Revenue Comprised of Three Largest Customers (Details) - Customer concentration - customer<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ConcentrationRiskNumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Largest wholesaler</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Second largest wholesaler</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Third largest wholesaler</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ConcentrationRiskNumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number of Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ConcentrationRiskNumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_ThreeLargestCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_ThreeLargestCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES HELD FOR SALE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Sep. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember', window );">Pacira CryoTech, Inc, and iovera&#176; | Held-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates', window );">Upfront payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Potential contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod', window );">Revenue threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember', window );">Pacira CryoTech, Inc, and iovera&#176; | Held-for-Sale | Subsequent Event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus', window );">Transaction bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember', window );">Pacira CryoTech, Inc, and iovera&#176; | Held-for-Sale | Revenue Milestone Tier 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Potential contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold', window );">Revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember', window );">Pacira CryoTech, Inc, and iovera&#176; | Held-for-Sale | Revenue Milestone Tier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Potential contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold', window );">Revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember', window );">Pacira CryoTech, Inc, and iovera&#176; | Held-for-Sale | Revenue Milestone Tier 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Potential contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold', window );">Revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember', window );">Pacira CryoTech, Inc, and iovera&#176; | Sold | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash received</a></td>
<td class="nump">$ 73,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transaction Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant, and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.Z.5.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480868/205-20-S45-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480837/205-20-S50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_RevenueMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_RevenueMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_RevenueMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_RevenueMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_RevenueMilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_RevenueMilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">0 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">4 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Schedule of Disaggregated Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">$ 192,399<span></span>
</td>
<td class="nump">$ 181,099<span></span>
</td>
<td class="nump">$ 369,775<span></span>
</td>
<td class="nump">$ 350,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">190,493<span></span>
</td>
<td class="nump">180,347<span></span>
</td>
<td class="nump">367,869<span></span>
</td>
<td class="nump">347,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_EXPARELMember', window );">EXPAREL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">147,823<span></span>
</td>
<td class="nump">142,917<span></span>
</td>
<td class="nump">291,097<span></span>
</td>
<td class="nump">279,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_ZILRETTAMember', window );">ZILRETTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">32,648<span></span>
</td>
<td class="nump">31,334<span></span>
</td>
<td class="nump">59,415<span></span>
</td>
<td class="nump">54,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_IoveraMember', window );">iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">6,806<span></span>
</td>
<td class="nump">5,588<span></span>
</td>
<td class="nump">12,982<span></span>
</td>
<td class="nump">10,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_BupivacaineLiposomeInjectableSuspensionMember', window );">Bupivacaine liposome injectable suspension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">$ 3,216<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 4,375<span></span>
</td>
<td class="nump">$ 3,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_EXPARELMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_EXPARELMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_ZILRETTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_ZILRETTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_IoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_IoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_BupivacaineLiposomeInjectableSuspensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_BupivacaineLiposomeInjectableSuspensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Schedule of Components of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 28,160<span></span>
</td>
<td class="nump">$ 43,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">38,096<span></span>
</td>
<td class="nump">28,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">68,319<span></span>
</td>
<td class="nump">81,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 134,575<span></span>
</td>
<td class="nump">$ 152,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 134,575<span></span>
</td>
<td class="nump">$ 152,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">28,160<span></span>
</td>
<td class="nump">43,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">38,096<span></span>
</td>
<td class="nump">28,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">68,319<span></span>
</td>
<td class="nump">$ 81,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176; | Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176; | Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176; | Finished Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=pcrx_WorkInProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=pcrx_WorkInProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=pcrx_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=pcrx_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS - Schedule of Fixed Assets Summarized by Major Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 281,157<span></span>
</td>
<td class="nump">$ 278,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(150,880)<span></span>
</td>
<td class="num">(137,703)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">130,277<span></span>
</td>
<td class="nump">140,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">162,840<span></span>
</td>
<td class="nump">163,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">77,653<span></span>
</td>
<td class="nump">77,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">26,979<span></span>
</td>
<td class="nump">26,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 11,584<span></span>
</td>
<td class="nump">$ 9,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480204/360-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 130,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Machinery and equipment, net</a></td>
<td class="nump">281,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligation</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Machinery and equipment, net</a></td>
<td class="nump">162,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Machinery and equipment, net</a></td>
<td class="nump">77,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Outside of the U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481999/410-20-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant, and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_NumberOfLeases', window );">Number of embedded leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Total operating lease expense, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease costs</a></td>
<td class="nump">$ 3,188<span></span>
</td>
<td class="nump">$ 3,232<span></span>
</td>
<td class="nump">$ 6,323<span></span>
</td>
<td class="nump">$ 6,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 3,808<span></span>
</td>
<td class="nump">$ 3,789<span></span>
</td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">7,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Supplemental cash flow information related to operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities, net of lease incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,466<span></span>
</td>
<td class="nump">6,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recorded in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,962<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (in percent)</a></td>
<td class="nump">6.98%<span></span>
</td>
<td class="nump">6.91%<span></span>
</td>
<td class="nump">6.98%<span></span>
</td>
<td class="nump">6.91%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2026 (remaining six months)</a></td>
<td class="nump">$ 6,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">13,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">12,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">12,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2030</a></td>
<td class="nump">6,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">8,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">58,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 48,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 19,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">$ 14,322<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
<td class="nump">$ 28,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Amortization expense, remainder of fiscal year</a></td>
<td class="nump">24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization expense year one</a></td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization expense year two</a></td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization expense year three</a></td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization expense year four</a></td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization expense year five</a></td>
<td class="nump">29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">53,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176; | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | Pacira CryoTech, Inc, and iovera&#176; | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in remainder of current fiscal year. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_PaciraCryoTechIncAndIoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (228,085)<span></span>
</td>
<td class="num">(256,274)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,816<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Value</a></td>
<td class="nump">513,569<span></span>
</td>
<td class="nump">624,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">285,484<span></span>
</td>
<td class="nump">368,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Value</a></td>
<td class="nump">33,569<span></span>
</td>
<td class="nump">34,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">33,569<span></span>
</td>
<td class="nump">34,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">480,000<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(228,085)<span></span>
</td>
<td class="num">(256,213)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 251,915<span></span>
</td>
<td class="nump">$ 333,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-Average Useful Lives</a></td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">10 years 5 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Asset, Finite-Lived, Acquired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-Average Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period of amortization for finite-lived intangible asset acquired in business combination, asset acquisition, and from joint venture formation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of indefinite-lived intangible asset. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccruedSellingGeneralAndAdministrativeExpenses', window );">Accrued selling, general and administrative expenses</a></td>
<td class="nump">$ 26,080<span></span>
</td>
<td class="nump">$ 17,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">8,243<span></span>
</td>
<td class="nump">6,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccruedProductionCost', window );">Accrued production costs</a></td>
<td class="nump">10,494<span></span>
</td>
<td class="nump">9,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued operating expenses</a></td>
<td class="nump">8,235<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">26,987<span></span>
</td>
<td class="nump">37,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Product returns and wholesaler service fees</a></td>
<td class="nump">12,682<span></span>
</td>
<td class="nump">11,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 93,499<span></span>
</td>
<td class="nump">$ 95,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedProductionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Production Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedProductionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services related to research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedSellingGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services related to selling, general, and administrative activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedSellingGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccruedExpensesLineItems', window );"><strong>Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Accrued expenses related</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Held-for-Sale | iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AccruedExpensesLineItems', window );"><strong>Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Accrued expenses related</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other accrued operating expenses</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent', window );">Product returns and wholesaler services</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Product Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_IoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pcrx_IoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Long-Term Debt Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>May 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 363,124<span></span>
</td>
<td class="nump">$ 372,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 282,124<span></span>
</td>
<td class="nump">$ 281,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2028 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 09, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax', window );">Purchase of capped calls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax', window );">Purchase of capped calls, tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentMarketPrice', window );">Market price of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.999000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_SettlementPeriodConvertibleDebtConversionRequest', window );">Settlement period - convertible debt conversion request</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0252752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock', window );">Convertible debt, premium on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Unsecured Debt | Terms one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount', window );">Required principal repayment on conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Unsecured Debt | Term two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice', window );">Percentage of last reported sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Unsecured Debt | Term three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity', window );">Scheduled trading day | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Repurchase price percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Convertible Debt | Capped Call</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DerivativeCappedCallPrice', window );">Cap price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DerivativePremiumPercentage', window );">Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Minimum | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Maximum | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent', window );">EBITDA (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Periodic payment, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember', window );">Wells Fargo Bank | Line of Credit | Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanAFacilityDueMarch2028Member', window );">Term loan A facility maturing March 2028 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Periodic payment, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Net proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepaidPrincipal', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Loss) gain on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanAFacilityDueMarch2028Member', window );">Term loan A facility maturing March 2028 | Term Loan | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">0.750% Convertible senior notes due August 2025 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepaidPrincipal', window );">Outstanding principal balance</a></td>
<td class="nump">$ 202,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Loss) gain on early extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Redemption, Trading Days From Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentCovenantIncrementalDebtMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Incremental Debt, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentCovenantIncrementalDebtMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Incremental Debt, Maximum Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt market price, per $1,000 principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentRepurchasedInConversionFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchased In Conversion Face Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentRepurchasedInConversionFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DerivativeCappedCallPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Capped Call Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DerivativeCappedCallPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DerivativePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DerivativePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SettlementPeriodConvertibleDebtConversionRequest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of trading days in a settlement period for convertible debt conversion requests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SettlementPeriodConvertibleDebtConversionRequest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepaidPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepaidPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479359/835-30-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis=pcrx_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleTermsOfConversionAxis=pcrx_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis=pcrx_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleTermsOfConversionAxis=pcrx_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleTermsOfConversionAxis=pcrx_DebtConversionTermsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleTermsOfConversionAxis=pcrx_DebtConversionTermsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pcrx_CappedCallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pcrx_CappedCallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_WellsFargoBankNationalAssociationCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanAFacilityDueMarch2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TermLoanAFacilityDueMarch2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>May 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of deferred financing costs</a></td>
<td class="nump">$ 363,124<span></span>
</td>
<td class="nump">$ 372,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2.125% Convertible senior notes due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">2.125% convertible senior notes due May 2029</a></td>
<td class="nump">$ 287,500<span></span>
</td>
<td class="nump">287,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(5,376)<span></span>
</td>
<td class="num">(6,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of deferred financing costs</a></td>
<td class="nump">$ 282,124<span></span>
</td>
<td class="nump">$ 281,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 3,045<span></span>
</td>
<td class="nump">$ 3,823<span></span>
</td>
<td class="nump">$ 6,167<span></span>
</td>
<td class="nump">$ 7,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalizedAdjustment', window );">Capitalized interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 3,622<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 7,321<span></span>
</td>
<td class="nump">$ 9,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on total debt (in percent)</a></td>
<td class="nump">3.72%<span></span>
</td>
<td class="nump">3.09%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalizedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalizedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share)</a></td>
<td class="nump">$ 25.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member', window );">2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share)</a></td>
<td class="nump">$ 39.56<span></span>
</td>
<td class="nump">$ 39.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">$ 7,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">17,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | 2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">282,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 1 | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 1 | 2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 2 | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 2 | 2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">287,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">7,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">17,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 3 | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements Using | Level 3 | 2.125% Convertible senior notes due May 2029 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Investments Without Readily Determinable Fair Value Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">$ 10,250<span></span>
</td>
<td class="nump">$ 27,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Realized gain of prior investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settled investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Foreign currency adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">10,250<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=pcrx_GQBioAcquisitionMember', window );">GQ Bio Acquisition | GQ Bio Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Investments Without Readily Determinable Fair Value Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Investments Without Readily Determinable Fair Value Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">7,750<span></span>
</td>
<td class="nump">15,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Realized gain of prior investments</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settled investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Foreign currency adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">7,750<span></span>
</td>
<td class="nump">7,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_ConvertibleNotesReceivableMember', window );">Convertible Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Investments Without Readily Determinable Fair Value Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">11,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Realized gain of prior investments</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settled investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Foreign currency adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Impairments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pcrx_GQBioAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pcrx_GQBioAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_GQBioAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_ConvertibleNotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_ConvertibleNotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,663)<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 3,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_NumberOfMajorCustomers', window );">Number of major customers | wholesaler</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Amount of allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerOneMember', window );">Major Customer One | Accounts Receivable | Customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerTwoMember', window );">Major Customer Two | Accounts Receivable | Customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerThreeMember', window );">Major Customer Three | Accounts Receivable | Customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,300<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="nump">$ 425,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ContingentConsiderationPaymentTerm', window );">Payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pcrx_ConvertibleNoteReceivableMember', window );">Convertible Note Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Convertible note receivable</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_EquityInvestmentAndConvertibleNoteReceivableMember', window );">Equity Investment And Convertible Note Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember', window );">Contingent Consideration | Flexion Acquisition | Weighted Average | Level 3 | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Key assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss for asset. Includes, but is not limited to, tangible and intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pcrx_ConvertibleNoteReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pcrx_ConvertibleNoteReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_EquityInvestmentAndConvertibleNoteReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_EquityInvestmentAndConvertibleNoteReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details) - Level 3 - Flexion Acquisition - Contingent Consideration<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Probability of payment for remaining regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Key assumptions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Minimum | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Key assumptions</a></td>
<td class="nump">0.076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Maximum | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Key assumptions</a></td>
<td class="nump">0.081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=pcrx_MeasurementInputExpectedMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=pcrx_MeasurementInputExpectedMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments and accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 18,066<span></span>
</td>
<td class="nump">20,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments and accretion</a></td>
<td class="num">(614)<span></span>
</td>
<td class="num">(2,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 17,452<span></span>
</td>
<td class="nump">$ 18,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Short-Term and Noncurrent Available-for-Sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 45,185<span></span>
</td>
<td class="nump">$ 79,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">45,156<span></span>
</td>
<td class="nump">79,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Current:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">27,158<span></span>
</td>
<td class="nump">54,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Current: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,134<span></span>
</td>
<td class="nump">54,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Current:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">18,027<span></span>
</td>
<td class="nump">24,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Current: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 18,022<span></span>
</td>
<td class="nump">$ 24,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (fff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (ff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (fff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (ff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (fff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (ff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_InvestmentCategorizationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_InvestmentCategorizationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">$ 653,893<span></span>
</td>
<td class="nump">$ 798,541<span></span>
</td>
<td class="nump">$ 693,111<span></span>
</td>
<td class="nump">$ 778,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period</a></td>
<td class="nump">671,976<span></span>
</td>
<td class="nump">757,767<span></span>
</td>
<td class="nump">671,976<span></span>
</td>
<td class="nump">757,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">4,327<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period</a></td>
<td class="nump">3,241<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Net Unrealized Gain (Loss) From Available-For-Sale Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Unrealized Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending of period</a></td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">$ 4,003<span></span>
</td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">$ 4,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Apr. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Aggregate purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock, inclusive of excise tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,244,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock, inclusive of excise tax and broker fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,394,000<span></span>
</td>
<td class="nump">$ 50,448,000<span></span>
</td>
<td class="nump">$ 50,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ShareRepurchaseProgramBrokerFees', window );">Broker fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTax', window );">Accrued excise tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining available for future purchases</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Withheld shares in common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common stock withheld for employee tax</a></td>
<td class="nump">$ 3,493,000<span></span>
</td>
<td class="nump">$ 5,286,000<span></span>
</td>
<td class="nump">$ 7,848,000<span></span>
</td>
<td class="nump">$ 5,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareRepurchaseProgramBrokerFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Broker Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareRepurchaseProgramBrokerFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>offering_period </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, ESPP (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Number of offering periods for ESPP | offering_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">ESPP purchasing period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member', window );">Inducement Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock incentive plan, awards reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for issuance (in shares)</a></td>
<td class="nump">703,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member', window );">Inducement Plan 2014 | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock incentive plan, awards reserved for issuance (in shares)</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for issuance (in shares)</a></td>
<td class="nump">869,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 14,958<span></span>
</td>
<td class="nump">$ 15,472<span></span>
</td>
<td class="nump">$ 28,497<span></span>
</td>
<td class="nump">$ 30,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
<td class="nump">8,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">11,159<span></span>
</td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">21,303<span></span>
</td>
<td class="nump">20,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_CostOfRevenue', window );">Income Statement Location [Axis]: us-gaap:CostOfRevenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense', window );">Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="nump">4,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_SellingGeneralAndAdministrativeExpense', window );">Income Statement Location [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 10,544<span></span>
</td>
<td class="nump">$ 11,383<span></span>
</td>
<td class="nump">$ 20,610<span></span>
</td>
<td class="nump">$ 21,979<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Schedule of Stock Option Activity and RSU and PSU Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning of period (in shares)</a></td>
<td class="nump">6,374,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">300,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(27,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(90,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(432,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding end of period (in shares)</a></td>
<td class="nump">6,123,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price (Per Share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 40.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">22.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">16.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">26.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">44.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">39.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember', window );">RSU and PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value (Per Share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">27.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">21.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">30.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">26.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="nump">4,160,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,245,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,205,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(355,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period in shares)</a></td>
<td class="nump">4,845,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">202,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period in shares)</a></td>
<td class="nump">202,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Schedule of Valuation Assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">56.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER COMMON SHARE - Schedule of Computation of EPS (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,653<span></span>
</td>
<td class="num">$ (4,847)<span></span>
</td>
<td class="nump">$ 7,569<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">39,462<span></span>
</td>
<td class="nump">45,459<span></span>
</td>
<td class="nump">39,961<span></span>
</td>
<td class="nump">45,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">40,300<span></span>
</td>
<td class="nump">45,459<span></span>
</td>
<td class="nump">40,605<span></span>
</td>
<td class="nump">45,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share based compensation arrangements (in shares)</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share based compensation arrangements (in shares)</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive effects of including these potential shares (in shares)</a></td>
<td class="nump">8,295<span></span>
</td>
<td class="nump">14,483<span></span>
</td>
<td class="nump">8,239<span></span>
</td>
<td class="nump">14,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Weighted average number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive effects of including these potential shares (in shares)</a></td>
<td class="nump">5,956<span></span>
</td>
<td class="nump">6,858<span></span>
</td>
<td class="nump">6,029<span></span>
</td>
<td class="nump">6,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive effects of including these potential shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Weighted average number of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive effects of including these potential shares (in shares)</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="nump">4,703<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Weighted average ESPP share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive effects of including these potential shares (in shares)</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Income Before Income Taxes and Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 5,946<span></span>
</td>
<td class="num">$ (4,214)<span></span>
</td>
<td class="nump">$ 10,113<span></span>
</td>
<td class="nump">$ 6,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(3,391)<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
<td class="num">(2,560)<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">2,555<span></span>
</td>
<td class="num">(1,927)<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
<td class="nump">6,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 2,098<span></span>
</td>
<td class="num">$ (2,920)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">$ (6,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (in percent)</a></td>
<td class="num">(82.00%)<span></span>
</td>
<td class="num">(152.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign', window );">Discrete benefit</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Income tax payable</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Gross deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne', window );">Gross deferred tax assets, deduction year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo', window );">Gross deferred tax assets, deduction year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlementsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlementsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER OPERATING EXPENSES, NET - Schedule of Other Operating Expenses, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses', window );">Divestiture-related expenses</a></td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration charges (gains)</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="num">(3,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Legal settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total other operating expenses, net</a></td>
<td class="nump">$ 7,594<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
<td class="nump">$ 5,317<span></span>
</td>
<td class="nump">$ 6,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Divestiture-related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER OPERATING EXPENSES, NET - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses', window );">Divestiture-related expenses</a></td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="num">(3,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Legal settlement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Divestiture-related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>manufacturer </div>
<div>certificate</div>
</th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>notice</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2025 </div>
<div>period</div>
</th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod', window );">Volumes distributed in US market in duration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods', window );">Increasing modestly period | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod', window );">Agreement period of volumes distributed in market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_NumberOfParagraphIVCertifications', window );">Number of paragraph certification | certificate</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_NumberOfGenericDrugManufacturers', window );">Number of generic drug manufacturers | manufacturer</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember', window );">GQ Bio Therapeutics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember', window );">GQ Bio Therapeutics GmbH | GQ Bio Therapeutics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember', window );">Johnson &amp; Johnson MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ContractualObligationMutualTerminationRightsTerm', window );">Mutual termination rights term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember', window );">Johnson &amp; Johnson MedTech | ZILRETTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ContractualObligationMinimumMonthlyCommissionDuration', window );">Option extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_GeneQuineMember', window );">GeneQuine | Achievement of Development and Regulatory Milestones | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Achievement of commercial milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_GeneQuineMember', window );">GeneQuine | Initiation of a Phase 2 Clinical Trial | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Achievement of commercial milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_GeneQuineMember', window );">GeneQuine | Development and Global Regulatory Approval Milestone Payments | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Achievement of commercial milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember', window );">Baylor College of Medicine (Baylor) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum', window );">Range of milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember', window );">Baylor College of Medicine (Baylor) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum', window );">Range of milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_LGChemPartnershipAgreementMember', window );">LG Chem, Partnership Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=pcrx_MyoScienceMilestoneLitigationMember', window );">MyoScience Milestone Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Repayments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=pcrx_ResearchDevelopmentFoundationMember', window );">Research Development Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Repayments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty', window );">Expect to receive partial summary judgment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Additional interest payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of notices are filed | notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContractualObligationMinimumMonthlyCommissionDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Minimum Monthly Commission, Duration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContractualObligationMinimumMonthlyCommissionDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContractualObligationMutualTerminationRightsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Mutual Termination Rights Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContractualObligationMutualTerminationRightsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Expected To Be Awarded from Other Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LitigationSettlementVolumeLimitedIncreasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Volume-Limited, Increase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LitigationSettlementVolumeLimitedIncreasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Volume-Limited, Maximum Percentage, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfGenericDrugManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Generic Drug Manufacturers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfGenericDrugManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfParagraphIVCertifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Paragraph IV Certifications</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfParagraphIVCertifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482645/405-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.W.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_ZILRETTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_ZILRETTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_GeneQuineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_GeneQuineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_InitiationOfAPhase2ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_InitiationOfAPhase2ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_LGChemPartnershipAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_LGChemPartnershipAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pcrx_MyoScienceMilestoneLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pcrx_MyoScienceMilestoneLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pcrx_ResearchDevelopmentFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pcrx_ResearchDevelopmentFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_PercentOfLongLivedAssets', window );">Percentage of long lived assets</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_PercentOfLongLivedAssets', window );">Percentage of long lived assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">U.K</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_PercentOfLongLivedAssets', window );">Percentage of long lived assets</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PercentOfLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent Of Long Lived Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PercentOfLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Feb. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 192,399<span></span>
</td>
<td class="nump">$ 181,099<span></span>
</td>
<td class="nump">$ 369,775<span></span>
</td>
<td class="nump">$ 350,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,497<span></span>
</td>
<td class="nump">30,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in the fair value of contingent consideration</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="num">(3,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Legal settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">188,132<span></span>
</td>
<td class="nump">172,600<span></span>
</td>
<td class="nump">358,606<span></span>
</td>
<td class="nump">339,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(1,712)<span></span>
</td>
<td class="num">(10,426)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="num">(3,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">2,555<span></span>
</td>
<td class="num">(1,927)<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
<td class="nump">6,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(6,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4,653<span></span>
</td>
<td class="num">(4,847)<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses', window );">Divestiture-related expenses</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember', window );">GQ Bio Therapeutics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized', window );">Key employee holdback agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized', window );">Key employee holdback agreement payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne', window );">Key employee holdback recognition year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo', window );">Key employee holdback recognition year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree', window );">Key employee holdback recognition year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for achievement of regulatory milestone</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember', window );">GQ Bio Therapeutics GmbH | GQ Bio Therapeutics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pcrx_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">192,399<span></span>
</td>
<td class="nump">181,099<span></span>
</td>
<td class="nump">369,775<span></span>
</td>
<td class="nump">350,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_CostOfGoodsSoldAdjusted', window );">Adjusted cost of goods sold</a></td>
<td class="nump">42,355<span></span>
</td>
<td class="nump">32,663<span></span>
</td>
<td class="nump">77,125<span></span>
</td>
<td class="nump">65,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_ResearchAndDevelopmentAdjusted', window );">Adjusted research and development</a></td>
<td class="nump">27,053<span></span>
</td>
<td class="nump">24,686<span></span>
</td>
<td class="nump">52,415<span></span>
</td>
<td class="nump">47,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_SellingAndMarketingAdjusted', window );">Adjusted selling and marketing</a></td>
<td class="nump">52,117<span></span>
</td>
<td class="nump">50,964<span></span>
</td>
<td class="nump">110,283<span></span>
</td>
<td class="nump">106,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_SellingGeneralAndAdministrativeAdjusted', window );">Adjusted general and administrative</a></td>
<td class="nump">29,148<span></span>
</td>
<td class="nump">26,231<span></span>
</td>
<td class="nump">54,860<span></span>
</td>
<td class="nump">46,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,958<span></span>
</td>
<td class="nump">15,472<span></span>
</td>
<td class="nump">28,497<span></span>
</td>
<td class="nump">30,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">14,322<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense', window );">Divestiture and acquisition-related expenses</a></td>
<td class="nump">6,516<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">7,396<span></span>
</td>
<td class="nump">3,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in the fair value of contingent consideration</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="num">(3,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Legal settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Decommissioning of manufacturing suite</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">188,132<span></span>
</td>
<td class="nump">172,600<span></span>
</td>
<td class="nump">358,606<span></span>
</td>
<td class="nump">339,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(1,712)<span></span>
</td>
<td class="num">(10,426)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="num">(3,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">2,555<span></span>
</td>
<td class="num">(1,927)<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
<td class="nump">6,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(6,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4,653<span></span>
</td>
<td class="num">$ (4,847)<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses', window );">Divestiture-related expenses</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition-Related Cost and Divestiture-related Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Liabilities Arising from Contingencies, Percent, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Liabilities Arising from Contingencies, Percent, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Liabilities Arising from Contingencies, Percent, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Liabilities Arising from Contingencies, Period Of Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CostOfGoodsSoldAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Goods Sold, Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CostOfGoodsSoldAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Divestiture-related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ResearchAndDevelopmentAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ResearchAndDevelopmentAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SellingAndMarketingAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling And Marketing, Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SellingAndMarketingAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SellingGeneralAndAdministrativeAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling, General And Administrative Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SellingGeneralAndAdministrativeAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability arising from contingency in business combination, measured at acquisition-date fair value and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 46<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-46<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pcrx_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pcrx_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>341</ContextCount>
  <ElementCount>414</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE</Role>
      <ShortName>ASSETS AND LIABILITIES HELD FOR SALE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETS</Role>
      <ShortName>FIXED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - STOCK PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANS</Role>
      <ShortName>STOCK PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE</Role>
      <ShortName>NET INCOME (LOSS) PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - OTHER OPERATING EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET</Role>
      <ShortName>OTHER OPERATING EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/REVENUE</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/INVENTORIES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETSTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FIXEDASSETS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/LEASES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/DEBT</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - STOCK PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSTables</Role>
      <ShortName>STOCK PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/STOCKPLANS</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables</Role>
      <ShortName>NET INCOME (LOSS) PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/INCOMETAXES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - OTHER OPERATING EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETTables</Role>
      <ShortName>OTHER OPERATING EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Revenue Comprised of Three Largest Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Revenue Comprised of Three Largest Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails</Role>
      <ShortName>ASSETS AND LIABILITIES HELD FOR SALE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - REVENUE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUENarrativeDetails</Role>
      <ShortName>REVENUE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - REVENUE - Schedule of Disaggregated Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails</Role>
      <ShortName>REVENUE - Schedule of Disaggregated Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - INVENTORIES - Schedule of Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails</Role>
      <ShortName>INVENTORIES - Schedule of Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - INVENTORIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIESNarrativeDetails</Role>
      <ShortName>INVENTORIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - FIXED ASSETS - Schedule of Fixed Assets Summarized by Major Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails</Role>
      <ShortName>FIXED ASSETS - Schedule of Fixed Assets Summarized by Major Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - FIXED ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETSNarrativeDetails</Role>
      <ShortName>FIXED ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails</Role>
      <ShortName>LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - ACCRUED EXPENSES - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - ACCRUED EXPENSES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails</Role>
      <ShortName>ACCRUED EXPENSES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails</Role>
      <ShortName>DEBT - Schedule of Long-Term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - DEBT - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTScheduleofDebtDetails</Role>
      <ShortName>DEBT - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - DEBT - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails</Role>
      <ShortName>DEBT - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Short-Term and Noncurrent Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Short-Term and Noncurrent Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - STOCK PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSNarrativeDetails</Role>
      <ShortName>STOCK PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - STOCK PLANS - Schedule of Stock Option Activity and RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails</Role>
      <ShortName>STOCK PLANS - Schedule of Stock Option Activity and RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - STOCK PLANS - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails</Role>
      <ShortName>STOCK PLANS - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Computation of EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails</Role>
      <ShortName>NET INCOME (LOSS) PER COMMON SHARE - Schedule of Computation of EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>NET INCOME (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - INCOME TAXES - Schedule of Income Before Income Taxes and Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Income Before Income Taxes and Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - OTHER OPERATING EXPENSES, NET - Schedule of Other Operating Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails</Role>
      <ShortName>OTHER OPERATING EXPENSES, NET - Schedule of Other Operating Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - OTHER OPERATING EXPENSES, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails</Role>
      <ShortName>OTHER OPERATING EXPENSES, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="pcrx-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails</Role>
      <ShortName>SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="pcrx-20260630.htm">pcrx-20260630.htm</File>
    <File>pcrx-20260630.xsd</File>
    <File>pcrx-20260630_cal.xml</File>
    <File>pcrx-20260630_def.xml</File>
    <File>pcrx-20260630_lab.xml</File>
    <File>pcrx-20260630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pcrx-20260630_g1.jpg</File>
    <File>pcrx-20260630_g2.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2026</BaseTaxonomy>
    <BaseTaxonomy items="1083">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pcrx-20260630.htm": {
   "nsprefix": "pcrx",
   "nsuri": "http://www.pacira.com/20260630",
   "dts": {
    "inline": {
     "local": [
      "pcrx-20260630.htm"
     ]
    },
    "schema": {
     "local": [
      "pcrx-20260630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pcrx-20260630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcrx-20260630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pcrx-20260630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcrx-20260630_pre.xml"
     ]
    }
   },
   "keyStandard": 352,
   "keyCustom": 62,
   "axisStandard": 37,
   "axisCustom": 3,
   "memberStandard": 57,
   "memberCustom": 47,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2026": 5,
    "http://fasb.org/us-gaap/2026": 1,
    "http://www.pacira.com/20260630": 3
   },
   "contextCount": 341,
   "entityCount": 1,
   "segmentCount": 111,
   "elementCount": 794,
   "unitCount": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 1083,
    "http://xbrl.sec.gov/dei/2026": 29,
    "http://xbrl.sec.gov/ecd/2026": 4,
    "http://fasb.org/srt/2026": 1
   },
   "report": {
    "R1": {
     "role": "http://www.pacira.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-58",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-58",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.pacira.com/role/DESCRIPTIONOFBUSINESS",
     "longName": "9952157 - Disclosure - DESCRIPTION OF BUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE",
     "longName": "9952159 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE",
     "shortName": "ASSETS AND LIABILITIES HELD FOR SALE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.pacira.com/role/REVENUE",
     "longName": "9952160 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.pacira.com/role/INVENTORIES",
     "longName": "9952161 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.pacira.com/role/FIXEDASSETS",
     "longName": "9952162 - Disclosure - FIXED ASSETS",
     "shortName": "FIXED ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.pacira.com/role/LEASES",
     "longName": "9952163 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS",
     "longName": "9952164 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSES",
     "longName": "9952165 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.pacira.com/role/DEBT",
     "longName": "9952166 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTS",
     "longName": "9952167 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952168 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.pacira.com/role/STOCKPLANS",
     "longName": "9952169 - Disclosure - STOCK PLANS",
     "shortName": "STOCK PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE",
     "longName": "9952170 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE",
     "shortName": "NET INCOME (LOSS) PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.pacira.com/role/INCOMETAXES",
     "longName": "9952171 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET",
     "longName": "9952172 - Disclosure - OTHER OPERATING EXPENSES, NET",
     "shortName": "OTHER OPERATING EXPENSES, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952173 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.pacira.com/role/SEGMENTINFORMATION",
     "longName": "9952174 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.pacira.com/role/REVENUETables",
     "longName": "9955513 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.pacira.com/role/INVENTORIESTables",
     "longName": "9955514 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.pacira.com/role/FIXEDASSETSTables",
     "longName": "9955515 - Disclosure - FIXED ASSETS (Tables)",
     "shortName": "FIXED ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.pacira.com/role/LEASESTables",
     "longName": "9955516 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "longName": "9955517 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSESTables",
     "longName": "9955518 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.pacira.com/role/DEBTTables",
     "longName": "9955519 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9955520 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955521 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.pacira.com/role/STOCKPLANSTables",
     "longName": "9955522 - Disclosure - STOCK PLANS (Tables)",
     "shortName": "STOCK PLANS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables",
     "longName": "9955523 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables)",
     "shortName": "NET INCOME (LOSS) PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.pacira.com/role/INCOMETAXESTables",
     "longName": "9955524 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETTables",
     "longName": "9955525 - Disclosure - OTHER OPERATING EXPENSES, NET (Tables)",
     "shortName": "OTHER OPERATING EXPENSES, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.pacira.com/role/SEGMENTINFORMATIONTables",
     "longName": "9955526 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
     "longName": "9955527 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "pcrx:ConcentrationRiskNumberOfProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "pcrx:ConcentrationRiskNumberOfProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails",
     "longName": "9955529 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Revenue Comprised of Three Largest Customers (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Revenue Comprised of Three Largest Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "pcrx:ConcentrationRiskNumberOfCustomers",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "pcrx:ConcentrationRiskNumberOfCustomers",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
     "longName": "9955530 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Details)",
     "shortName": "ASSETS AND LIABILITIES HELD FOR SALE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.pacira.com/role/REVENUENarrativeDetails",
     "longName": "9955531 - Disclosure - REVENUE - Narrative (Details)",
     "shortName": "REVENUE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-96",
      "name": "pcrx:AccountsReceivablePaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "pcrx:AccountsReceivablePaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails",
     "longName": "9955532 - Disclosure - REVENUE - Schedule of Disaggregated Revenue (Details)",
     "shortName": "REVENUE - Schedule of Disaggregated Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails",
     "longName": "9955533 - Disclosure - INVENTORIES - Schedule of Components of Inventories (Details)",
     "shortName": "INVENTORIES - Schedule of Components of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.pacira.com/role/INVENTORIESNarrativeDetails",
     "longName": "9955534 - Disclosure - INVENTORIES - Narrative (Details)",
     "shortName": "INVENTORIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-113",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails",
     "longName": "9955535 - Disclosure - FIXED ASSETS - Schedule of Fixed Assets Summarized by Major Category (Details)",
     "shortName": "FIXED ASSETS - Schedule of Fixed Assets Summarized by Major Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
     "longName": "9955536 - Disclosure - FIXED ASSETS - Narrative (Details)",
     "shortName": "FIXED ASSETS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.pacira.com/role/LEASESNarrativeDetails",
     "longName": "9955537 - Disclosure - LEASES - Narrative (Details)",
     "shortName": "LEASES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "pcrx:NumberOfLeases",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "pcrx:NumberOfLeases",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails",
     "longName": "9955538 - Disclosure - LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)",
     "shortName": "LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
     "longName": "9955539 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "shortName": "LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
     "longName": "9955540 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
     "longName": "9955541 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails",
     "longName": "9955542 - Disclosure - ACCRUED EXPENSES - Schedule of Accrued Expenses (Details)",
     "shortName": "ACCRUED EXPENSES - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "pcrx:AccruedSellingGeneralAndAdministrativeExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "pcrx:AccruedSellingGeneralAndAdministrativeExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
     "longName": "9955543 - Disclosure - ACCRUED EXPENSES - Narrative (Details)",
     "shortName": "ACCRUED EXPENSES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
     "longName": "9955544 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)",
     "shortName": "DEBT - Schedule of Long-Term Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.pacira.com/role/DEBTNarrativeDetails",
     "longName": "9955545 - Disclosure - DEBT - Narrative (Details)",
     "shortName": "DEBT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
     "longName": "9955546 - Disclosure - DEBT - Schedule of Debt (Details)",
     "shortName": "DEBT - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails",
     "longName": "9955547 - Disclosure - DEBT - Schedule of Interest Expense (Details)",
     "shortName": "DEBT - Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails",
     "longName": "9955548 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-179",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
     "longName": "9955549 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "longName": "9955550 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
     "longName": "9955551 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails",
     "longName": "9955552 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-195",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-218",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails",
     "longName": "9955553 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Short-Term and Noncurrent Available-for-Sale Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Short-Term and Noncurrent Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails",
     "longName": "9955554 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955555 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-251",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-251",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
     "longName": "9955556 - Disclosure - STOCK PLANS - Narrative (Details)",
     "shortName": "STOCK PLANS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails",
     "longName": "9955557 - Disclosure - STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details)",
     "shortName": "STOCK PLANS - Schedule of Recognized Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails",
     "longName": "9955558 - Disclosure - STOCK PLANS - Schedule of Stock Option Activity and RSU and PSU Activity (Details)",
     "shortName": "STOCK PLANS - Schedule of Stock Option Activity and RSU and PSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails",
     "longName": "9955559 - Disclosure - STOCK PLANS - Schedule of Valuation Assumptions (Details)",
     "shortName": "STOCK PLANS - Schedule of Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-269",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-269",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails",
     "longName": "9955560 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Computation of EPS (Details)",
     "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Schedule of Computation of EPS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-267",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails",
     "longName": "9955561 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities (Details)",
     "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails",
     "longName": "9955562 - Disclosure - INCOME TAXES - Schedule of Income Before Income Taxes and Income Tax Expense (Details)",
     "shortName": "INCOME TAXES - Schedule of Income Before Income Taxes and Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9955563 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:IncomeTaxReconciliationTaxSettlementsForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:IncomeTaxReconciliationTaxSettlementsForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails",
     "longName": "9955564 - Disclosure - OTHER OPERATING EXPENSES, NET - Schedule of Other Operating Expenses, Net (Details)",
     "shortName": "OTHER OPERATING EXPENSES, NET - Schedule of Other Operating Expenses, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails",
     "longName": "9955565 - Disclosure - OTHER OPERATING EXPENSES, NET - Narrative (Details)",
     "shortName": "OTHER OPERATING EXPENSES, NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955566 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-311",
      "name": "pcrx:LitigationSettlementVolumeLimitedIncreasePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-311",
      "name": "pcrx:LitigationSettlementVolumeLimitedIncreasePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "longName": "9955567 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails",
     "longName": "9955568 - Disclosure - SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details)",
     "shortName": "SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-330",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20260630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable Type [Axis]",
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r1470"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1567"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1352",
      "r1355"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1450"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1469"
     ]
    },
    "pcrx_AccountsReceivablePaymentTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AccountsReceivablePaymentTerms",
     "presentation": [
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment terms",
        "label": "Accounts Receivable, Payment Terms",
        "documentation": "Accounts Receivable, Payment Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net accretion of discount on available-for-sale investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "pcrx_AccruedExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AccruedExpensesLineItems",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses [Line Items]",
        "label": "Accrued Expenses [Line Items]",
        "documentation": "Accrued Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AccruedExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AccruedExpensesTable",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses [Table]",
        "label": "Accrued Expenses [Table]",
        "documentation": "Accrued Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r871",
      "r876",
      "r923",
      "r1362"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "pcrx_AccruedProductionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AccruedProductionCost",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued production costs",
        "label": "Accrued Production Cost",
        "documentation": "Accrued Production Cost"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services related to research and development activities."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AccruedSellingGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AccruedSellingGeneralAndAdministrativeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued selling, general and administrative expenses",
        "label": "Accrued Selling, General, And Administrative Expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services related to selling, general, and administrative activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization",
        "documentation": "Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r393",
      "r402",
      "r915",
      "r916",
      "r931",
      "r1494"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Unrealized Gain (Loss) From Available-For-Sale Investments",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r191",
      "r198",
      "r199",
      "r1379"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r722",
      "r723",
      "r724",
      "r725",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r31",
      "r180",
      "r499",
      "r870",
      "r871",
      "r883",
      "r928",
      "r967",
      "r968",
      "r1587"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r722",
      "r723",
      "r724",
      "r725",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r14",
      "r714",
      "r717",
      "r720",
      "r788",
      "r963",
      "r964",
      "r1379",
      "r1380",
      "r1381",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1534",
      "r1535"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Foreign Currency Translation",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r14",
      "r29",
      "r30",
      "r198",
      "r199",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r1379"
     ]
    },
    "pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AchievementOfDevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Development and Regulatory Milestones",
        "label": "Achievement of Development and Regulatory Milestones [Member]",
        "documentation": "Achievement of Development and Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AchievementOfMilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AchievementOfMilestoneAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Milestone [Axis]",
        "label": "Achievement of Milestone [Axis]",
        "documentation": "Information by categories of milestones achieved."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AchievementOfMilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AchievementOfMilestoneDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Milestone [Domain]",
        "label": "Achievement of Milestone [Domain]",
        "documentation": "Different categories of achievement of milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived, Acquired [Line Items]",
        "label": "Intangible Asset, Finite-Lived, Acquired [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r971",
      "r1075"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Useful Lives",
        "label": "Intangible Asset, Finite-Lived, Acquired, Weighted-Average Amortization Period",
        "documentation": "Weighted-average period of amortization for finite-lived intangible asset acquired in business combination, asset acquisition, and from joint venture formation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r1075"
     ]
    },
    "pcrx_AcquisitionRelatedCostAndDivestitureRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AcquisitionRelatedCostAndDivestitureRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestiture and acquisition-related expenses",
        "label": "Acquisition-Related Cost and Divestiture-related Expense",
        "documentation": "Acquisition-Related Cost and Divestiture-related Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r499",
      "r870",
      "r871",
      "r883",
      "r1205",
      "r1681"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r980",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1588",
      "r1684"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock withheld for employee withholding tax liabilities on vested restricted stock units",
        "terseLabel": "Common stock withheld for employee tax",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1566"
     ]
    },
    "pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of capped calls",
        "label": "Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Before Tax",
        "documentation": "Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of capped calls, tax",
        "label": "Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Tax",
        "documentation": "Adjustments To Additional Paid In Capital, Purchase Of Capped Calls, Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1325"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1261",
      "r1271",
      "r1303"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1264",
      "r1274",
      "r1306"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1299",
      "r1307",
      "r1311",
      "r1319"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r589",
      "r598"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r301",
      "r337"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r458",
      "r1615"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r458",
      "r1431",
      "r1615"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r1128",
      "r1129",
      "r1431",
      "r1615"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Intangible Asset, Finite-Lived, Amortization Expense",
        "documentation": "Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r205",
      "r372",
      "r379",
      "r1078",
      "r1096",
      "r1097",
      "r1099",
      "r1101",
      "r1494"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive effects of including these potential shares (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS PER SHARE",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments",
        "label": "Asset, Impairment Loss",
        "documentation": "Amount of impairment loss for asset. Includes, but is not limited to, tangible and intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r1217",
      "r1218",
      "r1382"
     ]
    },
    "us-gaap_AssetRetirementObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetRetirementObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset retirement obligation",
        "label": "Asset Retirement Obligation",
        "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r140",
      "r158",
      "r217",
      "r220",
      "r221",
      "r261",
      "r270",
      "r288",
      "r292",
      "r334",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r502",
      "r682",
      "r684",
      "r758",
      "r870",
      "r871",
      "r874",
      "r889",
      "r890",
      "r922",
      "r1009",
      "r1112",
      "r1113",
      "r1130",
      "r1205",
      "r1227",
      "r1228",
      "r1242",
      "r1525",
      "r1526",
      "r1619"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_AssetsAndLiabilitiesHeldForSalePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "AssetsAndLiabilitiesHeldForSalePolicyTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities Held for Sale",
        "label": "Assets And Liabilities Held For Sale [Policy Text Block]",
        "documentation": "Assets And Liabilities Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r140",
      "r187",
      "r217",
      "r220",
      "r221",
      "r334",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r502",
      "r682",
      "r684",
      "r758",
      "r1205",
      "r1348",
      "r1525",
      "r1526",
      "r1619"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r138",
      "r390",
      "r400",
      "r1082",
      "r1341",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r138",
      "r390",
      "r400",
      "r1341",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r351",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r921",
      "r1635"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r351",
      "r733",
      "r751",
      "r753",
      "r754",
      "r755",
      "r870",
      "r871",
      "r885",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r1190",
      "r1194",
      "r1201",
      "r1202",
      "r1471",
      "r1592",
      "r1593",
      "r1594",
      "r1622",
      "r1636"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1357",
      "r1524"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1434"
     ]
    },
    "pcrx_BaylorCollegeOfMedicineBaylorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "BaylorCollegeOfMedicineBaylorMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Baylor College of Medicine (Baylor)",
        "label": "Baylor College of Medicine (Baylor) [Member]",
        "documentation": "Baylor College of Medicine (Baylor)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan",
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_BupivacaineLiposomeInjectableSuspensionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "BupivacaineLiposomeInjectableSuspensionMember",
     "presentation": [
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bupivacaine liposome injectable suspension",
        "label": "Bupivacaine Liposome Injectable Suspension [Member]",
        "documentation": "Bupivacaine Liposome Injectable Suspension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r971",
      "r1075",
      "r1145",
      "r1146",
      "r1573",
      "r1576",
      "r1578"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r971",
      "r1075",
      "r1145",
      "r1146",
      "r1573",
      "r1576",
      "r1578"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting interests acquired",
        "label": "Business Combination, Voting Equity Interest Acquired, Percentage",
        "documentation": "Percentage of voting equity interest acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails": {
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition-related expenses",
        "label": "Business Combination, Acquisition-Related Cost, Expense",
        "documentation": "Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department."
       }
      }
     },
     "auth_ref": [
      "r1571",
      "r1575"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails": {
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in contingent consideration",
        "negatedLabel": "Contingent consideration gain",
        "verboseLabel": "Contingent consideration charges (gains)",
        "netLabel": "Changes in the fair value of contingent consideration",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1430"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition-related contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r675",
      "r735",
      "r736",
      "r737",
      "r1151",
      "r1155"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key assumptions",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure liability in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r675",
      "r735",
      "r736",
      "r737",
      "r1151",
      "r1155"
     ]
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key employee holdback agreement",
        "label": "Business Combination, Contingency Recognized at Acquisition Date, Liability Assumed, Fair Value",
        "documentation": "Amount of liability arising from contingency in business combination, measured at acquisition-date fair value and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r656",
      "r1151",
      "r1154",
      "r1156"
     ]
    },
    "pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key employee holdback recognition year one",
        "label": "Business Combination, Liabilities Arising from Contingencies, Percent, Year One",
        "documentation": "Business Combination, Liabilities Arising from Contingencies, Percent, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key employee holdback recognition year three",
        "label": "Business Combination, Liabilities Arising from Contingencies, Percent, Year Three",
        "documentation": "Business Combination, Liabilities Arising from Contingencies, Percent, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key employee holdback recognition year two",
        "label": "Business Combination, Liabilities Arising from Contingencies, Percent, Year Two",
        "documentation": "Business Combination, Liabilities Arising from Contingencies, Percent, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key employee holdback agreement payment period",
        "label": "Business Combination, Liabilities Arising from Contingencies, Period Of Recognized",
        "documentation": "Business Combination, Liabilities Arising from Contingencies, Period Of Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r1433"
     ]
    },
    "pcrx_CappedCallMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "CappedCallMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capped Call",
        "label": "Capped Call [Member]",
        "documentation": "Capped Call"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r1201",
      "r1608"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r211",
      "r214",
      "r1083",
      "r1622"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r211",
      "r214"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r46"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information related to operating leases",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1285"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of commercial milestones (up to)",
        "label": "Collaborative Arrangement, Milestone Payments to be Received, Maximum",
        "documentation": "Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r151",
      "r160",
      "r426",
      "r870",
      "r871",
      "r875",
      "r1234",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 17)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r870",
      "r871",
      "r879",
      "r925",
      "r996"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r1063",
      "r1508",
      "r1513",
      "r1514"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r498",
      "r870",
      "r871",
      "r882",
      "r1230",
      "r1231",
      "r1232",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1442",
      "r1443",
      "r1445",
      "r1588",
      "r1680",
      "r1684"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r1364",
      "r1533",
      "r1628",
      "r1629",
      "r1632"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r498",
      "r870",
      "r871",
      "r882",
      "r997"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r498",
      "r870",
      "r871",
      "r882"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r498",
      "r870",
      "r871",
      "r882",
      "r997",
      "r1015",
      "r1530",
      "r1684",
      "r1685"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value $0.001; 250,000,000 shares authorized; 48,840,889 shares issued and 39,822,298 shares outstanding at June\u00a030, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December\u00a031, 2025",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r469",
      "r475",
      "r498",
      "r870",
      "r871",
      "r882",
      "r927",
      "r1205"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1297"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1294"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK PLANS",
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r194",
      "r196",
      "r200",
      "r887",
      "r937",
      "r938"
     ]
    },
    "pcrx_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment and Software [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r299",
      "r972",
      "r973",
      "r1062",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r299",
      "r972",
      "r973",
      "r1062",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r299",
      "r972",
      "r973",
      "r1062",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Concentration of Major Customers",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r1062",
      "r1105",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "pcrx_ConcentrationRiskNumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ConcentrationRiskNumberOfCustomers",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of customers",
        "label": "Concentration Risk, Number of Customers",
        "documentation": "Concentration Risk, Number of Customers"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ConcentrationRiskNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ConcentrationRiskNumberOfProducts",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of products (in products)",
        "label": "Concentration Risk, Number Of Products",
        "documentation": "Concentration Risk, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of revenue from customers to total revenue",
        "terseLabel": "Concentration risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r299",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r1062",
      "r1105",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r299",
      "r972",
      "r973",
      "r1062",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r1103"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r1495"
     ]
    },
    "pcrx_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "documentation": "Contingent Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ContingentConsiderationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ContingentConsiderationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent Consideration, Noncurrent",
        "documentation": "Contingent Consideration, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ContingentConsiderationPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ContingentConsiderationPaymentTerm",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment term",
        "label": "Contingent Consideration, Payment Term",
        "documentation": "Contingent Consideration, Payment Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520",
      "r522",
      "r533"
     ]
    },
    "pcrx_ContractualObligationMinimumMonthlyCommissionDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ContractualObligationMinimumMonthlyCommissionDuration",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option extended term",
        "label": "Contractual Obligation, Minimum Monthly Commission, Duration",
        "documentation": "Contractual Obligation, Minimum Monthly Commission, Duration"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ContractualObligationMutualTerminationRightsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ContractualObligationMutualTerminationRightsTerm",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual termination rights term",
        "label": "Contractual Obligation, Mutual Termination Rights Term",
        "documentation": "Contractual Obligation, Mutual Termination Rights Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r437",
      "r438",
      "r448",
      "r449",
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129"
     ]
    },
    "pcrx_ConvertibleNoteReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ConvertibleNoteReceivableMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note Receivable",
        "label": "Convertible Note Receivable [Member]",
        "documentation": "Convertible Note Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ConvertibleNotesReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ConvertibleNotesReceivableMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Receivable",
        "label": "Convertible Notes Receivable [Member]",
        "documentation": "Convertible Notes Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ConvertibleSeniorNotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.750% Convertible senior notes due August 2025",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "documentation": "Convertible Senior Notes Due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ConvertibleSeniorNotesDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ConvertibleSeniorNotesDue2029Member",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.125% Convertible senior notes due May 2029",
        "label": "Convertible Senior Notes Due 2029 [Member]",
        "documentation": "Convertible Senior Notes Due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": [
      "r1687"
     ]
    },
    "pcrx_CostOfGoodsSoldAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "CostOfGoodsSoldAdjusted",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted cost of goods sold",
        "label": "Cost Of Goods Sold, Adjusted",
        "documentation": "Cost Of Goods Sold, Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold (exclusive of amortization of acquired intangible assets)",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r217",
      "r220",
      "r221",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r502",
      "r758",
      "r1112",
      "r1344",
      "r1347",
      "r1477",
      "r1525"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r217",
      "r225",
      "r226",
      "r440",
      "r482",
      "r789",
      "r792",
      "r815",
      "r920",
      "r1093",
      "r1094",
      "r1095",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1623",
      "r1624"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r160",
      "r426",
      "r870",
      "r871",
      "r875",
      "r1523"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r160",
      "r426",
      "r870",
      "r871",
      "r875",
      "r1523"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer concentration",
        "terseLabel": "Customer concentration",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1450"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r1166",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1487",
      "r1488",
      "r1492",
      "r1493"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "DE",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtConversionTermsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtConversionTermsOneMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms one",
        "label": "Debt Conversion Terms One [Member]",
        "documentation": "Debt Conversion Terms One"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtConversionTermsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtConversionTermsThreeMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term three",
        "label": "Debt Conversion Terms Three [Member]",
        "documentation": "Debt Conversion Terms Three"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtConversionTermsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtConversionTermsTwoMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term two",
        "label": "Debt Conversion Terms Two [Member]",
        "documentation": "Debt Conversion Terms Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r151",
      "r152",
      "r160",
      "r161",
      "r163",
      "r165",
      "r166",
      "r168",
      "r169",
      "r217",
      "r219",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r425",
      "r426",
      "r436",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r452",
      "r459",
      "r460",
      "r462",
      "r712",
      "r770",
      "r870",
      "r871",
      "r878"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r492",
      "r870",
      "r871",
      "r878",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1203",
      "r1435",
      "r1436",
      "r1437",
      "r1441",
      "r1509",
      "r1510",
      "r1511",
      "r1614",
      "r1616",
      "r1634"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net leverage ratio",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.125% convertible senior notes due May 2029",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r1628",
      "r1629",
      "r1630"
     ]
    },
    "pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentConversionObligationPremiumOnCommonStock",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt, premium on common stock",
        "label": "Debt Instrument, Conversion Obligation Premium on Common Stock",
        "documentation": "Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion price of notes into common stock (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r439"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion rate",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r152",
      "r167",
      "r439",
      "r870",
      "r871",
      "r878",
      "r1131"
     ]
    },
    "pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled trading day",
        "label": "Debt Instrument, Convertible, Redemption, Trading Days From Maturity",
        "documentation": "Debt Instrument, Convertible, Redemption, Trading Days From Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of last reported sale price of common stock",
        "label": "Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price",
        "documentation": "Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentCovenantIncrementalDebtMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentCovenantIncrementalDebtMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Debt Instrument, Covenant, Incremental Debt, Maximum",
        "documentation": "Debt Instrument, Covenant, Incremental Debt, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentCovenantIncrementalDebtMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentCovenantIncrementalDebtMaximumPercent",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EBITDA (in percent)",
        "label": "Debt Instrument, Covenant, Incremental Debt, Maximum Percent",
        "documentation": "Debt Instrument, Covenant, Incremental Debt, Maximum Percent"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentDiscountRate",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Debt Instrument, Discount Rate",
        "documentation": "Debt Instrument, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r770",
      "r771",
      "r1126",
      "r1127",
      "r1203"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r753",
      "r754",
      "r755",
      "r756",
      "r1126",
      "r1127",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1601"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate on total debt (in percent)",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r1353",
      "r1357",
      "r1614",
      "r1628",
      "r1629",
      "r1630"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r163",
      "r438",
      "r870",
      "r871",
      "r878"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r492",
      "r712",
      "r870",
      "r871",
      "r878",
      "r893",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1203",
      "r1435",
      "r1436",
      "r1437",
      "r1441",
      "r1614",
      "r1616"
     ]
    },
    "pcrx_DebtInstrumentMarketPrice": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentMarketPrice",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market price of principal amount of notes",
        "label": "Debt Instrument, Market Price",
        "documentation": "Debt market price, per $1,000 principal amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r492",
      "r870",
      "r871",
      "r878",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1203",
      "r1435",
      "r1436",
      "r1437",
      "r1441",
      "r1509",
      "r1510",
      "r1511",
      "r1614",
      "r1616",
      "r1634"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic payment, principal",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1357"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balloon payment to be paid",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase price percent",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_DebtInstrumentRepaidPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentRepaidPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance",
        "label": "Debt Instrument, Repaid, Principal",
        "documentation": "Amount of principal of debt repaid."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased aggregate principal",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DebtInstrumentRepurchasedInConversionFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DebtInstrumentRepurchasedInConversionFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required principal repayment on conversion",
        "label": "Debt Instrument, Repurchased In Conversion Face Amount",
        "documentation": "Debt Instrument, Repurchased In Conversion Face Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r68",
      "r70",
      "r71",
      "r152",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r492",
      "r712",
      "r870",
      "r871",
      "r878",
      "r893",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1203",
      "r1435",
      "r1436",
      "r1437",
      "r1441",
      "r1614",
      "r1616"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, unamortized discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1528",
      "r1613",
      "r1614",
      "r1616"
     ]
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred financing costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1528",
      "r1613",
      "r1614",
      "r1616"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r602",
      "r603",
      "r870",
      "r871",
      "r877",
      "r924"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "pcrx_DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Release of valuation allowance on deferred tax assets",
        "label": "Deferred Income Taxes, Valuation Allowance On Deferred Tax Assets",
        "documentation": "Deferred Income Taxes, Valuation Allowance On Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1570"
     ]
    },
    "pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross deferred tax assets, deduction year one",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year One",
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year One"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross deferred tax assets, deduction year two",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year Two",
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Deduction Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r204",
      "r391",
      "r1096",
      "r1097",
      "r1099",
      "r1101"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of fixed assets and amortization of intangible assets",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r206",
      "r261",
      "r275",
      "r292",
      "r1096",
      "r1112",
      "r1113",
      "r1489",
      "r1494",
      "r1499",
      "r1501"
     ]
    },
    "pcrx_DerivativeCappedCallPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DerivativeCappedCallPrice",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cap price (in USD per share)",
        "label": "Derivative, Capped Call Price",
        "documentation": "Derivative, Capped Call Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r811",
      "r986",
      "r988",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1092",
      "r1093",
      "r1095",
      "r1187",
      "r1188",
      "r1206",
      "r1230",
      "r1232",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1602",
      "r1603"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r811",
      "r986",
      "r988",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1092",
      "r1093",
      "r1095",
      "r1187",
      "r1188",
      "r1206",
      "r1230",
      "r1232",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1602",
      "r1603"
     ]
    },
    "pcrx_DerivativePremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DerivativePremiumPercentage",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premium",
        "label": "Derivative, Premium Percentage",
        "documentation": "Derivative, Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technologies",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1487",
      "r1488",
      "r1492",
      "r1493",
      "r1580"
     ]
    },
    "pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Global Regulatory Approval Milestone Payments",
        "label": "Development and Global Regulatory Approval Milestone Payments [Member]",
        "documentation": "Development and Global Regulatory Approval Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.pacira.com/role/REVENUENarrativeDetails",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.pacira.com/role/REVENUENarrativeDetails",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1537"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sold",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-for-Sale",
        "label": "Discontinued Operations, Held-for-Sale [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r136",
      "r137",
      "r138",
      "r1082"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r144",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r1082",
      "r1497",
      "r1504",
      "r1505",
      "r1506",
      "r1507"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r144",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r1082",
      "r1497",
      "r1504",
      "r1505",
      "r1506",
      "r1507"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1341",
      "r1345",
      "r1346",
      "r1496",
      "r1503"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration (up to)",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1502"
     ]
    },
    "pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential contingent consideration",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue threshold",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue threshold period",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold, Period",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration, Net Revenue Threshold, Period"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails": {
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestiture-related expenses",
        "label": "Disposal Group, Including Discontinued Operation, Divestiture-related Expenses",
        "documentation": "Disposal Group, Including Discontinued Operation, Divestiture-related Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1341",
      "r1345",
      "r1346",
      "r1496",
      "r1503"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1341",
      "r1345",
      "r1346",
      "r1496",
      "r1503"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued operating expenses",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1341",
      "r1345",
      "r1346",
      "r1496",
      "r1503"
     ]
    },
    "pcrx_DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product returns and wholesaler services",
        "label": "Disposal Group, Including Discontinued Operation, Product Liabilities, Current",
        "documentation": "Disposal Group, Including Discontinued Operation, Product Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment",
        "documentation": "Amount classified as property, plant, and equipment attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1341",
      "r1345",
      "r1346",
      "r1496",
      "r1503"
     ]
    },
    "pcrx_DisposalGroupIncludingDiscontinuedOperationTransactionBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionBonus",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction bonus",
        "label": "Disposal Group, Including Discontinued Operation, Transaction Bonus",
        "documentation": "Disposal Group, Including Discontinued Operation, Transaction Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decommissioning of manufacturing suite",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r398",
      "r1431",
      "r1497"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS AND LIABILITIES HELD FOR SALE",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r124",
      "r125",
      "r126",
      "r388"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r399",
      "r401",
      "r1145",
      "r1146",
      "r1342",
      "r1343",
      "r1504",
      "r1505",
      "r1506",
      "r1507"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1246"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "pcrx_EXPARELMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "EXPARELMember",
     "presentation": [
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EXPAREL",
        "label": "EXPAREL [Member]",
        "documentation": "EXPAREL/bupivacaine liposome injectable suspension [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net income (loss) per common share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r201",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r246",
      "r248",
      "r253",
      "r254",
      "r255",
      "r260",
      "r386",
      "r467",
      "r537",
      "r588",
      "r624",
      "r680",
      "r729",
      "r730",
      "r888",
      "r939",
      "r1104"
     ]
    },
    "pcrx_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share:",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income (loss) per common share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r201",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r248",
      "r253",
      "r254",
      "r255",
      "r260",
      "r386",
      "r467",
      "r537",
      "r588",
      "r624",
      "r680",
      "r729",
      "r730",
      "r888",
      "r939",
      "r1104"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET INCOME (LOSS) PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r256",
      "r257",
      "r258",
      "r259",
      "r507"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate (in percent)",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r1150"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation from:",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1565"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ESPP",
        "netLabel": "Employee stock purchase plan share options",
        "terseLabel": "Weighted average ESPP share options",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Weighted average number of stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1283"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r146",
      "r176",
      "r177",
      "r197",
      "r198",
      "r199",
      "r228",
      "r229",
      "r230",
      "r232",
      "r239",
      "r241",
      "r243",
      "r262",
      "r335",
      "r336",
      "r385",
      "r386",
      "r387",
      "r466",
      "r491",
      "r496",
      "r497",
      "r498",
      "r501",
      "r503",
      "r506",
      "r535",
      "r536",
      "r538",
      "r539",
      "r588",
      "r614",
      "r615",
      "r621",
      "r622",
      "r623",
      "r625",
      "r679",
      "r680",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r728",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r774",
      "r788",
      "r831",
      "r870",
      "r871",
      "r881",
      "r882",
      "r917",
      "r935",
      "r963",
      "r964",
      "r965",
      "r980",
      "r1035",
      "r1536"
     ]
    },
    "pcrx_EquityInvestmentAndConvertibleNoteReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "EquityInvestmentAndConvertibleNoteReceivableMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investment And Convertible Note Receivable",
        "label": "Equity Investment And Convertible Note Receivable [Member]",
        "documentation": "Equity Investment And Convertible Note Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment impairment",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1476"
     ]
    },
    "pcrx_EquityMethodInvestmentsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "EquityMethodInvestmentsAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments and other assets",
        "label": "Equity Method Investments and Other Assets",
        "documentation": "Equity Method Investments and Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1207",
      "r1238",
      "r1239",
      "r1240",
      "r1689"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r894",
      "r895",
      "r896",
      "r1628",
      "r1629",
      "r1633"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1261",
      "r1271",
      "r1303"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1248",
      "r1258",
      "r1268",
      "r1300"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements Using",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r753",
      "r754",
      "r756",
      "r1126",
      "r1127",
      "r1201"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r1151",
      "r1155",
      "r1194",
      "r1625"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r1151",
      "r1155",
      "r1194",
      "r1625"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Key Assumptions used in the Valuation of Contingent Consideration",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r1194"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Without Readily Determinable Fair Value Roll Forward [Abstract]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r1192"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r1192"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments without Readily Determinable Fair Value",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r743",
      "r747",
      "r1192"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r1201",
      "r1202",
      "r1608"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r755",
      "r1201",
      "r1202",
      "r1606",
      "r1608"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r731",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737",
      "r744",
      "r746",
      "r748",
      "r753",
      "r796",
      "r797",
      "r798",
      "r803",
      "r1126",
      "r1127",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1190",
      "r1194",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r1126",
      "r1127",
      "r1201",
      "r1608"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r1126",
      "r1127"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r541",
      "r546",
      "r547",
      "r734",
      "r746",
      "r753",
      "r796",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1190",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r541",
      "r546",
      "r547",
      "r549",
      "r734",
      "r735",
      "r746",
      "r753",
      "r797",
      "r1126",
      "r1127",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1190",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r734",
      "r735",
      "r736",
      "r737",
      "r746",
      "r753",
      "r798",
      "r1126",
      "r1127",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1190",
      "r1194",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amount and Fair Value of the Long-Term Debt",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1590",
      "r1591"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r743",
      "r747"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain of prior investments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r747",
      "r1192",
      "r1193"
     ]
    },
    "pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Impairments",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Impairments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1595",
      "r1603"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r745",
      "r747",
      "r1192"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settled investments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r747",
      "r1192"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r747",
      "r1192"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency adjustments",
        "terseLabel": "Fair value adjustments and accretion",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r747"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r747"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r731",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737",
      "r744",
      "r746",
      "r748",
      "r753",
      "r796",
      "r797",
      "r798",
      "r803",
      "r1126",
      "r1127",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1190",
      "r1194",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r461",
      "r490",
      "r712",
      "r749",
      "r757",
      "r760",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r812",
      "r813",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r919",
      "r936",
      "r1118",
      "r1190",
      "r1192",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1589",
      "r1592",
      "r1593",
      "r1594",
      "r1601",
      "r1604",
      "r1605",
      "r1606"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Liabilities:",
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_FinishedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "FinishedGoodsMember",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished Goods",
        "label": "Finished Goods [Member]",
        "documentation": "Finished Goods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Intangible Asset, Finite-Lived, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r356",
      "r378",
      "r1078",
      "r1494"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense year one",
        "label": "Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r1078"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense, remainder of fiscal year",
        "label": "Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in remainder of current fiscal year. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense year five",
        "label": "Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Five",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r1078"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense year four",
        "label": "Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r1078"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense year three",
        "label": "Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r1078"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense year two",
        "label": "Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r1078"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived, Class [Axis]",
        "label": "Intangible Asset, Finite-Lived, Class [Axis]",
        "documentation": "Information by class of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r382",
      "r383",
      "r834",
      "r835",
      "r971",
      "r1075",
      "r1078",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1494",
      "r1693",
      "r1694",
      "r1695"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "label": "Intangible Asset, Finite-Lived, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r378",
      "r835",
      "r1078",
      "r1494"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived, Class [Domain]",
        "label": "Intangible Asset, Finite-Lived, Class [Domain]",
        "documentation": "Class of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r382",
      "r383",
      "r971",
      "r1075",
      "r1078",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1494",
      "r1693",
      "r1694",
      "r1695"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible Assets, Net",
        "label": "Intangible Asset, Finite-Lived, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1488"
     ]
    },
    "pcrx_FlexionAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "FlexionAcquisitionMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Flexion Acquisition",
        "label": "Flexion Acquisition [Member]",
        "documentation": "Flexion Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_FlexionTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "FlexionTherapeuticsIncMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Flexion",
        "label": "Flexion Therapeutics, Inc. [Member]",
        "documentation": "Flexion Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1307"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1307"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1307"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1307"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1307"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1500",
      "r1501"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "GB",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.K",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_GQBioAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "GQBioAcquisitionMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GQ Bio Acquisition",
        "label": "GQ Bio Acquisition [Member]",
        "documentation": "GQ Bio Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_GQBioTherapeuticsGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "GQBioTherapeuticsGmbHMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GQ Bio Therapeutics GmbH",
        "label": "GQ Bio Therapeutics GmbH [Member]",
        "documentation": "GQ Bio Therapeutics GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) gain on early extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23",
      "r24"
     ]
    },
    "pcrx_GeneQuineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "GeneQuineMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GeneQuine",
        "label": "GeneQuine [Member]",
        "documentation": "GeneQuine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r156",
      "r357",
      "r870",
      "r871",
      "r872",
      "r1113",
      "r1119",
      "r1151",
      "r1153",
      "r1154",
      "r1185",
      "r1191",
      "r1205",
      "r1479",
      "r1480",
      "r1581"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Goodwill and Other [Abstract]",
        "label": "Intangible Asset, Goodwill and Other [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS",
        "label": "Intangible Asset and Goodwill [Text Block]",
        "documentation": "The entire disclosure for intangible asset and goodwill. Includes, but is not limited to, finite- and indefinite-lived intangible assets, capitalized cost for internal-use software and software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r1478",
      "r1481"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency adjustments",
        "label": "Goodwill, Foreign Currency Translation, Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r678"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r358",
      "r364",
      "r368",
      "r370",
      "r678",
      "r1119",
      "r1191"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired IPR&amp;D",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1491",
      "r1492",
      "r1493"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r222",
      "r605"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "terseLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r64",
      "r889",
      "r891",
      "r933",
      "r1080",
      "r1098",
      "r1100",
      "r1102",
      "r1107",
      "r1112",
      "r1448",
      "r1457",
      "r1463",
      "r1466",
      "r1467"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r222",
      "r605"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) before income taxes:",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r399",
      "r401",
      "r1145",
      "r1146",
      "r1342",
      "r1343",
      "r1504",
      "r1505",
      "r1506",
      "r1507"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Including Discontinued Operations [Line Items]",
        "label": "Disposal Group, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r1082",
      "r1342",
      "r1343",
      "r1497",
      "r1504",
      "r1505",
      "r1506",
      "r1507"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r1082",
      "r1342",
      "r1343",
      "r1497",
      "r1504",
      "r1505",
      "r1506",
      "r1507"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r223",
      "r601",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r616",
      "r618",
      "r619",
      "r620",
      "r918",
      "r970",
      "r979",
      "r1150"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesandIncomeTaxExpenseDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "negatedTerseLabel": "Income tax benefit (expense)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r76",
      "r217",
      "r242",
      "r243",
      "r261",
      "r278",
      "r292",
      "r604",
      "r606",
      "r617",
      "r940",
      "r1080",
      "r1098",
      "r1100",
      "r1102",
      "r1150"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlementsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxReconciliationTaxSettlementsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Discrete benefit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r1568",
      "r1569"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash paid for income taxes",
        "label": "Income Tax Paid, after Refund Received",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r213",
      "r612",
      "r613"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r1350",
      "r1365"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of share based compensation arrangements (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r255",
      "r556"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Indefinite-Lived, Class [Axis]",
        "label": "Intangible Asset, Indefinite-Lived, Class [Axis]",
        "documentation": "Information by class of indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r376",
      "r381",
      "r1078",
      "r1158",
      "r1159",
      "r1160",
      "r1169",
      "r1170",
      "r1184"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "label": "Intangible Asset, Excluding Goodwill, Indefinite-Lived",
        "documentation": "Amount of indefinite-lived intangible asset. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r381",
      "r1078"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Indefinite-Lived, Class [Domain]",
        "label": "Intangible Asset, Indefinite-Lived, Class [Domain]",
        "documentation": "Class of indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r376",
      "r381",
      "r1078",
      "r1158",
      "r1159",
      "r1160",
      "r1169",
      "r1170",
      "r1184"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1299",
      "r1307",
      "r1311",
      "r1319"
     ]
    },
    "pcrx_InducementPlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "InducementPlan2014Member",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Plan 2014",
        "label": "Inducement Plan 2014 [Member]",
        "documentation": "Inducement Plan 2014"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_InitiationOfAPhase2ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "InitiationOfAPhase2ClinicalTrialMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initiation of a Phase 2 Clinical Trial",
        "label": "Initiation of a Phase 2 Clinical Trial [Member]",
        "documentation": "Initiation of a Phase 2 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1323"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1323"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1323"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Carrying Value",
        "label": "Intangible Asset, Excluding Goodwill, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r156"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "label": "Intangible Asset, Excluding Goodwill, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r870",
      "r871",
      "r873",
      "r1488",
      "r1491"
     ]
    },
    "us-gaap_InterestCostsCapitalizedAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestCostsCapitalizedAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalized interest",
        "label": "Interest Costs Capitalized Adjustment",
        "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r456",
      "r465",
      "r1128",
      "r1129",
      "r1683"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r457",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r1098",
      "r1102",
      "r1384"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payment",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r1432"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r210",
      "r212"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r1350",
      "r1365",
      "r1686"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORIES",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r1087",
      "r1089"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "totalLabel": "Total",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r186",
      "r1084",
      "r1205"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r1087",
      "r1091"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESScheduleofComponentsofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r1087",
      "r1090"
     ]
    },
    "pcrx_InvestmentCategorizationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "InvestmentCategorizationAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Categorization [Axis]",
        "label": "Investment Categorization [Axis]",
        "documentation": "Investment Categorization"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_InvestmentCategorizationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "InvestmentCategorizationDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Categorization [Domain]",
        "label": "Investment Categorization [Domain]",
        "documentation": "Investment Categorization [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r273",
      "r292",
      "r1112",
      "r1383"
     ]
    },
    "pcrx_IoveraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "IoveraMember",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "iovera\u00b0",
        "label": "iovera\u00b0 [Member]",
        "documentation": "iovera\u00b0 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_JohnsonJohnsonMedTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "JohnsonJohnsonMedTechMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Johnson &amp; Johnson MedTech",
        "label": "Johnson &amp; Johnson MedTech [Member]",
        "documentation": "Johnson &amp; Johnson MedTech"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_LGChemPartnershipAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LGChemPartnershipAgreementMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LG Chem, Partnership Agreement",
        "label": "LG Chem, Partnership Agreement [Member]",
        "documentation": "LG Chem, Partnership Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_LargestCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LargestCustomerMember",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Largest wholesaler",
        "label": "Largest Customer [Member]",
        "documentation": "Represents the largest customer of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r1204"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease expense, net",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Expense and Other Operating Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1617"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r1500",
      "r1501"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1436",
      "r1441",
      "r1634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1436",
      "r1441",
      "r1634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1436",
      "r1441",
      "r1634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1436",
      "r1441",
      "r1634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1436",
      "r1441",
      "r1634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 (remaining six months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.pacira.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": [
      "r1637"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r140",
      "r217",
      "r220",
      "r221",
      "r334",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r502",
      "r683",
      "r684",
      "r685",
      "r758",
      "r995",
      "r1106",
      "r1130",
      "r1242",
      "r1369",
      "r1525",
      "r1619",
      "r1620"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r870",
      "r871",
      "r884",
      "r930",
      "r1205",
      "r1227",
      "r1228",
      "r1435",
      "r1439",
      "r1477",
      "r1610"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r140",
      "r145",
      "r162",
      "r217",
      "r220",
      "r221",
      "r334",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r502",
      "r683",
      "r684",
      "r685",
      "r758",
      "r1205",
      "r1525",
      "r1619",
      "r1620"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESNarrativeDetails",
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities held for sale",
        "verboseLabel": "Accrued expenses related",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r138",
      "r390",
      "r400",
      "r1341",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1360",
      "r1628",
      "r1629",
      "r1630",
      "r1638"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "documentation": "The effective interest rate at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1352",
      "r1354"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r1352",
      "r1354"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": [
      "r1517",
      "r1519"
     ]
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": [
      "r1517",
      "r1519"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments for royalties",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LitigationSettlementAmountExpectedToBeAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expect to receive partial summary judgment",
        "label": "Litigation Settlement, Amount Expected To Be Awarded from Other Party",
        "documentation": "Litigation Settlement, Amount Expected To Be Awarded from Other Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LitigationSettlementInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional interest payment",
        "label": "Litigation Settlement Interest",
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation."
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "us-gaap_LitigationSettlementLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LitigationSettlementLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails": {
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETNarrativeDetails",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal settlement",
        "label": "Litigation Settlement, Loss",
        "documentation": "Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r1515"
     ]
    },
    "pcrx_LitigationSettlementVolumeLimitedIncreasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LitigationSettlementVolumeLimitedIncreasePeriod",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volumes distributed in US market in duration period",
        "label": "Litigation Settlement, Volume-Limited, Increase Period",
        "documentation": "Litigation Settlement, Volume-Limited, Increase Period"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LitigationSettlementVolumeLimitedMaximumPercentagePeriod",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement period of volumes distributed in market",
        "label": "Litigation Settlement, Volume-Limited, Maximum Percentage, Period",
        "documentation": "Litigation Settlement, Volume-Limited, Maximum Percentage, Period"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increasing modestly period",
        "label": "Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods",
        "documentation": "Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "totalLabel": "Total debt, net of deferred financing costs",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r227",
      "r449",
      "r464",
      "r870",
      "r871",
      "r878",
      "r893",
      "r1126",
      "r1127",
      "r1203",
      "r1353",
      "r1360",
      "r1638"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1360"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r870",
      "r871",
      "r878",
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r152",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r870",
      "r871",
      "r878",
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r404",
      "r419",
      "r420",
      "r421",
      "r424",
      "r599",
      "r969",
      "r1124",
      "r1516",
      "r1518"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r404",
      "r419",
      "r420",
      "r421",
      "r424",
      "r599",
      "r969",
      "r1124",
      "r1516",
      "r1518"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of notices are filed",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1516",
      "r1518"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1500",
      "r1501"
     ]
    },
    "pcrx_MajorCustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "MajorCustomerOneMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customer One",
        "label": "Major Customer One [Member]",
        "documentation": "Represents the major customer of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_MajorCustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "MajorCustomerThreeMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customer Three",
        "label": "Major Customer Three [Member]",
        "documentation": "Represents the major customer of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_MajorCustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "MajorCustomerTwoMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customer Two",
        "label": "Major Customer Two [Member]",
        "documentation": "Represents the major customer of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customers [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1132",
      "r1135",
      "r1220",
      "r1225",
      "r1639",
      "r1641",
      "r1642",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1678",
      "r1679"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r82",
      "r83",
      "r85",
      "r102",
      "r104",
      "r105",
      "r110",
      "r111",
      "r141",
      "r143",
      "r265",
      "r420",
      "r421",
      "r422",
      "r423",
      "r550",
      "r582",
      "r583",
      "r584",
      "r599",
      "r737",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r832",
      "r959",
      "r961",
      "r969",
      "r987",
      "r988",
      "r1040",
      "r1042",
      "r1044",
      "r1045",
      "r1051",
      "r1057",
      "r1058",
      "r1060",
      "r1061",
      "r1073",
      "r1074",
      "r1117",
      "r1147",
      "r1151",
      "r1155",
      "r1157",
      "r1194",
      "r1195",
      "r1199",
      "r1200",
      "r1221",
      "r1527",
      "r1529"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rates",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1151",
      "r1155",
      "r1157",
      "r1208",
      "r1592",
      "r1593",
      "r1594"
     ]
    },
    "pcrx_MeasurementInputExpectedMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "MeasurementInputExpectedMilestonePaymentMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of payment for remaining regulatory milestones",
        "label": "Measurement Input, Expected Milestone Payment [Member]",
        "documentation": "Measurement Input, Expected Milestone Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r735",
      "r736",
      "r737",
      "r1151",
      "r1155",
      "r1157",
      "r1194",
      "r1625"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r1151",
      "r1155",
      "r1157",
      "r1194",
      "r1625"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r82",
      "r83",
      "r85",
      "r102",
      "r104",
      "r105",
      "r110",
      "r111",
      "r141",
      "r143",
      "r265",
      "r420",
      "r421",
      "r422",
      "r423",
      "r550",
      "r582",
      "r583",
      "r584",
      "r599",
      "r737",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r832",
      "r959",
      "r961",
      "r969",
      "r987",
      "r988",
      "r1040",
      "r1042",
      "r1044",
      "r1045",
      "r1051",
      "r1057",
      "r1058",
      "r1060",
      "r1061",
      "r1073",
      "r1074",
      "r1117",
      "r1147",
      "r1151",
      "r1155",
      "r1157",
      "r1194",
      "r1195",
      "r1199",
      "r1221",
      "r1527",
      "r1529"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "pcrx_MyoScienceMilestoneLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "MyoScienceMilestoneLitigationMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MyoScience Milestone Litigation",
        "label": "MyoScience Milestone Litigation [Member]",
        "documentation": "MyoScience Milestone Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Major Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1132",
      "r1135",
      "r1220",
      "r1225",
      "r1639",
      "r1641",
      "r1642",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1678",
      "r1679"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r49"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "netLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r49",
      "r65",
      "r113",
      "r134",
      "r140",
      "r192",
      "r195",
      "r199",
      "r217",
      "r220",
      "r221",
      "r224",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r252",
      "r334",
      "r386",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r467",
      "r470",
      "r472",
      "r476",
      "r502",
      "r537",
      "r588",
      "r624",
      "r680",
      "r730",
      "r758",
      "r934",
      "r1016",
      "r1033",
      "r1034",
      "r1098",
      "r1100",
      "r1102",
      "r1241",
      "r1525"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1265",
      "r1275",
      "r1299",
      "r1307"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside of the U.S.",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1688",
      "r1690",
      "r1691",
      "r1692"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "terseLabel": "Total other expense, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r1344",
      "r1347",
      "r1477"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReceivableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NotesReceivableFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes receivable",
        "label": "Notes Receivable, Fair Value Disclosure",
        "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date."
       }
      }
     },
     "auth_ref": [
      "r1605",
      "r1606",
      "r1607",
      "r1609"
     ]
    },
    "pcrx_NumberOfGenericDrugManufacturers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "NumberOfGenericDrugManufacturers",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of generic drug manufacturers",
        "label": "Number Of Generic Drug Manufacturers",
        "documentation": "Number Of Generic Drug Manufacturers"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_NumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "NumberOfLeases",
     "presentation": [
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of embedded leases",
        "label": "Number Of Leases",
        "documentation": "Number Of Leases"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_NumberOfMajorCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "NumberOfMajorCustomers",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of major customers",
        "label": "Number of Major Customers",
        "documentation": "Represents the number of major customers of the reporting entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1113",
      "r1456"
     ]
    },
    "pcrx_NumberOfParagraphIVCertifications": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "NumberOfParagraphIVCertifications",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of paragraph certification",
        "label": "Number Of Paragraph IV Certifications",
        "documentation": "Number Of Paragraph IV Certifications"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1116",
      "r1456"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1102",
      "r1107",
      "r1344",
      "r1347",
      "r1448",
      "r1457",
      "r1463",
      "r1466",
      "r1467",
      "r1477"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r1204"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r1086"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities, net of lease incentives",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r782"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate (in percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r1204"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1204"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DESCRIPTION OF BUSINESS",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r114",
      "r115",
      "r117",
      "r974",
      "r975"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued operating expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_OtherAmortizationOfDeferredCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAmortizationOfDeferredCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of cloud computing arrangements",
        "label": "Amortization of Other Deferred Charges",
        "documentation": "Amount of amortization of other deferred costs recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r62"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r935"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r62",
      "r193",
      "r196",
      "r239"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r190",
      "r332"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r189"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r1361"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r1186"
     ]
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER OPERATING EXPENSES, NET",
        "label": "Other Operating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for other operating income and other operating expense items."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETScheduleofOtherOperatingExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other operating expenses, net",
        "negatedTotalLabel": "Total other operating expenses, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1263",
      "r1273",
      "r1305"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1256",
      "r1266",
      "r1276",
      "r1308"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1256",
      "r1266",
      "r1276",
      "r1308"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r503"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r503"
     ]
    },
    "pcrx_PaciraCryoTechIncAndIoveraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "PaciraCryoTechIncAndIoveraMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pacira CryoTech, Inc, and iovera\u00b0",
        "label": "Pacira CryoTech, Inc, And iovera\u00b0 [Member]",
        "documentation": "Pacira CryoTech, Inc, And iovera\u00b0"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for achievement of regulatory milestone",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock, inclusive of broker fees",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of employee withholding taxes on restricted stock unit vests",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of convertible notes receivable investment",
        "label": "Payments to Acquire Long-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note receivable",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of fixed assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of available-for-sale investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "pcrx_PercentOfLongLivedAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "PercentOfLongLivedAssets",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of long lived assets",
        "label": "Percent Of Long Lived Assets",
        "documentation": "Percent Of Long Lived Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance share units",
        "verboseLabel": "Performance Share Units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1283"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1327"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r1201",
      "r1608"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r1349",
      "r1363",
      "r1532",
      "r1628",
      "r1629",
      "r1631"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r176",
      "r497",
      "r870",
      "r871",
      "r881",
      "r997"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r176",
      "r480",
      "r497",
      "r870",
      "r871",
      "r881"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r176",
      "r497",
      "r870",
      "r871",
      "r881",
      "r997",
      "r1015",
      "r1530",
      "r1684",
      "r1685"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at June\u00a030, 2026 and December\u00a031, 2025",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r176",
      "r469",
      "r474",
      "r497",
      "r870",
      "r871",
      "r881",
      "r926",
      "r1205"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment to be received",
        "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates",
        "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment received",
        "label": "Proceeds from Legal Settlements",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from loan",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1435",
      "r1437"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Revolving Credit Facility",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of available-for-sale investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from shares issued under employee stock purchase plan",
        "label": "Proceeds From Shares Issued Under Employee Stock Purchase Plans",
        "documentation": "The cash inflow from shares issued under Employee Stock Purchase Plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r1451"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProductMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product sales",
        "verboseLabel": "Total net product sales",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1102",
      "r1132",
      "r1133"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r108",
      "r295",
      "r833",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r1076",
      "r1097",
      "r1100",
      "r1102",
      "r1132",
      "r1133",
      "r1219",
      "r1221",
      "r1222",
      "r1226",
      "r1229",
      "r1340",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1519",
      "r1520",
      "r1639",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1667",
      "r1668",
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679"
     ]
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product returns and wholesaler service fees",
        "label": "Product Warranty Accrual, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1356",
      "r1521",
      "r1522"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r108",
      "r295",
      "r833",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r1076",
      "r1097",
      "r1100",
      "r1102",
      "r1132",
      "r1133",
      "r1219",
      "r1221",
      "r1222",
      "r1226",
      "r1229",
      "r1340",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1519",
      "r1520",
      "r1639",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1667",
      "r1668",
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment [Abstract]",
        "label": "Property, Plant, and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Asset, Class [Axis]",
        "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r787",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1494",
      "r1495",
      "r1626"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FIXED ASSETS",
        "label": "Property, Plant, and Equipment [Text Block]",
        "documentation": "The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r388",
      "r389",
      "r394",
      "r396",
      "r397",
      "r403"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "verboseLabel": "Machinery and equipment, net",
        "label": "Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization",
        "documentation": "Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r154",
      "r392",
      "r932",
      "r1494"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FIXED ASSETS",
        "label": "Property, Plant, and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r787",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1494",
      "r1495",
      "r1626"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Fixed assets, net",
        "label": "Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization",
        "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r870",
      "r871",
      "r886",
      "r915",
      "r916",
      "r932",
      "r1205",
      "r1500"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fixed Assets Summarized by Major Category",
        "label": "Property, Plant, and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Asset, Class [Domain]",
        "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r787",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1494",
      "r1495",
      "r1626"
     ]
    },
    "us-gaap_ProvisionForOtherLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProvisionForOtherLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other net gains",
        "label": "Provision for Other Losses",
        "documentation": "Amount of expense related to other loss."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r63"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Axis]",
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1366"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PublicUtilitiesInventoryRawMaterialsMember",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw Materials",
        "label": "Raw Materials [Member]",
        "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Domain]",
        "label": "Inventory [Domain]",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1366"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r82",
      "r83",
      "r85",
      "r102",
      "r104",
      "r105",
      "r110",
      "r111",
      "r141",
      "r143",
      "r265",
      "r420",
      "r421",
      "r422",
      "r423",
      "r540",
      "r550",
      "r582",
      "r583",
      "r584",
      "r587",
      "r599",
      "r737",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r814",
      "r832",
      "r959",
      "r961",
      "r969",
      "r987",
      "r988",
      "r1040",
      "r1042",
      "r1044",
      "r1045",
      "r1051",
      "r1057",
      "r1058",
      "r1060",
      "r1061",
      "r1073",
      "r1074",
      "r1117",
      "r1147",
      "r1151",
      "r1155",
      "r1157",
      "r1194",
      "r1195",
      "r1199",
      "r1200",
      "r1221",
      "r1232",
      "r1512",
      "r1527",
      "r1529",
      "r1593"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r82",
      "r83",
      "r85",
      "r102",
      "r104",
      "r105",
      "r110",
      "r111",
      "r141",
      "r143",
      "r265",
      "r420",
      "r421",
      "r422",
      "r423",
      "r540",
      "r550",
      "r582",
      "r583",
      "r584",
      "r587",
      "r599",
      "r737",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r814",
      "r832",
      "r959",
      "r961",
      "r969",
      "r987",
      "r988",
      "r1040",
      "r1042",
      "r1044",
      "r1045",
      "r1051",
      "r1057",
      "r1058",
      "r1060",
      "r1061",
      "r1073",
      "r1074",
      "r1117",
      "r1147",
      "r1151",
      "r1155",
      "r1157",
      "r1194",
      "r1195",
      "r1199",
      "r1200",
      "r1221",
      "r1232",
      "r1512",
      "r1527",
      "r1529",
      "r1593"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable [Domain]",
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r1470"
     ]
    },
    "us-gaap_ReceivablesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ReceivablesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets:",
        "label": "Receivables, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1248",
      "r1258",
      "r1268",
      "r1300"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of debt",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of Revolving Credit Facility",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r1435",
      "r1437"
     ]
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfSecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of Term loan A facility",
        "label": "Repayments of Secured Debt",
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "pcrx_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r217",
      "r225",
      "r226",
      "r440",
      "r482",
      "r789",
      "r792",
      "r815",
      "r920",
      "r1093",
      "r1094",
      "r1095",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1623",
      "r1624"
     ]
    },
    "pcrx_ResearchAndDevelopmentAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ResearchAndDevelopmentAdjusted",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted research and development",
        "label": "Research And Development, Adjusted",
        "documentation": "Research And Development, Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r1075",
      "r1098",
      "r1099",
      "r1112",
      "r1627"
     ]
    },
    "pcrx_ResearchDevelopmentFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ResearchDevelopmentFoundationMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Development Foundation",
        "label": "Research Development Foundation [Member]",
        "documentation": "Research Development Foundation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1259",
      "r1269",
      "r1301"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1250",
      "r1260",
      "r1270",
      "r1302"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1257",
      "r1267",
      "r1277",
      "r1309"
     ]
    },
    "pcrx_RestrictedStockUnitsAndPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitsMember",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU and PSU",
        "label": "Restricted Stock Units and Performance Stock Units [Member]",
        "documentation": "Restricted Stock Units and Performance Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "netLabel": "RSUs",
        "verboseLabel": "Weighted average number of RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated depreciation expense",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r499",
      "r870",
      "r871",
      "r883",
      "r929",
      "r966",
      "r968",
      "r978",
      "r998",
      "r1205"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r228",
      "r229",
      "r230",
      "r232",
      "r239",
      "r241",
      "r243",
      "r335",
      "r336",
      "r385",
      "r386",
      "r387",
      "r466",
      "r496",
      "r506",
      "r535",
      "r536",
      "r538",
      "r539",
      "r588",
      "r614",
      "r615",
      "r621",
      "r622",
      "r623",
      "r625",
      "r679",
      "r680",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r721",
      "r728",
      "r774",
      "r831",
      "r917",
      "r963",
      "r965",
      "r980",
      "r1534",
      "r1535",
      "r1684"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenues",
        "terseLabel": "Total net product sales",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r271",
      "r272",
      "r286",
      "r292",
      "r295",
      "r297",
      "r299",
      "r530",
      "r531",
      "r532",
      "r833",
      "r1098",
      "r1102"
     ]
    },
    "pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "RevenueFromContractWithCustomerMilestonePaymentsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of milestone payment",
        "label": "Revenue from Contract with Customer, Milestone Payments, Maximum",
        "documentation": "Revenue from Contract with Customer, Milestone Payments, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.pacira.com/role/REVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r534"
     ]
    },
    "pcrx_RevenueMilestoneOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "RevenueMilestoneOneMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Milestone Tier 1",
        "label": "Revenue Milestone One [Member]",
        "documentation": "Revenue Milestone One"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_RevenueMilestoneThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "RevenueMilestoneThreeMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Milestone Tier 3",
        "label": "Revenue Milestone Three [Member]",
        "documentation": "Revenue Milestone Three"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_RevenueMilestoneTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "RevenueMilestoneTwoMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Milestone Tier 2",
        "label": "Revenue Milestone Two [Member]",
        "documentation": "Revenue Milestone Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]",
        "label": "Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets recorded in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r1204",
      "r1433"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty revenue",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1537",
      "r1538"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r1450",
      "r1451"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r1339"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario, Unspecified [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r116",
      "r118",
      "r244",
      "r551",
      "r1329"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Loss",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1611",
      "r1612"
     ]
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived, Acquired [Table]",
        "label": "Intangible Asset, Finite-Lived, Acquired [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset acquired in business combination, asset acquisition, and from joint venture formation. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r971",
      "r1075"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Income Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r1447"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term and Noncurrent Available-for-Sale Investments",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.pacira.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r68",
      "r70",
      "r71",
      "r1126",
      "r1128",
      "r1353",
      "r1358",
      "r1359",
      "r1436",
      "r1441",
      "r1531",
      "r1614",
      "r1634"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Composition of the Company's Debt and Financing Obligations",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognized Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Business Combination, Intangible Asset, Acquired, Finite-Lived [Table Text Block]",
        "documentation": "Tabular disclosure of finite-lived intangible asset acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r1577",
      "r1579"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Before Income Taxes and Income Tax Expense",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1435",
      "r1440"
     ]
    },
    "pcrx_ScheduleOfInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Interest Expense Recognized Related to the Notes",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of interest rate expenses related to convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "presentation": [
      "http://www.pacira.com/role/OTHEROPERATINGEXPENSESNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Operating Expenses, Net",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofFixedAssetsSummarizedbyMajorCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]",
        "label": "Property, Plant, and Equipment [Table]",
        "documentation": "Disclosure of information about property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r787",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1494",
      "r1495",
      "r1626"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table]",
        "label": "Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table]",
        "documentation": "Disclosure of information about revenue attributed to and long-lived asset located in country of domicile and foreign country from which revenue is derived and in which asset is held, if it is not provided as part of reportable segment information. Long-lived asset excludes financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax asset. Includes, but is not limited to, subtotal of geographical information about group of countries."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Table]",
        "label": "Segment Reporting [Table]",
        "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Significant Expense Categories",
        "label": "Segment Reporting [Table Text Block]",
        "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1464",
      "r1465",
      "r1468"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r555",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity and RSU and PSU Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Schedule of Short-Term and Noncurrent Available-For-Sale Investments [Table]",
        "documentation": "Schedule of Short-Term and Noncurrent Available-For-Sale Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Revenue Comprised of Three Largest Customers",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1454"
     ]
    },
    "pcrx_SecondLargestCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "SecondLargestCustomerMember",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second largest wholesaler",
        "label": "Second Largest Customer [Member]",
        "documentation": "Represents the second largest customer of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1357",
      "r1586"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1243"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r261",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r299",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r384",
      "r395",
      "r401",
      "r414",
      "r416",
      "r672",
      "r675",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r1109",
      "r1112",
      "r1113",
      "r1119",
      "r1224",
      "r1639",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1678",
      "r1679"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r84",
      "r86",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r105",
      "r264",
      "r297",
      "r298",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r889",
      "r890",
      "r891",
      "r892",
      "r983",
      "r984",
      "r985",
      "r1041",
      "r1043",
      "r1046",
      "r1052",
      "r1057",
      "r1059",
      "r1060",
      "r1061",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1077",
      "r1105",
      "r1132",
      "r1134",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1223",
      "r1232",
      "r1639",
      "r1641",
      "r1642",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1678",
      "r1679"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting [Text Block]",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r282",
      "r284",
      "r285",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r1108",
      "r1110",
      "r1111",
      "r1112",
      "r1114",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Line Items]",
        "label": "Segment Reporting [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294"
     ]
    },
    "pcrx_SellingAndMarketingAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "SellingAndMarketingAdjusted",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted selling and marketing",
        "label": "Selling And Marketing, Adjusted",
        "documentation": "Selling And Marketing, Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_SellingGeneralAndAdministrativeAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "SellingGeneralAndAdministrativeAdjusted",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted general and administrative",
        "label": "Selling, General And Administrative Adjusted",
        "documentation": "Selling, General And Administrative Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r1097",
      "r1098",
      "r1099",
      "r1102",
      "r1423"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025 Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_SettlementPeriodConvertibleDebtConversionRequest": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "SettlementPeriodConvertibleDebtConversionRequest",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement period - convertible debt conversion request",
        "label": "Settlement Period - Convertible Debt Conversion Request",
        "documentation": "The number of trading days in a settlement period for convertible debt conversion requests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period when employee is required to provide service in exchange for share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning of period (in shares)",
        "periodEndLabel": "Unvested at end of period in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value (Per Share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plans",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r555",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1566"
     ]
    },
    "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of offering periods for ESPP",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock incentive plan, awards reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares remaining available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r1349",
      "r1363",
      "r1364",
      "r1532",
      "r1533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r1349",
      "r1363",
      "r1364",
      "r1532",
      "r1533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding beginning of period (in shares)",
        "periodEndLabel": "Outstanding end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price (Per Share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP purchasing period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r560",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharePrice",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "verboseLabel": "Closing sale price (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ShareRepurchaseProgramBrokerFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ShareRepurchaseProgramBrokerFees",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Broker fees",
        "label": "Share Repurchase Program, Broker Fees",
        "documentation": "Share Repurchase Program, Broker Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramExciseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareRepurchaseProgramExciseTax",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued excise tax",
        "label": "Share Repurchase Program, Excise Tax",
        "documentation": "Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1536"
     ]
    },
    "pcrx_ShareRepurchaseProgramExciseTaxPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ShareRepurchaseProgramExciseTaxPaid",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise taxes paid on treasury stock repurchases",
        "label": "Share Repurchase Program, Excise Tax Paid",
        "documentation": "Share Repurchase Program, Excise Tax Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramExciseTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareRepurchaseProgramExciseTaxPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise tax on treasury stock repurchases included in accrued liabilities",
        "label": "Share Repurchase Program, Excise Tax, Payable",
        "documentation": "Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1536"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, ESPP (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1566"
     ]
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares)",
        "terseLabel": "Withheld shares in common stock (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1566"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term available-for-sale investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r1367"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1054",
      "r1055",
      "r1079"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r261",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r299",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r384",
      "r395",
      "r401",
      "r414",
      "r416",
      "r672",
      "r675",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r1109",
      "r1112",
      "r1113",
      "r1119",
      "r1224",
      "r1639",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1678",
      "r1679"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r146",
      "r176",
      "r177",
      "r197",
      "r198",
      "r199",
      "r228",
      "r229",
      "r230",
      "r232",
      "r239",
      "r241",
      "r243",
      "r262",
      "r335",
      "r336",
      "r385",
      "r386",
      "r387",
      "r466",
      "r491",
      "r496",
      "r497",
      "r498",
      "r501",
      "r503",
      "r506",
      "r535",
      "r536",
      "r538",
      "r539",
      "r588",
      "r614",
      "r615",
      "r621",
      "r622",
      "r623",
      "r625",
      "r679",
      "r680",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r728",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r774",
      "r788",
      "r831",
      "r870",
      "r871",
      "r881",
      "r882",
      "r917",
      "r935",
      "r963",
      "r964",
      "r965",
      "r980",
      "r1035",
      "r1536"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r84",
      "r86",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r105",
      "r264",
      "r297",
      "r298",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r889",
      "r890",
      "r891",
      "r892",
      "r983",
      "r984",
      "r985",
      "r1041",
      "r1043",
      "r1046",
      "r1052",
      "r1057",
      "r1059",
      "r1060",
      "r1061",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1077",
      "r1105",
      "r1132",
      "r1134",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1223",
      "r1232",
      "r1639",
      "r1641",
      "r1642",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1678",
      "r1679"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r151",
      "r152",
      "r159",
      "r168",
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r181",
      "r228",
      "r229",
      "r230",
      "r262",
      "r468",
      "r469",
      "r471",
      "r473",
      "r478",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r505",
      "r506",
      "r518",
      "r774",
      "r833",
      "r870",
      "r871",
      "r880",
      "r881",
      "r882",
      "r976",
      "r981",
      "r982",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r997",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1017",
      "r1018",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1035",
      "r1085",
      "r1100",
      "r1102",
      "r1233",
      "r1682"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONScheduleofReconciliationofSignificantExpenseCategoriesDetails",
      "http://www.pacira.com/role/STOCKPLANSScheduleofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Information by location in statement of income line item where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r410",
      "r413",
      "r415",
      "r687",
      "r693",
      "r710",
      "r711",
      "r739",
      "r743",
      "r747",
      "r759",
      "r760",
      "r761",
      "r960",
      "r962",
      "r1020",
      "r1075",
      "r1151",
      "r1154",
      "r1188",
      "r1189",
      "r1193",
      "r1201",
      "r1202",
      "r1572",
      "r1574",
      "r1640"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r116",
      "r118",
      "r244",
      "r551",
      "r1329",
      "r1330"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r146",
      "r147",
      "r151",
      "r152",
      "r159",
      "r168",
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r181",
      "r228",
      "r229",
      "r230",
      "r262",
      "r300",
      "r468",
      "r469",
      "r471",
      "r473",
      "r478",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r505",
      "r506",
      "r518",
      "r774",
      "r833",
      "r870",
      "r871",
      "r880",
      "r881",
      "r882",
      "r917",
      "r976",
      "r981",
      "r982",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r997",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1017",
      "r1018",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1035",
      "r1085",
      "r1100",
      "r1102",
      "r1233",
      "r1682"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1252",
      "r1262",
      "r1272",
      "r1304"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1539",
      "r1540",
      "r1541",
      "r1542",
      "r1543",
      "r1544",
      "r1545",
      "r1546",
      "r1547",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1628",
      "r1629",
      "r1631",
      "r1632"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1628",
      "r1629",
      "r1631",
      "r1632"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKPLANSScheduleofStockOptionActivityandRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1628",
      "r1629",
      "r1631",
      "r1632"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1628",
      "r1629",
      "r1631",
      "r1632"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1628",
      "r1629",
      "r1631",
      "r1632"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1536"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining available for future purchases",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1536"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at ending of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r999",
      "r1015",
      "r1036",
      "r1037",
      "r1205",
      "r1242",
      "r1369",
      "r1435",
      "r1438",
      "r1439",
      "r1477",
      "r1610",
      "r1684"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r176",
      "r177",
      "r182",
      "r477",
      "r479",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r492",
      "r497",
      "r498",
      "r501",
      "r503",
      "r504",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r712",
      "r726",
      "r727",
      "r791",
      "r1038",
      "r1039",
      "r1056"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r1204"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r790"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r790"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r790"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1298"
     ]
    },
    "pcrx_TermLoanAFacilityDueMarch2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "TermLoanAFacilityDueMarch2028Member",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan A facility maturing March 2028",
        "label": "Term Loan A Facility Due March 2028 [Member]",
        "documentation": "Term Loan A Facility Due March 2028"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ThirdLargestCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ThirdLargestCustomerMember",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third largest wholesaler",
        "label": "Third Largest Customer [Member]",
        "documentation": "Represents the third largest customer of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_ThreeLargestCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ThreeLargestCustomersMember",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofRevenueComprisedofThreeLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Three Largest Customers [Member]",
        "documentation": "Three Largest Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1297"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofShortTermandNoncurrentAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r461",
      "r490",
      "r712",
      "r749",
      "r757",
      "r760",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r812",
      "r813",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r919",
      "r936",
      "r1190",
      "r1192",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1207",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1589",
      "r1592",
      "r1593",
      "r1594",
      "r1601",
      "r1604",
      "r1605",
      "r1606"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1320"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1320"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r871",
      "r882",
      "r1536"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "negatedPeriodEndLabel": "Treasury Shares, Beginning balance (in shares)",
        "negatedPeriodStartLabel": "Treasury Shares, Ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r1628",
      "r1629",
      "r1632"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at June\u00a030, 2026 and December\u00a031, 2025, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r518",
      "r1364",
      "r1533",
      "r1628",
      "r1629",
      "r1632"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury stock, inclusive of excise tax and broker fees (in shares)",
        "terseLabel": "Purchase of treasury stock, inclusive of excise tax (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r1364",
      "r1530",
      "r1533",
      "r1534",
      "r1535",
      "r1628",
      "r1629",
      "r1631",
      "r1632"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury stock, inclusive of excise tax and broker fees",
        "terseLabel": "Purchase of treasury stock, inclusive of excise tax and broker fees",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1363",
      "r1364",
      "r1530",
      "r1532",
      "r1533",
      "r1534",
      "r1535"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.pacira.com/role/ASSETSANDLIABILITIESHELDFORSALEDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "US",
     "presentation": [
      "http://www.pacira.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Debt",
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r1204"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1357",
      "r1524",
      "r1586"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1357",
      "r1524",
      "r1586"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r737",
      "r814",
      "r1073",
      "r1074",
      "r1194",
      "r1621"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted average number of shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r255"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding:",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.pacira.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofComputationofEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r255"
     ]
    },
    "pcrx_WellsFargoBankNationalAssociationCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "WellsFargoBankNationalAssociationCreditAgreementMember",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wells Fargo Bank",
        "label": "Wells Fargo Bank, National Association, Credit Agreement [Member]",
        "documentation": "Wells Fargo Bank, National Association, Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "pcrx_WorkInProcessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "WorkInProcessMember",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Work-in-process [Member]",
        "documentation": "Work-in-process"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "pcrx_ZILRETTAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacira.com/20260630",
     "localname": "ZILRETTAMember",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZILRETTA",
        "label": "ZILRETTA [Member]",
        "documentation": "ZILRETTA"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(ee)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.4-03(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480837/205-20-S50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-20"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482645/405-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481999/410-20-25-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.D.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "45",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/825/tableOfContent"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479359/835-30-S45-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.B.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(ff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(fff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483474/205-20-55-102"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "108",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481296/860-20-55-108"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "905",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r1694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r1695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001628280-26-052635-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-052635-xbrl.zip
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M5M-H7>@2!C"-\B*:UU5=:/BA@&_@864]*TUB5&%T25?"8NJRS OX2\WG)C7
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MK+MO?<:;&??JXNS-T'F]L'4N X49NGAOYT6^HM B*:_X;YY1CF*E8&V5))8
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M5"M,%71P8%-"RJ :*!9E;:0SZI)=&==7@_B6K?6^*[?>:<V?HV*S$6G^MSF
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M=O3LB7ZLDR/]Y,G3^/B;1\G3XT='S]3A\:/Y8?SO)U]]HM#630?R0Z) G_*
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M'#,^ /U,?>-33QKMRF4REFF&K)[!M1P9B5:0/QANO"O+:R!O\CQ;!?EDE';
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MW; F.O::Z/4TD2^H;G8F1C)4(@ZN\U@&/6V"CT;DT1IV9(/F9'D%Y$/0SU=
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MJ8)IP"UM9+\,>D8/:\:)%<G*M2E\@_]6K)F*K/+4KC*VQ^OM1)<#RP;S%0S
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MI?+?NXQP<FU;37C5THS+9UV#K(RE6?2HD[?3CSJ/$;3H3)D%=YP>3=_Q42)
M=AS\B\;Z2L<Q)5D'MAR0GW-X./4<D)6IYWQ5<>7N,TX?WG_[=F_.W0>GTZVX
MU=]4&-S U&;(/L7R5FO"_O'T0V;&\09F-_A@5'*'4\L=FC\,AWM[6[WM^MV_
MBC^$B72>!I_Q3B5B2^6(^>G"]0H>]G;J8<?[B\;TH]91!UJ4]VU_TJ$$MX>?
M<[ _TZC*8QS8S=<PS$?"XIG?L/CB;[^R4/.3IEMT4IT<D0;W$I:QH#IAD(Q*
MEC/S/UNB,W@!$95)@W1)-@<;%0 !%)8)Y$;V\]@B[HA(CVC=,&G5<KFINX=+
MFJ]/3;I8D#76HKVHU8ED=55WA7#[3<0':ZEDY79DVU/0Y\*60V6V*;*H<:GM
M[&:ZNS@Q?QEA65WJ2*(;SEMOMY!-HP*T0L"P1D5RR](*7@%6GE0H_4*=P*Z<
M*52A5 V 1.3?PH%(^M+1-G^G;+-7M 3GC4.X'6CVFSM@JAG8'@G\#-<EM;["
M2<FW[V"1(6PC]U1@([])$ZJ4QFC.F-FRJYFQY0?:%V %4D@U350N,=/*2D74
MLG,U=\JC0A)@PS0R5+:>BEH!%B\\(=-#K%4+[T#O$!4AF,%4$(4$FNXKHY%I
MD!@(0S4J:\ULG:I]!PW3CNVB*P?IZB1**[ T*:/75 89?^J"%N3Z+":Z)TI1
M2W1(#\0A&\-]P=:\\:V,%:$7#,18SMZ[3;RL2&TJ$!B'&%.YOL5V8*!C\@Z&
M8D(W+%NFLBS36"N61&N]Q^O+F[-6.(RS -@.6Q1!PVPA(H+,Z:$L"U\+=^'T
M:#E(;!\/?:[$6$J??EL #]&#"=XC[_(7Y^Z<I:FV:A>D IU\_A[9F2F 4/Z^
MG*3L[;Y9#5G"AZH>$ITVX66*))AN%X:H4HXH8 UW/+&%ZV88P!XFL$0F8+<5
M54[KAGFE\ZMVA-XOO@U4%XR=LP8#[VBP=&51B4LFCLAJ4#86%%4,-7QP_'*F
M4T5'Q<NK*G)9_>))SU;7)ID:DB/?8KY"?TKW_;*3#GUVTDL=U'F,">\:? ^-
M[.GAO!KV:GA:#:]PI."Q#E[Z],#E;X&.$FK8].%!TXIIDX$.,)&T*=6TX5@'
M#YM"+Z2MO-)[2:67IHUYQ.ND\4J[YHB41R-CM0*AH5\K+[]6D'PFLK1C[5DM
MNHVKQ<)%!>\;&J?I@/PJ5*#?A_?3YS2_Q'& 78,N);:1+)]%6<UEFUR>,JD*
M>PI@DR&$D90?##_EPWI/.#\2:1QT;A.(.6)MH6/[,L$D4.*R<IC)1O8UX1G/
M&QI$.X[C&FU6@;),6<G+R/+>/.+-54AL7U]\,><*.WY9R66I /XFDTI*]=R9
MZC&1(V(6IS 1[MJ0/,,I?&IA%..NYYG%7J_D$18/H10B,U:8B0Q=RWM(:F9D
MU+&7V+_&*F*PUU3'D>./K+=M,9?"EGM I\C6$6.M(DH>@J9%.N]FEEJ*^!J@
M/P@(3[EH)"DHF)C,.W&HS+;]+C-K4B&>2H-RD*#+2-]6DSU'7 (RD"$8Q1R!
M#T:Y27-X+K[.-0;!\QTM!>YPRB7^SUTQ3/,9$W1RKV -2O-P,-W4ZGM#G<>8
MB9S2R5XX$(C#*QF77Z2+IWZ[!'NN2Q%GB>)WMQ9)'(\*'<+O<A)C<;OQ(19V
MV\X__"K'.$I50>#QU6&8TZL62D4))%UO,4K(K?C&NLH^T@I-3=XJL-@EMP)U
ME&X&]8?XD"2K6" QQ:NC*"VG$R3PP'MMD*"&N*%&*F/P] ??7! I\+O<N&$Z
M#[XDCPM$\8*R=1IBG!+;JMQ11'E@3VB=+;=X]*@-M4;0L-\K3&(WB+D\IS&I
MB.7B5U5$?HHT94M;RBMD@;9B9-_*B7&\2$%B^UC#82DH6K=)MS*ZL6R1\=[N
M<8,QZVTV ;;4F$4.%"!KDF*EXK=4FU1(V ,KR*Y].;WVIPD64'@IQ]/H86=:
M/55T$]5HX9U%"SH%U5O$21"%[H([G?KK5+YS&PE2 R!) U.+("6#)0["+M85
MW;S%:7O6F^Y9O2^P,L=*<V6):U[MT79 9[/[9U@G'E0P^(PYC*/_D9:JA[DD
M:5A-_6%X,PQ/3,S1Q&O]F"[OS[%A%C3!;DQS-#/>\!X,2DPEOHI%,KT-C<0$
M:<Y(_2-EQ5CB5YU@+!PM3:K".^S56.(V7&1B=OFA:86]J9:XS58#7+%CN3B"
M44S,(+:J#MLJXQ[:R?0#0=_;9]:I,*:;7U[%XW&GJ+:H1HFA=$2_<]L<5Y4U
MS7B0%@RE'?P!#[ZK9(HK5@46,'Y3*2RJL,*2A4TNB<1Y-IGX@MT!VD2H%72<
M79MT>@L,A!TY>/Y84GX\T@; 0X:*:(&(#26)5&'KE&/$O!7P]AXQ#?2429W5
M0$-?:67)(T"]L#MMO>%%AJ1D1Z6^%%QB+K6A^!:M\)$D=[90"1JW]^JFYGR4
MZ3&=%ENR[&3U/6'Y2#)J\ GWHH_&(6S$PH#,=G4"&BHM^55$&)J<9;'"GE"C
MX*,:0MR$!>\,[_$9-E*:@I[FX0TKM9J=XK%NC5CZ*%@FD9A4%T2Y1HC875K-
M,^=WNPQY ^C8 M2"Z"2<+A6UK2)CM2RWXV^KPRHR)K]QS"1UKZ4^R/9M4TNF
M,NSN@L+!H4F;74+L%3"?)S:M+)I=H.C4G(VK9-M))&BG6JT MJL@6RRMRXIG
MQ6NN\LQY,E8UX4N1KHP/5STZI<$:!E8>6ICTK"(#D.HCD)H:VH**J:3!W+8;
M%,[0S+(O[#RV_JDP6)6ZOGB\':;?YPP3AH^&"7C?J)O5L M6)Q7(B&A,[J!@
M05YF1*_E"-J $DJ[0-5*)4&I#F7%1&?/IF1U<IU;;K05\5HFUBRC>^AE<Z_^
MCZIL3LT :<.Z5!0_.G?N;NZ&6C<5IJPB&C1D$Y(DP*C?YBM,\LRM2J[<@&0L
MN$_,F_X/KH2V_L[.U!9M6=S8 TRXE)WVAV  /KQ,:OI]UK&IEML7CC-<C#$
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MWIQA#L 5N^FML-S^NO^F<[RWUX'7+6N6>1[&9TO +2B'%!,KVB$#QS3_R\N
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MRVZJ**[DW$^;_$Z/+2H]K6N-R'6DZXNJ@-P6YXQPWTFQ_A/V!RHK5E0DP G
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MN^WE*;'1TT?=ZUEYEWUXA6-99B 75\8XF(QPH10A.)%E(AS8=Y<ON$=D-IG
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M_*UGJ@*U;45!P028GBR7'#$C=RHVQ900T#)@OCGL0Z1GY!6$3Q7$<^#TH[V
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M=9[1GS(9*Z,33K@JJN\L_6!7X?(2RB %A.G!=AC<X\,[0=]@@8S]$#,_(E^
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M5RZ]^BI?0J_4Y337A>F2(_"4W[:6V5O,P[[57&2+B;F_]S!W^YH&-T\J0]C
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M$Q;TV+:?\=/FX6>(P&:DJ! M=)_FQ76FE7O@X\XJ\Y6G/4S7;O.-71BS5C:
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MKS,%&^>CC[NE]@^.XG-+Q>T%\I\>G8PPD!\$R0U*G#40\.';B^@'6';IRJN
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MQMC2_F4M"(!T/D4.]S6RV!-6-M>9C[$4)L1[2$A/S_=1"\ETM$*R=1D! :C
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MJKSQ=V2ZH@UN-75  &22,/9'](/[K-^KW=?0XUC2DZ.SEX-+>EX#@62CG>?
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MXV2[,G,!8X7=U7=K34]AUB3H25YT9#PO-!\]T?:*O&L3VB-L+JENU6[QDT-
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M*P!^2-7\64BY1/4I<XI-_]9ZS8K,I\O"I.(2G]TJ?-R/X&K0<L NL) 6TH0
MHMO)G_+Q6]V.%S?JV;U;BUD$Z-VB;(%WF2!-H+NWO7RB]_>G8N=,Q7JXUK#M
M+O.ZJ>R/[&Z4O],,O0D=!R+=HLP+4W2$K:%!9QM?Z0EN6!WBG\A0%J[.PN2
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M'0\<91G1%PQ'N)SR<FZX+L7-DT_T. M13?K!.0W^R>NRJE;2M)'.Q2_HY/G
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MC ^3]:2</;E)[D."M.OJ:BL,WFV!?'%TS&^/.'N181D!%ELU")3D&LAQQT]
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MV@@ COS7;YF!)\\"]>Y/\#&;B <GS[P%L 2MRIU0)?*CR;V:>?4JPR_P [;
M)3V^RLX=)$UZ03,XO@PFF_BM^) :?62J RJEE01Q!,S;E.P$TT@L;!!@-(W]
M5G6 <>F[+KE7^=^*'DB3+.>H6^?&62N>,M1  +)$8HKI_?W(5/]S[!6^IX>V
MYGP'DT347\4^A0I'+&L7?C2L_^[T=&&AE\<_>4MO#4M#=\"!,/FUMCZ$$U6X
M>J&>:=MG\C;,Y'VY]OWVFK:S&TA:_NL_G[WX._=9HUW0)^"#HFTWD7;8X' ;
M^JDU5U6YNKQ2'&AJ4]4TOBO^8Z,]X<*VZ&Z156SR\8361IQQ=K=E6B[FC)_;
MTS]*4&TD%>V2N0HJ"[2,H Q)6'Q6*I(96K7,7,G,BK:Q)/FY&2""MD,@7R1"
MDI8+I'BG"A,7J#>DVW]23Q0@C$K8A-42OTK1^.?PX2T$VC8K'SM>"86"G<M9
M-PVTJ>WW>.P+^W+NG37\KD9I^#F*L9898P#X%JS4[BSAM^_*/ML>>)TT8BM7
M8QI*@U05 !0?(16T5$+D >>-JU<-:8M-G>R<(R.5EAS\M2J"QAK:T.N:?G+(
M9'Q>LGDZS>927<8/ISGE_F&)/>"N%8^BJ.B&-NJEDLT:.!F[H&KL:C"PK24\
M+SU'%K+A",5ZLSB6+K:XG? DE97IDZN!.F@$8QF[?-Q )U=;%7-A[$<US+V7
M):NU$J+=(HSP>MI=LWD<L4?\B#4TW<-CX0U4M5\^]&C1SN[+6-N^)Q JT<_[
M1CQ?O7K5CA(X+X=N&<TW;MBX\R7UHZ);Z*F<-?VU;6KA2RMEVZD!2,$[DDQL
M%#)4&A42//M\-H.A@E^]AOET/FV$1GLA*<D#C7Z]>W?^^CSD$V]1<[OB$Q?B
MY*9#FY@S>+24J;)N0CV=!$ZE;S"4"[G2DZ3.V5H3'>6X0ODE399 ^BOGEFF>
MA_Y JQP%'%NMUGBY,]4:5IF]-Z;QJ$LV[E?&MB_.,'F<#SZ1Z^B$<,<+1%[R
M4B?_O:6=L\:^E]X(3;7B7NY<\>TRV%F325=4LG+1Y-54_W8,'?6B8=HPA"H(
M!,4#<2&8NKAK_$4PZFW8'33PO\I)Q/9RK &F994SK)T)<SI1J5@R8?(!S'.V
MMF_I8WPJ>#]T'2R+)_H7 J^KVJOS_1G\Q;\F$^2%P *15&F-8]T>Y:/;M#__
M^N%\ZVUME+W"LZ(DI(VBV7(JE:!8!L0(U>M1_#]:O45U,L>J<I+WDH9V,-?"
M]ZMRQ<!3Y@"9":A7/HLC<XW>2.]AKI(_V7&CC]1;I4T".J79K:%^I;<O)+I*
M-AM:_'HNX"$/F$;,S%KB'U9<\B!_B.QHSO>:Q?/F*C-.L7"+@#I)V!W\T/W;
M0C^\L+O5P5\_'\(7@^1R]P'/$VOH $8LBB&7J\:RE) +?/D$CKKWP^0&/%'7
MR7P%M>%2$K5JI-1ZMQQ)4S]0KE>R^M_(L7MZ_/3Y-RYLWUJ,:U3%!+^7/?J?
M10ITR(P?HG/ TA@,$/2XKM/7F<9V.('@:."YOX42D$QH.9.<(0D]%72O-<K@
M4N)S5I,E_:C(_ZUU+*N"_W-35I]J;IH]%9Y0\C;*:<X7':&,;7C4C>47@%_$
MPP_Y60):G9"@I_&(@3B^\>6-9;V $=@%7'=6$R3&RS'7GM$I0Y0D;?;R09X9
MA-] 2:!K09?+3/M1<S\7LQ#2+G^;8XU(17BD_1)QNH(*$=X9Y=;10L* /<'!
MY'Y/%$4F1Z)U3J*?2M(O0@QT 4BG"BF/YX\EZK=($II;3,8B9SZ-6#K%O\F@
M08W;R;>-HS\DVH5/#">=%;?7SHVGV;^LDH42$OW!Y(HZO@_)+&L$"OZ/C!S8
MJ^A<JV(J4V'EQW#Z:8'\Z@PF7Y#XEY-ONI@U-QL5LBBHA_N4F;_ I+!J[)]R
MA\LJSZXE?Q[^YB:9?Z)5DNT"GH8E$J5T2,W+FR=I>0..G7(JE]A]:':=BV9X
MHJ#/WU@X![L@^U F)SEH=K-@V/ R:W*9URK3/6?#A5-D]2S$=QE2^9L?(GB?
M?>*-U+Z%^X5BNB><I91 J2M[O5L^PS5O;R*NO"F4\\F(@)MH!"W!H@F^'8QC
MGV_?--_^!:; MS_VV<*:QR;J)ZWA%NNZKD(FY:1L'X5&8?2<C"%6S[.5A:ZL
MLVNX*F#H;,9.[R/#ZEH,/THZ?50U*O>BT_.+,!1 OG&K>BVEZA/2QZ",Y'K3
MT!#QCAHF&79_+G%8TR%^IQDR5YXN_RU;JCGVDOP^+5SHZV=L=_B8%&MW,"':
M#*Y\_PC#$W-:Y:X0F\ZYY/]G[UV;VT:R;-&_PCAS3H<4 2O*=MFNNATQ$2K;
M-:-SZ^&PW3U]/X)$4D(9!#@ (5GSZ^]^9N[$@Z+D!T&;$1U=%@GBD<C<N1]K
MK\5I<;0)X![DJ>YSGO$+\0FK597)-W *1< *ZB5"1.0KH9XBQYCC6X.P+E!4
MSJ][DXF N-YTU_5":_S*Q]8-!*L8%V._((%J5G'LR!<&RX9<F3S$] $+VE&I
M0SZY3&OPFJ[T(W!,,A0O^?'%W_'?-[!G^S_TBK!Y(ZD)O7!\O(1J@DQ&!1%+
MN;CE3]#"X@Z[N,J+C-\YW'5>$W<&;/JKRA=6!H%'+KPZQ);7^76*IV[:^MKE
M14$3G-JC*Y@"%9]VGE<KAPI7V.::)O3_>"VIXO"-A3Y4?,V(/?G@W)IOJZ(H
M&9^IP"KA@M7;&AJ$%0P?/,=MM5S" ?-T\>$2UB!.VBNW^$#3F&-L\[ZSNKT4
M#H9%=545>LQIPGD+(@HOZ9^%@P".R0#GX!TMG#T/)SGRQ0<^#'X.HY'Z :2O
MI::]Y/<H>'Y938CE1'<6CB5' 1=Z7F7=^6I6RC5:2)FG]/CB-&GH!XYF3MR=
MU*,LJXE]<<(ZDH?.MP)1A@1@G5G:?V0>#W,;'HUZ-CNG$(\BEF'R-OA22?(%
MK=9XEME?#)ULRGB$8I-J,7RPNNZ-JN^(UM4KX/,R2O-0GI'_U@KY@(%U@^WT
MGI@RV.JQ_GDFO@UIM:S?]\J(P.W#,-#O'3_=8 +UH?9J6/-VBD61J,"P)S]C
M:W$A&:D6Q#W3F#*0#G@R$;,4KHCJE%06/H-;#'@>SVQ(]6=X0[F2AC8[^"1C
M?G..0%1XLO]N>1E;!,H.4/%F?&$V'NXA^P\E?W/N5=?\ UKHJFP;%Y,&1T"7
MVJW UM3!*6>HBRP9L29]5741=)+C%:["K@)EE;\7-WPB#:U/>E@1)3WJS\O<
MB>DSI"I;MJB G>Y@YF*S'B&KU\+RAG/&[U[<A5=1U:]QQ?)1^":&30UE@F,.
M824=8T)M3NN.!*[J5SGA0;#^-+<%]JP 0?;&UC2!;Z@%%2,7 6]%%XD<].4(
M@FON*)E-5Q5YW%?P^[/9>[8V/DG; ;AQY\H0(,Q_>&$LQLNPE;.T3R_U2E44
M^;>Y<34U"6U]6;#!J0%$HB;/2M-;]AMO%T1JE>HZUZQ)2"\KMG1U+P"D=>\1
MU=;%&'%4.&UF^3(P\\;S)=BS[13:WXO-FDJ;+Z4.OOPNC"LV1]2!--W3)FQ#
M&\Y?84P315Z6[P%_CX$ K]C_.G_[!Y7(=;^4IB8P@U_#K?!..2>Z0RW#P(F3
MB/UGZ(GA/BIEO<.M7.^#"7C,KR7<ZY1@3+S:\.DDT,:349ALE2/A-&6[FCOF
MQE%8L<D'RL/;D56F##.XWTD?_J2:3@=W8T*B8B@4N"Q@%!U'XLQVI+]Q]C<2
M/S-5"F54)&WX5UOG398OU"_U<!?,.9,*DT<8J)'?0<6CK$87D!?SZ/@2.^IY
MJ#,=%#B2>TAPX$%F)QY2X,C+ZZJXQH./99A=RS"?MO*__D*/LA&F%&Z](<T6
MPGRM6V'=#7 O^-$)U;9)?#1*69_:\C:QR8TNOG^4Q ;W#K,6':)]2M8/;EQW
MI^037/+F7I'K+/0A!):S(KU!P-&M*,=N[KC!A'?TDL@<L3I*V2R)HI$O>';Q
MZ&>.98>S!,JP03)(Q:UVUDD&2 "*@^0\G4Q6TN?AD2*51$E4U_424[X0T*UD
ML;@A):O0W67.8WB(WJL8KW[(]DV=I?TAFU$2X/6C?^(\O1WCO?1LFW0UCX?Q
M);\1%;N9I6H9##<C#I!A2QUR<0:K0XFW#:?C CY%5TJ NL0X%E6P(1J66\9@
M7(0,+SWA2UCR%0SRZY+T([G!:JIXQXN7K_<-=Q1'=X[A^A57C"VH!>[0X#66
M FA)64^1@12R--((H\)SVKP#.)?^VB3ET4(TPQ,;+-\")F4'[)$,0HF[X=[L
MO&O7AE**0BP4S-V(4X&<DLQ*ISN\]WRV6;,8L8'XL4WMV\O 'VA2%E:!GW>K
M#R*GJ_$W6;Q,<G^Z2-@KT]-A+"_C:H%N>)5$$I <1"P9FB0/U%SEZXBX+D"P
M<ZN*)"ORJ\?13Y_ON>OFY]GTLO@7X)43F*(UTJMGLP/O>/AYHI(8U#)/)9TD
M8+4$R ]^?[!X3".!U2T.B!-T8:A,FFYH/36MDW_;F(B;[+S[D>S07"%-%8/S
M $Q?XX'59 .&#ZMNRC[[K/I/8>'S$Q+@EAOJ,F:UO[26_O:&8:ML!,&B%9E%
M3J2V59E8I\!:?(A.(MY)2!L(=A;&W0 9%]7ZEO.']_TMMEN@&[$9./B$#%_T
M$1X37V*J'L3;\'XNWNS9E[#(_^M39,A 7!DV[/"($FJZ(-ZEE!QPV!$E*(D>
MPT]#H:=D3N<F#QA_<2RX*K4;\RN%!-^1KEU(A=](XL_$13#3D;TFBP&B&.Z$
M%#T,:=M(07;8A*2-5TCL@A &-&T]00.]W0T30;G+BNU)!)KU'?4"V-*":EXN
MT0634@3X0\0,O*YS;X![19#A.X_-7AR,"34?#AL]^Y]D*$='8-H%_V_")]B3
M6=O2 KG$&)?VY0*"7-V/?P.'O+&L:F]\UH.^FO *^![LXH+MHB=X20C"<>UJ
MR1,Q(H*KUCWJ%PT6A3;#J"N\\H*T<U_4J>*JL_XX(HH9/?I.!AFRM_>^.P+(
MQ( L_ ESF==8!TOSVI:V?]--8L2!K+>9QN]B1F6G/5T\GETN,TKLUEG1DH3/
MP1FT,B=T(T M?HQ "SB,DFN<SR0[T1&Q$,"?JM\,(HM.?5YVMU+(783X<P:N
MWJIQ8D+9QBUJ%]A&3$4>KT[90"\5PQX(WE%0CPE0 23Q4;.6N6M75&L[/[>&
M/QS>8,C2UJPB*W<\&/=P%H6K410-Z+O VTTTH0NV GMUJ7\.WQ^K]%0%YW_?
MT]._DZ</X=?+JESF^"K0][T(FO#= 6+2)SH4+- <?CS+VEH]7D\'&N/ J3PK
M<)5^(,E<AJ>VD9 PTGSGD87BB6:>/:A#$PP\F2G74V;(UP7@7(D(&_QXVTOQ
M$)CM @V8?KSE$ [9DR@]F+EEBD8+P>@D'N/OUJ^DL]EK3R004MS+JBBJ&TTB
M?BI35W.%#UH[#&P20<[E*PIH-N@TQE<3^ _W2!3N,BTD#$$H=YD-!3.!.8K.
M?2P0[EH@/*@^K2C3NKO][L/:AGP92M-L<662S\5;E[!+8?#=I32->+BIU"@M
MCB[QV+&$6VD8^D7K0E@60D0:NRH!/2[Z*Z9Q%&U;AGRMN P9/1/N1XU754>V
M*S# %7>Z.MLWFWIKJNW*%;05M7W!=8)$QFT#?O=/!EJ.8/2J6^:TH@R]R,:M
M4MR<X3Q$8:>*O!T,,GD0(;]OF?;J6&:,6OC,YMLRWO/N33>$/I:*+DC)^D9H
M3&,R>GMR(;,-/_<% MZ*D?\N7&MW.O&9L:\;W)J7P#6-S?+4!$35@R1JIKE'
M&4&BOR9D[JV3;'D+Q7H:.T*VFRJ1OA="+$O8(JPM[K));#,RIAQPQPT)JKCI
MWI, 1;??QLA&L#0/T]5YY!NQFU<,!X7 0^JM;%'GMS;D'W]NV?TDD=H%DZ(7
M&LHU/MO*C53<L='X32%PFVY]Z8*/Q9I.=1.UB%A$>T>@],Z=B^*,S@UQT%,Z
M0W3KO1"I5-]]MR,GD7L=0#W='?IRB&'W1*U)I!J?X%3=?F.)!"_WZEGV),6^
M)+_U&M_%9K#D/,O63'Q(L=E5,C<8O"C>'2Q1A+2KYEE)AK23:.WXJ)QP9?CX
M\+UI([4U'C0K U&])8W_#$0_$>M[5-QE.&K(0-O<E3YT-M.F$OJ;%G2<:F9L
M5G<,-.X=>EY%QB%.=JN99^ROMQUZ3I\ICV1+F%EZIO%*2+I$^%T#";X+R"NV
MML3H"26-B:D9:=3JJJ%0"VXGKE4N*Q:SU&ZG&!*PS7SY5IK2W:0%50<VK#$F
ML'M"*)J"-G)W=]\9)W3EZ2P.;XFM.2?/E(F*FY\$!\U"!F$PY!4M,+OAZ(73
MQ]O6FX20OILGFF@5;G:ZS=UQIN]#'7,B$AE,?[E3%D[F1 0&Z1J!)#(165ZT
MVTR#J6WX_6]W;,IWL=%-1)I"IDG'U&S2#UBYR)"K9(.=\&XMN2LTAPHG7A#^
MEM@K85=M$/)HR$K -&AOJF[7/CF>ZS9NR@A*:AJR4Z;"H."#(>=OR\8_Y"WO
MV'[T_+"GUV3I[^^24/ 9,A?#;R.$K5@LJ^ZCO?,AP^5[]$V>[/Z96/&ER'?;
M6&%1;;WGE"E#:&0*YH+U!?N)D^[4LU:8TE;"D!L8ZA:9[R&VI_Y_>E#W$>Y2
MF8?$L=BVKV)F4:0]D#]H@70;N?+BXTB5KM#S#'M#Q(!)&EC$=%.1ZZC^%S8%
M*F$=NIKYI@W, PWX'*B7A/UC+'9J@4(#M;QMKD8N0A>I9[BEF/HRUZFRC#U$
MSGN2AX,WPPE@DP<-KRN)L\!TE>^]IOW7E&S$^1WX*YQ97 X):2J97>Q &,*-
M7CD:J^KG2\3H4II&:85,0TNS@/.$Y6L)PS8" V:*<YHY9EI3:NA8O-M6O#N8
M8AVE&J-))7I&Q XW4JCS^PW,I3JCE!':7H^ \# 1K8R@":U;K],2N,S01"W3
MZZJKAV2EF$@!2AK3!OPA^JX1XCG;=1M6PUS80C@@]3UNC#0Q-X,=08,KD6))
MF[JKF=AK=[-Y\.)"'Z9@.=5Y/R]BL,F[6_#15\U0#7)'_*[ =%8K5R^DX(I,
M>>A$<8KUP9?CUH'+JLI,LZ-G=Q,P/J+3$@9>PB0,?,%UC?Z87V_8!X5!!3*E
M"75BOO&N%JW#18ND X0+:LAMZ+:A$P%,II3<1'W/\)C-R%/":H,'$=;_S#5Y
M3:ZE7G64"&)DI*.,M0_/Q9,<NOZ.+U!:61N3(A>;10Y5WRR8=+=Q:0G-X@L%
ME)>*[MBWXYF>6JK="-[1=_FNBW2Q'1)W#>_!4V(-S^B@(T([=DN\F0E'F4A+
MHZ*NGBDF5'D8890(D+=JS4$\YQ1NN:Q3M,[DD(_/]<%&5\.TN8)_HL!G+V1&
M];XU7ZD;,8<' WO T?$MNR2+$-!V<F](84D\'E<TE3G<X-FGTJ42;4FYD!$A
MW.RLM%$IPR?0P>'*C33 (#$DG*"JO=Z]?)'!3@!S/\UPKT0IW<[WY"K-J]6\
M^\7[NOH+0C4(.9K>CZ[SNFW\AW"3\CGX:BO]] 1!^.A_"<^J6"GJ2:=Z5[-!
MRZ(N7;7<W/ BY[$^C8/(!4KDX1*^%/R@&@/"^A$:$$.(=,UPK:6A94SB:$21
M8$N1<325U"QOZG:]D:P9DJO1/Z]2IG>,\F<Y1+Z9='_C^24&ZMJ5)+ BX<%M
M:3@!<'XU#8FPI31O6HS*&IJVU(GM-A29>B/*;Q"#60.)I)'!5ASP<'1HF@UF
MC+-8%C)+5^FE/$>&6!\F": X'QE+*V8^]S5"?!0P;D'B&=>'VY5H[O&AIX:+
M*;@-''#M#'XH)B@ &X,?!.= &_@"@O^T WH8[$7KN-AG/72W)X.X1QV7,CK^
M+]4UC_#!L@<KDX3JBZ +7A7(L\3?7;8YD4ZZF' ZWS06H46+-7H\!/"AC4(R
MR5P:TW6GV]4Y?])SSE$0<1+J6F%F/OGA8#02WS#C,[W75V@5X2E:3+I]0U*)
MDS.UZ>F@9ZW2!*3Y@ZLUD"**[PA;7LJ$C9QD[B#YO6-]MUG0]\XD,T-E..,U
M"RVXMP*);5Z>"]ZK5C4A QT_P1-/M659AX#D=(AH9%_ZH$'%]H_MH.IDAPXQ
M155;[-+0^QV<082D7J14+P_3)[0ZX(D&QBW>H3@_V<1!N@E C ",+\)96,O&
M+:X0,\%,ZAVM(!^]>.>80@TBG^?;&WHNQ:&0B?N%'J?+0Z4H!NPLJG-L?H$I
M;G\@8 B&.. ONKQNN._UV8&VH#S0X[>J48J#Z*;L1->*O-=^8Z5=RMJJX^$7
M'1JD[\*\=AK/=8Z-3TA+&71-7I),0%EO5[<-34>DV[]L2;YR;/9U"LD)Q6V7
M7,4BH\FY*N:<QS3*>Q^WX]>BA>UX,SX;:*"7C$?3$57"V<NM?H)ZDIH?92O>
MQWFP3IKF;/:.7#6]C=K97CM?9Q>1:\V-.6N*QC<<R^C<3PDG=^6E*$M@<P0S
M)C:L8\[Q58H;4]4VG;@9!D%B7 UP.6YF&KB1Z%0\5QD.[2#IO)A7V]=9PEF=
M0*1:5F/F=-N,P8N/3ICQM7PL['Q;!FUQ2BCJN(;SAIG_<!;&DQ/S)7-WE1;+
M'NBDQM07BJG,;X?RG;Q2.>O=(>\+OEX4)<S>\N)>>4H;SX,<]BBSM0<+RL!P
M 2$TO97/,&<"<IMD&5?-R8*@7J!M4?;'D/0(!IQHL26#Q+I*<Y=A DU6]JE)
ME/JR&LO+X'\#=3U;/1' V19SWTGGJ% .3JXVJH7<]T.HNY/M>,CI;RI]Y]T7
M/H(]LCS/ XW_#^@[];W[IMU-<<=X[Z-SH],BQTW^@VYIO'W!S_29N2=XR_[8
M [D'_:TPQ2_)$V/3#:OI$;M7?O*8"073H80OVAK.]$Z^9U5F?$.^4FDHJ'5K
M]F4"?]K!;?>3Q,/'2](#MO'3SSTI,KPGCR=(AG<.&_BC7^I\KCP>],'+JJ8,
M>U7N*Y\R%..$0@O7V0/EB\A,8;E ^JC&]I(314ZF(>77.9,!P!D5I[N;"4Z3
M;1+,B0) RUL!W(-KARUFK%.%#>WR%R(6VAIO0D-EANICZ4_P=ZR1A@XT^O&I
MN%R6!9,^P!WL.O4PM4 2@<'Y9;Z$\\SQU1,0N6B).<%?X4.^^(#E*H/&4&UP
M 7Q=^O!PYH1LMV9T1XXQR+J=@VGA_K!2X^!8(AHS,QO:\=B@46T(1B(3SUW/
M(8T*79D.'&MBL?T5=CA8]C.9MV!OM0!XSLTLCW]^\8(@?9<VI-5[G6%J"YDH
M>&9%K68"UX.Q@P%?^&ZW1-Z>?7=)3Y($8SI,%3N1%NO.M!ZH"GTF:0NGB)WQ
MFGIQ$1(,:!$#RTVUV[N76CE:[ =;["<3M-@7T7IBVI0@C+TW>]V-+.,&&D-@
M.=)-: 5/ U!B%R[U!^F;;J3=K#N2F(TR/;)#_4)"+WQ?_01]3B978 3T>(Z-
MRF4(PA6.'Y%!Z#6>=:B;T9OD!KSN4%!&*1Z*0& ^,A*6_W.75KHO\699"1->
M9-8R(&F3P@Q%D<VE&T2F^[R-4"SA[X<4DL&9KVK1KOU(_U3Z= WN[HA/='2N
M[SLX9B+M/$CC$RZ1)Y'L+D&TQEN#.Y$JHU_DB8ED'+ETO"(KLTXU?K"B;G#X
MU54^)\;N(/UXQYK:^UCQJ\;HN':/PA^&WIO0&>VF07TL<C B4G**V!#X<=?X
M\KCQ%<S%[)4(?]T1H-AU)*EO_OK>Z])XTN-C) :.G1J<!K SI)?H?@IT-R@>
MN2$G!O\S9AT[XDLFBK\['2!%IF&W6=BEE:L=>YC$6_*J"*&1%E[.2E!/Y@9N
M6$E/)[7E8-GV0G8K3OSP^<27]NX6/9V@6_16K,$;R3,:%L=]U4</1]CVL'EN
MGSP=YK[?%Y)J<J]WS] R<?[3V)T63]70@=P&@BOOF=IE?1LU)^*WOXB)?U.D
ML4"Y/U&(X$WW40VVX=(G>(,73M0LPOC:V=>$G1T#^H&'()H7Q&LJ-!@^,(0M
M'+"'3KGM#^5WUIC8S#ZKY6JH4#F-&X875)!K@E@C/HCEE5^<1A6]E&#EZ@F&
ME+VFL:2!I5?H'.D.)L(6WWP.CUNXM+&L$=%S1TP4A'=G%K2YHSC2>&-=LDVF
M8ZMS'M!C.7'7<N*GN2!?W^-0MJ2! A55@ @4&FVL789%/.P\M%]1?KMIVA6E
MMDV!*,*P#_$_/[P):XHXSQ\/!N?YZZMS>FMJ.7Y/-_#:]^;0/5QF]="DD-,I
MP.I5"AEK02/Z>0H^96YISR8=J<\DOA*"/T#) 30D$2B),$ZV?A(KNJ,=T:G(
M1@(NT,*4K+!J)DF[W/0;C;#-)=H*QXTA6&,51F,J^L!WE'_AI!0E"H.:F:&X
MPM\9D;\ "!AFLZ(^JNOJ [(AM W^D!(>3!\+M[<ZG$#%&K&CPS]5AS^1K"K-
M*5T2V*#:Q+V$2H)/8O1QPH4V86Y@?:>'QX(-7/<BEY$\6 2)$(V&P]F, )Q,
M."^3P*_^&>P"*2US)FJ0#)^R4G)]<:3?M/7BBEQA87)_<&O6H6TC\VEL(T\\
M98[/S[[1+/\=<"I/)0-_%>G<%?QQ_<'1 1E.)]9B"(EXG?^2EH=9X$.N+0@U
MW& *59K5Y+;99VJ#66-\Q.">J!H15G>7MT2\'=HR3*O#4&4D[%9&2H/9P6?<
M&^O/=3:[>*#,.-8"5YA");ETE.PCLBJO=FIP_$L)Y)=UVJ)5*S?F4+EG'+PH
MEN^S\5!!;YGFA4?8XK;A>E?J%)#TN*QS*2Z++:B;0(LO[!ND"^J@SC@%8)ZJ
M-I=?I1\ZWR=LQTXD-<Y=HV U3F<P&;')M;ER7.?W"/!YVN3!Z< ;PX:V$O=Z
MZFO[%4<LF?V#Q_>=7HD"]]_UH7_%[KED)B @GKL7!0DNP&M+-RU/JU]S3'N_
MP5X:0OMRW8YP-".5&+_&OA<*B\4TK!V%EP]=EU&K"(F&P[1Z].-/3U&L.N4<
M6>$H"J-&2' BD0^"B]S;[0G/;Y;_:!#%GF4UBH#[B8.IKF:9+FRN"<E!\9IC
M&ML/?4[QEYUG&Y R$2XB*[RL$--M#]9AHWTP ^W(M7L#GPR-/);"%MS5RBP>
M\48S>NM_5%LWQ<9A79*K:UF=WJ"&@EM0WSK?1B!KT#L2[G1%Y9'3Q*@%-*VN
M\6,]WE]T716P*:1U7MSZ"&A)7;[N8]Y(SO(N@:4@?\$$:'POWT4OT9Z$%\;)
M=!9PJ.^-6\/TT+^;#3@8VI(]L(>$F1B86+8CU@OJ#24^''\5PZ&)-X +33PK
M974:Q K=;5XV>/PN=^\57%A6"[E;2,##WR+E+K8VWM%:';)GXO@$$";: HBI
MVC3JAC>\-49Q+13D-6EQMPW7E:?K*W/SM%8?QV'TU1@3'LN$J9OKU[5=G)W4
MQOWLY_U7]J?#'+\,RS*G$/>B&S()NQ'2?CMT2<0KGR<HPWP37>1&-BD0C)(7
M'C?<F'"O;GS[2; 4W!Z'=#$A,B+/V\',1E<:C$XR>U6W+$WVLFI6#LP.H9!/
MGCPFL/++L]G3'Q[/D)S7_??9:=*Y!$%05FUQR?8$KT?K9M><P8M#*$ \.Y@"
MQ'^ZM-A<+= LO0VA^/[QMKMBC@[>(DVN$'$OBW05I@_O><%NS-L-004H#4^N
M0V(,6#!1 M"\SG5+[=@L#U>-4JL#MNM8*+]'H?R0ZN2R*3'.8^%JN N1[DAF
M_PT^H/_3= DQYD;1CP'189F1NC./>]"E!XCZZGEZSVA^Z]0+<!/.AMEC3#9S
MQ95<T[HX+'ND/0/OF)+)=VF>4VT,)OI*R"9E>VEFCQ\_^2FA_^>"'?[KEV3V
MXQ/=?L.13Y_\D#YZD<Q>(#@)CWUQ,C^UB_1EG:\X[^5*U@V$B ""TVO\\G=:
MB-S?2[FU&>\6LY?X(<32EW6ZHAJE\.G5+B!:A'AP*9X#M=W]O])R16=KA:M
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M75>4$5W[NXQ@&.3 8*!<1>H$'19KU;>B$'>4J4#3!5XBEV3D2(>%'5Y=&$=
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MN7VC8YY-$CQW$5[^VZBB/ VG.EV@0ZT2<8SZI&1MSC2J%%*V2NY)^4M^!JP
M<'1 //M509$J =D;UG7)]4QA!-9M#<9=E)_0GV>^;7 PX+G0?T?U:5P0Z2!&
MCIT>KV8NU^Y>$W[G(?+XO>I,5*KJ8H[%TEEW1,H9KL\G/_P='AU"C9QS\?@,
M%:W<)X__3G<C>]?*I>1DPI7>MG#;SWYXC/XI_AEDK5Z9<MT_2CHEL30U*H*#
M-W/.Q*V/?W[Z=':"1\I]3&Y.Q_>\IXDLK^+4OCZZ1ZJ0-II>\Y.:DF(XYR@Q
M5KM+K!'7D:Y#]UU(<\;0I.$"5XUI-EH\:)J#](^)?V"6H+M-_P!?E<4(I!00
M]'NV@TV^Q]+M%)&.[P+U\J_P\?X<F_.8CKD7IR>=W#A,IV2  _J5"B#P5_D*
M5?O@LP*CZ;RJ-5>X@1OG&+MJ-H_TU^JMF$SW'(8-GS%K^;QPB,@HB$"H45*C
M$_Z>%VA72S=[PV=K/!_X6C_@'TYN,APBNDJ7UXNS%WMM2B5,U6G2S9R3B3;\
MYHNTN6*Q9@7"7*?@*..,FE=U7=W@9XMTG2XP(<?SA)QQZD()ARSA@,([!W::
MAQ,N6]HT$-] ?T?E65P N"@$ZT"^D<G)^^EM5?D0_<"Z4]L7#>MWHQ[7-9.H
M"VJB=@N7K[T,/=\?^D=Y"7L(GFM^RS5^?@;.T(\?C>[54)JF$P<1A0\2OW,(
M+II;@^F<P2'8,?+X1L+NGR:X2WT3>'SC0=V)P0^S^ON X0\Y>I,3T'YV]O/!
M4")AP>NM.P"M[+[9/#0ZE4F1'P7#X>,O\3\7WAC)![A"):;,&:81Q%$T58(C
MBP8.MW$P$;F[T=R?^L?LVZ;%;4/"W RA3&9SDK*A$A?F$ F+"7X&92*CL_[5
M9I?D/L#%%US<8E"#YL"#:(W?PI,@-<//LJZK9NT6#^RV/3+Z?%9&G]VF(,T[
M%)F.PSK,)\ D::H"O5.JD.A<W&'^!?7UK8TN[B-^W< %IJTA=I]X[,4TPC$O
M;G!QL<]P#%_X0;_.J837DQ"K.)B!*RL<LP2'BJ7A#0G>T2Y-8AX?[=+1+GW7
M=@G_;?F2C;N<&#1*7IL46F*2:VS'R-U&M**BAA.J"97T+]]@@^C%,KVD#S%%
M4-TZT@.^9/9&:PZO\0M[13X)P6=*^7?4?B-I0;FC4'?2.S6 ;FF!EHX7(@S$
M0V)K3,!RML6W4<%KZ(S)[*;&E"S]"D:Y2-1X"]X'O=@$ >H%@\O C"/.DS4X
M-06Y2C>89;D!5[BIW#5YS 7C[)"HJO^"XEN1G]O?W T^1)RB3^B>G)_*[6QB
M_<ZNUB9BP6+<^<DO]J>L/;V05B6XGL/L5M-]2WE)0$RZAM=5I203OA*?N!X<
M?4[KFJD59IZ96F$2KMQJ[N(I:.?/EEE8N#*3K@DS(8\POMYEO]EX>C&->)I3
M.@0H$8NKE@.KD1G,S$MJ"=<<;:.+);)K\UM9 ERE$61L<W](%IL/V@M.7IW.
MANX+%O5??,*&J"#=(FV(3!)>[8KM.IRL%)!C=NDX9;-L-RU)"U^[LG74V(&2
M\&RSZ=]9CD?@2?50!%O2CTTNZ$2>'TT0;'/E1C)06)B3'U(!;EE4-]N.IC(3
M'R_5IK0P%:1M/XQY=TY@SA2\4Q:W;,H% ?/Z(PST(\4UMW!^0L^LN&>!<2#<
M,@6!1"]-XD$?.6;L..^.Q^IWDD81?.F6:SV<I/[Y\[,!+DS]=-)D,9XEYV(W
MFIR>0<.G[!LT_732S_[RSW^^_N/\C_?$B?/^/U_/7O[Y^YOS/_X_8LRYEQKJ
MM]/N^ARU'J<7E[UU*;B:Y!&=+[#E>G]TA=+- %9^<J-T,$'8 &@%5M'C_;*I
M'\SHV1 V:SV\%_;^O(+MSVUN<#L<QX_YVH!+X24P!J;"J,7W;(4.IH%?'Q%;
MGSUU\Z^]9N*J*)Z=G3"NB693Y*=-[I6_J9V'7KVA^]TS6CG.4!#8"]'BU,M:
MARTLI2TLBNT][*K;BAY"]KOB?0WB4PBEZ]+=BCH(Q 8I?\Y8_U1KD!K;BPDI
M,1U1^%KS[*IJZVX1.9%&K>R:N] E\:-:-I(!@<@'9@^F\9/9O*H^\(V0PXV/
MH>V:6+YLVIK.M*X*1 52"@*;W/D.(7#+*27B0S8_B+?4+ RQ%#O\&,HA0/4J
M+98=@)$252_;NLPAX(DR*G05G.Z=S$>'$:(Q?V ?/=/L(VY6X(.SS#&?!#4V
MX+B8+)3.![J0S?M$YT4($AZ@Q MX'92!@1\*0C<;N&Y_0+@;;W)K57-<>UJA
M"5?9:81E^>$ 8X#8EF80L[RIV_4F@EW0[ J1=9]/-@99(F_0!C,"GLP-#L.&
M$C\A>#74MWT2J $#PO%MU!N/6 $93YH?=DX101&;%VV1T-/-,1*FR<W> 2SC
MG/O T3 TKA!="4R%=IJ"(^@K?'2.'7,U1"_\)69 ]1?J0/B$)[9>YQC:Y"F#
M6#VPE/,G+T\Q/;)T.4]V-5]_^[<?7_Q]4>0V4P,VZQ)LU+K.KW/XIX.1V$B/
MAC2'((F>A_1D- ;4G$$MWBC<,3#";>,(6.QJX<TWIMHML?;8,#!01ASQ@"79
M"6H/:IA(BYCY?9>4?24Q)X>9;&LTB?D"+W3*8X'I#8$>T0=K;@$?2P%WK19<
MR?\:#W/E=5Y7"H9LJISZI"YK[-J]29GIS2)(;/Z<RP(TVF3.;Q%YXJUMX1C5
M5'6&$_:M=B.[0"[M]/0&/Q/U_X%R>S^?)%GAGV-5CKU%UZ]".--W[N*EBZO<
M2*IZ!AQTN-+&<!YXR]GG@XMJ2$-\%PFY#J.G8^.WH"/$ G"J<7*OVD[$<3&1
MO6W.0AZP-/1Z8CG8R$2T2B>,Y5;38G?):"]':W3EBLS );$2R2R4Z:V#"T*L
M,_<R3C!Q-E=@&R^O\&:F'?I<8#(U7\UD"<,:>9G6UPZ,[[X6;XB!<#_%W6F'
M/14]F45:!_Y$7V>5_EN(!?(2725$_+/LEG?+I")PRC6>FKJ+YNAT;?B2.>QZ
MBPW=BK8U&Y?.4@IC6P!,(J]=)J6< 5<N*K C_PT[=NC1D>3> *\GS4_81*_R
M>;Z)HZF;*T>FIV)"RKN?F6*L=4I;,#P3_HL,F*&CJ^60Q+>M8NB(GDLIDU\[
MK%THK;.CAO4@\AJ%*ZQ(;Y U%KOU\BRQ;;#AE/$9LW#*[XFAXSF21$[.1IR+
M)?T3C (ZKCBW_M2Y]9+FUH%L]!0+2)KJ%P.&1S:O@AWH).P#&Z0)PYT$ER"Y
MJ,H;YA$R1<&]@ZD6:.,0H8-5W&)L=Z>(?]*OG<%@;*\2R>1^M#?_=1H='4^>
MGKV@QT]7:''0H _0?U'BX^'\M--_%Y-H;8!W\9AZ&W#K]H1\X)EA&UW.+0HF
M??F:D%Z6>T'#W+QI6OXQ'_-)M)![,?WR1-OGW9<DS#S"K=P7D@W]SL%6^/"-
M*RA;I%Z?PC390UZ#!R^) R/D2UXI9XNB3109?YB$HL3>VJJ^10>RT=G'V"6<
M@0Z<4HROUZ%.*9>G8\A#)<X5Z;,G[L6Z!4/C85+<7D6ECL935"AE!>WZ"3G[
M=SO;]]E0/B/5UI[F7C:-N<>-<WD)UI7:'6%OIYQEFR(<V75$I],5T5?1S,K<
M' (0BNYPSC%!!%;0(.Q'J-[&ZYEF-7+\<!W;LT\P&Y1AD[C/Z_^,^)\]O7XW
MC=?/.,_@5Z3K'%/7!OC($>J"<S94QK@$/_^2BA5^-N "'_AMHQSG&EMDV\(0
M%K) =H/9_W[VPP\)#,'N<^+S\C7M:5(LIS I7IS]\"*:%& <,)ODU(3/J[)%
M2'M:D!"'UHH0DNJ(.)?W*<3/!G4;C \IFJ 0TR1KD+(N5%BL;H"OM<\J$U%_
ME@WD$$/#RRE,#A^.."\F;A/T(3^@54PE=Z[J$+W01*#7SW6OW:"P]UG?7__U
M_$)"X)O9FR(M[[.3]='-NT_%O>3@3JZF,@]_\BF*0 +N8OYMH@/GG.WOZL,H
M&/T^>TN?*F3B+RF?Q$MZ=O:<C 6SL'?>TC+-"S0 -:R<&T/ KO36NZ:6[A6"
M[G=__VL*;^6%O!2((#>LI8X[=UVM<,&0$UBD^2IRX/E0KZ(0CL>ZT7557!,.
M@XDSR/V?9>DJ1:X-*;/@;L$M>>K9[0I)^#9D/I]/4JCD]<=% :[3]3X5K>XH
M3)1".BYE,]6_B/!$#8$9"7<$@:18%V8?Q[F'0(&6",4;X3V./5,\#^&<8/*J
M1I B+6-'U<M$--2)%=:'9:B-L&E>>2JO;><R0T?Q/CJ(HE/#1<3 +V24%@+_
M-W6UKL#K/B(.!V'5%*=VFZNO3</YK#-YL.J*+Z4J*?1L2YE(5%4F(F].GT-,
MHJ*+!+1BVFW&\:U6;4ER(RI!-GPI$=S1%F.:?:2A0^"U_I5O_76/+WL8P3*Y
M$5FV-1J$_>)M#8:ZRWB5*)_C-J+CH<;_00NVJXDC$EK?;V]1FEWN 'LY^E6*
ML!7\E8?O\Z545V+8M!NFA,$^XR&#JNQ="E@VMYG(U?G2]GH+PNX:^)-0W:9E
MQ/\ 3T<LMRGRTN5L16#'&+H-#^<D\#"K),UO1RR*OKS)K8-#[ LR;MJQ(6[7
MAK@S.U1W03&F3['Z_.S9P5"LOG4( &-#^[*Z!LM3[@V'^/ V_@/(N4X)CG.'
MY*3O^9A=A.UKTG.BGX1__GCJ$V(J>;5G9"L53+J-8!>[B]!Q ,]&<S #WMT6
MPJ49,^8VW(NH_51YB2@ 00)'30V]_B.]X/ 4#2X.]S5Y5:3/=5J1(4)-.SX*
MSDZY+CG#'*8DAF+:R$TNH(?I9KW>QI>6$84[N @)C[D(\6=-=J$#3I826CIO
MG-<$=1'W/UZC5ON.'T2$C$>?[W/W@O]SG[W@!S-PQN5#1A JPEXBKY L%.%W
M$\-#D9;1_ B)$5Y#F"2C,@Q2%&56, ._?=ME15.D<1+B--.)Q-B$^YV3<<M5
M$G7\2C=GS_ZAL(^V@Q>WEA80!T"#MB-JL'?9S[#O?_TM/O12:A+8]%2:O:!M
M:%)P$UIB4H&=$B0,0EM<.LX=C^U6=S:^G'P\[=$8-H$:)^:A].+-S3%-\&72
M!,_V2YT3>B^X3;S?EG[I2I1IC$291!(2?<62Y(XXFPV^QR*J9F"?ATH*AU9K
MA()%8I#*.T=.T:TZ;L>9]YW,/-]A)RJB,D<:"C@B3%#9Q07-FFI65%CA:FR?
M(EM=)C=!IQUI7,H.(ZL(E)HY2?&./4VU1K TV.(-U5U\&KE+[6JC(&[D!V>!
M&P:;%-R!DYA'@*D!-KX1^93#%>*/'>&S=+@@%\Y#I[$VA6/)A;^5RVX[6? X
M&8_'#S=)R]UOY\O,2SD._YE0W++M9D6.C>AAHJSSN&.E#+LV>JGSQM-#?-$G
M,N*'P0DK\I50P<3;IYV?- @PW(&*@3A^T#U,:V1B\CR^'QP\W#HO\58+ES)W
MK\<[PL/5&1V-=4+Z[R)?\]ND,2[ [-):)C8B.3O1/%\&+(6]BT=:P$88/I*J
M]J@THAD)KQ""6H1":FE2R"C\,M&K)O9NA >$KG"JC*HZ*%T_.2J>;ID)L&O
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M@XZ'7I\&.5CN:J$EU95^)*9D[2D-4.?$RHB&V03/?)6O!0EB+AC#JD?8"6&
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M__7OYX/N8Z( VZAAPE<Y(6 L8#V?/'YRBDH3FRLJ),J>T$7]XO;TKITW>2:
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M*_P'Q@I(#[.N8,L5LD3#AALSK/96N<DPC2WX^SWH,&L%+&)N7/"<PUT#>B+
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M15#B'I5 [NS;\UL.\IS2]W,FDRXYIGS796T2>3ME68I^ "$_#@!L6:7766$
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M.U<X'^Y,?WW?62QUNQ(*S1X(;6Q[:H9:SKJN=S2QFW;^:"$[/BU/_( =4A7
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MAH36.:.O47_:.@-.<KOH.]C:T[+CDXW49$$#ZCDM8E]S)J3W\%'P_ _ \_^
M8\0\[YD) :A(DH1N4Z9MP)B!YT\#;JU3"H]U<!,:6!T:L.#3$@7+2I%P)3+Y
M.(MF+[VWLOJ9^Z:Y;GZX<NHVU\VKV]%JKQNNM::VCM7WR^;QF&<$M:DH&./5
M(QC#H7K=]KUU),;H^]<3>JG+Z57.>I6^NKK&\WZNV?<G^K8K!*CQ7U^! #<&
MQ6O>T<9_W27_U4)H;KS75=XK!GQ7!EQQ25_8FZW=KNRVCFJBIJ]O1ZN]=0AT
M[\%[IN8JUIDL8KPFJE6U8FB[2I=F\,CJ"/.WRR?GN'-2Y;$)L^81L\20<5+6
MZR\?%C+A8KGV3DM&3>HZE& <5,LB++ZY,H;V(KLD,P,=()]@NXK0CG1]*#+
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M=)-S"XX6HG*'>2.S^B:X8X0>N)#\FP@_D9N9XRUB[7.77XFE<7K95@7GO8>
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MY9>-]]HX$^LO'FR.^DZ@!AB^]D-LD!YC['JON_]?+97C2J.4VG)MRGEWG"Y
MXI:BBR)%\\ J!\9'V@7_:SNCF=; 7+A\I[R84W?>N#"-"[/3+@S(<.._[+;-
MV_@OKV<O:^"_Y)$;X?!BT_>-C7P78[+;<%FR-]!V7M@N+?8A,:RB9;T\9*B
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MN?D;R7:-RX)^F'+Z,6$K6HQA__Q\FZ#;?DD#ZX\?.H<,>Z>#JY[S8?!E>#I
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M)MMD^]9[Q/5GN-5\RK>I_P]02P,$%     @ Q:,$71=UKUK6!P  .RT  !<
M  !P8W)X+3 V,S R,#(V>&5X,S$R+FAT;>U:VVX;.1)]WZ_@*MB,#4BRKE8L
M.08RG@3KATUF[0!Y7%#-:C5A-ME#LJ5HOGZKR-;%EC219KQ>!4Z R.IFL5@D
M#T\=4KS,?*ZN+C/@XNIOEW]O--@O)BEST)XE%K@'P4HG]81]$>#N6:-165V;
M8F[E)/.LT^J<LR_&WLLIC^5>>@57"S^79_'Y\BPT<CDV8GYU*>242?&V)I,.
M=#OM\\[@O-WM);W.11__ONE?C).D=7'.S__3KF%5-(]UG)\K>%O+I6YD0.T/
M>YWFH%_XT4P*GPW;K=8_:L'TZC(UVF-[%NO'K]'-AC,/7WV#*SG1P]"E6JRZ
M*$Z,,G;XJA7^C:BDD?)<JOGPI\\R!\<^PHS=FISKG^H.K$RCC9._ X:#D87'
M68QV@"Z4U+"(OMVA>-]_S>18^M>OVN>M4;?=[#R,>'NL"0XNV/]EL+VMP<8H
MCR/"[<-Y_?[V\\V'F^MWGV\^?3R.0 \:RF>/XZ;.[C(^T^Q?379MC7,L >ME
M.F<^XPC+_ILC"/(;N"NX$$A4#06I'W;/T6688*D%3NZP@:L*6>+YI[C=7$3\
MK V/'@Q'IT==OV$9GP*S,)4P0V+WF73LMY);Q+Z:X_O"6,^,9A^,S>-HMUN-
M?S.3LE]Y(BUG/TMSETC0";AZ-+C129.=^ S8ZU=O.IW6Z!8FTGG+M0\OVJ-3
MA,_% =-6VTG<QS_9G>.9[)^YPRG&R<SG[%Z;F0(Q@7J<\VJFA<&VM<%,C_ZY
MU(SK.2NUMR5@Z)C[@PS V><LQR<KN6(I3_"592:7GGD3[38,-"!"'+=S,LGY
M/3!"R-*GPW<"@\$F5= 0V 89(,90,Z 9 0PC$6#9+)-)QEQ)'ZOZ,[!0.:$.
MY-(I%!>D4V;29]A!5T 2 B2_!89F!'9SBM4$&\_7A^$%P;/['< 36"HU H"P
MM)KP.F(3S;'8KI5+G2)3<2_1C]2)*@7Z1%"MS6X= 2F)W0K$!,&98*[4"J\5
M5-RCIG%)"$F.ZV11*C1 D!I$4FC.A7@2[C*6*C-S"P2OV(]Q>AGCQBCK:T!T
MBV VHGU!6.P=#Q8_/Y@X2EOMP<A5:*N$$%&+25.)CV%*;QBW$,"#8)!C!33)
M#!"Q8R5=1N9DEB.M$K72LY N4<:56(\(UQH54518DX# UXZ=(&@$( HC,MY_
M33*N)\#>(9?=E@I<E96[O-'NG\!I?"0G[;Z(KTZ#3TEZ5D<<4TN,J&\-WA%N
M%-5A3::;3:;8)/7],?S1@N3&=O'XA) >=(X%TOPX(-WL#ZCWN%_'K0W.:LB=
MWP9?G=)ZPDNW?Q7*KV-@RY9BQC:E10=(=5/I H&B%>C@AW83*^I=IV\+B@<\
M5BE[A:1Z1>U4*)&&,19GE!3A;,*58R>%Y%92!V04%B&A:/)4.DKV82&[H P"
MW1H'&)!'>J=*!>I?F92*4Y; ;H4@5J(!:T0)LJZ<\-L8R!")'.N#.("X":_?
M,\K'QX'R38COS7D;2-^?+?<&/"Z2J124(;@SFE."X [7 $E;?#GA5BR AM"7
M?"R5]'.2$=N:I647,!G@%E?, ],U:1SRT->J0T5I"X2["[(G28P5(8 @DB>@
M4<TH1#V60$'+B4QP Q"1C<M.%B$!O!AL)\>![8K!8<I5&6B.YA[2%'6JG.*L
MN2UZ<RE;]J#M^+A=@@8T8T6D7!>%[MB4?G<$^R06OK0&4O'IMS=E;+S8'X0%
M6HT$QA/ 2 V\#$"*XP!D(-LXT9N H5.#2C2&DJVH/(!B22.8)"DMP6(M(6_Q
MFAOGL2H=WZ(OEZ"CZCPKGDEMJ9(BOI'\'EE7@>.&#L*!!YV%Z'(9UVF,*N-N
MJ5Z(-L-Z !'R21B/BNOG3,E[4-7IQR/[^E\>HF=9 \>S4^P?SQKX<SO%<.JZ
M7#[U%;<1U:Y#>$5S!,(#],R&:%Z&QE$X>V/=4D*$%^@RSZ7W '^02,8&10J5
M"XGQ!2<G"'3D;4=Y ?^2?%^L3OBME!A^6(FE3L(AR>F/S=__23K0$1=I5(DX
MI-TX[?##P;VLTO]R$S8#?D_Y/&K$D-&#N@V'O(OCKH/@6.V7XOG(%D;D BLZ
M6!+B3NA6FABK(/Y0NM:CJ'"H*%R9Y[CI^QU"9ZI$M/5@\(4)AB/:G9$N2"WR
M31T1 8$B$5/AN+X"7SVF5:FG1DV!<JOFD^I7!UNQ*N2%,G/ TEEF(I7R!]!&
M*#Z)\&AN3/4^,#BZ'Y%]V&M6K8]QU8!M8!"*%PZ&BR\CS$:%XO.AU,%?J#3"
M%361NC$VWIM\2'<JII324"=5/0R=C<75=8N+B^:@-: ;%QX'R8M%P]5EC&:X
MC''FQ699K]GM]'>6MIKMG65_Z+7;[ UZ3^_V3?.BM;OJNMNS,!!Q,'"X7<'U
MVUJW]H@VAIWF.7(&:]-_8@KZ-EH#$ZVCQ\,?1_Y9 19NT_R"RS5D<K9<!M4H
M/'$'<RF$@N?OX+MR4J(*Z]7#9:8G[&2DA&/IYNM7/63$\,GN_OGNR\=PW>/V
MT]W=@R[OB> 6=;;V'6%ASS%Z<,ED=]\J:O6F(,\L'$FS163?)SX>7@'Z@8F#
M,7&TTQZ<#:7'AI(].GR=24C9AZ5&^A2WLS\0\6(1<?)K_#D P; !B]--7)P%
M07F@E'YTG[<P+ES &,:?!J>P<<-W1<5!L+965?@8^;CTNZOLDNT[KPM7G_'R
M\EFX-/U?4$L#!!0    ( ,6C!%TO_F,1YP0  /T?   7    <&-R>"TP-C,P
M,C R-GAE>#,R,2YH=&WM66USVC@0_GZ_0D?FVG0F.+8QD #)C MFPET.4DPN
MO4\WPI)C38SE2G(2[M>?7NPV*>%*>FV.3L(,'IO5[CZ[>B0]@WN)6*3'O01#
M=/Q3[^=Z'0QH5"QP)D#$,!08@8*3[!)<(,RO0+U>CNK3?,G(92* :[LM<$'9
M%;F&QBZ(2/%Q%:>W;YY[^SI);T[1\KB'R#4@Z*A&6A!&R'-QY,0MSVUX<[O5
M/F@=Q!%V/'GG_.74I*L<;GRX6*;XJ+8@63W!*G_'<ZUV,Q?=&X)$TG%L^Y>:
M'GK<BVDF9#XF_<VM";,23.!;48<IN<PZNJ2:<:W,$4TIZ^S8^M-5EGH,%R1=
M=E[/R )S,,8W8$H7,'N]QS$CL1G#R=]8PI'(]..-0=N6(5*2X0J]XRJ\P6U"
MYD2\VG%:=K?A6LY]Q ]CC61S,?N>8+T'P1J4VX'PX7;V@^EL-!SU_=EH,@[!
M9 AF)P'HGXR"(0C>!_WSV>B/0/XLAP13X(\'I6TX&OOC_L@_K6S;7.39^30\
M]\<S,)L YP"<6Z'5MT 8]%71P&DT[3W@A\ ?3,YFP0#<&;[-557X#^U6-6^A
M/WWKCX.P/GE_&OP)_/Y,65S;=K>CD*]?)21#$EW';>??=<]Y&.!9P7@!94I!
M/_''H%;7=M=0"'( $<W509#?\0AQ) C-]#S1&(@$@Q"R.<PPKT]N4[P$?B24
M1<W3GK87LEK&Y9S(4!%F@L1$%B(2* ,FA(-W!61RJM(EF.*<,NF=@2%E"X/)
ML>OO5+PS&!$&P5M"PXC@+,)\SPP899$%8LITK@\F%L R)P*_%ADN]U99D3JP
M]D!<I#)31!=YJF#<$)%H3X8_%(1A=7)QE:\LM 31V(5OS*U,Y#1W4?54M@!'
M!2-"!0QNHP1FE[CJ@W/8\ #,4%4P!B23:!=0MS&2TP6)Z@S)3#>8Z4$,B>I(
MSC!7B/:4':8ID'YRVF$JQ_%<0N2FQS')8!:IWV5$1'1LE52.*E)3$,TQTTGY
ME]M9(D4R&==QJO[*&(0B+M$@$BF58*TP?>WY^^55L('3]B_NSQ *.$]Q-6!.
MF5P+=8DTA3G'G>JFBPC/4[CLD$PGU4[=!6274N_,J1!TT5%:YUHMGPBF91*=
MSYA+&71X:+7MME)"0G92H"IQ*9(L+9+V!5JU>5;#;:ZUVI:SUO:O41N6U_:^
M?=@#Z]!>[WHW[+YNA&F&;#?/8794:]0JAQPB)&5NQ[5:;BZ H[Y6T]QU[\QG
MBN.5]IO./RD+M<H=R(7W:J=YT 4?F5AVX1L7N" (I?CI"_2+RX(+X)D]^QL6
M:5;EMI3Y:L=K=[F^@N'4'_\&!A8X#8)[!6_(7UN56ON!F+!AA^[MM^MK*S=6
M07,5&7":$@0J9#\F.X8,9E>:$1B_,.+1C-C:2=?!.D3(1-$&!?<3@F.I*J7"
M%.0:@TD<$ZFBM2H;2,$:"<I>Z/%LZ;%[QH@4_KE4_BL<>;/*BWVM+!\AKK].
MDC_>Z\EE<K/E?*5,;C2^ATQN>NO-_T$F'[CM%YG\(I.W?-/;6":')_[%&/QN
M@?YT$H9;>.[]7V1_SDHY3.!-IDG!*.<OI'B^:LB(Y>''/T-+(?1"B>=+B3L"
M>847FPCD303M9V^D<\KU/_ =AE.H!/G*.^I/F['6K/8G%SB7.W(AUKL\0G+?
MNYK7[_OZM?\_4$L#!!0    ( ,6C!%V2SM.U</P! %64&@ 1    <&-R>"TR
M,#(V,#8S,"YH=&WLO6MWXDBR+OQ]_PJ]S+Q[JM<2E*X@7-6<A6W<36^7[394
MS\SY,BN1$J,I(=&Z^#)K__B3F>)JP""04$K$OE1C)*3,B"<N&1D1^?7_O(X=
MX1G[@>VY/_]-KDE_$[!K>I;M/OW\MW;OJMO]V_]I_=?7_Z]:_<?EXZUP[9G1
M&+NA<.5C%&)+>+'#D1".L/!WS_]A/R/AP4'AT//'U6K\LRMO\N;;3Z-04"2E
M/KMM=M6_D.0FUA1-JQJRVJPVL-*H#M2A5C55%=5E:XB'345\NC#K:MW0)50U
ML"Q7M6&=W*;A8572Y:'<,"1)4BS1NC!5JS[0AKII&:J&\'"@-NN&BAK-@8Z-
MNB6Q]XY",F<R;S?XN3(*P\G%Y\\O+R^U%[7F^4^?Y6:S^?F5WE.);[JP7\-J
M@,V5F\G?M2?O^;/M.K:+*6T^ASYR SIU%!)B?E8D6:]*1E65%\]9><3KP'?8
M&\F=ZM*#EEZ[^?Z/WJE(54FIRLKL(:^!O6F2BB3)G__Q[;9GCO 856TW")%K
MXMFO++SX%7OM;+KD GU)?79C%%2?$)K,;QZB8,!>,+VP<G/@A^LWDB]7;C*]
MR W]M\VOGUY<^0&]P=Y&6(D2=G5N=N!IBMSXZ!?Q'<LOL-[18WIO_7-\<78K
M-JW- R<75@8],?U5,$R0:?NH9GIC=I]45Z79O839/SX8+;T\0,%\?J]K]Z\
MFUYEMUXXB,AX!;O5[[U*Z^L((ZOU=8Q#)-"?5O&?D?W\<^7*<T,B[]7^VX2\
MP8S_^KD2XM?P,Y.1SZW_^J__^AK:H8-;=%;5V?"_?HZ__/HY?O3 L]Y:7RW[
M60C"-P?_7+'L8.*@MPO7<S$9@/UZ06_$?OS1MBSLLH_D^AU1.KYMQN]_#1_Q
M\.>*626"Y:(Q?1*V+SHN>=W;%1F=CYRN:^'7_\%O%<$F#!E6%;W2(BI"IMI
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M,]0+NGO6.V$Z&4V6H]M4[1D4KB/\C?9\(+PP,M5'*EDDI.:N%73OJL2<7E$
M[WC]D0)X=^MQ"J"@FT5G!(MEEV0'+-)SFPNZJ7(NL-#WUQ9ZBMJB4=#-AZ+
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ML-7'YNC8]&[ZS@??LR(SO/=[V'^VS>5W_M_N[6.GWV]SI? :J7EJ7"YI4X9
M07FC<+>891QHFR.;V!OZD_OA?-VZQ**5&Y9,4]NU'O$3/1?4\]_F/]R5/[)S
M4!:V+V[Q$W(ZC$A+ [EQ\"NYI3_"/IK@*+3-H.N::>B+#P!*.SC_'MDNSM(,
MR(WT*G!5A;OTA_UPUG6)7S2-Q[8?1L0U4JX<V[5-Y/1]&SD K+R!Q5VNQ7[
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M02[@R9\)X_7T4MDAVLH'5XT51=V&*'IY^$KCX<(-,D//AZ26,^%YBAJZ&'&
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M'BM?:WP1.K]_[_;_F5)[6Y70P_(BNH&R$U79M#Y-ORMN=G,Z)]=WUDS7L='
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M]Y>8MD1FVBN4/51LZI564Q8-J6R%6("LO1W%C)#5J+0,0]2/;\D.R.(66;D
MBQYQ:>@;C[@$9)4%63M\QXR@18^X;.BBJG.U.796H<7VWEO($&P\V)E<)O+]
ML#NG;)L1-JG8:+3$4MMX,"PLYLN"J%T'6*:+*!D057I$G110"HM?U[6C#3L
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MT/DSLL.W39*D4&U>F"(F$"<0IU0,V"9Y6K->6]+[-PE60OM%*[.5!K%@ZYG
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MWN\ />(_(SNP0]S#_K-MXMC_>\2F]^2RIS!7,+'')Q./3Q.;.C0&*A(D06L
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M@V+8M'PY3"LPJ[F?4EB7>YG(/<A\@0 %,L\]BY(EM.U[\&06TJ]LDO[$N6V
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M6<1Z\'X3Z!'_&=F!'>(>]I]M$\?^WR,VO2>7/86Y@DD]/EFB/8-$K7ETRTZ
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MWSN;?!UF1J5EJ.MG3"7N'\T_O Z>0<FWN8Z8?BEVL79I]?T2N6D1T=%'M1W
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ML A85" 6G2H/(3UEK7&HK,\L.X$QL3J@$2 RW44(Z+S2"B V"BP"%@&+@$7
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M>I-[K!#W>+T4!#(DN<0(B#'W+#HRM^M0,58Y$N/T=YPY6-DV-G+[$CG(-;&
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M!L-A$QOV22]Q02EIF)FG'0*_<,K;PL<FS$8I4N%]KN' G@4*$PV:AT./]F?
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MV08Z/VXJDJ9&HNW  ;A\A5V[G+<9ACMO-I8N7T+8J=+M730?"IO8ND#W(+A
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M2^C"<ISYE348C8!S$(DR;8^-DWYG@RW&1F +,#]BV-C\)SQ.375!;83C=D3
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M/[:K@A;/2WG+RBKH8@!BQ;(A 4%%^\6R,=+%5J4/*:$\IGUDL2YE>P1B T2
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M*RZ;O?FE9ZN*EYYUI=?=V9$I^:RX?/;F]X.M*MX/5I4.PLD7A\_>=X[V\\8
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M\AM .<-!WD*Y<Q[AW+TQ;/%QG*;]GKG#,XK79M)U%2YCF21A54.[L4Z?;(H
M],:&MM8"Z8@\&29<F81CL;F#=*^-N>Z;'(N/X30@Z'[B"5>)N,(!9\2]A0CB
M9O39=V%1K@OB,S0LTC4)'ZI=K1]8!U6,K ):DH"F%4*0,EP!&05+GCHVYE91
M_W#5T<8D0SH',V1/D0\59COLZO;N_U,GTT\7RDK_ ;^:(GI*\#S$T>+:V(+-
M/\ZB)Z5)*SXJ7>CI5QH8 ALX0DSH0#3,L3%UHT>F?[4"BH7$F:18R2C!]=YJ
M&08/?&J[JDF:$328Z:/JH_9)Z?W*A)!M+7)DFJ W3OJMM7(NSQ2.,H7$U D'
MQ%)9MKF0U3WN<\V,XVJT_^9)W[(A@,9)J@LD8"K=!!#H63HCQ :W& CKI0+5
M.NU/ZQA$*':':R:(C#$RQ!,D,NN8FP+,'?9.;AGL]P_?$A1]-KPQH^P0VEC#
M@J_A:VY]$"G,< \>'4Y0;>*3_S8FL&BP11/;\8S_"/_&)D^/,. 71)=IF$'4
MV9#CTT.(6%4 TGF@,81%%1^F3<2VH"ZLO8)I$@9OYO%A-PIS.6?7ML=90]EC
M0FFI=4A78X)QB(^_Q3H\?PLV= \;>J/LUT'!["TS!^K2"&\9J!S[H&/GJR.E
M4((4'FMW;:-;J7:S=M'N'<^M7NDU\FKY+1?UZHMJ5>J=[CMKC@[@\]B&L&_'
MW"4-KI.+X;GCS-"@_UTU_4U ?(Z9)/&H/.X5O7.R)()C!9ZY2<W2,1,E0*@Y
ME1 U[(?+1[[)OB7&)N6.+W"093@7J;%AB2M0X@J\$FY^8\WLB17).C*5&4MF
MVM46ELQ4%=C]P=3FEA)82N#^*G%W$<&8:Q;WS#(+9?ND7Z]WE6HW63"_>2EN
M*8^E/!93'E]+','_SRQZ'1"]5DWIU0ZG5^40L9Q?*4K* \RYUJ@O\EQP+[J"
M]Q:P047<]<T8\51DYV>@J<NMB V[)_V>0')66$_BFRTM*]L@?@MRP_!UOOS,
MRT\M^U1)WK<D[W[;[5;5%N]+XP0:)"H8R/TBL;V^/!R6DM(1@)K]M%%)N2L:
MJBX7%= ?:A\7BH?+IL#\79\U;3-7ELY'RTW0Y8NL.(B*+C,Z0[V3?J.AM-J%
M H8IF6Q],R%5S)=G5. SRED1) *?G86_5CUVX=_F^^^[)SG9GYPHP*)BF4*U
M)F]^177$F:.\2',<2:6,ZI1N5G97J+63?JN6BT;-]VR+GO4MQ?H=BW6>*"K[
MO[FIU?._N2G%NQ3OHQ7O/5KM7(*@!LASMZ4T\QZP<+!"O=/W4Z.G>N<0\[S=
MC;*KE"A-ZU&FLE8M*&M]PK)6H,ADJCJBDR9H5Y:M!D'/LL-')M<\EQZ"G9@:
M]?9LV@P<[_;!)T3)9S7(1Z_H6JND9'Q3X&G*1H;W4YY?+JIL9%A>?9S 7'CG
MU=AE,T/9S% V,Y3-#*\46Y7-# 4*Y=]EZ6;S=9L9:H@SWBN;&4H)/&()S-C,
ML+T(YI42;V%%=5NIUY*HO&4S0RF/ARZ/KR6.6S0SU-I8PM-0.MW.>[*'93/#
MJF:&!$K5WIL9:IV3?JT:=#.T<NAF.*KQ*^>IP%SEL)4]:N'VKG%)4M5BPTZA
MAH^5/).S)[T]TRSUI)-LU#OIMVL%F;]3<E!1M [Y?@EFJ5<ALBJKLX_,/^OL
MW3]#1RQB(H1)KBXZ8\)9RR6GOOR0&L7UR>3L2J+XJ8DD?Z5*]XT49M;;BF-3
MI:^<5J[795IY=P=O^WNFMXJAWQL?9G(*WSRY6F_(Y&HG69^87W*UY,JWYLK7
M8<HM4HSUID@Q=FO+9I8<,1?F5@)[I)FM),A!F=7:8WS9?5NT@'H+5$%3J>]>
M*E_4D/0XF:Q$"RC^&>6L"/)OE*FWCUWX2[2 $BW@O91FE'V'&0*J_: %U#LG
M?8BNE$9*9/\^.P]+L2[%^LBR=]W\LW>E>)?B?;3BO4>KG4L0A'B)[:Y2R[O_
MX&"%>O=4Z7QO^6+-8+$G"<[-K.0O4VZYG-& Y<6IE9D'O]<:JT>/QE]],]I@
MBFJCFC'+L&;0>_8%8"%"LY)L$E@S"QU'6P+/CL6 S['#N2PP9=S"T9]I QLM
MG=J1%Z:*YGQ">=.GGO& UHRIS[X PD))F4V?Y8!<XV7SXUG FX"WR,&YJGAO
ML:7_UX7U2CJV>IW3.DUK]2?8!6[9$AO$70(.$HWP73+S5@R)'_F>[W#&70^.
M'-NIU26\31]>6=G":-#[,./@]C4::94['5OII5CH'9^H>'X.SB='5OP7%2TE
MF;()3-FL+.MOB/,@[MNAQR)58XP(E-UBRG6NV[V&YSX\<_.)?Z<UI>VTM0M:
MTH[K0^H_/-MIRVJ_];)0Y:<MK//&"_MB^ZD<"T%?LU=)1GQ;_&">R;FJC:EP
M3X#X $]W$.BG7D7-BDKU[?B;Z &?3:-'#ZM8*\O&K02; ]T(&ZDEK<#RV=)2
M&S?KE0["!26![D.4H+^=S'U1NMO5Z"OJ$)QKWUO^E42U:9[H".NAILC@W*J:
MX:B(VB0'MH-EN+*T"F/_9>SW^AXGE:]<5GR*[6N3A/WNJPZ<ACEC=WP*;(D&
M\ L$=:Q6/?V="%-K+[@9L3_Q@)%-#:VAMX?-44O3NXVFRD?#1J_=;:B=WK#%
MNVV]^G]ML$/R2V,G0MEXY*=#AZL_3]41K.),-9_5F8NQ3=QU ;]E@547N6PI
MX4:C?9R9<)] ^FV'9.S,1TLL!C_\JA9A&0R4/FBIOZP_&+ "#P0Z!E;^'!6<
MY;F__J+VTPX]Z4]*3="%U2:PS/8F1@GT$V+EZYN'2]:3E_6K:\B3%>0:S9^_
M56=(BH&EPT\<G^O?#'5HF*#BN'L!7I9IN^!"/L"3/INV]C-4T<VJ, Z@<[D^
M\.3/\#T<U/D4U1\\#7S:\_.['Y<7[/*?MY?7]Y?W2UO\B-KI[K%X\)HB^<4-
MWFMCKOLFOQDE-T:GG[*GQ.J7'W\]<?R%"##D7@/?WD4JN88;A K@])JF_8S.
M[@>*+&S?!2_ _7@6G,-!H/%U0"<VTG^5&82M5FG7>CDAP[5R7%1]]<OWCPQW
M7$!1F%-@X/2^<[RL./Q>EE:>DI\6"!GW8-\I+R70&]]3:5-@:%T.L:CUJ+!'
M;G%'-2FH5G5PX,'J.A13AL9X;V7O1WR!^=ZN*)< FD\UY^5,\MR]8+FO@N'0
M<Y]C-YE>R=S2UL0Y!6VEVGT_'6VE )8"N&&-P&L(8..D7^LHS=W[]U]' -]7
MVY(P]PYWN>IH8S+SN@!311C]I39^'X0Y6-G:P+C=20*#5%U$Y-U:I)HG_:Y2
M;Z95$.RIZZP\YXUT:,[GW#KIMY5:BN9\]P'*U+%U7QR99KM>+EC/1\NX&RBH
MVY">YT#.S(S:1F@5I=E+N^O=$VQ(>; ;::0=#[9STN\IU6H]9PUTP#[3C3?F
M#E.E'K*G'-UCZ[%TE7(8;$:T35YLG=.PI^S,VR4WJ9$LN"C=I+<K1\_YC'M@
M>>I*M[W&\KPG'^G<GJ JDC/1(*(;0D@_,DHG:1?5=#F9FO:,\SLQ5VYWSFU5
M*3'92T&L+GVFMU-/^9]S[:3?Z"C=9A+L-(N&"FH3X/M\^;'N\U/E O>\P*-R
MDX- W<"K7>YN!WWP7ERF-;;G2M)05K6%BBBI:^HG_4ZG6_J[!3(HFQ]> PZO
MFW>D?<!^K$Q=,(=[OF.YY,H^CVV3NT YA\%3GPR-LQ'/9]3;T3+H&NTBR?P/
MU7%4RYN1XE;-<U-U76-D<'U;OZ=)D5E['4>7_NVKJJ-]G78+3KNFM%IYQ^$'
M[ )M@!.5%2NLA(9X+=(<1]G'&M6?6QJNU3[I]QI*LY?7D(:#@(-8X2&7@EP*
M\BM:]?P$&2_\6DJ[FLQ6': @;X6K4NQ6J"N+@"2VZ>.O-7JK.YUC[',SNC#<
MJ0V1UE<XU>F5)0&#L'DNZ(^[$7>?MK48TT8MSZWN2;^Z%K/ 'H7WJ6&'ER/R
MK]C6;=@X[ 6^TFE_4F!/DZECN'CW.LIY_QFV3+=8<M\QLJ61H(<D6-?T#7NQ
MUUPL9V]L7[IA*A#(L%L9-*2IE\1^VU7<;S+H2^QWNE%X[RKLF3N(9Z&%,0HR
MA1FMA8VYJ1/P!7X3^^=A!W_XEB#0L^&-&368(#$-"[Z++8.WOJ.-59>SP:/#
M.14[TB?_;4Q ,U2P=9I-; <?)S0H/$N!17%V;7N<-90]-IG3P\X,B \,;9/N
M2 %E@O2+G1#[+:#*/5#EC3KB-P*VV;#OO!/VG2]%PWF;7F7!V;7J5AW+%WSH
MK>I(;M>2'<GM6K(C^>+R\\-67<CB82FOB%"8,O<FXZ:N+!=6AH+EINRJOD%/
M<I',[@.HC!"GZ$DU?1[T'N-MNVK-Z/ [GUQF^Y[K@2SB!W6@ S-<YOH3V!.\
M3F>J*[N5W66]RNMYO.QF7ONH0^IF/L8NRK(Q.9?&Y&.D2=EC7+ >XU6P.Z^>
M^[!\E)<D!F<U'LE<77])\Z,BER.X=+V#&/+>PT#RECO( NICA,P%'D[HCR#B
M8Z563X9I?T,L':(<V5QN&>!16Q "N$P')^"[.L-0O+?@Y^[:RG;LJ;X=]G\<
M^;P%ADYF]+[9UN,#=R;(UUF3> C15>_6E5H]YXD*&QW4X?4]E])V]-)6VZ.T
MM5#::DJMN_<.YWP3X^_D&OZ./]GF$X;CYP[7#8]]437,D<V6.J'E9+5:L[Y'
M@6F?]$%>JKO/#BCJ!+62@6K--:4'.S$07E(6CH'>4VEFGJ5-Y=2;5R;-<?AT
M^]0O79QNT\@_?BIV.5,YLJH4WF*4,^TDO#B:JE///QP[H!*F?5Z'9RQ.B&=/
M[T7V])JRIQ<^3\F<%OL6^,H*$KY-)7[Y2T5))J=9-&SJ&$^JQ]G45#516)*Y
M4*FY9N34?+(;XED^H-$Y*>4X'6PS[G8VF3JA/CXZ_)&6[AB69DP1]S,<R6-X
M+LN<M6_N-6O?J2W/VFNKLO;(=PJ#'^%?!#^*N2%T222Z%FWX 1/\AM.&J#@(
MC]N'3[ACU<'#=Z8(V,_9@^.[GL*N*X-*]-BKX+N*^#+L;,HUC\D"I.C5%?8P
M]V]9 Q:V3C(5_I^-C!=$:L/7P6D4[23JRT]BRAV:U:*PJ6B!@_.8&*IE^:II
MSHCQ' =^[^+$"A2O6BOO:J7V1D,T4N:FH/(Y;512ZB2&JLO%G AO_$;%5<2Q
MU_:3N&$NJ;8AU4!ZPOE!"=$#1P.E/>1$&M36JR0JJ;:MBEHRHZ'3.,!Z*(\F
MW5.-$]H_R09!752,J#A1L*Q[*NN>WD%E1UGW5-8]E75/9=W3@=0]=9I;1E!E
MW5-9B;&7NJ=Y?CZ7)?=!>B-;*K!#E1D=I97WE/JR#JJ4OJ)L/]<ZJ%REKWUX
MTO>>ZJ(N^(@[F.P<&99J:5@@M1I*_3BK6C[D;+X$4;\033EB;KO7/+OL=$[Z
M+:71:2<DYV-9''4,;+16#^?#1ET<(-&H)<$<WH:-C@^A\[AKN"BYJS"+TPV@
MOJ'!V.D^?>65^OMR4/,ET+%XL'OLF^GT]M0WD\])%CV@+ 6Z%.ABM>9TJWMJ
MS7E+@=ZE(JP0=\<#%[T)O"D39]"H*A+.:N'>>*QB/17LX"<X(%,'P7ZQE*K7
MZU%1R5^I!2!1K%1A5Q8]B3_)XBN1R78)P6=LFW ^+GNV?0&/\V@SU339R*>+
M_[#F9JK."+L$ZX)FP,%3%<Y170 UIPH,?-74=EV#D'=F^,*1[Q"8D^O9VD^Y
M<G4Z=8!1"7NEPGY,;;%(^!DWI@O+A)_^Z</S74$2EWN>&9:2+5ZN&[#Z(2P!
M%SCU'==7K;#(")8Y<>>^%%8E+9#)&V.5$3PJ^0:L=9*7 5R?KWL35!QR6K#A
M"&@FAP/QZ&,9J]Y:J]"JYC)3=WPJ\9OT*^L\I-O*2KAN;>-*N(BE!-0+0DJI
M[EAASW"J'*L9J.8O/"XXV8GA3]+)0?^DT\%2)U$L. 0/.BB6P"<3(U%5F1O4
MVL&G)K8E6>B#ZJ6#S4SQ*1\KAU1$>>O@59)D4,0](JD>^BY\TJ4B,/Q%^&\=
M> DQN700'6[.D-8:)W2=6.D3*9!N0H'$.)>NL6S+1%D&!4"?% 4I%,<8CN9/
M$+='X^X9^V!\9+I/@&%T8,!)EJXZ[$]?!1EPZ&RXB(#4D2>?EO@4%R! MD3L
MDVJN"8<)ATU+D>]P?6V<^/I'A1E"%$W5192TJ8WR)S#.0F4HF0(YY9XX!0&_
M@%E,CE]:*GZ>H^+:_@^(FQ3#=J8KQUB![\,8^!<5[(-X_(4ZBQ#QJI$@8K%@
M,B?,Y*+PQ%WV 42-=*BX=L1%NESSL;XL.ALT X:MKRR(W/-6SZ-UQ79=2]MV
MXZ3?2-EV;&?S)(CX)^2"V.^#TT^7C00S&O \^+N)@@<D?00U)A@79#_SI?3N
M9(NNI6]&Q+BWR-$/X/H\X@N3-]5=A)-/(=_? CK,J6.2#DO4^8'A-<&10OD/
MR+<)*IU4B%)U->N5#E:-)8L=PV*QO\T7[4D7L1I]11V"-^A[R[^2*-O(LT!C
MHV).T,XJZ$*5?3;L>\W@%@$P7EE:A;'_,O9[?8^HARN7%2^>>6V2L-^%#(&
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MX:(^2J;&4O/8!]_OQ-+=8F@(!?D$MS1*8^ENL2JJ8D/5\#A'-DN?DGK/#,R
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MHAJL"LX>3GALN.XK^A1BTN@\A!$"3"D*$5@,"T0P0>19X1_H ,&MPH,"$R*
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M!2XB[6^6J<W?OSIG@BQ[(0CV7* !WSF3YL$!KZXZ,#3'J(G^)/&:P9)_!K;
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MM^J=03I8/9.,687W[[XX+GRT&2XHM\>OR>.4JM+HH'Z*!X.'O_8CI!&$37[
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M;7M&+;<N=&5I:(6+IS\O."Y[PXNK!&D/Q*:[%F?G^5F=H_A9+?2STB'C+^@
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M)XE7T9L67B3>@Y46Q./I9>PWT\O8;Z:7<37K5R$!B\[ZQ$$G@B(UG*['P+T
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MD;"@(]P>T_+&+B="2.! 9\YMN-+]@8H8GP=F[W&*H*+/0,+9*[/YH^-;=$#
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MUV.Z0F*!MS8SG=I0J^O-3GW02X.$J.+7:O+G"7E!J]AS=3ZM6TF45L6<Y^4
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MM(HM>V%>6_7N=FW8++[Z0/RQ>&BV&&5RAR$&%J9-"C-'@YV>KMJ1.Q>("]+
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M6Q'5AVQ,A)?!MI";,/* A<\+KF;&2X/=QS%X,HB088UX;B@;^,V<0WQ@(]_
MU$'&0OLDT]7I1^A-K4>4O0JD4_XW9^0AZ]0AYC#IW90@"7G4$F$;?B<XF4U<
M$*D7Q_U!MXO<KN=+9'7B7^,9/I$IA,LI^B363B;2P^ V,<0&A(AH)QW7)+U
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MZ(>-%_)0J(EQO]T^7 N5K'7#@W$+I37+^YW+#L,MZMS;L/9 .'27MBF["3S
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M$.Y<MIY]CH=MI_6Z]"M=;;]^@60>H*<%.W:C&J9DUEL05=3Y%]VRK@#A);L
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M_7W.' ,?@WKE"0\-5<+/?D7+J](5C9W%FIMJ.)G!IRO'OY3[3ZA4,L^<Y5(
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MQ,O(ST\S<>?6M7B(;KM=R+FK,HO_2</XQ),]E1_Z"B^+O$*&;2,1[BLOBZ_
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MPR#G@_KLCXJ(!XB@[O<?CN^UIN3C<?X?%24/$6\U')X\&$I^4F5H3K7*#T9
M**9^:CV77O&UX[+&-=[ YZUY3)K0O_(J[\]'HP-5GJO!L@])X?Y)Q(2E=$%'
M/H!;IJ:C(Q1.NWJ=-]+3&LET6AAQNS46I2::(Q8^.VF5MQ8^G58;-<+1T=3Y
M>4INWR\B55Y>=OW>4/WF\;\"Q=;RH@Q;Q:AA'\ P.Z8%^]M1+-#.Y'SDY](6
MUSA09VZZ[B]7.L_>].S!H7TFA]G)>W.JU Q=,_011 ANR=I=9.U1[W ^_9JK
M:ZY^0EQ]T$#)+7FY1Z&-P8$=PC5#UPS]A!CZ9R&_BJQ=P;U4)/I1',-D][],
M'?BJ:NM$_W6HG1QM[TC5H:ULO[ NYL)RO+^R)*5:MI83"VL9PW[%\"U+-<]*
M(QA7Y'YO8&<JE#EY!UYK(C"U.8SPOD0LG1B>@$<=>)>%W[3\5"R:Q2Y6]S/=
MS@OK'1>APL8'Z3P6W"XL\7]8"WA\GE@B]& :?\]"P6="MV5;8-\-;'H$.P\[
M(2Z+&\U"^+9G_>TV=FB_T'VC4(@"F"'(D-0JRU%L[,>1L\[ 8)W![<[ANQKF
M\-F;?G/]=-YP7 -U!+*#L)=_9ZW?FUU-SNG<C[T&4&NZ JJ-+WT7B R)(:"J
MM5.!3U[-?7=N70G@"=SRV.-G.85G/:V?LGE47PU8#0^O>M1( X4(?3I)X?\A
MJ^&X(QT6/P;^. VM#V(29TZ\0IKO%VE>=VG&B[%8.#[5=]M(5Z"0342\3EI=
MD[0ZFRIP&YUHOHK8A?5R9N)L^L\H-2 !?!>,25-3HV.0T^C9F]%ZL95?<.$_
M_L/ZU4<B<&"_X 0 "0\"S'*"6#C>RHJNPN9-145IV?S0S6)<MFM[$L*0]A,D
MW58UAUY3R;RZN4\U)YX\>]-N;DI 5XR'Z['GJ-L_<]3MUK,WG>8F1*D<M0VT
MFRR%BQT8@Y5M(1WO+1FP/7GD^O3$E9_.:<>-#<Y)[$YEB#5.+!PW7L;'EUGL
MSN' MIP9T"\^8.^[89V]-TR5N?=%,HYA/<)9#@6:B=#%ZU0H_YL^1"LW$RMY
M-C=A#@S9+Q<.]B$(0!<QSV;<M*4#O!V!*J8DU9=L ?+179MIMW#(W6QB(*K\
MR#N;FE,SC-1&(MQ77A9? 14D(C0FVWGVAF7,2CAQHB8MA_H&-S+)'-AO(!S'
M^BY6EE@L@V@%#\RCP$-=-]]C)!Z0.C$W)\ EVE=&%W?]],N'PRP-2O'_AOF=
MA:)28+>[</ZO"YU?[&.;P,555#V!'I@H%1,@0CRV.2"Y5<\"#*T*?,8O1<G9
M!,O!3_!2%J!, J([[ GVU5DA 7^(XFW]-,Z4$!WCV&@!*B4*:,&MYB8@P<\[
MU X_$2P1L^V<,^4@'E$^7DE@X^$PPCEZ G8Q6BJ!L?]I@X+M)G94\?B]P7+W
M[GJY1[C<FZKVW8)N^G<]D9-=Z.8FV]HOR892RVKXGK0-'3;HC.[A8)G-_)"\
M+1JLZB,=IJ\Z'31<[M3#1780ND06PDFPFSB0?")F1/T.-8^W2.@MHQA9(PI-
M79]JB@Y?)T7VF3B!$[K"2N9"X$O@#,<R$/RVIG6>38#!8'&< )TFH,-(Y:W\
M4OEY],]DB73)9$L<"%@PB25+;B,O>R* ;2#CQ0_#Z)*ZC8->"89'M/0CGY0B
M&GGL+(%62.F-G3!!586^C<^3YK"$9U&+(-42_EYG:**0=\(5>(A9W7:%#:2G
M$$38)A[>[:G9D%J<V^=!Y#KR,,'G_VB>-ZW-_L9-!^>@TL*D8U,>@&?33S"4
M3SB2,0VD\B#LM#88D#<ZSH>'&A4HQJ-UI$'I>'Y!HM5FA3$ 18%JCJ1D GP4
MH)&":;K_RHX.-8<.UBTXU,J>'&I4H'^N>Y]^>4&C8GK\_0;TV&L=:GR]RO'=
M:-%Z[4,-"K3%=2OMEQ=-"PXN8&0V?\A6JQ:65*M9R@.DX2E0*E#MER@5%J@+
MZB@Y_!E +WOE@S#VW1U.A0\T3EZ)GS>H:X>PS[DJ'^QUFD/T_BTC]DR\(D<'
M[.GK*]]+YRI(:SPH R.M_!%G J=9EFY^Q(A\(.$ N1UN:4YV=%Y^=5P_=M#E
M<@Z6#ARX0$RGH=NTK/_/LO[1^8ET=.VP\(@\]*=W71+K'YD#:DH,!^LWTEB0
M!3_@&=]N-?Y!"X,EU@HD9?PW;C!RN>]VO<&D-^V[WJC;<\1TTCT9C+K.\&32
M%Z.!U_J_;?1?R*?FL9KBTIF)QB06SO>&,X5AO'*"*V>58 #,U/] ^2O1:IG,
M-J[<=/HS-HUU4 ]]=<16KS)01V.\"X;C',,P+%#-08S_/]MW!BS%"PPSHNZ&
M5@3J<O_QTGE3M>L'C3FL37%8'7( RY+UR4[S/D1]]:@^C[^,/[[__/[+Q=&<
M/O*X/)HE.K?>G9Z__>/\_/3LBS7^\@[^,_[TW^>GY];9!^O#Z9?QE[>GXT_6
MV[,O[TXOU#W?WI__\>F";CG[^O[;&'\XWQ#X>O,?D_CEF[4?2V:C/*QH&G=D
M.NZY<9^=T.$^L5KCP5!IQM8:JF[CT E6B4_VU0<_!&,1;$'D5H]C"7C/-W*S
MT2UY*BV:HAR/SY:H7V7Q)A?.5+]6.W-T='/N7 IK(D0(=AA&[]G\<EP,59#A
M2@&.F0CALV2BNJY8IA30<M&-CV8F6'#P^B78&=IT _T3[CG'S]&PQ^3*=JSG
M'\?CKZQ25WR&8HM9( ,NL9AE@9RKM(J+[ST7;A:3OX/N?__#I5:\J&-*>]BV
M0 L]?_]V/;Y:4%Z.B6S:??)!P.9>?W[CC%T1IVC+<S0).V^!XN_*)5LX'NSL
MRLK((T'W@39^Y<1>(XBB[]2,2Y.#<A*F[/Q0O;O.!=L3G?9[M07&HNL%'[OD
M'6R?='LV(3\6["EZC@\@X7=:K\V;Z5+[-5NI]-:OL7\)8S'?GG>%@_F3;T)_
MYJ1O8XR#H0<VC3W*4BOP%[#"*>V[,;4\N/>*(W7L-D,S ]23 #:*+P,Q Q6S
MUX93C#3=&0@#O.1C1,DYM#0>Y(K=7N12H=T3>JG90YQ=&88$$H.5&3AXA[W[
M.%*J21Z',WC]NK!#L-3_XR] =+ R3]S,%ZSGH(IED\3W?,0KZ!O1 EB(U/HM
M"I VI!7P@CPA61A$[G?ZP#0+ FL9H4*$8E%OJ1K$_^[_Z+;^MTU"=19'5RE[
MS2<R[ (+A3"GV8KOF&9,&%F*C,7.+[A#A#/YG)A.80M<&B<^X(,J%@3 6QE\
M?!FC5QUF"_]();]QZ!*'9X$$6"2%[\@!Y</'N^5ON:C'BWE\.98G"/$;C,R3
MKUP&3HC_G/S%KB/X-T94W50*D>?Y"V'M2<Y<^8E0$IQ&$.$;-#OFKV69+MU2
M'%K'^.R2'=OY6GAB CR'ZVH7F!#6P\O@291]4SC,(EX6>=6,8,"U6>S@,LF-
M\5WTI?H.&X*;1_,E"AMGY!1-0 3!&^%E8\_S>1>D//S"0NBY%&1?SKZ.3[\H
M$49""<>%+C66PX;H(80)^FP17@(R/8WP% PL[(>8L(\D15&_S&)@8F'36_*(
M"P-4$@:G%",QI9=9"4C   47'?T8), S>K/$;UI_HBB##41_,LV3XM)*7.<;
M8<NIJE\F(#]@I<J772=<NX1#*E]$.;JH>"V37?DJD=C:.Q;.JGP)]WCM6AS]
M5?%.7JKR5000K%W#&]4UCH6 &'2H?C-04D(L J0T%\$2C&5DANGJFE.6%AT6
MBO8SH0C#*LIXFY$7U-H@(\#/BR4S(8D0DRL)[ "S ]4-OZY5.-"F8KBKB42)
MHD5Q/:P7'&%3]*WAZV..-DSCB/S]"1;@\WSVO8/"D&2@%UZC*A"TDU^-E'CI
MQ'X$2H:_0$9%F (29!07A$+L)]_E24RHJ@AFN(A06B#+)*_D#65@C0&J0>;&
M@6$(!>4(W,\+I\$W2/%*0K-*^!+X2X4:<,EPW2>"Y-8LYNAF!OILDN!YL++Y
M??05=0LR/JX>/+7 2H6XBKX+,X>;X2AL(+-E"Q)[J( E*:PKO"64^X5!HC@?
MIKY8UB\H_B)]MWJDD0NZT.L-*V-H),EK(IYBGU6BUFRYA/& WN6#1C0+HHD\
M%PIJ-)VJ&&L!T0_3B1:,CF'S TZ ?!-3V.GIE/9URHHYZ^F$-J E0UB>A2N;
M2-T.!Z;VI'Q(D+S-< #Y(:,_; .?)$"&072EK %M ^51:%87Y":J$R5QE 51
M7!(XA8% R491H3.Y_*@YBQ@'X/_;40BN]__U=?SM_:<CU_(:77K?0]'RK.>3
M; FJONL@-#SP85*8$^Z'**C)595D"2*Z8**L9/S/Z:=O[R\NQO4^''8?4C@%
M%JX?PM=#%* BC4(XPCA,",8;HE2%DVS:&^8\9'6))T'\&;=[CK]CI)O\!&3:
MY[Q4V%#)NVA^X66IU2KLHE9N^7V,-ZEZC18SAEF'N$W4:4"E4L^_-O12N ,D
ML3(]4?W9,$2*GWHLD& H\I349W)$0@1C;3X=V?*%<##D$EA+)DX<8$O4A0TA
MU0TW(2C,S=8?MW.UDN4::Y=*_P4UPB/_3E*PA2=@!^/A0;8P&;VV]?7MM_]J
M=%IMZSD<.W":QP[Z<^"I?SN@LX 6X3*KR?M:G=<EJ6C.8_-6:CN[<OX4S?\0
M18S+?!=G,]"TX4:?5';EJ_GP;FSSN47*!GP:J9_OAHMJ^>G>Y,N[L5SV)2+2
MB>Y@[OY4WF;UVZWGWU\DNPSO?89F&'#E9P&;C.>5-4;8W(H^]?XS#.LS?0&?
M'6= 6[$Z*]8&]GD\7J.W2R?(4.M5=@L/&X&=PB2Q]=VULA3H^M_:LH)AQKY(
MT>J= T,W7&?IN$CWO)=^#*J8,E5^>SOVM*$"VPQ:&0XI16^*M+27J$8ZP;4G
MH?PN#HQ.3R;$O^!43:2I= \A419C1R-0GX/B+'Q:&-@ M)5QT9PX#4&]!6E9
M9OFB$D(*(W""5"1SZ8<[*+.NUDCCM?3YEG>,-1]%JT@?"ACZ>DU0&NHOI74%
M(D4+98GSMJ3])/DGRE*JWR)E6:#=<XJ]7'*AY*X;_):' 7U*&W%^2%7\==&V
M*>FUK@:[:4.69R7=!J7'"0N%XE.93MH38JJ/9=U9H%.%$UC(&^3XL84,*DKH
MJ]=:IIM^B6D6>G*C3#V>5,^Y0T!_#;V7GHE-^3U;PAQ'YYS6 +EKS$,^C!2,
M:ZL?&Q8+D:DA6\"7OJ -4QLQ];$(J(7DSI>VO:]IG9;M4(O\$$ 0=-(C Q2M
M8^"#C<9Q5#".$=("/.*SG;QY#>31G; M>662C[(Q)XGX5X:S)J=34@;E2H,U
M'S,O# R5O>A-=+Z#@H4?B84R?E<HS_$L0F4M<*YL_#8%CE/G.SJA<I<=B:A)
MH#SLZ!Y=\BJ38>9CVDAX_1ROYH+D7<D?$ +)&< ?6S&DG*CI1K2E90='%VR3
M=&&A]A)C"JE$#%WOB=#DHPY(DX)P!C0I8[VEYR^G*$UDV^B+(]5$9(^$G66L
M"3U US+T912 /OT]C*[X=,E"_C>Y)FSX4P:B="B.-03%?T3RZ$79Q(*V%2#I
M\YXQB!GT+K#RB8K(AL!'YNAWE([5+3PK'71K/,ON+M,C)Z<OARJ%%R4M)]:"
M>04>A>D(/]3' 7PT19+U.)8KDXT(O8;@(Y)]7X&*F&1.&SG0H3UN*N_B-W1A
M?> /*R>C*3QQG;;H-[? GNQG]-XA*.90 Y,PF7F:+I-7+U]>75TU$^$V9]'E
M2__'_^M%[G^^',,IC7ZTE\*;.?%+D G.RS:":-J]ES")]J SZHQ:G4&KW>F<
M#%\B/+*!^.9VI]MNSM/%LS?C,$0Z7C^(?M=(>LSIDLCY-:"T"<:Y=T%0"-?B
MZ*S"[)0A\5H1MW5Z"J<M4+;5'N]VV+]6@7^6#PRD1PQH8&925L;K'Q<LY(\0
M0=DJ[0;'J$[QQ#P=M4 A@2=WAJ&..E1A[)G46JM^^B9F9&B':]$0D#+E2UEB
MQCQ4+$3D,FK7<S+'\U;@,Z5L1) F446:Y!%=.$<V0S9J;&N-;=T!V]H[#+:U
M7V-;'P.VM?J(&/W<!+-J\.39)985$%?W;2?L('0T:%'GE['JS2EF!\PO^U,0
M3&(:N>31P>>O(OD.D:6(YP!V([O.$U,_U-I\P2DO06QD8)!CDXL5*2]V$4BR
M]C /@7RR: $9+]/.NP+HQ%]2;*=IG87TJ(.KL\3R%!G0&-Y."R&;F>AO)AAE
M]?!>4 R#%<=-+Y55GJ0B M$V1Q <>Y//QC:_:*&QI$WMA4?<* R04NO0<L(0
M@+$3\$0P$PDLWY3<BAO&EK^/G<V"WYJ%/MC,UO+S/S]9'KK@Y;[#P@MWCI&C
MV8J-.SB5G&6":$UX%&]--"C/"5*A*JGX8*Y%@7 SQ%" .I*YY!E@VXFB3:03
M+;AB@P/?2\BQL:3""F2@ WF#TIDG"-KF4I";$NMY*%]I[KK!^6-^8:#7Q+$N
MX3]^"-JGC$ @V2F2M&"I.?>5:C*P51MX."R&IK*_OOPRM HQ2PHH8A*CQ8HK
M'8@?66*%%)2:( ;-MA+T1\*V&!<5W&@9@;6:"@3V1$GBL"O)P^D@Q  _F-_O
M>&@^TX)P *.P')H'R$-3'@^_!-XY%0L0Q$%A+&2\ $FG"F^$M-.0@7>XBZA'
M#T#[NQS0Y07"D*I?DD0+FG75R\AX3Q9@R#=08BR$YV<+$ED8IY%$>X45W9+\
MPXR"G?N!!VKRQBTC\>+!\C22N;_4*^3Y")8)R!$.]ED#)$^L(-7D(".OU#)P
M7,ZWO9H#[2*X("8OEOEX!GN@@X:2)]<"J7#<P>21PV/B3;4[.%MB;6!UZWLH
M>$%@T(2 L1!<$:@P+#G4])=</!) -Z6(5YA2(1L@%)&_15JA&)N5.=RP#3$B
MN*;%$3LFGA!9-N2]07S1R@F N$(4PJ[OD5#Z;4RPNA2F!J8+ LGA+]B]?)BY
MIZ]*SFFRR/7\B@-.B,ZPT_LY!]Q]J<W5,6R0@AC-TU$8"G[&JSSLYB0;A;QQ
MTA+<, C$)48[%!GQN>8$"0:S+Q%H@](8CM>O%*+HY,>;PE'2L=]YO4/<&#C?
MPG\%-DM7S!"045U"(-(#/,!57EO E E \](-BT1K%P/1^/K"@MCF*E!Q'9DB
MH%Y2>?@!ZVO,R9:#4,]9'B? NIY:%Y91NT9AF4_>CH%A2J%7E7LA0E1@$W4N
M%:+A.!]</!27"QV2QL692P1<SJ\YMGEMN>&@G6$4"N//N.">G_ QZTRG@A=1
M5GY@A4S X2-ND"UQ')[O:QGO3X6_HRA*Q,4*\=]^B% ZBZA ZXJQ2&"CI>?%
M1(N0@E0&B970$,QF0F6P1/%*N;612S<A6124 6B-0 F&XME(L !>!3I <FH.
MK-/T6P)TR"D0E#2<LT^]$#U>!\OYY&V@L'&^1!C=44+)+L$M<[60A5$<9;-Y
M#IHWE.?7&I^(MCM75I,^]<W$9]0*.3F26B&@=_T]"U:RMLV5T#%T;W/:".<8
MH&2#;?#FJ"ZY\2K*-4E8)]^5@4*I<2.Z%J4 (4@*YP JVXUIK(Y[96QD"2=F
M"9<<B:JA(HS+BV3%05@>W+$%J6$X0BH6D:+ P/&3-DAY$\44C'WR+C00A6]2
M'F0&OB^X\[<1*$R$X,3_[A$E_H]EX16@5Z/$EO4;[AMR\CD(UGM2)6AW]LS[
MRR-,'-+:E=WNWDWRD?'*[Q4F6:=$$G&9 .0+QB5;.\8%4'@<H2QY1_:$C)"P
M<8%2& $XI SP<E1!M"D!0%F/3I+:$@*T,H\YK"PY<[@\#$9$,6FDB,ZN0&%O
M1EYCZ2+$R=.+.,- Q4X)Z4X#)Y4B1H3I3%OQ]!X-(.=D*4P=R$MG2I@Y16ZQ
MD"'I*VIZ,=7C)/&U6$2>A%ZJS(!IAIHH:U><?6*F&6#8@F23!"O .U%Y$XS<
MYX,Y=JYT2!F3H?Z5^>SNR</:LPAG00>8K _Z6D:VM?. ?&08^F"3W14!*W&L
M8X,]B;!]FGLL$+7AH8S/-Z:,D.?CLGK_""SIBS@IS-N8HGI,[Q6L\BR.$MPT
M9(*$3Q08+.JZC93(66KJ0!$Y6 Q'3NX:^*;4#E*58T# 7[EJ6T7*<?/AGW,?
MS&TXRXFM$(V":F/L<V#?T?-4F\"H TFSN/%T2%-H#TO_A@A]<.-(,ZX(P3R(
M0B(J+J0,JM$J=/ WUHHH&8_24\&LDW5,E;(/:ZT'H*! 9P8;JVR5,DFQPQ3V
M.<K3<<JX."EBBL-U#;&;JYEDS'/A25*659XVYQ=BYC%8&LL,-%1R3B$0TB>W
MG[T!Q!T+0P$E#S#,?XH&T9R5%M1_D558EW%*&8#KV1Y1/'-"I:D7T])_A]^]
M:"$37WYOYM!MTM*!C^<.*"4N.9X)]PT:N><SZ@F>&7\]M4E8 "'/#1,=YL!&
M@V<4-5-95CG"&$8AT<[OFW]P4NLYK/^_11S .-"=;(WA^<#JF,7GOP)'4XJ9
MSH5'0+6?)!E1)3)GX,A:2Q1/R9.WNQWUS 5MS7NT!<B=KS.J!_ MEL)YG@\*
M"I5A7EJ1' V\D+7P)*R*!D79Z^0^*T *] R0=L_P9XU-)M@:VUJ<]HI+6/U)
MVR1;V D3<*2'!4N1)/X403^\%K_!NR(NA\G:@G7N F%EP.G/?[LX?\$#=R,/
MS7%T7E ,8AR&XH=U2B A:WWXO&*" (9 DZL&YI:B+\[,E%(<T^[_4KFP:RN9
M$PQ1Q]\=V"S;.H\RH+7?06=V;)-<I&(*AA<L&XS;#_FP<*QV2WT0OW?-=ZBN
M&:?;&4X%\B0J;&#K%]N42X["]-&J4489OF-MQWQR->G2Q$WKZY;-+8VN7-\
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M@W6OA%%LQ3AQ#*,=SL(L2>.5+87M#,YR=(M0X#591MBM8K):/XLB]F*8W^$
M%)61D=B'TCWD056'$QY6%.73!U(.S%])&$'1*"PH!?=>(VM;]"8_I)4:1W45
M3%V.3':G[/)8\WCHH*CQ2D[05 =P8=L([2I?A?FU5(2;8G>X:__"UAQ8]Z-0
MX4'>3FJU,@LH/ICRZV@S/5;W.),:3'U6Q\(9^>XC]#23<@S_<E>FWX (%4/&
M3L*%/PP0@'49X0%+3AN@#5)_I%9*8 F@S6B1J)?&PJ7Y<Q$MT+IEE@RKK:2I
MQ)QCG&0>$( E,+$X=%0*$;J0"W5IQ \A<_/@D;D_Y8Q17X=PZ4%.;&5]%2G2
MX=0/,!@HST,Z&,F,-&:S $4LP7Y-Q4H<N(*@V@C725)VY''%'R[>Q"X-4]=5
M4;9+S'9'* 1M9.[\G&4^E:0#:X772*T%5\N1.&WIF]$.40K@YGWTB#11_]>\
MR"Y&GC-A-'2$C8T 2=/$W\:DV6#(V=CL5&1("K6M1FC3+CB-I&FO'$ PIP E
M"PL>RB[7KEW3$XP+&2I-EJ. 4;G2W$' ^C]9J%2'&+X1]5N_(?("+R>[#U:U
M@FQ@\])7W4')$FJTN_<C)\FE,OB)A2:NTS,*:X*/R AI*/((*>GGRH!VK'/L
M*\F%,#'09GU5F;-CW="()),,,U+>%\>BC6 JF39L]_^MW6LU6PK48-I5L!#9
M<@H2-+6,$F1_&QJW%UVMFW.1M9?!"<WD_>*[I*WHS& B,_()PV=)UE"]3G8W
MZI0V5@_(W2_SO>$]R&T(^U ?\W10G6(AC(H4G(U<RBWJM@N^MXN\P% >A;U@
MCZ"N/.0&D<2^45!;)BD-<!%U'S,Z,:B' R58TPIVFX-2DS72TJ50(AA3G@^-
MH6U#4C:MCY&$\F#^(9&(](<$@3.)J,*(20&X2SF*"6,4)B$D&/_BDU:!=MBS
M%1K5.A@:DR5< 9*FD[?,HGTW^IM2MCEE1.I<>17EEZ3@$!Q4 7<HVIIY*^7+
M5WFG)A9$%EU@-00UMA)3Y M'P&G60?-F=)6<P<'_4*@B4C*9"O<41M_<-3A:
M*=KN1=V3=>:DNF20J437,$+&6"!>O-! I5L3/RIY&EW5SQ+58?08R,* ^"XL
M^JA+.TIV@V,\!R\0%%ZI% CSM;'N / T1RDH3I3Z2;&,!F&L9/"/H1WRR,8J
MM0R#0]V_ .-DM Y)+:Y0@JK$SO4K\7VR,@'K2CFH.5=]8C63M88]QTX;-7CD
MP8!':GWI=OK2Q1Q>GUA_^K,9E3"%?XM J&@N]>2>$\1=J_&3"$Y1;HH<$^H4
M3MC/B("7KYB@TU?*O+F_8$:BBH6]EL3-P\,!EV1 M'P>_+8P+HRR*'<^FT:#
M&\5+/JX+(A0,0C<C89SGKYC5IJ4X#?RIP*P(SG;-?2@.)N8$ 173,(Q<8U0X
M5I24FV2]B44TSG"SM&1QB="JI@IBE-* *MK4F$6$9AOJ(5/@8%SP:S[+UG_^
M3?'#3_/!%#K&QD;I6N.PDZD5"W3&AQ$>-0CJ:4PQ#X(2RN,%)@.SIQE6M--J
MM^@))!7\V*;A<^*$XV-]!0OKN =TNSDFH+#W@0^"*^"X")!DJ[A2^!$0&KD7
M!32;R ^->/!7 A33U]Z:6A65:$]3V6+N2\0^!00T?L2#+"2 *OYT#G3@Y#"4
M_#D9MZB@]UHH_12A9,)<L81M1G@8TI 85_&;<()T[CJQD*AD<E\BGA2(=TX_
M AEA0#(NM'AC!1UUXA]4P@D^U,O-**HJ!1^BI$'YXC"Z4FH,LNK2(;$#)])B
MDL4)BY@"RIH%5Y2E4A."A]*4L6"Y@3B/$JY[9=SGX<M3(P +7Y!:/"808"X<
M1YR4OTI6T5'0?C4"TLCR$6+%PA0-2@7,T-D($V#L@+,40/^=^6@OEI<7U$FT
M] C(9E2_*1JC22J6Y!PNJY(P%#-7<RT5PA#3T5**QS_9G, \(4_59UT;U5\1
M0ID<JN2(WT,<!14$4G81V+^B6!9X+-(0I-=;D.SP_RZ^G;Z%U:*%_BW#<13D
M?XC]D-$QK[/O9'D])$'ET-M.#9P^B%T8[1+5M?L;R*Y KDA\[&?6Z[G]HZ6M
MH@, OCAW@BF9D($&")*L3;+\V[Q\5S Y26(BY*"^UNII-#-,JD'!GH_*F:*!
MPHD>*LUN?7<M+X]5L]VN*%NE<.+485;H_L533RN&$R>._6LA^[5\/8A\56#$
M0KF^W/(5WBXE/FT9G:*4A)GBR=VRMLI)6N2E0&Z0OBHTALFUM3&?A&"O2<(%
MR+QB U,93BMY4<KPOK5"AU(L46:RRHS1H";,4ZD> ?*O<^GX-&!;I7WG.DSB
MQD*$[/$A?!$C)ZCBS:]*[5"I<^/SM^^_O&./3]-Z'V*2A6JJ3$_0PLF[4%72
MU9U,KRA)5TS[#:DPF6,4"I=AI=#3@2A4TF_H<J\Q&34F8P=,QF S)F.?RBFC
MNG+*8T!RW'E4KE1X_RAK+&[+"JPL3V&B#!]\70I[I\(4YZ"#RBBV;H*D\RH(
MNF ZT#74U_A\7=UBE^H6114F#Y 58U-Y(KMA'"-Q46IIC&-79,:P^?QS:*3,
M*C+#C\#)KB;R5I4Q^%5693X$+F%T)!!G(R"FYHLQ(; JL3Z)V<C ;+ A\<-
M."@&0,O#N**@C<X6RT0UTR%WHI/',Q= ??XB\B@-8 8S"*6<RDLO7.<W:%J_
MZB(JA>I)H-IJ%GYU4S?=H%LV(SO#IVU$=J09K5UBM%&XV>2&H=.%L%KEP^%U
MO0>'W@.?,TX<;]5((RPI9!8IJ=?[X.O-[DVLI99@MAU'7!RRI*G\"?9, U'T
M#7$\>0R?;%>9VP2;A<G#NMC8)?RV$/56'7RK\+RBS%3#T[23^DN0ZTH!1O<:
M2EG!7_RS"[!1HEU-)H<FDZGC8JR/(,*Y?BU#. ZU&Q3<8$3K'XF?7E<P>'TK
MCE2CH\/CN^ B8%$H[8I=U2ZEJ\F(B(09LS-4LAH'?1)#06.,F*&@Y46NR,?)
MP+XNEQ,BIV<OOQ_=GE3R/V>Z_!6Q2&'+EC+X(.-_LHE,HA[-+;JJ.G:)'#"H
MMIC^?469^?Z"])QM.NBN1<([QT,.ZS[^O)P0.9/;K)[GYAHC#1'Z5[ 2J79J
M9,D:XU0DL&3'6>IS^1=$[KS6_FZ=.+[UD_@%66&P\&4<BOEE69F(8IX.ID!P
M9C^'.1S5[2KOH&"U[\;FO-8C5>Y!^/!<4F:I1VYY$B>RIDE(>,-BK4I;5IUL
M)/,H+1>N/!WG51[+42*C?*7^I  *BU8)%RE09?/L]?J8"Q]E_)(R6XP"LT"A
M$]FKJ;IE(67J4ODT+@H3EL)9=EX\:T,M3CM/?X=G46GTW88;-6;!RL4<D+SN
MY==/'^%#"V2%'[(FRJ79-9'%D"JPB7?+XIKHJ@K7YZPKZEZ*N>\&DA%\;#V2
M.I.(60&3.IQX@HDS?O0#/\<(GY2;[_AI7CV7@F%2CX%] BJ3.!K?R-_EKCW*
M?6;&SU1FN)2I$J[*2'&]G\8^@1P/HBN9URX33Z(L(0'.$T224ZGR1!S&HIF
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M[E;6\]./9]]>/#S/< F2BE5C(D9IXRFHO*J(*G>"QE44!YZRW;#+*A7Z)A?
MSBM%!Q<NEK)VV&W!ITU#]672WYA1E@[;R'FFMLX\1E80W/;'-3-V*,$KI1*)
MG"PK?=7*PDSTT6CK2L<-[GI _N.&*G^A!L8M)#F?@B=D8J6NYA%[.772.J;^
MYDHM:F"DCTG+KU"&C30]^I7Z,478X"3E=;KX?<P%0!T+5?Y%MJ JFB/I 6U:
M8]4[:2H<5?T=%Y>5%-17#+59I: ;R1MY>Q3I6+/9L>XZ2PF5IKS2).*WY<K
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M68]/"I9#E*6-  -128'X;EAV=$UB'8.(TO6TCET<?<' -U>W[_1+K<4=[$<
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MC.G^TTZV5D3(,10\HV5A1KZ:T5I)6K"M>(Z%FKF(SZ)29%C+!8Z^)(U"W=6
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M-+D$,T[%@7<-)3P"X3EY_[V%[X%HZ[6N":;6BG*M*.^@*+<W*\K[Y/_VGAU
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M+^[8[71YJ43ZTA?Z14CO(S""@&T(FR< 2;Q%#4 K[Y-(7"<A""=X"_U[((F
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M"ZW 9S-/:5D-FKD*@C9]*4U')HT[ R"=XM-&R1"!H64C%=CP&$=,(@'Q[<^
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M9&=V7MXKI6>\+*TOK3@<<)\/X9@W\9@_HR<6;XFR)H$8D!"-(K&)L4^I SB
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MYNO;L:DJW\#[$5LVRZ/&OYR-7#Z$-]3E^!5=CH=I2:3X>P9@(O]NT@Y.*"R
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M0PMD/*&_S0RF?JYU DP(%TQ]NO26)GH/$QUF16&A\R'"?]%KA(,J(52!A:8
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MYUD/XAE22-;/A06:I%GRUR_W'CFGL&J*Q!LX]T\;$G#%8QM\9X7\8M.O^S"
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M(^FC%MR% "L,P+;C#NDV5-/@G^^A\AA9+S3RSH="86X+#KW0K0731_4'Q 2
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MMHSTSS_//VSR"?[YM_\/4$L#!!0    ( ,6C!%V'8BC=/'\  -%%!P 5
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MPG/PFDAN]#Z"Y$ZNKLZNKTZ^?/Q\?O+A_//Y]?G9U=_./G_\='%Y=?+YK$.
M6\M/[AR<MLT($@66/513>V[@^4$/=:3^ZM;[Z<G(O52H_3B8E-$]9<.,#S_B
M-_?%1 ]_&1>S^TG\B.&L+#%6_DTQF@Y&,^\N[OV#>B:O%!E8.75XA7@9K!V
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M:4@QJJ77=+GT1HW+6O'A1\-S$NNEWHU\BM:<W'KW2U&X%3R26!I]8J> 8H@
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M>.!N?)GX5HTG4 >,)1)X)"BTV""=?,)?QG $5'<R:\);P<EX^L]+/;JISH[
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M23U2&BAB*/ 2,RD%M%0LA8>UVN(N/N.PR4YIP IB.Q^1OG)AFER7$!307!/
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M >PWJ-0T%&9(C7SJ]%'O4@K$RNXB#OA@K6=$&IE\J[^*XF@TTM' "=-%YI[
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MXXP[!LCXR[/NOO>UIMUMT;Q$,5^>]U5F_M7SSASC#G :@2,,D]78Y)4 P[&
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M7U+[5YL-W2LG_.(%>=#D4S_HFV+/=#JQ[L,B3\5Q9MQ? 6B/3STM@D]1XJ\
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MN\?#O,8Q<]C)UE\<=+=,-(P(, G#98R1,0\C9D= H3=TC.2P^1Z;G Y59%S
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MRVZ=O#W,S@!927/9#<RR!N:FRI!DO;U';Q",37,OP<< NXM]JD4!=A#["0Z
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MTI3H)3:?K5=8,V>IJ=(YW="4(Z^FIQCE-H,&GK ]MSC%4$ ] Q3<AQ!K"DF
M",J;HC=6..AVZ_KHRQ#-A>W,DJ:>&]1NH!,"8;D]F34Y2V!="<08T66W-JVC
MLRFX)WEI:@W!9+W8]6%]!4$D&-@3,,W8G@@?/<6.P8'@(\P>/,SZ"5#E@MV6
M-7R@*GJU8\,A.%](B,"B0Q[<KL#8)L'9H0=3ZV28>J/:G==M14_*%6(.C@7G
M%E(ETLIYA8.V9=N6:SA,D_5N4C9[< ,?\/U0A$*.EWP4&VR0 YM17,S,3 .>
M#R17(0R]00I L7?FZ,B7E]K&67)C!<AH5FBEO@Y36L7R4HOV_($\:.=.ZM()
M.]-&($7919,=NJ;4M\I8LH8VJ_%K?<?E)E>L0_08;6;:NC1IC756M%23SHJ1
MLZ)HHY:R1<NRHG4WC-6"]98#9;53XIXK,PM88&$JIJ6\:UAI(W'LL 9(@6..
M;RN86>/[8X+6NSJK*Y-C=[Q8Q)7NV:')E*H?CH1PLBJ@_;*G'.4:,4,GE'&V
M8\6);>CH^- F,(Z1#2L#1P)N]]H11EVTU$\7&J*PD13%JIQ;3:WN)HO^,9O(
M8P8K5E>0 @XCK0=EI3E"&^L(6)@,QA@%):L>N,>/?+FQ4<^10WG=)KXV7$]A
MBG<M,*T19E<,Z]%<GJHN&T:S=117 $@R<W +FE*Q)9;3.-B4+)\IIG(@(U16
M%F> ,9B*B 8O5[G+UU61P,0HBI,@2")KMMLNTSD@<7T@LOQ#'U,T&V'Y@C\3
M,2X;::_Y0UP@'3JV\)*-SP"!%JV,:% ?JED]Q""KWE-Q8 UTBBY+7.ZRTK)'
M,QS;[<G)P)DK(Q-(9Q,P,X!@@\P=JS=V#!$<?8>74^@,<,N67GQ0#ON$K@AS
M#ZM+E(^T= >,BFEE\^I(]981,HL+E<<HGW.:NL9;SVX 9U-,9QG,#&%@G-43
M"QL>E=*U!V7.;==N/N!E,M'F#+B?JIA.KVC'E$-R:3BIUGN&< "E4T\2&Q0;
M;<!E<@#2!I7]E51-E;Y@]3;=]%ACUXO$13?[*"R2EMW44W$,^YYNQ!$4K9")
MT[C,0EUTV7H5CU0\EC#08N<S1F3C*@S)&G;&3-8M0U/!N>.!I%YZFB\.R@4O
M[B#0PW>FQZCJT$QIC$ VO6*4EEZL+'=+S= 1&D):;O6>CVYU)I>MC:U7X:1.
M3-%3U=&15O!R6.OYRC198YI#@T'5)_#4V2B+%@UJ/BF][7A5:*HZ3MQ6CYW(
MX0;)6F"LQ"(:+^@8B1;,DJMW[9H_'F*0&FZNJL6T%@<#=5SSJZQ&!)37)'XI
MQ\R&W<VB!1[VK%A)6K7M9B91X'HGZI,^;<%5OSFI5,9&1;<V>@0\L'/66FZ%
MW1K!4!M?P@7/"-ZHF]!11SF:[*83MMBFLL'P'#'ITRBS&>?CQAL,YS%OE1)/
MKT),:,9+ON..)YSAQJH7 X*Q-$^Q!#E- 442!ND06DTM/:I<F8Y(GG<,:LBF
M!*GTLM&SE@F*VK#Y)3Q#B-!M'+I 5N Q.,1]7M_ Y0@ME_-JFN7:-( GO%V[
MU:*-U^E@O@;E* 'V&NVM%OE^[+/""N5X4X%VRYD5B,7()A&E=MD&(8Z^C$1C
MB75SQ 2UL"D"GLG5*5L;1H)R@%C%"!9 ,F3.J&U/[G0HB-B-F?.<!*QZM6P=
M2-31C.@R)6*0XYF#TNDMB0$X7BX&"D 2S3QI &I.@GMBXX*0 8:'I5_Z "<9
M?3YN]CNP!"5(\*)VRL*>[T]HR>>&X]U2W!P->R[ET:$JYM T 9(YM14]^S"G
M>6L_2(:] EPNV^7M'#57);Y.W=VF@(LHB,52D?!F>G#D=CR!^X3CSC.L.29Z
M40?J/L<-5O4BBEU(XY1%@?"RH OI(D=\"[>MHN/:O8KHDE=.^N)RB,2&E J'
M#<QTTIA+PP2H&\EN[#/ FAK%3ILPHPQTK9)@I):"67:';#U*F?>;FLJ'#H4F
MRPFDA&B]MF-E?@@IR.H<IEC&#<=LIFU*,V;4S>\N111&62T#=:5QB9\.YUT_
M;J3V!3^X+N49SXT%>HE5#+A8I 8+:U:=#S(=AI%X$]>YK8_2:)6I]"2AT_R8
M1EN6X(=K&\*''8ASAA9ZK#^I8XJG/:L!K$$V5'1T6RV0FN?IF99L6&DQ4C2I
M+ ?[G!A2A;8:1UX@&NWF^)(KGH<V.EY578NDX,R;H.T KDLOH>=\HJ[LU%*'
M<> M%*.72^_1L9?2^!#@H[HMY)U-AQ2QSDX%@R+@T?6Z?1:&L-\Q=;N8-J9Z
M&)9&O#6)W9;W(&JC]?[<4R!E$RLN7742+0I[4%B@?*B.88(8Z?)VLR-)EH#\
MXDC-\D,<]QEKNEML1JO))/4FI&E$:.DGT"XRS-UTK4I:7BF(Z$X\)$Q75;A0
MP,UTMEG*.=>V.+].4IS&"CXYFLVVQA<-V!<4()[VQMSZ'-CRX,9?[W+#/5B[
M;5]C*I:32-5LVG+KKM:+NFY18249@K*'&W=G8FN &OHT-#F>.2BU!K6:>W#W
M&ZZG2;$-T_DV$5"RV0YKN".U,00OEV+;)96[/W2XC*ASV R*0;G"R]E*FYNV
MT9(LL-'J(P%/$;]1O#G7UR;^%DBKM';JUJ&!'1@@BY1A#J,B,:9, \4"D&7:
MTLI=1:?%!NS+OX&9CX'6$88CD_')(Z,O=LV\.GALZ^\F(U_*IB'?KZH/G[RW
M-+:S;M' KDU;S"A)W=ATIX"T3[PL=-(%4T_J.ICYA-V$8[<K[?%1R\2NS:)1
MVXR=#2*B(E3M%[V2RLW8Q$L7/SUD03ESA!C$I@MG#*=-, BOY%&)]L7HPLG]
M&1.,Y6$26/71;/RZKQG;J4=A.SW36MHO07$SGFWGGL^M*J-(TH7,+L!@L!Z-
M#E,7Q$>2Z[F2J![ L0083!HRJI+GN##(CTRJ&T,(7SN:2,9"L.ZR9NNF"Y42
MIW,8J7AIX85*6PL@XEC:UL)5=&-K.XX,:"L;'^155<<^)9(!"=D@?72]35^?
MR T[7H+[HFA@:=H3G!S,H\P%5X"?KZ9V,AZ6*# <C+V!Q'@6ROE+-EW*XM*8
M\O92K(?JT.M=U&F/+Q<T&U1Z6QUAI" KW6PE! @M,M4$S4'1'@I#)J6G\Z3<
MI-:\X!?KC581->N%%<.N<4LKY)ZHXZM! ":V=51*O^JH(HW#<JD32T7.PSG1
M$.X@-OU-O&C=W;(O%;AVE3'"KET-3G\)X*Q)  C=6S*0#.U=TO!S^[" S/S(
MZ&UK%.UHC!NO+([8"=MUXW<AA WE7<W']K)(328U&VWG^7FY"ME)M[1#9NT+
MP5C(B?+0(<"*\J+QU!SOSP '13T7S4KH9;\' D8W,T^>]_F.FO-\9X_<0UCA
M?:F5-B*8@IJ[0N-QA-A0B,"ZH?*3W2C1AZ&E<7L//I[.S:06+_J" )C01K)+
M(Q08\:P^1<OA%#&[&<^+ILW)J[7"8&P:K_Q)$68[LH$80=.'H## B_JP;OM%
M*-21WK9FNB^$>-N)]*K+1W-V&76)&>9]G<V6>5Y&O=83(\LR,#>D*0[FPA1<
ML@#G5Q),0L;4AGQY!!3[PHB.7,_:"4T.3/LG#H%"T:>9)15NJJ]KSZ! 08(+
MSTFPKA/VZ&+I[?-9-S*K;9R%DH--!*;>JLE"VRP,=#"SCG9(DZ4 8"A@%9ZW
MDH35T/8B$0M;19)K<LYC>U<>[FN>&O<KK2?E<N1AW<Q5$GP@#71X!, SE&P)
MXX!QP/%5)LXN45VC:<!H8FL5;M6E.L.8/KF(4+H9LY8ODI6S1^">^X*E$P&&
MNP(7$5C,>H=HQ4.#CJNF@P'#RZSCT;T[ .*#T8SES,-R&/1A?"7O<]P1X>Y
M5GPGE5(7L=.EQ ZF"0YZ:N[W?'L&>A@:)*!D86I/;O(D-H/P>'XX5>"Y+E(8
M:A%N/042)Q.U0[.>^'"_(JNOT>ERP:$X'B$C="T-%*%M#D.BZ#/=<D_E#,)J
MM8:-LMP"ZB,+F#LXS&BN<K8EJYE2?74P L<J"U+-Z5%GQOH' T=*-!L"E3+V
MYG-S+GNP1=OA:"?OHR",2:?:( P[/48;1;;-T(IX09D:0\QW1H!O(.Y2Z5;K
MR8;R)S&>,J5GC%K7*UA+AY),%,=3A'>-U3XBE%!N5QB[G(@VD1]?+HQ,B<T&
M0[XI9#)=NZXFK00YQN5RYAG-0&@\3Y>$WF55N1N@5@M4J\$FMO"6ZRE6J<RB
M"BSA8F(2B[P['K,,2" IVVEACMB0:C*%[>;1"(6:$!2'W5QH=9XO&(RDQ)(>
M+^4I64M) >_6SAB$MCZ\6(+BK@0S!812Z7@J@G$)D@#N8.OI33>R%;J>LFG3
M0/74Q!%C"JZ6-A#)&#$R)D9EVAO808R6191PL :&:"Y-NI4/WZWV8Z)/>]WS
MIJ  FI ?Z'4'Y..\HJ)2(-838* FI3G<NLWX=#E2/,UKI:='7)_.V*@!G<0:
M(I/-^L -8Y0X4C.-=\9)F4CAV ;JX9[53 5F@20"B@K$YE_6.8:+LP98!7UH
M[TH69 V@OR>I(%0#D53Z8Q5FCV8#L(57'!"O[JI8.NAZOY2Q+HU3'PC9E3,?
MLJ J]Q4%[RM^&G6(":QKQE?M-E4'<5H7F:"5?EFWK(.[QY*X"6<R?J#VR#)*
M6O( 0-IXO]E,$6#I!KO"UZ?L#MZN0W2V";*>?05,O>^*EM^M]X* 8"4A"V1.
M8]UHC,+:W4FJ8\>4(X@0B59YS<% "V]$F.0M154DEB1%<IQ5,RC.@,E0[>O4
M;DT32]F>F*18+19\9$BHVP4S$42.7^ )H.C ^Y:+&+LY :63OK)?3ONRE\<M
M63W$.(VSL][?-"I,G!8U25(@M^AFZQK@HM";MI3B9C79"=-8MX]OP.EBNR4K
MKB2$(IE7 @*ZL-%?I!O:R31O6NT,IRQ\/Y5PZ[#7&\2S %RTEKHJ2K@H,:5!
MUKR(DCK'ML=BB5-A@0+)!A6@GL[,JF8HK7W 6<UQ>*A('0HS$)PMJVHI%E,C
M350"[8MKA(GFM5VR1"?TT;Y4C$%7"?;Q9,D,:;Q/.SFZT_U45#(H1<VX+OC*
M,KM$R,:5HPPQP[='$84Y"U9PG!WG^8,P[54'WZVZ%(4\5&^/K]3-$4_:A\(Q
M9%+O=J6CVNF,"#N-W<>!O<HQ/&EAI"P(,%[X>V6?5[+4;7NV?R#7XWTRSH1#
MF$260# Z"Q_Y\N*@JC'8(%2.5N@ E^.8]#G$M=O]S$+ :*<I/0%#L86F1X M
M-BN? PK/Z,GB7$^AOH+>\;@Y0.L]91Z35&U$TR64^%&?2@MCOU@/9I$W: 2R
M7AY(M>[CO<Z;^51'$POV6W4I+L+]@*JW7;+6Z[%SL XS?[AT9 LMCVGT4*LF
MY4T#4MQI4 S..G99-<O*[^@*V4Y2R#KHS*A&"GAEF BI,0=CW75.5Z)6-B1Z
MHD'8O.'OECVS!+/C<1^8ZX<IY>>DUH<8,!3'+1"!Y2DS6$_9GG868X/,]E7=
M%4N\)</E/MOT;IB5@WJZB#<H;-"'DHK=$*Z/7(]4*U7F:0&:=EMA-@8)-TU9
M#FVV41%/YX+2, O6FW82?UA;H</%9.QS[&2?]ZY=]&60.IBET3BQAY3='LT&
M (.9A9J:B&6Q%50]<]!00@B"T3(_K%"M%_PR'R*1GA;6P;9T(#62$AXR:$P?
MN,!BRD6'ZRXA%S%E'F4HH5G5\EBW6*KI;"GL+7V8#<&%1D]*MS:!U7HJ919A
M36"\\LV!0H[#$C^,[!@;C0WQ]'MDOG>(LBR:M^/CH:XL#0?H/$$KSYVD^J27
M';:65<E:%K9:L;Z*IP8$YY!CN5ZN)K@&+N4N,[>;LD-XDV>TLAF1$WR[R27A
M>'Z8>=X@3B(4<LQ\8JGC&54/)68YUB(EG,W:45)(2W[I T;2(E7OD&7>9]<]
MF5$[L*F&Z*ZO2AHQU)'$T(]\.=%5<Q"O!5$?S(6M:JT6FNG9=H3,)NA4A^L"
MBJ6T1':U["U::U!O"K?@Z#"V/$2G&5>1TVAY^CYWH$#'\ 4NU=ANH\VP<:+.
M"9D\(W@,83L<0 7-0 J='&[KI,]\A8ZB6JQ2RSTS<\R^]%AV'">@!$-+6)AS
M"VI\S"FPVUKVJF;!6=C!K%X9:C&?-Z*JHE'L$9Z"07/-38CM.-XL.6Y@2O;$
MH&*20^;"NIU5>&%[9B^"A<84QV/GS![7"+>U"6<OE1J,V$G$H<[:'-2:4BP8
MA$#'O3Z%M;$E)ZV]6.19)!5CH-=ET#"\+[*9/I[JX^4AP8^OU&?\@9YQU4">
M&Y"_*DMQZ4^C:.OY6VMD+K<#N>=%7<9UDH3XZWG,6H#A+Q*XT*83',FD2AZ
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M+@"C00F=NEJ;0'W$EP 4^3MZK4=M,Y^'GAPQE')6 5"^52$@">WU=C]V9S:
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M&]\U,,E#4@OH@ZT%&RM!G1 (JX'6VE+Q5%I5B6GL3K?Y%C[D&H1U P\?5=O
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M'=N8=Y[@83N:]?*IFXPT#F .E&)AB9F<LTRW0]82SH2FP>-\SHL[^3B=4$.
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MD:Q.YN1 \(5JAX0SDI4F)^)5$>_;B8\S!Y4\F]X8G%IP+5GQZ(APE8HL("5
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MVN/X/@2A'DD^Y.%FF'G'4_6(NRK]S&]]_MK=@YV-$OE&\*XOWO7!O\U5WCV
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M.'KD%]K\+=*:>G]M?D8AJ4I LN(]K<+6"\*7])0M/,35@.S4=(%N.7_CYP6
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M\@E/9L-2C7XA/@B$O<Y[D%33&;19[QQ*GFMS+6/=6A:7RZKI>L@Q:M8S"S!
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M@.>TKVE,<)DO:#]AXFD#VE1>D7+5PL:IW).50Y;J/FRJ;9.9YB2\]WO1F^D
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M>ROZ@PL_?39SW_P$9#".]=@/N*?R(&7'37VS=KOO%HV4EI@P$A;6JE>\*&F
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M\J5>-AWV: 4NIUE%/I\@,LCE0XF@13\.<[X)/2Q)ERF^*I4*OO\:HMB+ [9
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MIV:'9__ :1EZ-+.>U_6[L7P*5">>)Y;*J[,CT;.6R:5O 166/R02B[S-82$
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MK2RJ?'CX!??XKUQ8UUG#(D 1%1-9^9>LN_PJ56?,@1^^^>74?B4+ @J!">*
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M%H=96AJW-WQM"9+P\93)037L&_V#6IC(RQ6IT]"K_F<\;>>X5:U6$XUJ*.-
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M+*&EVQ@@7-$LYM#H+N>L1*PDC@&&@H4"=_2BNCONQA/'L!F4&&:E(OV[=Z^
MIFLT@N[(-99W^M0/ERN#=V$40 ^'N!PP?=6P5KC&,6/92\1'!BNL5X$)GVQ
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MO7-9;2@W8ZX4;T<E5ANFCA5DC]W-38KUN!?T'HT2A0MVI?J3-/*RX07P.O]
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M11:$U?=GWGID"IL@;VB[5[ I/9P[XP9*6O7#$L)[8>"X%MM(%+O>A,'6& :
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M,SW%G=_1Q!J#;,3+.1K+U(;+LM4>.6(<$7_-D0CQ1+LE# L<!>>46'VLLXH
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MF6#E@?HR7X>U/%!^(@/_26>UOY]K,$/\3_DQX]ZWF=A'CC;52IKF'PG6CVW
MEKWFZ2Z[-F!S'DGQP 30SA7K.N<Y"9AK[O/E!1F+ZIR^%\V8R'W+],51!^TF
M8QA"+VS9GYLY 2,[WJ_FT"0A\Q&20NF9'?5=C_]I-5L,YU9.T>K?9)BI?)?0
MXF>IM[D"$45REC@#!XS8"E=*4?Q.NP4._>6<24IZ@T(E/.V%\4].1,6^J<-?
M4P ,0:O<*?^6RP5. 6WI?)4%%#_/N"W@M=R@(I!Y0",M^GBIMWI/>7@1#.-Y
M<_B7]TRU40ML2H/>P=Y"S@^'$\43LQO//S=W[58$I@_**^0,7JG?77MVZSG,
MD1/T+-C\@\V;;9M5U\I5*"Z31-7+E)LN[MGV-5QV! >"OW+OU\WE+5;@.;63
MH/P3(^$$U,+0*#UV7V/)"&C@N'VWF>(D!%HD1(F[1/O,/#R+J<,Y5K,TM18%
M"8>$2_K:#D\;#.575P3I:O-S-)(I^%#=]);EK1*>36F]5#70":PBOSQ<'83+
M&?*_?%5*W[/CN#8:(;6@4SBM!SC4Y)2'9*ZNE1V)3Q1_A6Z\5%VMEA*^ IT!
M&?-1IR_GDL/M+@?6X][-J_'.5_3@@R">3O%^+M)H3CRJ/5)A?^/R+:&C.]BH
M:]CTP.FI:15S]4::YH?)P@FI0:G)8"[D%=6E$ Y2G^+[87'([>MW!((E)JV:
MC([[UCXLGZTL8^D*X(V8\4Z8=PK!.J\0T_+I.!*4YBC=D(9<BTQWK1(>R227
M$5QK*I>F&;9 ZW$P>3Y2)E@. [".'7IQ$$X?S >*O)@(Y38A$ET2TR6@(0:*
M:,NG?DEL=*IL^KH)=]V@;CS,%0D+KZ\X[2CCN>!;9+QA=L#LWSRNRTPIRQ::
M^]I-%C&\T:988R!L=CI#\= R,LV+:0A*X[S(F30J;.[@!I>=**+ $MRO/*DO
M -OKC8NH4-VH_<BC_,.]Y]_6.LLL^<GH1:X[1:UR7(+EA)NQ=W_JK8C?#>/\
MYA.!PA-V:FNBDVQ,0EC<!PDVA)&37/1WC/ MR:>[V-X7D2U3S%X_=2GBWR8:
M-5S:MO*"I<W]["E  YF\7, P) *)J]V"XPBH^.T78\0QBT+A_F7#BG&CQZ]U
MZZWWDC@8V^2 A81N=R=_N6O5[>E4#2'>')N6YYB147D&^G72&:$60(J6]1#,
MZ'OZ?;:?XYO)@ZW15=2C%5!$0])$P4?/7'<II)-*6-U7UI\0B"./T<(*C<[O
MFC'[!S2W\E!@09;@CL]Y=R]QL\2YZ93 $]49R5DC5Y>XQ+%_$EW_48R_C/Z/
M;[!*HOMW#"R@;@ZRX87S60#]BVWEV7?3%7NW+3*<#%^*OW>8:]!;#FF$RNGU
M/Q(^X+\!2JF?>YOQE=]ZAX9</J^MT3G1Y\^&J"R*K(,04PV! ^"O[ ^K00?
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M$8;<@V61*J9A/%4\;Y*TP&, \'"BSS,MX%4V--0::/;'U92HIFP!C[X(R6/
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M>N_0*^3M*-)0+8==3\ZJ8H\L(L?9666IEZ-L@C? 'OK.+:#^M_SY07FYI8O
M[C67]F;@@A5KG>O96K@C7&]GRO@.0>=:*/_)3O[WLN"C%*[<XNHWN="J?^^5
M]A$W:=1B@KN<30*\F[O,>_A3=5T%X-&(-!VV\Y8-VG7\I-!>S+8$V3O"I5B>
MC$0Z[T\IFZ@.F%.^>+"]C;V= YW$6LQ"","UVR&@Z8&I\0\3JW^DZ(A;,)<
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MN^+J.5)6!^]"'V]@V%$K%?&]YOR!VQ">_5V/9,L ^_W'4:1^R$J>BO]1\MK
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MG2HGL3O**Y!O7>RO54YZ:7 2[>4;C5]/#*Z@Q;+UG9R^*TCM!9!QA."))FB
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M5H.@\)ZR<N,YS+,"3SD?P!@W8ZJ(H@E5HC$\CW4M@>Y*>KR*N>CD%=\QA(W
M">3PBH-DHGA$KDZ&C> CV4Z%8TO^_LJLG0J)-KS4N0*)#E_[.[7%C,W+R,\<
M7VL-]0813)T-P:#F!7@*JZ\NDR8%\S_+=*C:&N=B>WW2?5?"&E9FRATPX[V(
MSE1S$)<BS<1<TP7C&1V=T!VIB<9 T5)H!-K5)D]TVR#F7U,?#H[/@_];GOT'
M @1>''\_&_E3#ATZV AKXWXS"3*&'#@"$+YZQ*]'ZDAX_DAQN8%-L7R3HMQN
M3OC),DSA=BA=8J4M\=9A4=%SV,<U7O< ]S? &@U Q'OG&3L8J]BPPJD>7>5)
MX2?;U:]EG(6?3AP&,N+:W3KE[;*Z+R5?OCO@9A!:.C745D#G#P9!"SM;?R"/
MDH[NUA)%/'ROB1+D.LW#,9CT7++/MX9(3SF'[S1?#F%9TPW$(MJW2+_-G$>>
MWJ57UM?(GGM-F8BM[XHOX9%E]&N_YI=F^2/U L0?K]/1:G0K7<ORCH9GT:A<
MV"^]Y1^?;02.YR+,=* -.JV.M9P>_UVJ<=XS>';[QOO#7UP9(J+[,] :9T%:
ME=W-X$>*2)D\[EDE')FS$]6I<(%WY3UA1?''1SXK!Y<PACQI=B]\@*TAU[&?
M.:RW0Q:%4*M4;JA[+;IA0^ ;W_JH7"6']P"'C7IH-LT#Y$D"JT$!O>;T9?.
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MS+M%,[FV;",8<@&L$I+DP)0IZS!_W?MIRMA,(!TZ!):Q)2[C',J>#&4&Z9H
M3!0M >9'4^M[5<#;--1(A:\F7NM-8=X3^"^AD$62=Q7[,HWD>#S7\^[=XA'X
MP,NP*MY;V>@2'%%LZ)K,Q)2;*%,)"7.[=L"0S$3?$JN;:[CO@LLF#9X(E4\4
ML3+TOX;V(L6QA<XE90OIT^*O;# S]($K+A1UNWS_$5F L4.N1_J<]7-S;EI1
M8,)IU\D >8#2O9:T%<+\^=\,@O\.;I[N\/DKQ[;(CU7D'NNWO8W?BK.?;/:]
M8#,S6)(*#[6C<5;$C*J.$QK>-; O6S.X3<WB>L+Z8KY!6$( W2DJSX\B\A<>
M&^YZ<WL@CV 1)[SW 3>>;G /[*?-6;92>EK&M'J*#25S>:1RU>TPX$GA_@<M
ME[ABV\@#KG2#ZH3]33)I84%K!B_.^<?S#-\OHI;D,9OZ+H;^-!I0U$D-?9\.
MJ;2!/@"^(G)-[K:31#CJ:R+3T#,JE=/:JVIWI?,3>G-WSO(S9NQV:/30'N(S
MA\S1-5/&7-JTWUA"9EG%XPW<TZ69X%S!XS^U.Q7;#F7>WDW">@<ES6B>%QW>
M&>A?#4E%!@<%:Z3DJ)?ZR?U+68E\'OZ/TOAK%L'FVY5C)Q;$)<3(]9DZ>$$K
MP*MQ3:9;]KLBNW5-L%LDES #DD!0I.UI=U/YYK$\3!E%D)WOHR6XU#75C/,'
M 6UO5B/ IX9@3MZM1@.[;#$><<,*AZ@9@&5_K/).=+UCME(,)!J'<0D]/G]^
M7GW-(I=GAF[F'^K'^*[2)SV>WR-*W>C<S.J+MM^FU*E.S$RB'6SP)^;"V+QD
M"HA^MQO^!%*\5N^HI]$#: T9+JMV4RT"$C0M<K.5\5 %-G%@0\"D)GVI'3R:
M>4@#:)8F8HGP7"O[?$V[>PDWJ/P!?5LD'M@46R_+O(A39$IASJ^;+/+/^C'\
M(RY\F+.I5<EV5;O*BQIE!RG?36/(HB;,$ARG\#[XR7+>.C-[^&Y(^<5[OIJ]
M89U_2N<+*D*7VD.Q4J8TS6QA!>[T:;;KNHH4/A[OF\FFZU*4S$%<W)9?9I1A
MP+==7%/:CC&9GF@(1@GM^N3)%M;,V&C/.!PTL0Z]HU$^H<&^GX)O5I]+'CYN
M";GNT"[&_AD$3RB=C.W9R3Z O4\IPE7T_#HKT6NH_2#*S$_CY<2$0$@(E[=\
M.T!/P^S%$J.3%2]JE!E(+"VN'M^/QN6(&D)CTV:<+I2O2_=^HRJM2Q7YL2Q>
M879UB]RA52$2&T+_VZ(UL%1\^L&%/P7EO%/[T<UJX3=H.5-D($OQG-1$-R'A
M(:MNE4PV%YD6-4B6G8D<OWO,+0RP W^,6K/.89I ?@]X5W43-KTB[%ZMFE#N
MT.&\\#M-$SM];V,%B$N6OS&.SJW-!D=C\G#IJ2_:37FY]/;GN,B]0LW3G:HC
M3YS[JOHB[G?@*BOJ.@%N!#?4W.;8SAW[-66!V?.RR-CR"]2]BH=UK#GE+:/B
M#X6RJ2=^!<:.O%R_=(#>N][#3,A2>KX4F1F6XJ+/I.I:#3EC_QI3NN@2# J3
MJ]@'O4;2#/A/OIA<PS8RL'S<^<N)LSQEL-WW8;7]>,>5=)0\'!E+R5_@'@5*
M 4982L53#C#B33-L^FC0)<A\6J&,D@G4\+3V_F3K9 '7:QPI, O1804TIBB=
M&0)6R=(*HD@S;C?^ JB@TVR[,433Q6)P>6#(8HIJ\/9)-P);ZX43\XY]-7%4
M+&MHOQ7^U)'IU.D6##Y0FE,3J_9)Z3+:A5R_430FC5,9I\_I9A<&?#78&Z9,
MK*AN+J1XHI6ILNA,>:OUQ"L&DO)6NL^'YC-!,8'F2/%7BD"X^ MP?>C'"D3)
M9PXN>F_WI##=(YER_X)9@?#?W..KOF/_"<;D36)ST:Q8=2X)B2C&C_EIDG.,
MRB 9OEXJ/.Y=^+'0>Q7AE(A?TY_V.S^Q]+W5A2@J>FR7[/2((*"1#D/VSR ]
ME-&2O56CGBOT24Z0 B= BV:N#M1=1V%09X@.KX737-@J)3O#?88]@MZ3JBKW
M:H1_F]4GI&[8Z,_2]_LCG TGG ^0\[Z7H%QW;>"$."(?^"C!@6>G^2-%:CRZ
M*@<"2HD9RN%F6_>#-6[5H-@HBJMQVU?1]>!F+DZK0:MVH&DC.&9QJ$&\-J8T
MUR*?03(YLIHH&*%QRD*UOMGYKUHVXZ*]&CYG'YLTZG%.3J GES[VS#BTS7-(
M=,=*:GZ[UZL4U#!VP@FHNJM._[JA*&WDE;F)6?.8:$.>L@0+CWMM7Q.7Z%ZQ
MQO6 B/;(@D*OE?L47(2W\)>P$Z\%YX#%<WA@ *XBTUMY+L=W/[4.:M\5]-BS
MW#!HD8X3@=;],9OD0KW0I0;#B</L37W\5EV E-,-_[AEF:. 66-)7>ZYS<D@
MWW)U/_XZN=H[8ENH?(&8NNZ$FGH(_AV]J7.VZ:O[H7M#(F&J84->%2]Z,?E-
M^#X)3-Q=KL+]>U%#C8 >#YLEYHAZ"HW?@21OFJRG(I8'29W;BF_".DT'A_GO
M'8@.K!H0L&8^<:Z"K56D\T*1HVS53HD8!A:UJA0_^IL^@2&M+*"H#-O-TLIG
M7:EU^7,MZRD9EL8'D7@$RX\VD3"TB#2S:724$HFI3R [X':5=WK*ZD%^2D 0
MPI@&  #4^VA69[1O(R-='8U"W\YTN8U*^/Z(2OZW:R*_$<TM/DU.(IZ^RQB^
M9C"#/<E2M%;1WTM]2[U28\AH,.T?MVXD+"G-;&0X_A:3JEE\(P]IK;966\QM
M'RK&O4O4A6W1\;;C&C7,2RV?OI$G';YM*'X5!W#"DA&-QNO45)5#/*<PSYPY
M>:OQPBOB$LE\B^G:N4F=7$@,H5S\*)13]Z)6T/0C73JH(Q/XI^F)-Q3ECA&%
M<F((R<X9#V_=T'U\:!<A/^"=R)(;,T\W-Z0UF&:W3K*M:M)Y&4I361Z-6G'C
MJ]_,)HR";X9R9T0O65I1@' (PY/""6 E3P[GNV@WN*@VQFGS<L:4E;ED8,*Z
MM@;N>1%_GD@Z\8[%NP\$OX;Q:4C=,LP?L'X]1#=*T*C(M\[)!N"5&(GMOV3.
M07R*-45<NOIU'J\1#\]>$\"F\!MGC,:!S@?H(R)555N=Z\AE\E94T.()H8Q3
MP7,RU(31-!(] X^>ZUK/TM%3!\:58;4[<QW'MO*@9IH$1E&-=OI,VD7HB+J
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M@^S2.2L?:H2G[SA58$ STPZ\XUU!KW(6:,S B$0O9OI ;5?%UVKM-$DZ&7)
M5U],;FSTZIT*O(1)TN-2);Q 3H@+;SGMEB.U:@(3($AY!TS],&1= 4C/P;#L
M]@S"3>_<DE#'$)WQULH5@%[QGDD]2V>PHSY=H,UID:GWEYM/+]BWKO[:^OO-
MIYKI!V3TL^\N#WWCERG]&#K4\*9V"&@6C&F(4L5:92J#)E4'E:CS833)$T4E
MHA8=L=U;"<)$XNG*M@?.TPG2!"L;IJ%*EX?1R^,>]O_VQ.]#.LWA)-#E3S$/
M&9]/G71M6X\._F!5IFUR.'-N_WHL[[A^L>,F<$W),FIMYOO_?.JKY4EC6 HC
M N,U49YBMXH+)>!@:Q0BX8XK,D5K[FK_9%4S88\&?AHV2L]6>&/F^')+^YIZ
MVATW>V!;K!9WB_R^1UY1CTH*4LY/R=8*_9BT/],V.?R%2\KSF&UK-4Z_#QAQ
MG G. G6!5JJ$%CZF*C9]BG_[^92HQB:R'H>^?2SXRYH<7SWM@2X^#YXJ7&54
M$ASPR*?6M-'9FVBOP'_T>HT=O768WN62I_5C.GM WA<+&1&A0/4BZC19QV_&
MS2WZ[:!QE;Z5I(4A"R7V(X*5K#12+$%F6"8N5J/&BY48X#MB8"TZM1CTPZ?_
M49?WW\ 5F8EP*\<-?:ME*$^]4GT.HF8\NXQ^I?_6G<69=;N&<E[_Z8<]9;+;
M=9N^:49SO^:2 6*7Y@5>]KYFWP/J#@QZ[U?V>6>#B[M7R$F,<^%Y=>4IO>A"
M@!#FMR--BT5\),G?KM1G%PUP,(I.>?;BCK+)$M\YEP@)C49I[_O7:G05T2Q:
M]90?[T- \XI&YG9J"ICF%AFFJ'H"Q0RA;<G\Q=@V;%F-P'V!PP=R495)P#0Q
M5AI"';PV=^3.X8FP=&IX8=FAM18YR9!;A&]D9]%\H-:\W0*Q5-PDCBV.2FJE
M/VT'NC4/ ":%TTZ$*U/2^1/^L'L45PK(-7VOOC/WD08,,7LPO_.N@:!J*R.'
M_89&HZOUJN8Z8J%BM1LY6>RS$*TO<=WZUO2]8M]<M*U+6Y0:XH*R<-ZO_ESG
MC.HK2+.N53RB*R+'+EH8G$2%P;8,A<"CQ6ZS-*[9*\2.O\-;72AYL-FE;Q[1
M>[; 1_/AWWL;Y_[UCHA?<#J[_O.I-PB4M+I:XP=' %].CA^GZ)5AYSKDF@HF
M'A3[>F93P5Y&Y4=&W0,_N^Y5RWIR2,TWOW3!=^6,&$"?3SM9/G>B7G4'.)D4
M32 [K9_AU17L=8=:99!Z)-+2;ST&DX%4"Z5.UX,Q?.!Q-]Y7M1+]L<+*-#K'
ML:CL\RD!>:W8*Q8$B7$'XU]G\R9A8A>RB7Z@125=G*_XZ\B%[]]7V;% 9L*$
M'ODN3\L>1[T['EW@Q;3(O/$!0@,^8R%T!5]1.%"WE@W]\MD5P&=0YYN"GMM#
M%I2IQ5+OAV R"_67>!LOIYZS$EA(!DSJ7T/$;#>IW\2I_),TE_)<>K<XTADW
MZZ4\ (6XF\M#>N6>UNFB15B7N3GU\\?5XVD2]L;2K0(IK74TQ:\8R3X&Z!Y^
M"'C8K \S"VCQ/KZB_L9N:!G/F? B:(U56IO;Q^:B',O?T^T*G'6\1^BR"=K%
MK#X5@ ! *^#2X;F/."/9N'6YA4/<0BI"XG4)1TKTCXD\JJ%P]>$#"&B$7 4N
M2__IKYH^2:#@,A:*Y?/VEC>V?,'H+0F3L![ 2$_*I'%^EK6II%;^V+R(C?0M
MRB(Y+9M#[197O?;"M<8RS<+S@<K<G7['7-Q6*VX)Q=LN-/=4W:A.D[@UC='B
M*,_NI</(F>F=D1VMU*!_W%7V[^"KA$&[$$N[0!VI2TOZ%7[RDH<_8WK*-6^R
MFJ6\5[*AXQ [LDM5Y04?:2AL>NSKTAF*:!#SY59$&?[:NA=O1-3JAY9PH&O0
MQ<,*\HH5>ETWTN@<5D>FP1Q>Q2>S 2K64542, #"E@_8^:&TF*>T[$YK(??G
MSK">'6)$ //]DU%*PD^_ST/WWJ>./OQC%)I+(.1,Y\*&U[F0_ARJH .,1/E&
MK_/0OHNKB;F2HLFH%=*#MTI\/E5MFTMEF,I,U*YDW%-?KU(B,,K)U=JV\$V!
M6Y;B7&T.:WLQA4,6>DY5%G:1=*E!D6BGN&TUM<0TMF1PD<K:KN:A*4=8\F_#
M[5FQ)A?0,&+28V;W3P':14^SMH^KM./?5E^+E?.IZVYT$\@3R3$"VNI>C1IK
MF!LP]VX *C X@T.J*\\![ZX\<SK#'W"C<'V]]C%>I+C-O(L.O,9LIPML9*/>
M.R'?+E=RM#9C;XP+6;XRNEHX*1#U:<_[0^NKT<3_JWYN+3C<11'&<KWQW%SP
M>Z!;T- C>)43'LC;*T?N;]T[0;\JP\?XH,_[)C$)9V@3(SLL4W[3F77YE3O;
MW%IFW@_ MPEXNR&.L#:A!P9Y[6FO-9J#=#>K)TMJI:&T'H]05<PAHGJ89:!E
MW:>LV]WOG"_0,97&@W(I(J8Q11.4)FS;-*'EW^'1/\*_M./U%7O2N#)-\"X&
M=HS4%@[144X)G_#$S+2H,;UFA@Y5,?[M+?ZMC]O)/I\(PL^SQ2YB.XKSPG6K
M=87R)"Z:08TRN"=3#NXD#RY/8C!+;FHEO!:V']<HE1E  4-[V&(IQ8M6I1J0
M4 DL(TE*>I%T4\ _X82_? L^VY0UX\RHP>BWN:>_]Q516!(2-_B4+S:$@R.:
M:M6].ZO*M7U+H.J&,HM9<NE=Z<ML\LFF)EV"J7"5&>ZQF*JQ.2#?@08N+O@@
MLK3'CU:Y:YT,XW"\>=/E;!#1OE@&*?[\MU#RFUR=H=(U"C<WM] 2M1PAWU%N
MS6U@_.>@&Y^*?OG_[7UEY:601:I@!E,Q)BV;-W::4,3U"RN(W]X_8;Q2TRL^
MS:Z4<RG:)L]'L6__=7OP[(<E=H;!@S68134+7.!(9RO$"W[ N:MMJ)G=(2('
MO3, D,XBO@D%#5=V2O=:C=Z?L.*=N1P+0%E]N/GJN:FU"9&X?4ZS7GA$E-"Q
M[N*; ES]@]^G<?H=Z/ZLB%6'B.FGB7NN5+@]1ZDF0&<[VT+C1;,#P0%6-='B
M[E]?BY5YGC8*D62)?UI=-G7Q'6XJMU2MBU!^QI!/[T?8"Z/057MFF5[>;-_*
MG 2Y5'G2 ;XK,SMZ-(+JNDH)+PRF\AQ-3$KDKPDM\(^-2O)6OTLLL>]7=)U^
M,!\4-Y%M.MPQP]]W:VUUYV*)3&!\@#Q(WOXLV(+7U"[>A;)5\(V70[2B='_
M#3M7 T;7E+^][QS/0%[F4JX<,K*6:MY56S($5*7P4CISXK(WS;91S_ZN?)#H
MO][IYPO[CQ^X[EO5\,DI]*1)T$93A5_0-E>;-SXQS*LIP8 4$CNAV"9]& ^$
MC!>9G "!*@!5NM(U XBRCIB89O]@T/$\<@%%*"EU+@H':A^&NUNG]>O.I+2#
MY^5;=86*2E6;NJ9@C^%^IJ14Z3 +,BTG*ZT^A556VW^->B_6W@,N/PR)AJ\J
MZN\[CC%J-I*S6(45%!VED$5:3KM5% F>ZV=P[$<->L8<+H2D>TZ4XJ=@74L)
M)6ON#8.3GY9G2GGF8HG_+#N%19;TV_Q"BH04)QI=FXK'.QC:[1Z]]!!&'@1P
MO7"D2\YLA=1CRU;9JU__=NZ;;%A(C6W],7[QECU)V!'R \N+Y4;P)^0@Z*X'
MF]Z7H\6.KVT28W%?0H/)E++:/+K$F1L$L-=R<^_H=$5W3&&J=.8UPJ2JH_2F
MM1WTE%^Z.BC<?3&7&3]Z HAW41@=,',EW7Y+T);\P;5(C!Y6"W)7K)X9J&.Z
MU?=UXX9CN1WMUX1G795"_:*OTK3/@-4?AV I@:S@@=K?]ZF4&;P )27=*IDY
M6[*JA>ICC)1)U(U9_=]OKIW>'O]\2JL''QWV;+E1=G:NZ X]#*%>X&:/0,]R
MRB7;<;=Q.X)I/CA?8+>Z4X3E<!'.5H3/.\M5.9+ G3ZSF+"F4<X[1K2J)@3F
M%).B2+[9.Y,L7BJLOK+PMT$7GO^R1VY<K[0,F#$)%.1:-](DJ4;S5LL//5H"
M!]+-J]^?797MD3?!/LI[_B(XR]7$./K3RU:*"S)#2W"<7-BQG$F9%U1*^7R*
M]Z%2EA]0K^\]7:4CX-!Q6@P3,>UF&Z'NT^*5-W(PCH[?(K;/K([\+R/0WT"#
M$N2KPQ.]!$XKK8LJ:#AI&M^S-/G)2RV#^N= X%-IO&DM4^[JCWF(=Y768QGV
M;CV&NJ/5]V.=L'S/:(4,L8%-X;R!=WD_I(/6' HO<ANR@2'VL+>8 O>ZG.QA
MS&_W&BDZDBX=?<%@ A SXR@;'[\SA)W+$@IR_F[#'A%0Y/H=L+=VH+5ERF;A
M2&M:Z:73MZ;E]1-@_Z2E3+9=4M^-5U<X%Q)Q1:T6, S'>0L5WL"/U[A,&#-O
M@=P97!?1OV@XF@S/E<T>;H!;*>#+7P%)M5,T9+!E )]OVP2&'$W*H4P7P31(
M6X'>_R%0\T[TW@! +D=8LQ[=N*)N.W'GL+"Z;JI!S"T+:![A"5$OA3 GX._+
M)*X8I44US\"8KQ,H^ >YXT- M5)Y\+>K->XSKB%E^<L<C%:V@!(<7"7\RNW(
MD&W-P[AF#;+&12GSE+:WW]\X/$&_9S3H-927[L\\.QQO$I5(_>N#6OIIJU6\
ML66F86^'2E1F-F[J3=]P?7'#$ 1?* A$0Y&Y4%6;=,R0C(4V_9/^N ^&5)P@
MYD4L$!-/ZA^4CEOE'EMZTN< ^KB DB"*Y#TE7'*Y,TK7MJO=W,MD)*/72E5?
ML%54+UA$,"9R8A],FV<.VSS#1.9< :HX)6 C>EA\'=8-'*:GMKQ*AT;?=4??
MEKX4R=5!?[82NUB!#E09%+V:ZY[^8TA*>W@Y/W@5FS,UG\*]HO6-]<2WOT_^
M-&7BI="9^FW!!;V*#]4E T8XO,9)WP0]VYGM6[.DHV8@Y?\*((,9Z@;4R%5T
M:QRII\TB)<%YX6B, -A'?#)Z PHCA&232XI]]A5!ADD2RMNC>56Z)L-A'1BW
M!JHQ5&V^,(A+6['54IG7 E>Q8)^KI^<\3D) =%'"M8Y5AV?J+F=VN-6]KQGS
MVZFO>%_G"%7KQOY(<()^*/FN?NWC^Q>M I[(X72U<>GTX?0R&<NTU<FFA!9G
M*1ZPO1*_7"X&@\[!8# %OAATX5^4?'2\/+^/BTL6?W9W.;7G'PG0_5OXE[9<
M0@ _"?$QFPS"E)X%-)@S1N+I7='V \J: <XQPC2M%8:8;*#?ID0 [NMB7BQ:
MVE>.UPD&@MF(W_5M7GXF=#',J;V;X%H=FHP9Q.RSZI?&\3S<SF+'UGI7R"WR
M !Y5R[1KUKR@(KZ<L ?F\OV>>S7^^9N%GS@9OO7>;1R9]WHZ'T'0#W5<K]Y5
MR%X :BTJCT7<' CL\>M"FA3-A_ YNJKKX*2S.T1>UKZINPY+[DRB<%]/:0/+
M<R:8WH?MXY&65*CPY/G4=F!K-AWMRS3?OC6.] JOX[0OFD.4E;%P,I *! R^
M&XUXX*3D->)C'NX5X159S?FN;?(?-.'Y%Q!ILO8MZR&Y#C1E0'2"6=_\OIZ!
MZO+RN+'F=:=^8\HB_KLKQAE7;4.NQ0HZVCY_ S1%.]K5ZC>$*#@0+=BJ0,-Q
MV7CDVYSX^'B:Y&_" NOQ*4J*&VZ2*H4FE^$1']DLO;#-AMHSI$OUI#%V383H
MO9YT%'B/I5_8(+N8T.GK]/E4.4BHO92@*)(F85OF4N =%=5@%XM@O)JXK-W/
M:G:I)?@B@QZ4_.HVK:VD%HR<712267M%;;+030<C>8[:+BZ9@^U*:$$HLDZ3
M4!,JI\SUXT^_FR7[W6+:W%4BSS #[$I/3"-<ZDK2A%G]LFJ:2:+9K#,<I^<.
M6+1A%+_+:\Z>I,.5H1O@UX4[SXO3#WMI30;!M6-_'HM:G:ZB22<\UFS*"^U5
MF:.7.X6<+)73EHCVV]V%$T(S-UNFWBF9'RQ)^NRY,PMTD<]2<YR9?\?17_WK
MW1"^/%SM8LY_CZ^.Y@!=TN[.=YFDD38.#D&N[3BEJ_4YG3WOR+:0%^,Y C_:
MQFM,U!&[0!&Z.KPFFA<AKPP)3HX \2E8EO9J?M899S;">2>G3I89WCRGW$E-
MF'%\/*34V[#5#PP9'<M&F:Q15#9T4A77,L*KMT)?Z=T*&8S!C\UM!DPNTAHR
M_WE22;HN)4X!0(^6KNZL=V"A[^E"G5V3X[>&;ZFT/[T('16)=6/LT(Z;%],4
M.&J&A)OI&^6&FHK?(0KUPV8KQ\*_@VYQO)9+O*LRMFM "<NN"PXT[\L@BU#?
MQE?FA@B9E%X_RF3IXXK-RQ^5HOF*' )5=PZC]:&Y;4M=97^,;U,^G-Q3!M/+
MMX=^%TJ,M+/J@-:\=EUWT_XNT$L=NW,GJVJM9YB/XSOC)R=!FD7LD8^E?76Q
MYPT?Y5J?7\I"VO48&39IJ?W<(>"JG,3+[^6FDLKEOL#OIM-\)8^7JC-?GJ;<
ME;1I_N+SJ6?O]V2V:4O9.ZBD"-*!0*C>O8A_K%[]]TCR1-&^ZTI.^\[)3PM7
M%"%F?&2\1XPQQT&)L>9%W+G(9[CI/.$M[VP:OICV$#;P9,LNWL#/%1.ZB[6M
M[#[@YI ?,-/NL';N-,$^5AHI<O$,_CJ17;RMQ+)H&#*,=JSB#1/30'Z8.B!(
M=P!ZWRX-%FJ&NT^X2Q\2._\@IN#J5FB@O/VQ8-\5.987VD85V=&^:RDN8K8=
M0*_(,^W<D<HPJ,.[R%;YOYO M_.SK()+IA6C3<IL";)P B75<^9RK:;:Z!BJ
MHV,*Y@HS-Y9=V^[H"[*/ @Y%D]S"MJ$^.F)"-=[^$-^Y^(.QA!+&E-XN:2QG
M+>W53__I@G.I46&:]RMO;A%G:9Z0>LG)W.5&'^QI7(:Q;W^9AU.RY?27DI3^
MNE8^#ZG]4T-X0Y=C!%J!@7:,OK)5'QPT^HD!7O74N#BR_>ZZ67-%$T/87'%0
M)J&D+G?5L!P>)A>^3/M\"KVF2A4AO5WJ(K1-T*)*LRT_@;[^8_0_93EG.9]5
MZM2[0'FM^3Q#";&@-,NH0<Z:0GGSO(?YM,R3T9Q+=K5!HQ I@[$Q,=HPQ<0:
M]LYF*7*ZI MS)2NOLQP2$K]1_H18:?+*T"XX!>C&'@[@M8ID#"=R\XC(VZU8
M*)<%X52ZUPI/7YS"I!:"9G9U"PNCF2$J'R)S=Q_^.]SY1_@7),N^0+2L[3:S
MW&UNK^ZKGT<5PIPA>;-V(#/NSENO0 6AW=5^"3,"0^[5CF_PID39J6!BG\\+
M)ZMA K^IB(*^Z-/>-?6:6YUS?(^O1P!!Q$#B<*[\D#D5#+?R5*'P*.M^.$$C
M,4L),LF^.</BO>6#AB>9H;'F(O).57))$/#,JSS#/#NG;O,E^1MI]ALWVX%0
MTL[[QQ:R95/AZVA89Z)M>:<?7<)B.37>#+HUU%*PYDX@UO'.0"V"_>JN^!)^
MKM'J3(?,.%<654\,RY:/4JXYS8S0PN:=GJ!.NY?K^ ,[T7LZ0T>KKG^.&/WI
M_^VV?Q4WSFP'K2T6/.\4UB<+P6@9LT=A_0)T[:L0Z67"MA$MM]WL&CMQ,FJ>
MIEB3\Y1/3,9@Q\[D.R V.D$4MB7%R*TF5W;YB<BVC.04I'*Y2=5PQ\;G3F>O
M$F-SES QI38SC!]>L$=1/%:5Q<%%*D> 550EXM'TM[\/?3DZ_'O-ZSNBO1-&
MZPESFK?&0F"_U/DE7@JALQ2\!7Q/LF-.^QM"'/&2"[%^VOE92[DV*:H^QADQ
M $.N.)*_'UZ#D]Q;1Z)J3=\Y@MO)91_RR2;#RWLL&'R+*8M$K:"L[\;8+*?M
MT4(@ $<0)2M_NI_-EN_[>RX4_7<4BK<52_4M_.CH0?GU@A\N-V"++%T_GSJ7
MM\'_\/OBZTB)2C'R74@M0^J>YUX\N8;X"%O=3[Y_,#P]D8T$)9X%6HM.PK;?
M"9:.EH_-]10W[IS4O;/S3GW6HL3&Q&47G?'2"T/ XX9E"+R&(=+TP;XUH'L
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M\IKPI9"V) J5U_,Z.+HOOC)X"L=64PRKAW3U=,Q0BQ[Z?*E]R:)";15AQA6
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MJ\1*\;)N%.N7#F K504@PAQ\+S+3B\73$\NCYRI*/?(9X]G]#C(OQ\5\[0+
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M"S*S@DDW+1[[?.H'++*MG5YS8_X<+^/:-!349I6'A04H*<_E^L07AAM?W^1
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M1H\,;S%CE B;G;.0=B&)69Q8=63_Q'VPHU7*>UX@8[KH_2P5,:U E!J*#5C
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M'NSI '&B%%(%B3CL.'EA4]4^KV8]'<?F%L8T^S#Y5EL[GB7*HGWL%J84E,T
MBJR<%IGF@S(^ "E_WJ>]3"D@U*^%;MF&R73$C+I4C[JD?B3+5#VK)@-4,K^K
MIL.OY3T8XS8R3R[XC:+&6%'1H@]L2@"J^[&W==__\R8_T]L/0_Z\N/_>$F_)
MV&E28 <HG1/TP<GB)0&11)=[1N[5;TS:/.5JV@5G6@-+.&?,2S]F;^"NGG*D
M02TKWVF^G+#?%(^M4TUEQ.&+3SEX'/;[^<6JG6;#$(MT7LDZ6QC+GE?B=K.C
MFAU>XWBP'264,Q'WTD^,0N_T7"5Z.C\; UT?O'Z8H"E\I7]L^'FERM/RUTVW
MV *([Y\1<#[J/8!;:6*]!N9]DI-M_3MY2;OXYFWQT;BZXECZ4?.N<W04U7L/
MY>DX'>J!G1]<-41:'.2$,BN"3B3<Y2$X-:A3U%J.XL*L,$N^/F;VE.-6+?P5
MZ-8,9G_T,'.)O/3J;#U3NM9V.=7P6B27!3.H3<CM1OMUK)V==HG_O3Y0GT,H
MF[*V0^U9-NCTM.0;#I5,G;K-ZZJ4>Q:1"2L[F.U7E0-^Q;0#?_[YL"CO)#\M
MQ;+'8PM[=+9]$SUHW,G_J!7B&8J<.+)D"=*B3_]UJ='4=528"[$.YV_Q-K(?
MHVT_BQ%-_NS?X"3BI1R)\Z1;90*"/=9']26S[)[-A!7,)[89T0?<R[S5,M8K
M=<HAZ)@_3"/L@L&P$D#721V@<],[7NM(QR6^Q9MHVZ?]N>J8L*?&Z_E<HGY1
M6B'RNKS1:Z-[!X]/*(XB!Z3^G%K?= FTUC ]<YA:U8/@\OO:=? "=E_^TYJZ
M#%$3Q10Z?+#/#3_XQG7$OE$^<+2@'IQ.=>:,2SP;>"_!8I)H,E9KL8O$/<1H
M0G^;<@9UY*2B,:&+3.%HIG &%!(;MCS-J>QYL5.MH5/6AXA.Y"JF&5_^93<]
MHUV;9ZE 5CL91J<'U,]?AW?P3#\'$CN,*$:#RA#H[MXIAZ=J8/7AF>@=.=IL
M>NG7?=8@.W\8M#:A)["(957+YJ$4PB8>MCEN*.!B%DLF=YE9FJ[>Q/_8$71&
MNA$/=XHK*Y0K&WDU H<(F74+WM'+D 9= *FUPYYZ:D'G>BS\VF9KQ<3L,NS0
MN/"= LMBG.1,XKN#:ZY;OTRDRDMCPY'QW7*MAL*JLG:5OAFK4X;/YR<'*E"\
M'\VH'\@.<.6./"?GR4'5K:KYRW]J-7<>,GZG@_3OZ=LXG[TF\= W__&(6$<9
MV<*JXFN)AW/EWP]:N%0-7I7;O_SA&L"",&A")2RGB"8OE6 P5DO:RU,;PQW1
ML5W+$,5#J-RTK(G?,B9&HD*-O307?!;E>8V\C  V7!TVVQ28^ >1)?+O,V)H
M=V[34?[C=X[R(O0O+X2QATJ6+N6B9O<[OMK-4"5+1R#W>:2J_&?F'_WSR>6S
M; 0.WRQZ54.ZNWDP-NPJ5/>HIOTFT7/( 6XJ-='@D#N][_JCN&Z,Q5M=B4M/
M_*/UPR^*&]51DU?M0^[,^[U:(XK5*2JX<87,\1<EXG?TT:D+T9OZ8S@*6]X&
M3?^,TSM7HJ*W38 -6."\WY6_[F3_-3$_WRVLK"W'?I'4!>_^),"^.BH9/:%M
M'S<Q1BLOS]3"BA-24[^OQ8#US/SS[>%E+6L-+3CAK%K#)_2OD[2'(BQFB3*P
MCOL[RHNUA0'E2W@-'R;_^F!/0$"#IRV180O$*.T)<.D(^G[[M\;OHUD[%@H'
MMW_.U536@$;5[[D:UR'H@_P]5U,).(_/N?J02]D$9 *SV'R2=1)QD%XCU-+%
M5\H'[(U(U\RAUMY^ZWR 9U^Y@GMGR]RO+AHUF FX.=%]0 ]6-D*_TVM2&QO"
M3.XA/Q[$!C1P$^.)2O1>OVYGL4Y85'H9EUZ_*,FM>H+/&I8@1,16<O,#M-U#
MPNR1SUOVJD^"_;IZZ+FQEN+[#!JD*%![O($YVCZ>5+Q-H9@_-$@8NIC]BZ.O
MK+F KV+J$6E-&+:/;W&UU9>8?E@_7F!CL2/%_(8Y:'_M<"O03HCM7!=$C.E9
M-XL?<!]"06*'=D:P:CLXL@)O:2\0A[;\;+>+)27HN.E*$U?YAU@\KLD9^-7N
MH1L]6U@C30+__PB9\]_"A,JK_#&.B!&-0&<WC1+-JF#ST716/7[_Q>/U!X0J
M9KQ!HS,9Q^8="?;,*T$D!*DS@5*6R=H(K]<S^R?G2BNUFJ<V,I#A),JAOQU1
M)T0ZIIBJ/*4!$TI<C4VAEY0A7#/KIOU3<VH,EUKF5%+M"KEG=V_$;S9]Z=*>
M'G'[E]CP2D;J"#+?Q&PRI31UZ5.PG_<-?<M4<>OO^M-78&NVB[/Z$C.H3_YW
M1CQ/I-N7]0]K55P42JUS"$>RH $J#?*"4+I.11/,3$+HMDJYP2\&RGGK;?7T
MNT/WP1O ?+IGQ%.AQWM?#/.@X27W5M'P6/<!1,Y<W%AQ[,_PZK>#9:B%:O1?
M]H=D@YM:*MG]#0G]=1T>NGV\S\V+"YL/6\8M-XENX,#JIU^ >_,R/L^X4SL-
M+\AVHE"\J!2A=#-VVP8;*AH\(-H\IV;B< GLX3<R<.$D @8I_O[)_)_VO?-A
M:>%#\<MM.F7T*5>6KWWC;.J9.WK)RM\-=Y0_SIR$.Y-M G#FI>T(_25PY0XD
M5*+K B)ETS>Y;,3NPI:(^1KDQA.L<W%,EY>>03D_3?](V6<V^U9LEEB3O5G+
M(/PL_Z?B$M),:+EN+WIJ+/3%SW\HE<Q8-.R53O+'Q+N4+ 9DLE_5Q7+F^^=D
MI,3>+_?^C(%'+/S?*!,DP?U2:^^P6&Q^<FB36[$1\G/B.;,$V#05 VB#4Z80
MFV0[\95LY,':&X^RI)*=^F#\78C-%X5(/^'M(UEI$4GM_US&O_'%3B3<Y6%0
M;!M<KK?JW6K/# ];]Y60/)@34+T$B/"MU!G*R$>RIY1]Z0_&'9!#T<C+D#;P
MBL5QPT<_\1U3NIOZC@7+E%LFK]<T2[04L 1-T$Y2FL)&375#9^D=U3%SZ:$!
MQRDA!V+[9+JFHL\W?V@]E]8@&:*Z_(9R&9=RAZ\.QL3$C]IP9200YF^4HF7T
M2\RL?F7OCANYW:OR%'B;&KH78,+'HQ\LG@SI%KH3$#ECL. FF8>3=\V(CU7D
M&OA 9SE!<Y7 K@S% 5JKQ]O^'-9W!%H'\O 6QHV>(_)U<1128^[7?RD=_QWY
MRQCIX!BN]>Z4(TIBVX/LYMMPK?%7*\[)R2P?J,K=;0R-$6X'%.9\D_/G9W]V
M(1FUDSD]N3H ;SK\ZN>P,K+(DG3$\:VI"+G"O#'=@LI#DH6B1ASP_=_H^==;
M"5X$'EC6&"1HKYLO=I5BA\?AKWIEGMRXV4 ; TO0E1HOB+,262,7C?O,S!I]
M[$7J';0R[&S2O@P[*[^6">"F&)H /IF2O:[&)WV@*:8\#J@7,A/$MMG'P!H@
M5U!&3A2\E@<^-M,;BYP+YN5[/Q6F;=\XPUHQE'^!JH%^O<^S]L];4%ARYR\L
MQOLK'&'$J$G%4XY*S"[A2,_AW8ND%'B7EV5LI0[@2+BY)UPJ/:!NST/X6@K_
MXT(O@%*33XG?=B%T4M5CL"78IGL]:%Q'8":@G_;VH(R'QR8/ZU;=UZ E>^QL
MC[,@\V*<C?!#.S7UM O/J!DYA$EGH(C)9F)$9ZN(%LH0=7<_JVY".M(U OHB
MHP:W>X-V(+7B5S5+%  EFTMR*HY;[ F.'3#+&39W,JN/GD,SN^OM?BZC+7,&
M:O,&.K_S\;J14+[IIH,1==V5RX02 7:[[\;A9AWW,8@@6'(O#-#I$V?I%]?*
M BA^6F&#!N@YX?%BG>O?T6Q1'<+!;?5;/39XTM(P,Z%F&DL4]&FC8JVIV,\3
M'LR:2M!Y%17C)(D1E8R:XK0XY3A_</K_LN;Q.>E4EX=R^AX]ZW'H;UM\>_Y2
M-5#N<ATWQTQ\;&G5:?0RNAI-R3/13"%9/R"8)]Q9XC.RK%K;'MXH3Y<1=GY>
M=B;=FA!QUC=;FNB;"<NK6<7&Y'E@M9*X.9<RL9B0X=XV,_KEZ^NQE,O# G$Q
M54Z'$W;YZ0?-5_,,?.4&7I?P,I[ G7 %U!6!%WWG])M7E&<&H;9QJ9.O[EM3
MC,R&Q9,+=&PGSNMICZYX0N)&NV&=E2&$;.\-6@L M/R.8J*O(*B$:0OPB%K.
M"(V3"XXMGV;LSPK;A^<F6G8$2= ."R'J%-<VG(WN\N5:N5Q._LS(,#SCA2U>
M5=7:J]Y65;%T]#JOR\;5I>KI#J=/%,9V?I_WC<T\V'K[AH;RVMW 5WXW0B]L
M&HKF6^V8<N(",CW6ZF#W&F#WAJ!8=[0/_I4O3ME71@[^M,W#!#Q<RX!PZFWF
M1G3N?ORY(?T/XYYI$S&3XS39RB]3F%+ISD(G6B'#?<X.*Q6F\=>XLFA\A^AA
MCSMBXL6^'ZXX&YMCL4ITK&^4>9(>]7#PZ>U]H2:9F)G^U-7Q5NN<OC YWN-K
M'9('^QCGU$I^&)=&@ZN/H8-<K5 YET[TL[S^6<&O_]#Y14.90?NC8M+3;+7S
MK3?OMP>8ONZ5Y.L&6'179CGK5F#U'V"/^$'BF9O1!38%0F65#GXD]TE$30CR
M49AP<&5M:I:7HX(E8:KC_7BE??:1EJ[7%2U-VS(W*2IC3!.+02GH<GN<_Y#P
MC_;$1_S[U!G_.\AX2LZ8=8X=*!C\10$##E0F^J=2J5?N/%=YKC&!^L6A7+\Z
M15O_3HH:FN!AA$\!2#L4+FB?=,UM51Z"4N>'^Y-^Z;V]%Q]:?WE)+L#G8*)C
M-B3QDFM=>'=&HHE[C-GD:^B?6D;/YR<^PM*[=%R@V'OF9AD+R^<?866%<%<W
M":FA8H)Z,>4;N,$V PS=W+TI,K"%@=-NKZ^WWW,HU+&:"@")]OLSG6\WN-FI
M!X4JV&<NTI<0=NXT4[ '3BO1#3:TTX/:;CV0V!_^4H/J^_Z_#X]3X" )V3IE
M"$A/D[%1ZJ(1:[\:-U*',R?*LK^<2KD;?I<GY-(A[Q%!VY&J4NA>G5J6"$IS
M$]-*F[8IR&^"899(.O#='5C^C9\KKPME9-9[(D3%T7Y<&B8/\Y\'Q=1V1!?4
M8#4(C#S[.H&,J7?VLB!JP[)S+I&QML]]L"1)D\C6-OB>L9%%4[?,^U@IY,.E
M=LI1-&?K>=U_A <@ ,<]"=Z+>8S6,"[Z23"8SY "-4D^+'^DM\8T[28Z#+("
M0_%Y<?9G.)=6WF+4F H*@$"GB+?DPJ<M'6K11&'NDN:ZE"T?+5>/F'88 $0A
M+#NG$2=7UC?O=HC.[?SZ__8\YU++6ALJP\P^0"F]O_HH^&NU:@?'78@A?W":
M#=;6@YH%N)8B7H6%F6X? #>Q'OB,O)KH/.?[T4QN[GYQS=PU\1<:J(.D?5:+
MR*O;V?DAAUY*R+JIZ;!^.JUK\G'H65SNM2,=[MJ&6+PQWYA+E5)O*)-OCRM=
MGS]>6%MZ'IC.3AL$!0H$3RE^G3/9"7A38K5> Q5[#['8932S +7,TCY+3!_2
MA 4&^^9Z/>OW"8)+XL-NXA?G5\ #Y!(_;1T-FO?=HEYW%5EP^4G'X1OJC=+C
MLT0PHK5:8P9,H"Q-BW1L;JPDGKWDTA8\*FZ2W'+-.$E,KR1:/V1[PO43.Y:T
MM-3JIN9@,:.@B%&\3*UU-AVX,-T6(!'G70=0ZF5=@]@GR0&?]:[7]//.&^>T
M!P$)HSJTFIUWL=H__VZ]=>[AJ3CQXT'R*S[KBA9"LY_LA:0W7AHLA*%% _V7
MJ9QM"U5VF<[;60*BV&%BL #GT'-38@AUM=SOQ60.Q,TJT>)AN\T4'7-UAR%!
MT@DLNS(2-7MG1YVA,4L9\"?KCNJ%27H*-:G]V?;ZRVCA1!CKM9I(EPRT0DP2
M#91=I0WK VSVVFT[J^8*?EZ.7-0'CQF\SK*[ &NXE5E<J&E)V%RA<IH*:H'J
M/4OXWNZ4=$GFVW<M.94KO@UV;C9M#-I4?S$ 7+)>/,E8-VRE#FXX3_[\U\#X
M0E?W87^'[V*WL/"25*=YYH=M<>?RP:OX6HO;<\,C7LPKG<8\OCB5XOOD*(!E
M\J!QOE)>B?5-):!+]CG?HLJ*&W.!A8(&+M!VDM^.=GHMIGXOI"3-M=&*%@WG
M"9DD>I&B<TT6UQ6&4-W,/Z/T\G2(*I);07E>A3U<Y.%S%*E(X8_I\@:''XBI
M(1,E>BO2/<VSB_7&^;)&J6MI:?O57AT=:_6DA45R-L7>H_)07=\:!..,:J4)
M;074!>!Z3^;?,Z*.A[>F"J5&>T+, M;"6D.4,]A3!.8GR,U_*3O^/1&GT&@L
MC]G(HQ]U\TW1FBD+!3M?=H:?'#%CS2I$"E0:69M+0>NHKW<__7[U^08=]%HI
MC?>4(R 4_KG(T#LS&YY^RF%F<\JQ:'AI'ZG-.W@LF\L8>I,Q[!3^-YK.G&NL
M&-AZO<=]>&[RE&-7%YO0'G(1)3D&G+RNV]FJAA\\ODK++'L2X[<6R?_''>IN
M/\$,V#K;0V/!K,SETI7X2CPRGYB:81(I*SL?_#R7SW>.?G$YC?:%JG6=GF5#
MBD7 L1\9+@Y7O]+/W.IVCTUY] ZRUJ:Q2%U7P=92:)7V^,Q]AP*LULTQ^"8+
MS+68S9M)&Q&7+O&6$;-Z5)TJ<]V@ME6AE/M*N?[F'DQ..FKTC?/>#D8W!5KF
MQ' G5G1K4@D;^E>>*VIUW,AR?1A'5\ C7*^7L.7M\,$TWQ60'1*8BL5FY&HD
MZ5^CY]W*?Z[ Q347R1JX</S/.H-3+?B4@^+\0EMEP\BNEK/"QD^C]D=?A-C;
M=WIZ7;LG3IEFX3T??4),GPM_<$7!925)$P4VLF#K:V./)==X*2 &?FYW*Z1F
MX$SE=<"=):FA5;G=ZG5JW33"0]'.;%?38KSV+4NI3:,W**@^7."L*1&[42>9
MH*A#:]&X^X6088-!_>2\1MG>.5*=9IN]EFV2U*1=<*F7>4G6;'5DB06EX17A
M01_IV-\$8U$]01P3J!S+=AR F@2#@?7X+J+5H%?@87VL5:J'GILFT" ER%-?
MX1.<(O*HA06^MJAA O%%C$<G$'C,RBS5<A35VIP(>8G9HZL)?O.YL?>V*F=0
MMW?^&0L)4[8/6?2!$XZPZ*B1ZO.C WIC)\+R([H!1K6/J<;Z!;F\)YSVLTW7
MLCKLCI0B-/3CKX!2+2<<:E9(^AYC[[1GM[T9^,UZ<56N%_M"56"63DESFPH+
M6[S2X 4\&V%%QH$MVD:CAM!5#3G<RFU32A@)'&R$TC&HQ9S85%4@]PPKO,>'
MZ#I^D%.7/O*8I"6Z2H<D^M@^:B-,KO88(EMH-OIO[[96G'+X4&X6#18,]86D
MS\(,<-T K1(:9HMTQTLD\-IX+]PZCNY:1$6!GF-<L9)K39%,7QH*#)J"@P17
M=]5U.%6;G;;SW(H#2>$79G5F]H77<C4:_J!%VNHI02CU0X8.BR[CMMO-13>X
M48^+WV(:YAJ6%6TGM[Y:,M*U-G(H%R\M.7JR=-.A%$24CBTYV\#(;# E]0<^
M);9$7B(N$'2H*1MK\8Y3<]=VWJGF']B!%N+-EC1;@'^:6,!R&_K8/[8R>#$Z
M#(K&K?WEHY60[$1W<H9%6\7E L_2L<Y\J;M&1-KM?']]6X#M7B8U&O(<FOB+
M!G(J9-^TWSF$M*=E<">ANK[^YO60*K+]Y%D\R7MI*SYHTRXK5WA%>P-86]8^
MX4B33OD'?O[_8&GYWT&77_ F//KT%460,"N,\\A]X66]*1_PZ7+'BL61QFU&
M6A*SR*W-O!";,P0?!D(;=SSH^\A3#EG[@P"1.UGS3A5ATVY6;;-!QF/L/1M>
M%BTY5&YAR_ 6VNG6>E!L<BC_4J)>#S[R5OBWOZLZEXJZ55O@@RBY_'!AT_KP
M>Y\F'T>DOHNX]N.AKY>EG4(E/0#J5MT ;RGU%7$<-1F!#[:,ITCM&V+LSU#0
MZ"R#S(,TY1:[67QF&YV?-;H-5V8.F#*<&8^5D3X'H5+BVHM[U[HTLOP>_-?A
MG8E3%5\</@JA[AM,,NAGKE/Y![Y^:O/B?H8+304>$.JG;&V=T";H2PA!=D_=
M='?Z7FTAP+9+[KM4 1_*FXN[^[QWLU9T8&YBHT?*R_;P<#R.%T=6!EOL#OB#
M3'RP6(PD)CT3FQZ5D=@_2P]P1Z>Y2N:I][X#4IPI(H1 WTUM,7)W[;F7PR6V
M=>#YEZJ\X0"&^I&1F5FV_07.KLER855%$G48O_JX3'6YUE!6SFRA>SG0#_6-
M+SPWUN;'^K6SZ6[6^A:?%G.J>7NW]K=/.1(0AE]E!CV,9AFDY9?8^MB&!_NN
M5K\+(7N-!@R@2=J3BJ)\ O'-&]ZY 77 #'\20]RH9GPU\ :PO\86P9WK:S*Z
M-=?E,ZHH;O)Z*0M)NU900P ;_59Y-\&M"= VK.=#3*;,H D(H-2JKT3F>JNG
MYQT5-<4E*"H8[NJ*S/%Z$>&U_D\%%6?2E<<]_IW$2V'%M]T^O&[M5'S3N&SU
M<DX?*=^>PFM\\>[@3$?P!>O?SF^8_T9T6B 5H2H[&!"#L\-($2U,3$Q@W-S-
M3DY!)B;>Z3E>NVH^"? ?MJD[/VP28U8?$@KEK1HVYPWT3:3]K'CZYX4:?_JT
M.Y?U$Y\X!6W'&T7_,55,MLV2UVBMXYYO_'=\47%Y19#..NI";'F=,Y\B/ H=
M+/ZQGP"X1M;)J[/8!4-SU((SR!WE0D;.5F@>BD9'W0>WM&4/ S&;U+H3DG;C
MI!?Y\LKZ?(X@>+ZZUK1W>I?>L2N$5_213'*."J@N9?\E6T'NT+*>]55-J/HY
M9<D.,5*J;7#N,[1!\@PD%YKLV^"]TK]:W1%XH[ SN^R#7?-$=IA0.*EO(1%?
M&9#M7BOH_-F=H%)]?[*68-GEF/+8_#*GHO25M42M ,T0[\C?EJHXKZ-^VAV!
MV"<(CL9JYZ)>E-LY^L*%F;B@ODJO>*O ZH:9GGA\TV6?7\@YRK@'39P\9O=Q
M()L. V.BS!KY6_SXHL5$*VBTNU1<-#,_$:6H,,F_/N2?OE-;KS=+0ZXF=C_+
MZ9^S_>K/=/"#KJ'(/A7_^)2C;O;)*4?JI0[K!O53#IK5JXBWK,G9?IO*IA]K
M#XO8:!&=Z_]E84-<>NE-/RP5Z=%;RN-C?'A]X5CZJ9G4^C)%CE?R4)IN&%?,
MDP>S>PX^WKQ>AH2L29OVJ]/=[O8V#=NDED>3CR#I3OC];3Q::'!72#/L^%6S
MWQAI9#_1&:"P?B3#S#5O^"O,S@Y/.8:9<+_%\R6;)4+K<@-7&Y(+-45SN6W
M!U=RV(=O7EB475L*4688(1V*/V<JHX"?-%XO1J+#7DV:BIW'-_[:LUZMQ8!*
M<!=^'I0/_Z[?+%UK4C2_)*W-OAM;^&F/7U7')O3G?RF#_AWY$FZ'"J_.>1C1
MRGV@M%A9:Q_C\$ F<FVM7XT@\-T!"+;:)%>8>/[C .*/RT/)BXT'?3Y>;+?J
MR>-G/^A %A-W>)I.DKV;TD"#<)&AT6.&U(UL XE/?Z/FWV@&?X80=O640[.I
MQ6L3NK=UB)@^?V5"?OA0^Y3CWLCD-,W>@.\(Y'4PJW,DL^JOD_]/&N/\QUEU
M2\6GS,#>#J5.S_34FW%C<_:;6KG?DWZJ>"BC$NHGG:3#"JH;SXG_DN$5*420
MI>7X7'ZC]#G[/-CT#M*R=XPA/GEO71LJ$%*3%^L/4J;9@4U? 93(W,I@Q691
M45>'63 (H @&<9D$]%S-AFA;(",E;@YJ*TK>V+E=S!L6F1JLG'''&3QVLWTV
MWW *4D-Q^LG*M_BG.P++R(I9\[5FF]28]IJ2-4:?OR9K$.9.K"S56P3?0)*J
M<B6PJX,:[?5'ES/SG-M8C&C66()BXD#PV(=PP5..C,07**'2^V[!JUY5=XZ>
M/EK.:KHY4%F*_S1+$^_U$V#T?-]5QI8P?R:'G& ')LDQO9,LZ4:W"FW![L\*
ME):3AY(/#^5Z?(_RS\!DNDNM6URH'DMT C3&G:BO/3QHHJ_4X?75O$9-'YCR
M^U89BZT,IGQ7#NQ_-FK]O\JYGT,\#Z+W*]]3G$ELS7JC61%!V8C+7VCTN#JX
ME-UN]>RM&G;-APGEWXPE'(I$(V):W..A-:+S+HZI2\-!Y5!2?6XFNV0PXI%J
M/)^?%BG&%U5<9K6^>ROQ;$ Q$R_&R0W@Z0,I*MOFP1D9V5!\@T;ERKI5N\2E
M IZ!9Y4,+6:?[OGK#S@+Y\$( :1$*RR(V=\&+]VDP%VG,CT$&5SE?;7/;]IW
MBX2$JUKYIC>-I(??A5/77%_Y$$(3;A+NW=TIN<^"!(=FT7'#S+!SY"ED3PG>
M@Q!+P 7!ZK>CRNYE2J='YYX/R)3SX%8P(1> >FZG'ZFH9'L.Q---MA)A4_&.
M"QLRP;^%YU*@=KH3Y.Q^/B](]GZ\1/1XK)->(/UNKT[+6(0"G&KOT2U)M$82
MP%)&Q1;%RBL.O\Z%UF"QJI$O:7J]D!O4BT[.SUK;Q:E)W!-'"K;>1%T<9<U(
MH2.TZT^2GC..X0GH>LM@AQ[TQ86U#MN:K7@&DW(+\/"MC7@7X6Z&H>!6WNL5
M^\[KZP7<UI)*D! R0=(A,L1W!(^+[U)0*'R:KUAKPF;9Q6"T<;>R466P5Y[+
M1R<S 3MBDP]L63_V_/#W/<SY[W/-_"_!15$=PEZ(-Z+D:+,"HY$WY/7M9F\+
MW=Q9%&O9@K@27GOMK?5-+,:I EIG1-O1-T.-K\Z"K=EN-3+^<YH9H[UZ_0VV
M%0S\)%6YLE!X[7QAX!5!)>"61DC-8?EA<"Y0Y/ELEWW0GPF%>)+E^2:(:*4C
M7%/0]59S.7LPMM]5VE.M]JO&C2UH&_'-  J^9^"TOYY(>BL5FP^'$'B.\AK#
M%XV?QKE.5W9.T8C7;5XIEEW!J'(J^ZYD:@SRKU-#U3NJNI:6YE0."Q^>M(.=
M-;S\_BO-RQ=S$>:-V/%'BT]+!M,1:'*&<&?7HSX_\$*]I:V^Y^7H.W<:1:9?
MTW=LKC<*7+0NRJ#5%N\%7$WY[IE1VDJK;SDIOA\>P%8,?C^C,DT%0XMV#.1F
M@$_*N3M,!1%VZ3NIQ1N%SRA*9CC_O8?CJ+C+C80N:NVLB5]NC%;3\?T4Y(VE
MI&X\!JTZG[/7?6+Z04:Q0+/4_\6M[2*-'IL?0V)=I(G6XTC3R<U:,XA%?Z.M
MU'$[),7FI_2H%Z(*=!U6H&XY'=.-^K$R-60TOMM)X7K=*^[PHPX1_K)2(C=+
M9K#@VE8ZMA9+JK%4%(H0<+!>WGO5G3XK,C![RK$4W&J1\\T_'0*]).Z7ATVQ
MZ#LM-37[E15]@(KR0E2//2C*-N6<>;IUDI5*7:GJU>.R;]_97HT1M2-]:DWG
MYE^E+]?$4)2W;>Y7"N@2]@&]L1[O4GUJP2,;N/'"A[2*W\CT($ -6)X'/H,)
M,--RP)70/"%\,A0EFM"[B?G[:Q;G"F<T1]JCYRD*V5PD5\E8_=@@?9\ZE?@1
MO_"-HJX>'A5]LZ)-#\;BS$PD)/$>4AK\_0_8T4C[&M6^00&-T1@O.._*D9SS
M2Q ./"71WC:2,'G^;7@Q46BXU1ZCE(#KD\*K6Y[1)(8:/VR0K%MNK X[)J\&
MURK7M"P;.6:8V4--/&15?OL$&YF.BGSUQR=8-++0!GPM19Q@E&2_?< 9LX3!
M2F5*1\=,^Z?G<',+3CLW=(H,_[:&):QZ\.2D, %Q\F$=2$^S23.-UX4(Y1YO
MA.[AV/B^QC2[+<.F"RK9_35_HK S(?;Q'J_3L+637K:1X'-R'P9!8FU8BN6-
M%$W!41.3E_2([H)1&7JZ$058<-_E6MEFU0I-PK3.W\"O,LU)K-F4CX];NY++
M+CIJ2X^B$3S;O>NW$.A<:8U:A/^P=[/K/UV9!"PZ+V7I0N5#TY"R'=*<VLWE
MUI+M_ E8B;/#_&M?_72+#L9:T-T[BI+Q36%+'OHE%2G6H-J3^(=J[U<UW98-
M<E3X5_I#C@6XP]>\5O<#?!.^^:1.L/-L7]YWTN;Z9J.W5OM/PN@O:[6OO'O[
M2?MFC83S70]H4A6*J(P%64NE6'8U.JA(C:\9B)&[9F>5[3R8]A2(U\U3#CE\
M,NE'YOR=2=-!)W'DTAR/]<F7,3*! _+G"S\(YCU)(0_WK!BN(+<W]NQ+7Q%S
M_J4D]O<$4%)61B7W<.[]$F&0K1(H/6B\=/;E\?%^!V_^8UTC.(HV.[SQZ>#&
MROO?K^8,0:E.6N%E3Y9WZ:<<[Z+.=Q\KG.013SF&$O@VET)D\P]L=.L*[BH6
MM?[M&>-_O4U.0-DO#O.!>_ 3@(-P!'S\AREZVT&N6].B@,"1-:NS^90CYC/X
MLRV<?)[='SG\3Y)T^Q^B;5G,0&"#O"_C*+G_>KO"[GC 9"S3^VI?A_I(K=1#
MT+)3.J_R!M>,@[R\:#(H!IL9>2%GK0?UXFHAJ%_E3& HN+[^(#YWU$1KHK47
MB8= 8J%M#?[H-+R'@K[":#^VL"WO<W$<O;&A5J)F',Z[O2CTBJ[(^";CE .,
MKQ[/64(E&;?C7SL,:SE4V7G(?\T\44"^W+[ >O&Y]$!T!>!6JO3L/_1DFIM7
MNS-EQE8( )TKTE[@Q3N:C\8G/JD8^@<9^00X*=#M[/CMVFTQHAY4+5A0B-J>
M "KI;5]/KH,MF9*7PY/8N\;$+@W$.E>DL^<;49WL(WMY>>M_.B+"Z[X<V,)!
M,ISKN*WFU'4:!WP$DB!Q-DK-:T0MMUL=B#BS^] IE\;1F99:&Y>"*Y(Z<(WG
MX(M8V+9E5=GS#)?: )\G=2ES5)EI7_HV0%76+@^=RL*$5V-_(]O;- 'R[>@C
M;7[OQ)8 $KQ)1"3G8-4J6?'N>(P%]"\4*1ZT\&RXHINQY:(4]D%K1*7KC<?Q
M>O1LFZKENN/7NBV!UC"I,U_=)<-HN_LA0C18\PKO(@$[R5_2@P<S#3T/4E?\
MF(9(- %9 S2?!2G1$P _#R"'J*KK^4?#80H+*_"GO-WE64R!\CDU^[N/>WQD
M,FE7V F/]QA#/*L?PBO'K?32^6RT)\:VT_D$PCI7;\*U>F+A'CAI(VKD^YI>
M87GY-MOWS!7;ROA*VT$[TF*F=![6[3X&"XW*A$9/*2AP7P$ +"@F8)-6LO:[
M0V9[Q*\<&H7]IQQ;^>/=IQPW@2]/.0B\C_QD&:@'OO+;E;^<*'KL.36UTOZ
M7Q*ABW^%7[:-B;I;]5KHSS>9&J[4X8 Q&CXH8$7B=J5(6UGME<^/C(&=$->;
M(PL?XFW_@3,C_GWRHO\E,"4U8&ZIOA5:2I03A"IR.<[(N&<E\%]W2*O=&$=2
MN/"^]D"RY60*ZKEL&VCGJ+[IRV*C0+Y!",\2KG7FE:*B[_#T0G98^K@>F6LF
M1CS=VV0N6U$ZFTS)77:<>K*M2/GY=R7"A=OZC:J)R,>?GK'=FA F\5N/RH?T
M0KKR$]23Z*LUY-L\#Z-!C6T4>H53G1%YK 0HE6 9OT]]M?I2+;@-X>R^TJ9@
MVVYC%V*:BZ, NG*TJ]JTW5>H8J8:6D<5_AUCN?02C'_.K_]E5.=_R7;38"[)
MI>]Y-G@],?]0K9Z88JW="WQH&9)5P;JGJH:0H[^K9KV4ADQ9T[?@>[Q*M<+,
MT +0=,V@17'1@:;WL?!6PPISL<]/_L(O(S;*1UM<A8GA'KG\_0+VW! U_&J*
M&:Q:&B\Z?E#:HT3\I;#8(,7)5<TP,#5<;A)Y9^('7VX_WS1/E[J6\.5+NSVC
MHX0/].?LFTV=Q@EF4CYM!@3K;V^_D$T_T83"!UPO5U]2^/0A(;FJ!5"=*9Y=
MZ4GMG=$4>3TR>HQNL6EVN1X24F63I_VY!,6!:1 -%AZ*KV6"05JV4BNLM%4
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M3?=V199-8S8&_%VI7]@BJ3");5/$>F $I@X.H,KYHIR[\Y&2BR"+_:D5X Q
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M!#ZW.*2X:7/])S975F7PQ4V#*IQ:H5>6R=9!@==/<Y 3M6_3/^ N'._YI\W
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MRJ8":JUK.7NL^@'1Z('N%:@!9D?S?/K*@ HNB M:4^N=&._:_C"9_TID>V!
M9CEIZUM&GBN!91%<M)"G?-B3N97)[G-,LJT::T44>8F8YD$'U5;!)S"?2*Q?
M,Y)80VI!T=1>F<K[I,JAM8&\O+RB1<QF9$4R<DZN1.]&ST5,W$__Q=RSA6Z&
MNW:F><]FO2'^4/I:J=W5AS#L%R>-CXI05E]X0E,Q;]\V=VP\:><NF ,[R!T[
M?4S#:F! &#2^+ +9#5\:]Q<T6LCN7KI6P"T#TQT.P!5.43.A>(@#;7S+J:0B
M5FB##E#?5:$*F.841)071%D$A'PZ-V*4^<!]P5&H/'8T1"-AJ,/IVGS-4EX
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MZAUAVD]M*\K,G#\2(I*GGTU_:+2E.-]"C,T"M.18?I<#W (A-1F\H([.YA
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M9LGGI^R 7G??EST=T#JZ/5*7F>5OCEI<D989+DM7W%?%[90[BRJAI<R/H92
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M\ R[A$08DDH8MIGN\-SOK>_*;G+8W7)7\<^ECPBD-%,CV_K?ELS#F=>6E=?
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M]"/M[<IYM@:X3@L@,=\'D B-2SL9+!S;)JT'"*1]:PZL"9?Q[/L'-.W(\B!
MPN2-S4!-0]/\N%3(Y/!*KRL&[LN'D,QM+^#F?(9S[> :R\S[5I._<_S9KXP"
M0FGYQ,;^95X-O,F/G^SQ_U2*U_Z^6!E53:_-:FP%H7?/\55LI->_'ZQZ\?!
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MN+R>7<Q89?!YR3)5D[]T@1UZ8#/021]H5XVY/\/I>4\\$ =4&)9LFYO.."K
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M$ 1)TP0"E-L'0""E5I&LV.SLA>\_<T#%R^/<YQ2KH\TNBTPVR+8Z:F]&<?N
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M>@#%^F.B9&&<B[%[LC)JL%:I$_;%HI_:0 *ET>F#]?TLQ>,?_]Q\_\V&B%_
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M'_)HV5M-2,NL<0Z.8SRRX_6MFVA*B/ZA;:H#=I#S(1Z%[ZP':1^G7&W7IX%
MID #!160@JEIUZ;? D49T%=[=9BKTU5)B*#CKVH.E*D_,<)9A-+!RFWR@\9=
M/F/%E:I&#7*$'I,2W$.XLB'D!AQC^:S%X[6862=!UI$U>#_3<,J% 'FS$])+
M!#Q)6%??"&JBM'@;K[5[&O+E%'761H\EU?8NK/& 8U:H5X<K0*VUVB.-<,?+
MTW6SA<&HH8R(;U;W:S?"97;_%(!P,RVD18N)EC\SRM<FE)WA!<C.L/5)D!<@
M#@OS!'5OF22$0K!\8"2@*X'ZLAA3V;SRHN^2A9EZ,2%=*I^H,;"U^E2R?2F[
M:=)K(<A$A4F!@,L+XV#8TF:W^[-<%?W+7-Q*7'I,LA0)[%"H4ED^(MI;E0S0
M_<Y91TL]$!LT$'/\W=' $\9VLH?K1I&E)N'<=/=<>Z1&7_X6X):<:*HH\>OQ
M3"RQR.[AO802W'B)YXCJ[GYTEO<]A"_:+I$%A++#377*\\(N\\5FU2*T5$9@
ME!QW'DCE0HB1@\'YL\]+ST=C.K3G$H;"]H8ZYH=G%/VVWOS'VK\GENU'RVU1
M,6;#C2X9SYFJ-C=*]><->:>LK\XO6R?<O36N=7=T$NTK+QNMDDY?TDT0NTPW
M[7OTR$(HXJ+1,),7M:@J'VJK=1W[(0&GBO&Q0>9S@29BVVC,JF@,DV]CA>I'
M&@- PZW]HW<-ORW':(=H/]XC'>5\NM*I]=3GCX8>YZ$'Z%[9ZK;+=UE"QNX.
M0STW3E]W\U'>PA=T'$"GHT=F;[JK!>*4+M>0&J9MH.DB?UDL*\:;ZF)?W?>]
M;1_4/.D5!2"B%>(G3$]GG&0[)E<&<Y!E6/5AO]B\@$JF+R# 7-8EP=23^\AY
M?:K-$;-;OKE<L)&LC"MY<PI?'OQEROT-2;IDZ3/'3;^LM*?I4+\%%=$?Z!.[
M33&T7N2I6<:[(4]\E-6S(V^+.A5=[@I36#KT'K+JP5$'\S24HE/1OHH)-Q]:
M'22LZ;L;'*F8'FC1#P_JVWT388^Q4H55?-DQO\SZJFZBH+O-P$&M4H+8%/"I
M]M_^^=[Q&WJ3[3YS6"P2/LB$M22&25+F0CW3$@L1.AE>4;K\-VF3W\[9ARGO
M/5[AI< BZ_!7+5_&^QN'T-SR"_CSG$*TXRU/NZ;T#'+'X-CJ^M!P@RG>KHU*
M9BP]P5 QWU>W=U"HRDT33-$_9N$ 5M/)][+=E)UW:Z-&<">U$^9=NO.H?8GP
M:I1<(%&IH@JV>DPXR?<2^+"O)=I7^UW^G @[HEL^\)K'#N5Y;U@)?BG/%[2:
M$UC(?]?R=^[?P:W&*KD>19:&F05TFE^FC1$G.TG\X@JN ELE,:+/C"A*G<CL
M;%\^%G8!"/%7 @_6*AX[+[7\AV#44C]2/W.H,_)G:I/T/G.,7Q[37%P>VV'
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M=3O8"!'6"IFB'*TQO@//I:T_?5K$&"XTC7[A7VU7@:2Y5;3.:. 6V/X"EA>
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M8?4W>Z/+JAU)"Z37$$0$J@)-+PH.:BZX<(U;/=\O)Y)P/1\R8*&NQQEU1B6
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M.G%44F;J\/G(7Z%%W)>N-MD8*0]!+=_:(?FYVF/#+-@X%.J(ZR78?*/;S5\
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M:1XL.70U3:5 D6OO2<)*U WC !9FT#@@/]A2BR$V&'TMMK1%6PT9;;=1M*G
M.8OX=8_!,S#[>I*C?'[LF*%$4]<1Q\W!-IW<E:/;'O;[RW%X&0!M][=,1LH*
MV5"BQ^KM'?1=<#UZA8YT@$H&/#6)23//7%9E@^/[ I,59X> -F"<#QV(!E$=
MUXP-\!J>P7^E\8L W \Q1)E19:G";ZZVA_AP=<NONS,5T<4$YM,KQ(5C82<,
M*RF YF :</\(][9-(FFD'_M>E,@T@S==8D1Q^PV+F9+?TI*_DR5V\CK:!*FG
MT:\[$ 7?E4B55X9Y;YN;#$(/3P.9NFM^B45:%P9!"K0T_D%J(!B!RM)]H=$C
M:*WV]9Q+5L6<<83ZR2YME1GLK[T F"$?\ST.5%;MX4MGQ!K-*NV7F/46E=4%
M]3];,U \D6Z32/\>:MEQ.W*WVO[WRR8V,\:HZ.'>$F@#_KZ='V4QKW5TV4$F
MQRF9@+'TOV8-$$U56N&90Y )\%H])4_B&JD+051AR-\ZQ$T0_,A\R-3[&"\S
M.1L3KZ&>Z<CW:PW':XT>1[IG27<_OPM&'K]<F8V(#6C78.:O9;413Y*R[-4"
M@_XS_6?\__VGK'->XFB;7UK<QYW)83/'@BH;Y<LQM3-TQ]8^0]:$_GZB7ZJ0
MM'2<5_2M"$G\\\_/]$IX!Q.S>8_-=?4*<A8 ZN]B2Z>%GPK,AE K)NDE6XWT
M5QBLG9#B],]D>7EG8;LT' $90G#S%'6"X!6HBGHC9GD>"NXB?E-C!68$&_@
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MKH$,<FQMM0&S]]-C[TT9>U6FFT;W29],KN1<WQAI[:BU_*[HZ=HRIC=MH'4
M^Z3NZ>#M)CWH=6NX457)J@7DD,>0&C]_8-8B\/<1)#M(HSBW4+'@NCBJ:GM,
M,MG2F&.IM=@6&="HU@*E!1V8;Q-B9P>N2]/G:@)P@3:_.+)V/I1UP_VG8>N^
MJI<>CT]E=E9,WJW2R&Q,0N ,49-6:.UK-PS"W)7:N_IP49*#%4T"\U4RA[F[
MG:-5VK9M;N%=P>"5^"&.5R/YL,-[=IARGM,:)RRI;L.N>W!B?[ J)#125TZZ
M2-/LQG;?U3\+K1:F;^^4X.(@\C>ZL+&_SS$Y:C$/3C1IA07WJBE?\C<?JJ \
M0!\?@D+*:.^(:70'-]<RHVS4&X 'DW+3[2,.U$]8F-.E(%E3Y=5U32U?W");
MRWOK\@MCU%H<>0&8AF8BT;XPA$G*/RJPYE>=Q@N'"-^-?RB+;I&K"6YL@O\J
M)&)8\J*P".G>Q'!<OHRZ.MJ/OE9RLVV&PNP?11[JFTC=&][;UHO.F)V9"Y-J
MF7Z^!O&L:Z14I M?C*7>.2/H":BO[]?0-,3-^JLZSINI4TZ1Q3$KCH%?S_V:
M;N KF3ZV-N2KO\RX D4J)D"&2 6<34TN2WZ=&W/'4P?7H)7UAQ)3!'W^R'IH
MU\>XR,""&_K0(T_^<(&7IUQ #-[?U7>-2RT@&;\*EX5!@-TB[LG;*.6!RI50
MS8J\@X_C KODL+&2'TNR>@H7T\:W;)Z3SI,^0\F11>;<R[.3VDK46\513^Q;
MSRJQWALQ@NMD@>6C,!VG'??Z?6,/6VW&1![*-&Y#B'RVNH15V5E;H,*_(5@J
M:DA8H*/XKAS%H.(G1;$6]7;!C*QFA%7N![;S=+<BQUBKD76H#9A-GL\'!N:Y
M66312_L]3!N28BOH-BZ792T_.V@0@*K+GUVE2=C;-6\)4;;43%#@4BK '8]2
M,]XI5#G$L00;CP4KX1J=4:-R*DJ;J#;X9,C/'>-$KU1BY,S.M"7WLIV\4T9V
ME]ZOI0JT,/5A)\\NIRWD.@X4J@@R-(P*1R0;KN>)/W:B/:LG%+KO.H9,I %Y
MIFK\HD[LH=2@OO;-.-4Q]W9"_6UB:[S)K1Z\_.;:A@:"7ABD5KW9[=$Q>%33
ML,UYCK-.PJV+,^V5U-QM6K2^MPC>S[]$''R-(%O)W'RN;?/>?G0*DX6- CP:
M70E25P8I/[ASX3)K/;:)FV=^Q?D4J.B$$&\ P-R?+I5\:H*Y;VPA6>9"9GPS
MHTLS1EG/C\J6G?5R%\.8=3\5(65##L2:'>7P>4@3=3&+C;"G-Q%]((E#21RR
M7FK"6(C[.[<"V0OD)A6?"',_F#="8YS$Q<72^81$(HMPEO):-I^+=([._:MH
M[=[I?FA,%:F9OQWS<C?+(T*3\GVR0'<-[?G T/%I%/&IGV##J%<]+>^]VE(@
M7&918>!J UX@P,H0;$_)U(AVEKOR6_MTCSN&5O>R3I?JU+_^5X*<N_VW#A$B
M,#=1N[S<A/A]$WFK+H5NG-E]<\9'@U\TO%Z%GGAE1:,;['<VGCFA+^4GSXU8
M\-#X%H(A)5=*:J ?[EHEA+&J]UN^:;*Y,*AAJN]NJ%B+D5F3DHUUC$CDT_F#
M-Z'L;B8T9&(B4FIL:8*2G[N&B" + %(40/RC?M$0F%Z8F[A1<)  5J+\"E?L
MUW,"^@6BM?"5'79HV'#)C7=%6__3 08&K -6Y=D&$)7UB^TGCQU3,V?;/NQH
M&RSP?CT72SC1AZ%R8MJP+"#8 %S0 <9^^R@D;>K,T2^YH!T<8)PYW;J[^FE,
M>=%J[@",SUE+*7_3?%UV<>V+IU=7AS,R//Q.$:\?"/BEW"C$["4,0+T[_!#3
MVMBL$'ZRCE"/KEG:3)N)/OKRCAG1]2^_=!X>+"RI*M95D+[B)7" &!NC]@BG
MBT".=Q5:W5]L*B8[,VO>3WXQ]AO*>%3^I0KR.@)(-?OX!*WU*I4%Z/%%3+C&
MZ.%40V\(QX^YB>PCI6 A*PH@( 6OW5",]$D[8/F<,K@I=4Y6(Q]BSMBO#H?6
MN]>%*T;_-MH: -7KCX[5[A !=7\]Y\[A8<9/I-LCT ;]N,7PB2!(1%8X>E*E
ML\>J7BP$!%G9B!["%5X-<R\<LF$'LI7%.X>)EGJQ%37<FNQ-8_J<1G&!'K!T
M$#Q@!G77[G:8"Y4@""7N]=P(V,0*M3@(:C880MFGF[_Y7U=R$39RN3_M87N/
M-13UG5&Q]]*=W@?*X")3(ZG-F39%_AT#G[$LD,_K$WH]_8IR?I:)C5(8=\YR
M8S@596RC B&M%!\,N[O,<O>0M*:&XUYCWTP@O_5#Z)F.\B]1*]AC+W[;CD:[
M?+]X'*BNNP*!\0V"&3Q#,U9)XI,F#S3Z]35A8D86%47]OYL.<*;8("G#7Y3B
M@_.')I\B@YC)#VM\"D,(O!""C\+*+L/<"<L\"EADA]9,&,WJ$'1'0HEFQ>%-
MXZ8S_YW#[@:R9;8J?*@6M"G:/%7#4> ]G<1'T;L%D9/7D''P#^4CD1JVK*_G
MT.C@CQS7K8D4I]6..2@U]-2QLC@/6;FKJSO(,=OQE$CUR4V(H!'4.O9:/E?F
MF:0.:VD5.Q%DK6/ROQ^RI1%^%L,9D@.6W(Y3"Q9$W+Q\PDHN)QMD&9)J(4NF
M>R?) 33ZE&KYHO.(9XPA 10Y/E<!EW;L'$("-%J@&MCKR^Z_XQ@;H]@/(7!=
MGQWY\,B&R&#(WL";\FK91_X,XDUB>Z%?)Y-(_2'#RKQ?[*&_'9FMY''-5#9A
M>[M'J(P+9(TKSM"5G*P[O:)<DF>B+#]H:I<]P4K"@&*9$15UNE/PN87TC)1(
M#N'L>OK'KI"1_"<'X9QT_H.1JBLY>6%=CQ=Z^/?>9N.U-Q7H),TF#X<2J11Z
M]&IG[D,WU:J \+$,,Q[00Z@E;'.F$'5HA!D._FFB@,]ZF;1,>*O%!,]/(F9X
MIP\Z.X^+%WLV_,SEG,*\ WA>U'U#@SGVY5_2 ^:^GA-1ZPM17>+W[*!I]-+6
MJT>0)'$N:HYW9-B-]UQ6%@[XD>Y]!8&'DU%O!WS*)(Q>BJ%#3'CGLU="J*LR
MN=/6:TJ/P5BQWFJMRO*L@;UA -.L-FE;/A0)B ,K= 8F)'S9SZD3@'X]5^R(
M,EV=$UI.5Q"..3)KD;0<[LL0HPJ_OW? N[O9NK.^@-5@9%FF$1E)R,PR:QP(
M,M/VU!;Q34??+Q:YGS FHJ*K&YB0MO)FZ"1]_S_*Q@1>0)'5Q<-]I2VM? 1$
M12=HPBI-P.==#Z9-)T4VHUL<73:P/@I/>D&_=H;^BB_56OJUTYN%7LE^^PY7
M3EFY,PRJ._)@KJAWVK<OV48"FG+\0+=&]8"S\C3Y=A%%&#(7D9N7FWC&HF%8
M 7[3QE2-XEL>J_"U9>H)C_^=1:R4NZU2NMPZB<_8\\^DKA9(JP9Q =K8#\1)
MX$4]HO0ED=B$-@HR^;OA(?M1PX:FUZV8,,Y8T,.9G^F3)JGYN9H)%##!A=]_
M(0X32NL8H4SNDWONDKIES <#!XM39'.P:]:B=42X<O11C.!N.6G1J^G<=RIM
MUEA>.#EZZT]5(!@GD>*0"<-,T=>77\O1,G *I%\?H#BRR"0'J!0S^$S*^NNY
M3!32"%<F984&L:0^^DU8%O@QN&O#4-0[&0N2ZY;T^"Y(:.*9$)!_E]2UF?""
M>=;SJDMO-9V7&#,QM^G=G\A6_S=B16'4)WGC5PXKM_TZ.Y=.X%G/[)S58>Z6
M',FV[]^Y4</#!A1:>QT@V ['9PVMXQ:0@S8]\"%X;EGEJA(D9[9_NWZ_.CQ?
M<8H@N.>(\$9J$CU=3\VM1JULS#")%,TR5#WE<T]8[$=R%/S' #FW?'_'.75Y
M_@ Y$3T>U^&:)D\S\ 8';"@(^HG.9?AM;TC9QUZ.O1PL7+1T&PT?WLZ[KJ;0
M_:S&QM=QKCS=<\EZ?6ZR.\\"3>6#D@+A#B @D-6->:IIR?D?!NT")))R'+M?
M_JNM\H9.P!#J>L6R\96H'8PDN\2^6NL1XI9>M$S)LZBKQ=G19_6NC>R3["PF
M@J-/N,<&\^O>0"E?''-0HA<.1 %QW$%WJW$@+C,U[#-<D:(=)1JBX8EDAAVR
M$3#BGN,>(=M27Q:P7RC1R<F*.&EU,?O@?S?.#'KM?&T@79NPY9OLX#M]<Q6E
M9??6XP&?7_/DBCFBM&Y# 0LH[2B\Q"[5RVRG)S^40K=VI#V<Y\6,/S3>O3]E
MC.R.>#<OX[938"(("8..V,-*,H\0  "L,C>I$@F %4LF)LQ19:@^!'P@ +90
M8)2:[G/RYW\9O["_6Z_<!&Z*AW.GA;Y-6R(L]N)G?&TDLI/K+XXZK\;R=,_L
M1;QW-@'O25PQK(A5*5"Z>\>S2DF6SO=BOSO+T@D(DA<DF9@#@2OQ'&Z%X?KA
M#WL+AB$-Z]@_6B]5<>?G%Z_][>)SH/=4F(/G!LY";BSKD:Y)%V08S"_>@/QX
MRPTMD<EF9TY]@"&>PC?.!T4]I13T>&W=<D05VD;ZM(.PL8T^:(AF'8;(9E0Q
M5NP'M]DM'E/U.X<S9UC;D!NH\@I]P2?O&EK+%OR6\/*T>;]+/?*"(3F#S#>
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MOL1:W08&R:X-5'V_B%!_#VSAZ8VH1TMF25C8$8S(UAR!BB%*9IG5>!D%!](
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M[&U62$.;WBN8"&5F5JY<H#9?@!F[28#.$$/2MP7;N8N;+EY^087DCY/PD6U
MD)_X]MZ!9%NYUZIE&<D\9,[S2[01R@"WALN#F=QNM:,K_!0-.D;,?5N"<98R
M0L1YE*[,#79KZ-KE6E\G"!6K3CO6U17+'G5*Q*9MJXVNGC%I"T^EFP>L#V=B
M9/*/HDFNKEKKTR.BGDD-"B&[^N7@06S/3=&N/D A<PLO_:4HSGUT93R]I=/4
M>E,]=VZH^ ;N$=ENBA/JT??\5BJ1R(PON)VEH/>>N&@*-459]A\%7!=/>3$R
M6D=)<A;/JG!IP]'*R5TY?D-33MT;>WI(-JU<>+Q__D%(-<J#01G8J:I11%:4
M"P#CBCFZ7967&N:-=,LUTTP.OFV:E(M#(E=Q!R<[D5EIEZ@RG?YASMC.N[4^
M"LEN'F-"I9-=KP485WBI::.Y,#1ZL[>\*:_U_Z<;RW.N8$RG#N+?6!K93KSQ
MZ]VU-TTK 045%7NV]J-=" *++_\7E_5ZYY'$6YP:8VD%KY)T6)@_0B6\9!:,
M4(&\'6P,.1H?[F',.A/9X,/I5:"JVT5?TPKA.:W@:IB8HT0$DCV7)3M;QE(V
M<O:X<B:FC354)7XG !=BO'5PR\PY,_>65M7 T5_W%5P\#S;J-N6!=U%V/_BW
M\S6$N4,&NV-MP9<"B>;APF?-F5=K"'?M7 +8T(";F4?0T-Q':[X1G">TT:XF
MCYW#_!](3CT)8I3\;WUSC$!]YVEA)@,(.U'U3#) H'M@+E.TH>ULHL(&5;FM
M=-Y ($0<_XZ>]_M/?Z5?R"M,ZQ;/NO%+I*H7A.6U002+1G]TB.LB]N6>N?Q:
M6[&[XFYF!\HF/U4]MW->-J;D?EJ:__/+XFIV<8QM%Z.Q>NR3O8J7Y'CB[4Y5
M1\]O0SW<'F97\;M26*^0O@P$&N>A7;-,#)N*L/5[L_/@0BF6U3]M3.H;97'Z
MY:MJ/;_]TP5 _,!.YV[(>8;FC:$@6-R/\TZ6W>5U+Y;%.LNGQS\1DZG9,'GJ
MX*%#D8##VGL?O_IPD*.]\$S>2?J\-41Q5X6 'N\9G>K1=A\9BE-6ZWL*P>@*
M'H;M+%L!V(WE#U)&1"<D6X)]!,#Y+HC 70J]E:OV++QF[Y_L_F;M@*?O1%V6
M8LN!\)'=HB]'5=>J39_C*>?BP6Y*ZBUR))J<PONO/.+$9E_=C_)^$0BJ1];F
M[8&\D';+IK>;$X3D0#"7S?T\%RE\NWSH^K=+4W[7Y-,L7U [I>MDDI_3AF)B
MJ(;_H P 9?/@:RL-;=J)\I,HR==6O?I:FZ%JYHP2 _-3FT F.XX5_J99("=T
M0]H=V3;>!I2;+=.(($I0B<ZJD4XHP:MK@L7257!^3CSR]4Q:+?W#\A4=CO@*
MN:*"P^PX-?5I_<HS9&,8'*[>(]OR9"FO*Q6FS?B=.,3BQL)=Y9:-;!A-%<'R
M^_*Y9OW-E6ZI!PV*O@:FX)9_1A ,++U[JN0%3'^J=*?HY5VP)0,O#$76<::D
M6/)C=%F1'VL<"D8)^H<->LN'\[%A2A]=Y=<SXX403HQ<&Z#-H8>TRZ"=S;/8
MS.A;]V<R).#];I_(:S3&V4L/WK;8/]O-"Q"ZXW$#&^]#3VK=N53)@&*?%JL5
M0"T_AG9ERU;NP;(S_$>_M9/+]?"\XN'AV>#AQ70_:5WN;Y+'6^HV6'+T.ES:
M;H1$HJK6QK;V#ZQ&#$@A05/,J)_6]VBYSN@HF0.E]D5S/2&['S1],@<<_]!A
M85,XW?K-[7A$Y9:%2RJ'H,W&I4G9X&RR=LM_IR,K>9W]-G8/'#):_;1;VL2[
MS<W],_.PJLW.^>5XAN*]NKF1M%VIQ\Z;HWD;WYK=Q[U&-D(0? ++R%5.6J(B
MN'L(SFP,<Q'?/G%C.W2M7PL]EA9OS0Y2FP<(,/0S8S(VU(=TI3V>'+SLBOKA
M_\;Y3)H:YBTG)W%D. _=GW4DQ;YQ7[/6FI,P69M+"UA-&2\0V$9;RI$04I7]
ML!CV3&^^ O.'CS&,]S_6,10(+8?A7WF\5 #IG;Z>5*/8JI>_,[$=(H1BF]KB
M'Y/$_I.)$7]G8@59N,S8$P5'2F@MV5L:-Y_Z2^+)M1-=-O9O/=/UKV;JE&E]
M78<55Z>? JX9L< +LG)FUE=[OVE96"S^RO/8*#0WK\,9>B&AJ)_JYL<P+NI>
MXD2>R*CFS@#&T",&%_\VG.B1M;_C.RV93L;(M%0I=[:8[Y"8*T-ZCK?G[B&L
M?,\7+[-!,7NR6R'A#<F*&7TIXPO_+.;2E$IEEC%SOC/<P]M>5;7C<8V/G*+7
M)GJUR-_T1J*=CO+;BR<IVY)_#AT6T=XF1L"O11]54/&GG^#8+HBR?L'>5YZ!
M).%-7%A._+'+S=I2BY>EFAK_Y^O^TL7!\Z C_/S)2]^O/$<WAXS=]+[53^7*
MK"7<G'$5M?,ZC87UV'ULO;?7G/B/.\3P7S(.QDYO1*78T?,Y0=]KH38BL2-K
MAP_:OO((U6W>;9S*CF+)[DUZ!ORV(\KS[]BE/F3OPJU8Y#?5X_?DVVJ9YOQH
M^YUW9G5@FU&PLU+'17B!")CL1G$:TA.2BG;[)59,F7O]3 - GPU^[D^0M%;K
M\F7JB8<^= N"AHYWPIU&6U:D.'D*3MZ4Y[C2#3Q9Q)SEZA'*ND._ALY.KX^D
M41LRU#I+6UO&JXI<7?5P]:?.B[O8!NG)#SMS :4!.>4.*]W6!R]]+HD</&NK
M/+XO16Z$-4RS.."E1&V._W.I[Y#1PTC!$^]B*$$@JU2N&,9.=T#/CC AGAJ=
MON 6]\SXP%$2:LP*)-C_AX:%<J_,Z*RNDT:='-FFW\G<CK^HI5$DI._+_X;
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MU(W3A.+PB5-U^K[8<\QUJDZFI1T@-+4_*"^G7@RY0]E86L:*A5CDEWD$7Z!
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M<N:R9X8&R?377S+21R1:LJ9@VYR9AKC^AX[O<0\6=L=I8VO"\FP*.D'\)I_
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M1)5_1"]E+H_UR *Q\1]0_TL[M_,D>E:_V[Z,*FV> 7;51=T ]S4<=17"5;H
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MZ:G*:8NSM;SUKS?&Y4JWM4BKW @5MO,>@P],TWW'\NI82\18SD#B&\[P2/W
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MO&7/W63]$?.!<615,'7_#I-%H'B78@@ZT%PMD.&BF+=<+*9DTL;<0*>&,%X
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MA3],*CD.AF=/D-/!%2&9E[82#&PB:G&W"TBCJ^L[$X5*WU.GIJM88H*/R(8
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MBKT[V[%O=!<\=\Q;S_3:[B(E-A\JE@4T9@STB55^?#'E+&.5UD80OX*3:E'
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M?N9:B02))FSS'0)K"EON1*;$^#@4']XBJCF=X5N8NJSZ]R?0Q#^<%@+WD:<
M)[%().NGZ?'.PT+WUD5AX6/(\ONVSUQQR,]<]B53S_,'HT?^NU_6?Q7QK/[U
M!!57MF""G+.+9E=PU*RRX+>?N6)AZ LVE@E./]8S"?>:;+U]I"$$'T$(L-%;
MM09,_JC;])US<N^&O^MFW]Z;T2,0PJ@/1$/-\4X!_,U 9@<N+DX#UE0'E2]1
M9[9K<0WV-#<B/>*'3>ZYL.H$1EYJ])$0T%M_@"B"[%\SL7<G[IC@T,VM]JY3
MRE/A'J8/#Z[N?/<70QG3U^?*3:1:;5&?N;"*&^KN97\P^]#5_0356%QKWDQ9
M\JTEF1PY:MX^%,2P[C!^5I)+F?&55U@3ZAAH.,Z#;X<!.7=_[H^T  ,CQ.B+
MH:F8O-GO:LG']T=&67YH=%?2B(#-3(O$UA]D%'EE6;SRD@S:=- N$^7:#'^$
MLI0%Z=-&'5-#,>-)6+&\,+=L/,3XMVZX2T!!KW< KM*Q^@MJ5=H??4^_\4E9
MZX$&=W<YH[BE0'_!P,\X]FY1SU,I0YG*J=B[DFM&F5>!BL:I F:!?-2-V3M+
MORPK52W)IK^R+GJ)^Y);Y.Y]YC+RMR]2A&;A)BQY>7DKS"QD8CFQ*YD5<VW!
MK;^?&+S]4\M]T\=T2C[J2ZE'7!-[-@(5]H%QE\6!Q1G7GF\IUAFA[M&CYEBY
MU?<RXD$MZ4B0?;:LIP[\7AH)(X.'+ZIP,&.<C'?FKC59+,5S9X3V]U:'4=+F
MO2%44<_&LA)(B6U,(DP<4P[V!HV0S&C@EVIPT^B"5!0*I<:\JV^]<$V#[TF9
MP059&^WQ2G37=(1D&LK(M42L"Y7R!OK#G#&1#+[U^')OU%)CX]D (RBQ-]2/
M:A!XP =^/KJB+ZG5W57)O]'N7!2,8-2;31(?L3'J+CG%Z>_I4GIT\1\[6.P(
MEPG][#W-T!:J;9[2]LGV\#2"GI?4@TUMV@W'6\Y65Q]<V6EUG7"QOW9B65][
MT:C/C0QUM7(Q =DG2MW*UA#0D6S"E)VWVTB:]$^?[)JD.@KR)!^(IH$KS,7/
M\MMBX06]JP&X5E\I31  #(MESQB:M4\Y5^4)"#^*"]G366*O^B8_("*NIKV2
MN7<U[<;YKV,G8DVL<M!?KR*K'"!)QN+M3_,P=[OY7>_M?[+)S!14,36(:*VO
M3IA*)'ET'_Q<RG;P9O)J%MI,=^;+FEP/V2G?7-R&HZC< ]1+-3>6]O"$^:A;
M)3VO>UR,%I[H+'2AHCV;%&41C56:8]@$MU*V,D^%90Q9W(U4,5A(@.:43JL8
M61^RAKXQUQY,:3O1KXTXOVE1K[]2KE(A?(=NAP43:B]K!72HY(G_V.A2CU8(
MCZO32(B4J 2$3*!K6$7U>_U]3]6UQQWT<P(M0FQJ\'*.[+LKW6=R/\K/9[LQ
ME>9&XZU99-]8>LXG@@3.$QOJXN)B?[7!LZBLJ.X+NY$23]/M_GN[IT$Y=RO_
MKIM1\"C%57O\BV_/C(5'CSF(P.<=4&5?&S]5K:QS*&5X'>JB06\9M@$6-R,5
MFR@EG6!FH9FU&MF4]M?M]9VR^$& ][E85G*OD+%2P -MIL_*'RL<X<@7#3/=
MO.,'[SLR14'N7JQ[?/[4&\Z.2O:2-,$'X5.SB1(!EI3 )^FK>VKE7KLV_<>O
M75'[VT"1.^#EPE?]:-M&E:WL.2/(6'GY%J%5I5=%"62Y%$H]+,HZOKW/)E.G
ML(46*04K?Q)7W)^I_X-G*EQ<Y])8-9]RJ<;9<84!S#RW]HVF)5\;C->$=OJ2
M[B)0I+QY-= NRT&!;M8V;=AL/1SX2=!Z?UAUXZCKV"M7L)6SXG43Z"X]0)SH
M*SMQY3W$#A9T9372"31=+3O"E'?8\D>7N_T"THF]$K)K2;RK?KL[L/(TL:25
M..DN1TUX[Q%R+B?,9.:C;LH;/?>\<>2!EB@?4XC)\'GNDW&(>' ,CGL+E[-(
M=R@"031V4.^W9]L8M$IRL!IZ:1J_<LG'.C@2.(7+QDH67C3R*[FDENA.F1IC
M%B<)S;>8M&CN9[-GHPU1I2R(]2*4-P:J(='U2J:3H4K]4(RJL/L%6IYV8..5
M[R9YJXZ=L1,*.EIN@OK%K!:J2O>(.9FO$!]>^H!\!GP SI]6<%DZ0?"J/*\G
M5L:T"BP2B,L@,&_WHWQI"\M0^6[;G=VEG%!V0FC.48,N(5W [/K=&X"DXT<I
MXG^;]^6KFU7E6O?W>5_1=N&9EE_G??&E?YU%"A$0DBN:X_%E==HLQ61EY;NX
M!)M9>%D\;A*SE\[=%Z<><_V+G%F *@3*T=I$L0.H?'0#2]S05J#O\2/>5=[7
MC4X"Q>W1_.3'C\([P\_?NXJQ:?TC>@&]4Z&'(SKA<N2I0@,@,R-ET2V5UX;!
M;J<=9H,I \N%0MJ7=GZ9$W]KT5%7GHW(LPIT.]Z>,DG&K/1W@9-)>N4/O,HC
M?()_.^$WJ>54#6LI2K4\6BULD<BUHVCX-=Z@DQ,'O5PJTTY)3QG\UD.!$ :$
MIB):Z<L1\EUXMR(_9WMT#"<K6X3;ZYWJQWATQXLEBWB>>:.4-SP':+\!]$Q8
M&0CH%A;RRJ!I,]P=G3F82H5J OA"6*:!%42HDT.Y3?%\K?^<4,#HRW6F)@OZ
MYKPY.IM*]92VC=]?.MP)EKJS*QL'QVDM:\8M,O)5>+I9MF-,UR2I+[:/T-I_
MA6VYN4W\*'ANG&S")EXG32ID0J$;"/<ISJI[KK-Y729<9K[V@=?.D3Q)0YLH
M2^CZ7>JFXL3+#*MG-\X?*"$#.YOR/PY8(Q\@XYK_($1V;(,^/IE\N"Y0%!\
M+_FA'(MKA)5E9Q<&1K]UOM/Z<U%6>6O>H7O\!RN/S3_/F/\H6Y(9X2*'3_P>
M!4()RS.GWR7,<S:X'S(A\SJ'Y,>-/B\*IN0<?,/XQ^6RO>;EMHLRNP@)P'40
M!OA)#BK8JK>XPF?I_N/ AH%D*462.\*5Q[5<' IHG(@\QSO^$<LZ<+PLJ?AN
M)FBB2/MDHRU<>6B<EGUJ':)[T[+O^=KS,)R;5YFYXG?UL_AT9 /%@\DJDJE5
M([T:>6@U@1&^C^C(*0(Z+D>0,*$GSI43FHN4//VIQU0ZI_5WXF>N"U/ET6']
M+NX]IE\B;9*E-N1)3-*7\@M6&A;&"?(Q?-(K@U*K[GI!)E8;FK;,[[O[S:B1
M2<:RY4UCD+GQ$ZI0+241W$!45B@W'IY_=B#9MZ27NOA-@T)5G$?O5H5"GIM3
MQ0SV"5E[LDOB,Y=5;GHD!%=7T/,ET"PB_Q9H\_"U).55W]WM8*BL?-;=Q_=R
M1?=3)?2W[7QNW9T-5G[<[0,P$+M_&7.YZDBQJ S";R(CB_DZ]U?>&FS4*S%7
M'X>G\2@K:W=T;&85C!;T!.G666BL&Y3L_X<V6@T4;D#[968BXEJT?!"^7D=F
MY*M4N_!JGEP/1F)#0[ Z:R ]-2SV-RC+1Q5OE;D*H#W"("R*TO&:8C3O^X&-
MO+S"P+Q?[V0NGGB65X+6/#M;FA=W\7T]U4\[7?2?HG#%K>9BV=.K-3)=W ^C
M[^Q>0C*2K-8N ;M-+YQRFW;=V95"#:1U"CMX;I_OAV)F0E:9]0\!5UFEY*,J
MR!9NI.TXG'3<1YI0KQ67CZOPBG!*&%!6;E-TR&H;+5B,Q2DZE9LS/:N]'53C
MBAU<QT?'CHW"O&D G@DQU6.>U;Z'QU;;M&TR6TV![)5J[7"@E]MFBG!\]+ZQ
MW0X95R6+T[EQ<>E(53[4]CT9/T)))/N26%/(U\-JX0' .*?><3<*.?3(CE']
MO&LXS6TG@OQ'R3M&":PN#MMD")I2M2?SZH94MDFR1GN>J&O2+!P)AW5'><W*
M2F@?+U/^=Q4"+/#Y+I]C'<%JY8>U"=X"U=#*H[,X-3D(1:]V")YX=>)LG T)
M?X7J81%R>F;!"Z9Q/6L&T0431$UULO(]"5\/38%3() 9364N.Y/T;^U4V^<2
M/G/]]"]6?-)TJK$QLZR-'%QXY=_<->>3*1'>-FT _G5+VB)?>>Y]IKI7O8#T
M39-,V?MQT"0%$P@=1R?A$9""P\D1CEZN_UAU%GN1!%#FHUZ+K^3A$3(T- HQ
M-'P2D\3#/>@UEDWW*'%2U5=BMG<1.Q<>G,*?B$\>G!R3D4[CNNT;N5-?:FC=
MLX7.%D7<I.A$I_C!Q&/*1X/FC<T)4J37%G>7=T3V1_FC'\*OA%?H>AX[^GO/
M9WYSLI:<P2D_<L^*4 G='OK&?13XZ2G'F0V>V2J.5*WC7@L+^[=?#[J@WU9H
M*([@%FH5S!<^P+R-#&7/-7J>CLV+)TR>J+RUV^4[_/'(-HBVW_1I:D#QS-&4
MN,(X>'?HSC%L;['@VZ$W)</G_O&O[Q^@F*VUP=%LC5:S=8'PY_HQ^G0QM0@E
M;8TMT]].][K[T+23ZGZ#Z\V'[K]5K\ALW]_>S\BDUEVB@5F\P&4SV=VZY)\<
MV%??*7OY+I7>%: FMX':ACRC%2O%?9[)( _V91X"$";T-,XTVV]EZV[U4EBW
M<'R'\T[L$JO9MR$@"4C#E26ZVE'\&?&'V(D&:8@,5KKGRFPU[<_[3[F.HP*(
M;Q1>)=B_R<]^YB+,>ZE)XP%A/R,@T:YJQ66)$I%&]GTS-6VO ,S%(+8MZ>DF
M8BB'['F[!XH)$<"8UN?=P\LH.T)YH,S)@#] S9ATYQ11%)^V@XC)<:]RM0T"
M]GSF,ELP%3.R80=T[D18=(6U1.:V*F[LW7;XHV=#W]^'J!>0;M@7L');!B^;
M7NU%AEK7TB"6';(QD(C8,;$,G>FQ"$R>X]U!Y.\ER\JUASN+XUM'?JCM(2]
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M@)GYK>U@WT@1M'^+]B;1E ,-C;!HKT7*(Q2I8V<2:8[6?U S?D"6B]1[86L
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M/ <$Z4K)3Y;P6)LWP%6GCQ4LE779 %?2G&6F*R%D''3D4]):3'$ +%HL$=^
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M7=5PQ$'-QM+$+]?TA."@NS*:Z*&G[!P5-SR<A<'@;?7R\O)V>K=R-OCX6O4
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M")K**T+NWM221[,+^&"=D:)YY-18?O[D&C)2H/7B6\ODC6=LVYO*6NL@^MY
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M<SMLLM#PW^YMG<]CF1^_"U1$ ;[NXT8LV$QKV]P-R% $/WDK\Y3CHJ$;2(U
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M;NQSFN#6;(K/2SPK*TLN?F=+&6=9QRGI+O\\OFM-I>S1&\<"VO-SDY!,FF=
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ML?:S>Y\7'GZ(#HC("*Q$.HA8:<6,0D?-@E KXLNG$JDM,NT:,BG>R<<M2!=
M1,R-51S>&,\M>I@F0;BZIKE&J/.P2"_;(E:G"%#8B0UU:=  UDUQN0FZ]:N1
MC[ ;KH_82;>TIFU-(QZ )M?*P2[[&!A2E:P3F6L>,EI,'=CSUY\T1[1:(J(H
M"Z=9:\5ZB:5]<\S-I;MR%Z\!5L!H#SICLRY]4,QD]5<<T(C@.2,5PSUP)OX]
M!#G]B7^%J\$IOK]R5<[NXX"WS@]!68EH:HI7VRP*ZV);JI=N4KEN'K>60%1
MX9*E1FWB>_=N-/DA5Z=@WK4J_(M2NGA(G6_. @-AC.[RM"<" 5A%FZ4%8,*Q
ME$/;T O_22?/HR@)]X43BRNYC-V8&^?Q*TWG5/Z^C73=.ZL=D V!WK>*#=/
MF;%JV,K;:L&Q5J)='.7NS<[O\A9D!A\1#^&:G#58 1C8?""T)QHPJFINM9R0
MC<(D?L#XX*3D4OL6E 9$G4XX#JO+TIQ$#4(^#?W)",T,G3FSZE52Z)T2%%\+
MLLZO&_/,LUO-77^:7F!S%^$_PX^&N $,:P\<K0@?2C/2'CWDBG;Z?3IZT^O
M_;3^64,_I?7AXAIZTD=4H<K,6*B!*!Y.PP_3UB9*VKVS5\(^ D*C$:(1Y.V>
M$'8Z=8YW8S%;/B0,H(80ZG71@UJIZH7F=F'R0M4,_&8UD,EOVAPZZX0TFO>.
M#R%IP /!W%LSDXTAVF/T5*:2UGC6M'_ WQO\?\]-IZ!K0,ECW<X>A7RCP 86
MILD041D_D5<ZP,-+,;?M4:^)F9 :=ZG3'@6NOH_"=1= OA4N_]YI%NV*$XN]
M^+ROQ *\*6S;?W(:Y]7>IE),PC4!P_9)[0#@ONI9M,S![2\OKKS*O>3X==9R
M(<I^0@LJ]AIZ#U^JTN*T*\P"EWE8W>W8\4.!]2H2>UC@?#113J0<5K<@XG-D
M6RQ7_E6L7VO!SGL1:Z:%V&[Y#NWQGQ:8>+-1[XH%J0 :BN8SB4D,2<!(A59F
M2V>^ZIA,;N>7R4E$21<K<E?^TO[?& 70\[^0#F3L_T_C_H>3VN?(/XN-"Q?&
MD"PL6]6?95/3-E+\;"0_UD/@T2K0B,T?G=-F?Q*X:@=(/3PQWD@16&A-0YZ\
M;(L1BUC>$WC".MZX.&E['/5'AX=RNT0T>/+ ^.5.J]6Z2[7-YTE7[#9?*)Y<
MJ.W78QF8Z37Y0I2G V0.B:E60 *V]NJ!45V'\QP<X;<F); NLF0NIY\GM1MR
M-F&#L+^>5VT(_41$IE?ED7^*GOX(QM?U<CM[!97*A4A[.,"20A-I*^K,1*R'
M0?3M:,G1K1?A0YM0/#2WYW7GAOKM5B4(^G78YC>?!F#1;)'.!R%P V_GQJ>)
M-D/U+'QR;7XOK0A\V@7JUREMB_F1=9@N0B7&>F^UOLN&G0\5>B*EH:MAX$ '
MJ'<FS84P6\U#>^R/-Q9%U >HW>6^%Z"FF2SYX6W)(UHXJ[X3UE TLVN6+C/=
M@B$9OUU@N3TJ (B8(K!D7K)9\#)5514 LF6"0LTHMD,VJKI2R_V;DQJ*9A3G
MO5SX9Y;8IVNU!=I?),='\E2P6OPB)9[KD,!P4R[#&=T_LN7!'G?^V6<=G9^)
MZ7M$A4\1%+"'?F"A3+^:H<1%V7VM?72+?$"D\6;^,V8U9^J@AU#>:)6%V%7N
M> */\!JF"9//"^+I\"$@\DJ06FL;'Z?M-'C*;<F4$J3O-[M&4(?17HJVITZ]
MAB^'*=9%X7S'XJ3=(Z_QU+KQ'Z>.7L>4 @HV^%4KLN/[P]I#SU["@CZ<RAI4
M;E7L3GRS:S;_9=? #IU)SCB6S?*V'7301AL1[LMP.9X_XD<@XADQ2X-'_S)L
M/ #2:+$R152 :KOO.L)K43L*%$5%"GE +9Z6.]F$5A4$KP(:KUI7&E(@HSZ&
MSW$4="#OX1MOB*P&O="LIR_-VKZXJM.^QL\2$'.[<C8_?7.XC31KF4T]':X_
M@7K3EC?U_O$Y,F);V@$I-TF36\RZ?__5<<F".V,3\SO"=5VI9R\]W(^W?,()
MGR8[<4:/\*L,D-4[\W.T\\[9T@D_::C)_6;;2#/]2(M217!=V>U"^Q1WZ2?Q
M*>Z2*U:O.D;_Y=%/)X?]X_,.E]]*D5"B^T47K^/T"3%UYF'14$V[![41L.NO
M.4OCO[C7SN\SW8ST85FVH@.D$P>#;R+:L.V1A_A0=#4$Q 2+"9%R&:3P/8;>
MUDR>#'JBRSA/[%O%[;,8TVKEF\-I-LJ?/Y[AWGM("2=Z-@UEL8T7_C)Q%-<S
M+9.U13SB;YZ(!X>,X;%(402/ZN!'P<@X[ICA]*IPG4RKLJ,>.X^TS#.*(5_D
MEX2]3@SQ&JK1TOQ#@NW(\>-NLU3;$>0<L??OF3&IQ[.&MNB)8=. GOM+W 41
M?I@,5-E?(%>OL-UR>0N/K$"G"():3^_0G\,P*XL\F[L#>\:W':D80DG(+EE7
M4__&MKUI41N%P,XYFH4%!)JAG] ;$E*G0U"PTLV]* R+:<:*(LTV%("0H[WA
MA[%*[F[*43[[5C=GWDX&[@I.KLD1N$S-#Y;JS-Q5;P+=W(NKNMU8H.HBHHK[
MQLG*TDCF@G-?$+N@(L^[3W6;*<KHOOWD5#M($SO4O".0G97?7[$EQW^K-\K(
M/&'\K^N8:=-\50@@$NJT!:[5C?$S^L7/4JX:CY1BU[9JO< /J2.H#W"T%Q.;
M-S; JR?=%V5=QOH[AC;3Z-BJUCI\<"<M#6"UW=,U5*S4_/B :WY1,0QV1&J9
M$;WF?T1'^C_#&D]KU_SD8/TA/V7D40>]Y9>NJ?<9('-\E#D.8F,R447&([]Y
M-RSZFVU4DHY&WL+Z8"79#,#R=P<48U&4V2I:#BO?Y4XQ54]=0HGD%DXOB2S<
M(>FI#%!'5PB@\'_C4.,>RQX7Z0<6/8(/@6L?0"+XNJ:J:Z[3?=[1>3=A6)@\
M_'J,7?X 3E%AP.\G)W13<DPDK59O^HG'TI&+<_T9N<TBF7V_95UQ]9ZM52:K
MK&LDKJ2XT+6R5L5N[8"LBSH0A*3R@%\GNB<<'M^<O> R#3T^CMF<VK/\/# T
M9&PA%JR?VL(BVT%62=B7@<,OJ.\K;K XM_ZY'&YD\,8Q)D"BR,-"FW!,,OV.
M2]+$;1W4..WXP A^/%R[5^@((WUF&6W64?/U\.&^'X]/-<FZ+'HI1'PYOP#G
M5*C5<S<GSS?1#X7QR%G848?;+;)R)XH1NNDB[UDJG7--_W<?D^K_#]K<\'_K
MPUEK+C/+\9T_8[UUF(=+@Q9_GCJ=.P<KS1[K+S84K#XXA1@75<<X?@_T13[[
MSP>$*XQOD8\Z8_Z\>_$T=^%N@W[/;2L=[FD[2/MO]M-XQ@F$7M;"4&XXO.5S
M+ ]TN+/$R( QB0JJ;U4,ZC%/H]_$W)HK;7PZYA30Z)> _VU0"3*$^$5NK 6P
MOH)AD3L=.B&5CM@AW47:X'014!( FD13/&H+U!6E,.XR[7,B;>&LO;VC=(-E
MKKM'TK<;49\8N-/NPJY#.P(10T7$&>(,<<SK*Z-R0^D,L*1:1Z!F@ZE?1$76
MB<\O>E\VT7TR04DPO>J--Q-+3L%U3; /TP.C2-ENJPE4!,BLYP:6ADZS6VXN
M\<$5:8.$I3R>%@G$= _J3=<AU'#%VQ.Z[^=YWNL+P,.O#&ST_"'<.GI6T@F2
M>IPWJ9QXZ."6>N!@X8JK?A+4\['F6DNEG5SEA<2+K,$P$=.$)/6J/A-?A@Q6
M4WVW0>)*"R1^4/VQ2)F18E=W\PI@&_QE9X.>.G=G66W(2C#T ],*EVG:U^$N
MU[$HVVXY,2+V$-'SE^=-5\D::,Z$3L[BD922YK"#>[UG$VM10;C,#YO(_EYO
M;#0HS3C?9UU%>TZVT6HEH[([9,L$_ 5M>-PB)?%=$O%WDI7Z#B( %-#L7?A-
M:]D.%P 22]Q#-JU\,'(H.72*JF#;_O^:&5>F,W4N.4QH9Q_;=Q0*7^US77)X
M@\_>Q"Z^3(9),_7#+KS>,#[&"<0P["\Y"M*K8[WO%I^G_9M>3. ^FH\]N[ID
M>\$ZOU.LJS#N?6+V[QWFKN:!U$%;88:+JD5!@>F   ]W'?!"KS\:F^KL K4
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M1ZML:D%M@IW^5H[V2\#XA]L$Z^Z>Q>_Z^-7^[)P8WD .',[;@HH;1Q](XE_
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MQ@FAN^_M2Y2B<'56<YJ'%4TIF\))GM$6G?U.:^U]ONE9YSR[&K[8OIT8[K7
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M_%)-.;DCEV-^R@WF#06'!8WU%W7OU=YI\^;])3+OH7D"@8=.-&UT"08 3-.
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M7G!#^I,M>LZ_S99,'3( M(/]YD! WB6J%H4"U*VB]B,W;T%KX:K8<O*)3NH
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M5;'UL]94%PP4&<=<G_G==D:WP^\O;]^\Y=RGE&-&6;1XDR'9DF9V>W2@L;?
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M%9-(P4TW_0FKQ:"FVES&V.?^FIP$35PV*L^*%UT$MR$JL1 LZ_?]%=6</ 8
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M&8;,>O9>^NZ4RQ3+U[XT?L52U[$;'";1N!ZH?=MQ<OV"U!C?2K L_'X\?&E
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M53^]DL6076CU6=JF4ZH)V:-EYLHI12I1&*_QZ&*E1ML9HB)%?ZUSV6GK4]?
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M8V'7=?%BD>V@"+]YB4Z!RBF/I9SL]NE[Z(:B@N/1X!4'G)8OVD7>KG2U9NX
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M5^*I1E;?XIWO^'_K!HV#.&2A%ZP4%!3*OM5F8F8QTZ0S?I@_IK/^!&+^MP1
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M@EW'[,8)UP.BM<&_6$J(Y&W?[>];K$Z?GJ>&!DT-?UKQFI.-^/%9?:M*?NK
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M2 NL(M7J&AJT*1=RA\GNA!*U;2X1*9\52DBGBZ?D@#Z&&B'+!R$)&B*PI<=
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MX*DY[;\UZOXW54GQO8<O%G<4(8U1GVM["N34'L!J)P*T<;^^()"G:4[/KF^
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M2#OM)ZL84\G9&N!RF6N$?7O_CGT#(\>NFE-!J!:0M_'14XV! *$87[!45FR
M#Z#,H[63TBRV>G]"IA$L=7<RNS"AC,RM-$./]GZT]M.^YPF7_K%ON&^-R&X6
M.?+8A\D(*Q];_R)?,+GVB-7T&P<8IG@<O?-CF%)$482:CAKHTJ')W.+4%&'\
M*/_XU/6CJ=#R)TUITZ8ZA6&?1$R=EZ;[S?MM7GXUC57W" 0LA^1.^J4C(J!
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MY2:NCJJ, M=3W9RU0]-7_L44FD2.L'?;UK_8$-VX4]P[&F4J4>R75<H^5?F
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M96ZOE.X]<7<;F9L(9CZ[+]$W\C5 (3Y)8;]D3N,;!ZR3"M@Q$8BV,I6:UP_
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MZ+FD46!S/9]U/<&C7NTQ$0DZYR)H.8#J4AEKTUZAT,H]I)<7AYK9#H[8H>8
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M]O!)#W9T4$["JZ"B?@AF;-VUB@FXY\*'V:<=NZ5'JWR]N9$-$(R'*[Y ?FP
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MMWX*(3BI_I:BN4%))B=.(2MNU;VT,[WW;AZK5@M25NW%'NA(-&G.+DMVKFI
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M#;!^X5QI6SVVKE@)5QBF0JLGX(JT2,YI[VL3ZQ3Y@TJXN>4E"YIPP:(%D=6
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MU0Q9E8 2\'K-.S::X[25F'Y8IZ76==H+KTYW-2<TF00"47E!O'@5?'T9[O5
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MR@8&=]]!?F$7*XJP.=S8A_196D_(N#+J5F/>P"%^,^=\YN_J<D)2"<%J'S9
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M*-8?Q M]N0\OUJ$>,(A4$Z>M_1%2Z_A$]5*>A/]BJ665IIFV8S>DT]ZMW=I
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MF:=JU<JB@FOG>PP1?R8_:9Y<9WL:'93?+7"GG!=8IB9^1RH#ET5'.XWX?F'
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M%JQ3_(KC1PH7M;G/ .O"901>EMUT/*ZPX3B/<I6I>=<-K3U]:N7#99CX#]5
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M\^0_JH"OHL76)_(KCSGG];&\1?4B<W2QD\*[C<"\5R^FO:Z(NL*4ZN/>49E
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M-J8B8-:->*#,U@H6&Q5QN)QK]D*J7 VAH)_:C4BO&3QWM6:P9*M@?Z[51'W
M'%*^;HQ;'FTA-527Z>%V"],%ZZ]SM)&?I_2Z*3F,NIEN0O&JA0(B8)N>=#&9
MUI-N7 @;C7*-?K=T[KW!7_]_<D82UA%OQK>O#760)ZHTWOKJYP(-6QQ>3RUH
MW.1M'OU&O6O,V8OO-68,I9A17)Z)+> ^;#WC@5W+OR]$OO"BR9&4+@(#6INO
M3E>:!\R)Z2*W7>7FE 4N?]D:L!D_(>E6(CE/$:M^&X\1%A2NNE&YD9",*4_4
M+E\M2#:X;\,2!0K:<+;9F-CV>VGCC!1"Q^"PL.:0PA#TJ)&TR\0@LJ4@2YK1
MNCM$PY/!:-!/7$--O0,4&\0%J EOZF['%BMN(696#%+G8S-C"\LZ8U)G/_1V
MG6QH]#AIN) O[-Q#-M\3//ABQIMOJ-7RQ_'3"Q6 E;8I4/IM?L1UX@DM<@2@
M"LF$[V\ZG1(%"7G@5&842650*;2>7AW?ZM0<1*^",M'Y:K&6KD/Z#8ENDW%J
M=SKY;3UN/[1/$5$!U@!T>%]G77/)L&S(=4=_S)KT0E,-RV3+KF10"?I/WX'!
M8)H:745MD/DIZ/.('*3 ]V*MC__7%'*4U_VB]V6/G^#ID%?;/:_=?N^;\].7
M5ZXWW?(=2[O1(%W+?1##JU\_$E(F:%AELSE)V.3:=LW?(1R8J_6SIG*H]MXH
M3PN6JUO<EW.+L>G\D OQ.0&.*_%B9F]SO!6_[9[1GG6[L]G6!1].'\M6OQ[;
M#N0.J6E<CVF8YM!M#JTR("DP4+MUFBTCIKZ#IC97%STZ'2QB3DTDFP^&PX2E
MGOYZ0HS\JI'ADW]_0CC_YR=$<7<70M:599GLF1P-[[4K)2-+U!64JEB\5J%7
M^F754QCL\H^ES9(Z(?LZD9SO$$6M&'\^_@:2>W)A@Y+ZX :-1K5G0];F>N-$
M5CXYIH%D\GCG.&9LQ!#^_<HEHU<#?TNR51<UPO==Q%<===;_-<$W"3)E>F6!
MAN1%V^%P9EYE8$9_/=#@Y]>]FZY*\["MG$1F4S!0#>OQBU,:"T'4\(M)JL9-
M2B3])\?$O^+<&?W_?NKQWP>Q9^_^4,?O![%G(W^HX_>#V+/1/]3Q^T'LOPQV
M_ /_Y8C]EV8]?^"_'/_ZA-H?^"_'?XL<VW\?Q/X1=_R>\$?<\;O"'W''[PI_
MQ!V_*_P1=_RN\$?<\;O"'W''[PJQ9Q/_#U!+ P04    " #%HP1=)0B_T2!5
M P#:5 , %    '!C<G@M,C R-C V,S!?9S(N9VEF #M Q+]'248X.6&R!!L#
M<   (?D$ 0  _P L     +($&P.'____[_?_]___G #F]_?_ +VU,3$Q&4+>
M (2<" B4YN;WA'O%UM[_0DJMQ<7F8V-CYN;_UN_O[^;_0DI"Q<7%",6UG*WO
MM<7WM;7%>Y3O<W-[.EKF6JW%Q<[WWO?_I2'OE)2,<];6C*7OK;7OM>;O&<6U
MSHSWI<[F6M;6G.;>Q7/W<[W%M5+OO=[OA(R46GO>>[W6(4+>G*6M8X3OA-;6
MG,[6UL7_Q<[6 (R<YL[_I:76I>;OO5KWWK7_<X3FUJ7OSM[WO>_W.J6MYN_O
M,92UE!#O4M;%6EJUC,7>G)366H2UQ83WM4+O(9RM(8RMQ>;OWM;>UM[O.L7%
M(<7%.CHZ,<7%SN_W.L7.K3KOC,76K:VEK2GOI4+OSISWO6OW6KW.:V-SI8R<
M$(R<4JVU<W/%C-;F:];6:V.U0JVU4DJ]C.;FM=[>2E)2$)2<UJ7_&93>4MZE
MA"&,I1#O,4K6C)3O2M;%.J6]E #OUK7_4N8AYIRU4K4A&5(IC)3.2G/>2B&,
M$-YK$)1KM2&,$-XA$)0A__?_$!G64N9C4K5C&2&$&5*$$(RMO;768ZW.YMYS
MYMXA4H09K:VUK5J,O=XAO90AE-XAE)0A:QG60AG62J7.C-ZEC(S%M7/WO=YC
MO91C4H1*E-YCE)1C6F/>A(2,A%(9A!D9&>;>2AD9YAFM6G/>YJ5KYD)KYJ4A
MYD(AYG-KYA!KYG,AYA AO=:E8][>&1D0G%+.A%)*A!E*YMZ]M5(9YEJMM1D9
MG CFYAG>2B%*,5K6&=:U2EJ$M5)*YEK>M1E*2EHA$!E"E"'.O2'.YO__$-:<
M2H1S$%+%WHSOO5+.4DJM&<7FM<[F2D(9YO_6M0#6YDK_A._.YO]"E)2<"%KO
M.N;>&0!S.H2<C*64A'NE4EIC6N_%C #%C"GW&7N<A)2M(0"<A*VU[\[O<XQS
M,1!"6M;O"$+O&;VU6DI2  "E0EJM0DI:E'N,C #F]^;O '.<,3%""$+>  "4
M8U)C +V] (2E +VM (24" "4YN;O    "/\  0@<2+"@P8,($RI<R+"APX<0
M(TJ<2+&BQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX
M<^K<R;.GSY] @PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@
MPXH=2[:LV;-HTZI=R[:MV[=PXZZ4() N +N%DA4"D+=0W[]Z ?L-')BNX;N(
M#RM.?%>O!,>0"SV6''FRY<N.,4O&+.%QYV2?/P_I+&%T9].E2:->?;IU:M>F
M8[<>+3LU;=NX;^M.'2%U,H%1HO@+/EPX\>/&DQ=?CIRY\N;0GTMW3CUZ]>G6
MLV/?/MRNW._@PXO_'T]R=.\H$M"K3\]^O?OV\-_+CT]_OOWZ](<P\ ?\ J-H
MC/P7H'\!!JA#@0<RDN"!.C#H8(,01BCAA$DT6.&%&":AX89)R+#A)AIN J*(
M))9HX@(E+H#B)BJRJ"**9&P2XP(QDD'CC638F.../)ZA!(]D^!CDD&<$><:1
M11YQI)),GG$$DT\J^<P14U9)Y97///,.E5EFV< S7S80IIAB@BDF(P"<T\^:
M;+;IYIMPQBGGG'36:>>=>.9)YSUD" 3:GYX!*FB@A YJ:*&('JIHHHPNZFBC
MD#XJ::243FIII9A>JFFFG&[JJ6?DA2JJ1^GYX\\0IZ:*ZJJJMLKJJZ[&_PKK
MK++62BNLIIIJES\.,.( @< RXM^PP@8X@H+^+<C(" PJJ* .S&(PX;0Z5-B@
MA]5BZV&'&O;!;1+D;!AN$B.::"Z)*+ZH+CDMUB@CC3+*&*,W-BY +QGW[EBD
M-T7V2X821Q))QA$#!TFPDP@W"67"3D8YY9405]GEQ!2#"2::T=R3P,8<=^SQ
MQR"'+/+())=L\LDHITSR G55YC)E,%OVLLPQSVQSS3C3K//-.^?,\\\^!]WS
MT$ 3+7312!^MM-%,)]WTTG^.*O74%*$J@3_L88V>UE=G[?767W<-]MABE\WU
MV6&C3;;:[ T1!7"_^@J@KQ=@0&"!SAY[K+,70*FK( ;,/OLWA,Q2:*$.,E2K
M^(75)M%'M=YN&#FX(9)KN>6;])%YBBSVL8#G?;#KN;KQUN@-C>3L2&..J^=(
M[[U%]AAPP0?[2/#MM _<<,)1.MSPPU9N:>7$[W3YI<4Z   %QXELL['S"33_
M_,;2)P!]]==#G_WTT6M/O??=<X_]]^*#/W[XUI.?/OK;KW_^^^9KWR=?G];?
MZ?WVYX___OKWS____@L@  ,%_QJJ&?" #$D/JK26*W\P8(%1&(UP<O5 4T6P
M5!2$H 0;6,'A;#"#%OR@J3IXP0F.4(.ET15_ ! %![B0;KTJ$+&.E2QC->M
M@6-0X7)(+<,=[G$5 J(.'N>MR!6Q6XXK5^8T![K/?8Y%G5/1Z)RHKBJN#EXY
M2IWK@!2[?P6,7SGRD;]JMR2 04EW3]K=PGKWI.%=J7A'@&/QM.0E+Z&I ]"C
MWL<2L<<^>HR/?_1CQP Y2$$RSY!Z#*0B"[G(0S8RD2!C66-D-ID_408RCYFD
M7BSY&$S^)E!YD9DG-1E*R(P2E)Q,QBDMF<I55E*4E,DD*F$9*%*V,I:?9"4M
MHS9+4__BTI:[E*4N?5G+7E[RE\;L)#*'><QB,E.9SGPE,7F92DK^!H'8S"8
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M'JGI>@@W&JG5<6IFD/\%,C>RA89U<R F1U"%\WP2$H<0\CC8LE!X>*40M1<
M\"$CLA<"*TF,X#D",0( "P"C^SF_,0)29!<2, *I0YT#,03R @5W@9W8*8E&
MXG0NM:=+\IUHI+L,8R40<UX^N5Z%2HH78XJY%FO%5@YZ=XMQ?)\21L?[.6MW
M7&MY?&M['(OS:7=^S%\#-L<85JJ:<HS3%&0$M'G+6F,>2GKEZ\AA&WH'+,E0
M>[8%9,G*B,G*2F.;S(P<-E<IBHV:A&2!EXY=VTJ/#"H-W,I304X<?'OOJ)E:
M=C:S?'!D(QPP.J[[X39X"V5@]K90")!06'MU@68$>3<HC) BEWQQMIN"$R'_
M,CPM-'R'D2-S,'>Y=4$.W%<N=.4/(E+$FG,0$: B L&P?7!- V$C!C$$-#*Q
MM-LC6Z1=0T(P>HHDFGAJ\@>HXIEJ(]L JV8\:PP$0EEV>I1'O 9M@-2HGAIV
MEUJ #\V $>W0%]BI&-C0O+:!7\DQSN/&P#:JI"H0]FN8R1I*C,)7W$:#\MM5
MYIO*]Q:$Z];2*OV_+$VU/[A8?BG3]@;3[:;39#G RVJ6/GB7!%QNY8:"775N
MKKS43P%"PKQ %?1Z(K2:XTI9=WM"6BB%ZN%.W?2V\UB:%;="4<!:9$W6=?-/
M;8:&SH)#MJ5\]"JYU$R1TY<M%6)]2+21?2#% DN<_YM %WM]SBQ2%R,@ X9A
MS@# Q%+,"&2  1*@(D"  3DBQ?AR#M6I.OMRIT$",-P9?^X7=;=#?W]Z:CG9
M.R'[1N991Z5X XUJ@!>62'&<O WVVKDHVZM(VW+LB[6-V[?-B[N]VT*%Q\-&
M7\Y#H-0(MH G8WN5H,4=MD:KC8URW)2<*= ]C(?LC9SL*-/-R)4RH<ZM*)C<
M3) <MF;)U.2]%.DD91;,A.@4H_28-3 JA>>MU1-GKG,;R[JRRYWI-F 8( 4Y
MA@?9D$R:I'%&9P8US7"H9S!'7-G<.!YR <!!41QI&($]IN,, (S (G%*Q!8^
ML !0SB*E T>\SF0 !'<!._\GA9W]LE*VBXE?? 2:2'4>ZR2^FW^GO7^HS5,M
MVY6.!(QM3&P?#: >[6L&J(H_+L@^+N1 ?N0^GN22NN3N::D,G= +/91-'I;>
M>]./"8+EJX-Q6:L!S+XD6+]?WK]A'K[]"^:))>:.1=(SJ.;P2^9I;N9JKK[@
MVX-$S6TU[8.+ IA<5=Y^?A1\^Z(&UZ-;368@7,O[D4(*YX02Y\&GF<$#YW"%
M[K<CA#4;%R#1$$,%R4]F&"#PRB MO"P#Q4,Q'-<2(D0O=[ETR'W"A28L=',C
M K "NPGGC"*UO@EF-N&*#<3U,G1)<! Y8L5R"B24&#O%OET8:\\QV;%JA# /
M,Y[_.EF>$Q.*/<EU#3 "I@@]#/U?K:VS!EW'PLV*=A?'?)QWXF[NP.UVY![(
M_K7N$O;:O<B ;B>I ]HRAA+*WCV.RBTH3FO3W:UYD3+) D^T9%NUX!CP4&MX
M"&_P .\H V_PHAPI9PM7(W9)I\S*?Y[Q01&C$;0VZ]3+P6Q9YAJC/QIE[IA[
M@WNW)%_+5?;+PVQFPN="<3-\ROS?SC)R; TX#*)RI0[7UW(X4SJ',.<A0#0N
M'S(0QL5$=#&ZM#ZFX>STN"X0ALVP .O.[6)F24 &KIXC\ P[2:>=0M(OQWXP
M^=PPWDEJ-7E>HZU>P*/&K;;&B IM'2UKR2N]0_Z*5:[16)I*:UKY,0J8]Q!8
MJ1[S]T"ET8(OJ?@)R(7_@:<Z3.?6^.Z&YGQ9;XZ/JG!>@Q:ZF))OYD*]5G<^
M^2_]59;_^9S?2WKU^4+XYJ3?&?DK^I1_;2U]YA0:^FW_J?&V_Q.HDNB[%ZX8
MM,%,^$&Q7(7\V/+8REDA]$T/5"J>1=\4+-;JZBLR1(:U:2PL'*_,QWPJ-[D(
M-7T88J75@M=F-@2>JP/IL0E _/07WO0,NP ,(!"ZSOZU;L1D$*<B8F;X\C82
MH))-!T;:220 <>:,$H$%SY Y@C#APB-GCBAI>"2BQ&<.)5X\\HSBD7?/.CX#
MZ?%9@Y D&0'HT"_!RI6)5+YTZ5*ERP3]8MK$"3-G@D0\<=:\.=,G39PR>0[5
M:;3G3: [E_XLVD\HTYE2?5:MV52GRJPT$RP  &!(,@G)"I5%:S9MV;-LUY)5
MFPSN6;AIZ<9-"^#MWKIRW<YE_XM7,%^^=/\6$FRX+V' C1$K5LSX+>3 E!=?
MGFRWLF;,E^DBEMSW[E_29CT?YAQ9<&+&85V_AAU;]FS:M6W?QIU;]V[>O7W_
M!AY<^'#BQ8WKEN!OB(0H_IPS3S[$7Y3D$H90;]X<^O3GUY,KQUZ=N_+DVJE/
MK^[=W_?GSMVS;Z\>O?NP41PP<G"!D?[]C/S['P% 1@(,$(,+=&!$AP!UP& $
M!AUD4 <)$Y2PP@J3J% &##'484,9).PCB3XZ##$)$35,HI#8_-ED" !8W"2L
M"S8!"X 9-XDBK 5JC&:!)&);X*38R"#C'+&(](9()<DXB,B#!GJ2R8((<FB@
MAB"RJ/_*,S2R"".--@(IHW<R"M,C,M, B20U3X*BJ9[<S$JJGN2,,ZN5;(H3
MSP3*B7/.FO3D$Z8\WPP4J$%7*A3/EP#M<U YI2KJSSD5C530I%;:9B5OPB(+
MM+H\E0" SB0 #510.R5+U+7*0E6"P$AMU=169T6+K\5*_?36Q6Q="U>T3H5U
MU<MT#9968UT=ME=:@066UUAS139::%5=MB]BE0TMK6-EM2O6X[X%-UQQQR6W
M7'//1??;YZ)8CMWWJ).N/?+6BT"Y]=9KSCD&[HV7 >FJRY<]YN*]=[IV!P88
MX?.T>T]?YU3T!S^)[[N XOXN'@&# 1/T#T$$'>1X0I%'MO#_P@XK'!'#$C'4
M,$0=R#%1Q"3(P5'%^I+81,5S-NDC+$86B!$ '6C,$8 =PQIZ 1U<%(L1,A:X
M(:Q"H@: R*B':!+)K*.4DDF$O$[((2D%BD@AB:H\NR*,ULZH;8U" JFCCT:B
M^Z0.,KTS**1:RNFF3(/2&^^_'S5*\*L"Q_3PG0R7"?$$!H^JJIU^\LE-JP"?
M_*B5:GQ+K\[N4HVTOTXS[2VR0@-6M%?C^JRT;EUGW3'4/&LL-=E9+ZQVQVYO
MG7;8/^.]L,XYR^QSV%E5S3++B-]U,+C2A3YZZ:>GOGKKKX\-OGNW:WC?^=Z-
MCN'PQ9/O/>_4V^Z\[PCV_E_PQ(/W_[Q[ 2C$GXJC\2^___8/<..-$3S0_T(&
M,@E!J&0EXY#)3L:A$84H92Z36<QPM@D*5M""0 .:!2E(!AKMJ \[ F$(=\3!
M)2U@22=TTI+.D"0R>*-)!TD(0L@&0[051"(RG C;O-0V,(U)(SZ,&]W2I ,
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M*;T\YG0"IJ1]\^M("/NQPO7-:JOORRQ"XG?L\UWD?A]@ "I $EH9W@LV#&
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M#;CR#AM<#D6-! D@1QD@1Q=8CU%HAPQ\  P8,2@ @Q*$ATCP!PRH!UI(#A>
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MY*4I!Q2UP>!E1D\&1+9>"<AM=X1OLVA'S?6<&BSQTJC!NB-"Q59EM5!41)4
M2J4[7M?=W8[!0(J"SFUS1WYL"8!5#E1SR AM0W;L=B"+)S<+7.;[/U]M1Z8"
M22W*=T1N[$WTLZ!D&: +7B9K1;U!LBCN&G3'"8B&-&?/#VS_23 @]630_.8D
MMM&XG6Z4;EB'_=COL(79*^P^03!8Z.58NU'8*[DW@# 8@MV7#@2=.S?\9]WW
MU/4HRNM][\0WRKR2=A.,!/9^=/A(CK!@ $80,B'KI>[O_HD!?^\7__$??_UX
MMU["C_//CQM(?T9@?W>C&AW(H ZB?Z#AH U2/ONG_]>J($X$B$T+-@E<,- @
M0H(&!2HD2*;APX$8  !HT."9Q8P8-6;LZ/&BQ8T<1WXL:=(C(P!0$O1+Q-)E
MOY;]6,I,5+-E@@3;6/*<^3*FS: S^T4!X*]?$HID "3[<T]I@@84IU),<&\$
M@"$Y618M"B!)SGY4J>8LJK4G39<)U,KQ#!M4ITR<0^7^=*DVIS>*R21(V%MH
M+V"^A?H2!ISLKP3$B@,G8URX[]](!@Q@2.QBLH;)-Y)-[DSE ;8(B9-E[KQ9
M H '!J@XW@N S60 C_=2F-!9 V!LDRGP?;TZF>K.!O"-N@$ PV1LCPLA-X#-
MM?#5H*,DTVT@DFO8K DC'C6YJ'4PDRM[P/QW,IB^UC$ CT[\QM]D&((;D(%Z
M\H/<D[&CEFS 177CH=9<&.T)]TT\\+57#U-\#8$-%9.UXYIU]@6V6&&(7>A7
M:\L!IN%HD(TU_R*))9IX(HHIJK@BBRVZ^"*,,<HX(XTUVG@CCC4.X8\_$O@3
MA01#3.9"D$7R"%L840PA@7=L\,67:!' ]@!?2OKC7Y#>/; D;,H-X5\D3!I
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MWE*MS^>5)Z-GV'L'"S'5'T:+@GVOXAC;,J;0MS"R69HG*W8X]HX-V?2M_<4
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M@0IH+H [)D38&:% .J%KEME&Z!VQ:%44/AJF56'!O-E=*)$3J<43N<5=_>;
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MKJ^+L?DW4('SF(P&K&\]@,'4(;4-8IW^3@JTHO?;!N%6ETI4(P0->8I ; L
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MTY*JY%D%]D^R@I6GLY&497G/F][UCHJDH)MFLY1%N&W1H5Z.:%#$*;>@/8R
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MWKT[P.3W>^55_KU;_AS@N^5[H /PH,#QX!PZ( =VON=YGN=OWN9_WN>)/@>
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MM_<.^NTBKLXZ[\FL][KL[BU_W>Z5Q_Y\[JDOB'Q\J&>.9/;:&__9:)1U-CE
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MQ7]BFQRX3H+*O&VBC7NBLAEC*(3:LM?HC/=,O<\@*-!)J-QPO?S4J-I+#M)
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M$2TMY,TJWTUS>48S@Q(DN<UU,9B&!2Z1"CL!* C7 )%="BZH4-FIC,( ;
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M!\( 'E9%6&]<#[*(6DZ)C&CE8DN(3K8B8<BU<$E;8@YE9VY*"08$3E1@B=$
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M\7K7J ; !$ D0*(W(I^7G?3U!E;ORH S&<AQ(%3O.W(3.N!! T1V/H&Y_20
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M&.IZ,D6':QDRA2(97-ZF8&YD1Z8EC(*T:(<_C!VJ<%Q2#QJEG4R/;OJ!A*C
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M[_JD\( MJ<Q*I70Y[F!"F<.OFI-"G/.FCI!#@Z"P3P2G YDR#5"S TF16XD
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M90">'KW,;&(9!/]Z5E8F7//@SI9%5$DIYT+!F2S:6.HYH]!0QJ-)9Z.Q!)I
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M()\P"I<U5O_Q6L?TK7)!0THLA.K$*+0S043"!%PL %JLKEDJ17@S!GBL05!
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M"DXD>UE<+1:TM>I+8R?&V<R.4&.UWZ/8#RG[LNM^L8V%_8%,2&M:VWHJB@/
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MC*4"+"AOBL4<2,>4TL:,$GLJ3*)NJ@G[29]64BD?2J"$4J9TLLF6<LF.4E6
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M #Q>X.3K25C4XE=!9R"P'HXXX.$7AZ:%(@83L4N]V2?PCDA.U6%1Q!PND,-
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MQ,%#=?<JVTI&P__XLV.+*(B+J=LZC,+E=IIXB-I3##]#UMKT8V9>UL^FR4"
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M)"2(0@M'$1 ;@S!4L,&!$-3B0/P,!&!!!T\$$<#^) 2A0H*&(%! $R&$T4,
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MG4@B[\YK7+WU6%&0+!L.+WN]]U]E'.Q91 XIELD\ZCAR7N@)Z16._C!QQQU
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M)%=GA"PMX!,*6(F8!D9!BZNP85FTT()5%J8LL6)ED!,#RP2PL14VX.,JM-"
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MF]&MQZ892XA%"$Y1#KPE [[-6WT-1#N@"P#0 L)%5"00Q ;>0$1AP,,A!K+
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MNKKD1N/>4+.)?#G ]&B+T @E[ZLE[R2*MMD@ (,"1)@6D&(4OH&N#6!QF=D
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MIBDZ*EG3<M!MW9)H1_^FZ1:33>"][IVLZ=QILFY,3<JNF2@7N\\=\TU+Z@$
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M:[$BV[$C^[HD^[.7V$DL>\.JZXV)HXRB.W+_+4Q\(\>7RY-_G7*BU@BB*YJ
MPW,H]\@IKR(3%$> 16M.RFHXS5.L.3HK[>@17ARDKF*U(+>/$*=0'97&LI*!
MY=NXI&FED2M2;1JWSH(IA?N2=3M1@^JE>CIX,,F<(9E7AIIR@9>GCHNW8HK(
M@XRHW1&1,6G!=8J&43BE+G>XBC?(>D6G< MX*PD3'OS)H)RYGDNJIFO$^W5;
MPO>JR#5\C8.7JSRSMLM)ZV&\C.FJM2RKN+R7S(O+NZS+.\N8N1N5BSFK_3;$
MVBA.^G>BDE)<*4S#T&@I2MO%V=(H.KQ.\D1A"Y:8^P2LVFL_+&&]F?F]X3-Q
M  1RW_,3/RB")YA0_T,Z,_##/ZRYOM]*0"BFAMN9PNRKK\_!MQ5L1NUKGO^S
M+0C+FQ@,9R\8172FD19<P,EYG&-X0"28P<,IP=#9'#%YP(PFT>[;L*;YN&4(
MP-@IO_P2RB1=TJ ,P^^1."&:TL*5RB'\NLA7NL('TS,-TR@+RR9KPQN;TS#-
MPQB;TSKBNCILJ<"'2L![RNEC/9N2JRAJ7_6$S)P2JU+<JOMYHXJ*I!P'82G5
M3ZUB4&N<8!MGU?$#CU=+<4Z[M=8:ID(<4?&8<FJ,I&O\CU];D *IR>11,X?'
MSPEHUQZ-=TDEI\ RJ(K+R&1JD#))V(2MUR25'7*:J(-+R'GWIWIMIHD]D_]_
M^M>';,A%Z*=;>,=];<@K6=,F/=JD392>N'RP_-(Q/'PUK<+[B;J_U8G,1LQ$
MS)2:>MNV'4K[1<N\^LN^;<N9:GSCP\O$7<O7ZZJLBCR%XYB& \S_=<3'G)>X
MK&_UI6_( YGV5LW5F*O1ZF$6)[P@%Q(3Z+T;J&&[^\[2B(+/+)P.EJWO/(8L
M.*YBBRPB-F/,$IT,C%<+#(1'$8,WQJ;T'<$IP]'X?4:N*3/*F;#H*K=@&!85
M79[TZJ7QBJ\7;)II^.#OFYK_X[_]&D5W3>%:L; $VYWH"S.E?>(H_KGT.9^I
M"\*"(V#[:=/(E;Q' ]OK(8JG730XW*G$5\P@:Q[_I_JQA"+:T7B[UI/$M2J-
MK)Q*P'/+4TF8(Q?54GZBJ0)/]*2.-/K$OMO,:H2DS4L^NZM;55O%9TO%%";&
M/PK&UQC&JF+&@95Q]>@S]3BE:_O6"KFV=&VFCSVH'76E_$HJ,3C)FTRY>^>2
M"DVH<8RED)RV8/OA;^O(84C9>-S'DMXR>0V3?SZG^GVXCX[HBAO:>TOAD;S9
MDMVW*7[JJ)XT*-V>XO3*H)C;HO0>RB?;S782OJ42V&/*FXI\YW'"L5Q__)5*
M#Z>Z^Q?K01WK_ >8G\@XN,IO2 [=RDS-/8X\1'QQP QA2LN\L-)0^A4]%49C
MH62/_N:])=%AXOV9I;FL_RS8K.H-CN3MF>M+%/#-WP.][OP=T-(Q+2S&';89
MXOU]G0K.X"75SUM40O L,U\*8PD.+")-GF)XA65DSP4DMQ:ML)-,I?.Z8HO6
MX0+\T?#+\5 HX%5HT"7NL*E^\B@?RILDVI_$\IX8NKSNXB[_:46N[:4T\TCC
MC)]8PK?+(Y]JTS<.'S7MZLE^LLN-[-_(\QL+]  W\\?>U#A^GSW"\LKXU$4_
MPZW=Z__FRD?.VDI-?##>PC_<)[G5Y&1_\\7\NIW8Y&(_.&V_6U1\6];MLS2K
MC;IUF)=XPIV4L[LZ3\PVQ;MJ@"2Z* 5(PCU,Y$D?JP_FT_<&^ NG?,DU[8;R
MLB&)+Q/*EST(A++JI*/0G?*>__F@'_JB/_JD7_JF?_JHG_K_DVH%$=#ZKO_Z
ML!_[LC_[M%_[MG_[M,_ZNF\%O+_[$<#[O]_[PC_\Q%_\QG_\Q1_\Q!_\S _\
MSJ_[OQ_]T#_]T5_]K&_]K4_]VI_[U3_[UW_]N!_^XC_^Y'_[0U#^KG_^KZ_^
MK:_^Y^_^Z1\![R__]%__L@__\Y__]?_^^@__ !%A2 2!!0<..6A0X,&$"!TN
M?#@PF<!D$BE>'#(QHT2$'A!6W!@2Y,B/)46:)'E294J6*%UNK!@3)LQY,FT.
MD3"S(@"=&P'<!-IS9\::0WX:35:4Y\ZD,I?Z)#KTZ%2F2(TB57J5YU:M7;EN
ME6ITWL^: ,J>3;95K5&S:<NR9:MV_RT NF;IQI4 H-#/O7L!Y.VK5W#=OW33
M$BZ4-G%=OXT/&Z:;5Z]BNHOKII6\E[+?PH@K?WY,^##GP'X!?R:,NG#BQ:PG
M#V[,M_)FP9I1<T[M^79NU)0%8\Z=S/;IP(-K,]ZM.CEIV9%K"S^^.G5LV*JI
MQRYM/'GUZKAY?P<?GMT^\N7-GT>?7OUZ]NW=OX<?7_Y\\Q7(V]^'7W]^_O;]
M][>OA  'K$!  PM$L 0#%520G09+<)!!"2>D<,(IIB@!PPLWY+!##SNLXL(0
M1YRB"A-/1#%%%5&LX\06JVCQBAAGK$)&&V>\,<<Z;+S"B!Y_]#'('H4,LL@B
M41@2!2.,0/^2R2655-)))6<QP@PIG:0R2R.TG,7*+K?TTHPPQ233C"[/-#/-
M,T-8<Y99V&3SS3?AG#,$.^_$,T\][:1!SSY#^!-0/@6EH5!#"P64!C42/;30
M,A0M5(U(#=VAT$IIN+32%&C85-,=4@ 5U$]3&'744$TE5=13UR"5U1W6*!56
M6%M]M599:4TAB%EUW:&%7&'E-5A@A]TAV!:*74/7()0-HH5EDVUV66FCA=;9
M:*UP%ML@K-BV!6ZM^';;;<$EMUQSST77B@C4!7?="#QHUX-WK9"W7GK?Q;=>
M>=^M-P()Y)U(7WG_?7>(@0WV-^&))/#7HW]QRBD9"220>&**+:[_^.*)*^;8
MXHL[UCCCCS?&F&2)10899(])9KGCDUGV(&23-RZD99MEQEGEC"N.^=^5=R[9
M9YQO?EECF5.>N&>D-5;ZYZ"!/IKHD9.^N6FCE\8Z:*.M3CD\K[\F; KZQB:[
M;/CVRR\?_M9&N^W[WF8;;K?CIKMMM2NX.^T2]BDAGPK8^;O ?/H.'/"^ 4>\
M\+_[AE#P!0NL4$$,,Z1<PP\KIUQRS4NH@G//3>0<Q=!+3'&*%DTW/<0Z4D^]
M1==A9!%VV5_?$7;:;811QQN)E+'((8=<,G@EKX 2^.&CA-)'*)-GODHFK83>
M^>BG1P%Z,ZN\7DOKR^2^>S/L_'Y/.^L4_W_//L\?]/P^%V5_?45#D)1]^.&'
M5-+ZXX^_?DPAK33__CE5PZ,J-4!+T4" !NP4IY"P@S+LH :5.@&I'JBJ3U4P
M5:FR8 8Q.*L=U*I6I/I@!V%E*Q&6T%:\2M:OE/6J9P4A!<Y*5@R5)4,KQ+"&
MNKIA$&[0K!M&@(?> J*V@@"$;G&+B. "0KF2F*YRR:M=]U(7$.0EQ0A$H5Y6
MU!<6(\  #VC1 U^,6<&^F).8E;%G,7M9&C]VLC2VD6)NE%ABUJC&Q*@Q&7>4
M0!W7.+(VVI&/=P3D'O$X2#Z^\8][O)@>_;A(0\)QD'8,)"$?V<@Y4E*.?:38
M)0\YR45BDHV-A/_DR!0)R4Y2\I.2%.0I'7G*0X+-E>'9F]KR(4M:[F.6MJSE
M+7692U[BTI>[_&4O@3G,7N)M;6JSI7EDF4QF(A.9S"S/,\DC36A.\SS2E.5^
M_&9+^P!N'X#+!SCYQLW!#2YPY62<XP('(0%%:$(1<M 4!J<AS$W.<O7$7.?T
M2;K0?6Y$_:P", (*HQ+4H: '!=U 2X0Z%Y'.1*M[J.U*]"**V@YV,JI1'5PG
MHXWN:$<^ZM%'@?0[)OT(24TB:?&<)*4>(>])3/K"E5"P/"=9::;0JY[T="HF
M['FOI]X#:O?F1+[R"0I0UBA#")"JU*0N=5%+)114WT>#I99A4>]KGZ3_'F6_
M_'454R$@H*3"F@*K[H^ %<0460=(*DZM]:PI.$%:'YA6#6:0@R,$X0CQZJMC
M]>J%GSJ6"X.EPF+E"EDK#&P,#ZLL&,Z06\PBXK(>&P0?;FL-C[TL937K0VY%
MX ;@NNP3@1!:=B'17.YB5Q+?!80(2)&U\)H7;+LH+RY:\5U1(%ANN\@P,_(V
MC!5AV$0DYH'A2BP"C#Q9S80CG$P6<I#*A>XGF\M<ZIKL+VR$[L>4FT9-4K>[
MRIUN>*O+W>D6;;S:36YRRYO=\6Y7O,X%+WG'VT;V.E>[]V7E>1<97]:4-V3L
M9:\=X\O'^ H8O_#](W\E\TH&AZT_#_Y/A"$\_V$)5YC"%[9PAB_LS&0:T\-Y
M8QN(/YPV$H_8Q'=#<8E%S,W[C&>;V_0/.!DW./[,6'&&FS'C^C:%"LB3'3P&
M,H,FUV/,U9.>]-2GYS#4N<^52*!/'JA 3U0BSHG(R:E[J)1-)U#4M4C*K\/R
MZW(WN]RYKJ-7*+-'1RI2W_%N>$LBWI645]*2QI2F*+#S%Z!D4SL[KWIVMFGT
MJC=HGA:ZT-CK*:*#*J80,/I[X2O?+*S!IDF78=)L2NKX,+WI.V5:?DF5WZ(>
M-3](16JK](O?5O?GU?QM2@UB+6 *XD?  Y8A@61EZUL[B*FZ1G 'OH8KJ8!M
MUPIRL%5!*+8(77A"9O_+"H7(3J&R5-A8&4Y+5]Z2H0VU+2X=?DO;-0P7N78(
M;G-]MK1+C (28;NN),+V7JZ=K17IU:_9ZHM?"0OCP-Y%QMY*S& 1B]@B<?*3
MJ:F1X'+LKL80#D<"OZR_W.W8PA.IQHE7/([YS>3%"ZG(C+/&X1JG>,CS^'%1
M2NS@= 1YR2_V%YE)_.06K[@F]2C'EZ>\Y>FUK\8EKO&:C]SG,B=YSR5N\087
MG2YB:Z8UD[YT#C-=Z4V'^M.E[G2JOQ@_U7SF,K->3:5'\YI?5R;8LYDWOY&=
M<.'$6S<#Y+=T&@Z=CAM<A@HDS\9)KD __IL],Y<YO1_9R!FB,I4[9]"%ZE/_
M= -%O)1%!]$3 >-%#94=C"9*YHJ^#J,TXJA'-<K1S .)S4%J4IO=/*0OM/2E
M>(:IZ96D9R.PW@QX7OU-G]?ZF\9T>J\_=)E^NNB@-MKWWZL3434=@DP7E:E,
MG07ZI"JH]KW/TJ!&M?-9S3_]_8^LL#ZKHG#M5KJ:%8/>'^!<+9BJ$VBP_"#<
M8 4]2"N]EI!7AGTVLHK%PEX92]K1FN&UH<4LS68VLY8%MV4Q-W 9%RLX(LY"
MEPCPEM,JK09D%]AZK==2EW6!EWBK%P;(EWK#HB_:M][:M^,*KC(:+I]YF8P
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M>-BK7O'P5\;*E;".B*PI(*L$VU(6L)CEK!+ (8K.6I:SKG5%8%QK6T\4E[6
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M2B.1*V1(YO^V8F3(HMU61B[&(F9T1BTX:=^"QM^TJY.TRY,,XV@4 ^&"!C(
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MIO7#@AVJAQ>LUL=Z&*H;[N\S20SBJ$JXJG:%&%VW&4W(YL,("VJ+360'*J%
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M<(?)+>%C_E5Q6_7V"CGWX@)><ZS[* %K<529>B))0@ 8!15<E@R/GM,BHW@
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M:4<[WXG/JI(5*_U%ZFPA\95&'.BKE##P3@3JF@%SE3\$560C*J&(2#QXN(U
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MHLZ8S30G&N#72J0A&+%&1BL2&Q=Q!,49;?%K3^R0%ZE8F\]EKG#&P9M R@2
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M,[AW]_YB.WCQVV?X\)'=QXOSZLVW;Y^A/'SS_^7;EX]_WD>&_/OU]\^? <
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M8 HF"8B"#/2J+*#"!PX3*3 SC!+-*OSLTOPB,)AB$@]#."-H!B*+TY@B\P#
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M9L R;W$#-G&,W<@"-(4H)  (_  R?-,H1D T +FO_=I45;6S-L!U9<,/-A$
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MFPRE*"5+"LM6UI29.:65.<O95F+I%;=4Y9:WC M5X*(7H1E-EWF9B]+L(DS
M0.TNR(Q:7@C'S-10!SC6@8YT2&.;S'WFF84CG'1:0TWD3#.:W8QF;V8CSN0L
MKIR,H<[>H(D<NGG3.*31&SN'$T[>D/\S.N,T)SV=4YRWX=.<R>FF9V*33M 9
M]'.B,YUX#*'0\X2O.V&2CY#*TR%#L6AT,;@1=F24G?"TAT&C"Y_IF'$ '!U
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MN 7W;<2[V9R*[TFY@]KX.QM STO'T[KO>.!]ITM=2%-GN@.$[SR^,U&04GH
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M:'AUHO.()6)W<@A39::(XE&)0/ AO\!EEX@=.L ['+11/88=26 B.C \BPD
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M7"9HSRF,X9LEYHHG '2=N2P!/K"=&\ @W,$ SAB=G"(_<#6> 'L\J<+.V\$
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M"UWDZ!:1W05E)"-,RE:F,L/PY66,Z>/+%#/(R102,H&QS,YLEAF@5:8TJ6'
MT%+S2$C:AC>2[ UM4I.;J7G -Y[T#=5<\[2^8>A V$&E@-93R@O]#6_):9!W
MNJ:A5<9GE:8T)8)::9^RC4>5O*QE*N$C'PC9DI;5.9 J;9G,5O82.>DYIB^#
M:1RWD4V5N50;>:2#(=)UDW0E.M+N<O0[(,&N>.&44I5BI/^BVS')$#UBTO)@
M)\\D#6](2KK=.I&W3B(%B9ZF&].,O(0B<$XO>[]@TT&U!SXZ>6]\X3L?]_HT
M43FE(5'NDY.AXL>GB^9O3XAZ'X( T %)P:]2_NO4I53*J012RG^F6BE,9Q"H
M42%P@;!B%4Y?I:I6X>I6/]V5JRIX06)YT%@-0:I!DA41%RHKALHR2 PKLBT:
M<FLAW=+6#L'%PY&,*X?CJDD12X*NC\0+)S1Q%Q*7:"^AX*2*-Z&BOZH85Z:(
MX 17= I4!J9%@NTU85Z,BAK#N,;!4HR,970C8C<6QS=R3"QTQ$L=2Y:7E.5Q
MCX)961]A9C.8;29F-6M,SSBCF4;_=L9GGS$::AB0F\XX;;6M%4UK/6 ;TYCF
M:41;VM-&,[6E^28"6P-NX2H7.,Q1CFZ:RU!QD7NV!$U(;05BCML@1%P&>4Y!
M#P(<*^_F2E?B36^=>V[=&I>XN'D.N&ZK9GF/R[>[&4ZY[]W<X]+6.?CH\CV-
M\V9^190EW^7.G_3TI^N -^#=J<AURD.1@)=W.P4?V, GNI&"V?G?U EXG 16
MY^I.9[H# -1*THN>F*@GXNBIJ<0)G<.=&$H^A]()3Q'=4XPI^KXT<-10Z)N3
MI/QWOQS/SU#]X]_^]@=  8Z*@$<&U:=VFJI519" H/(#JV:54R4KT*>X\JD%
M.SB0I?HJ_UE?+A8)1WA"IQ(D(<:B5D58.,.JAH1;U1*7#G68P[":A"1C90D1
M\_RN)C*Q)T.!J[Z*4A2Y-@6O6<QKHK<"V(4Y;(QDF5BDOU(5P2+6THQ%2S3P
M@!:X7$#3<XRLR/A2V;_XA3"$81EF"_-'F!WRD(U!I*LOPTC0JM;6G6&M;5=#
MM-:8YFBA.4UO;NM;W@QA-\0.;C*RMJ!F<G<ZP'R;A5@9G6M>MV_%Y$XL 61M
M66I(VM,TIC.Q,S9H+[.5T-1:+:=];6RNASG/_G:UV?VWY8"[.:PLA'[U[:&"
MMHYU[X01P.,)8'3JB!GOO-V.$OY?&-%3G:QKYXH ?KJ)$_SA$_^NT2_B26(0
M1X^@"E6H]<"7IA0O]'O?*].7^%0^EA]JY2[?@$4Y.M'VY2]]HL"Q_'3.*/CM
MN%,OO=1+4^JIEG(*R5-6%:5V6D G^Q18%*QR3XM%JQ&&.<PI+&&QH#J#1ABK
MZR8TLPR;)78:3O6J9Y?(5KN5PXRLA%PB$:O;V763)#)1K>Z*B0Y@LJ^84+'O
M^!*T4:;X+T1;8*]\Y>L6$3^5@7UQ896F=!O5HD8TIE'R8\%8'!>KZ<4^-K)T
M*;4=37W'4:=Z]"X+Y*H-.;//+G*1G DM9TH#&M-",C:K.6UJ2R,THO%ZMZ/A
MY.^#_4E15FU"@/-;<=*[W&D7-[S8#2\YZ-R#7N0[,_KEA5MQP3O,XU]?N(>C
M[G:-J_W(I;=RW+?^,$/W?>I6,_G)CV_SQX_]\=(?_NA/?O@=_[=O_O>A("7T
M 3+XOX, P $\"!%2*@/T,@,DP 040 9DP!*2P ,\P *LP 3D( &T0 I$P E\
MP E$P! TB&LYP(8PB#-3L[1K,QFZH:E2B!;T@91XP1E4B8NXH3ZX(3JX03K
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M-$CP0 \.:9N$;,B#?,@,:<B Y$>#'$B-E!R*-$A_[,B*A,@$V4B![,>1#$F
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M.U?K/]]SPLYSYMK\M=[7K!;D^4K8QW;:R@:O$!5L_&0^6=>/55?HP(X0##
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M7#2@ 8]^4PO)(%]&6<B8@IV3,=U09C?V&3^XH"RDKC%IQT!ZKV0MK*<8M1@
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MY,$94'7UCO)PH,(EG,0]"TN^%U#UI>!9C'RQ';8DG$GJDS=QQKF('(U)C00
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M8E6V6"A"R<'F^1F@F&9G\XV1E3/C4\R4$VA0T:QG)OWCF02]'IH>T-#H ^@
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MU5>)]5AUU5B#55F1M5F=]5F'-0;\P =&(&(&4(V$]&=$:A0=BDH^ICL@[S;
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M=W4[%W4?8A2H $"P,$)J^3[*"W,@!U*%&2%N5R#?L$*".3-_64^'%Q[CIKV
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M90ALL TV*C,PH VQ50/SRJXT0#2PF.Q:9?'AP0R)2*YU:&I@*X[4&-DT?_G
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M(6RGQ2_:B352PZO;B:[5]UJ6V4.8:AQT:[=60;=Z<15Y&XM3D;=WJ[=X>QR
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MQA'3E,P1?/O)9TL5N2TXCE1OC=.=R*;<GLQOTG34^5HB 'C+FOMO%!JAH7N
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M"C:@A0F #UR@ EI U,@ @4=%U:$8 @V(5'3XU*&@@ > 5"I@50!PU4>=U,<
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M<!L%.E4,;9.1:+L:7\5<"K!4+04 =#C=@:/5:3W=H7A.:P4 U1W5:BU62GT
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M2F(__[!WGR/JX"GO>JU$(_]4.28K)=F)$@-0[91M>G^2_ZS78"WQ>M\N7P]
MGB8'8HF(6Y;W0?EJ>9T7\6!T=%#V%T'P=S[DW?3#G"#*R30/7G##/'@G&76+
M6ZAL=?[H8&#4CG(+>O("2.JHRX[1I#2OS#I*,$6J2$RD2 P3SH9'>N0,&\WT
M>Z[D2Q]F'D'E'5U5</$' %Q@ O1G1 AT,F=$ S2@( W 4H.D5F\5*4;A&PI2
M'@%@ABD@&5[8(!=R5)'"-I=U4P$ #&RU?5P7'T1S1O83AD455FE!0-W4($&
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M7>MS66&U/'L5U@ATPW.UOL4S5TOW=,]S/IL3/C/\A]DY5JW5Q*F@'L(8 "A
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M4\KFSD;&J:@L*A]#FL+BTK&7=65I=7$,;N92M</ ;"!:N!@" 3"IV$#!(6Q
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M:XLM,?KL.T^XP;:[4[/MQ./MN-MN2S2TX/;_K&@V0!&]5+9)S^L3(CJ#  E
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MK)%QG$YK E0"HS"  ;1@%"J,(EXG6M*.K@3/@)J]G')9=^0-PP9:8$/RT=-
MY=D$!EJ  *.&>@SUHH.!P$.!:>69M[Z[JQE_O,"X =]R# R1YMG[>^"V'Z[
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ML:0"TP,\K P\2IX'%%9;./1+?)0!:6 #TV/$6?Y1RS,]+<  % 5F?_9"QP4
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MRSH!:YL$\R0-JWQ;VK%GH@FKXY(?X4<*ILFJ>SIX[/S;Z; 7X9QVC?\7%]C
M($ZTU0;8A)2 (.8K_2!6"ID ?/AJ ^CK4Q_W,+A9!Y785 ?K!83A'1EM99V
M0A#8O 8 ?$"'@7!]H8#U)%; O%8*FZWWLR4*.8Z22FS),!Z(T+YLBI!L2<[M
M0J#9"F'M@JV0Y/X1-IC^?+WDIZQK_*0(,$#+X >(9  D)"LHP8",9 0-C *0
MS( 6A1(+29!A0"(^#0HGA%&(L- - Q@4AM0B892!E 8<4DR&S\"#B00)MFQ)
M<Z;,9"US#LQ)4"). $*'$BUJ]"C2I$8IJ#1 1<,-H5I28CB:$AL $%2'#ID
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M=B:#S00SO362!%,I-*F-$XSBT9[5&>!",M]@U:B<FMHY6J*0GOJ-!@7V21
M&=F(T* %3@""DPQ)!.@-9-I9B$6*&M!K,DQ5I<$W,UET0R&F"@3&!*ANJ2D
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M 85YX V2T:>>' 14(3$ FB RDPFX8""T6D@8)'"7IN3D+@5Q@0'@ :QA:=
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M8#:F8P8FH,1D4Q,NGL/\5^@%Y&,^C((\H5+9SH7PCAA^I)Y!B!^^#NGU39#
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MVANK#I]Y:>Y!*>L<6K<**]?JE.AHK3\W-+3J\T,/_\_^2J>E/3"$3V^[#E4
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M?,E[/,D# <F?/,:'O,@_O,MWO,P#P<)#@16H?,5'0!20_,[OO,[S_,K_O!6
MO+K_O-'O_- #O=$OO<\S?= W?=!'O=1//=57O=5?/=4/0=!KO=9'0-=__=2#
MO=>3/->/?2V1O=FG?=FOO=JK/=?7TMG'O=?+/=S7?=W/_=S;?=[;_=O_]SW?
M_SW@U[T$U-+@#T$R$'XM'7X$%/[A#P'C([[C0W[C-WXA)+[E&_[E3[[DUU)<
M@(SAS\/A'_[@AW[DBS[FDW[H@S[()(/J'S[2?K[K>S[KQS[2SK[G.X3JO[[N
MY_[M]WZ*_OX4WHWP+\<0$+]_W WH=_$_"445)G_SXRH=NR':UGH;XBB#<SBD
MU[<8M^A?>]D<9ZLZVV&P;K-^S^BU_I1C8WI$WB8:W[4W_R^IXUF S[=%S?,8
M6Q1QWA3Q3"2H;S% % ( (-E @P4-&A28$&&RA0(=$GPX<"& B0(Q6M18"&%"
MCQ]!AOPH!D%)DR=/\N.'DF5+ER]AQI0YDV9-_QPUVY3,B6#G(@1B](D1XW.H
MT$5&C;89JG014Z9-FX@9UZ2-$ZA-IE)MTL3J5B=:MV9M0X0JV:UEMQ(9VX3L
M6+)OV;*%2Y:;7"%VB>05DE<O7R%V_/8ELG=P82%[#]M)O%AQX[^'%Z-QK!B-
MD#&4)5_6C$9S9\YC0(<6/9IT)@Z@&XTYO5JU:@ZO8<>6+=L<AT:OS=UNE-LV
M[]V-=G\)WF@%<>$KBB<GOKQX%N;(&V7YXAQY=>M9JB-!CAW&"NW>P6L7CQT)
M>?/DO6=1OSY+>??MV[M',I_^_!KU[2.YOU^__AK[_P,PP '_.Z'  PU,L(84
M_DOAA =K6"/"&AY<P__!"B,\88T*+=1PC0\U/"&:#4D\H04-1XSFQ#5:&+%%
M%E5D4<866F"QQAMGK!&(-7:DL<<=@0R2QQ: Y!$(((@D$H@;K#A2R2.;A/+(
M):UH,LHF(X R"BNW!,**"+:,P@,@(F @@C'!/#,*-3U0D\TWVXS3 S$]&,*#
M.N\\,T\))(@@F3LE:#/0/OM,9HA #Y7@T#J3X5."1A]U--)))874 SX;S133
M32>]U%%-(9TTU$@UI;344"%-E51.51V44DY-_93565<]5=9'"]G45E%O5;74
M7OGT5-)A4=65UTII?;355HU=]M9A:1T56F2G=?;85CVUME61N.T6I"9J"E?_
MW'')+=>EFQ! %X>;</ I)W>)RJFH-HXJZJA[YVWJ7GJ=TI??19R@-^"OJ@H+
MJR86X4JKK*;Z:JJ""R9B*K/4>FLLMS#.JPEN^*I88XZ;( RQD LS;##$#CL9
M,955ANRPRAYK3.:_&KO,#LUNOKDSG4?C&32>?<XD-*&)'H/HTXY^3>A&A(9M
MC-1FBUKJ%3BHC>HOS/F" ZJ+TQJYX[K^^HL5CCN.N.30MJXZ[,Y&KKNOS>%N
M!1CH[LXY)!KYKCOQD..;;_0 _[N]\, ;G+W#$:^!/<49;^^^_OB+'(DR_J,<
M"0LH+T-!)!14D$($#4200@@-W)!"!S-\\(0=1@^Q_\054=QPQ1)E1W&'-:+9
M04431S2Q11I5O%'X''FT<<CBBTR^^!:L('*-+)_?T0HFJ:_22B:GM])+(,*T
M(LPRL_0>3._%!%_,-<TT<\[USY^3T"C>OU1,0ND_D\]#(XCT4ELSU92C1CE"
MJF2 2ED#[)^R)!! !0ZP5OT#(*@(R, '-K!6")1@!0\HP0P:4( 6M*#_(IC
M"P9P@[J"H =+.$('4M" +>1@!B-%0@%J\(,89*$(:WA!%[XP@CMTX0Q;F$,1
MII"(*'R4MY#HK7&8BXE-=*(3;T(2*?ZD).ZB8AN"0A0$P.LG4JQ74<"(KT6,
MHRE.$$-4 H;&JHC!*E5I __"WNC&KZ218 ICRUH.MI6+4<PM1*B+'T-&E;N$
MK TCN\M=-(;(P;#ED(LTV<I0]A>5369FBAF#$BR)2<U@TC)*($+.+FD'4-Y,
M"9D0)<Z,QC.A&8V5H%FE*X<&&M:TAC50>]HMI18;JFVM:BMXVFFT5IO;^-)K
MO.0E,7.#M>!DK6UG<Z9RYO:<:%('!M$9V]RPB<VW<4<[W=D;-K%#.+^AISSG
M0=PYTW-.Q)43/O?)PN,D]Q_(62! *?!/#2A'(?^<0#^=^UR"'H2ZTK6.0A)2
M78@.6B+7+71#NJM=C6*T!H?&R$4S@I%%?X<[&FUT><I+'I$B4+PFK6&D9'+>
M2+7_5R4O,8E,V\M2!&[P4I>V]$MK$A.9T'13\+&/I^<CU)G,U"=!V2]_@KJ4
M!QKEI_T5:@@$;*H-015 4@& 5+FJ*E2;E:M,:157H**J0[K:P:WVCZL0U.I9
M<956L*Y5JVRM55G+>M54Q76K:JWK6NWZ5K7*]:MJM2I5U=I7LE;U5&AU*UX=
MLM:OPE6N:$WK7A/[6+!"]JI^I:QAY:K73'TUB9T5";B>&%K1CI9=Z2H)2?1A
M$I_H0UX_"<IK28)%H<S67DC!5VW=6$9Z%25@8TS8&=>8QW'4D6$(X\8;IY*5
MX]XQ+QG#6%K.(I>X\&4M&ELDQ\@BLD0^TF2*^>0D]Z*$_\<\A@A*N,PG)5F9
M\L8,#430#,UR9@?SVD$R.A/""WX&2SL(36?[A>4JBX8T =-REK;,Y=9<D^#7
MC(%KK_D"@QV\&PX$TVO+P5K9&G'-#&<-;<V$SG:<*1WJ.(?$C?"F-K-)';^)
MD\7J*1QV#%<X[;C8<.I,G'H4IY]WEL>=\?2/?^PI('K>)W2A8YT_D3PZ@4[(
MH!5"J$)IY^0-Y:YWKPN1[EQ$91F9B'?"4U'P6-0C&?5(>#JRD14Z:B0>32]Y
M.\K2D8:4O96&[P;;4RF6O/2][I&) 3:=$YC:9*;VE4\"Y;N3F.P4)Z$*%4^7
MRI_][$2H4#WUJ2&<H PC.T$$8O\:AU'-- YCJ"I.@Q"'4D5LJ7VUJFLUB]4R
M-/6E/;WI"1*0T[76-*EMS<)4+Y#5C2+(K$+XZU2'T-05S'6G;4C"5T=KU*'>
M%*]G'2G/3CLA.QGMM;'=1)+HA(I4!(JWLTB2>NG#)UJLUQ=O*\8VD'&- W,C
M5<SHA*^,$=[PIN,;H_N5L^B[8GMT2UW<(DBV_)$N)-M+70QI<$8R4B\*1YEA
M8M:8PBC&DQ*/&7S1(!G+G+(Q2N#,*$&)2IUI4I6M?&718'F:UKAF-:>Q)=18
MXTM?PJ;!#=;::W:9G*H=AY<7GG#6+DP<9B8';&VKIMNDV9VV-<<Z>/-.=,!#
MMQ6$<V__4!>/U5E<GO2D<SU<M_'7U5-.Q>&8QY S.X#L4R#],,A _;RG/ME>
M ]:=#J"M:S*&#%K0#&U(0Q3: 4-%1*(JRRX:+C*11G6'HQO%2/'#0Y*9/^H\
MCP;A!D$ DN7EG*46,.FE:Y92]JH4TY;*-'Q;,I/XUH2F](%OI^AK_9P88"?X
M/=K1\@O4[/]$J*,F-?=+316E3WU7R'*$L8@E/J\@&$'!8M;2PW_K6+N:V T:
M%K'"M[X BZ]9[4<5JQ&DJV'/VOP!@A_[W/>^LL#O_;LN'ZKD-S_ZCXC^]P<_
M^,7/%;7Q#]IL[Y__,$&728(" 5*K)TZ+M0(PMER+MO!EBV8+_U]VJ[?8*([T
MA8R& BL Y@'?Z+<,QF$49KCRZ+@(IM_H0BW.8C "SBRV N'B(I#F@F3P N+Z
M I+0:^((0[QBA@@J8S+0@!M0Z2_:R[S^ F=$2;Y$[C+,"V?X2[^.$,!:235*
M*30XX&C0@#5:#I=D@^4@K.5F8Y=X*36N!L*(8\*&R<*8XSF>"9H^K#J>PSG>
M9FV(XSM*;)OR9NKLIF^V8\:F3G!D;.I>+.RF+@M"X' "$>S>*>QZ3,=V+)[0
MSG+D"4"*#)\>,1)'IW6*S'2.3'5,A^^<#$5$9'46:D5.9$5R!W=N9Q131*-Z
M9_%L),LNJLR6!_)XA/(L+\[J#'EF4?]ZT"Q(KH?-5*I+L*3.2L][A-%,@*!-
M^"P" "T9!PU/YN?1^H0!C(JH$.6H),W1)$U1'B5_&J72<.A02"W:;*79BLW5
M(@O9R-'88,T<#TBJSI%2>&U52,C7.@T<4:W7ZA'ZXM'9OC& A W9Z-%9SE&P
M*@BPZ#'7B*U4FNT@N\\?)8 @G8TA Q(>AVVJ\&_:](]<_B\C34(C2X(C3:LC
M-S(D07(D/[(D/?(D1;(D=\+:MJTE#Q"VB.(HMJB+?J(IAH(!;<LHQF&WCB*-
MWNB,EN)@D N-IN*,\JA@],@K]JUBF NZ1% (]FB1 FG@X@*1N &1$*.06+"1
M( DP$,,KR6O_+R;CXN++#KB!XD1IXT2)DW:&XT)),TPIOVY&:#PN"6$IY<;@
MP5A)Y0QLP?S2"EGN"AL,P;BPYKJP.(YI:[+FF!:SPQSS.8XNFK))Z=30Z=HP
MF[;CZ<();\@I.C:S<+;.Q;2NG$+S#]G#-+]N[-II/=SI["!G/_BI$?7IG]SN
M<_[I-CM'0B:$=.QN-_F.=N2.0P(/\$A$%'<'=S2*1AR*1HP'>&QDHWSD%75D
M\W(1>22/I$B*>:H'I*;$I7@D IC'>JCD>B+@2_",]-:DI71J]=B339:13>H$
M&F>/T68/3WY*4^HD4#2%&Y.OK9POT\Y/A]YOJBC+_ 12_#)+@K[/,HC&;_MZ
MS3_-JD 3M+&NK_XF]+ * OXV"X/H:K#NZOHLR_CF;[$@B_T.JT [5$(1U(#<
M_Z\BI\W:^B]&9;0EONW;9G+;B.( J>@H9.O<D**VEL)?CB(J\,6,X(U>#H;>
M! :-ZBVY.M"X_$T$HY0I^P*/-(8%L\L%WZ)D2F8O#(Z[PFLOVFN\U@LMP[0L
MU3)G:&:^@A -YLLM;T8(_*!G3BZ5[M+D:&DO%:P*8>XTJ(;! /4*9>-/J<8+
M<>Y0N2;#ML;"."P,'?.:/LS$BN-MHL/HUJ8YYK!2]28[,K.;^/!OYG#%:BP/
M\W ]9HP0LX &3+5QVHG'R,['!(2?\@GM0H<VD\QS;/,$+H1U--$3,^17I^S)
M0D04'8K+2/%#@N?P4.1%7H1WGK,5+TIYH!,ZI6=(X/\,29HG>Y G>HR$S:"D
MSKZ$I<IS2H+1],HS/=MD39"Q?0!M&9=Q"(**]NA$40#E4NPD][Q1&^UU(:WJ
MUI+M&]71'__1V1)2'1_(7V5((@D6@!1VUA@(VNJ1KH8((@=64_H1'-6O@O01
M'3N-UXJ-UM91AQIV8Q,29/]U8TTVUB"6^!B60UW4LYQ@1F5V__YOVU*KVUJ+
MM:2(M<I-W'Q6W&HR)WE+#-I-)]%H*,CH8)(6WX!+N SF::-+8>JB*3VFX*34
MD<9"D5B0X2#)X2;N9 S#*[U+3 <C+7&0+#7.DD2)!VLF3D_)XT0I,^0R-#(N
M+CT.+D6#"9F0E4Q#ECA@"JO_<,&\D,!8;N9DCC /%<%NSC 3L^8RS%'1<#F(
M P8TK#HB4YLJU6VL8YNP"6^T8PX[U^JP3C0_-3S,"7"ZKIP&\<;80^QV+!'+
M3A%K$S9MLW+:+E>1(.Z.+'4NY*!(Y^XV\3>)\\JB(79JAQ2K#!1E)'B8DSG!
M#$FDL\P\*LRV]5KC#*2T$\VP)#Q92J7R[$I(;_1>2M"\9WV*T?5ZRGW4Y!GM
MY$R*2O8\(/:,*C^+:JFT$5$BQ1N]$?OX]T2#[T)#M$0Y-$&Y:F1UZ']4=("M
M+U<D5OP6M$(QQ?TNU/T>V/@2>"(WU'^SST)[*()#M(+]4[,T^((_5D.KZF4[
M"T9A_V(%#&((UH EUF @7I@E5L *AJ"%K: &8&(,;'@@AB "5N D;A@ (@ !
M^ &)AD"(JPTF;/:*2B( 7[**G)AH<1(GT:T!=\M>,!!?M&*WM.*,DG:X""9A
MLJ+>PD+>-@;?HO1BH+($77 OW (JF\M+L2N[UH(POG1EOG1LNXMFKE+BQ&LL
M 6.^?O RV-9M3TD(C?!G[#(3T #E;@8-\*L)5RD*94E/_3)P5<[ELC"7;HD+
M':PV%C4+$[50KR9KS &:,@P-(Y<RL4E20>S$I$[J8!EP0!/&_G . X=41_54
M_1!5$T=56Q/'6E5V\^G' J0_^$E![,ESG/E *+%T("03K_\L=:)LH3@1.;D,
MHII5%4,Q=VI$0UX$S)C513C*><Q,%F_@I.J,>5B$%]6,%Z=DS<"5%[N7\\25
M2;HG/<=W?/I,&05M3N#5?=5'J. U4/)G?GY*J/RA7@FETN[74"QM?RLV8-_Q
M82MZ8,]19,=/(1.6T_I1V9JO8$,:^BQ6U$(VK$8Z9;&*TZ#*I"?68Q%4U3)Z
M81>2'D/-UUA:HV$Z9>71UU 8B2X2)F(X(<8 )2)@((H8),=@B$%B",9 (]L@
MJ4$B E8" 0QBJ9/()++ (W28)&$B $]+BH6BB[+H1G\V*(!")M,-2'OK)XF4
MW;@B MM(*(^2*QI&:9-2*?^(N2C_ABFG]H_N0K"EZY!(IDL9;N$>KBO+%@=/
MII+2RRP-V68PKKZ,,#- 29-([I%#[FYWII4X8V]?*37RM&DTV>4XF;0--U!S
M[I<&TVOR,@R+J7$?%VRV)FU8^0R/+G/3IIJHR0[OIE))+'11%S0YTSRV;C1/
ME\: ^7 8QU4/$>WDZ9Z&+#9KM7)JP +8#@GFKNX"BC?S;C>#TW?[SA,7JEBC
M#'8D*D7"F9N1D_%<\7>F%:*F%TF0Y!9;@/)R47J4A*2.9!9!#WNNQ$JL)'S&
MYTR^5Z<4_,_&A'W<4U (C4UBKTQTSWZL<5 >K5&.:G^72C_SUW\O^*4;.( ]
M;=3NBOQ(__Q"1?0_1SQ#5]R"3ZA"^[7XEB] 6_SX%O@_NT^K2+0@QDKY/CA
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MC62$OQU9NJGTR]'\C 0DIB(I24FJ'Y2,U*0>B4F!5 (K5^MDP %V"4M<.M,
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M5W'U<G&'Y''4E98#LP8$8UT),W(# S%5.)<.4X43,Y<6<856.!$PEQ(G,1%
MD',CL5ZNY%^PE$JIY!)MF!,W Q2Y-!1"L71T>(=7X0\,<!4+EC1-04Q"HV%7
MIQ5-4TY]H7AM=WAV5W?GU$Z%AYH"]4ZK27ACUQ=&QG9QEXK3%'E]<1=Y=QJS
MN7C:I!IM9YIY079D4YS%_\D8I:DWM&EWU!2;VN1/LFDWS(D7M$B+!W5F])"+
M]( [ % #7<8[] ",5G",9+91 &!ZQHAZR@@<S^%ZP?%FY"D<)B4Z[M%2P6&-
M^E$@S-,?S\-2T?,\T"-H#A(A,V4@XI,]U?-\B[ ]AK9\$*(^\Z@^SY=4[%-I
M/G)I1P4B^C,D15)5I+8D 9158#4C2G"05D(F8N4E77)K%)16<,5 47)K;D4G
MOU:C;&4F(01L>/)K?+(GB*)L)7F B'4HBY4IC](H#!AMFD*3#SA9DU59&*A9
M4YJ!MH*!G94L5DI%O *464J"4:1NQK)N^:9:*"A&3LF"+QB54;F"57E;-GAP
M[?\"1WDD7':D6V*)I\BU+X64+_H22!EWA--570?#2(RD,!$3$2BW Q03A0R!
M,2]GEY_$A1G1A:!4J1_!<V&(2B=32OOU2C+CAHU9% %V' 4V%91)F0RF-)M)
M8</TAUFA-&)1B&%A%A[F88,1BG*WG*4H8WWS.#=&B7?7B9I8%M^DJUR1=C^F
MB2UVB<1J%H)GB2XF%X)#-^ $K'FSG)/X3H:AB(VQJ]<ZK9LX>:HH&JR8K5_3
M3=9I>;9X9:D'4LG0>1P%C&DF'//*#_2 &],XC/2:C/1Z49<C9O/I._L9',D#
M'[679_>)']*SL  Z:#4U: RBH,;G4QU"CD3U(<D'5.7_,WPJLFGMDZ%(E3Z@
MIB)%HB)"T@97U:%$4++^:&H%1'ZH5GZLME4'2;,*>4$&Q"6YIFOXUR;VEVMF
MH@0VRI%P,K0\RG\AU$)_$J2*XE<GN;0T)$-3^VPO>4.> BD^Q&V? FY2FEE=
M2X%+M$1-="I2! .R$D6C%91@>H)D"D;SID7Z-D;W1BU.J2P!-RTR2'!MA"T'
MMY5XQ%M\%''>4@9RE$?V\I7O0G'))9;X4H1'F)8?EY;@Q3 $TT@(\5T4@UT;
MHTGFU1"<Q')^&1(+T1$E4S(F\Q(Z-Q+QM4J&^88VTQ)0,!*-F1.VA'1*UW2]
M1(>;Z3-'T9E LZI=)Q5>L16A_VD5L.%AIG&<K1F='Z8U=L%X)@:;W)2MQ?D:
MQ,D7>K>)?A-VL+&\]C2<R#F=DB<7J@%08V<YI@B=C#=X[]1B@'=-WLN:E(>]
MDE=VS:L9ZCIEF7>+JF.,S^B=$(4 ^'H;))50MW$"", /W0EG&H6,I0>?!'4=
M[(%G^*D\P)&?_+%GS:-[-!53X0@]'()\(NP@#+I3'L*@',(]SP<B$&II)U(A
M%8I4-T(CT3>R&SI5_7,C4S4_U]<D4^55 >153!)6"VFB!DDE6C)K/6LF5\(E
M\+=6%:1_F?"0^E>C(M21B_*C ;AL2UND)XF -+18@*4I8[RDF )$CB6!3WJ3
MVV:!XO_&*E*4*AF8I:*5I:<515[**V :E*J5;[:"6K)U@F:J+-"2IE!Y+5&9
M1E@I+N?RMW+$6W8$<7:Z@_""N/>"N,O%N/E2A)P<,$F8+XU4,:,<A97[A 21
MN0]SERFG,5@H<QVS7IL4!):*$JR[$3W7A2*3NBV#F">C7S#!<P#V$Z*:%)-I
MASX3%0AF%$%#%14F85JG3!=V81QV8QZVK:5H.$^V8LCZJS;V8D=&.3K69(I3
MK6/CO=SLF[1YK<T:K'!Q9*!8K.#,%N+$JU+C8]LZOG178V>SK,[$SJ<8S] T
MFXNH&*)!-?HK9>Q*C0?,GG9@' *,  S,KV\& $30.N<!C0C_]<!KQL"7$P$!
MZQ[3*!W"4[#ZJ3S%DSQ\UI\-\L$#*B'^$7P*BFC#1U3=\R'@XSTL#&DFPH]'
ME3XP,C\U<C_TB+)#_:$>&FJ@)J)8%<2L%B-$_&KFYT"P)B53,M5/7%:]EE:T
M9D$_NT$[:D+#EK0GQ%?&!L8M!%B&DD,V- ;-YH"!U8 \1"DTI"EK?&U%Y$-A
MBT10-&X].;9C6VZG@FY5%"PP$(*D-:9**;=N>V]T:[>(?+>UI<APF@5MY+>[
M!<D_Z'!AF8-XVH/.A7'JTG'.%3 9-]J1"X6/-! CE]IWZ820)#&1:H5VJ9>:
MI%Y;>*FF1!&EJTHN@1$CP7.P% $=_^%*."$3MG0< -83 ?:8O50438>J$:84
MO_M@3R%AR1 55N&'Q(L5VLT99.&<KFF;FP&MT3E/NLF\H]F;DV'>92>=\^LW
MB =YJED:@H'>B,&;]7N:^A0:N"G>S0G@Y9K/X[UV_ET9;0>MPYF*6(/0!86=
M9Y:+P!&OO@@<_ ", & %*X =J]/ P;$[MI$"FX,&:S $WPG!P^%1_$ [PNCA
MMZ'0\Z&?TK$Y"ZN?^W%[!:)[SK/2 <JP.N4?"#HA[DB.YD@B&6*Q)0*A+KP^
M'P*AW*"AU&?#\R@DF):R^"-50X(C]VA5J2:B_K-54&*B9]555+)^785688(F
M5-V0^F=_7_^2)FREHSDZ5V-MUGG"5X+R?TM;*'\%M2J4I#LD*8QBQM+6*1'(
MM=DFI4:4DSE)QTUT1+0"*[IRMN0V*W9,1<.BQX2M6M*RE*M%IM3B@F4T<+05
M+04W6Y>-6P\7+HY,R7E41SX(ZT 8A/Y2+[.^2(F$VHG$74R8<I5KR@Z!RBVG
M,19C,7R),:8;,C+7J4$ ,\S.J3%Q$D&'$BWA<R1!$XEI=#8S%4 P%7'8[42Q
M,S^3-%.7APQ0%49A=5MQ3-@=FH5HJ^X,[VESS]0:BO6\8PLNBSMFT)WHB0$=
MS]'J[_5.[P/=S?9.[]9*KN<:B<Z:[^?<S^:*SD3VS_?DB@#_K%;_TV0-3E O
MCHO&P>*ZF!MIQN&\,5'"0=&[X5 ;G7I98!T!RV;>^7K$8\$(<#RU=SS_X6=^
MMK!MP.."5J X93TB;([$1R$$NF@0>C[+AR(>BR(SS(_T:%0]4N68%E56WJ&?
MIM0O^[)"C&I%+,0&Y)!5LL1F)2:[!B:W=D%MCG\6B5=P\@(-5&QAO7_#IN>*
MHFR M><KZ=8SU-9(^FQG/$1/BK51&K9/E%F'3[9\_9-Y7$7F=I1@5*9&>5I,
M&49T6[>QM2W5HOFU]:;H\LCHLMGK8D<.!Y:B'99_BG'197%]NB\=%ZCU LJI
M/4D5DS")).R5U)9YB?NT+=L7L4GG]87TC.7;7.@1Q"U?A(F8^Z4R,>&&,H/<
M).$3/<$3O*1@3!'=UL^92O.'5T%AT%QA3)-,Q;L6R>N<[DN]TEG^[PVLXZO@
MQ?J]\WS?^YW^X5N]\YN:[*VKE &_^)N:  40$I(5$BB08#*#!0<B9"@084*&
M!Q4>+-1PH$*% #!>C AQH\2.(4&"_#C1(0"4*56N_V39TB6 )@ADSL0Q<R:]
M-2@CV$3 #XC*G3=SOERSB"<"-$->9I&9,BA/IS.' FAS%,&8J#01U)Q9U2@"
M?6(0B#4:=JR^JF*,BE7K58Q:M6,7P9W;9BY<,4[:Z'4BILFX17\#YVWSMXGA
M<4WX'M[+F$ACQ4Z:<&OSN(GER8\U$VDB9/-AST+:A*Y,A+/GSJ93AR8B9'5K
M(G8\RVYM!S9M-$30>%8B1+8=V;F5C/'-FSAP-,.1 Q^SO/EP-)F4VQE3'0UU
M.VBJ9ZK>? QW[M_%CVDDGCL'-.@YC%G?GCS[+^S'K."PGK[]^ASHQU]1GGXC
M_O034#\ ">SOBT;ZV\^<+_\.5+"_!!N!887^)I1PA0DQO!!#"B?,T,/^D%@A
MBT9$')%#$D7,8@452V1QQ!57%%'%+%2T$488L]!Q1QYUK*%')+)(H48B:PCR
M1R2,5#+))&NPH 8E3X!2RB:EE+*&,JZD4LL:K.RRAC6ZW.'+-4XPT\H3RCQ3
MS3+9C"9-.%N LTTYZUPCFAWH3-/.%J)9H\\6 FWA3T#_!,)/00D%8HU%&VTT
MB!M::)111UN( (@@K&C!"B TO=2*&SJ]@5-21XW""DX_[?34*%:-X%4@/+C4
M@U@CB,*#6W/%558&(I @@EXEN#6"7645UH-?)?!@"&3]63899)%-QM=DAH!6
M@B'_!,K6(@DJ*JB@BA#RUEMNR]WH7(O([;8A;\%EB%MUPT7778S49==<<<VU
M=]UZ%^IW7(0 >.A>?I,1>*. +<*77G_S50C>=_MEN&!Z]X7X7(LI!GCB?#<F
M>.%X"9ZXD)=*-KFEJJS:RJ8L4+*"'Y[:B""E+&">B1\BUIC9J36(4%FF+*R8
MQRDK5IA)*0" L-DFI&^8:6>G5388)9[$DLGJJV=::RP$V@A+#+/>FFNMN1"X
M:VRQTUYDK[;HLLNOO0HCS(FUF_!++\40.RPQO1YS(K&\#R."F\LJ$YQPS2[C
M#''#3:L,-==,XPRVR2-G+;37+J=-B-PZ[_PWWX*+K;G?_Z@+73;OA!A#B>N\
M8RX[ZKS+)/;M8O=CN^[&&\^]]<YCK[[?URLOO_: KV_X^XC7C[SD!:3O^0&A
M5S!!!%=@D/H$*9Q>>PHCY!Z&!$'D$$028VQDQ1>1.)_%]6E,GT49=X0_?OI[
M#*%'_+/X4?\=?S12?R8M28 ![%( 3Y"D Q;P2UWR$@-K,"8KA0E-9^I2F-ID
MI@O."8,:E-,%.WB"0>TI3=$(U)XZ6*A _6E/)"34H *UJ$'!D%$SA.&C;A $
M("S*"FL E:9N&"H@C"J(/4R5J(C8J1Q>Z@:PNE0$K!"%)O8*BK2R%15WI2LH
M_LH##&"6KWR%*RUZ$5G$<E:TDO\5@6H5Q%<%\<#"MF4ODHC$)"'QB,$,PI$Z
M2L0A(YD('3FBD9#X40)WM!A%2F)'0=)Q7O@B%R!-DL<Y&C(DCN0('ROID#DN
M\I"'Q&.ZZ@@12W[$DP/;""4%0LDX9C(9JXPCR4[V2I/Y[&='H<?2>$*/GN#R
M*/S@1RUG^<N>6,66P/RE+G^FCZYD+656 QM9Y&(VKKTE;6:3)E[6M@C O*TO
M?/$+8>8B&,/8I2^*Z>9A##.9RD!F;^ML0F$P8\[%'89PE[F,9QYWFLQT9C6C
M@0WD8I,:VURN-<7Q36T*"CHB]"9TPE%=097CG822[CK)<9UWJF,'Z> .H]W1
M3GC$LQ[_)9P'//+QG?%^=]+R#&\^'/ /?H@'O98ZKS[_N<_S$F0@ GV!00_*
MGO>T)Z$->6A#)+(04<>GO0RQKWPGDA%31^0B'<$(JC&J48ZJ>M4=W2]_-:+!
MCI)4I*_R;X!*@A(!%PBE!7HI!4CP4@/;ZD UC0E,9IKK7#<(IQ/L0(-EZN"=
M/AA"%=XIL'WZDPH)ZT+$,HJ%,4PA$%ZXAB \UK$WA"&H<HC#38DJ4YG%(:<V
M%2I4D0H($5ABIV#UQ">.ME>CC140H C%6$4A5U74%;"(-2QC$<L#93Q6LL;H
MVT&.D2'(LA:V&+*MAPVR81+CUL$<]ER*D3)CJXPNQY2KKX]A_U)>TH6NPZ9;
M,871R[G5A:Z]LKNP[I)7DQY;U\:\=;!V>;<AIH0O=D6),>XF5[[,+=B]S-LM
MY8H7E@-&&3$-?& $)UC!!N;*,I$)EJRMQ2QK84O7P#87L[R-+AMN"]NNJ<VV
M\*5N?ED$WA)S-[X41C*!D8QA^M9.SM"3<8D;C3E=PSC,34Z?DJM<:^K9SQ^'
M9C:S:8T2#$I0V1CY.J +#G!,EQO4*0%VV"$=E;]#'=:-H76TV^A%Q^.[W)%4
M/L8S*?#B4QX$C5EX*V /]&8ZAB^PM*;1F^E-;4HA UVO>WM6$/@PU* .^51#
M2-6>^I9JZ!<Y=443FE'[Y&=HJL9O?O\Q&E&0MKI5__E(TY;^WUC+BB6T)A"!
M95!@ A/XI1.D -52@N #VWHF*4D0@Q7<X 7]!*=;EVD'?N+K"%T(0D0M%H2%
M#=1B2;A80;E0AI/2X: TU:@=8BI4/!Q59JLM1"&B:HBL_12G6E7$)H8;MK>E
MXFP9<,4K_HH!ZOYB%([EK"_&6UG"99:RM'6NAQ7"6JF\I!_C&]Z(C+)<@)0D
M*%79[WD9?&#\_N0H05(NBC RDHLLN!P1/DI(]IO?>D2O0Y8K<8AG/)( GSBW
M[DAQCRA\CZ4D<,M3$I.C<&7!,Z=YS6TN$Z_8)&Q<,TK9RL;ANU 3+G8!3-NV
M"3=LEAANXTS_3-Q*;#<7MU,R@*.,9?Q6N'?24S2JT;&-=;PXU8C&<J<).]G[
M2>3+L88V"2U.;(ICF^'X1CC'>9UN=H.=AU+4#E)N3G2:$QZ,#L<\7[:.\4;*
MNS$'3WCO,9Y_R%,\R#=OSC*%GD[C?.<(-<A[/>T>H"-D(>T9]:D@2FJ'0N^B
M#*7H151='U.C>M4;1?K26^TJCRP=I"-]-8"[)RM;>T\EM/H^K6Y]ZP1C#28&
M0M""=[U@F=ZDU^:/4$TAI/Z>^'JG7?^)A"C<_@P#=0,6.E91,:0AHR#U64F9
MO]J.M6QGB=C#4:$*M$(D+:I8A5I61=%65I BNFGK_S#2HEM9EG,K_Z,RJC<O
M0HC?JK??2B,'#+""J"^$D1CMVJ_\*J^. YGT"IF3:Z[YLL"+29> L2Y^8:_O
M8B_^6A@)#,%%.J\.+$%V";#]RA@:C)CX B\8[)<-M, )=$%Y<267:[EQF"69
MNSDC/$(%PP&L<2:LJ8HV$ NT"(L,>R:XX#FRL*:ANR9K>INZD9MQ2CH7*PR^
MD3K%*(PR/ PGT(QTVHPU;)PV=!PXU S7B!S3( W/J,-^RL.Q$ZB ZL,[9+*W
M\PTID[O141W6<3+2"1V)FAWMH++8"2GKX [:(;R1JH[R&#SB23R32JGE,;,W
MJZG?>9XV8Q[FF:F<HCSGX;P5J)X'X:D]\_\SI,H>#5DJ&& T%WFJIH(!]&$T
MIPJ2]6FJJ J2^9D12GN]V=L?3<LT)%$2 %J2M5(24FN2,J@2!9H2!"H@56NK
M;$23"EHU65.3-*&U<-2@7 ,A<]03P1HV$A*A0>F^=DPL%R*4%BJL24F_1K''
M35$_3N&A(9(4*X 43ND424&B@ PMUDH55?D45J$B!K "VX*B7NF5*R(W=R.6
MV](B+@*C=E,6=P.C:&&6;&FC>\M E+LX5>*DC3LD2SH(4Q(XD>LD4D*OBF.X
M3CH(DK0X?.$(BU,YA6DE59K)3<*X@$,7EL2D3OJ6H[S)3R(7FN3)E"28('0Y
MF).)(D1"J[Q*(ZS_,"FLL"L,&S%(B[O "[5YPKG0"V_*"[0\.J7#F\:(&\D@
MNG6:NKQY2S6LR](PG'R"#7XBN\[@AAB[,:T+NQWC2[0;*+=S.R'#C4 ,1$!D
M#FYP,D<4/"NC,HJRJ.SX.XNJCMO1'8\*CY(:L_0@L\7C@/AHC^89GOQ8J>2Y
M*=;DCYO2*9S:GNWQJ0O9D/,)'],#GP_A$.[!Q?6I10I1O0QID1EAJALI3JR*
M/1VQ-![1JOQASN5<SOU!DF;DO24!/@$R$KJJ@;6Z$E3[SBM9OBFI*[RR*SBQ
MJ^A+3SRYM1,:H3PA++YJ1^QS(40!E,-JK/1KK!9JK/.#-DHQ/_@KE<_:_Z%/
M*:T>&JUL:Y4F&JU3X39;>95AF1790C<L L!;T2)C698&]")[$TEJ^="1U);C
M&J\3',H9U,#^4J\2M2YRZ3A'(E&1820>-+GE,L&+<2\7_#C\DL&"X4!SJ4#]
MBJX:G!<X6@AS6<$<_"Z"\5'^0M*!BTH"2QFLG%(J/3 EQ#EHD@FS.(MF0HNQ
MZ-*><Z:S$4NTH8ML^C"]6)L4PYN\H!LQ-"?  1R]R9NZ9$,XK+'&29QYBC'%
MT2<ZS#$]#%2!$H(ADPW&?$P[X(;5 43788ZW6U1%E#)'O#+J>('6R4SN\ /M
MT [9P9W#T\23*IZ3BC/@42E29;/+4QY17!X[:_^$5$Q5!3$0.V-%[-DS69S-
M6)Q%#*E%642?%YF019.17U2JU4N?8)0T_)F?29N]+* !)'%6_A&2&F%&:NV]
M3_M.5+M&+;$2)$B!XFL@O0K';CQ/"W(U#=*@72/'-NFUP/*37?NU0,D^=UPL
M1M%/Q&*V%AB5>J4L2;%'@'P43-$A@LPA'>*4^$,B)W(MASS(_%,MVY*B7J&M
MAZ5(CQ2C8O&'=2.6C%26+T((#E5 33K*EPPEF6RXH'RXDU2DI)2DD0@Y?_LC
MD^W)C$C9%R1)C&BXARO*=YFNE3REE;,XGH4(?]LD< $EB .YBHBCHTW9C=,X
M*"4P(OC*KJF)-J!:JYW_6JRMVJR]6JT5@YKPVK'@6J[%TJXAVZX5VZW%6K#5
M6K8=VR=L [O@PBW\L$6@V[BMV[=IIV]".BUL A8CP[=D)\D87#0LW!9KG,(U
M)WD"#;#+#-7PR]. W#O$P\X0,L.TW+1+NX$B5()Z.\\YG86**-^H*-BIS.>P
MS-S)#D[MN^H0O,[,G4S@ $CTJ.#ACI12/)9Z#U=-S?S@Q%3%CP,QQ<E[GLK;
MCU5DD)VRL^T!M%7\*5\E$=/C31 I3EX\$1$9SO<I3NU=O>6T*AKA$:N:/>9$
M1ORI 1K@O2;QM"9YQFOEDB_Q/=^[DNX$SP52/C/Q5G",*[S2W[PZ@3=ION;[
MHM\3\JO#,BQ ";;"6H,.:*'P4Q1Z+#\82C]-0;]]7)0(^*Q.8912.5 +-J*"
MM#^&75@K@((G>M!9>=!AD<@*Q:UA.19RXU 8)JXQDI:/%0@01:[B>D"FS*XA
MK2_V<A@)=*1_R\&$::\/I$#[ L$^XM$;!>( $^*!V:\D!>)\\6$;? @GI9<I
M#ED V\%!VAA3\A@.+%(DWN(?#C <U9@CWI>-.?^7IWUC.(YC.9YC.JYC.[YC
M/ Y"D@'"EB@$(/1C0 9DE>#CE!#DJ-SC/$YD1=;CD^%C0D;D18YD29YD2JYD
M/";D0K9D3=YD3NYD3_YD4 YE41YE4BYE4SYE5$YE55YE5FYE5WYE6(YE69YE
M6JYE6[YE7,[E/IYC3$:)7M;EEOMED^EE2';D0<YD1$[F3 8 2$9F9GYFE)@:
M.I9FE:#FE9@::;9F;*[F:':)BF")J?EFDMEF81Z(DY& ;F9F@\%D96[G9P9D
M=/;C@4C:9T9G@4F);4YG<C:8?)X:I$F&H0$ I2"9@2[H>UX(@A"8A$9H=$;G
MBU#HA$YHA_;CAM8(A5[_9X0V9X>^Z'O^9GZ^Z*2])$"R:&F>:#L":9^MI(P.
M:99>:9=>Z):.N)@^:9K^YHDVZ:3%Z3]Z:9X.Z7L^I8PFZ9%VZ9%.:985Z9Y>
M")+V::-.ZIF&Z9[V691^:)V&:J@>:IM&I)B6ZH_F:I:^:9 FZI06ZHT&9K,^
M:[2&)6%NY&7VY;9FB5]V);F>Y6*&9G=6YG?.ZV6NZS_VYD*>&GL&;'56Z(XV
M9Y^^YX.V:'W&Y\3FYFPF:[<FF7BVZ<&F[&]>ZI.>;#N2;,6VYVZ19XOF%XM.
MX_?B9WFNZ"4]48HYZ!)L)'%)X] &XRV&KR VXHJ^[8.10(]N:'^1%X%Y+N<:
M_Y<(_&*1N4%^.>Z8-$IPB>9O41<6?0CC)B6DA,#DEFX:I>[IOL'KUF*':6[K
MQNYON=GJGN[I3B^3VQ?RANZ&*.^;;1?W_F[Q!N_K#B_VIACOSN[M1N_J8N_U
MAF\E':2T#G !!^:YCNR\ONN7B.L$=^N2J6MH#N7 =B6,CN9Q1HF-ONP)1VR,
M'F<.)^P-)VQZOG#&=FMJ+O '9_ ];F9[ENMU?F>69F;.'G&0UG @;/$]MO%P
M'NR?7NS$WN; YO$?]W .IVC&-N<>%^<)-^UN3FC"-@AF!NMYQNRDG7*$IO*K
MAO+0_FV=I6I$(KB3Z,#W4C@O9Z4O-^H^2J6Q5CB6M/_PB E2D;4(0(+)G#5:
MI^S HM[9?)LCG91!2QJ8.)_S=QGSE!9:FR19G?5).<=9/$<X3&IT,E_T.H)9
MAPM*1R^DGVTXG-3S0C^XB /:C!AP4 ]U4=]EO;;K$S]PN$;Q4Z=F([]LQ'[U
M?N9QP>YL"U?G"M]K4S?Q!^=KO2YP$S?F4Q]L(Z=P8C=GFA[M"4?R=-YQ5XIG
MPZ[U5[=GQ>YP2%YQ6S?L9P\8>J9P>A;G9K]U9W_GC]YL9)=GC[;I<6YHR>;L
M==$(0'[MA'%WC-[H=N?M+#=C*HYMFK9W>._R=>%GAP[XS?:7("YBCR%I?K^O
M"!S!WB9)-N]1+V:E'^UNZF+_N'T9+_5V8_YR;A:$F!B<K^OB[8VG^"=6RNVB
M].S2"(K[&))@4NVV;1$4TO3">/XFXAZT[_Y.49+@XO<:=9__^5)V<+5F9+\>
M>E-/=01/^F GL%DG[&<V<FJ6=L5V^LMN]I2P=FRO[%?7:VL_^J5'\6='9*EW
M^G#.\""'^KRF]VZ>Z'JN=:B_\79><83V\"5G^T >]RR?\G!'>Z4>=]#^\0@W
MZIS^Z:X^<BJW=;:_(X7FZBR/B"V7::\>P=QFB#&_\Y9-"(BH_"!%2D/'9J8M
MB9*+>:&D292-='S[.%0ZVI9'%T@/I)#]N)[=<S77]))<V957KO_249I-))PE
M=)-%_R5%%UJ49TK6=W*@/WY0]V<9?^QE9WY87W[H;WY?-O)X+G5?5_43UW5<
M[_66H.85D25<"G\$"'^8J27S[R7T/W]?0O]@\J7Q?W_Q-R;XG__X?_^;L(GZ
MKW^9,*;\IW^ 0$!/(,&! Q$@-%BP(#^!#>GQ@R@Q(L6)""IBO#@1HL.$"Q4J
M](B0X,B0!S^B-/EP94>.'#6F)%E29DR0+%^RA-E0(T6>/#EBW)BQ8<^>+G,^
M++DS9TB9)TF>?'IPZM*652]VQ(J5R)@:0P DDY ,K%@)A<*&/2L! %NS:,NF
M?:L6;5RX;N^653OW;MV]?9.]_<LW;%ZY@?E**%Q8L-V]>N+K"GXKUJ]=M)0/
M8U9\N/'AQY45J]4,^:[GR*0/ _@\^C)BRIXYMPY+=B_;VK9OX\ZM>S?OWKY_
M P\N?#CQXL:/(T^N_'@AMLT!/,\]%BS;Z=:K8Z>>.OO8L]"O:P???*USZ">$
M/!VI?CW[]N[?PX\O?S[]^O;OX\^O?S___O[_ QB@@ ..1,0)DR4&F&IB58>@
M97 5 J&#$V96X8+)1)A9AAFJQB&&'4[VH(*!$8;97!Y>B**(@7FX864M.NCB
MAR*>E>&,<*5F(H,7WMBC6!;J&.2+=,%%XX\4R@BA924FN&"(_\M!&:644U)9
MI957LO45EEOF]IR7Y4$'9I>Z?1FFF;K50*"::[+9IIMOPAFGG'/2B=\*AMU%
MEFQMX0GDA:!A.)J>L86H69%\.=99H'9]-JA:L]5%:**'CE8I8J:QIB&1AD)F
MFJ)X6>H9;7T>V:FAHFKZ9ZJE+OI7:%S"&JNLL]):JZVUE5GF;<U%AUQTO(JY
MFW?5-7>"&'4BFZRRRS+;K+//$BC&"4, F2&QI28Y%I(.YL@HBTI2*&%@.<*X
MK60KDONBJJK".&-H[H8KHJKIPJN@@YAU*Z^1/A+Y;87MQFCNB4[R&_"2._+K
M(L+>DG>KPP]#'/&LTV57&\7:59SQQ?\78]SQQF%BN"N8N8Z,ZV\D]VI;!&A
MV[+++\,<L\PSPT<$$*4A5EN3K+GF9URD9GHII^LN:2EL03^V&HD$^PEIJ9H%
M;=BG/3=Y;F5X3HIUA3Y7O>");SD-FZ5CESBVQ&>CG;;:O7$,,;!FI@SEQ6_K
MVEN9-:1'L]Y[\]VWWW^[ET6/ U,\8H(>^FMPB.VB94 WJ5&8[X9!<GB# 5H@
MK $;D/L;=8WQKH6CN#):J_B,E$N@P3>#B^MCMN(6^3E@]4X.^Y(JDFXNPO7&
MJR*XB1=,N[XY;K>V\5;*0,L#6]Y BP''"T<%+138UC9OUNN&O6_U3&]WR<6#
MWS!YWGW97.'_%NN<OOF]3K<"X._/C /\\[LG/_URCH%GH]\)_2@%!A@ &X8#
M !4,,(IW?48O!I!! OV$,[0 P'("+ L -( /(O',, "D0(<^-3:B]0P? !RA
M ::G@0><:C.M$EO.9%.6O/QI+=@P  8*%;7&=,, -R!46AIH0Z!YT(>#VDS4
MT/:_$I;P 9& GFTF8,#B@,  R\/2$:6D!5I0 0K!T8 !)H"<#09'>QZ[7O7*
M:!LPMB5]TID2R8"3,B+(QW[MD:,<[]>R.K('C_;1HX#HN!X^Z@>0]Q&D'>M$
M2 $1(4? TYGH,(.!+C[ 0S.<P 0!4SJK7:Y:8L&'!H(GH_]I(3 G_TR8[K Q
M@0F$X6#!$XOFZ 4PWL$R-:-XWEB2,4K;U4Y?MN/1*PLQ"BJ0108Z5*&2 ";,
M&^@+=Y])T>CV!2+,=(Z"1@1@ >LA/2T81P/*@Q4;GDB<&4[Q2E6,TB.I<(/@
MS')SQP$@!MCV,';Z9GQG8LL,GR>L\M1M..8[4QOV2)]#[L>/^1'H'$="T(("
MB(\ ]<]"\\BLAJH'HGN3:'\62M'[\ -0BN&3B>+RR# 8@ )Q>8 I1P$JS@ &
M +1@H&Q:>IH'=-*'@8'" O-T0A9F!BPD51T+D[86"Z;J@T&-8HF *C0+':E&
MJ<J:V$P9.\@XC4E^T8(.!S.D!J[PAA8ZB_^@ZM(MJDTSI "@@!/A81PV4"&<
MQYNE6JOT2'LRT3=H/-Y<C3-+N)[/C+:A6WGR.L_;P+&0#*W/0>MGT/=<]+ .
MC>BR\)A8_$#TL7\DK&(1(MF #A2R !)"\"!X+5B*Y9&1H"1:+'<#TDK@B :X
M8(0,$ D IC*3A5">6.IIP&2HU@# 3 9( 3B*#UD.@,*4@2@?D$/=IH8*&L@1
M2,\)E_]AX)%0^)!K ?BXUP)0 ZTE(8;NZK@(/3*X8MWD"*GWF5D&JA G/.[F
M)E-  'Y( _*5(H:Z6<+I2@ $;'AK2-$BPON&!03 %,LL"4C"&SS2O-@-8&H>
MD%U+ONB8 # E?V?_Y%WSW@B7"X.EC;K&M>&%E7H3!F!ML,$&YU&R-EJP[W(-
M/,+-#8&+713Q!&B!#;90P'EL>0 MM,#C&\>XQD@<!0# P&"VC,*)5+@Q $;!
MX^QJ"9RXH< #G$@+-F"3+1MDL8H=G$01CQ, (!"R\]1)Y1).  0JMB\Z<$QB
M ,3XQ+HE,FZH.L5N8H"+RHM ;C!0XPE05:QPUH"0O]%.MJS8>8I&\I^9;)LX
M.X\*O]TQ+?*<1"VR9;2T #0\;Q/D3;<SSFBFLY<!2 M$MT.WVBU9R,8HLK_R
MJGV!_ ]!*6I1F"7VL@A=K&$GJRQ=PPG8C!T0( DI[/J,84&I>13GA/A(M RX
MP "R 6H[?FLYZAA0+.ST3DTG\ # 4!69 +@M #A)EG"/)=O),( &UF)=FZZV
M.6Q@0S*B^*-;OD4+$TCW;[7MVM3X&2P2! PZ6)N,4;0[&>$>PEM_NN]D?".5
M%7QX4I,QPZ*RF]]GF4 GFVP 5F;\+/@@[L3/,DF=3F M#]B<POOK5,#,<BTN
M\.)8PIN,9Y]%VE0="P@B\:ECMIP**F<#@3\.  Q\XVD*8NH'$V6:J)8&;/]G
M>ZN([\H6&9.0R/P%XWL!N+Q22U'+1W[KCKL(P!O;UP#U.#L '*SFMI/0 %J,
M>]C%7'?;1#'N(J:[ =[^C;A[\>AOONO:O3[6KK-]ZV(=9V[9?ANVECWN;05
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M-5-L>:81>*%)' ,42CE":V%;)4@A"W@ .P*-Y.FK'H%AAHH3;1I3<W>%T[U
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M.E*Q8[7ID+,J;PPRS"#=7'V\:+IC'7BX0)<O)-OP0/)]T"$O$[5C'[7\(R[
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MX2>QDK0L&A$ FI"=\-U-E$B.X9=(+7F-MD124%U&8XK<NM9!4OB>&9!]3R&
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MV?')C4HWG^A<WE&%HI'$(_2;X!EH:_3-HIQ]>I.Y@=FT_K2,IX-UIN6=PK2
M#9QV"#4917U\K6I(M<-Y:GSU$U#8!38W:@]L//93E27MF5)+XYZ63Z?[01+P
M3@#$QZ[C^C:-7#N-I,RP)+V%C>M."=FK3X"]D01.$GM#O=)#7;(=;71$_&)O
ME^ZU0P+8..J%1FT+.1,BV*927N#1[:7$,.MM-.5E.MIR EZ;V1;U4E1*:E,
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MYB_MF#Z4\U;K:*!Y4N6.#=YNJH#>\<#,O%X<)N;Z]@Y=D4W,U8_/B_8&"\L
MI;E#IR;FWJ1YIUY@S_7UU$SE1STO/O2+Z9X5FR$F:4APE"2!Y451:#N@+A0K
M\;WJ.7$E=<JHUJ%FG5G^4<Z'%UX!%IBV'_!<>)F^/>MP_7_9>?!$;Z%UR2ON
M$^@#YVXXU]KE;KX?A]B(7;:I2V);LGC,X.A+>^D-K4HQ7/\8"$G76%4\F%V3
MEPSNLPY)H,OE/!I[78]Q2*R>PS?XD'IBS$&1]XW?>PIE$4Q<S\5)$-(DM*GM
M>U)QD!-TEO:'KM_=PY-?AO"0TRL-4D*/0*.ZD\#&W )&$PFBFA-?1L32F/<R
M1&7UM)<148>R7L8>5ZBEO%MW=\5A!TO:6S8.$Z:.J6TZ7NB9IAU$TG64AR@L
M?A*U*R8,J#Q_'HYQ;=0B)'"EDY0/5BIY3(8Y99('QUVO1/*86$?ED4<?U- *
MZ&I#JBI+L[B)=MZ[DFGHV 8F/M,R/^*N9!A0[)#03@,:I,#N$9,45ST30,<<
MJ*:(3J(HN5[JQ&;.GAL,R[S&.6.B+M$,9Y#>VS6X&1-_M&G-Z(NJ#G#3#?-#
MEO-M+@]"J3[W:_,9-,)!&MLX3<(PIKZ1T(!^S4542W(/\8,'R4E]YV'SG?>(
M KS%MG%K*JCS\Z68,P!UD8<1DW61U0&8D4]055M.3@095;I[8HV+I,T]'J:R
MLGL\*FK?/1Y_7"'VJ"T'<YDGOY#R=\KK^C7!9#0YU5D2.3@*' -'3DA<F]+(
M<.4CBT8(+1TOV)+9U2D2,19/.R8 \2IC6(UKJTX$H&=&C<R\5M:>[ 7:$=8D
M/2 61Q,*:I$VJFC 8FDD1!R-E!E[?[TX& DICJ)<9)Z'QRC?TN(RKK=DLWF]
M)9DHR'[Y5,M&* ^_O;"]N;V^03NJB),]:8@@JK#)AR:?06#<X.@1'F9JYLD-
M"D0>%TTI#/G,D*L%(8^+U U!GGA2]?XGWC+/0B2\#1:'B=T8AR1)<.K2T/7=
MV$Q]"W8'=$)A835LZD 4Y'PW=DD@Y!SQ6>)!UW1!2B26+E GYJPDVNZ#3L=?
M^4[HC'C]>Z%S#ZH6MV;N.EL>AXK=<@US;0,'GI-@&L>I$2:18R?!U[JHR49.
MPTX)@!1L3T9>P?@KJ-C7:8=5K3V+BIRZS9$5IFV"DM@S3!:752A-/2R%MGK4
M)\.O7(1Z6+A^Y>DSS^FH3?@Q9TL'K>HOI&YB,)(VD9L\T--"I"ZE.+383S3V
MPS0-0HOX4M= <-)+WP\)<JB4KEFC )[L^=02D*@<677J-.S80)R/"]2B=6!E
MJ1J',N(O4O5PE/ ;UD&4 62\,J+4"(HN<5W$OS\6&_9&=?V/;5:_GIZ(F=3%
M81A%V"%10-V$FF8 6K'[)%99LZL.V7_]E\ R_7]#5) '^LJ3",4\&S&B)G9=
M8C.;&OL6L15ZF,["2;G=:!NKQQM0#G0;U8V5Y:<X\NR +42>:WIF%%K4!G<
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M3"FAA& W,DWL,R.&(\>Q>(F6-+ #US-#4$0KA/C"%NRNV$!M%00Y2?NT$!Y
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MW=@%]30;)[?TH5.'.,])(_$_MJ) 7+;G0VEW-(&AY+V4-F2@NYV][(+4!?K
MMNLUQ9_8;KUI]7@ ;:HU)_SR24IJ79=.X\36O6R2$KQWR23WEF+YREY W^>B
MII<1/[J)Z]/V-$&0X,CG]0G2-'%=$GD.+/IWG-S"IF P.I731[_M. !VBIE
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M#OJ!1^W8XDVIKPQ:!G;)#8O%P(19Z+GDJYNZ*9Y'E=-]X60W&?=N G*=:5D
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M?<^/B4=LF1?))!73;X@!.?0[)RA9ICH-S;2!UR8PS')#9)76?RE9IAQ/ML#
MZ62_[1W.Z;4746@I\7I-E;M8+3#N<X@^TO;?V_(J3:LMS?K$](*.VE5;OHUC
M)XYP$ON9FSA^[N2@Z%>&J.E#VY9@?UX+S,"10DTN7M6-!?3,M<L7_*FG_S.O
M^NS1&?"@+^J$2*PIM)0BN6C\" 'A.$@$W:LZ7ZAL*I(V?RV:I^MMW6R>:;4K
M53FV![:3XCC.$IRE.;53XJ5.FL$F!DU0,VP(?GMA#X=70K?9-= Y0%,PR1D
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M8C+^2AJ^:_-V;%7"*,(D=2/L!G9"8RMW/$=JB^5"/DRGK7536PX*W)5;E((
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MMBV2>J'EN[DKE;,)H&E\?Z=G@L<1! D^D(-Z3I!@!9!=+HGDM+H;P@<:H<E
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MG@/"? ?^I#^R?\4&D&0X?N)6TS[\GB+Z2/G.1-$=2W(&_D,^$C\E]7P0?J'
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MX)J>3:^RH-(HM^>7+=-\GES_PNE>E=FW3=[\0:IQ<7:;CY Z.**QASTGC//
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M8C( %6EYUYNZ&1U[9BPF(5Z8XRP* ^KX<9Q%H/)<>=*&%75 %5<M642[N<S
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MWY,5?>0C-3;5&WKNF93<.59!>UK_#6,(,PG#E@^"D;9B51P-[GC9;:*HU-'
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MX"!*<!)0#Y/((W[J6EGN6M+5>'/43+L2OR!.?X4&'* ="X#ZM%G4IDV+=BR
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M:<%00,8)P> 5X)WL;O[5O%W]464U>R_6-]_3]>-?R/KK2]4P2M^VS\_5&V_
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MT?YV]9ZL*,R<%>-O?]3I?5VD5'K*[,Y3QM/V:)T6#46"&&":[*YH\P%==:F
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M5HKRTD>VS(%NBF[DGL?'=ULA=E+;=N.(#\_,(;IYFI1A!1T1[FNT.6E%-9T
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M44 2.\P3J=CT'"'#MOOS?R)&&HUI(TX<D&,[A=*TS=4I.\Q4GA)[OJT13'Y
MZK F'-0R@L%? UANKX1LDRF[4\\OEXDK(<5.@JW,Y]7.N'=#@.H+979Q2,M]
M.W!=,7L4T<S!-$K#P H#.Z*@>6TGZ"P3 =[$0E><.%IMDX]A)\M38,F=!S5
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M>'+#;,(=N==ERQ@Z''K6Y:+E.(KMD.W':9PG21J37"J#=']AP]M?1PHXS>Q
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M$76]XF_]>,SK'[1.BX9F^R8G=@,<VX&+?>I0/\_]*,@SB,D!<V#8\ QT>$>
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M#982+/O626T1A1Y\J]5C3?CHEW'I3%_=(-N&;V(-P[:#D48][9U2-T SOBD
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M])5OOU\V32SVK)WCLI\(Y?^T'#\+TRR)0.&S>9*&;=JGF_][_1%=/CQ</S[
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M([=L&VA)X0]:/<L^I[F=\^>Z.AQEZ"44QVQWQVRWCVB81:Z;PB(7D^0,&P%
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M,_GXS'(P<*,;M4-<'.5>CB/7B2++M[W$!L73)F@9MDXG;AXPLS0%E9SMT00
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M5*[4Z..&]5I<X1D9>9_%(,:\;T)! N!E8XYYD%MACUTE]\&PQF)N@CVFQ^Z
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M;)&HV)ZA3<+FR0FRH4-QE#+7E01D%="(T"A*@6Z\CXYQ1RZH\);F*!<K*OK
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M<TM)#=,FYTZ_L\F N5X-2 ,=D->.(&=H-\5[6<9[2^AO%ZE/\TOUB-3 \7>
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M5',?<7_[^1J^^[!=O9G\IJ(B]'6?!U%?NNN\BFIZNLTK#:,,QU8\T7OR^QZ
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MVYC0E&#/L3TO=;+,]4#IAS%BAEW%39EODOQY32O1<J/+"/BNP;#"Y+R#+C7
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M'VUU]VOZYU\/JPB'2.C\%Z</]_[?_S 9W-T/_=/W;L<^_/L?[NWX!T@:A9S
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MA\;_:Z;'\8G#ATM_7XU7Y,"1 %()#!16EDJFI7 BB_+?O+@1#G#Y.-A%GH5
MXL*/!Y4['KFCN/F^9<!I$W='JX#!FD#OA>0F#R!>O;81'$CY<&@ORT+ <#W6
MH\D@"7X]H$F0P""E@6/1.R)040-EGMWAS9L;08*6#XF=)-HS*HY'T\'TX?-@
MZ,]F=\:/5VB7'"BJ"'#(.$[CEU;NAH:W;VR$ E8N"G:28!':O_0W@R2$T?1,
MWZW8-,I81"]T\:3E*(&"$R-P!@2\?FLC%/#24;"#)(M PDD\Q(^C"9L+_BK*
MWQ]6L]%T_'!8N15V#+? 2*V Y=AHA10GBF< QD8B&N%$E(Z3?'(N C;7^L>)
MB^(;A,$B.K'>$F*B@!0& \(1#M0%"17+ )B:US>"BBP=*CED6P1(#IR+*I@\
M_G4Z&'FTLE4R XR1#&@O/13&8\AVBZ?4OKH1.%3IX-A5IB4!XS!^/!]?5[^/
MWK*@>-HR20KB0L4I1%@PF \6+R]N%KJ"'P05+05:$B;F6^/Y^&)<?1^,[,K.
M&#TH8*QTP"*-,*=:$DSS >/-VYNAH^#(9C;1E@21BVHRU</_.[A?YSI)AX"&
MW@#))*<2&\AY#A=UW;N;P:/@@&<FL?8,CF3U#L9>K_6D8?2DH14@6*Q-\$Y0
M;W:[KUEZ6S, %!SB;"VZGE6>[D2'%[?5J"8"PPT$AL0]#ROM/(&6&+F;VM^^
ML9GJ"PYE[B3"GM5_Y>UL'*&+L+D>3(>K81>*@=+16D'DG)+"46IVVP3>OK&9
M^@N.8>XDPI[5?SW6*>_DZN'.5,.5G<HBH)PA0*>P.Q<FP!V#EZ]>UTSQ!8<M
MVPNOD$5__,/>ZM&-7Q=O-3J>>K'0(%".C3'4&+_;\6#=6YMAH."0Y,ZB+.(X
M<#@;)W$M;N 2I*,.9I.W?"!N@*:81_>58$LLQ(3DN,Y:__9FT"@^!)E!M$5
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M@'): *L8BJ<'KYP/N7>Q#?3TTS"C._QDDWT!.$I+8!1_Y"&RL-(#A&.@*'+
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M2U&)9;$N1+W2THI0H RC@"KA32!:X>QM1??+8;_GL\Y62L$P*6#CR&HQ-/)
M"ZZ $YXYR8.2-K>[T_UFT-EYL$R(;Z7$'2>3Y1MREY7E>8<IQ1F 'EE/B'3$
MY4Z\ZAZWG1TI/P9N-RJQD F@5[/[^^%<E'KX),J34:C&=PMEU@C54 'BQJ$
M5S@H+QFW/'?#NX:D]7N&[ R)72BF !?Y9!2?%1=0BB['P^^*J3?Q\"RX!!I+
MJ^.Y%FN1OZ'#*Q)ZGH37A9I7RIC;R[P(R#R/BJCA(& +I$($4!C_A-@)E[W]
MYBH5/==G[@4X.TF^ .R<52,;A?.2B#IRS[&UDVBXZ_OB004,<SJN#(H9A4QC
MDGL 0F/B^FWBVET29B?**0!UCSTHYEV9W& Z2]E2(SM+E'R:3<^JZ5_]].EZ
M]55"B0G I#M6)34D7$,MLWM536GK.>NR&VBL>/L=Z*D _+U[L[^V8Q/'!,@
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M=#3WL>M]JCY8X]J-6&G<N+:=3LHT-XM6L>TMS:O?S]:ZMD/[\DX+4\[3AL$
MT]@A 2'D-G>2=>X&MO%IA]7DG9V02@T4] 1 @X@CVC&A\W>N74M*T2UK-^E[
MM67M[J(NX")C7>?=ISO$AZ]Z.AO'OS>SR'$\QCD$ 2160B.T-R2WQ]N"S'X3
M!;(BK5L5E;D7;>A!W'Z#>O^AW79/[G KVZG/+88,2&8L@)I8Z(4*5N>.%.ZU
MA_++&?'S8#28QO7RW:^\]L!&)RZ"_6!RH<?3\_!I-AF,XF([K.[,8%3;4&$Q
MC(!8H!2!@&MEA>=>1//>V3$_$Q,?N!/S1H361PCZT'Z9]O1-6^3V-G3]@_(W
M;NXRK-"\Z2ZG D@#HQ-G,64&"A)$;E>YP_;-+RMAM?WO!I<A]?PT#"B?QM 9
MQ810@A.5?9!R8^H^3)/FC7BIMU-9M5.F 4I]D=M;G:7?SM2CN4/[TJQ3KU*I
M A@;8(W5T$O"O,Q=X]Y-I^87W*;G+_7TK.\C[BC02$L0*$,&!D0YRCT+Z'VJ
M/D+_YHVHJ#<@61110#SB-4>;C2#C"F@)$=!4!*(9$HAE+]#;0$^_$8;.X;2#
M\/LN0UB^(HR/])/I4SN&C3R)X(#FD@,LF<1!N@ I?V]GVN:%_18>9$1,9U(N
MTW=9UZU]EPO9VJ=UU%F^0U]GFY[A(3JL2B;U2X8<#M :F3LAJ]/^\D_/7O+3
MOWJ=WN'.1Y?>SL;CP>AF7B18[[JK-*"!!B E]A8[@HW*'6MK1>C'Z3V_$4<K
MO><[5UH!;M,SDXO85AU_WT:5F?CQ]V0.3D;WLVG\YVIDHU0VQ+LB^UB)M-DS
M *46P6A+2';W/3,+_3IGW:.Y!T67A_/7!8]KA!%_X*P:C5_))OW^HQ3L[6CP
MO[/W@BT<P>@1$0=,D![:P(2GN6. >V&L7_=S7VNB %"4M%(:;'MMK041""@>
MK85BD8-H/+#7G<T+RLA'OU6W17@ZG:B\ -@OA=2_Z\$PL?=8 W^5^)_+Y VK
M&Y<YLBG" 2T(UA,!L3&>Y&X5O"O-_1;N=@;GO:JRS+C#ZL2F'<IVZY[5R62I
M#B,.VTW@\"Z>W*0P "'HO=$$HNSSL#N>+[5\2SB[FPWU--KSU'4VM5<8^UL_
MF@R^^T7GV=-J4N^X+(8GV2@0JCW UEBL5/RKPZAY*Y(_TH27C?C:>.';L2H+
MMFCSJ5 [6K+E9V2=5E6,Y8+* 06Y!I9I:J7TQICL+6OV9+F>9AE=19=S8/WZ
M#C$'P_DC'PM(;74S&OS=NPL_'E0N95JO#<_-1872/12Q&$"N'+)Q+>BWC:,R
MVK3,S'PD:[<1D_76KD_U%W4H6<_Y7 >+_DB3 SL=?-^4T#WG. H?&!=XRHF$
MW&!-O.XNGZ(MU?W&8/>"[+THM% (7^B'>7W=[WKLECE^CJ4=3":SN\7W-G./
MD4G3J110CD!M-?,Z^Y2RO!ST&TK=,[3WI.@R/=8-D_W:N[#O/[3;F80=.KE-
M)](YE#)EL0:.V7B*LA*Z[.F/74TF7/)LWKPA!5?MP<@=#8:S>+9[Y_R6FIH'
M&\^.S%OJB$#4=.BV;D/JQYAJN!%#&]S1SI16U$Y],)H.7&)I\'TI9'K\PPYG
M<9DO^@'=W<^>!B0UGOJ8!L+I:,6CN^V1(9QY@K*/;,_.1;_.:,>([D759>[7
M2R,U=VG1]/8A>8=]=MJBJ?EX1T*!\H: ($6 F@NN?.Y0<(<C/Y?S3]-+/OE0
MC?W+"^-?D^G<L'^.WQ_<U-\/S:5A$ *2"P0"8L831H+1V<?;[$9RWPV=\B!K
M4T.GKO58ILVJG=C9WH*]]\@NYXQV:-TZF?>(5+J6-@$@[I!+/<)HR!U^*&+:
MZ,M*>SVU,H577V96?GI(SD(UJNENM!A?B71T#(@#'#N&<""(A^X"D-M2^Q/.
M)-V(T7J+VJF>RS2FJU/S=KAJK'M6)]/]NKQZ;#C'S4$$%!80..*U)])AK7-'
M93J;\?<2NGSSAI-1]"CNYAKZ]/#XC_60-Q@8S2$0DO,0O0G$1'81M"/U8\P"
MW(BA#?'FSI16IITZ.KXZO#RY2 O__/.G;U<G9\=75T=^J@?#EB7R&YZ7I6B^
M*;V%^GKSUBW6(*"E4@#Y%& AGBB:VW$IPM=[-1,@S0*8[RXK37&1!XHY#YB
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MT")ZA2(@ [0*&"!'$(6&P)"]*=$[)/4;H_@(GD%.G98-T:75O,00\QIHY@Q
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M&ZT%^8^^%O:)B[Z3;K<+^J:9>Y'#U?"OCHL=4$@BS\(KH%'\4@LC,4,^K#0
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MK.[NJU%\^*0*3RT=!O%\V/XNH,UK,EP)[,Q=IIN!Y[X8+ZF]=1%>FWJL>LI
MH)K$35,916#FA;^!G-U;L#X^^E+__E5'Z [T<'+FIVFQ3OSXNU]9I"8UP]$R
MM3P@R@2(G)"Y4R;?IZKO?HYY\+':I#2K-@K86I\Y^G,U_I^3T;S"8K*9)1@H
M,(1BH"(LL.$B0-DHP:8-P.K)ZKMS8L<(RZ2/DB#V>3 :3.*N\:6JW&:6$.1
M4:X!DM1S"ZG$U'4%L7JR^NY8V#'$,NFC)(@]-OYY?3Q70"EMXY<NRL4126'N
M[*_E]_?=\Z]CT&PKX?;HJ*9ZV'?3/0$%8"QU%C06 0UE-+4BNN$R[N:(YVZJ
M^B&;[G6#M^YU5OSY,4?1W*;'Y3T/[J5X;@NTN32JPP0+G&-&6V<#%IV9_0[/
M?8\=BUX&+/! #/!$HFAXF0$R6 $HQE9)#H/%G;E)RX1\F-/=1A34[G&M95Z
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MCF?\3+?>6T$JEQYZA%2:3?O<8.J+KV[&^OYV8/5PG2D/A@!-4J- 2 5VFK.
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MWZEE!%,:&&D]"%(H1H,7;'<B\ICNXJYD3UN"=S2X'EO!)X?IMYI-8$^!LBH
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M"Q+%_^_62;[QZZ?UJXT)C %B+, _<;F^\\LG3IYG>\[\ZK%?6XT;X2#0"#$
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M"(^? @K:8,5A[I-G#RG3]M88U^O;3][%P>:Y#O]*KQ\S2-TWO[1)3;<U:=&
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M4YE38$EJDTNH1Z93&&R:RZ6%L_?@ BC[NLD%J_?UT+GVZ_7<-YX\VCL@!93
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M3::=BYN,IREA6DC!."86#D+0E,979DUVP4</L19PQ_W:75L;J/FLA! "@X4
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M)%!&*R^D)%I.]$@]+(0])1KSO")&55T)T+P\_WRV7B]GYF&=A'53?=LH(-X
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M84 3"@&._V<)%X@%_)8-U6FEB3/U\V,FOWP+.)6:^;GXT\Y6ON$9@9Q/@A+
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M/@K"4G-AF.<&&&0XL%QB1T5@PHR%IA(*,OMK<@\D>HAU:G_NYX5[L)LMDYC
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M6IJ3GL2=P09[V;D-Z+]Z6X#YQD:A>!E*^JXRS\"C$7N59GL> I+$.MEXZ44
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M,2YH=&U02P$"% ,4    " #%HP1=SY**1N4'  !4+0  %P
M@ &HZ@$ <&-R>"TP-C,P,C R-GAE>#,Q,2YH=&U02P$"% ,4    " #%HP1=
M%W6O6M8'   [+0  %P              @ '"\@$ <&-R>"TP-C,P,C R-GAE
M>#,Q,BYH=&U02P$"% ,4    " #%HP1=+_YC$><$  #]'P  %P
M    @ '-^@$ <&-R>"TP-C,P,C R-GAE>#,R,2YH=&U02P$"% ,4    " #%
MHP1=DL[3M7#\ 0!5E!H $0              @ 'I_P$ <&-R>"TR,#(V,#8S
M,"YH=&U02P$"% ,4    " #%HP1=5( /,SP8   Y% $ $0
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H>"TR,#(V,#8S,%]P<F4N>&UL4$L%!@     -  T ;0,  ,[A#P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>pcrx-20260630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2026"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pcrx="http://www.pacira.com/20260630"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcrx-20260630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2026-08-03</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:RevenueMilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:RevenueMilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:RevenueMilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-31</startDate>
            <endDate>2026-07-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pcrx:WorkInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pcrx:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:PaciraCryoTechIncAndIoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pcrx:IoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtInstrumentConvertibleTermsOfConversionAxis">pcrx:DebtConversionTermsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pcrx:CappedCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:WellsFargoBankNationalAssociationCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2028-03-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanAFacilityDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ConvertibleNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pcrx:GQBioAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:EquityInvestmentAndConvertibleNoteReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">pcrx:ConvertibleNoteReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:InvestmentCategorizationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2025-04-17</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:CostOfRevenue</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:MyoScienceMilestoneLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:MyoScienceMilestoneLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2025-04-07</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pcrx:ResearchDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:LGChemPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:JohnsonJohnsonMedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:JohnsonJohnsonMedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:InitiationOfAPhase2ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:BaylorCollegeOfMedicineBaylorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:BaylorCollegeOfMedicineBaylorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-27</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-27</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:GQBioTherapeuticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>pcrx:product</measure>
    </unit>
    <unit id="customer">
        <measure>pcrx:customer</measure>
    </unit>
    <unit id="lease">
        <measure>pcrx:lease</measure>
    </unit>
    <unit id="trading_day">
        <measure>pcrx:trading_day</measure>
    </unit>
    <unit id="wholesaler">
        <measure>pcrx:wholesaler</measure>
    </unit>
    <unit id="offering_period">
        <measure>pcrx:offering_period</measure>
    </unit>
    <unit id="period">
        <measure>pcrx:period</measure>
    </unit>
    <unit id="certificate">
        <measure>pcrx:certificate</measure>
    </unit>
    <unit id="manufacturer">
        <measure>pcrx:manufacturer</measure>
    </unit>
    <unit id="notice">
        <measure>pcrx:notice</measure>
    </unit>
    <unit id="segment">
        <measure>pcrx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001396814</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod contextRef="c-89" id="f-481">P5Y</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThresholdPeriod>
    <pcrx:AccountsReceivablePaymentTerms contextRef="c-95" id="f-493">P0D</pcrx:AccountsReceivablePaymentTerms>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-148"
      decimals="INF"
      id="f-762"
      unitRef="number">0.0252752</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <pcrx:DebtInstrumentMarketPrice
      contextRef="c-140"
      decimals="INF"
      id="f-763"
      unitRef="number">0.999000</pcrx:DebtInstrumentMarketPrice>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-35060</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">PACIRA BIOSCIENCES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">51-0619477</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">2000 Sierra Point Parkway, Suite 900</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">242-8052</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">PCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">39861886</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">205875000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">158545000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">45156000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">79879000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">132420000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">124069000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">134575000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">152863000</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">67337000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">29852000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">32618000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">615215000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">547974000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">130277000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">140690000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">44920000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">41777000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">19642000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">20214000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">285484000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">368100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">124598000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">123854000</us-gaap:DeferredIncomeTaxAssetsNet>
    <pcrx:EquityMethodInvestmentsAndOtherAssets contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">23842000</pcrx:EquityMethodInvestmentsAndOtherAssets>
    <pcrx:EquityMethodInvestmentsAndOtherAssets contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">22308000</pcrx:EquityMethodInvestmentsAndOtherAssets>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">1243978000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">1264917000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">17509000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">15150000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">93499000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">95601000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">10298000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">9839000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">705000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">122011000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">120590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">363124000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">372189000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">38695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">36176000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <pcrx:ContingentConsiderationNoncurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">17452000</pcrx:ContingentConsiderationNoncurrent>
    <pcrx:ContingentConsiderationNoncurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">18066000</pcrx:ContingentConsiderationNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">4070000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">4213000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">26650000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">20572000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">572002000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">571806000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-80" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-81" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-83"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-84" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-85" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-86" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-87" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-89" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-94" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-95" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-96" unitRef="shares">48840889</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-97" unitRef="shares">39822298</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-98" unitRef="shares">47890777</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-99" unitRef="shares">41116739</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-100" unitRef="usd">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">48000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-102" unitRef="shares">9018591</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-103" unitRef="shares">6774038</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-3" id="f-104" unitRef="usd">227013000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">176565000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-106" unitRef="usd">1087452000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">1064623000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-108" unitRef="usd">-191753000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">-199322000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-110" unitRef="usd">3241000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">4327000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-112" unitRef="usd">671976000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">693111000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-114" unitRef="usd">1243978000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">1264917000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">190493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">180347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-118" unitRef="usd">367869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-119" unitRef="usd">347941000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-120" unitRef="usd">1906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-121" unitRef="usd">752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-122" unitRef="usd">1906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-123" unitRef="usd">2081000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-124" unitRef="usd">192399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-125" unitRef="usd">181099000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">369775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-127" unitRef="usd">350022000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-13" decimals="-3" id="f-128" unitRef="usd">44164000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-14" decimals="-3" id="f-129" unitRef="usd">40866000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">80577000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-15" decimals="-3" id="f-131" unitRef="usd">75172000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-132" unitRef="usd">30243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-133" unitRef="usd">28200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">58315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-135" unitRef="usd">53893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-136" unitRef="usd">91809000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-137" unitRef="usd">88578000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">185753000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-139" unitRef="usd">175354000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-140" unitRef="usd">14322000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-3" id="f-141" unitRef="usd">14322000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">28644000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-3" id="f-143" unitRef="usd">28644000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-13" decimals="-3" id="f-144" unitRef="usd">-7594000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-14" decimals="-3" id="f-145" unitRef="usd">-634000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">-5317000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-3" id="f-147" unitRef="usd">-6470000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-3" id="f-148" unitRef="usd">188132000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-14" decimals="-3" id="f-149" unitRef="usd">172600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">358606000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-3" id="f-151" unitRef="usd">339533000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-152" unitRef="usd">4267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-153" unitRef="usd">8499000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">11169000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-155" unitRef="usd">10489000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-13" decimals="-3" id="f-156" unitRef="usd">1944000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-14" decimals="-3" id="f-157" unitRef="usd">5008000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">3874000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-3" id="f-159" unitRef="usd">11903000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-160" unitRef="usd">3622000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-161" unitRef="usd">4695000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">7321000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-3" id="f-163" unitRef="usd">9275000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">-34000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-165" unitRef="usd">-10739000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-169000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-167" unitRef="usd">-6338000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-168" unitRef="usd">-1712000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-169" unitRef="usd">-10426000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-3616000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-171" unitRef="usd">-3710000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-172" unitRef="usd">2555000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-173" unitRef="usd">-1927000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">7553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-175" unitRef="usd">6779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-176" unitRef="usd">-2098000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-177" unitRef="usd">2920000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">-16000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-179" unitRef="usd">6814000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">4653000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-181" unitRef="usd">-4847000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-183" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-184"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-185"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-186"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-187"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-188"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-189"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-190"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-192" unitRef="shares">39462000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-193" unitRef="shares">45459000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-194" unitRef="shares">39961000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-195" unitRef="shares">45867000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-196" unitRef="shares">40300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-3" id="f-197" unitRef="shares">45459000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-198" unitRef="shares">40605000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-199" unitRef="shares">45867000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-200" unitRef="usd">4653000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-201" unitRef="usd">-4847000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-203" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-3" id="f-204" unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-14" decimals="-3" id="f-205" unitRef="usd">-45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-42000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-15" decimals="-3" id="f-207" unitRef="usd">-131000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-208" unitRef="usd">-229000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-209" unitRef="usd">2756000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">-1044000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-211" unitRef="usd">3850000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-212" unitRef="usd">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-213" unitRef="usd">2711000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">-1086000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-215" unitRef="usd">3719000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-216" unitRef="usd">4439000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-217" unitRef="usd">-2136000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">6483000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-219" unitRef="usd">3684000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-220" unitRef="shares">48328000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-17" decimals="-3" id="f-221" unitRef="shares">9019000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-222" unitRef="usd">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-223" unitRef="usd">-227013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-224" unitRef="usd">1073809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-225" unitRef="usd">-196406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-226" unitRef="usd">3455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-227" unitRef="usd">653893000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-22" decimals="-3" id="f-228" unitRef="shares">28000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-23" decimals="-3" id="f-229" unitRef="usd">457000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-230" unitRef="usd">457000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-22" decimals="-3" id="f-231" unitRef="shares">559000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-22" decimals="-3" id="f-232" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-23" decimals="-3" id="f-233" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-234" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-22" decimals="-3" id="f-235" unitRef="shares">157000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-23" decimals="-3" id="f-236" unitRef="usd">3493000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-237" unitRef="usd">3493000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-22" decimals="-3" id="f-238" unitRef="shares">83000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-239" unitRef="usd">1722000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-3" id="f-240" unitRef="usd">1722000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-241" unitRef="usd">14958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-242" unitRef="usd">14958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-24" decimals="-3" id="f-243" unitRef="usd">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-244" unitRef="usd">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-245" unitRef="usd">4653000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-246" unitRef="usd">4653000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="-3" id="f-247" unitRef="shares">48841000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-27" decimals="-3" id="f-248" unitRef="shares">9019000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-249" unitRef="usd">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-250" unitRef="usd">-227013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-251" unitRef="usd">1087452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-252" unitRef="usd">-191753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-253" unitRef="usd">3241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-254" unitRef="usd">671976000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-255" unitRef="shares">47121000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-32" decimals="-3" id="f-256" unitRef="shares">837000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-257" unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-258" unitRef="usd">-25121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-259" unitRef="usd">1023808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-260" unitRef="usd">-201544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-261" unitRef="usd">1351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-262" unitRef="usd">798541000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-37" decimals="-3" id="f-263" unitRef="shares">669000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-37" decimals="-3" id="f-264" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-14" decimals="-3" id="f-265" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-37" decimals="-3" id="f-266" unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-38" decimals="-3" id="f-267" unitRef="usd">5286000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-14" decimals="-3" id="f-268" unitRef="usd">5286000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-37" decimals="-3" id="f-269" unitRef="shares">101000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-38" decimals="-3" id="f-270" unitRef="usd">1569000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-14" decimals="-3" id="f-271" unitRef="usd">1569000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-3" id="f-272" unitRef="usd">15472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-273" unitRef="usd">15472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-39" decimals="-3" id="f-274" unitRef="shares">1956000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-39" decimals="-3" id="f-275" unitRef="usd">50394000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-14" decimals="-3" id="f-276" unitRef="usd">50394000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-40" decimals="-3" id="f-277" unitRef="usd">2711000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-278" unitRef="usd">2711000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-41" decimals="-3" id="f-279" unitRef="usd">-4847000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-280" unitRef="usd">-4847000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-281" unitRef="shares">47691000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-43" decimals="-3" id="f-282" unitRef="shares">2793000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-283" unitRef="usd">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-284" unitRef="usd">-75515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-285" unitRef="usd">1035563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-286" unitRef="usd">-206391000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-287" unitRef="usd">4062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-288" unitRef="usd">757767000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-48" decimals="-3" id="f-289" unitRef="shares">47891000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-49" decimals="-3" id="f-290" unitRef="shares">6774000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-291" unitRef="usd">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-292" unitRef="usd">-176565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-293" unitRef="usd">1064623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-294" unitRef="usd">-199322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-295" unitRef="usd">4327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-296" unitRef="usd">693111000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-53" decimals="-3" id="f-297" unitRef="shares">28000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-54" decimals="-3" id="f-298" unitRef="usd">459000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">459000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-53" decimals="-3" id="f-300" unitRef="shares">1206000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-53" decimals="-3" id="f-301" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-54" decimals="-3" id="f-302" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-53" decimals="-3" id="f-304" unitRef="shares">367000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-54" decimals="-3" id="f-305" unitRef="usd">7848000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">7848000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-53" decimals="-3" id="f-307" unitRef="shares">83000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-54" decimals="-3" id="f-308" unitRef="usd">1722000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">1722000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-54" decimals="-3" id="f-310" unitRef="usd">28497000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">28497000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-55" decimals="-3" id="f-312" unitRef="shares">2245000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-55" decimals="-3" id="f-313" unitRef="usd">50448000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">50448000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-56" decimals="-3" id="f-315" unitRef="usd">-1086000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-1086000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-57" decimals="-3" id="f-317" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="-3" id="f-319" unitRef="shares">48841000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-27" decimals="-3" id="f-320" unitRef="shares">9019000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-321" unitRef="usd">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-322" unitRef="usd">-227013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-323" unitRef="usd">1087452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-324" unitRef="usd">-191753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-325" unitRef="usd">3241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-326" unitRef="usd">671976000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-58" decimals="-3" id="f-327" unitRef="shares">47078000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-59" decimals="-3" id="f-328" unitRef="shares">837000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-329" unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="-3" id="f-330" unitRef="usd">-25121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-331" unitRef="usd">1009435000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-332" unitRef="usd">-206356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-333" unitRef="usd">343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-334" unitRef="usd">778348000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-64" decimals="-3" id="f-335" unitRef="shares">722000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-64" decimals="-3" id="f-336" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-65" decimals="-3" id="f-337" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-3" id="f-338" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-64" decimals="-3" id="f-339" unitRef="shares">210000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-65" decimals="-3" id="f-340" unitRef="usd">5467000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-15" decimals="-3" id="f-341" unitRef="usd">5467000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-64" decimals="-3" id="f-342" unitRef="shares">101000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-65" decimals="-3" id="f-343" unitRef="usd">1569000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-15" decimals="-3" id="f-344" unitRef="usd">1569000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-65" decimals="-3" id="f-345" unitRef="usd">30025000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-346" unitRef="usd">30025000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-66" decimals="-3" id="f-347" unitRef="shares">1956000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-66" decimals="-3" id="f-348" unitRef="usd">50394000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-15" decimals="-3" id="f-349" unitRef="usd">50394000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-67" decimals="-3" id="f-350" unitRef="usd">3719000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-351" unitRef="usd">3719000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-68" decimals="-3" id="f-352" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-353" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-354" unitRef="shares">47691000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-43" decimals="-3" id="f-355" unitRef="shares">2793000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-356" unitRef="usd">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-357" unitRef="usd">-75515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-358" unitRef="usd">1035563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-359" unitRef="usd">-206391000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-360" unitRef="usd">4062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-361" unitRef="usd">757767000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-363" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">6397000</pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets>
    <pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets contextRef="c-15" decimals="-3" id="f-365" unitRef="usd">0</pcrx:DeferredIncomeTaxesValuationAllowanceOnDeferredTaxAssets>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-15" decimals="-3" id="f-367" unitRef="usd">11000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">5644000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-15" decimals="-3" id="f-369" unitRef="usd">2149000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">42626000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-15" decimals="-3" id="f-371" unitRef="usd">48490000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">1154000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-15" decimals="-3" id="f-373" unitRef="usd">1739000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:OtherAmortizationOfDeferredCharges contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">663000</us-gaap:OtherAmortizationOfDeferredCharges>
    <us-gaap:OtherAmortizationOfDeferredCharges contextRef="c-15" decimals="-3" id="f-375" unitRef="usd">186000</us-gaap:OtherAmortizationOfDeferredCharges>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">28497000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-377" unitRef="usd">30025000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">-614000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-379" unitRef="usd">-3032000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">927000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-15" decimals="-3" id="f-381" unitRef="usd">3444000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ProvisionForOtherLosses contextRef="c-1" decimals="-3" id="f-382" unitRef="usd">0</us-gaap:ProvisionForOtherLosses>
    <us-gaap:ProvisionForOtherLosses contextRef="c-15" decimals="-3" id="f-383" unitRef="usd">-5887000</us-gaap:ProvisionForOtherLosses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">12074000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-385" unitRef="usd">1046000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">-8451000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-3" id="f-387" unitRef="usd">22871000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">-378000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-15" decimals="-3" id="f-389" unitRef="usd">15377000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">2248000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-15" decimals="-3" id="f-391" unitRef="usd">9344000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">1563000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-15" decimals="-3" id="f-393" unitRef="usd">-14675000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">4359000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-15" decimals="-3" id="f-395" unitRef="usd">10905000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">83140000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-397" unitRef="usd">47471000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">335000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-15" decimals="-3" id="f-399" unitRef="usd">16702000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">4060000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-401" unitRef="usd">11245000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">3905000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-15" decimals="-3" id="f-403" unitRef="usd">74685000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">39500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-15" decimals="-3" id="f-405" unitRef="usd">140416000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-1" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-15" decimals="-3" id="f-407" unitRef="usd">1250000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">31200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-409" unitRef="usd">36534000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">459000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-15" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans contextRef="c-1" decimals="-3" id="f-412" unitRef="usd">1722000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans>
    <pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans contextRef="c-15" decimals="-3" id="f-413" unitRef="usd">1569000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">7848000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-15" decimals="-3" id="f-415" unitRef="usd">5466000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">50045000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-15" decimals="-3" id="f-417" unitRef="usd">50039000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <pcrx:ShareRepurchaseProgramExciseTaxPaid contextRef="c-1" decimals="-3" id="f-418" unitRef="usd">1336000</pcrx:ShareRepurchaseProgramExciseTaxPaid>
    <pcrx:ShareRepurchaseProgramExciseTaxPaid contextRef="c-15" decimals="-3" id="f-419" unitRef="usd">0</pcrx:ShareRepurchaseProgramExciseTaxPaid>
    <us-gaap:RepaymentsOfSecuredDebt contextRef="c-1" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt contextRef="c-15" decimals="-3" id="f-421" unitRef="usd">6563000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">10000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-15" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-424" unitRef="usd">-67048000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-425" unitRef="usd">-60499000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-426" unitRef="usd">38000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-15" decimals="-3" id="f-427" unitRef="usd">204000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">47330000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-429" unitRef="usd">23710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-430" unitRef="usd">158545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-63" decimals="-3" id="f-431" unitRef="usd">276774000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-432" unitRef="usd">205875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-47" decimals="-3" id="f-433" unitRef="usd">300484000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">6171000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-15" decimals="-3" id="f-435" unitRef="usd">7687000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-436" unitRef="usd">910000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-15" decimals="-3" id="f-437" unitRef="usd">8233000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-438" unitRef="usd">1506000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-439" unitRef="usd">1431000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ShareRepurchaseProgramExciseTaxPayable contextRef="c-3" decimals="-3" id="f-440" unitRef="usd">403000</us-gaap:ShareRepurchaseProgramExciseTaxPayable>
    <us-gaap:ShareRepurchaseProgramExciseTaxPayable contextRef="c-47" decimals="-3" id="f-441" unitRef="usd">354000</us-gaap:ShareRepurchaseProgramExciseTaxPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-442">DESCRIPTION OF BUSINESS&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacira BioSciences, Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d; or &#x201c;Pacira&#x201d;) deliver innovative, non-opioid pain therapies to transform the lives of patients. The Company&#x2019;s long-acting, local analgesic, EXPAREL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company&#x2019;s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia in adults via (i) an interscalene brachial plexus block in adults; (ii) a sciatic nerve block in the popliteal fossa; or (iii) an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks other than an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, and an adductor canal block). In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the &#x201c;Flexion Acquisition&#x201d;), and added ZILRETTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. The Company is also advancing two Phase 2 clinical programs&#x2014;PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy for OA of the knee, and PCRX-2002, a complementary, long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. PCRX-201 is the lead program from the Company&#x2019;s proprietary high-capacity adenovirus, or HCAd, vector platform, which enables local administration of genetic medicines and has the potential to unlock gene therapy for large prevalent diseases affecting millions of people. In February 2025, the Company acquired the remaining 81 percent equity interest that it did not already own in GQ Bio Therapeutics GmbH, or GQ Bio (the &#x201c;GQ Bio Acquisition&#x201d;), a privately-held biopharmaceutical company, which included the novel HCAd platform, a preclinical portfolio of HCAd-based assets and research and development talent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies and potential generic entrants, reliance on revenue from two commercialized products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, tariffs, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company divested iovera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#xb0;, a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to Zimmer, Inc., or Zimmer, a subsidiary of Zimmer Biomet Holdings, Inc. on July 31, 2026. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-69" decimals="2" id="f-443" unitRef="number">0.81</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <pcrx:ConcentrationRiskNumberOfProducts
      contextRef="c-70"
      decimals="INF"
      id="f-444"
      unitRef="product">2</pcrx:ConcentrationRiskNumberOfProducts>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-445">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#x201c;2025 Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#x2019;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities available for sale and expected to be sold within one year are classified as either assets or liabilities held for sale on the condensed consolidated balance sheets at the lower of their carrying value or fair value less any costs to sell. Any loss, or gain up until any previously recorded loss, is recognized in the period in which the held for sale criteria are met. The Company will recognize contingent consideration related to the sale of a business as a gain contingency. Under this policy, contingent consideration is excluded from the initial measurement of gain or loss upon the divestiture of a business and is recognized in earnings when the contingency is resolved and the consideration becomes realizable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, the Company agreed to divest its cryoanalgesia business&#x2014;including iovera&#xb0;&#x2014;to Zimmer and reclassified certain of its assets and liabilities to assets and liabilities held for sale. For more information, refer to Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants performance share units, or PSUs, under its Amended and Restated 2011 Stock Incentive Plan to certain of its employees, including its executive officers. The expense associated with these awards is recognized in the Company&#x2019;s consolidated statements of operations based on their grant date fair values at the closing price of the Company&#x2019;s common stock on the date of grant. The expense is recognized over a four-year service period using graded vesting based on the Company&#x2019;s interim estimates of achievement of a stated performance objective during the one year period subsequent to the grant date. Changes in estimates are recorded on a cumulative catch-up basis. After the one year performance period, the number of shares the employee is entitled to is fixed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes the percentage of revenues comprised by the Company&#x2019;s three largest wholesalers in each period presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Second largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Third largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Adopted as of June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU amendment improves financial reporting by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU&#x2019;s amendments are effective for annual reporting periods beginning after December 31, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. This ASU amendment can be applied on a prospective basis or retrospectively. The Company is currently evaluating the impact of adopting ASU 2024-03 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40), Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU amendment removed all references to prescriptive and sequential software development stages (referred to as project stages) throughout Subtopic 350-40. This had been replaced by the requirement to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding a software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#x201c;probable-to-complete recognition threshold&#x201d;). The ASU&#x2019;s amendments are effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The ASU&#x2019;s amendments may be adopted on a prospective, modified transition approach that is based on the status of a current project and whether software costs were capitalized before the date of adoption or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-06 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU 2025-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Grants (Topic 832), Accounting for Government Grants Received by Business Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU provides the recognition requirements for a government grant received, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. This ASU provides for adoption either on a modified prospective, modified retrospective, or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU 2025-11,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU is intended to update the guidance in Topic 270 by improving navigability of the required interim disclosures and establishing a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted at any time prior to the effective date and should be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2025-11 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#x201c;2025 Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#x2019;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-446">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules&#160;and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules&#160;and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2025 (the &#x201c;2025 Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements at June&#160;30, 2026, and for the three and six-month periods ended June&#160;30, 2026 and 2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December&#160;31, 2025 is derived from the audited consolidated financial statements included in the Company&#x2019;s 2025 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current presentation. Intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <pcrx:AssetsAndLiabilitiesHeldForSalePolicyTextBlock contextRef="c-1" id="f-448">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities available for sale and expected to be sold within one year are classified as either assets or liabilities held for sale on the condensed consolidated balance sheets at the lower of their carrying value or fair value less any costs to sell. Any loss, or gain up until any previously recorded loss, is recognized in the period in which the held for sale criteria are met. The Company will recognize contingent consideration related to the sale of a business as a gain contingency. Under this policy, contingent consideration is excluded from the initial measurement of gain or loss upon the divestiture of a business and is recognized in earnings when the contingency is resolved and the consideration becomes realizable. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, the Company agreed to divest its cryoanalgesia business&#x2014;including iovera&#xb0;&#x2014;to Zimmer and reclassified certain of its assets and liabilities to assets and liabilities held for sale. For more information, refer to Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;.</pcrx:AssetsAndLiabilitiesHeldForSalePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-449">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;The Company grants performance share units, or PSUs, under its Amended and Restated 2011 Stock Incentive Plan to certain of its employees, including its executive officers. The expense associated with these awards is recognized in the Company&#x2019;s consolidated statements of operations based on their grant date fair values at the closing price of the Company&#x2019;s common stock on the date of grant. The expense is recognized over a four-year service period using graded vesting based on the Company&#x2019;s interim estimates of achievement of a stated performance objective during the one year period subsequent to the grant date. Changes in estimates are recorded on a cumulative catch-up basis. After the one year performance period, the number of shares the employee is entitled to is fixed.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-1" id="f-450">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-1" id="f-451">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes the percentage of revenues comprised by the Company&#x2019;s three largest wholesalers in each period presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Second largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Third largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <pcrx:ConcentrationRiskNumberOfCustomers
      contextRef="c-71"
      decimals="INF"
      id="f-453"
      unitRef="customer">3</pcrx:ConcentrationRiskNumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-454" unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-455" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-456" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-457" unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-458" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-459" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-78" decimals="2" id="f-460" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-79" decimals="2" id="f-461" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="2" id="f-462" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="2" id="f-463" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="2" id="f-464" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="2" id="f-465" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-84" decimals="2" id="f-466" unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-85" decimals="2" id="f-467" unitRef="number">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="2" id="f-468" unitRef="number">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-87" decimals="2" id="f-469" unitRef="number">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Adopted as of June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU amendment improves financial reporting by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU&#x2019;s amendments are effective for annual reporting periods beginning after December 31, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. This ASU amendment can be applied on a prospective basis or retrospectively. The Company is currently evaluating the impact of adopting ASU 2024-03 on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40), Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU amendment removed all references to prescriptive and sequential software development stages (referred to as project stages) throughout Subtopic 350-40. This had been replaced by the requirement to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding a software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#x201c;probable-to-complete recognition threshold&#x201d;). The ASU&#x2019;s amendments are effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The ASU&#x2019;s amendments may be adopted on a prospective, modified transition approach that is based on the status of a current project and whether software costs were capitalized before the date of adoption or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-06 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU 2025-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Grants (Topic 832), Accounting for Government Grants Received by Business Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU provides the recognition requirements for a government grant received, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. This ASU provides for adoption either on a modified prospective, modified retrospective, or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU 2025-11,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU is intended to update the guidance in Topic 270 by improving navigability of the required interim disclosures and establishing a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted at any time prior to the effective date and should be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2025-11 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-471">ASSETS AND LIABILITIES HELD FOR SALE&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, the Company and Pacira CryoTech, Inc.&#x2014;its wholly-owned subsidiary (the &#x201c;Subsidiary&#x201d;)&#x2014;entered into a Stock and Asset Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Zimmer, a subsidiary of Zimmer Biomet Holdings, Inc. Pursuant to the Purchase Agreement, the Company agreed to divest to Zimmer (i) all of the issued and outstanding capital stock of the Subsidiary and (ii) certain assets and liabilities of the Company and certain of its subsidiaries relating to the Company&#x2019;s handheld cryoanalgesia devices and related products&#x2014;including iovera&#xb0; (the &#x201c;Transaction&#x201d;)&#x2014;for up to $140.0&#160;million, including an upfront payment of $70.0&#160;million, subject to customary adjustments for cash, accounts receivable, indebtedness, transaction expenses and inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, the iovera&#xb0; assets and liabilities included in the Purchase Agreement were reclassified to assets and liabilities held for sale due to meeting the required held for sale criteria. As of June&#160;30, 2026, assets held for sale of $67.3 million consisted of $53.3 million of intangible assets, $9.8 million of inventory, $3.7 million of accounts receivable and $0.5 million of fixed assets, net of depreciation. As of June&#160;30, 2026, liabilities held for sale of $0.7 million consisted of accrued expenses. The Company determined that the held for sale disposal group was not impaired because its fair value less the cost to sell exceeded its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase Agreement provides for potential contingent consideration of up to an additional $70.0&#160;million in the aggregate, payable upon the achievement of the following revenue-based milestones (in each case, excluding any net revenue previously applied towards the achievement of any other milestone threshold) up to and through the period ending December 31, 2031:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;If net revenue from the sale of the current version of iovera&#xb0; available for sale to end users as of the closing date of the Transaction (the &#x201c;Business Products&#x201d;) during any of the &lt;span style="-sec-ix-hidden:f-481"&gt;five&lt;/span&gt; (5) calendar year periods commencing on January 1, 2027 through December 31, 2031 (each an &#x201c;Applicable Milestone Period&#x201d;) equals or exceeds $50.0&#160;million, the Company will receive $18.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $60.0&#160;million, the Company will receive $23.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;If net revenue from the sale of the Business Products during any Applicable Milestone Period equals or exceeds $70.0&#160;million, the Company will receive $28.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;If net revenue from the sale of the Business Products during any single year equals or exceeds the sum of any two or more milestones, then the highest applicable milestone payment shall be paid with respect to such year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that execution of the Purchase Agreement did not qualify as discontinued operations since it did not have a major effect on the Company&#x2019;s operations and financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Transaction closed on July 31, 2026 in which the Company received cash of $73.6&#160;million, after customary purchase price adjustments. The $70.0&#160;million of additional contingent milestones will be recognized in the period if and when they are each earned. As part of the Transaction, there are $2.2&#160;million of transaction bonuses payable to certain employees of the Company that were hired by Zimmer at close that the Company will record as an expense in the third quarter of 2026. The $2.2&#160;million of transaction bonuses will be paid by Zimmer. &lt;/span&gt;&lt;/div&gt;Upon the close of the Transaction on July 31, 2026, the Company entered into a transitional services arrangement, pursuant to which the Company will provide recordkeeping and other services; a development and commercialization agreement, pursuant to which both parties intend to continue the label expansion of iovera&#xb0; in the field of spasticity through United States Food and Drug Administration, or FDA, approval; and a sublease agreement, all of which are expected to operate through 2028.</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-88" decimals="-5" id="f-472" unitRef="usd">140000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates contextRef="c-89" decimals="-5" id="f-473" unitRef="usd">70000000.0</us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-88" decimals="-5" id="f-474" unitRef="usd">67300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="c-88" decimals="-5" id="f-475" unitRef="usd">53300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="c-88" decimals="-5" id="f-476" unitRef="usd">9800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-88" decimals="-5" id="f-477" unitRef="usd">3700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="c-88" decimals="-5" id="f-478" unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-88" decimals="-5" id="f-479" unitRef="usd">700000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-88" decimals="-5" id="f-480" unitRef="usd">70000000.0</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold contextRef="c-90" decimals="-5" id="f-482" unitRef="usd">50000000.0</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-90" decimals="-5" id="f-483" unitRef="usd">18500000</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold contextRef="c-91" decimals="-5" id="f-484" unitRef="usd">60000000.0</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-91" decimals="-5" id="f-485" unitRef="usd">23500000</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold contextRef="c-92" decimals="-5" id="f-486" unitRef="usd">70000000.0</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNetRevenueThreshold>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-92" decimals="-5" id="f-487" unitRef="usd">28000000.0</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-93" decimals="-5" id="f-488" unitRef="usd">73600000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-88" decimals="-5" id="f-489" unitRef="usd">70000000.0</pcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationTransactionBonus contextRef="c-94" decimals="-5" id="f-490" unitRef="usd">2200000</pcrx:DisposalGroupIncludingDiscontinuedOperationTransactionBonus>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationTransactionBonus contextRef="c-94" decimals="-5" id="f-491" unitRef="usd">2200000</pcrx:DisposalGroupIncludingDiscontinuedOperationTransactionBonus>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-492">REVENUE&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales are primarily within the U.S. and consist of EXPAREL, ZILRETTA, and sales of bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of the Company&#x2019;s bupivacaine liposome injectable suspension for veterinary use. In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#xb0;. The Transaction closed on July 31, 2026, and as such, the Company will no longer recognize revenue associated with iovera&#xb0; after this date. For additional information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, customer rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to Department of Veterans Affairs hospitals, participating GPO members, 340B qualified entities and other contracted customers at prices lower than the list price. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers claim the difference between the amount invoiced and the discounted selling price through a chargeback issued by a wholesaler. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are determined at the time of sale and the Company generally issues credits for such amounts within weeks of receiving notification from a wholesaler. Reserves for chargebacks consist of anticipated credits the Company expects to issue based on expected units sold and chargebacks that customers have claimed for which credits have not yet been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from&#160;&lt;span style="-sec-ix-hidden:f-493"&gt;zero&lt;/span&gt; to four months from the date of the transaction, and accordingly, there is no significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract&#x2019;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company&#x2019;s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company&#x2019;s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregated Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregated net product sales in the periods presented as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;EXPAREL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;ZILRETTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;iovera&#xb0; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Bupivacaine liposome injectable suspension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#xb0;. The Transaction closed on July 31, 2026, after which the Company will no longer recognize revenue associated with iovera&#xb0;. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <pcrx:AccountsReceivablePaymentTerms contextRef="c-96" id="f-494">P4M</pcrx:AccountsReceivablePaymentTerms>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregated net product sales in the periods presented as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;EXPAREL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;ZILRETTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;iovera&#xb0; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Bupivacaine liposome injectable suspension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#xb0;. The Transaction closed on July 31, 2026, after which the Company will no longer recognize revenue associated with iovera&#xb0;. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-496" unitRef="usd">147823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-497" unitRef="usd">142917000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-498" unitRef="usd">291097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-499" unitRef="usd">279446000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-500" unitRef="usd">32648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-501" unitRef="usd">31334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-502" unitRef="usd">59415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-503" unitRef="usd">54672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-504" unitRef="usd">6806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-3" id="f-505" unitRef="usd">5588000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-506" unitRef="usd">12982000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-507" unitRef="usd">10711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-508" unitRef="usd">3216000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-3" id="f-509" unitRef="usd">508000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-3" id="f-510" unitRef="usd">4375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-3" id="f-511" unitRef="usd">3112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-512" unitRef="usd">190493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-513" unitRef="usd">180347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-514" unitRef="usd">367869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-515" unitRef="usd">347941000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-516">INVENTORIES&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories, net are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, $9.8 million of inventories related to iovera&#xb0;, comprised of $5.6 million of raw materials, $1.2 million of work-in-process and $3.0 million of finished goods, were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-517">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories, net are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-3" decimals="-3" id="f-518" unitRef="usd">28160000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">43335000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-3" id="f-520" unitRef="usd">38096000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">28201000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-3" id="f-522" unitRef="usd">68319000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-523" unitRef="usd">81327000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-524" unitRef="usd">134575000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-525" unitRef="usd">152863000</us-gaap:InventoryNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="c-88" decimals="-5" id="f-526" unitRef="usd">9800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="c-113" decimals="-5" id="f-527" unitRef="usd">5600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="c-114" decimals="-5" id="f-528" unitRef="usd">1200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="c-115" decimals="-5" id="f-529" unitRef="usd">3000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-530">FIXED ASSETS&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets, net, summarized by major category, consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fixed assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, $0.5 million of fixed assets related to iovera&#xb0;, comprised of $0.5 million of machinery and equipment, net, along with nominal amounts of computer equipment and software, net, and office furniture and equipment, net, were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Depreciation on these fixed assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2026, depreciation expense was $7.0 million and $14.0 million, respectively. For the three and six months ended June&#160;30, 2025, depreciation expense was $13.0 million and $19.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $5.5&#160;million of accelerated depreciation expense during the three and six months ended June&#160;30, 2025 as a result of decommissioning its 45-liter EXPAREL batch manufacturing suite located at its Science Center Campus in San Diego, California. The Company continues to operate its 200-liter EXPAREL batch manufacturing suite at the same facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026 and December&#160;31, 2025, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located outside of the U.S. in the amount of $38.0 million and $41.9&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026 and December&#160;31, 2025, the Company had asset retirement obligations of $4.1&#160;million and $3.9&#160;million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets, net, summarized by major category, consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fixed assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-116" decimals="-3" id="f-532" unitRef="usd">162840000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-117" decimals="-3" id="f-533" unitRef="usd">163144000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-118" decimals="-3" id="f-534" unitRef="usd">77653000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-119" decimals="-3" id="f-535" unitRef="usd">77450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-120" decimals="-3" id="f-536" unitRef="usd">26979000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-121" decimals="-3" id="f-537" unitRef="usd">26187000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-122" decimals="-3" id="f-538" unitRef="usd">2101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-123" decimals="-3" id="f-539" unitRef="usd">2127000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-124" decimals="-3" id="f-540" unitRef="usd">11584000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-125" decimals="-3" id="f-541" unitRef="usd">9485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-542" unitRef="usd">281157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">278393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-544" unitRef="usd">150880000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-545" unitRef="usd">137703000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-546" unitRef="usd">130277000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-547" unitRef="usd">140690000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="c-88" decimals="-5" id="f-548" unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="c-126" decimals="-5" id="f-549" unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-550" unitRef="usd">7000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-551" unitRef="usd">14000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-552" unitRef="usd">13000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-553" unitRef="usd">19800000</us-gaap:Depreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-14" decimals="-5" id="f-554" unitRef="usd">5500000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-15" decimals="-5" id="f-555" unitRef="usd">5500000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-127" decimals="-5" id="f-556" unitRef="usd">38000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-128" decimals="-5" id="f-557" unitRef="usd">41900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetRetirementObligation contextRef="c-3" decimals="-5" id="f-558" unitRef="usd">4100000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation contextRef="c-4" decimals="-5" id="f-559" unitRef="usd">3900000</us-gaap:AssetRetirementObligation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-560">LEASES&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases all of its facilities, including its EXPAREL and iovera&#xb0; handpiece manufacturing and research facilities at its Science Center Campus in San Diego, California. In April 2025, the Company moved its principal executive offices and corporate headquarters to Brisbane, California and in June 2026, the Company entered into a new lease in Brisbane, California to retain this office through 2036. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services, or Thermo Fisher, for the use of their manufacturing facility in Swindon, U.K. for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees have been allocated to the lease components based on a relative fair value basis. As part of the GQ Bio Acquisition in February 2025, the Company assumed GQ Bio&#x2019;s European offices that include a research and development lab and offices in Luckenwalde, Germany.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between February 2023 and April 2025, the Company had been recognizing sublease income for a portion of office space leased in Burlington, Massachusetts that was assumed as part of the Flexion Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera&#xb0;. The Transaction closed on July 31, 2026, upon which the Company also entered into a sublease agreement through 2028. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities, net of lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recorded in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to net the reduction of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.94 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.79 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Minimum&lt;br/&gt;Payments Due&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <pcrx:NumberOfLeases contextRef="c-3" decimals="INF" id="f-561" unitRef="lease">2</pcrx:NumberOfLeases>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-562">Total operating lease expense, net is as follows (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities, net of lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recorded in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.94 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.79 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-3" id="f-563" unitRef="usd">3188000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-3" id="f-564" unitRef="usd">3232000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-565" unitRef="usd">6323000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-15" decimals="-3" id="f-566" unitRef="usd">6534000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-13" decimals="-3" id="f-567" unitRef="usd">620000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-14" decimals="-3" id="f-568" unitRef="usd">576000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-569" unitRef="usd">1180000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-15" decimals="-3" id="f-570" unitRef="usd">1115000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-13" decimals="-3" id="f-571" unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-14" decimals="-3" id="f-572" unitRef="usd">19000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-15" decimals="-3" id="f-574" unitRef="usd">76000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-3" id="f-575" unitRef="usd">3808000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-14" decimals="-3" id="f-576" unitRef="usd">3789000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-577" unitRef="usd">7503000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-15" decimals="-3" id="f-578" unitRef="usd">7573000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-579" unitRef="usd">6466000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-15" decimals="-3" id="f-580" unitRef="usd">6458000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-581" unitRef="usd">7962000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-582" unitRef="usd">1875000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-583">P4Y11M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-47" id="f-584">P4Y9M14D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="4" id="f-585" unitRef="number">0.0698</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-47" decimals="4" id="f-586" unitRef="number">0.0691</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-587">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Minimum&lt;br/&gt;Payments Due&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-588" unitRef="usd">6284000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-589" unitRef="usd">13268000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-590" unitRef="usd">12239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-591" unitRef="usd">12159000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-592" unitRef="usd">6995000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <pcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-593" unitRef="usd">8020000</pcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-594" unitRef="usd">58965000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-595" unitRef="usd">9972000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-596" unitRef="usd">48993000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-597">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s goodwill arose from the GQ Bio Acquisition in February 2025. As of June&#160;30, 2026 and December 31, 2025, the goodwill balance was $19.6&#160;million and $20.2&#160;million, respectively. The change in the goodwill balance from December 31, 2025 was due to $0.6&#160;million in foreign currency translation adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had goodwill resulting from the acquisition of Pacira Pharmaceuticals, Inc. (the Company&#x2019;s California operating subsidiary) from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc, a subsidiary of Molex Asia Holdings Ltd.) in 2007, the acquisition of MyoScience, Inc. (the &#x201c;MyoScience Acquisition&#x201d;) in 2019 and the Flexion Acquisition in 2021. Accumulated goodwill impairment charges through June&#160;30, 2026 were $163.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, consists of in-process research and development, or IPR&amp;amp;D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition. In June 2026, $53.2&#160;million, net, of developed technologies and a nominal amount of customer relationships related to iovera&#xb0; from the MyoScience Acquisition were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Amortization on these intangible assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, as of June&#160;30, 2026 are summarized as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 years, 9 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(1) The change in the gross carrying value compared to December&#160;31, 2025 reflects the impact of foreign currency translation adjustments related to the IPR&amp;amp;D acquired from the GQ Bio Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years, 5 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense on intangible assets was $14.3&#160;million for both the three months ended June&#160;30, 2026 and 2025. Amortization expense on intangible assets was $28.6&#160;million for both the six months ended June&#160;30, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $24.7&#160;million for the remaining six months of 2026, $49.4&#160;million each year from 2027 to 2030, and $29.5&#160;million in 2031</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill contextRef="c-3" decimals="-5" id="f-598" unitRef="usd">19600000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-599" unitRef="usd">20200000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-15" decimals="-5" id="f-600" unitRef="usd">600000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-601" unitRef="usd">163200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="c-1" id="f-602">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, consists of in-process research and development, or IPR&amp;amp;D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition. In June 2026, $53.2&#160;million, net, of developed technologies and a nominal amount of customer relationships related to iovera&#xb0; from the MyoScience Acquisition were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer. Amortization on these intangible assets ceased being recorded at the time the assets were classified as held for sale. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, as of June&#160;30, 2026 are summarized as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 years, 9 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(1) The change in the gross carrying value compared to December&#160;31, 2025 reflects the impact of foreign currency translation adjustments related to the IPR&amp;amp;D acquired from the GQ Bio Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years, 5 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="c-129" decimals="-5" id="f-603" unitRef="usd">53200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="c-130" decimals="-5" id="f-604" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-131" decimals="-3" id="f-605" unitRef="usd">480000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-131" decimals="-3" id="f-606" unitRef="usd">228085000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-131" decimals="-3" id="f-607" unitRef="usd">251915000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-132" id="f-608">P9Y9M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-133" decimals="-3" id="f-609" unitRef="usd">33569000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-133" decimals="-3" id="f-610" unitRef="usd">33569000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-3" decimals="-3" id="f-611" unitRef="usd">513569000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-612" unitRef="usd">228085000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-613" unitRef="usd">285484000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-134" decimals="-3" id="f-614" unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-134" decimals="-3" id="f-615" unitRef="usd">256213000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-134" decimals="-3" id="f-616" unitRef="usd">333787000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-135" id="f-617">P10Y5M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-136" decimals="-3" id="f-618" unitRef="usd">90000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-136" decimals="-3" id="f-619" unitRef="usd">61000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-136" decimals="-3" id="f-620" unitRef="usd">29000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-137" id="f-621">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-622" unitRef="usd">590090000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-623" unitRef="usd">256274000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-624" unitRef="usd">333816000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-138" decimals="-3" id="f-625" unitRef="usd">34284000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-138" decimals="-3" id="f-626" unitRef="usd">34284000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-3" id="f-627" unitRef="usd">624374000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-628" unitRef="usd">256274000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-629" unitRef="usd">368100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-5" id="f-630" unitRef="usd">14300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-631" unitRef="usd">14300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-632" unitRef="usd">28600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-633" unitRef="usd">28600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-5" id="f-634" unitRef="usd">24700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-5" id="f-635" unitRef="usd">49400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-5" id="f-636" unitRef="usd">49400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-5" id="f-637" unitRef="usd">49400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-5" id="f-638" unitRef="usd">49400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-3" decimals="-5" id="f-639" unitRef="usd">29500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-640">ACCRUED EXPENSES&lt;div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,243&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued production costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,235&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,864&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,987&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,841&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and wholesaler service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,682&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,554&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, $0.7&#160;million of accrued expenses related to iovera&#xb0;, comprised of $0.5&#160;million of other accrued operating expenses and $0.2&#160;million of product returns and wholesaler services, were reclassified to liabilities held for sale in conjunction with entering into the Purchase Agreement with Zimmer. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-641">&lt;div style="margin-bottom:2pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,243&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued production costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,235&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,864&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,987&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,841&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and wholesaler service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,682&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,554&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pcrx:AccruedSellingGeneralAndAdministrativeExpenses contextRef="c-3" decimals="-3" id="f-642" unitRef="usd">26080000</pcrx:AccruedSellingGeneralAndAdministrativeExpenses>
    <pcrx:AccruedSellingGeneralAndAdministrativeExpenses contextRef="c-4" decimals="-3" id="f-643" unitRef="usd">17429000</pcrx:AccruedSellingGeneralAndAdministrativeExpenses>
    <pcrx:AccruedResearchAndDevelopmentExpenses contextRef="c-3" decimals="-3" id="f-644" unitRef="usd">8243000</pcrx:AccruedResearchAndDevelopmentExpenses>
    <pcrx:AccruedResearchAndDevelopmentExpenses contextRef="c-4" decimals="-3" id="f-645" unitRef="usd">6129000</pcrx:AccruedResearchAndDevelopmentExpenses>
    <pcrx:AccruedProductionCost contextRef="c-3" decimals="-3" id="f-646" unitRef="usd">10494000</pcrx:AccruedProductionCost>
    <pcrx:AccruedProductionCost contextRef="c-4" decimals="-3" id="f-647" unitRef="usd">9002000</pcrx:AccruedProductionCost>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-648" unitRef="usd">8235000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-649" unitRef="usd">12864000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-650" unitRef="usd">26987000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-651" unitRef="usd">37841000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-3" decimals="-3" id="f-652" unitRef="usd">778000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-653" unitRef="usd">782000</us-gaap:InterestPayableCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-3" decimals="-3" id="f-654" unitRef="usd">12682000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-4" decimals="-3" id="f-655" unitRef="usd">11554000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-656" unitRef="usd">93499000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-657" unitRef="usd">95601000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-139" decimals="-5" id="f-658" unitRef="usd">700000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities contextRef="c-139" decimals="-5" id="f-659" unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent contextRef="c-139" decimals="-5" id="f-660" unitRef="usd">200000</pcrx:DisposalGroupIncludingDiscontinuedOperationProductLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-661">DEBT&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s outstanding debt is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.125% Convertible senior notes due May 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes Due 2029&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company completed a private placement of $287.5&#160;million in aggregate principal amount of its 2.125% convertible senior notes due 2029, or 2029 Notes, and entered into an indenture with Computershare Corporate Trust, N.A., or 2029 Indenture, with respect to the 2029 Notes. The 2029 Notes accrue interest at a fixed rate of 2.125% per year, payable semiannually in arrears on May 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and November 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year. The 2029 Notes mature on May 15, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the 2029 Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.125% convertible senior notes due May 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total debt, net of deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026, the 2029 Notes had a market price of $999 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2029 Notes will be paid pursuant to the terms of the 2029 Indenture. In the event that all of the 2029 Notes are converted, the Company would be required to repay the $287.5&#160;million in principal value in cash, whereas any conversion premium would be required to be repaid in any combination of cash and shares of its common stock (at the Company&#x2019;s option).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding November 15, 2028, the 2029 Notes are convertible only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on June 30, 2024 (and only during such calendar quarter), if the last reported sale price of the Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is equal to or greater than 130% of the conversion price on each applicable trading &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;day; (ii) during the five business-day period after any five consecutive trading-day period (the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of the 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day; (iii) upon the occurrence of specified corporate events; or (iv) upon a Company redemption. On or after November 15, 2028, until the close of business on the second scheduled trading day immediately preceding May 15, 2029, holders of the 2029 Notes may convert all or a portion of their 2029 Notes, at any time. No sinking fund is provided for the 2029 Notes. As of&#160;June&#160;30, 2026, the conditions for conversion were not met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2029 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 50 consecutive trading days during the observation period (as more fully described in the 2029 Indenture). For the principal, the Company will settle in cash per the terms of the 2029 Notes. For any excess conversion value, holders may receive cash, shares of the Company&#x2019;s common stock or a combination of cash and shares of the Company&#x2019;s common stock, at the Company&#x2019;s option. The initial conversion rate for the 2029 Notes is 25.2752 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $39.56 per share of the Company&#x2019;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2029 Notes represents a premium of approximately 32.5% to the closing sale price of $29.86 per share of the Company&#x2019;s common stock on the Nasdaq Global Select Market on May 9, 2024, the date that the Company priced the private offering of the 2029 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after May 17, 2027 and on or before the 50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; scheduled trading day immediately before the maturity date, the Company may redeem for cash all or part of the 2029 Notes if (i) the 2029 Notes are &#x201c;freely tradable&#x201d; (as defined in the 2029 Indenture) and any accrued and unpaid additional interest has been paid as of the date the Company sends the related notice of the redemption and (ii) the last reported sales price of the Company&#x2019;s common stock exceeds 130% of the conversion price then in effect for (1) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of the redemption; and (2) the trading day immediately before the date the Company sends such notice. The redemption price of each 2029 Note to be redeemed will be the principal amount of such 2029 Note, plus accrued and unpaid interest, if any. In addition, calling any 2029 Notes for redemption will constitute a make-whole fundamental change, in which case the conversion rate applicable to those 2029 Notes, if converted in connection with the redemption, will be increased in certain circumstances. Upon the occurrence of a &#x201c;make-whole fundamental change&#x201d; (as defined in the 2029 Indenture), subject to a limited exception for certain cash mergers, holders may require the Company to repurchase all or a portion of their 2029 Notes for cash at a price equal to 100% of the principal amount of the 2029 Notes to be repurchased plus any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the 2029 Notes are currently classified on the Company&#x2019;s condensed consolidated balance sheet at June&#160;30, 2026 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company&#x2019;s common stock during the prescribed measurement periods. In the event that the holders of the 2029 Notes have the election to convert the 2029 Notes at any time during the prescribed measurement period, the 2029 Notes would then be considered a current obligation and classified as such.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 9, 2024, in connection with the pricing of the 2029 Notes, and on May 10, 2024, in connection with the exercise in full by the initial purchasers of the 2029 Notes (the &#x201c;Initial Purchasers&#x201d;) of their option to purchase additional 2029 Notes, the Company entered into privately negotiated capped call transactions (the &#x201c;Capped Call Transactions&#x201d;) with certain of the Initial Purchasers of the 2029 Notes and/or their respective affiliates and/or other financial institutions (the &#x201c;Option Counterparties&#x201d;). The Capped Call Transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2029 Notes, the number of shares of the Company&#x2019;s common stock underlying the 2029 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Capped Call Transactions are expected to reduce the potential dilution to the Company&#x2019;s common stock upon any conversion of the 2029 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2029 Notes, as the case may be, upon any conversion of the 2029 Notes, with such reduction and/or offset subject to a cap. The cap price of the Capped Call Transactions will initially be approximately $53.75 per share, representing a premium of approximately 80% over the closing price of $29.86 per share of the Company&#x2019;s common stock on May 9, 2024, and is subject to certain adjustments under the terms of the Capped Call Transactions. During the year ended December 31, 2024, the capped call was recorded as a reduction to additional paid-in capital at its cost of $26.7&#160;million, partially offset by a $6.5&#160;million deferred tax asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Capped Call Transactions are separate transactions entered into by the Company with the Option Counterparties, are not part of the terms of the 2029 Notes and will not affect any holder&#x2019;s rights under the 2029 Notes. Holders of the 2029 Notes will not have any rights with respect to the Capped Call Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2025, the Company entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) with Wells Fargo Bank, N.A., as administrative agent, swingline lender and an issuing bank, and certain lenders, to, among other things, retire the indebtedness outstanding under the Company&#x2019;s then-existing TLA Credit Agreement and provide ongoing working capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for a senior secured revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) in an aggregate commitment amount of $300.0&#160;million, with a letter of credit sublimit of $10.0&#160;million and swingline loan sublimit of $15.0&#160;million. The credit facility is secured by substantially all of the Company&#x2019;s and each subsidiary guarantor&#x2019;s assets and is scheduled to mature on July 3, 2030, subject to certain exceptions set forth in the Credit Agreement. Subject to certain conditions, the Company may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of any existing class of term loans by requesting one or more incremental term facilities in an aggregate principal amount not to exceed the greater of $225.0&#160;million and 100% of Consolidated Earnings Before Interest Taxes Depreciation and Amortization (EBITDA) (as defined in the Credit Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each revolving loan borrowing which is an alternate base rate borrowing will bear interest at a rate per annum equal to (i) a base rate, plus (ii) a spread based on the Company&#x2019;s Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) ranging from 1.50% to 2.25%. Each revolving loan borrowing which is a term benchmark borrowing or daily simple SOFR (as defined in the Credit Agreement) borrowing will bear interest at a rate per annum equal to (i) a forward-looking term rate based on SOFR or a rate determined by reference to the daily simple SOFR, plus (ii) a spread based on the Company&#x2019;s Senior Secured Net Leverage Ratio ranging from 2.50% to 3.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of June&#160;30, 2026, the Company was in compliance with all covenants under the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2025, the Company incurred financing fees of approximately $2.1&#160;million which were recorded as a noncurrent other asset on the Company&#x2019;s condensed consolidated balance sheet. The financing fees are amortized over the term of the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into the Credit Agreement, the Company borrowed $101.0&#160;million under the Revolving Credit Facility, of which $81.0&#160;million is outstanding as of June&#160;30, 2026 after the Company made repayments of $10.0&#160;million during the six months ended June&#160;30, 2026 and $10.0&#160;million during the year ended December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026, borrowings under the Revolving Credit Facility consisted entirely of term SOFR borrowings at an approximate all-in rate of 6.72%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2028 Term Loan A Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2023, the Company entered into a credit agreement (as amended and/or restated to date, the &#x201c;TLA Credit Agreement&#x201d;) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders. The term loan issued under the TLA Credit Agreement (the &#x201c;TLA Term Loan&#x201d;) was issued at a 0.30% discount and provided for a single-advance term loan A facility in the principal amount of $150.0&#160;million, which was secured by substantially all of the Company&#x2019;s and any subsidiary guarantor&#x2019;s assets. The net proceeds of the TLA Term Loan were approximately $149.6&#160;million after deducting an original issue discount of $0.4&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The TLA Term Loan was scheduled to mature on March 31, 2028 and the TLA Credit Agreement required quarterly repayments of principal in the amount of $2.8&#160;million which commenced on June 30, 2023 and increased to $3.8&#160;million on March 31, 2025, with an originally stated balloon payment of approximately $85.3&#160;million due at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2025, the Company used a portion of the $300.0&#160;million of Revolving Credit Facility to repay the remaining indebtedness outstanding under the TLA Credit Agreement, which consisted of $98.8&#160;million and its final interest payment of $0.1&#160;million, and terminated the TLA Credit Agreement. The Company did not incur any prepayment penalties or fees in connection with the termination of the TLA Credit Agreement. The prepayment resulted in a loss on early extinguishment of debt of approximately $1.0&#160;million which was recognized during the three months ended September 30, 2025. Prior to the TLA Credit Agreement extinguishment, the Company made voluntary principal prepayments of $6.6&#160;million during the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes Due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company completed a private placement of $402.5&#160;million in aggregate principal amount of 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), with respect to the 2025 Notes. The 2025 Notes accrued interest at a fixed rate of 0.750% per year, which was payable semiannually in arrears on February 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and August 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company used part of the net proceeds from the issuance of the 2029 Notes to repurchase $200.0&#160;million aggregate principal amount of the 2025 Notes in privately negotiated transactions at a discount for $191.4&#160;million in cash (including accrued interest). The partial repurchase of the 2025 Notes resulted in a $7.5&#160;million gain on early extinguishment of debt during the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2025, the 2025 Notes matured and the Company settled the remaining outstanding principal balance of $202.5&#160;million in cash. Upon the maturity of the 2025 Notes, a nominal gain on extinguishment of debt was recognized due to certain holders having converted their 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized interest (Note 6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate on total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-662">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s outstanding debt is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.125% Convertible senior notes due May 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-140"
      decimals="INF"
      id="f-663"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-140" decimals="-3" id="f-664" unitRef="usd">282124000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-141" decimals="-3" id="f-665" unitRef="usd">281189000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-142" decimals="-3" id="f-666" unitRef="usd">81000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-143" decimals="-3" id="f-667" unitRef="usd">91000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-668" unitRef="usd">363124000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-669" unitRef="usd">372189000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-144" decimals="-5" id="f-670" unitRef="usd">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-144"
      decimals="INF"
      id="f-671"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-144"
      decimals="INF"
      id="f-672"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-673">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the 2029 Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.125% convertible senior notes due May 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total debt, net of deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-140"
      decimals="INF"
      id="f-674"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-140" decimals="-3" id="f-675" unitRef="usd">287500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-141" decimals="-3" id="f-676" unitRef="usd">287500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-140" decimals="-3" id="f-677" unitRef="usd">5376000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-141" decimals="-3" id="f-678" unitRef="usd">6311000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-140" decimals="-3" id="f-679" unitRef="usd">282124000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-141" decimals="-3" id="f-680" unitRef="usd">281189000</us-gaap:LongTermDebt>
    <pcrx:DebtInstrumentRepurchasedInConversionFaceAmount contextRef="c-145" decimals="-5" id="f-681" unitRef="usd">287500000</pcrx:DebtInstrumentRepurchasedInConversionFaceAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-146"
      decimals="INF"
      id="f-682"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-146"
      decimals="INF"
      id="f-683"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-146"
      decimals="INF"
      id="f-684"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-147"
      decimals="INF"
      id="f-685"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-147"
      decimals="INF"
      id="f-686"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <pcrx:DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice
      contextRef="c-147"
      decimals="INF"
      id="f-687"
      unitRef="number">0.98</pcrx:DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice>
    <pcrx:SettlementPeriodConvertibleDebtConversionRequest contextRef="c-148" id="f-688">P50D</pcrx:SettlementPeriodConvertibleDebtConversionRequest>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-144"
      decimals="INF"
      id="f-689"
      unitRef="usdPerShare">39.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock contextRef="c-144" decimals="3" id="f-690" unitRef="number">0.325</pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock>
    <us-gaap:SharePrice
      contextRef="c-149"
      decimals="INF"
      id="f-691"
      unitRef="usdPerShare">29.86</us-gaap:SharePrice>
    <pcrx:DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity
      contextRef="c-150"
      decimals="INF"
      id="f-692"
      unitRef="trading_day">50</pcrx:DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-151"
      decimals="INF"
      id="f-693"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-151"
      decimals="INF"
      id="f-694"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-151"
      decimals="INF"
      id="f-695"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-151"
      decimals="INF"
      id="f-696"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pcrx:DerivativeCappedCallPrice
      contextRef="c-152"
      decimals="2"
      id="f-697"
      unitRef="usdPerShare">53.75</pcrx:DerivativeCappedCallPrice>
    <pcrx:DerivativePremiumPercentage contextRef="c-152" decimals="2" id="f-698" unitRef="number">0.80</pcrx:DerivativePremiumPercentage>
    <us-gaap:SharePrice
      contextRef="c-149"
      decimals="2"
      id="f-699"
      unitRef="usdPerShare">29.86</us-gaap:SharePrice>
    <pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax contextRef="c-153" decimals="-5" id="f-700" unitRef="usd">26700000</pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsBeforeTax>
    <pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax contextRef="c-153" decimals="-5" id="f-701" unitRef="usd">6500000</pcrx:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallsTax>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-154" decimals="INF" id="f-702" unitRef="usd">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-155" decimals="INF" id="f-703" unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-156" decimals="INF" id="f-704" unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <pcrx:DebtInstrumentCovenantIncrementalDebtMaximum contextRef="c-157" decimals="INF" id="f-705" unitRef="usd">225000000.0</pcrx:DebtInstrumentCovenantIncrementalDebtMaximum>
    <pcrx:DebtInstrumentCovenantIncrementalDebtMaximumPercent
      contextRef="c-154"
      decimals="INF"
      id="f-706"
      unitRef="number">1</pcrx:DebtInstrumentCovenantIncrementalDebtMaximumPercent>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-158"
      decimals="INF"
      id="f-707"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-159"
      decimals="INF"
      id="f-708"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-160"
      decimals="INF"
      id="f-709"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-161"
      decimals="INF"
      id="f-710"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c-162" decimals="-5" id="f-711" unitRef="usd">2100000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-163" decimals="-5" id="f-712" unitRef="usd">101000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:LineOfCredit contextRef="c-164" decimals="-5" id="f-713" unitRef="usd">81000000.0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-163" decimals="-5" id="f-714" unitRef="usd">10000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-165" decimals="-5" id="f-715" unitRef="usd">10000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c-164" decimals="4" id="f-716" unitRef="number">0.0672</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <pcrx:DebtInstrumentDiscountRate contextRef="c-166" decimals="4" id="f-717" unitRef="number">0.0030</pcrx:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-166" decimals="-5" id="f-718" unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-167" decimals="-5" id="f-719" unitRef="usd">149600000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-166" decimals="-5" id="f-720" unitRef="usd">400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-168" decimals="-5" id="f-721" unitRef="usd">2800000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-169" decimals="-5" id="f-722" unitRef="usd">3800000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c-170" decimals="-5" id="f-723" unitRef="usd">85300000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-154" decimals="INF" id="f-724" unitRef="usd">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentRepaidPrincipal contextRef="c-171" decimals="-5" id="f-725" unitRef="usd">98800000</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:InterestPaid contextRef="c-171" decimals="-5" id="f-726" unitRef="usd">100000</us-gaap:InterestPaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-172" decimals="-5" id="f-727" unitRef="usd">-1000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-173" decimals="-5" id="f-728" unitRef="usd">6600000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-174" decimals="-5" id="f-729" unitRef="usd">402500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-174"
      decimals="INF"
      id="f-730"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-174"
      decimals="INF"
      id="f-731"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-175" decimals="-5" id="f-732" unitRef="usd">200000000.0</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-176" decimals="-5" id="f-733" unitRef="usd">191400000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-177" decimals="-5" id="f-734" unitRef="usd">7500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepaidPrincipal contextRef="c-178" decimals="-5" id="f-735" unitRef="usd">202500000</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-178" decimals="-5" id="f-736" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <pcrx:ScheduleOfInterestExpenseTableTextBlock contextRef="c-1" id="f-737">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized interest (Note 6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate on total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pcrx:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-13" decimals="-3" id="f-738" unitRef="usd">3045000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-14" decimals="-3" id="f-739" unitRef="usd">3823000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-1" decimals="-3" id="f-740" unitRef="usd">6167000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-15" decimals="-3" id="f-741" unitRef="usd">7685000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-13" decimals="-3" id="f-742" unitRef="usd">521000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-14" decimals="-3" id="f-743" unitRef="usd">849000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-744" unitRef="usd">1042000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-15" decimals="-3" id="f-745" unitRef="usd">1694000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-13" decimals="-3" id="f-746" unitRef="usd">56000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-14" decimals="-3" id="f-747" unitRef="usd">23000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-748" unitRef="usd">112000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-15" decimals="-3" id="f-749" unitRef="usd">45000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-13" decimals="-3" id="f-750" unitRef="usd">0</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-14" decimals="-3" id="f-751" unitRef="usd">0</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-1" decimals="-3" id="f-752" unitRef="usd">0</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-15" decimals="-3" id="f-753" unitRef="usd">149000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestExpenseDebt contextRef="c-13" decimals="-3" id="f-754" unitRef="usd">3622000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-14" decimals="-3" id="f-755" unitRef="usd">4695000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-756" unitRef="usd">7321000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-15" decimals="-3" id="f-757" unitRef="usd">9275000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-13" decimals="4" id="f-758" unitRef="number">0.0372</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-14" decimals="4" id="f-759" unitRef="number">0.0309</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-1" decimals="4" id="f-760" unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-15" decimals="4" id="f-761" unitRef="number">0.0310</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-764">FINANCIAL INSTRUMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The Revolving Credit Facility reprices within a maximum of three months due to its variable interest rate terms. The fair value of the Company&#x2019;s Revolving Credit Facility approximates carrying value (Level 2) due to its repricing feature. The fair value of the Company&#x2019;s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company&#x2019;s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amount of equity investments and convertible notes receivable without readily determinable fair values included in investments and other assets on the consolidated balance sheet are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2026, the carrying values and fair values of the Company&#x2019;s financial assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Liabilities Measured at Amortized Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2.125% convertible senior notes due 2029 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) The closing price of the Company&#x2019;s common stock as reported on the Nasdaq Global Select Market was $25.37 per share on June&#160;30, 2026, compared to a conversion price of $39.56 per share. At June&#160;30, 2026, as the conversion price was above the stock price, the requirements for conversion have not been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are measured at fair value on a non-recurring basis, including assets and liabilities acquired in a business combination and long-lived assets, which would be recognized at fair value if deemed impaired. The fair value in these instances would be determined using Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity and Convertible Note Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. For the equity investments as of June&#160;30, 2026, there have not been any impairments or upward adjustments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Convertible Notes Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gain of prior investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014; No activity for the six months ended June&#160;30, 2026 &#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company&#x2019;s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2&#160;million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7&#160;million in interest income. These gains were included in the condensed consolidated statement of cash flows for the six months ended June&#160;30, 2025 within other net gains&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2025, an impairment of an equity investment and convertible note receivable totaling $11.0&#160;million was recorded in other, net in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2025, the Company invested $1.3&#160;million in a convertible note receivable related to one of its existing early-stage strategic investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition-Related Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recognized a contingent consideration liability related to the Flexion Acquisition in the amount of $17.5&#160;million and $18.1&#160;million as of June&#160;30, 2026 and December&#160;31, 2025, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a Monte Carlo simulation. These inputs include, as applicable, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3&#160;million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5&#160;million prior to the Company&#x2019;s September 2022 decision to formally discontinue further development of Flexion&#x2019;s investigational product candidate, PCRX-301. The Company&#x2019;s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended June&#160;30, 2026, the Company recognized contingent consideration charges of $1.7&#160;million due to revisions to the latest discount rates. During the six months ended June&#160;30, 2026, the Company recognized contingent consideration gains of $0.6&#160;million due to a reduction in its sales forecast through the milestone expiration date of December 31, 2030, partially offset by revisions to the latest discount rates. During the three and six months ended June&#160;30, 2025, the Company recognized contingent consideration gains of $0.4&#160;million and $3.0&#160;million, respectively, due to revisions to the latest discount rates. These adjustments were recorded within other operating expenses, net in the condensed consolidated statements of operations. At June&#160;30, 2026, the weighted average discount rate was 7.8%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the key assumptions used in the valuation of the Company&#x2019;s contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ranges Utilized as of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6% to 8.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for remaining regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the Company&#x2019;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Fair value adjustments and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-Sale &lt;span id="i82c77417cd18446ea0aa2ecbfbc45bff_9868"&gt;&lt;/span&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency, government and Yankee bonds with maturities greater than three months, but less than one year. Net unrealized gains and losses (excluding credit losses, if any) from the Company&#x2019;s short-term investments are reported in other comprehensive income (loss). At June&#160;30, 2026 and December&#160;31, 2025, all of the Company&#x2019;s short-term investments are classified as available-for-sale investments and are determined to be Level 2 instruments which are measured at fair value using standard industry models with observable inputs, with the exception of U.S. government bonds. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an &#x201c;A&#x201d; or better rating by Standard&#160;&amp;amp; Poor&#x2019;s.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the Company&#x2019;s available-for-sale investments at June&#160;30, 2026 and December&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June&#160;30, 2026 Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025 Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2026, there were no investments available for sale that were materially less than their amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company elects to recognize its interest receivable separate from its available-for-sale investments. At June&#160;30, 2026 and December&#160;31, 2025, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.2&#160;million and $0.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As of June&#160;30, 2026, three wholesalers each accounted for over 10% of the Company&#x2019;s accounts receivable, at 32%, 27% and 17%, which excludes the amounts that were reclassified to assets held for sale in conjunction with entering into the Purchase Agreement with Zimmer (for more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). At December&#160;31, 2025, three wholesalers each accounted for over 10% of the Company&#x2019;s accounts receivable, at 32%, 23% and 17%. For additional information regarding the Company&#x2019;s wholesalers, see Note 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company&#x2019;s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of June&#160;30, 2026, the allowance for credit losses on the Company&#x2019;s accounts receivable was not material. As of December&#160;31, 2025, there were $0.7&#160;million of allowances for credit losses on the Company&#x2019;s accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-765">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2026, the carrying values and fair values of the Company&#x2019;s financial assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Liabilities Measured at Amortized Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2.125% convertible senior notes due 2029 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) The closing price of the Company&#x2019;s common stock as reported on the Nasdaq Global Select Market was $25.37 per share on June&#160;30, 2026, compared to a conversion price of $39.56 per share. At June&#160;30, 2026, as the conversion price was above the stock price, the requirements for conversion have not been met.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-179" decimals="-3" id="f-766" unitRef="usd">7750000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-180" decimals="-3" id="f-767" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-181" decimals="-3" id="f-768" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-182" decimals="-3" id="f-769" unitRef="usd">7750000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-179" decimals="-3" id="f-770" unitRef="usd">2500000</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-180" decimals="-3" id="f-771" unitRef="usd">0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-181" decimals="-3" id="f-772" unitRef="usd">0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-182" decimals="-3" id="f-773" unitRef="usd">2500000</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-179" decimals="-3" id="f-774" unitRef="usd">17452000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-180" decimals="-3" id="f-775" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-181" decimals="-3" id="f-776" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-182" decimals="-3" id="f-777" unitRef="usd">17452000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-140"
      decimals="INF"
      id="f-778"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue contextRef="c-183" decimals="-3" id="f-779" unitRef="usd">282124000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-184" decimals="-3" id="f-780" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-185" decimals="-3" id="f-781" unitRef="usd">287322000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-186" decimals="-3" id="f-782" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-187" decimals="-3" id="f-783" unitRef="usd">81000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-188" decimals="-3" id="f-784" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-189" decimals="-3" id="f-785" unitRef="usd">81000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-190" decimals="-3" id="f-786" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SharePrice
      contextRef="c-3"
      decimals="INF"
      id="f-787"
      unitRef="usdPerShare">25.37</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-140"
      decimals="INF"
      id="f-788"
      unitRef="usdPerShare">39.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-789">The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):&lt;div style="margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Convertible Notes Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gain of prior investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014; No activity for the six months ended June&#160;30, 2026 &#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company&#x2019;s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2&#160;million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7&#160;million in interest income. These gains were included in the condensed consolidated statement of cash flows for the six months ended June&#160;30, 2025 within other net gains&lt;/span&gt;.</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-191" decimals="-3" id="f-790" unitRef="usd">15877000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-192" decimals="-3" id="f-791" unitRef="usd">11898000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-63" decimals="-3" id="f-792" unitRef="usd">27775000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-193" decimals="-3" id="f-793" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-194" decimals="-3" id="f-794" unitRef="usd">1250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-195" decimals="-3" id="f-795" unitRef="usd">1250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments contextRef="c-193" decimals="-3" id="f-796" unitRef="usd">4000000</pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments>
    <pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments contextRef="c-194" decimals="-3" id="f-797" unitRef="usd">7000000</pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments>
    <pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments contextRef="c-195" decimals="-3" id="f-798" unitRef="usd">11000000</pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-193" decimals="-3" id="f-799" unitRef="usd">4189000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-194" decimals="-3" id="f-800" unitRef="usd">1674000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-195" decimals="-3" id="f-801" unitRef="usd">5863000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-193" decimals="-3" id="f-802" unitRef="usd">8277000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-194" decimals="-3" id="f-803" unitRef="usd">5322000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-195" decimals="-3" id="f-804" unitRef="usd">13599000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-193" decimals="-3" id="f-805" unitRef="usd">-39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-194" decimals="-3" id="f-806" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-195" decimals="-3" id="f-807" unitRef="usd">-39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-196" decimals="-3" id="f-808" unitRef="usd">7750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-197" decimals="-3" id="f-809" unitRef="usd">2500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-4" decimals="-3" id="f-810" unitRef="usd">10250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-198" decimals="-3" id="f-811" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-199" decimals="-3" id="f-812" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-813" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-200" decimals="-3" id="f-814" unitRef="usd">7750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-201" decimals="-3" id="f-815" unitRef="usd">2500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-3" decimals="-3" id="f-816" unitRef="usd">10250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-202" decimals="2" id="f-817" unitRef="number">0.81</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-198" decimals="-5" id="f-818" unitRef="usd">4200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-199" decimals="-5" id="f-819" unitRef="usd">1700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:AssetImpairmentCharges contextRef="c-203" decimals="-5" id="f-820" unitRef="usd">11000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-204" decimals="-5" id="f-821" unitRef="usd">1300000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-205" decimals="-5" id="f-822" unitRef="usd">17500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-206" decimals="-5" id="f-823" unitRef="usd">18100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-207" decimals="-5" id="f-824" unitRef="usd">372300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-208" decimals="-5" id="f-825" unitRef="usd">425500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pcrx:ContingentConsiderationPaymentTerm contextRef="c-209" id="f-826">P60D</pcrx:ContingentConsiderationPaymentTerm>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-210" decimals="-5" id="f-827" unitRef="usd">-1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-211" decimals="-5" id="f-828" unitRef="usd">-600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-212" decimals="-5" id="f-829" unitRef="usd">-400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-213" decimals="-5" id="f-830" unitRef="usd">-3000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-214" decimals="3" id="f-831" unitRef="number">0.078</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-832">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the key assumptions used in the valuation of the Company&#x2019;s contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ranges Utilized as of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6% to 8.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment for remaining regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-215" decimals="3" id="f-833" unitRef="number">0.076</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-216" decimals="3" id="f-834" unitRef="number">0.081</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-217" decimals="2" id="f-835" unitRef="number">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-836">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the Company&#x2019;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Fair value adjustments and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-218" decimals="-3" id="f-837" unitRef="usd">20241000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-219" decimals="-3" id="f-838" unitRef="usd">-2175000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-220" decimals="-3" id="f-839" unitRef="usd">18066000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-221" decimals="-3" id="f-840" unitRef="usd">-614000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-222" decimals="-3" id="f-841" unitRef="usd">17452000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-842">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the Company&#x2019;s available-for-sale investments at June&#160;30, 2026 and December&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June&#160;30, 2026 Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025 Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-223" decimals="-3" id="f-843" unitRef="usd">27158000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-223" decimals="-3" id="f-844" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-223" decimals="-3" id="f-845" unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-224" decimals="-3" id="f-846" unitRef="usd">27134000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-225" decimals="-3" id="f-847" unitRef="usd">18027000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-225" decimals="-3" id="f-848" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-225" decimals="-3" id="f-849" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-226" decimals="-3" id="f-850" unitRef="usd">18022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-851" unitRef="usd">45185000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-852" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-853" unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-3" id="f-854" unitRef="usd">45156000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-228" decimals="-3" id="f-855" unitRef="usd">54971000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-228" decimals="-3" id="f-856" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-228" decimals="-3" id="f-857" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-3" id="f-858" unitRef="usd">54976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-230" decimals="-3" id="f-859" unitRef="usd">24881000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-230" decimals="-3" id="f-860" unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-230" decimals="-3" id="f-861" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-3" id="f-862" unitRef="usd">24903000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-863" unitRef="usd">79852000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-864" unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-865" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-3" id="f-866" unitRef="usd">79879000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivable contextRef="c-3" decimals="-5" id="f-867" unitRef="usd">200000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable contextRef="c-4" decimals="-5" id="f-868" unitRef="usd">300000</us-gaap:InterestReceivable>
    <pcrx:NumberOfMajorCustomers
      contextRef="c-1"
      decimals="INF"
      id="f-869"
      unitRef="wholesaler">3</pcrx:NumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-233" decimals="2" id="f-870" unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-234" decimals="2" id="f-871" unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-235" decimals="2" id="f-872" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <pcrx:NumberOfMajorCustomers
      contextRef="c-195"
      decimals="INF"
      id="f-873"
      unitRef="wholesaler">3</pcrx:NumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-236" decimals="2" id="f-874" unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-237" decimals="2" id="f-875" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-238" decimals="2" id="f-876" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-3" decimals="-5" id="f-877" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-5" id="f-878" unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-879">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables illustrate the changes in the balances of the Company&#x2019;s accumulated other comprehensive income for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gain (Loss) From Available-For-Sale Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Net unrealized loss on investments, net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gain (Loss) From Available-For-Sale Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Net unrealized loss on investments, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) Net of a nominal tax benefit for both the six months ended June&#160;30, 2026 and 2025, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2025, the Company announced that its board of directors approved a share repurchase program which authorizes the Company to repurchase up to an aggregate of $300.0&#160;million of its outstanding common stock. Repurchases under this program may be made at management&#x2019;s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026. During the six months ended June&#160;30, 2026, the Company repurchased 2,244,553 shares of its common stock through open market transactions for $50.4&#160;million which included less than $0.1&#160;million of broker fees and $0.4&#160;million of accrued excise tax. As of June&#160;30, 2026, $100.0 million remains available for future repurchases under this authorization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchases of the Company&#x2019;s common stock are accounted for at cost and recorded as treasury stock. The broker fees incurred and excise tax on repurchases of the Company&#x2019;s common stock are recorded as a cost of acquiring treasury stock. Any reissued treasury stock will be accounted for at average cost. Gains or losses on reissued treasury stock arising from the difference between the average cost and the fair value of the award will be recorded in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company&#x2019;s share repurchase plan, during the six months ended June&#160;30, 2026, the Company withheld 366,650 shares of common stock to cover employee tax withholding obligations of $7.8&#160;million for vested restricted stock units. All shares of common stock withheld to cover employee tax withholding obligations are retired and are done so pursuant to the terms of the Company&#x2019;s stock incentive plans and related equity grant agreements rather than the Company&#x2019;s share repurchase program. Retired shares of common stock are not available for future issuance under the Company&#x2019;s stock incentive plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-880">&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables illustrate the changes in the balances of the Company&#x2019;s accumulated other comprehensive income for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gain (Loss) From Available-For-Sale Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Net unrealized loss on investments, net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gain (Loss) From Available-For-Sale Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Net unrealized loss on investments, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Net of a nominal tax benefit for both the six months ended June&#160;30, 2026 and 2025, respectively.</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-239" decimals="-3" id="f-881" unitRef="usd">97000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-240" decimals="-3" id="f-882" unitRef="usd">4230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-883" unitRef="usd">4327000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-241" decimals="-3" id="f-884" unitRef="usd">-42000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-242" decimals="-3" id="f-885" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-886" unitRef="usd">-42000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-241" decimals="-3" id="f-887" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-242" decimals="-3" id="f-888" unitRef="usd">-1044000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-889" unitRef="usd">-1044000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-243" decimals="-3" id="f-890" unitRef="usd">55000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-244" decimals="-3" id="f-891" unitRef="usd">3186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-892" unitRef="usd">3241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-245" decimals="-3" id="f-893" unitRef="usd">190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-246" decimals="-3" id="f-894" unitRef="usd">153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-895" unitRef="usd">343000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-247" decimals="-3" id="f-896" unitRef="usd">-131000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-248" decimals="-3" id="f-897" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-15" decimals="-3" id="f-898" unitRef="usd">-131000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-247" decimals="-3" id="f-899" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-248" decimals="-3" id="f-900" unitRef="usd">3850000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-901" unitRef="usd">3850000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-249" decimals="-3" id="f-902" unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-250" decimals="-3" id="f-903" unitRef="usd">4003000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-904" unitRef="usd">4062000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-15" decimals="-5" id="f-905" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-1" decimals="-5" id="f-906" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-251" decimals="INF" id="f-907" unitRef="usd">300000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="INF" id="f-908" unitRef="shares">2244553</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-5" id="f-909" unitRef="usd">50400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pcrx:ShareRepurchaseProgramBrokerFees contextRef="c-1" decimals="-5" id="f-910" unitRef="usd">100000</pcrx:ShareRepurchaseProgramBrokerFees>
    <us-gaap:ShareRepurchaseProgramExciseTax contextRef="c-1" decimals="-5" id="f-911" unitRef="usd">400000</us-gaap:ShareRepurchaseProgramExciseTax>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-3" decimals="-5" id="f-912" unitRef="usd">100000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="INF" id="f-913" unitRef="shares">366650</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-914" unitRef="usd">7800000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="c-1" id="f-915">STOCK PLANS&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pacira BioSciences, Inc. Amended and Restated 2011 Stock Incentive Plan, or 2011 Plan, was originally adopted by the Company&#x2019;s board of directors and approved by its stockholders in June 2011 and was amended and restated in June 2014, June 2016, June 2019, June 2021, June 2023 and June 2025. The 2011 Plan allows for the granting of incentive stock options, non-statutory stock options, restricted stock units, and other stock-based awards&#x2014;including PSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan, or as amended and restated to date, the A&amp;amp;R Inducement Plan, was originally approved and adopted by the Company&#x2019;s board of directors in April 2014, pursuant to which awards could be made to new employees as a material inducement to such persons entering into employment with the Company. The A&amp;amp;R Inducement Plan was amended and restated in December 2023, September 2024, January 2025 and January 2026. The January 2026 amendment and restatement added an additional 750,000 shares of the Company&#x2019;s common stock to bring the total amount of shares reserved for issuance under the A&amp;amp;R Inducement Plan to 3,060,000, of which 703,390 shares remained available for issuance as of June&#160;30, 2026, and extended the term of the A&amp;amp;R Inducement Plan such that it will now expire on January 1, 2036. The A&amp;amp;R Inducement Plan allows for the granting of nonstatutory stock options, restricted stock awards and other stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The A&amp;amp;R Inducement Plan was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with this rule, awards under the A&amp;amp;R Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors or the board of directors or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if they are granted such award in connection with their commencement of employment with the Company or a subsidiary and such grant is an inducement material to their entering into employment with the Company or such subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the board of directors, upon recommendation of the People and Compensation Committee of the board of directors, has approved individually negotiated grants of options and restricted stock units for certain of the Company&#x2019;s officers in connection with their respective appointments, in each case, pursuant to the inducement plan in effect at such time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables contain information about the Company&#x2019;s stock option, RSU and PSU activity for the six months ended June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Number of Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Weighted Average Exercise Price (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Outstanding at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Outstanding at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,123,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Weighted Average Grant Date Fair Value (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,205,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,845,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of stock options granted during the six months ended June&#160;30, 2026 was $12.58 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Black-Scholes Weighted Average Assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP. The ESPP was amended to increase the number of shares of common stock that may be sold under the ESPP by an additional 800,000 shares, bringing the total amount of shares reserved for issuance under the ESPP to 1,800,000, of which 869,062 shares remained available for issuance as of June&#160;30, 2026, and extended the term of the ESPP such that it will now expire on June 9, 2036.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP features two six-month offering periods per year, running from January 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to June 30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and July 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company&#x2019;s common stock on either the offering date or the purchase date, whichever is lesser. During the six months ended June&#160;30, 2026, 82,837 shares were purchased and issued through the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-252"
      decimals="INF"
      id="f-916"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-253"
      decimals="INF"
      id="f-917"
      unitRef="shares">3060000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-254"
      decimals="INF"
      id="f-918"
      unitRef="shares">703390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-919">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-255" decimals="-3" id="f-920" unitRef="usd">1809000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-256" decimals="-3" id="f-921" unitRef="usd">1682000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-257" decimals="-3" id="f-922" unitRef="usd">3452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-258" decimals="-3" id="f-923" unitRef="usd">3398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-259" decimals="-3" id="f-924" unitRef="usd">2605000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-260" decimals="-3" id="f-925" unitRef="usd">2407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-261" decimals="-3" id="f-926" unitRef="usd">4435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-262" decimals="-3" id="f-927" unitRef="usd">4648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-263" decimals="-3" id="f-928" unitRef="usd">10544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-264" decimals="-3" id="f-929" unitRef="usd">11383000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-265" decimals="-3" id="f-930" unitRef="usd">20610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-266" decimals="-3" id="f-931" unitRef="usd">21979000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-932" unitRef="usd">14958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-933" unitRef="usd">15472000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-934" unitRef="usd">28497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-935" unitRef="usd">30025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-267" decimals="-3" id="f-936" unitRef="usd">2941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-268" decimals="-3" id="f-937" unitRef="usd">4309000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-269" decimals="-3" id="f-938" unitRef="usd">5949000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-270" decimals="-3" id="f-939" unitRef="usd">8749000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-271" decimals="-3" id="f-940" unitRef="usd">11159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-272" decimals="-3" id="f-941" unitRef="usd">10681000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-273" decimals="-3" id="f-942" unitRef="usd">21303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-274" decimals="-3" id="f-943" unitRef="usd">20287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-275" decimals="-3" id="f-944" unitRef="usd">560000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-276" decimals="-3" id="f-945" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-277" decimals="-3" id="f-946" unitRef="usd">696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-278" decimals="-3" id="f-947" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-279" decimals="-3" id="f-948" unitRef="usd">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-280" decimals="-3" id="f-949" unitRef="usd">482000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-281" decimals="-3" id="f-950" unitRef="usd">549000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-282" decimals="-3" id="f-951" unitRef="usd">989000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-952" unitRef="usd">14958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-953" unitRef="usd">15472000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-954" unitRef="usd">28497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-955" unitRef="usd">30025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-956">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables contain information about the Company&#x2019;s stock option, RSU and PSU activity for the six months ended June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Number of Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Weighted Average Exercise Price (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Outstanding at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Outstanding at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,123,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Weighted Average Grant Date Fair Value (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,205,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,845,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-957" unitRef="shares">6374481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-958"
      unitRef="usdPerShare">40.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-959" unitRef="shares">300603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-960"
      unitRef="usdPerShare">22.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-961" unitRef="shares">27947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-962"
      unitRef="usdPerShare">16.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-963" unitRef="shares">90771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-964"
      unitRef="usdPerShare">26.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-965" unitRef="shares">432996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-966"
      unitRef="usdPerShare">44.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-967" unitRef="shares">6123370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-968"
      unitRef="usdPerShare">39.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-283"
      decimals="INF"
      id="f-969"
      unitRef="shares">4160697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-284"
      decimals="INF"
      id="f-970"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-285"
      decimals="2"
      id="f-971"
      unitRef="usdPerShare">27.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-273"
      decimals="INF"
      id="f-972"
      unitRef="shares">2245413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-277"
      decimals="INF"
      id="f-973"
      unitRef="shares">202112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-286"
      decimals="2"
      id="f-974"
      unitRef="usdPerShare">21.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-273"
      decimals="INF"
      id="f-975"
      unitRef="shares">1205978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-277"
      decimals="INF"
      id="f-976"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-286"
      decimals="2"
      id="f-977"
      unitRef="usdPerShare">30.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-273"
      decimals="INF"
      id="f-978"
      unitRef="shares">355041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-277"
      decimals="INF"
      id="f-979"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-286"
      decimals="2"
      id="f-980"
      unitRef="usdPerShare">26.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-287"
      decimals="INF"
      id="f-981"
      unitRef="shares">4845091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-288"
      decimals="INF"
      id="f-982"
      unitRef="shares">202112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-289"
      decimals="2"
      id="f-983"
      unitRef="usdPerShare">24.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-269"
      decimals="2"
      id="f-984"
      unitRef="usdPerShare">12.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-985">The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Black-Scholes Weighted Average Assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-269"
      decimals="INF"
      id="f-986"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-269" decimals="4" id="f-987" unitRef="number">0.0410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-269" decimals="4" id="f-988" unitRef="number">0.566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-269" id="f-989">P5Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-290"
      decimals="INF"
      id="f-990"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-291"
      decimals="INF"
      id="f-991"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-291"
      decimals="INF"
      id="f-992"
      unitRef="shares">869062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="c-281"
      decimals="INF"
      id="f-993"
      unitRef="offering_period">2</pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod contextRef="c-281" id="f-994">P6M</pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-1" decimals="INF" id="f-995" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-1" decimals="INF" id="f-996" unitRef="shares">82837</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-997">NET INCOME (LOSS) PER COMMON SHARE&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and PSUs and the purchase of shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible senior notes are treated under the if-converted method. Adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible senior notes on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible senior notes on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per common share for the three and six mon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ths ended June&#160;30, 2026 and 2025 (in thousands, except per common share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Weighted average common shares outstanding&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computation of diluted securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Dilutive effect of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Weighted average common shares outstanding&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Basic and diluted net income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average ESPP share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table above does not include contingent shares associated with the 2029 Notes being convertible at a premium, nor does it include PSUs as their performance targets have not yet been achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-998">&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per common share for the three and six mon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ths ended June&#160;30, 2026 and 2025 (in thousands, except per common share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Weighted average common shares outstanding&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computation of diluted securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Dilutive effect of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Weighted average common shares outstanding&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Basic and diluted net income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-999" unitRef="usd">4653000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-1000" unitRef="usd">-4847000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1001" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-1002" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-13"
      decimals="-3"
      id="f-1003"
      unitRef="shares">39462000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="-3"
      id="f-1004"
      unitRef="shares">45459000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1005" unitRef="shares">39961000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1006"
      unitRef="shares">45867000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-267"
      decimals="-3"
      id="f-1007"
      unitRef="shares">30000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-268"
      decimals="-3"
      id="f-1008"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-269"
      decimals="-3"
      id="f-1009"
      unitRef="shares">21000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-270"
      decimals="-3"
      id="f-1010"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-271"
      decimals="-3"
      id="f-1011"
      unitRef="shares">808000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-272"
      decimals="-3"
      id="f-1012"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-273"
      decimals="-3"
      id="f-1013"
      unitRef="shares">623000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-274"
      decimals="-3"
      id="f-1014"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-13"
      decimals="-3"
      id="f-1015"
      unitRef="shares">40300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-14"
      decimals="-3"
      id="f-1016"
      unitRef="shares">45459000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1017" unitRef="shares">40605000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="-3"
      id="f-1018"
      unitRef="shares">45867000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-1019"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-1020"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-1021"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-1022"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1023"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1024"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-1025"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-1026"
      unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1027">&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average ESPP share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-292"
      decimals="-3"
      id="f-1028"
      unitRef="shares">5956000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-293"
      decimals="-3"
      id="f-1029"
      unitRef="shares">6858000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-294"
      decimals="-3"
      id="f-1030"
      unitRef="shares">6029000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-295"
      decimals="-3"
      id="f-1031"
      unitRef="shares">6921000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-296"
      decimals="-3"
      id="f-1032"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-297"
      decimals="-3"
      id="f-1033"
      unitRef="shares">2821000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-298"
      decimals="-3"
      id="f-1034"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-299"
      decimals="-3"
      id="f-1035"
      unitRef="shares">2821000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-300"
      decimals="-3"
      id="f-1036"
      unitRef="shares">2256000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-301"
      decimals="-3"
      id="f-1037"
      unitRef="shares">4703000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-302"
      decimals="-3"
      id="f-1038"
      unitRef="shares">2127000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-303"
      decimals="-3"
      id="f-1039"
      unitRef="shares">4417000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-304"
      decimals="-3"
      id="f-1040"
      unitRef="shares">83000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-305"
      decimals="-3"
      id="f-1041"
      unitRef="shares">101000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-306"
      decimals="-3"
      id="f-1042"
      unitRef="shares">83000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-307"
      decimals="-3"
      id="f-1043"
      unitRef="shares">102000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-13"
      decimals="-3"
      id="f-1044"
      unitRef="shares">8295000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-14"
      decimals="-3"
      id="f-1045"
      unitRef="shares">14483000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-1046" unitRef="shares">8239000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-15"
      decimals="-3"
      id="f-1047"
      unitRef="shares">14261000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1048">INCOME TAXES&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax expense represents the estimated annual effective tax rate applied to the year-to-date operating re&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sults, adjusted for certain discrete tax items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective tax rate for the three and six months ended June&#160;30, 2026 was primarily impacted by the reversal of its U.K. operating subsidiary&#x2019;s valuation allowance, partially offset by costs related to non-deductible stock-based compensation and non-deductible executive compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective tax rate for the three and six months ended June&#160;30, 2025 was primarily impacted by costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2026, the Company recorded a discrete benefit of $6.4&#160;million resulting from a change in judgment regarding future-year realizability of deferred tax assets in its U.K. operations, primarily related to fixed asset temporary differences. The reduction reflects management&#x2019;s conclusion, based on all available positive and negative evidence, that realization of the U.K. deferred tax assets is more likely than not. As a result, the discrete benefit significantly reduced the Company&#x2019;s effective tax rate for the three and six months ending June 30, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest the Company&#x2019;s iovera&#xb0; business. The Transaction closed on July 31, 2026. The parties agreed to treat the transaction as a deemed asset sale for U.S. federal income tax purposes through an election under Section 338(h)(10) of the Internal Revenue Code. As the Transaction closed subsequent to June 30, 2026, the income tax effects of the transaction, including changes in the valuation allowance for capital-loss carryforwards, were not recognized in the income tax provisions for the three and six months ending June 30, 2026. For more information on the divestiture of iovera&#xb0;, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both June&#160;30, 2026 and December&#160;31, 2025, the Company had an income taxes payable balance of $6.1&#160;million that was included in other liabilities within the condensed consolidated balance sheet, related to unrecognized tax benefits. As of both June&#160;30, 2026 and December&#160;31, 2025, the Company had less than $0.1&#160;million of current income taxes payable that was included in accrued expenses within the condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026 and December&#160;31, 2025, the Company had income taxes receivable and prepaid income taxes of $8.4&#160;million and $8.2&#160;million, respectively, which were included in prepaid expenses and other current assets within the condensed consolidated balance sheet. The balances include a $4.6&#160;million tax refund claim for estimated federal taxes made prior to the July 2025 enactment of federal legislation known as the One Big Beautiful Bill Act (the &#x201c;OBBBA&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Tax Reform&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The OBBBA resulted in changes to U.S. federal income tax law. Significant provisions of the OBBBA include the permanent extension of certain provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. In accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company was required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring its estimated U.S. deferred tax assets and liabilities. The Company had $124.6&#160;million of a gross deferred tax asset attributed to unamortized U.S. capitalized research and development costs as of December&#160;31, 2024, of which $62.3&#160;million will be deductible on both its 2025 and 2026 income tax returns. There are no other material impacts to the Company related to the enactment of the OBBBA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1049">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-3" id="f-1050" unitRef="usd">5946000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-14" decimals="-3" id="f-1051" unitRef="usd">-4214000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-1052" unitRef="usd">10113000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-15" decimals="-3" id="f-1053" unitRef="usd">6459000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-3" id="f-1054" unitRef="usd">-3391000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-14" decimals="-3" id="f-1055" unitRef="usd">2287000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-1056" unitRef="usd">-2560000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-15" decimals="-3" id="f-1057" unitRef="usd">320000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-1058" unitRef="usd">2555000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-1059" unitRef="usd">-1927000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1060" unitRef="usd">7553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-1061" unitRef="usd">6779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1062" unitRef="usd">-2098000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1063" unitRef="usd">2920000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1064" unitRef="usd">-16000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1065" unitRef="usd">6814000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="2" id="f-1066" unitRef="number">-0.82</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="2" id="f-1067" unitRef="number">-1.52</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-1068" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="2" id="f-1069" unitRef="number">1.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationTaxSettlementsForeign contextRef="c-13" decimals="-5" id="f-1070" unitRef="usd">-6400000</us-gaap:IncomeTaxReconciliationTaxSettlementsForeign>
    <us-gaap:AccruedIncomeTaxes contextRef="c-3" decimals="-5" id="f-1071" unitRef="usd">6100000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes contextRef="c-4" decimals="-5" id="f-1072" unitRef="usd">6100000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="-5" id="f-1073" unitRef="usd">100000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-3" decimals="-5" id="f-1074" unitRef="usd">100000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-3" decimals="-5" id="f-1075" unitRef="usd">8400000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="-5" id="f-1076" unitRef="usd">8200000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-308" decimals="-5" id="f-1077" unitRef="usd">4600000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-63" decimals="-5" id="f-1078" unitRef="usd">124600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <pcrx:DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne contextRef="c-63" decimals="-5" id="f-1079" unitRef="usd">62300000</pcrx:DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearOne>
    <pcrx:DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo contextRef="c-63" decimals="-5" id="f-1080" unitRef="usd">62300000</pcrx:DeferredTaxAssetsTaxCreditCarryforwardsResearchDeductionYearTwo>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="c-1" id="f-1081">OTHER OPERATING EXPENSES, NET&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other operating expenses, net for the six months ended June&#160;30, 2026 and 2025 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration charges (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Divestiture-Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized divestiture-related expenses of $5.9&#160;million during the three and six months ended June&#160;30, 2026, primarily related to third-party services and legal fees associated with divesting iovera&#xb0; to Zimmer. For more information, see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Flexion Acquisition Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized contingent consideration charges of $1.7&#160;million and gains of $0.6&#160;million during the three and six months ended June&#160;30, 2026, respectively. The Company recognized contingent consideration gains of $0.4&#160;million and $3.0&#160;million during the three and six months ended June&#160;30, 2025, respectively. See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition-Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized acquisition-related expenses of $1.0&#160;million and $2.5&#160;million during the three and six months ended June&#160;30, 2025, respectively, primarily related to third-party services and legal fees associated with the GQ Bio Acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.0&#160;million&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of costs during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2025&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the patent infringement suits against the eVenus ANDA Filers (as defined below). For more information, see Note 17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="c-1" id="f-1082">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other operating expenses, net for the six months ended June&#160;30, 2026 and 2025 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration charges (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other operating expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-13" decimals="-3" id="f-1083" unitRef="usd">5931000</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-14" decimals="-3" id="f-1084" unitRef="usd">0</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-1" decimals="-3" id="f-1085" unitRef="usd">5931000</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-15" decimals="-3" id="f-1086" unitRef="usd">0</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-13" decimals="-3" id="f-1087" unitRef="usd">1663000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-14" decimals="-3" id="f-1088" unitRef="usd">-357000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-1089" unitRef="usd">-614000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-1090" unitRef="usd">-3032000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-13" decimals="-3" id="f-1091" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-14" decimals="-3" id="f-1092" unitRef="usd">991000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-1" decimals="-3" id="f-1093" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-15" decimals="-3" id="f-1094" unitRef="usd">2502000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LitigationSettlementLoss contextRef="c-13" decimals="-3" id="f-1095" unitRef="usd">0</us-gaap:LitigationSettlementLoss>
    <us-gaap:LitigationSettlementLoss contextRef="c-14" decimals="-3" id="f-1096" unitRef="usd">0</us-gaap:LitigationSettlementLoss>
    <us-gaap:LitigationSettlementLoss contextRef="c-1" decimals="-3" id="f-1097" unitRef="usd">0</us-gaap:LitigationSettlementLoss>
    <us-gaap:LitigationSettlementLoss contextRef="c-15" decimals="-3" id="f-1098" unitRef="usd">7000000</us-gaap:LitigationSettlementLoss>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-13" decimals="-3" id="f-1099" unitRef="usd">-7594000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-14" decimals="-3" id="f-1100" unitRef="usd">-634000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-1101" unitRef="usd">-5317000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-3" id="f-1102" unitRef="usd">-6470000</us-gaap:OtherOperatingIncomeExpenseNet>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-13" decimals="-5" id="f-1103" unitRef="usd">5900000</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-1" decimals="-5" id="f-1104" unitRef="usd">5900000</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-13" decimals="-5" id="f-1105" unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-1106" unitRef="usd">-600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-14" decimals="-5" id="f-1107" unitRef="usd">-400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-5" id="f-1108" unitRef="usd">-3000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-14" decimals="-5" id="f-1109" unitRef="usd">1000000.0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-15" decimals="-5" id="f-1110" unitRef="usd">2500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LitigationSettlementLoss contextRef="c-15" decimals="-5" id="f-1111" unitRef="usd">7000000.0</us-gaap:LitigationSettlementLoss>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1112">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:7pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to its patents and intellectual property, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows. The Company is not in a position to assess the likelihood of any potential losses or adverse effect on its financial condition or to estimate the amount or range of potential losses, if any, from the following actions at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MyoScience Milestone Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (&#x201c;Pacira CryoTech&#x201d;), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (&#x201c;Fortis&#x201d;), solely in its capacity as representative for the former securityholders of MyoScience and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the &#x201c;MyoScience Merger Agreement&#x201d;), specifically related to the achievement of certain milestone payments under the MyoScience Merger Agreement. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the MyoScience Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial was conducted in September 2023. In January 2025, the Court issued its decision, finding that the disputed milestones were not met and therefore granted judgment to the Company in full. In March 2025, the Company filed a motion to recover attorney fees, and the parties subsequently agreed to settle the amount of expenses owed to the Company, whereby Fortis agreed to pay the Company $5.2&#160;million and waived its rights to appeal the decision. A final judgment and order was entered in April 2025. The $5.2&#160;million payment received was accounted for as a recovery of losses and recorded against selling, general and administrative expense in the six months ended June&#160;30, 2025 within the condensed consolidated statement of operations, consistent with where the previous expenses were recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;eVenus Pharmaceutical Laboratories Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, December 2021, April 2023 and May 2024, the Company received Notice Letters advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application, or ANDA, with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic bupivacaine liposome injectable suspension in the U.S. prior to the expiration of certain of the Company&#x2019;s U.S. patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in November 2021, the Company filed various patent infringement suits against eVenus, its parent company (Jiangsu Hengrui Pharmaceuticals, Co. Ltd., or Jiangsu Hengrui) and Fresenius Kabi USA, LLC, or Fresenius, (together, the &#x201c;eVenus ANDA Filers&#x201d;) in the U.S. District Court for the District of New Jersey asserting infringement of U.S. Patent No. 11,033,495 (the &#x2018;495 patent) (21-cv-19829), U.S. Patent No. 11,179,336 (the &#x2018;336 patent) (22-cv-00718), U.S. Patent No. 11,426,348 (the &#x2018;348 patent) (23-cv-02367), U.S. Patent Nos. 11,819,574 (the &#x2018;574 patent) and 11,819,575 (the &#x2018;575 patent) (24-cv-06294), and U.S. Patent No. 11,925,706 (the &#x2018;706 patent) (24-cv-07680). In December 2024, the Company filed a patent infringement suit against Fresenius and Jiangsu Hengrui in the Northern District of Illinois (24-cv-12416) asserting that the ANDA products will infringe U.S. Patent No. 12,156,940 (the &#x2018;940 patent). Also in December 2024, the eVenus ANDA Filers filed an action for declaratory judgment of non-infringement and invalidity with respect to the &#x2018;940 patent in the District Court of New Jersey (24-cv-11014).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2025, the Company, along with its operating subsidiary, Pacira Pharmaceuticals, Inc., entered into a settlement agreement with the eVenus ANDA Filers with respect to the litigations noted above. Pursuant to the settlement agreement, the eVenus ANDA Filers will be enjoined from marketing a generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit, except as provided for in the settlement agreement, as described below. In settlement of all outstanding claims in the litigations, the Company agreed to provide the eVenus ANDA Filers with a license to the Company&#x2019;s patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date that is sometime in early 2030. While the agreed-upon volume-limited percentages are confidential, they begin at a high single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement. In addition, the Company has agreed to provide the eVenus ANDA Filers with a license to its patents required to manufacture and sell an unlimited quantity of a generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date in 2039. In addition, in recognition of the Company&#x2019;s expected savings with respect to, among other things, the avoidance of fees, costs, time and resources associated with continuing the litigations, the Company paid the eVenus ANDA Filers $7.0&#160;million. This legal settlement cost was recorded within other operating expenses, net in the six months ended June&#160;30, 2025 in the Company&#x2019;s condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The WhiteOak Group and Qilu Pharmaceutical Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2025, the Company received two separate Paragraph IV Certifications from two Chinese generic drug manufacturers (The WhiteOak Group, Inc., or WhiteOak, of Rockville, Maryland (a subsidiary of Zhejiang Haichang Biotechnology Co., Ltd.) and Qilu Pharmaceutical (Hainan) Co., Ltd., or Qilu), each advising that they had submitted an ANDA to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of EXPAREL in the U.S. Each letter alleged that EXPAREL patents listed in the FDA&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Approved Drug Products with Therapeutic Equivalence Evaluations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Orange Book&#x201d;) are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed products described in these ANDA submissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November, 26, 2025, the Company filed a patent infringement suit against WhiteOak and Qilu in the U.S. District Court of the District of Delaware (25-cv-1445) asserting infringement of U.S. Patent No. 11,033,495 (the &#x2018;495 patent), U.S. Patent Nos. 11,819,574 (the &#x2018;574 patent) U.S. Patent No. 12,144,890 (the &#x2018;890 patent), U.S. Patent No. 12,151,024 (the &#x2018;024 Patent), U.S. Patent No. 12,156,940 (the &#x2018;940 patent), U.S. Patent No. 12,251,468 (the &#x2018;468 Patent), U.S. Patent No. 12,296,047 (the &#x2019;047 Patent), U.S. Patent No. 12,318,483 (the &#x2018;483 Patent), and U.S. Patent No. 12,370,142 (the &#x2018;142 Patent). On January 23, 2026 and February 5, 2026, Qilu and WhiteOak, respectively, each answered the complaint and asserted affirmative &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defenses and counterclaims asserting, inter alia, invalidity, unenforceability and non-infringement. On June 24, 2026, WhiteOak amended their answer to assert counterclaims for inequitable conduct. The Company intends to vigorously defend its intellectual property rights relating to EXPAREL. The Company is unable to predict the outcome of this litigation at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 13, 2025, Leandro Alvarez filed a putative class action on behalf of Company shareholders between August 2, 2023 and August 8, 2024 against the Company and certain of its officers, in the District Court of New Jersey (25-cv-322). The complaint alleged that the Company made materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The Company filed a motion to dismiss the complaint, and in February 2026, the suit was dismissed with prejudice. An appeal was filed in March 2026 which was voluntarily dismissed with prejudice in May 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2025, a Shareholder Derivative suit, Young v. Lee, et al, was filed in the District of New Jersey (25-cv-11841). The complaint alleges that certain of the Company&#x2019;s officers and members of the Company&#x2019;s board of directors breached their fiduciary duties by making materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The suit was voluntarily dismissed without prejudice in May 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research Development Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company&#x2019;s &#x2018;495 patent was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company&#x2019;s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit sought a declaration from the court that the Company owed no royalties to RDF with respect to its EXPAREL product after December 24, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the U.S. District Court, District of Nevada granted the Company&#x2019;s motion for partial summary judgment in respect to the Company&#x2019;s claim for a declaration that it no longer owes royalties for EXPAREL made under its 45-liter batch manufacturing process as of December 24, 2021. A trial as to whether royalties were owed on EXPAREL made under the Company&#x2019;s enhanced, larger-scale manufacturing process was conducted in September 2024. In April 2025, the Court issued judgment in favor of the Company. As a result, the low single-digit royalty that the Company had been paying RDF is eliminated, and the Company sought repayment of up to $23.1&#160;million, plus interest, from RDF, representing the royalties that the Company paid to RDF under protest on the collection of revenues of EXPAREL that occurred after December 24, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2025, the U.S. District Court for the District of Nevada issued judgment in favor of the Company declaring that RDF is required to repay Pacira $23.1&#160;million in royalties on EXPAREL sales that were previously paid under protest. The Nevada Court also awarded Pacira an additional interest payment of $5.2&#160;million in statutory interest on the royalties paid under protest. In July 2025, the Company received a $28.3&#160;million cash payment for which $23.1&#160;million was recorded within other operating expenses, net and $5.2&#160;million was recorded within interest income in the three months ended September 30, 2025 in the Company&#x2019;s condensed consolidated statements of operations. In May and September 2025, RDF filed two notices of appeal. A consolidated appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments, Contingencies and Commercial Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LG Chem&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2026, the Company and LG Chem, Ltd., or LG Chem, entered into a partnership agreement to expand access to EXPAREL in select Asia&#x2013;Pacific markets. Under the terms of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. The Company received a $2.0&#160;million upfront payment that it will recognize over the license term upon commercialization and will receive a contractually stated price and tiered royalties on future commercial sales by LG Chem in its licensed territories. The Company will manufacture EXPAREL and LG Chem will be responsible for securing regulatory approvals in the licensed territories. LG Chem has filed for marketing authorization in South Korea and plans to do so in Thailand in the second half of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson MedTech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2025, the Company entered into a co-promotion agreement, with Johnson &amp;amp; Johnson MedTech, or J&amp;amp;J MedTech, (the &#x201c;J&amp;amp;J Agreement&#x201d;), to market and promote the use of ZILRETTA for OA knee pain in the U.S. J&amp;amp;J MedTech&#x2019;s specialized early intervention sales force will extend the reach of ZILRETTA beyond orthopedic practices, into multiple new physician specialties, including sports medicine, osteopathy, pain management and rheumatology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the J&amp;amp;J Agreement, J&amp;amp;J MedTech is the exclusive third-party co-promoter for ZILRETTA in the U.S. The initial term of the J&amp;amp;J Agreement extends through 2031 with an option to extend under mutual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will continue to recognize all revenue from sales of ZILRETTA. As compensation for its promotional efforts, for the first 12 months of the J&amp;amp;J Agreement the Company will pay J&amp;amp;J MedTech a minimum monthly commission. For the remaining term of the agreement, Pacira will pay a tier-based commission with higher commission percentages earned at higher annual ZILRETTA sales levels. J&amp;amp;J MedTech will receive a tiered commission ranging from low single digits to double digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and J&amp;amp;J MedTech have mutual termination rights under the J&amp;amp;J Agreement, subject to certain terms, conditions and advance notice requirements, provided that the Company or J&amp;amp;J MedTech generally may not terminate the J&amp;amp;J Agreement, without cause, within one year of the effective date of the J&amp;amp;J Agreement. The Company also has additional unilateral termination rights under certain circumstances. The J&amp;amp;J Agreement contains customary representations, warranties, covenants and confidentiality provisions, as well as mutual indemnification obligations. J&amp;amp;J MedTech is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and the Company&#x2019;s policies, in connection with fulfilling their obligations under the J&amp;amp;J Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pediatric Trial Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL for infiltration and as a brachial plexus block in pediatric patients. The Company was granted deferrals for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the European Union, or E.U. Despite the U.K.&#x2019;s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received notification from both the FDA and EMA that its pediatric studies requirement had been waived for the indications of brachial plexus interscalene nerve block, lower extremity nerve block, sciatic nerve block in the popliteal fossa and adductor canal block indications to produce postsurgical regional analgesia in pediatric patients. The Company is still working with the FDA, EMA and Medicines and Healthcare products Regulatory Agency (MHRA) to finalize the regulatory pathways for its remaining pediatric commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has successfully completed Part 1 of a Phase 1 pharmacokinetic pediatric study in children aged two to less than six years of age and has completed enrollment for Part 2 of the study in children aged six months to less than two years of age using the same dosage that was utilized in Part 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 11,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information on potential contingent milestone payments related to the Flexion Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PCRX-201&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PCRX-201 (enekinragene inzadenovec) is a novel, locally administered gene therapy product candidate that boosts cellular production of the anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) for treating OA pain in the knee. PCRX-201 was added to the Company&#x2019;s portfolio as part of the Flexion Acquisition in November 2021. In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy designation to PCRX-201.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Flexion Acquisition, in 2017, Flexion entered into an agreement with GQ Bio to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0&#160;million of payments could have become due upon the achievement of certain development and regulatory milestones, including up to $4.5&#160;million through initiation of a Phase 2 clinical trial and up to an additional $51.5&#160;million in development and global regulatory approval milestone payments. In February 2025, Pacira Therapeutics, Inc., a wholly-owned subsidiary of the Company, completed the GQ Bio Acquisition and acquired the remaining 81% of GQ Bio that was not already owned by the Company. As of the date hereof, GQ Bio is a wholly-owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in 2017, in an agreement between The Baylor College of Medicine, or BCM, and GQ Bio, the Company (through the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Flexion Acquisition) became the direct licensee of certain underlying BCM patents and other proprietary rights related to PCRX-201. The license agreement grants the Company an exclusive, royalty-bearing, world-wide right and license under its patent and other proprietary rights directly related to PCRX-201. The license agreement with BCM includes a low single-digit royalty on net product sales of PCRX-201. Milestone payments range from $0.1&#160;million up to $0.6&#160;million based on the completion of a Phase 1 FDA trial up to a Phase 3 clinical trial.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-309" decimals="-5" id="f-1113" unitRef="usd">5200000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-310" decimals="-5" id="f-1114" unitRef="usd">5200000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <pcrx:LitigationSettlementVolumeLimitedIncreasePeriod contextRef="c-311" id="f-1115">P12M</pcrx:LitigationSettlementVolumeLimitedIncreasePeriod>
    <pcrx:LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods
      contextRef="c-311"
      decimals="INF"
      id="f-1116"
      unitRef="period">2</pcrx:LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods>
    <pcrx:LitigationSettlementVolumeLimitedIncreasePeriod contextRef="c-311" id="f-1117">P12M</pcrx:LitigationSettlementVolumeLimitedIncreasePeriod>
    <pcrx:LitigationSettlementVolumeLimitedMaximumPercentagePeriod contextRef="c-311" id="f-1118">P3Y</pcrx:LitigationSettlementVolumeLimitedMaximumPercentagePeriod>
    <us-gaap:LitigationSettlementLoss contextRef="c-15" decimals="-5" id="f-1119" unitRef="usd">7000000.0</us-gaap:LitigationSettlementLoss>
    <pcrx:NumberOfParagraphIVCertifications
      contextRef="c-312"
      decimals="INF"
      id="f-1120"
      unitRef="certificate">2</pcrx:NumberOfParagraphIVCertifications>
    <pcrx:NumberOfGenericDrugManufacturers
      contextRef="c-312"
      decimals="INF"
      id="f-1121"
      unitRef="manufacturer">2</pcrx:NumberOfGenericDrugManufacturers>
    <pcrx:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty contextRef="c-313" decimals="-5" id="f-1122" unitRef="usd">23100000</pcrx:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-314" decimals="-5" id="f-1123" unitRef="usd">23100000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementInterest contextRef="c-314" decimals="-5" id="f-1124" unitRef="usd">5200000</us-gaap:LitigationSettlementInterest>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c-315" decimals="-5" id="f-1125" unitRef="usd">28300000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-315" decimals="-5" id="f-1126" unitRef="usd">23100000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementInterest contextRef="c-315" decimals="-5" id="f-1127" unitRef="usd">5200000</us-gaap:LitigationSettlementInterest>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-316"
      decimals="INF"
      id="f-1128"
      unitRef="notice">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:ContractWithCustomerLiability contextRef="c-317" decimals="-5" id="f-1129" unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiability>
    <pcrx:ContractualObligationMinimumMonthlyCommissionDuration contextRef="c-318" id="f-1130">P12M</pcrx:ContractualObligationMinimumMonthlyCommissionDuration>
    <pcrx:ContractualObligationMutualTerminationRightsTerm contextRef="c-319" id="f-1131">P1Y</pcrx:ContractualObligationMutualTerminationRightsTerm>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum contextRef="c-320" decimals="-5" id="f-1132" unitRef="usd">56000000.0</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum contextRef="c-321" decimals="-5" id="f-1133" unitRef="usd">4500000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum contextRef="c-322" decimals="-5" id="f-1134" unitRef="usd">51500000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-323"
      decimals="2"
      id="f-1135"
      unitRef="number">0.81</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <pcrx:RevenueFromContractWithCustomerMilestonePaymentsMaximum contextRef="c-324" decimals="-5" id="f-1136" unitRef="usd">100000</pcrx:RevenueFromContractWithCustomerMilestonePaymentsMaximum>
    <pcrx:RevenueFromContractWithCustomerMilestonePaymentsMaximum contextRef="c-325" decimals="-5" id="f-1137" unitRef="usd">600000</pcrx:RevenueFromContractWithCustomerMilestonePaymentsMaximum>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1138">SEGMENT INFORMATION&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain therapies. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer&#x2014;who is the Company&#x2019;s chief operating decision maker, or CODM&#x2014;manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one operating segment and one reportable segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key measure of the Company is GAAP net income. The CODM uses this measure to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are significant expense categories and amounts that are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company&#x2019;s financial results. The table below reconciles the significant expense categories provided to the CODM to the Company&#x2019;s expenses as disclosed under GAAP (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost of goods sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted selling and marketing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture and acquisition-related expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in the fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decommissioning of manufacturing suite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) The adjustments are primarily related to stock-based compensation being noted separately as a line item.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(2) During the three and six months ended June&#160;30, 2026, the Company recognized $5.9&#160;million of divestiture-related expenses, primarily related to third-party services and legal fees, which were recorded to other operating expenses, net in the condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February 2025, the Company acquired the remaining 81% of GQ Bio that it did not already own. During the three and six months ended June&#160;30, 2025, the Company incurred acquisition-related expenses of $1.0&#160;million and $2.5&#160;million, respectively, mainly related to third-party services and legal fees associated with the acquisition of GQ Bio, which were recorded to other operating expenses, net in the condensed consolidated statement of operations. As part of the purchase agreement, $7.8&#160;million of expense will be recognized and paid over three years pursuant to a key employee holdback agreement in increments of 50%, 30% and 20%, respectively. This resulted in $0.6&#160;million and $1.5&#160;million recognized within research and development in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2026, respectively, and $1.1&#160;million and $1.5&#160;million for the three and six months ended June&#160;30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measure of segment assets is reported on the Company&#x2019;s consolidated balance sheet as total assets. Substantially all of the Company&#x2019;s assets are used to support its mission in delivering innovative, non-opioid pain therapies to transform the lives of patients. As of June&#160;30, 2026 and December 31, 2025, the Company&#x2019;s long-lived assets were primarily located in the U.S. (81% and 83%, respectively), and, to a lesser extent, Germany (10% and 9%) and the U.K. (9% and 8%). For information on the Company&#x2019;s fixed assets, refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1139"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1140"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1141">The table below reconciles the significant expense categories provided to the CODM to the Company&#x2019;s expenses as disclosed under GAAP (in thousands):&lt;div style="margin-bottom:2pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost of goods sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted selling and marketing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture and acquisition-related expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in the fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decommissioning of manufacturing suite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) The adjustments are primarily related to stock-based compensation being noted separately as a line item.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(2) During the three and six months ended June&#160;30, 2026, the Company recognized $5.9&#160;million of divestiture-related expenses, primarily related to third-party services and legal fees, which were recorded to other operating expenses, net in the condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February 2025, the Company acquired the remaining 81% of GQ Bio that it did not already own. During the three and six months ended June&#160;30, 2025, the Company incurred acquisition-related expenses of $1.0&#160;million and $2.5&#160;million, respectively, mainly related to third-party services and legal fees associated with the acquisition of GQ Bio, which were recorded to other operating expenses, net in the condensed consolidated statement of operations. As part of the purchase agreement, $7.8&#160;million of expense will be recognized and paid over three years pursuant to a key employee holdback agreement in increments of 50%, 30% and 20%, respectively. This resulted in $0.6&#160;million and $1.5&#160;million recognized within research and development in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2026, respectively, and $1.1&#160;million and $1.5&#160;million for the three and six months ended June&#160;30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-326" decimals="-3" id="f-1142" unitRef="usd">192399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-327" decimals="-3" id="f-1143" unitRef="usd">181099000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-328" decimals="-3" id="f-1144" unitRef="usd">369775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-329" decimals="-3" id="f-1145" unitRef="usd">350022000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pcrx:CostOfGoodsSoldAdjusted contextRef="c-326" decimals="-3" id="f-1146" unitRef="usd">42355000</pcrx:CostOfGoodsSoldAdjusted>
    <pcrx:CostOfGoodsSoldAdjusted contextRef="c-327" decimals="-3" id="f-1147" unitRef="usd">32663000</pcrx:CostOfGoodsSoldAdjusted>
    <pcrx:CostOfGoodsSoldAdjusted contextRef="c-328" decimals="-3" id="f-1148" unitRef="usd">77125000</pcrx:CostOfGoodsSoldAdjusted>
    <pcrx:CostOfGoodsSoldAdjusted contextRef="c-329" decimals="-3" id="f-1149" unitRef="usd">65253000</pcrx:CostOfGoodsSoldAdjusted>
    <pcrx:ResearchAndDevelopmentAdjusted contextRef="c-326" decimals="-3" id="f-1150" unitRef="usd">27053000</pcrx:ResearchAndDevelopmentAdjusted>
    <pcrx:ResearchAndDevelopmentAdjusted contextRef="c-327" decimals="-3" id="f-1151" unitRef="usd">24686000</pcrx:ResearchAndDevelopmentAdjusted>
    <pcrx:ResearchAndDevelopmentAdjusted contextRef="c-328" decimals="-3" id="f-1152" unitRef="usd">52415000</pcrx:ResearchAndDevelopmentAdjusted>
    <pcrx:ResearchAndDevelopmentAdjusted contextRef="c-329" decimals="-3" id="f-1153" unitRef="usd">47787000</pcrx:ResearchAndDevelopmentAdjusted>
    <pcrx:SellingAndMarketingAdjusted contextRef="c-326" decimals="-3" id="f-1154" unitRef="usd">52117000</pcrx:SellingAndMarketingAdjusted>
    <pcrx:SellingAndMarketingAdjusted contextRef="c-327" decimals="-3" id="f-1155" unitRef="usd">50964000</pcrx:SellingAndMarketingAdjusted>
    <pcrx:SellingAndMarketingAdjusted contextRef="c-328" decimals="-3" id="f-1156" unitRef="usd">110283000</pcrx:SellingAndMarketingAdjusted>
    <pcrx:SellingAndMarketingAdjusted contextRef="c-329" decimals="-3" id="f-1157" unitRef="usd">106535000</pcrx:SellingAndMarketingAdjusted>
    <pcrx:SellingGeneralAndAdministrativeAdjusted contextRef="c-326" decimals="-3" id="f-1158" unitRef="usd">29148000</pcrx:SellingGeneralAndAdministrativeAdjusted>
    <pcrx:SellingGeneralAndAdministrativeAdjusted contextRef="c-327" decimals="-3" id="f-1159" unitRef="usd">26231000</pcrx:SellingGeneralAndAdministrativeAdjusted>
    <pcrx:SellingGeneralAndAdministrativeAdjusted contextRef="c-328" decimals="-3" id="f-1160" unitRef="usd">54860000</pcrx:SellingGeneralAndAdministrativeAdjusted>
    <pcrx:SellingGeneralAndAdministrativeAdjusted contextRef="c-329" decimals="-3" id="f-1161" unitRef="usd">46840000</pcrx:SellingGeneralAndAdministrativeAdjusted>
    <us-gaap:ShareBasedCompensation contextRef="c-326" decimals="-3" id="f-1162" unitRef="usd">14958000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-327" decimals="-3" id="f-1163" unitRef="usd">15472000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-328" decimals="-3" id="f-1164" unitRef="usd">28497000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-329" decimals="-3" id="f-1165" unitRef="usd">30025000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-326" decimals="-3" id="f-1166" unitRef="usd">14322000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-327" decimals="-3" id="f-1167" unitRef="usd">14322000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-328" decimals="-3" id="f-1168" unitRef="usd">28644000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-329" decimals="-3" id="f-1169" unitRef="usd">28644000</us-gaap:AmortizationOfIntangibleAssets>
    <pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense contextRef="c-326" decimals="-3" id="f-1170" unitRef="usd">6516000</pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense>
    <pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense contextRef="c-327" decimals="-3" id="f-1171" unitRef="usd">2098000</pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense>
    <pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense contextRef="c-328" decimals="-3" id="f-1172" unitRef="usd">7396000</pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense>
    <pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense contextRef="c-329" decimals="-3" id="f-1173" unitRef="usd">3960000</pcrx:AcquisitionRelatedCostAndDivestitureRelatedExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-326" decimals="-3" id="f-1174" unitRef="usd">1663000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-327" decimals="-3" id="f-1175" unitRef="usd">-357000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-328" decimals="-3" id="f-1176" unitRef="usd">-614000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-329" decimals="-3" id="f-1177" unitRef="usd">-3032000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LitigationSettlementLoss contextRef="c-326" decimals="-3" id="f-1178" unitRef="usd">0</us-gaap:LitigationSettlementLoss>
    <us-gaap:LitigationSettlementLoss contextRef="c-327" decimals="-3" id="f-1179" unitRef="usd">0</us-gaap:LitigationSettlementLoss>
    <us-gaap:LitigationSettlementLoss contextRef="c-328" decimals="-3" id="f-1180" unitRef="usd">0</us-gaap:LitigationSettlementLoss>
    <us-gaap:LitigationSettlementLoss contextRef="c-329" decimals="-3" id="f-1181" unitRef="usd">7000000</us-gaap:LitigationSettlementLoss>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-326" decimals="-3" id="f-1182" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-327" decimals="-3" id="f-1183" unitRef="usd">-6521000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-328" decimals="-3" id="f-1184" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-329" decimals="-3" id="f-1185" unitRef="usd">-6521000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:CostsAndExpenses contextRef="c-326" decimals="-3" id="f-1186" unitRef="usd">188132000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-327" decimals="-3" id="f-1187" unitRef="usd">172600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-328" decimals="-3" id="f-1188" unitRef="usd">358606000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-329" decimals="-3" id="f-1189" unitRef="usd">339533000</us-gaap:CostsAndExpenses>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-326" decimals="-3" id="f-1190" unitRef="usd">-1712000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-327" decimals="-3" id="f-1191" unitRef="usd">-10426000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-328" decimals="-3" id="f-1192" unitRef="usd">-3616000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-329" decimals="-3" id="f-1193" unitRef="usd">-3710000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-326" decimals="-3" id="f-1194" unitRef="usd">2555000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-327" decimals="-3" id="f-1195" unitRef="usd">-1927000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-328" decimals="-3" id="f-1196" unitRef="usd">7553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-329" decimals="-3" id="f-1197" unitRef="usd">6779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-326" decimals="-3" id="f-1198" unitRef="usd">-2098000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-327" decimals="-3" id="f-1199" unitRef="usd">2920000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-328" decimals="-3" id="f-1200" unitRef="usd">-16000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-329" decimals="-3" id="f-1201" unitRef="usd">6814000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-326" decimals="-3" id="f-1202" unitRef="usd">4653000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-327" decimals="-3" id="f-1203" unitRef="usd">-4847000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-328" decimals="-3" id="f-1204" unitRef="usd">7569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-329" decimals="-3" id="f-1205" unitRef="usd">-35000</us-gaap:NetIncomeLoss>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-326" decimals="-5" id="f-1206" unitRef="usd">5900000</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses contextRef="c-328" decimals="-5" id="f-1207" unitRef="usd">5900000</pcrx:DisposalGroupIncludingDiscontinuedOperationDivestitureRelatedExpenses>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-323"
      decimals="2"
      id="f-1208"
      unitRef="number">0.81</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-330" decimals="-5" id="f-1209" unitRef="usd">1000000.0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-331" decimals="-5" id="f-1210" unitRef="usd">2500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized contextRef="c-332" decimals="-5" id="f-1211" unitRef="usd">7800000</us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized>
    <pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized contextRef="c-333" id="f-1212">P3Y</pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPeriodOfRecognized>
    <pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne
      contextRef="c-332"
      decimals="INF"
      id="f-1213"
      unitRef="number">0.50</pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearOne>
    <pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo
      contextRef="c-332"
      decimals="INF"
      id="f-1214"
      unitRef="number">0.30</pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearTwo>
    <pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree
      contextRef="c-332"
      decimals="INF"
      id="f-1215"
      unitRef="number">0.20</pcrx:BusinessCombinationLiabilitiesArisingFromContingenciesPercentYearThree>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities contextRef="c-330" decimals="-5" id="f-1216" unitRef="usd">600000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities contextRef="c-331" decimals="-5" id="f-1217" unitRef="usd">1500000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities contextRef="c-334" decimals="-5" id="f-1218" unitRef="usd">1100000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities contextRef="c-335" decimals="-5" id="f-1219" unitRef="usd">1500000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <pcrx:PercentOfLongLivedAssets
      contextRef="c-336"
      decimals="2"
      id="f-1220"
      unitRef="number">0.81</pcrx:PercentOfLongLivedAssets>
    <pcrx:PercentOfLongLivedAssets
      contextRef="c-337"
      decimals="2"
      id="f-1221"
      unitRef="number">0.83</pcrx:PercentOfLongLivedAssets>
    <pcrx:PercentOfLongLivedAssets
      contextRef="c-338"
      decimals="2"
      id="f-1222"
      unitRef="number">0.10</pcrx:PercentOfLongLivedAssets>
    <pcrx:PercentOfLongLivedAssets
      contextRef="c-339"
      decimals="2"
      id="f-1223"
      unitRef="number">0.09</pcrx:PercentOfLongLivedAssets>
    <pcrx:PercentOfLongLivedAssets
      contextRef="c-340"
      decimals="2"
      id="f-1224"
      unitRef="number">0.09</pcrx:PercentOfLongLivedAssets>
    <pcrx:PercentOfLongLivedAssets
      contextRef="c-341"
      decimals="2"
      id="f-1225"
      unitRef="number">0.08</pcrx:PercentOfLongLivedAssets>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-13" id="f-1226">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-13" id="f-1227">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-13" id="f-1228">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-13" id="f-1229">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
